
APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2003

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2001.

23RD EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2003

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

PREFACE TO TWENTY THIRD EDITION v

1. INTRODUCTION vii
1.1 Content and Exclusion vii
1.2 Therapeutic Equivalence-Related Terms vii
1.3 Statistical Criteria for Bioequivalence ix
1.4 Reference Listed Drug x
1.5 General Policies and Legal Status xi
1.6 Practitioner/User Responsibilities xi
1.7 Therapeutic Equivalence Evaluations Codes xiii
1.8 Description of Special Situations xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity xxi
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product xxii
1.11 Availability of Internal Policy and Procedure Guides xxii
1.12 Discontinued Section xxii

2. HOW TO USE THE DRUG PRODUCTS LISTS 2-1
2.1 Key Sections for Using the Drug Product Lists 2-1
2.2 Drug Product Illustration 2-3
2.3 Therapeutic Equivalence Evaluations Illustration 2-4

DRUG PRODUCT LISTS
Prescription Drug Product List 3-1
OTC Drug Product List 4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 5-1
Discontinued Drug Product List 6-1
Orphan Products Designations and Approvals List 7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 8-1

APPENDICES
A. Product Name Index A-1
B. Product Name Index Listed by Applicant B-1
C. Uniform Terms C-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM AD1
A. Patent and Exclusivity Lists ADA1
B. Patent and Exclusivity Terms ADB1

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

PREFACE TO TWENTY THIRD EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate

FDA data supplied by DrugPatentWatch.com

corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Divison of Labeling and Program Support HFD-610, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7500 Standish Place, Rockville, MD 20855. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

FDA data supplied by DrugPatentWatch.com

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided. An *Addendum* contains drug patent and exclusivity information for the Prescription and OTC Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research.

This publication also includes additional information, such as Orphan Drug Product Designations and other data that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products were given tentative approvals. Prior to the effective date, the Agency will not include drug products with tentative approval in the List; however, they are available in the *FDA Drug Product Approvals List* on the Internet World Wide Web. When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final, effective approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different

FDA data supplied by DrugPatentWatch.com

salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharamaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(7)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

FDA data supplied by DrugPatentWatch.com

> the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (Cmax), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product

FDA data supplied by DrugPatentWatch.com

is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and Cmax) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (Cmax and AUC). The confidence interval for both pharmacokinetic parameters, AUC and Cmax, must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials, pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both, differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and Cmax) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and Cmax. The observed average differences between the reference and generic products were $\pm$ 3.47% (SD 2.84) for $AUC_{(0-t)}$, $\pm$ 3.25% (SD 2.97) for $AUC_{(0-inf)}$, and $\pm$ 4.29% (SD 3.72) for Cmax (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to

FDA data supplied by DrugPatentWatch.com

different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes Products meeting necessary bioequivalence requirements* explains the (***AB, AB1, AB2, AB3***... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which may be purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due

FDA data supplied by DrugPatentWatch.com

to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes.*

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

FDA data supplied by DrugPatentWatch.com

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX**, or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

FDA data supplied by DrugPatentWatch.com

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio- equivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

FDA data supplied by DrugPatentWatch.com

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents)* generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic drug products

FDA data supplied by DrugPatentWatch.com

bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, *Injectable; Injection*. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are all considered to be pharmaceutically and therapeutically equivalent provided they are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in

FDA data supplied by DrugPatentWatch.com

plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including solutions, creams, ointments, gels, lotions, pastes, sprays, and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio- equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

FDA data supplied by DrugPatentWatch.com

The specific coding definitions and policies for the "**B**" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach.
Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded AB.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded AB. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded AB.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other

FDA data supplied by DrugPatentWatch.com

pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon® 's activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Metaxalone Tablets. In Cumulative Supplement 6 of the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition, (the Orange Book), the Agency proposed to reclassifiy metaxalone tablets from a drug product not presenting bioequivalence problems to one that has a known or potential bioequivalence problem that requires an in vivo demonstration of bioequivalence as a condtiion of approval for an ANDA. The Agency solicited comments from interested persons to be received no later than November 30, 2001. No comments were received. Accordingly, the therapeutic equivalence category for metaxalone tablets will be changed from a "nonbioproblem drug" to a "bioproblem drug." An ANDA for metaxalone tablets must include acceptable in vivo bioequivalence study or studies. As long as metaxalone tablets are a single source drug product, no therapeutic equivalence code will be assigned to the product in the Orange Book. If the Agency approves an ANDA for metaxalone tablets, the innovator's NDA for metaxalone (Skelaxin) tablets and the approved ANDA will both be coded as "AB".

Patent Certification(s) Reference Listed Drug based upon a suitability petition. An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed

FDA data supplied by DrugPatentWatch.com

drug which served as the basis for the approved suitability petition.

Ribavirin 200MG Oral Capsule. Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

Tramadol Hydrochloride 50 mg tablet. Products approved under section 505(j) are marked with (*) because there are special considerations governing the substitution of these products. The tramadol hydrochloride 50 mg tablets marked with a (*) are therapeutically equivalent (AB) to RW Johnson's Ultram (Tramadol Hydrochloride) 50 mg tablets. However, because of RW Johnson's exclusivity and patent protection for the 25 mg titration dosing regimen, tramadol hydrochloride drug products approved under section 505(j) may not carry the labeling for the 25 mg titration dosing regimen. Ultram 50 mg tablets are scored for use in the 25 mg titration schedule; tramadol hydrochloride 50 mg tablets approved under 505(j) are not scored. Prescribers and dispensers should be aware of this scoring difference between Ultram and other tramadol hydrochloride tablets and take it into account when writing a prescription or practicing drug product selection.

Waived exclusivity. If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waiver its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waivers its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical

FDA data supplied by DrugPatentWatch.com

procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Availability of Internal Policy and Procedure Guides

The Office of Generic Drugs maintains internal policy and procedure guides. Although these guides are designed for Office personnel and are subject to change without public notice, they are available to members of the public who may wish to know more about the Office's policies and procedures. Copies of these guides may be obtained from the FDA, Center for Drug Evaluation and Research, HFD-240, Office of Training and Communications, Division of Drug Information, 5600 Fishers Lane, Rockville, MD 20857. The Agency welcomes public comment on the policies, procedures, and practices employed in the approval of generic drugs. Such comments may be sent to the Director, Office of Generic Drugs, (MPN-2) HFD-600, 7500 Standish Place, Rockville, MD 20855.

1.12 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not marketed or withdrawn for safety or efficacy reasons have been designated by the symbol "*". Those drug products with the symbol "*" are only reflective of citizen petitions approved since 1995.

The identification of these drug products in the Discontinued Section of the Orange Book with the symbol "*" should avoid the submission of multiple citizen petitions for the same drug product.

FDA data supplied by DrugPatentWatch.com

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982.

The abridged Discontinued Product List, arranged alphabetically by active ingredient(s), contain product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly. The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 22nd Edition List have been added to the Discontinued Drug Product List appearing in the 23rd Edition. In addition, approved drug products that are not in the commercial distribution channel

FDA data supplied by DrugPatentWatch.com

e.g. approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

Orphan Drug Product Designations. Drugs and biologicals that have been granted Orphan Designation pursuant to Section 526 as amended by the Orphan Drug Act [P.L. 97-414, January 4, 1983] are listed in Section 3.5.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.


Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists)*. This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.


FDA data supplied by DrugPatentWatch.com

2.2 DRUG PRODUCT ILLUSTRATION


SINGLE INGREDIENT



MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



WITH CROSS-REFERENCE



THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER

	SULFASALAZINE			
	TABLET; ORAL			
	FAZINE			
AB	PARKLAND	**500MG**		N42999 001
	SULAZINE			
AB	URSA	**500MG**		N40222 001

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED

	SULFASALAZINE			
	TABLET; ORAL			
	FAZINE			
AB	PARKLAND	**500MG**		N42999 001
BP	BROWN	500MG		N41297 001

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO EACH OTHER

	SULFASALAZINE			
BP	BROWN	500MG		N41297 001
BP	SOUTH	500MG		N40627 001

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

ABACAVIR SULFATE

SOLUTION; ORAL
ZIAGEN
+ GLAXOSMITHKLINE — EQ 20MG BASE/ML — N20978 001 DEC 17, 1998

TABLET; ORAL
ZIAGEN
+ GLAXOSMITHKLINE — EQ 300MG BASE — N20977 001 DEC 17, 1998

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
TRIZIVIR
+ GLAXOSMITHKLINE — EQ 300MG BASE;150MG;300MG — N21205 001 NOV 14, 2000

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER PHARMS — 25MG — N20482 004 MAY 29, 1997
50MG — N20482 001 SEP 06, 1995
+ 100MG — N20482 002 SEP 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
ACEBUTOLOL HCL

AB	MYLAN	**EQ 200MG BASE**	**N74288 001** APR 24, 1995
AB		**EQ 400MG BASE**	**N74288 002** APR 24, 1995
AB	PAR PHARM	**EQ 200MG BASE**	**N75047 001** DEC 30, 1999
AB		**EQ 400MG BASE**	**N75047 002** DEC 30, 1999
AB	WATSON LABS	**EQ 200MG BASE**	**N74007 001** OCT 18, 1995
AB		**EQ 400MG BASE**	**N74007 002** OCT 18, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
SECTRAL

AB	ESP PHARMA	**EQ 200MG BASE**	**N18917 001** DEC 28, 1984
AB +		**EQ 400MG BASE**	**N18917 003** DEC 28, 1984

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
+ MIKART — 150MG;180MG;30MG — N81096 001 OCT 26, 1990

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
BUCET

AB	MALLINCKRODT	**650MG;50MG**	**N88991 001** JUN 28, 1985

PHRENILIN FORTE

AB +	AMARIN PHARMS	**650MG;50MG**	**N88831 001** JUN 19, 1985

TENCON

AB	MALLINCKRODT	**650MG;50MG**	**N89405 001** MAY 15, 1990

TABLET; ORAL
BUTAPAP

AB	MIKART	**325MG;50MG**	**N89987 001** OCT 26, 1992
AB		**650MG;50MG**	**N89988 001** OCT 26, 1992

PHRENILIN

AB +	AMARIN PHARMS	**325MG;50MG**	**N87811 001** JUN 19, 1985

SEDAPAP

AB +	MAYRAND	**650MG;50MG**	**N88944 001** OCT 17, 1985

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ACETAMINOPHEN, BUTALBITAL AND CAFFEINE

AB	+ GILBERT LABS	325MG;50MG;40MG	N88825 001	DEC 05, 1984

ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE

AB	MIKART	325MG;50MG;40MG	N89007 001	MAR 17, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	WEST WARD	500MG;50MG;40MG	N40261 001	OCT 28, 1998

ESGIC-PLUS

AB	+ MIKART	500MG;50MG;40MG	N40085 001	MAR 28, 1996

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001
AB		500MG;50MG;40MG	N40394 001	JUL 23, 2001
AB	MALLINCKRODT	325MG;50MG;40MG	N87804 001	JAN 24, 1985
AB	MIKART	325MG;50MG;40MG	N89175 001	JAN 21, 1987
AB	+	500MG;50MG;40MG	N89451 001	MAY 23, 1988
AB	WATSON LABS	500MG;50MG;40MG	N40267 001	JUL 30, 1998
AB	WEST WARD	325MG;50MG;40MG	N89718 001	JUN 12, 1995

BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE

AB	WEST WARD	500MG;50MG;40MG	N40336 001	AUG 18, 1999

BUTALBITAL, APAP, AND CAFFEINE

AB	HALSEY	325MG;50MG;40MG	N89536 001	FEB 16, 1988

FIORICET

AB	+ NOVARTIS	325MG;50MG;40MG	N88616 001	NOV 09, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE

AB	VINTAGE PHARMS	325MG;50MG;40MG;30MG	N75929 001	APR 22, 2002

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001

FIORICET W/ CODEINE

AB	+ NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992

PHRENILIN WITH CAFFEINE AND CODEINE

AB	AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001	AUG 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

+	MIKART	356.4MG;30MG;16MG	N40109 001	AUG 26, 1997

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

+	MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PHENAPHEN W/ CODEINE NO. 3

+	ROBINS AH	325MG;30MG	N84445 001

PHENAPHEN W/ CODEINE NO. 4

+	ROBINS AH	325MG;60MG	N84446 001

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ ALPHARMA	120MG/5ML;12MG/5ML	N85861 001	
AA	CLONMEL	120MG/5ML;12MG/5ML	N40098 001	SEP 20, 1996
AA	HI TECH PHARMA	120MG/5ML;12MG/5ML	N40119 001	APR 26, 1996
AA	MIKART	120MG/5ML;12MG/5ML	N89450 001	OCT 27, 1992
AA	MORTON GROVE	120MG/5ML;12MG/5ML	N87006 001	
AA	PHARM ASSOC	120MG/5ML;12MG/5ML	N87508 001	

ACETAMINOPHEN W/ CODEINE

AA	ROXANE	120MG/5ML;12MG/5ML	N86366 001	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001	
	CAPITAL AND CODEINE			
AA	ALPHARMA	120MG/5ML;12MG/5ML	N85883 001	

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	ABLE	300MG;30MG	N40452 001	AUG 01, 2002
AA		300MG;60MG	N40459 001	AUG 01, 2002
AA	DURAMED PHARM BARR	300MG;15MG	N40223 001	NOV 18, 1997
AA		300MG;30MG	N40223 002	NOV 18, 1997
AA		300MG;60MG	N40223 003	NOV 18, 1997
AA	GENEVA PHARMS	300MG;30MG	N81250 001	JUL 16, 1992
AA		300MG;60MG	N81249 001	JUL 16, 1992
AA	IVAX PHARMS	300MG;60MG	N87083 001	
AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001
AA		300MG;30MG	N40419 002	MAY 31, 2001
AA		300MG;60MG	N40419 003	MAY 31, 2001
AA	MIKART	300MG;30MG	N89238 001	FEB 25, 1986
+		650MG;30MG	N89231 001	MAR 03, 1986
+		650MG;60MG	N89363 001	SEP 09, 1991
AA	MUTUAL PHARM	300MG;15MG	N89671 001	FEB 10, 1988
AA		300MG;30MG	N89672 001	FEB 10, 1988
AA		300MG;60MG	N89673 001	FEB 10, 1988
AA	PHARMERAL	300MG;30MG	N87762 001	DEC 10, 1982
AA	PUREPAC PHARM	300MG;30MG	N86681 001	
AA	TEVA	300MG;15MG	N88627 001	MAR 06, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	TEVA	300MG;30MG	N88628 001	MAR 06, 1985
AA		300MG;60MG	N88629 001	MAR 06, 1985
AA	VINTAGE PHARMS	300MG;15MG	N89990 001	SEP 30, 1988
AA		300MG;30MG	N89805 001	SEP 30, 1988
AA		300MG;60MG	N89828 001	SEP 30, 1988
AA	WATSON LABS	300MG;15MG	N89997 001	DEC 28, 1994
AA		300MG;30MG	N89998 001	DEC 28, 1994
AA		300MG;60MG	N89999 001	DEC 28, 1994
	ACETAMINOPHEN AND CODEINE PHOSPHATE #2			
AA	SUPERPHARM	300MG;15MG	N89183 001	OCT 18, 1985
	ACETAMINOPHEN W/ CODEINE NO. 3			
AA	ROXANE	300MG;30MG	N84656 001	
	ACETAMINOPHEN W/ CODEINE PHOSPHATE #3			
AA	IVAX PHARMS	300MG;30MG	N85868 001	
	TYLENOL W/ CODEINE NO. 1			
+	ORTHO MCNEIL PHARM	300MG;7.5MG	N85055 001	
	TYLENOL W/ CODEINE NO. 2			
AA +	ORTHO MCNEIL PHARM	300MG;15MG	N85055 002	
	TYLENOL W/ CODEINE NO. 3			
AA +	ORTHO MCNEIL PHARM	300MG;30MG	N85055 003	
	TYLENOL W/ CODEINE NO. 4			
AA +	ORTHO MCNEIL PHARM	300MG;60MG	N85055 004	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ACETAMINOPHEN AND HYDROCODONE BITARTRATE			
AA	CENT PHARMS	500MG;5MG	N88898 001	MAR 27, 1985
	ALLAY			
AA	IVAX PHARMS	500MG;5MG	N89907 001	JAN 13, 1989
	HYDROCET			
AA	MALLINCKRODT	500MG;5MG	N89006 001	AUG 09, 1985

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;5MG	N88956 001	JUL 19, 1985
AA	MIKART	500MG;5MG	N81067 001	NOV 30, 1989
AA		500MG;5MG	N81068 001	NOV 30, 1989
AA		500MG;5MG	N81069 001	NOV 30, 1989
AA		500MG;5MG	N81070 001	NOV 30, 1989
AA		500MG;5MG	N89008 001	FEB 21, 1986

LORCET-HD

AA +	MALLINCKRODT	500MG;5MG	N87336 001	JUL 08, 1982

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	KV PHARM	500MG/15ML;7.5MG/15ML	N40366 001	JAN 23, 2002
AA	MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001
AA +	MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992
		500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992
+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998

TABLET; ORAL

ANEXSIA

AA	MALLINCKRODT	500MG;5MG	N89160 001	APR 23, 1987

ANEXSIA 5/325

AA	MALLINCKRODT	325MG;5MG	N40409 001	OCT 20, 2000

ANEXSIA 7.5/325

AA	MALLINCKRODT	325MG;7.5MG	N40405 001	SEP 08, 2000

ANEXSIA 7.5/650

AA	MALLINCKRODT	650MG;7.5MG	N89725 001	SEP 30, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

CO-GESIC

AA	SCHWARZ PHARMA	500MG;5MG	N87757 001	MAY 03, 1982

HY-PHEN

AA	ASCHER	500MG;5MG	N87677 001	MAY 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ABLE	325MG;5MG	N40478 001	NOV 08, 2002
AA		325MG;7.5MG	N40464 001	OCT 23, 2002
AA		325MG;10MG	N40464 002	OCT 23, 2002
AA		500MG;5MG	N40477 001	NOV 06, 2002
AA		500MG;10MG	N40473 001	NOV 06, 2002
AA		650MG;10MG	N40476 001	OCT 23, 2002
AA		750MG;7.5MG	N40469 001	OCT 25, 2002
AA	BARR	500MG;2.5MG	N40307 001	JUL 26, 2000
AA		500MG;5MG	N40308 001	JUL 26, 2000
AA		500MG;7.5MG	N40307 002	JUL 26, 2000
AA		500MG;10MG	N40309 001	JUL 26, 2000
AA		650MG;7.5MG	N40307 003	JUL 26, 2000
AA		650MG;10MG	N40307 004	JUL 26, 2000
AA		750MG;7.5MG	N40308 002	JUL 26, 2000
AA	ENDO PHARMS	500MG;5MG	N40281 001	SEP 30, 1998
AA		500MG;7.5MG	N40280 001	SEP 30, 1998
AA		650MG;7.5MG	N40280 002	SEP 30, 1998
AA		650MG;10MG	N40280 003	SEP 30, 1998
AA		750MG;7.5MG	N40281 002	SEP 30, 1998

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
	+ ENDO PHARMS	400MG;5MG	N40288 001 NOV 27, 1998		
	+	400MG;7.5MG	N40288 002 NOV 27, 1998		
	+	400MG;10MG	N40288 003 NOV 27, 1998		
AA	EON	500MG;5MG	**N40149 001** JAN 27, 1997		
AA		750MG;7.5MG	**N40149 002** JAN 27, 1997		
AA	HALSEY	500MG;5MG	**N40236 001** SEP 25, 1997		
AA		650MG;7.5MG	**N40240 002** NOV 26, 1997		
AA		650MG;10MG	**N40240 001** NOV 26, 1997		
AA		750MG;7.5MG	**N40236 002** SEP 25, 1997		
AA	IVAX PHARMS	500MG;5MG	**N89696 001** APR 21, 1988		
AA	MALLINCKRODT	325MG;10MG	**N40400 001** JUL 26, 2000		
AA		500MG;5MG	**N40084 002** JUN 01, 1995		
AA		500MG;7.5MG	**N40201 001** FEB 27, 1998		
AA		500MG;10MG	**N40201 002** FEB 27, 1998		
AA		650MG;10MG	**N40084 004** OCT 16, 1996		
AA +		660MG;10MG	**N40084 003** JUL 29, 1996		
AA		750MG;7.5MG	**N40084 001** JUN 01, 1995		
AA		750MG;10MG	**N40468 001** OCT 31, 2002		
AA +	MIKART	500MG;2.5MG	**N89698 001** AUG 25, 1989		
AA		500MG;5MG	**N89271 001** JUL 16, 1986		
AA		500MG;5MG	**N89697 001** JAN 28, 1992		
AA +		500MG;7.5MG	**N89699 001** AUG 25, 1989		

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA +	MIKART	650MG;7.5MG	**N89689 001** JUN 29, 1988		
AA +		650MG;10MG	**N81223 001** MAY 29, 1992		
AA	UCB	500MG;10MG	**N40210 001** AUG 13, 1997		
AA		650MG;7.5MG	**N40134 001** NOV 21, 1996		
AA	VINTAGE PHARMS	325MG;10MG	**N40355 001** MAY 31, 2000		
AA		500MG;2.5MG	**N40144 002** APR 25, 1997		
AA		500MG;5MG	**N89831 001** SEP 07, 1988		
AA		500MG;5MG	**N89971 001** DEC 02, 1988		
AA		500MG;7.5MG	**N40144 001** FEB 22, 1996		
AA		500MG;10MG	**N40356 001** MAY 31, 2000		
AA		650MG;7.5MG	**N40155 001** APR 14, 1997		
AA		650MG;10MG	**N40143 001** FEB 22, 1996		
AA		660MG;10MG	**N40358 001** MAY 31, 2000		
AA		750MG;7.5MG	**N40157 001** APR 12, 1996		
AA	WATSON LABS	325MG;10MG	**N40248 002** APR 28, 2000		
AA		500MG;2.5MG	**N40123 003** MAR 04, 1996		
AA		500MG;2.5MG	**N81079 001** AUG 30, 1991		
AA		500MG;5MG	**N40122 001** MAR 04, 1996		
AA		500MG;5MG	**N89883 001** DEC 01, 1988		
AA		500MG;7.5MG	**N40123 004** MAR 04, 1996		
AA		500MG;7.5MG	**N81080 001** AUG 30, 1991		
AA		500MG;10MG	**N40148 002** FEB 14, 1997		

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
AA		WATSON LABS	650MG;7.5MG	N40094 001 SEP 29, 1995
AA			650MG;7.5MG	N40123 001 MAR 04, 1996
AA			650MG;10MG	N40094 002 SEP 29, 1995
AA			650MG;10MG	N40123 002 MAR 04, 1996
AA			660MG;10MG	N40094 003 AUG 08, 2000
AA			750MG;7.5MG	N40122 002 MAR 04, 1996
AA			750MG;7.5MG	N81083 001 AUG 30, 1991
AA	+		750MG;10MG	N40094 004 MAR 22, 1999
LORTAB				
AA		MALLINCKRODT	500MG;5MG	N87722 001 JUL 09, 1982
AA	+	UCB	500MG;10MG	N40100 001 JAN 26, 1996
NORCO				
AA	+	WATSON LABS	325MG;5MG	N40099 001 JUN 25, 1997
AA	+		325MG;7.5MG	N40148 003 SEP 12, 2000
AA	+		325MG;10MG	N40148 001 FEB 14, 1997
VICODIN				
AA	+	ABBOTT	500MG;5MG	N88058 001 JAN 07, 1983
VICODIN ES				
AA	+	ABBOTT	750MG;7.5MG	N89736 001 DEC 09, 1988
VICODIN HP				
AA		ABBOTT	660MG;10MG	N40117 001 SEP 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN				
AA		AMIDE PHARM	500MG;5MG	N40199 001 DEC 30, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN				
AA		BARR	500MG;5MG	N40304 001 OCT 02, 2000
AA		DURAMED PHARM BARR	500MG;5MG	N40289 001 MAR 16, 1999
AA		ENDO PHARMS	500MG;5MG	N40303 001 DEC 30, 1999
AA		HALSEY	500MG;5MG	N40219 001 JAN 22, 1998
AA		MALLINCKRODT	500MG;5MG	N40257 001 AUG 04, 1998
AA		VINTAGE PHARMS	500MG;5MG	N40106 001 JUL 30, 1996
AA		WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997
ROXILOX				
AA		ROXANE	500MG;5MG	N40061 001 JUL 03, 1995
TYLOX				
AA	+	ORTHO MCNEIL PHARM	500MG;5MG	N88790 001 DEC 12, 1984

SOLUTION; ORAL

ROXICET				
		ROXANE	325MG/5ML;5MG/5ML	N89351 001 DEC 03, 1986

TABLET; ORAL

OXYCET				
AA		MALLINCKRODT	325MG;5MG	N87463 001 DEC 07, 1983
OXYCODONE AND ACETAMINOPHEN				
AA		AMIDE PHARM	325MG;5MG	N40203 001 MAR 15, 1999
AA		BARR	325MG;5MG	N87406 001
AA		DURAMED PHARM BARR	325MG;5MG	N40272 001 JUN 30, 1998
AA		VINTAGE PHARMS	325MG;5MG	N40105 001 JUL 30, 1996
AA		WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997
AA			500MG;7.5MG	N40371 001 DEC 29, 2000
AA			650MG;10MG	N40371 002 DEC 29, 2000

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	PERCOCET			
AA	ENDO PHARMS	325MG;5MG	N40330 002	
			JUN 25, 1999	
AA	+	325MG;5MG	N85106 002	
AA	+	500MG;7.5MG	N40341 001	
			JUL 26, 1999	
AA	+	650MG;10MG	N40341 002	
			JUL 26, 1999	
	+	325MG;2.5MG	N40330 001	
			JUN 25, 1999	
	+	325MG;7.5MG	N40434 001	
			NOV 23, 2001	
	+	325MG;10MG	N40434 002	
			NOV 23, 2001	
	ROXICET			
AA	ROXANE	325MG;5MG	N87003 001	
	ROXICET 5/500			
	+ ROXANE	500MG;5MG	N89775 001	
			JAN 12, 1989	

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	ACETAMINOPHEN AND PENTAZOCINE HCL			
AB	AMIDE PHARM	650MG;EQ 25MG BASE	N76202 001	
			AUG 02, 2002	
	PENTAZOCINE HCL AND ACETAMINOPHEN			
AB	WATSON LABS	650MG;EQ 25MG BASE	N74699 001	
			MAR 24, 2000	
	TALACEN			
AB	+ SANOFI SYNTHELABO	650MG;EQ 25MG BASE	N18458 001	
			SEP 23, 1982	

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

	PROPOXYPHENE HCL AND ACETAMINOPHEN			
AA	GENEVA PHARMS	650MG;65MG	N89959 001	
			JUL 18, 1989	
AA	MYLAN	650MG;65MG	N83978 001	
AA	WATSON LABS	650MG;65MG	N40139 001	
			DEC 16, 1996	
	WYGESIC			
AA	+ WOMEN FIRST HLTHCARE	650MG;65MG	N84999 001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	DARVOCET-N 100			
AB	+ AAIPHARMA LLC	650MG;100MG	N17122 002	
	DARVOCET-N 50			
AB	AAIPHARMA LLC	325MG;50MG	N17122 001	
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
AB	ABLE	650MG;100MG	N75838 001	
			JUL 11, 2001	
AB	GENEVA PHARMS	650MG;100MG	N70443 001	
			JAN 23, 1986	
AB	HALSEY	650MG;100MG	N70615 001	
			MAR 21, 1986	
AB		650MG;100MG	N70771 001	
			MAR 21, 1986	
AB		650MG;100MG	N70775 001	
			MAR 21, 1986	
AB	IVAX PHARMS	650MG;100MG	N70146 001	
			AUG 02, 1985	
AB	MALLINCKRODT	650MG;100MG	N75738 001	
			FEB 02, 2001	
AB	MYLAN	650MG;100MG	N70145 001	
			JUN 12, 1985	
AB		650MG;100MG	N72195 001	
			FEB 16, 1988	
AB	PUREPAC PHARM	650MG;100MG	N70910 001	
			JAN 02, 1987	
AB	TEVA	650MG;100MG	N74119 001	
			DEC 19, 1994	
AB	VINTAGE PHARMS	325MG;50MG	N74843 002	
			FEB 15, 2001	
AB		650MG;100MG	N74843 001	
			FEB 12, 1997	

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

	ULTRACET		
	+ ORTHO MCNEIL PHARM	325MG;37.5MG	N21123 001
			AUG 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX		
	+ LEDERLE	500MG	N12945 003
			APR 25, 1995

FDA data supplied by DrugPatentWatch.com

ACETAZOLAMIDE

TABLET; ORAL

	ACETAZOLAMIDE			
AB	LANNETT	250MG	N84840 001	
AB	MUTUAL PHARM	125MG	N89752 001	JUN 22, 1988
AB		250MG	N89753 001	JUN 22, 1988
AB	TARO	125MG	N40195 001	MAY 28, 1997
AB		250MG	N40195 002	MAY 28, 1997
AB	WATSON LABS	250MG	N88882 001	OCT 22, 1985
	DIAMOX			
AB	LEDERLE	125MG	N08943 001	
AB	+	250MG	N08943 002	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM			
AP	ABBOTT	EQ 500MG BASE/VIAL	N40108 001	OCT 30, 1995
AP	BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995
	DIAMOX			
AP	+ LEDERLE	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

	ACETIC ACID 0.25% IN PLASTIC CONTAINER			
AT	ABBOTT	250MG/100ML	N17656 001	
AT	B BRAUN	250MG/100ML	N18161 001	
AT	BAXTER HLTHCARE	250MG/100ML	N18523 001	FEB 19, 1982

SOLUTION/DROPS; OTIC

	ACETASOL			
AT	ALPHARMA	2%	N87146 001	
	ACETIC ACID			
AT	MORTON GROVE	2%	N40166 001	JUL 26, 1996

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

	ACETIC ACID			
AT	TARO	2%	N88638 001	SEP 06, 1984
	VOSOL			
AT	+ WALLACE LABS	2%	N12179 001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE			
AT	BAUSCH AND LOMB	2%;0.79%	N40063 001	FEB 25, 1994
	DOMEBORO			
AT	+ BAYER	2%;0.79%	N84476 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

	ACETASOL HC			
AT	ALPHARMA	2%;1%	N87143 001	JAN 13, 1982
	HYDROCORTISONE AND ACETIC ACID			
AT	MORTON GROVE	2%;1%	N40168 001	AUG 30, 1996
AT	TARO	2%;1%	N88759 001	MAR 04, 1985
	VOSOL HC			
AT	+ WALLACE LABS	2%;1%	N12770 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

	NEO-CORT-DOME		
	+ BAYER	2%;1%;EQ 0.35% BASE	N50238 001

ACETOHEXAMIDE

TABLET; ORAL

	ACETOHEXAMIDE			
AB	BARR	250MG	N70869 001	FEB 09, 1987

FDA data supplied by DrugPatentWatch.com

ACETOHEXAMIDE

TABLET; ORAL

		ACETOHEXAMIDE		
AB	+ BARR	**500MG**	**N70870 001**	FEB 09, 1987
AB	WATSON LABS	**250MG**	**N71893 001**	NOV 25, 1987
AB		**500MG**	**N71894 001**	NOV 25, 1987

ACETOHYDROXAMIC ACID

TABLET; ORAL

	LITHOSTAT		
+	MISSION PHARMA	250MG	N18749 001 MAY 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

	MIOCHOL		
+	NOVARTIS	20MG/VIAL	N16211 001
	MIOCHOL-E		
+	NOVARTIS	20MG/VIAL	N20213 001 SEP 22, 1993

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

		ACETYLCYSTEINE		
AN	ABBOTT	**10%**	**N73664 001**	AUG 30, 1994
AN		**20%**	**N74037 001**	AUG 30, 1994
AN	BEDFORD	**10%**	**N72323 001**	APR 30, 1992
AN		**20%**	**N72324 001**	APR 30, 1992
AN	FAULDING	**10%**	**N71364 001**	MAY 01, 1989
AN		**10%**	**N71365 002**	JAN 18, 2002
AN		**20%**	**N71364 002**	JAN 15, 2002

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

		ACETYLCYSTEINE		
AN	FAULDING	**20%**	**N71365 001**	MAY 01, 1989
AN	LUITPOLD	**10%**	**N72489 001**	JUL 28, 1995
AN		**20%**	**N72547 001**	JUL 28, 1995
AN	ROXANE	**10%**	**N72621 001**	SEP 30, 1992
AN		**20%**	**N72622 001**	SEP 30, 1992
		MUCOMYST		
AN	+ APOTHECON	**10%**	**N13601 002**	
AN	+	**20%**	**N13601 001**	
		MUCOSIL-10		
AN	DEY	**10%**	**N70575 001**	OCT 14, 1986
		MUCOSIL-20		
AN	DEY	**20%**	**N70576 001**	OCT 14, 1986

ACITRETIN

CAPSULE; ORAL

	SORIATANE		
	HLR	10MG	N19821 001 OCT 28, 1996
+		25MG	N19821 002 OCT 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D		
+	CELLTECH PHARMS	8MG;60MG	N19806 001 MAR 25, 1994

ACYCLOVIR

CAPSULE; ORAL

		ACYCLOVIR		
AB	AESGEN	**200MG**	**N74833 001**	APR 22, 1997

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	APOTHECON	200MG	N74889 001	OCT 31, 1997
AB	COPLEY PHARM	200MG	N74914 001	NOV 26, 1997
AB	ESI LEDERLE	200MG	N74872 001	APR 22, 1997
AB	GENPHARM	200MG	N74977 001	APR 13, 1998
AB	IVAX PHARMS	200MG	N74674 001	APR 22, 1997
AB	MYLAN	200MG	N74727 001	APR 22, 1997
AB	PUREPAC PHARM	200MG	N74906 001	AUG 26, 1997
AB	RANBAXY	200MG	N74975 001	SEP 30, 1998
AB	STASON	200MG	N75090 001	JAN 26, 1999
AB	TEVA	200MG	N74578 001	APR 22, 1997
AB		200MG	N74828 001	APR 22, 1997
AB	WATSON LABS	200MG	N75101 001	APR 15, 1998
	ZOVIRAX			
AB	+ GLAXOSMITHKLINE	200MG	N18828 001	JAN 25, 1985

CREAM; TOPICAL

	ZOVIRAX			
	+ GLAXOSMITHKLINE	5%	N21478 001	DEC 30, 2002

OINTMENT; TOPICAL

	ZOVIRAX			
	+ GLAXOSMITHKLINE	5%	N18604 001	MAR 29, 1982

SUSPENSION; ORAL

	ACYCLOVIR			
AB	ALPHARMA	200MG/5ML	N74738 001	APR 28, 1997
	ZOVIRAX			
AB	+ GLAXOSMITHKLINE	200MG/5ML	N19909 001	DEC 22, 1989

ACYCLOVIR

TABLET; ORAL

	ACYCLOVIR			
AB	APOTHECON	400MG	N74891 001	OCT 31, 1997
AB		800MG	N74891 002	OCT 31, 1997
AB	CARLSBAD	400MG	N75382 001	APR 30, 1999
AB		800MG	N75382 002	APR 30, 1999
AB	COPLEY PHARM	400MG	N75021 001	MAR 18, 1998
AB		800MG	N75021 002	MAR 18, 1998
AB	ESI LEDERLE	400MG	N74834 001	APR 24, 1997
AB		800MG	N74834 002	APR 24, 1997
AB	GENPHARM	400MG	N74976 001	APR 13, 1998
AB		800MG	N74976 002	APR 13, 1998
AB	IVAX PHARMS	400MG	N74836 001	APR 22, 1997
AB		800MG	N74836 002	APR 22, 1997
AB	MYLAN	400MG	N75211 001	SEP 28, 1998
AB		800MG	N75211 002	SEP 28, 1998
AB	NEOSAN PHARMS	400MG	N74946 001	NOV 19, 1997
AB		800MG	N74946 002	NOV 19, 1997
AB	PUREPAC PHARM	400MG	N74870 001	JUN 05, 1997
AB		800MG	N74870 002	JUN 05, 1997
AB	RANBAXY	400MG	N74980 001	SEP 30, 1998
AB		800MG	N74980 002	SEP 30, 1998
AB	TEVA	400MG	N74556 002	APR 22, 1997
AB		800MG	N74556 003	APR 22, 1997

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR

TABLET; ORAL

ZOVIRAX

AB		GLAXOSMITHKLINE	**400MG**	**N20089 001** APR 30, 1991
AB	+		**800MG**	**N20089 002** APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP		ABBOTT	**EQ 50MG BASE/ML**	**N75114 001** JUL 26, 1999
AP		GENSIA SICOR PHARMS	**EQ 50MG BASE/ML**	**N75627 001** MAR 28, 2001
		ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE		
	+	ESI LEDERLE	EQ 500MG BASE/VIAL	N74885 001 DEC 19, 1997
			EQ 1GM BASE/VIAL	N74885 002 DEC 19, 1997

ACYCLOVIR SODIUM

AP		ABBOTT	**EQ 500MG BASE/VIAL**	**N74663 001** APR 22, 1997
AP			**EQ 500MG BASE/VIAL**	**N74758 001** APR 22, 1997
AP			**EQ 1GM BASE/VIAL**	**N74663 002** APR 22, 1997
AP			**EQ 1GM BASE/VIAL**	**N74758 002** APR 22, 1997
AP	+	AM PHARM PARTNERS	**EQ 50MG BASE/ML**	**N74930 001** MAY 13, 1998
AP			**EQ 500MG BASE/VIAL**	**N75015 001** APR 30, 1998
AP		BEDFORD	**EQ 500MG BASE/VIAL**	**N74596 002** APR 22, 1997
AP			**EQ 1GM BASE/VIAL**	**N74596 001** APR 22, 1997
AP		ESI LEDERLE	**EQ 500MG BASE/VIAL**	**N74913 001** OCT 15, 1997
AP			**EQ 1GM BASE/VIAL**	**N74913 002** OCT 15, 1997
	+	FAULDING	EQ 25MG BASE/ML	N74720 001 APR 22, 1997
AP		GENSIA SICOR PHARMS	**EQ 500MG BASE/VIAL**	**N74969 001** AUG 26, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP		GENSIA SICOR PHARMS	**EQ 1GM BASE/VIAL**	**N74969 002** AUG 26, 1997
AP		MERIDIAN MEDCL TECHN	**EQ 50MG BASE/ML**	**N75065 001** FEB 25, 1999

ZOVIRAX

AP	+	GLAXOSMITHKLINE	**EQ 500MG BASE/VIAL**	**N18603 001** OCT 22, 1982
AP	+		**EQ 1GM BASE/VIAL**	**N18603 002** JUN 29, 1989

ADAPALENE

CREAM; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N20748 001 MAY 26, 2000

GEL; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N20380 001 MAY 31, 1996

SOLUTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N20338 001 MAY 31, 1996

ADEFOVIR DIPIVOXIL

TABLET; ORAL

HEPSERA

+	GILEAD	10MG	N21449 001 SEP 20, 2002

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

+	FUJISAWA HLTHCARE	3MG/ML	N19937 002 OCT 30, 1989

ADENOSCAN

+	FUJISAWA HLTHCARE	3MG/ML	N20059 001 MAY 18, 1995

FDA data supplied by DrugPatentWatch.com

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION
TROVAN PRESERVATIVE FREE

	PFIZER	EQ 200MG BASE/VIAL	N20760 001	DEC 18, 1997
+		EQ 300MG BASE/VIAL	N20760 002	DEC 18, 1997

ALBENDAZOLE

TABLET; ORAL
ALBENZA

+	GLAXOSMITHKLINE	200MG	N20666 001	JUN 11, 1996

ALBUMIN HUMAN

INJECTABLE; INJECTION
OPTISON

+	MALLINCKRODT	10MG/ML	N20899 001	DEC 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

	MALLINCKRODT	10 uCi/ML	N17844 001	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION
MEGATOPE

	ISO TEX	0.5mCi/VIAL	N17837 001	
		1mCi/VIAL	N17837 002	

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	ARMSTRONG PHARMS	**0.09MG/INH**	**N72273 001**	AUG 14, 1996
AB	GENPHARM	**0.09MG/INH**	**N73045 001**	AUG 19, 1997

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	IVAX PHARMS	**0.09MG/INH**	**N73272 001**	DEC 28, 1995
AB	SIDMAK LABS	**0.09MG/INH**	**N74072 001**	AUG 01, 1996

PROVENTIL

BN	+ SCHERING	0.09MG/INH	N17559 001	

VENTOLIN

AB	+ GLAXOSMITHKLINE	**0.09MG/INH**	**N18473 001**	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA

BX	+ 3M	EQ 0.09MG BASE/INH	N20503 001	AUG 15, 1996

VENTOLIN HFA

BX	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001

SOLUTION; INHALATION
ACCUNEB

	+ DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001
	+	EQ 0.042% BASE	N20949 001	APR 30, 2001

ALBUTEROL SULFATE

AN	ALPHARMA	**EQ 0.083% BASE**	**N73533 001**	SEP 26, 1995
AN	BAUSCH AND LOMB	**EQ 0.083% BASE**	**N75358 001**	MAR 29, 2000
AN		**EQ 0.5% BASE**	**N75050 001**	JUN 18, 1998
AN	DEY	**EQ 0.083% BASE**	**N72652 001**	FEB 21, 1992
AN	HI TECH PHARMA	**EQ 0.083% BASE**	**N75063 001**	FEB 09, 1999
AN		**EQ 0.5% BASE**	**N74543 001**	JAN 15, 1998
AN	IVAX PHARMS	**EQ 0.083% BASE**	**N75343 001**	NOV 09, 1999
AN	MORTON GROVE	**EQ 0.083% BASE**	**N75394 001**	NOV 22, 1999
AN	NEPHRON	**EQ 0.083% BASE**	**N74880 001**	SEP 17, 1997

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE			
AN	NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001
AN	ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001
	PROVENTIL			
AN	+ SCHERING	EQ 0.083% BASE	N19243 002	JAN 14, 1987
AN	+	EQ 0.5% BASE	N19243 001	JAN 14, 1987

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	ALPHARMA	EQ 2MG BASE/5ML	N74454 001	SEP 25, 1995
AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001	JAN 30, 1998
AA	TEVA	EQ 2MG BASE/5ML	N73419 001	MAR 30, 1992
AA	UDL	EQ 2MG BASE/5ML	N75262 001	MAR 30, 1999
	PROVENTIL			
AA	+ SCHERING	EQ 2MG BASE/5ML	N18062 001	JAN 19, 1983

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	GENEVA PHARMS	EQ 2MG BASE	N72151 001	DEC 05, 1989
AB		EQ 4MG BASE	N72152 001	DEC 05, 1989
AB	LEDERLE	EQ 2MG BASE	N72859 001	DEC 20, 1989
AB		EQ 4MG BASE	N72860 001	DEC 20, 1989
AB	MUTUAL PHARM	EQ 2MG BASE	N72636 001	DEC 05, 1989
AB		EQ 4MG BASE	N72637 001	DEC 05, 1989
AB	MYLAN	EQ 2MG BASE	N72893 001	JAN 17, 1991
AB		EQ 4MG BASE	N72894 001	JAN 17, 1991
AB	SIDMAK LABS NJ	EQ 2MG BASE	N72316 001	DEC 05, 1989

ALBUTEROL SULFATE

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	SIDMAK LABS NJ	EQ 4MG BASE	N72317 001	DEC 05, 1989
AB	TEVA	EQ 2MG BASE	N72619 001	DEC 05, 1989
AB		EQ 2MG BASE	N72779 001	JUN 25, 1993
AB		EQ 2MG BASE	N72938 001	MAR 30, 1990
AB		EQ 4MG BASE	N72620 001	DEC 05, 1989
AB		EQ 4MG BASE	N72780 001	JUN 25, 1993
AB		EQ 4MG BASE	N72939 001	MAR 30, 1990
AB	WATSON LABS	EQ 2MG BASE	N72629 001	JAN 31, 1991
AB		EQ 2MG BASE	N72764 001	AUG 28, 1991
AB		EQ 4MG BASE	N72630 001	JAN 31, 1991
AB		EQ 4MG BASE	N72765 001	AUG 28, 1991
	PROVENTIL			
AB	SCHERING	EQ 2MG BASE	N17853 001	MAY 07, 1982
AB	+	EQ 4MG BASE	N17853 002	MAY 07, 1982

TABLET, EXTENDED RELEASE; ORAL

	ALBUTEROL SULFATE			
AB	SIDMAK LABS	EQ 4MG BASE	N76130 002	SEP 26, 2002
AB		EQ 8MG BASE	N76130 003	SEP 26, 2002
	PROVENTIL			
BC	SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987
	VOLMAX			
AB	+ MURO	EQ 4MG BASE	N19604 002	DEC 23, 1992
AB	+	EQ 8MG BASE	N19604 001	DEC 23, 1992

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
COMBIVENT
+ BOEHRINGER INGELHEIM — EQ 0.09MG BASE/INH; 0.018MG/INH — N20291 001 OCT 24, 1996

SOLUTION; INHALATION
DUONEB
+ DEY — EQ 0.083% BASE;0.017% — N20950 001 MAR 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL
ACLOVATE
+ GLAXOSMITHKLINE — 0.05% — N18707 001 DEC 14, 1982

OINTMENT; TOPICAL
ACLOVATE
+ GLAXOSMITHKLINE — 0.05% — N18702 001 DEC 14, 1982

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION
ALCOHOL 10% AND DEXTROSE 5%
+ B BRAUN — 10ML/100ML;5GM/100ML — N04589 006
ALCOHOL 5% AND DEXTROSE 5%
AP + B BRAUN — **5ML/100ML;5GM/100ML** — **N04589 004**
ALCOHOL 5% IN D5-W
AP ABBOTT — **5ML/100ML;5GM/100ML** — **N83263 001**

ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX
MERCK — EQ 5MG BASE — N20560 003 APR 25, 1997
EQ 10MG BASE — N20560 001 SEP 29, 1995
EQ 35MG BASE — N20560 004 OCT 20, 2000

ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX
MERCK — EQ 40MG BASE — N20560 002 SEP 29, 1995
+ — EQ 70MG BASE — N20560 005 OCT 20, 2000

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ALFENTA
AP + GD SEARLE LLC — **EQ 0.5MG BASE/ML** — **N19353 001** DEC 29, 1986
ALFENTANIL
AP ABBOTT — **EQ 0.5MG BASE/ML** — **N75221 001** OCT 28, 1999

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE
+ GENZYME — 80 UNITS/ML — N20057 003 APR 05, 1991

ALITRETINOIN

GEL; TOPICAL
PANRETIN
+ LIGAND — EQ 0.1% BASE — N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL
AB GENEVA PHARMS — **100MG** — **N70268 001** DEC 31, 1985
AB — **300MG** — **N70269 001** DEC 31, 1985
AB MUTUAL PHARM — **100MG** — **N71449 001** JAN 09, 1987
AB — **300MG** — **N71450 001** JAN 09, 1987

FDA data supplied by DrugPatentWatch.com

ALLOPURINOL

TABLET; ORAL

	ALLOPURINOL			
AB	MYLAN	100MG	**N18659 001**	OCT 24, 1986
AB		300MG	**N18659 002**	OCT 24, 1986
AB	PAR PHARM	100MG	**N70150 001**	DEC 10, 1985
AB		300MG	**N70147 001**	DEC 10, 1985
AB	SUPERPHARM	300MG	**N70951 001**	NOV 30, 1988
AB	WATSON LABS	100MG	**N18832 002**	SEP 28, 1984
AB		300MG	**N18877 001**	SEP 28, 1984
	LOPURIN			
AB	BASF	100MG	**N71586 001**	APR 02, 1987
AB		300MG	**N71587 001**	APR 02, 1987
	ZYLOPRIM			
AB	PROMETHEUS LABS	100MG	**N16084 001**	
AB +		300MG	**N16084 002**	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

	ALOPRIM		
+	DSM PHARMS	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

	AXERT		
	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001 MAY 07, 2001
+		EQ 12.5MG BASE	N21001 002 MAY 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

	LOTRONEX		
+	GLAXOSMITHKLINE	EQ 1MG BASE	N21107 001 FEB 09, 2000

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

	CERNEVIT-12		
+	BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL	N20924 001 APR 06, 1999

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

	INFUVITE ADULT		
+	SABEX 2002	2 IU/ML;20MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;80 UGM/ML;8MG/ML; 0.8MG/ML;0.72MG/ML;0.6MG/ML; 600 IU/ML	N21163 001 MAY 18, 2000

ALPRAZOLAM

CONCENTRATE; ORAL

	ALPRAZOLAM		
+	ROXANE	1MG/ML	N74312 001 OCT 31, 1993

TABLET; ORAL

	ALPRAZOLAM		
AB	ALPHAPHARM	0.25MG	**N74046 001** OCT 19, 1993
AB		0.5MG	**N74046 002** OCT 19, 1993

FDA data supplied by DrugPatentWatch.com

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ALPHAPHARM	1MG	**N74046 003** OCT 19, 1993
AB		2MG	**N74046 004** MAY 07, 1997
AB	GENEVA PHARMS	0.25MG	**N74112 001** DEC 29, 1995
AB		0.5MG	**N74112 002** DEC 29, 1995
AB		1MG	**N74112 003** DEC 29, 1995
AB		2MG	**N74909 001** MAR 25, 1998
AB	IVAX PHARMS	0.25MG	**N74294 001** JUL 29, 1994
AB		0.5MG	**N74294 002** JUL 29, 1994
AB		1MG	**N74294 003** JUL 29, 1994
AB		2MG	**N74294 004** JUL 29, 1994
AB	LEDERLE	0.25MG	**N74174 001** OCT 19, 1993
AB		0.5MG	**N74174 002** OCT 19, 1993
AB		1MG	**N74174 003** OCT 19, 1993
AB		2MG	**N74174 004** OCT 19, 1993
AB	MYLAN	0.25MG	**N74215 001** JAN 27, 1994
AB		0.5MG	**N74215 002** JAN 27, 1994
AB		1MG	**N74215 003** JAN 27, 1994
AB		2MG	**N74215 004** JAN 27, 1994
AB	PUREPAC PHARM	0.25MG	**N74342 001** OCT 31, 1993
AB		0.5MG	**N74342 002** OCT 31, 1993
AB		1MG	**N74342 003** OCT 31, 1993
AB		2MG	**N74342 004** OCT 31, 1993

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	TEVA	0.25MG	**N74085 001** FEB 16, 1994
AB		0.5MG	**N74085 002** FEB 16, 1994
AB		1MG	**N74085 003** FEB 16, 1994
AB		2MG	**N74085 004** FEB 26, 1996
AB	WATSON LABS	0.25MG	**N74456 001** AUG 31, 1995
AB		0.25MG	**N74479 001** JAN 21, 1997
AB		0.5MG	**N74456 002** AUG 31, 1995
AB		0.5MG	**N74479 002** JAN 21, 1997
AB		1MG	**N74456 003** AUG 31, 1995
AB		1MG	**N74479 003** JAN 21, 1997

XANAX

AB	PHARMACIA AND UPJOHN	0.25MG	**N18276 001**
AB		0.5MG	**N18276 002**
AB	+	1MG	**N18276 003**
AB		2MG	**N18276 004** NOV 27, 1985

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	BEDFORD	0.5MG/ML	**N74815 001** JAN 20, 1998
AP	GENSIA SICOR PHARMS	0.5MG/ML	**N75196 001** APR 30, 1999

CAVERJECT

AP	PHARMACIA AND UPJOHN	0.01MG/VIAL	**N20379 001** JUL 06, 1995
AP		0.02MG/VIAL	**N20379 002** JUL 06, 1995
AP	+	0.04MG/VIAL	**N20379 004** MAY 19, 1997
		0.005MG/VIAL	N20379 003 JUN 27, 1996

FDA data supplied by DrugPatentWatch.com

ALPROSTADIL

INJECTABLE; INJECTION

	CAVERJECT				
	PHARMACIA AND UPJOHN	0.01MG/ML	N20755 002 OCT 01, 1997		
		0.01MG/VIAL	N21212 001 JUN 11, 2002		
+		0.02MG/ML	N20755 003 OCT 01, 1997		
		0.02MG/VIAL	N21212 002 JUN 11, 2002		
	EDEX				
AP	SCHWARZ PHARMA	**0.01MG/VIAL**	**N20649 002** JUN 12, 1997		
AP		**0.02MG/VIAL**	**N20649 003** JUN 12, 1997		
AP +		**0.04MG/VIAL**	**N20649 004** JUN 12, 1997		
+		0.01MG/VIAL	N20649 005 JUL 30, 1998		
+		0.02MG/VIAL	N20649 006 JUL 30, 1998		
+		0.04MG/VIAL	N20649 007 JUL 30, 1998		
	PROSTIN VR PEDIATRIC				
AP +	PHARMACIA AND UPJOHN	**0.5MG/ML**	**N18484 001**		

SUPPOSITORY; URETHRAL

MUSE			
	VIVUS	0.125MG	N20700 001 NOV 19, 1996
		0.25MG	N20700 002 NOV 19, 1996
		0.5MG	N20700 003 NOV 19, 1996
+		1MG	N20700 004 NOV 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN			
+	MGI PHARMA INC	50MG	N19926 001 DEC 26, 1990

ALUMINUM ACETATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; ALUMINUM ACETATE

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

	AMANTADINE HCL				
AB	GENEVA PHARMS TECH	**100MG**	**N71293 001** FEB 18, 1987		
AB +	USL PHARMA	**100MG**	**N70589 001** AUG 05, 1986		

SYRUP; ORAL

	AMANTADINE HCL				
AA	ALPHARMA	**50MG/5ML**	**N72655 001** OCT 30, 1990		
AA	CAROLINA MEDCL	**50MG/5ML**	**N75819 001** SEP 11, 2002		
AA	COPLEY PHARM	**50MG/5ML**	**N73115 001** AUG 23, 1991		
AA	HI TECH PHARMA	**50MG/5ML**	**N74170 001** OCT 28, 1994		
AA	MIKART	**50MG/5ML**	**N74028 001** JUN 28, 1993		
AA	MORTON GROVE	**50MG/5ML**	**N75060 001** DEC 24, 1998		
AA	PHARM ASSOC	**50MG/5ML**	**N74509 001** JUL 17, 1995		
	SYMMETREL				
AA +	ENDO PHARMS	**50MG/5ML**	**N16023 002**		

TABLET; ORAL

	AMANTADINE HCL				
AB	USL PHARMA	**100MG**	**N76186 001** DEC 16, 2002		
	SYMMETREL				
AB +	ENDO PHARMS	**100MG**	**N18101 001**		

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE			
+	SANOFI SYNTHELABO	10MG	N10155 002

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT			
+	FUJISAWA HLTHCARE	0.1%	N18116 002

FDA data supplied by DrugPatentWatch.com

AMCINONIDE

LOTION; TOPICAL

	AMCINONIDE			
AB	ALTANA	0.1%	**N76329 001**	NOV 06, 2002
	CYCLOCORT			
AB	+ FUJISAWA HLTHCARE	0.1%	**N19729 001**	JUN 13, 1988

OINTMENT; TOPICAL

	AMCINONIDE			
AB	ALTANA	0.1%	**N76096 001**	NOV 19, 2002
	CYCLOCORT			
AB	+ FUJISAWA HLTHCARE	0.1%	**N18498 001**	

AMIFOSTINE

INJECTABLE; INJECTION

	ETHYOL			
	+ MEDIMMUNE ONCOLOGY	500MG/VIAL	N20221 001	DEC 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE			
AP	ABBOTT	EQ 50MG BASE/ML	**N63263 001**	NOV 30, 1994
AP		EQ 250MG BASE/ML	**N63264 001**	NOV 30, 1994
AP		EQ 250MG BASE/ML	**N64098 001**	JUN 26, 1995
		EQ 62.5MG BASE/ML	N63283 001	OCT 31, 1994
AP	BEDFORD	EQ 50MG BASE/ML	**N63313 001**	APR 11, 1994
AP		EQ 250MG BASE/ML	**N63315 001**	APR 11, 1994
AP	FAULDING	EQ 50MG BASE/ML	**N63350 001**	JUL 30, 1993
AP		EQ 250MG BASE/ML	**N63350 002**	JUL 30, 1993
AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	**N64045 001**	SEP 28, 1993

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE			
AP	GENSIA SICOR PHARMS	EQ 250MG BASE/ML	**N64045 002**	SEP 28, 1993
	AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	ABBOTT	EQ 500MG BASE/100ML	N64146 001	APR 02, 1997
	AMIKIN			
AP	+ APOTHECON	EQ 50MG BASE/ML	**N62311 001**	
AP	+	EQ 250MG BASE/ML	**N62311 002**	

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

	AMILORIDE HCL			
AB	PAR PHARM	5MG	**N70346 001**	JAN 22, 1986
	MIDAMOR			
AB	+ MERCK	5MG	**N18200 001**	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	AMILORIDE HCL AND HYDROCHLOROTHIAZIDE			
AB	BARR	EQ 5MG ANHYDROUS;50MG	**N71111 001**	MAY 10, 1988
AB	GENEVA PHARMS	EQ 5MG ANHYDROUS;50MG	**N73357 001**	NOV 27, 1991
AB	MYLAN	EQ 5MG ANHYDROUS;50MG	**N73209 001**	OCT 31, 1991
AB	TEVA	EQ 5MG ANHYDROUS;50MG	**N70795 001**	APR 17, 1988
AB	WATSON LABS	EQ 5MG ANHYDROUS;50MG	**N73334 001**	JUL 19, 1991
	HYDRO-RIDE			
AB	PAR PHARM	EQ 5MG ANHYDROUS;50MG	**N70347 001**	DEC 25, 1990
	MODURETIC 5-50			
AB	+ MERCK	EQ 5MG ANHYDROUS;50MG	**N18201 001**	

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE			
FRESENIUS KABI	5.2% (5.2GM/100ML)	N18901 001	APR 06, 1984
AMINOSYN 10%			
ABBOTT	10% (10GM/100ML)	N17673 003	
AMINOSYN 10% (PH6)			
ABBOTT	10% (10GM/100ML)	N17673 008	NOV 18, 1985
AMINOSYN 3.5%			
ABBOTT	3.5% (3.5GM/100ML)	N17789 004	
AMINOSYN 5%			
ABBOTT	5% (5GM/100ML)	N17673 001	
AMINOSYN 7% (PH6)			
ABBOTT	7% (7GM/100ML)	N17673 006	NOV 18, 1985
AMINOSYN 8.5% (PH6)			
ABBOTT	8.5% (8.5GM/100ML)	N17673 007	NOV 18, 1985
AMINOSYN II 10%			
ABBOTT	10% (10GM/100ML)	N19438 005	APR 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
ABBOTT	10% (10GM/100ML)	N20015 001	DEC 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
ABBOTT	15% (15GM/100ML)	N20041 001	DEC 19, 1991
AMINOSYN II 7%			
ABBOTT	7% (7GM/100ML)	N19438 003	APR 03, 1986
AMINOSYN II 8.5%			
ABBOTT	8.5% (8.5GM/100ML)	N19438 004	APR 03, 1986
AMINOSYN-HBC 7%			
ABBOTT	7% (7GM/100ML)	N19374 001	JUL 12, 1985
AMINOSYN-HF 8%			
ABBOTT	8% (8GM/100ML)	N20345 001	APR 04, 1996
AMINOSYN-PF 10%			
ABBOTT	10% (10GM/100ML)	N19492 002	OCT 17, 1986
AMINOSYN-PF 7%			
ABBOTT	7% (7GM/100ML)	N19398 001	SEP 06, 1985
AMINOSYN-RF 5.2%			
ABBOTT	5.2% (5.2GM/100ML)	N18429 001	

AMINO ACIDS

INJECTABLE; INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4% (4GM/100ML)	N18684 001	SEP 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
CLINTEC NUTR	15% (15GM/100ML)	N20512 001	AUG 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N16822 006	MAY 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N16822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N16822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N18676 001	AUG 03, 1982
HEPATASOL 8%			
BAXTER HLTHCARE	8% (8GM/100ML)	N20360 001	APR 04, 1996
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N17766 001	
NOVAMINE 11.4%			
FRESENIUS KABI	11.4% (11.4GM/100ML)	N17957 003	AUG 09, 1982
NOVAMINE 15%			
FRESENIUS KABI	15% (15GM/100ML)	N17957 004	NOV 28, 1986
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20% (20GM/100ML)	N20849 001	AUG 26, 1998
RENAMIN W/O ELECTROLYTES			
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N17493 007	OCT 15, 1982
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10MG/100ML)	N18931 003	AUG 23, 1984
TRAVASOL 10% W/O ELECTROLYTES			
BAXTER HLTHCARE	10% (10GM/100ML)	N17493 006	
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N18931 001	AUG 23, 1984
TRAVASOL 5.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N17493 004	
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N18931 002	AUG 23, 1984

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE; INJECTION
TRAVASOL 8.5% W/O ELECTROLYTES
BAXTER HLTHCARE 8.5% (8.5GM/100ML) N17493 005
TROPHAMINE
\+ B BRAUN 6% (6GM/100ML) N19018 001
JUL 20, 1984
TROPHAMINE 10%
\+ B BRAUN 10% (10GM/100ML) N19018 003
SEP 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
PROCALAMINE
B BRAUN 3%;26MG/100ML;3GM/100ML;54MG/100ML;
41MG/100ML;150MG/100ML;200MG/100ML;
120MG/100ML N18582 001
MAY 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 3.5%;36.8MG/100ML;25GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML N19683 001
NOV 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 4.25%;36.8MG/100ML;20GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML N19683 002
NOV 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 4.25%;36.8MG/100ML;25GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML N19683 003
NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML;
51MG/100ML;261MG/100ML;217MG/100ML;
112MG/100ML N20678 002
MAR 26, 1997
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML;
51MG/100ML;261MG/100ML;217MG/100ML;
112MG/100ML N20678 005
MAR 26, 1997
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML;
51MG/100ML;261MG/100ML;217MG/100ML;
112MG/100ML N20678 001
MAR 26, 1997
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 009
MAR 26, 1997
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 011
MAR 26, 1997
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 012
MAR 26, 1997
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 008
MAR 26, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 019 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 021 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML N19681 001 NOV 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML N19681 002 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;10GM/100ML N19681 004 NOV 01, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
ABBOTT 4.25%;20GM/100ML N19681 005 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 4.25%;25GM/100ML N19681 003 NOV 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 5%;25GM/100ML N19681 006 NOV 01, 1988

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML N20734 002 SEP 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N20734 005 SEP 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N20734 001 SEP 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008 SEP 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010 SEP 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011 SEP 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007 SEP 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;10GM/100ML N20734 014 SEP 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;15GM/100ML N20734 015 SEP 29, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;20GM/100ML N20734 016 SEP 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;25GM/100ML N20734 017 SEP 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;35GM/100ML N20734 018 SEP 29, 1997

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML N19520 002 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML N19520 003 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML N19520 004 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N19520 005 SEP 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N19520 001 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N19520 007 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML N19520 008 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N19520 009 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N19520 010 SEP 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N19520 006 SEP 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 001 NOV 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 002 NOV 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 002 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 003 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 004 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 005 OCT 23, 1995

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML N20147 001 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 007 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 008 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 009 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 010 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 006 OCT 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
FREAMINE III 8.5% W/ ELECTROLYTES
B BRAUN 8.5%;110MG/100ML;230MG/100ML; 10MG/100ML;440MG/100ML; 690MG/100ML N16822 007 JUL 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 3.5% M
ABBOTT 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML N17789 003

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
FREAMINE III 3% W/ ELECTROLYTES
B BRAUN 3%;54MG/100ML;40MG/100ML; 150MG/100ML;200MG/100ML; 120MG/100ML N16822 003

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 10% W/ ELECTROLYTES
ABBOTT 10%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 004 APR 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 005 APR 03, 1986

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N20177 001 OCT 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N17493 003

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N20173 001 OCT 27, 1995

TRAVASOL 5.5% W/ ELECTROLYTES
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N17493 001

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N20173 002 OCT 27, 1995

TRAVASOL 8.5% W/ ELECTROLYTES
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N17493 002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES
ABBOTT 7%;102MG/100ML;522MG/100ML; 410MG/100ML N17789 002

AMINOSYN 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;522MG/100ML; 410MG/100ML N17673 005

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR
AP + XANODYNE PHARM **250MG/ML** **N15229 002**

AMINOCAPROIC ACID
AP ABBOTT **250MG/ML** **N70888 001** JUN 16, 1988

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID
AP + ELKINS SINN **250MG/ML** **N18590 001** OCT 29, 1982

AP LUITPOLD **250MG/ML** **N71192 001** DEC 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER
AP ABBOTT **250MG/ML** **N70010 001** MAR 09, 1987

SYRUP; ORAL

AMICAR
AA + XANODYNE PHARM **1.25GM/5ML** **N15230 002**

AMINOCAPROIC ACID
AA MIKART **1.25GM/5ML** **N74759 001** SEP 02, 1998

TABLET; ORAL

AMICAR
AB + XANODYNE PHARM **500MG** **N15197 001**

AMINOCAPROIC
AB MIKART **500MG** **N75602 001** MAY 24, 2001

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN
+ NOVARTIS 250MG N18202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM
+ MERCK 20% N05619 001

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN
+ DUSA 20% N20965 001 DEC 03, 1999

FDA data supplied by DrugPatentWatch.com

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP		ABBOTT	25MG/ML	**N87242 001** OCT 26, 1983
AP			25MG/ML	**N87601 001** JUL 23, 1982
AP	+	ELKINS SINN	25MG/ML	**N87239 001**
AP		GENSIA SICOR PHARMS	25MG/ML	**N81142 001** SEP 25, 1991
AP		INTL MEDICATION	25MG/ML	**N87209 001** FEB 01, 1982
AP		LUITPOLD	25MG/ML	**N87240 001**
AP			25MG/ML	**N87600 001**
AP		PHARMA SERVE NY	25MG/ML	**N87392 001** DEC 15, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

	+	ABBOTT	100MG/100ML	N88147 002 MAY 03, 1983
	+		200MG/100ML	N88147 003 MAY 03, 1983

SOLUTION; ORAL

AMINOPHYLLINE

AA	+	ROXANE	105MG/5ML	**N88126 001** AUG 19, 1983

AMINOPHYLLINE DYE FREE

AA	+	ALPHARMA	105MG/5ML	**N87727 001** APR 16, 1982

SUPPOSITORY; RECTAL

TRUPHYLLINE

		G AND W LABS	250MG	N85498 001 MAR 23, 1983
	+		500MG	N85498 002 JAN 03, 1983

TABLET; ORAL

AMINOPHYLLINE

AB		GENEVA PHARMS	100MG	**N85262 002**
AB			200MG	**N85261 002**
AB	+	ROXANE	100MG	**N87500 001** FEB 09, 1982
AB	+		200MG	**N87501 001** FEB 09, 1982
AB		WEST WARD	100MG	**N84540 001**
AB			200MG	**N85003 001**

AMINOSALICYLATE SODIUM

TABLET; ORAL

SODIUM P.A.S.

	+	LANNETT	500MG	N80138 002

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

	+	JACOBUS	4GM/PACKET	N74346 001 JUN 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP		ABBOTT	50MG/ML	**N75955 001** OCT 18, 2002
AP		AM PHARM PARTNERS	50MG/ML	**N75761 001** OCT 15, 2002
AP		BEDFORD	50MG/ML	**N76018 001** OCT 15, 2002
AP		BEDFORD LABS	50MG/ML	**N76299 001** OCT 24, 2002
AP		BEN VENUE	50MG/ML	**N76088 001** OCT 15, 2002
AP		BIONICHE (CANADA)	50MG/ML	**N76217 001** OCT 15, 2002
AP		FAULDING	50MG/ML	**N76108 001** OCT 15, 2002

CORDARONE

AP	+	WYETH AYERST	50MG/ML	**N20377 001** AUG 03, 1995

TABLET; ORAL

AMIODARONE HCL

AB		ALPHAPHARM	200MG	**N75188 001** FEB 24, 1999
AB		BARR	200MG	**N75389 001** JAN 25, 2001
AB		COPLEY PHARM	200MG	**N74739 001** NOV 30, 1998
AB		EON	200MG	**N75315 001** DEC 23, 1998
AB	+		400MG	**N75315 002** JUN 30, 2000

FDA data supplied by DrugPatentWatch.com

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

AB	TARO	200MG	N75424 001 MAR 30, 2001
AB		400MG	N76362 001 NOV 29, 2002
+		100MG	N75424 002 DEC 18, 2002
AB	TEVA	200MG	N74895 001 APR 16, 1999

CORDARONE

AB	WYETH AYERST	200MG	N18972 001 DEC 24, 1985

PACERONE

AB	UPSHER SMITH	200MG	N75135 001 APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

+	ROCHE	40MG/ML	N85749 001

INJECTABLE; INJECTION

ELAVIL

+	ASTRAZENECA	10MG/ML	N12704 001

TABLET; ORAL

AMITRIPTYLINE HCL

AB	GENEVA PHARMS	10MG	N85969 001
AB		25MG	N85966 001
AB		50MG	N85968 001
AB		75MG	N85971 001
AB		100MG	N85967 001
AB		150MG	N85970 001
AB	MUTUAL PHARM	10MG	N89398 001 JUL 14, 1987
AB		25MG	N89399 001 JUL 14, 1987
AB		50MG	N89400 001 JUL 14, 1987
AB		75MG	N89401 001 JUL 14, 1987
AB		100MG	N89402 001 JUL 14, 1987

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

AB	MUTUAL PHARM	150MG	N89403 001 JUL 14, 1987
AB	MYLAN	10MG	N86157 001
AB		25MG	N86010 001
AB		50MG	N86009 001
AB		75MG	N86011 001
AB		100MG	N86158 001
AB		150MG	N86153 001
AB	SIDMAK LABS NJ	10MG	N88883 001 SEP 26, 1984
AB		25MG	N88884 001 SEP 26, 1984
AB		50MG	N88885 001 SEP 26, 1984
AB		75MG	N88886 001 SEP 26, 1984
AB		100MG	N88887 001 SEP 26, 1984
AB		150MG	N88888 001 SEP 26, 1984
AB	SUPERPHARM	10MG	N88853 001 NOV 13, 1984
AB		25MG	N88854 001 NOV 13, 1984
AB		50MG	N88855 001 NOV 13, 1984
AB		75MG	N88856 001 NOV 13, 1984
AB		100MG	N88857 001 NOV 13, 1984
AB	TEVA	10MG	N84910 003
AB		25MG	N85031 001
AB		50MG	N85032 001
AB		100MG	N85836 001

AMITRIPTYLINE HYDROCHLORIDE

AB	VINTAGE PHARMS	10MG	N40218 001 SEP 11, 1997
AB		25MG	N40218 002 SEP 11, 1997
AB		50MG	N40218 003 SEP 11, 1997
AB		75MG	N40218 004 SEP 11, 1997
AB		100MG	N40218 005 SEP 11, 1997

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIPTYLINE HYDROCHLORIDE			
AB	VINTAGE PHARMS	150MG	N40218 006	SEP 11, 1997
	ELAVIL			
AB	ASTRAZENECA	10MG	N12703 001	
AB	+	25MG	N12703 003	
AB		50MG	N12703 004	
AB		75MG	N12703 005	
AB		100MG	N12703 006	
AB		150MG	N12703 007	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

	CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL			
AB	MYLAN	EQ 12.5MG BASE;5MG	N71296 001	DEC 10, 1986
AB		EQ 25MG BASE;10MG	N71297 001	DEC 10, 1986
AB	PAR PHARM	EQ 12.5MG BASE;5MG	N72277 001	MAY 09, 1988
AB		EQ 25MG BASE;10MG	N72278 001	MAY 09, 1988
AB	WATSON LABS	EQ 12.5MG BASE;5MG	N72052 001	DEC 16, 1988
AB		EQ 25MG BASE;10MG	N72053 001	DEC 16, 1988
	LIMBITROL			
AB	ICN	EQ 12.5MG BASE;5MG	N16949 001	
	LIMBITROL DS			
AB	+ ICN	EQ 25MG BASE;10MG	N16949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	ETRAFON 2-10			
BP	SCHERING	10MG;2MG	N14713 007	
	ETRAFON 2-25			
BP	SCHERING	25MG;2MG	N14713 004	
	ETRAFON-FORTE			
BP	SCHERING	25MG;4MG	N14713 006	
	PERPHENAZINE AND AMITRIPTYLINE HCL			
AB	GENEVA PHARMS	10MG;2MG	N71062 001	NOV 27, 1987

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE AND AMITRIPTYLINE HCL			
AB	GENEVA PHARMS	10MG;4MG	N71862 001	DEC 21, 1987
AB		25MG;2MG	N71063 001	NOV 27, 1987
AB		25MG;4MG	N71064 001	NOV 27, 1987
AB		50MG;4MG	N71863 001	DEC 21, 1987
AB	MYLAN	10MG;2MG	N70336 001	NOV 10, 1988
AB		10MG;4MG	N71442 001	NOV 10, 1988
AB		25MG;2MG	N70337 001	NOV 10, 1988
AB	+	25MG;4MG	N70338 001	NOV 10, 1988
AB	+	50MG;4MG	N71443 001	NOV 10, 1988
AB	WATSON LABS	10MG;2MG	N73007 001	OCT 17, 1991
AB		10MG;4MG	N73009 001	OCT 17, 1991
AB		25MG;2MG	N73008 001	OCT 17, 1991
AB		25MG;4MG	N73010 001	OCT 17, 1991

AMLEXANOX

PASTE; DENTAL

	APHTHASOL		
	+ GLAXOSMITHKLINE CONS	5%	N20511 001 DEC 17, 1996

AMLODIPINE BESYLATE

TABLET; ORAL

	NORVASC		
	PFIZER	EQ 2.5MG BASE	N19787 001 JUL 31, 1992
		EQ 5MG BASE	N19787 002 JUL 31, 1992

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE

TABLET; ORAL

NORVASC					
+ PFIZER	EQ 10MG BASE	N19787 003 JUL 31, 1992			

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL					
NOVARTIS	EQ 2.5MG BASE;10MG	N20364 002 MAR 03, 1995			
	EQ 5MG BASE;10MG	N20364 003 MAR 03, 1995			
	EQ 5MG BASE;20MG	N20364 004 MAR 03, 1995			
+	EQ 10MG BASE;20MG	N20364 005 JUN 20, 2002			

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER					
+ ABBOTT	5MEQ/ML	N88366 001 JUN 13, 1984			

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE					
AB CLAY PARK	**EQ 12% BASE**	**N75774 001** MAY 01, 2002			
LAC-HYDRIN					
AB + WESTWOOD SQUIBB	**EQ 12% BASE**	**N20508 001** AUG 29, 1996			

LOTION; TOPICAL

AMMONIUM LACTATE					
AB PADDOCK	**EQ 12% BASE**	**N75575 001** JUN 11, 2002			
LAC-HYDRIN					
AB + WESTWOOD SQUIBB	**EQ 12% BASE**	**N19155 001** APR 24, 1985			

AMOXAPINE

TABLET; ORAL

AMOXAPINE					
	GENEVA PHARMS	**25MG**			**N72943 001** JUN 28, 1991
		50MG			**N72944 001** JUN 28, 1991
		100MG			**N72878 001** JUN 28, 1991
		150MG			**N72879 001** JUN 28, 1991
	WATSON LABS	**25MG**			**N72418 001** MAY 11, 1989
		25MG			**N72688 001** AUG 28, 1992
		50MG			**N72419 001** MAY 11, 1989
		50MG			**N72689 001** AUG 28, 1992
		100MG			**N72420 001** MAY 11, 1989
		100MG			**N72690 001** AUG 28, 1992
+		**150MG**			**N72421 001** MAY 11, 1989
		150MG			**N72691 001** AUG 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN					
	BIOCHEMIE	**250MG**			**N64076 001** SEP 30, 1994
		500MG			**N64076 002** SEP 30, 1994
	CLONMEL	**250MG**			**N62884 001** FEB 25, 1988
		500MG			**N62881 001** FEB 25, 1988
	CONSOLIDATED PHARM	**250MG**			**N62058 001**
		500MG			**N62058 002**
	RANBAXY	**250MG**			**N65016 001** APR 08, 1999
		500MG			**N65016 002** APR 08, 1999
	TEVA	**250MG**			**N61926 001**

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	TEVA	250MG	N62853 001	
			DEC 22, 1987	
AB		500MG	N61926 003	
AB		500MG	N62854 001	
			DEC 22, 1987	
	AMOXIL			
AB	GLAXOSMITHKLINE	250MG	N62216 001	
AB	+	500MG	N62216 004	
	TRIMOX			
AB	APOTHECON	250MG	N61885 001	
AB		500MG	N61885 002	

FOR SUSPENSION; ORAL

	AMOXICILLIN			
AB	CLONMEL	125MG/5ML	N62927 001	
			NOV 25, 1988	
AB		250MG/5ML	N62927 002	
			NOV 25, 1988	
AB	CONSOLIDATED PHARM	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	
AB	RANBAXY	200MG/5ML	N65113 001	
			NOV 29, 2002	
AB		400MG/5ML	N65113 002	
			NOV 29, 2002	
AB	TEVA	125MG/5ML	N61931 001	
AB		125MG/5ML	N62946 001	
			NOV 01, 1988	
AB		200MG/5ML	N65119 001	
			DEC 04, 2002	
AB		250MG/5ML	N61931 002	
AB		250MG/5ML	N63001 001	
			JAN 06, 1989	
AB		400MG/5ML	N65119 002	
			DEC 04, 2002	
	AMOXICILLIN PEDIATRIC			
AB	TEVA	50MG/ML	N61931 003	
			DEC 01, 1982	
	AMOXIL			
AB	GLAXOSMITHKLINE	125MG/5ML	N62226 001	
AB		200MG/5ML	N50760 001	
			APR 15, 1999	
AB	+	250MG/5ML	N62226 002	
AB	+	50MG/ML	N62226 005	
AB	+	400MG/5ML	N50760 002	
			APR 15, 1999	

AMOXICILLIN

FOR SUSPENSION; ORAL

	LAROTID			
AB	GLAXOSMITHKLINE	125MG/5ML	N62226 003	
AB		250MG/5ML	N62226 004	
	TRIMOX			
AB	APOTHECON	125MG/5ML	N62885 001	
			MAR 08, 1988	
AB		250MG/5ML	N62885 002	
			MAR 08, 1988	
	WYMOX			
AB	WYETH AYERST	125MG/5ML	N62131 001	
AB		250MG/5ML	N62131 002	

TABLET; ORAL

	AMOXICILLIN			
AB	RANBAXY	500MG	N65059 001	
			NOV 24, 2000	
AB		875MG	N65059 002	
			NOV 24, 2000	
AB	TEVA	500MG	N65056 001	
			SEP 18, 2000	
AB		875MG	N65056 002	
			SEP 18, 2000	
	AMOXIL			
AB	GLAXOSMITHKLINE	500MG	N50754 002	
			JUL 10, 1998	
AB	+	875MG	N50754 001	
			JUL 10, 1998	

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	CLONMEL	125MG	N64139 001	
			JAN 29, 1996	
AB		250MG	N64139 002	
			JAN 29, 1996	
AB	RANBAXY	125MG	N65021 001	
			DEC 23, 1999	
AB		200MG	N65060 001	
			NOV 29, 2000	
AB		250MG	N65021 002	
			DEC 23, 1999	
AB		400MG	N65060 002	
			NOV 29, 2000	
AB	TEVA	125MG	N64013 002	
			SEP 11, 1995	
AB		125MG	N64031 001	
			DEC 19, 1996	

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	TEVA	250MG	**N64013 001**	DEC 22, 1992
AB		250MG	**N64031 002**	DEC 19, 1996
	AMOXIL			
AB	GLAXOSMITHKLINE	125MG	**N50542 002**	
AB		200MG	**N50761 001**	APR 15, 1999
AB		250MG	**N50542 001**	
AB	+	400MG	**N50761 002**	APR 15, 1999

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL

	PREVPAC			
+	TAP PHARM	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A, 30MG	N50757 001	DEC 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	GENEVA PHARMS	200MG/5ML; EQ 28.5MG BASE/5ML	**N65066 001**	JUN 05, 2002
AB		400MG/5ML; EQ 57MG BASE/5ML	**N65066 002**	JUN 05, 2002
AB	LEK SVCS	200MG/5ML; EQ 28.5MG BASE/5ML	**N65098 001**	DEC 16, 2002
AB		400MG/5ML; EQ 57MG BASE/5ML	**N65098 002**	DEC 16, 2002
	AUGMENTIN '125'			
	GLAXOSMITHKLINE	125MG/5ML; EQ 31.25MG BASE/5ML	N50575 001	AUG 06, 1984
	AUGMENTIN '200'			
AB	GLAXOSMITHKLINE	200MG/5ML; EQ 28.5MG BASE/5ML	**N50725 001**	MAY 31, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	AUGMENTIN '250'			
+	GLAXOSMITHKLINE	250MG/5ML; EQ 62.5MG BASE/5ML	N50575 002	AUG 06, 1984
	AUGMENTIN '400'			
AB	GLAXOSMITHKLINE	400MG/5ML; EQ 57MG BASE/5ML	**N50725 002**	MAY 31, 1996
	AUGMENTIN ES-600			
+	GLAXOSMITHKLINE	600MG/5ML; EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001

TABLET; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	GENEVA PHARMS	500MG;EQ 125MG BASE	**N65064 001**	MAR 15, 2002
AB		875MG;EQ 125MG BASE	**N65063 001**	MAR 14, 2002
AB	LEK SVCS	875MG;EQ 125MG BASE	**N65093 001**	NOV 21, 2002
AB	RANBAXY	500MG;EQ 125MG BASE	**N65109 001**	NOV 04, 2002
AB		875MG;EQ 125MG BASE	**N65102 001**	SEP 17, 2002
AB	TEVA	500MG;EQ 125MG BASE	**N65101 001**	OCT 30, 2002
AB		875MG;EQ 125MG BASE	**N65096 001**	OCT 29, 2002
	AMOXICILLIN AND CLAVULANATE POTSSSIUM			
AB	LEK SVCS	500MG;EQ 125MG BASE	**N65117 001**	NOV 27, 2002
	AUGMENTIN '250'			
	GLAXOSMITHKLINE	250MG;EQ 125MG BASE	N50564 001	AUG 06, 1984
	AUGMENTIN '500'			
AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	**N50564 002**	AUG 06, 1984
	AUGMENTIN '875'			
AB	+ GLAXOSMITHKLINE	875MG;EQ 125MG BASE	**N50720 001**	FEB 13, 1996

TABLET, CHEWABLE; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	GENEVA PHARMS	200MG;EQ 28.5MG BASE	**N65065 001**	APR 18, 2002

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	**400MG;EQ 57MG BASE**	**N65065 002**	APR 18, 2002

AUGMENTIN '125'

	GLAXOSMITHKLINE	125MG;EQ 31.25MG BASE	N50597 001	JUL 22, 1985

AUGMENTIN '200'

AB	GLAXOSMITHKLINE	**200MG;EQ 28.5MG BASE**	**N50726 001**	MAY 31, 1996

AUGMENTIN '250'

+	GLAXOSMITHKLINE	250MG;EQ 62.5MG BASE	N50597 002	JUL 22, 1985

AUGMENTIN '400'

AB	+ GLAXOSMITHKLINE	**400MG;EQ 57MG BASE**	**N50726 002**	MAY 31, 1996

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

+	GLAXOSMITHKLINE	1GM;62.5MG	N50785 001	SEP 25, 2002

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

	SHIRE PHARM	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001

ADDERALL XR 15

	SHIRE PHARM	3.75MG;3.75MG;3.75MG; 3.75MG	N21303 006	MAY 22, 2002

ADDERALL XR 20

	SHIRE PHARM	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001

ADDERALL XR 25

	SHIRE PHARM	6.25MG;6.25MG;6.25MG; 6.25MG	N21303 004	MAY 22, 2002

ADDERALL XR 30

+	SHIRE PHARM	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 5

	SHIRE PHARM	1.25MG;1.25MG;1.25MG; 1.25MG	N21303 005	MAY 22, 2002

TABLET; ORAL

ADDERALL 10

AB	SHIRE LABS	**2.5MG;2.5MG;2.5MG;2.5MG**	**N11522 007**	FEB 13, 1996

ADDERALL 12.5

	SHIRE LABS	3.125MG;3.125MG;3.125MG; 3.125MG	N11522 012	AUG 31, 2000

ADDERALL 15

	SHIRE LABS	3.75MG;3.75MG;3.75MG; 3.75MG	N11522 013	AUG 31, 2000

ADDERALL 20

AB	SHIRE LABS	**5MG;5MG;5MG;5MG**	**N11522 008**	FEB 13, 1996

ADDERALL 30

AB	+ SHIRE LABS	**7.5MG;7.5MG;7.5MG;7.5MG**	**N11522 010**	MAY 12, 1997

ADDERALL 5

AB	SHIRE LABS	**1.25MG;1.25MG;1.25MG; 1.25MG**	**N11522 009**	MAY 12, 1997

ADDERALL 7.5

	SHIRE LABS	1.875MG;1.875MG;1.875MG; 1.875MG	N11522 011	AUG 31, 2000

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR	**1.25MG;1.25MG;1.25MG; 1.25MG**	**N40422 001**	FEB 11, 2002
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**N40422 002**	FEB 11, 2002
AB		**5MG;5MG;5MG;5MG**	**N40422 003**	FEB 11, 2002
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**N40422 004**	FEB 11, 2002

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.25MG;1.25MG;1.25MG; 1.25MG	**N40444 001** JUN 19, 2002	
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40444 002** JUN 19, 2002	
AB		5MG;5MG;5MG;5MG	**N40444 003** JUN 19, 2002	
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40444 004** JUN 19, 2002	
AB	EON	1.25MG;1.25MG;1.25MG; 1.25MG	**N40470 001** SEP 27, 2002	
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40439 001** JUN 14, 2002	
AB		5MG;5MG;5MG;5MG	**N40439 002** JUN 14, 2002	
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40439 003** JUN 14, 2002	

AMPHETAMINE SULFATE; *MULTIPLE*

SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

+	APOTHECON	3%	N50314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	GENSIA SICOR PHARMS	50MG/VIAL	**N64062 001** MAR 31, 1995
AP	PHARMA TEK	50MG/VIAL	**N63206 001** APR 29, 1992

FUNGIZONE

AP	+ APOTHECON	50MG/VIAL	**N60517 001**

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+	ENZON	5MG/ML	N50724 001 NOV 20, 1995

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	INTERMUNE PHARMS	50MG/VIAL	N50729 001 NOV 22, 1996
+		100MG/VIAL	N50729 002 NOV 22, 1996

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+	FUJISAWA HLTHCARE	50MG/VIAL	N50740 001 AUG 11, 1997

LOTION; TOPICAL

FUNGIZONE

+	APOTHECON	3%	N60570 001

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	APOTHECON	EQ 125MG BASE/VIAL	**N61395 001**
AP		EQ 125MG BASE/VIAL	**N62860 001** FEB 05, 1988
AP		EQ 250MG BASE/VIAL	**N61395 002**
AP		EQ 250MG BASE/VIAL	**N62860 002** FEB 05, 1988
AP		EQ 500MG BASE/VIAL	**N61395 003**
AP		EQ 500MG BASE/VIAL	**N62860 003** FEB 05, 1988
AP		EQ 1GM BASE/VIAL	**N61395 004**
AP		EQ 1GM BASE/VIAL	**N62738 001** FEB 19, 1987
AP		EQ 1GM BASE/VIAL	**N62860 004** FEB 05, 1988
AP		EQ 2GM BASE/VIAL	**N61395 005**
AP		EQ 2GM BASE/VIAL	**N62738 002** FEB 19, 1987
AP		EQ 2GM BASE/VIAL	**N62860 005** FEB 05, 1988
AP		EQ 10GM BASE/VIAL	**N61395 006**
AP	IBI	EQ 250MG BASE/VIAL	**N62719 001** MAY 12, 1987
AP		EQ 500MG BASE/VIAL	**N62719 003** MAY 12, 1987
AP		EQ 1GM BASE/VIAL	**N62719 002** MAY 12, 1987

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM			
AP	MARSAM PHARMS LLC	EQ 125MG BASE/VIAL	N62816 001	OCT 24, 1988
AP		EQ 250MG BASE/VIAL	N62816 002	OCT 24, 1988
AP		EQ 500MG BASE/VIAL	N62816 003	OCT 24, 1988
AP		EQ 1GM BASE/VIAL	N62816 004	OCT 24, 1988
AP		EQ 2GM BASE/VIAL	N62816 005	OCT 24, 1988
	OMNIPEN-N			
AP +	WYETH AYERST	EQ 125MG BASE/VIAL	N60626 001	
AP +		EQ 250MG BASE/VIAL	N60626 002	
AP +		EQ 500MG BASE/VIAL	N60626 003	
AP +		EQ 1GM BASE/VIAL	N60626 004	
AP +		EQ 2GM BASE/VIAL	N60626 005	
	TOTACILLIN-N			
AP	GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	N60677 001	
AP		EQ 250MG BASE/VIAL	N60677 002	
AP		EQ 500MG BASE/VIAL	N60677 003	
AP		EQ 1GM BASE/VIAL	N60677 004	
AP		EQ 2GM BASE/VIAL	N60677 005	
		EQ 10GM BASE/VIAL	N60677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

	AMPICILLIN AND SULBACTAM			
AP	ESI LEDERLE	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N65074 001	MAR 19, 2002
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	N65074 002	MAR 19, 2002
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	N65076 001	MAR 19, 2002
	UNASYN			
AP +	PFIZER	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986
AP +		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

	UNASYN			
AP +	PFIZER	EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993
		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N62901 001	NOV 23, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CLONMEL	EQ 250MG BASE	N62883 001	FEB 25, 1988
AB		EQ 500MG BASE	N62882 001	FEB 25, 1988
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	PUREPAC PHARM	EQ 500MG BASE	N61853 002	
AB	TEVA	EQ 250MG BASE	N61502 001	
AB		EQ 500MG BASE	N61502 002	
	OMNIPEN (AMPICILLIN)			
AB	WYETH AYERST	250MG	N60624 001	
AB		500MG	N60624 002	
	PRINCIPEN			
AB	APOTHECON	EQ 250MG BASE	N61392 001	
AB		EQ 500MG BASE	N61392 002	
AB		EQ 250MG BASE	N62888 001	MAR 04, 1988
AB +		EQ 500MG BASE	N62888 002	MAR 04, 1988
	TOTACILLIN			
AB	GLAXOSMITHKLINE	EQ 250MG BASE	N62212 001	
AB		EQ 500MG BASE	N62212 002	

FOR SUSPENSION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CLONMEL	EQ 125MG BASE/5ML	N62982 001	FEB 10, 1989
AB		EQ 250MG BASE/5ML	N62982 002	FEB 10, 1989
AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	PUREPAC PHARM	EQ 250MG BASE/5ML	N61980 002	
AB	TEVA	EQ 125MG BASE/5ML	N61370 001	

FDA data supplied by DrugPatentWatch.com

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	TEVA	**EQ 250MG BASE/5ML**	**N61370 002**	
	OMNIPEN (AMPICILLIN)			
AB	WYETH AYERST	**100MG/ML**	**N60625 001**	
AB		**125MG/5ML**	**N60625 002**	
AB		**250MG/5ML**	**N60625 003**	
	PRINCIPEN			
AB	APOTHECON	**EQ 100MG BASE/ML**	**N61394 001**	
AB		**EQ 125MG BASE/5ML**	**N61394 002**	
AB	+	**EQ 250MG BASE/5ML**	**N61394 003**	

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN			
SHIRE LABS	EQ 0.5MG BASE	N20333 001	MAR 14, 1997
+	EQ 1MG BASE	N20333 002	MAR 14, 1997

ANASTROZOLE

TABLET; ORAL

ARIMIDEX			
+ ASTRAZENECA	1MG	N20541 001	DEC 27, 1995

ANISINDIONE

TABLET; ORAL

MIRADON			
+ SCHERING	50MG	N10909 003	

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE			
+ ALCON	EQ 0.5% BASE	N20258 001	JUL 30, 1993
+	EQ 1% BASE	N19779 001	DEC 31, 1987

APROTININ BOVINE

INJECTABLE; INJECTION

TRASYLOL			
+ BAYER	10,000KIU/ML	N20304 001	DEC 29, 1993

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN			
+ TX BIOTECH	100MG/ML	N20883 001	JUN 30, 2000

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10			
+ PHARMACIA AND UPJOHN	10GM/100ML	N16931 001	

ARIPIPRAZOLE

TABLET; ORAL

ABILIFY			
OTSUKA	2MG	N21436 006	NOV 15, 2002
	5MG	N21436 005	NOV 15, 2002
	10MG	N21436 001	NOV 15, 2002
	15MG	N21436 002	NOV 15, 2002
	20MG	N21436 003	NOV 15, 2002
+	30MG	N21436 004	NOV 15, 2002

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX			
+ CELL THERAP	1MG/ML	N21248 001	SEP 25, 2000

FDA data supplied by DrugPatentWatch.com

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAINE
\+ DEPROCO 4%;EQ 0.01MG BASE/ML N20971 001
APR 03, 2000

ASCORBIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC
\+ SABEX 2002 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL; 0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL; 17MG/VIAL;1MG/VIAL;1.4MG/VIAL; 1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL; 0.2MG/VIAL N21265 001
FEB 21, 2001

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)
M.V.I. PEDIATRIC
\+ AAIPHARMA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL; 5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL; 17MG/VIAL;0.2MG/VIAL;1MG/VIAL; 1.4MG/VIAL;EQ 1.2MG BASE/VIAL; 0.7MG/VIAL;7MG/VIAL N18920 001
SEP 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.I.-12
AP \+ AAIPHARMA **10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML** **N08809 004**
AUG 08, 1985

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
FIORINAL
AB \+ NOVARTIS **325MG;50MG;40MG** **N17534 005**
APR 16, 1986

LANORINAL
AB LANNETT **325MG;50MG;40MG** **N86996 002**
OCT 11, 1985

TABLET; ORAL
ASPIRIN AND CAFFEINE W/ BUTALBITAL
AB PUREPAC PHARM **325MG;50MG;40MG** **N86710 002**
AUG 23, 1983

BUTAL COMPOUND
AB GENEVA PHARMS **325MG;50MG;40MG** **N86398 002**
APR 06, 1984

BUTALBITAL W/ ASPIRIN & CAFFEINE
AB PHARMERAL **325MG;50MG;40MG** **N87048 002**
DEC 09, 1983

BUTALBITAL, ASPIRIN AND CAFFEINE
AB WEST WARD **325MG;50MG;40MG** **N86162 002**
FEB 16, 1984

FIORINAL
AB \+ NOVARTIS **325MG;50MG;40MG** **N17534 003**
APR 16, 1986

FDA data supplied by DrugPatentWatch.com

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	ANABOLIC	325MG;50MG;40MG;30MG	N75231 001	NOV 30, 2001
AB	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001	MAR 05, 1999
AB	STEVENS J	325MG;50MG;40MG;30MG	N74951 001	AUG 31, 1998
AB	WATSON LABS	325MG;50MG;40MG;30MG	N74359 001	AUG 31, 1995

FIORINAL W/CODEINE NO 3

AB	+ NOVARTIS	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

	+ WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N11483 004	SEP 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996

INVAGESIC FORTE

AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996

NORGESIC

AB	3M	385MG;30MG;25MG	N13416 003	OCT 27, 1982

NORGESIC FORTE

AB	+ 3M	770MG;60MG;50MG	N13416 004	OCT 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	EON	385MG;30MG;25MG	N74654 001	DEC 31, 1996
AB		770MG;60MG;50MG	N74654 002	DEC 31, 1996
AB	STEVENS J	385MG;30MG;25MG	N74988 001	APR 30, 1999
AB		770MG;60MG;50MG	N74988 002	APR 30, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

AB	PAR PHARM	385MG;30MG;25MG	N75141 001	MAY 29, 1998

ORPHENGESIC FORTE

AB	PAR PHARM	770MG;60MG;50MG	N75141 002	MAY 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

	+ AAIPHARMA LLC	389MG;32.4MG;32MG	N10996 006	MAR 08, 1983

DARVON COMPOUND-65

AA	+ AAIPHARMA LLC	389MG;32.4MG;65MG	N10996 007	MAR 08, 1983

PROPOXYPHENE COMPOUND 65

AA	TEVA	389MG;32.4MG;65MG	N89025 001	MAR 29, 1985

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	AMIDE PHARM	325MG;200MG	N40252 001	DEC 10, 1997
AB	EON	325MG;200MG	N40116 001	APR 25, 1996
AB	PAR PHARM	325MG;200MG	N89594 001	MAR 31, 1989

SOMA COMPOUND

AB	+ WALLACE PHARMS	325MG;200MG	N12365 005	JUL 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	AMIDE PHARM	325MG;200MG;16MG	N40283 001	DEC 29, 1998
AB	EON	325MG;200MG;16MG	N40118 001	APR 16, 1996

FDA data supplied by DrugPatentWatch.com

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

	SOMA COMPOUND W/ CODEINE			
AB	+ WALLACE PHARMS	325MG;200MG;16MG	**N12366 002**	JUL 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

	AGGRENOX			
	+ BOEHRINGER INGELHEIM	25MG;200MG	N20884 001	NOV 22, 1999

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

	AZDONE			
	+ CENT PHARMS	500MG;5MG	N89420 001	JAN 25, 1988

ASPIRIN; MEPROBAMATE

TABLET; ORAL

	EQUAGESIC			
AB	+ WOMEN FIRST HLTHCARE	325MG;200MG	**N11702 003**	DEC 29, 1983
	MICRAININ			
AB	WALLACE PHARMS	325MG;200MG	**N84978 001**	

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
AB	IVAX PHARMS	325MG;400MG	**N87211 001**	DEC 22, 1982
AB	PAR PHARM	325MG;400MG	**N89657 001**	NOV 04, 1988
AB	STEVENS J	325MG;400MG	**N81145 001**	JAN 31, 1995
	ROBAXISAL			
AB	+ ROBINS AH	325MG;400MG	**N12281 001**	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

	OXYCODONE AND ASPIRIN			
AA	HALSEY	325MG;4.5MG;0.38MG	**N40260 001**	JUL 17, 1998
AA		325MG;4.5MG;0.38MG	**N87794 001**	MAY 26, 1982
AA	WATSON LABS	325MG;4.5MG;0.38MG	**N40255 001**	FEB 27, 1998
	PERCODAN			
AA	+ ENDO PHARMS	325MG;4.5MG;0.38MG	**N07337 006**	
	PERCODAN-DEMI			
AA	+ ENDO PHARMS	325MG;2.25MG;0.19MG	**N07337 005**	

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON W/ ASA			
	+ AAIPHARMA LLC	325MG;65MG	N10996 005	

ATENOLOL

INJECTABLE; INJECTION

	TENORMIN			
	+ ASTRAZENECA	0.5MG/ML	N19058 001	SEP 13, 1989

TABLET; ORAL

	ATENOLOL			
AB	COPLEY PHARM	50MG	**N74120 001**	FEB 24, 1995
AB		100MG	**N74120 002**	FEB 24, 1995
AB	GENEVA PHARMS	25MG	**N74052 001**	MAY 01, 1992
AB		50MG	**N73025 001**	SEP 17, 1991
AB		100MG	**N73026 001**	SEP 17, 1991
AB	GENEVA PHARMS TECH	25MG	**N74265 001**	FEB 28, 1994
AB		50MG	**N74265 002**	FEB 28, 1994
AB		100MG	**N74265 003**	FEB 28, 1994

FDA data supplied by DrugPatentWatch.com

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	IPR	25MG	N73646 001	JUL 31, 1992
AB		50MG	N72303 001	JUL 15, 1988
AB		100MG	N72304 001	JUL 15, 1988
AB	LEDERLE	25MG	N74099 001	APR 28, 1992
AB		50MG	N73542 001	DEC 19, 1991
AB		100MG	N73543 001	DEC 19, 1991
AB	MARTEC	50MG	N74127 001	FEB 21, 1995
AB		100MG	N74127 002	FEB 21, 1995
AB	MUTUAL PHARM	25MG	N74499 001	JUL 30, 1997
AB		50MG	N73475 001	MAR 30, 1993
AB		100MG	N73476 001	MAR 30, 1993
AB	MYLAN	50MG	N73456 001	JAN 24, 1992
AB		100MG	N73457 001	JAN 24, 1992
		25MG	N73457 002	APR 26, 1999
AB	SCS	50MG	N73676 001	OCT 30, 1992
AB		100MG	N73676 002	OCT 30, 1992
AB	SIDMAK LABS NJ	25MG	N74101 001	JUL 17, 1997
AB		50MG	N74101 002	JUL 17, 1997
AB		100MG	N74101 003	JUL 17, 1997
AB	TEVA	50MG	N73315 001	MAY 28, 1993
AB		50MG	N74056 001	JAN 18, 1995
AB		100MG	N73316 001	MAY 28, 1993

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	TEVA	100MG	N74056 002	JAN 18, 1995
AB	WATSON LABS	50MG	N73352 001	DEC 27, 1991
AB		100MG	N73353 001	DEC 27, 1991

TENORMIN

AB	ASTRAZENECA	25MG	N18240 004	APR 09, 1990
AB		50MG	N18240 001	
AB +		100MG	N18240 002	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	IPR	50MG;25MG	N72301 001	MAY 31, 1990
AB		100MG;25MG	N72302 001	MAY 31, 1990
AB	MARTEC	50MG;25MG	N74404 001	MAY 14, 1998
AB		100MG;25MG	N74404 002	MAY 14, 1998
AB	MUTUAL PHARM	50MG;25MG	N73581 001	APR 29, 1993
AB		100MG;25MG	N73582 001	APR 29, 1993
AB	MYLAN	50MG;25MG	N74203 001	OCT 31, 1993
AB		100MG;25MG	N74203 002	OCT 31, 1993
AB	SIDMAK LABS NJ	50MG;25MG	N74107 001	SEP 24, 1997
AB		100MG;25MG	N74107 002	SEP 24, 1997
AB	WATSON LABS	50MG;25MG	N73665 001	JUL 02, 1992
AB		100MG;25MG	N73665 002	JUL 02, 1992

TENORETIC 100

AB +	ASTRAZENECA	100MG;25MG	N18760 001	JUN 08, 1984

FDA data supplied by DrugPatentWatch.com

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
TENORETIC 50

AB	ASTRAZENECA	**50MG;25MG**	**N18760 002**	JUN 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
STRATTERA

	LILLY	5MG	N21411 001 NOV 26, 2002
		10MG	N21411 002 NOV 26, 2002
		18MG	N21411 003 NOV 26, 2002
		25MG	N21411 004 NOV 26, 2002
		40MG	N21411 005 NOV 26, 2002
+		60MG	N21411 006 NOV 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	PFIZER	EQ 10MG BASE	N20702 001 DEC 17, 1996
		EQ 20MG BASE	N20702 002 DEC 17, 1996
		EQ 40MG BASE	N20702 003 DEC 17, 1996
+		EQ 80MG BASE	N20702 004 APR 07, 2000

ATOVAQUONE

SUSPENSION; ORAL
MEPRON

+	GLAXOSMITHKLINE	750MG/5ML	N20500 001 FEB 08, 1995

TABLET; ORAL
MEPRON

+	GLAXOSMITHKLINE	250MG	N20259 001 NOV 25, 1992

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL
MALARONE

+	GLAXOSMITHKLINE	250MG;100MG	N21078 001 JUL 14, 2000

MALARONE PEDIATRIC

+	GLAXOSMITHKLINE	62.5MG;25MG	N21078 002 JUL 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	ABBOTT	**10MG/ML**	**N74632 001**	DEC 23, 1996
AP	BAXTER HLTHCARE CORP	**10MG/ML**	**N74753 001**	JAN 23, 1997
AP	BEDFORD	**10MG/ML**	**N74901 001**	JUL 18, 1997
AP	ESI LEDERLE	**10MG/ML**	**N74824 001**	SEP 30, 1997
AP	FAULDING	**10MG/ML**	**N74740 001**	MAR 28, 1997
AP	GENSIA SICOR PHARMS	**10MG/ML**	**N74784 001**	JUN 11, 1997
AP	MARSAM PHARMS LLC	**10MG/ML**	**N74945 001**	JUL 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	ABBOTT	**10MG/ML**	**N74633 001**	DEC 23, 1996
AP		**10MG/ML**	**N74639 001**	MAR 25, 1997
AP	BAXTER HLTHCARE CORP	**10MG/ML**	**N74768 001**	JAN 23, 1997
AP	BEDFORD	**10MG/ML**	**N74900 001**	JUL 18, 1997
AP	ESI LEDERLE	**10MG/ML**	**N74825 001**	SEP 30, 1997
AP	FAULDING	**10MG/ML**	**N74741 001**	MAR 28, 1997
AP	MARSAM PHARMS LLC	**10MG/ML**	**N74944 001**	JUL 28, 1998

TRACRIUM

AP	+ ABBOTT	**10MG/ML**	**N18831 002**	JUN 20, 1985

TRACRIUM PRESERVATIVE FREE

AP	+ ABBOTT	**10MG/ML**	**N18831 001**	NOV 23, 1983

FDA data supplied by DrugPatentWatch.com

ATROPINE

INJECTABLE; INJECTION
ATROPEN
+ MERIDIAN MEDCL TECHN EQ 2MG SULFATE/0.7ML N17106 001

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR PLASTIC SYRINGE
ABBOTT 0.05MG/ML N21146 002 JUL 09, 2001
+ 0.1MG/ML N21146 001 JUL 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN
+ AMARIN PHARMS 0.025MG;1MG N17744 002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
SCHERER RP 0.025MG;2.5MG N86440 001

SOLUTION; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA ROXANE **0.025MG/5ML;2.5MG/5ML** **N87708 001** MAY 03, 1982
LOMOTIL
AA + GD SEARLE LLC **0.025MG/5ML;2.5MG/5ML** **N12699 001**

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA ABLE **0.025MG;2.5MG** **N40395 001** NOV 27, 2000
AA LANNETT **0.025MG;2.5MG** **N85372 001**
AA MYLAN **0.025MG;2.5MG** **N85762 001**
AA PAR PHARM **0.025MG;2.5MG** **N40357 001** MAY 02, 2000
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
AA EON **0.025MG;2.5MG** **N86173 001**
AA IVAX PHARMS **0.025MG;2.5MG** **N86727 001**
LOMOTIL
AA + GD SEARLE LLC **0.025MG;2.5MG** **N12462 001**

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
LONOX
AA GENEVA PHARMS **0.025MG;2.5MG** **N85311 002**

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS
+ BAXTER HLTHCARE CORP 0.14MG/ML;10MG/ML N19677 001 NOV 06, 1991
+ 0.14MG/ML;10MG/ML N19678 001 NOV 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ATROPINE AND DEMEROL
+ ABBOTT 0.4MG/ML;50MG/ML N87853 001 NOV 26, 1982
+ 0.4MG/ML;75MG/ML N87847 001 NOV 26, 1982
+ 0.4MG/ML;100MG/ML N87848 001 NOV 26, 1982

AURANOFIN

CAPSULE; ORAL
RIDAURA
+ PROMETHEUS LABS 3MG N18689 001 MAY 24, 1985

AZATADINE MALEATE

TABLET; ORAL
OPTIMINE
+ SCHERING 1MG N17601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
TRINALIN
+ SCHERING 1MG;120MG N18506 001 MAR 23, 1982

FDA data supplied by DrugPatentWatch.com

AZATHIOPRINE

TABLET; ORAL

	AZATHIOPRINE			
AB	APPLIED ANAL	**50MG**	**N75252 001**	JUN 07, 1999
AB	GENPHARM	**50MG**	**N75568 001**	DEC 13, 1999
AB	ROXANE	**50MG**	**N74069 001**	FEB 16, 1996
	IMURAN			
AB	+ PROMETHEUS LABS	**50MG**	**N16324 001**	

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

	AZATHIOPRINE SODIUM			
AP	BEDFORD	**EQ 100MG BASE/VIAL**	**N74419 001**	MAR 31, 1995
	IMURAN			
AP	+ PROMETHEUS LABS	**EQ 100MG BASE/VIAL**	**N17391 001**	

AZELAIC ACID

CREAM; TOPICAL

	AZELEX		
+	ALLERGAN	20%	N20428 001 SEP 13, 1995

GEL; TOPICAL

	FINACEA		
+	BERLEX	15%	N21470 001 DEC 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OPTIVAR		
+	MURO	0.05%	N21127 001 MAY 22, 2000

SPRAY, METERED; NASAL

	ASTELIN		
+	WALLACE PHARMS	EQ 0.125MG BASE/SPRAY	N20114 001 NOV 01, 1996

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL

	ZITHROMAX			
+	PFIZER	EQ 250MG BASE	N50670 001	NOV 01, 1991

FOR SUSPENSION; ORAL

	ZITHROMAX			
+	PFIZER	EQ 1GM BASE/PACKET	N50693 001	SEP 28, 1994
		EQ 100MG BASE/5ML	N50710 001	OCT 19, 1995
+		EQ 200MG BASE/5ML	N50710 002	OCT 19, 1995

INJECTABLE; INJECTION

	ZITHROMAX			
+	PFIZER	EQ 500MG BASE/VIAL	N50733 001	JAN 30, 1997

TABLET; ORAL

	ZITHROMAX			
	PFIZER	EQ 250MG BASE	N50711 001	JUL 18, 1996
+		EQ 500MG BASE	N50784 001	MAY 24, 2002
+		EQ 600MG BASE	N50730 001	JUN 12, 1996

AZTREONAM

INJECTABLE; INJECTION

	AZACTAM IN PLASTIC CONTAINER			
+	BRISTOL MYERS SQUIBB	20MG/ML	N50632 002	MAY 24, 1989
+		40MG/ML	N50632 001	MAY 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

	SPECTROBID			
+	PFIZER	125MG/5ML	N50556 001	MAR 23, 1982

TABLET; ORAL

	SPECTROBID		
+	PFIZER	400MG	N50520 001

FDA data supplied by DrugPatentWatch.com

BACITRACIN

INJECTABLE; INJECTION

	BACIIM			
AP	PHARMA TEK	**50,000 UNITS/VIAL**	**N64153 001**	
			MAY 09, 1997	
	BACITRACIN			
AP	AM PHARM PARTNERS	**50,000 UNITS/VIAL**	**N65116 001**	
			DEC 03, 2002	
AP	+ PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**	**N60733 002**	
		10,000 UNITS/VIAL	N60733 001	

OINTMENT; OPHTHALMIC

	BACITRACIN		
	+ ALTANA	500 UNITS/GM	N61212 001

POWDER; FOR RX COMPOUNDING

	BACI-RX		
AA	PHARMA TEK	**5,000,000 UNITS/BOT**	**N61580 001**
	BACITRACIN		
AA	APOTHEKERNES	**5,000,000 UNITS/BOT**	**N61699 001**

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE		
	+ PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	CORTISPORIN		
AT	+ MONARCH PHARMS	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50416 002**
	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE		
AT	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64068 001** OCT 30, 1995

OINTMENT; TOPICAL

	CORTISPORIN		
	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002 MAY 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN-NEOMYCIN-POLYMYXIN		
AT	ALTANA	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N60764 002**
	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC		
AT	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64064 001** OCT 30, 1995
	NEOSPORIN		
AT	+ MONARCH PHARMS	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50417 001**

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN ZINC AND POLYMYXIN B SULFATE		
AT	AKORN	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001** JAN 30, 1995
AT	ALTANA	**500 UNITS/GM; 10,000 UNITS/GM**	**N65022 001** FEB 27, 2002
AT	BAUSCH AND LOMB	**500 UNITS/GM; 10,000 UNITS/GM**	**N64046 001** JAN 26, 1995
	POLYSPORIN		
AT	+ MONARCH PHARMS	**500 UNITS/GM; 10,000 UNITS/GM**	**N61229 001**

BACLOFEN

INJECTABLE; INTRATHECAL

	LIORESAL		
	+ MEDTRONIC	0.05MG/ML	N20075 003 NOV 07, 1996
	+	0.5MG/ML	N20075 001 JUN 17, 1992
	+	2MG/ML	N20075 002 JUN 17, 1992

TABLET; ORAL

	BACLOFEN		
AB	IVAX PHARMS	**10MG**	**N72234 001** JUL 21, 1988

FDA data supplied by DrugPatentWatch.com

BACLOFEN

TABLET; ORAL

	BACLOFEN			
AB	IVAX PHARMS	**20MG**	**N72235 001**	JUL 21, 1988
AB	USL PHARMA	**10MG**	**N74584 001**	AUG 19, 1996
AB		**20MG**	**N74584 002**	AUG 19, 1996
AB	WATSON LABS	**10MG**	**N72824 001**	SEP 18, 1991
AB		**10MG**	**N73092 001**	JAN 28, 1994
AB		**10MG**	**N74698 001**	AUG 20, 1996
AB		**20MG**	**N72825 001**	SEP 18, 1991
AB	+	**20MG**	**N73093 001**	JAN 28, 1994
AB		**20MG**	**N74698 002**	AUG 20, 1996

BALSALAZIDE DISODIUM

CAPSULE; ORAL

	COLAZAL			
	+ SALIX PHARMS	750MG	N20610 001	JUL 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

	BECLOVENT			
BN	GLAXOSMITHKLINE	0.042MG/INH	N18153 001	
	QVAR 40			
	+ 3M	0.04MG/INH	N20911 002	SEP 15, 2000
	QVAR 80			
	+ 3M	0.08MG/INH	N20911 001	SEP 15, 2000
	VANCERIL			
BN	+ SCHERING	0.042MG/INH	N17573 001	
	VANCERIL DOUBLE STRENGTH			
	+ SCHERING	0.084MG/INH	N20486 001	DEC 24, 1996

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

	BECONASE			
BN	+ GLAXOSMITHKLINE	0.042MG/INH	N18584 001	
	VANCENASE			
BN	SCHERING	0.042MG/INH	N18521 001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

	BECONASE AQ			
BN	+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389 001	JUL 27, 1987
	VANCENASE AQ			
BN	+ SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589 001	DEC 23, 1987

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN			
NOVARTIS	5MG	N19851 001	JUN 25, 1991
	10MG	N19851 002	JUN 25, 1991
	20MG	N19851 003	JUN 25, 1991
+	40MG	N19851 004	JUN 25, 1991

BENAZEPRIL HYDROCHLORIDE; *MULTIPLE*

SEE AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

LOTENSIN HCT			
NOVARTIS	5MG;6.25MG	N20033 001	MAY 19, 1992
	10MG;12.5MG	N20033 002	MAY 19, 1992
	20MG;12.5MG	N20033 004	MAY 19, 1992

FDA data supplied by DrugPatentWatch.com

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL				
LOTENSIN HCT				
+	NOVARTIS	20MG;25MG	N20033 003	
			MAY 19, 1992	

BENDROFLUMETHIAZIDE

TABLET; ORAL				
NATURETIN-5				
+	APOTHECON	5MG	N12164 002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL				
CORZIDE				
	KING PHARMS	5MG;40MG	N18647 001	
			MAY 25, 1983	
+		5MG;80MG	N18647 002	
			MAY 25, 1983	

BENZONATATE

CAPSULE; ORAL				
BENZONATATE				
AA	BANNER PHARMACAPS	**100MG**	**N81297 001**	
			JAN 29, 1993	
TESSALON				
AA +	FOREST LABS	**100MG**	**N11210 001**	
+		200MG	N11210 003	
			JUN 25, 1999	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL				
BENZACLIN				
+	DERMIK LABS	5%;EQ 1% BASE	N50756 001	
			DEC 21, 2000	
DUAC				
+	STIEFEL	5%;EQ 1% BASE	N50741 001	
			AUG 26, 2002	

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL				
BENZAMYCIN				
+	DERMIK LABS	5%;3%	N50557 001	
			OCT 26, 1984	
BENZAMYCIN PAK				
+	DERMIK LABS	5%;3%	N50769 001	
			NOV 27, 2000	

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL				
DIDREX				
+	PHARMACIA AND UPJOHN	50MG	N12427 002	

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION				
EMETE-CON				
+	PFIZER	EQ 50MG BASE/VIAL	N16820 001	

BENZTROPINE MESYLATE

INJECTABLE; INJECTION				
COGENTIN				
+	MERCK	1MG/ML	N12015 001	
TABLET; ORAL				
BENZTROPINE MESYLATE				
AA	COREPHARMA	**0.5MG**	**N72264 001**	
			FEB 27, 1989	
AA		**1MG**	**N72265 001**	
			FEB 27, 1989	
AA		**2MG**	**N72266 001**	
			FEB 27, 1989	
AA	MUTUAL PHARM	**1MG**	**N81264 001**	
			JAN 23, 1992	
AA		**2MG**	**N81265 001**	
			JAN 23, 1992	
AA +	PAR PHARM	**0.5MG**	**N88877 001**	
			APR 11, 1985	
AA +		**1MG**	**N88894 001**	
			APR 11, 1985	
AA +		**2MG**	**N88895 001**	
			APR 11, 1985	

FDA data supplied by DrugPatentWatch.com

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	SIDMAK LABS NJ	0.5MG	N89058 001 AUG 10, 1988	
AA		1MG	N89059 001 AUG 10, 1988	
AA		2MG	N89060 001 AUG 10, 1988	
AA	USL PHARMA	0.5MG	N40103 001 DEC 12, 1996	
AA		1MG	N40103 002 DEC 12, 1996	
AA		2MG	N40103 003 DEC 12, 1996	

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+	SCHWARZ PHARMA	60 UMOLAR	N50114 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

	ORTHO MCNEIL PHARM	200MG	N19002 001 DEC 28, 1990
+		300MG	N19002 002 DEC 28, 1990

BERACTANT

SUSPENSION; INTRATRACHEAL
SURVANTA

+	ROSS LABS	25MG/ML	N20032 001 JUL 01, 1991

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE

+	ORPHAN MEDCL	1GM/SCOOPFUL	N20576 001 OCT 25, 1996

BETAMETHASONE

SYRUP; ORAL
CELESTONE

+	SCHERING	0.6MG/5ML	N14215 002

TABLET; ORAL
CELESTONE

+	SCHERING	0.6MG	N12657 003

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
CELESTONE SOLUSPAN

+	SCHERING	3MG/ML;EQ 3MG BASE/ML	N14602 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
ALPHATREX

AB	SAVAGE LABS	EQ 0.05% BASE	N19138 001 JUN 26, 1984

BETAMETHASONE DIPROPIONATE

AB	ALPHARMA US PHARM	EQ 0.05% BASE	N70885 001 FEB 03, 1987
AB	FOUGERA	EQ 0.05% BASE	N19137 001 JUN 26, 1984
AB	TARO	EQ 0.05% BASE	N71143 001 JUN 17, 1987
AB		EQ 0.05% BASE	N73552 001 APR 30, 1992
AB	TEVA	EQ 0.05% BASE	N71476 001 AUG 10, 1987

DIPROSONE

AB	+ SCHERING	EQ 0.05% BASE	N17536 001

CREAM, AUGMENTED; TOPICAL
DIPROLENE AF

+	SCHERING	EQ 0.05% BASE	N19555 001 APR 27, 1987

GEL; TOPICAL
DIPROLENE

+	SCHERING	EQ 0.05% BASE	N19408 002 NOV 22, 1991

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

	ALPHATREX			
AB	SAVAGE LABS	EQ 0.05% BASE	N70273 001	AUG 12, 1985
	BETAMETHASONE DIPROPIONATE			
AB	ALPHARMA	EQ 0.05% BASE	N70281 001	JUL 31, 1985
AB	CLAY PARK	EQ 0.05% BASE	N72538 001	JAN 31, 1990
AB	COPLEY PHARM	EQ 0.05% BASE	N71882 001	JUN 06, 1988
AB	FOUGERA	EQ 0.05% BASE	N70275 001	AUG 12, 1985
AB	TARO	EQ 0.05% BASE	N72276 001	AUG 24, 1988
AB		EQ 0.05% BASE	N74272 001	SEP 30, 1994
AB	TEVA	EQ 0.05% BASE	N71467 001	AUG 10, 1987
	DIPROSONE			
AB	+ SCHERING	EQ 0.05% BASE	N17781 001	

LOTION, AUGMENTED; TOPICAL

	DIPROLENE			
	+ SCHERING	EQ 0.05% BASE	N19716 001	AUG 01, 1988

OINTMENT; TOPICAL

	ALPHATREX			
AB	SAVAGE LABS	EQ 0.05% BASE	N19143 001	SEP 04, 1984
	BETAMETHASONE DIPROPIONATE			
AB	ALPHARMA US PHARM	EQ 0.05% BASE	N71012 001	FEB 03, 1987
AB	+ FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984
AB	TARO	EQ 0.05% BASE	N74271 001	SEP 15, 1994
AB	TEVA	EQ 0.05% BASE	N71477 001	AUG 10, 1987

OINTMENT, AUGMENTED; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	ALPHARMA US PHARM	EQ 0.05% BASE	N74304 001	AUG 31, 1995
AB	ALTANA	EQ 0.05% BASE	N75373 001	JUN 22, 1999

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

	DIPROLENE			
AB	+ SCHERING	EQ 0.05% BASE	N18741 001	JUL 27, 1983

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE			
AB	ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002
AB	ALTANA	EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001
AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001
	LOTRISONE			
AB	+ SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984

LOTION; TOPICAL

	LOTRISONE			
	+ SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	DEC 08, 2000

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	BETAMETHASONE SODIUM PHOSPHATE		
AP	STERIS	EQ 3MG BASE/ML	N85738 001
	CELESTONE		
AP	+ SCHERING	EQ 3MG BASE/ML	N17561 001

BETAMETHASONE SODIUM PHOSPHATE; *MULTIPLE*

SEE BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

BETAMETHASONE VALERATE

AEROSOL; TOPICAL

	LUXIQ			
	+ CONNETICS	EQ 0.12% BASE	N20934 001	FEB 28, 1999

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE VALERATE

CREAM; TOPICAL

	BETA-VAL			
AB	TEVA	EQ 0.1% BASE	N18642 001	MAR 24, 1983
	BETADERM			
AB	ROACO	EQ 0.1% BASE	N18839 001	JUN 30, 1983
	BETAMETHASONE VALERATE			
AB	+ FOUGERA	EQ 0.1% BASE	N18861 001	AUG 31, 1983
AB	TARO	EQ 0.1% BASE	N70062 001	MAY 14, 1985
	BETATREX			
AB	SAVAGE LABS	EQ 0.1% BASE	N18862 001	AUG 31, 1983
	DERMABET			
AB	TARO	EQ 0.1% BASE	N72041 001	JAN 06, 1988
	VALNAC			
AB	ALPHARMA US PHARM	EQ 0.1% BASE	N70050 001	OCT 10, 1984

LOTION; TOPICAL

	BETA-VAL			
AB	TEVA	EQ 0.1% BASE	N70072 001	JUN 27, 1985
	BETAMETHASONE VALERATE			
AB	ALPHARMA	EQ 0.1% BASE	N70052 001	JUL 31, 1985
AB	COPLEY PHARM	EQ 0.1% BASE	N71883 001	APR 22, 1988
AB	+ FOUGERA	EQ 0.1% BASE	N18866 001	AUG 31, 1983
	BETATREX			
AB	SAVAGE LABS	EQ 0.1% BASE	N18867 001	AUG 31, 1983

OINTMENT; TOPICAL

	BETA-VAL			
AB	TEVA	EQ 0.1% BASE	N70069 001	DEC 19, 1985
	BETAMETHASONE VALERATE			
AB	ALPHARMA US PHARM	EQ 0.1% BASE	N70051 001	OCT 10, 1984
AB	+ FOUGERA	EQ 0.1% BASE	N18865 001	AUG 31, 1983

BETAMETHASONE VALERATE

OINTMENT; TOPICAL

	BETATREX			
AB	SAVAGE LABS	EQ 0.1% BASE	N18863 001	AUG 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAXOLOL			
AT	AKORN	EQ 0.5% BASE	N75386 001	JUN 30, 2000
AT	NOVEX	EQ 0.5% BASE	N75446 001	SEP 28, 2000
	BETAXOLOL HCL			
AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001
	BETOPTIC			
AT	+ ALCON	EQ 0.5% BASE	N19270 001	AUG 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

	BETOPTIC S			
	+ ALCON	EQ 0.25% BASE	N19845 001	DEC 29, 1989

TABLET; ORAL

	BETAXOLOL HCL			
AB	AMIDE PHARM	10MG	N75541 001	OCT 22, 1999
AB		20MG	N75541 002	OCT 22, 1999
	KERLONE			
AB	LOREX	10MG	N19507 001	OCT 27, 1989
AB	+	20MG	N19507 002	OCT 27, 1989

BETHANECHOL CHLORIDE

TABLET; ORAL

	URECHOLINE			
	+ ODYSSEY PHARMS	5MG	N89095 001	DEC 19, 1985
	+	10MG	N88440 001	MAY 29, 1984

FDA data supplied by DrugPatentWatch.com

BETHANECHOL CHLORIDE

TABLET; ORAL
URECHOLINE
+ ODYSSEY PHARMS 25MG N88441 001 MAY 29, 1984
+ 50MG N89096 001 DEC 19, 1985

BEXAROTENE

CAPSULE; ORAL
TARGRETIN
+ LIGAND 75MG N21055 001 DEC 29, 1999

GEL; TOPICAL
TARGRETIN
+ LIGAND 1% N21056 001 JUN 28, 2000

BICALUTAMIDE

TABLET; ORAL
CASODEX
+ ASTRAZENECA 50MG N20498 001 OCT 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC
LUMIGAN
+ ALLERGAN 0.03% N21275 001 MAR 16, 2001

BIOTIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

BIOTIN; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL
AKINETON
+ ABBOTT 2MG N12003 001

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC
+ PROMETHEUS LABS 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A,500MG N50719 001 AUG 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL
BISOPROLOL FUMARATE
AB COPLEY PHARM 5MG **N75644 001** JUN 26, 2001
AB 10MG **N75644 002** JUN 26, 2001
AB EON 5MG **N75643 001** NOV 16, 2000
AB 10MG **N75643 002** NOV 16, 2000
AB MUTUAL PHARM 5MG **N75474 001** OCT 25, 2002
AB 10MG **N75474 002** OCT 25, 2002
ZEBETA
AB LEDERLE 5MG **N19982 002** JUL 31, 1992

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB	+ LEDERLE	10MG	**N19982 001** JUL 31, 1992	

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	EON	2.5MG;6.25MG	**N75579 001** SEP 25, 2000
AB		5MG;6.25MG	**N75579 002** SEP 25, 2000
AB		10MG;6.25MG	**N75579 003** SEP 25, 2000
AB	GENEVA PHARMS TECH	2.5MG;6.25MG	**N75527 001** SEP 25, 2000
AB		5MG;6.25MG	**N75527 003** SEP 25, 2000
AB		10MG;6.25MG	**N75527 002** SEP 25, 2000
AB	IVAX PHARMS	2.5MG;6.25MG	**N75632 001** SEP 27, 2000
AB		5MG;6.25MG	**N75632 002** SEP 27, 2000
AB		10MG;6.25MG	**N75632 003** SEP 27, 2000
AB	MYLAN	2.5MG;6.25MG	**N75768 001** SEP 25, 2000
AB		5MG;6.25MG	**N75768 002** SEP 25, 2000
AB		10MG;6.25MG	**N75768 003** SEP 25, 2000
AB	PUREPAC PHARM	2.5MG;6.25MG	**N75672 001** SEP 25, 2000
AB		5MG;6.25MG	**N75672 002** SEP 25, 2000
AB		10MG;6.25MG	**N75672 003** SEP 25, 2000
AB	TEVA	2.5MG;6.25MG	**N75686 001** JAN 19, 2001
AB		5MG;6.25MG	**N75686 002** JAN 19, 2001
AB		10MG;6.25MG	**N75686 003** JAN 19, 2001

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	2.5MG;6.25MG	**N75469 001** SEP 25, 2000
AB		5MG;6.25MG	**N75469 002** SEP 25, 2000
AB		10MG;6.25MG	**N75469 003** SEP 25, 2000

ZIAC

AB	LEDERLE	2.5MG;6.25MG	**N20186 003** MAR 26, 1993
AB		5MG;6.25MG	**N20186 001** MAR 26, 1993
AB	+	10MG;6.25MG	**N20186 002** MAR 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

+	MEDS (TMC)	250MG/VIAL	N20873 001 DEC 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

AP	+ BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	**N50443 001**
AP	+	EQ 30 UNITS BASE/VIAL	**N50443 002** SEP 07, 1995

BLEOMYCIN

AP	BEDFORD	EQ 15 UNITS BASE/VIAL	**N65042 002** OCT 17, 2001
AP		EQ 30 UNITS BASE/VIAL	**N65042 001** OCT 17, 2001
AP	FAULDING	EQ 15 UNITS BASE/VIAL	**N65031 001** MAR 10, 2000
AP		EQ 30 UNITS BASE/VIAL	**N65031 002** MAR 10, 2000
AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	**N65033 001** JUN 27, 2000
AP		EQ 30 UNITS BASE/VIAL	**N65033 002** JUN 27, 2000

BLEOMYCIN SULFATE

AP	PHARMACIA AND UPJOHN	EQ 15 UNITS BASE/VIAL	**N64084 001** JUN 01, 1996

FDA data supplied by DrugPatentWatch.com

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	PHARMACIA AND UPJOHN	**EQ 30 UNITS BASE/VIAL**	**N64084 002**	JUN 01, 1996

BOSENTAN

TABLET; ORAL
TRACLEER

	ACTELION	62.5MG	N21290 001	NOV 20, 2001
+		125MG	N21290 002	NOV 20, 2001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

AP	+ ABBOTT	**50MG/ML**	**N19033 001**	APR 29, 1986
AP	ELKINS SINN	**50MG/ML**	**N70545 001**	MAY 14, 1986
AP		**50MG/ML**	**N70546 001**	MAY 14, 1986
AP	INTL MEDICATION	**50MG/ML**	**N70119 001**	APR 29, 1986
AP	LUITPOLD	**50MG/ML**	**N70891 001**	JUL 26, 1988

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ ABBOTT	**200MG/100ML**	**N19008 002**	APR 29, 1986
AP	+	**400MG/100ML**	**N19008 003**	APR 29, 1986
AP	+ B BRAUN	**200MG/100ML**	**N19121 002**	APR 29, 1986
AP	+	**400MG/100ML**	**N19121 003**	APR 29, 1986
	+	100MG/100ML	N19121 001	APR 29, 1986

BRETYLIUM TOSYLATE IN PLASTIC CONTAINER

AP	+ ABBOTT	**50MG/ML**	**N19030 001**	APR 29, 1986

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN P

+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

+	ALCON	1%	N20816 001	APR 01, 1998

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL
PARLODEL

+	NOVARTIS	EQ 5MG BASE	N17962 002	MAR 01, 1982

TABLET; ORAL
BROMOCRIPTINE MESYLATE

AB	LEK SVCS	**EQ 2.5MG BASE**	**N74631 001**	JAN 13, 1998

PARLODEL

AB	+ NOVARTIS	**EQ 2.5MG BASE**	**N17962 001**	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL
AMBENYL

AA	+ FORREST LABS	**12.5MG/5ML;10MG/5ML**	**N09319 006**	JAN 10, 1984

MYBANIL

AA	MORTON GROVE	**12.5MG/5ML;10MG/5ML**	**N88626 001**	OCT 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL
BROMPHENIRAMINE MALEATE

+	KV PHARM	2MG/5ML	N85466 001

INJECTABLE; INJECTION
BROMPHENIRAMINE MALEATE

+	STERIS	10MG/ML	N83821 001

FDA data supplied by DrugPatentWatch.com

BROMPHENIRAMINE MALEATE

TABLET; ORAL

	BROMPHENIRAMINE MALEATE			
AA	NYLOS	4MG	N85592 001	
AA	PHOENIX LABS NY	4MG	N85521 001	
AA	PVT FORM	4MG	N85888 001	
	VELTANE			
AA	LANNETT	4MG	N84088 001	

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	BROMANATE DC			
AA	ALPHARMA	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88723 001 FEB 25, 1985	
	MYPHETANE DC			
AA	+ MORTON GROVE	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985	

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

	BROMFED-DM			
AA	VERUM PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	N89681 001 DEC 22, 1988	
	DIMETANE-DX			
AA	+ ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N19279 001 AUG 24, 1984	
	MYPHETANE DX			
AA	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811 001 JUN 07, 1985	

BUDESONIDE

AEROSOL, METERED; NASAL

	RHINOCORT			
+	ASTRAZENECA	0.032MG/INH	N20233 001 FEB 14, 1994	

CAPSULE; ORAL

	ENTOCORT EC			
+	ASTRAZENECA	3MG	N21324 001 OCT 02, 2001	

BUDESONIDE

POWDER, METERED; INHALATION

	PULMICORT			
+	ASTRAZENECA	0.16MG/INH	N20441 002 JUN 24, 1997	

SPRAY, METERED; NASAL

	RHINOCORT			
	ASTRAZENECA	0.032MG/INH	N20746 001 OCT 01, 1999	
+		0.064MG/INH	N20746 002 OCT 01, 1999	

SUSPENSION; INHALATION

	PULMICORT RESPULES			
	ASTRAZENECA	0.25MG/2ML	N20929 001 AUG 08, 2000	
+		0.5MG/2ML	N20929 002 AUG 08, 2000	

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE			
AP	ABBOTT	0.25MG/ML	N74160 001 OCT 30, 1997	
AP		0.25MG/ML	N74332 001 OCT 31, 1994	
AP	BEDFORD	0.25MG/ML	N74441 001 JAN 27, 1995	
AP	GENSIA SICOR PHARMS	0.25MG/ML	N74613 001 NOV 18, 1997	
	BUMEX			
AP	+ ROCHE	0.25MG/ML	N18226 001 FEB 28, 1983	

TABLET; ORAL

	BUMETANIDE			
AB	EON	0.5MG	N74700 001 NOV 21, 1996	
AB		1MG	N74700 002 NOV 21, 1996	
AB		2MG	N74700 003 NOV 21, 1996	
AB	IVAX PHARMS	0.5MG	N74225 001 APR 24, 1995	

FDA data supplied by DrugPatentWatch.com

BUMETANIDE

TABLET; ORAL

	BUMETANIDE			
AB	IVAX PHARMS	1MG	N74225 002	APR 24, 1995
AB		2MG	N74225 003	APR 24, 1995
	BUMEX			
AB	ROCHE	0.5MG	N18225 002	FEB 28, 1983
AB		1MG	N18225 001	FEB 28, 1983
AB	+	2MG	N18225 003	JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPIVACAINE HCL			
AP	ABBOTT	0.25%	N18053 002	
AP		0.25%	N70583 001	FEB 17, 1987
AP		0.25%	N70586 001	MAR 03, 1987
AP		0.25%	N70590 001	FEB 17, 1987
AP		0.5%	N18053 001	
AP		0.5%	N70584 001	FEB 17, 1986
AP		0.5%	N70597 001	MAR 03, 1987
AP		0.5%	N70609 001	MAR 03, 1987
AP		0.75%	N18053 003	
AP		0.75%	N70585 001	MAR 03, 1987
AP		0.75%	N70587 001	MAR 03, 1987
	BUPIVACAINE HCL PRESERVATIVE FREE			
AP	INTL MEDICATED	0.25%	N76012 001	JAN 09, 2002
AP		0.5%	N76012 002	JAN 09, 2002
AP		0.75%	N76012 003	JAN 09, 2002
	MARCAINE HCL			
AP	+ ABBOTT	0.25%	N16964 001	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MARCAINE HCL			
AP	+ ABBOTT	0.5%	N16964 006	
	MARCAINE HCL PRESERVATIVE FREE			
AP	+ ABBOTT	0.25%	N16964 012	
AP	+	0.5%	N16964 005	
AP	+	0.75%	N16964 009	
	SENSORCAINE			
AP	ASTRAZENECA	0.25%	N18304 001	
AP		0.25%	N70552 001	MAY 21, 1986
AP		0.5%	N18304 002	
AP		0.5%	N70553 001	MAY 21, 1986
AP		0.75%	N18304 003	
AP		0.75%	N70554 001	MAY 21, 1986

INJECTABLE; SPINAL

	BUPIVACAINE			
AP	ABBOTT	0.75%	N71810 001	DEC 11, 1987
	MARCAINE			
AP	+ ABBOTT	0.75%	N18692 001	MAY 04, 1984
	SENSORCAINE			
AP	ASTRAZENECA	0.75%	N71202 001	APR 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

	BUPIVACAINE HCL AND EPINEPHRINE			
	+ ABBOTT	0.25%;0.005MG/ML	N71165 001	JUN 16, 1988
		0.25%;0.005MG/ML	N71166 001	JUN 16, 1988
		0.25%;0.005MG/ML	N71167 001	JUN 16, 1988
	+	0.5%;0.005MG/ML	N71168 001	JUN 16, 1988
		0.5%;0.005MG/ML	N71169 001	JUN 16, 1988
		0.5%;0.005MG/ML	N71170 001	JUN 16, 1988

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
BUPIVACAINE HCL AND EPINEPHRINE

	+	ABBOTT	0.75%;0.005MG/ML	N71171 001 JUN 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
MARCAINE HCL W/ EPINEPHRINE

AP	+	ABBOTT	**0.25%;0.0091MG/ML**	**N16964 004**
AP	+		**0.5%;0.0091MG/ML**	**N16964 008**
		MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE		
AP	+	ABBOTT	**0.25%;0.0091MG/ML**	**N16964 013**
AP	+		**0.5%;0.0091MG/ML**	**N16964 007**
AP	+		**0.75%;0.0091MG/ML**	**N16964 010**
		SENSORCAINE		
AP		ASTRAZENECA	**0.25%;0.0091MG/ML**	**N70966 001** OCT 13, 1987
AP			**0.25%;0.0091MG/ML**	**N70967 001** OCT 13, 1987
AP			**0.5%;0.0091MG/ML**	**N18304 004** SEP 02, 1983
AP			**0.5%;0.0091MG/ML**	**N70968 001** OCT 13, 1987
AP			**0.75%;0.0091MG/ML**	**N18304 005** SEP 02, 1983

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENEX

AP	+	RECKITT BENCKISER	**EQ 0.3MG BASE/ML**	**N18401 001**
		BUPRENORPHINE HCL		
AP		ABBOTT	**EQ 0.3MG BASE/ML**	**N74137 001** JUN 03, 1996

TABLET; SUBLINGUAL
SUBUTEX

		RECKITT BENCKISER	EQ 2MG BASE	N20732 002 OCT 08, 2002
	+		EQ 8MG BASE	N20732 003 OCT 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL
SUBOXONE

		RECKITT BENCKISER	2MG;0.5MG	N20733 001 OCT 08, 2002
	+		8MG;2MG	N20733 002 OCT 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HCL

AB		EON	**75MG**	**N75613 002** OCT 10, 2000
AB			**100MG**	**N75613 001** OCT 10, 2000
AB		GENEVA PHARMS TECH	**75MG**	**N75584 001** FEB 07, 2000
AB			**100MG**	**N75584 002** FEB 07, 2000
AB		MYLAN	**75MG**	**N75491 001** APR 17, 2000
AB			**100MG**	**N75491 002** APR 17, 2000
AB		TEVA	**75MG**	**N75310 001** NOV 29, 1999
AB			**100MG**	**N75310 002** NOV 29, 1999
		WELLBUTRIN		
AB		GLAXOSMITHKLINE	**75MG**	**N18644 002** DEC 30, 1985
AB	+		**100MG**	**N18644 003** DEC 30, 1985

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR

		GLAXOSMITHKLINE	50MG	N20358 001 OCT 04, 1996
			100MG	N20358 002 OCT 04, 1996
			150MG	N20358 003 OCT 04, 1996
	+		200MG	N20358 004 JUN 14, 2002
		ZYBAN		
	+	GLAXOSMITHKLINE	150MG	N20711 003 MAY 14, 1997

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

AB	BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986
AB		10MG	N18731 002	SEP 29, 1986
AB		15MG	N18731 003	APR 22, 1996
AB	+	30MG	N18731 004	APR 22, 1996

BUSPIRONE HCL

AB	EGIS	5MG	N75119 001	MAR 14, 2002
AB		10MG	N75119 002	MAR 14, 2002
AB	GENEVA PHARMS	5MG	N75413 001	MAR 19, 2002
AB		10MG	N75413 002	MAR 19, 2002
AB		15MG	N75413 003	MAR 19, 2002
AB	KV PHARM	5MG	N75572 001	FEB 27, 2002
AB		10MG	N75572 002	FEB 27, 2002
AB		15MG	N75572 003	FEB 27, 2002
AB	MYLAN	5MG	N75272 001	MAR 01, 2002
AB		10MG	N75272 002	MAR 01, 2002
AB		15MG	N75272 003	MAR 28, 2001
AB		30MG	N76008 001	JUN 28, 2001
AB	PAR PHARM	5MG	N75467 001	FEB 28, 2002
AB		7.5MG	N75467 002	MAR 28, 2001
AB		10MG	N75467 003	FEB 28, 2002
AB		15MG	N75467 004	FEB 28, 2002
AB	PHARMEX PRODS	5MG	N75388 001	MAY 09, 2002
AB		10MG	N75388 002	MAY 09, 2002

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB	PHARMEX PRODS	15MG	N75388 003	MAY 09, 2002
AB	TEVA	5MG	N75022 001	FEB 28, 2002
AB		10MG	N75022 002	FEB 28, 2002
AB		15MG	N75022 003	FEB 28, 2002
AB	TORPHARM	5MG	N75521 001	APR 05, 2002
AB		10MG	N75521 002	APR 05, 2002
AB		15MG	N75521 003	APR 05, 2002
AB	WATSON LABS	5MG	N74253 001	MAR 28, 2001
AB		10MG	N74253 002	MAR 28, 2001
AB		15MG	N74253 003	MAR 13, 2002
AB	ZENITH GOLDLINE	5MG	N75385 001	MAR 01, 2002
AB		10MG	N75385 002	MAR 01, 2002
AB		15MG	N75385 003	MAR 01, 2002

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+	ORPHAN MEDCL	6MG/ML	N20954 001 FEB 04, 1999

TABLET; ORAL

MYLERAN

+	GLAXOSMITHKLINE	2MG	N09386 001

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM

+	WALLACE LABS	30MG/5ML	N85380 001

FDA data supplied by DrugPatentWatch.com

BUTABARBITAL SODIUM

TABLET; ORAL

	BUTABARBITAL			
AA	BUNDY	**30MG**	**N85550 001**	
	BUTISOL SODIUM			
AA	+ WALLACE LABS	**30MG**	**N00793 004**	
	+	50MG	N00793 003	
	SODIUM BUTABARBITAL			
	MARSHALL PHARMA	16.2MG	N83524 001	
		32.4MG	N83858 001	

BUTALBITAL; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX			
+ BERTEK PHARMS	1%	N20524 001	
		OCT 18, 1996	
MENTAX-TC			
+ BERTEK	1%	N21408 001	
		OCT 17, 2002	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1			
+ KV PHARM	2%	N19881 001	
		FEB 07, 1997	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	ABBOTT	**1MG/ML**	**N75559 001**	
			MAR 20, 2000	
AP		**2MG/ML**	**N75559 002**	
			MAR 20, 2000	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	APOTEX	**2MG/ML**	**N75697 001**	
			OCT 23, 2001	
AP	BEDFORD	**2MG/ML**	**N75046 001**	
			AUG 12, 1998	
AP	MERIDIAN MEDCL TECHN	**1MG/ML**	**N75342 001**	
			NOV 04, 1999	
AP		**2MG/ML**	**N75342 002**	
			NOV 04, 1999	
	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	**1MG/ML**	**N74620 001**	
			JAN 22, 1997	
AP		**1MG/ML**	**N74626 001**	
			JAN 23, 1997	
AP		**2MG/ML**	**N74620 002**	
			JAN 22, 1997	
AP		**2MG/ML**	**N74626 002**	
			JAN 23, 1997	
AP	APOTEX	**1MG/ML**	**N75695 001**	
			OCT 23, 2001	
AP		**2MG/ML**	**N75695 002**	
			OCT 23, 2001	
AP	BEDFORD	**1MG/ML**	**N75045 001**	
			AUG 12, 1998	
AP		**2MG/ML**	**N75045 002**	
			AUG 12, 1998	
AP	FAULDING	**1MG/ML**	**N75170 001**	
			SEP 28, 1998	
AP		**2MG/ML**	**N75170 002**	
			SEP 28, 1998	
	STADOL			
AP	+ APOTHECON	**2MG/ML**	**N17857 004**	
	STADOL PRESERVATIVE FREE			
AP	+ APOTHECON	**1MG/ML**	**N17857 001**	
AP	+	**2MG/ML**	**N17857 002**	

SPRAY, METERED; NASAL

	BUTORPHANOL TARTRATE			
AB	MYLAN	**1MG/SPRAY**	**N75759 001**	
			AUG 08, 2001	
AB	NOVEX	**1MG/SPRAY**	**N75499 001**	
			DEC 04, 2002	
AB	ROXANE	**1MG/SPRAY**	**N75824 001**	
			MAR 12, 2002	
	STADOL			
AB	+ BRISTOL MYERS SQUIBB	**1MG/SPRAY**	**N19890 001**	
			DEC 12, 1991	

FDA data supplied by DrugPatentWatch.com

CABERGOLINE

TABLET; ORAL
DOSTINEX
+ PHARMACIA AND UPJOHN 0.5MG — N20664 001 DEC 23, 1996

CAFFEINE; *MULTIPLE*
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
CAFERGOT
+ NOVARTIS 100MG;2MG — N09000 002

TABLET; ORAL
ERCATAB
+ GENEVA PHARMS 100MG;1MG — N84294 001

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
CAFCIT
+ OPR DEVELOP LP EQ 10MG BASE/ML — N20793 001 SEP 21, 1999

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005% — N20554 001 JUL 22, 1996

OINTMENT; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005% — N20273 001 DEC 29, 1993

CALCIPOTRIENE

SOLUTION; TOPICAL
DOVONEX
+ BRISTOL MYERS SQUIBB 0.005% — N20611 001 MAR 03, 1997

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR
AP + AVENTIS **200 IU/ML** — **N17769 001**
MIACALCIN
AP + NOVARTIS **200 IU/ML** — **N17808 002** MAR 29, 1991

SPRAY, METERED; NASAL
MIACALCIN
+ NOVARTIS 200 IU/SPRAY — N20313 002 AUG 17, 1995

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL
AB TEVA **0.25 UGM** — **N75765 001** OCT 12, 2001
AB **0.5 UGM** — **N75765 002** OCT 12, 2001
ROCALTROL
AB ROCHE **0.25 UGM** — **N18044 001**
AB + **0.5 UGM** — **N18044 002**

INJECTABLE; INJECTION
CALCIJEX
AP + ABBOTT **0.001MG/ML** — **N18874 001** SEP 25, 1986
AP + **0.002MG/ML** — **N18874 002** SEP 25, 1986
CALCITRIOL
AP AM PHARM PARTNERS **0.001MG/ML** — **N75836 001** DEC 31, 2002
AP **0.002MG/ML** — **N75836 002** DEC 31, 2002

SOLUTION; ORAL
ROCALTROL
+ ROCHE 1 UGM/ML — N21068 001 NOV 20, 1998

FDA data supplied by DrugPatentWatch.com

CALCIUM ACETATE

CAPSULE; ORAL
PHOSLO GELCAPS
\+ BRAINTREE EQ 169MG CALCIUM N21160 003
APR 02, 2001

TABLET; ORAL
PHOSLO
\+ BRAINTREE EQ 169MG CALCIUM N19976 001
DEC 10, 1990

CALCIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
\+ ABBOTT 100MG/ML N21117 001
JAN 28, 2000

CALCIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
BSS PLUS
AT ALCON **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N18469 001**

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA
AT AKORN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001**
NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001
JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001
DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 37MG/100ML;5GM/100ML;30MG/100ML; 119MG/100ML;161MG/100ML;94MG/100ML; 138MG/100ML N17390 001

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN — 510MG/100ML;30GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML — N18807 001 AUG 26, 1983

510MG/100ML;30GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML — N18807 003 AUG 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN — 510MG/100ML;50GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML — N18807 002 AUG 26, 1983

510MG/100ML;50GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML — N18807 004 AUG 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18379 002

AT — 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18883 001 NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML — N18883 004 NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML — N20171 001 AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18379 003

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18883 002 NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML — N18883 005 NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML — N20171 002 AUG 19, 1992

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18379 007 JUN 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18379 001

AT — 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML — N18883 003 NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML — N18883 006 NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL — 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML — N20171 003 AUG 19, 1992

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 004** JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 005** JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 008** JUN 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 006** JUL 07, 1982

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;1.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 007 JAN 29, 1986

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;2.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 005 NOV 02, 1983

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;4.25GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 009 JAN 29, 1986

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 001**

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 003**

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 002**

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 001** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 002** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 003** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 004** DEC 04, 1992

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 007** JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 008** JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 010** NOV 18, 1985

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 009** JUL 09, 1984

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 004**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20163 001 DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N17512 005
AT		25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20163 002 DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N17512 011 NOV 18, 1985

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N17512 006
AT		25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20163 003 DEC 04, 1992

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 001 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 002 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 003 JUN 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 004 JUN 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	ORPHAN MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML; 1.9MG/ML;7.3MG/ML; 0.2MG/ML	N20577 001 SEP 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML; 380MG/100ML;600MG/100ML	N18258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18254 001

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18256 001
AP		33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N20000 001 APR 17, 1992
AP	BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N16695 001

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML;160MG/100ML	N19634 001 FEB 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML**	**N17608 001**

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML**	**N19634 003** FEB 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML**	**N16679 001**

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 002 APR 05, 1985
		20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19367 003 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 006** APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 002** OCT 17, 1988
AP		**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 008** OCT 17, 1988
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 004** APR 05, 1985
AP		**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 005** APR 05, 1985

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 007** APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 004** OCT 17, 1988
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 008** APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 001 APR 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML	N18895 001 JUL 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989

SOLUTION; IRRIGATION

BSS

+	ALCON	0.48MG/ML;0.3MG/ML;0.75MG/ML; 3.9MG/ML;6.4MG/ML; 1.7MG/ML	N20742 001 DEC 10, 1997

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
PLASMA-LYTE R IN PLASTIC CONTAINER

	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML; 74.6MG/100ML;640MG/100ML; 496MG/100ML;89.6MG/100ML	N17438	001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N75323	001
			APR 21, 2000	

PLEGISOL IN PLASTIC CONTAINER

AT	+ ABBOTT	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608	001
			FEB 26, 1982	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	33MG/100ML;30MG/100ML; 860MG/100ML	N18251	001
AP	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML	N18721	001
			NOV 09, 1982	
AP		33MG/100ML;30MG/100ML; 860MG/100ML	N20002	001
			APR 17, 1992	
AP	BAXTER HLTHCARE	33MG/100ML;30MG/100ML; 860MG/100ML	N16693	001

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	33MG/100ML;30MG/100ML; 860MG/100ML	N17635	001
AT	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML	N18156	001
AT	BAXTER HLTHCARE	33MG/100ML;30MG/100ML; 860MG/100ML	N18495	001
			FEB 19, 1982	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N17641	001
AP	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19632	001
			FEB 29, 1988	
AP	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N16682	001

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19416	001
			JAN 17, 1986	
AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681	001
			DEC 27, 1982	
AT	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18494	001
			FEB 19, 1982	
AT		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18921	001
			APR 03, 1984	
AT		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19933	001
			AUG 29, 1989	

CALFACTANT

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE

	+ ONY	35MG/ML	N20521	001
			JUL 01, 1998	

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

	ASTRAZENECA	4MG	N20838	001
			JUN 04, 1998	
		8MG	N20838	002
			JUN 04, 1998	

FDA data supplied by DrugPatentWatch.com

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND
ASTRAZENECA 16MG N20838 003 JUN 04, 1998
\+ 32MG N20838 004 JUN 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ATACAND HCT
ASTRAZENECA 16MG;12.5MG N21093 001 SEP 05, 2000
\+ 32MG;12.5MG N21093 002 SEP 05, 2000

CAPECITABINE

TABLET; ORAL
XELODA
HLR 150MG N20896 001 APR 30, 1998
\+ 500MG N20896 002 APR 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION
CAPASTAT SULFATE
\+ LILLY EQ 1GM BASE/VIAL N50095 001

CAPTOPRIL

TABLET; ORAL
CAPOTEN

AB	PAR PHARM	**12.5MG**	**N18343 005** JAN 17, 1985
AB		**25MG**	**N18343 002**
AB		**50MG**	**N18343 001**
AB	\+	**100MG**	**N18343 003**

CAPTOPRIL

AB	APOTHECON	**12.5MG**	**N74472 001** MAR 31, 1995

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	APOTHECON	**25MG**	**N74472 002** MAR 31, 1995
AB		**50MG**	**N74472 003** MAR 31, 1995
AB		**100MG**	**N74472 004** MAR 31, 1995
AB	CLONMEL HLTHCARE	**12.5MG**	**N74423 001** FEB 13, 1996
AB		**25MG**	**N74423 002** FEB 13, 1996
AB		**50MG**	**N74423 003** FEB 13, 1996
AB		**100MG**	**N74423 004** FEB 13, 1996
AB	COPLEY PHARM	**12.5MG**	**N74462 001** FEB 13, 1996
AB		**25MG**	**N74462 002** FEB 13, 1996
AB		**50MG**	**N74462 003** FEB 13, 1996
AB		**100MG**	**N74462 004** FEB 13, 1996
AB	EGIS PHARMS	**12.5MG**	**N74748 004** MAY 29, 1997
AB		**25MG**	**N74748 002** MAY 29, 1997
AB		**50MG**	**N74748 001** MAY 29, 1997
AB		**100MG**	**N74748 003** MAY 29, 1997
AB	ENDO LABS	**12.5MG**	**N74418 001** FEB 13, 1996
AB		**25MG**	**N74418 002** FEB 13, 1996
AB		**50MG**	**N74418 003** FEB 13, 1996
AB		**100MG**	**N74418 004** FEB 13, 1996
AB	EON	**12.5MG**	**N74519 001** FEB 13, 1996
AB		**25MG**	**N74519 002** FEB 13, 1996
AB		**50MG**	**N74519 003** FEB 13, 1996

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	EON	100MG	N74519 004	FEB 13, 1996
AB	GENEVA PHARMS	12.5MG	N74363 001	NOV 09, 1995
AB		25MG	N74363 002	NOV 09, 1995
AB		50MG	N74363 003	NOV 09, 1995
AB		100MG	N74363 004	NOV 09, 1995
AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996
AB		25MG	N74481 002	FEB 13, 1996
AB		50MG	N74481 003	FEB 13, 1996
AB		100MG	N74481 004	FEB 13, 1996
AB	HALLMARK PHARMS	12.5MG	N74477 001	FEB 13, 1996
AB		25MG	N74477 002	FEB 13, 1996
AB		50MG	N74477 003	FEB 13, 1996
AB		100MG	N74477 004	FEB 13, 1996
AB	IVAX PHARMS	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996
AB	MYLAN	12.5MG	N74434 001	FEB 13, 1996
AB		25MG	N74434 002	FEB 13, 1996
AB		50MG	N74434 003	FEB 13, 1996
AB		100MG	N74434 004	FEB 13, 1996
AB	PAR PHARM	12.5MG	N74493 001	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	PAR PHARM	25MG	N74493 002	FEB 13, 1996
AB		50MG	N74493 003	FEB 13, 1996
AB		100MG	N74493 004	FEB 13, 1996
AB	STASON	12.5MG	N74677 004	MAY 30, 1997
AB		25MG	N74677 002	MAY 30, 1997
AB		50MG	N74677 001	MAY 30, 1997
AB		100MG	N74677 003	MAY 30, 1997
AB	TEVA	12.5MG	N74322 001	FEB 13, 1996
AB		12.5MG	N74433 001	FEB 13, 1996
AB		12.5MG	N74483 001	FEB 13, 1996
AB		25MG	N74322 002	FEB 13, 1996
AB		25MG	N74433 002	FEB 13, 1996
AB		25MG	N74483 002	FEB 13, 1996
AB		50MG	N74322 003	FEB 13, 1996
AB		50MG	N74433 003	FEB 13, 1996
AB		50MG	N74483 003	FEB 13, 1996
AB		100MG	N74322 004	FEB 13, 1996
AB		100MG	N74433 004	FEB 13, 1996
AB		100MG	N74483 004	FEB 13, 1996
AB	TORPHARM	12.5MG	N74737 001	OCT 28, 1998
AB		25MG	N74737 002	OCT 28, 1998
AB		50MG	N74737 003	OCT 28, 1998

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	TORPHARM	100MG	**N74737 004** OCT 28, 1998	
AB	WATSON LABS	12.5MG	**N74386 001** MAY 23, 1996	
AB		12.5MG	**N74451 001** FEB 13, 1996	
AB		12.5MG	**N74576 001** APR 23, 1996	
AB		25MG	**N74386 002** MAY 23, 1996	
AB		25MG	**N74451 002** FEB 13, 1996	
AB		25MG	**N74576 002** APR 23, 1996	
AB		50MG	**N74386 003** MAY 23, 1996	
AB		50MG	**N74451 003** FEB 13, 1996	
AB		50MG	**N74576 003** APR 23, 1996	
AB		100MG	**N74386 004** MAY 23, 1996	
AB		100MG	**N74451 004** FEB 13, 1996	
AB		100MG	**N74576 004** APR 23, 1996	
AB	WEST WARD	12.5MG	**N74505 001** FEB 13, 1996	
AB		25MG	**N74505 002** FEB 13, 1996	
AB		50MG	**N74505 003** FEB 13, 1996	
AB		100MG	**N74505 004** FEB 13, 1996	
AB	WOCKHARDT	12.5MG	**N74532 001** MAR 28, 1997	
AB		25MG	**N74532 002** MAR 28, 1997	
AB		50MG	**N74532 003** MAR 28, 1997	
AB		100MG	**N74532 004** MAR 28, 1997	

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

AB	APOTHECON	25MG;15MG	**N18709 001** OCT 12, 1984	

CAPOZIDE 25/25

AB	+ APOTHECON	25MG;25MG	**N18709 002** OCT 12, 1984	

CAPOZIDE 50/15

AB	+ APOTHECON	50MG;15MG	**N18709 004** OCT 12, 1984	

CAPOZIDE 50/25

AB	APOTHECON	50MG;25MG	**N18709 003** OCT 12, 1984	

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	ENDO LABS	25MG;15MG	**N74788 001** DEC 29, 1997	
AB		25MG;25MG	**N74788 002** DEC 29, 1997	
AB		50MG;15MG	**N74788 004** DEC 29, 1997	
AB		50MG;25MG	**N74788 003** DEC 29, 1997	
AB	IVAX PHARMS	25MG;15MG	**N75055 001** JUN 18, 1998	
AB		25MG;25MG	**N75055 002** JUN 18, 1998	
AB		50MG;15MG	**N75055 004** JUN 18, 1998	
AB		50MG;25MG	**N75055 003** JUN 18, 1998	
AB	MYLAN	25MG;15MG	**N74896 001** DEC 29, 1997	
AB		25MG;25MG	**N74896 002** DEC 29, 1997	
AB		50MG;15MG	**N74896 004** DEC 29, 1997	
AB		50MG;25MG	**N74896 003** DEC 29, 1997	
AB	TEVA	25MG;15MG	**N74827 001** DEC 29, 1997	
AB		25MG;25MG	**N74827 002** DEC 29, 1997	
AB		50MG;15MG	**N74827 004** DEC 29, 1997	
AB		50MG;25MG	**N74827 003** DEC 29, 1997	

FDA data supplied by DrugPatentWatch.com

CARBACHOL

SOLUTION; INTRAOCULAR

	CARBASTAT			
AT	NOVARTIS	**0.01%**	**N73677 001**	APR 28, 1995
	MIOSTAT			
AT	+ ALCON	**0.01%**	**N16968 001**	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

	CARBATROL			
	+ SHIRE PHARM	100MG	N20712 003	SEP 30, 1997
	+	200MG	N20712 001	SEP 30, 1997
	+	300MG	N20712 002	SEP 30, 1997

SUSPENSION; ORAL

	CARBAMAZEPINE			
AB	MORTON GROVE	**100MG/5ML**	**N75714 001**	JUN 05, 2002
AB	TARO	**100MG/5ML**	**N75875 001**	DEC 21, 2000
	TEGRETOL			
AB	+ NOVARTIS	**100MG/5ML**	**N18927 001**	DEC 18, 1987

TABLET; ORAL

	CARBAMAZEPINE			
AB	APOTEX	**200MG**	**N75948 001**	FEB 27, 2002
AB	INWOOD LABS	**200MG**	**N70231 001**	AUG 14, 1986
AB	PUREPAC PHARM	**200MG**	**N71696 001**	NOV 09, 1987
AB	SIDMAK LABS NJ	**200MG**	**N71479 001**	JUL 24, 1987
AB	TARO	**200MG**	**N74649 001**	OCT 03, 1996
	EPITOL			
AB	TEVA	**200MG**	**N70541 001**	SEP 17, 1986
	TEGRETOL			
AB	+ NOVARTIS	**200MG**	**N16608 001**	

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

	CARBAMAZEPINE			
AB	CARACO	**100MG**	**N75712 001**	JUL 05, 2001
AB	TARO PHARM INDS	**100MG**	**N75687 001**	OCT 24, 2000
	+	200MG	N75687 002	JUL 29, 2002
AB	WARNER CHILCOTT	**100MG**	**N71940 001**	FEB 01, 1988
	EPITOL			
AB	TEVA	**100MG**	**N73524 001**	JUL 29, 1992
	TEGRETOL			
AB	+ NOVARTIS	**100MG**	**N18281 001**	

TABLET, EXTENDED RELEASE; ORAL

TEGRETOL-XR			
NOVARTIS	100MG	N20234 001	MAR 25, 1996
	200MG	N20234 002	MAR 25, 1996
+	400MG	N20234 003	MAR 25, 1996

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN			
+ PFIZER	EQ 382MG BASE	N50435 001	

CARBIDOPA

TABLET; ORAL

LODOSYN			
+ BRISTOL MYERS SQUIBB	25MG	N17830 001	

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	GENEVA PHARMS	**10MG;100MG**	**N73586 001**	JUN 29, 1995

FDA data supplied by DrugPatentWatch.com

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	GENEVA PHARMS	25MG;100MG	N73587 001	JUN 29, 1995
AB		25MG;250MG	N73620 001	JUN 29, 1995
AB	PUREPAC PHARM	10MG;100MG	N74260 001	SEP 03, 1993
AB		25MG;100MG	N74260 002	SEP 03, 1993
AB		25MG;250MG	N74260 003	SEP 03, 1993
AB	TEVA	10MG;100MG	N73618 001	AUG 28, 1992
AB		25MG;100MG	N73589 001	AUG 28, 1992
AB		25MG;250MG	N73607 001	AUG 28, 1992

SINEMET

AB	BRISTOL MYERS SQUIBB	10MG;100MG	N17555 001	
AB		25MG;100MG	N17555 003	
AB	+	25MG;250MG	N17555 002	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	MYLAN	25MG;100MG	N75091 002	APR 21, 2000
AB		50MG;200MG	N75091 001	SEP 30, 1999

SINEMET CR

AB	BRISTOL MYERS SQUIBB	25MG;100MG	N19856 002	DEC 24, 1992
AB	+	50MG;200MG	N19856 001	MAY 30, 1991

CARBOPLATIN

INJECTABLE; INJECTION

PARAPLATIN

+	BRISTOL MYERS SQUIBB	50MG/VIAL	N19880 001	MAR 03, 1989
+		150MG/VIAL	N19880 002	MAR 03, 1989
+		450MG/VIAL	N19880 003	MAR 03, 1989

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N17989 001

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	ABLE	350MG	N40421 001	JUN 21, 2001
AA	AMIDE PHARM	350MG	N40188 001	MAR 07, 1997
AA	COREPHARMA	350MG	N40397 001	SEP 21, 2000
AA	GENEVA PHARMS	350MG	N81025 001	APR 13, 1989
AA	MUTUAL PHARM	350MG	N89346 001	OCT 17, 1991
AA	VINTAGE PHARMS	350MG	N40245 001	SEP 08, 1997
AA	WATSON LABS	350MG	N40152 001	DEC 03, 1996
AA		350MG	N86179 001	
AA		350MG	N87499 001	APR 20, 1982
AA	WEST WARD	350MG	N40124 001	JAN 24, 1996

SOMA

AA	+ WALLACE LABS	350MG	N11792 001	

CARISOPRODOL; *MULTIPLE*

SEE ASPIRIN; CARISOPRODOL

SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+	GUILFORD PHARMS	7.7MG	N20637 001	SEP 23, 1996

INJECTABLE; INJECTION

BICNU

+	BRISTOL	100MG/VIAL	N17422 001	

FDA data supplied by DrugPatentWatch.com

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CARTEOLOL HCL				
AT	ALCON	1%	**N75476 001**		
			JAN 03, 2000		
AT	BAUSCH AND LOMB	1%	**N75546 001**		
			JAN 20, 2000		
AT	NOVEX	1%	**N76097 001**		
			FEB 06, 2002		
	OCUPRESS				
AT +	NOVARTIS	1%	**N19972 001**		
			MAY 23, 1990		

TABLET; ORAL

CARTROL			
ABBOTT	2.5MG	N19204 001	
		DEC 28, 1988	
+	5MG	N19204 002	
		DEC 28, 1988	

CARVEDILOL

TABLET; ORAL

COREG		
GLAXOSMITHKLINE	3.125MG	N20297 004
		MAY 29, 1997
	6.25MG	N20297 003
		SEP 14, 1995
	12.5MG	N20297 002
		SEP 14, 1995
+	25MG	N20297 001
		SEP 14, 1995

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS		
+ MERCK RES	50MG/VIAL	N21227 001
		JAN 26, 2001
+	70MG/VIAL	N21227 002
		JAN 26, 2001

CEFACLOR

CAPSULE; ORAL

	CECLOR			
AB	CEPH INTL	EQ 250MG BASE	**N62205 001**	
AB		EQ 500MG BASE	**N62205 002**	
AB	LILLY	EQ 250MG BASE	**N50521 001**	
AB +		EQ 500MG BASE	**N50521 002**	
	CEFACLOR			
AB	IVAX PHARMS	EQ 250MG BASE	**N64061 001**	
			APR 27, 1995	
AB		EQ 500MG BASE	**N64061 002**	
			APR 27, 1995	
AB	MARSAM PHARMS LLC	EQ 250MG BASE	**N64148 001**	
			MAY 23, 1996	
AB		EQ 500MG BASE	**N64148 002**	
			MAY 23, 1996	
AB	RANBAXY	EQ 250MG BASE	**N64156 001**	
			AUG 28, 1997	
AB		EQ 500MG BASE	**N64156 002**	
			AUG 28, 1997	
AB	TEVA	EQ 250MG BASE	**N64145 001**	
			JUN 24, 1996	
AB		EQ 500MG BASE	**N64145 002**	
			JUN 24, 1996	

FOR SUSPENSION; ORAL

	CECLOR			
AB	LILLY	EQ 125MG BASE/5ML	**N50522 001**	
AB		EQ 125MG BASE/5ML	**N62206 001**	
AB		EQ 187MG BASE/5ML	**N62206 003**	
			APR 20, 1988	
AB +		EQ 250MG BASE/5ML	**N50522 002**	
AB		EQ 250MG BASE/5ML	**N62206 002**	
AB +		EQ 375MG BASE/5ML	**N62206 004**	
			APR 20, 1988	
	CEFACLOR			
AB	IVAX PHARMS	EQ 375MG BASE/5ML	**N64070 001**	
			APR 28, 1995	
AB	MARSAM PHARMS LLC	EQ 125MG BASE/5ML	**N64204 001**	
			FEB 18, 1998	
AB		EQ 187MG BASE/5ML	**N64205 001**	
			FEB 18, 1998	
AB		EQ 250MG BASE/5ML	**N64206 001**	
			FEB 18, 1998	
AB		EQ 375MG BASE/5ML	**N64207 001**	
			FEB 18, 1998	
AB	RANBAXY	EQ 125MG BASE/5ML	**N64166 001**	
			OCT 02, 1997	

FDA data supplied by DrugPatentWatch.com

CEFACLOR

FOR SUSPENSION; ORAL

	CEFACLOR			
AB	RANBAXY	**EQ 187MG BASE/5ML**	**N64165 001**	
			OCT 02, 1997	
AB		**EQ 250MG BASE/5ML**	**N64164 001**	
			OCT 02, 1997	
AB		**EQ 375MG BASE/5ML**	**N64155 001**	
			OCT 02, 1997	

TABLET, EXTENDED RELEASE; ORAL

	CECLOR CD			
AB	+ LILLY	**EQ 500MG BASE**	**N50673 002**	
			JUN 28, 1996	
	CEFACLOR			
AB	IVAX PHARMS	**EQ 500MG BASE**	**N65057 001**	
			JAN 05, 2001	
AB	TEVA	**EQ 500MG BASE**	**N65058 002**	
			SEP 04, 2002	
		EQ 375MG BASE	N65058 001	
			SEP 04, 2002	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL			
AB	APOTHECON	**EQ 500MG BASE**	**N62291 001**	
AB	BARR	**EQ 500MG BASE**	**N65015 001**	
			JUN 22, 1999	
AB	IVAX PHARMS	**EQ 500MG BASE**	**N62766 001**	
			MAR 03, 1987	
	DURICEF			
AB	+ WARNER CHILCOTT	**EQ 500MG BASE**	**N50512 001**	

FOR SUSPENSION; ORAL

	DURICEF		
	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002
		EQ 250MG BASE/5ML	N50527 003
	+	EQ 500MG BASE/5ML	N50527 001

TABLET; ORAL

	CEFADROXIL			
AB	RANBAXY	**EQ 1GM BASE**	**N65018 001**	
			APR 23, 1999	
	DURICEF			
AB	+ WARNER CHILCOTT	**EQ 1GM BASE**	**N50528 001**	

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL		
	+ LILLY	EQ 1GM BASE/VIAL	N50504 002
	+	EQ 2GM BASE/VIAL	N50504 003

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANCEF			
AP	+ GLAXOSMITHKLINE	**EQ 500MG BASE/VIAL**	**N50461 002**	
AP	+	**EQ 1GM BASE/VIAL**	**N50461 003**	
AP	+	**EQ 5GM BASE/VIAL**	**N50461 004**	
AP	+	**EQ 10GM BASE/VIAL**	**N50461 005**	
	ANCEF IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 10MG BASE/ML	N63002 001	
			MAR 28, 1991	
	+	EQ 20MG BASE/ML	N63002 002	
			MAR 28, 1991	
	CEFAZOLIN AND DEXTROSE			
	+ B BRAUN	EQ 500MG BASE/VIAL	N50779 001	
			JUL 27, 2000	
	+	EQ 1GM BASE/VIAL	N50779 002	
			JUL 27, 2000	
	CEFAZOLIN SODIUM			
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N64169 001**	
			AUG 14, 1998	
AP		**EQ 1GM BASE/VIAL**	**N64169 002**	
			AUG 14, 1998	
AP		**EQ 10GM BASE/VIAL**	**N64170 001**	
			MAR 18, 1998	
AP		**EQ 20GM BASE/VIAL**	**N64170 002**	
			MAR 18, 1998	
AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N62831 001**	
			DEC 09, 1988	
AP		**EQ 1GM BASE/VIAL**	**N62831 002**	
			DEC 09, 1988	
AP		**EQ 10GM BASE/VIAL**	**N62831 003**	
			SEP 25, 1992	
AP	GLAXOSMITHKLINE	**EQ 1GM BASE/VIAL**	**N64033 001**	
			OCT 31, 1993	
AP	HANFORD GC	**EQ 1GM BASE/VIAL**	**N63207 001**	
			DEC 27, 1991	
AP		**EQ 1GM BASE/VIAL**	**N63208 001**	
			DEC 27, 1991	
AP		**EQ 10GM BASE/VIAL**	**N63209 001**	
			DEC 27, 1991	

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HANFORD GC	EQ 500MG BASE/VIAL	N63214 001	DEC 27, 1991
AP		EQ 500MG BASE/VIAL	N63216 001	DEC 27, 1991
AP	MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62988 001	DEC 29, 1989
AP		EQ 500MG BASE/VIAL	N62988 002	DEC 29, 1989
AP		EQ 1GM BASE/VIAL	N62988 003	DEC 29, 1989
AP		EQ 5GM BASE/VIAL	N62989 001	DEC 29, 1989
AP		EQ 10GM BASE/VIAL	N62989 002	DEC 29, 1989
AP		EQ 20GM BASE/VIAL	N62989 003	DEC 29, 1989
AP	TEVA	EQ 5GM BASE/VIAL	N63018 001	MAR 05, 1990
AP		EQ 10GM BASE/VIAL	N63018 002	MAR 05, 1990
AP	WESTWARD	EQ 500MG BASE/VIAL	N65047 001	SEP 18, 2001
AP		EQ 1GM BASE/VIAL	N65047 002	SEP 18, 2001

KEFZOL

AP	+ LILLY	EQ 250MG BASE/VIAL	N61773 001	
AP		EQ 500MG BASE/VIAL	N61773 002	
AP		EQ 1GM BASE/VIAL	N61773 003	
AP		EQ 10GM BASE/VIAL	N61773 004	
AP	+	EQ 20GM BASE/VIAL	N61773 005	SEP 08, 1987

CEFDINIR

CAPSULE; ORAL

OMNICEF

+	ABBOTT	300MG	N50739 001 DEC 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

+	ABBOTT	125MG/5ML	N50749 001 DEC 04, 1997

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

+	TAP PHARM	200MG	N21222 001 AUG 29, 2001

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION

MAXIPIME

+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N50679 001 JAN 18, 1996
+		EQ 1GM BASE/VIAL	N50679 002 JAN 18, 1996
+		EQ 2GM BASE/VIAL	N50679 003 JAN 18, 1996

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+	LEDERLE	100MG/5ML	N50622 001 APR 28, 1989

TABLET; ORAL

SUPRAX

+	LEDERLE	200MG	N50621 001 APR 28, 1989
+		400MG	N50621 002 APR 28, 1989

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

+	PFIZER	EQ 1GM BASE/VIAL	N50551 001 NOV 18, 1982
+		EQ 2GM BASE/VIAL	N50551 002 NOV 18, 1982
+		EQ 10GM BASE/VIAL	N50551 003 MAR 05, 1990

CEFOBID IN PLASTIC CONTAINER

+	PFIZER	EQ 20MG BASE/ML	N50613 002 JUL 31, 1987

FDA data supplied by DrugPatentWatch.com

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID IN PLASTIC CONTAINER

	+	PFIZER	EQ 40MG BASE/ML	N50613 001 JUL 23, 1986

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

AP		AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N64200 001** MAR 24, 2000
AP			**EQ 1GM BASE/VIAL**	**N64200 002** MAR 24, 2000
AP			**EQ 2GM BASE/VIAL**	**N64200 003** MAR 24, 2000
AP			**EQ 10GM BASE/VIAL**	**N64201 001** MAR 24, 2000
	+		EQ 20GM BASE/VIAL	N64201 002 MAR 24, 2000
AP		HIKMA	**EQ 500MG BASE/VIAL**	**N65072 001** NOV 20, 2002
AP			**EQ 1GM BASE/VIAL**	**N65072 002** NOV 20, 2002
AP			**EQ 2GM BASE/VIAL**	**N65072 003** NOV 20, 2002
AP			**EQ 10GM BASE/VIAL**	**N65071 001** NOV 20, 2002

CLAFORAN

AP	+	AVENTIS PHARMS	**EQ 500MG BASE/VIAL**	**N50547 001**
AP	+		**EQ 1GM BASE/VIAL**	**N50547 002**
AP	+		**EQ 2GM BASE/VIAL**	**N50547 003**
AP	+		**EQ 10GM BASE/VIAL**	**N50547 004** DEC 29, 1983
			EQ 1GM BASE/VIAL	N62659 001 JAN 13, 1987
			EQ 2GM BASE/VIAL	N62659 002 JAN 13, 1987

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 002 MAY 20, 1985
	+		EQ 40MG BASE/ML	N50596 004 MAY 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 001 MAY 20, 1985

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	AVENTIS PHARMS	EQ 40MG BASE/ML	N50596 003 MAY 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

	+	ASTRAZENECA	EQ 1GM BASE/VIAL	N50588 001 DEC 27, 1985
			EQ 1GM BASE/VIAL	N63293 001 APR 29, 1993
	+		EQ 2GM BASE/VIAL	N50588 002 DEC 27, 1985
			EQ 2GM BASE/VIAL	N63293 002 APR 29, 1993
	+		EQ 10GM BASE/VIAL	N50588 003 APR 25, 1988

CEFOTAN IN PLASTIC CONTAINER

	+	ASTRAZENECA	EQ 20MG BASE/ML	N50694 002 JUL 30, 1993
	+		EQ 40MG BASE/ML	N50694 001 JUL 30, 1993

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP		AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N65012 001** JUL 03, 2000
AP			**EQ 2GM BASE/2VIAL**	**N65012 002** JUL 03, 2000
AP			**EQ 10GM BASE/VIAL**	**N65011 001** JUL 03, 2000
AP		ESI LEDERLE	**EQ 1GM BASE/VIAL**	**N65051 001** SEP 11, 2000
AP			**EQ 2GM BASE/VIAL**	**N65051 002** SEP 11, 2000
AP			**EQ 10GM BASE/VIAL**	**N65050 001** SEP 11, 2000

MEFOXIN

AP	+	MERCK	**EQ 1GM BASE/VIAL**	**N50517 001**
AP			**EQ 1GM BASE/VIAL**	**N62757 001** JAN 08, 1987

FDA data supplied by DrugPatentWatch.com

CEFOXITIN SODIUM

INJECTABLE; INJECTION

		MEFOXIN			
AP	+	MERCK	**EQ 2GM BASE/VIAL**	**N50517 002**	
AP			**EQ 2GM BASE/VIAL**	**N62757 002**	JAN 08, 1987
AP	+		**EQ 10GM BASE/VIAL**	**N50517 003**	
		MEFOXIN IN PLASTIC CONTAINER			
		MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993
			EQ 40MG BASE/ML	N63182 002	JAN 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

		CEFPODOXIME PROXETIL			
AB		RANBAXY	**EQ 50MG BASE/5ML**	**N65082 001**	MAY 31, 2002
AB			**EQ 100MG BASE/5ML**	**N65082 002**	MAY 31, 2002
		VANTIN			
AB		PHARMACIA AND UPJOHN	**EQ 50MG BASE/5ML**	**N50675 001**	AUG 07, 1992
AB	+		**EQ 100MG BASE/5ML**	**N50675 002**	AUG 07, 1992

TABLET; ORAL

		VANTIN			
		PHARMACIA AND UPJOHN	EQ 100MG BASE	N50674 001	AUG 07, 1992
	+		EQ 200MG BASE	N50674 002	AUG 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

		CEFZIL			
		BRISTOL MYERS SQUIBB	125MG/5ML	N50665 001	DEC 23, 1991
	+		250MG/5ML	N50665 002	DEC 23, 1991

TABLET; ORAL

		CEFZIL			
		BRISTOL MYERS SQUIBB	250MG	N50664 001	DEC 23, 1991

CEFPROZIL

TABLET; ORAL

		CEFZIL			
	+	BRISTOL MYERS SQUIBB	500MG	N50664 002	DEC 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

		FORTAZ			
AP	+	GLAXOSMITHKLINE	**500MG/VIAL**	**N50578 001**	JUL 19, 1985
AP	+		**1GM/VIAL**	**N50578 002**	JUL 19, 1985
AP	+		**2GM/VIAL**	**N50578 003**	JUL 19, 1985
AP	+		**6GM/VIAL**	**N50578 004**	JUL 19, 1985
		TAZICEF			
AP		ABBOTT	**500MG/VIAL**	**N62662 001**	MAR 06, 1986
AP			**1GM/VIAL**	**N62662 002**	MAR 06, 1986
AP			**1GM/VIAL**	**N64032 001**	OCT 31, 1993
AP			**2GM/VIAL**	**N62662 003**	MAR 06, 1986
AP			**2GM/VIAL**	**N64032 002**	OCT 31, 1993
AP			**6GM/VIAL**	**N62662 004**	MAR 06, 1986
		TAZIDIME			
AP		LILLY	**500MG/VIAL**	**N62640 001**	NOV 20, 1985
AP			**1GM/VIAL**	**N62640 002**	NOV 20, 1985
AP			**1GM/VIAL**	**N62655 001**	NOV 20, 1985
AP			**2GM/VIAL**	**N62640 003**	NOV 20, 1985
AP			**2GM/VIAL**	**N62655 002**	NOV 20, 1985

FDA data supplied by DrugPatentWatch.com

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
	+ GLAXOSMITHKLINE	1GM/VIAL	N50646 002	SEP 27, 1990
	+	2GM/VIAL	N50646 003	SEP 27, 1990
	+	10GM/VIAL	N50646 004	SEP 27, 1990

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

	CEFTAZIDIME SODIUM IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	**EQ 20MG BASE/ML**	**N63221 002**	APR 29, 1993
AP		**EQ 40MG BASE/ML**	**N63221 003**	APR 29, 1993
	+	EQ 10MG BASE/ML	N63221 001	APR 29, 1993
	FORTAZ IN PLASTIC CONTAINER			
AP	+ GLAXOSMITHKLINE	**EQ 20MG BASE/ML**	**N50634 002**	APR 28, 1989
AP	+	**EQ 40MG BASE/ML**	**N50634 003**	APR 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

	CEDAX			
	+ BIOVAIL	EQ 400MG BASE	N50685 002	DEC 20, 1995

FOR SUSPENSION; ORAL

	CEDAX			
	BIOVAIL	EQ 90MG BASE/5ML	N50686 001	DEC 20, 1995
	+	EQ 180MG BASE/5ML	N50686 002	DEC 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

	CEFIZOX			
	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N63294 002	MAR 31, 1994
	AM PHARM PARTNERS	EQ 2GM BASE/VIAL	N63294 003	MAR 31, 1994
	+ FUJISAWA HLTHCARE	EQ 1GM BASE/VIAL	N50560 002	SEP 15, 1983
	+	EQ 2GM BASE/VIAL	N50560 003	SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005	MAR 19, 1993
	CEFIZOX IN PLASTIC CONTAINER			
	+ FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003	APR 13, 1995
	+	EQ 40MG BASE/ML	N50589 004	APR 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

	ROCEPHIN			
	+ HLR	EQ 250MG BASE/VIAL	N50585 001	DEC 21, 1984
		EQ 250MG BASE/VIAL	N63239 001	AUG 13, 1993
	+	EQ 500MG BASE/VIAL	N50585 002	DEC 21, 1984
		EQ 500MG BASE/VIAL	N63239 002	AUG 13, 1993
	+	EQ 1GM BASE/VIAL	N50585 003	DEC 21, 1984
		EQ 1GM BASE/VIAL	N62654 002	APR 30, 1987
		EQ 1GM BASE/VIAL	N63239 003	AUG 13, 1993
	+	EQ 2GM BASE/VIAL	N50585 004	DEC 21, 1984
		EQ 2GM BASE/VIAL	N62654 003	APR 30, 1987
	+	EQ 10GM BASE/VIAL	N50585 005	DEC 21, 1984
	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER			
	+ HLR	EQ 20MG BASE/ML	N50624 002	FEB 11, 1987
	+	EQ 40MG BASE/ML	N50624 003	FEB 11, 1987

FDA data supplied by DrugPatentWatch.com

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

	CEFTIN			
	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
+		EQ 250MG BASE/5ML	N50672 002	APR 29, 1997

TABLET; ORAL

	CEFTIN			
AB	GLAXOSMITHKLINE	**EQ 125MG BASE**	**N50605 001**	DEC 28, 1987
AB		**EQ 250MG BASE**	**N50605 002**	DEC 28, 1987
AB +		**EQ 500MG BASE**	**N50605 003**	DEC 28, 1987
	CEFUROXIME AXETIL			
AB	APOTEX	**EQ 250MG BASE**	**N65069 001**	OCT 02, 2002
AB		**EQ 500MG BASE**	**N65069 002**	OCT 02, 2002
AB	RANBAXY	**EQ 125MG BASE**	**N65043 003**	FEB 15, 2002
AB		**EQ 250MG BASE**	**N65043 002**	FEB 15, 2002
AB		**EQ 500MG BASE**	**N65043 001**	FEB 15, 2002

CEFUROXIME SODIUM

INJECTABLE; IM-IV

	CEFUROXIME			
AB	AM PHARM PARTNERS	**EQ 750MG BASE/VIAL**	**N65001 001**	MAY 30, 2001
AB	TEVA	**EQ 750MG BASE/VIAL**	**N64192 002**	APR 16, 1998
	CEFUROXIME SODIUM			
AB	HANFORD GC	**EQ 750MG BASE/VIAL**	**N64125 001**	MAY 30, 1997
AB	MARSAM PHARMS LLC	**EQ 750MG BASE/VIAL**	**N64035 001**	FEB 26, 1993
	KEFUROX			
AB	LILLY	**EQ 750MG BASE/VIAL**	**N62591 001**	JAN 10, 1986
	ZINACEF			
AB +	GLAXOSMITHKLINE	**EQ 750MG BASE/VIAL**	**N50558 002**	OCT 19, 1983

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME			
AP	AM PHARM PARTNERS	**EQ 1.5GM BASE/VIAL**	**N65001 002**	MAY 30, 2001
AP	TEVA	**EQ 1.5GM BASE/VIAL**	**N64192 001**	APR 16, 1998
AP		**EQ 7.5GM BASE/VIAL**	**N64191 001**	APR 16, 1998
	CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER			
+	B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001
+		EQ 30MG BASE/ML	N50780 002	FEB 21, 2001
	CEFUROXIME SODIUM			
AP	AM PHARM PARTNERS	**EQ 7.5GM BASE/VIAL**	**N65002 001**	SEP 28, 1998
AP	HANFORD GC	**EQ 1.5GM BASE/VIAL**	**N64125 002**	MAY 30, 1997
AP		**EQ 7.5GM BASE/VIAL**	**N64124 001**	MAY 30, 1997
AP	MARSAM PHARMS LLC	**EQ 1.5GM BASE/VIAL**	**N64035 002**	FEB 26, 1993
AP		**EQ 7.5GM BASE/VIAL**	**N64036 001**	FEB 26, 1993
	KEFUROX			
AP	LILLY	**EQ 1.5GM BASE/VIAL**	**N62591 002**	JAN 10, 1986
AP		**EQ 1.5GM BASE/VIAL**	**N62592 002**	JAN 10, 1986
AP		**EQ 7.5GM BASE/VIAL**	**N62591 003**	DEC 17, 1987
	ZINACEF			
AP +	GLAXOSMITHKLINE	**EQ 1.5GM BASE/VIAL**	**N50558 003**	OCT 19, 1983
AP +		**EQ 7.5GM BASE/VIAL**	**N50558 004**	OCT 23, 1986
	ZINACEF IN PLASTIC CONTAINER			
+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N50643 001	APR 28, 1989
+		EQ 30MG BASE/ML	N50643 002	APR 28, 1989

INJECTABLE; INTRAVENOUS

	KEFUROX			
AP	LILLY	**EQ 750MG BASE/VIAL**	**N62592 001**	JAN 10, 1986

FDA data supplied by DrugPatentWatch.com

CELECOXIB

CAPSULE; ORAL
CELEBREX

GD SEARLE LLC	100MG	N20998 001 DEC 31, 1998		
	200MG	N20998 002 DEC 31, 1998		
+	400MG	N20998 003 AUG 29, 2002		

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND

+ MISSION PHARMA	300GM/BOT	N18757 003 OCT 16, 1984	

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	APOTHECON	**EQ 250MG BASE**	**N63063 001** SEP 29, 1989	
AB		**EQ 250MG BASE**	**N63186 001** DEC 30, 1994	
AB		**EQ 500MG BASE**	**N63063 002** SEP 29, 1989	
AB		**EQ 500MG BASE**	**N63186 002** DEC 30, 1994	
AB	BARR	**EQ 250MG BASE**	**N62773 001** JUN 26, 1987	
AB		**EQ 500MG BASE**	**N62775 001** APR 22, 1987	
AB	IVAX PHARMS	**EQ 250MG BASE**	**N61969 001**	
AB		**EQ 500MG BASE**	**N61969 002**	
AB	LABS ATRAL	**EQ 250MG BASE**	**N62713 001** JUL 15, 1988	
AB		**EQ 500MG BASE**	**N62713 002** JUL 15, 1988	
AB	MJ PHARMS	**EQ 250MG BASE**	**N62791 001** JUN 11, 1987	
AB		**EQ 500MG BASE**	**N62791 002** JUN 11, 1987	
AB	RANBAXY	**EQ 250MG BASE**	**N65007 001** SEP 16, 1999	

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	RANBAXY	**EQ 500MG BASE**	**N65007 002** SEP 16, 1999	
AB	STEVENS J	**EQ 250MG BASE**	**N62870 001** MAR 17, 1988	
AB	TEVA	**EQ 250MG BASE**	**N62702 001** FEB 13, 1987	
AB		**EQ 250MG BASE**	**N62760 001** APR 24, 1987	
AB		**EQ 250MG BASE**	**N62821 001** FEB 05, 1988	
AB		**EQ 500MG BASE**	**N62702 002** FEB 13, 1987	
AB		**EQ 500MG BASE**	**N62761 001** APR 24, 1987	

KEFLEX

AB	CEPH INTL	**EQ 250MG BASE**	**N62118 001**	
AB		**EQ 500MG BASE**	**N62118 002**	
AB	LILLY	**EQ 250MG BASE**	**N50405 002**	
AB	+	**EQ 500MG BASE**	**N50405 003**	

FOR SUSPENSION; ORAL
CEPHALEXIN

AB	APOTHECON	**EQ 125MG BASE/5ML**	**N62986 001** APR 18, 1991	
AB		**EQ 250MG BASE/5ML**	**N62987 001** JUL 25, 1989	
AB	BARR	**EQ 250MG BASE/5ML**	**N62777 001** AUG 06, 1987	
AB	RANBAXY	**EQ 125MG BASE/5ML**	**N65081 001** JUL 27, 2001	
AB		**EQ 250MG BASE/5ML**	**N65081 002** JUL 27, 2001	
AB	TEVA	**EQ 125MG BASE/5ML**	**N62703 001** FEB 13, 1987	
AB		**EQ 125MG BASE/5ML**	**N62767 001** JUN 16, 1987	
AB		**EQ 250MG BASE/5ML**	**N62703 002** FEB 13, 1987	
AB		**EQ 250MG BASE/5ML**	**N62768 001** JUN 16, 1987	

KEFLEX

AB	CEPH INTL	**EQ 125MG BASE/5ML**	**N62117 002**	
AB	+	**EQ 250MG BASE/5ML**	**N62117 003**	
	+	EQ 100MG BASE/ML	N62117 001	

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN

TABLET; ORAL					
CEPHALEXIN					
AB TEVA	**EQ 250MG BASE**	**N63023 001**			
		JAN 12, 1989			
	EQ 500MG BASE	N63024 001			
		JAN 12, 1989			
KEFLET					
AB LILLY	**EQ 250MG BASE**	**N50440 003**			
		FEB 26, 1987			

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL					
KEFTAB					
+ LILLY	EQ 500MG BASE	N50614 002			
		OCT 29, 1987			

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION					
CEPHALOTHIN SODIUM					
AP BRISTOL	**EQ 1GM BASE/VIAL**	**N62464 001**			
		MAY 07, 1984			
AP	**EQ 2GM BASE/VIAL**	**N62464 002**			
		MAY 07, 1984			
AP	**EQ 4GM BASE/VIAL**	**N62464 003**			
		MAY 07, 1984			
KEFLIN					
AP + LILLY	**EQ 1GM BASE/VIAL**	**N50482 001**			
AP +	**EQ 2GM BASE/VIAL**	**N50482 002**			
AP +	**EQ 4GM BASE/VIAL**	**N50482 003**			

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION		
CEFADYL		
APOTHECON	EQ 1GM BASE/VIAL	N61769 001
	EQ 2GM BASE/VIAL	N61769 002
	EQ 4GM BASE/VIAL	N61769 003
	EQ 500MG BASE/VIAL	N62961 001
		SEP 20, 1988

CEPHRADINE

CAPSULE; ORAL			
ANSPOR			
AB GLAXOSMITHKLINE	**250MG**	**N61859 001**	
AB	**500MG**	**N61859 002**	
CEPHRADINE			
AB TEVA	**250MG**	**N62683 001**	
		JAN 09, 1987	
AB	**500MG**	**N62683 002**	
		JAN 09, 1987	
VELOSEF			
AB APOTHECON	**250MG**	**N61764 001**	
AB +	**500MG**	**N61764 002**	
FOR SUSPENSION; ORAL			
ANSPOR			
AB GLAXOSMITHKLINE	**125MG/5ML**	**N61866 001**	
AB	**250MG/5ML**	**N61866 002**	
CEPHRADINE			
AB TEVA	**125MG/5ML**	**N62693 001**	
		JAN 09, 1987	
AB	**250MG/5ML**	**N62693 002**	
		JAN 09, 1987	
VELOSEF '125'			
AB + APOTHECON	**125MG/5ML**	**N61763 001**	
VELOSEF '250'			
AB + APOTHECON	**250MG/5ML**	**N61763 002**	

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL			
ZYRTEC			
+ PFIZER	5MG/5ML	N20346 001	
		SEP 27, 1996	
TABLET; ORAL			
ZYRTEC			
PFIZER	5MG	N19835 001	
		DEC 08, 1995	
+	10MG	N19835 002	
		DEC 08, 1995	

FDA data supplied by DrugPatentWatch.com

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYRTEC-D 12 HOUR
+ PFIZER — 5MG;120MG — N21150 001 AUG 10, 2001

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE
+ SERONO INC — EQ 0.25MG BASE/ML — N21197 001 AUG 11, 2000
+ — EQ 3MG BASE/ML — N21197 002 AUG 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL
EXOSURF NEONATAL
+ GLAXOSMITHKLINE — 12MG/VIAL;108MG/VIAL; 8MG/VIAL — N20044 001 AUG 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC
+ DAIICHI — EQ 30MG BASE — N20989 002 JAN 11, 2000

CHLORAMBUCIL

TABLET; ORAL
LEUKERAN
+ GLAXOSMITHKLINE — 2MG — N10669 002

CHLORAMPHENICOL

CAPSULE; ORAL
MYCHEL
+ ARMENPHARM — 250MG — N60851 001

OINTMENT; OPHTHALMIC
CHLORAMPHENICOL
AT ALTANA — **1%** — **N60133 001**

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC
CHLOROMYCETIN
AT + PARKEDALE — **1%** — **N50156 001**
CHLOROPTIC S.O.P.
AT ALLERGAN — **1%** — **N61187 001**

SOLUTION/DROPS; OPHTHALMIC
CHLOROPTIC
+ ALLERGAN — 0.5% — N50091 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN
+ PARKEDALE — 0.5% — N50205 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL
ELASE-CHLOROMYCETIN
+ PARKE DAVIS — 10MG/GM;666 UNITS/GM; 1 UNIT/GM — N50294 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE
AP AM PHARM PARTNERS — **EQ 1GM BASE/VIAL** — **N62365 001** AUG 25, 1982
AP GRUPPO LEPETIT — **EQ 1GM BASE/VIAL** — **N62278 001**
CHLOROMYCETIN
AP + PARKEDALE — **EQ 1GM BASE/VIAL** — **N50155 001**

CHLORDIAZEPOXIDE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
AB BARR — **5MG** — **N84768 001**
AB — **10MG** — **N83116 001**
AB — **25MG** — **N84769 001**
AB IMPAX LABS — **10MG** — **N85113 001**
AB USL PHARMA — **10MG** — **N84623 001**

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZEPOXIDE HCL			
AB	WATSON LABS	5MG	N86383 001	
AB		10MG	N86294 001	
AB		25MG	N86382 001	
	LIBRIUM			
AB	ICN	5MG	N85461 001	
AB		10MG	N85472 001	
AB	+	25MG	N85475 001	

INJECTABLE; INJECTION

	LIBRIUM			
	+ ICN	100MG/AMP	N12301 001	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	CHLORHEXIDINE GLUCONATE			
AT	ALPHARMA	0.12%	N74291 001	DEC 28, 1995
AT	HI TECH PHARMA	0.12%	N74356 001	MAY 07, 1996
AT	NOVEX	0.12%	N75561 001	NOV 14, 2000
AT	TEVA	0.12%	N74522 001	DEC 15, 1995
	PERIDEX			
AT	+ ZILA	0.12%	N19028 001	AUG 13, 1986
	PERIOGARD			
AT	COLGATE	0.12%	N73695 001	JAN 14, 1994

TABLET; DENTAL

	PERIOCHIP			
	+ DEXCEL PHARMA	2.5MG	N20774 001	MAY 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLOROPROCAINE HCL			
AP	ABBOTT	2%	N87447 001	APR 16, 1982

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLOROPROCAINE HCL			
AP	ABBOTT	3%	N87446 001	APR 16, 1982
AP	BEDFORD	2%	N40273 001	SEP 09, 1998
AP		3%	N40273 002	SEP 09, 1998
	NESACAINE			
	+ ASTRAZENECA	1%	N09435 001	
		2%	N09435 002	
	NESACAINE-MPF			
AP	+ ASTRAZENECA	2%	N09435 006	MAY 02, 1996
AP	+	3%	N09435 007	MAY 02, 1996

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ARALEN HCL			
	+ SANOFI SYNTHELABO	EQ 40MG BASE/ML	N06002 002	

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	ARALEN			
AA	+ SANOFI SYNTHELABO	EQ 300MG BASE	N06002 001	
	CHLOROQUINE PHOSPHATE			
AA	IMPAX LABS	EQ 150MG BASE	N80880 001	
AA	+ WATSON LABS	EQ 150MG BASE	N87979 001	DEC 21, 1982
AA		EQ 300MG BASE	N88030 001	DEC 21, 1982
AA	WEST WARD	EQ 150MG BASE	N83082 001	
AA		EQ 300MG BASE	N83082 002	SEP 17, 1999

CHLOROTHIAZIDE

SUSPENSION; ORAL

	DIURIL			
	+ MERCK	250MG/5ML	N11870 001	

FDA data supplied by DrugPatentWatch.com

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

AB	MYLAN	**250MG**	**N84388 001**	
AB		**500MG**	**N84217 001**	
AB	WEST WARD	**250MG**	**N86028 001**	
			JUL 14, 1982	
AB		**500MG**	**N87736 001**	
			JUL 14, 1982	

DIURIL

AB	MERCK	**250MG**	**N11145 004**	
AB	+	**500MG**	**N11145 002**	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

	MERCK	150MG;250MG	N16016 001

ALDOCLOR-250

+	MERCK	250MG;250MG	N16016 002

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

DIUPRES-250

BP	MERCK	250MG;0.125MG	N11635 003
			AUG 26, 1987

DIUPRES-500

BP	+	MERCK	500MG;0.125MG	N11635 006
				AUG 26, 1987

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

+	MERCK	EQ 500MG BASE/VIAL	N11145 005

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

+	WESTWOOD SQUIBB	2%	N17594 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

AA	+	ICN	**4MG**	**N80598 001**
AA		MARSHALL PHARMA	**4MG**	**N83286 001**
AA		PHOENIX LABS NY	**4MG**	**N85522 001**
AA		SUPERPHARM	**4MG**	**N87747 001**
				APR 20, 1982
AA		TABLICAPS	**4MG**	**N83394 001**

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX

+	CELLTECH PHARMS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001	
			DEC 31, 1987	

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

+	GLAXOSMITHKLINE	25MG	N09149 024	
+		100MG	N09149 033	

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

+	GLAXOSMITHKLINE	200MG	N11120 019	
+		300MG	N11120 020	

CONCENTRATE; ORAL

CHLORPROMAZINE HCL

AA		ALPHARMA	**100MG/ML**	**N86863 001**
AA		PHARM ASSOC	**30MG/ML**	**N40231 001**
				DEC 30, 1999
AA			**100MG/ML**	**N40224 001**
				JAN 26, 1999

CHLORPROMAZINE HCL INTENSOL

AA		ROXANE	**30MG/ML**	**N88157 001**
				APR 27, 1983
AA			**100MG/ML**	**N88158 001**
				APR 27, 1983

SONAZINE

AA		GENEVA PHARMS	**30MG/ML**	**N80983 004**

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	SONAZINE			
AA	GENEVA PHARMS	100MG/ML	N80983 005	
	THORAZINE			
AA	+ GLAXOSMITHKLINE	30MG/ML	N09149 032	
AA	+	100MG/ML	N09149 043	

INJECTABLE; INJECTION

	CHLORPROMAZINE HCL			
AP	ELKINS SINN PHARM	25MG/ML	N83329 001	
	THORAZINE			
AP	+ GLAXOSMITHKLINE	25MG/ML	N09149 011	

SYRUP; ORAL

	SONAZINE			
AA	GENEVA PHARMS	10MG/5ML	N83040 001	
	THORAZINE			
AA	+ GLAXOSMITHKLINE	10MG/5ML	N09149 022	

TABLET; ORAL

	CHLORPROMAZINE HCL			
BP	GENEVA PHARMS	10MG	N80439 001	
BP		25MG	N80439 002	
BP		50MG	N80439 003	
BP		100MG	N80439 004	
BP		200MG	N80439 005	
BP	LEDERLE	10MG	N84803 001	
BP	USL PHARMA	10MG	N83386 001	
BP		25MG	N84112 001	
BP		50MG	N84113 001	
BP		100MG	N84114 001	
BP		200MG	N84115 001	
	THORAZINE			
BP	+ GLAXOSMITHKLINE	10MG	N09149 002	
BP		25MG	N09149 007	
BP		50MG	N09149 013	
BP	+	100MG	N09149 018	
BP		200MG	N09149 020	

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
AB	GENEVA PHARMS	100MG	N88725 001	AUG 31, 1984

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
AB	GENEVA PHARMS	250MG	N88726 001	AUG 31, 1984
AB	MYLAN	100MG	N88548 001	JUN 01, 1984
AB		250MG	N88549 001	JUN 01, 1984
AB	PAR PHARM	100MG	N88175 001	FEB 27, 1984
AB		250MG	N88176 001	FEB 27, 1984
AB	SIDMAK LABS NJ	100MG	N88921 001	APR 12, 1985
AB		250MG	N88922 001	APR 12, 1985
AB	SUPERPHARM	100MG	N88694 001	SEP 17, 1984
AB	WATSON LABS	100MG	N88852 001	SEP 26, 1984
AB		250MG	N88826 001	SEP 26, 1984
	DIABINESE			
AB	PFIZER	100MG	N11641 003	
AB	+	250MG	N11641 006	

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	GENEVA PHARMS	50MG	N87381 001	
AB	IVAX PHARMS	25MG	N88164 001	JAN 09, 1984
AB		50MG	N87176 001	
AB	MUTUAL PHARM	25MG	N89285 001	JUL 21, 1986
AB		50MG	N89286 001	JUL 21, 1986
AB	MYLAN	25MG	N87180 001	
AB		50MG	N86831 001	
AB	SIDMAK LABS NJ	25MG	N88902 001	SEP 19, 1985
AB		50MG	N88903 001	SEP 19, 1985
AB	USL PHARMA	25MG	N89051 001	JUN 01, 1987

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	WATSON LABS	25MG	N87100 001	
	HYGROTON			
AB	AVENTIS PHARMS	25MG	N12283 004	
AB	+	50MG	N12283 003	
	THALITONE			
BX	MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992
	+	15MG	N19574 001	DEC 20, 1988

CHLORTHALIDONE; *MULTIPLE*
SEE ATENOLOL; CHLORTHALIDONE

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

	CLORPRES			
AB	MYLAN	15MG;0.1MG	N71323 001	FEB 09, 1987
AB		15MG;0.2MG	N71324 001	FEB 09, 1987
	+	15MG;0.3MG	N71325 001	FEB 09, 1987

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	AMIDE PHARM	250MG	N88928 001	MAY 08, 1987
AA		500MG	N40113 001	SEP 29, 1995
AA	BARR	500MG	N89895 001	MAY 04, 1988
AA	GENEVA PHARMS	250MG	N89852 001	MAY 04, 1988
AA		500MG	N89853 001	MAY 04, 1988
AA	MUTUAL PHARM	500MG	N89970 001	SEP 27, 1990
AA	OHM LABS	250MG	N81298 001	DEC 29, 1993

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	OHM LABS	500MG	N81299 001	DEC 29, 1993
AA	PAR PHARM	250MG	N87981 001	SEP 20, 1983
AA	TEVA	500MG	N89859 001	MAY 04, 1988
AA	WATSON LABS	500MG	N40137 001	AUG 09, 1996
AA		500MG	N81040 001	AUG 22, 1989
	PARAFON FORTE DSC			
AA	+ ORTHO MCNEIL PHARM	500MG	N11529 002	JUN 15, 1987
	STRIFON FORTE DSC			
AA	FERNDALE LABS	500MG	N81008 001	DEC 23, 1988

CHOLECALCIFEROL; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74554 001	OCT 02, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74554 002	OCT 02, 1996
AB	EON	EQ 4GM RESIN/PACKET	N74557 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74557 002	AUG 15, 1996

FDA data supplied by DrugPatentWatch.com

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	IVAX PHARMS	**EQ 4GM RESIN/PACKET**	**N74771 001**	JUL 09, 1997
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74771 002**	JUL 09, 1997
AB	TEVA	**EQ 4GM RESIN/PACKET**	**N74347 001**	MAY 28, 1998
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74347 002**	MAY 28, 1998
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	**EQ 4GM RESIN/PACKET**	**N74555 001**	SEP 30, 1998
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74555 002**	SEP 30, 1998
AB	EON	**EQ 4GM RESIN/PACKET**	**N74558 001**	AUG 15, 1996
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74558 002**	AUG 15, 1996
AB	TEVA	**EQ 4GM RESIN/PACKET**	**N74348 001**	MAY 28, 1998
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74348 002**	MAY 28, 1998
	LOCHOLEST			
AB	EON	**EQ 4GM RESIN/PACKET**	**N74561 001**	AUG 15, 1996
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74561 002**	AUG 15, 1996
	LOCHOLEST LIGHT			
AB	EON	**EQ 4GM RESIN/PACKET**	**N74562 001**	AUG 15, 1996
AB		**EQ 4GM RESIN/SCOOPFUL**	**N74562 002**	AUG 15, 1996
	PREVALITE			
AB	UPSHER SMITH	**EQ 4GM RESIN/PACKET**	**N73263 001**	FEB 22, 1996
	QUESTRAN			
AB	+ BRISTOL MYERS	**EQ 4GM RESIN/PACKET**	**N16640 001**	
AB		**EQ 4GM RESIN/SCOOPFUL**	**N16640 003**	
	QUESTRAN LIGHT			
AB	BRISTOL MYERS	**EQ 4GM RESIN/PACKET**	**N19669 001**	DEC 05, 1988
AB		**EQ 4GM RESIN/SCOOPFUL**	**N19669 003**	DEC 05, 1988

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

	OVIDREL			
+	SERONO INC	0.25MG/VIAL	N21149 001	SEP 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

	CHROMIC CHLORIDE IN PLASTIC CONTAINER			
+	ABBOTT	EQ 0.004MG CHROMIUM/ML	N18961 001	JUN 26, 1986

CHROMIC PHOSPHATE, P-32

INJECTABLE; INJECTION

	PHOSPHOCOL P32			
+	MALLINCKRODT	5mCi/ML	N17084 001	

CICLOPIROX

CREAM; TOPICAL

	LOPROX			
+	MEDICIS	0.77%	N18748 001	DEC 30, 1982

GEL; TOPICAL

	LOPROX			
+	MEDICIS	0.77%	N20519 001	JUL 21, 1997

LOTION; TOPICAL

	LOPROX			
+	MEDICIS	0.77%	N19824 001	DEC 30, 1988

SOLUTION; TOPICAL

	PENLAC			
+	DERMIK LABS	8%	N21022 001	DEC 17, 1999

FDA data supplied by DrugPatentWatch.com

CIDOFOVIR

INJECTABLE; INJECTION
VISTIDE
+ GILEAD — EQ 75MG BASE/ML — N20638 001 JUN 26, 1996 — AB

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
PRIMAXIN

+ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N50587 001 NOV 26, 1985	AB	
	EQ 250MG BASE/VIAL; 250MG/VIAL	N62756 001 JAN 08, 1987	AB	
+	EQ 500MG BASE/VIAL; 500MG/VIAL	N50587 002 NOV 26, 1985	AB	
	EQ 500MG BASE/VIAL; 500MG/VIAL	N50630 001 DEC 14, 1990	AB	
	EQ 500MG BASE/VIAL; 500MG/VIAL	N62756 002 JAN 08, 1987	AB	
+	EQ 750MG BASE/VIAL; 750MG/VIAL	N50630 002 DEC 14, 1990	AB	

CILOSTAZOL

TABLET; ORAL
PLETAL

OTSUKA	50MG	N20863 001 JAN 15, 1999	AB	
+	100MG	N20863 002 JAN 15, 1999	AB	

CIMETIDINE

SOLUTION; ORAL
CIMETIDINE HCL

AA DURAMED PHARM BARR	**300MG/5ML**	**N75110 001** JUN 18, 1998	AB	

CIMETIDINE

TABLET; ORAL
CIMETIDINE

CLONMEL HLTHCARE	**300MG**	**N74340 001** JUN 23, 1995	AB	
	400MG	**N74340 002** JUN 23, 1995	AB	
	800MG	**N74339 001** JUN 23, 1995	AB	
ENDO PHARMS	**200MG**	**N74281 001** MAY 17, 1994	AB	
	300MG	**N74281 002** MAY 17, 1994	AB	
	400MG	**N74281 003** MAY 17, 1994	AB	
	800MG	**N74329 001** MAY 17, 1994	AB	
GENEVA PHARMS	**200MG**	**N74100 001** JAN 31, 1995	AB	
	300MG	**N74100 002** JAN 31, 1995	AB	
	400MG	**N74100 003** JAN 31, 1995	AB	
	800MG	**N74100 004** JAN 31, 1995	AB	
GENEVA PHARMS TECH	**200MG**	**N74506 001** JAN 24, 1996	AB	
	300MG	**N74506 002** JAN 24, 1996	AB	
	400MG	**N74506 003** JAN 24, 1996	AB	
	800MG	**N74506 004** JAN 24, 1996	AB	
IVAX PHARMS	**200MG**	**N74401 001** MAY 30, 1995	AB	
	200MG	**N74424 001** JUL 28, 1995	AB	
	300MG	**N74401 002** MAY 30, 1995	AB	
	300MG	**N74424 002** JUL 28, 1995	AB	
	400MG	**N74401 003** MAY 30, 1995	AB	
	400MG	**N74424 003** JUL 28, 1995	AB	
	800MG	**N74402 001** MAY 30, 1995	AB	

FDA data supplied by DrugPatentWatch.com

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	IVAX PHARMS	800MG	**N74424 004**	JUL 28, 1995
AB	LEK LJUBLJANA	300MG	**N74250 002**	JUN 29, 1995
AB		400MG	**N74250 003**	JUN 29, 1995
AB		800MG	**N74250 004**	JUN 29, 1995
AB	MYLAN	200MG	**N74246 001**	MAY 17, 1994
AB		300MG	**N74246 002**	MAY 17, 1994
AB		400MG	**N74246 003**	MAY 17, 1994
AB		800MG	**N74246 004**	MAY 17, 1994
AB	SIDMAK LABS NJ	200MG	**N74568 001**	FEB 27, 1997
AB		300MG	**N74568 002**	FEB 27, 1997
AB		400MG	**N74568 003**	FEB 27, 1997
AB		800MG	**N74566 001**	FEB 27, 1997
AB	TEVA	200MG	**N74151 001**	MAY 17, 1994
AB		200MG	**N74365 001**	FEB 28, 1995
AB		300MG	**N74151 002**	MAY 17, 1994
AB		300MG	**N74365 002**	FEB 28, 1995
AB		400MG	**N74151 003**	MAY 17, 1994
AB		400MG	**N74365 003**	FEB 28, 1995
AB		800MG	**N74365 004**	FEB 28, 1995
AB		800MG	**N74463 001**	MAY 17, 1994
AB	TORPHARM	200MG	**N74890 001**	DEC 18, 1998
AB		300MG	**N74890 002**	DEC 18, 1998

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	TORPHARM	400MG	**N74890 003**	DEC 18, 1998
AB		800MG	**N74890 004**	DEC 18, 1998
AB	WATSON LABS	200MG	**N74349 001**	AUG 30, 1996
AB		300MG	**N74349 002**	AUG 30, 1996
AB		400MG	**N74349 003**	AUG 30, 1996
AB		800MG	**N74316 001**	FEB 28, 1996

TAGAMET

AB	GLAXOSMITHKLINE	200MG	**N17920 002**	
AB		300MG	**N17920 003**	
AB		400MG	**N17920 004**	DEC 14, 1983
AB	+	800MG	**N17920 005**	APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	**N74296 001**	MAR 28, 1997
AP		EQ 300MG BASE/2ML	**N74344 001**	JAN 31, 1995
AP		EQ 300MG BASE/2ML	**N74345 001**	JAN 31, 1995
AP		EQ 300MG BASE/2ML	**N74412 001**	MAR 28, 1997
AP		EQ 300MG BASE/2ML	**N74422 001**	JAN 31, 1995
AP	CLONMEL HLTHCARE	EQ 300MG BASE/2ML	**N74428 001**	APR 25, 1996
AP	ENDO PHARMS	EQ 300MG BASE/2ML	**N74005 001**	AUG 31, 1994
AP	GENSIA SICOR PHARMS	EQ 300MG BASE/2ML	**N74252 001**	NOV 26, 1997
AP	LUITPOLD	EQ 300MG BASE/2ML	**N74353 001**	DEC 20, 1994

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 6MG BASE/ML	**N74269 001**	DEC 27, 1994

FDA data supplied by DrugPatentWatch.com

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	ABBOTT	EQ 90MG BASE/100ML	N74468 005 DEC 29, 1994
	+		EQ 120MG BASE/100ML	N74468 006 DEC 29, 1994
	+		EQ 180MG BASE/100ML	N74468 003 DEC 29, 1994
	+		EQ 240MG BASE/100ML	N74468 004 DEC 29, 1994
	+		EQ 360MG BASE/100ML	N74468 001 DEC 29, 1994
	+		EQ 480MG BASE/100ML	N74468 002 DEC 29, 1994

TAGAMET

AP	+	GLAXOSMITHKLINE	**EQ 300MG BASE/2ML**	**N17939 002**

TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	GLAXOSMITHKLINE	**EQ 6MG BASE/ML**	**N19434 001** OCT 31, 1985

SOLUTION; ORAL

CIMETIDINE HCL

AA		ALPHARMA	**EQ 300MG BASE/5ML**	**N74176 001** JUN 01, 1994
AA		COPLEY PHARM	**EQ 300MG BASE/5ML**	**N74859 001** JUL 09, 1998
AA		ENDO PHARMS	**EQ 300MG BASE/5ML**	**N74251 001** DEC 22, 1994
AA		HI TECH PHARMA	**EQ 300MG BASE/5ML**	**N74664 001** OCT 28, 1997
AA		MORTON GROVE	**EQ 300MG BASE/5ML**	**N74757 001** OCT 17, 1997
AA		NOVEX	**EQ 300MG BASE/5ML**	**N75560 001** MAR 15, 2000
AA		PHARM ASSOC	**EQ 300MG BASE/5ML**	**N74553 001** JAN 27, 1997
AA		ROXANE	**EQ 300MG BASE/5ML**	**N74541 001** AUG 05, 1997
AA		TEVA	**EQ 300MG BASE/5ML**	**N74610 001** SEP 26, 1996

TAGAMET

AA	+	GLAXOSMITHKLINE	**EQ 300MG BASE/5ML**	**N17924 001**

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

	BAYER	250MG/5ML	N20780 001 SEP 26, 1997
+		500MG/5ML	N20780 002 SEP 26, 1997

INJECTABLE; INJECTION

CIPRO

+	BAYER	10MG/ML	N19847 001 DEC 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAYER	200MG/100ML	N19857 001 DEC 26, 1990

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+	BAYER PHARMS	212.6MG;EQ 287.5MG BASE	N21473 001 DEC 13, 2002

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+	ALCON	EQ 0.3% BASE	N20369 001 MAR 30, 1998

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

+	ALCON	EQ 0.3% BASE	N19992 001 DEC 31, 1990

TABLET; ORAL

CIPRO

	BAYER	EQ 100MG BASE	N19537 001 APR 08, 1996
		EQ 250MG BASE	N19537 002 OCT 22, 1987
		EQ 500MG BASE	N19537 003 OCT 22, 1987
+		EQ 750MG BASE	N19537 004 OCT 22, 1987

FDA data supplied by DrugPatentWatch.com

CIPROFLOXACIN HYDROCHLORIDE; *MULTIPLE*
SEE CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
CIPRO HC
\+ ALCON — EQ 0.2% BASE;1% — N20805 001 FEB 10, 1998

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
NIMBEX
\+ ABBOTT — EQ 2MG BASE/ML — N20551 001 DEC 15, 1995

NIMBEX PRESERVATIVE FREE
\+ ABBOTT — EQ 2MG BASE/ML — N20551 003 DEC 15, 1995
\+ — EQ 10MG BASE/ML — N20551 002 DEC 15, 1995

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP AM PHARM PARTNERS — **1MG/ML** — **N74735 001** JUL 16, 1999
AP BEDFORD — **1MG/ML** — **N75036 001** NOV 07, 2000
AP — **10MG/VIAL** — **N74713 001** NOV 14, 2000
AP — **50MG/VIAL** — **N74713 002** NOV 14, 2000
AP GENSIA SICOR PHARMS — **1MG/ML** — **N74814 001** MAY 16, 2000
AP PHARMACHEMIE — **1MG/ML** — **N74656 001** MAY 16, 2000

PLATINOL
AP \+ BRISTOL MYERS — **10MG/VIAL** — **N18057 001**
AP \+ — **50MG/VIAL** — **N18057 002**

PLATINOL-AQ
AP \+ BRISTOL MYERS — **1MG/ML** — **N18057 004** NOV 08, 1988

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL
CELEXA
\+ FOREST LABS — EQ 10MG BASE/5ML — N21046 001 DEC 22, 1999

TABLET; ORAL
CELEXA
FOREST LABS — EQ 10MG BASE — N20822 001 APR 27, 2000
EQ 20MG BASE — N20822 002 JUL 17, 1998
\+ — EQ 40MG BASE — N20822 003 JUL 17, 1998

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION
RENACIDIN
UNITED GUARDIAN — 6.602GM/100ML;198MG/100ML; 3.177GM/100ML — N19481 001 OCT 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION
IRRIGATING SOLUTION G IN PLASTIC CONTAINER
AT BAXTER HLTHCARE — **3.24GM/100ML;380MG/100ML; 430MG/100ML** — **N18519 001** JUN 22, 1982

UROLOGIC G IN PLASTIC CONTAINER
AT ABBOTT — **3.24GM/100ML;380MG/100ML; 430MG/100ML** — **N18904 001** MAY 27, 1983

CITRIC ACID; UREA, C-13

TABLET, FOR SOLUTION; FOR SOLUTION; ORAL
IDKIT:HP
\+ ORIDION — N/A,4GM;75MG,N/A — N21314 001 DEC 17, 2002

FDA data supplied by DrugPatentWatch.com

CLADRIBINE

INJECTABLE; INJECTION

	CLADRIBINE			
AP	BEDFORD	**1MG/ML**	**N75405 001**	
			FEB 28, 2000	
	LEUSTATIN			
	+ ORTHO BIOTECH	1MG/ML	N20229 001	
			FEB 26, 1993	

CLARITHROMYCIN

FOR SUSPENSION; ORAL

	BIAXIN		
	ABBOTT	125MG/5ML	N50698 001
			DEC 23, 1993
	+	250MG/5ML	N50698 002
			DEC 23, 1993

TABLET; ORAL

	BIAXIN		
	+ ABBOTT	250MG	N50662 001
			OCT 31, 1991
	+	500MG	N50662 002
			OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL

	BIAXIN XL		
	+ ABBOTT	500MG	N50775 001
			MAR 03, 2000

CLARITHROMYCIN; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CLAVULANATE POTASSIUM; *MULTIPLE*
SEE AMOXICILLIN; CLAVULANATE POTASSIUM

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

	TIMENTIN		
	+ GLAXOSMITHKLINE	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N50590 001
			APR 01, 1985

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

	TIMENTIN		
	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N62691 001
			DEC 19, 1986
	+	EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N50590 002
			APR 01, 1985
	+	EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N50590 003
			AUG 18, 1987
	TIMENTIN IN PLASTIC CONTAINER		
	+ GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N50658 001
			DEC 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	ALPHARMA	**EQ 0.5MG BASE/5ML**	**N74075 001**	
			OCT 31, 1993	
AA	COPLEY PHARM	**EQ 0.5MG BASE/5ML**	**N73095 001**	
			APR 21, 1992	
AA	MORTON GROVE	**EQ 0.5MG BASE/5ML**	**N74863 001**	
			MAR 13, 1998	
AA	NOVEX	**EQ 0.5MG BASE/5ML**	**N75703 001**	
			NOV 27, 2000	
AA	SILARX	**EQ 0.5MG BASE/5ML**	**N74884 001**	
			DEC 17, 1997	
AA	TEVA	**EQ 0.5MG BASE/5ML**	**N73399 001**	
			JUN 30, 1994	
	TAVIST			
AA	+ NOVARTIS	**EQ 0.5MG BASE/5ML**	**N18675 001**	
			JUN 28, 1985	

TABLET; ORAL

	CLEMASTINE FUMARATE			
AB	GENEVA PHARMS	**2.68MG**	**N73459 001**	
			OCT 31, 1993	
AB	TEVA	**2.68MG**	**N73283 001**	
			JAN 31, 1992	
	TAVIST			
AB	+ NOVARTIS	**2.68MG**	**N17661 001**	

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HCL

AB		PHARMACIA AND UPJOHN	EQ 75MG BASE	N50162 001
AB			EQ 150MG BASE	N50162 002
AB	+		EQ 300MG BASE	N50162 003
				APR 14, 1988

CLINDAMYCIN HCL

AB		RANBAXY	EQ 150MG BASE	N65061 001
				FEB 02, 2001
AB			EQ 300MG BASE	N65061 002
				FEB 02, 2001
AB		TEVA	EQ 75MG BASE	N63027 001
				SEP 20, 1989
AB			EQ 150MG BASE	N63029 001
				SEP 20, 1989
AB		WATSON LABS	EQ 150MG BASE	N63083 001
				JUL 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

		PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644 001
				APR 07, 1986

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

	+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002
				MAR 02, 1998

GEL; TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50615 001
				JAN 07, 1987

CLINDAGEL

BT		GALDERMA LABS LP	EQ 1% BASE	N50782 001
				NOV 27, 2000

CLINDAMYCIN PHOSPHATE

AB		ALTANA	EQ 1% BASE	N64160 001
				JAN 28, 2000

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP	+	PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	N50441 001

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP		PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	N62803 001
				OCT 16, 1987

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N50639 001
				AUG 30, 1989
AP	+		EQ 12MG BASE/ML	N50639 002
				AUG 30, 1989
AP	+		EQ 18MG BASE/ML	N50639 003
				APR 10, 1991

CLINDAMYCIN PHOSPHATE

AP		ABBOTT	EQ 150MG BASE/ML	N62800 001
				JUL 24, 1987
AP			EQ 150MG BASE/ML	N62801 001
				JUL 24, 1987
AP		LEDERLE	EQ 150MG BASE/ML	N62889 001
				APR 25, 1988
AP		LOCH	EQ 150MG BASE/ML	N62905 001
				MAY 09, 1988

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP	+	AM PHARM PARTNERS	EQ 900MG BASE/100ML	N50635 001
				DEC 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	EQ 6MG BASE/ML	N65027 001
				JUN 29, 2001
AP			EQ 12MG BASE/ML	N65027 002
				JUN 29, 2001
AP			EQ 18MG BASE/ML	N65027 003
				JUN 29, 2001
AP	+	BAXTER HLTHCARE	EQ 6MG BASE/ML	N50648 001
				DEC 29, 1989
AP	+		EQ 900MG BASE/100ML	N50648 003
				DEC 29, 1989
AP	+		EQ 12MG BASE/ML	N50648 002
				DEC 29, 1989

LOTION; TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50600 001
				MAY 31, 1989

CLINDAMYCIN PHOSPHATE

AB		ALTANA	EQ 1% BASE	N65067 001
				JAN 31, 2002

SOLUTION; TOPICAL

CLEOCIN T

AT	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50537 001

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

	CLINDA-DERM			
AT	PADDOCK	EQ 1% BASE	**N63329 001**	SEP 30, 1992
	CLINDAMYCIN PHOSPHATE			
AT	ALPHARMA	EQ 1% BASE	**N62811 001**	SEP 01, 1988
AT	CLAY PARK	EQ 1% BASE	**N64050 001**	NOV 30, 1995
AT	FOUGERA	EQ 1% BASE	**N64159 001**	JUN 05, 1997
AT	MORTON GROVE	EQ 1% BASE	**N63304 001**	JUL 15, 1997
AT	STIEFEL	EQ 1% BASE	**N64108 001**	SEP 27, 1996

SUPPOSITORY; VAGINAL

	CLEOCIN			
+	PHARMACIA AND UPJOHN	100MG	N50767 001	AUG 13, 1999

SWAB; TOPICAL

	CLEOCIN			
AT	PHARMACIA AND UPJOHN	EQ 1% BASE	**N50537 002**	FEB 22, 1994
	CLINDAMYCIN PHOSPHATE			
AT	CLAY PARK	EQ 1% BASE	**N65049 001**	MAY 25, 2000
	CLINDETS			
AT	STIEFEL	EQ 1% BASE	**N64136 001**	SEP 30, 1996

CLINDAMYCIN PHOSPHATE; *MULTIPLE*
SEE BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL

	OLUX FOAM			
+	CONNETICS	0.05%	N21142 001	MAY 26, 2000

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB1	ALPHARMA US PHARM	**0.05%**	**N74139 001**	AUG 03, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB1	COPLEY PHARM	**0.05%**	**N74087 001**	FEB 16, 1994
AB1	FOUGERA	**0.05%**	**N74392 001**	SEP 30, 1996
AB1	STIEFEL	**0.05%**	**N75338 001**	FEB 09, 2001
AB2		**0.05%**	**N75733 001**	AUG 22, 2001
AB1	TARO	**0.05%**	**N74249 001**	JUL 08, 1996
	CLOBETASOL PROPIONATE (EMOLLIENT)			
AB2	ALTANA	**0.05%**	**N75430 001**	MAY 26, 1999
AB2	TARO	**0.05%**	**N75633 001**	MAY 17, 2000
	CORMAX			
AB1	HEALTHPOINT	**0.05%**	**N74220 001**	MAY 16, 1997
	EMBELINE E			
AB2	HEALTHPOINT	**0.05%**	**N75325 001**	DEC 24, 1998
	TEMOVATE			
AB1 +	GLAXOSMITHKLINE	**0.05%**	**N19322 001**	DEC 27, 1985
	TEMOVATE E			
AB2 +	GLAXOSMITHKLINE	**0.05%**	**N20340 001**	JUN 17, 1994

GEL; TOPICAL

	CLOBETASOL PROPIONATE			
AB	ALTANA	**0.05%**	**N75368 001**	FEB 15, 2000
AB	STIEFEL	**0.05%**	**N75027 001**	OCT 31, 1997
AB	TARO	**0.05%**	**N75279 001**	MAY 28, 1999
	EMBELINE			
AB	HEALTHPOINT	**0.05%**	**N76141 001**	APR 12, 2002
	TEMOVATE			
AB +	GLAXOSMITHKLINE	**0.05%**	**N20337 001**	APR 29, 1994

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	ALPHARMA US PHARM	**0.05%**	**N74128 001**	AUG 03, 1994

FDA data supplied by DrugPatentWatch.com

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	COPLEY PHARM	0.05%	N74089 001	FEB 16, 1994
AB	FOUGERA	0.05%	N74407 001	FEB 23, 1996
AB	STIEFEL	0.05%	N75057 001	AUG 12, 1998
AB	TARO	0.05%	N74248 001	JUL 12, 1996
	EMBELINE			
AB	HEALTHPOINT	0.05%	N74221 001	MAR 31, 1995
	TEMOVATE			
AB	+ GLAXOSMITHKLINE	0.05%	N19323 001	DEC 27, 1985

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE			
AT	ALPHARMA US PHARM	0.05%	N74331 001	DEC 15, 1995
AT	ALTANA	0.05%	N75391 001	FEB 08, 1999
AT	MORTON GROVE	0.05%	N75205 001	NOV 13, 1998
AT	TARO	0.05%	N75224 001	NOV 16, 1998
AT		0.05%	N75363 001	DEC 29, 2000
	EMBELINE			
AT	DPT	0.05%	N74222 001	DEC 06, 1995
	TEMOVATE			
AT	+ GLAXOSMITHKLINE	0.05%	N19966 001	FEB 22, 1990

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

	CLODERM		
+	HEALTHPOINT	0.1%	N17765 001

CLOFAZIMINE

CAPSULE; ORAL

	LAMPRENE		
	NOVARTIS	50MG	N19500 002 DEC 15, 1986

CLOFIBRATE

CAPSULE; ORAL

	ATROMID-S		
AB	+ WYETH AYERST	500MG	N16099 002
	CLOFIBRATE		
AB	BANNER PHARMACAPS	500MG	N73396 001 MAR 20, 1992
AB	TEVA	500MG	N72600 001 JUL 25, 1991
AB	USL PHARMA	500MG	N70531 001 JUN 16, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

	CLOMID		
AB	+ AVENTIS PHARMS	50MG	N16131 002
	CLOMIPHENE CITRATE		
AB	PAR PHARM	50MG	N75528 001 AUG 30, 1999
	MILOPHENE		
AB	MILEX	50MG	N72196 001 DEC 20, 1988
	SEROPHENE		
AB	SERONO	50MG	N18361 001 MAR 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	ANAFRANIL		
AB	TYCO HLTHCARE	25MG	N19906 001 DEC 29, 1989
AB	+	50MG	N19906 002 DEC 29, 1989
AB		75MG	N19906 003 DEC 29, 1989

FDA data supplied by DrugPatentWatch.com

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB	GENEVA PHARMS	25MG	N74364 001	MAR 29, 1996
AB		50MG	N74364 002	MAR 29, 1996
AB		75MG	N74364 003	MAR 29, 1996
AB	GENEVA PHARMS TECH	25MG	N74953 001	JUN 25, 1997
AB		50MG	N74953 002	JUN 25, 1997
AB		75MG	N74953 003	JUN 25, 1997
AB	MYLAN	25MG	N74947 001	APR 30, 1998
AB		50MG	N74947 002	APR 30, 1998
AB		75MG	N74947 003	APR 30, 1998
AB	TARO	25MG	N74694 001	DEC 31, 1996
AB		50MG	N74694 002	DEC 31, 1996
AB		75MG	N74694 003	DEC 31, 1996
AB	TEVA	25MG	N74849 001	APR 04, 1997
AB		25MG	N74958 001	AUG 26, 1997
AB		50MG	N74849 002	APR 04, 1997
AB		50MG	N74958 002	AUG 26, 1997
AB		75MG	N74849 003	APR 04, 1997
AB		75MG	N74958 003	AUG 26, 1997
AB	WATSON LAB	25MG	N74600 001	NOV 27, 1996
AB		50MG	N74600 002	NOV 27, 1996
AB		75MG	N74600 003	NOV 27, 1996
AB	WATSON LABS	25MG	N74751 001	SEP 30, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB	WATSON LABS	50MG	N74751 002	SEP 30, 1998
AB		75MG	N74751 003	SEP 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	ALPHAPHARM	0.5MG	N74940 001	OCT 30, 1997
AB		1MG	N74940 002	OCT 30, 1997
AB		2MG	N74940 003	OCT 30, 1997
AB	CARACO	0.5MG	N75423 001	APR 27, 2001
AB		1MG	N75423 002	APR 27, 2001
AB		2MG	N75423 003	APR 27, 2001
AB	EON	0.5MG	N74979 001	AUG 29, 1997
AB		1MG	N74979 002	AUG 29, 1997
AB		2MG	N74979 003	AUG 29, 1997
AB	GENEVA PHARMS TECH	0.5MG	N74925 001	SEP 30, 1997
AB		1MG	N74925 002	SEP 30, 1997
AB		2MG	N74925 003	SEP 30, 1997
AB	MYLAN	0.5MG	N75150 001	OCT 05, 1998
AB		1MG	N75150 002	OCT 05, 1998
AB		2MG	N75150 003	OCT 05, 1998
AB	PUREPAC PHARM	0.5MG	N74869 001	OCT 31, 1996
AB		1MG	N74869 002	OCT 31, 1996

FDA data supplied by DrugPatentWatch.com

CLONAZEPAM

TABLET; ORAL

	CLONAZEPAM			
AB	PUREPAC PHARM	2MG	N74869 003	OCT 31, 1996
AB	TEVA	0.5MG	N74569 001	SEP 10, 1996
AB		0.5MG	N74920 001	AUG 04, 1998
AB		1MG	N74569 002	SEP 10, 1996
AB		1MG	N74920 002	AUG 04, 1998
AB		2MG	N74569 003	SEP 10, 1996
AB		2MG	N74920 003	AUG 04, 1998
AB	TORPHARM	0.5MG	N75468 001	OCT 06, 2000
AB		1MG	N75468 002	OCT 06, 2000
AB		2MG	N75468 003	OCT 06, 2000
AB	WATSON LABS	0.5MG	N74964 001	DEC 30, 1997
AB		1MG	N74964 002	DEC 30, 1997
AB		2MG	N74964 003	DEC 30, 1997
	KLONOPIN			
AB	ROCHE	0.5MG	N17533 001	
AB	+	1MG	N17533 002	
AB		2MG	N17533 003	

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	CATAPRES-TTS-1			
	BOEHRINGER INGELHEIM	0.1MG/24HR	N18891 001	OCT 10, 1984
	CATAPRES-TTS-2			
	BOEHRINGER INGELHEIM	0.2MG/24HR	N18891 002	OCT 10, 1984
	CATAPRES-TTS-3			
+	BOEHRINGER INGELHEIM	0.3MG/24HR	N18891 003	OCT 10, 1984

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DURACLON			
+	ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996

TABLET; ORAL

	CATAPRES			
AB	BOEHRINGER INGELHEIM	0.1MG	N17407 001	
AB		0.2MG	N17407 002	
AB	+	0.3MG	N17407 003	
	CLONIDINE HCL			
AB	GENEVA PHARMS	0.1MG	N70887 001	AUG 31, 1988
AB		0.2MG	N70886 001	AUG 31, 1988
AB		0.3MG	N71294 001	AUG 31, 1988
AB	HALSEY	0.1MG	N70925 001	SEP 04, 1987
AB	LEDERLE	0.1MG	N71783 001	APR 05, 1988
AB		0.2MG	N71784 001	APR 05, 1988
AB		0.3MG	N71785 001	APR 05, 1988
AB	MYLAN	0.1MG	N70315 001	JUN 09, 1987
AB		0.2MG	N70316 001	JUN 09, 1987
AB		0.3MG	N70317 001	JUN 09, 1987
AB	PUREPAC PHARM	0.1MG	N70974 001	DEC 16, 1986
AB		0.2MG	N70975 001	DEC 16, 1986
AB		0.3MG	N70976 001	DEC 16, 1986
AB	WATSON LABS	0.1MG	N70965 001	JUL 08, 1986
AB		0.2MG	N70964 001	JUL 08, 1986
AB		0.3MG	N70963 001	JUL 08, 1986

CLONIDINE HYDROCHLORIDE; *MULTIPLE*
SEE CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CLOPIDOGREL BISULFATE

TABLET; ORAL

	PLAVIX				
+	SANOFI SYNTHELABO	EQ 75MG BASE	N20839 001 NOV 17, 1997		

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

	CLORAZEPATE DIPOTASSIUM				
AB	GENEVA PHARMS	3.75MG	**N72219 001** AUG 26, 1988		
AB		7.5MG	**N72220 001** AUG 26, 1988		
AB		15MG	**N72112 001** AUG 26, 1988		
AB	LEDERLE	3.75MG	**N71742 001** DEC 14, 1987		
AB		7.5MG	**N71743 001** DEC 14, 1987		
AB		15MG	**N71744 001** DEC 14, 1987		
AB	MYLAN	3.75MG	**N71509 001** OCT 19, 1987		
AB		7.5MG	**N71510 001** OCT 19, 1987		
AB	+	15MG	**N71511 001** OCT 19, 1987		

TABLET; ORAL

	CLORAZEPATE DIPOTASSIUM				
AB	ABLE	3.75MG	**N71780 001** JUN 26, 1987		
AB		7.5MG	**N71781 001** JUN 26, 1987		
AB		15MG	**N71782 001** JUN 26, 1987		
AB	GENEVA PHARMS	7.5MG	**N72513 001** MAY 11, 1990		
AB		15MG	**N72514 001** MAY 11, 1990		
AB	MYLAN	3.75MG	**N71856 001** JUL 17, 1987		
AB		7.5MG	**N71857 001** JUL 17, 1987		
AB		15MG	**N71858 001** JUL 17, 1987		

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

	CLORAZEPATE DIPOTASSIUM				
AB	TARO	3.75MG	**N75731 003** APR 27, 2000		
AB		7.5MG	**N75731 002** APR 27, 2000		
AB		15MG	**N75731 001** APR 27, 2000		
AB	WATSON LABS	3.75MG	**N71852 001** FEB 09, 1988		
AB		7.5MG	**N71853 001** FEB 09, 1988		
AB		15MG	**N71854 001** FEB 09, 1988		
	GEN-XENE				
AB	ALRA	3.75MG	**N71787 001** APR 26, 1988		
AB		7.5MG	**N71788 001** APR 26, 1988		
AB		15MG	**N71789 001** APR 26, 1988		
	TRANXENE				
AB	OVATION PHARMS	3.75MG	**N17105 006**		
AB		7.5MG	**N17105 007**		
AB	+	15MG	**N17105 008**		
	TRANXENE SD				
	OVATION PHARMS	11.25MG	N17105 005		
	+	22.5MG	N17105 004		

CLOTRIMAZOLE

CREAM; TOPICAL

	CLOTRIMAZOLE				
AB	TARO	1%	**N72640 001** AUG 31, 1993		
	LOTRIMIN				
AB	+ SCHERING PLOUGH	1%	**N17619 001**		
	MYCELEX				
BT	BAYER	1%	N18183 001		

LOTION; TOPICAL

	LOTRIMIN				
+	SCHERING	1%	N18813 001 FEB 17, 1984		

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE

SOLUTION; TOPICAL

	CLOTRIMAZOLE			
AT	TARO	1%	**N74580 001**	JUL 29, 1996
AT	TEVA	1%	**N73306 001**	FEB 28, 1995
	LOTRIMIN			
AT	+ SCHERING PLOUGH	1%	**N17613 001**	
	MYCELEX			
AT	+ BAYER	1%	**N18181 001**	

TROCHE/LOZENGE; ORAL

	MYCELEX		
+	BAYER	10MG	N18713 001 JUN 17, 1983

CLOTRIMAZOLE; *MULTIPLE*
SEE BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CLOXACILLIN SODIUM

CAPSULE; ORAL

	CLOXACILLIN SODIUM			
AB	TEVA	EQ 250MG BASE	**N62240 001**	
AB		EQ 500MG BASE	**N62240 002**	
	CLOXAPEN			
AB	GLAXOSMITHKLINE	EQ 250MG BASE	**N61806 001**	
AB	+	EQ 500MG BASE	**N61806 002**	

FOR SOLUTION; ORAL

	CLOXACILLIN SODIUM		
+	TEVA	EQ 125MG BASE/5ML	N62268 001

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	CARACO	25MG	**N75713 001**	NOV 15, 2002
AB		100MG	**N75713 002**	NOV 15, 2002
AB	IVAX PHARMS	25MG	**N74949 001**	NOV 26, 1997

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	IVAX PHARMS	100MG	**N74949 002**	NOV 26, 1997
AB	MYLAN	25MG	**N75417 001**	MAY 27, 1999
AB		100MG	**N75417 002**	MAY 27, 1999
	CLOZARIL			
AB	NOVARTIS	25MG	**N19758 001**	SEP 26, 1989
AB	+	100MG	**N19758 002**	SEP 26, 1989

COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

	RUBRATOPE-57 KIT		
	BRACCO	N/A;N/A;N/A;N/A	N16089 001

CODEINE PHOSPHATE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
SEE BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN VC W/ CODEINE			
AA	+ WYETH AYERST	10MG/5ML;5MG/5ML; 6.25MG/5ML	**N08306 005**	APR 02, 1984
	PROMETH VC W/ CODEINE			
AA	ALPHARMA	10MG/5ML;5MG/5ML; 6.25MG/5ML	**N88764 001**	OCT 31, 1984

FDA data supplied by DrugPatentWatch.com

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC W/ CODEINE

AA		MORTON GROVE	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88896 001** JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE

AA	+	WYETH AYERST	**10MG/5ML;6.25MG/5ML**	**N08306 004** APR 02, 1984

PROMETH W/ CODEINE

AA		ALPHARMA	**10MG/5ML;6.25MG/5ML**	**N88763 001** OCT 31, 1984

PROMETHAZINE HCL AND CODEINE PHOSPHATE

AA		HI TECH PHARMA	**10MG/5ML;6.25MG/5ML**	**N40151 001** AUG 26, 1997
AA		PHARM ASSOC	**10MG/5ML;6.25MG/5ML**	**N89647 001** DEC 22, 1988

PROMETHAZINE W/ CODEINE

AA		MORTON GROVE	**10MG/5ML;6.25MG/5ML**	**N88875 001** DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

AA		ALPHARMA	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N88704 001** MAR 22, 1985

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	+	MORTON GROVE	**10MG/5ML;30MG/5ML; 1.25MG/5ML**	**N88833 001** NOV 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

BP	+	WATSON LABS	0.5MG;500MG	N84279 001

PROBENECID AND COLCHICINE

BP		IVAX PHARMS	0.5MG;500MG	N83734 001

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

WELCHOL

	+	SANKYO	625MG	N21176 001 MAY 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

		PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N17563 003 SEP 22, 1995
	+		5GM/PACKET	N17563 004 SEP 22, 1995

FLAVORED COLESTID

	+	PHARMACIA AND UPJOHN	5GM/PACKET	N17563 001
			5GM/SCOOPFUL	N17563 002

TABLET; ORAL

COLESTID

		PHARMACIA AND UPJOHN	1GM	N20222 001 JUL 19, 1994

COLFOSCERIL PALMITATE; *MULTIPLE*

SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP		PHARMA TEK	**EQ 150MG BASE/VIAL**	**N64216 001** FEB 26, 1999

COLY-MYCIN M

AP	+	PARKEDALE	**EQ 150MG BASE/VIAL**	**N50108 002**

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

	+	PARKEDALE	EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML	N50356 001

FDA data supplied by DrugPatentWatch.com

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A

	+	POPULATION COUNCIL	309MG/COPPER	N18680 001 NOV 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION
ACTHREL

	+	FERRING	EQ 0.1MG BASE/VIAL	N20162 001 MAY 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN

BC		ORGANICS LAGRANGE	80 UNITS/ML	N10831 002
	+		40 UNITS/ML	N10831 001
		H.P. ACTHAR GEL		
BC	+	QUESTCOR PHARMS	80 UNITS/ML	N08372 008

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

BP		PHARMACIA AND UPJOHN	25MG	N08126 001
			5MG	N08126 003
			10MG	N08126 004
BP		WEST WARD	25MG	N80776 002
		CORTONE		
BP	+	MERCK	25MG	N07750 003

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN

	+	ORGANON	0.25MG/VIAL	N16750 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL

	+	AVENTIS	0.8MG/INH	N18887 001 DEC 05, 1985

SOLUTION; INHALATION
CROMOLYN SODIUM

AN		ALPHARMA	**10MG/ML**	**N75067 001** JUL 19, 1999
AN		BAUSCH AND LOMB	**10MG/ML**	**N75585 001** DEC 21, 2000
AN		DEY	**10MG/ML**	**N74209 001** APR 26, 1994
AN		IVAX PHARMS	**10MG/ML**	**N75271 001** JAN 18, 2000
AN		MORTON GROVE	**10MG/ML**	**N75346 001** OCT 25, 1999
AN		NOVEX	**10MG/ML**	**N75333 001** APR 30, 2002
AN		ROXANE	**10MG/ML**	**N75175 001** SEP 30, 1999
AN		WARRICK PHARMS	**10MG/ML**	**N75437 001** APR 21, 2000

INTAL

AN	+	AVENTIS PHARMS	**10MG/ML**	**N18596 001** MAY 28, 1982

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

	+	CELLTECH PHARMS	100MG/5ML	N20479 001 FEB 29, 1996

SOLUTION/DROPS; OPHTHALMIC
CROLOM

AT		BAUSCH AND LOMB	**4%**	**N74443 001** JAN 30, 1995

CROMOLYN SODIUM

AT		AKORN	**4%**	**N74706 001** APR 29, 1998
AT		ALCON	**4%**	**N75282 001** JUN 16, 1999
AT		NOVEX	**4%**	**N75615 001** JAN 26, 2001

CROMOPTIC

AT		KING PHARMS	**4%**	**N75088 001** APR 27, 1999

FDA data supplied by DrugPatentWatch.com

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

		OPTICROM			
AT	+	ALLERGAN	**4%**	**N18155 001**	OCT 03, 1984

CROTAMITON

CREAM; TOPICAL

		EURAX		
	+	WESTWOOD SQUIBB	10%	N06927 001

LOTION; TOPICAL

		CROTAN		
AT		SUMMERS	**10%**	**N87204 001**
		EURAX		
AT	+	WESTWOOD SQUIBB	**10%**	**N09112 003**

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

	+	ABBOTT	EQ 0.4MG COPPER/ML	N18960 001 JUN 26, 1986

CYANOCOBALAMIN

GEL, METERED; NASAL

		NASCOBAL		
	+	NASTECH PHARM	0.5MG/INH	N19722 001 NOV 05, 1996

INJECTABLE; INJECTION

		CYANOCOBALAMIN		
AP		AM PHARM PARTNERS	**0.1MG/ML**	**N80557 002**
AP		ELKINS SINN	**1MG/ML**	**N80515 002**
AP		LUITPOLD	**1MG/ML**	**N80737 001**
AP		STERIS	**0.1MG/ML**	**N80573 002**
AP			**1MG/ML**	**N80573 001**
AP			**1MG/ML**	**N83120 002**
AP		WYETH AYERST	**0.1MG/ML**	**N80554 001**
AP			**1MG/ML**	**N80554 002**
		RUBRAMIN PC		
AP	+	BRISTOL MYERS SQUIBB	**1MG/ML**	**N06799 010** APR 28, 1988

CYANOCOBALAMIN

INJECTABLE; INJECTION

		VIBISONE		
AP		AM PHARM PARTNERS	**1MG/ML**	**N80557 003**

TABLET; ORAL

CYANOCOBALAMIN

	+	WEST WARD	1MG	N84264 001

CYANOCOBALAMIN; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL

		RUBRATOPE-57		
		BRACCO	0.5-1 uCi	N16089 002

CYANOCOBALAMIN, CO-57; *MULTIPLE*

SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

FDA data supplied by DrugPatentWatch.com

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL			
AB	GENEVA PHARMS	10MG	N72854 001	NOV 19, 1991
AB	GENEVA PHARMS TECH	10MG	N73683 001	FEB 26, 1993
AB	HALSEY	10MG	N73541 001	MAY 23, 1995
AB	MYLAN	10MG	N73144 001	MAY 30, 1991
AB	SIDMAK LABS NJ	10MG	N74421 001	SEP 29, 1995
AB	WATSON LABS	10MG	N71611 001	MAY 03, 1989
AB		10MG	N73143 001	NOV 27, 1991
AB		10MG	N74436 001	NOV 30, 1994
	FLEXERIL			
AB	+ MCNEIL CONS SPECLT	10MG	N17821 002	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPENTOLATE			
AT	AKORN	1%	N40164 001	JAN 13, 1997
AT		2%	N40165 001	JAN 13, 1997
	CYCLOGYL			
AT	+ ALCON	0.5%	N84109 001	
AT	+	1%	N84110 001	
AT	+	2%	N84108 001	
	CYCLOPENTOLATE HCL			
AT	ALCON UNIVERSAL	1%	N89162 001	JAN 24, 1991
	PENTOLAIR			
AT	BAUSCH AND LOMB	1%	N40075 001	APR 29, 1994

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CYCLOMYDRIL		
	+ ALCON	0.2%;1%	N84300 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	BAXTER HLTHCARE	1GM/VIAL	N88374 001	SEP 24, 1986
AP		100MG/VIAL	N88371 001	JUL 03, 1986
AP		200MG/VIAL	N88372 001	JUL 03, 1986
AP		500MG/VIAL	N88373 001	JUL 03, 1986
	LYOPHILIZED CYTOXAN			
AP	+ BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 006	DEC 05, 1985
AP	+	200MG/VIAL	N12142 007	DEC 10, 1985
AP	+	500MG/VIAL	N12142 008	JAN 04, 1984
AP	+	1GM/VIAL	N12142 010	SEP 24, 1985
AP	+	2GM/VIAL	N12142 009	DEC 10, 1984
	NEOSAR			
AP	PHARMACIA AND UPJOHN	100MG/VIAL	N40015 001	APR 29, 1993
AP		100MG/VIAL	N87442 001	FEB 16, 1982
AP		200MG/VIAL	N40015 002	APR 29, 1993
AP		200MG/VIAL	N87442 002	FEB 16, 1982
AP		500MG/VIAL	N40015 003	APR 29, 1993
AP		500MG/VIAL	N87442 003	FEB 16, 1982
AP		1GM/VIAL	N40015 004	APR 29, 1993
AP		1GM/VIAL	N87442 004	JUL 08, 1983
AP		2GM/VIAL	N40015 005	APR 29, 1993
AP		2GM/VIAL	N87442 005	MAR 30, 1989

TABLET; ORAL

	CYCLOPHOSPHAMIDE			
AB	ROXANE	25MG	N40032 001	AUG 17, 1999

FDA data supplied by DrugPatentWatch.com

CYCLOPHOSPHAMIDE

TABLET; ORAL

	CYCLOPHOSPHAMIDE			
AB	ROXANE	**50MG**	**N40032 002**	AUG 17, 1999
	CYTOXAN			
AB	BRISTOL MYERS SQUIBB	**25MG**	**N12141 002**	
AB +		**50MG**	**N12141 001**	

CYCLOSERINE

CAPSULE; ORAL

	SEROMYCIN		
+	LILLY	250MG	N60593 001

CYCLOSPORINE

CAPSULE; ORAL

	CYCLOSPORINE			
AB1	ABBOTT	**25MG**	**N65003 001**	MAY 12, 2000
AB1		**100MG**	**N65003 003**	MAY 12, 2000
BX		50MG	N65003 002	MAY 12, 2000
AB1	EON	**25MG**	**N65017 002**	JAN 13, 2000
AB1		**100MG**	**N65017 001**	JAN 13, 2000
AB1	SIDMAK LABS	**25MG**	**N65044 002**	DEC 20, 2000
AB1		**100MG**	**N65044 001**	DEC 20, 2000
AB2	TORPHARM	**25MG**	**N65040 001**	MAY 09, 2002
AB2		**100MG**	**N65040 002**	MAY 09, 2002
	NEORAL			
AB1	NOVARTIS	**25MG**	**N50715 001**	JUL 14, 1995
AB1 +		**100MG**	**N50715 002**	JUL 14, 1995
	SANDIMMUNE			
AB2	NOVARTIS	**25MG**	**N50625 001**	MAR 02, 1990

CYCLOSPORINE

CAPSULE; ORAL

	SANDIMMUNE			
AB2 +	NOVARTIS	**100MG**	**N50625 002**	MAR 02, 1990
BX		50MG	N50625 003	NOV 23, 1992

EMULSION; OPHTHALMIC

	RESTASIS		
+		0.05%	N21023 001 DEC 23, 2002

INJECTABLE; INJECTION

	CYCLOSPORINE			
AP	BEDFORD	**50MG/ML**	**N65004 001**	OCT 29, 1999
	SANDIMMUNE			
AP +	NOVARTIS	**50MG/ML**	**N50573 001**	NOV 14, 1983

SOLUTION; ORAL

	CYCLOSPORINE			
AB	ABBOTT	**100MG/ML**	**N65025 001**	MAR 03, 2000
AB	SIDMAK LABS	**100MG/ML**	**N65054 001**	DEC 18, 2001
	NEORAL			
AB +	NOVARTIS	**100MG/ML**	**N50716 001**	JUL 14, 1995
	SANDIMMUNE			
BX +	NOVARTIS	100MG/ML	N50574 001	NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

	CYPROHEPTADINE HCL		
AA	ALPHARMA	**2MG/5ML**	**N86833 001**
	PERIACTIN		
AA +	MERCK	**2MG/5ML**	**N13220 002**

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	ABC HOLDING	**4MG**	**N88212 001**	MAY 26, 1983
AA +	IVAX PHARMS	**4MG**	**N87056 001**	

FDA data supplied by DrugPatentWatch.com

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

AA	PAR PHARM	4MG	N87129 001	
AA	SIDMAK LABS NJ	4MG	N88205 001	JUL 26, 1983

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

	MYLAN	EQ 50MG BASE	N20392 001	AUG 15, 1994
+		EQ 150MG BASE	N20392 002	AUG 15, 1994

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	BEDFORD	1GM/VIAL	N74245 001	AUG 31, 1994
AP		2GM/VIAL	N74245 002	AUG 31, 1994
AP		100MG/VIAL	N71471 001	AUG 02, 1989
AP		500MG/VIAL	N71472 001	AUG 02, 1989
+	FAULDING	20MG/ML	N71868 001	JUN 04, 1990
+		20MG/ML	N72168 001	AUG 31, 1990
+		20MG/ML	N72945 001	FEB 28, 1994
+		100MG/ML	N75383 001	NOV 22, 1999
AP	GENSIA SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998
AP +		500MG/VIAL	N75206 002	DEC 30, 1998
AP		1GM/VIAL	N75206 004	DEC 30, 1998
AP		2GM/VIAL	N75206 003	DEC 30, 1998

CYTOSAR-U

AP +	PHARMACIA AND UPJOHN	100MG/VIAL	N16793 001	

CYTARABINE

INJECTABLE; INJECTION

CYTOSAR-U

AP +	PHARMACIA AND UPJOHN	500MG/VIAL	N16793 002	
AP +		1GM/VIAL	N16793 003	DEC 21, 1987
AP +		2GM/VIAL	N16793 004	DEC 21, 1987

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+	SKYEPHARMA	10MG/ML	N21041 001	APR 01, 1999

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001	AUG 27, 1999
AP		200MG/VIAL	N75371 002	AUG 27, 1999
AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001
AP		500MG/VIAL	N75812 002	OCT 31, 2002
AP	FAULDING	200MG/VIAL	N75940 001	OCT 18, 2001
AP	GENSIA SICOR PHARMS	200MG/VIAL	N75259 002	AUG 27, 1998
AP +		500MG/VIAL	N75259 001	SEP 22, 2000

DTIC-DOME

AP +	BAYER	100MG/VIAL	N17575 001	
AP +		200MG/VIAL	N17575 002	

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

+	MERCK	0.5MG/VIAL	N50682 001	

FDA data supplied by DrugPatentWatch.com

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)
SYNERCID
+ AVENTIS — 350MG/VIAL;150MG/VIAL — N50748 001 SEP 21, 1999
420MG/VIAL;180MG/VIAL — N50747 002 AUG 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
+ PHARMACIA AND UPJOHN — 10,000 IU/ML — N20287 004 JAN 30, 1998
+ — 2,500 IU/0.2ML — N20287 001 DEC 22, 1994
+ — 5,000 IU/0.2ML — N20287 003 MAR 18, 1996

DANAZOL

CAPSULE; ORAL
DANAZOL
AB BARR — **50MG** — **N74582 003** MAY 29, 1998
AB — **100MG** — **N74582 002** MAY 29, 1998
AB — **200MG** — **N74582 001** AUG 09, 1996

DANOCRINE
AB SANOFI SYNTHELABO — **50MG** — **N17557 003**
AB — **100MG** — **N17557 004**
AB + — **200MG** — **N17557 002**

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM
PROCTER AND GAMBLE — 25MG — N17443 001
50MG — N17443 003
+ 100MG — N17443 002

INJECTABLE; INJECTION
DANTRIUM
+ PROCTER AND GAMBLE — 20MG/VIAL — N18264 001

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
REV-EYES
+ ANGELINI — 0.5% — N19849 001 DEC 31, 1990

DAPSONE

TABLET; ORAL
DAPSONE
JACOBUS — 25MG — N86841 001
+ 100MG — N86842 001

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
+ GILEAD — EQ 2MG BASE/ML — N50704 002 APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE
AP + BEDFORD — **EQ 20MG BASE/VIAL** — **N64103 001** FEB 03, 1995

DAUNORUBICIN HCL
AP + BEDFORD — **EQ 5MG BASE/ML** — **N50731 001** JAN 30, 1998
AP BIGMAR — **EQ 20MG BASE/VIAL** — **N65000 001** MAY 25, 1999
AP GENSIA SICOR PHARMS — **EQ 5MG BASE/ML** — **N65035 001** JAN 24, 2000
AP — **EQ 20MG BASE/VIAL** — **N64212 001** JUN 23, 1998
+ EQ 50MG BASE/VIAL — N64212 002 MAY 03, 1999
AP SUPERGEN — **EQ 5MG BASE/VIAL** — **N65034 001** NOV 20, 2001

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DESFERAL
+ NOVARTIS — 500MG/VIAL — N16267 001

FDA data supplied by DrugPatentWatch.com

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DESFERAL
\+ NOVARTIS 2GM/VIAL N16267 002 MAY 25, 2000 AB

DELAVIRDINE MESYLATE

TABLET; ORAL
RESCRIPTOR
AGOURON 100MG N20705 001 APR 04, 1997 AB
\+ 200MG N20705 002 JUL 14, 1999 AB

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN
LEDERLE 150MG N50261 002 AB
\+ 300MG N50261 003 AB

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL
ENDURONYL
ABBOTT 0.25MG;5MG N12775 001 AB
ENDURONYL FORTE
\+ ABBOTT 0.5MG;5MG N12775 002 AB

DESFLURANE

LIQUID; INHALATION
SUPRANE
BAXTER HLTHCARE CORP 99.9% N20118 001 SEP 18, 1992 AB

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB EON **10MG** **N74430 001** FEB 09, 1996

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
EON 25MG **N71601 001** JUN 05, 1987
50MG **N71588 001** JUN 05, 1987
75MG **N71602 001** OCT 05, 1987
100MG **N71766 001** OCT 05, 1987
150MG **N74430 002** FEB 09, 1996
GENEVA PHARMS 10MG **N72099 001** MAY 24, 1988
25MG **N72100 001** MAY 24, 1988
50MG **N72101 001** MAY 24, 1988
75MG **N72102 001** JUN 20, 1988
100MG **N72103 001** JUN 20, 1988
150MG **N72104 001** JUN 20, 1988
SIDMAK LABS NJ 25MG **N71800 001** DEC 08, 1987
50MG **N71801 001** DEC 08, 1987
75MG **N71802 001** DEC 08, 1987
100MG **N71803 001** MAY 29, 1997
150MG **N71804 001** MAY 29, 1997

NORPRAMIN
AVENTIS PHARMS 10MG **N14399 007** FEB 11, 1982
25MG **N14399 001**
\+ 50MG **N14399 003**
75MG **N14399 004**
\+ 100MG **N14399 005**
150MG **N14399 006**

FDA data supplied by DrugPatentWatch.com

DESLORATADINE

TABLET; ORAL
CLARINEX
+ SCHERING PLOUGH 5MG N21165 001 DEC 21, 2001

TABLET, ORALLY DISINTEGRATING; ORAL
CLARINEX
+ SCHERING 5MG N21312 001 JUN 26, 2002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP
AP + AVENTIS **0.004MG/ML** **N18938 001** MAR 30, 1984
+ 0.015MG/ML N18938 002 APR 25, 1995

DESMOPRESSIN ACETATE
AP ABBOTT **0.004MG/ML** **N75220 001** AUG 28, 2000
AP BEDFORD **0.004MG/ML** **N74575 001** FEB 18, 2000
AP GENSIA SICOR PHARMS **0.004MG/ML** **N74888 001** OCT 15, 1997

DESMOPRESSIN ACETATE PRESERVATIVE FREE
AP BEDFORD **0.004MG/ML** **N74574 001** FEB 18, 2000

SOLUTION; NASAL
DDAVP
+ AVENTIS 0.01% N17922 001

SPRAY; NASAL
DESMOPRESSIN ACETATE
+ FERRING 0.1MG/SPRAY N21333 001 SEP 16, 2002

SPRAY, METERED; NASAL
DDAVP (NEEDS NO REFRIGERATION)
AB + AVENTIS **0.01MG/SPRAY** **N17922 003** AUG 07, 1996

DESMOPRESSIN ACETATE
AB + BAUSCH AND LOMB **0.01MG/SPRAY** **N74830 001** JAN 25, 1999

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE
+ AVENTIS BEHRING 0.15MG/SPRAY N20355 001 MAR 07, 1994

TABLET; ORAL
DDAVP
AVENTIS 0.1MG N19955 001 SEP 06, 1995
+ 0.2MG N19955 002 SEP 06, 1995

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGESTREL AND ETHINYL ESTRADIOL
AB DURAMED PHARM BARR **0.15MG;0.03MG** **N75256 001** AUG 12, 1999

ORTHO-CEPT
AB + ORTHO MCNEIL PHARM **0.15MG;0.03MG** **N20301 001** DEC 14, 1992

TABLET; ORAL-28
CYCLESSA
+ ORGANON INC 0.1MG,0.125MG,0.15MG;0.025MG, 0.025MG,0.025MG N21090 001 DEC 20, 2000

DESOGEN
AB ORGANON **0.15MG;0.03MG** **N20071 002** DEC 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL
AB DURAMED PHARM BARR **0.15MG;0.03MG** **N75256 002** AUG 12, 1999

KARIVA
AB BARR **0.15MG,N/A;0.02MG,0.01MG** **N75863 001** APR 05, 2002

MIRCETTE
AB + ORGANON **0.15MG,N/A;0.02MG,0.01MG** **N20713 001** APR 22, 1998

ORTHO-CEPT
AB ORTHO MCNEIL PHARM **0.15MG;0.03MG** **N20301 002** DEC 14, 1992

FDA data supplied by DrugPatentWatch.com

DESONIDE

CREAM; TOPICAL

	DESONIDE			
AB	COPLEY PHARM	0.05%	N74027 001	SEP 28, 1992
AB	TARO	0.05%	N73548 001	JUN 30, 1992
	DESOWEN			
AB	GALDERMA LABS LP	0.05%	N19048 001	DEC 14, 1984
	TRIDESILON			
AB	+ CLAY PARK	0.05%	N17010 001	

LOTION; TOPICAL

	DESONIDE			
AB	ALTANA	0.05%	N75860 001	MAR 19, 2002
	DESOWEN			
AB	+ GALDERMA LABS LP	0.05%	N72354 001	JAN 24, 1992

OINTMENT; TOPICAL

	DESONIDE			
AB	ALTANA	0.05%	N75751 001	MAR 12, 2001
AB	TARO	0.05%	N74254 001	AUG 03, 1994
	DESOWEN			
AB	GALDERMA LABS LP	0.05%	N71425 001	JUN 15, 1988
	TRIDESILON			
AB	+ CLAY PARK	0.05%	N17426 001	

DESOXIMETASONE

CREAM; TOPICAL

	DESOXIMETASONE			
AB	TARO	0.05%	N73210 001	NOV 30, 1990
AB		0.25%	N73193 001	NOV 30, 1990
	TOPICORT			
AB	+ MEDICIS	0.25%	N17856 001	
	TOPICORT LP			
AB	+ MEDICIS	0.05%	N18309 001	

DESOXIMETASONE

GEL; TOPICAL

	DESOXIMETASONE			
AB	TARO	0.05%	N74904 001	JUL 14, 1998
	TOPICORT			
AB	+ MEDICIS	0.05%	N18586 001	MAR 29, 1982

OINTMENT; TOPICAL

	DESOXIMETASONE			
AB	TARO	0.25%	N74286 001	JUN 07, 1996
	TOPICORT			
AB	+ MEDICIS	0.25%	N18763 001	SEP 30, 1983

DESOXYRIBONUCLEASE; *MULTIPLE*
SEE CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

DEXAMETHASONE

CONCENTRATE; ORAL

	DEXAMETHASONE INTENSOL			
	+ ROXANE	1MG/ML	N88252 001	SEP 01, 1983

ELIXIR; ORAL

	DECADRON			
AA	+ MERCK	0.5MG/5ML	N12376 002	
	DEXAMETHASONE			
AA	ALPHARMA	0.5MG/5ML	N84754 001	
	HEXADROL			
AA	ORGANON	0.5MG/5ML	N12674 001	
	MYMETHASONE			
AA	MORTON GROVE	0.5MG/5ML	N88254 001	JUL 27, 1983

SOLUTION; ORAL

	DEXAMETHASONE			
	+ ROXANE	0.5MG/5ML	N88248 001	SEP 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

	MAXIDEX			
	+ ALCON	0.1%	N13422 001	

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE

TABLET; ORAL

		DECADRON		
AB		MERCK	**0.5MG**	**N11664 001**
AB	+		**0.75MG**	**N11664 002**
AB			**1.5MG**	**N11664 003**
AB			**4MG**	**N11664 005**
BP			0.25MG	N11664 004
BP	+		6MG	N11664 006
				JUL 30, 1982
		DEXAMETHASONE		
BP		PAR PHARM	0.25MG	N88149 001
				APR 28, 1983
BP			0.5MG	N88148 001
				APR 28, 1983
BP			0.75MG	N88160 001
				APR 28, 1983
BP			1.5MG	N88237 001
				APR 28, 1983
BP			4MG	N88238 001
				APR 28, 1983
BP			6MG	N88481 001
				NOV 28, 1983
AB		ROXANE	**0.5MG**	**N84611 001**
AB			**0.75MG**	**N84613 001**
AB			**1.5MG**	**N84610 001**
AB			**4MG**	**N84612 001**
BP			6MG	N88316 001
				SEP 15, 1983
			1MG	N88306 001
				SEP 15, 1983
			2MG	N87916 001
				AUG 26, 1982
		HEXADROL		
BP		ORGANON	4MG	N12675 010

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		MAXITROL		
AT	+	FALCON PHARMS	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50065 002**
		NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE		
AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64063 001**
				JUL 25, 1994

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE		
AT		FOUGERA	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N62938 001**
				JUL 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

		DEXACIDIN		
AT		NOVARTIS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62544 001**
				OCT 29, 1984
		DEXASPORIN		
AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64135 001**
				SEP 13, 1995
		MAXITROL		
AT		ALCON	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62341 001**
				MAY 22, 1984
AT	+	FALCON PHARMS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50023 002**
		NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE		
AT		ALCON UNIVERSAL	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62721 001**
				NOV 17, 1986

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

		TOBRADEX		
	+	ALCON	0.1%;0.3%	N50616 001
				SEP 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

		TOBRADEX		
AB	+	ALCON	**0.1%;0.3%**	**N50592 001**
				AUG 18, 1988
		TOBRAMYCIN AND DEXAMETHASONE		
AB		BAUSCH AND LOMB	**0.1%;0.3%**	**N64134 001**
				OCT 27, 1999

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		DEXAMETHASONE		
AP		ELKINS SINN	**EQ 4MG PHOSPHATE/ML**	**N84282 001**

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DEXAMETHASONE			
AP	ELKINS SINN	EQ 10MG PHOSPHATE/ML	N87702 001	SEP 07, 1982
	DEXAMETHASONE SODIUM PHOSPHATE			
AP	AM PHARM PARTNERS	EQ 4MG PHOSPHATE/ML	N84916 001	
AP +	GENSIA SICOR PHARMS	EQ 10MG PHOSPHATE/ML	N81126 001	AUG 31, 1990
AP +	LUITPOLD	EQ 4MG PHOSPHATE/ML	N87440 001	JUL 21, 1982

SOLUTION/DROPS; OPHTHALMIC, OTIC

	DECADRON			
AT +	MERCK	EQ 0.1% PHOSPHATE	N11984 001	
	DEXAMETHASONE SODIUM PHOSPHATE			
AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001	JAN 16, 1985
AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N40069 001	JUL 26, 1996

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEODECADRON			
+	MERCK	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N50322 001	

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

	MYLARAMINE			
AA	MORTON GROVE	2MG/5ML	N88251 001	MAR 23, 1984
	POLARAMINE			
AA	SCHERING	2MG/5ML	N86837 001	JUL 19, 1982

TABLET; ORAL

	DEXCHLORPHENIRAMINE MALEATE			
AA	SIDMAK LABS NJ	2MG	N88682 001	JAN 17, 1986
	POLARAMINE			
AA +	SCHERING	2MG	N86835 001	

DEXMEDETOMIDINE

INJECTABLE; INJECTION

	PRECEDEX			
+	ABBOTT	EQ 100 UGM BASE/ML	N21038 001	DEC 17, 1999

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	FOCALIN			
	NOVARTIS	2.5MG	N21278 001	NOV 13, 2001
		5MG	N21278 002	NOV 13, 2001
+		10MG	N21278 003	NOV 13, 2001

DEXPANTHENOL; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

	ZINECARD			
+	PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N20212 001	MAY 26, 1995
+		EQ 500MG BASE/VIAL	N20212 002	MAY 26, 1995

FDA data supplied by DrugPatentWatch.com

DEXTROAMPHETAMINE SACCHARATE; *MULTIPLE*
SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

		DEXEDRINE			
AB	+	GLAXOSMITHKLINE	5MG		N17078 001
AB	+		10MG		N17078 002
AB	+		15MG		N17078 003
		DEXTROAMPHETAMINE SULFATE			
AB		BARR	5MG		N76137 001 JAN 18, 2002
AB			10MG		N76137 002 JAN 18, 2002
AB			15MG		N76137 003 JAN 18, 2002

TABLET; ORAL

		DEXEDRINE			
AA		GLAXOSMITHKLINE	5MG		N84935 001
		DEXTROAMPHETAMINE SULFATE			
AA		BARR	5MG		N40361 001 JAN 31, 2001
AA			10MG		N40361 002 JAN 31, 2001
AA		ENDO PHARMS	5MG		N40299 001 MAY 13, 1999
AA		KV PHARM	5MG		N40365 001 OCT 31, 2002
AA			10MG		N40367 001 OCT 31, 2002
AA		MALLINCKRODT	5MG		N40436 001 JAN 29, 2002
AA			10MG		N40436 002 JAN 29, 2002
		DEXTROSTAT			
AA	+	SHIRE RICHWOOD	5MG		N84051 001
AA	+		10MG		N84051 002

DEXTROAMPHETAMINE SULFATE; *MULTIPLE*
SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

		PHENERGAN W/ DEXTROMETHORPHAN			
AA	+	WYETH AYERST	15MG/5ML;6.25MG/5ML		N11265 002 APR 02, 1984
		PROMETH W/ DEXTROMETHORPHAN			
AA		ALPHARMA	15MG/5ML;6.25MG/5ML		N88762 001 OCT 31, 1984
		PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE			
AA		HI TECH PHARMA	15MG/5ML;6.25MG/5ML		N40027 001 JUL 31, 1996
		PROMETHAZINE W/ DEXTROMETHORPHAN			
AA		MORTON GROVE	15MG/5ML;6.25MG/5ML		N88864 001 JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION

		DEXTROSE 10% IN PLASTIC CONTAINER			
AP		ABBOTT	10GM/100ML		N18080 001
AP		B BRAUN	10GM/100ML		N18046 001
AP			10GM/100ML		N19626 004 FEB 02, 1988
AP		BAXTER HLTHCARE	10GM/100ML		N16694 001
		DEXTROSE 2.5% IN PLASTIC CONTAINER			
		B BRAUN	2.5GM/100ML		N18358 001
		DEXTROSE 20% IN PLASTIC CONTAINER			
AP		ABBOTT	20GM/100ML		N18564 001 MAR 23, 1982
AP		BAXTER HLTHCARE	20GM/100ML		N17521 004
		DEXTROSE 25%			
		ABBOTT	250MG/ML		N19445 002 NOV 23, 1998
		DEXTROSE 30% IN PLASTIC CONTAINER			
AP		ABBOTT	30GM/100ML		N19345 001 JAN 26, 1985
AP		BAXTER HLTHCARE	30GM/100ML		N17521 003
		DEXTROSE 40% IN PLASTIC CONTAINER			
AP		ABBOTT	40GM/100ML		N18562 001 MAR 23, 1982
AP		BAXTER HLTHCARE	40GM/100ML		N17521 002
		DEXTROSE 5% IN PLASTIC CONTAINER			
AP		ABBOTT	5GM/100ML		N19466 001 JUL 15, 1985
AP			5GM/100ML		N19479 001 SEP 17, 1985
AP			50MG/ML		N16367 002

FDA data supplied by DrugPatentWatch.com

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	50MG/ML	N19222 001 JUL 13, 1984
AP	B BRAUN	5GM/100ML	N16730 001
AP		50MG/ML	N16730 002
AP		5GM/100ML	N19626 002 FEB 02, 1988
AP	BAXTER HLTHCARE	5GM/100ML	N16673 001
AP		50MG/ML	N16673 003 OCT 30, 1985
AP		5GM/100ML	N20179 001 DEC 07, 1992
AP		50MG/ML	N20179 002 DEC 07, 1992
AP	DHL	5GM/100ML	N19971 001 SEP 28, 1995

DEXTROSE 50% IN PLASTIC CONTAINER

AP	ABBOTT	50GM/100ML	N18563 001 MAR 23, 1982
AP		50GM/100ML	N19894 001 DEC 26, 1989
AP	BAXTER HLTHCARE	50GM/100ML	N17521 001
AP		50GM/100ML	N20047 001 JUL 02, 1991

DEXTROSE 60% IN PLASTIC CONTAINER

AP	ABBOTT	60GM/100ML	N19346 001 JAN 25, 1985
AP	BAXTER HLTHCARE	60GM/100ML	N17521 005 MAR 26, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	ABBOTT	70GM/100ML	N18561 001 MAR 23, 1982
AP		70GM/100ML	N19893 001 DEC 26, 1989
AP	BAXTER HLTHCARE	70GM/100ML	N17521 006 MAR 26, 1982
AP		70GM/100ML	N20047 003 JUL 02, 1991

DEXTROSE; *MULTIPLE*

SEE ALCOHOL; DEXTROSE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

DEXTROSE; *MULTIPLE*

SEE AMINO ACIDS; DEXTROSE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610 001

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML; 234MG/100ML	N17385 001

FDA data supplied by DrugPatentWatch.com

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19873 001 JUN 10, 1993

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19025 001 DEC 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100ML; 16MG/100ML N19515 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML; 20MG/100ML;12MG/100ML; 260MG/100ML N17484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML; 25MG/100ML N19513 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N19844 001 JUN 10, 1993

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N18273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N19843 001** AUG 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N18274 001**

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;37MG/100ML; 222MG/100ML;526MG/100ML; 502MG/100ML N17609 001

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;30MG/100ML;37MG/100ML; 368MG/100ML;526MG/100ML; 502MG/100ML N17451 001**

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;75MG/100ML N17634 004**

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;150MG/100ML N17634 001**

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;224MG/100ML N17634 003**

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP BRISTOL MYERS SQUIBB **5GM/100ML;300MG/100ML** **N17634 002**

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;75MG/100ML** **N18744 001**
NOV 09, 1982

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML** **N18744 002**
NOV 09, 1982

AP **5GM/100ML;150MG/100ML** **N19699 004**
SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;220MG/100ML N18744 003
NOV 09, 1982

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;300MG/100ML** **N18744 004**
NOV 09, 1982

AP **5GM/100ML;300MG/100ML** **N19699 006**
SEP 29, 1989

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 5GM/100ML;149MG/100ML N18371 001

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP ABBOTT **5GM/100ML;224MG/100ML** **N18371 003**

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 5GM/100ML;298MG/100ML N18371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 5GM/100ML;111MG/100ML;256MG/100ML;
146MG/100ML;207MG/100ML N19514 001
MAY 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;
280MG/100ML;91MG/100ML N19870 001
JUN 10, 1993

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;
280MG/100ML;91MG/100ML N18270 001

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML;
120MG/100ML;220MG/100ML N18840 001
JUN 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP BAXTER HLTHCARE **5GM/100ML;75MG/100ML; 200MG/100ML** **N18037 006**
APR 13, 1982

AP **5GM/100ML;150MG/100ML; 200MG/100ML** **N18037 007**
APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP BAXTER HLTHCARE **5GM/100ML;224MG/100ML; 200MG/100ML** **N18037 004**

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP BAXTER HLTHCARE **5GM/100ML;150MG/100ML; 200MG/100ML** **N18037 008**
APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP BAXTER HLTHCARE **5GM/100ML;300MG/100ML; 200MG/100ML** **N18037 001**

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 200MG/100ML **N18037 005** APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 200MG/100ML **N18037 009** APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 200MG/100ML **N18037 002**

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 200MG/100ML **N18037 003**

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 330MG/100ML **N18629 005** MAR 23, 1982

AP 5GM/100ML;150MG/100ML; 330MG/100ML **N18629 002** MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 330MG/100ML **N18629 003** MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;150MG/100ML; 330MG/100ML **N18629 004** MAR 23, 1982

AP 5GM/100ML;300MG/100ML; 330MG/100ML **N18629 006** MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;224MG/100ML; 330MG/100ML **N18629 007** MAR 23, 1982

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 330MG/100ML **N18629 008** MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML; 330MG/100ML **N18629 001** MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP BAXTER HLTHCARE 5GM/100ML;300MG/100ML; 450MG/100ML **N18008 010**

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML; 200MG/100ML N19630 031 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML; 450MG/100ML N19630 037 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;37MG/100ML; 900MG/100ML N19630 043 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 110MG/100ML N19630 001 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 200MG/100ML N19630 007 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN 5GM/100ML;37MG/100ML; 330MG/100ML N19630 013 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML; 450MG/100ML N19630 019 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML; 900MG/100ML N19630 025 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML; 200MG/100ML N19630 032 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML; 450MG/100ML N19630 038 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML; 900MG/100ML N19630 044 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML; 300MG/100ML N19630 049 MAY 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML; 110MG/100ML N19630 002 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 200MG/100ML N19630 008** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 330MG/100ML N19630 014** FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 450MG/100ML N19630 020** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML; 900MG/100ML N19630 026** FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 200MG/100ML N19630 033 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 450MG/100ML N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML; 900MG/100ML N19630 045 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML; 300MG/100ML N19630 050 MAY 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 110MG/100ML N19630 003 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 200MG/100ML N19630 009 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 330MG/100ML N19630 015 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 450MG/100ML N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 900MG/100ML N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 200MG/100ML N19630 034 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 450MG/100ML N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 900MG/100ML N19630 046 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML; 300MG/100ML N19630 051 MAY 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML; 110MG/100ML N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 200MG/100ML N19630 010** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 330MG/100ML N19630 016** FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 450MG/100ML N19630 022** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;150MG/100ML; 900MG/100ML N19630 028** FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 200MG/100ML N19630 035 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 450MG/100ML N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 900MG/100ML N19630 047 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML; 300MG/100ML N19630 052 MAY 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 110MG/100ML N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 200MG/100ML N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML; 330MG/100ML N19630 017 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 450MG/100ML	N19630 023	FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 900MG/100ML	N19630 029	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 200MG/100ML	N19630 036	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 450MG/100ML	N19630 042	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 900MG/100ML	N19630 048	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML; 300MG/100ML	N19630 053	MAY 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;300MG/100ML; 110MG/100ML	N19630 006	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 200MG/100ML**	**N19630 012**	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 330MG/100ML**	**N19630 018**	FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 450MG/100ML**	**N19630 024**	FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 900MG/100ML**	**N19630 030**	FEB 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 002	JUL 05, 1983
		5GM/100ML;149MG/100ML; 225MG/100ML	N18365 006	MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 001	JAN 17, 1986
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 006	MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 005**	MAR 28, 1988
AP		**5GM/100ML;74.5MG/100ML; 450MG/100ML**	**N18362 009**	JUL 05, 1983
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML; 450MG/100ML**	**N18008 005**	APR 28, 1982
AP		**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18008 006**	APR 28, 1982

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**5GM/100ML;74.5MG/100ML; 900MG/100ML**	**N19691 002**	MAR 24, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;149MG/100ML; 900MG/100ML	N19691 004 MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 900MG/100ML	N19308 004 APR 05, 1985
AP		5GM/100ML;150MG/100ML; 900MG/100ML	N19308 002 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 008 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 007 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 006 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 900MG/100ML	N19691 006 MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 001
		5GM/100ML;298MG/100ML; 225MG/100ML	N18365 009 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 008 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;149MG/100ML; 450MG/100ML	N18362 010 JUL 05, 1983
AP		5GM/100ML;298MG/100ML; 450MG/100ML	N18362 007 MAR 28, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 450MG/100ML	N18008 007 APR 28, 1982

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;149MG/100ML; 900MG/100ML	N19691 005 MAR 24, 1988
AP		5GM/100ML;298MG/100ML; 900MG/100ML	N19691 008 MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 900MG/100ML	N19308 005 APR 05, 1985
AP		5GM/100ML;300MG/100ML; 900MG/100ML	N19308 003 APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 300MG/100ML	N18876 002 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 003 JUL 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 003 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 002

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 450MG/100ML	N18008 008	APR 28, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 900MG/100ML	N19691 007	MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 900MG/100ML	N19308 006	APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 225MG/100ML	N18365 004	JUL 05, 1983

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 004	MAR 28, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;298MG/100ML; 450MG/100ML	N18362 003	
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 450MG/100ML	N18008 009	APR 28, 1982

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;298MG/100ML; 900MG/100ML	N19691 009	MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 900MG/100ML	N19308 007	APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 005	MAR 28, 1988
		5GM/100ML;149MG/100ML; 225MG/100ML	N18365 007	MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 005	MAR 28, 1988
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 009	MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 450MG/100ML	N18362 008	MAR 28, 1988
AP		5GM/100ML;149MG/100ML; 450MG/100ML	N18362 004	MAR 28, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 450MG/100ML	N18008 004	

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 900MG/100ML	N19691 001	MAR 24, 1988
AP		5GM/100ML;149MG/100ML; 900MG/100ML	N19691 003	MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 900MG/100ML	N19308 001	APR 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;110MG/100ML	N19631 011	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;200MG/100ML	N19631 012	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;330MG/100ML	N19631 013	FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;450MG/100ML	N19631 014	FEB 24, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML;900MG/100ML	N19631 015	FEB 24, 1988
AP	BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N16696 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;110MG/100ML	N19631 001	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;200MG/100ML	N19631 002	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;330MG/100ML	N19631 003	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	2.5GM/100ML;450MG/100ML	N18096 001	
AP	B BRAUN	2.5GM/100ML;450MG/100ML	N19631 004	FEB 24, 1988
AP	BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N16697 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;900MG/100ML	N19631 005	FEB 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML	N19631 016	JAN 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N19631 006	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;200MG/100ML	N19631 007	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;225MG/100ML	N17606 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;300MG/100ML	N17799 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;330MG/100ML	N19631 008	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;450MG/100ML	N17607 001	
AP	B BRAUN	5GM/100ML;450MG/100ML	N19631 009	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;900MG/100ML	N17585 001	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;900MG/100ML	N19631 010	FEB 24, 1988

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;200MG/100ML	N16689 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;330MG/100ML	N16687 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;450MG/100ML	N16683 001	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;900MG/100ML	N16678 001	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAQUE

AP	+ AMERSHAM HLTH	30%	N16403 002	
AP	+	60%	N16403 001	

RENO-60

AP	+ BRACCO	60%	N10040 016	

RENO-DIP

AP	+ BRACCO	30%	N10040 012	

SOLUTION; URETERAL

RENO-30

	BRACCO	30%	N10040 021	

SOLUTION; URETHRAL

CYSTOGRAFIN

AT	BRACCO	30%	N10040 018	

CYSTOGRAFIN DILUTE

	BRACCO	18%	N10040 022	NOV 09, 1982

HYPAQUE-CYSTO

AT	AMERSHAM HLTH	30%	N16403 003	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE-76

AP	AMERSHAM HLTH	66%;10%	N86505 001	

MD-76R

AP	+ MALLINCKRODT	66%;10%	N19292 001	SEP 29, 1989

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOCAL-76

AP	BRACCO	**66%;10%**	**N89347 001**	JUN 01, 1988

RENOGRAFIN-60

+	BRACCO	52%;8%	N10040 006

RENOGRAFIN-76

AP	+	BRACCO	**66%;10%**	**N10040 001**

SOLUTION; ORAL, RECTAL

GASTROGRAFIN

AA	+	BRACCO	**66%;10%**	**N11245 003**

MD-GASTROVIEW

AA		MALLINCKRODT	**66%;10%**	**N87388 001**

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN

	BRACCO	52.7%;26.8%	N11324 002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

	AMERSHAM HLTH	100%	N11386 001

INJECTABLE; INJECTION

HYPAQUE

+	AMERSHAM HLTH	50%	N09561 001

DIATRIZOATE SODIUM; *MULTIPLE*

SEE DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL

+	ROXANE	5MG/ML	N71415 001	APR 03, 1987

GEL; RECTAL

DIASTAT

+	XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997

DIAZEPAM

GEL; RECTAL

DIASTAT

	XCEL PHARMS	5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997
		15MG/3ML	N20648 004	JUL 29, 1997
+		20MG/4ML	N20648 005	JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP	+	ABBOTT	**5MG/ML**	**N71583 001**	OCT 13, 1987
AP			**5MG/ML**	**N71584 001**	OCT 13, 1987
AP			**5MG/ML**	**N72079 001**	DEC 20, 1988
AP		ELKINS SINN	**5MG/ML**	**N70311 001**	DEC 16, 1985
AP			**5MG/ML**	**N70312 001**	DEC 16, 1985
AP			**5MG/ML**	**N70313 001**	DEC 16, 1985
AP		LEDERLE	**5MG/ML**	**N71309 001**	JUL 17, 1987
AP			**5MG/ML**	**N71310 001**	JUL 17, 1987
AP		MARSAM PHARMS LLC	**5MG/ML**	**N72370 001**	JAN 29, 1993
AP			**5MG/ML**	**N72397 001**	JAN 29, 1993
AP		STERIS	**5MG/ML**	**N70296 001**	FEB 12, 1986

SOLUTION; ORAL

DIAZEPAM

+	ROXANE	5MG/5ML	N70928 001	APR 03, 1987

TABLET; ORAL

DIAZEPAM

AB		BARR	**2MG**	**N70152 001**	NOV 01, 1985
AB			**5MG**	**N70153 001**	NOV 01, 1985

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

TABLET; ORAL

	DIAZEPAM			
AB	BARR	10MG	N70154 001	NOV 01, 1985
AB	GENEVA PHARMS	2MG	N70302 001	DEC 20, 1985
AB		5MG	N70303 001	DEC 20, 1985
AB		10MG	N70304 001	DEC 20, 1985
AB	IVAX PHARMS	2MG	N71307 001	DEC 10, 1986
AB		5MG	N71321 001	DEC 10, 1986
AB		10MG	N71322 001	DEC 10, 1986
AB	LEDERLE	2MG	N70226 001	SEP 26, 1985
AB		5MG	N70227 001	SEP 26, 1985
AB		10MG	N70228 001	SEP 26, 1985
AB	MYLAN	2MG	N70323 001	SEP 04, 1985
AB		5MG	N70324 001	SEP 04, 1985
AB		10MG	N70325 001	SEP 04, 1985
AB	PAR PHARM	2MG	N70462 001	FEB 25, 1986
AB		5MG	N70463 001	FEB 25, 1986
AB		10MG	N70464 001	FEB 25, 1986
AB	PUREPAC PHARM	2MG	N70781 001	MAR 19, 1986
AB		5MG	N70706 001	MAR 19, 1986
AB		10MG	N70707 001	MAR 19, 1986
AB	WATSON LABS	2MG	N71134 001	FEB 03, 1987
AB		5MG	N71135 001	FEB 03, 1987
AB		10MG	N71136 001	FEB 03, 1987
	VALIUM			
AB	ROCHE	2MG	N13263 002	

DIAZEPAM

TABLET; ORAL

	VALIUM			
AB	ROCHE	5MG	N13263 004	
AB +		10MG	N13263 006	

DIAZOXIDE

INJECTABLE; INJECTION

	HYPERSTAT		
+	SCHERING	15MG/ML	N16996 001

SUSPENSION; ORAL

	PROGLYCEM		
+	BAKER NORTON	50MG/ML	N17453 001

DICHLORPHENAMIDE

TABLET; ORAL

	DARANIDE		
+	MERCK	50MG	N11366 001

DICLOFENAC POTASSIUM

TABLET; ORAL

	CATAFLAM			
AB	+ NOVARTIS	50MG	N20142 002	NOV 24, 1993
	DICLOFENAC POTASSIUM			
AB	EON	50MG	N75582 001	FEB 23, 2001
AB	GENEVA PHARMS TECH	50MG	N75229 001	NOV 20, 1998
AB	MUTUAL PHARM	50MG	N75470 001	FEB 21, 2002
AB	MYLAN	50MG	N75463 001	JUL 26, 1999
AB	TEVA	50MG	N75219 001	AUG 06, 1998
AB	WATSON LABS	50MG	N75152 001	NOV 27, 1998

FDA data supplied by DrugPatentWatch.com

DICLOFENAC SODIUM

GEL; TOPICAL

	SOLARAZE			
+	BIOGLAN PHARMA	3%	N21005 001	
			OCT 16, 2000	

SOLUTION/DROPS; OPHTHALMIC

	VOLTAREN			
+	NOVARTIS	0.1%	N20037 001	
			MAR 28, 1991	

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	ALPHAPHARM	**50MG**	**N75281 002**	
			FEB 12, 2002	
AB		**75MG**	**N75281 003**	
			FEB 12, 2002	
AB	CARLSBAD	**25MG**	**N75185 002**	
			NOV 13, 1998	
AB		**50MG**	**N75185 003**	
			NOV 13, 1998	
AB		**75MG**	**N75185 001**	
			NOV 13, 1998	
AB	COPLEY PHARM	**25MG**	**N74459 001**	
			JUN 25, 1997	
AB		**50MG**	**N74459 002**	
			JUN 25, 1997	
AB		**75MG**	**N74459 003**	
			JUN 25, 1997	
AB	GENEVA PHARMS	**25MG**	**N74376 001**	
			SEP 28, 1995	
AB		**50MG**	**N74376 002**	
			SEP 28, 1995	
AB		**75MG**	**N74394 001**	
			NOV 30, 1995	
AB	MARTEC	**50MG**	**N74986 001**	
			FEB 26, 1999	
AB		**75MG**	**N74986 002**	
			FEB 26, 1999	
AB	PUREPAC PHARM	**50MG**	**N74514 001**	
			MAR 26, 1996	
AB		**75MG**	**N74514 002**	
			MAR 26, 1996	
AB	ROXANE	**25MG**	**N74391 001**	
			JUN 29, 1995	
AB		**50MG**	**N74391 002**	
			JUN 29, 1995	

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	ROXANE	**75MG**	**N74391 003**	
			JUN 29, 1995	
AB	SIDMAK LABS NJ	**50MG**	**N74432 002**	
			JUL 29, 1999	
AB		**75MG**	**N74432 003**	
			JUL 29, 1999	
AB	TEVA	**50MG**	**N74723 001**	
			MAR 30, 1999	
AB		**75MG**	**N74390 001**	
			AUG 15, 1996	
	VOLTAREN			
AB	+ NOVARTIS	**25MG**	**N19201 001**	
			JUL 28, 1988	
AB	+	**50MG**	**N19201 002**	
			JUL 28, 1988	
AB	+	**75MG**	**N19201 003**	
			JUL 28, 1988	

TABLET, EXTENDED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	BIOVAIL	**100MG**	**N75492 001**	
			FEB 11, 2000	
AB	DEXCEL LTD	**100MG**	**N76201 001**	
			NOV 06, 2002	
AB	MYLAN	**100MG**	**N76152 001**	
			DEC 13, 2001	
AB	PUREPAC PHARM	**100MG**	**N75910 001**	
			JAN 07, 2002	
	VOLTAREN-XR			
AB	+ NOVARTIS	**100MG**	**N20254 001**	
			MAR 08, 1996	

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

	ARTHROTEC			
+	GD SEARLE LLC	50MG;0.2MG	N20607 001	
			DEC 24, 1997	
+		75MG;0.2MG	N20607 002	
			DEC 24, 1997	

FDA data supplied by DrugPatentWatch.com

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DICLOXACILLIN SODIUM			
AB	APOTHECON	EQ 250MG BASE	N61454 001	
AB	+	EQ 500MG BASE	N61454 003	
		EQ 125MG BASE	N61454 002	
AB	TEVA	EQ 250MG BASE	N62286 001	JUN 03, 1982
AB		EQ 500MG BASE	N62286 002	JUN 03, 1982
	PATHOCIL			
AB	WYETH AYERST	EQ 250MG BASE	N50011 002	
AB		EQ 500MG BASE	N50011 003	MAR 28, 1983

FOR SUSPENSION; ORAL

	DICLOXACILLIN SODIUM			
AB	+ APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	
	PATHOCIL			
AB	WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	BENTYL			
AB	+ AVENTIS PHARMS	10MG	N07409 003	OCT 15, 1984
	DICYCLOMINE HCL			
AB	LANNETT	10MG	N84285 001	
AB	MYLAN	10MG	N40319 001	SEP 07, 1999
AB	WATSON LABS	10MG	N85082 001	JUN 19, 1986
AB	WEST WARD	10MG	N40204 001	FEB 28, 1997

INJECTABLE; INJECTION

	BENTYL			
AP	+ AVENTIS PHARMS	10MG/ML	N08370 001	OCT 15, 1984
	BENTYL PRESERVATIVE FREE			
AP	+ AVENTIS PHARMS	10MG/ML	N08370 002	OCT 15, 1984

SYRUP; ORAL

	BENTYL			
	+ AVENTIS PHARMS	10MG/5ML	N07961 002	OCT 15, 1984

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

	BENTYL			
AB	+ AVENTIS PHARMS	20MG	N07409 001	OCT 15, 1984
	DICYCLOMINE HCL			
AB	LANNETT	20MG	N40230 001	FEB 26, 1999
AB	MYLAN	20MG	N40317 001	SEP 07, 1999
AB	WATSON LABS	20MG	N85223 001	JUL 30, 1986
AB	WEST WARD	20MG	N40161 001	OCT 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

	VIDEX EC			
	+ BRISTOL MYERS SQUIBB	125MG	N21183 001	OCT 31, 2000
	+	200MG	N21183 002	OCT 31, 2000
	+	250MG	N21183 003	OCT 31, 2000
	+	400MG	N21183 004	OCT 31, 2000

FOR SOLUTION; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	OCT 09, 1991
		100MG/PACKET	N20155 003	OCT 09, 1991
		167MG/PACKET	N20155 004	OCT 09, 1991
	+	250MG/PACKET	N20155 005	OCT 09, 1991

TABLET, CHEWABLE; ORAL

	VIDEX			
	+ BRISTOL MYERS SQUIBB	25MG	N20154 002	OCT 09, 1991
		50MG	N20154 003	OCT 09, 1991
		100MG	N20154 004	OCT 09, 1991

FDA data supplied by DrugPatentWatch.com

DIDANOSINE

TABLET, CHEWABLE; ORAL
VIDEX
BRISTOL MYERS SQUIBB 150MG N20154 005 OCT 09, 1991
200MG N20154 006 OCT 28, 1999

DIENESTROL

CREAM; VAGINAL
DIENESTROL
+ ORTHO MCNEIL 0.01% N06110 005

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL
AA ABC HOLDING **25MG** **N88267 001** AUG 25, 1983
AA **25MG** **N88268 001** AUG 25, 1983

TENUATE
AA + AVENTIS PHARMS **25MG** **N11722 002**

TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN
+ AVENTIS PHARMS 75MG N12546 001

DIFENOXIN HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE
AB1 ALTANA **0.05%** **N75187 001** MAR 30, 1998
AB2 **0.05%** **N76263 001** DEC 20, 2002
AB1 TARO **0.05%** **N75508 001** APR 24, 2000

FLORONE
BX + PHARMACIA AND UPJOHN 0.05% N17741 001

DIFLORASONE DIACETATE

CREAM; TOPICAL
FLORONE E
AB2 + PHARMACIA AND UPJOHN **0.05%** **N19259 001** AUG 28, 1985

PSORCON
AB1 + DERMIK LABS **0.05%** **N20205 001** NOV 20, 1992

OINTMENT; TOPICAL
DIFLORASONE DIACETATE
AB ALTANA **0.05%** **N75374 001** APR 27, 1999
AB TARO **0.05%** **N75331 001** MAY 14, 1999

FLORONE
+ PHARMACIA AND UPJOHN 0.05% N17994 001
PSORCON
AB + PHARMACIA AND UPJOHN **0.05%** **N19260 001** AUG 28, 1985

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
AB GENEVA PHARMS **500MG** **N74604 001** JUN 10, 1996
AB ROXANE **250MG** **N73562 001** NOV 27, 1992
AB **500MG** **N73563 001** NOV 27, 1992
AB TEVA **250MG** **N73679 001** JUL 31, 1992
AB **500MG** **N73673 001** JUL 31, 1992
AB WATSON LABS **250MG** **N74400 001** JUL 17, 1997
AB **500MG** **N74400 002** JUL 17, 1997

DOLOBID
AB MERCK **250MG** **N18445 001** APR 19, 1982
AB + **500MG** **N18445 002** APR 19, 1982

FDA data supplied by DrugPatentWatch.com

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

	GLAXO WELLCOME	0.05MG	N18118 002	JUL 26, 1982
		0.1MG	N18118 003	JUL 26, 1982
+		0.2MG	N18118 001	JUL 26, 1982

INJECTABLE; INJECTION

DIGOXIN

AP	ABBOTT	**0.25MG/ML**	**N40093 001**	MAY 16, 1996
AP		**0.25MG/ML**	**N40206 001**	AUG 28, 1998
AP	ELKINS SINN	**0.25MG/ML**	**N83391 001**	
AP	WYETH AYERST	**0.25MG/ML**	**N84386 001**	

DIGOXIN PEDIATRIC

AP	ABBOTT	**0.1MG/ML**	**N40092 001**	APR 25, 1996

LANOXIN

AP	+ GLAXOSMITHKLINE	**0.25MG/ML**	**N09330 002**	

LANOXIN PEDIATRIC

AP	+ GLAXOSMITHKLINE	**0.1MG/ML**	**N09330 004**	

TABLET; ORAL

DIGOXIN

AB	AMIDE PHARM	**0.125MG**	**N40282 001**	DEC 23, 1999
AB		**0.25MG**	**N40282 002**	DEC 23, 1999
AB	STEVENS J	**0.125MG**	**N76268 001**	JUL 26, 2002
AB		**0.25MG**	**N76268 002**	JUL 26, 2002

LANOXIN

AB	GLAXO WELLCOME	**0.125MG**	**N20405 002**	SEP 30, 1997
AB	+	**0.25MG**	**N20405 004**	SEP 30, 1997

DIHYDROCODEINE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

	XCEL PHARMS	1MG/ML	N05929 001	

SPRAY, METERED; NASAL

MIGRANAL

+	XCEL PHARM	0.5MG/INH	N20148 001	DEC 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3	+ AVENTIS PHARMS	**120MG**	**N20062 001**	AUG 10, 1992
AB3	+	**180MG**	**N20062 002**	DEC 27, 1991
AB3	+	**240MG**	**N20062 003**	DEC 27, 1991
AB3	+	**300MG**	**N20062 004**	DEC 27, 1991

CARDIZEM SR

AB1	+ AVENTIS PHARMS	**60MG**	**N19471 001**	JAN 23, 1989
AB1	+	**90MG**	**N19471 002**	JAN 23, 1989
AB1	+	**120MG**	**N19471 003**	JAN 23, 1989

CARTIA XT

AB3	ANDRX PHARMS	**120MG**	**N74752 002**	JUL 09, 1998
AB3		**180MG**	**N74752 001**	JUL 09, 1998
AB3		**240MG**	**N74752 003**	JUL 09, 1998
AB3		**300MG**	**N74752 004**	JUL 09, 1998

DILACOR XR

AB2	+ WATSON LABS	**120MG**	**N20092 001**	MAY 29, 1992
AB2	+	**180MG**	**N20092 002**	MAY 29, 1992
AB2	+	**240MG**	**N20092 003**	MAY 29, 1992

DILTIAZEM HCL

AB2	ANDRX	**120MG**	**N74852 001**	OCT 10, 1997

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

AB2	ANDRX	180MG	N74852 002 OCT 10, 1997
AB2		240MG	N74852 003 OCT 10, 1997
AB1	BIOVAIL	60MG	N74845 001 SEP 15, 1999
AB1		90MG	N74845 002 SEP 15, 1999
AB3		120MG	N20939 001 JAN 28, 2000
AB1		120MG	N74845 003 SEP 15, 1999
AB3		120MG	N75116 001 DEC 23, 1999
AB3		180MG	N20939 002 JAN 28, 2000
AB3		180MG	N75116 002 DEC 23, 1999
AB3		240MG	N20939 003 JAN 28, 2000
AB3		240MG	N75116 003 DEC 23, 1999
AB3		300MG	N20939 004 JAN 28, 2000
AB3		300MG	N75116 004 DEC 23, 1999
AB1	MYLAN	60MG	N74910 001 MAY 02, 1997
AB1		90MG	N74910 002 MAY 02, 1997
AB1		120MG	N74910 003 MAY 02, 1997
AB2		120MG	N75124 002 MAR 18, 1998
AB2		180MG	N75124 003 MAR 18, 1998
AB2		240MG	N75124 001 MAR 18, 1998
AB3	PUREPAC PHARM	120MG	N74984 001 DEC 20, 1999
AB3		180MG	N74984 002 DEC 20, 1999
AB3		240MG	N74984 003 DEC 20, 1999

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

AB3	PUREPAC PHARM	300MG		N74984 004 DEC 20, 1999
AB1	TEVA	60MG		N74079 001 NOV 30, 1993
AB1		90MG		N74079 002 NOV 30, 1993
AB1		120MG		N74079 003 NOV 30, 1993
AB2	TORPHARM	120MG		N74943 003 DEC 19, 2000
AB2		180MG		N74943 002 DEC 19, 2000
AB2		240MG		N74943 001 AUG 06, 1998

TIAZAC

BC	+	BIOVAIL	120MG	N20401 001 SEP 11, 1995
BC	+		180MG	N20401 002 SEP 11, 1995
BC	+		240MG	N20401 003 SEP 11, 1995
BC	+		300MG	N20401 004 SEP 11, 1995
	+		360MG	N20401 005 SEP 11, 1995
	+		420MG	N20401 006 OCT 16, 1998

INJECTABLE; INJECTION

CARDIZEM

AP	+	AVENTIS PHARMS	100MG/VIAL	N20792 001 SEP 05, 1997
AP	+	BIOVAIL	5MG/ML	N20027 001 OCT 24, 1991
	+		25MG/VIAL	N20027 003 AUG 18, 1995

DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998
AP		5MG/ML	N75004 001 FEB 16, 2000
AP		100MG/VIAL	N75853 001 DEC 17, 2002
AP	APOTEX	5MG/ML	N75375 001 SEP 30, 1999

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HCL

AP	BEDFORD	5MG/ML	**N74617 001**	FEB 28, 1996
AP	GENSIA SICOR PHARMS	5MG/ML	**N74894 001**	AUG 26, 1997
+		10MG/ML	N74894 002	APR 19, 2002
AP	INTL MEDICATION	5MG/ML	**N75749 001**	NOV 21, 2001
AP	MERIDIAN MEDCL TECHN	5MG/ML	**N75106 001**	APR 29, 1999
AP	TAYLOR PHARMA	5MG/ML	**N75086 001**	APR 09, 1998

TABLET; ORAL

CARDIZEM

AB	AVENTIS PHARMS	30MG	**N18602 001**	NOV 05, 1982
AB		60MG	**N18602 002**	NOV 05, 1982
AB		90MG	**N18602 003**	DEC 08, 1986
AB +		120MG	**N18602 004**	DEC 08, 1986

DILTIAZEM HCL

AB	APOTHECON	30MG	**N74051 001**	MAR 31, 1993
AB		60MG	**N74051 002**	MAR 31, 1993
AB		90MG	**N74051 003**	MAR 31, 1993
AB		120MG	**N74051 004**	MAR 31, 1993
AB	COPLEY PHARM	30MG	**N74067 001**	NOV 05, 1992
AB		60MG	**N74067 002**	NOV 05, 1992
AB		90MG	**N74067 003**	NOV 05, 1992
AB		120MG	**N74067 004**	NOV 05, 1992
AB	IVAX PHARMS	30MG	**N74168 001**	MAR 03, 1995
AB		60MG	**N74168 002**	MAR 03, 1995

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HCL

AB	IVAX PHARMS	90MG	**N74168 003**	MAR 03, 1995
AB		120MG	**N74168 004**	MAR 03, 1995
AB	LEDERLE	30MG	**N74093 001**	NOV 05, 1992
AB		60MG	**N74093 002**	NOV 05, 1992
AB		90MG	**N74093 003**	NOV 05, 1992
AB		120MG	**N74093 004**	NOV 05, 1992
AB	MYLAN	30MG	**N73185 001**	NOV 05, 1992
AB		60MG	**N73186 001**	NOV 05, 1992
AB		90MG	**N72837 001**	NOV 05, 1992
AB		120MG	**N72838 001**	NOV 05, 1992
AB	TEVA	30MG	**N74185 001**	MAY 31, 1995
AB		60MG	**N74185 002**	MAY 31, 1995
AB		90MG	**N74185 003**	MAY 31, 1995
AB		120MG	**N74185 004**	MAY 31, 1995

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

+	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996
+		EQ 180MG HCL	N20506 002	OCT 04, 1996
+		EQ 240MG HCL	N20506 003	OCT 04, 1996

FDA data supplied by DrugPatentWatch.com

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL
TECZEM
+ BIOVAIL — EQ 180MG HCL;5MG — N20507 001 — OCT 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
AP + STERIS — **50MG/ML** — **N80615 001**
AP + WYETH AYERST — **50MG/ML** — **N84316 001**

DIMERCAPROL

INJECTABLE; INJECTION
BAL
+ AKORN — 10% — N05939 001

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL
DIMETHYL SULFOXIDE
AT BIONICHE (CANADA) — **50%** — **N76185 001** — NOV 29, 2002

RIMSO-50
AT + RES INDS — **50%** — **N17788 001**

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT
+ ALLIANCE PHARM — 0.92MG/VIAL;0.092MG/VIAL — N21191 001 — MAY 31, 2002

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL
+ PHARMACIA AND UPJOHN — 0.5MG/3GM — N19617 001 — DEC 09, 1992

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL
+ CONTROLLED THERAP — 10MG — N20411 001 — MAR 30, 1995

SUPPOSITORY; VAGINAL
PROSTIN E2
+ PHARMACIA AND UPJOHN — 20MG — N17810 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA		BARR	**50MG**	**N80738 001**
AA	+	GENEVA PHARMS	**25MG**	**N80832 001**
AA	+		**50MG**	**N80832 002**
AA		HALSEY	**25MG**	**N84506 001**
AA		ICN	**25MG**	**N80596 001**
AA			**50MG**	**N80592 001**
AA		LNK	**25MG**	**N87977 001** JAN 27, 1983
AA			**50MG**	**N87978 001** JAN 27, 1983
AA		MK LABS	**25MG**	**N83087 001**
AA			**50MG**	**N83087 002**
AA		MUTUAL PHARM	**25MG**	**N89488 001** JAN 02, 1987
AA			**50MG**	**N89489 001** JAN 02, 1987
AA		PVT FORM	**25MG**	**N83027 001**
AA			**50MG**	**N83027 002**
AA		SUPERPHARM	**25MG**	**N89040 001** MAY 15, 1985
AA		WATSON LABS	**25MG**	**N80728 001**
AA			**50MG**	**N80727 001**

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

AA		LANNETT	**12.5MG/5ML**	**N80939 002**
AA		MK LABS	**12.5MG/5ML**	**N83088 002**
AA		PHARM ASSOC	**12.5MG/5ML**	**N87513 001** FEB 10, 1982
AA	+	ROXANE	**12.5MG/5ML**	**N80643 001**

INJECTABLE; INJECTION
BENADRYL
AP + PARKE DAVIS — **50MG/ML** — **N06146 002**

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL PRESERVATIVE FREE

AP	+ PARKE DAVIS	50MG/ML	N09486 001	

DIPHENHYDRAMINE HCL

AP	ABBOTT	50MG/ML	N40140 001	NOV 20, 1998
AP	AM PHARM PARTNERS	50MG/ML	N40466 001	MAY 28, 2002
AP	ELKINS SINN	50MG/ML	N80817 002	
AP	STERIS	50MG/ML	N80873 002	
	+	10MG/ML	N80873 001	
AP	WYETH AYERST	50MG/ML	N80577 001	

DIPHENHYDRAMINE HCL PRESERVATIVE FREE

AP	INTL MEDICATION	50MG/ML	N84094 001	
AP	STERIS	50MG/ML	N80873 003	

DIPHENOXYLATE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AT	AKORN	0.1%	N74382 001	SEP 29, 1995

DIPIVEFRIN HCL

AT	BAUSCH AND LOMB	0.1%	N74188 001	MAY 19, 1995
AT	FALCON PHARMS	0.1%	N73636 001	JUN 30, 1994

PROPINE

AT	+ ALLERGAN	0.1%	N18239 001	

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	ABBOTT	5MG/ML	N74601 001	DEC 19, 1997
AP	AM PHARM PARTNERS	5MG/ML	N74956 001	SEP 30, 1998
AP	APOTEX	5MG/ML	N75769 001	NOV 27, 2002

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	BEDFORD	5MG/ML	N74939 001	APR 13, 1998
AP	ELKINS SINN	5MG/ML	N74521 001	OCT 18, 1996
AP	GENSIA SICOR PHARMS	5MG/ML	N74952 001	NOV 26, 1997

IV PERSANTINE

AP	+ BOEHRINGER INGELHEIM	5MG/ML	N19817 001	DEC 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

AB	BARR	25MG	N87184 001	OCT 03, 1990
AB		50MG	N87716 001	OCT 03, 1990
AB		75MG	N87717 001	OCT 03, 1990
AB	GENEVA PHARMS	25MG	N86944 002	APR 16, 1991
AB		50MG	N87562 001	FEB 25, 1992
AB		75MG	N87561 001	FEB 25, 1992
AB	LEDERLE	25MG	N88999 001	FEB 05, 1991
AB		50MG	N89000 001	FEB 05, 1991
AB		75MG	N89001 001	FEB 05, 1991
AB	PUREPAC PHARM	25MG	N89425 001	JUL 12, 1990
AB	WATSON LABS	50MG	N87160 001	JUN 07, 1996

PERSANTINE

AB	BOEHRINGER INGELHEIM	25MG	N12836 003	DEC 22, 1986
AB	+	50MG	N12836 004	FEB 06, 1987
AB		75MG	N12836 005	FEB 06, 1987

DIPYRIDAMOLE; *MULTIPLE*
SEE ASPIRIN; DIPYRIDAMOLE

FDA data supplied by DrugPatentWatch.com

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC			
	+ LILLY RES LABS	250MG	N50678 001	JUN 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	GENEVA PHARMS	**EQ 100MG BASE**	**N70470 001**	DEC 10, 1985
AB		**EQ 150MG BASE**	**N70471 001**	DEC 10, 1985
AB	IVAX PHARMS	**EQ 100MG BASE**	**N70186 001**	NOV 18, 1985
AB		**EQ 150MG BASE**	**N70187 001**	NOV 18, 1985
AB	SUPERPHARM	**EQ 100MG BASE**	**N70940 001**	FEB 09, 1987
AB	TEVA	**EQ 100MG BASE**	**N70101 001**	FEB 22, 1985
AB		**EQ 150MG BASE**	**N70102 001**	FEB 22, 1985
AB	WATSON LABS	**EQ 100MG BASE**	**N70173 001**	MAY 31, 1985
AB		**EQ 150MG BASE**	**N70174 001**	MAY 31, 1985
	NORPACE			
AB	GD SEARLE LLC	**EQ 100MG BASE**	**N17447 001**	
AB	+	**EQ 150MG BASE**	**N17447 002**	

CAPSULE, EXTENDED RELEASE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	KV PHARM	**EQ 150MG BASE**	**N71200 001**	DEC 15, 1987
	NORPACE CR			
AB	+ GD SEARLE LLC	**EQ 150MG BASE**	**N18655 002**	JUL 20, 1982
		EQ 100MG BASE	N18655 001	JUL 20, 1982

DISULFIRAM

TABLET; ORAL

	ANTABUSE			
	+ ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	DEPAKOTE			
	+ ABBOTT	EQ 125MG VALPROIC ACID	N19680 001	SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL

	DEPAKOTE			
	+ ABBOTT	EQ 125MG VALPROIC ACID	N18723 003	OCT 26, 1984
	+	EQ 250MG VALPROIC ACID	N18723 001	MAR 10, 1983
	+	EQ 500MG VALPROIC ACID	N18723 002	MAR 10, 1983

TABLET, EXTENDED RELEASE; ORAL

	DEPAKOTE ER			
	ABBOTT	EQ 250MG VALPROIC ACID	N21168 002	MAY 31, 2002
	+	EQ 500MG VALPROIC ACID	N21168 001	AUG 04, 2000

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTAMINE HCL			
AP	ABBOTT	**EQ 1.25GM BASE/100ML**	**N74634 001**	SEP 27, 1996
AP		**EQ 12.5MG BASE/ML**	**N74086 001**	NOV 29, 1993
AP		**EQ 12.5MG BASE/ML**	**N74292 001**	FEB 16, 1995
AP	ASTRAZENECA	**EQ 12.5MG BASE/ML**	**N74098 001**	FEB 21, 1995
AP	BEDFORD	**EQ 12.5MG BASE/ML**	**N74277 001**	OCT 31, 1994
AP	ELKINS SINN	**EQ 12.5MG BASE/ML**	**N74381 001**	SEP 26, 1996

FDA data supplied by DrugPatentWatch.com

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP		GENSIA SICOR PHARMS	EQ 12.5MG BASE/ML	N74206 001 OCT 19, 1993
AP		LUITPOLD	EQ 12.5MG BASE/ML	N74545 001 JUN 25, 1998
AP		MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	N74279 001 FEB 18, 1998
AP			EQ 12.5MG BASE/ML	N74995 001 MAR 31, 1998
AP		STERIS	EQ 12.5MG BASE/ML	N74114 001 NOV 30, 1993

DOBUTAMINE HCL IN DEXTROSE 5%

AP	+	ABBOTT	EQ 50MG BASE/100ML	N20269 001 OCT 19, 1993
AP	+		EQ 100MG BASE/100ML	N20269 002 OCT 19, 1993
AP	+		EQ 200MG BASE/100ML	N20269 003 OCT 19, 1993

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	EQ 50MG BASE/100ML	N20201 003 OCT 19, 1993
AP	+		EQ 100MG BASE/100ML	N20201 002 OCT 19, 1993
AP	+		EQ 200MG BASE/100ML	N20201 001 OCT 19, 1993
AP	+		EQ 400MG BASE/100ML	N20201 006 JUL 07, 1994
AP	+	BAXTER HLTHCARE	EQ 50MG BASE/100ML	N20255 001 OCT 19, 1993
AP	+		EQ 100MG BASE/100ML	N20255 003 OCT 19, 1993
AP	+		EQ 200MG BASE/100ML	N20255 004 OCT 19, 1993
AP	+		EQ 400MG BASE/100ML	N20255 005 OCT 19, 1993

DOBUTREX

AP	+	LILLY	EQ 12.5MG BASE/ML	N17820 002

DOCETAXEL

INJECTABLE; INJECTION

TAXOTERE

	+	AVENTIS PHARMS	EQ 40MG BASE/ML	N20449 001 MAY 14, 1996

DOFETILIDE

CAPSULE; ORAL

TIKOSYN

		PFIZER	0.125MG	N20931 001 OCT 01, 1999
			0.25MG	N20931 002 OCT 01, 1999
	+		0.5MG	N20931 003 OCT 01, 1999

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION

ANZEMET

		AVENTIS PHARMS	EQ 12.5MG BASE/ML	N20624 002 SEP 11, 1997
	+		EQ 20MG BASE/ML	N20624 001 SEP 11, 1997

TABLET; ORAL

ANZEMET

		AVENTIS PHARMS	EQ 50MG BASE	N20623 001 SEP 11, 1997
	+		EQ 100MG BASE	N20623 002 SEP 11, 1997

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

		EISAI MEDCL RES	5MG	N20690 002 NOV 25, 1996
	+		10MG	N20690 001 NOV 25, 1996

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP	+	ABBOTT	**80MG/100ML**	**N18132 002** FEB 04, 1982
AP	+		**160MG/100ML**	**N18132 003** FEB 04, 1982
AP	+		**40MG/ML**	**N18132 001**

FDA data supplied by DrugPatentWatch.com

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP		ABBOTT	40MG/ML	N74403 001 MAY 23, 1996
AP	+		80MG/ML	N18132 004 JUL 09, 1982
AP		AM PHARM PARTNERS	80MG/ML	N70013 001 JUN 12, 1985
AP	+	ASTRAZENECA	40MG/ML	N18656 001 JUN 28, 1983
AP			80MG/ML	N70091 001 OCT 23, 1985
AP			160MG/ML	N70092 001 OCT 23, 1985
AP	+	ELKINS SINN	40MG/ML	N18398 001
AP	+		80MG/ML	N18398 002 MAR 22, 1982
AP		GENSIA SICOR PHARMS	40MG/ML	N72999 001 OCT 23, 1991
AP			80MG/ML	N73000 001 OCT 23, 1991
AP	+	INTL MEDICATION	40MG/ML	N18014 001
AP		LUITPOLD	40MG/ML	N70799 001 FEB 11, 1987
AP			80MG/ML	N70820 001 FEB 11, 1987
AP			160MG/ML	N70826 001 FEB 11, 1987

DOPAMINE HCL AND DEXTROSE 5%

AP	+	B BRAUN	80MG/100ML	N19099 002 OCT 15, 1986
AP	+		320MG/100ML	N19099 004 OCT 15, 1986

DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	160MG/100ML	N19099 003 OCT 15, 1986
	+		40MG/100ML	N19099 001 OCT 15, 1986

DOPAMINE HCL IN DEXTROSE 5%

AP	+	ABBOTT	1.6MG/ML	N20542 001 AUG 30, 1995

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	80MG/100ML	N18826 001 SEP 30, 1983
AP	+		160MG/100ML	N18826 002 SEP 30, 1983

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ABBOTT	320MG/100ML	N18826 003 SEP 30, 1983
AP	+	BAXTER HLTHCARE	80MG/100ML	N19615 001 MAR 27, 1987
AP	+		160MG/100ML	N19615 002 MAR 27, 1987
AP	+		320MG/100ML	N19615 003 MAR 27, 1987
	+		640MG/100ML	N19615 004 MAR 27, 1987

INTROPIN

AP	+	FAULDING	40MG/ML	N17395 001
AP	+		80MG/ML	N17395 002
AP	+		160MG/ML	N17395 003

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

TRUSOPT

	+	MERCK	EQ 2% BASE	N20408 001 DEC 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

	+	MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

	+	ABBOTT	EQ 1MG BASE/ML	N19946 001 MAR 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+	ROBINS AH	20MG/ML	N14879 001

FDA data supplied by DrugPatentWatch.com

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

	DOXAPRAM HCL			
AP	STERIS	20MG/ML	N73529 001	JAN 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

	CARDURA			
AB	+ PFIZER	EQ 1MG BASE	N19668 001	NOV 02, 1990
AB		EQ 2MG BASE	N19668 002	NOV 02, 1990
AB		EQ 4MG BASE	N19668 003	NOV 02, 1990
AB		EQ 8MG BASE	N19668 004	NOV 02, 1990
	DOXAZOSIN MESYLATE			
AB	EON	EQ 1MG BASE	N75646 001	OCT 18, 2000
AB		EQ 2MG BASE	N75646 002	OCT 18, 2000
AB		EQ 4MG BASE	N75646 003	OCT 18, 2000
AB		EQ 8MG BASE	N75646 004	OCT 18, 2000
AB	GENEVA PHARMS TECH	EQ 1MG BASE	N75432 001	OCT 18, 2000
AB		EQ 2MG BASE	N75432 002	OCT 18, 2000
AB		EQ 4MG BASE	N75432 003	OCT 18, 2000
AB		EQ 8MG BASE	N75432 004	OCT 18, 2000
AB	GENPHARM	EQ 1MG BASE	N75466 001	OCT 18, 2000
AB		EQ 2MG BASE	N75466 002	OCT 18, 2000
AB		EQ 4MG BASE	N75466 003	OCT 18, 2000
AB		EQ 8MG BASE	N75466 004	OCT 18, 2000
AB	IVAX PHARMS	EQ 1MG BASE	N75453 001	OCT 18, 2000
AB		EQ 2MG BASE	N75453 002	OCT 18, 2000

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE			
AB	IVAX PHARMS	EQ 4MG BASE	N75453 003	OCT 18, 2000
AB		EQ 8MG BASE	N75453 004	OCT 18, 2000
AB	KV PHARM	EQ 1MG BASE	N75609 001	OCT 18, 2000
AB		EQ 2MG BASE	N75609 002	OCT 18, 2000
AB		EQ 4MG BASE	N75609 003	OCT 18, 2000
AB		EQ 8MG BASE	N75609 004	OCT 18, 2000
AB	MYLAN	EQ 1MG BASE	N75509 001	OCT 19, 2000
AB		EQ 2MG BASE	N75509 002	OCT 19, 2000
AB		EQ 4MG BASE	N75509 003	OCT 19, 2000
AB		EQ 8MG BASE	N75509 004	OCT 19, 2000
AB	PUREPAC PHARM	EQ 1MG BASE	N75574 001	OCT 18, 2000
AB		EQ 2MG BASE	N75574 002	OCT 18, 2000
AB		EQ 4MG BASE	N75574 003	OCT 18, 2000
AB		EQ 8MG BASE	N75574 004	OCT 18, 2000
AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001
AB		EQ 1MG BASE	N75536 001	OCT 18, 2000
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001
AB		EQ 2MG BASE	N75536 002	OCT 18, 2000

FDA data supplied by DrugPatentWatch.com

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE			
AB	TEVA	EQ 4MG BASE	N75353 003	JAN 12, 2001
AB		EQ 4MG BASE	N75536 003	OCT 18, 2000
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001
AB		EQ 8MG BASE	N75536 004	OCT 18, 2000
AB	TORPHARM	EQ 1MG BASE	N75580 001	OCT 18, 2000
AB		EQ 2MG BASE	N75580 002	OCT 18, 2000
AB		EQ 4MG BASE	N75580 003	OCT 18, 2000
AB		EQ 8MG BASE	N75580 004	OCT 18, 2000
AB	WATSON LABS	EQ 1MG BASE	N75426 001	OCT 18, 2000
AB		EQ 2MG BASE	N75426 002	OCT 18, 2000
AB		EQ 4MG BASE	N75426 003	OCT 18, 2000
AB		EQ 8MG BASE	N75426 004	OCT 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	DOXEPIN HCL			
AB	GENEVA PHARMS	EQ 10MG BASE	N71487 001	MAR 02, 1987
AB		EQ 25MG BASE	N70827 001	MAY 15, 1986
AB		EQ 50MG BASE	N70828 001	MAY 15, 1986
AB		EQ 75MG BASE	N70825 001	MAY 15, 1986
AB		EQ 100MG BASE	N71562 001	MAR 02, 1987
AB	MYLAN	EQ 10MG BASE	N70789 001	MAY 13, 1986
AB		EQ 25MG BASE	N70790 001	MAY 13, 1986

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	DOXEPIN HCL			
AB	MYLAN	EQ 50MG BASE	N70791 001	MAY 13, 1986
AB		EQ 75MG BASE	N70792 001	MAY 13, 1986
AB		EQ 100MG BASE	N70793 001	MAY 13, 1986
AB	PAR PHARM	EQ 10MG BASE	N71697 001	NOV 09, 1987
AB		EQ 25MG BASE	N71437 001	NOV 09, 1987
AB		EQ 50MG BASE	N71595 001	NOV 09, 1987
AB		EQ 75MG BASE	N71608 001	NOV 09, 1987
AB		EQ 100MG BASE	N71422 001	NOV 09, 1987
AB		EQ 150MG BASE	N71669 001	NOV 09, 1987
AB	WATSON LABS	EQ 10MG BASE	N71485 001	APR 30, 1987
AB		EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N71486 001	APR 30, 1987
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N71238 001	APR 30, 1987
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991
AB		EQ 75MG BASE	N71326 001	APR 30, 1987
AB		EQ 100MG BASE	N71239 001	APR 30, 1987
	SINEQUAN			
AB	PFIZER	EQ 10MG BASE	N16798 003	
AB	+	EQ 25MG BASE	N16798 001	
AB		EQ 50MG BASE	N16798 002	
AB		EQ 75MG BASE	N16798 006	
AB	+	EQ 100MG BASE	N16798 005	
AB		EQ 150MG BASE	N16798 007	

CONCENTRATE; ORAL

	DOXEPIN HCL			
AA	COPLEY PHARM	EQ 10MG BASE/ML	N71609 001	NOV 09, 1987

FDA data supplied by DrugPatentWatch.com

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

	DOXEPIN HCL			
AA	MORTON GROVE	**EQ 10MG BASE/ML**	**N71918 001**	JUL 20, 1988
AA	SILARX	**EQ 10MG BASE/ML**	**N74721 001**	DEC 29, 1998
	SINEQUAN			
AA	+ PFIZER	**EQ 10MG BASE/ML**	**N17516 001**	

CREAM; TOPICAL

ZONALON			
+ BIOGLAN PHARMS	5%	N20126 001	APR 01, 1994

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL			
+ BONE CARE	2.5 UGM	N20862 001	JUN 09, 1999

INJECTABLE; INJECTION

HECTOROL			
+ BONE CARE	2 UGM/ML	N21027 001	APR 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	ADRIAMYCIN PFS			
AP	+ PHARMACIA AND UPJOHN	**2MG/ML**	**N50629 001**	DEC 23, 1987
AP	+	**200MG/100ML**	**N50629 002**	MAY 03, 1988
AP		**2MG/ML**	**N63165 001**	JAN 30, 1991
AP		**200MG/100ML**	**N63165 002**	JAN 30, 1991
	ADRIAMYCIN RDF			
AP	+ PHARMACIA AND UPJOHN	**10MG/VIAL**	**N50467 001**	
AP	+	**20MG/VIAL**	**N50467 003**	MAY 20, 1985
AP	+	**50MG/VIAL**	**N50467 002**	
	+	150MG/VIAL	N50467 004	JUL 22, 1987

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	DOXORUBICIN HCL			
AP	AM PHARM PARTNERS	**2MG/ML**	**N63277 001**	OCT 26, 1995
AP	BEDFORD	**2MG/ML**	**N62975 001**	MAR 17, 1989
AP		**200MG/100ML**	**N64097 001**	SEP 13, 1994
AP		**10MG/VIAL**	**N62921 001**	MAR 17, 1989
AP		**20MG/VIAL**	**N62921 002**	MAR 17, 1989
AP		**50MG/VIAL**	**N62921 003**	MAR 17, 1989
AP	GENSIA SICOR PHARMS	**2MG/ML**	**N64140 001**	JUL 28, 1995
AP		**200MG/100ML**	**N64140 002**	JUL 28, 1995
AP	PHARMACHEMIE	**2MG/ML**	**N63336 001**	FEB 28, 1995
AP		**200MG/100ML**	**N63336 004**	FEB 28, 1995
AP		**10MG/VIAL**	**N63097 001**	MAY 21, 1990
AP		**20MG/VIAL**	**N63097 002**	MAY 21, 1990
AP		**50MG/VIAL**	**N63097 003**	MAY 21, 1990
	RUBEX			
AP	BRISTOL MYERS SQUIBB	**10MG/VIAL**	**N62926 001**	APR 13, 1989
AP		**50MG/VIAL**	**N62926 002**	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL			
+ ALZA	2MG/ML	N50718 001	NOV 17, 1995

DOXYCYCLINE

CAPSULE; ORAL

	DOXYCYCLINE			
AB	EON	**EQ 50MG BASE**	**N65032 001**	JUN 30, 2000

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE

CAPSULE; ORAL

	DOXYCYCLINE			
AB	EON	EQ 100MG BASE	N65032 002	JUN 30, 2000
AB	HALSEY	EQ 50MG BASE	N65041 001	APR 28, 2000
AB		EQ 100MG BASE	N65041 002	APR 28, 2000
AB	PAR PHARM	EQ 50MG BASE	N65055 001	DEC 01, 2000
AB		EQ 100MG BASE	N65055 002	DEC 01, 2000
AB	RANBAXY	EQ 50MG BASE	N65053 001	NOV 22, 2000
AB		EQ 100MG BASE	N65053 002	NOV 22, 2000
	MONODOX			
AB	OCLASSEN	EQ 50MG BASE	N50641 002	FEB 10, 1992
AB +		EQ 100MG BASE	N50641 001	DEC 29, 1989

FOR SUSPENSION; ORAL

	VIBRAMYCIN		
	+ PFIZER	EQ 25MG BASE/5ML	N50006 001

TABLET; ORAL

	DOXYCYCLINE		
	PAR PHARM	EQ 50MG BASE	N65070 001 DEC 15, 2000
		EQ 75MG BASE	N65070 003 DEC 30, 2002
	+	EQ 100MG BASE	N65070 002 DEC 15, 2000

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

	VIBRAMYCIN		
	+ PFIZER	EQ 50MG BASE/5ML	N50480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXYCYCLINE HYCLATE		
AB	HALSEY	EQ 50MG BASE	N61717 001
AB	HALSEY	EQ 100MG BASE	N61717 002
AB	IVAX PHARMS	EQ 50MG BASE	N62500 001 SEP 11, 1984
AB		EQ 100MG BASE	N62500 002 SEP 11, 1984
AB	MUTUAL PHARM	EQ 50MG BASE	N62675 001 JUL 10, 1986
AB		EQ 100MG BASE	N62676 001 JUL 10, 1986
AB	MYLAN	EQ 50MG BASE	N62337 001 MAR 29, 1982
AB		EQ 100MG BASE	N62337 002 MAR 29, 1982
AB	WATSON LABS	EQ 50MG BASE	N62031 002 OCT 13, 1982
AB		EQ 100MG BASE	N62031 001
AB	WEST WARD	EQ 50MG BASE	N62396 002 NOV 07, 1984
AB		EQ 100MG BASE	N62396 001 MAY 07, 1984
	VIBRAMYCIN		
AB	PFIZER	EQ 50MG BASE	N50007 001
AB +		EQ 100MG BASE	N50007 002

CAPSULE, COATED PELLETS; ORAL

	DORYX		
AB +	FAULDING	EQ 100MG BASE	N50582 001 JUL 22, 1985
AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001 OCT 30, 1985

INJECTABLE; INJECTION

	DOXY 100		
AP	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001 DEC 09, 1983
	DOXY 200		
AP	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002 DEC 09, 1983
	VIBRAMYCIN		
AP +	PFIZER	EQ 100MG BASE/VIAL	N50442 002
AP +		EQ 200MG BASE/VIAL	N50442 001

LIQUID, EXTENDED RELEASE; PERIODONTAL

	ATRIDOX		
	+ ATRIX	EQ 10% W/W	N50751 001 SEP 03, 1998

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	HALSEY	**EQ 100MG BASE**	**N62269 001**	
AB		**EQ 100MG BASE**	**N62269 002**	NOV 08, 1982
AB	IVAX PHARMS	**EQ 100MG BASE**	**N62505 001**	SEP 11, 1984
AB	MUTUAL PHARM	**EQ 100MG BASE**	**N62677 001**	JUL 10, 1986
AB	MYLAN	**EQ 100MG BASE**	**N62432 001**	FEB 15, 1983
AB	VINTAGE PHARMS	**EQ 100MG BASE**	**N62538 001**	APR 07, 1986
AB	WATSON LABS	**EQ 100MG BASE**	**N62421 001**	FEB 02, 1983

PERIOSTAT

+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001

VIBRA-TABS

AB	+ PFIZER	**EQ 100MG BASE**	**N50533 001**	

DRONABINOL

CAPSULE; ORAL

MARINOL

	UNIMED	2.5MG	N18651 001	MAY 31, 1985
		5MG	N18651 002	MAY 31, 1985
+		10MG	N18651 003	MAY 31, 1985

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP	ABBOTT	**2.5MG/ML**	**N71981 001**	FEB 29, 1988
AP		**2.5MG/ML**	**N72272 001**	AUG 31, 1995
AP	FAULDING	**2.5MG/ML**	**N71645 001**	APR 07, 1988
AP	LUITPOLD	**2.5MG/ML**	**N72123 001**	OCT 24, 1988

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP	LUITPOLD	**2.5MG/ML**	**N72335 001**	OCT 24, 1988

INAPSINE

AP	+ AKORN	**2.5MG/ML**	**N16796 001**	

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

	+ ABBOTT	2.5MG/ML; EQ 0.05MG BASE/ML	N71982 001	MAY 04, 1988

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28

YASMIN

	+ BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001

DUTASTERIDE

CAPSULE; ORAL

AVODART

	+ GLAXOSMITHKLINE	0.5MG	N21319 001	NOV 20, 2001

DYPHYLLINE

TABLET; ORAL

DILOR

BP	SAVAGE LABS	200MG	N84514 001	

DILOR-400

BP	+ SAVAGE LABS	400MG	N84751 001	

LUFYLLIN

BP	WALLACE LABS	200MG	N84566 001	
BP		400MG	N84566 002	

FDA data supplied by DrugPatentWatch.com

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC
PHOSPHOLINE IODIDE
+ AYERST 0.125% N11963 001

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE
AB ALTANA **1%** **N76075 001**
NOV 26, 2002
AB TARO **1%** **N76005 001**
NOV 26, 2002

SPECTAZOLE
AB + JOHNSON AND JOHNSON **1%** **N18751 001**
DEC 23, 1982

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION
CALCIUM DISODIUM VERSENATE
+ 3M 200MG/ML N08922 001

EDETATE DISODIUM

INJECTABLE; INJECTION
EDETATE DISODIUM
AP APOTEX **150MG/ML** **N40376 001**
NOV 04, 2002
AP BIONICHE (CANADA) **150MG/ML** **N40437 001**
JUL 09, 2002
AP STERIS **150MG/ML** **N80391 001**
ENDRATE
AP + ABBOTT **150MG/ML** **N11355 001**

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE
AP ABBOTT **10MG/ML** **N40131 001**
FEB 24, 1998

ENLON
AP BAXTER HLTHCARE CORP **10MG/ML** **N88873 001**
AUG 06, 1985

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
REVERSOL
AP ORGANON **10MG/ML** **N89624 001**
MAY 13, 1988

TENSILON
AP + ICN **10MG/ML** **N07959 001**

TENSILON PRESERVATIVE FREE
AP + ICN **10MG/ML** **N07959 002**

EDROPHONIUM CHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; EDROPHONIUM CHLORIDE

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA
BRISTOL MYERS SQUIBB 50MG N20972 001
SEP 17, 1998
100MG N20972 002
SEP 17, 1998
+ 200MG N20972 003
SEP 17, 1998

TABLET; ORAL
SUSTIVA
BRISTOL MYERS SQUIBB 300MG N21360 001
FEB 01, 2002
+ 600MG N21360 002
FEB 01, 2002

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
VANIQA
+ WOMEN FIRST HLTHCARE 13.9% N21145 001
JUL 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL
RELPAX
PFIZER EQ 20MG BASE N21016 001
DEC 26, 2002

FDA data supplied by DrugPatentWatch.com

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL
RELPAX
+ PFIZER — EQ 40MG BASE — N21016 002 DEC 26, 2002

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC
EMADINE
+ ALCON — 0.05% — N20706 001 DEC 29, 1997

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	APOTHECON	2.5MG	**N75583 001** AUG 22, 2000
AB		5MG	**N75583 002** AUG 22, 2000
AB		10MG	**N75583 003** AUG 22, 2000
AB		20MG	**N75583 004** AUG 22, 2000
AB	EON	2.5MG	**N75621 001** AUG 22, 2000
AB		5MG	**N75621 002** AUG 22, 2000
AB		10MG	**N75621 003** AUG 22, 2000
AB		20MG	**N75621 004** AUG 22, 2000
AB	GENEVA PHARMS	2.5MG	**N75048 001** AUG 22, 2000
AB		5MG	**N75048 002** AUG 22, 2000
AB		10MG	**N75048 003** AUG 22, 2000
AB		20MG	**N75048 004** AUG 22, 2000
AB	GENPHARM	2.5MG	**N75472 001** AUG 22, 2000
AB		5MG	**N75472 002** AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	GENPHARM	10MG	**N75472 003** AUG 22, 2000
AB		20MG	**N75472 004** AUG 22, 2000
AB	IVAX PHARMS	2.5MG	**N75482 001** AUG 22, 2000
AB		5MG	**N75482 002** AUG 22, 2000
AB		10MG	**N75482 003** AUG 22, 2000
AB		20MG	**N75482 004** AUG 22, 2000
AB	KRKA DD NOVO MESTO	2.5MG	**N75370 001** AUG 22, 2000
AB		5MG	**N75370 002** AUG 22, 2000
AB		10MG	**N75369 001** AUG 22, 2000
AB		20MG	**N75369 002** AUG 22, 2000
AB	LEK PHARM	2.5MG	**N75496 001** AUG 22, 2000
AB		5MG	**N75496 002** AUG 22, 2000
AB		10MG	**N75459 001** AUG 22, 2000
AB		20MG	**N75459 002** AUG 22, 2000
AB	MYLAN	2.5MG	**N75480 001** AUG 22, 2000
AB		5MG	**N75480 002** AUG 22, 2000
AB		10MG	**N75480 003** AUG 22, 2000
AB		20MG	**N75480 004** AUG 22, 2000
AB	RANBAXY	2.5MG	**N75556 001** AUG 22, 2000
AB		5MG	**N75556 002** AUG 22, 2000
AB		10MG	**N75556 003** AUG 22, 2000
AB		20MG	**N75556 004** AUG 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	TARO	2.5MG	N75657 001	JAN 23, 2001
AB		5MG	N75657 002	JAN 23, 2001
AB		10MG	N75657 003	JAN 23, 2001
AB		20MG	N75657 004	JAN 23, 2001
AB	TEVA	2.5MG	N75479 001	AUG 22, 2000
AB		5MG	N75479 002	AUG 22, 2000
AB		10MG	N75479 003	AUG 22, 2000
AB		20MG	N75479 004	AUG 22, 2000
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001
AB		5MG	N75178 001	MAR 23, 2001
AB		10MG	N75178 003	MAR 23, 2001
AB		20MG	N75178 004	MAR 23, 2001
AB	WATSON LABS	2.5MG	N75501 001	AUG 22, 2000
AB		5MG	N75501 002	AUG 22, 2000
AB		10MG	N75501 003	AUG 22, 2000
AB		20MG	N75501 004	AUG 22, 2000
AB	WOCKHARDT	2.5MG	N75483 001	AUG 22, 2000
AB		5MG	N75483 002	AUG 22, 2000
AB		10MG	N75483 003	AUG 22, 2000
AB		20MG	N75483 004	AUG 22, 2000

VASOTEC

AB	BIOVAIL	2.5MG	N18998 005	JUL 26, 1988
AB		5MG	N18998 001	DEC 24, 1985

ENALAPRIL MALEATE

TABLET; ORAL
VASOTEC

AB	BIOVAIL	10MG	N18998 002	DEC 24, 1985
AB +		20MG	N18998 003	DEC 24, 1985

ENALAPRIL MALEATE; *MULTIPLE*
SEE DILTIAZEM MALATE; ENALAPRIL MALEATE

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL

+	ASTRAZENECA	5MG;2.5MG	N20668 002	OCT 28, 1998
+		5MG;5MG	N20668 001	DEC 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001
AB		10MG;25MG	N75909 002	OCT 15, 2001
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001
AB		10MG;25MG	N76116 002	SEP 19, 2001
AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001
AB		10MG;25MG	N75624 002	SEP 18, 2001
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001
AB		10MG;25MG	N75788 002	SEP 18, 2001
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001
AB		10MG;25MG	N75727 002	SEP 18, 2001

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB		BIOVAIL	**5MG;12.5MG**	**N19221 003** JUL 12, 1995
AB	+		**10MG;25MG**	**N19221 001** OCT 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP		ABBOTT	**1.25MG/ML**	**N75456 001** AUG 22, 2000
AP			**1.25MG/ML**	**N75458 001** AUG 22, 2000
AP		BEDFORD	**1.25MG/ML**	**N75634 001** AUG 22, 2000
AP		FAULDING	**1.25MG/ML**	**N75571 001** AUG 22, 2000
AP		GENSIA SICOR PHARMS	**1.25MG/ML**	**N75578 001** AUG 22, 2000

VASOTEC

AP	+	BIOVAIL	**1.25MG/ML**	**N19309 001** FEB 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

AN		ABBOTT	**99.9%**	**N70803 001** SEP 08, 1987
AN		MINRAD	**99.9%**	**N74396 001** JUL 29, 1994

ETHRANE

AN	+	BAXTER HLTHCARE CORP	**99.9%**	**N17087 001**

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

	+	AVENTIS	30MG/0.3ML	N20164 001 MAR 29, 1993
	+		40MG/0.4ML	N20164 002 JAN 30, 1998

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

+	AVENTIS	60MG/0.6ML	N20164 003 MAR 27, 1998
+		80MG/0.8ML	N20164 004 MAR 27, 1998
+		100MG/ML	N20164 005 MAR 27, 1998
+		120MG/0.8ML	N20164 007 JUN 02, 2000
+		150MG/ML	N20164 008 JUN 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

+	ORION	200MG	N20796 001 OCT 19, 1999

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR

EPIPEN

+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 001 DEC 22, 1987

EPIPEN JR.

+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 002 DEC 22, 1987

EPINEPHRINE; *MULTIPLE*

SEE ARTICAINE HYDROCHLORIDE; EPINEPHRINE

SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	ABBOTT	**0.005MG/ML;0.5%**	**N89635 001** JUN 21, 1988
AP		**0.005MG/ML;1%**	**N89649 001** JUN 21, 1988

FDA data supplied by DrugPatentWatch.com

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP		ABBOTT	0.005MG/ML;1.5%	N88571 001 SEP 13, 1985
AP			0.005MG/ML;1.5%	N89645 001 JUN 21, 1988
AP			0.005MG/ML;1.5%	N89650 001 JUN 21, 1988
AP			0.005MG/ML;2%	N89651 001 JUN 21, 1988
AP			0.01MG/ML;1%	N89644 001 JUN 21, 1988
AP			0.01MG/ML;2%	N89646 001 JUN 21, 1988
AP		EASTMAN KODAK	0.01MG/ML;2%	N40057 002 FEB 26, 1993
AP			0.02MG/ML;2%	N40057 001 FEB 26, 1993
AP		ELKINS SINN	0.01MG/ML;1%	N80406 001
AP			0.01MG/ML;2%	N80406 002
AP		GRAHAM CHEM	0.01MG/ML;2%	N80504 004 OCT 19, 1983
AP			0.02MG/ML;2%	N80504 005 OCT 19, 1983

LIDOCAINE HCL W/ EPINEPHRINE

AP		DELL LABS	0.01MG/ML;1%	N83389 001
AP			0.01MG/ML;2%	N83390 001

LIDOCATON

AP		PHARMATON	0.01MG/ML;2%	N84729 001 AUG 17, 1983

OCTOCAINE

AP		SEPTODONT	0.01MG/ML;2%	N84048 001
AP	+		0.02MG/ML;2%	N84048 002

XYLOCAINE W/ EPINEPHRINE

AP	+	ASTRAZENECA	0.005MG/ML;0.5%	N06488 012
AP	+		0.005MG/ML;1%	N06488 018 NOV 13, 1986
AP	+		0.005MG/ML;1.5%	N06488 017
AP	+		0.005MG/ML;2%	N06488 019 NOV 13, 1986
AP	+		0.01MG/ML;1%	N06488 004
	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381 001
			0.02MG/ML;2%	N21381 002

SOLUTION; IONTOPHORESIS

IONTOCAINE

	+	IOMED	0.01MG/ML;2%	N20530 001 DEC 21, 1995

EPINEPHRINE BITARTRATE; *MULTIPLE*

SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

	+	ASTRAZENECA	0.005MG/ML;1%	N17751 006
	+	DENTSPLY PHARM	0.005MG/ML;1.5%	N21384 001

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

	+	DEPROCO	EQ 0.02MG BASE/ML;2%	N88389 001 JAN 22, 1985

LIGNOSPAN STANDARD

	+	DEPROCO	EQ 0.01MG BASE/ML;2%	N88390 001 JAN 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

	+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLENCE

BX	+	PHARMACIA AND UPJOHN	2MG/ML	N50778 001 SEP 15, 1999

EPLERENONE

TABLET; ORAL

INSPRA

		GD SEARLE LLC	25MG	N21437 001 SEP 27, 2002
			50MG	N21437 002 SEP 27, 2002
	+		100MG	N21437 003 SEP 27, 2002

FDA data supplied by DrugPatentWatch.com

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION				
FLOLAN				
+	GLAXOSMITHKLINE	EQ 0.5MG BASE/VIAL	N20444 001	
			SEP 20, 1995	
+		EQ 1.5MG BASE/VIAL	N20444 002	
			SEP 20, 1995	

EPROSARTAN MESYLATE

TABLET; ORAL				
TEVETEN				
	BIOVAIL PHARMS	EQ 300MG BASE	N20738 004	
			DEC 22, 1997	
		EQ 400MG BASE	N20738 005	
			DEC 22, 1997	
+		EQ 600MG BASE	N20738 006	
			MAY 27, 1999	

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL				
TEVETEN HCT				
	BIOVAIL PHARMS	600MG;12.5MG	N21268 001	
			NOV 01, 2001	
+		600MG;25MG	N21268 002	
			NOV 01, 2001	

EPTIFIBATIDE

INJECTABLE; INJECTION				
INTEGRILIN				
+	MILLENNIUM PHARMS	75MG/100ML	N20718 002	
			MAY 18, 1998	
+		2MG/ML	N20718 001	
			MAY 18, 1998	

ERGOCALCIFEROL

CAPSULE; ORAL					
DRISDOL					
AA	+ SANOFI SYNTHELABO	**50,000 IU**	**N03444 001**		
VITAMIN D					
AA	BANNER PHARMACAPS	**50,000 IU**	**N80704 001**		

ERGOCALCIFEROL; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

ERGOLOID MESYLATES

TABLET; ORAL					
ERGOLOID MESYLATES					
AB	MUTUAL PHARM	**1MG**	**N81113 001**		
			OCT 31, 1991		
HYDERGINE					
AB	+ NOVARTIS	**1MG**	**N17993 001**		
TABLET; SUBLINGUAL					
ERGOLOID MESYLATES					
AA	WATSON LABS	**0.5MG**	**N87233 001**		
GERIMAL					
AA	WATSON LABS	**0.5MG**	**N86189 001**		
AA		**1MG**	**N86188 001**		
HYDERGINE					
AA	+ NOVARTIS	**0.5MG**	**N09087 002**		
AA	+	**1MG**	**N09087 001**		
HYDROGENATED ERGOT ALKALOIDS					
AA	IVAX PHARMS	**1MG**	**N87185 001**		

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL				
ERGOMAR				
+	NEW RIVER	2MG	N87693 001	
			FEB 24, 1983	

ERGOTAMINE TARTRATE; *MULTIPLE*

SEE CAFFEINE; ERGOTAMINE TARTRATE

FDA data supplied by DrugPatentWatch.com

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

	INVANZ			
	+ MERCK	EQ 1GM BASE/VIAL	N21337 001	NOV 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	+ FAULDING	**250MG**	**N50536 001**	
	ERYTHROMYCIN			
AB	ABBOTT	**250MG**	**N62746 001**	DEC 22, 1986
AB	BARR	**250MG**	**N63098 001**	MAY 04, 1989

GEL; TOPICAL

	E-GLADES			
AT	GLADES PHARMS	**2%**	**N65009 001**	MAR 18, 2002
	EMGEL			
AT	GLAXOSMITHKLINE	**2%**	**N63107 001**	AUG 23, 1991
	ERYGEL			
AT	+ ALLERGAN HERBERT	**2%**	**N50617 001**	OCT 21, 1987
	ERYTHROMYCIN			
AT	ALTANA	**2%**	**N64184 001**	SEP 30, 1997
AT	STIEFEL	**2%**	**N63211 001**	JAN 29, 1993

LOTION; TOPICAL

	E-SOLVE 2			
	+ SYOSSET	2%	N62467 001	JUL 03, 1985

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN			
AT	AKORN	**0.5%**	**N64030 001**	JUL 18, 1996
AT	BAUSCH AND LOMB	**0.5%**	**N64067 001**	JUL 29, 1994
AT	FOUGERA	**0.5%**	**N62447 001**	SEP 26, 1983
	ILOTYCIN			
AT	+ DISTA	**0.5%**	**N50368 001**	

ERYTHROMYCIN

OINTMENT; TOPICAL

	AKNE-MYCIN			
	+ HEALTHPOINT	2%	N50584 001	JAN 10, 1985

SOLUTION; TOPICAL

	A/T/S			
AT	AVENTIS PHARMS	**2%**	**N62405 001**	NOV 18, 1982
	C-SOLVE-2			
AT	BIOGLAN PHARMA	**2%**	**N62468 001**	JUL 03, 1985
	ERYDERM			
AT	ABBOTT	**2%**	**N62290 001**	
	ERYMAX			
AT	ALLERGAN HERBERT	**2%**	**N62508 002**	JUL 11, 1985
	ERYTHRA-DERM			
AT	PADDOCK	**2%**	**N62687 001**	FEB 05, 1988
	ERYTHRO-STATIN			
AT	HI TECH PHARMA	**2%**	**N64101 001**	OCT 22, 1996
	ERYTHROMYCIN			
AT	ALPHARMA	**2%**	**N62326 001**	APR 19, 1982
AT	ALTANA	**2%**	**N64187 001**	SEP 30, 1997
AT	BAUSCH AND LOMB	**2%**	**N64039 001**	JAN 27, 1994
AT	CLAY PARK	**2%**	**N63038 001**	JAN 11, 1991
AT	MORTON GROVE	**2%**	**N62825 001**	OCT 23, 1987
AT	STIEFEL	**2%**	**N64127 001**	FEB 14, 1997
	SANSAC			
AT	HEALTHPOINT	**2%**	**N62522 001**	JAN 24, 1985
	STATICIN			
AT	+ WESTWOOD SQUIBB	**1.5%**	**N50526 001**	
	T-STAT			
AT	+ WESTWOOD SQUIBB	**2%**	**N62436 001**	MAR 09, 1983

SWAB; TOPICAL

	C-SOLVE-2			
AT	IVAX PHARMS	**2%**	**N62751 001**	JUL 30, 1993

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

SWAB; TOPICAL

	ERYCETTE			
AT	+ J AND J	2%	N50594 001	
			FEB 15, 1985	
	ERYTHROMYCIN			
AT	STIEFEL	2%	N64126 001	
			JUL 03, 1996	
AT		2%	N64128 001	
			JUL 03, 1996	
	T-STAT			
AT	WESTWOOD SQUIBB	2%	N62748 001	
			JUL 23, 1987	

TABLET; ORAL

	ERYTHROMYCIN			
	ABBOTT	250MG	N61621 001	
	+	500MG	N61621 002	

TABLET, COATED PARTICLES; ORAL

	PCE			
	ABBOTT	333MG	N50611 001	
			SEP 09, 1986	
	+	500MG	N50611 002	
			AUG 22, 1990	

TABLET, DELAYED RELEASE; ORAL

	E-BASE			
AB	BARR	333MG	N63086 001	
			MAY 15, 1990	
AB		500MG	N62999 001	
			NOV 25, 1988	
	E-MYCIN			
AB	ABBOTT	250MG	N60272 001	
AB		333MG	N60272 002	
	ERY-TAB			
AB	+ ABBOTT	250MG	N62298 001	
AB	+	333MG	N62298 003	
			MAR 29, 1982	
AB	+	500MG	N62298 002	

ERYTHROMYCIN; *MULTIPLE*
SEE BENZOYL PEROXIDE; ERYTHROMYCIN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE			
+ BARR	EQ 250MG BASE	N62162 002	

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE			
AB ALPHARMA	EQ 125MG BASE/5ML	N62353 001	
		NOV 18, 1982	
AB	EQ 250MG BASE/5ML	N62409 001	
		DEC 16, 1982	
ILOSONE			
AB LILLY	EQ 125MG BASE/5ML	N50010 001	
AB +	EQ 250MG BASE/5ML	N50010 002	

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.			
AB ABBOTT	EQ 200MG BASE/5ML	N50207 001	
ERYPED			
AB ABBOTT	EQ 200MG BASE/5ML	N50207 003	
		MAR 30, 1987	
+	EQ 400MG BASE/5ML	N50207 002	
ERYTHROMYCIN ETHYLSUCCINATE			
AB BARR	EQ 200MG BASE/5ML	N62055 001	

SUSPENSION; ORAL

E.E.S. 200			
AB ABBOTT	EQ 200MG BASE/5ML	N61639 001	
E.E.S. 400			
AB + ABBOTT	EQ 400MG BASE/5ML	N61639 002	
ERYTHROMYCIN ETHYLSUCCINATE			
AB ALPHARMA	EQ 200MG BASE/5ML	N62200 001	
AB	EQ 400MG BASE/5ML	N62200 002	
PEDIAMYCIN			
AB ROSS LABS	EQ 200MG BASE/5ML	N62304 001	
PEDIAMYCIN 400			
AB ROSS LABS	EQ 400MG BASE/5ML	N62304 002	

TABLET; ORAL

E.E.S. 400			
AB + ABBOTT	EQ 400MG BASE	N61905 002	
		AUG 12, 1982	
ERYTHROMYCIN ETHYLSUCCINATE			
AB MYLAN	EQ 400MG BASE	N62847 001	
		SEP 14, 1988	

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE; ORAL

		E.E.S.		
AB	+	ABBOTT	EQ 200MG BASE	N50297 002
		ERYPED		
AB		ABBOTT	EQ 200MG BASE	N50297 003 JUL 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

		ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL		
AB		BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62759 001 MAY 20, 1988
		ERYZOLE		
AB		ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62758 001 JUN 15, 1988
		PEDIAZOLE		
AB	+	ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N50529 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

		ERYTHROCIN		
AP	+	ABBOTT	EQ 500MG BASE/VIAL	N50182 002
AP			EQ 500MG BASE/VIAL	N50609 001 SEP 24, 1986
AP			EQ 500MG BASE/VIAL	N62638 001 OCT 31, 1986
AP	+		EQ 1GM BASE/VIAL	N50182 003
AP			EQ 1GM BASE/VIAL	N50609 002 SEP 24, 1986
AP			EQ 1GM BASE/VIAL	N62638 002 OCT 31, 1986
		ERYTHROMYCIN		
AP		ELKINS SINN	EQ 500MG BASE/VIAL	N62563 001 MAR 28, 1985
AP			EQ 1GM BASE/VIAL	N62563 002 MAR 28, 1985
		ERYTHROMYCIN LACTOBIONATE		
AP		GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N63253 001 JUL 30, 1993

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

		ERYTHROMYCIN LACTOBIONATE		
AP		GENSIA SICOR PHARMS	EQ 1GM BASE/VIAL	N63253 002 JUL 30, 1993
AP		LEDERLE	EQ 500MG BASE/VIAL	N62993 001 MAY 09, 1989
AP			EQ 1GM BASE/VIAL	N62993 002 MAY 09, 1989

ERYTHROMYCIN STEARATE

TABLET; ORAL

		ERYTHROCIN STEARATE		
AB		ABBOTT	EQ 250MG BASE	N60359 001
AB	+		EQ 500MG BASE	N60359 003
		ERYTHROMYCIN STEARATE		
AB		BARR	EQ 250MG BASE	N61591 001
AB		MYLAN	EQ 250MG BASE	N61505 001
AB			EQ 500MG BASE	N61505 002
AB		WATSON LABS	EQ 250MG BASE	N62121 002
AB			EQ 500MG BASE	N62121 001

ESCITALOPRAM OXALATE

SOLUTION; ORAL

		LEXAPRO		
	+	FOREST LABS	EQ 5MG BASE/5ML	N21365 001 NOV 27, 2002

TABLET; ORAL

		LEXAPRO		
		FOREST LABS	5MG	N21323 001 AUG 14, 2002
			10MG	N21323 002 AUG 14, 2002
	+		20MG	N21323 003 AUG 14, 2002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

		BREVIBLOC		
	+	BAXTER HLTHCARE CORP	10MG/ML	N19386 001 AUG 15, 1988

FDA data supplied by DrugPatentWatch.com

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	BREVIBLOC				
+	BAXTER HLTHCARE CORP	250MG/ML	N19386 002 DEC 31, 1986		

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	NEXIUM				
+	ASTRAZENECA	EQ 20MG BASE	N21153 001 FEB 20, 2001		
+		EQ 40MG BASE	N21153 002 FEB 20, 2001		

ESTAZOLAM

TABLET; ORAL

	ESTAZOLAM				
AB	IVAX PHARMS	**1MG**	**N74826 001** JUL 03, 1997		
AB		**2MG**	**N74826 002** JUL 03, 1997		
AB	TEVA	**1MG**	**N74921 001** JUL 10, 1997		
AB		**2MG**	**N74921 002** JUL 10, 1997		
AB	WATSON LABS	**1MG**	**N74818 001** AUG 19, 1997		
AB		**2MG**	**N74818 002** AUG 19, 1997		
	PROSOM				
AB	ABBOTT	**1MG**	**N19080 001** DEC 26, 1990		
AB +		**2MG**	**N19080 002** DEC 26, 1990		

ESTRADIOL

CREAM; VAGINAL

	ESTRACE				
+	WARNER CHILCOTT	0.01%	N86069 001 JAN 31, 1984		

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	ALORA				
BX	WATSON LABS		0.025MG/24HR		N20655 004 APR 05, 2002
BX			0.05MG/24HR		N20655 001 DEC 20, 1996
BX			0.075MG/24HR		N20655 002 DEC 20, 1996
BX			0.1MG/24HR		N20655 003 DEC 20, 1996
	CLIMARA				
AB2 +	BERLEX LABS		**0.05MG/24HR**		**N20375 001** DEC 22, 1994
AB2 +			**0.1MG/24HR**		**N20375 002** DEC 22, 1994
BX +			0.025MG/24HR		N20375 004 MAR 05, 1999
BX +			0.075MG/24HR		N20375 003 MAR 23, 1998
	ESCLIM				
BX	WOMEN FIRST HLTHCARE		0.025MG/24HR		N20847 001 AUG 04, 1998
BX			0.0375MG/24HR		N20847 002 AUG 04, 1998
BX			0.05MG/24HR		N20847 003 AUG 04, 1998
BX			0.075MG/24HR		N20847 004 AUG 04, 1998
BX			0.1MG/24HR		N20847 005 AUG 04, 1998
	ESTRADERM				
BX +	NOVARTIS		0.05MG/24HR		N19081 002 SEP 10, 1986
BX +			0.1MG/24HR		N19081 003 SEP 10, 1986
	ESTRADIOL				
AB2	MYLAN TECHNOLOGIES		**0.05MG/24HR**		**N75233 001** FEB 24, 2000
AB2			**0.1MG/24HR**		**N75182 001** FEB 24, 2000
	VIVELLE				
AB1 +	NOVARTIS		**0.0375MG/24HR**		**N20323 001** OCT 28, 1994
AB1 +			**0.05MG/24HR**		**N20323 002** OCT 28, 1994
AB1 +			**0.075MG/24HR**		**N20323 003** OCT 28, 1994

FDA data supplied by DrugPatentWatch.com

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	VIVELLE				
AB1	+ NOVARTIS	**0.1MG/24HR**	**N20323 004**		
			OCT 28, 1994		
	+	0.025MG/24HR	N20323 005		
			AUG 16, 2000		
	VIVELLE-DOT				
AB1	NOVARTIS	**0.0375MG/24HR**	**N20538 005**		
			JAN 08, 1999		
AB1		**0.05MG/24HR**	**N20538 006**		
			JAN 08, 1999		
AB1		**0.075MG/24HR**	**N20538 007**		
			JAN 08, 1999		
AB1		**0.1MG/24HR**	**N20538 008**		
			JAN 08, 1999		

INSERT, EXTENDED RELEASE; VAGINAL

	ESTRING		
	+ PHARMACIA AND UPJOHN	0.0075MG/24HR	N20472 001
			APR 26, 1996

TABLET; ORAL

	ESTRACE		
AB	BRISTOL MYERS SQUIBB	**0.5MG**	**N81295 001**
			JUN 30, 1993
AB		**1MG**	**N84499 001**
AB	+	**2MG**	**N84500 001**
	ESTRADIOL		
AB	APPLIED ANAL	**0.5MG**	**N40138 001**
			JAN 30, 1998
AB		**1MG**	**N40138 002**
			JAN 30, 1998
AB		**2MG**	**N40138 003**
			JAN 30, 1998
AB	BARR	**0.5MG**	**N40197 001**
			OCT 22, 1997
AB		**1MG**	**N40197 002**
			OCT 22, 1997
AB		**2MG**	**N40197 003**
			OCT 22, 1997
AB	ESI LEDERLE	**0.5MG**	**N40275 001**
			DEC 29, 1998
AB		**1MG**	**N40275 002**
			DEC 29, 1998
AB		**2MG**	**N40275 003**
			DEC 29, 1998

ESTRADIOL

TABLET; ORAL

	ESTRADIOL		
AB	MYLAN	**0.5MG**	**N40326 001**
			APR 21, 1999
AB		**1MG**	**N40326 002**
			APR 21, 1999
AB		**2MG**	**N40326 003**
			APR 21, 1999
AB	USL PHARMA	**0.5MG**	**N40297 001**
			APR 17, 2002
AB		**1MG**	**N40297 002**
			APR 17, 2002
AB		**2MG**	**N40297 003**
			APR 17, 2002
AB	WATSON LABS	**0.5MG**	**N40114 003**
			MAR 14, 1996
AB		**1MG**	**N40114 001**
			MAR 14, 1996
AB		**2MG**	**N40114 002**
			MAR 14, 1996
	GYNODIOL		
AB	DURAMED PHARM BARR	**0.5MG**	**N40212 001**
			DEC 29, 1997
AB		**1MG**	**N40212 002**
			DEC 29, 1997
AB		**2MG**	**N40212 004**
			DEC 29, 1997
		1.5MG	N40212 003
			DEC 29, 1997
	INNOFEM		
AB	NOVO NORDISK	**0.5MG**	**N40312 001**
			NOV 19, 1999
AB		**1MG**	**N40312 002**
			NOV 19, 1999
AB		**2MG**	**N40312 003**
			NOV 19, 1999

TABLET; VAGINAL

	VAGIFEM		
	+ NOVO NORDISK	25 UGM	N20908 001
			MAR 26, 1999

FDA data supplied by DrugPatentWatch.com

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	
			AUG 07, 1998	
+		0.05MG/24HR;0.25MG/24HR	N20870 002	
			AUG 07, 1998	

TABLET; ORAL
ACTIVELLA

+	NOVO NORDISK	1MG;0.5MG	N20907 001	
			NOV 18, 1998	

ESTRADIOL; NORGESTIMATE

TABLET; ORAL
ORTHO-PREFEST

+	KING PHARMS	1MG,1MG;0.09MG,N/A	N21040 001	
			OCT 22, 1999	

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

AO	+ PHARMACIA AND UPJOHN	**5MG/ML**	**N85470 003**	

ESTRADIOL CYPIONATE

AO	STERIS	**5MG/ML**	**N85620 001**	

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR
LUNELLE

+	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N20874 001	
			OCT 05, 2000	

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
DEPO-TESTADIOL

+	PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N17968 001	

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN

AO	+ KING PHARMS	**20MG/ML**	**N09402 004**	
AO	+	**40MG/ML**	**N09402 003**	
	+	10MG/ML	N09402 002	

ESTRADIOL VALERATE

AO	STERIS	**20MG/ML**	**N83547 001**	
AO		**40MG/ML**	**N83714 001**	

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL
EMCYT

+	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N18045 001	

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN

+	AYERST	0.625MG/GM	N20216 001	

INJECTABLE; INJECTION
PREMARIN

+	WYETH AYERST	25MG/VIAL	N10402 001	

TABLET; ORAL
PREMARIN

	WYETH AYERST	0.3MG	N04782 003	
+		0.625MG	N04782 004	
		0.9MG	N04782 005	
			JAN 26, 1984	
+		1.25MG	N04782 001	
		2.5MG	N04782 002	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPHASE 14/14

+	WYETH AYERST	0.625MG,0.625MG;N/A,5MG	N20527 002	
			NOV 17, 1995	

PREMPRO

+	WYETH AYERST	0.625MG,0.625MG;2.5MG, 2.5MG	N20527 001	
			NOV 17, 1995	

FDA data supplied by DrugPatentWatch.com

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPRO
+ WYETH AYERST 0.625MG,0.625MG;5MG,5MG N20527 003 JAN 09, 1998

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL
CENESTIN
DURAMED 0.3MG N20992 001 JUN 21, 2002
0.625MG N20992 002 MAR 24, 1999
0.9MG N20992 003 MAR 24, 1999
+ 1.25MG N20992 004 MAR 13, 2000

ESTROGENS, ESTERIFIED

TABLET; ORAL
MENEST
+ MONARCH PHARMS 0.3MG N84951 001
0.625MG N84948 001
1.25MG N84950 001
+ 2.5MG N84949 001

ESTRONE

INJECTABLE; INJECTION
ESTRONE
+ STERIS 5MG/ML N85239 001

ESTROPIPATE

CREAM; VAGINAL
OGEN
+ PHARMACIA AND UPJOHN 1.5MG/GM N84710 001

TABLET; ORAL
ESTROPIPATE
AB BARR **0.75MG** **N40135 001** NOV 27, 1996

ESTROPIPATE

TABLET; ORAL
ESTROPIPATE
AB BARR **1.5MG** **N40135 002** NOV 27, 1996
AB **3MG** **N40135 003** NOV 27, 1996
AB DURAMED PHARM BARR **0.75MG** **N40296 001** NOV 01, 1999
AB **1.5MG** **N40296 002** NOV 01, 1999
AB **3MG** **N40296 003** NOV 01, 1999
AB MYLAN **0.75MG** **N40359 001** AUG 26, 1999
AB **1.5MG** **N40359 002** AUG 26, 1999
AB **3MG** **N40359 003** AUG 26, 1999
AB WATSON LABS **0.75MG** **N81213 001** SEP 23, 1993
AB **1.5MG** **N81214 001** SEP 23, 1993
AB **3MG** **N81215 001** SEP 23, 1993
AB **6MG** **N81216 001** SEP 23, 1993
OGEN .625
AB PHARMACIA AND UPJOHN **0.75MG** **N83220 001**
OGEN 1.25
AB PHARMACIA AND UPJOHN **1.5MG** **N83220 002**
OGEN 2.5
AB + PHARMACIA AND UPJOHN **3MG** **N83220 003**
OGEN 5
AB PHARMACIA AND UPJOHN **6MG** **N83220 004**
ORTHO-EST
AB WOMEN FIRST HLTHCARE **0.75MG** **N89567 001** FEB 27, 1991
AB **1.5MG** **N89582 001** JUL 17, 1991

ETHACRYNATE SODIUM

INJECTABLE; INJECTION
EDECRIN
+ MERCK EQ 50MG BASE/VIAL N16093 001

FDA data supplied by DrugPatentWatch.com

ETHACRYNIC ACID

TABLET; ORAL
EDECRIN
MERCK 25MG N16092 001
\+ 50MG N16092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL
ETHAMBUTOL HCL
AB BARR **400MG** **N76057 001** NOV 26, 2001
AB WEST WARD **100MG** **N75095 001** NOV 30, 1999
AB **400MG** **N75095 002** NOV 30, 1999
MYAMBUTOL
AB LEDERLE **100MG** **N16320 001**
AB \+ **400MG** **N16320 003**

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION
ETHAMOLIN
\+ QUESTCOR PHARMS 50MG/ML N19357 001 DEC 22, 1988

ETHINYL ESTRADIOL

TABLET; ORAL
ESTINYL
SCHERING 0.02MG N05292 001
0.05MG N05292 002
\+ 0.5MG N05292 003

ETHINYL ESTRADIOL; *MULTIPLE*
SEE DESOGESTREL; ETHINYL ESTRADIOL
SEE DROSPIRENONE; ETHINYL ESTRADIOL

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21
DEMULEN 1/35-21
AB \+ GD SEARLE LLC **0.035MG;1MG** **N18168 001**

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21
DEMULEN 1/50-21
AB \+ GD SEARLE LLC **0.05MG;1MG** **N16927 001**
ZOVIA 1/35E-21
AB WATSON LABS **0.035MG;1MG** **N72720 001** DEC 30, 1991
ZOVIA 1/50E-21
AB WATSON LABS **0.05MG;1MG** **N72722 001** DEC 30, 1991

TABLET; ORAL-28
DEMULEN 1/35-28
AB GD SEARLE LLC **0.035MG;1MG** **N18160 001**
DEMULEN 1/50-28
AB GD SEARLE LLC **0.05MG;1MG** **N16936 001**
ZOVIA 1/35E-28
AB WATSON LABS **0.035MG;1MG** **N72721 001** DEC 30, 1991
ZOVIA 1/50E-28
AB WATSON LABS **0.05MG;1MG** **N72723 001** DEC 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL
NUVARING
\+ ORGANON INC 0.015MG;0.12MG N21187 001 OCT 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
PREVEN EMERGENCY CONTRACEPTIVE KIT
\+ GYNETICS 0.05MG;0.25MG N20946 001 SEP 01, 1998

TABLET; ORAL-21
ALESSE
AB1 \+ WYETH AYERST **0.02MG;0.1MG** **N20683 001** MAR 27, 1997
AVIANE-21
AB1 DURAMED PHARM BARR **0.02MG;0.1MG** **N75796 002** APR 30, 2001

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	ENPRESSE-21			
AB	DURAMED PHARM BARR	0.03MG,0.05MG,0.075MG;0.04MG,0.03MG, 0.125MG	N75809 001	JUL 16, 2001
	LESSINA-21			
AB2	BARR	0.02MG;0.1MG	N75803 001	MAR 20, 2002
	LEVLITE			
AB2	+ BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998
	LEVORA 0.15/30-21			
AB	WATSON LABS	0.03MG;0.15MG	N73592 001	DEC 13, 1993
	NORDETTE-21			
AB	+ WYETH AYERST	0.03MG;0.15MG	N18668 001	MAY 10, 1982
	PORTIA-21			
AB	BARR	0.03MG;0.15MG	N75866 001	MAY 23, 2002
	TRIPHASIL-21			
AB	+ WYETH AYERST	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N19192 001	NOV 01, 1984
	TRIVORA-21			
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 001	DEC 18, 1997

TABLET; ORAL-28

	ALESSE			
AB1	WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997
	AVIANE-28			
AB1	DURAMED PHARM BARR	0.02MG;0.1MG	N75796 001	APR 30, 2001
	ENPRESSE-28			
AB	DURAMED PHARM BARR	0.03MG,0.03MG,0.075MG;0.04MG,0.05MG, 0.125MG	N75809 002	JUL 16, 2001
	LESSINA-28			
AB	BARR	0.02MG;0.1MG	N75803 002	MAR 20, 2002
	LEVLITE			
AB	BERLEX LABS	0.02MG;0.1MG	N20860 002	JUL 13, 1998

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

	LEVORA 0.15/30-28			
AB	WATSON LABS	0.03MG;0.15MG	N73594 001	DEC 13, 1993
	NORDETTE-28			
AB	WYETH AYERST	0.03MG;0.15MG	N18782 001	JUL 21, 1982
	PORTIA-28			
AB	BARR	0.03MG;0.15MG	N75866 002	MAY 23, 2002
	TRIPHASIL-28			
AB	WYETH AYERST	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N19190 001	NOV 01, 1984
	TRIVORA-28			
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 002	DEC 18, 1997

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	ORTHO EVRA			
	+ ORTHO MCNEIL PHARM	0.02MG/24HR;0.015MG/24HR	N21180 001	NOV 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	WATSON LABS	0.035MG;0.5MG	N17566 001	
	GENCEPT 10/11-21			
AB	BARR	0.035MG,0.035MG;0.5MG,1MG	N72694 001	FEB 28, 1992
	MODICON 21			
AB	+ ORTHO MCNEIL PHARM	0.035MG;0.5MG	N17488 001	
	NORCEPT-E 1/35 21			
AB	GYNOPHARMA	0.035MG;1MG	N71545 001	FEB 09, 1989
	NORETHIN 1/35E-21			
AB	WATSON LABS	0.035MG;1MG	N71480 001	APR 12, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	WATSON LABS	0.035MG;0.5MG	N70684 001	JAN 29, 1987

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL

AB WATSON LABS 0.035MG;1MG **N70685 001** JAN 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

AB WATSON LABS 0.035MG,0.035MG;0.5MG,1MG **N71043 001** APR 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

AB + WATSON LABS 0.035MG,0.035MG;0.5MG,1MG **N71041 001** SEP 24, 1991

NORINYL 1+35 21-DAY

AB WATSON LABS 0.035MG;1MG **N17565 001**

NORTREL 0.5/35-21

AB BARR 0.035MG;0.5MG **N72692 001** FEB 28, 1992

NORTREL 1/35-21

AB BARR 0.035MG;1MG **N72693 001** FEB 28, 1992

NORTREL 7/7/7

AB BARR 0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG **N75478 001** AUG 30, 2002

ORTHO-NOVUM 1/35-21

AB + ORTHO MCNEIL PHARM 0.035MG;1MG **N17489 002**

ORTHO-NOVUM 10/11-21

AB + ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG **N18354 001** JAN 11, 1982

ORTHO-NOVUM 7/7/7-21

AB + ORTHO MCNEIL PHARM 0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG **N18985 001** APR 04, 1984

OVCON-35

+ WARNER CHILCOTT 0.035MG;0.4MG N18127 001

TRI-NORINYL 21-DAY

+ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG N18977 001 APR 13, 1984

TABLET; ORAL-28

BREVICON 28-DAY

AB WATSON LABS 0.035MG;0.5MG **N17743 001**

GENCEPT 10/11-28

AB BARR 0.035MG,0.035MG;0.5MG,1MG **N72697 001** FEB 28, 1992

MODICON 28

AB ORTHO MCNEIL PHARM 0.035MG;0.5MG **N17735 001**

NORCEPT-E 1/35 28

AB GYNOPHARMA 0.035MG;1MG **N71546 001** FEB 09, 1989

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHIN 1/35E-28

AB WATSON LABS 0.035MG;1MG **N71481 001** APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB WATSON LABS 0.035MG;0.5MG **N70686 001** JAN 29, 1987

AB 0.035MG;1MG **N70687 001** JAN 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

AB WATSON LABS 0.035MG,0.035MG;0.5MG,1MG **N71044 001** APR 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

AB WATSON LABS 0.035MG,0.035MG;0.5MG,1MG **N71042 001** SEP 24, 1991

NORINYL 1+35 28-DAY

AB WATSON LABS 0.035MG;1MG **N17565 002**

NORTREL 0.5/35-28

AB BARR 0.035MG;0.5MG **N72695 001** FEB 28, 1992

NORTREL 1/35-28

AB BARR 0.035MG;1MG **N72696 001** FEB 28, 1992

NORTREL 7/7/7

AB BARR 0.035MG,0.035MG,0.035MG;0.05MG, 0.75MG,1MG **N75478 002** AUG 30, 2002

ORTHO-NOVUM 1/35-28

AB ORTHO MCNEIL PHARM 0.035MG;1MG **N17919 002**

ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER

AB ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG **N18354 002** JAN 11, 1982

ORTHO-NOVUM 7/14-28

AB + ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG **N19004 002** APR 04, 1984

ORTHO-NOVUM 7/7/7-28

AB ORTHO MCNEIL PHARM 0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG **N18985 002** APR 04, 1984

OVCON-35

WARNER CHILCOTT 0.035MG;0.4MG N17716 001

OVCON-50

WARNER CHILCOTT 0.05MG;1MG N17576 001

TRI-NORINYL 28-DAY

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG N18977 002 APR 13, 1984

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
FEMHRT
+ PFIZER PHARMS 0.005MG;1MG N21065 002 OCT 15, 1999

TABLET; ORAL-21
LOESTRIN 21 1.5/30
+ PARKE DAVIS 0.03MG;1.5MG N17875 001
LOESTRIN 21 1/20
+ PARKE DAVIS 0.02MG;1MG N17876 001

TABLET; ORAL-28
ESTROSTEP FE
+ PARKE DAVIS 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N20130 002 OCT 09, 1996

LOESTRIN FE 1.5/30
AB + PARKE DAVIS **0.03MG;1.5MG** **N17355 001**
LOESTRIN FE 1/20
AB + PARKE DAVIS **0.02MG;1MG** **N17354 001**
MICROGESTIN FE 1.5/30
AB WATSON LABS **0.03MG;1.5MG** **N75548 001** FEB 05, 2001
MICROGESTIN FE 1/20
AB WATSON LABS **0.02MG;1MG** **N75647 001** FEB 05, 2001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
ORTHO CYCLEN-28
AB + ORTHO MCNEIL PHARM **0.035MG;0.25MG** **N19653 002** DEC 29, 1989
ORTHO TRI-CYCLEN
AB + ORTHO MCNEIL PHARM **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG** **N19697 001** JUL 03, 1992
ORTHO TRI-CYCLEN LO
+ JOHNSON AND JOHNSON 0.025MG,0.025MG,0.25MG;0.18MG,0.215MG,0.25MG N21241 001 AUG 22, 2002
SPRINTEC
AB BARR **0.035MG;0.25MG** **N75804 001** SEP 25, 2002

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
TRI-SPRINTEC
AB BARR **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG** **N75808 001** DEC 18, 2002

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21
CRYSELLE
AB DURAMED PHARM BARR **0.03MG;0.3MG** **N75840 001** NOV 30, 2001
LO/OVRAL
AB + WYETH AYERST **0.03MG;0.3MG** **N17612 001**
LOW-OGESTREL-21
AB WATSON LABS **0.03MG;0.3MG** **N75288 001** JUL 28, 1999
OGESTREL 0.5/50-21
AB SCS **0.05MG;0.5MG** **N75406 001** DEC 15, 1999
OVRAL
AB + WYETH AYERST **0.05MG;0.5MG** **N16672 001**

TABLET; ORAL-28
CRYSELLE
AB DURAMED PHARM BARR **0.03MG;0.3MG** **N75840 002** NOV 30, 2001
LO/OVRAL-28
AB WYETH AYERST **0.03MG;0.3MG** **N17802 001**
LOW-OGESTREL-28
AB WATSON LABS **0.03MG;0.3MG** **N75288 002** JUL 28, 1999
OGESTREL 0.5/50-28
AB SCS **0.05MG;0.5MG** **N75406 002** DEC 15, 1999
OVRAL-28
AB WYETH AYERST **0.05MG;0.5MG** **N16806 001**

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE
ETHIODOL
SAVAGE LABS 99% N09190 001

FDA data supplied by DrugPatentWatch.com

ETHIONAMIDE

TABLET; ORAL

	TRECATOR-SC		
+	WYETH AYERST	250MG	N13026 002

ETHOSUXIMIDE

CAPSULE; ORAL

	ETHOSUXIMIDE		
AB	BANNER PHARMACAPS	**250MG**	**N40430 001** OCT 28, 2002
	ZARONTIN		
AB +	PARKE DAVIS	**250MG**	**N12380 001**

SYRUP; ORAL

	ETHOSUXIMIDE		
AA	COPLEY PHARM	**250MG/5ML**	**N81306 001** JUL 30, 1993
AA	PHARM ASSOC	**250MG/5ML**	**N40253 001** NOV 22, 2000
	ZARONTIN		
AA +	PARKE DAVIS	**250MG/5ML**	**N80258 001**

ETHOTOIN

TABLET; ORAL

	PEGANONE		
+	ABBOTT	250MG	N10841 001

ETHYNODIOL DIACETATE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

ETIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

	DIDRONEL		
+	MGI PHARMA INC	50MG/ML	N19545 001 APR 20, 1987

TABLET; ORAL

	DIDRONEL		
	PROCTER AND GAMBLE	200MG	N17831 001

ETIDRONATE DISODIUM

TABLET; ORAL

	DIDRONEL		
+	PROCTER AND GAMBLE	400MG	N17831 002

ETODOLAC

CAPSULE; ORAL

	ETODOLAC		
AB	ENDO PHARMS	**200MG**	**N74842 001** JUL 17, 1997
AB		**300MG**	**N74842 002** JUL 17, 1997
AB	GENEVA PHARMS	**200MG**	**N74840 001** AUG 29, 1997
AB		**300MG**	**N74840 002** AUG 29, 1997
AB	GENEVA PHARMS TECH	**200MG**	**N74942 001** SEP 30, 1997
AB		**300MG**	**N74942 002** SEP 30, 1997
AB	GENPHARM	**200MG**	**N75071 001** SEP 30, 1998
AB		**300MG**	**N75071 002** SEP 30, 1998
AB	IVAX PHARMS	**200MG**	**N74899 001** JUL 08, 1997
AB		**300MG**	**N74899 002** JUL 08, 1997
AB	MYLAN	**200MG**	**N74932 001** MAY 16, 1997
AB		**300MG**	**N74932 002** MAY 16, 1997
AB	NEOSAN PHARMS	**300MG**	**N74929 001** JAN 30, 1998
AB	TARO	**200MG**	**N75078 001** APR 30, 1998
AB		**300MG**	**N75078 002** APR 30, 1998
AB	TEVA	**200MG**	**N75126 001** SEP 16, 1999
AB		**300MG**	**N75126 002** SEP 16, 1999
AB	TORPHARM	**200MG**	**N75419 001** JUL 28, 2000
AB		**300MG**	**N75419 002** JUL 28, 2000

FDA data supplied by DrugPatentWatch.com

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
AB	WATSON LABS	200MG	**N74844 001**	DEC 23, 1997
AB		300MG	**N74844 002**	DEC 23, 1997
	LODINE			
AB	WYETH AYERST	200MG	**N18922 002**	JAN 31, 1991
AB	+	300MG	**N18922 003**	JAN 31, 1991

TABLET; ORAL

	ETODOLAC			
AB	APOTEX	400MG	**N76004 001**	DEC 03, 2002
AB		500MG	**N76004 002**	DEC 03, 2002
AB	ENDO PHARMS	400MG	**N74841 001**	JUN 27, 1997
AB	EON	400MG	**N74903 001**	APR 11, 1997
AB		500MG	**N74903 002**	APR 19, 1999
AB	GENEVA PHARMS	400MG	**N74839 001**	JUL 11, 1997
AB	GENEVA PHARMS TECH	400MG	**N74846 001**	FEB 28, 1997
AB	GENPHARM	400MG	**N75012 001**	SEP 30, 1998
AB		500MG	**N75012 002**	SEP 30, 1998
AB	IVAX PHARMS	400MG	**N74883 001**	FEB 28, 1997
AB		500MG	**N74883 002**	NOV 20, 1998
AB	MYLAN	400MG	**N75104 001**	FEB 06, 1998
AB		500MG	**N75104 002**	NOV 20, 1998
AB	NEOSAN PHARMS	400MG	**N74927 001**	OCT 30, 1997
AB	PUREPAC PHARM	400MG	**N74819 001**	FEB 28, 1997
AB	RANBAXY	400MG	**N75226 001**	NOV 24, 1998

ETODOLAC

TABLET; ORAL

	ETODOLAC			
AB	RANBAXY	500MG	**N75226 002**	NOV 24, 1998
AB	TARO PHARM INDS	400MG	**N75074 001**	MAR 11, 1998
AB		500MG	**N75074 002**	APR 25, 2000
AB	TEVA	400MG	**N74847 001**	APR 23, 1999
AB		400MG	**N75009 001**	NOV 26, 1997
AB		500MG	**N74847 002**	APR 23, 1999
AB		500MG	**N75009 002**	DEC 28, 1999
AB	WATSON LABS	400MG	**N74892 001**	APR 16, 1997
AB		400MG	**N75069 001**	APR 16, 1998
AB		500MG	**N74892 002**	OCT 29, 1998
	LODINE			
AB	WYETH AYERST	400MG	**N18922 004**	JUL 29, 1993
AB	+	500MG	**N18922 005**	JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	ANDRX PHARM	400MG	**N75829 001**	NOV 30, 2001
AB		500MG	**N75829 002**	NOV 30, 2001
AB	EON	400MG	**N75943 001**	JUL 26, 2002
AB		500MG	**N75943 002**	JUL 26, 2002
AB		600MG	**N75943 003**	JUL 26, 2002
AB	POINT HOLDINGS	400MG	**N75696 001**	JUL 31, 2000
AB	TEVA	400MG	**N75665 003**	FEB 05, 2001
AB		500MG	**N75665 002**	JUL 31, 2000

FDA data supplied by DrugPatentWatch.com

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	TEVA	600MG	**N75665 001**	JUL 31, 2000
	LODINE XL			
AB	+ WYETH AYERST	400MG	**N20584 001**	OCT 25, 1996
AB	+	500MG	**N20584 003**	JAN 20, 1998
AB	+	600MG	**N20584 002**	OCT 25, 1996

ETOMIDATE

INJECTABLE; INJECTION

	AMIDATE			
AP	+ ABBOTT	2MG/ML	**N18227 001**	SEP 07, 1982
	ETOMIDATE			
AP	BEDFORD	2MG/ML	**N74593 001**	NOV 04, 1996

ETONOGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; ETONOGESTREL

ETOPOSIDE

CAPSULE; ORAL

	ETOPOSIDE			
AB	GENPHARM	50MG	**N75635 001**	SEP 19, 2001
	VEPESID			
AB	+ BRISTOL	50MG	**N19557 001**	DEC 30, 1986

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	ABBOTT	20MG/ML	**N74320 001**	AUG 30, 1995
AP		20MG/ML	**N74351 001**	AUG 30, 1995
AP	AM PHARM PARTNERS	20MG/ML	**N74983 001**	SEP 30, 1998

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	BEDFORD	20MG/ML	**N74290 001**	JUL 17, 1995
AP	GENSIA SICOR PHARMS	20MG/ML	**N74284 001**	FEB 10, 1994
AP		20MG/ML	**N74529 001**	JUL 24, 1996
AP	MARSAM PHARMS LLC	20MG/ML	**N74968 001**	JAN 09, 1998
AP	PHARMACHEMIE	20MG/ML	**N74227 001**	FEB 22, 1996
AP	SUPERGEN	20MG/ML	**N74513 001**	MAR 14, 1996
	TOPOSAR			
AP	PHARMACIA AND UPJOHN	20MG/ML	**N74166 001**	FEB 27, 1995
	VEPESID			
AP	+ BRISTOL MYERS SQUIBB	20MG/ML	**N18768 001**	NOV 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

	ETOPOPHOS PRESERVATIVE FREE		
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996

EXEMESTANE

TABLET; ORAL

	AROMASIN		
+	PHARMACIA AND UPJOHN	25MG	N20753 001 OCT 21, 1999

EZETIMIBE

TABLET; ORAL

	ZETIA		
+	MSP SINGAPORE	10MG	N21445 001 OCT 25, 2002

FDA data supplied by DrugPatentWatch.com

FAMCICLOVIR

TABLET; ORAL

FAMVIR				
NOVARTIS	125MG		N20363 003	DEC 11, 1995
	250MG		N20363 001	APR 26, 1996
+	500MG		N20363 002	JUN 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

PEPCID				
+ MERCK	40MG/5ML		N19527 001	FEB 02, 1987

INJECTABLE; INJECTION

FAMOTIDINE				
AP	ABBOTT	**10MG/ML**	**N75870 001**	NOV 23, 2001
AP		**10MG/ML**	**N75905 001**	NOV 23, 2001
AP	AM PHARM PARTNERS	**10MG/ML**	**N75709 001**	APR 16, 2001
AP	APOTEX	**10MG/ML**	**N75942 001**	AUG 02, 2002
AP	BAXTER HLTHCARE	**10MG/ML**	**N75799 001**	APR 30, 2002
AP	BEDFORD	**10MG/ML**	**N75651 001**	APR 16, 2001
AP		**10MG/ML**	**N75684 001**	APR 16, 2001
AP	ESI LEDERLE	**10MG/ML**	**N75488 001**	APR 16, 2001
AP	FAULDING	**10MG/ML**	**N75705 001**	APR 16, 2001
FAMOTIDINE PRESERVATIVE FREE				
AP	AM PHARM PARTNERS	**10MG/ML**	**N75813 001**	APR 16, 2001
AP	APOTEX	**10MG/ML**	**N76324 001**	NOV 27, 2002
AP	BAXTER HLTHCARE	**10MG/ML**	**N75789 001**	APR 30, 2002
AP	BEDFORD	**10MG/ML**	**N75622 001**	APR 16, 2001

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE				
AP	BEN VENUE	**10MG/ML**	**N75825 001**	APR 17, 2001
AP	ESI LEDERLE	**10MG/ML**	**N75486 001**	APR 16, 2001
AP	FAULDING	**10MG/ML**	**N75669 001**	APR 16, 2001
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)				
AP	APOTEX	**10MG/ML**	**N76322 001**	NOV 27, 2002
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER				
AP	ABBOTT	**0.4MG/ML**	**N75729 001**	DEC 17, 2001
AP	BAXTER HLTHCARE	**0.4MG/ML**	**N75591 001**	MAY 10, 2001
PEPCID				
AP +	MERCK	**10MG/ML**	**N19510 001**	NOV 04, 1986
PEPCID PRESERVATIVE FREE				
AP +	MERCK	**10MG/ML**	**N19510 004**	NOV 04, 1986
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER				
AP +	MERCK	**0.4MG/ML**	**N20249 001**	FEB 18, 1994

TABLET; ORAL

FAMOTIDINE				
AB	CARLSBAD	**20MG**	**N75805 001**	APR 16, 2001
AB		**40MG**	**N75805 002**	APR 16, 2001
AB	DR REDDYS LABS LTD	**20MG**	**N75718 001**	APR 16, 2001
AB		**40MG**	**N75718 002**	APR 16, 2001
AB	EON	**20MG**	**N75793 001**	APR 16, 2001
AB		**40MG**	**N75793 002**	APR 16, 2001
AB	GENEVA PHARMS	**20MG**	**N75302 001**	APR 16, 2001
AB		**40MG**	**N75302 002**	APR 16, 2001
AB	GENPHARM	**20MG**	**N75457 001**	APR 18, 2001

FDA data supplied by DrugPatentWatch.com

FAMOTIDINE

TABLET; ORAL

	FAMOTIDINE			
AB	GENPHARM	40MG	N75457 002	APR 18, 2001
AB	INVAMED	20MG	N75607 001	MAY 10, 2001
AB		40MG	N75607 002	MAY 10, 2001
AB	IVAX PHARMS	20MG	N75511 001	APR 16, 2001
AB		40MG	N75511 002	APR 16, 2001
AB	MUTUAL PHARM	20MG	N75639 002	DEC 12, 2001
AB		40MG	N75639 001	DEC 12, 2001
AB	MYLAN	20MG	N75704 001	APR 16, 2001
AB		40MG	N75704 002	APR 16, 2001
AB	PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001
AB		40MG	N75650 002	SEP 14, 2001
AB	TEVA	20MG	N75311 001	APR 16, 2001
AB		40MG	N75311 002	APR 16, 2001
AB	TORPHARM	20MG	N75611 001	JUL 23, 2001
AB		40MG	N75611 002	JUL 23, 2001
AB	WATSON LABS	20MG	N75062 002	APR 16, 2001
AB		40MG	N75062 001	APR 16, 2001
AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001
AB		40MG	N75786 002	APR 16, 2001
	PEPCID			
AB	MERCK	20MG	N19462 001	OCT 15, 1986
AB +		40MG	N19462 002	OCT 15, 1986

FELBAMATE

SUSPENSION; ORAL

	FELBATOL		
+	WALLACE LABS	600MG/5ML	N20189 003 JUL 29, 1993

TABLET; ORAL

	FELBATOL		
	WALLACE LABS	400MG	N20189 001 JUL 29, 1993
+		600MG	N20189 002 JUL 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

	PLENDIL		
	ASTRAZENECA	2.5MG	N19834 004 SEP 22, 1994
		5MG	N19834 001 JUL 25, 1991
+		10MG	N19834 002 JUL 25, 1991

FELODIPINE; *MULTIPLE*

SEE ENALAPRIL MALEATE; FELODIPINE

FENOFIBRATE

CAPSULE; ORAL

	FENOFIBRATE (MICRONIZED)			
AB	TEVA	67MG	N75753 001	SEP 03, 2002
AB		134MG	N75753 002	APR 09, 2002
AB		200MG	N75753 003	APR 09, 2002
	TRICOR (MICRONIZED)			
AB	ABBOTT	67MG	N19304 002	FEB 09, 1998
AB		134MG	N19304 003	JUN 30, 1999
AB +		200MG	N19304 004	JUN 30, 1999

FDA data supplied by DrugPatentWatch.com

FENOFIBRATE

TABLET; ORAL
TRICOR

	ABBOTT	54MG		N21203 001 SEP 04, 2001
+		160MG		N21203 003 SEP 04, 2001

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM

+	ABBOTT	EQ 10MG BASE/ML		N19922 001 SEP 23, 1997

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

AB	GENEVA PHARMS	**EQ 200MG BASE**		**N72394 001** OCT 17, 1988
AB		**EQ 300MG BASE**		**N72395 001** OCT 17, 1988
AB	PAR PHARM	**EQ 200MG BASE**		**N72437 001** AUG 22, 1988
AB		**EQ 300MG BASE**		**N72438 001** AUG 22, 1988

NALFON

AB	+ RANBAXY	**EQ 300MG BASE**		**N17604 002**

NALFON 200

AB	RANBAXY	**EQ 200MG BASE**		**N17604 003**

TABLET; ORAL
FENOPROFEN CALCIUM

AB	GENEVA PHARMS	**EQ 600MG BASE**		**N72396 001** OCT 17, 1988
AB	IVAX PHARMS	**EQ 600MG BASE**		**N72557 001** AUG 29, 1988
AB	LEDERLE	**EQ 600MG BASE**		**N72326 001** AUG 17, 1988
AB	MUTUAL PHARM	**EQ 600MG BASE**		**N72902 001** DEC 21, 1990
AB	+ MYLAN	**EQ 600MG BASE**		**N72267 001** AUG 17, 1988
AB	PAR PHARM	**EQ 600MG BASE**		**N72429 001** AUG 17, 1988

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM

AB	PUREPAC PHARM	**EQ 600MG BASE**		**N72274 001** MAY 02, 1988
AB	WATSON LABS	**EQ 600MG BASE**		**N72407 001** AUG 17, 1988
AB		**EQ 600MG BASE**		**N72602 001** OCT 11, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC

+	ALZA	0.6MG/24HR		N19813 004 AUG 07, 1990
		1.2MG/24HR		N19813 003 AUG 07, 1990
		1.8MG/24HR		N19813 002 AUG 07, 1990
		2.4MG/24HR		N19813 001 AUG 07, 1990

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

AP	ABBOTT	**EQ 0.05MG BASE/ML**		**N19115 001** JAN 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE

AP	ABBOTT	**EQ 0.05MG BASE/ML**		**N72786 001** SEP 24, 1991
AP	+ ELKINS SINN	**EQ 0.05MG BASE/ML**		**N19101 001** JUL 11, 1984

SUBLIMAZE PRESERVATIVE FREE

AP	+ AKORN MFG	**EQ 0.05MG BASE/ML**		**N16619 001**

TROCHE/LOZENGE; ORAL
ACTIQ

	ANESTA	EQ 0.2MG BASE		N20747 001 NOV 04, 1998
		EQ 0.4MG BASE		N20747 002 NOV 04, 1998
		EQ 0.6MG BASE		N20747 003 NOV 04, 1998

FDA data supplied by DrugPatentWatch.com

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

ACTIQ			
ANESTA	EQ 0.8MG BASE	N20747 004	NOV 04, 1998
	EQ 1.2MG BASE	N20747 005	NOV 04, 1998
+	EQ 1.6MG BASE	N20747 006	NOV 04, 1998

FENTANYL CITRATE; *MULTIPLE*
SEE DROPERIDOL; FENTANYL CITRATE

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.			
+ ADV MAGNETICS	EQ 11.2MG IRON/ML	N20416 001	AUG 30, 1996

FERUMOXSIL

SUSPENSION; ORAL

GASTROMARK			
+ ADV MAGNETICS	EQ 0.175MG IRON/ML	N20410 001	DEC 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA			
+ AVENTIS PHARMS	60MG	N20625 001	JUL 25, 1996

TABLET; ORAL

ALLEGRA			
AVENTIS PHARMS	30MG	N20872 001	FEB 25, 2000
	60MG	N20872 002	FEB 25, 2000
+	180MG	N20872 004	FEB 25, 2000

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D			
+ AVENTIS PHARMS	60MG;120MG	N20786 001	DEC 24, 1997

FIBRINOLYSIN; *MULTIPLE*
SEE CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

FINASTERIDE

TABLET; ORAL

PROPECIA			
+ MERCK	1MG	N20788 001	DEC 19, 1997
PROSCAR			
+ MERCK	5MG	N20180 001	JUN 19, 1992

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

URISPAS			
+ GLAXOSMITHKLINE	100MG	N16769 001	

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE				
AB	ALPHAPHARM	**50MG**	**N75442 001**	JUL 31, 2001
AB		**100MG**	**N75442 002**	JUL 31, 2001
AB		**150MG**	**N75442 003**	JUL 31, 2001
AB	BARR	**50MG**	**N75882 001**	OCT 28, 2002
AB		**100MG**	**N75882 002**	OCT 28, 2002
AB		**150MG**	**N75882 003**	OCT 28, 2002
AB	GENEVA PHARMS TECH	**50MG**	**N76030 001**	OCT 28, 2002

FDA data supplied by DrugPatentWatch.com

FLECAINIDE ACETATE

TABLET; ORAL

	FLECAINIDE ACETATE			
AB	GENEVA PHARMS TECH	**100MG**	**N76030 002**	OCT 28, 2002
AB		**150MG**	**N76030 003**	OCT 28, 2002
	TAMBOCOR			
AB	3M	**50MG**	**N18830 004**	AUG 23, 1988
AB		**100MG**	**N18830 001**	OCT 31, 1985
AB +		**150MG**	**N18830 003**	JUN 03, 1988

FLOXURIDINE

INJECTABLE; INJECTION

	FLOXURIDINE			
AP	AM PHARM PARTNERS	**500MG/VIAL**	**N75837 001**	FEB 22, 2001
AP	BEDFORD	**500MG/VIAL**	**N75387 001**	APR 16, 2000
	FUDR			
AP +	FAULDING	**500MG/VIAL**	**N16929 001**	

FLUCONAZOLE

FOR SUSPENSION; ORAL

	DIFLUCAN			
	PFIZER	50MG/5ML	N20090 001	DEC 23, 1993
+		200MG/5ML	N20090 002	DEC 23, 1993

INJECTABLE; INJECTION

	DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+	PFIZER	200MG/100ML	N19950 003	SEP 29, 1992
	DIFLUCAN IN SODIUM CHLORIDE 0.9%			
+	PFIZER	200MG/100ML	N19950 001	JAN 29, 1990
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+	PFIZER	200MG/100ML	N19950 002	JAN 29, 1990

FLUCONAZOLE

TABLET; ORAL

	DIFLUCAN			
	PFIZER	50MG	N19949 001	JAN 29, 1990
		100MG	N19949 002	JAN 29, 1990
		150MG	N19949 004	JUN 30, 1994
+		200MG	N19949 003	JAN 29, 1990

FLUCYTOSINE

CAPSULE; ORAL

	ANCOBON		
	ICN	250MG	N17001 001
+		500MG	N17001 002

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

	FLUDARA			
+	BERLEX	50MG/VIAL	N20038 001	APR 18, 1991

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

	FLUDEOXYGLUCOSE F 18			
+	DOWNSTATE CLINCL	4-90mCi/ML	N20306 002	SEP 25, 2001

FLUDROCORTISONE ACETATE

TABLET; ORAL

	FLORINEF			
AB +	KING PHARMS	**0.1MG**	**N10060 001**	
	FLUDROCORTISONE ACETATE			
AB	IMPAX LABS	**0.1MG**	**N40431 001**	MAR 18, 2002

FDA data supplied by DrugPatentWatch.com

FLUMAZENIL

INJECTABLE; INJECTION
ROMAZICON
+ HLR 0.1MG/ML N20073 001 DEC 20, 1991

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROBID
+ SYNTEX (USA) INC LLC 0.25MG/INH N18340 001 AUG 17, 1984

SPRAY, METERED; NASAL
FLUNISOLIDE
AB BAUSCH AND LOMB **0.025MG/SPRAY** **N74805 001** FEB 20, 2002

NASALIDE
AB + IVAX RES **0.025MG/SPRAY** **N18148 001**
NASAREL
BX + IVAX RES 0.025MG/SPRAY N20409 001 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT FOUGERA **0.01%** **N88170 001** DEC 16, 1982
AT **0.025%** **N88169 001** DEC 16, 1982
AT G AND W LABS **0.01%** **N89526 001** JUL 26, 1988
AT **0.025%** **N89525 001** JUL 26, 1988
AT TARO **0.01%** **N40035 001** OCT 31, 1994
AT **0.01%** **N87102 001** APR 27, 1982
AT **0.025%** **N40042 001** OCT 31, 1994
AT **0.025%** **N87104 001** APR 27, 1982

SYNALAR
AT + MEDICIS **0.01%** **N12787 004**
AT + **0.025%** **N12787 002**

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
SYNALAR
AT + MEDICIS **0.025%** **N12787 005**

OIL; TOPICAL
DERMA-SMOOTHE/FS
+ HILL DERMAC 0.01% N19452 001 FEB 03, 1988

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT FOUGERA **0.025%** **N88168 001** DEC 16, 1982
AT G AND W LABS **0.025%** **N89524 001** JUL 26, 1988
AT TARO **0.025%** **N40041 001** SEP 15, 1994

SYNALAR
AT + MEDICIS **0.025%** **N13960 001**

SHAMPOO; TOPICAL
FS SHAMPOO
+ GALDERMA LABS LP 0.01% N20001 001 AUG 27, 1990

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT ALPHARMA **0.01%** **N87159 001** JUN 16, 1982
AT FOUGERA **0.01%** **N88167 001** DEC 16, 1982
AT TARO **0.01%** **N89124 001** SEP 11, 1985

SYNALAR
AT + MEDICIS **0.01%** **N15296 001**

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL
TRI-LUMA
+ HILL DERMAC 0.01%;4%;0.05% N21112 001 JAN 18, 2002

FDA data supplied by DrugPatentWatch.com

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB	ALPHARMA US PHARM	0.05%	**N73085 001**	FEB 14, 1992
AB	DRAXIS HLTH	0.05%	**N72494 001**	JAN 19, 1989
AB	FOUGERA	0.05%	**N73030 001**	OCT 17, 1994
AB	TARO	0.05%	**N19117 001**	JUN 26, 1984
AB		0.05%	**N71500 001**	JUN 10, 1987
AB	TEVA	0.05%	**N72488 001**	FEB 06, 1989
	FLUOCINONIDE EMULSIFIED BASE			
AB	ALPHARMA US PHARM	0.05%	**N74204 001**	JUN 13, 1995
AB	TEVA	0.05%	**N72490 001**	FEB 07, 1989
	LIDEX			
AB	+ MEDICIS	0.05%	**N16908 002**	
	LIDEX-E			
AB	MEDICIS	0.05%	**N16908 003**	

GEL; TOPICAL

	FLUOCINONIDE			
AB	FOUGERA	0.05%	**N72933 001**	DEC 30, 1994
AB	TARO	0.05%	**N74935 001**	JUL 29, 1997
AB	TEVA	0.05%	**N72537 001**	FEB 07, 1989
	LIDEX			
AB	+ MEDICIS	0.05%	**N17373 001**	

OINTMENT; TOPICAL

	FLUOCINONIDE			
AB	ALTANA	0.05%	**N74905 001**	AUG 26, 1997
AB	TARO	0.05%	**N75008 001**	JUN 30, 1999
AB	TEVA	0.05%	**N73481 001**	DEC 27, 1991
	LIDEX			
AB	+ MEDICIS	0.05%	**N16909 002**	

FLUOCINONIDE

SOLUTION; TOPICAL

	FLUOCINONIDE			
AT	ALPHARMA	0.05%	**N71535 001**	DEC 02, 1988
AT	COPLEY PHARM	0.05%	**N72522 001**	SEP 28, 1990
AT	FOUGERA	0.05%	**N72934 001**	FEB 27, 1995
AT	TARO	0.05%	**N72857 001**	AUG 02, 1989
AT		0.05%	**N74799 001**	DEC 31, 1996
AT	TEVA	0.05%	**N72511 001**	FEB 07, 1989
	LIDEX			
AT	+ MEDICIS	0.05%	**N18849 001**	APR 06, 1984

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

	FUNDUSCEIN-25		
+	NOVARTIS	25%	N17869 001

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

	FML		
+	ALLERGAN	0.1%	N17760 001 SEP 04, 1985

SUSPENSION; OPHTHALMIC

	FLUOR-OP		
AB	NOVARTIS	0.1%	**N70185 001** FEB 27, 1986

SUSPENSION/DROPS; OPHTHALMIC

	FML		
AB	+ ALLERGAN	0.1%	**N16851 002** JUL 28, 1982
	FML FORTE		
	ALLERGAN	0.25%	N19216 001 APR 23, 1986

FDA data supplied by DrugPatentWatch.com

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

	FML-S			
+	ALLERGAN	0.1%;10%	N19525 001	SEP 29, 1989

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

	FLAREX			
+	ALCON	0.1%	N19079 001	FEB 11, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

	TOBRASONE			
+	ALCON	0.1%;0.3%	N50628 001	JUL 21, 1989

FLUOROURACIL

CREAM; TOPICAL

	CARAC			
+	DERMIK LABS	0.5%	N20985 001	OCT 27, 2000
	EFUDEX			
+	ICN	5%	N16831 003	
	FLUOROPLEX			
+	ALLERGAN HERBERT	1%	N16988 001	

INJECTABLE; INJECTION

	ADRUCIL			
AP	PHARMACIA AND UPJOHN	50MG/ML	**N40023 001**	OCT 18, 1991
AP	+	50MG/ML	**N81225 001**	AUG 28, 1991
	FLUOROURACIL			
AP	AM PHARM PARTNERS	50MG/ML	**N40278 001**	SEP 30, 1998
AP		50MG/ML	**N40279 001**	SEP 30, 1998
AP	BEDFORD	50MG/ML	**N89508 001**	JAN 26, 1988

FLUOROURACIL

INJECTABLE; INJECTION

	FLUOROURACIL			
AP	BIGMAR	50MG/ML	**N40291 001**	MAR 24, 1999
AP		50MG/ML	**N40379 001**	NOV 15, 2000
AP	GENSIA SICOR PHARMS	50MG/ML	**N40333 001**	JAN 27, 2000
AP		50MG/ML	**N40334 001**	FEB 25, 2000
AP	+ ICN PUERTO RICO	50MG/ML	**N12209 001**	
AP	STERIS	50MG/ML	**N87792 001**	OCT 13, 1982

SOLUTION; TOPICAL

	EFUDEX			
+	ICN	2%	N16831 001	
+		5%	N16831 002	
	FLUOROPLEX			
+	ALLERGAN HERBERT	1%	N16765 001	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

	FLUOXETINE			
AB	ALPHAPHARM	EQ 10MG BASE	**N75577 001**	JAN 29, 2002
AB		EQ 20MG BASE	**N75577 002**	JAN 29, 2002
AB	BARR	EQ 10MG BASE	**N74803 002**	JAN 30, 2002
AB		EQ 20MG BASE	**N74803 001**	AUG 02, 2001
AB	CARLSBAD	EQ 10MG BASE	**N76022 001**	JAN 30, 2002
AB		EQ 20MG BASE	**N76022 002**	JAN 30, 2002
AB	DR REDDYS LABS INC	EQ 10MG BASE	**N75465 001**	JAN 29, 2002
AB		EQ 20MG BASE	**N75465 002**	JAN 29, 2002
AB		EQ 40MG BASE	**N75465 003**	AUG 02, 2001
AB	EON	EQ 10MG BASE	**N75807 001**	JAN 29, 2002

FDA data supplied by DrugPatentWatch.com

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

AB	EON	EQ 20MG BASE	N75807 002	JAN 29, 2002
AB	GENEVA PHARMS	EQ 10MG BASE	N75049 001	AUG 02, 2001
AB	IVAX PHARMS	EQ 10MG BASE	N75245 002	JAN 31, 2002
AB		EQ 20MG BASE	N75245 001	JAN 31, 2002
AB	MALLINCKRODT	EQ 10MG BASE	N75658 001	JAN 29, 2002
AB		EQ 20MG BASE	N75658 002	JAN 29, 2002
AB	MUTUAL PHARMA	EQ 10MG BASE	N75787 001	JAN 29, 2002
AB		EQ 20MG BASE	N75787 002	JAN 29, 2002
AB	MYLAN	EQ 10MG BASE	N75207 001	JAN 30, 2002
AB		EQ 20MG BASE	N75207 002	JAN 30, 2002
AB	RANBAXY	EQ 10MG BASE	N76165 001	FEB 01, 2002
AB		EQ 20MG BASE	N76165 002	FEB 01, 2002
AB	SIDMAK LABS	EQ 10MG BASE	N76001 001	JAN 29, 2002
AB		EQ 20MG BASE	N76001 002	JAN 29, 2002
AB	SIEGFRIED	EQ 10MG BASE	N75464 001	JAN 30, 2002
AB		EQ 20MG BASE	N75464 002	JAN 30, 2002
AB	TEVA	EQ 10MG BASE	N75452 001	JAN 29, 2002
AB		EQ 20MG BASE	N75452 002	JAN 29, 2002
AB		EQ 40MG BASE	N75452 003	JAN 29, 2002
AB	WATSON LABS	EQ 10MG BASE	N75662 001	JAN 29, 2002
AB		EQ 20MG BASE	N75662 002	JAN 29, 2002

FLUOXETINE HCL

AB	GENEVA PHARMS	EQ 20MG BASE	N75049 002	JAN 29, 2002
AB		EQ 40MG BASE	N75049 003	JAN 29, 2002

PROZAC

AB	LILLY	EQ 10MG BASE	N18936 006	DEC 23, 1992
AB		EQ 20MG BASE	N18936 001	DEC 29, 1987
AB	+	EQ 40MG BASE	N18936 003	JUN 15, 1999

SARAFEM

	LILLY	EQ 10MG BASE	N18936 007	JUL 06, 2000
	+	EQ 20MG BASE	N18936 008	JUL 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

PROZAC WEEKLY

	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001

SOLUTION; ORAL

FLUOXETINE

AA	ALPHARMA	EQ 20MG BASE/5ML	N75690 001	JAN 31, 2002
AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920 001	JAN 29, 2002
AA	NOVEX	EQ 20MG BASE/5ML	N75292 001	FEB 07, 2002
AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015 001	JAN 30, 2002
AA	TEVA	EQ 20MG BASE/5ML	N75506 001	AUG 02, 2001

FLUOXETINE HCL

AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525 001	JUN 27, 2002
AA	MORTON GROVE	EQ 20MG BASE/5ML	N75514 001	AUG 29, 2002

PROZAC

AA	+ LILLY	EQ 20MG BASE/5ML	N20101 001	APR 24, 1991

TABLET; ORAL

FLUOXETINE HCL

AB	ALPHAPHARM	EQ 10MG BASE	N75755 001	AUG 02, 2001

FDA data supplied by DrugPatentWatch.com

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
FLUOXETINE HCL

+	ALPHAPHARM	EQ 20MG BASE	N75755 002	
			AUG 02, 2001	
AB	BARR	EQ 10MG BASE	N75810 001	
			FEB 01, 2002	
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001	
			JAN 30, 2002	
AB	EON	EQ 10MG BASE	N76024 001	
			JAN 29, 2002	
AB	TEVA	EQ 10MG BASE	N75872 001	
			JAN 29, 2002	
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001	
			FEB 28, 2002	

PROZAC

AB +	LILLY	EQ 10MG BASE	N20974 001	
			MAR 09, 1999	

FLUOXYMESTERONE

TABLET; ORAL
FLUOXYMESTERONE

BP	USL PHARMA	10MG	N88342 001	
			OCT 21, 1983	

HALOTESTIN

BP +	PHARMACIA AND UPJOHN	10MG	N10611 010	
		2MG	N10611 002	
		5MG	N10611 006	

FLUPHENAZINE DECANOATE

INJECTABLE; IM-SC
FLUPHENAZINE DECANOATE

AO	APOTEX	25MG/ML	N75918 001	
			AUG 17, 2001	

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO	AM PHARM PARTNERS	25MG/ML	N71413 001	
			JUL 14, 1987	
AO	BEDFORD	25MG/ML	N74531 001	
			AUG 30, 1996	
AO	GENSIA SICOR PHARMS	25MG/ML	N74795 001	
			SEP 10, 1996	

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO	KING PHARMS	25MG/ML	N74966 001	
			APR 16, 1998	

PROLIXIN DECANOATE

AO +	BRISTOL MYERS SQUIBB	25MG/ML	N16727 001	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HCL

AA	COPLEY PHARM	5MG/ML	N73058 001	
			AUG 30, 1991	
AA	PHARM ASSOC	5MG/ML	N74725 001	
			SEP 16, 1996	

PERMITIL

AA +	SCHERING	5MG/ML	N16008 001	

PROLIXIN

AA	APOTHECON	5MG/ML	N70533 001	
			NOV 07, 1985	

ELIXIR; ORAL
FLUPHENAZINE HCL

AA	COPLEY PHARM	2.5MG/5ML	N81310 001	
			APR 29, 1993	
AA	PHARM ASSOC	2.5MG/5ML	N40146 001	
			AUG 21, 1996	

PROLIXIN

AA +	APOTHECON	2.5MG/5ML	N12145 003	

INJECTABLE; INJECTION
FLUPHENAZINE HCL

AP	AM PHARM PARTNERS	2.5MG/ML	N89556 001	
			APR 16, 1987	

PROLIXIN

AP +	APOTHECON	2.5MG/ML	N11751 005	

TABLET; ORAL
FLUPHENAZINE HCL

AB	GENEVA PHARMS	1MG	N89583 001	
			OCT 16, 1987	
AB		2.5MG	N89584 001	
			OCT 16, 1987	
AB		5MG	N89585 001	
			OCT 16, 1987	

FDA data supplied by DrugPatentWatch.com

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL
FLONASE
+ GLAXOSMITHKLINE — 0.05MG/SPRAY — N20121 001 OCT 19, 1994

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION
ADVAIR DISKUS 100/50
+ GLAXOSMITHKLINE — 0.1MG/INH; EQ 0.05MG BASE/INH — N21077 001 AUG 24, 2000

ADVAIR DISKUS 250/50
+ GLAXOSMITHKLINE — 0.25MG/INH; EQ 0.05MG BASE/INH — N21077 002 AUG 24, 2000

ADVAIR DISKUS 500/50
+ GLAXOSMITHKLINE — 0.5MG/INH; EQ 0.05MG BASE/INH — N21077 003 AUG 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL
LESCOL
NOVARTIS — EQ 20MG BASE — N20261 001 DEC 31, 1993
+ — EQ 40MG BASE — N20261 002 DEC 31, 1993

TABLET, EXTENDED RELEASE; ORAL
LESCOL XL
+ NOVARTIS — 80MG — N21192 001 OCT 06, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	25MG	**N75897 001** JAN 25, 2001
AB		50MG	**N75897 002** JAN 25, 2001

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	100MG	**N75897 003** JAN 25, 2001
AB	EON	25MG	**N75888 001** NOV 29, 2000
AB		50MG	**N75888 002** NOV 29, 2000
AB +		100MG	**N75888 003** NOV 29, 2000
AB	GENPHARM	50MG	**N75950 001** OCT 15, 2001
AB		100MG	**N75950 002** OCT 15, 2001
AB	INVAMED	25MG	**N75887 001** JAN 05, 2001
AB		50MG	**N75887 002** JAN 05, 2001
AB		100MG	**N75887 003** JAN 05, 2001
AB	IVAX PHARMS	25MG	**N75898 001** MAR 12, 2001
AB		50MG	**N75898 002** MAR 12, 2001
AB		100MG	**N75898 003** MAR 12, 2001
AB	MUTUAL PHARM	25MG	**N76125 001** APR 29, 2002
AB		50MG	**N76125 002** APR 29, 2002
AB		100MG	**N76125 003** APR 29, 2002
AB	MYLAN	25MG	**N75889 001** NOV 29, 2000
AB		50MG	**N75889 002** NOV 29, 2000
AB		100MG	**N75889 003** NOV 29, 2000
AB	PUREPAC PHARM	25MG	**N75901 001** DEC 28, 2000
AB		50MG	**N75901 002** DEC 28, 2000
AB		100MG	**N75901 003** DEC 28, 2000
AB	SYNTHON PHARMS	25MG	**N75899 001** JAN 17, 2001

FDA data supplied by DrugPatentWatch.com

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	SYNTHON PHARMS	50MG	N75899 002	JAN 17, 2001
AB		100MG	N75899 003	JAN 17, 2001
AB	TEVA	25MG	N75893 001	SEP 10, 2002
AB		50MG	N75893 002	SEP 10, 2002
AB		100MG	N75893 003	SEP 10, 2002
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001
AB		50MG	N75902 002	MAY 07, 2001
AB		100MG	N75902 003	MAY 07, 2001
AB	WATSON LABS	25MG	N75894 001	APR 18, 2001
AB		50MG	N75894 002	APR 18, 2001
AB		100MG	N75894 003	APR 18, 2001

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP	AM PHARM PARTNERS	5MG/ML	N89202 001	FEB 18, 1986
AP	LOCH	5MG/ML	N81066 001	DEC 29, 1993

FOLVITE

AP	+ LEDERLE	5MG/ML	N05897 008	

TABLET; ORAL

FOLIC ACID

AA	ICN	1MG	N80903 001	
AA	IVAX PHARMS	1MG	N83000 001	
AA	MK LABS	1MG	N83526 001	
AA	PVT FORM	1MG	N85061 001	
AA	TABLICAPS	1MG	N83133 002	
AA	+ WATSON LABS	1MG	N80680 001	
AA	WEST WARD	1MG	N80600 001	

FOLICET

AA	MISSION PHARMA	1MG	N87438 001	

FOLIC ACID; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOLLITROPIN ALFA

INJECTABLE; INJECTION

GONAL-F

+	SERONO	1,200 IU/VIAL	N20378 004	FEB 28, 2001

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

FOLLISTIM

BX	ORGANON	75 IU/VIAL	N20582 001	SEP 29, 1997
BX		150 IU/VIAL	N20582 002	SEP 29, 1997

GONAL-F

BX	SERONO	75 IU/VIAL	N20378 001	SEP 29, 1997
BX		150 IU/VIAL	N20378 002	SEP 29, 1997

FDA data supplied by DrugPatentWatch.com

FOMEPIZOLE

INJECTABLE; INJECTION
ANTIZOL
+ ORPHAN MEDCL 1GM/ML N20696 001 DEC 04, 1997

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
+ NOVARTIS 6.6MG/ML N20961 001 AUG 26, 1998

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS
ARIXTRA
+ FONDA BV 2.5MG/0.5ML N21345 001 DEC 07, 2001

FORMOTEROL FUMARATE

CAPSULE; INHALATION
FORADIL
+ NOVARTIS 0.012MG/INH N20831 001 FEB 16, 2001

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCAVIR
+ ASTRAZENECA 2.4GM/100ML N20068 001 SEP 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL
MONUROL
+ ZAMBON EQ 3GM BASE/PACKET N50717 001 DEC 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL
BRISTOL MYERS SQUIBB 10MG N19915 002 MAY 16, 1991
20MG N19915 003 MAY 16, 1991
+ 40MG N19915 004 MAR 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL
MONOPRIL-HCT
BRISTOL MYERS SQUIBB 10MG;12.5MG N20286 002 NOV 30, 1994
+ 20MG;12.5MG N20286 001 NOV 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
CEREBYX
+ PARKE DAVIS EQ 50MG PHENYTOIN NA/ML N20450 001 AUG 05, 1996

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVA
+ ELAN PHARMS EQ 2.5MG BASE N21006 001 NOV 08, 2001

FULVESTRANT

INJECTABLE; INTRAMUSCULAR
FASLODEX
+ ASTRAZENECA 50MG/ML N21344 001 APR 25, 2002

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE			
AP	ABBOTT	10MG/ML	**N18667 001**	
			MAY 28, 1982	
AP		10MG/ML	**N70578 001**	
			JUL 08, 1987	
AP		10MG/ML	**N72080 001**	
			AUG 13, 1991	
AP		10MG/ML	**N74337 001**	
			OCT 31, 1994	
AP		10MG/ML	**N75241 001**	
			MAY 28, 1999	
AP	AM PHARM PARTNERS	10MG/ML	**N18902 001**	
			MAY 22, 1984	
AP	ELKINS SINN	10MG/ML	**N18267 001**	
AP	INTL MEDICATION	10MG/ML	**N18025 001**	
AP	LEDERLE	10MG/ML	**N71439 001**	
			SEP 14, 1990	
AP	LUITPOLD	10MG/ML	**N18579 001**	
			NOV 30, 1983	
AP	MARSAM PHARMS LLC	10MG/ML	**N74017 001**	
			JUN 30, 1994	
	LASIX			
AP	+ AVENTIS PHARMS	10MG/ML	**N16363 001**	

SOLUTION; ORAL

	FUROSEMIDE			
AA	MORTON GROVE	10MG/ML	**N70655 001**	
			OCT 02, 1987	
AA	ROXANE	10MG/ML	**N70434 001**	
			APR 22, 1987	
		40MG/5ML	N70433 001	
			APR 22, 1987	
	LASIX			
AA	+ AVENTIS PHARMS	10MG/ML	**N17688 001**	

TABLET; ORAL

	FUROSEMIDE			
AB	GENEVA PHARMS	20MG	**N18569 002**	
AB		40MG	**N18569 001**	
AB		80MG	**N18569 005**	
			AUG 14, 1984	
AB	INTL MEDICATION	20MG	**N18753 001**	
			FEB 28, 1984	
AB		40MG	**N18753 002**	
			FEB 28, 1984	

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
AB	IVAX PHARMS	20MG	**N18413 001**	
			NOV 30, 1983	
AB		40MG	**N18413 002**	
			NOV 30, 1983	
AB	KALAPHARM	20MG	**N18868 001**	
			JUN 28, 1983	
AB		40MG	**N18868 002**	
			JUN 28, 1983	
AB	LEDERLE	20MG	**N18415 001**	
			JUL 27, 1982	
AB		40MG	**N18415 002**	
			JUL 27, 1982	
AB		80MG	**N18415 003**	
			NOV 26, 1984	
AB	MYLAN	20MG	**N18487 001**	
AB		40MG	**N18487 002**	
AB		80MG	**N70082 001**	
			OCT 29, 1986	
AB	ROXANE	20MG	**N18823 001**	
			NOV 10, 1983	
AB		40MG	**N18823 002**	
			NOV 10, 1983	
AB		80MG	**N70086 001**	
			JAN 24, 1986	
AB	WATSON LABS	20MG	**N70412 001**	
			FEB 26, 1986	
AB		20MG	**N70449 001**	
			NOV 22, 1985	
AB		20MG	**N71379 001**	
			JAN 02, 1987	
AB		40MG	**N70413 001**	
			FEB 26, 1986	
AB		40MG	**N70450 001**	
			NOV 22, 1985	
AB		80MG	**N70528 001**	
			JAN 07, 1986	
AB		80MG	**N71594 001**	
			FEB 09, 1988	
	LASIX			
AB	AVENTIS PHARMS	20MG	**N16273 002**	
AB		40MG	**N16273 001**	
AB	+	80MG	**N16273 003**	

FDA data supplied by DrugPatentWatch.com

GABAPENTIN

CAPSULE; ORAL				
NEURONTIN				
PFIZER PHARMS	100MG	N20235 001 DEC 30, 1993		
	300MG	N20235 002 DEC 30, 1993		
+	400MG	N20235 003 DEC 30, 1993		
SOLUTION; ORAL				
NEURONTIN				
+ PARKE DAVIS	250MG/5ML	N21129 001 MAR 02, 2000		
TABLET; ORAL				
NEURONTIN				
PFIZER PHARMS	600MG	N20882 001 OCT 09, 1998		
+	800MG	N20882 002 OCT 09, 1998		

GADODIAMIDE

INJECTABLE; INJECTION		
OMNISCAN		
+ AMERSHAM HLTH	287MG/ML	N20123 001 JAN 08, 1993

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION		
MAGNEVIST		
+ BERLEX	469.01MG/ML	N19596 001 JUN 02, 1988
+ BERLEX LABS	469.01MG/ML	N21037 001 MAR 10, 2000

GADOTERIDOL

INJECTABLE; INJECTION		
PROHANCE		
+ BRACCO	279.3MG/ML	N20131 001 NOV 16, 1992

GADOVERSETAMIDE

INJECTABLE; INJECTION		
OPTIMARK		
+ MALLINCKRODT	330.9MG/ML	N20937 001 DEC 08, 1999
+	330.9MG/ML	N20975 001 DEC 08, 1999
OPTIMARK IN PLASTIC CONTAINER		
+ MALLINCKRODT	330.9MG/ML	N20976 001 DEC 08, 1999

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL		
REMINYL		
+ JANSSEN PHARMA	4MG/ML	N21224 001 JUN 22, 2001
TABLET; ORAL		
REMINYL		
JANSSEN PHARMA	EQ 4MG BASE	N21169 001 FEB 28, 2001
	EQ 8MG BASE	N21169 002 FEB 28, 2001
+	EQ 12MG BASE	N21169 003 FEB 28, 2001

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION			
GALLIUM CITRATE GA 67			
BS	BRISTOL MYERS SQUIBB	2mCi/ML	N17478 001
BS	MALLINCKRODT	2mCi/ML	N18058 001

GALLIUM NITRATE

INJECTABLE; INJECTION		
GANITE		
+ GENTA	25MG/ML	N19961 002 JAN 17, 1991

FDA data supplied by DrugPatentWatch.com

GANCICLOVIR

CAPSULE; ORAL
CYTOVENE
SYNTEX (USA) INC LLC 250MG N20460 001 DEC 22, 1994
+ 500MG N20460 002 DEC 12, 1997

IMPLANT; IMPLANTATION
VITRASERT
+ BAUSCH AND LOMB 4.5MG N20569 001 MAR 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
CYTOVENE IV
+ SYNTEX (USA) INC LLC EQ 500MG BASE/VIAL N19661 001 JUN 23, 1989

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON
+ ORGANON INC EQ 250 UGM BASE/0.5ML N21057 001 JUL 29, 1999

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN
BRISTOL MYERS SQUIBB EQ 2MG /ML(200MG/100ML) N21062 001 DEC 17, 1999
EQ 2MG /ML(400MG/200ML) N21062 002 DEC 17, 1999
EQ 10MG /ML(200MG) N21062 003 DEC 17, 1999
+ EQ 10MG /ML(400MG) N21062 004 DEC 17, 1999

TABLET; ORAL
TEQUIN
BRISTOL MYERS SQUIBB 200MG N21061 001 DEC 17, 1999

GATIFLOXACIN

TABLET; ORAL
TEQUIN
+ BRISTOL MYERS SQUIBB 400MG N21061 002 DEC 17, 1999

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMZAR
+ LILLY EQ 200MG BASE/VIAL N20509 001 MAY 15, 1996
+ EQ 1GM BASE/VIAL N20509 002 MAY 15, 1996

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
AB GENEVA PHARMS TECH **600MG** **N74615 001** SEP 29, 1995
AB LEDERLE **600MG** **N74270 001** SEP 27, 1993
AB MYLAN **600MG** **N74452 001** FEB 16, 1995
AB TEVA **600MG** **N74256 001** OCT 31, 1993
AB TORPHARM **600MG** **N75034 001** JUL 20, 1998
AB WATSON LABS **600MG** **N74442 001** APR 28, 1995

LOPID
AB + PFIZER PHARMS **600MG** **N18422 003** NOV 20, 1986

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG
+ WYETH AYERST 5MG/VIAL N21174 001 MAY 17, 2000

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

CREAM; TOPICAL

	GARAMYCIN			
AT	+ SCHERING	EQ 0.1% BASE	N60462 001	
	GENTAMICIN			
AT	CLAY PARK	EQ 0.1% BASE	N62307 001	
	GENTAMICIN SULFATE			
AT	FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984
AT	TARO	EQ 0.1% BASE	N62427 001	MAY 26, 1983

INJECTABLE; INJECTION

	GARAMYCIN			
AP	+ SCHERING	EQ 1MG BASE/ML	N61716 002	
AP	+	EQ 40MG BASE/ML	N61716 001	
	GENTAMICIN SULFATE			
AP	ABBOTT	EQ 10MG BASE/ML	N62420 001	AUG 15, 1983
AP		EQ 10MG BASE/ML	N62612 004	FEB 20, 1986
AP		EQ 40MG BASE/ML	N62420 002	AUG 15, 1983
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982
AP		EQ 40MG BASE/ML	N62356 002	MAR 04, 1982
AP		EQ 40MG BASE/ML	N62366 001	AUG 04, 1983
AP	+ ELKINS SINN	EQ 10MG BASE/ML	N62251 002	
AP		EQ 40MG BASE/ML	N62251 001	
AP	KALAPHARM	EQ 40MG BASE/ML	N62354 001	APR 05, 1982
AP	PHARM SPEC	EQ 40MG BASE/ML	N62340 001	MAR 28, 1983
	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	EQ 60MG BASE/100ML	N62414 006	AUG 15, 1983
AP		EQ 70MG BASE/100ML	N62414 007	AUG 15, 1983
AP		EQ 80MG BASE/100ML	N62414 008	AUG 15, 1983
AP		EQ 90MG BASE/100ML	N62414 009	AUG 15, 1983
AP		EQ 100MG BASE/100ML	N62414 010	AUG 15, 1983

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	EQ 1.2MG BASE/ML	N62414 001	AUG 15, 1983
AP		EQ 1.4MG BASE/ML	N62414 002	AUG 15, 1983
AP		EQ 1.6MG BASE/ML	N62414 003	AUG 15, 1983
AP		EQ 1.8MG BASE/ML	N62414 004	AUG 15, 1983
AP		EQ 2MG BASE/ML	N62414 005	AUG 15, 1983
AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008	AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009	AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010	AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001	AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011	AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012	AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013	AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002	AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014	AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003	AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004	AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005	AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006	AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007	AUG 28, 1987
	ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	EQ 40MG BASE/100ML	N62373 003	SEP 07, 1982
AP		EQ 60MG BASE/100ML	N62373 004	SEP 07, 1982

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	EQ 0.8MG BASE/ML	N62373 001 SEP 07, 1982
AP			EQ 80MG BASE/100ML	N62373 002 SEP 07, 1982
AP			EQ 100MG BASE/100ML	N62373 005 SEP 07, 1982
AP			EQ 120MG BASE/100ML	N62373 006 SEP 07, 1982
AP			EQ 1.2MG BASE/ML	N62373 007 SEP 07, 1982
AP			EQ 1.6MG BASE/ML	N62373 008 SEP 07, 1982
AP			EQ 2MG BASE/ML	N62373 009 SEP 07, 1982
AP			EQ 2.4MG BASE/ML	N62373 010 SEP 07, 1982

OINTMENT; OPHTHALMIC

GARAMYCIN

AT	+	SCHERING	EQ 0.3% BASE	N50425 001

GENTAMICIN SULFATE

AT		AKORN	EQ 0.3% BASE	N64093 001 AUG 31, 1995

OINTMENT; TOPICAL

GENTAMICIN

AT	+	CLAY PARK	EQ 0.1% BASE	N62351 001 FEB 18, 1982

GENTAMICIN SULFATE

AT		FOUGERA	EQ 0.1% BASE	N62533 001 OCT 05, 1984
AT		TARO	EQ 0.1% BASE	N62477 001 DEC 23, 1983

SOLUTION; OPHTHALMIC

GARAMYCIN

AT	+	SCHERING	EQ 0.3% BASE	N50039 002

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT		ALLERGAN	EQ 0.3% BASE	N62452 001 OCT 10, 1984

GENTACIDIN

AT		NOVARTIS	EQ 0.3% BASE	N62480 001 MAR 30, 1984

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTAK

AT		AKORN	EQ 0.3% BASE	N64163 001 OCT 12, 2001

GENTAMICIN SULFATE

AT		AKORN	EQ 0.3% BASE	N62635 001 JAN 08, 1987
AT		BAUSCH AND LOMB	EQ 0.3% BASE	N64048 001 MAY 11, 1994
AT		FALCON PHARMS	EQ 0.3% BASE	N62196 001

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

	+	ALLERGAN	EQ 0.3% BASE;0.6%	N50612 001 DEC 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

	+	ALLERGAN	EQ 0.3% BASE;1%	N50586 001 JUN 10, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

	+	SAVAGE LABS	0.4%	N83513 001

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

	+	TEVA	20MG/VIAL	N20622 001 DEC 20, 1996

INJECTABLE; SUBCUTANEOUS

COPAXONE

	+	TEVA	20MG/ML	N20622 002 FEB 12, 2002

FDA data supplied by DrugPatentWatch.com

GLIMEPIRIDE

TABLET; ORAL				
AMARYL				
	AVENTIS PHARMS	1MG		N20496 001 NOV 30, 1995
		2MG		N20496 002 NOV 30, 1995
+		4MG		N20496 003 NOV 30, 1995

GLIPIZIDE

TABLET; ORAL				
GLIPIZIDE				
AB	ALPHAPHARM	**5MG**		**N74438 001** JUN 20, 1995
AB		**10MG**		**N74438 002** JUN 20, 1995
AB	DURAMED PHARM BARR	**5MG**		**N74550 001** SEP 11, 1997
AB		**10MG**		**N74550 002** SEP 11, 1997
AB	ENDO PHARMS	**5MG**		**N74378 001** NOV 28, 1994
AB		**10MG**		**N74378 002** NOV 28, 1994
AB	GENEVA PHARMS	**5MG**		**N74305 001** APR 07, 1995
AB		**10MG**		**N74305 002** APR 07, 1995
AB	GENEVA PHARMS TECH	**5MG**		**N74542 001** JUN 20, 1995
AB		**10MG**		**N74542 002** JUN 20, 1995
AB	IVAX PHARMS	**5MG**		**N74497 001** AUG 31, 1995
AB		**10MG**		**N74497 002** AUG 31, 1995
AB	MYLAN	**5MG**		**N74226 001** MAY 10, 1994
AB		**10MG**		**N74226 002** MAY 10, 1994
AB	SIDMAK LABS NJ	**5MG**		**N74619 001** APR 04, 1997
AB		**10MG**		**N74619 002** APR 04, 1997

GLIPIZIDE

TABLET; ORAL				
GLIPIZIDE				
AB	TEVA	**5MG**		**N74387 001** MAR 04, 1996
AB		**10MG**		**N74387 002** MAR 04, 1996
AB	TORPHARM	**5MG**		**N75795 001** JUN 13, 2001
AB		**10MG**		**N75795 002** JUN 13, 2001
AB	WATSON LAB	**5MG**		**N74370 001** NOV 22, 1994
AB		**10MG**		**N74370 002** NOV 22, 1994
AB	WATSON LABS	**5MG**		**N74223 001** FEB 27, 1995
AB		**10MG**		**N74223 002** FEB 27, 1995
GLUCOTROL				
AB	PFIZER	**5MG**		**N17783 001** MAY 08, 1984
AB	+	**10MG**		**N17783 002** MAY 08, 1984
TABLET, EXTENDED RELEASE; ORAL				
GLUCOTROL XL				
	PFIZER	2.5MG		N20329 003 AUG 10, 1999
		5MG		N20329 001 APR 26, 1994
+		10MG		N20329 002 APR 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL				
METAGLIP				
	BRISTOL MYERS SQUIBB	2.5MG;250MG		N21460 001 OCT 21, 2002
		2.5MG;500MG		N21460 002 OCT 21, 2002
+		5MG;500MG		N21460 003 OCT 21, 2002

FDA data supplied by DrugPatentWatch.com

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN
+ NOVO NORDISK — EQ 1MG BASE/VIAL — N20918 001 JUN 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION
GLUCAGON
+ LILLY — 1MG/VIAL — N20928 001 SEP 11, 1998

GLUCONOLACTONE; *MULTIPLE*
SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

GLUTATHIONE DISULFIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

GLYBURIDE

TABLET; ORAL
DIABETA

BX	AVENTIS PHARMS	1.25MG	N17532 001 MAY 01, 1984
BX		2.5MG	N17532 002 MAY 01, 1984
BX		5MG	N17532 003 MAY 01, 1984

GLYBURIDE

AB	AMIDE PHARM	**1.5MG**	**N75947 001** NOV 14, 2002
AB		**3MG**	**N75947 002** NOV 14, 2002
AB		**6MG**	**N75947 003** NOV 14, 2002
AB	COREPHARMA	**1.25MG**	**N76257 001** JUN 27, 2002
AB		**2.5MG**	**N76257 002** JUN 27, 2002
AB		**5MG**	**N76257 003** JUN 27, 2002

GLYBURIDE

TABLET; ORAL
GLYBURIDE

AB	TEVA	**1.25MG**	**N74388 001** AUG 29, 1995
AB		**2.5MG**	**N74388 002** AUG 29, 1995
AB		**5MG**	**N74388 003** AUG 29, 1995

GLYBURIDE (MICRONIZED)

AB	AVENTIS PHARMS	**1.5MG**	**N20055 001** APR 17, 1992
AB		**3MG**	**N20055 002** APR 17, 1992
AB		**6MG**	**N20055 003** MAR 08, 2000
AB	CLONMEL HLTHCARE	**1.5MG**	**N74591 001** DEC 22, 1997
AB		**3MG**	**N74591 002** DEC 22, 1997
AB		**4.5MG**	**N74591 003** DEC 22, 1997
AB		**6MG**	**N74591 004** DEC 22, 1997
AB	GENEVA PHARMS TECH	**1.5MG**	**N75174 001** JUN 22, 1998
AB		**3MG**	**N75174 002** JUN 22, 1998
AB	MYLAN	**1.5MG**	**N74792 001** JUN 26, 1998
AB		**3MG**	**N74792 002** JUN 26, 1998
AB		**6MG**	**N74792 003** AUG 17, 1999
AB	TEVA	**1.5MG**	**N74686 001** APR 20, 1999
AB		**3MG**	**N74686 002** APR 20, 1999
AB		**4.5MG**	**N74686 003** APR 20, 1999
AB		**6MG**	**N74686 004** APR 20, 1999

GLYNASE

AB	PHARMACIA AND UPJOHN	**1.5MG**	**N20051 001** MAR 04, 1992
AB		**3MG**	**N20051 002** MAR 04, 1992

FDA data supplied by DrugPatentWatch.com

GLYBURIDE

TABLET; ORAL

		GLYNASE			
AB	+	PHARMACIA AND UPJOHN	**6MG**	**N20051 004** SEP 24, 1993	
		MICRONASE			
AB		PHARMACIA AND UPJOHN	**1.25MG**	**N17498 001** MAY 01, 1984	
AB			**2.5MG**	**N17498 002** MAY 01, 1984	
AB	+		**5MG**	**N17498 003** MAY 01, 1984	

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOVANCE			
	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001 JUL 31, 2000	
		2.5MG;500MG	N21178 002 JUL 31, 2000	
	+	5MG;500MG	N21178 003 JUL 31, 2000	

GLYCERIN; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

GLYCINE

SOLUTION; IRRIGATION

	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER			
AT	BAXTER HLTHCARE	**1.5GM/100ML**	**N17865 001**	
	GLYCINE 1.5% IN PLASTIC CONTAINER			
AT	ABBOTT	**1.5GM/100ML**	**N17633 001**	
AT		**1.5GM/100ML**	**N18315 001**	
AT	B BRAUN	**1.5GM/100ML**	**N16784 001**	

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE			
AP	LUITPOLD	**0.2MG/ML**	**N89335 001** JUL 23, 1986	

GLYCOPYRROLATE

INJECTABLE; INJECTION

	ROBINUL			
AP	+ ROBINS AH	**0.2MG/ML**	**N17558 001**	

TABLET; ORAL

	ROBINUL		
	+ FIRST HORIZON	1MG	N12827 001
	ROBINUL FORTE		
	+ FIRST HORIZON	2MG	N12827 002

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

	FACTREL		
	+ WYETH AYERST	EQ 0.1MG BASE/VIAL	N18123 001 SEP 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

	A.P.L.			
AP	+ WYETH AYERST	**5,000 UNITS/VIAL**	**N17055 001**	
AP	+	**10,000 UNITS/VIAL**	**N17055 002**	
	CHORIONIC GONADOTROPIN			
AP	+ AM PHARM PARTNERS	**10,000 UNITS/VIAL**	**N17067 002**	
AP	+ STERIS	**5,000 UNITS/VIAL**	**N17016 006**	
AP	+	**10,000 UNITS/VIAL**	**N17016 007**	
	PREGNYL			
AP	+ ORGANON	**10,000 UNITS/VIAL**	**N17692 001**	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

	ZOLADEX		
	+ ASTRAZENECA	EQ 3.6MG BASE	N19726 001 DEC 29, 1989
	+	EQ 10.8MG BASE	N20578 001 JAN 11, 1996

FDA data supplied by DrugPatentWatch.com

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
AT	BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N64047 001 JAN 31, 1996	
	NEOSPORIN			
AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001	

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	KYTRIL			
	+ ROCHE	EQ 1MG BASE/ML	N20239 002 MAR 11, 1994	

TABLET; ORAL

	KYTRIL			
	+ ROCHE	EQ 1MG BASE	N20305 001 MAR 16, 1995	

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	RAXAR			
	OTSUKA	EQ 200MG BASE	N20695 001 NOV 06, 1997	
		EQ 400MG BASE	N20695 002 MAY 14, 1998	
	+	EQ 600MG BASE	N20695 003 MAY 14, 1998	

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

	GRIFULVIN V			
	+ J AND J	125MG/5ML	N62483 001 JAN 26, 1984	

TABLET; ORAL

	FULVICIN-U/F			
AB	SCHERING	250MG	N60569 002	
AB	+	500MG	N60569 001	
	GRIFULVIN V			
AB	J AND J	250MG	N62279 002	

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

	GRIFULVIN V			
AB	J AND J	500MG	N62279 003	
		125MG	N62279 001	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

	FULVICIN P/G			
AB	SCHERING	125MG	N61996 001	
AB	+	250MG	N61996 002	
	FULVICIN P/G 165			
AB	SCHERING	165MG	N61996 003 APR 06, 1982	
	FULVICIN P/G 330			
AB	+ SCHERING	330MG	N61996 004 APR 06, 1982	
	GRIS-PEG			
AB	PEDINOL	125MG	N50475 001	
AB		250MG	N50475 002	

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	COPLEY PHARM	EQ 4MG BASE	N74267 001 JUN 01, 1994	
AB		EQ 8MG BASE	N74267 002 JUN 01, 1994	
AB	EON	EQ 4MG BASE	N74517 001 SEP 30, 1998	
AB		EQ 8MG BASE	N74517 002 SEP 30, 1998	
AB	IVAX PHARMS	EQ 4MG BASE	N74149 001 APR 07, 1995	
AB		EQ 8MG BASE	N74149 002 APR 07, 1995	
AB	WATSON LABS	EQ 4MG BASE	N74025 001 FEB 28, 1994	
AB		EQ 8MG BASE	N74025 002 FEB 28, 1994	
	WYTENSIN			
AB	WYETH AYERST	EQ 4MG BASE	N18587 001 SEP 07, 1982	

FDA data supplied by DrugPatentWatch.com

GUANABENZ ACETATE

TABLET; ORAL

	WYTENSIN			
AB	+ WYETH AYERST	EQ 8MG BASE	**N18587 002**	SEP 07, 1982

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL		
AB	AMIDE PHARM	EQ 1MG BASE	**N74673 001** FEB 28, 1997
AB		EQ 2MG BASE	**N74673 002** FEB 28, 1997
AB	GENPHARM	EQ 1MG BASE	**N75109 001** NOV 25, 1998
AB		EQ 2MG BASE	**N75109 002** NOV 25, 1998
AB	MYLAN	EQ 1MG BASE	**N74796 001** JAN 27, 1997
AB		EQ 2MG BASE	**N74796 002** JAN 27, 1997
AB	WATSON LABS	EQ 1MG BASE	**N74145 001** OCT 17, 1995
AB		EQ 1MG BASE	**N74762 001** JUN 25, 1997
AB		EQ 2MG BASE	**N74145 002** OCT 17, 1995
AB		EQ 2MG BASE	**N74762 002** JUN 25, 1997
	TENEX		
AB	ESP PHARMA	EQ 1MG BASE	**N19032 001** OCT 27, 1986
AB	+	EQ 2MG BASE	**N19032 002** NOV 07, 1988

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

	GUANIDINE HCL		
	SCHERING	125MG	N01546 001

HALAZEPAM

TABLET; ORAL

	PAXIPAM		
	SCHERING	20MG	N17736 003
	+	40MG	N17736 004

HALCINONIDE

CREAM; TOPICAL

	HALOG		
	+ WESTWOOD SQUIBB	0.1%	N17556 001
	HALOG-E		
	WESTWOOD SQUIBB	0.1%	N18234 001

OINTMENT; TOPICAL

	HALOG		
	+ WESTWOOD SQUIBB	0.1%	N17824 001

SOLUTION; TOPICAL

	HALOG		
	WESTWOOD SQUIBB	0.1%	N17823 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

	ULTRAVATE		
	+ WESTWOOD SQUIBB	0.05%	N19967 001 DEC 27, 1990

OINTMENT; TOPICAL

	ULTRAVATE		
	+ WESTWOOD SQUIBB	0.05%	N19968 001 DEC 17, 1990

HALOPERIDOL

TABLET; ORAL

	HALOPERIDOL		
AB	GENEVA PHARMS	**0.5MG**	**N71206 001** NOV 17, 1986
AB		**1MG**	**N71207 001** NOV 17, 1986
AB		**2MG**	**N71208 001** NOV 17, 1986

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL

TABLET; ORAL

	HALOPERIDOL			
AB	GENEVA PHARMS	5MG	N71209 001	NOV 17, 1986
AB		10MG	N71210 001	MAR 11, 1988
+		20MG	N71211 001	MAR 11, 1988
AB	MYLAN	0.5MG	N70276 001	JUN 10, 1986
AB		1MG	N70277 001	JUN 10, 1986
AB		2MG	N70278 001	JUN 10, 1986
AB		5MG	N70279 001	JUN 10, 1986
AB	PAR PHARM	0.5MG	N71233 001	NOV 03, 1986
AB		1MG	N71234 001	NOV 03, 1986
AB		2MG	N71235 001	NOV 03, 1986
AB		5MG	N71236 001	NOV 03, 1986
AB		10MG	N71237 001	JUL 20, 1987
AB	WATSON LABS	0.5MG	N70981 001	MAR 06, 1987
AB		2MG	N70983 001	MAR 06, 1987
AB		5MG	N70984 001	MAR 06, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALDOL			
AO	+ ORTHO MCNEIL	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986
AO	+	EQ 100MG BASE/ML	N18701 002	JAN 31, 1997
	HALOPERIDOL DECANOATE			
AO	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74893 001	DEC 19, 1997
AO		EQ 100MG BASE/ML	N74893 002	DEC 19, 1997

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALOPERIDOL DECANOATE			
AO	APOTEX	EQ 50MG BASE/ML	N75440 001	FEB 28, 2000
AO		EQ 100MG BASE/ML	N75440 002	FEB 28, 2000
AO	BEDFORD	EQ 50MG BASE/ML	N74811 001	JAN 30, 1998
AO		EQ 100MG BASE/ML	N75305 001	SEP 28, 1998
AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001	MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002	MAY 11, 1999
AO	KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000
AO		EQ 100MG BASE/ML	N75176 002	FEB 09, 2000

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

	HALOPERIDOL			
AA	COPLEY PHARM	EQ 2MG BASE/ML	N71617 001	DEC 01, 1988
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001	FEB 26, 1993
AA	SILARX	EQ 2MG BASE/ML	N73364 001	SEP 28, 1993
AA	+ TEVA	EQ 2MG BASE/ML	N71015 001	AUG 25, 1987

INJECTABLE; INJECTION

	HALDOL			
AP	+ ORTHO MCNEIL	EQ 5MG BASE/ML	N15923 001	
	HALOPERIDOL			
AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001
AP	BEDFORD	EQ 5MG BASE/ML	N75858 001	JUN 18, 2001
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N76035 001	AUG 29, 2001
AP	STERIS	EQ 5MG BASE/ML	N70714 001	MAY 17, 1988

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL LACTATE

SOLUTION; ORAL
HALOPERIDOL LACTATE

	UDL	EQ 1MG BASE/ML	N74536 001	
			NOV 02, 1995	

HALOTHANE

LIQUID; INHALATION
HALOTHANE

AN	+ ABBOTT	**99.99%**	**N83254 001**	
AN	HALOCARBON	**99.99%**	**N80810 001**	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP-LOCK

AP	+ ELKINS SINN	**10 UNITS/ML**	**N17037 007**	
AP	+	**100 UNITS/ML**	**N17037 006**	
	HEP-LOCK U/P			
AP	ELKINS SINN	**10 UNITS/ML**	**N17037 010**	
			JUN 10, 1983	
AP		**100 UNITS/ML**	**N17037 011**	
			JUN 10, 1983	
	HEPARIN LOCK FLUSH			
AP	ABBOTT	**10 UNITS/ML**	**N05264 001**	
AP		**10 UNITS/ML**	**N40082 001**	
			FEB 28, 1995	
AP		**10 UNITS/ML**	**N88097 001**	
			APR 28, 1983	
AP		**10 UNITS/ML**	**N88346 001**	
			MAY 18, 1983	
AP		**100 UNITS/ML**	**N40082 002**	
			FEB 28, 1995	
AP		**100 UNITS/ML**	**N88098 001**	
			APR 28, 1983	
AP		**100 UNITS/ML**	**N88347 001**	
			MAY 18, 1983	
AP	AM PHARM PARTNERS	**10 UNITS/ML**	**N17029 007**	
			MAY 06, 1982	
AP		**100 UNITS/ML**	**N17029 006**	
	HEPARIN LOCK FLUSH IN PLASTIC CONTAINER			
AP	ABBOTT	**10 UNITS/ML**	**N05264 015**	
			MAY 21, 1985	
AP		**100 UNITS/ML**	**N05264 016**	
			MAY 21, 1985	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP	+ ABBOTT	**2,500 UNITS/ML**	**N88099 001**	
			APR 28, 1983	
AP		**5,000 UNITS/ML**	**N88100 001**	
			APR 28, 1983	
AP	AM PHARM PARTNERS	**1,000 UNITS/ML**	**N17029 001**	
AP		**1,000 UNITS/ML**	**N17979 001**	
AP		**5,000 UNITS/ML**	**N17651 006**	
AP		**10,000 UNITS/ML**	**N17029 003**	
AP		**10,000 UNITS/ML**	**N17979 002**	
AP	+	**20,000 UNITS/ML**	**N17029 004**	
AP	ELKINS SINN	**1,000 UNITS/ML**	**N17037 001**	
AP		**5,000 UNITS/ML**	**N17037 002**	
AP		**10,000 UNITS/ML**	**N17037 003**	
AP		**5,000 UNITS/0.5ML**	**N17037 013**	
			APR 07, 1986	
AP	LILLY	**10,000 UNITS/ML**	**N05521 002**	
AP	MARSAM PHARMS LLC	**1,000 UNITS/ML**	**N40007 001**	
			JUN 07, 1996	
AP		**1,000 UNITS/ML**	**N40008 001**	
			OCT 10, 1995	
AP	+ PHARMACIA AND UPJOHN	**1,000 UNITS/ML**	**N04570 001**	
AP	+	**5,000 UNITS/ML**	**N04570 002**	
AP	+	**10,000 UNITS/ML**	**N04570 003**	
	HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	**200 UNITS/100ML**	**N18609 001**	
			APR 28, 1982	
	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	**200 UNITS/100ML**	**N18916 010**	
			JUN 23, 1989	
AP	B BRAUN	**200 UNITS/100ML**	**N19953 001**	
			JUL 20, 1992	
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	**10,000 UNITS/100ML**	**N19339 003**	
			MAR 27, 1985	
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
	ABBOTT	5,000 UNITS/100ML	N19339 001	
			MAR 27, 1985	
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	ABBOTT	5,000 UNITS/100ML	N18916 006	
			JAN 31, 1984	

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	200 UNITS/100ML	N18609 002	APR 28, 1982

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	200 UNITS/100ML	N18916 011	JUN 23, 1989

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	4,000 UNITS/100ML	N18814 001	OCT 31, 1983

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	4,000 UNITS/100ML	N19805 001	JAN 25, 1989
AP	B BRAUN	4,000 UNITS/100ML	N19952 001	JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5,000 UNITS/100ML	N18814 003	JUL 09, 1985
AP		10,000 UNITS/100ML	N18814 004	JUL 02, 1987

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	5,000 UNITS/100ML	N19339 004	MAR 27, 1985
AP		5,000 UNITS/100ML	N19805 002	JAN 25, 1989
AP		10,000 UNITS/100ML	N19339 002	MAR 27, 1985
AP	B BRAUN	5,000 UNITS/100ML	N19952 004	JUL 20, 1992
AP		10,000 UNITS/100ML	N19952 005	JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	5,000 UNITS/100ML	N18916 007	JAN 31, 1984
	10,000 UNITS/100ML	N18916 008	JAN 31, 1984

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013	DEC 05, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	5,000 UNITS/ML	N17029 014	DEC 05, 1985
AP		10,000 UNITS/ML	N17029 015	DEC 05, 1985
AP		20,000 UNITS/ML	N17029 016	DEC 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP +	ABBOTT	2,500 UNITS/ML	N05264 014	APR 07, 1986
AP +		10,000 UNITS/ML	N89522 001	MAY 04, 1987
+		2,000 UNITS/ML	N05264 013	APR 07, 1986
AP +	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010	APR 28, 1986
AP	MARSAM PHARMS LLC	1,000 UNITS/ML	N89464 001	JUN 03, 1986

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009	JUN 26, 1984

SODIUM HEPARIN

AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17036 001	

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

+	SANOFI SYNTHELABO	3%	N06882 001

SPONGE; TOPICAL

PRE-OP

AT +	DAVIS AND GECK	480MG	N17433 001	

PRE-OP II

AT	DAVIS AND GECK	480MG	N17433 002	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

AA +	ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213 002	JUL 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999

FDA data supplied by DrugPatentWatch.com

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

	HYDROCODONE COMPOUND			
AA	ALPHARMA	1.5MG/5ML;5MG/5ML	N88017 001	JUL 05, 1983
	MYCODONE			
AA	MORTON GROVE	1.5MG/5ML;5MG/5ML	N88008 001	MAR 03, 1983

TABLET; ORAL

	HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE			
AA	AMIDE PHARM	1.5MG;5MG	N40295 001	DEC 01, 2000
	HYCODAN			
AA +	ENDO PHARMS	1.5MG;5MG	N05213 001	JUL 26, 1988
	TUSSIGON			
AA	JONES PHARMA	1.5MG;5MG	N88508 001	JUL 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL			
AP	AM PHARM PARTNERS	20MG/ML	N40388 001	MAR 13, 2001
AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001	FEB 23, 2000
AP +	LUITPOLD	20MG/ML	N40136 001	JUN 30, 1997

TABLET; ORAL

	APRESOLINE			
AA +	NOVARTIS	10MG	N08303 004	
AA +		25MG	N08303 001	
AA +		50MG	N08303 002	
AA +		100MG	N08303 005	
	HYDRALAZINE HCL			
AA	ABC HOLDING	10MG	N88846 001	FEB 26, 1985
AA		25MG	N88847 001	FEB 26, 1985
AA		50MG	N88848 001	FEB 26, 1985
AA		100MG	N88849 001	FEB 26, 1985
AA	GENEVA PHARMS	10MG	N83241 001	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	HYDRALAZINE HCL			
AA	GENEVA PHARMS	25MG	N83560 001	
AA		50MG	N83561 001	
AA	IMPAX LABS	50MG	N84923 001	
AA	LEDERLE	25MG	N86243 001	
AA		50MG	N86242 002	
AA	MUTUAL PHARM	10MG	N89359 001	JUL 25, 1986
AA		25MG	N89258 001	MAY 05, 1986
AA		50MG	N89259 001	MAY 05, 1986
AA	PAR PHARM	10MG	N87836 001	OCT 05, 1982
AA		25MG	N86961 002	
AA		50MG	N86962 001	
AA		100MG	N88391 001	SEP 27, 1983
AA	SIDMAK LABS NJ	10MG	N89097 001	DEC 18, 1985
AA		25MG	N88467 001	MAY 01, 1984
AA		50MG	N88468 001	MAY 01, 1984
AA		100MG	N89098 001	DEC 18, 1985
AA	WATSON LABS	25MG	N84504 001	
AA		50MG	N84503 001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	APRESAZIDE			
AB	NOVARTIS	25MG;25MG	N84735 001	
AB		50MG;50MG	N84810 001	
	HYDRA-ZIDE			
AB	PAR PHARM	25MG;25MG	N88957 001	OCT 21, 1985
AB		50MG;50MG	N88946 001	OCT 21, 1985
+		100MG;50MG	N88961 001	OCT 21, 1985
	HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
AB	SUPERPHARM	50MG;50MG	N89201 001	FEB 09, 1987

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE			
AB	MYLAN	12.5MG	**N75640 001**	JAN 28, 2000
AB	VINTAGE PHARMS	12.5MG	**N75907 001**	SEP 17, 2002
	MICROZIDE			
AB	+ WATSON LABS	12.5MG	**N20504 001**	DEC 27, 1996

SOLUTION; ORAL

	HYDROCHLOROTHIAZIDE			
	+ ROXANE	50MG/5ML	N88587 001	JUL 02, 1984

TABLET; ORAL

	ESIDRIX			
AB	NOVARTIS	25MG	**N11793 005**	
AB		50MG	**N11793 008**	
	HYDROCHLOROTHIAZIDE			
AB	ABC HOLDING	25MG	**N85683 001**	
AB		50MG	**N83965 001**	
AB		50MG	**N85672 001**	
AB	EON	50MG	**N85219 001**	
AB	GENEVA PHARMS	25MG	**N87565 001**	MAR 09, 1982
AB		50MG	**N84912 001**	
AB	IVAX PHARMS	25MG	**N83177 001**	
AB		50MG	**N83177 002**	
AB	+	100MG	**N85022 001**	
AB	LEDERLE	25MG	**N87059 001**	
AB		50MG	**N87068 001**	
AB	PUREPAC PHARM	25MG	**N85054 002**	
AB		50MG	**N85208 001**	
AB	PVT FORM	25MG	**N85181 001**	
AB		50MG	**N85182 001**	
AB	ROXANE	50MG	**N84536 002**	
AB	VINTAGE PHARMS	25MG	**N40412 001**	MAR 29, 2002
AB		50MG	**N40412 002**	MAR 29, 2002
AB	WATSON LABS	25MG	**N81189 001**	JAN 24, 1992
	ORETIC			
AB	ABBOTT	50MG	**N11971 002**	

HYDROCHLOROTHIAZIDE; *MULTIPLE*

SEE AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; *MULTIPLE*

SEE BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
SEE CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
SEE CAPTOPRIL; HYDROCHLOROTHIAZIDE
SEE ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
SEE EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
SEE FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	AVALIDE			
	SANOFI SYNTHELABO	12.5MG;150MG	N20758 002	SEP 30, 1997
	+	12.5MG;300MG	N20758 003	AUG 31, 1998

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

	LISINOPRIL AND HYDROCHLOROTHIAZIDE			
AB	EON	12.5MG;10MG	**N76262 001**	JUL 01, 2002
AB		12.5MG;20MG	**N76262 002**	JUL 01, 2002
AB		25MG;20MG	**N76262 003**	JUL 01, 2002
AB	GENEVA PHARMS TECH	12.5MG;10MG	**N75926 001**	JUL 01, 2002
AB		12.5MG;20MG	**N75926 002**	JUL 01, 2002
AB		25MG;20MG	**N75926 003**	JUL 01, 2002
AB	IVAX PHARMS	12.5MG;10MG	**N75776 001**	JUL 01, 2002
AB		12.5MG;20MG	**N75776 002**	JUL 01, 2002
AB		25MG;20MG	**N75776 003**	JUL 01, 2002
AB	MYLAN	12.5MG;10MG	**N76113 001**	JUL 01, 2002
AB		12.5MG;20MG	**N76113 002**	JUL 01, 2002
AB		25MG;20MG	**N76113 003**	JUL 01, 2002

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

	LISINOPRIL AND HYDROCHLOROTHIAZIDE			
AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	JUL 01, 2002
AB		12.5MG;20MG	N76230 002	JUL 01, 2002
AB		25MG;20MG	N76230 003	JUL 01, 2002
AB	RANBAXY	12.5MG;10MG	N76007 001	JUL 01, 2002
AB		12.5MG;20MG	N76007 002	JUL 01, 2002
AB		25MG;20MG	N76007 003	JUL 01, 2002
AB	TEVA	12.5MG;10MG	N75869 001	JUL 01, 2002
AB		12.5MG;20MG	N75869 002	JUL 01, 2002
AB		25MG;20MG	N75869 003	JUL 01, 2002
AB	WATSON LABS	12.5MG;10MG	N76194 003	JUL 01, 2002
AB		12.5MG;20MG	N76194 001	JUL 01, 2002
AB		25MG;20MG	N76194 002	JUL 01, 2002
AB	WEST WARD	12.5MG;10MG	N76265 001	JUL 08, 2002
AB		12.5MG;20MG	N76265 002	JUL 08, 2002
AB		25MG;20MG	N76265 003	JUL 08, 2002
	PRINZIDE			
AB	MERCK	12.5MG;10MG	N19778 003	NOV 18, 1993
AB		12.5MG;20MG	N19778 001	FEB 16, 1989
AB	+	25MG;20MG	N19778 002	FEB 16, 1989
	ZESTORETIC			
AB	ASTRAZENECA	12.5MG;10MG	N19888 003	NOV 18, 1993
AB		12.5MG;20MG	N19888 001	SEP 20, 1990
AB		25MG;20MG	N19888 002	JUL 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

	HYZAAR			
	MERCK	12.5MG;50MG	N20387 001	APR 28, 1995
	+	25MG;100MG	N20387 002	NOV 10, 1998

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDORIL 15			
AB	MERCK	15MG;250MG	N13402 001	
	ALDORIL 25			
AB	MERCK	25MG;250MG	N13402 002	
	ALDORIL D30			
AB	MERCK	30MG;500MG	N13402 003	
	ALDORIL D50			
AB	+ MERCK	50MG;500MG	N13402 004	
	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB	GENEVA PHARMS	15MG;250MG	N70182 001	JAN 15, 1986
AB		25MG;250MG	N70183 001	JAN 15, 1986
AB		30MG;500MG	N70543 001	JAN 15, 1986
AB		50MG;500MG	N70544 001	JAN 15, 1986
AB	LEDERLE	15MG;250MG	N72507 001	JUN 02, 1989
AB		25MG;250MG	N72508 001	JUN 02, 1989
AB		30MG;500MG	N72509 001	JUN 02, 1989
AB		50MG;500MG	N72510 001	JUN 02, 1989
AB	MYLAN	15MG;250MG	N70264 001	JAN 23, 1986
AB		25MG;250MG	N70265 001	JAN 23, 1986
AB	PAR PHARM	15MG;250MG	N70616 001	FEB 02, 1987
AB		25MG;250MG	N70612 001	FEB 02, 1987
AB		30MG;500MG	N70613 001	FEB 02, 1987

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM	50MG;500MG	**N70614 001**	FEB 02, 1987
AB	WATSON LABS	15MG;250MG	**N70958 001**	FEB 06, 1989
AB		25MG;250MG	**N70959 001**	JAN 19, 1989
AB		30MG;500MG	**N71069 001**	JAN 19, 1989
AB		50MG;500MG	**N70960 001**	FEB 06, 1989

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

	NOVARTIS	25MG;50MG	N18303 001	DEC 31, 1984
		25MG;100MG	N18303 002	DEC 31, 1984
+		50MG;100MG	N18303 003	DEC 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001	JUN 27, 1997
		12.5MG;15MG	N20729 003	FEB 14, 2002
+		25MG;15MG	N20729 002	JUN 27, 1997

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	WYETH AYERST	25MG;40MG	**N18031 001**	

INDERIDE-80/25

AB	+ WYETH AYERST	25MG;80MG	**N18031 002**	

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;40MG	**N70704 001**	OCT 01, 1986

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;80MG	**N70705 001**	OCT 01, 1986
AB	GENEVA PHARMS	25MG;40MG	**N71060 001**	AUG 26, 1987
AB		25MG;80MG	**N71061 001**	AUG 26, 1987
AB	MYLAN	25MG;40MG	**N70946 001**	MAR 04, 1987
AB		25MG;80MG	**N70947 001**	APR 01, 1987
AB	PUREPAC PHARM	25MG;40MG	**N70851 001**	MAY 15, 1986
AB		25MG;80MG	**N70852 001**	MAY 15, 1986
AB	SIDMAK LABS NJ	25MG;40MG	**N72042 001**	MAR 14, 1988
AB		25MG;80MG	**N72043 001**	MAR 14, 1988
AB	WATSON LABS	25MG;40MG	**N70301 001**	APR 18, 1986
AB		25MG;80MG	**N70305 001**	APR 18, 1986

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001	DEC 28, 1999
		12.5MG;EQ 20MG BASE	N20125 002	DEC 28, 1999
+		25MG;EQ 20MG BASE	N20125 003	DEC 28, 1999

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB	GD SEARLE LLC	25MG;25MG	**N12616 004**	DEC 30, 1982
+		50MG;50MG	N12616 005	DEC 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	GENEVA PHARMS	25MG;25MG	**N86881 001**	

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	HALSEY	25MG;25MG	N87267 001	
AB	MUTUAL PHARM	25MG;25MG	N89534 001	JUL 02, 1987
AB	MYLAN	25MG;25MG	N86513 001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

AB	PARKE DAVIS	25MG;25MG	N87948 001	FEB 22, 1983

SPIRONOLACTONE/HYDROCHLOROTHIAZIDE

AB	WATSON LABS	25MG;25MG	N87398 001	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;40MG	N21162 001	NOV 17, 2000
+		12.5MG;80MG	N21162 002	NOV 17, 2000

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

+	MERCK	25MG;10MG	N18061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	+	GLAXOSMITHKLINE	25MG;37.5MG	N16042 003	MAR 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N74970 001	JAN 06, 1998
AB	DURAMED PHARM BARR	25MG;37.5MG	N75052 001	JUN 18, 1999
AB	GENEVA PHARMS	25MG;37.5MG	N74821 001	JUN 05, 1997
AB +		25MG;50MG	N73191 001	JUL 31, 1991
AB	IVAX PHARMS	25MG;50MG	N74259 001	MAR 30, 1995

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;37.5MG	N74701 001	JUN 07, 1996

TABLET; ORAL

MAXZIDE

AB	+ MYLAN	50MG;75MG	N19129 001	OCT 22, 1984

MAXZIDE-25

AB	MYLAN	25MG;37.5MG	N19129 003	MAY 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N71251 002	MAY 05, 1998
AB		50MG;75MG	N71251 001	APR 17, 1988
AB	GENEVA PHARMS	25MG;37.5MG	N73281 001	APR 30, 1992
AB		50MG;75MG	N72011 001	JUN 17, 1988
AB	SIDMAK LABS NJ	25MG;37.5MG	N74026 001	APR 26, 1996
AB		50MG;75MG	N73467 001	JAN 31, 1996
AB	WATSON LABS	25MG;37.5MG	N73449 001	SEP 23, 1993
AB		50MG;75MG	N71851 001	NOV 30, 1988
AB		50MG;75MG	N71969 001	APR 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

	NOVARTIS	12.5MG;80MG	N20818 001	MAR 06, 1998
+		12.5MG;160MG	N20818 002	MAR 06, 1998

HYDROCODONE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; HYDROCODONE BITARTRATE

SEE ASPIRIN; HYDROCODONE BITARTRATE

SEE HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

FDA data supplied by DrugPatentWatch.com

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

	VICOPROFEN			
+	ABBOTT	7.5MG;200MG	N20716 001	
			SEP 23, 1997	

HYDROCODONE POLISTIREX; *MULTIPLE*

SEE CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

HYDROCORTISONE

CREAM; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	1%	**N80706 006**	
	ANUSOL HC			
AT	PARKEDALE	2.5%	**N88250 001**	
			JUN 06, 1984	
	HI-COR			
AT	C AND M PHARMA	2.5%	**N80483 001**	
	HYDROCORTISONE			
AT	ALPHARMA	2.5%	**N89682 001**	
			MAR 10, 1988	
AT	ALPHARMA US PHARM	1%	**N87795 001**	
			MAY 03, 1983	
AT	ALTANA	0.5%	**N80848 002**	
AT		1%	**N80848 003**	
AT	CLAY PARK	2.5%	**N85025 001**	
AT	EVERYLIFE	1%	**N80452 002**	
AT	FOUGERA	1%	**N80693 003**	
AT		2.5%	**N89414 001**	
			DEC 16, 1986	
AT	INGRAM PHARM	0.5%	**N80456 002**	
AT		1%	**N80456 003**	
AT	PHARMADERM	2.5%	**N89413 001**	
			DEC 16, 1986	
AT	SYOSSET	0.5%	**N85527 001**	
AT	TARO	1%	**N86155 001**	
AT		2.5%	**N88799 001**	
			NOV 09, 1984	
	HYTONE			
AT	+ DERMIK LABS	1%	**N80472 003**	
AT	+	2.5%	**N80472 004**	
	PENECORT			
AT	ALLERGAN HERBERT	1%	**N88216 001**	
			JUN 06, 1984	
	SYNACORT			
AT	MEDICIS	1%	**N87458 001**	

HYDROCORTISONE

CREAM; TOPICAL

	SYNACORT			
AT	MEDICIS	2.5%	**N87457 001**	

ENEMA; RECTAL

	COLOCORT			
AB	PADDOCK	100MG/60ML	**N75172 001**	
			DEC 03, 1999	
	CORTENEMA			
AB	+ SOLVAY	100MG/60ML	**N16199 001**	
	HYDROCORTISONE			
AB	COPLEY PHARM	100MG/60ML	**N74171 001**	
			MAY 27, 1994	

LOTION; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	1%	**N83201 001**	
	ALA-SCALP			
	DEL RAY LABS	2%	N83231 001	
	CETACORT			
AT	HEALTHPOINT	0.5%	**N80426 002**	
AT		1%	**N80426 001**	
	EPICORT			
AT	BLULINE	0.5%	**N83219 002**	
	HYDROCORTISONE			
AT	ALTANA	2.5%	**N40351 001**	
			JUL 25, 2000	
AT	TARO	2.5%	**N40247 001**	
			JUL 23, 1999	
	HYTONE			
AT	+ DERMIK LABS	1%	**N80473 003**	
AT	+	2.5%	**N80473 004**	
			NOV 30, 1982	
	NUTRACORT			
AT	HEALTHPOINT	1%	**N80443 003**	
AT		2.5%	**N87644 001**	
			AUG 24, 1982	
	STIE-CORT			
AT	STIEFEL	1%	**N89066 001**	
			NOV 25, 1985	
AT		2.5%	**N89074 001**	
			NOV 26, 1985	

OINTMENT; TOPICAL

	CORTRIL			
AT	+ PFIPHARMECS	1%	**N09176 001**	
AT	+	2.5%	**N09176 002**	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

OINTMENT; TOPICAL

	HYDROCORTISONE			
AT	ALPHARMA US PHARM	1%	**N87796 001**	
			OCT 13, 1982	
AT	ALTANA	1%	**N80489 003**	
AT		1%	**N80692 001**	
AT	CLAY PARK	2.5%	**N85027 001**	
AT	FOUGERA	2.5%	**N81203 001**	
			MAY 28, 1993	
AT	TARO	1%	**N86257 001**	
AT		2.5%	**N40310 001**	
			DEC 29, 2000	
	HYDROCORTISONE IN ABSORBASE			
AT	CAROLINA MEDCL	1%	**N88138 001**	
			SEP 06, 1985	

POWDER; FOR RX COMPOUNDING

	HYDROCORTISONE			
AA	PADDOCK	100%	**N88082 001**	
			APR 08, 1983	
AA	PHARMA TEK	100%	**N85982 001**	

SOLUTION; TOPICAL

	PENECORT			
AT	ALLERGAN HERBERT	1%	**N88214 001**	
			JUN 06, 1984	
	TEXACORT			
AT +	SIRIUS LABS	1%	**N80425 001**	
+		2.5%	N81271 001	
			APR 17, 1992	

TABLET; ORAL

	CORTEF			
BP	PHARMACIA AND UPJOHN	10MG	N08697 001	
BP +		20MG	N08697 002	
		5MG	N08697 003	
	HYDROCORTISONE			
BP	WEST WARD	20MG	N83365 001	
	HYDROCORTONE			
BP	MERCK	10MG	N08506 007	
BP +		20MG	N08506 011	

HYDROCORTISONE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; HYDROCORTISONE
SEE ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

	NEO-CORT-DOME			
+	BAYER	0.5%;EQ 3.5MG BASE/GM	N50237 006	
			JUN 05, 1984	
+		1%;EQ 3.5MG BASE/GM	N50237 005	
			JUN 05, 1984	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

	CORTISPORIN			
AT +	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N50479 001**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE			
AT	BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N64053 001**	
			DEC 29, 1995	

SUSPENSION/DROPS; OPHTHALMIC

	CORTISPORIN		
+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

SUSPENSION/DROPS; OTIC

	CORTISPORIN			
AT +	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N60613 001**	
	OTICAIR			
AT	BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N64065 001**	
			AUG 28, 1996	
	PEDIOTIC			
AT	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	**N62822 001**	
			SEP 29, 1987	

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

	OTOBIOTIC		
+	SCHERING	5MG/ML; EQ 10,000 UNITS BASE/ML	N62302 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL
CORTIFOAM
+ SCHWARZ PHARMA 10% N17351 001 FEB 10, 1982

CREAM; TOPICAL
HYDROCORTISONE ACETATE
+ FERNDALE LABS 2.5% N40259 001 JUL 29, 1999

MICORT-HC
+ FERNDALE LABS 2% N40398 001 MAR 29, 2002
2.5% N40396 001 FEB 27, 2001

LOTION; TOPICAL
DRICORT
+ INGRAM PHARM 0.5% N86207 001

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE
+ ALTANA 0.5% N80828 001

PASTE; TOPICAL
ORABASE HCA
COLGATE 0.5% N83205 001

POWDER; FOR RX COMPOUNDING
HYDROCORTISONE ACETATE
PHARMA TEK 100% N85981 001

HYDROCORTISONE ACETATE; *MULTIPLE*
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
CORTISPORIN
+ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50218 001 AUG 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
TERRA-CORTRIL
+ PFIZER 1.5%;EQ 5MG BASE/ML N61016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%
BX COPLEY PHARM 1%;1% N89440 001 MAY 17, 1988

PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

CREAM; TOPICAL
PRAMOSONE
FERNDALE LABS 0.5%;1% N83778 001
1%;1% N85368 001

LOTION; TOPICAL
PRAMOSONE
FERNDALE LABS 1%;1% N85980 001
2.5%;1% N85979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC
AT + KENWOOD LABS 1%;10% N80505 001
U-CORT
AT TARO 1%;10% N89472 001 JUN 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
+ FERNDALE LABS 0.1% N18514 001 MAR 31, 1982

LOCOID LIPOCREAM
+ FERNDALE LABS 0.1% N20769 001 SEP 08, 1997

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL
LOCOID
+ FERNDALE LABS 0.1% N18652 001
OCT 29, 1982

SOLUTION; TOPICAL
LOCOID
+ FERNDALE LABS 0.1% N19116 001
FEB 25, 1987

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL
CORTEF
+ PHARMACIA AND UPJOHN EQ 10MG BASE/5ML N09900 001

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL
PANDEL
+ SAVAGE LABS 0.1% N20453 001
FEB 28, 1997

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDROCORTONE
+ MERCK EQ 50MG BASE/ML N12052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT
AP ABBOTT **EQ 1GM BASE/VIAL** **N85932 001**
AP **EQ 100MG BASE/VIAL** **N85929 001**
AP **EQ 250MG BASE/VIAL** **N85930 001**
AP **EQ 500MG BASE/VIAL** **N85931 001**
HYDROCORTISONE SODIUM SUCCINATE
AP INTL MEDICATION **EQ 100MG BASE/VIAL** **N87532 001**
MAR 19, 1982
SOLU-CORTEF
AP + PHARMACIA AND UPJOHN **EQ 100MG BASE/VIAL** **N09866 001**
AP + **EQ 250MG BASE/VIAL** **N09866 002**

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
SOLU-CORTEF
AP + PHARMACIA AND UPJOHN **EQ 500MG BASE/VIAL** **N09866 003**
AP + **EQ 1GM BASE/VIAL** **N09866 004**

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE
AB CLAY PARK **0.2%** **N75666 001**
MAY 24, 2000
AB COPLEY PHARM **0.2%** **N74489 001**
AUG 12, 1998
AB TARO **0.2%** **N75042 001**
AUG 25, 1998
WESTCORT
AB + WESTWOOD SQUIBB **0.2%** **N17950 001**

OINTMENT; TOPICAL
HYDROCORTISONE VALERATE
AB ALTANA **0.2%** **N75085 001**
JUL 31, 2001
AB TARO **0.2%** **N75043 001**
AUG 25, 1998
WESTCORT
AB + WESTWOOD SQUIBB **0.2%** **N18726 001**
AUG 08, 1983

HYDROFLUMETHIAZIDE

TABLET; ORAL
DIUCARDIN
AB WYETH AYERST **50MG** **N83383 001**
HYDROFLUMETHIAZIDE
AB PAR PHARM **50MG** **N88850 001**
MAY 31, 1985
SALURON
AB + SHIRE LABS **50MG** **N11949 001**

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL
SALUTENSIN
+ SHIRE LABS 50MG;0.125MG N12359 003

FDA data supplied by DrugPatentWatch.com

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID-HP

AP	+ ABBOTT	10MG/ML	N19034 001	JAN 11, 1984
	+	250MG/VIAL	N19034 002	AUG 04, 1994

HYDROMORPHONE HCL

AP	ABBOTT	10MG/ML	N74598 001	JUN 19, 1997
AP	STERIS	10MG/ML	N74317 001	AUG 23, 1995

SOLUTION; ORAL

DILAUDID

AA	+ ABBOTT	5MG/5ML	N19891 001	DEC 07, 1992

HYDROMORPHONE HCL

AA	ROXANE	5MG/5ML	N74653 001	JUL 29, 1998

TABLET; ORAL

DILAUDID

AB	+ ABBOTT	8MG	N19892 001	DEC 07, 1992

HYDROMORPHONE HCL

AB	ROXANE	8MG	N74597 001	JUL 29, 1998

HYDROQUINONE; *MULTIPLE*

SEE FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

HYDROXOCOBALAMIN

	+ STERIS	1MG/ML	N85998 001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

	+ AKORN	1%;0.25%	N19261 001	JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	MYLAN	200MG	N40274 001	MAY 29, 1998

HYDROXYCHLOROQUINE SULFATE

AB	COPLEY PHARM	200MG	N40081 001	SEP 30, 1994
AB	GENEVA PHARMS	200MG	N40104 001	NOV 30, 1995
AB	GENEVA PHARMS TECH	200MG	N40150 001	JAN 27, 1996
AB	WATSON LABS	200MG	N40133 001	NOV 30, 1995

PLAQUENIL

AB	+ SANOFI SYNTHELABO	200MG	N09768 001	

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

	+ MERCK	5MG	N18771 001	

HYDROXYUREA

CAPSULE; ORAL

DROXIA

	BRISTOL MYERS SQUIBB	200MG	N16295 002	FEB 25, 1998
		300MG	N16295 003	FEB 25, 1998
	+	400MG	N16295 004	FEB 25, 1998

HYDREA

AB	+ BRISTOL MYERS SQUIBB	500MG	N16295 001	

HYDROXYUREA

AB	BARR	250MG	N75143 002	SEP 21, 2000
AB		500MG	N75143 001	OCT 16, 1998
AB	+ DURAMED PHARM BARR	250MG	N75020 002	JUN 26, 2000
AB		500MG	N75020 001	JUL 30, 1998
AB	PAR PHARM	500MG	N75340 001	FEB 24, 1999

FDA data supplied by DrugPatentWatch.com

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA			
AB	ROXANE	500MG	N74476 001	AUG 18, 1995

TABLET; ORAL

	HYDROXYUREA			
	+ BARR	1GM	N75734 001	AUG 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE			
AP	ELKINS SINN	50MG/ML	N85551 002	
	HYDROXYZINE HCL			
AP	ABBOTT	25MG/ML	N87416 001	
AP		50MG/ML	N87546 001	
AP	AM PHARM PARTNERS	25MG/ML	N87329 001	
AP		50MG/ML	N87329 002	
AP	ELKINS SINN	25MG/ML	N85551 001	
AP	LUITPOLD	25MG/ML	N87408 001	
AP		50MG/ML	N87408 002	
AP	STERIS	50MG/ML	N85779 001	
	VISTARIL			
AP	+ PFIZER	25MG/ML	N11111 001	
AP	+	50MG/ML	N11111 002	

SYRUP; ORAL

	ATARAX			
AA	+ ROERIG	10MG/5ML	N10485 001	
	HYDROXYZINE HCL			
AA	ALPHARMA	10MG/5ML	N86880 001	
AA	HI TECH PHARMA	10MG/5ML	N40010 001	OCT 28, 1994
AA	MORTON GROVE	10MG/5ML	N87294 001	APR 12, 1982
AA	VINTAGE PHARMS	10MG/5ML	N40391 001	APR 10, 2002

TABLET; ORAL

	ATARAX			
AB	+ ROERIG	10MG	N10392 001	
AB	+	25MG	N10392 004	
AB	+	50MG	N10392 006	
AB	+	100MG	N10392 005	

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
AB	GENEVA PHARMS	10MG	N87869 001	DEC 20, 1982
AB		25MG	N87870 001	DEC 20, 1982
AB		50MG	N87871 001	DEC 20, 1982
AB	MUTUAL PHARM	10MG	N89381 001	MAY 19, 1986
AB		25MG	N89382 001	MAY 19, 1986
AB		50MG	N89383 001	MAY 19, 1986
AB	SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986
AB		25MG	N88618 001	JAN 10, 1986
AB		50MG	N88619 001	JAN 10, 1986
AB		100MG	N81054 001	SEP 25, 1995
AB	WATSON LABS	10MG	N81149 001	MAR 18, 1994
AB		10MG	N88348 001	SEP 15, 1983
AB		25MG	N81150 001	MAR 18, 1994
AB		25MG	N88349 001	SEP 15, 1983
AB		50MG	N81151 001	MAR 18, 1994
AB		50MG	N88350 001	SEP 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	BARR	EQ 25MG HCL	N88496 001	JUN 15, 1984
AB		EQ 50MG HCL	N88487 001	JUN 15, 1984
AB		EQ 100MG HCL	N88488 001	JUN 15, 1984
AB	EON	EQ 25MG HCL	N87479 001	

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	EON	EQ 50MG HCL	**N86183 001**	
AB	GENEVA PHARMS	EQ 25MG HCL	**N81127 001**	JUN 28, 1991
AB	IVAX PHARMS	EQ 25MG HCL	**N87761 001**	MAR 05, 1982
AB		EQ 50MG HCL	**N87760 001**	MAR 05, 1982
AB	WATSON LABS	EQ 25MG HCL	**N40156 001**	JUL 15, 1996
AB		EQ 25MG HCL	**N81165 001**	JUL 31, 1991
AB		EQ 50MG HCL	**N40156 002**	JUL 15, 1996
	VISTARIL			
AB	PFIZER	EQ 25MG HCL	**N11459 002**	
AB	+	EQ 50MG HCL	**N11459 004**	
AB		EQ 100MG HCL	**N11459 006**	

SUSPENSION; ORAL

	VISTARIL		
	PFIZER	EQ 25MG HCL/5ML	N11795 001

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S ADVIL		
BX	WYETH CONS	100MG/5ML	N19833 002 SEP 19, 1989
	IBUPROFEN		
AB	ALPHARMA	100MG/5ML	**N74978 001** MAR 25, 1998
	MOTRIN		
AB	+ MCNEIL CONS SPECLT	100MG/5ML	**N19842 001** SEP 19, 1989

TABLET; ORAL

	IBU		
AB	BASF	400MG	**N18197 001**
AB		400MG	**N70083 001** FEB 22, 1985
AB		600MG	**N70099 001** MAR 29, 1985
AB		800MG	**N70745 001** JUL 23, 1986

IBUPROFEN

TABLET; ORAL

	IBU		
	BASF	600MG	N70088 001 FEB 08, 1985
	IBU-TAB		
AB	ALRA	400MG	**N71058 001** AUG 11, 1988
AB		600MG	**N71059 001** AUG 11, 1988
	IBUPROFEN		
AB	BASF	400MG	**N75682 001** NOV 14, 2001
AB		600MG	**N75682 002** NOV 14, 2001
AB		800MG	**N75682 003** NOV 14, 2001
AB	DR REDDYS LABS INC	400MG	**N76112 001** OCT 31, 2001
AB		600MG	**N76112 002** OCT 31, 2001
AB		800MG	**N76112 003** OCT 31, 2001
AB	GENEVA PHARMS	300MG	**N70734 001** JUN 12, 1986
AB		400MG	**N70735 001** JUN 12, 1986
AB		600MG	**N70736 001** JUN 12, 1986
AB		800MG	**N72169 001** DEC 11, 1987
AB	INTERPHARM	400MG	**N71334 001** NOV 25, 1986
AB		600MG	**N71335 001** NOV 25, 1986
AB		800MG	**N71935 001** OCT 13, 1987
AB	IVAX PHARMS	400MG	**N71145 001** SEP 23, 1986
AB		600MG	**N71146 001** SEP 23, 1986
AB		800MG	**N71769 001** MAY 08, 1987
AB	MUTUAL PHARM	300MG	**N71230 001** OCT 22, 1986
AB		400MG	**N71231 001** OCT 22, 1986

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	MUTUAL PHARM	600MG	N71232 001	OCT 22, 1986
AB		800MG	N72004 001	NOV 18, 1987
AB	MYLAN	400MG	N70045 001	SEP 24, 1985
AB		600MG	N70057 001	SEP 24, 1985
AB		800MG	N71999 001	DEC 03, 1987
AB	OHM LABS	400MG	N70818 001	DEC 26, 1985
AB	PAR PHARM	400MG	N70329 001	AUG 06, 1985
AB		600MG	N70330 001	AUG 06, 1985
AB		800MG	N70986 001	JUL 25, 1986
AB	PVT FORM	300MG	N71266 001	OCT 15, 1986
AB		400MG	N71267 001	OCT 15, 1986
AB		600MG	N71268 001	OCT 15, 1986
AB		800MG	N72300 001	JUL 01, 1988
AB	SIDMAK LABS NJ	400MG	N71666 001	JUN 18, 1987
AB		600MG	N71667 001	JUN 18, 1987
AB		800MG	N71668 001	JUN 18, 1987
AB	VINTAGE PHARMS	400MG	N71644 001	FEB 01, 1988
AB	WATSON LABS	400MG	N70436 001	AUG 21, 1985
AB		600MG	N70437 001	AUG 21, 1985
AB		800MG	N71547 001	JUL 02, 1987

IBUPROHM

AB	OHM LABS	400MG	N70469 001	AUG 29, 1985

MOTRIN

AB	MCNEIL CONS SPECLT	300MG	N17463 003	

IBUPROFEN

TABLET; ORAL

MOTRIN

AB	MCNEIL CONS SPECLT	400MG	N17463 002	
AB		600MG	N17463 004	
AB	+	800MG	N17463 005	MAY 22, 1985

IBUPROFEN; *MULTIPLE*

SEE HYDROCODONE BITARTRATE; IBUPROFEN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

+	PHARMACIA AND UPJOHN	0.1MG/ML	N20491 001	DEC 28, 1995

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+	BAXTER HLTHCARE	7.5GM/100ML	N21321 001	DEC 20, 2002

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

AP	+ PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997

IDARUBICIN HCL

AP	GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002
	+	10MG/VIAL	N65037 002	MAY 01, 2002
	+	20MG/VIAL	N65037 001	MAY 01, 2002

IDARUBICIN HCL PFS

AP	GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002

FDA data supplied by DrugPatentWatch.com

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

	DENDRID			
AT	+ ALCON	**0.1%**	**N14169 001**	
	HERPLEX			
AT	+ ALLERGAN	**0.1%**	**N13935 002**	

IFOSFAMIDE

INJECTABLE; INJECTION

	IFSOFAMIDE		
	+ AM PHARM PARTNERS	1GM/VIAL	N76078 001 MAY 28, 2002
	+	3GM/VIAL	N76078 002 MAY 28, 2002

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

	IFEX/MESNEX KIT		
	+ BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003 OCT 10, 1992
	+	3GM/VIAL;100MG/ML	N19763 004 OCT 10, 1992

INJECTABLE; INTRAVENOUS

	IFOSFAMIDE/MESNA KIT		
	+ GENSIA SICOR PHARMS	1GM /20ML(50MG/ML); 1GM /10ML(100MG/ML)	N75874 001 FEB 26, 2002
	+	3GM /60ML(50MG/ML); 1GM /10ML(100MG/ML)	N75874 002 FEB 26, 2002

IMATINIB MESYLATE

CAPSULE; ORAL

	GLEEVEC		
	NOVARTIS	50MG	N21335 001 MAY 10, 2001
	+	100MG	N21335 002 MAY 10, 2001

IMIGLUCERASE

INJECTABLE; INJECTION

	CEREZYME		
	GENZYME	200 UNITS/VIAL	N20367 001 MAY 23, 1994
	+	400 UNITS/VIAL	N20367 002 SEP 22, 1999

IMIPENEM; *MULTIPLE*
SEE CILASTATIN SODIUM; IMIPENEM

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

	IMIPRAMINE HCL		
	NOVARTIS	25MG/ML	N86765 001

TABLET; ORAL

	IMIPRAMINE HCL		
AB	GENEVA PHARMS	**10MG**	**N84936 002**
AB		**25MG**	**N83745 001**
AB		**50MG**	**N84937 001**
AB	MUTUAL PHARM	**10MG**	**N81048 001** JUN 05, 1990
AB		**25MG**	**N81049 001** JUN 05, 1990
AB		**50MG**	**N81050 001** JUN 05, 1990
AB	PAR PHARM	**10MG**	**N88292 001** OCT 21, 1983
AB		**10MG**	**N89422 001** JUL 14, 1987
AB		**25MG**	**N88262 001** OCT 21, 1983
AB		**25MG**	**N89497 001** JUL 14, 1987
AB		**50MG**	**N88276 001** OCT 21, 1983
AB	ROXANE	**10MG**	**N83799 001**
AB	TEVA	**10MG**	**N83729 001**
AB		**25MG**	**N83729 004**
AB		**50MG**	**N83729 003**
	TOFRANIL		
AB	TYCO HLTHCARE	**10MG**	**N87844 001** MAY 22, 1984

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	TOFRANIL			
AB	TYCO HLTHCARE	25MG	**N87845 001**	MAY 22, 1984
AB +		50MG	**N87846 001**	MAY 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

	TOFRANIL-PM			
	TYCO HLTHCARE	EQ 75MG HCL	N17090 001	
		EQ 100MG HCL	N17090 004	
		EQ 125MG HCL	N17090 003	
+		EQ 150MG HCL	N17090 002	

IMIQUIMOD

CREAM; TOPICAL

	ALDARA			
+	3M	5%	N20723 001	FEB 27, 1997

INAMRINONE LACTATE

INJECTABLE; INJECTION

	AMRINONE			
AP	+ ABBOTT	EQ 5MG BASE/ML	**N74616 001**	AUG 03, 1998
AP	BEDFORD	EQ 5MG BASE/ML	**N75513 001**	MAY 09, 2000
	AMRINONE LACTATE			
AP	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	**N75542 001**	MAY 10, 2000

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	ALPHAPHARM	1.25MG	**N75105 001**	JUL 23, 1998
AB		2.5MG	**N75105 002**	JUL 23, 1998

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	GENEVA PHARMS TECH	1.25MG	**N74594 001**	MAY 23, 1996
AB		2.5MG	**N74594 002**	MAY 23, 1996
AB	IVAX PHARMS	1.25MG	**N74299 002**	APR 29, 1996
AB		2.5MG	**N74299 001**	JUL 27, 1995
AB	MYLAN	1.25MG	**N74461 002**	MAR 26, 1997
AB		2.5MG	**N74461 001**	MAR 27, 1996
AB	PUREPAC PHARM	1.25MG	**N74722 001**	JUN 17, 1996
AB		2.5MG	**N74722 002**	JUN 17, 1996
AB	TEVA	1.25MG	**N74498 002**	FEB 12, 1998
AB		2.5MG	**N74498 001**	OCT 31, 1996
AB	TRIGEN	1.25MG	**N75201 001**	DEC 04, 1998
AB		2.5MG	**N75201 002**	DEC 04, 1998
AB	WATSON LABS	1.25MG	**N74585 001**	SEP 26, 1996
AB		2.5MG	**N74585 002**	SEP 26, 1996
	LOZOL			
AB	AVENTIS	1.25MG	**N18538 002**	APR 29, 1993
AB +		2.5MG	**N18538 001**	JUL 06, 1983

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN			
MERCK	EQ 100MG BASE	N20685 006	APR 19, 2000
	EQ 200MG BASE	N20685 003	MAR 13, 1996
	EQ 333MG BASE	N20685 005	DEC 17, 1998

FDA data supplied by DrugPatentWatch.com

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN				
+ MERCK	EQ 400MG BASE	N20685 001 MAR 13, 1996		

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE				
AMERSHAM HLTH	1mCi/ML	N19044 001 DEC 24, 1985		

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111				
AMERSHAM HLTH	1mCi/ML	N17707 001 FEB 18, 1982		

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN				
MALLINCKRODT	3mCi/ML	N20314 001 JUN 02, 1994		

INDOCYANINE GREEN

INJECTABLE; INJECTION

CARDIO-GREEN				
+ AKORN	25MG/VIAL	N11525 001		

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON				
AB TEVA	**25MG**	**N70266 001** NOV 07, 1985		
AB	**50MG**	**N70267 001** NOV 07, 1985		
INDOCIN				
AB MERCK	**25MG**	**N16059 001**		

INDOMETHACIN

CAPSULE; ORAL

INDOCIN				
AB + MERCK	**50MG**	**N16059 002**		
INDOMETHACIN				
AB GENEVA PHARMS	**25MG**	**N70673 001** APR 29, 1987		
AB	**50MG**	**N70674 001** APR 29, 1987		
AB IVAX PHARMS	**25MG**	**N70719 001** FEB 12, 1986		
AB	**50MG**	**N70756 001** FEB 12, 1986		
AB LEDERLE	**25MG**	**N18851 001** MAY 18, 1984		
AB	**50MG**	**N18851 002** MAY 18, 1984		
AB MUTUAL PHARM	**25MG**	**N70899 001** FEB 09, 1987		
AB	**50MG**	**N70900 001** FEB 09, 1987		
AB MYLAN	**25MG**	**N18858 001** APR 20, 1984		
AB	**50MG**	**N18858 002** APR 20, 1984		
AB	**50MG**	**N70624 001** SEP 04, 1985		
AB PAR PHARM	**25MG**	**N18829 002** AUG 06, 1984		
AB	**50MG**	**N18829 001** AUG 06, 1984		
AB	**50MG**	**N70651 001** MAR 05, 1986		
AB SIDMAK LABS NJ	**25MG**	**N71148 001** MAR 18, 1987		
AB	**50MG**	**N71149 001** MAR 18, 1987		
AB TEVA	**25MG**	**N71342 001** APR 18, 1988		
AB	**50MG**	**N71343 001** APR 18, 1988		

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR				
AB + EON	**75MG**	**N74464 001** MAY 28, 1998		
INDOMETHACIN				
AB ABLE	**75MG**	**N76114 001** FEB 06, 2002		

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

	INDOMETHACIN			
AB	INWOOD LABS	**75MG**	**N72410 001**	MAR 15, 1989

SUPPOSITORY; RECTAL

	INDOMETHEGAN			
+	G AND W LABS	50MG	N73314 001	AUG 31, 1992

SUSPENSION; ORAL

	INDOCIN			
AB	+ MERCK	**25MG/5ML**	**N18332 001**	OCT 10, 1985
	INDOMETHACIN			
AB	ROXANE	**25MG/5ML**	**N71412 001**	MAR 18, 1987

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

	INDOCIN I.V.			
+	MERCK	EQ 1MG BASE/VIAL	N18878 001	JAN 30, 1985

INSULIN ASPART

INJECTABLE; SUBCUTANEOUS

	NOVOLOG			
+	NOVO NORDISK	100 UNITS/ML	N20986 001	JUN 07, 2000

INSULIN ASPART; INSULIN ASPART PROTAMINE

INJECTABLE; SUBCUTANEOUS

	NOVOLOG MIX 70/30			
+	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N21172 001	NOV 01, 2001

INSULIN ASPART PROTAMINE; *MULTIPLE*
SEE INSULIN ASPART; INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INJECTABLE; INJECTION

	LANTUS			
+	AVENTIS PHARMS	100 UNITS/ML	N21081 001	APR 20, 2000

INSULIN LISPRO

INJECTABLE; INJECTION

	HUMALOG			
+	LILLY	100 UNITS/ML	N20563 001	JUN 14, 1996
	HUMALOG PEN			
+	LILLY	100 UNITS/ML	N20563 002	AUG 06, 1998

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION

	HUMALOG MIX 50/50			
+	LILLY	50 UNITS/ML;50 UNITS/ML	N21018 001	DEC 22, 1999
	HUMALOG MIX 75/25			
+	LILLY	25 UNITS/ML;75 UNITS/ML	N21017 001	DEC 22, 1999

INSULIN LISPRO PROTAMINE; *MULTIPLE*
SEE INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

	ILETIN II			
+	LILLY	500 UNITS/ML	N18344 002	

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

	HUMULIN R			
+	LILLY	500 UNITS/ML	N18780 004	MAR 31, 1994

FDA data supplied by DrugPatentWatch.com

INTRINSIC FACTOR; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
+ QUESTCOR PHARMS 100MG/ML N02282 001

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131
CIS 2.3mCi/ML N20084 001 MAR 25, 1994

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE
+ BRACCO 52% N09321 003

IODIPAMIDE MEGLUMINE; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
+ AMERSHAM HLTH 55% N20351 001 MAR 22, 1996

VISIPAQUE 320
+ AMERSHAM HLTH 65.2% N20351 002 MAR 22, 1996

IOHEXOL

INJECTABLE; INJECTION
OMNIPAQUE 140
+ AMERSHAM HLTH 30.2% N18956 005 NOV 30, 1988

IOHEXOL

SOLUTION; INJECTION, ORAL
OMNIPAQUE 350
+ AMERSHAM HLTH 75.5% N18956 004 DEC 26, 1985
75.5% N20608 003 OCT 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180
+ AMERSHAM HLTH 38.8% N18956 001 DEC 26, 1985

OMNIPAQUE 240
+ AMERSHAM HLTH 51.8% N18956 002 DEC 26, 1985
51.8% N20608 001 OCT 24, 1995

OMNIPAQUE 300
+ AMERSHAM HLTH 64.7% N18956 003 DEC 26, 1985
64.7% N20608 002 OCT 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL
AP ELKINS SINN PHARM **41%** **N74629 001** NOV 06, 1996
AP **51%** **N74629 004** MAR 31, 1998
AP **61%** **N74629 002** NOV 06, 1996
AP **76%** **N74629 003** NOV 06, 1996

IOPAMIDOL-200
AP ABBOTT **41%** **N74898 001** DEC 30, 1997
AP COOK IMAGING **41%** **N74881 001** JUL 28, 2000

IOPAMIDOL-200 IN PLASTIC CONTAINER
AP ABBOTT **41%** **N74636 001** DEC 30, 1997

IOPAMIDOL-250
AP ABBOTT **51%** **N74898 002** DEC 30, 1997

FDA data supplied by DrugPatentWatch.com

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL-250			
AP	ABBOTT	51%	**N75005 001**	
			FEB 24, 1998	
AP	AM PHARM PARTNERS	51%	**N74679 001**	
			APR 02, 1997	
AP	COOK IMAGING	51%	**N74881 002**	
			JUL 28, 2000	
	IOPAMIDOL-250 IN PLASTIC CONTAINER			
AP	ABBOTT	51%	**N74636 002**	
			DEC 30, 1997	
	IOPAMIDOL-300			
AP	ABBOTT	61%	**N74898 003**	
			DEC 30, 1997	
AP		61%	**N75005 002**	
			FEB 24, 1998	
AP	AM PHARM PARTNERS	61%	**N74679 002**	
			APR 02, 1997	
AP	COOK IMAGING	61%	**N74881 003**	
			JUL 28, 2000	
	IOPAMIDOL-300 IN PLASTIC CONTAINER			
AP	ABBOTT	61%	**N74636 003**	
			DEC 30, 1997	
AP		61%	**N74637 001**	
			APR 03, 1997	
	IOPAMIDOL-370			
AP	ABBOTT	76%	**N74898 004**	
			DEC 30, 1997	
AP		76%	**N75005 003**	
			FEB 24, 1998	
AP	AM PHARM PARTNERS	76%	**N74679 003**	
			APR 02, 1997	
AP	COOK IMAGING	76%	**N74881 004**	
			JUL 28, 2000	
	IOPAMIDOL-370 IN PLASTIC CONTAINER			
AP	ABBOTT	76%	**N74636 004**	
			DEC 30, 1997	
	ISOVUE-200			
AP	+ BRACCO	41%	**N18735 006**	
			JUL 07, 1987	
	ISOVUE-250			
AP	+ BRACCO	51%	**N18735 007**	
			JUL 06, 1992	
AP	+	51%	**N20327 002**	
			OCT 12, 1994	
	ISOVUE-300			
AP	+ BRACCO	61%	**N18735 002**	
			DEC 31, 1985	

IOPAMIDOL

INJECTABLE; INJECTION

	ISOVUE-300			
AP	+ BRACCO	61%	**N20327 003**	
			OCT 12, 1994	
	ISOVUE-370			
AP	+ BRACCO	76%	**N18735 003**	
			DEC 31, 1985	
AP	+	76%	**N20327 004**	
			OCT 12, 1994	
	ISOVUE-M 200			
	+ BRACCO	41%	N18735 001	
			DEC 31, 1985	
	ISOVUE-M 300			
	+ BRACCO	61%	N18735 004	
			DEC 31, 1985	

IOPANOIC ACID

TABLET; ORAL

	TELEPAQUE		
	+ AMERSHAM HLTH	500MG	N08032 001

IOPROMIDE

INJECTABLE; INJECTION

	ULTRAVIST (PHARMACY BULK)		
	+ BERLEX LABS	300MG/ML	N21425 001
			SEP 20, 2002
	+	370MG/ML	N21425 002
			SEP 20, 2002
	ULTRAVIST 150		
	+ BERLEX LABS	31.2%	N20220 004
			MAY 10, 1995
	ULTRAVIST 240		
	+ BERLEX LABS	49.9%	N20220 003
			MAY 10, 1995
	ULTRAVIST 300		
	+ BERLEX LABS	62.3%	N20220 002
			MAY 10, 1995
	ULTRAVIST 370		
	+ BERLEX LABS	76.9%	N20220 001
			MAY 10, 1995

FDA data supplied by DrugPatentWatch.com

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY
+ MALLINCKRODT 60% N13295 001
CONRAY 30
+ MALLINCKRODT 30% N16983 001
CONRAY 43
+ MALLINCKRODT 43% N13295 002

SOLUTION; INTRAVESICAL
CYSTO-CONRAY II
MALLINCKRODT 17.2% N17057 002

SOLUTION; INTRAVESICAL, URETERAL
CYSTO-CONRAY
MALLINCKRODT 43% N17057 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION
VASCORAY
+ MALLINCKRODT 52%;26% N16783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
CONRAY 400
+ MALLINCKRODT 66.8% N14295 001

IOTHALAMATE SODIUM; *MULTIPLE*
SEE IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
QUESTCOR PHARMS 250-300 uCi/ML N17279 001

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 160
+ MALLINCKRODT 34% N19710 003
DEC 30, 1988

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 240
+ MALLINCKRODT 51% N19710 002
DEC 30, 1988
+ 51% N20923 001
MAY 28, 1998

OPTIRAY 300
+ MALLINCKRODT 64% N19710 004
JAN 22, 1992

OPTIRAY 320
+ MALLINCKRODT 68% N19710 001
DEC 30, 1988
+ 68% N20923 002
MAY 29, 1998

OPTIRAY 350
+ MALLINCKRODT 74% N19710 005
JAN 22, 1992
+ 74% N20923 003
MAY 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION
HEXABRIX
+ MALLINCKRODT 39.3%;19.6% N18905 002
JUL 26, 1985

IOXAGLATE SODIUM; *MULTIPLE*
SEE IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

IOXILAN

INJECTABLE; INJECTION
OXILAN-300
GUERBET 62% N20316 001
DEC 21, 1995

OXILAN-350
GUERBET 73% N20316 002
DEC 21, 1995

FDA data supplied by DrugPatentWatch.com

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT
+ BOEHRINGER INGELHEIM 0.018MG/INH N19085 001 DEC 29, 1986

SOLUTION; INHALATION
ATROVENT
AN + BOEHRINGER INGELHEIM **0.02%** **N20228 001** SEP 29, 1993

IPATROPIUM BROMIDE
AN ROXANE **0.02%** **N75867 001** JUL 22, 2002

IPRATROPIUM BROMIDE
AN ALPHARMA **0.02%** **N75111 001** APR 22, 1999
AN ASLUNG PHARM **0.02%** **N75693 001** JAN 26, 2001
AN BAUSCH AND LOMB **0.02%** **N75835 001** OCT 15, 2001
AN DEY **0.02%** **N74755 001** JAN 10, 1997
AN IVAX PHARMS **0.02%** **N75313 001** FEB 07, 2000
AN NEPHRON **0.02%** **N75562 001** SEP 27, 2001
AN NOVEX **0.02%** **N75441 001** MAR 28, 2001
AN WARRICK PHARMS **0.02%** **N75507 001** JAN 19, 2001

SPRAY, METERED; NASAL
ATROVENT
+ BOEHRINGER INGELHEIM 0.021MG/SPRAY N20393 001 OCT 20, 1995
+ 0.042MG/SPRAY N20394 001 OCT 20, 1995

IPRATROPIUM BROMIDE; *MULTIPLE*
SEE ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

IRBESARTAN

TABLET; ORAL
AVAPRO
SANOFI SYNTHELABO 75MG N20757 001 SEP 30, 1997

IRBESARTAN

TABLET; ORAL
AVAPRO
SANOFI SYNTHELABO 150MG N20757 002 SEP 30, 1997
+ 300MG N20757 003 SEP 30, 1997

IRBESARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; IRBESARTAN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR
+ PHARMACIA AND UPJOHN 20MG/ML N20571 001 JUN 14, 1996

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
BP LUITPOLD EQ 50MG IRON/ML N40024 001 FEB 23, 1996
INFED
BP + SCHEIN EQ 50MG IRON/ML N17441 001
PROFERDEX
BP NEW RIVER EQ 50MG IRON/ML N17807 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER
+ LUITPOLD EQ 20MG BASE/ML N21135 001 NOV 06, 2000

ISOCARBOXAZID

TABLET; ORAL
MARPLAN
+ OXFORD PHARM 10MG N11961 001

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	BETA-2			
AN	NEPHRON	1%	**N86711 001**	
	ISOETHARINE HCL			
	DEY	0.1%	N87389 001	
	INTL MEDICATION	0.08%	N86651 002	
		0.143%	N86651 004	
AN	+ ROXANE	1%	**N86899 001**	
	+	0.167%	N88226 001	
			SEP 16, 1983	
	+	0.2%	N87324 001	

ISOFLURANE

LIQUID; INHALATION

	FORANE			
AN	+ BAXTER HLTHCARE CORP	99.9%	**N17624 001**	
	ISOFLURANE			
AN	ABBOTT	99.9%	**N74097 001**	
			JAN 25, 1993	
AN	HALOCARBON PRODS	99.9%	**N75225 001**	
			OCT 20, 1999	
AN	MARSAM PHARMS LLC	99.9%	**N74393 001**	
			MAY 12, 1995	
AN	MINRAD	99.9%	**N74416 001**	
			SEP 30, 1994	
AN	RHODIA	99.9%	**N74502 001**	
			JUN 27, 1995	

ISONIAZID

INJECTABLE; INJECTION

	NYDRAZID			
	+ APOTHECON	100MG/ML	N08662 001	

SYRUP; ORAL

	ISONIAZID			
	+ CAROLINA MEDCL	50MG/5ML	N88235 001	
			NOV 10, 1983	

TABLET; ORAL

	ISONIAZID			
AA	BARR	100MG	**N80936 001**	
AA		300MG	**N80937 002**	

ISONIAZID

TABLET; ORAL

	ISONIAZID			
AA	DURAMED PHARM BARR	300MG	**N88119 001**	
			MAR 17, 1983	
AA	+ EON	100MG	**N08678 002**	
AA	+	300MG	**N08678 003**	
AA	HALSEY	300MG	**N83633 001**	
AA	MIKART	100MG	**N40090 001**	
			JUN 26, 1997	
AA		300MG	**N40090 002**	
			JUN 26, 1997	
AA	WATSON LABS	300MG	**N80521 001**	
AA	WEST WARD	100MG	**N80212 001**	
AA		300MG	**N87425 001**	
	LANIAZID			
AA	LANNETT	100MG	**N80140 002**	
AA		300MG	**N89776 001**	
			JUN 13, 1988	
		50MG	N80140 001	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER			
+ AVENTIS PHARMS	50MG;300MG;120MG	N50705 001	
		MAY 31, 1994	

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE			
+ AVENTIS PHARMS	150MG;300MG	N61884 001	

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

	ISOPROTERENOL HCL			
AP	ABBOTT	0.2MG/ML	**N83346 001**	
		0.02MG/ML	N83283 001	
AP	ELKINS SINN	0.2MG/ML	**N83486 001**	
AP	INTL MEDICATION	0.2MG/ML	**N83724 001**	
	ISUPREL			
AP	+ ABBOTT	0.2MG/ML	**N10515 001**	

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

	DILATRATE-SR			
BC	SCHWARZ PHARMA	40MG	N19790 001	SEP 02, 1988
	ISORDIL			
BC	+ WYETH AYERST	40MG	N12882 002	JUL 29, 1988

TABLET; ORAL

	ISORDIL			
AB	WYETH AYERST	**5MG**	**N12093 007**	JUL 29, 1988
AB		**10MG**	**N12093 002**	JUL 29, 1988
AB		**20MG**	**N12093 006**	JUL 29, 1988
AB	+	**30MG**	**N12093 005**	JUL 29, 1988
AB		**40MG**	**N12093 001**	JUL 29, 1988
	ISOSORBIDE DINITRATE			
AB	GENEVA PHARMS	**5MG**	**N86221 001**	JAN 07, 1988
AB		**10MG**	**N86223 001**	JAN 07, 1988
AB		**20MG**	**N89367 001**	APR 07, 1988
AB	PAR PHARM	**5MG**	**N86923 001**	MAR 12, 1987
AB		**10MG**	**N86925 001**	MAR 12, 1987
AB		**20MG**	**N87537 001**	OCT 02, 1987
AB		**30MG**	**N87946 001**	JAN 12, 1988
AB	WATSON LABS	**5MG**	**N86034 001**	JAN 06, 1988
AB		**10MG**	**N86032 001**	JAN 07, 1988
AB	WEST WARD	**5MG**	**N86067 001**	OCT 29, 1987
AB		**10MG**	**N86066 001**	OCT 29, 1987
AB		**20MG**	**N88088 001**	NOV 02, 1987
	SORBITRATE			
AB	ASTRAZENECA	**20MG**	**N86405 002**	AUG 21, 1990

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE			
AB	ASTRAZENECA	**40MG**	**N88125 001**	AUG 21, 1990

TABLET; SUBLINGUAL

	ISORDIL			
AB	WYETH AYERST	**2.5MG**	**N12940 004**	JUL 29, 1988
AB		**5MG**	**N12940 003**	JUL 29, 1988
	+	10MG	N12940 005	JUL 29, 1988
	ISOSORBIDE DINITRATE			
AB	GENEVA PHARMS	**2.5MG**	**N86225 001**	FEB 19, 1988
AB		**5MG**	**N86222 001**	FEB 19, 1988
AB	WATSON LABS	**2.5MG**	**N86033 001**	FEB 26, 1988
AB		**5MG**	**N86031 001**	SEP 29, 1987
AB	WEST WARD	**2.5MG**	**N86054 001**	OCT 29, 1987
AB		**5MG**	**N86055 001**	NOV 02, 1987

TABLET, CHEWABLE; ORAL

	SORBITRATE			
	+ ASTRAZENECA	10MG	N16776 003	APR 01, 1996

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE DINITRATE			
	+ INWOOD LABS	40MG	N40009 001	DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO			
AB	ESP PHARMA	**20MG**	**N19091 001**	DEC 30, 1991
	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	**10MG**	**N75037 002**	OCT 30, 1998

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	20MG	**N75037 001**	OCT 30, 1998
AB	TEVA	20MG	**N75147 001**	NOV 27, 1998
AB	WEST WARD	20MG	**N75361 001**	OCT 05, 2000
	MONOKET			
AB	SCHWARZ	10MG	**N20215 002**	JUN 30, 1993
AB +		20MG	**N20215 001**	JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL

	IMDUR			
AB +	SCHERING	30MG	**N20225 001**	AUG 12, 1993
AB +		60MG	**N20225 002**	AUG 12, 1993
AB +		120MG	**N20225 003**	MAR 30, 1995
	ISOSORBIDE MONONITRATE			
AB	BRIGHTSTONE	60MG	**N75166 001**	OCT 07, 1999
AB	DEXCEL LTD	60MG	**N75522 001**	APR 17, 2000
AB	ELAN PHARM	60MG	**N75041 001**	SEP 22, 1998
AB	IVAX PHARMS	30MG	**N75448 002**	AUG 07, 2001
AB		60MG	**N75448 001**	JUN 19, 2000
AB		120MG	**N75448 003**	AUG 07, 2001
AB	KREMERS URBAN	30MG	**N75155 002**	JAN 13, 2000
AB		60MG	**N75155 001**	OCT 30, 1998
AB		120MG	**N75155 003**	AUG 04, 2000
AB	KV PHARM	30MG	**N75395 001**	MAR 16, 2000
AB		60MG	**N75395 002**	MAR 16, 2000
AB		120MG	**N75395 003**	MAR 16, 2000

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	30MG	**N75306 001**	DEC 31, 1998
AB		60MG	**N75306 002**	DEC 31, 1998

ISOSULFAN BLUE

INJECTABLE; INJECTION

	LYMPHAZURIN		
+	US SURGCL	1%	N18310 001

ISOTRETINOIN

CAPSULE; ORAL

	ACCUTANE			
AB	HLR	10MG	**N18662 002**	MAY 07, 1982
AB +		20MG	**N18662 004**	MAR 28, 1983
AB +		40MG	**N18662 003**	MAY 07, 1982
	AMNESTEEM			
AB	GENPHARM	10MG	**N75945 001**	NOV 08, 2002
AB		20MG	**N75945 002**	NOV 08, 2002
AB		40MG	**N75945 003**	NOV 08, 2002
	ISOTRETINOIN			
AB	RANBAXY	10MG	**N76041 001**	DEC 24, 2002
AB		20MG	**N76041 002**	DEC 24, 2002
AB		40MG	**N76041 003**	DEC 24, 2002

ISRADIPINE

CAPSULE; ORAL

	DYNACIRC		
	NOVARTIS	2.5MG	N19546 001 DEC 20, 1990

FDA data supplied by DrugPatentWatch.com

ISRADIPINE

CAPSULE; ORAL
DYNACIRC
+ NOVARTIS 5MG N19546 002 DEC 20, 1990

TABLET, EXTENDED RELEASE; ORAL
DYNACIRC CR
+ NOVARTIS 5MG N20336 001 JUN 01, 1994
+ 10MG N20336 002 JUN 01, 1994

ITRACONAZOLE

CAPSULE; ORAL
SPORANOX
+ JANSSEN PHARMA 100MG N20083 001 SEP 11, 1992

INJECTABLE; INJECTION
SPORANOX
+ JANSSEN PHARMA 10MG/ML N20966 001 MAR 30, 1999

SOLUTION; ORAL
SPORANOX
+ JANSSEN PHARMA 10MG/ML N20657 001 FEB 21, 1997

IVERMECTIN

TABLET; ORAL
STROMECTOL
MERCK 3MG N50742 002 OCT 08, 1998
+ 6MG N50742 001 NOV 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
+ APOTHECON EQ 500MG BASE N62726 001 MAR 06, 1987

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN
AP AM PHARM PARTNERS **EQ 500MG BASE/2ML** **N65111 001** DEC 17, 2002
AP **EQ 1GM BASE/3ML** **N65111 002** DEC 17, 2002

KANTREX
AP + APOTHECON **EQ 500MG BASE/2ML** **N61901 001**
AP + **EQ 1GM BASE/3ML** **N61901 002**
+ EQ 75MG BASE/2ML N61901 003

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR
AP + PARKEDALE **EQ 50MG BASE/ML** **N16812 002**
AP + **EQ 100MG BASE/ML** **N16812 003**
+ EQ 10MG BASE/ML N16812 001

KETAMINE HCL
AP ABBOTT **EQ 50MG BASE/ML** **N74549 001** JUN 27, 1996
AP **EQ 100MG BASE/ML** **N74549 002** JUN 27, 1996
AP BEDFORD **EQ 50MG BASE/ML** **N74524 001** MAR 22, 1996
AP **EQ 100MG BASE/ML** **N74524 002** MAR 22, 1996
AP BIONICHE (CANADA) **EQ 50MG BASE/ML** **N76092 002** DEC 28, 2001
AP **EQ 100MG BASE/ML** **N76092 003** OCT 25, 2002

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE
AB TEVA **2%** **N75581 001** APR 25, 2000

KETOZOLE
AB TARO **2%** **N75638 001** DEC 18, 2002

NIZORAL
AB + JANSSEN PHARMA **2%** **N19084 001** DEC 31, 1985

FDA data supplied by DrugPatentWatch.com

KETOCONAZOLE

SHAMPOO; TOPICAL

	NIZORAL			
+	MCNEIL CONS SPECLT	2%	N19927 001	AUG 31, 1990

TABLET; ORAL

	KETOCONAZOLE			
AB	MUTUAL PHARMA	200MG	**N75314 001**	JUN 15, 1999
AB	MYLAN	200MG	**N75597 001**	DEC 23, 1999
AB	NEOSAN PHARMS	200MG	**N75341 001**	JUL 27, 1999
AB	SIDMAK LABS	200MG	**N75362 001**	JUN 15, 1999
AB	TARO	200MG	**N75319 001**	JUN 15, 1999
AB	TEVA	200MG	**N74971 001**	JUN 15, 1999
AB		200MG	**N75273 001**	JUN 15, 1999
AB	TORPHARM	200MG	**N75912 001**	JAN 10, 2002
	NIZORAL			
AB +	JANSSEN	200MG	**N18533 001**	

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN			
AB	GENEVA PHARMS	50MG	**N74024 001**	DEC 29, 1995
AB		75MG	**N74024 002**	DEC 29, 1995
AB	LEDERLE	25MG	**N74014 001**	JAN 29, 1993
AB		50MG	**N74014 002**	JAN 29, 1993
AB		75MG	**N74014 003**	JAN 29, 1993
AB	MYLAN	50MG	**N74035 002**	DEC 31, 1996
AB		75MG	**N74035 003**	DEC 31, 1996
AB	TEVA	25MG	**N73515 001**	DEC 22, 1992

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN			
AB	TEVA	50MG	**N73516 001**	DEC 22, 1992
AB		75MG	**N73517 001**	DEC 22, 1992
	ORUDIS			
AB	WYETH AYERST	25MG	**N18754 001**	JUL 31, 1987
AB		50MG	**N18754 002**	JAN 09, 1986
AB +		75MG	**N18754 003**	JAN 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	100MG	**N75270 002**	MAR 24, 1999
AB		150MG	**N75270 003**	MAR 24, 1999
AB		200MG	**N75270 001**	MAR 24, 1999
AB	ELAN PHARM	200MG	**N74879 001**	DEC 10, 1997
AB	MYLAN	100MG	**N75679 003**	FEB 20, 2002
AB		150MG	**N75679 002**	FEB 20, 2002
AB		200MG	**N75679 001**	FEB 20, 2002
	ORUVAIL			
AB	WYETH AYERST	100MG	**N19816 003**	FEB 08, 1995
AB		150MG	**N19816 002**	FEB 08, 1995
AB +		200MG	**N19816 001**	SEP 24, 1993

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	15MG/ML	**N74801 001**	JUN 05, 1997
AP		15MG/ML	**N74802 001**	JUN 05, 1997

FDA data supplied by DrugPatentWatch.com

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	15MG/ML	**N74993 001**	JAN 27, 1999
AP		30MG/ML	**N74801 002**	JUN 05, 1997
AP		30MG/ML	**N74802 002**	JUN 05, 1997
AP		30MG/ML	**N74993 002**	JAN 27, 1999
AP	AM PHARM PARTNERS	15MG/ML	**N75784 001**	JAN 11, 2002
AP		30MG/ML	**N75784 002**	JAN 11, 2002
AP	APOTEX	15MG/ML	**N75631 002**	JUN 29, 2001
AP		30MG/ML	**N75626 001**	JUL 24, 2001
AP		30MG/ML	**N75631 001**	JUN 29, 2001
AP	BAXTER HLTHCARE CORP	15MG/ML	**N75299 001**	NOV 03, 1999
AP		30MG/ML	**N75299 002**	NOV 03, 1999
AP	BEDFORD	15MG/ML	**N75222 001**	APR 26, 1999
AP		30MG/ML	**N75222 002**	APR 26, 1999
AP		30MG/ML	**N75228 001**	APR 26, 1999
	TORADOL			
AP	+ SYNTEX (USA) INC LLC	15MG/ML	**N19698 001**	NOV 30, 1989
AP	+	30MG/ML	**N19698 002**	NOV 30, 1989

SOLUTION/DROPS; OPHTHALMIC

	ACULAR		
+	ALLERGAN	0.5%	N19700 001 NOV 09, 1992
	ACULAR PRESERVATIVE FREE		
+	ALLERGAN	0.5%	N20811 001 NOV 03, 1997

TABLET; ORAL

	KETOROLAC TROMETHAMINE			
AB	MYLAN	10MG	**N74761 001**	MAY 16, 1997
AB	SIDMAK LABS	10MG	**N75284 001**	JUN 23, 1999
AB	TEVA	10MG	**N74754 001**	MAY 16, 1997
AB	WATSON LABS	10MG	**N74955 001**	SEP 19, 1997
	TORADOL			
AB	+ SYNTEX (USA) INC LLC	10MG	**N19645 001**	DEC 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

	ZADITOR		
+	NOVARTIS	EQ 0.025% BASE	N21066 001 JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	LABETALOL HCL			
AP	ABBOTT	5MG/ML	**N75239 001**	NOV 29, 1999
AP		5MG/ML	**N75240 001**	NOV 29, 1999
AP	APOTEX	5MG/ML	**N76051 001**	JUL 05, 2002
AP	BEDFORD	5MG/ML	**N75303 001**	MAY 28, 1999
AP	FAULDING	5MG/ML	**N75242 001**	SEP 30, 1999
AP	TAYLOR	5MG/ML	**N75431 001**	NOV 29, 1999
AP		5MG/ML	**N75524 001**	NOV 29, 1999
	NORMODYNE			
AP	+ SCHERING	5MG/ML	**N18686 001**	AUG 01, 1984
	TRANDATE			
AP	+ PROMETHEUS LABS	5MG/ML	**N19425 001**	DEC 31, 1985

FDA data supplied by DrugPatentWatch.com

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	LABETALOL HCL			
AB	APOTHECON	100MG	N75223 001	NOV 20, 1998
AB		200MG	N75223 002	NOV 20, 1998
AB		300MG	N75223 003	NOV 20, 1998
AB	EON	100MG	N75113 001	AUG 04, 1998
AB		200MG	N75113 002	AUG 04, 1998
AB		300MG	N75113 003	AUG 04, 1998
AB	IVAX PHARMS	100MG	N74787 001	AUG 03, 1998
AB		200MG	N74787 002	AUG 03, 1998
AB		300MG	N74787 003	AUG 03, 1998
AB	MUTUAL PHARM	100MG	N75215 001	JUL 29, 1999
AB		200MG	N75215 002	JUL 29, 1999
AB		300MG	N75215 003	JUL 29, 1999
AB	TEVA	100MG	N74989 001	SEP 30, 1998
AB		200MG	N74989 002	SEP 30, 1998
AB		300MG	N74989 003	SEP 30, 1998
AB	WATSON LABS	100MG	N75133 001	AUG 03, 1998
AB		200MG	N75133 002	AUG 03, 1998
AB		300MG	N75133 003	AUG 03, 1998
	NORMODYNE			
AB	SCHERING	100MG	N18687 001	AUG 31, 1987
AB		200MG	N18687 002	AUG 01, 1984
AB	+	300MG	N18687 003	AUG 01, 1984
	TRANDATE			
AB	PROMETHEUS LABS	100MG	N18716 001	MAY 24, 1985

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	TRANDATE			
AB	PROMETHEUS LABS	200MG	N18716 002	AUG 01, 1984
AB		300MG	N18716 003	AUG 01, 1984

LACTULOSE

FOR SOLUTION; ORAL

	LACTULOSE			
+	INALCO	10GM/PACKET	N74712 001	DEC 10, 1997
+		20GM/PACKET	N74712 002	DEC 10, 1997

SOLUTION; ORAL

	CHRONULAC			
AA	+ AVENTIS PHARMS	10GM/15ML	N17884 001	
	CONSTILAC			
AA	ALRA	10GM/15ML	N71054 001	JUL 26, 1988
	CONSTULOSE			
AA	ALPHARMA	10GM/15ML	N70288 001	AUG 15, 1988
	EVALOSE			
AA	COPLEY PHARM	10GM/15ML	N73497 001	MAY 28, 1993
	LACTULOSE			
AA	HI TECH PHARMA	10GM/15ML	N74076 001	JUL 03, 1995
AA	LACHMAN CONSULT	10GM/15ML	N74138 001	SEP 30, 1992
AA	MORTON GROVE	10GM/15ML	N74602 001	NOV 14, 1996
AA	NOVEX	10GM/15ML	N75911 001	FEB 21, 2002
AA	PHARM ASSOC	10GM/15ML	N74623 001	JUL 30, 1996
AA	ROXANE	10GM/15ML	N73591 001	MAY 29, 1992
AA	VINTAGE PHARMS	10GM/15ML	N75993 001	JUL 26, 2001
	LAXILOSE			
AA	TECHNILAB	10GM/15ML	N73686 001	MAY 28, 1993

FDA data supplied by DrugPatentWatch.com

LACTULOSE

SOLUTION; ORAL, RECTAL

	ACILAC			
AA	TECHNILAB	**10GM/15ML**	**N73685 001**	MAY 28, 1993
	CHOLAC			
AA	ALRA	**10GM/15ML**	**N71331 001**	JUL 26, 1988
	ENULOSE			
AA	+ ALPHARMA	**10GM/15ML**	**N71548 001**	AUG 15, 1988
	GENERLAC			
AA	MORTON GROVE	**10GM/15ML**	**N74603 001**	OCT 31, 1996
	HEPTALAC			
AA	COPLEY PHARM	**10GM/15ML**	**N73504 001**	MAY 28, 1993
	LACTULOSE			
AA	HI TECH PHARMA	**10GM/15ML**	**N74077 001**	JUL 03, 1995

LAMIVUDINE

SOLUTION; ORAL

	EPIVIR			
+	GLAXOSMITHKLINE	10MG/ML	N20596 001	NOV 17, 1995
	EPIVIR-HBV			
+	GLAXOSMITHKLINE	5MG/ML	N21004 001	DEC 08, 1998

TABLET; ORAL

	EPIVIR			
+	GLAXOSMITHKLINE	150MG	N20564 001	NOV 17, 1995
	EPIVIR-HBV			
+	GLAXOSMITHKLINE	100MG	N21003 001	DEC 08, 1998

LAMIVUDINE; *MULTIPLE*
SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

	COMBIVIR			
+	GLAXOSMITHKLINE	150MG;300MG	N20857 001	SEP 26, 1997

LAMOTRIGINE

TABLET; ORAL

	LAMICTAL			
	GLAXOSMITHKLINE	25MG	N20241 005	DEC 27, 1994
		100MG	N20241 001	DEC 27, 1994
		150MG	N20241 002	DEC 27, 1994
+		200MG	N20241 003	DEC 27, 1994

TABLET, CHEWABLE; ORAL

	LAMICTAL CD			
	GLAXOSMITHKLINE	2MG	N20764 004	SEP 08, 2000
		5MG	N20764 001	AUG 24, 1998
+		25MG	N20764 002	AUG 24, 1998

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

	PREVACID			
	TAP PHARM	15MG	N20406 001	MAY 10, 1995
+		30MG	N20406 002	MAY 10, 1995

FOR SUSPENSION, EXTENDED RELEASE; ORAL

	PREVACID			
	TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001
+		30MG/PACKET	N21281 002	MAY 03, 2001

TABLET, ORALLY DISINTEGRATING; ORAL

	PREVACID			
	TAP PHARM	15MG	N21428 001	AUG 30, 2002

FDA data supplied by DrugPatentWatch.com

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL
PREVACID
+ TAP PHARM 30MG N21428 002 AUG 30, 2002

LANSOPRAZOLE; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
XALATAN
+ PHARMACIA AND UPJOHN 0.005% N20597 001 JUN 05, 1996

LEFLUNOMIDE

TABLET; ORAL
ARAVA
AVENTIS PHARMS 10MG N20905 001 SEP 10, 1998
20MG N20905 002 SEP 10, 1998
+ 100MG N20905 003 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN
+ BERLEX LABS 50MG/VIAL N20807 001 MAR 06, 1998

LETROZOLE

TABLET; ORAL
FEMARA
+ NOVARTIS 2.5MG N20726 001 JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP		BEDFORD	**EQ 50MG BASE/VIAL**	**N89384 001** SEP 14, 1987
AP			**EQ 100MG BASE/VIAL**	**N89717 001** MAR 28, 1988
AP		ELKINS SINN	**EQ 50MG BASE/VIAL**	**N70480 001** JAN 02, 1987
AP			**EQ 100MG BASE/VIAL**	**N81224 001** JUN 03, 1994
AP		GENSIA SICOR PHARMS	**EQ 50MG BASE/VIAL**	**N81278 001** SEP 28, 1993
AP			**EQ 100MG BASE/VIAL**	**N81277 001** SEP 28, 1993
AP			**EQ 350MG BASE/VIAL**	**N40174 001** JUN 12, 1997
AP		PHARMACHEMIE	**EQ 350MG BASE/VIAL**	**N40262 001** DEC 15, 1999
AP		PHARMACHEMIE USA	**EQ 50MG BASE/VIAL**	**N89628 001** APR 17, 1997
AP			**EQ 100MG BASE/VIAL**	**N89915 001** APR 17, 1997
AP	+	XANODYNE PHARM	**EQ 50MG BASE/VIAL**	**N08107 002**
AP	+		**EQ 100MG BASE/VIAL**	**N08107 004** MAY 23, 1988
AP	+		**EQ 350MG BASE/VIAL**	**N08107 005** APR 05, 1989

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	+	ABBOTT	**EQ 10MG BASE/ML**	**N40147 001** JUN 25, 1997
AP		BEDFORD	**EQ 10MG BASE/ML**	**N40347 001** APR 25, 2000
AP	+		**EQ 200MG BASE/VIAL**	**N40056 001** MAY 23, 1995
AP			**EQ 350MG BASE/VIAL**	**N40335 001** APR 20, 2000
AP		BIGMAR	**EQ 200MG BASE/VIAL**	**N40258 001** FEB 26, 1999
	+		EQ 500MG BASE/VIAL	N40286 001 FEB 26, 1999
AP		GENSIA SICOR PHARMS	**EQ 10MG BASE/ML**	**N40332 001** JUN 28, 1999
AP		LUITPOLD	**EQ 50MG BASE/VIAL**	**N40338 001** JAN 31, 2001

WELLCOVORIN
+ GLAXOSMITHKLINE EQ 5MG BASE/ML N87439 001 OCT 19, 1982

FDA data supplied by DrugPatentWatch.com

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

AB	BARR	EQ 5MG BASE	N71198 001	SEP 24, 1987
AB		EQ 25MG BASE	N71199 001	SEP 24, 1987
AB	GENEVA PHARMS TECH	EQ 15MG BASE	N75327 001	MAR 24, 1999
AB	PAR PHARM	EQ 5MG BASE	N74544 001	AUG 28, 1997
AB		EQ 25MG BASE	N74544 002	AUG 28, 1997
AB	PHARMACHEMIE	EQ 5MG BASE	N73099 001	MAR 28, 1997
AB		EQ 25MG BASE	N73101 001	MAR 28, 1997
AB	ROXANE	EQ 5MG BASE	N72733 001	FEB 22, 1993
AB		EQ 10MG BASE	N72734 001	FEB 22, 1993
AB		EQ 15MG BASE	N72735 001	FEB 22, 1993
AB +		EQ 25MG BASE	N72736 001	FEB 22, 1993
AB	XANODYNE PHARM	EQ 10MG BASE	N71962 001	NOV 19, 1987
AB		EQ 15MG BASE	N71104 001	MAR 04, 1987
BX		EQ 5MG BASE	N18459 001	JAN 30, 1986

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

+	ALZA	EQ 65MG BASE	N21088 001	MAR 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	BEDFORD LABS	1MG/0.2ML	N74728 001	AUG 04, 1998
AP	GENSIA SICOR PHARMS	1MG/0.2ML	N75471 001	OCT 25, 2000
AP	GENZYME	1MG/0.2ML	N75721 001	NOV 29, 2001

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON

AP	+ TAP PHARM	1MG/0.2ML	N19010 001	APR 09, 1985

LUPRON DEPOT

	+ TAP PHARM	3.75MG/VIAL	N20011 001	OCT 22, 1990
	+	7.5MG/VIAL	N19732 001	JAN 26, 1989
	+	22.5MG/VIAL	N20517 001	DEC 22, 1995

LUPRON DEPOT-3

	+ TAP PHARM	11.25MG/VIAL	N20708 001	MAR 07, 1997

LUPRON DEPOT-4

	+ TAP PHARM	30MG/VIAL	N20517 002	MAY 30, 1997

LUPRON DEPOT-PED

	+ TAP PHARM	7.5MG/VIAL	N20263 002	APR 16, 1993
	+	11.25MG/VIAL	N20263 005	JAN 21, 1994
	+	15MG/VIAL	N20263 006	JAN 21, 1994

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+ ATRIX	7.5MG/VIAL	N21343 001	JAN 23, 2002
	+	22.5MG/VIAL	N21379 001	JUL 24, 2002

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

	+ SEPRACOR	EQ 0.0105% BASE	N20837 003	JAN 30, 2002
	+	EQ 0.021% BASE	N20837 001	MAR 25, 1999
	+	EQ 0.042% BASE	N20837 002	MAR 25, 1999

FDA data supplied by DrugPatentWatch.com

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL
ERGAMISOL
+ JANSSEN PHARMA — EQ 50MG BASE — N20035 001 JUN 18, 1990

LEVETIRACETAM

TABLET; ORAL
KEPPRA
UCB — 250MG — N21035 001 NOV 30, 1999
500MG — N21035 002 NOV 30, 1999
+ 750MG — N21035 003 NOV 30, 1999

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETAXON
+ ALCON — EQ 0.5% BASE — N21114 001 FEB 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AKBETA
AT AKORN — **0.25%** — **N74779 001** OCT 29, 1996
AT — **0.5%** — **N74780 001** OCT 29, 1996

BETAGAN
AT + ALLERGAN — **0.25%** — **N19814 001** JUN 28, 1989
AT + — **0.5%** — **N19219 002** DEC 19, 1985

LEVOBUNOLOL HCL
AT BAUSCH AND LOMB — **0.25%** — **N74307 001** MAR 04, 1994
AT — **0.5%** — **N74326 001** MAR 04, 1994
AT FALCON PHARMS — **0.25%** — **N74851 001** OCT 28, 1996

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
LEVOBUNOLOL HCL
AT FALCON PHARMS — **0.5%** — **N74850 001** OCT 28, 1996
AT NOVEX — **0.25%** — **N75473 001** AUG 03, 2000
AT — **0.5%** — **N75475 001** AUG 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
PURDUE PHARMA LP — EQ 2.5MG BASE/ML — N20997 001 AUG 05, 1999
EQ 5MG BASE/ML — N20997 002 AUG 05, 1999
+ EQ 7.5MG BASE/ML — N20997 003 AUG 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN
+ NOVARTIS — EQ 0.05% BASE — N20219 001 NOV 10, 1993

LEVOCARNITINE

INJECTABLE; INJECTION
CARNITOR
AP + SIGMA TAU — **200MG/ML** — **N20182 001** DEC 16, 1992

LEVOCARNITINE
AP BEDFORD — **200MG/ML** — **N75567 001** MAR 29, 2001
AP GENSIA SICOR PHARMS — **200MG/ML** — **N75881 001** MAR 29, 2001
AP LUITPOLD — **200MG/ML** — **N75861 001** JUN 22, 2001

SOLUTION; ORAL
CARNITOR
+ SIGMA TAU — 1GM/10ML — N19257 001 APR 10, 1986

FDA data supplied by DrugPatentWatch.com

LEVOCARNITINE

TABLET; ORAL
CARNITOR
+ SIGMA TAU 330MG N18948 001 DEC 27, 1985

LEVODOPA; *MULTIPLE*
SEE CARBIDOPA; LEVODOPA

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVAQUIN
+ ORTHO MCNEIL PHARM 25MG/ML N20635 001 DEC 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ ORTHO MCNEIL PHARM 5MG/ML N20635 002 DEC 20, 1996
+ 500MG/100ML N20635 003 DEC 20, 1996

SOLUTION/DROPS; OPHTHALMIC
QUIXIN
+ SANTEN 0.5% N21199 001 AUG 18, 2000

TABLET; ORAL
LEVAQUIN
ORTHO MCNEIL PHARM 250MG N20634 001 DEC 20, 1996
500MG N20634 002 DEC 20, 1996
+ 750MG N20634 003 SEP 08, 2000

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL
ORLAAM
+ ROXANE 10MG/ML N20315 001 JUL 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CARBOCAINE W/ NEO-COBEFRIN
AP + EASTMAN KODAK **0.05MG/ML;2%** **N12125 002**
ISOCAINE HCL W/ LEVONORDEFRIN
AP NOVOCOL **0.05MG/ML;2%** **N84697 001**
MEPIVACAINE HCL W/ LEVONORDEFRIN
AP GRAHAM CHEM **0.05MG/ML;2%** **N84850 002** OCT 21, 1983
POLOCAINE W/ LEVONORDEFRIN
AP DENTSPLY PHARM **0.05MG/ML;2%** **N89517 001** APR 14, 1988
SCANDONEST L
AP DEPROCO **0.05MG/ML;2%** **N88388 001** OCT 10, 1984

LEVONORGESTREL

IMPLANT; IMPLANTATION
LEVONORGESTREL
BX + WYETH AYERST 75MG/IMPLANT N20627 001 AUG 15, 1996
NORPLANT II
BX POPULATION COUNCIL 75MG/IMPLANT N20544 001 NOV 01, 1996
NORPLANT SYSTEM IN PLASTIC CONTAINER
+ WYETH AYERST 36MG/IMPLANT N20088 001 DEC 10, 1990

INTRAUTERINE DEVICE; INTRAUTERINE
MIRENA
+ BERLEX LABS 52MG N21225 001 DEC 06, 2000

TABLET; ORAL
PLAN B
+ WOMENS CAPITAL 0.75MG N21045 001 JUL 28, 1999

LEVONORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; LEVONORGESTREL

FDA data supplied by DrugPatentWatch.com

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

	LEVO-DROMORAN			
	+ ICN	2MG/ML	N08719 001	DEC 19, 1991

TABLET; ORAL

	LEVO-DROMORAN			
AB	+ ICN	**2MG**	**N08720 001**	DEC 19, 1991
	LEVORPHANOL TARTRATE			
AB	ROXANE	**2MG**	**N74278 001**	MAR 31, 2000

LEVOTHYROXINE SODIUM

TABLET; ORAL

	LEVO-T			
BX	MOVA	0.025MG	N21342 001	MAR 01, 2002
BX		0.05MG	N21342 002	MAR 01, 2002
BX		0.075MG	N21342 003	MAR 01, 2002
BX		0.088MG	N21342 004	MAR 01, 2002
BX		0.1MG	N21342 005	MAR 01, 2002
BX		0.112MG	N21342 006	MAR 01, 2002
BX		0.125MG	N21342 007	MAR 01, 2002
BX		0.15MG	N21342 008	MAR 01, 2002
BX		0.175MG	N21342 009	MAR 01, 2002
BX		0.2MG	N21342 010	MAR 01, 2002
BX	+	0.3MG	N21342 011	MAR 01, 2002
	LEVOTHYROXINE SODIUM			
AB	MYLAN	**0.025MG**	**N76187 001**	JUN 05, 2002
AB		**0.05MG**	**N76187 002**	JUN 05, 2002
AB		**0.075MG**	**N76187 003**	JUN 05, 2002

LEVOTHYROXINE SODIUM

TABLET; ORAL

	LEVOTHYROXINE SODIUM			
AB	MYLAN	**0.088MG**	**N76187 004**	JUN 05, 2002
AB		**0.1MG**	**N76187 005**	JUN 05, 2002
AB		**0.112MG**	**N76187 006**	JUN 05, 2002
AB		**0.125MG**	**N76187 007**	JUN 05, 2002
AB		**0.15MG**	**N76187 008**	JUN 05, 2002
AB		**0.175MG**	**N76187 009**	JUN 05, 2002
AB		**0.2MG**	**N76187 010**	JUN 05, 2002
AB		**0.3MG**	**N76187 011**	JUN 05, 2002
	LEVOXYL			
BX	JONES PHARMA	0.025MG	N21301 001	MAY 25, 2001
BX		0.05MG	N21301 002	MAY 25, 2001
BX		0.075MG	N21301 003	MAY 25, 2001
BX		0.088MG	N21301 004	MAY 25, 2001
BX		0.1MG	N21301 005	MAY 25, 2001
BX		0.112MG	N21301 006	MAY 25, 2001
BX		0.125MG	N21301 007	MAY 25, 2001
BX		0.137MG	N21301 008	MAY 25, 2001
BX		0.15MG	N21301 009	MAY 25, 2001
BX		0.175MG	N21301 010	MAY 25, 2001
BX		0.2MG	N21301 011	MAY 25, 2001
BX	+	0.3MG	N21301 012	MAY 25, 2001
	NOVOTHYROX			
BX	GENPHARM	0.025MG	N21292 001	MAY 31, 2002

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM

TABLET; ORAL

	NOVOTHYROX				
BX	GENPHARM	0.05MG	N21292 002 MAY 31, 2002		
BX		0.075MG	N21292 003 MAY 31, 2002		
BX		0.088MG	N21292 004 MAY 31, 2002		
BX		0.1MG	N21292 005 MAY 31, 2002		
BX		0.112MG	N21292 006 MAY 31, 2002		
BX		0.125MG	N21292 007 MAY 31, 2002		
BX		0.137MG	N21292 008 MAY 31, 2002		
BX		0.15MG	N21292 009 MAY 31, 2002		
BX		0.175MG	N21292 010 MAY 31, 2002		
BX		0.2MG	N21292 011 MAY 31, 2002		
BX	+	0.3MG	N21292 012 MAY 31, 2002		
	SYNTHROID				
BX	ABBOTT	0.025MG	N21402 001 JUL 24, 2002		
BX		0.05MG	N21402 002 JUL 24, 2002		
BX		0.075MG	N21402 003 JUL 24, 2002		
BX		0.088MG	N21402 004 JUL 24, 2002		
BX		0.1MG	N21402 005 JUL 24, 2002		
BX		0.112MG	N21402 006 JUL 24, 2002		
BX		0.125MG	N21402 007 JUL 24, 2002		
BX		0.137MG	N21402 008 JUL 24, 2002		
BX		0.15MG	N21402 009 JUL 24, 2002		
BX		0.175MG	N21402 010 JUL 24, 2002		
BX		0.2MG	N21402 012 JUL 24, 2002		

LEVOTHYROXINE SODIUM

TABLET; ORAL

	SYNTHROID				
BX	+ ABBOTT	0.3MG	N21402 011 JUL 24, 2002		
	THYRO-TABS				
BX	LLOYD	0.025MG	N21116 001 OCT 24, 2002		
BX		0.05MG	N21116 002 OCT 24, 2002		
BX		0.075MG	N21116 003 OCT 24, 2002		
BX		0.088MG	N21116 010 OCT 24, 2002		
BX		0.1MG	N21116 004 OCT 24, 2002		
BX		0.112MG	N21116 011 OCT 24, 2002		
BX		0.125MG	N21116 005 OCT 24, 2002		
BX		0.15MG	N21116 006 OCT 24, 2002		
BX		0.175MG	N21116 007 OCT 24, 2002		
BX		0.2MG	N21116 008 OCT 24, 2002		
BX	+	0.3MG	N21116 009 OCT 24, 2002		
	UNITHROID				
AB	STEVENS J	**0.025MG**	**N21210 001** AUG 21, 2000		
AB		**0.05MG**	**N21210 002** AUG 21, 2000		
AB		**0.075MG**	**N21210 003** AUG 21, 2000		
AB		**0.088MG**	**N21210 004** AUG 21, 2000		
AB		**0.1MG**	**N21210 005** AUG 21, 2000		
AB		**0.112MG**	**N21210 006** AUG 21, 2000		
AB		**0.125MG**	**N21210 007** AUG 21, 2000		
AB		**0.15MG**	**N21210 008** AUG 21, 2000		
AB		**0.175MG**	**N21210 009** AUG 21, 2000		

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM

TABLET; ORAL

UNITHROID

AB	STEVENS J	0.2MG	N21210 010	AUG 21, 2000
AB +		0.3MG	N21210 011	AUG 21, 2000

LIDOCAINE

FILM, EXTENDED RELEASE; BUCCAL

LIDOCAINE

+	NOVEN	46.1MG/PATCH	N20575 002	MAY 21, 1996

FILM, EXTENDED RELEASE; TOPICAL

LIDODERM

+	TEIKOKU PHARMA USA	700MG/12HR	N20612 001	MAR 19, 1999

OINTMENT; TOPICAL

ALPHACAINE

AT	CARLISLE	5%	N84947 001	

LIDOCAINE

AT +	FOUGERA	5%	N80198 001	
AT	GRAHAM CHEM	5%	N80210 001	
AT	TARO	5%	N86724 001	

SOLUTION; TOPICAL

XYLOCAINE

+	ASTRAZENECA	5%	N14127 001	

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

+	ASTRAZENECA	2.5%;2.5%	N19941 001	DEC 30, 1992

DISC; TOPICAL

EMLA

+	ASTRAZENECA	2.5%;2.5%	N20962 001	FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

AP	ABBOTT	0.5%	N88328 001	MAY 17, 1984
AP		1%	N40013 001	JUN 23, 1995
AP		1%	N83158 001	
AP		1%	N88329 001	MAY 17, 1984
AP		2%	N40078 001	JUN 23, 1995
AP		2%	N83158 002	
AP		2%	N88294 001	MAY 17, 1984
AP		2%	N88331 001	MAY 17, 1984
AP		20%	N83158 003	
AP	ELKINS SINN	1%	N80407 001	
AP		2%	N80407 002	
AP	GRAHAM CHEM	2%	N80504 001	
AP	INTL MEDICATION	1%	N83173 001	
AP		2%	N83173 002	
AP	LUITPOLD	1%	N80850 001	
AP		2%	N83198 001	
AP	WYETH AYERST	1%	N83083 001	
AP		2%	N83083 002	

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	200MG/100ML	N18967 001	MAR 30, 1984
AP		200MG/100ML	N19830 002	APR 08, 1992
AP	BAXTER HLTHCARE	200MG/100ML	N18461 002	

LIDOCAINE HCL 0.2% IN DEXTROSE 5%

AP	ABBOTT	200MG/100ML	N83158 005	

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	200MG/100ML	N18388 001	

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	400MG/100ML	N18967 002	MAR 30, 1984
AP		400MG/100ML	N19830 003	APR 08, 1992
AP	BAXTER HLTHCARE	400MG/100ML	N18461 003	

LIDOCAINE HCL 0.4% IN DEXTROSE 5%

AP	ABBOTT	400MG/100ML	N83158 006	

LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	400MG/100ML	N18388 002	

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	800MG/100ML	N18967 003	
			MAR 30, 1984	
AP		800MG/100ML	N19830 004	
			APR 08, 1992	
AP	BAXTER HLTHCARE	800MG/100ML	N18461 004	
			FEB 22, 1982	

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	800MG/100ML	N18388 003	
			NOV 05, 1982	

LIDOCAINE HCL IN PLASTIC CONTAINER

AP	ABBOTT	0.5%	N88325 001	
			JUL 31, 1984	
AP		1%	N88299 001	
			JUL 31, 1984	
AP		1.5%	N88326 001	
			JUL 31, 1984	
AP		2%	N88327 001	
			JUL 31, 1984	
AP		10%	N88367 001	
			JUL 31, 1984	
AP		20%	N88368 001	
			JUL 31, 1984	
AP	AM PHARM PARTNERS	1%	N88586 001	
			JUL 24, 1985	

LIDOCAINE HCL PRESERVATIVE FREE

AP	ABBOTT	1%	N80408 001	
AP		1.5%	N80408 002	
AP		4%	N88295 001	
			MAY 17, 1984	
AP	AM PHARM PARTNERS	1%	N80404 002	
AP		2%	N17584 001	
AP		2%	N80404 003	
AP		4%	N17584 002	
AP	ELKINS SINN	1%	N84625 001	
AP		2%	N84625 002	
AP	INTL MEDICATION	20%	N17702 001	

LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	ABBOTT	1%	N40302 001	
			SEP 28, 1998	
AP		2%	N40302 002	
			SEP 28, 1998	

LIDOPEN

AP	MERIDIAN MEDCL TECHN	10%	N17549 001	

XYLOCAINE

AP	+ ASTRAZENECA	0.5%	N06488 008	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE

AP	+ ASTRAZENECA	1%	N06488 007	
AP	+	1.5%	N06488 010	
AP	+ DENTSPLY PHARM	2%	N21380 001	

XYLOCAINE 4% PRESERVATIVE FREE

AP	+ ASTRAZENECA	4%	N10417 001	

XYLOCAINE PRESERVATIVE FREE

AP	ASTRAZENECA	1%	N16801 005	
			JAN 19, 1988	
AP		2%	N16801 001	
AP		4%	N16801 002	
AP	+	10%	N16801 003	
AP	+	20%	N16801 004	

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%

+	ABBOTT	5%	N83914 001

XYLOCAINE 1.5% W/ DEXTROSE 7.5%

+	ASTRAZENECA	1.5%	N16297 001

JELLY; TOPICAL

LIDOCAINE HCL

AT	COPLEY PHARM	2%	N81318 001	
			APR 29, 1993	
AT	INTL MEDICATION	2%	N86283 001	

XYLOCAINE

AT	+ ASTRAZENECA	2%	N08816 001	

SOLUTION; ORAL

LIDOCAINE HCL

AT	HI TECH PHARMA	2%	N40014 001	
			JUL 10, 1995	
AT	MORTON GROVE	2%	N87872 001	
			NOV 18, 1982	

LIDOCAINE HCL VISCOUS

AT	ALPHARMA	2%	N86578 001	

LIDOCAINE VISCOUS

AT	ROXANE	2%	N88802 001	
			APR 26, 1985	

XYLOCAINE VISCOUS

AT	+ ASTRAZENECA	2%	N09470 001	

SOLUTION; TOPICAL

ANESTACON

AT	+ POLYMEDICA	2%	N80429 001	

LARYNG-O-JET KIT

AT	INTL MEDICATION	4%	N86364 001	

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL
LIDOCAINE HCL
AT MORTON GROVE **4%** **N87881 001** NOV 18, 1982
AT ROXANE **4%** **N88803 001** APR 03, 1985

LTA II KIT
AT ABBOTT **4%** **N80409 001**
AT **4%** **N88542 001** JUL 31, 1984

PEDIATRIC LTA KIT
AT ABBOTT **2%** **N85995 001**
XYLOCAINE 4% PRESERVATIVE FREE
AT + ASTRAZENECA **4%** **N10417 002**

LIDOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION
TERRAMYCIN
PFIZER 2%;50MG/ML N60567 001
2%;125MG/ML N60567 002

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LINCOCIN
+ PHARMACIA AND UPJOHN EQ 300MG BASE/ML N50317 001

LINDANE

LOTION; TOPICAL
LINDANE
AT + ALPHARMA **1%** **N87313 001**
AT MORTON GROVE **1%** **N88190 001** AUG 16, 1984

SHAMPOO; TOPICAL
LINDANE
AT + ALPHARMA **1%** **N87266 001**

LINDANE

SHAMPOO; TOPICAL
LINDANE
AT MORTON GROVE **1%** **N88191 001** SEP 18, 1984

LINEZOLID

FOR SUSPENSION; ORAL
ZYVOX
+ PHARMACIA AND UPJOHN 100MG/5ML N21132 001 APR 18, 2000

INJECTABLE; INJECTION
ZYVOX
+ PHARMACIA AND UPJOHN 200MG/100ML N21131 001 APR 18, 2000

TABLET; ORAL
ZYVOX
+ PHARMACIA AND UPJOHN 600MG N21130 002 APR 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION
TRIOSTAT
+ JONES PHARMA EQ 0.01MG BASE/ML N20105 001 DEC 31, 1991

TABLET; ORAL
CYTOMEL
JONES PHARMA EQ 0.005MG BASE N10379 001
EQ 0.025MG BASE N10379 002
+ EQ 0.05MG BASE N10379 003

LIOTRIX (T4;T3)

TABLET; ORAL
THYROLAR-0.25
FORREST LABS 0.0125MG;0.0031MG N16807 001
THYROLAR-0.5
FORREST LABS 0.025MG;0.00625MG N16807 005
THYROLAR-1
FORREST LABS 0.05MG;0.0125MG N16807 004

FDA data supplied by DrugPatentWatch.com

LIOTRIX (T4;T3)

TABLET; ORAL

	THYROLAR-2			
	FORREST LABS	0.1MG;0.025MG	N16807 002	
	THYROLAR-3			
+	FORREST LABS	0.15MG;0.0375MG	N16807 003	

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	APOTEX	2.5MG	**N76102 001** SEP 30, 2002
AB		5MG	**N76102 002** SEP 30, 2002
AB		10MG	**N76102 003** SEP 30, 2002
AB		20MG	**N76102 004** SEP 30, 2002
AB		30MG	**N76102 005** SEP 30, 2002
AB		40MG	**N76102 006** SEP 30, 2002
AB	EON	2.5MG	**N75994 001** JUL 01, 2002
AB		5MG	**N75994 002** JUL 01, 2002
AB		10MG	**N75994 003** JUL 01, 2002
AB		20MG	**N75994 004** JUL 01, 2002
AB		30MG	**N75994 005** JUL 01, 2002
AB		40MG	**N75994 006** JUL 01, 2002
AB	GENEVA PHARMS TECH	2.5MG	**N75903 001** JUL 01, 2002
AB		5MG	**N75903 002** JUL 01, 2002
AB		10MG	**N75903 003** JUL 01, 2002
AB		20MG	**N75903 004** JUL 01, 2002
AB		30MG	**N75903 005** JUL 01, 2002
AB		40MG	**N75903 006** JUL 01, 2002

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	IVAX PHARMS	2.5MG	**N75752 001** JUL 01, 2002
AB		5MG	**N75752 002** JUL 01, 2002
AB		10MG	**N75752 003** JUL 01, 2002
AB		20MG	**N75752 004** JUL 01, 2002
AB		30MG	**N75752 005** JUL 01, 2002
AB		40MG	**N75752 006** JUL 01, 2002
AB	LEK PHARM	2.5MG	**N75999 001** JUL 01, 2002
AB		5MG	**N75999 002** JUL 01, 2002
AB		10MG	**N75999 003** JUL 01, 2002
AB		20MG	**N75999 004** JUL 01, 2002
AB		30MG	**N75999 005** JUL 01, 2002
AB		40MG	**N75999 006** JUL 01, 2002
AB	MYLAN	2.5MG	**N76071 001** JUL 01, 2002
AB		5MG	**N76071 002** JUL 01, 2002
AB		10MG	**N76071 003** JUL 01, 2002
AB		20MG	**N76071 004** JUL 01, 2002
AB		30MG	**N76071 005** JUL 01, 2002
AB		40MG	**N76071 006** JUL 01, 2002
AB	PAR PHARM	2.5MG	**N75743 001** JUL 01, 2002
AB		5MG	**N75743 002** JUL 01, 2002
AB		10MG	**N75743 003** JUL 01, 2002
AB		20MG	**N75743 004** JUL 01, 2002

FDA data supplied by DrugPatentWatch.com

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	PAR PHARM	30MG	**N75743 005** JUL 01, 2002	
AB		40MG	**N75743 006** JUL 01, 2002	
AB	PUREPAC PHARM	2.5MG	**N76180 001** JUL 01, 2002	
AB		5MG	**N76180 002** JUL 01, 2002	
AB		10MG	**N76180 003** JUL 01, 2002	
AB		20MG	**N76164 001** JUL 01, 2002	
AB		30MG	**N76164 002** JUL 01, 2002	
AB		40MG	**N76164 003** JUL 01, 2002	
AB	RANBAXY	2.5MG	**N75944 001** JUL 01, 2002	
AB		5MG	**N75944 002** JUL 01, 2002	
AB		10MG	**N75944 003** JUL 01, 2002	
AB		20MG	**N75944 004** JUL 01, 2002	
AB		40MG	**N75944 005** JUL 01, 2002	
AB	TEVA	2.5MG	**N75783 001** JUL 01, 2002	
AB		5MG	**N75783 002** JUL 01, 2002	
AB		10MG	**N75783 003** JUL 01, 2002	
AB		20MG	**N75783 004** JUL 01, 2002	
AB		30MG	**N75783 005** JUL 01, 2002	
AB		40MG	**N75783 006** JUL 01, 2002	
AB	WATSON LABS	2.5MG	**N76059 001** JUL 01, 2002	
AB		5MG	**N76059 002** JUL 01, 2002	
AB		10MG	**N76059 003** JUL 01, 2002	

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	WATSON LABS	20MG	**N76059 004** JUL 01, 2002
AB		30MG	**N76059 005** JUL 01, 2002
AB		40MG	**N76059 006** JUL 01, 2002
AB	WEST WARD	2.5MG	**N76063 001** JUL 01, 2002
AB		5MG	**N76063 002** JUL 01, 2002
AB		10MG	**N76063 003** JUL 01, 2002
AB		20MG	**N76063 004** JUL 01, 2002
AB		40MG	**N76063 005** JUL 01, 2002

PRINIVIL

AB	MERCK	2.5MG	**N19558 006** JAN 28, 1994
AB		5MG	**N19558 001** DEC 29, 1987
AB		10MG	**N19558 002** DEC 29, 1987
AB		20MG	**N19558 003** DEC 29, 1987
AB		40MG	**N19558 004** OCT 25, 1988

ZESTRIL

AB	ASTRAZENECA	2.5MG	**N19777 005** APR 29, 1993
AB		5MG	**N19777 001** MAY 19, 1988
AB		10MG	**N19777 002** MAY 19, 1988
AB		20MG	**N19777 003** MAY 19, 1988
AB +		30MG	**N19777 006** JAN 20, 1999
AB +		40MG	**N19777 004** MAY 19, 1988

LISINOPRIL; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; LISINOPRIL

FDA data supplied by DrugPatentWatch.com

LITHIUM CARBONATE

CAPSULE; ORAL

	ESKALITH			
AB	GLAXOSMITHKLINE	**300MG**	**N16860 001**	
	LITHIUM CARBONATE			
AB	ABLE	**300MG**	**N76121 001**	SEP 27, 2001
AB	ROXANE	**300MG**	**N17812 001**	
		150MG	N17812 002	JAN 28, 1987
+		600MG	N17812 003	JAN 28, 1987
AB	WEST WARD	**300MG**	**N76243 001**	JUN 27, 2002

TABLET; ORAL

	LITHIUM CARBONATE			
AB	+ PFIZER	**300MG**	**N16834 001**	
AB	ROXANE	**300MG**	**N18558 001**	JAN 29, 1982

TABLET, EXTENDED RELEASE; ORAL

	ESKALITH CR			
+	GLAXOSMITHKLINE	450MG	N18152 001	MAR 29, 1982
	LITHIUM CARBONATE			
AB	BARR	**300MG**	**N76170 001**	JUN 10, 2002
	LITHOBID			
AB	+ SOLVAY	**300MG**	**N18027 001**	

LITHIUM CITRATE

SYRUP; ORAL

	LITHIUM CITRATE			
AA	MORTON GROVE	**EQ 300MG CARBONATE/5ML**	**N70755 001**	MAY 21, 1986
AA	+ ROXANE	**EQ 300MG CARBONATE/5ML**	**N18421 001**	

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

	ALOMIDE			
+	ALCON	EQ 0.1% BASE	N20191 001	SEP 23, 1993

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	MAXAQUIN			
+	PHARMACIA	EQ 400MG BASE	N20013 001	FEB 21, 1992

LOMUSTINE

CAPSULE; ORAL

	CEENU			
	BRISTOL MYERS SQUIBB	10MG	N17588 001	
		40MG	N17588 002	
+		100MG	N17588 003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	IMODIUM			
AB	+ MCNEIL CONS SPECLT	**2MG**	**N17694 001**	
	LOPERAMIDE HCL			
AB	GENEVA PHARMS	**2MG**	**N72993 001**	AUG 28, 1992
AB	MYLAN	**2MG**	**N72741 001**	SEP 18, 1991
AB	TEVA	**2MG**	**N73122 001**	AUG 30, 1991
AB		**2MG**	**N73192 001**	APR 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

	KALETRA			
+	ABBOTT	133.3MG;33.3MG	N21226 001	SEP 15, 2000

SOLUTION; ORAL

	KALETRA			
+	ABBOTT	80MG/ML;20MG/ML	N21251 001	SEP 15, 2000

FDA data supplied by DrugPatentWatch.com

LORACARBEF

CAPSULE; ORAL
LORABID
KING PHARMS 200MG N50668 001 DEC 31, 1991
\+ 400MG N50668 002 APR 05, 1996

FOR SUSPENSION; ORAL
LORABID
KING PHARMS 100MG/5ML N50667 001 DEC 31, 1991
\+ 200MG/5ML N50667 002 DEC 31, 1991

LORATADINE

SYRUP; ORAL
CLARITIN
\+ SCHERING 1MG/ML N20641 001 OCT 10, 1996

TABLET; ORAL
CLARITIN
\+ SCHERING 10MG N19658 001 APR 12, 1993

TABLET, ORALLY DISINTEGRATING; ORAL
CLARITIN REDITABS
\+ SCHERING 10MG N20704 001 DEC 23, 1996

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARITIN-D
\+ SCHERING 5MG;120MG N19670 001 NOV 14, 1994

CLARITIN-D 24 HOUR
\+ SCHERING 10MG;240MG N20470 001 AUG 23, 1996

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM INTENSOL
ROXANE 2MG/ML N72755 001 JUN 28, 1991

INJECTABLE; INJECTION
ATIVAN
AP \+ WYETH AYERST **2MG/ML** **N18140 001**
AP \+ **4MG/ML** **N18140 002**
LORAZEPAM
AP ABBOTT **2MG/ML** **N74243 001** APR 12, 1994
AP **2MG/ML** **N74280 001** MAY 27, 1994
AP **2MG/ML** **N74282 001** MAY 27, 1994
AP **2MG/ML** **N74300 001** APR 12, 1994
AP **4MG/ML** **N74243 002** APR 12, 1994
AP **4MG/ML** **N74280 002** MAY 27, 1994
AP **4MG/ML** **N74282 002** MAY 27, 1994
AP **4MG/ML** **N74300 003** MAR 19, 1997
AP AKORN **2MG/ML** **N74974 001** JUL 23, 1998
AP CLONMEL HLTHCARE **2MG/ML** **N74793 001** MAR 16, 2000
AP **4MG/ML** **N74793 002** MAR 16, 2000
AP ELKINS SINN **2MG/ML** **N74496 001** SEP 28, 1998
AP **4MG/ML** **N74496 002** SEP 28, 1998
AP MARSAM PHARMS LLC **2MG/ML** **N74535 001** SEP 12, 1996
AP **2MG/ML** **N74551 001** SEP 12, 1996
AP **1MG/0.5ML** **N74551 003** SEP 12, 1996
AP **4MG/ML** **N74535 002** SEP 12, 1996
AP **4MG/ML** **N74551 002** SEP 12, 1996

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM			
AP	STERIS	2MG/ML	**N74276 001**	APR 15, 1994
AP		4MG/ML	**N74276 002**	APR 15, 1994
AP	TAYLOR	2MG/ML	**N75025 001**	JUL 23, 1998

SOLUTION; ORAL

	LORAZEPAM			
+	ROXANE	0.5MG/5ML	N74648 001	MAR 18, 1997

TABLET; ORAL

	ATIVAN			
AB	WYETH AYERST	0.5MG	**N17794 001**	
AB		1MG	**N17794 002**	
AB	+	2MG	**N17794 003**	
	LORAZEPAM			
AB	GENEVA PHARMS	0.5MG	**N71193 001**	APR 15, 1988
AB		1MG	**N71194 001**	APR 15, 1988
AB		2MG	**N71195 001**	APR 15, 1988
AB	MUTUAL PHARM	0.5MG	**N72553 001**	MAR 29, 1991
AB		1MG	**N72554 001**	MAR 29, 1991
AB		2MG	**N72555 001**	MAR 29, 1991
AB	MYLAN	0.5MG	**N71589 001**	OCT 13, 1987
AB		1MG	**N71590 001**	OCT 13, 1987
AB		2MG	**N71591 001**	OCT 13, 1987
AB	PUREPAC PHARM	0.5MG	**N71403 001**	APR 21, 1987
AB		1MG	**N71404 001**	APR 21, 1987
AB		2MG	**N71141 001**	APR 21, 1987
AB	RANBAXY	0.5MG	**N76045 001**	AUG 29, 2001

LORAZEPAM

TABLET; ORAL

	LORAZEPAM			
AB	RANBAXY	1MG	**N76045 002**	AUG 29, 2001
AB		2MG	**N76045 003**	AUG 29, 2001
AB	WATSON LABS	0.5MG	**N71117 001**	JUL 24, 1986
AB		0.5MG	**N72926 001**	OCT 31, 1991
AB		1MG	**N71087 001**	MAR 23, 1987
AB		1MG	**N71118 001**	JUL 24, 1986
AB		1MG	**N72927 001**	OCT 31, 1991
AB		2MG	**N71088 001**	MAR 23, 1987
AB		2MG	**N71110 001**	JUL 24, 1986
AB		2MG	**N72928 001**	OCT 31, 1991

LOSARTAN POTASSIUM

TABLET; ORAL

	COZAAR		
	MERCK	25MG	N20386 001 APR 14, 1995
		50MG	N20386 002 APR 14, 1995
+		100MG	N20386 003 OCT 13, 1998

LOSARTAN POTASSIUM; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

	ALREX		
+	BAUSCH AND LOMB	0.2%	N20803 001 MAR 09, 1998

FDA data supplied by DrugPatentWatch.com

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

	LOTEMAX				
+	BAUSCH AND LOMB	0.5%	N20583 001		MAR 09, 1998

LOVASTATIN

TABLET; ORAL

	LOVASTATIN			
AB	CARLSBAD	**10MG**	**N75991 001**	JUN 05, 2002
AB		**20MG**	**N75991 002**	JUN 05, 2002
AB		**40MG**	**N75991 003**	JUN 05, 2002
AB	EON	**10MG**	**N75636 001**	DEC 17, 2001
AB		**20MG**	**N75636 002**	DEC 17, 2001
AB		**40MG**	**N75636 003**	DEC 17, 2001
AB	GENEVA PHARMS	**10MG**	**N75300 001**	DEC 17, 2001
AB		**20MG**	**N75300 002**	DEC 17, 2001
AB		**40MG**	**N75300 003**	DEC 17, 2001
AB	GENPHARM	**10MG**	**N75935 001**	DEC 17, 2001
AB		**20MG**	**N75935 002**	DEC 17, 2001
AB		**40MG**	**N75935 003**	DEC 17, 2001
AB	MYLAN	**10MG**	**N75451 001**	DEC 17, 2001
AB		**20MG**	**N75451 002**	DEC 17, 2001
AB		**40MG**	**N75451 003**	DEC 17, 2001
AB	PUREPAC PHARM	**10MG**	**N75828 001**	DEC 17, 2001
AB		**20MG**	**N75828 002**	DEC 17, 2001
AB		**40MG**	**N75828 003**	DEC 17, 2001

LOVASTATIN

TABLET; ORAL

	LOVASTATIN			
AB	TEVA	**10MG**	**N75551 003**	DEC 17, 2001
AB		**20MG**	**N75551 002**	DEC 17, 2001
AB		**40MG**	**N75551 001**	DEC 17, 2001
	MEVACOR			
AB	MERCK	**10MG**	**N19643 002**	MAR 28, 1991
AB		**20MG**	**N19643 003**	AUG 31, 1987
AB	+	**40MG**	**N19643 004**	DEC 14, 1988

TABLET, EXTENDED RELEASE; ORAL

	ALTOCOR			
	ANDRX	10MG	N21316 001	JUN 26, 2002
		20MG	N21316 002	JUN 26, 2002
		40MG	N21316 003	JUN 26, 2002
	+	60MG	N21316 004	JUN 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

	ADVICOR			
	KOS	20MG;500MG	N21249 001	DEC 17, 2001
		20MG;750MG	N21249 002	DEC 17, 2001
	+	20MG;1GM	N21249 003	DEC 17, 2001

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXAPINE SUCCINATE			
AB	WATSON LABS	**EQ 5MG BASE**	**N72204 001**	JUN 15, 1988

FDA data supplied by DrugPatentWatch.com

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXAPINE SUCCINATE			
AB	WATSON LABS	**EQ 10MG BASE**	**N72205 001**	JUN 15, 1988
AB		**EQ 25MG BASE**	**N72206 001**	JUN 15, 1988
AB		**EQ 50MG BASE**	**N72062 001**	JUN 15, 1988
	LOXITANE			
AB	WATSON LABS	**EQ 5MG BASE**	**N17525 001**	
AB		**EQ 10MG BASE**	**N17525 002**	
AB	+	**EQ 25MG BASE**	**N17525 003**	
AB		**EQ 50MG BASE**	**N17525 004**	

MAFENIDE ACETATE

CREAM; TOPICAL

	SULFAMYLON		
+	BERTEK PHARMS	EQ 85MG BASE/GM	N16763 001

FOR SOLUTION; TOPICAL

	SULFAMYLON		
+	MYLAN	5%	N19832 003 JUN 05, 1998

MAGNESIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; *MULTIPLE*

SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE	32MG/100ML;128MG/100ML; 234MG/100ML	N19047 001	JUN 15, 1984

MAGNESIUM CARBONATE; *MULTIPLE*

SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

MAGNESIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN **30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N18252 001**
AP **30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19711 001** SEP 29, 1989
NORMOSOL-R IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N17586 001
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N17378 001**

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
PLASMA-LYTE A IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N17378 002** NOV 22, 1982

SOLUTION; IRRIGATION
PHYSIOLYTE IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19024 001 JUN 08, 1984
PHYSIOSOL IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N17637 002 JUL 08, 1982
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N18406 002 JUL 08, 1982

MAGNESIUM OXIDE; *MULTIPLE*
SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE
AP ABBOTT **500MG/ML N75151 001** APR 25, 2000
AP + AM PHARM PARTNERS **500MG/ML N19316 001** SEP 08, 1986
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
\+ ABBOTT 1GM/100ML N20488 001 JUL 11, 1995
\+ 2GM/100ML N20488 002 JUL 11, 1995
MAGNESIUM SULFATE IN PLASTIC CONTAINER
\+ ABBOTT 4GM/100ML N20309 001 JUN 24, 1994
\+ 80MG/ML N20309 002 JUN 24, 1994

FDA data supplied by DrugPatentWatch.com

MAGNESIUM SULFATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

AT	BAXTER HLTHCARE	20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML	N18508 001 FEB 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML	N18336 001

MALATHION

LOTION; TOPICAL

OVIDE

+	MEDICIS	0.5%	N18613 001 AUG 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

+	AMERSHAM HLTH	37.9MG/ML	N20652 001 NOV 26, 1997

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	ABBOTT	EQ 0.1MG MANGANESE/ML	N18962 001 JUN 26, 1986

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

AP	B BRAUN	10GM/100ML	N16080 002

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ABBOTT	10GM/100ML	N19603 002 JAN 08, 1987
AP	B BRAUN	10GM/100ML	N20006 002 JUL 26, 1993

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

AP	B BRAUN	10GM/100ML	N16080 006

MANNITOL 15%

AP	B BRAUN	15GM/100ML	N16080 003

MANNITOL 15% IN PLASTIC CONTAINER

AP	ABBOTT	15GM/100ML	N19603 003 JAN 08, 1990
AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

AP	B BRAUN	15GM/100ML	N16080 005

MANNITOL 20%

AP	B BRAUN	20GM/100ML	N14738 001
AP		20GM/100ML	N16080 004

MANNITOL 20% IN PLASTIC CONTAINER

AP	ABBOTT	20GM/100ML	N19603 004 JAN 08, 1990
AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993

MANNITOL 25%

AP	ABBOTT	12.5GM/50ML	N16269 006 AUG 25, 1994
AP	AM PHARM PARTNERS	12.5GM/50ML	N80677 001
AP	INTL MEDICATION	12.5GM/50ML	N83051 001
AP	LUITPOLD	12.5GM/50ML	N87409 001 JAN 21, 1982

MANNITOL 5%

AP	B BRAUN	5GM/100ML	N16080 001

MANNITOL 5% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML	N19603 001 JAN 08, 1987
AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

AP	B BRAUN	5GM/100ML	N16080 007

OSMITROL 10% IN WATER

AP	BAXTER HLTHCARE	10GM/100ML	N13684 002

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	10GM/100ML	N13684 006

OSMITROL 15% IN WATER

AP	BAXTER HLTHCARE	15GM/100ML	N13684 004

FDA data supplied by DrugPatentWatch.com

MANNITOL

INJECTABLE; INJECTION

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	15GM/100ML	N13684	008

OSMITROL 20% IN WATER

AP	BAXTER HLTHCARE	20GM/100ML	N13684	003

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20GM/100ML	N13684	007

OSMITROL 5% IN WATER

AP	BAXTER HLTHCARE	5GM/100ML	N13684	001

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML	N13684	005

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N16772	002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

AT	ABBOTT	540MG/100ML;2.7GM/100ML	N17636	001
AT		540MG/100ML;2.7GM/100ML	N18316	001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

AB	NOVARTIS	25MG	N17543	001
AB	+	50MG	N17543	002
AB		75MG	N17543	003
			SEP 30, 1982	

MAPROTILINE HCL

AB	MYLAN	25MG	N72284	001
			OCT 03, 1988	
AB		50MG	N72285	001
			OCT 03, 1988	
AB		75MG	N72286	001
			OCT 03, 1988	
AB	WATSON LABS	25MG	N72162	001
			JUN 01, 1988	
AB		50MG	N72163	001
			JUN 01, 1988	
AB		75MG	N72164	001
			JUN 01, 1988	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

AB	COPLEY PHARM	100MG	N73580	001
			JAN 04, 1995	

VERMOX

AB	+ MCNEIL CONS SPECLT	100MG	N17481	001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

	+ LAYTON	2.5MG	N10251	001

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

	+ MERCK	10MG/VIAL	N06695	001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+ PFIZER	12.5MG	N10721	006
AA	+	25MG	N10721	004
AA	+	50MG	N10721	001
			JAN 20, 1982	

MECLIZINE HCL

AA	ABC HOLDING	12.5MG	N85253	001
AA		25MG	N85252	001
AA	BUNDY	12.5MG	N84382	001
AA		25MG	N84872	001
AA	GENEVA PHARMS	12.5MG	N84843	002
			MAY 22, 1989	
AA		25MG	N84092	003
			MAY 22, 1989	
AA	IVAX PHARMS	12.5MG	N84975	001
AA		25MG	N84657	001
AA	PAR PHARM	12.5MG	N87127	001
AA		25MG	N87128	001
AA		50MG	N89674	001
			MAR 31, 1988	
AA	SIDMAK LABS NJ	12.5MG	N88732	001
			DEC 11, 1985	

FDA data supplied by DrugPatentWatch.com

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

	MECLIZINE HCL			
AA	SIDMAK LABS NJ	25MG	**N88734 001**	DEC 11, 1985
AA	VINTAGE PHARMS	12.5MG	**N40179 001**	JAN 30, 1997
AA		25MG	**N40179 002**	JAN 30, 1997
AA	WATSON LABS	25MG	**N85740 001**	

TABLET, CHEWABLE; ORAL

	ANTIVERT			
AA	+ PFIZER	25MG	**N10721 005**	
	MECLIZINE HCL			
AA	SIDMAK LABS NJ	25MG	**N88733 001**	DEC 11, 1985

MECLOFENAMATE SODIUM

CAPSULE; ORAL

	MECLOFENAMATE SODIUM			
AB	GENEVA PHARMS	EQ 50MG BASE	**N72262 001**	NOV 29, 1988
AB		EQ 100MG BASE	**N72263 001**	NOV 29, 1988
AB	MYLAN	EQ 50MG BASE	**N71080 001**	SEP 03, 1986
AB		EQ 100MG BASE	**N71081 001**	SEP 03, 1986
AB	WATSON LABS	EQ 50MG BASE	**N71468 001**	APR 15, 1987
AB		EQ 100MG BASE	**N71469 001**	APR 15, 1987
	MECLOMEN			
AB	PARKE DAVIS	EQ 50MG BASE	**N18006 001**	
AB	+	EQ 100MG BASE	**N18006 002**	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA			
	+ PHARMACIA AND UPJOHN	150MG/ML	N20246 001	OCT 29, 1992
	+	400MG/ML	N12541 003	

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

	MEDROXYPROGESTERONE ACETATE			
AB	BARR	2.5MG	**N40159 001**	AUG 09, 1996
AB		5MG	**N40159 002**	AUG 09, 1996
AB		10MG	**N40159 003**	AUG 09, 1996
AB	DURAMED PHARM BARR	2.5MG	**N40311 001**	DEC 01, 1999
AB		5MG	**N40311 002**	DEC 01, 1999
AB		10MG	**N40311 003**	DEC 01, 1999
BP	USL PHARMA	10MG	N88484 001	JUL 26, 1984
	PROVERA			
AB	PHARMACIA AND UPJOHN	2.5MG	**N11839 001**	
AB		5MG	**N11839 003**	
AB	+	10MG	**N11839 004**	

MEDROXYPROGESTERONE ACETATE; *MULTIPLE*

SEE ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

SEE ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

MEDRYSONE

SUSPENSION; OPHTHALMIC

	HMS		
+	ALLERGAN	1%	N16624 003

MEFENAMIC ACID

CAPSULE; ORAL

	PONSTEL		
+	FIRST HORIZON	250MG	N15034 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

	LARIAM			
AB	+ ROCHE	250MG	**N19591 001**	MAY 02, 1989

FDA data supplied by DrugPatentWatch.com

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

	MEFLOQUINE HCL			
AB	GENEVA PHARMS TECH	250MG	**N76175 001**	FEB 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

	MEGACE			
AB	+ BRISTOL MYERS SQUIBB	40MG/ML	**N20264 001**	SEP 10, 1993
	MEGESTROL ACETATE			
AB	PAR PHARM	40MG/ML	**N75671 001**	JUL 25, 2001
AB	ROXANE	40MG/ML	**N75997 001**	FEB 15, 2002

TABLET; ORAL

	MEGACE			
AB	BRISTOL MYERS SQUIBB	20MG	**N16979 001**	
AB	+	40MG	**N16979 002**	
	MEGESTROL ACETATE			
AB	BARR	20MG	**N74621 002**	AUG 16, 1996
AB		40MG	**N74621 001**	NOV 30, 1995
AB	PAR PHARM	20MG	**N72422 001**	AUG 08, 1988
AB		40MG	**N72423 001**	AUG 08, 1988
AB	ROXANE	20MG	**N74458 001**	SEP 29, 1995
AB		40MG	**N74458 002**	SEP 29, 1995
AB	TEVA	40MG	**N74745 001**	FEB 27, 1998

MELOXICAM

TABLET; ORAL

	MOBIC			
	BOEHRINGER INGELHEIM	7.5MG	N20938 001	APR 13, 2000
	+	15MG	N20938 002	AUG 23, 2000

MELPHALAN

TABLET; ORAL

	ALKERAN			
	+ GLAXOSMITHKLINE	2MG	N14691 002	

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

	ALKERAN			
	+ GLAXOSMITHKLINE	EQ 50MG BASE/VIAL	N20207 001	NOV 18, 1992

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	PERGONAL			
BX	+ SERONO	75 IU/AMP;75 IU/AMP	N17646 001	
	REPRONEX			
BX	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999
	+	150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999

MEPENZOLATE BROMIDE

TABLET; ORAL

	CANTIL			
	+ AVENTIS PHARMS	25MG	N10679 003	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DEMEROL			
AP	+ ABBOTT	25MG/ML	**N21171 001**	
AP	+	50MG/ML	**N21171 002**	
AP	+	75MG/ML	**N21171 003**	
AP	+	100MG/ML	**N21171 004**	
	MEPERIDINE HCL			
AP	ELKINS SINN	25MG/ML	**N80445 001**	
AP		50MG/ML	**N80445 002**	
AP		75MG/ML	**N80445 003**	
AP		100MG/ML	**N80445 004**	
AP	STERIS	50MG/ML	**N73444 001**	MAR 17, 1992

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPERIDINE HCL			
AP	STERIS	100MG/ML	N73445 001	MAR 17, 1992
AP	WYETH AYERST	25MG/ML	N80455 007	
AP		50MG/ML	N80455 008	
AP		75MG/ML	N80455 009	
AP		100MG/ML	N80455 010	
	MEPERIDINE HCL PRESERVATIVE FREE			
AP	+ ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
AP	ASTRAZENECA	10MG/ML	N81002 001	JUL 30, 1993
AP	FAULDING	10MG/ML	N40305 001	MAR 10, 1999
AP	INTL MEDICATION	10MG/ML	N81309 001	AUG 30, 1993
AP	MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997
AP	STERIS	10MG/ML	N73443 001	MAR 17, 1992

SYRUP; ORAL

	DEMEROL			
AA	+ SANOFI SYNTHELABO	50MG/5ML	N05010 005	
	MEPERIDINE HCL			
AA	ROXANE	50MG/5ML	N88744 001	JAN 30, 1985

TABLET; ORAL

	DEMEROL			
AA	+ SANOFI SYNTHELABO	50MG	N05010 001	
AA	+	100MG	N05010 004	
	MEPERIDINE HCL			
AA	AMIDE PHARM	50MG	N40331 001	MAY 28, 1999
AA		100MG	N40331 002	MAY 28, 1999
AA	BARR	50MG	N88639 001	JUL 02, 1984
AA		100MG	N88640 001	SEP 19, 1984
AA	CARACO	50MG	N40446 001	AUG 08, 2002
AA		100MG	N40446 002	AUG 08, 2002

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

	MEPERIDINE HCL			
AA	DURAMED PHARM BARR	50MG	N40318 001	OCT 05, 1999
AA		100MG	N40318 002	OCT 05, 1999
AA	HALSEY	50MG	N80448 001	
AA		100MG	N80448 002	
AA	MALLINCKRODT	50MG	N40352 001	JUN 13, 2000
AA		100MG	N40352 002	JUN 13, 2000
AA	ROXANE	50MG	N40110 001	MAR 12, 1997
AA		100MG	N40110 002	MAR 12, 1997
AA	VINTAGE PHARMS	50MG	N40191 001	DEC 17, 1998
AA		100MG	N40191 002	DEC 17, 1998
AA	WATSON LABS	50MG	N40186 001	JUN 30, 1997
AA		100MG	N40186 002	JUN 30, 1997
AA	WYETH AYERST	50MG	N80454 001	

MEPERIDINE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CARBOCAINE			
AP	+ EASTMAN KODAK	3%	N12125 003	
AP	+ STERLING WINTHROP	1%	N12250 001	
AP	+	1.5%	N12250 005	
AP	+	2%	N12250 002	
	ISOCAINE HCL			
AP	NOVOCOL	3%	N80925 001	
	MEPIVACAINE HCL			
AP	GRAHAM CHEM	3%	N83559 001	
AP	STERIS	1%	N88769 001	NOV 20, 1984
AP		2%	N88770 001	NOV 20, 1984

FDA data supplied by DrugPatentWatch.com

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	POLOCAINE			
AP	ASTRAZENECA	1%	N89407 001	DEC 01, 1986
AP		2%	N89410 001	DEC 01, 1986
AP	DENTSPLY PHARM	3%	N88653 001	AUG 21, 1984
	POLOCAINE-MPF			
AP	ASTRAZENECA	1%	N89406 001	DEC 01, 1986
AP		1.5%	N89408 001	DEC 01, 1986
AP		2%	N89409 001	DEC 01, 1986
	SCANDONEST PLAIN			
AP	DEPROCO	3%	N88387 001	OCT 10, 1984

MEPIVACAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

MEPROBAMATE

TABLET; ORAL

	EQUANIL			
AA	+ WYETH AYERST	200MG	N10028 005	
AA	+	400MG	N10028 004	
	MEPROBAMATE			
AA	EON	200MG	N14547 002	
AA		400MG	N14547 001	
AA	GENEVA PHARMS	400MG	N80655 001	
AA	MYLAN	400MG	N83618 001	
AA	ROXANE	600MG	N84332 001	
AA	SCHERER LABS	400MG	N83343 001	
AA	TABLICAPS	400MG	N83494 001	
AA	WATSON LABS	200MG	N83304 001	
AA		200MG	N85720 001	
AA		400MG	N83308 001	
AA		400MG	N85721 001	
AA	WEST WARD	200MG	N15417 003	
AA		400MG	N15417 002	
	MILTOWN			
AA	WALLACE LABS	200MG	N09698 004	
AA		400MG	N09698 002	

MEPROBAMATE

TABLET; ORAL

	MILTOWN			
AA	+ WALLACE PHARMS	600MG	N83919 001	
	TRANMEP			
AA	SOLVAY	400MG	N16249 001	

MEPROBAMATE; *MULTIPLE*
SEE ASPIRIN; MEPROBAMATE

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

	SOLAGE		
	+ GALDERMA LABS	2%;0.01%	N20922 001 DEC 10, 1999

MERCAPTOPURINE

TABLET; ORAL

	PURINETHOL		
	+ GLAXOSMITHKLINE	50MG	N09053 002

MEROPENEM

INJECTABLE; INJECTION

	MERREM I.V.		
	+ ASTRAZENECA	500MG/VIAL	N50706 003 JUN 21, 1996
	+	1GM/VIAL	N50706 001 JUN 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

	PENTASA		
	+ SHIRE LABS	250MG	N20049 001 MAY 10, 1993

ENEMA; RECTAL

	ROWASA		
	+ SOLVAY	4GM/60ML	N19618 001 DEC 24, 1987

FDA data supplied by DrugPatentWatch.com

MESALAMINE

SUPPOSITORY; RECTAL

	CANASA			
+	AXCAN SCANDIPHARM	500MG	N21252 001	
			JAN 05, 2001	

TABLET, DELAYED RELEASE; ORAL

	ASACOL			
+	PROCTER AND GAMBLE	400MG	N19651 001	
			JAN 31, 1992	

MESNA

INJECTABLE; INTRAVENOUS

	MESNA			
AP	AM PHARM PARTNERS	**100MG/ML**	**N75811 001**	
			APR 26, 2001	
AP	GENSIA SICOR PHARMS	**100MG/ML**	**N75764 001**	
			APR 27, 2001	
	MESNEX			
AP	+ BAXTER HLTHCARE	**100MG/ML**	**N19884 001**	
			DEC 30, 1988	

TABLET; ORAL

	MESNEX			
+	BAXTER HLTHCARE	400MG	N20855 001	
			MAR 21, 2002	

MESNA; *MULTIPLE*
SEE IFOSFAMIDE; MESNA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

	SERENTIL			
+	NOVARTIS	EQ 25MG BASE/ML	N16997 001	

TABLET; ORAL

	SERENTIL			
	NOVARTIS	EQ 10MG BASE	N16774 001	
		EQ 25MG BASE	N16774 002	
		EQ 50MG BASE	N16774 003	
+		EQ 100MG BASE	N16774 004	

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

	NORETHIN 1/50M-21			
AB	WATSON LABS	**0.05MG;1MG**	**N71539 001**	
			APR 12, 1988	
	NORETHINDRONE AND MESTRANOL			
AB	WATSON LABS	**0.05MG;1MG**	**N70758 001**	
			JUL 01, 1988	
	NORINYL 1+50 21-DAY			
AB	WATSON LABS	**0.05MG;1MG**	**N13625 002**	
	ORTHO-NOVUM 1/50 21			
AB	+ ORTHO MCNEIL PHARM	**0.05MG;1MG**	**N12728 004**	

TABLET; ORAL-28

	NORETHIN 1/50M-28			
AB	WATSON LABS	**0.05MG;1MG**	**N71540 001**	
			APR 12, 1988	
	NORETHINDRONE AND MESTRANOL			
AB	WATSON LABS	**0.05MG;1MG**	**N70759 001**	
			JUL 01, 1988	
	NORINYL 1+50 28-DAY			
AB	WATSON LABS	**0.05MG;1MG**	**N16659 001**	
	ORTHO-NOVUM 1/50 28			
AB	ORTHO MCNEIL PHARM	**0.05MG;1MG**	**N16709 001**	

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

	ALUPENT			
+	BOEHRINGER INGELHEIM	0.65MG/INH	N16402 001	

SOLUTION; INHALATION

	ALUPENT			
AN	+ BOEHRINGER INGELHEIM	**0.4%**	**N18761 002**	
			OCT 10, 1986	
AN	+	**0.6%**	**N18761 001**	
			JUN 30, 1983	
	METAPROTERENOL SULFATE			
AN	DEY	**0.4%**	**N71786 001**	
			AUG 05, 1988	
AN		**0.6%**	**N70804 001**	
			AUG 17, 1987	
AN	MORTON GROVE	**0.4%**	**N75586 001**	
			MAY 30, 2002	
AN		**0.6%**	**N75586 002**	
			MAY 30, 2002	

FDA data supplied by DrugPatentWatch.com

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE			
AN	NEPHRON	0.4%	N71855 001	JUL 14, 1988
AN		0.6%	N71726 001	JUL 14, 1988
AN	NOVEX	0.4%	N75402 001	FEB 28, 2001
AN		0.6%	N75403 001	FEB 28, 2001

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	+ MORTON GROVE	10MG/5ML	N74702 001	MAR 24, 1997
AA	NOVEX	10MG/5ML	N75235 001	JAN 27, 2000
AA	SILARX	10MG/5ML	N73632 001	JUL 22, 1992

TABLET; ORAL

	METAPROTERENOL SULFATE			
AB	PAR PHARM	10MG	N72024 001	JUN 28, 1988
AB	+	20MG	N72025 001	JUN 28, 1988
AB	TEVA	10MG	N72519 001	MAR 30, 1990
AB		20MG	N72520 001	MAR 30, 1990
AB	WATSON LABS	10MG	N73013 001	JAN 31, 1991
AB		20MG	N72795 001	JAN 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

	ARAMINE			
AP	+ MERCK	EQ 10MG BASE/ML	N09509 002	DEC 22, 1987
	METARAMINOL BITARTRATE			
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N80722 001	

METAXALONE

TABLET; ORAL

	SKELAXIN			
	ELAN PHARMS	400MG	N13217 001	
	+	800MG	N13217 003	AUG 30, 2002

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
AB	BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995
AB		850MG	N20357 002	MAR 03, 1995
AB	+	1GM	N20357 005	NOV 05, 1998
	METFORMIN HCL			
AB	ALPHAPHARM	500MG	N75969 001	JAN 29, 2002
AB		850MG	N75969 002	JAN 29, 2002
AB		1GM	N75969 003	JAN 29, 2002
AB	ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002
AB		850MG	N75961 002	JAN 25, 2002
AB		1GM	N75961 003	JAN 25, 2002
AB	BARR	500MG	N75971 001	JAN 25, 2002
AB		850MG	N75971 002	JAN 25, 2002
AB		1GM	N75971 003	JAN 25, 2002
AB	CARACO	500MG	N75967 001	JAN 29, 2002
AB		850MG	N75967 002	JAN 29, 2002
AB		1GM	N75967 003	JAN 29, 2002
AB	EON	500MG	N75965 001	JAN 25, 2002
AB		850MG	N75965 002	JAN 25, 2002

FDA data supplied by DrugPatentWatch.com

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HCL

AB	EON	1GM	N75965 003	JAN 25, 2002
AB	GENEVA PHARMS	500MG	N75985 001	JAN 25, 2002
AB		850MG	N75985 002	JAN 25, 2002
AB		1GM	N75985 003	JAN 25, 2002
AB	GENPHARM	500MG	N75973 001	JAN 25, 2002
AB		850MG	N75973 002	JAN 25, 2002
AB		1GM	N75973 003	JAN 25, 2002
AB	GOLDLINE	500MG	N75972 001	JAN 24, 2002
AB		625MG	N75972 005	JAN 24, 2002
AB		750MG	N75972 004	JAN 24, 2002
AB		850MG	N75972 002	JAN 24, 2002
AB		1GM	N75972 003	JAN 24, 2002
AB	MUTUAL PHARMA	500MG	N76038 001	FEB 21, 2002
AB		850MG	N76038 002	FEB 21, 2002
AB		1GM	N76038 003	FEB 21, 2002
AB	MYLAN	500MG	N75976 001	JAN 24, 2002
AB		850MG	N75976 002	JAN 24, 2002
AB		1GM	N75976 003	JAN 24, 2002
AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002
AB		850MG	N76033 002	JAN 24, 2002
AB		1GM	N76033 003	JAN 24, 2001
AB	TEVA	500MG	N75978 001	JAN 25, 2002

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HCL

AB	TEVA	500MG	N76328 001	DEC 16, 2002
AB		850MG	N75978 002	JAN 25, 2002
AB		850MG	N76328 002	DEC 16, 2002
AB		1GM	N75978 003	NOV 05, 2002
AB		1GM	N76328 003	DEC 16, 2002
AB	TORPHARM	500MG	N75984 001	APR 23, 2002
AB		850MG	N75984 002	APR 23, 2002
AB		1GM	N75984 003	APR 23, 2002
AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002
AB		850MG	N75979 002	JAN 24, 2002
AB		1GM	N75979 003	JAN 24, 2002
AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002
AB		625MG	N75975 004	JAN 24, 2002
AB		750MG	N75975 005	JAN 24, 2002
AB		850MG	N75975 002	JAN 24, 2002
AB		1GM	N75975 003	JAN 24, 2002

TABLET, EXTENDED RELEASE; ORAL
GLUCOPHAGE XR

+	BRISTOL MYERS SQUIBB	500MG	N21202 001	OCT 13, 2000

METFORMIN HYDROCHLORIDE; *MULTIPLE*
SEE GLIPIZIDE; METFORMIN HYDROCHLORIDE
SEE GLYBURIDE; METFORMIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDAMET
GLAXOSMITHKLINE
500MG;EQ 1MG BASE N21410 001 OCT 10, 2002
500MG;EQ 2MG BASE N21410 002 OCT 10, 2002
+ 500MG;EQ 4MG BASE N21410 003 OCT 10, 2002

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION
PROVOCHOLINE
METHAPHARM
100MG/VIAL N19193 001 OCT 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL
AA ROXANE **10MG/ML** **N40180 001** APR 30, 1998
AA UDL **10MG/ML** **N40088 001** NOV 30, 1994

METHADONE HCL INTENSOL
AA ROXANE **10MG/ML** **N89897 001** SEP 06, 1988

METHADOSE
AA + MALLINCKRODT **10MG/ML** **N17116 002**

INJECTABLE; INJECTION
DOLOPHINE HCL
+ ROXANE 10MG/ML N06134 006

POWDER; FOR RX COMPOUNDING
METHADONE HCL
MALLINCKRODT
50GM/BOT N06383 002
100GM/BOT N06383 003
500GM/BOT N06383 004

SOLUTION; ORAL
METHADONE HCL
+ ROXANE
5MG/5ML N87393 001
+ 10MG/5ML N87997 001 AUG 30, 1982

METHADONE HYDROCHLORIDE

TABLET; ORAL
DOLOPHINE HCL
AA + ROXANE **5MG** **N06134 002**
AA + **10MG** **N06134 010**
METHADONE HCL
AA EON **5MG** **N40241 001** MAY 29, 1998
AA **10MG** **N40241 002** MAY 29, 1998
AA **40MG** **N75082 001** MAR 25, 1998
AA ROXANE **5MG** **N88108 001** MAR 08, 1983
AA **10MG** **N88109 001** MAR 08, 1983
AA + **40MG** **N17058 001**
AA **40MG** **N74081 001** APR 28, 1995

METHADOSE
AA MALLINCKRODT **5MG** **N40050 001** APR 15, 1993
AA **10MG** **N40050 002** APR 15, 1993
AA **40MG** **N74184 001** APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
DESOXYN
+ OVATION PHARMS 5MG N05378 002

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE
AB COPLEY PHARM **25MG** **N40001 001** JUN 30, 1993
AB **50MG** **N40001 002** JUN 30, 1993
AB GENEVA PHARMS **25MG** **N40036 001** JUN 30, 1993
AB **50MG** **N40036 002** JUN 30, 1993

FDA data supplied by DrugPatentWatch.com

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE			
AB	INVAMED	25MG	N40102 001	AUG 28, 1996
AB		50MG	N40102 002	AUG 28, 1996
AB	MIKART	25MG	N40062 001	JAN 27, 1994
AB		50MG	N40062 002	JAN 27, 1994
	NEPTAZANE			
AB	LEDERLE	25MG	N11721 002	NOV 25, 1991
AB +		50MG	N11721 001	

METHENAMINE HIPPURATE

TABLET; ORAL

	HIPREX			
AB	+ AVENTIS PHARMS	1GM	N17681 001	
	UREX			
AB	3M	1GM	N16151 001	

METHIMAZOLE

TABLET; ORAL

	METHIMAZOLE			
AB	EON	5MG	N40411 001	MAR 27, 2001
AB		10MG	N40411 002	MAR 27, 2001
AB	GENPHARM	5MG	N40350 001	MAR 29, 2000
AB		10MG	N40350 002	MAR 29, 2000
+		20MG	N40350 003	JUN 07, 2001
AB	JONES PHARMA	5MG	N40320 001	MAR 31, 2000
AB		10MG	N40320 002	MAR 31, 2000
	TAPAZOLE			
AB	LILLY	5MG	N07517 002	
AB +		10MG	N07517 004	

METHOCARBAMOL

INJECTABLE; INJECTION

	METHOCARBAMOL		
AP	STERIS	100MG/ML	N86459 001
	ROBAXIN		
AP +	ROBINS AH	100MG/ML	N11790 001

TABLET; ORAL

	METHOCARBAMOL		
AA	EON	500MG	N87283 001
AA		750MG	N87282 001
AA	GENEVA PHARMS	500MG	N84616 001
AA		750MG	N84615 001
AA	IMPAX LABS	500MG	N84927 001
AA		750MG	N84928 001
AA	LANNETT	750MG	N84756 001
AA	LEDERLE	500MG	N85961 001
AA		750MG	N85963 001
AA	NYLOS	750MG	N85033 001
AA	PAR PHARM	500MG	N86989 001
AA		750MG	N86988 001
AA	SUPERPHARM	500MG	N87589 001 JAN 22, 1982
AA		750MG	N87590 001 JAN 22, 1982
AA	TABLICAPS	500MG	N84846 001
AA	WATSON LABS	500MG	N84277 001
AA		500MG	N85180 001
AA		750MG	N84276 002
AA		750MG	N85192 001
AA	WEST WARD	500MG	N85159 001
AA		750MG	N85123 001
	ROBAXIN		
AA +	SCHWARZ PHARMA	500MG	N11011 004
	ROBAXIN-750		
AA +	SCHWARZ PHARMA	750MG	N11011 006

METHOCARBAMOL; *MULTIPLE*
SEE ASPIRIN; METHOCARBAMOL

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

	BREVITAL SODIUM		
+	KING PHARMS	500MG/VIAL	N11559 001
+		2.5GM/VIAL	N11559 002

FDA data supplied by DrugPatentWatch.com

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM
+ KING PHARMS — 5GM/VIAL — N11559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX
PHARMACIA AND UPJOHN — EQ 25MG BASE/VIAL — N87695 001 APR 08, 1983
+ — EQ 50MG BASE/VIAL — N87695 002 APR 08, 1983
+ — EQ 100MG BASE/VIAL — N87695 003 APR 08, 1983
EQ 250MG BASE/VIAL — N88954 001 OCT 24, 1985

METHOTREXATE
AP BIGMAR — **EQ 25MG BASE/ML** — **N40263 001** FEB 26, 1999

METHOTREXATE LPF
AP + LEDERLE — **EQ 25MG BASE/ML** — **N11719 007** MAR 31, 1982

METHOTREXATE PRESERVATIVE FREE
AP BIGMAR — **EQ 1GM BASE/VIAL** — **N40266 001** FEB 26, 1999
AP — **EQ 25MG BASE/ML** — **N40265 001** FEB 26, 1999

METHOTREXATE SODIUM
AP BEDFORD — **EQ 25MG BASE/ML** — **N89340 001** SEP 16, 1986
AP — **EQ 25MG BASE/ML** — **N89341 001** SEP 16, 1986
AP — **EQ 25MG BASE/ML** — **N89342 001** SEP 16, 1986
AP — **EQ 25MG BASE/ML** — **N89343 001** SEP 16, 1986
AP + LEDERLE — **EQ 25MG BASE/ML** — **N11719 005**
+ — EQ 20MG BASE/VIAL — N11719 001
AP NORBROOK — **EQ 25MG BASE/ML** — **N88648 001** MAY 09, 1986
AP PHARMACHEMIE USA — **EQ 25MG BASE/ML** — **N89158 001** JUL 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE
AP + LEDERLE — **EQ 1GM BASE/VIAL** — **N11719 009** APR 07, 1988

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ
AP BRISTOL MYERS — **EQ 25MG BASE/ML** — **N88760 001** FEB 14, 1985

TABLET; ORAL
METHOTREXATE SODIUM
AB BARR — **EQ 2.5MG BASE** — **N81099 001** OCT 15, 1990
AB + CLONMEL HLTHCARE — **EQ 2.5MG BASE** — **N08085 002**
AB DURAMED PHARM BARR — **EQ 2.5MG BASE** — **N40233 001** JUN 17, 1999
AB MYLAN — **EQ 2.5MG BASE** — **N81235 001** MAY 15, 1992
AB ROXANE — **EQ 2.5MG BASE** — **N40054 001** AUG 01, 1994

TREXALL
BARR — EQ 5MG BASE — N40385 001 MAR 21, 2001
EQ 7.5MG BASE — N40385 002 MAR 21, 2001
EQ 10MG BASE — N40385 003 MAR 21, 2001
+ — EQ 15MG BASE — N40385 004 MAR 21, 2001

METHOXSALEN

CAPSULE; ORAL
8-MOP
+ ICN — 10MG — N09048 001
OXSORALEN-ULTRA
+ ICN — 10MG — N19600 001 OCT 30, 1986

INJECTABLE; INJECTION
UVADEX
+ THERAKOS — 0.02MG/ML — N20969 001 FEB 25, 1999

LOTION; TOPICAL
OXSORALEN
+ ICN — 1% — N09048 002

FDA data supplied by DrugPatentWatch.com

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

	PAMINE			
+	BRADLEY PHARMS	2.5MG	N08848 001	

METHSUXIMIDE

CAPSULE; ORAL

	CELONTIN			
	PARKE DAVIS	150MG	N10596 007	
+		300MG	N10596 008	

METHYCLOTHIAZIDE

TABLET; ORAL

	AQUATENSEN			
AB	WALLACE LABS	**5MG**	**N17364 001**	
	ENDURON			
AB	ABBOTT	**2.5MG**	**N12524 001**	
AB +		**5MG**	**N12524 004**	
	METHYCLOTHIAZIDE			
AB	GENEVA PHARMS	**2.5MG**	**N89835 001** AUG 18, 1988	
AB		**5MG**	**N89837 001** AUG 18, 1988	
AB	IVAX PHARMS	**2.5MG**	**N87913 001** JUN 03, 1982	
AB	MYLAN	**5MG**	**N87672 001** AUG 17, 1982	
AB	WATSON LABS	**5MG**	**N88724 001** SEP 06, 1984	

METHYCLOTHIAZIDE; *MULTIPLE*
SEE DESERPIDINE; METHYCLOTHIAZIDE

METHYLDOPA

TABLET; ORAL

	ALDOMET			
AB	MERCK	**125MG**	**N13400 003**	
AB		**250MG**	**N13400 001**	
AB +		**500MG**	**N13400 002**	
	METHYLDOPA			
AB	GENEVA PHARMS	**125MG**	**N71700 001** MAR 02, 1988	

METHYLDOPA

TABLET; ORAL

	METHYLDOPA			
AB	GENEVA PHARMS	**250MG**	**N18934 001** JUN 29, 1984	
AB		**500MG**	**N18934 002** JUN 29, 1984	
AB	IVAX PHARMS	**250MG**	**N70098 001** FEB 20, 1986	
AB		**500MG**	**N70343 001** FEB 20, 1986	
AB	LEDERLE	**250MG**	**N70084 001** OCT 15, 1985	
AB		**500MG**	**N70085 001** OCT 15, 1985	
AB	MYLAN	**250MG**	**N70075 001** APR 18, 1985	
AB		**500MG**	**N70076 001** APR 18, 1985	
AB	PAR PHARM	**125MG**	**N70535 001** JAN 02, 1987	
AB		**250MG**	**N70536 001** JAN 02, 1987	
AB		**500MG**	**N70537 001** JAN 02, 1987	
AB	SIDMAK LABS NJ	**125MG**	**N72126 001** JUL 07, 1988	
AB		**250MG**	**N72127 001** JUL 07, 1988	
AB		**500MG**	**N72128 001** JUL 07, 1988	
AB	SUPERPHARM	**250MG**	**N70669 001** JUN 23, 1989	
AB		**500MG**	**N70670 001** JUN 23, 1989	
AB	WATSON LABS	**250MG**	**N70703 001** JUN 06, 1986	
AB		**500MG**	**N70625 001** JUN 06, 1986	

METHYLDOPA; *MULTIPLE*
SEE CHLOROTHIAZIDE; METHYLDOPA
SEE HYDROCHLOROTHIAZIDE; METHYLDOPA

FDA data supplied by DrugPatentWatch.com

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	ALDOMET			
AP	+ MERCK	50MG/ML	N13401 001	
	METHYLDOPATE HCL			
AP	ABBOTT	50MG/ML	N70698 001	JUN 15, 1987
AP		50MG/ML	N70699 001	JUN 15, 1987
AP	ELKINS SINN	50MG/ML	N70291 001	JUL 01, 1986
AP	GENSIA SICOR PHARMS	50MG/ML	N72974 001	NOV 22, 1991
AP	LUITPOLD	50MG/ML	N71279 001	OCT 02, 1987

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

	METHERGINE		
+	NOVARTIS	0.2MG/ML	N06035 004

TABLET; ORAL

	METHERGINE		
	NOVARTIS	0.2MG	N06035 003

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	METADATE CD			
BX	+ CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001
	RITALIN LA			
BX	NOVARTIS	20MG	N21284 001	JUN 05, 2002
		30MG	N21284 002	JUN 05, 2002
	+	40MG	N21284 003	JUN 05, 2002

SOLUTION; ORAL

	METHYLIN			
	+ MALLINCKRODT BAKER	5MG/5ML	N21419 001	DEC 19, 2002
	+	10MG/5ML	N21419 002	DEC 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	METHYLPHENIDATE HCL			
AB	ABLE	5MG	**N40404 001**	MAR 29, 2001
AB		10MG	**N40404 002**	MAR 29, 2001
AB		20MG	**N40404 003**	MAR 29, 2001
AB	CELLTECH MFG	5MG	**N86429 001**	
AB		10MG	**N85799 001**	
AB		20MG	**N86428 001**	
AB	MALLINCKRODT	5MG	**N40300 001**	NOV 27, 1998
AB		10MG	**N40300 002**	NOV 27, 1998
AB		20MG	**N40300 003**	NOV 27, 1998
AB	PUREPAC PHARM	5MG	**N40321 001**	FEB 05, 2002
AB		10MG	**N40321 002**	FEB 05, 2002
AB		20MG	**N40321 003**	FEB 05, 2002
AB	WATSON LABS	5MG	**N40220 001**	AUG 29, 1997
AB		10MG	**N40220 002**	AUG 29, 1997
AB		20MG	**N40220 003**	AUG 29, 1997
	RITALIN			
AB	NOVARTIS	5MG	**N10187 003**	
AB		10MG	**N10187 006**	
AB	+	20MG	**N10187 010**	

TABLET, EXTENDED RELEASE; ORAL

	CONCERTA			
	+ ALZA	18MG	N21121 001	AUG 01, 2000
	+	27MG	N21121 004	APR 01, 2002
	+	36MG	N21121 002	AUG 01, 2000
	+	54MG	N21121 003	DEC 08, 2000
	METADATE ER			
AB	+ CELLTECH MFG	20MG	**N89601 001**	JUN 01, 1988

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	METADATE ER			
AB	CELLTECH PHARMS	10MG	N40306 001	OCT 20, 1999
	METHYLIN ER			
AB	MALLINCKRODT	10MG	N75629 001	MAY 09, 2000
AB		20MG	N75629 002	MAY 09, 2000
	METHYLPHENIDATE HCL			
AB	ABLE	20MG	N76032 001	MAY 09, 2001
AB	PUREPAC PHARM	20MG	N75450 001	DEC 21, 2001
AB	WATSON LABS	20MG	N40410 001	FEB 09, 2001
	RITALIN-SR			
AB	NOVARTIS	20MG	N18029 001	MAR 30, 1982

METHYLPREDNISOLONE

TABLET; ORAL

	MEDROL			
AB	PHARMACIA AND UPJOHN	4MG	N11153 001	
AB		8MG	N11153 004	
AB		16MG	N11153 003	
AB		24MG	N11153 005	
AB	+	32MG	N11153 006	
		2MG	N11153 002	
	METHYLPREDNISOLONE			
AB	DURAMED PHARM BARR	4MG	N88497 001	FEB 21, 1984
AB	GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997
AB	PAR PHARM	16MG	N89207 001	APR 25, 1988
AB		24MG	N89208 001	APR 25, 1988
AB		32MG	N89209 001	APR 25, 1988
AB	TRIGEN	4MG	N40189 001	OCT 31, 1997
AB		8MG	N40189 002	OCT 31, 1997

METHYLPREDNISOLONE

TABLET; ORAL

	METHYLPREDNISOLONE			
AB	VINTAGE PHARMS	4MG	N40183 001	DEC 22, 1998
AB	WATSON LABS	4MG	N40232 001	OCT 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

	DEPO-MEDROL			
BP	PHARMACIA AND UPJOHN	20MG/ML	N11757 002	
		40MG/ML	N11757 001	
+		80MG/ML	N11757 004	

OINTMENT; TOPICAL

	MEDROL ACETATE			
+	PHARMACIA AND UPJOHN	0.25%	N12421 001	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-METHAPRED			
AP	ABBOTT	EQ 1GM BASE/VIAL	N85852 001	
AP		EQ 1GM BASE/VIAL	N89174 001	AUG 18, 1987
AP		EQ 40MG BASE/VIAL	N85853 001	
AP		EQ 125MG BASE/VIAL	N85855 001	
AP		EQ 500MG BASE/VIAL	N85854 001	
AP		EQ 500MG BASE/VIAL	N89173 001	AUG 18, 1987
	METHYLPREDNISOLONE SODIUM SUCCINATE			
AP	GENSIA SICOR PHARMS	EQ 125MG BASE/VIAL	N81266 001	NOV 30, 1992
	SOLU-MEDROL			
AP +	PHARMACIA AND UPJOHN	EQ 40MG BASE/VIAL	N11856 003	
AP +		EQ 125MG BASE/VIAL	N11856 004	
AP +		EQ 500MG BASE/VIAL	N11856 005	
AP +		EQ 1GM BASE/VIAL	N11856 006	
+		EQ 2GM BASE/VIAL	N11856 007	FEB 27, 1985

FDA data supplied by DrugPatentWatch.com

METHYLTESTOSTERONE

CAPSULE; ORAL

	TESTRED			
BP	+ ICN	10MG	N83976 001	
	VIRILON			
BP	STAR PHARMS FL	10MG	N87750 001	NOV 24, 1982

TABLET; ORAL

	ANDROID 10			
AB	ICN	**10MG**	**N86450 001**	
	ANDROID 25			
AB	+ ICN	**25MG**	**N87147 001**	
	METHYLTESTOSTERONE			
BP	IMPAX LABS	10MG	N80767 002	
BP		25MG	N84310 001	

METHYSERGIDE MALEATE

TABLET; ORAL

	SANSERT			
	+ NOVARTIS	2MG	N12516 001	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	METIPRANOLOL			
AT	FALCON PHARMS	**0.3%**	**N75720 001**	AUG 06, 2001
	OPTIPRANOLOL			
AT	+ BAUSCH AND LOMB	**0.3%**	**N19907 001**	DEC 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

	METOCLOPRAMIDE INTENSOL			
	ROXANE	EQ 10MG BASE/ML	N72995 001	JAN 30, 1992

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	ABBOTT	**EQ 5MG BASE/ML**	**N70505 001**	JUN 23, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	ABBOTT	**EQ 5MG BASE/ML**	**N73117 001**	JAN 17, 1991
AP		**EQ 5MG BASE/ML**	**N73118 001**	JAN 17, 1991
AP		**EQ 5MG BASE/ML**	**N74147 001**	AUG 02, 1996
AP	FAULDING	**EQ 5MG BASE/ML**	**N70847 001**	NOV 07, 1988
AP		**EQ 5MG BASE/ML**	**N71291 001**	MAR 03, 1989
AP	GENSIA SICOR PHARMS	**EQ 5MG BASE/ML**	**N73135 001**	NOV 27, 1991
	REGLAN			
AP	+ ROBINS AH	**EQ 5MG BASE/ML**	**N17862 001**	

SOLUTION; ORAL

	METOCLOPRAMIDE			
AA	JVL	**EQ 5MG BASE/5ML**	**N74703 001**	OCT 31, 1997
AA	UDL	**EQ 5MG BASE/5ML**	**N75051 001**	JAN 26, 2001
	METOCLOPRAMIDE HCL			
AA	ALPHARMA	**EQ 5MG BASE/5ML**	**N71340 001**	AUG 18, 1988
AA	PHARM ASSOC	**EQ 5MG BASE/5ML**	**N72744 001**	MAY 28, 1991
AA	PHARM VENTURES	**EQ 5MG BASE/5ML**	**N71402 001**	JUN 25, 1993
AA	ROXANE	**EQ 5MG BASE/5ML**	**N72038 001**	DEC 05, 1988
AA	SILARX	**EQ 5MG BASE/5ML**	**N73680 001**	OCT 27, 1992
AA	+ TEVA	**EQ 5MG BASE/5ML**	**N70819 001**	JUL 10, 1987
AA		**EQ 5MG BASE/5ML**	**N71315 001**	JUN 30, 1993

TABLET; ORAL

	METOCLOPRAMIDE HCL			
AB	GENEVA PHARMS	**EQ 10MG BASE**	**N72215 001**	JAN 30, 1990
AB	GENEVA PHARMS TECH	**EQ 5MG BASE**	**N74478 001**	OCT 05, 1995
AB		**EQ 10MG BASE**	**N74478 002**	OCT 05, 1995

FDA data supplied by DrugPatentWatch.com

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

	METOCLOPRAMIDE HCL			
AB	LEDERLE	EQ 10MG BASE	N72639 001	MAY 09, 1991
AB	PUREPAC PHARM	EQ 10MG BASE	N70581 001	OCT 17, 1985
AB	SIDMAK LABS NJ	EQ 5MG BASE	N72750 001	DEC 28, 1995
AB		EQ 10MG BASE	N71250 001	FEB 03, 1988
AB	TEVA	EQ 5MG BASE	N72801 001	JUN 15, 1993
AB		EQ 10MG BASE	N70184 001	JUL 29, 1985
AB	WATSON LABS	EQ 10MG BASE	N70511 001	JAN 22, 1986
	REGLAN			
AB	SCHWARZ PHARMA	EQ 5MG BASE	N17854 002	MAY 05, 1987
AB +		EQ 10MG BASE	N17854 001	

METOLAZONE

TABLET; ORAL

	MYKROX		
+	CELLTECH PHARMS	0.5MG	N19532 001 OCT 30, 1987
	ZAROXOLYN		
+	CELLTECH PHARMS	2.5MG	N17386 001
		5MG	N17386 002
+		10MG	N17386 003

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

	TOPROL-XL		
	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004 FEB 05, 2001
+		EQ 50MG TARTRATE	N19962 001 JAN 10, 1992
		EQ 100MG TARTRATE	N19962 002 JAN 10, 1992
+		EQ 200MG TARTRATE	N19962 003 JAN 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

	LOPRESSOR			
AP +	NOVARTIS	1MG/ML	N18704 001	MAR 30, 1984
	METOPROLOL TARTRATE			
AP	ABBOTT	1MG/ML	N74133 001	DEC 21, 1993
AP		1MG/ML	N75160 001	JUL 06, 1998
AP	STERIS	1MG/ML	N74032 001	DEC 21, 1993

TABLET; ORAL

	LOPRESSOR			
AB	NOVARTIS	50MG	N17963 001	
AB +		100MG	N17963 002	
	METOPROLOL TARTRATE			
AB	APOTHECON	50MG	N74258 001	JAN 27, 1994
AB		100MG	N74258 002	JAN 27, 1994
AB	CARACO	50MG	N74644 001	DEC 10, 1996
AB		100MG	N74644 002	DEC 10, 1996
AB	COPLEY PHARM	50MG	N74333 001	JAN 27, 1994
AB		100MG	N74333 002	JAN 27, 1994
AB	GENEVA PHARMS	50MG	N73288 001	MAR 25, 1994
AB		100MG	N73289 001	MAR 25, 1994
AB	MUTUAL PHARM	50MG	N73653 001	DEC 21, 1993
AB		100MG	N73654 001	DEC 21, 1993
AB	MYLAN	50MG	N73666 001	DEC 21, 1993
AB		100MG	N73666 002	DEC 21, 1993
AB	PAR PHARM	50MG	N74453 001	APR 27, 1995
AB		100MG	N74453 002	APR 27, 1995
AB	TEVA	50MG	N74141 001	JAN 31, 1995

FDA data supplied by DrugPatentWatch.com

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE			
AB	TEVA	50MG	**N74143 001**	
			SEP 30, 1994	
AB		100MG	**N74141 002**	
			JAN 31, 1995	
AB		100MG	**N74143 002**	
			SEP 30, 1994	
AB	WATSON LABS	50MG	**N74217 001**	
			MAY 27, 1994	
AB		100MG	**N74217 002**	
			MAY 27, 1994	

METOPROLOL TARTRATE; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

METRONIDAZOLE

CAPSULE; ORAL

	FLAGYL		
+	GD SEARLE LLC	375MG	N20334 001
			MAY 03, 1995

CREAM; TOPICAL

	METROCREAM		
+	GALDERMA LABS LP	0.75%	N20531 001
			SEP 20, 1995
	NORITATE		
+	DERMIK LABS	1%	N20743 001
			SEP 26, 1997

GEL; TOPICAL

	METROGEL		
+	GALDERMA LABS LP	0.75%	N19737 001
			NOV 22, 1988

GEL; VAGINAL

	METROGEL-VAGINAL		
+	3M	0.75%	N20208 001
			AUG 17, 1992

INJECTABLE; INJECTION

	FLAGYL I.V. RTU IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	500MG/100ML	**N18657 001**	
AP	+ GD SEARLE LLC	500MG/100ML	**N18353 002**	

METRONIDAZOLE

INJECTABLE; INJECTION

	METRO I.V. IN PLASTIC CONTAINER			
AP	+ B BRAUN	500MG/100ML	**N18900 001**	
			SEP 29, 1983	
	METRONIDAZOLE IN PLASTIC CONTAINER			
AP	+ ABBOTT	500MG/100ML	**N18890 002**	
			NOV 18, 1983	

LOTION; TOPICAL

	METROLOTION		
+	GALDERMA LABS LP	0.75%	N20901 001
			NOV 24, 1998

TABLET; ORAL

	FLAGYL			
AB	GD SEARLE LLC	250MG	**N12623 001**	
AB	+	500MG	**N12623 003**	
	METROMIDOL			
AB	LABS AF	250MG	**N74523 001**	
			OCT 24, 1996	
AB		500MG	**N74523 002**	
			OCT 24, 1996	
	METRONIDAZOLE			
AB	EON	250MG	**N18620 001**	
			MAR 04, 1982	
AB		500MG	**N18620 002**	
			JUN 02, 1983	
AB	GENEVA PHARMS	250MG	**N18740 001**	
			OCT 22, 1982	
AB		500MG	**N18740 002**	
			OCT 22, 1982	
AB	IVAX PHARMS	250MG	**N18517 001**	
AB		500MG	**N18517 002**	
			MAY 05, 1982	
AB	LNK	250MG	**N19029 001**	
			APR 10, 1984	
AB	MUTUAL PHARM	250MG	**N70772 001**	
			JUL 16, 1986	
AB		500MG	**N70773 001**	
			JUL 16, 1986	
AB	PAR PHARM	250MG	**N18845 001**	
			AUG 18, 1983	
AB		250MG	**N70040 001**	
			JAN 29, 1985	
AB		500MG	**N18930 001**	
			AUG 18, 1983	

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB	PAR PHARM	500MG	**N70039 001**	JAN 29, 1985
AB	SIDMAK LABS NJ	250MG	**N70027 001**	NOV 06, 1984
AB		500MG	**N70033 001**	DEC 06, 1984
AB	TEVA	250MG	**N70035 001**	DEC 20, 1984
AB		500MG	**N70044 001**	FEB 08, 1985
AB	WATSON LABS	250MG	**N18764 001**	SEP 17, 1982
AB		500MG	**N18764 002**	DEC 20, 1982

TABLET, EXTENDED RELEASE; ORAL
FLAGYL ER

+	GD SEARLE LLC	750MG	N20868 001	NOV 26, 1997

METRONIDAZOLE; *MULTIPLE*
SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

+	GD SEARLE LLC	EQ 500MG BASE/VIAL	N18353 001

METYRAPONE

CAPSULE; ORAL
METOPIRONE

+	NOVARTIS	250MG	N12911 002	AUG 09, 1996

METYROSINE

CAPSULE; ORAL
DEMSER

+	MERCK	250MG	N17871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	GENEVA PHARMS	150MG	**N74450 001**	MAY 16, 1996
AB		200MG	**N74450 002**	MAY 16, 1996
AB		250MG	**N74450 003**	MAY 16, 1996
AB	TEVA	150MG	**N74377 001**	MAY 16, 1995
AB		200MG	**N74377 002**	MAY 16, 1995
AB		250MG	**N74377 003**	MAY 16, 1995
AB	WATSON LABS	150MG	**N74711 001**	FEB 26, 1997
AB		150MG	**N74865 001**	APR 13, 1998
AB		200MG	**N74711 002**	FEB 26, 1997
AB		200MG	**N74865 002**	APR 13, 1998
AB		250MG	**N74711 003**	FEB 26, 1997
AB		250MG	**N74865 003**	APR 13, 1998

MEXITIL

AB	BOEHRINGER INGELHEIM	150MG	**N18873 002**	DEC 30, 1985
AB		200MG	**N18873 003**	DEC 30, 1985
AB	+	250MG	**N18873 004**	DEC 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN

+	BAYER	EQ 1GM BASE/VIAL	N50549 001
+		EQ 2GM BASE/VIAL	N50549 002
+		EQ 3GM BASE/VIAL	N50549 003
+		EQ 4GM BASE/VIAL	N50549 004
+		EQ 20GM BASE/VIAL	N50549 005 MAR 02, 1988

FDA data supplied by DrugPatentWatch.com

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM
+ JOHNSON AND JOHNSON 2% N17494 001

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
AB ALPHARMA US PHARM **200MG** **N73508 001**
NOV 19, 1993

MONISTAT 3
AB + ORTHO MCNEIL PHARM **200MG** **N18888 001**
AUG 15, 1984

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL
AP + ABBOTT **EQ 1MG BASE/ML** **N75293 001**
JUN 20, 2000
AP **EQ 1MG BASE/ML** **N75409 002**
JUN 20, 2000
AP **EQ 1MG BASE/ML** **N75857 001**
JUL 22, 2002
AP + **EQ 5MG BASE/ML** **N75293 002**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75409 001**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75857 002**
JUL 22, 2002
AP AM PHARM PARTNERS **EQ 1MG BASE/ML** **N75154 002**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75154 001**
JUN 20, 2000
AP APOTEX **EQ 1MG BASE/ML** **N75637 001**
OCT 31, 2000
AP **EQ 5MG BASE/ML** **N75637 002**
OCT 31, 2000
AP BAXTER HLTHCARE CORP **EQ 1MG BASE/ML** **N75324 001**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75324 002**
JUN 20, 2000
AP BEDFORD **EQ 1MG BASE/ML** **N75247 002**
JUN 23, 2000
AP **EQ 5MG BASE/ML** **N75247 001**
JUN 23, 2000
AP BEN VENUE **EQ 1MG BASE/ML** **N75421 002**
JUN 20, 2000

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL
AP BEN VENUE **EQ 5MG BASE/ML** **N75421 001**
JUN 20, 2000
AP ESI LEDERLE **EQ 1MG BASE/ML** **N75243 001**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75243 002**
JUN 20, 2000
AP FAULDING **EQ 1MG BASE/ML** **N75396 001**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75396 002**
JUN 20, 2000
AP **EQ 5MG BASE/ML** **N75484 001**
JUN 20, 2000
AP ROSS LABS **EQ 1MG BASE/ML** **N75856 001**
JUN 13, 2002
AP **EQ 5MG BASE/ML** **N75856 002**
JUN 13, 2002
AP TAYLOR **EQ 5MG BASE/ML** **N75481 001**
JUN 30, 2000
AP TAYLOR PHARMA **EQ 1MG BASE/ML** **N75494 001**
JUN 30, 2000
AP **EQ 5MG BASE/ML** **N75494 002**
JUN 30, 2000

SYRUP; ORAL
MIDAZOLAM HCL
AA RANBAXY **EQ 2MG BASE/ML** **N76058 001**
MAR 15, 2002
AA + ROXANE **EQ 2MG BASE/ML** **N75873 001**
APR 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE
SHIRE PHARM 2.5MG N19815 001
SEP 06, 1996
+ 5MG N19815 002
SEP 06, 1996
10MG N19815 003
MAR 20, 2002

FDA data supplied by DrugPatentWatch.com

MIFEPRISTONE

TABLET; ORAL
MIFEPREX
+ DANCO LABS LLC 200MG N20687 001 SEP 28, 2000

MIGLITOL

TABLET; ORAL
GLYSET
PHARMACIA AND UPJOHN 25MG N20682 001 DEC 18, 1996
50MG N20682 002 DEC 18, 1996
+ 100MG N20682 003 DEC 18, 1996

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

AP	ABBOTT	EQ 1MG BASE/ML	N75884 001 MAY 28, 2002
AP	AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001 MAY 28, 2002
AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001 MAY 28, 2002
AP	BEDFORD	EQ 10MG /10ML(10MG/ML)	N75660 001 MAY 28, 2002
AP	ESI LEDERLE	EQ 1MG BASE/ML	N75530 001 MAY 28, 2002
AP	FAULDING	EQ 1MG BASE/ML	N75830 001 MAY 28, 2002
AP	INTL MEDICATED	EQ 1MG BASE/ML	N76013 001 AUG 02, 2002

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 20MG BASE/100ML	N75885 001 MAY 28, 2002
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001 MAY 28, 2002
AP		EQ 40MG BASE/200ML	N75834 002 MAY 28, 2002
AP	ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001 MAY 28, 2002

MILRINONE LACTOSE IN 5% DEXTROSE

AP	ESI LEDERLE	EQ 20MG BASE/100ML	N76259 001 AUG 08, 2002

MILRINONE LACTATE

INJECTABLE; INJECTION
PRIMACOR

AP	+ SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003 AUG 09, 1994
AP	+	EQ 40MG BASE/200ML	N20343 004 AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

AB	LEDERLE	EQ 50MG BASE	N50649 001 MAY 31, 1990
AB		EQ 75MG BASE	N50649 003 FEB 12, 2001
AB	+	EQ 100MG BASE	N50649 002 MAY 31, 1990

MINOCYCLINE HCL

AB	IMPAX LABS	EQ 50MG BASE	N65005 001 MAR 23, 1999
AB		EQ 75MG BASE	N65005 003 APR 18, 2001
AB		EQ 100MG BASE	N65005 002 MAR 23, 1999
AB	RANBAXY	EQ 50MG BASE	N65062 001 NOV 30, 2000
AB		EQ 75MG BASE	N65062 002 NOV 30, 2000
AB		EQ 100MG BASE	N65062 003 NOV 30, 2000
AB	TEVA	EQ 50MG BASE	N63011 001 MAR 02, 1992
AB		EQ 100MG BASE	N63009 001 MAR 02, 1992
AB	WATSON LABS	EQ 50MG BASE	N63181 001 DEC 30, 1991
AB		EQ 75MG BASE	N63065 002 JUN 10, 1999
AB		EQ 100MG BASE	N63065 001 DEC 30, 1991

VECTRIN

AB	MEDICIS	EQ 50MG BASE	N63066 001 AUG 14, 1990

FDA data supplied by DrugPatentWatch.com

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
MINOCIN
+ LEDERLE — EQ 100MG BASE/VIAL — N50444 001

POWDER, EXTENDED RELEASE; DENTAL
ARESTIN
+ ORAPHARMA — EQ 1MG BASE — N50781 001 FEB 16, 2001

MINOXIDIL

TABLET; ORAL
LONITEN
AB PHARMACIA AND UPJOHN — 2.5MG — N18154 001
AB + — 10MG — N18154 003
MINOXIDIL
AB MUTUAL PHARM — 2.5MG — N72708 001 DEC 14, 1995
AB — 10MG — N72709 001 DEC 14, 1995
AB PAR PHARM — 2.5MG — N71826 001 NOV 14, 1988
AB — 10MG — N71839 001 NOV 14, 1988
AB WATSON LABS — 2.5MG — N71344 001 MAR 03, 1987
AB — 10MG — N71345 001 MAR 03, 1987

MIRTAZAPINE

TABLET; ORAL
REMERON
+ ORGANON — 15MG — N20415 001 JUN 14, 1996
— 30MG — N20415 002 JUN 14, 1996
— 45MG — N20415 003 MAR 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB
+ ORGANON INC — 15MG — N21208 001 JAN 12, 2001

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB
ORGANON INC — 30MG — N21208 002 JAN 12, 2001
— 45MG — N21208 003 JAN 12, 2001

MISOPROSTOL

TABLET; ORAL
CYTOTEC
AB GD SEARLE LLC — 0.1MG — N19268 003 SEP 21, 1990
AB + — 0.2MG — N19268 001 DEC 27, 1988
MISOPROSTOL
AB IVAX PHARMS — 0.1MG — N76095 001 JUL 10, 2002
AB — 0.2MG — N76095 002 JUL 10, 2002

MISOPROSTOL; *MULTIPLE*
SEE DICLOFENAC SODIUM; MISOPROSTOL

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN
AP BEDFORD — 5MG/VIAL — N64117 001 APR 19, 1995
AP — 20MG/VIAL — N64117 002 APR 19, 1995
AP ESI LEDERLE — 5MG/VIAL — N64180 001 DEC 23, 1999
AP — 20MG/VIAL — N64180 002 DEC 23, 1999
AP FAULDING — 20MG/VIAL — N64106 001 NOV 29, 1995
AP SUPERGEN — 5MG/VIAL — N64144 001 APR 30, 1998
AP — 20MG/VIAL — N64144 002 APR 30, 1998
MUTAMYCIN
AP + BRISTOL MYERS — 5MG/VIAL — N62336 001

FDA data supplied by DrugPatentWatch.com

MITOMYCIN

INJECTABLE; INJECTION

	MUTAMYCIN			
AP	+ BRISTOL MYERS	**20MG/VIAL**	**N62336 002**	
	+	40MG/VIAL	N62336 003	
			MAR 10, 1988	
	MYTOZYTREX			
	+ SUPERGEN	5MG/VIAL	N50763 001	
			NOV 14, 2002	

MITOTANE

TABLET; ORAL

	LYSODREN		
	+ BRISTOL	500MG	N16885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVANTRONE		
	+ SERONO INC	EQ 2MG BASE/ML	N19297 001
			DEC 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

	MIVACRON		
	+ ABBOTT	EQ 2MG BASE/ML	N20098 001
			JAN 22, 1992
	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER		
	+ ABBOTT	EQ 50MG BASE/100ML	N20098 003
			JAN 22, 1992

MODAFINIL

TABLET; ORAL

	PROVIGIL		
	CEPHALON	100MG	N20717 001
			DEC 24, 1998
	+	200MG	N20717 002
			DEC 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIVASC		
	SCHWARZ PHARMA	7.5MG	N20312 001
			APR 19, 1995
	+	15MG	N20312 002
			APR 19, 1995

MOEXIPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL

	MOBAN		
	+ ENDO PHARMS	20MG/ML	N17938 001

TABLET; ORAL

	MOBAN		
	ENDO PHARMS	5MG	N17111 004
		10MG	N17111 005
	+	25MG	N17111 006
		50MG	N17111 007
	+	100MG	N17111 008

MOMETASONE FUROATE

CREAM; TOPICAL

	ELOCON		
	+ SCHERING	0.1%	N19625 001
			MAY 06, 1987

LOTION; TOPICAL

	ELOCON		
	+ SCHERING	0.1%	N19796 001
			MAR 30, 1989

OINTMENT; TOPICAL

	ELOCON			
AB	+ SCHERING	**0.1%**	**N19543 001**	
			APR 30, 1987	
	MOMETASONE FUROATE			
AB	CLAY PARK	**0.1%**	**N76067 001**	
			MAR 18, 2002	

FDA data supplied by DrugPatentWatch.com

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX
+ SCHERING PLOUGH — EQ 0.05MG BASE/SPRAY — N20762 001 OCT 01, 1997

MONOBENZONE

CREAM; TOPICAL
BENOQUIN
+ ICN — 20% — N08173 003

MONTELUKAST SODIUM

GRANULE; ORAL
SINGULAIR
+ MERCK — EQ 4MG BASE/PACKET — N21409 001 JUL 26, 2002

TABLET; ORAL
SINGULAIR
+ MERCK — EQ 10MG BASE — N20829 002 FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR
MERCK — EQ 4MG BASE — N20830 002 MAR 03, 2000
+ — EQ 5MG BASE — N20830 001 FEB 20, 1998

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
SHIRE LABS — 200MG — N19753 001 JUN 19, 1990
250MG — N19753 002 JUN 19, 1990
+ 300MG — N19753 003 JUN 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA
BX + ELAN PHARM — 30MG — N21260 001 MAR 20, 2002
BX + — 60MG — N21260 002 MAR 20, 2002
+ — 90MG — N21260 003 MAR 20, 2002
+ — 120MG — N21260 004 MAR 20, 2002

KADIAN
BX + FAULDING PHARMS — 30MG — N20616 004 MAR 09, 2001
BX + — 60MG — N20616 005 MAR 09, 2001
+ — 20MG — N20616 001 JUL 03, 1996
+ — 50MG — N20616 002 JUL 03, 1996
+ — 100MG — N20616 003 JUL 03, 1996

INJECTABLE; INJECTION
ASTRAMORPH PF
AP ASTRAZENECA — **0.5MG/ML** — **N71050 001** OCT 07, 1986
AP — **0.5MG/ML** — **N71051 001** OCT 07, 1986
AP — **1MG/ML** — **N71052 001** OCT 07, 1986
AP — **1MG/ML** — **N71053 001** OCT 07, 1986

DURAMORPH PF
AP + ELKINS SINN — **0.5MG/ML** — **N18565 001** SEP 18, 1984
AP + — **1MG/ML** — **N18565 002** SEP 18, 1984

INFUMORPH
+ ELKINS SINN — 10MG/ML — N18565 003 JUL 19, 1991
+ — 25MG/ML — N18565 004 JUL 19, 1991

MORPHINE SULFATE
AP + ABBOTT — **0.5MG/ML** — **N19917 001** OCT 30, 1992
AP — **0.5MG/ML** — **N71849 001** MAY 11, 1988

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE

INJECTABLE; INJECTION

	MORPHINE SULFATE			
AP	ABBOTT	0.5MG/ML	N73509 001	SEP 30, 1992
AP +		1MG/ML	N19916 001	OCT 30, 1992
AP		1MG/ML	N71850 001	MAY 11, 1988
AP		1MG/ML	N73510 001	SEP 30, 1992
AP	MALLINCKRODT	1MG/ML	N20631 001	JUL 03, 1996
+		2MG/ML	N20631 002	JUL 03, 1996
+	MERIDIAN MEDCL TECHN	15MG/ML	N19999 001	JUL 12, 1990
AP	STERIS	0.5MG/ML	N73373 001	SEP 30, 1991
AP		0.5MG/ML	N73375 001	SEP 30, 1991
AP		1MG/ML	N73374 001	SEP 30, 1991
AP		1MG/ML	N73376 001	SEP 30, 1991

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	AB GENERICS	15MG	N74862 001	JUL 07, 1998
AB		30MG	N74862 002	JUL 07, 1998
AB		60MG	N74862 003	JUL 07, 1998
AB		100MG	N74769 001	JUL 02, 1998
AB		200MG	N74769 002	JUL 02, 1998
AB	ENDO PHARMS	15MG	N75295 001	OCT 28, 1998
AB		30MG	N75295 002	OCT 28, 1998
AB		60MG	N75295 003	OCT 28, 1998
AB		100MG	N75295 004	SEP 15, 2000
AB		200MG	N75295 005	SEP 15, 2000

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE			
AB	ESI LEDERLE	15MG	N75407 001	JAN 28, 2000
AB	WATSON LABS	100MG	N75656 001	JAN 30, 2001
	MS CONTIN			
AB	PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989
AB		30MG	N19516 001	MAY 29, 1987
AB +		60MG	N19516 002	APR 08, 1988
AB		100MG	N19516 004	JAN 16, 1990
AB		200MG	N19516 005	NOV 08, 1993
	ORAMORPH SR			
BC	ELAN PHARMS	15MG	N19977 004	NOV 23, 1994
BC		30MG	N19977 001	AUG 15, 1991
BC		60MG	N19977 002	AUG 15, 1991
BC		100MG	N19977 003	AUG 15, 1991

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER			
+	BAYER	160MG/100ML	N21277 001 NOV 30, 2001

TABLET; ORAL

AVELOX			
+	BAYER	EQ 400MG BASE	N21085 001 DEC 10, 1999

MUPIROCIN

OINTMENT; TOPICAL

	BACTROBAN			
BX +	GLAXOSMITHKLINE	2%	N50591 001	DEC 31, 1987

FDA data supplied by DrugPatentWatch.com

MUPIROCIN

OINTMENT; TOPICAL
MUPIROCIN
CLAY PARK LABS 2% N50788 001 DEC 04, 2002

MUPIROCIN CALCIUM

CREAM, AUGMENTED; TOPICAL
BACTROBAN
+ GLAXOSMITHKLINE 2% N50746 001 DEC 11, 1997

OINTMENT; NASAL
BACTROBAN
+ GLAXOSMITHKLINE EQ 2% BASE N50703 001 SEP 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
CELLCEPT
+ ROCHE GLOBAL DEV 250MG N50722 001 MAY 03, 1995

SUSPENSION; ORAL
CELLCEPT
+ ROCHE GLOBAL DEV 200MG/ML N50759 001 OCT 01, 1998

TABLET; ORAL
CELLCEPT
+ ROCHE GLOBAL DEV 500MG N50723 001 JUN 19, 1997

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION
CELLCEPT
+ ROCHE GLOBAL DEV 500MG/VIAL N50758 001 AUG 12, 1998

NABUMETONE

TABLET; ORAL
NABUMETONE

AB	COPLEY PHARM	750MG		**N75179 001** JUN 06, 2000
AB	EON	500MG		**N75280 001** FEB 25, 2002
AB		750MG		**N75280 002** FEB 25, 2002
AB	INVAMED	500MG		**N75590 001** FEB 25, 2002
AB		750MG		**N75590 002** FEB 25, 2002
AB	TEVA	500MG		**N75189 001** MAY 26, 2000
AB		750MG		**N75189 002** SEP 24, 2001

RELAFEN

AB	GLAXOSMITHKLINE	500MG		**N19583 001** DEC 24, 1991
AB	+	750MG		**N19583 002** DEC 24, 1991

NADOLOL

TABLET; ORAL
CORGARD

AB	APOTHECON	20MG		**N18063 005** OCT 28, 1986
AB		40MG		**N18063 001**
AB		80MG		**N18063 002**
AB		120MG		**N18063 003**
AB	+	160MG		**N18063 004**

NADOLOL

AB	COPLEY PHARM	80MG		**N74368 001** AUG 31, 1994
AB		120MG		**N74368 002** AUG 31, 1994
AB		160MG		**N74368 003** AUG 31, 1994
AB	GENEVA PHARMS TECH	20MG		**N74501 001** NOV 09, 1995
AB		40MG		**N74501 002** NOV 09, 1995
AB		80MG		**N74501 003** NOV 09, 1995

FDA data supplied by DrugPatentWatch.com

NADOLOL

TABLET; ORAL
NADOLOL

AB	IVAX PHARMS	**20MG**	**N74229 001**	AUG 30, 1996
AB		**40MG**	**N74229 002**	AUG 30, 1996
AB		**80MG**	**N74255 001**	JAN 24, 1996
AB		**120MG**	**N74255 002**	JAN 24, 1996
AB		**160MG**	**N74255 003**	JAN 24, 1996
AB	MYLAN	**20MG**	**N74172 001**	OCT 31, 1993
AB		**40MG**	**N74172 002**	OCT 31, 1993
AB		**80MG**	**N74172 003**	OCT 31, 1993

NADOLOL; *MULTIPLE*
SEE BENDROFLUMETHIAZIDE; NADOLOL

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N19886 001	FEB 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	APOTHECON	**EQ 1GM BASE/VIAL**	**N62527 002**	AUG 02, 1984
AP		**EQ 1GM BASE/VIAL**	**N62732 001**	DEC 23, 1986
AP		**EQ 2GM BASE/VIAL**	**N62527 003**	AUG 02, 1984
AP		**EQ 2GM BASE/VIAL**	**N62732 002**	DEC 23, 1986
AP		**EQ 10GM BASE/VIAL**	**N62527 004**	AUG 02, 1984

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

+	APOTHECON	EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984

NALLPEN IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N50655 001	OCT 31, 1989
+		EQ 2GM BASE/100ML	N50655 002	OCT 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

+	ALLERGAN HERBERT	1%	N19599 001	FEB 29, 1988

GEL; TOPICAL
NAFTIN

+	ALLERGAN HERBERT	1%	N19356 001	JUN 18, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	ABBOTT	**10MG/ML**	**N70914 001**	FEB 03, 1989
AP		**10MG/ML**	**N70915 001**	FEB 03, 1989
AP		**20MG/ML**	**N70916 001**	FEB 03, 1989
AP		**20MG/ML**	**N70917 001**	FEB 03, 1989
AP		**20MG/ML**	**N70918 001**	FEB 03, 1989
AP	KING PHARMS	**10MG/ML**	**N74471 001**	MAR 19, 1998
AP		**20MG/ML**	**N74471 002**	MAR 19, 1998

NUBAIN

AP	+ ENDO PHARMS	**10MG/ML**	**N18024 001**	
AP	+	**20MG/ML**	**N18024 002**	MAY 27, 1982

FDA data supplied by DrugPatentWatch.com

NALIDIXIC ACID

TABLET; ORAL

	NALIDIXIC ACID			
AB	WATSON LABS	1GM	**N71919 001**	JUN 29, 1988
AB		250MG	**N71936 001**	JUN 29, 1988
AB		500MG	**N72061 001**	JUN 29, 1988
	NEGGRAM			
AB	SANOFI SYNTHELABO	250MG	**N14214 002**	
AB		500MG	**N14214 004**	
AB	+	1GM	**N14214 005**	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

	REVEX			
	+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N20459 001	APR 17, 1995
	+	EQ 1MG BASE/ML	N20459 002	APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE			
AP	ELKINS SINN	0.4MG/ML	**N70299 001**	SEP 24, 1986
AP	ELKINS SINN PHARM	0.4MG/ML	**N70298 001**	SEP 24, 1986
	NALOXONE HCL			
AP	ABBOTT	0.02MG/ML	**N70171 001**	SEP 24, 1986
AP		0.02MG/ML	**N70252 001**	JAN 16, 1987
AP		0.02MG/ML	**N70253 001**	JAN 16, 1987
AP		0.4MG/ML	**N70254 001**	JAN 07, 1987
AP		0.4MG/ML	**N70255 001**	JAN 07, 1987
AP		0.4MG/ML	**N70256 001**	JAN 07, 1987
AP		0.4MG/ML	**N70257 001**	JAN 07, 1987

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE HCL			
AP	ELKINS SINN	0.02MG/ML	**N71272 001**	MAY 24, 1988
AP		1MG/ML	**N71273 001**	MAY 24, 1988
AP		1MG/ML	**N71274 001**	MAY 24, 1988
AP		1MG/ML	**N71287 001**	MAY 24, 1988
AP	INTL MEDICATION	0.4MG/ML	**N70639 001**	SEP 24, 1986
AP		1MG/ML	**N72076 001**	MAR 24, 1988
	NARCAN			
AP	+ ENDO PHARMS	0.02MG/ML	**N16636 002**	
AP	+	0.4MG/ML	**N16636 001**	
AP	+	1MG/ML	**N16636 003**	JUN 14, 1982

NALOXONE HYDROCHLORIDE; *MULTIPLE*
SEE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	NALOXONE HCL AND PENTAZOCAINE			
AB	AMIDE PHARM	EQ 0.5MG BASE; EQ 50MG BASE	**N75735 001**	JUL 11, 2001
	PENTAZOCINE AND NALOXONE HYDROCHLORIDES			
AB	RANBAXY	EQ 0.5MG BASE; EQ 50MG BASE	**N75523 001**	MAR 17, 2000
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	**N74736 001**	JAN 21, 1997
	TALWIN NX			
AB	+ SANOFI SYNTHELABO	EQ 0.5MG BASE; EQ 50MG BASE	**N18733 001**	DEC 16, 1982

FDA data supplied by DrugPatentWatch.com

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

	NALTREXONE HCL			
AB	AMIDE PHARM	50MG	**N75274 001**	MAY 26, 1999
AB	BARR	50MG	**N74918 001**	MAY 08, 1998
AB	EON	50MG	**N75434 001**	MAR 08, 2000
AB	MALLINCKRODT	50MG	**N76264 002**	MAR 22, 2002
		25MG	N76264 001	MAR 22, 2002
+		100MG	N76264 003	MAR 22, 2002
	REVIA			
AB	+ BARR PHARMS	50MG	**N18932 001**	NOV 20, 1984

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	DECA-DURABOLIN			
AO	+ ORGANON	50MG/ML	**N13132 001**	JUN 12, 1986
AO	+	100MG/ML	**N13132 002**	JUN 12, 1986
AO	+	200MG/ML	**N13132 003**	JUN 12, 1986
	NANDROLONE DECANOATE			
AO	STERIS	50MG/ML	**N86385 001**	JAN 13, 1984
AO		100MG/ML	**N86598 001**	JAN 13, 1984
AO		200MG/ML	**N88128 001**	DEC 05, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	ALBALON			
AT	+ ALLERGAN	0.1%	**N80248 001**	
	NAFAZAIR			
AT	BAUSCH AND LOMB	0.1%	**N40073 001**	MAY 25, 1994
	NAPHAZOLINE HCL			
AT	TAYLOR	0.1%	**N83590 001**	

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	VASOCON			
AT	NOVARTIS	0.1%	**N80235 002**	MAR 24, 1983

NAPROXEN

SUSPENSION; ORAL

	NAPROSYN			
AB	+ SYNTEX (USA) INC LLC	25MG/ML	**N18965 001**	MAR 23, 1987
	NAPROXEN			
AB	ROXANE	25MG/ML	**N74190 001**	MAR 30, 1994

TABLET; ORAL

	NAPROSYN			
AB	SYNTEX (USA) INC LLC	250MG	**N17581 002**	
AB		375MG	**N17581 003**	
AB	+	500MG	**N17581 004**	APR 15, 1982
	NAPROXEN			
AB	CLONMEL HLTHCARE	250MG	**N74410 001**	APR 28, 1995
AB		375MG	**N74410 002**	APR 28, 1995
AB		500MG	**N74410 003**	APR 28, 1995
AB	COPLEY PHARM	250MG	**N74207 001**	DEC 21, 1993
AB		375MG	**N74207 002**	DEC 21, 1993
AB		500MG	**N74207 003**	DEC 21, 1993
AB	GENEVA PHARMS	250MG	**N74140 001**	DEC 21, 1993
AB		375MG	**N74140 002**	DEC 21, 1993
AB		500MG	**N74140 003**	DEC 21, 1993
AB	INTERPHARM	250MG	**N75927 001**	DEC 18, 2001
AB		375MG	**N75927 002**	DEC 18, 2001
AB		500MG	**N75927 003**	DEC 18, 2001

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	IVAX PHARMS	250MG	**N74111 001**	FEB 28, 1995
AB		375MG	**N74111 002**	FEB 28, 1995
AB		500MG	**N74111 003**	FEB 28, 1995
AB	LEDERLE	250MG	**N74105 001**	DEC 21, 1993
AB		375MG	**N74105 002**	DEC 21, 1993
AB		500MG	**N74105 003**	DEC 21, 1993
AB	MYLAN	250MG	**N74121 001**	DEC 21, 1993
AB		375MG	**N74121 002**	DEC 21, 1993
AB		500MG	**N74121 003**	DEC 21, 1993
AB	PUREPAC PHARM	250MG	**N74263 001**	DEC 21, 1993
AB		375MG	**N74263 002**	DEC 21, 1993
AB		500MG	**N74263 003**	DEC 21, 1993
AB	ROXANE	250MG	**N74211 001**	FEB 28, 1994
AB		375MG	**N74211 002**	FEB 28, 1994
AB		500MG	**N74211 003**	FEB 28, 1994
AB	SIDMAK LABS NJ	250MG	**N74182 001**	JUN 27, 1996
AB		375MG	**N74182 002**	JUN 27, 1996
AB		500MG	**N74182 003**	JUN 27, 1996
AB	TEVA	250MG	**N74129 001**	DEC 21, 1993
AB		250MG	**N74201 001**	DEC 21, 1993
AB		250MG	**N74216 001**	APR 11, 1996
AB		375MG	**N74129 002**	DEC 21, 1993

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	TEVA	375MG	**N74201 002**	DEC 21, 1993
AB		375MG	**N74216 002**	APR 11, 1996
AB		500MG	**N74129 003**	DEC 21, 1993
AB		500MG	**N74201 003**	DEC 21, 1993
AB		500MG	**N74216 003**	APR 11, 1996
AB	WATSON LABS	250MG	**N74163 001**	FEB 10, 1995
AB		250MG	**N74457 001**	MAY 31, 1995
AB		375MG	**N74163 002**	FEB 10, 1995
AB		375MG	**N74457 002**	MAY 31, 1995
AB		500MG	**N74163 003**	FEB 10, 1995
AB		500MG	**N74457 003**	MAY 31, 1995

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB	+ SYNTEX (USA) INC LLC	375MG	**N20067 002**	OCT 14, 1994
AB	+	500MG	**N20067 003**	OCT 14, 1994

NAPROXEN

AB	GENEVA PHARMS TECH	375MG	**N75061 001**	FEB 18, 1998
AB		500MG	**N75061 002**	FEB 18, 1998
AB	PUREPAC PHARM	375MG	**N74936 001**	FEB 24, 1998
AB		500MG	**N74936 002**	FEB 24, 1998
AB	SIDMAK LABS	375MG	**N75337 001**	MAY 26, 1999
AB		500MG	**N75337 002**	MAY 26, 1999
AB	TEVA	375MG	**N75227 001**	JUN 30, 1998

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

	NAPROXEN			
AB	TEVA	500MG	N75227 002	JUN 30, 1998

TABLET, EXTENDED RELEASE; ORAL

	NAPROXEN			
AB	+ ALPHAPHARM	375MG	N75390 001	APR 19, 2001
AB	+	500MG	N75390 002	APR 19, 2001

NAPROXEN SODIUM

TABLET; ORAL

	ANAPROX			
AB	SYNTEX (USA) INC LLC	EQ 250MG BASE	N18164 001	
	ANAPROX DS			
AB	+ SYNTEX (USA) INC LLC	EQ 500MG BASE	N18164 003	SEP 30, 1987
	NAPROXEN SODIUM			
AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998
AB		EQ 500MG BASE	N74480 001	MAY 14, 1996
AB	COPLEY PHARM	EQ 250MG BASE	N74289 001	JAN 27, 1994
AB		EQ 500MG BASE	N74289 002	JAN 27, 1994
AB	GENEVA PHARMS	EQ 250MG BASE	N74162 001	DEC 21, 1993
AB		EQ 500MG BASE	N74162 002	DEC 21, 1993
AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994
AB	IVAX PHARMS	EQ 250MG BASE	N74230 001	MAR 14, 1995
AB		EQ 500MG BASE	N74230 002	MAR 14, 1995
AB	MYLAN	EQ 250MG BASE	N74367 001	AUG 31, 1994
AB		EQ 500MG BASE	N74367 002	AUG 31, 1994

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	ROXANE	EQ 250MG BASE	N74257 001	DEC 21, 1993
AB		EQ 500MG BASE	N74257 002	DEC 21, 1993
AB	SIDMAK LABS NJ	EQ 250MG BASE	N74242 001	JUN 20, 1996
AB		EQ 500MG BASE	N74242 002	JUN 20, 1996
AB	TEVA	EQ 250MG BASE	N74142 001	DEC 21, 1993
AB		EQ 250MG BASE	N74198 001	DEC 21, 1993
AB		EQ 500MG BASE	N74142 002	DEC 21, 1993
AB		EQ 500MG BASE	N74198 002	DEC 21, 1993
AB	WATSON LABS	EQ 250MG BASE	N74195 001	DEC 21, 1993
AB		EQ 250MG BASE	N74455 001	MAY 31, 1995
AB		EQ 500MG BASE	N74195 002	DEC 21, 1993
AB		EQ 500MG BASE	N74455 002	MAY 31, 1995

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN		
+	ELAN PHARM	EQ 375MG BASE	N20353 001 JAN 05, 1996
+		EQ 500MG BASE	N20353 002 JAN 05, 1996

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

	AMERGE		
	GLAXOSMITHKLINE	EQ 1MG BASE	N20763 002 FEB 10, 1998
+		EQ 2.5MG BASE	N20763 001 FEB 10, 1998

FDA data supplied by DrugPatentWatch.com

NATAMYCIN

SUSPENSION; OPHTHALMIC
NATACYN
+ ALCON 5% N50514 001

NATEGLINIDE

TABLET; ORAL
STARLIX
NOVARTIS 60MG N21204 001 DEC 22, 2000
+ 120MG N21204 002 DEC 22, 2000

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE
+ AVENTIS 1.75MG/INH N19660 001 DEC 30, 1992

SOLUTION/DROPS; OPHTHALMIC
ALOCRIL
+ ALLERGAN 2% N21009 001 DEC 08, 1999

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE
BRISTOL MYERS SQUIBB 50MG N20152 001 DEC 22, 1994
100MG N20152 002 DEC 22, 1994
150MG N20152 003 DEC 22, 1994
200MG N20152 004 DEC 22, 1994
+ 250MG N20152 005 DEC 22, 1994

NELFINAVIR MESYLATE

FOR SUSPENSION; ORAL
VIRACEPT
+ AGOURON EQ 50MG BASE/SCOOPFUL N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
+ AGOURON EQ 250MG BASE N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK **100%** **N61579 001**

SOLUTION; ORAL
NEO-FRADIN
+ PHARMATEK EQ 87.5MG BASE/5ML N65010 001 MAY 23, 2002

TABLET; ORAL
NEOMYCIN SULFATE
+ TEVA EQ 350MG BASE N60304 001

NEOMYCIN SULFATE; *MULTIPLE*
SEE ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

FDA data supplied by DrugPatentWatch.com

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

	NIFEDIPINE			
AB2	BIOVAIL	**60MG**	**N75289 001**	SEP 27, 2000
AB1		**90MG**	**N76070 001**	AUG 16, 2002
AB1	ELAN PHARM	**30MG**	**N75128 001**	MAR 10, 2000
AB1		**60MG**	**N75659 001**	OCT 26, 2001
	PROCARDIA XL			
AB2	+ PFIZER	**30MG**	**N19684 001**	SEP 06, 1989
AB2	+	**60MG**	**N19684 002**	SEP 06, 1989
BC	+	90MG	N19684 003	SEP 06, 1989

NILUTAMIDE

TABLET; ORAL

	NILANDRON		
+	AVENTIS PHARMS	150MG	N20169 002 APR 30, 1999

NIMODIPINE

CAPSULE; ORAL

	NIMOTOP		
+	BAYER	30MG	N18869 001 DEC 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

	SULAR		
+	FIRST HORIZON	10MG	N20356 001 FEB 02, 1995
		20MG	N20356 002 FEB 02, 1995
+		30MG	N20356 003 FEB 02, 1995
+		40MG	N20356 004 FEB 02, 1995

NITAZOXANIDE

FOR SUSPENSION; ORAL

	ALINIA		
+	ROMARK	100MG/5ML	N21498 001 NOV 22, 2002

NITISINONE

CAPSULE; ORAL

	ORFADIN		
	SWEDISH ORPHAN	2MG	N21232 001 JAN 18, 2002
		5MG	N21232 002 JAN 18, 2002
+		10MG	N21232 003 JAN 18, 2002

NITRIC OXIDE

GAS; INHALATION

	INOMAX		
	INO	100PPM	N20845 002 DEC 23, 1999
+		800PPM	N20845 003 DEC 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

	FURADANTIN		
+	FIRST HORIZON	25MG/5ML	N09175 001

TABLET; ORAL

	FURADANTIN		
AB	PROCTER AND GAMBLE	**50MG**	**N08693 001**
AB	+	**100MG**	**N08693 002**
	NITROFURANTOIN		
AB	WATSON LAB	**50MG**	**N80447 001**
AB	WHITEWORTH TOWN PLSN	**100MG**	**N84085 002**

FDA data supplied by DrugPatentWatch.com

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	MACROBID			
	+ PROCTER AND GAMBLE	75MG;25MG	N20064 001	
			DEC 24, 1991	

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	MACRODANTIN			
AB	PROCTER AND GAMBLE	25MG	**N16620 003**	
AB		50MG	**N16620 001**	
AB	+	100MG	**N16620 002**	
	NITROFURANTION			
AB	MYLAN	100MG	**N74967 002**	
			JUL 09, 1997	
	NITROFURANTOIN			
AB	GENEVA PHARMS	25MG	**N74336 001**	
			JAN 25, 1995	
AB		50MG	**N74336 002**	
			JAN 25, 1995	
AB		100MG	**N74336 003**	
			JAN 25, 1995	
AB	IVAX PHARMS	50MG	**N73671 001**	
			JAN 28, 1993	
AB		100MG	**N73652 001**	
			JAN 28, 1993	
AB	MYLAN	50MG	**N74967 001**	
			JUL 09, 1997	
AB	WATSON LABS	25MG	**N73696 001**	
			DEC 31, 1992	
AB		50MG	**N73696 002**	
			DEC 31, 1992	
AB		100MG	**N73696 003**	
			DEC 31, 1992	

NITROFURANTOIN, MACROCRYSTALLINE; *MULTIPLE*
SEE NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

NITROFURAZONE

OINTMENT; TOPICAL

	FURACIN		
	+ SHIRE PHARM	0.2%	N05795 001
	NITROFURAZONE		
AT	TARO	**0.2%**	**N86156 001**

NITROFURAZONE

OINTMENT; TOPICAL

	NITROFURAZONE		
AT	WENDT	**0.2%**	**N86766 001**

SOLUTION; TOPICAL

	NITROFURAZONE		
	+ WENDT	0.2%	N87081 001

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN		
AB	3M	**0.1MG/HR**	**N89771 001**
			AUG 30, 1996
AB		**0.2MG/HR**	**N89772 001**
			AUG 30, 1996
AB		**0.4MG/HR**	**N89773 001**
			AUG 30, 1996
AB		**0.6MG/HR**	**N89774 001**
			AUG 30, 1996
	NITRO-DUR		
AB	+ KEY PHARMS	**0.1MG/HR**	**N20145 001**
			APR 04, 1995
AB	+	**0.2MG/HR**	**N20145 002**
			APR 04, 1995
AB	+	**0.4MG/HR**	**N20145 004**
			APR 04, 1995
AB	+	**0.6MG/HR**	**N20145 005**
			APR 04, 1995
BX	+	0.8MG/HR	N20145 006
			APR 04, 1995
	+	0.3MG/HR	N20145 003
			APR 04, 1995
	NITROGLYCERIN		
AB	HERCON LABS	**0.2MG/HR**	**N89884 001**
			OCT 30, 1998
AB		**0.4MG/HR**	**N89885 001**
			OCT 30, 1998
AB		**0.6MG/HR**	**N89886 001**
			OCT 30, 1998
AB	MYLAN	**0.1MG/HR**	**N75033 001**
			FEB 06, 1998
AB		**0.2MG/HR**	**N74609 001**
			AUG 30, 1996
AB		**0.4MG/HR**	**N74607 001**
			AUG 30, 1996

FDA data supplied by DrugPatentWatch.com

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

		NITROGLYCERIN		
AB2		MYLAN	0.6MG/HR	N74559 001 AUG 30, 1996
AB1		MYLAN TECHNOLOGIES	0.1MG/HR	N75076 001 NOV 12, 1999
AB1			0.2MG/HR	N75073 001 NOV 12, 1999
AB1			0.4MG/HR	N75075 001 NOV 12, 1999
AB1			0.6MG/HR	N74992 001 NOV 12, 1999
		TRANSDERM-NITRO		
AB2	+	NOVARTIS	0.1MG/HR	N20144 001 FEB 27, 1996
AB2	+		0.2MG/HR	N20144 002 FEB 27, 1996
AB2	+		0.4MG/HR	N20144 003 FEB 27, 1996
AB2	+		0.6MG/HR	N20144 004 FEB 27, 1996
BX	+		0.8MG/HR	N20144 005 FEB 27, 1996

INJECTABLE; INJECTION

		NITRO-BID		
AP	+	AVENTIS PHARMS	5MG/ML	N18621 001 JAN 05, 1982
		NITROGLYCERIN		
AP	+	ABBOTT	5MG/ML	N18531 001
AP		LUITPOLD	5MG/ML	N72034 001 MAY 24, 1988
		NITROGLYCERIN IN DEXTROSE 5%		
AP		ABBOTT	10MG/100ML	N71846 001 AUG 31, 1990
AP			0.1MG/ML	N74083 001 OCT 26, 1994
AP			20MG/100ML	N71847 001 AUG 31, 1990
AP			40MG/100ML	N71848 001 AUG 31, 1990
AP	+	BAXTER HLTHCARE	10MG/100ML	N19970 001 DEC 29, 1989
AP	+		20MG/100ML	N19970 002 DEC 29, 1989
AP	+		40MG/100ML	N19970 003 DEC 29, 1989

NITROGLYCERIN

INJECTABLE; INJECTION

		TRIDIL		
AP	+	FAULDING	5MG/ML	N18537 001
	+		0.5MG/ML	N18537 002 JUN 16, 1983

OINTMENT; TRANSDERMAL

		NITROGLYCERIN		
	+	ALTANA	2%	N87355 001 JUL 08, 1988

SPRAY, METERED; SUBLINGUAL

		NITROLINGUAL PUMPSPRAY		
	+	POHL BOSKAMP	0.4MG/SPRAY	N18705 002 JAN 10, 1997

TABLET; SUBLINGUAL

		NITROSTAT		
		PFIZER PHARMS	0.3MG	N21134 001 MAY 01, 2000
			0.4MG	N21134 002 MAY 01, 2000
	+		0.6MG	N21134 003 MAY 01, 2000

NIZATIDINE

CAPSULE; ORAL

		AXID		
AB		RELIANT PHARMS	150MG	N19508 001 APR 12, 1988
AB	+		300MG	N19508 002 APR 12, 1988
		NIZATIDINE		
AB		EON	150MG	N76178 001 JUL 05, 2002
AB			300MG	N76178 002 JUL 05, 2002
AB		GENPHARM	150MG	N75934 001 JUL 09, 2002
AB			300MG	N75934 002 JUL 09, 2002
AB		MYLAN	150MG	N75806 001 JUL 05, 2002
AB			300MG	N75806 002 JUL 05, 2002

FDA data supplied by DrugPatentWatch.com

NIZATIDINE

CAPSULE; ORAL

	NIZATIDINE			
AB	TEVA	150MG	**N75668 001**	SEP 12, 2002
AB		300MG	**N75668 002**	SEP 12, 2002
AB	WATSON LABS	150MG	**N75616 001**	JUL 09, 2002
AB		300MG	**N75616 002**	JUL 09, 2002
AB	ZENITH GOLDLINE	150MG	**N75461 001**	JUL 08, 2002
AB		300MG	**N75461 002**	JUL 08, 2002

NORELGESTROMIN; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORELGESTROMIN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

	LEVOPHED		
+	ABBOTT	EQ 1MG BASE/ML	N07513 001

NORETHINDRONE

TABLET; ORAL-28

	CAMILA		
AB1	BARR	0.35MG	**N76177 001** OCT 21, 2002
	ERRIN		
AB2	BARR	0.35MG	**N76225 001** OCT 21, 2002
	MICRONOR		
AB2 +	ORTHO MCNEIL PHARM	0.35MG	**N16954 001**
	NOR-QD		
AB1 +	WATSON LABS (UTAH)	0.35MG	**N17060 001**

NORETHINDRONE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORETHINDRONE
SEE MESTRANOL; NORETHINDRONE

NORETHINDRONE ACETATE

TABLET; ORAL

	AYGESTIN			
AB +	WYETH AYERST	5MG	**N18405 001**	APR 21, 1982
	NORETHINDRONE ACETATE			
AB	BARR	5MG	**N75951 001**	MAY 25, 2001

NORETHINDRONE ACETATE; *MULTIPLE*
SEE ESTRADIOL; NORETHINDRONE ACETATE
SEE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

	CHIBROXIN		
+	MERCK	0.3%	N19757 001 JUN 17, 1991

TABLET; ORAL

	NOROXIN		
+	MERCK	400MG	N19384 002 OCT 31, 1986

NORGESTIMATE; *MULTIPLE*
SEE ESTRADIOL; NORGESTIMATE
SEE ETHINYL ESTRADIOL; NORGESTIMATE

NORGESTREL

TABLET; ORAL

	OVRETTE		
+	WYETH AYERST	0.075MG	N17031 001

NORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORGESTREL

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	AVENTYL HCL		
BD	LILLY	EQ 10MG BASE	N14684 001

FDA data supplied by DrugPatentWatch.com

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	AVENTYL HCL			
BD	LILLY	EQ 25MG BASE	N14684 002	
	NORTRIPTYLINE HCL			
AB	GENEVA PHARMS	**EQ 10MG BASE**	**N74054 001**	DEC 31, 1992
AB		**EQ 25MG BASE**	**N74054 002**	DEC 31, 1992
AB		**EQ 50MG BASE**	**N74054 003**	DEC 31, 1992
AB		**EQ 75MG BASE**	**N74054 004**	DEC 31, 1992
AB	GENEVA PHARMS TECH	**EQ 10MG BASE**	**N74835 001**	JUN 30, 1997
AB		**EQ 25MG BASE**	**N74835 002**	JUN 30, 1997
AB		**EQ 50MG BASE**	**N74835 003**	JUN 30, 1997
AB		**EQ 75MG BASE**	**N74835 004**	JUN 30, 1997
AB	MYLAN	**EQ 10MG BASE**	**N74234 001**	JUL 26, 1993
AB		**EQ 25MG BASE**	**N74234 002**	JUL 26, 1993
AB		**EQ 50MG BASE**	**N74234 003**	JUL 26, 1993
AB		**EQ 75MG BASE**	**N74234 004**	JUL 26, 1993
AB	TARO	**EQ 10MG BASE**	**N75520 004**	MAY 08, 2000
AB		**EQ 25MG BASE**	**N75520 003**	MAY 08, 2000
AB		**EQ 50MG BASE**	**N75520 001**	MAY 08, 2000
AB		**EQ 75MG BASE**	**N75520 002**	MAY 08, 2000
AB	TEVA	**EQ 10MG BASE**	**N73667 001**	APR 11, 1996
AB		**EQ 10MG BASE**	**N74132 001**	MAR 27, 1995
AB		**EQ 25MG BASE**	**N73667 002**	APR 11, 1996
AB		**EQ 25MG BASE**	**N74132 002**	MAR 27, 1995
AB		**EQ 50MG BASE**	**N73667 003**	APR 11, 1996

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	TEVA	**EQ 50MG BASE**	**N74132 003**	MAR 27, 1995
AB		**EQ 75MG BASE**	**N73667 004**	APR 11, 1996
AB		**EQ 75MG BASE**	**N74132 004**	MAR 27, 1995
AB	WATSON LABS	**EQ 10MG BASE**	**N73553 001**	MAR 30, 1992
AB		**EQ 25MG BASE**	**N73554 001**	MAR 30, 1992
AB		**EQ 50MG BASE**	**N73555 001**	MAR 30, 1992
AB		**EQ 75MG BASE**	**N73556 001**	MAR 30, 1992
	PAMELOR			
AB	TYCO HLTHCARE	**EQ 10MG BASE**	**N18013 001**	
AB		**EQ 25MG BASE**	**N18013 002**	
AB		**EQ 50MG BASE**	**N18013 004**	
AB	+	**EQ 75MG BASE**	**N18013 003**	

SOLUTION; ORAL

	AVENTYL HCL			
AA	+ RANBAXY	**EQ 10MG BASE/5ML**	**N14685 001**	
	NORTRIPTYLINE HCL			
AA	PHARM ASSOC	**EQ 10MG BASE/5ML**	**N75606 001**	AUG 28, 2000
	PAMELOR			
AA	TYCO HLTHCARE	**EQ 10MG BASE/5ML**	**N18012 001**	

NYSTATIN

CREAM; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	**100,000 UNITS/GM**	**N60575 001**	
	NYSTATIN			
AT	ALPHARMA	**100,000 UNITS/GM**	**N62949 001**	JUN 13, 1988
AT	ALTANA	**100,000 UNITS/GM**	**N62129 001**	
AT	CLAY PARK	**100,000 UNITS/GM**	**N62225 001**	
AT	TARO	**100,000 UNITS/GM**	**N62457 001**	JUL 28, 1983
AT		**100,000 UNITS/GM**	**N64022 001**	JAN 29, 1993

FDA data supplied by DrugPatentWatch.com

NYSTATIN

OINTMENT; TOPICAL

	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	**N62840 001** NOV 13, 1987	
AT	+ ALTANA	100,000 UNITS/GM	**N62124 002** SEP 23, 1982	
AT	CLAY PARK	100,000 UNITS/GM	**N62472 001** FEB 13, 1984	

PASTILLE; ORAL

	MYCOSTATIN			
+	BRISTOL MYERS SQUIBB	200,000 UNITS	N50619 001 APR 09, 1987	

POWDER; ORAL

	NILSTAT			
AA	+ LEDERLE	100%	**N50576 001** DEC 22, 1983	
	NYSTATIN			
AA	PADDOCK	100%	**N62613 001** NOV 26, 1985	

POWDER; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	**N60578 001**	
	NYSTOP			
AT	PADDOCK	100,000 UNITS/GM	**N64118 001** AUG 16, 1996	

SUSPENSION; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	100,000 UNITS/ML	**N61533 001**	
	NILSTAT			
AA	+ LEDERLE	100,000 UNITS/ML	**N50299 001**	
	NYSTATIN			
AA	ALPHARMA	100,000 UNITS/ML	**N62349 001** JUL 14, 1982	
AA	BAUSCH AND LOMB	100,000 UNITS/ML	**N64042 001** FEB 28, 1994	
AA	FOUGERA	100,000 UNITS/ML	**N62517 001** JUN 07, 1984	
AA	MORTON GROVE	100,000 UNITS/ML	**N62512 001** OCT 29, 1984	
AA	UDL	100,000 UNITS/ML	**N64142 001** JUN 25, 1998	
	NYSTEX			
AA	SAVAGE LABS	100,000 UNITS/ML	**N62519 001** JUL 06, 1984	

NYSTATIN

TABLET; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	500,000 UNITS	**N60574 001**	
	NYSTATIN			
AA	MUTUAL PHARM	500,000 UNITS	**N62838 001** DEC 22, 1988	
AA	PAR PHARM	500,000 UNITS	**N62474 001** DEC 22, 1983	
AA	TEVA	500,000 UNITS	**N62506 001** JAN 16, 1984	

TABLET; VAGINAL

	NYSTATIN			
AT	FOUGERA	100,000 UNITS	**N62459 001** NOV 09, 1983	
AT	ODYSSEY PHARMS	100,000 UNITS	**N62615 001** OCT 17, 1985	
AT	PHARMADERM	100,000 UNITS	**N62460 001** NOV 09, 1983	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYCO-TRIACET II			
AT	TEVA	100,000 UNITS/GM;0.1%	**N61954 002** SEP 20, 1985	
	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	**N62606 001** MAY 15, 1985	
	MYKACET			
AT	ALPHARMA US PHARM	100,000 UNITS/GM;0.1%	**N62367 001** MAY 28, 1985	
	MYTREX F			
AT	SAVAGE LABS	100,000 UNITS/GM;0.1%	**N62597 001** OCT 08, 1985	
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	100,000 UNITS/GM;0.1%	**N62347 001** MAR 30, 1987	
AT		100,000 UNITS/GM;0.1%	**N62364 001** DEC 22, 1987	
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	100,000 UNITS/GM;0.1%	**N62599 001** OCT 08, 1985	

OINTMENT; TOPICAL

	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	**N60572 001** JUN 28, 1985	

FDA data supplied by DrugPatentWatch.com

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	MYKACET			
AT	ALPHARMA US PHARM	**100,000 UNITS/GM;0.1%**	**N62733 001**	MAR 09, 1987
	MYTREX F			
AT	SAVAGE LABS	**100,000 UNITS/GM;0.1%**	**N62601 001**	OCT 09, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	**100,000 UNITS/GM;0.1%**	**N63305 001**	MAR 29, 1993
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	**100,000 UNITS/GM;0.1%**	**N62602 001**	OCT 09, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

	SANDOSTATIN			
+	NOVARTIS	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988
+		EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
+		EQ 0.2MG BASE/ML	N19667 004	JUN 12, 1991
+		EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988
+		EQ 1MG BASE/ML	N19667 005	JUN 12, 1991
	SANDOSTATIN LAR			
	NOVARTIS	EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998
		EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998
+		EQ 30MG BASE/VIAL	N21008 003	NOV 25, 1998

OFLOXACIN

INJECTABLE; INJECTION

	FLOXIN			
AP	+ ORTHO MCNEIL PHARM	**40MG/ML**	**N20087 003**	MAR 31, 1992
	FLOXIN IN DEXTROSE 5%			
	+ ORTHO MCNEIL PHARM	400MG/100ML	N20087 001	MAR 31, 1992

OFLOXACIN

INJECTABLE; INJECTION

	FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
+	ORTHO MCNEIL PHARM	400MG/100ML	N20087 005	MAR 31, 1992
	OFLOXACIN			
AP	BEDFORD	**40MG/ML**	**N75762 001**	JAN 16, 2002

SOLUTION/DROPS; OPHTHALMIC

	OCUFLOX			
+	ALLERGAN	0.3%	N19921 001	JUL 30, 1993

SOLUTION/DROPS; OTIC

	FLOXIN			
+	DAIICHI	0.3%	N20799 001	DEC 16, 1997

TABLET; ORAL

	FLOXIN			
	ORTHO MCNEIL PHARM	200MG	N19735 001	DEC 28, 1990
		300MG	N19735 002	DEC 28, 1990
+		400MG	N19735 003	DEC 28, 1990

OLANZAPINE

TABLET; ORAL

	ZYPREXA			
	LILLY	2.5MG	N20592 001	SEP 30, 1996
		5MG	N20592 002	SEP 30, 1996
		7.5MG	N20592 003	SEP 30, 1996
		10MG	N20592 004	SEP 30, 1996
		15MG	N20592 005	SEP 09, 1997
+		20MG	N20592 006	SEP 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

	ZYPREXA ZYDIS			
	LILLY	5MG	N21086 001	APR 06, 2000

FDA data supplied by DrugPatentWatch.com

OLANZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

ZYPREXA ZYDIS				
LILLY	10MG	N21086 002 APR 06, 2000		
	15MG	N21086 003 APR 06, 2000		
+	20MG	N21086 004 APR 06, 2000		

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR				
SANKYO	5MG	N21286 001 APR 25, 2002		
	20MG	N21286 003 APR 25, 2002		
+	40MG	N21286 004 APR 25, 2002		

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PATANOL				
+ ALCON	EQ 0.1% BASE	N20688 001 DEC 18, 1996		

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM				
+ PHARMACIA AND UPJOHN	250MG	N19715 001 JUL 31, 1990		

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE				
AB ANDRX PHARMS	**10MG**	**N75347 001** NOV 16, 2001		
AB	**20MG**	**N75347 002** NOV 16, 2001		

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE				
AB ANDRX PHARMS	**40MG**	**N75347 003** NOV 16, 2001		
AB EON	**10MG**	**N75791 001** DEC 23, 2002		
AB	**20MG**	**N75791 002** DEC 23, 2002		
AB IMPAX LABS	**10MG**	**N75785 001** NOV 08, 2002		
AB	**20MG**	**N75785 002** NOV 08, 2002		
AB KREMERS URBAN DEV	**10MG**	**N75410 001** NOV 01, 2002		
AB	**20MG**	**N75410 002** NOV 01, 2002		
PRILOSEC				
AB ASTRAZENECA	**10MG**	**N19810 003** OCT 05, 1995		
AB +	**20MG**	**N19810 001** SEP 14, 1989		
AB +	**40MG**	**N19810 002** JAN 15, 1998		

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ZOFRAN ODT			
GLAXOSMITHKLINE	EQ 4MG BASE	N20781 001 JAN 27, 1999	
+	EQ 8MG BASE	N20781 002 JAN 27, 1999	

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ZOFRAN			
+ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N20007 001 JAN 04, 1991	
ZOFRAN IN PLASTIC CONTAINER			
+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N20403 001 JAN 31, 1995	
ZOFRAN PRESERVATIVE FREE			
+ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N20007 003 DEC 10, 1993	

FDA data supplied by DrugPatentWatch.com

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

	ZOFRAN			
+	GLAXOSMITHKLINE	EQ 4MG BASE/5ML	N20605 001	JAN 24, 1997

TABLET; ORAL

	ZOFRAN			
	GLAXOSMITHKLINE	EQ 4MG BASE	N20103 001	DEC 31, 1992
		EQ 8MG BASE	N20103 002	DEC 31, 1992
+		EQ 24MG BASE	N20103 003	AUG 27, 1999

ORLISTAT

CAPSULE; ORAL

	XENICAL			
+	HLR	120MG	N20766 001	APR 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

	NORFLEX			
AP	+ 3M	**30MG/ML**	**N13055 001**	
	ORPHENADRINE CITRATE			
AP	STERIS	**30MG/ML**	**N84779 001**	MAR 15, 1982
AP		**30MG/ML**	**N87062 001**	

TABLET, EXTENDED RELEASE; ORAL

	NORFLEX			
AB	+ 3M	**100MG**	**N12157 001**	
	ORPHENADRINE CITRATE			
AB	EON	**100MG**	**N40327 001**	FEB 15, 2000
AB	GENEVA PHARMS TECH	**100MG**	**N40284 001**	JUN 19, 1998
AB	IMPAX PHARM	**100MG**	**N40368 001**	JUN 23, 2000
AB	KIEL	**100MG**	**N40249 001**	JAN 29, 1999

ORPHENADRINE CITRATE; *MULTIPLE*
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

	TAMIFLU			
+	ROCHE	EQ 75MG BASE	N21087 001	OCT 27, 1999

FOR SUSPENSION; ORAL

	TAMIFLU			
+	ROCHE	EQ 12MG BASE/ML	N21246 001	DEC 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

	BACTOCILL			
AB	GLAXOSMITHKLINE	**EQ 250MG BASE**	**N61336 001**	
AB		**EQ 250MG BASE**	**N62241 001**	
AB	+	**EQ 500MG BASE**	**N61336 002**	
AB		**EQ 500MG BASE**	**N62241 002**	
	OXACILLIN SODIUM			
AB	TEVA	**EQ 250MG BASE**	**N62222 001**	
AB		**EQ 500MG BASE**	**N62222 002**	

FOR SOLUTION; ORAL

	BACTOCILL			
AA	GLAXOSMITHKLINE	**EQ 250MG BASE/5ML**	**N62321 001**	
	OXACILLIN SODIUM			
AA	APOTHECON	**EQ 250MG BASE/5ML**	**N61457 001**	
AA	TEVA	**EQ 250MG BASE/5ML**	**N62252 001**	

INJECTABLE; INJECTION

	BACTOCILL IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N50640 001	OCT 26, 1989
+		EQ 40MG BASE/ML	N50640 002	OCT 26, 1989
	OXACILLIN SODIUM			
AP	APOTHECON	**EQ 250MG BASE/VIAL**	**N61490 001**	
AP	+	**EQ 500MG BASE/VIAL**	**N61490 002**	
AP	+	**EQ 1GM BASE/VIAL**	**N61490 003**	
AP		**EQ 1GM BASE/VIAL**	**N62737 001**	DEC 23, 1986
AP	+	**EQ 2GM BASE/VIAL**	**N62737 002**	DEC 23, 1986
AP	+	**EQ 10GM BASE/VIAL**	**N61490 006**	MAY 09, 1991

FDA data supplied by DrugPatentWatch.com

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP	MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62856 001	OCT 26, 1988
AP		EQ 500MG BASE/VIAL	N62856 002	OCT 26, 1988
AP		EQ 1GM BASE/VIAL	N62856 003	OCT 26, 1988
AP		EQ 2GM BASE/VIAL	N62856 004	OCT 26, 1988
AP		EQ 10GM BASE/VIAL	N62984 001	SEP 29, 1988
		EQ 4GM BASE/VIAL	N62856 005	OCT 26, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)
ELOXATIN

	SANOFI	50MG/VIAL	N21492 001	AUG 09, 2002
+		100MG/VIAL	N21492 002	AUG 09, 2002

OXAMNIQUINE

CAPSULE; ORAL
VANSIL

+	PFIZER	250MG	N18069 001	

OXANDROLONE

TABLET; ORAL
OXANDRIN

	BIO TECH GEN	2.5MG	N13718 001	
+		10MG	N13718 002	NOV 05, 2001

OXAPROZIN

TABLET; ORAL
DAYPRO

AB	+ GD SEARLE LLC	600MG	N18841 004	OCT 29, 1992

OXAPROZIN

TABLET; ORAL
OXAPROZIN

AB	CARACO	600MG	N75844 001	JAN 03, 2002
AB	DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001
AB	EON	600MG	N75845 001	JAN 31, 2001
AB	GENEVA PHARMS	600MG	N75850 001	APR 27, 2001
AB	GENPHARM	600MG	N75847 001	FEB 28, 2001
AB	INVAMED	600MG	N75842 001	APR 12, 2001
AB	IVAX PHARMS	600MG	N75846 001	MAY 13, 2002
AB	MYLAN	600MG	N75851 001	AUG 17, 2001
AB	PUREPAC PHARM	600MG	N75843 001	OCT 03, 2001
AB	TEVA	600MG	N75849 001	JUL 03, 2002
AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL
DAYPRO ALTA

+	PHARMACIA	600MG	N20776 001	OCT 17, 2002

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	GENEVA PHARMS	10MG	N71813 001	APR 19, 1988
AB		15MG	N71756 001	APR 19, 1988
AB		30MG	N71814 001	APR 19, 1988
AB	IVAX PHARMS	10MG	N70943 001	AUG 03, 1987

FDA data supplied by DrugPatentWatch.com

OXAZEPAM

CAPSULE; ORAL

	OXAZEPAM			
AB	IVAX PHARMS	15MG	**N70944 001**	AUG 03, 1987
AB		30MG	**N70945 001**	AUG 03, 1987
AB	PUREPAC PHARM	10MG	**N72251 001**	APR 14, 1988
AB		15MG	**N72252 001**	APR 14, 1988
AB		30MG	**N72253 001**	APR 14, 1988
AB	WATSON LABS	10MG	**N72952 001**	SEP 28, 1990
AB		15MG	**N72953 001**	SEP 28, 1990
AB		30MG	**N72954 001**	SEP 28, 1990
	SERAX			
AB	FAULDING PHARMS	10MG	**N15539 002**	
AB		15MG	**N15539 004**	
AB	+	30MG	**N15539 006**	

TABLET; ORAL

	SERAX			
	+ FAULDING PHARMS	15MG	N15539 008	

OXCARBAZEPINE

SUSPENSION; ORAL

	TRILEPTAL			
	+ NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001

TABLET; ORAL

	TRILEPTAL			
	NOVARTIS	150MG	N21014 001	JAN 14, 2000
		300MG	N21014 002	JAN 14, 2000
	+	600MG	N21014 003	JAN 14, 2000

OXICONAZOLE NITRATE

CREAM; TOPICAL

	OXISTAT			
	+ GLAXOSMITHKLINE	EQ 1% BASE	N19828 001	DEC 30, 1988

LOTION; TOPICAL

	OXISTAT			
	+ GLAXOSMITHKLINE	EQ 1% BASE	N20209 001	SEP 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	CHOLEDYL SA			
	+ PARKE DAVIS	400MG	N87863 001	MAY 24, 1983
	+ WARNER CHILCOTT	600MG	N86742 001	

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

	DITROPAN			
AA	+ ALZA	5MG/5ML	**N18211 001**	
	OXYBUTYNIN CHLORIDE			
AA	MIKART	5MG/5ML	**N75039 001**	JAN 29, 1999
AA	MORTON GROVE	5MG/5ML	**N74868 001**	FEB 12, 1997
AA	NOVEX	5MG/5ML	**N74997 001**	OCT 15, 1997
AA	PHARM ASSOC	5MG/5ML	**N75137 001**	DEC 18, 1998
AA	SILARX	5MG/5ML	**N74520 001**	MAR 29, 1996

TABLET; ORAL

	DITROPAN			
AB	+ ALZA	5MG	**N17577 001**	
	OXYBUTYNIN CHLORIDE			
AB	SIDMAK LABS NJ	5MG	**N71655 001**	NOV 14, 1988
AB	USL PHARMA	5MG	**N74625 001**	JUL 31, 1996
AB	VINTAGE PHARMS	5MG	**N75079 001**	OCT 31, 1997

FDA data supplied by DrugPatentWatch.com

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL

+	ALZA	5MG	N20897 001 DEC 16, 1998
+		10MG	N20897 002 DEC 16, 1998
+		15MG	N20897 003 JUN 22, 1999

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
ROXICODONE

	ELAN PHARMS	15MG	N21011 001 AUG 31, 2000
+		30MG	N21011 002 AUG 31, 2000

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

	PURDUE PHARMA LP	10MG	N20553 001 DEC 12, 1995
		20MG	N20553 002 DEC 12, 1995
+		40MG	N20553 003 DEC 12, 1995
+		80MG	N20553 004 JAN 06, 1997

OXYCODONE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYCODONE TEREPHTHALATE; *MULTIPLE*
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYMETHOLONE

TABLET; ORAL
ANADROL-50

+	UNIMED PHARMS	50MG	N16848 001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
NUMORPHAN

+	ENDO PHARMS	1MG/ML	N11707 002
+		1.5MG/ML	N11707 001

SUPPOSITORY; RECTAL
NUMORPHAN

+	ENDO PHARMS	5MG	N11738 004

OXYTETRACYCLINE; *MULTIPLE*
SEE LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TERRAMYCIN

+	PFIZER	EQ 250MG BASE	N50286 002

OXYTETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE

+	PFIZER	EQ 5MG BASE/GM; 10,000 UNITS/GM	N61015 001

OXYTOCIN

INJECTABLE; INJECTION

	OXYTOCIN			
AP	AM PHARM PARTNERS	**10 USP UNITS/ML**	**N18248 001**
	PITOCIN			
AP	+ PARKEDALE	**10 USP UNITS/ML**	**N18261 001**
	SYNTOCINON			
AP	NOVARTIS	**10 USP UNITS/ML**	**N18245 001**

FDA data supplied by DrugPatentWatch.com

PACLITAXEL

INJECTABLE; INJECTION

	PACLITAXEL			
AP	ABBOTT	6MG/ML	N76131 001	MAY 08, 2002
AP	BAKER NORTON	6MG/ML	N75184 001	JAN 25, 2002
AP	BEDFORD	6MG/ML	N75190 001	JAN 28, 2002
AP	IVAX PHARMS	6MG/ML	N75297 001	JAN 25, 2002
AP	MYLAN	6MG/ML	N75278 001	JAN 25, 2002
AP	NAPRO	6MG/ML	N76233 001	AUG 01, 2002
	TAXOL			
AP +	BRISTOL MYERS SQUIBB	6MG/ML	N20262 001	DEC 29, 1992

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

	AREDIA			
AP +	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991
AP +		90MG/VIAL	N20036 004	MAY 06, 1993
+		60MG/VIAL	N20036 003	MAY 06, 1993
	PAMIDRONATE DISODIUM			
AP	AESGEN	30MG/VIAL	N75594 001	MAY 06, 2002
AP		90MG/VIAL	N75594 002	MAY 06, 2002
AP	AM PHARM PARTNERS	30MG/VIAL	N75773 001	MAY 06, 2002
AP		30MG /10ML(3MG/ML)	N76207 001	MAY 17, 2002
AP		90MG/VIAL	N75773 002	MAY 06, 2002
AP		90MG /10ML(9MG/ML)	N76207 002	MAY 17, 2002
AP	BEDFORD	30 MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002
AP		30MG/VIAL	N75290 001	APR 30, 2001

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

	PAMIDRONATE DISODIUM			
AP +	BEDFORD	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002
AP		90MG/VIAL	N75290 003	APR 30, 2001
AP	FAULDING	EQ 30MG /10ML(3MG/ML)	N75841 001	JUN 27, 2002
AP		EQ 60MG /10ML(6MG/ML)	N75841 002	JUN 27, 2002
AP		EQ 90MG /10ML(9MG/ML)	N75841 003	JUN 27, 2002
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

	PANCURONIUM			
AP	ELKINS SINN	1MG/ML	N72058 001	MAR 23, 1988
AP		2MG/ML	N72059 001	MAR 23, 1988
AP		2MG/ML	N72060 001	MAR 23, 1988
	PANCURONIUM BROMIDE			
AP	ABBOTT	1MG/ML	N72320 001	JAN 19, 1989
AP		2MG/ML	N72321 001	JAN 19, 1989
AP	GENSIA SICOR PHARMS	1MG/ML	N72759 001	JUL 31, 1990
AP		2MG/ML	N72760 001	JUL 31, 1990
	PAVULON			
AP +	ORGANON	1MG/ML	N17015 002	
AP +		2MG/ML	N17015 001	

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

	PROTONIX IV			
+	WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001

FDA data supplied by DrugPatentWatch.com

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PROTONIX
+ WYETH AYERST — EQ 20MG BASE — N20987 002 JUN 12, 2001
+ — EQ 40MG BASE — N20987 001 FEB 02, 2000

PANTOTHENIC ACID; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT — 0.005MG/ML — N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AA + PARKEDALE — **EQ 250MG BASE** — **N62310 001**
PAROMOMYCIN SULFATE
AA CARACO — **EQ 250MG BASE** — **N64171 001** JUN 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ GLAXOSMITHKLINE — EQ 10MG BASE/5ML — N20710 001 JUN 25, 1997

TABLET; ORAL
PAXIL
GLAXOSMITHKLINE — EQ 10MG BASE — N20031 001 DEC 29, 1992
EQ 20MG BASE — N20031 002 DEC 29, 1992
EQ 30MG BASE — N20031 003 DEC 29, 1992

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
+ GLAXOSMITHKLINE — EQ 40MG BASE — N20031 005 DEC 29, 1992

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
GLAXOSMITHKLINE — EQ 12.5MG BASE — N20936 001 FEB 16, 1999
EQ 25MG BASE — N20936 002 FEB 16, 1999
+ EQ 37.5MG BASE — N20936 003 DEC 06, 2000

PEGADEMASE BOVINE

INJECTABLE; INJECTION
ADAGEN
+ ENZON — 250 UNITS/ML — N19818 001 MAR 21, 1990

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST
+ SANTEN — 0.1% — N21079 001 SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB + ABBOTT — **18.75MG** — **N16832 001**
AB — **37.5MG** — **N16832 002**
AB + — **75MG** — **N16832 003**
PEMOLINE
AB AMIDE PHARM — **18.75MG** — **N75595 001** FEB 28, 2000
AB — **37.5MG** — **N75595 002** FEB 28, 2000
AB — **75MG** — **N75595 003** FEB 28, 2000
AB COPLEY PHARM — **18.75MG** — **N75030 003** FEB 22, 2000

FDA data supplied by DrugPatentWatch.com

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	COPLEY PHARM	37.5MG	N75030 001	JAN 29, 1999
AB		75MG	N75030 002	JAN 29, 1999
AB	GENEVA PHARMS TECH	18.75MG	N75286 001	DEC 27, 1999
AB		37.5MG	N75286 002	JUN 30, 1999
AB		75MG	N75286 003	JUN 30, 1999
AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001
AB		37.5MG	N75726 002	MAR 30, 2001
AB		75MG	N75726 001	MAR 30, 2001
AB	VINTAGE PHARMS	18.75MG	N75328 001	APR 19, 2000
AB		37.5MG	N75328 002	APR 19, 2000
AB		75MG	N75328 003	APR 19, 2000
AB	WATSON LABS	18.75MG	N75287 001	JUN 13, 2001
AB		37.5MG	N75287 002	SEP 18, 2000
AB		75MG	N75287 003	SEP 18, 2000

TABLET, CHEWABLE; ORAL

	CYLERT			
AB	+ ABBOTT	37.5MG	N17703 001	
	PEMOLINE			
AB	AMIDE PHARM	37.5MG	N75678 001	JUL 26, 2000
AB	COPLEY PHARM	37.5MG	N75555 001	FEB 18, 2000

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL			
	+ SCHWARZ PHARMA	20MG	N18976 004	JAN 05, 1989

PENCICLOVIR SODIUM

CREAM; TOPICAL

	DENAVIR			
	+ NOVARTIS	1%	N20629 001	SEP 24, 1996

PENICILLAMINE

CAPSULE; ORAL

	CUPRIMINE			
	MERCK	125MG	N19853 002	
	+	250MG	N19853 001	

TABLET; ORAL

	DEPEN			
	+ WALLACE LABS	250MG	N19854 001	

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

	BICILLIN L-A			
BC	+ KING PHARMS	600,000 UNITS/ML	N50141 001	
	+	300,000 UNITS/ML	N50141 003	
	PERMAPEN			
BC	PFIZER	600,000 UNITS/ML	N60014 001	

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	BICILLIN C-R			
	+ KING PHARMS	150,000 UNITS/ML; 150,000 UNITS/ML	N50138 002	
	+	300,000 UNITS/ML; 300,000 UNITS/ML	N50138 001	
	BICILLIN C-R 900/300			
	+ KING PHARMS	900,000 UNITS/2ML; 300,000 UNITS/2ML	N50138 003	

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
AP	GENEVA PHARMS	1,000,000 UNITS/VIAL	N65079 001	AUG 30, 2002

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
AP	GENEVA PHARMS	**5,000,000 UNITS/VIAL**	**N65079 002**	
			AUG 30, 2002	
AP		**20,000,000 UNITS/VIAL**	**N65079 003**	
			AUG 30, 2002	
AP	MARSAM PHARMS LLC	**1,000,000 UNITS/VIAL**	**N62991 001**	
			SEP 13, 1988	
AP		**5,000,000 UNITS/VIAL**	**N62991 002**	
			SEP 13, 1988	
AP		**10,000,000 UNITS/VIAL**	**N62991 003**	
			SEP 13, 1988	
AP		**20,000,000 UNITS/VIAL**	**N62991 004**	
			SEP 13, 1988	
AP	PFIZER	**20,000,000 UNITS/VIAL**	**N60074 003**	
	PENICILLIN G POTASSIUM	IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	20,000 UNITS/ML	N50638 001	
			JUN 25, 1990	
+		40,000 UNITS/ML	N50638 002	
			JUN 25, 1990	
+		60,000 UNITS/ML	N50638 003	
			JUN 25, 1990	
	PFIZERPEN			
AP +	PFIZER	**1,000,000 UNITS/VIAL**	**N60657 001**	
AP +		**5,000,000 UNITS/VIAL**	**N60657 002**	
AP +		**20,000,000 UNITS/VIAL**	**N60657 003**	

TABLET; ORAL

	PENICILLIN G POTASSIUM		
	WYETH AYERST	200,000 UNITS	N60413 001
		250,000 UNITS	N60413 002
+		400,000 UNITS	N60413 003

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	WYCILLIN		
+	KING PHARMS	300,000 UNITS/ML	N60101 002
+		600,000 UNITS/ML	N60101 001

PENICILLIN G PROCAINE; *MULTIPLE*

SEE PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

PENICILLIN G SODIUM

INJECTABLE; IM-IV

	PENICILLIN G SODIUM			
+	BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	
			FEB 26, 2001	

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

	BEEPEN-VK			
AA	GLAXOSMITHKLINE	**EQ 125MG BASE/5ML**	**N62270 001**	
AA		**EQ 250MG BASE/5ML**	**N62270 002**	
	LEDERCILLIN VK			
AA	LEDERLE	**EQ 125MG BASE/5ML**	**N60136 001**	
AA		**EQ 250MG BASE/5ML**	**N60136 002**	
	PENICILLIN V POTASSIUM			
AA	CLONMEL	**EQ 125MG BASE/5ML**	**N62981 001**	
			FEB 10, 1989	
AA		**EQ 250MG BASE/5ML**	**N62981 002**	
			FEB 10, 1989	
AA	CONSOLIDATED PHARM	**EQ 125MG BASE/5ML**	**N61529 001**	
AA		**EQ 250MG BASE/5ML**	**N61529 002**	
	PENICILLIN-VK			
AA	TEVA	**EQ 125MG BASE/5ML**	**N60456 001**	
AA		**EQ 250MG BASE/5ML**	**N60456 002**	
	VEETIDS			
AA	APOTHECON	**EQ 125MG BASE/5ML**	**N61410 001**	
AA		**EQ 250MG BASE/5ML**	**N61410 002**	

TABLET; ORAL

	BEEPEN-VK			
AB	GLAXOSMITHKLINE	**EQ 250MG BASE**	**N62273 001**	
AB		**EQ 500MG BASE**	**N62273 002**	
	BETAPEN-VK			
AB	BRISTOL	**EQ 250MG BASE**	**N61150 001**	
AB		**EQ 500MG BASE**	**N61150 002**	
	LEDERCILLIN VK			
AB	LEDERLE	**EQ 250MG BASE**	**N60134 001**	
AB		**EQ 500MG BASE**	**N60134 002**	
	PEN-VEE K			
AB	WYETH AYERST	**EQ 250MG BASE**	**N60006 002**	
AB +		**EQ 500MG BASE**	**N60006 003**	
	PENICILLIN V POTASSIUM			
AB	BIOCHEMIE	**EQ 250MG BASE**	**N64071 001**	
			NOV 30, 1995	
AB +		**EQ 500MG BASE**	**N64071 002**	
			NOV 30, 1995	

FDA data supplied by DrugPatentWatch.com

PENICILLIN V POTASSIUM

TABLET; ORAL

	PENICILLIN V POTASSIUM			
AB	CLONMEL	**EQ 250MG BASE**	**N62936 001**	
			NOV 25, 1988	
AB		**EQ 500MG BASE**	**N62935 001**	
			NOV 23, 1988	
AB	CONSOLIDATED PHARM	**EQ 250MG BASE**	**N61528 001**	
AB		**EQ 500MG BASE**	**N61528 002**	
	PENICILLIN-VK			
AB	TEVA	**EQ 250MG BASE**	**N60711 002**	
AB		**EQ 500MG BASE**	**N60711 003**	
	UTICILLIN VK			
AB	PHARMACIA AND UPJOHN	**EQ 250MG BASE**	**N61651 001**	
	VEETIDS			
AB	APOTHECON	**EQ 250MG BASE**	**N61411 001**	
AB		**EQ 500MG BASE**	**N61411 002**	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

	NEBUPENT			
	+ AM PHARM PARTNERS	300MG/VIAL	N19887 001	
			JUN 15, 1989	
		600MG/VIAL	N19887 002	
			MAR 22, 1996	

INJECTABLE; INJECTION

	PENTAM			
AP	+ AM PHARM PARTNERS	**300MG/VIAL**	**N19264 001**	
			OCT 16, 1984	
	PENTAMIDINE ISETHIONATE			
AP	ABBOTT	**300MG/VIAL**	**N73479 001**	
			JUN 30, 1992	
AP	ELKINS SINN	**300MG/VIAL**	**N73617 001**	
			DEC 18, 1995	
AP	STERIS	**300MG/VIAL**	**N74303 001**	
			AUG 17, 1995	

PENTAZOCINE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE
SEE NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

	TALWIN		
	+ ABBOTT	EQ 30MG BASE/ML	N16194 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

	NEMBUTAL SODIUM		
AA	+ ABBOTT	**100MG**	**N83245 001**
	+	30MG	N84095 001
	SODIUM PENTOBARBITAL		
AA	ICN	**100MG**	**N83264 001**

INJECTABLE; INJECTION

	NEMBUTAL SODIUM		
AP	+ ABBOTT	**50MG/ML**	**N83246 001**
	SODIUM PENTOBARBITAL		
AP	WYETH AYERST	**50MG/ML**	**N83261 001**

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON		
+ JOHNSON AND JOHNSON	100MG	N20193 001
		SEP 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT		
+ SUPERGEN	10MG/VIAL	N20122 001
		OCT 11, 1991

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE		
AB	BIOVAIL	**400MG**	**N75028 001**
			JUL 20, 1998
AB	ESI LEDERLE	**400MG**	**N74877 001**
			JUL 08, 1997
AB	IMPAX LABS	**400MG**	**N75093 001**
			AUG 10, 1999

FDA data supplied by DrugPatentWatch.com

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	MYLAN	**400MG**	**N74425 001**	JUL 08, 1997
AB	PUREPAC PHARM	**400MG**	**N74878 001**	JUL 09, 1997
AB	SIDMAK LABS NJ	**400MG**	**N74874 001**	MAY 25, 1999
AB	TEVA	**400MG**	**N75199 001**	SEP 03, 1999
AB	TORPHARM	**400MG**	**N75191 001**	JUN 09, 1999
AB	WATSON LABS	**400MG**	**N75107 001**	SEP 04, 1998
	PENTOXIL			
AB	UPSHER SMITH	**400MG**	**N74962 001**	MAR 31, 1999
	TRENTAL			
AB	+ AVENTIS PHARMS	**400MG**	**N18631 001**	AUG 30, 1984

PERFLEXANE; *MULTIPLE*

SEE DIMYRISTOYL LECITHIN; PERFLEXANE

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

+	US ARMY	50%;50%	N21084 001 FEB 17, 2000

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+	BRISTOL MYERS SQUIBB	6.52MG/ML	N21064 001 JUL 31, 2001

PERGOLIDE MESYLATE

TABLET; ORAL

	PERGOLIDE MESYLATE			
AB	TEVA	**EQ 0.05MG BASE**	**N76061 001**	NOV 27, 2002
AB		**EQ 0.25MG BASE**	**N76061 002**	NOV 27, 2002
AB		**EQ 1MG BASE**	**N76061 003**	NOV 27, 2002
	PERMAX			
AB	+ LILLY	**EQ 0.05MG BASE**	**N19385 001**	DEC 30, 1988
AB		**EQ 0.25MG BASE**	**N19385 002**	DEC 30, 1988
AB		**EQ 1MG BASE**	**N19385 003**	DEC 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

	SOLVAY PHARMA	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL

	ELIMITE			
AB	+ ALLERGAN	**5%**	**N19855 001**	AUG 25, 1989
	PERMETHRIN			
AB	ALPHARMA	**5%**	**N74806 001**	JAN 23, 1998

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

+	PHARM ASSOC	16MG/5ML	N40360 001 MAY 25, 2001

FDA data supplied by DrugPatentWatch.com

PERPHENAZINE

INJECTABLE; INJECTION
TRILAFON
+ SCHERING 5MG/ML N11213 002

TABLET; ORAL
PERPHENAZINE

AB	GENEVA PHARMS	2MG	**N89683 001**	DEC 08, 1988
AB		4MG	**N89684 001**	DEC 08, 1988
AB		8MG	**N89685 001**	DEC 08, 1988
AB		16MG	**N89686 001**	DEC 08, 1988
AB	IVAX PHARMS	2MG	**N89707 001**	SEP 10, 1987
AB		4MG	**N89708 001**	SEP 10, 1987
AB		8MG	**N89456 001**	SEP 10, 1987
AB		16MG	**N89457 001**	SEP 10, 1987
AB	VINTAGE PHARMS	2MG	**N40226 001**	DEC 31, 1998
AB		4MG	**N40226 002**	DEC 31, 1998
AB		8MG	**N40226 003**	DEC 31, 1998
AB		16MG	**N40226 004**	DEC 31, 1998

TRILAFON

AB	SCHERING	2MG	**N10775 001**	
AB		4MG	**N10775 002**	
AB		8MG	**N10775 003**	
AB	+	16MG	**N10775 004**	

PERPHENAZINE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

AA	+ EON	35MG	**N85695 001**	

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
X-TROZINE

AA	SHIRE RICHWOOD	35MG	**N87394 001**	SEP 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL

BC	MALLINCKRODT	105MG	N88021 001	SEP 21, 1982

PHENDIMETRAZINE TARTRATE

BC	+ EON	105MG	N18074 001	

X-TROZINE L.A.

BC	SHIRE RICHWOOD	105MG	N87371 001	AUG 24, 1982

TABLET; ORAL
BONTRIL PDM

AA	AMARIN PHARMS	35MG	**N85272 001**	

CAM-METRAZINE

AA	+ ABC HOLDING	35MG	**N83922 001**	
AA		35MG	**N85318 001**	
AA		35MG	**N85320 001**	
AA		35MG	**N85321 001**	
AA		35MG	**N85511 001**	
AA	CAMALL	35MG	**N85756 001**	

PHENDIMETRAZINE TARTRATE

AA	ABC HOLDING	35MG	**N85761 001**	
AA		35MG	**N85941 001**	JUN 27, 1983
AA	EON	35MG	**N85588 001**	
AA		35MG	**N85830 001**	
AA	MIKART	35MG	**N89452 001**	OCT 30, 1991

X-TROZINE

AA	SHIRE RICHWOOD	35MG	**N86553 001**	
AA		35MG	**N86554 001**	

PHENELZINE SULFATE

TABLET; ORAL
NARDIL
+ PARKE DAVIS EQ 15MG BASE N11909 002

FDA data supplied by DrugPatentWatch.com

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIBENZYLINE			
	+ WELLSPRING PHARM	10MG		N08708 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	ADIPEX-P			
AA	+ TEVA	**37.5MG**		**N88023 001**
				AUG 02, 1983
	ONA-MAST			
AA	MAST MM	**30MG**		**N86511 001**
AA		**30MG**		**N86516 001**
	PHENTERMINE HCL			
AA	ABC HOLDING	**30MG**		**N85417 001**
AA		**30MG**		**N86732 002**
AA		**30MG**		**N87215 001**
AA		**37.5MG**		**N87915 001**
				DEC 22, 1983
AA		**37.5MG**		**N87918 001**
				DEC 22, 1983
AA		**37.5MG**		**N87930 001**
				OCT 14, 1983
AA		**37.5MG**		**N88610 001**
				JUN 04, 1984
AA		**37.5MG**		**N88611 001**
				JUN 04, 1984
AA		**37.5MG**		**N88625 001**
				AUG 23, 1984
		18.75MG		N88576 001
				MAY 23, 1984
AA	ABLE	**30MG**		**N40403 001**
				AUG 30, 2001
AA		**30MG**		**N40427 001**
				AUG 30, 2001
AA	AMIDE PHARM	**30MG**		**N40227 001**
				JUN 18, 1997
AA		**37.5MG**		**N40228 001**
				JUN 19, 1997
AA	CAMALL	**15MG**		**N86735 001**
AA		**30MG**		**N87226 001**
AA	+ EON	**15MG**		**N87301 001**
AA	+	**30MG**		**N86945 001**
				JUL 20, 1983
AA		**30MG**		**N87190 001**
AA		**30MG**		**N87208 001**

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
AA	EON	**30MG**		**N87223 001**
AA	KING PHARMS	**30MG**		**N40083 001**
				MAR 07, 1997
AA	USL PHARMA	**30MG**		**N88797 001**
				DEC 10, 1984
AA	VINTAGE PHARMS	**37.5MG**		**N40377 001**
				JAN 04, 2002

TABLET; ORAL

	ADIPEX-P			
AA	+ TEVA	**37.5MG**		**N85128 001**
	ONA MAST			
AA	MAST MM	**8MG**		**N86260 001**
	PHENTERMINE HCL			
AA	+ ABC HOLDING	**8MG**		**N83923 001**
AA		**8MG**		**N85319 001**
AA		**37.5MG**		**N87805 001**
				DEC 06, 1982
AA		**37.5MG**		**N88596 001**
				APR 04, 1984
AA	ABLE	**37.5MG**		**N40402 001**
				AUG 30, 2001
AA	AMIDE PHARM	**37.5MG**		**N40190 001**
				MAY 30, 1997
	+ EON	30MG		N88605 001
				SEP 28, 1987
AA	PUREPAC PHARM	**37.5MG**		**N40276 001**
				NOV 25, 1998
AA	USL PHARMA	**8MG**		**N83804 001**
AA		**37.5MG**		**N88910 001**
				JUL 17, 1985
AA		**37.5MG**		**N88917 001**
				JUL 17, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	IONAMIN			
	CELLTECH PHARMS	EQ 15MG BASE		N11613 004
	+	EQ 30MG BASE		N11613 002

FDA data supplied by DrugPatentWatch.com

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

	PHENTOLAMINE MESYLATE			
AP	BEDFORD	**5MG/VIAL**	**N40235 001**	MAR 11, 1998
	REGITINE			
AP	+ NOVARTIS	**5MG/VIAL**	**N08278 003**	

PHENYLEPHRINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN VC			
AA	+ WYETH AYERST	**5MG/5ML;6.25MG/5ML**	**N08604 003**	APR 02, 1984
	PROMETH VC PLAIN			
AA	ALPHARMA	**5MG/5ML;6.25MG/5ML**	**N88761 001**	NOV 08, 1984
	PROMETHAZINE VC PLAIN			
AA	MORTON GROVE	**5MG/5ML;6.25MG/5ML**	**N88897 001**	JAN 04, 1985

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*

SEE BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PHENYTOIN

SUSPENSION; ORAL

	DILANTIN-125			
AB	+ PARKE DAVIS	**125MG/5ML**	**N08762 001**	
	PHENTYTOIN			
AB	MORTON GROVE	**125MG/5ML**	**N40420 001**	APR 19, 2002
	PHENYTOIN			
AB	ALPHARMA	**125MG/5ML**	**N89892 001**	SEP 25, 1992
AB	UDL	**125MG/5ML**	**N40342 001**	JAN 31, 2001

PHENYTOIN

TABLET, CHEWABLE; ORAL

	DILANTIN		
+	PFIZER PHARMS	50MG	N84427 001

PHENYTOIN SODIUM

INJECTABLE; INJECTION

	DILANTIN			
AP	+ PARKE DAVIS	**50MG/ML**	**N10151 001**	
	PHENYTOIN			
AP	ELKINS SINN	**50MG/ML**	**N84307 001**	
	PHENYTOIN SODIUM			
AP	ABBOTT	**50MG/ML**	**N89521 001**	MAR 17, 1987
AP		**50MG/ML**	**N89744 001**	DEC 18, 1987

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL

	DILANTIN			
AB	+ PARKE DAVIS	**100MG**	**N84349 002**	
	+	30MG	N84349 001	
	EXTENDED PHENYTOIN SODIUM			
AB	MYLAN	**100MG**	**N40298 001**	DEC 28, 1998
	PHENYTEK			
	+ MYLAN	200MG	N40298 002	DEC 06, 2001
	+	300MG	N40298 003	DEC 06, 2001

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

	PROMPT PHENYTOIN SODIUM		
+	IVAX PHARMS	100MG	N80259 001

PHOSPHORIC ACID; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

FDA data supplied by DrugPatentWatch.com

PHOSPHORIC ACID; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

PHYTONADIONE

	INJECTABLE; INJECTION			
	AQUAMEPHYTON			
BP	+ MERCK	1MG/0.5ML	N12223 002	
BP	+	10MG/ML	N12223 001	
	PHYTONADIONE			
BP	INTL MEDICATION	1MG/0.5ML	N83722 001	
	VITAMIN K1			
BP	ABBOTT	1MG/0.5ML	N87954 001 JUL 25, 1983	
BP		10MG/ML	N87955 001 JUL 25, 1983	
	TABLET; ORAL			
	MEPHYTON			
	+ MERCK	5MG	N10104 003	

PHYTONADIONE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC			
PILOPINE HS			
+ ALCON	4%	N18796 001 OCT 01, 1984	
TABLET; ORAL			
SALAGEN			
+ MGI PHARMA INC	5MG	N20237 001 MAR 22, 1994	

PIMECROLIMUS

CREAM; TOPICAL			
ELIDEL			
+ NOVARTIS	1%	N21302 001 DEC 13, 2001	

PIMOZIDE

TABLET; ORAL			
ORAP			
TEVA	1MG	N17473 003 AUG 27, 1997	
+	2MG	N17473 001 JUL 31, 1984	

PINDOLOL

TABLET; ORAL			
PINDOLOL			
AB GENEVA PHARMS	**5MG**	**N73608 001** MAR 29, 1993	
AB	**10MG**	**N73609 001** MAR 29, 1993	
AB GENPHARM	**5MG**	**N74013 001** SEP 24, 1992	
AB	**10MG**	**N74018 001** SEP 24, 1992	
AB IVAX PHARMS	**5MG**	**N73687 001** FEB 26, 1993	
AB	**10MG**	**N73687 002** FEB 26, 1993	
AB MARTEC	**5MG**	**N74474 001** OCT 28, 1996	
AB	**10MG**	**N74474 002** OCT 28, 1996	
AB MUTUAL PHARM	**5MG**	**N74063 001** JAN 27, 1994	
AB	**10MG**	**N74063 002** JAN 27, 1994	
AB MYLAN	**5MG**	**N74019 001** SEP 03, 1992	
AB	**10MG**	**N74019 002** SEP 03, 1992	
AB TEVA	**5MG**	**N73661 001** OCT 31, 1993	

FDA data supplied by DrugPatentWatch.com

PINDOLOL

TABLET; ORAL

	PINDOLOL			
AB	TEVA	5MG	**N74123 001**	APR 17, 1997
AB		10MG	**N73661 002**	OCT 31, 1993
AB		10MG	**N74123 002**	APR 17, 1997
AB	WATSON LABS	5MG	**N74437 001**	FEB 27, 1995
AB		10MG	**N74437 002**	FEB 27, 1995
	VISKEN			
AB	NOVARTIS	5MG	**N18285 001**	SEP 03, 1982
AB +		10MG	**N18285 002**	SEP 03, 1982

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	ACTOS		
	TAKEDA PHARMS NA	EQ 15MG BASE	N21073 001 JUL 15, 1999
		EQ 30MG BASE	N21073 002 JUL 15, 1999
+		EQ 45MG BASE	N21073 003 JUL 15, 1999

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

	PIPRACIL		
+	LEDERLE	EQ 2GM BASE/VIAL	N50545 002
		EQ 2GM BASE/VIAL	N62750 001 OCT 13, 1987
+		EQ 3GM BASE/VIAL	N50545 003
		EQ 3GM BASE/VIAL	N62750 002 OCT 13, 1987
+		EQ 4GM BASE/VIAL	N50545 004
		EQ 4GM BASE/VIAL	N62750 003 OCT 13, 1987

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

	ZOSYN		
+	WYETH AYERST	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N50684 001 OCT 22, 1993
+		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N50684 002 OCT 22, 1993
+		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N50684 003 OCT 22, 1993
+		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N50684 004 OCT 22, 1993
	ZOSYN IN PLASTIC CONTAINER		
+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001 FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003 FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002 FEB 24, 1998

PIPERAZINE CITRATE

SYRUP; ORAL

	MULTIFUGE		
AA +	BLULINE	**EQ 500MG BASE/5ML**	**N09452 001**
	PIPERAZINE CITRATE		
AA	LUITPOLD	**EQ 500MG BASE/5ML**	**N80671 001**

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

	MAXAIR		
+	3M	EQ 0.2MG BASE/INH	N19009 001 DEC 30, 1986
+		EQ 0.2MG BASE/INH	N20014 001 NOV 30, 1992

FDA data supplied by DrugPatentWatch.com

PIROXICAM

CAPSULE; ORAL

	FELDENE			
AB	PFIZER	10MG	**N18147 002**	APR 06, 1982
AB	+	20MG	**N18147 003**	APR 06, 1982
	PIROXICAM			
AB	COPLEY PHARM	10MG	**N74103 001**	AUG 28, 1992
AB		20MG	**N74103 002**	AUG 28, 1992
AB	EGIS	10MG	**N74808 001**	JUL 08, 1997
AB		20MG	**N74808 002**	JUL 08, 1997
AB	GENPHARM	10MG	**N74043 001**	SEP 22, 1992
AB		20MG	**N74043 002**	SEP 22, 1992
AB	IVAX PHARMS	10MG	**N74148 001**	JUN 03, 1996
AB		20MG	**N74148 002**	JUN 03, 1996
AB	MEPHA	10MG	**N74116 001**	JUN 15, 1993
AB		20MG	**N74118 001**	JUN 15, 1993
AB	MUTUAL PHARM	10MG	**N73535 001**	MAR 12, 1993
AB		20MG	**N73536 001**	MAR 12, 1993
AB	MYLAN	10MG	**N74102 001**	JUL 31, 1992
AB		20MG	**N74102 002**	JUL 31, 1992
AB	SCS	10MG	**N74036 001**	MAY 29, 1992
AB		20MG	**N74036 002**	MAY 29, 1992
AB	TEVA	10MG	**N73637 001**	JAN 28, 1994
AB		10MG	**N74131 001**	DEC 11, 1992
AB		20MG	**N73638 001**	JAN 28, 1994
AB		20MG	**N74131 002**	DEC 11, 1992

PIROXICAM

CAPSULE; ORAL

	PIROXICAM			
AB	WATSON LABS	10MG	**N74287 001**	MAY 16, 1996
AB		10MG	**N74460 001**	SEP 29, 1995
AB		20MG	**N74287 002**	MAY 16, 1996
AB		20MG	**N74460 002**	SEP 29, 1995

PLICAMYCIN

INJECTABLE; INJECTION

	MITHRACIN		
+	PFIZER	2.5MG/VIAL	N50109 001

PODOFILOX

GEL; TOPICAL

	CONDYLOX		
+	OCLASSEN	0.5%	N20529 001 MAR 13, 1997

SOLUTION; TOPICAL

	CONDYLOX		
AT +	PADDOCK	0.5%	**N19795 001** DEC 13, 1990
	PODOFILOX		
AT	PADDOCK	0.5%	**N75600 001** JAN 29, 2002

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

	MIRALAX		
+	BRAINTREE	17GM/SCOOPFUL	N20698 001 FEB 18, 1999

FDA data supplied by DrugPatentWatch.com

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 001	APR 22, 1991

NULYTELY-FLAVORED

+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 002	NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

+	ABBOTT	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001	APR 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

AA	+	SCHWARZ PHARMA	**227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT**	**N18983 010**	JAN 31, 1989
AA	+		**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 007**	JUN 12, 1987

COLYTE WITH FLAVOR PACKS

AA	+	SCHWARZ PHARMA	**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 012**	OCT 08, 1998

COLYTE-FLAVORED

AA	+	SCHWARZ PHARMA	**227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT**	**N18983 008**	NOV 14, 1991
AA	+		**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 009**	NOV 14, 1991

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

AA	+	BRAINTREE	**227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET**	**N19011 002**	JUN 02, 1992
AA	+		**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N19011 001**	JUL 13, 1984

FOR SUSPENSION; ORAL

CO-LAV

AA		COPLEY PHARM	**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N73428 001**	JAN 28, 1992

COLOVAGE

AA		DYNAPHARM	**227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET**	**N71320 001**	APR 20, 1988

E-Z-EM PREP LYTE

AA		E Z EM	**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N71278 001**	NOV 21, 1988

GLYCOPREP

AA		GOLDLINE	**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N72319 001**	DEC 23, 1988

GO-EVAC

AA		COPLEY PHARM	**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N73433 001**	APR 28, 1992

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

AP	+	BEDFORD	**EQ 500,000 U BASE/VIAL**	**N60716 001**	
AP		PHARMA TEK	**EQ 500,000 U BASE/VIAL**	**N63000 001**	SEP 30, 1994

POWDER; FOR RX COMPOUNDING

POLY-RX

+	PHARMA TEK	100,000,000 UNITS/BOT	N61578 001	

FDA data supplied by DrugPatentWatch.com

POLYMYXIN B SULFATE; *MULTIPLE*
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
SEE OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

POLYMYXIN B SULFATE; TRIMETHOPRIM

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	TAYLOR PHARMA	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N65006 001** DEC 17, 1998	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

AT	+ ALLERGAN	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N50567 001** OCT 20, 1988	

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64120 001** FEB 14, 1997	
AT	FALCON PHARMS	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001** APR 13, 1998	

POLYTETRAFLUOROETHYLENE; *MULTIPLE*
SEE PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

POLYTHIAZIDE

TABLET; ORAL

RENESE			
	PFIZER	1MG	N12845 001
		2MG	N12845 002
	+	4MG	N12845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE			
	PFIZER	0.5MG;EQ 1MG BASE	N17986 001
		0.5MG;EQ 2MG BASE	N17986 002
	+	0.5MG;EQ 5MG BASE	N17986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R			
	+ PFIZER	2MG;0.25MG	N13636 001

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF			
	+ DEY	80MG/ML	N20744 001 NOV 18, 1999

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN			
	+ AXCAN SCANDIPHARM	75MG/VIAL	N20451 001 DEC 27, 1995

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER			
	+ ABBOTT	2MEQ/ML	N18896 001 JUL 20, 1984

FDA data supplied by DrugPatentWatch.com

POTASSIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

	PASKALIUM			
+	GLENWOOD	500MG		N09395 004

TABLET; ORAL

	PASKALIUM			
+	GLENWOOD	1GM		N09395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	MICRO-K			
AB	KV PHARM	**8MEQ**		**N18238 001**
	MICRO-K 10			
AB	+ KV PHARM	**10MEQ**		**N18238 002**
				MAY 14, 1984
	POTASSIUM CHLORIDE			
AB	KV PHARM	**10MEQ**		**N70980 001**
				FEB 17, 1987
AB	TEVA	**8MEQ**		**N73531 001**
				APR 26, 1996
AB		**10MEQ**		**N73532 001**
				APR 26, 1996

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	+ ABBOTT	**2MEQ/ML**		**N80205 001**
AP		**2MEQ/ML**		**N83345 002**
	+	1.5MEQ/ML		N83345 001
AP	AM PHARM PARTNERS	**2MEQ/ML**		**N80225 001**
AP		**2MEQ/ML**		**N87817 001**
				OCT 20, 1982
	+	3MEQ/ML		N80225 003

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	B BRAUN	**2MEQ/ML**		**N85870 001**
AP	BAXTER HLTHCARE	**2MEQ/ML**		**N85499 001**
AP	INTL MEDICATION	**2MEQ/ML**		**N83163 001**
AP	LUITPOLD	**2MEQ/ML**		**N87584 001**
AP		**2MEQ/ML**		**N87585 001**
AP	PHARMA SERVE NY	**2MEQ/ML**		**N86297 001**
AP		**2MEQ/ML**		**N87362 001**
				MAR 08, 1983
	POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	746MG/100ML		N19904 005
				DEC 17, 1990
	+	14.9MG/ML		N19904 001
				DEC 26, 1989
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	**29.8MG/ML**		**N20161 006**
				AUG 11, 1998
AP	+ BAXTER HLTHCARE	**29.8MG/ML**		**N19904 002**
				DEC 26, 1989
	+	1.49GM/100ML		N19904 006
				DEC 17, 1990
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	**2.24GM/100ML**		**N20161 003**
				AUG 11, 1998
AP	+ BAXTER HLTHCARE	**2.24GM/100ML**		**N19904 003**
				DEC 26, 1989
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
AP	+ ABBOTT	**2.98GM/100ML**		**N20161 004**
				AUG 11, 1998
AP	+ BAXTER HLTHCARE	**2.98GM/100ML**		**N19904 004**
				DEC 26, 1989
	POTASSIUM CHLORIDE IN PLASTIC CONTAINER			
AP	AM PHARM PARTNERS	**2MEQ/ML**		**N88901 001**
				JAN 25, 1985
AP		**2MEQ/ML**		**N88908 001**
				JAN 25, 1985

TABLET, EXTENDED RELEASE; ORAL

	K+10			
BC	ALRA	10MEQ		N70999 001
				OCT 22, 1987
	K+8			
AB	ALRA	**8MEQ**		**N70998 001**
				JAN 25, 1993
	K-DUR 10			
AB	KEY PHARMS	**10MEQ**		**N19439 002**
				JUN 13, 1986

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	K-DUR 20			
AB	+ KEY PHARMS	**20MEQ**	**N19439 001**	
			JUN 13, 1986	
	K-TAB			
BC	ABBOTT	10MEQ	N18279 001	
	KLOR-CON			
AB	UPSHER SMITH	**8MEQ**	**N19123 001**	
			APR 17, 1986	
BC		10MEQ	N19123 002	
			APR 17, 1986	
	KLOR-CON M10			
AB	UPSHER SMITH	**10MEQ**	**N74726 002**	
			AUG 09, 2000	
	KLOR-CON M20			
AB	UPSHER SMITH	**20MEQ**	**N74726 001**	
			NOV 20, 1998	
	KLOTRIX			
BC	APOTHECON	10MEQ	N17850 001	
	POTASSIUM CHLORIDE			
BC	ABBOTT	8MEQ	N18279 002	
			AUG 01, 1988	
AB	ANDRX PHARMS	**10MEQ**	**N75604 001**	
			APR 10, 2002	
AB		**20MEQ**	**N75604 002**	
			APR 10, 2002	
AB	COPLEY PHARM	**8MEQ**	**N70618 001**	
			SEP 09, 1987	
AB	KV PHARM	**20MEQ**	**N76044 001**	
			APR 05, 2002	
	SLOW-K			
AB	+ NOVARTIS	**8MEQ**	**N17476 002**	

POTASSIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

POTASSIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE DEXTROSE; POTASSIUM CHLORIDE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE; *MULTIPLE*
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	150MG/100ML;900MG/100ML	N19708 004	SEP 29, 1989

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	149MG/100ML;900MG/100ML	N19686 001	OCT 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	298MG/100ML;900MG/100ML	N19686 002	OCT 17, 1988

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	150MG/100ML;900MG/100ML	N17648 001	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%

	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N17648 003	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N17648 002	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

	MISSION PHARMA	5MEQ	N19071 001	AUG 30, 1985
+		10MEQ	N19071 002	AUG 31, 1992

POTASSIUM LACTATE; *MULTIPLE*
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

+	MALLINCKRODT	200MG	N17551 001

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC
BETADINE
+ ALCON 5% N18634 001 DEC 17, 1986

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE
+ MERIDIAN MEDCL TECHN 300MG/ML N18986 001 APR 26, 1983

PROTOPAM CHLORIDE
+ WYETH AYERST 1GM/VIAL N14134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
+ PHARMACIA AND UPJOHN 0.125MG N20667 001 JUL 01, 1997
0.25MG N20667 002 JUL 01, 1997
0.5MG N20667 006 FEB 12, 1998
1MG N20667 003 JUL 01, 1997
+ 1.5MG N20667 005 JUL 01, 1997

PRAMOXINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL
BRISTOL MYERS SQUIBB 10MG N19898 002 OCT 31, 1991
20MG N19898 003 OCT 31, 1991
40MG N19898 004 MAR 22, 1993
+ 80MG N19898 008 DEC 18, 2001

PRAZIQUANTEL

TABLET; ORAL
BILTRICIDE
+ BAYER 600MG N18714 001 DEC 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIPRESS
AB PFIZER EQ 1MG BASE **N17442 002**
AB + EQ 2MG BASE **N17442 003**
AB EQ 5MG BASE **N17442 001**

PRAZOSIN HCL
AB GENEVA PHARMS EQ 1MG BASE **N72576 001** MAY 16, 1989
AB EQ 2MG BASE **N72577 001** MAY 16, 1989
AB EQ 5MG BASE **N72578 001** MAY 16, 1989
AB IVAX PHARMS EQ 1MG BASE **N71994 001** SEP 12, 1988
AB EQ 2MG BASE **N71995 001** SEP 12, 1988
AB EQ 5MG BASE **N71745 001** SEP 12, 1988
AB LEDERLE EQ 1MG BASE **N72705 001** MAY 16, 1989
AB EQ 2MG BASE **N72706 001** MAY 16, 1989
AB EQ 5MG BASE **N72707 001** MAY 16, 1989

FDA data supplied by DrugPatentWatch.com

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	PRAZOSIN HCL			
AB	MYLAN	EQ 1MG BASE	N72573 001	MAY 16, 1989
AB		EQ 2MG BASE	N72574 001	MAY 16, 1989
AB		EQ 5MG BASE	N72575 001	MAY 16, 1989
AB	WATSON LABS	EQ 1MG BASE	N72352 001	MAY 16, 1989
AB		EQ 2MG BASE	N72333 001	MAY 16, 1989
AB		EQ 5MG BASE	N72609 001	MAY 16, 1989

TABLET, EXTENDED RELEASE; ORAL

	MINIPRESS XL			
+	PFIZER	2.5MG	N19775 001	JAN 29, 1992
+		5MG	N19775 002	JAN 29, 1992

PRAZOSIN HYDROCHLORIDE; *MULTIPLE*
SEE POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

PREDNICARBATE

CREAM; TOPICAL

	DERMATOP			
+	DERMIK LABS	0.1%	N20279 001	OCT 29, 1993

OINTMENT; TOPICAL

	DERMATOP			
+	DERMIK LABS	0.1%	N19568 001	SEP 23, 1991

PREDNISOLONE

SYRUP; ORAL

	PREDNISOLONE			
AA	COPLEY PHARM	15MG/5ML	N40322 001	JAN 19, 2000
AA	HALSEY	15MG/5ML	N40287 001	MAY 28, 1999
AA	KV PHARM	5MG/5ML	N40423 001	OCT 22, 2001
AA		15MG/5ML	N40364 001	APR 10, 2002
AA	UDL	15MG/5ML	N40323 001	MAY 13, 1999
AA	WE PHARMS	15MG/5ML	N40192 001	MAY 28, 1998
	PRELONE			
AA +	MURO	5MG/5ML	N89654 001	JAN 17, 1989
AA +		15MG/5ML	N89081 001	FEB 04, 1986

TABLET; ORAL

	PREDNISOLONE		
BX	EVERYLIFE	2.5MG	N84439 002
BX		5MG	N84439 003
BX	LANNETT	5MG	N80531 002
BX	MARSHALL PHARMA	5MG	N80307 001
BX	SPERTI	2.5MG	N80358 002
BX		5MG	N80358 003
		1MG	N80358 001
BX +	WATSON LABS	5MG	N80354 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

	PREDNISOLONE ACETATE		
+	STERIS	25MG/ML	N83398 001
		50MG/ML	N83764 001
+		50MG/ML	N85781 001

SUSPENSION/DROPS; OPHTHALMIC

	ECONOPRED		
+	ALCON	0.125%	N17468 001
	ECONOPRED PLUS		
AB	FALCON PHARMS	1%	N17469 001
	PRED FORTE		
AB +	ALLERGAN	1%	N17011 001
	PRED MILD		
+	ALLERGAN	0.12%	N17100 001

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE ACETATE; *MULTIPLE*
SEE GENTAMICIN SULFATE; PREDNISOLONE ACETATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

	BLEPHAMIDE S.O.P.			
+	ALLERGAN	0.2%;10%	N87748 001	DEC 03, 1986
	CETAPRED			
+	ALCON	0.25%;10%	N87771 001	AUG 06, 1993
	VASOCIDIN			
+	NOVARTIS	0.5%;10%	N88791 001	OCT 05, 1984

SUSPENSION; OPHTHALMIC

	BLEPHAMIDE			
+	ALLERGAN	0.2%;10%	N12813 002	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

		ORAPRED			
AA	+	ASCENT PEDS	**EQ 15MG BASE/5ML**	**N75117 001**	DEC 14, 2000
		PEDIAPRED			
AA	+	CELLTECH PHARMS	**EQ 5MG BASE/5ML**	**N19157 001**	MAY 28, 1986
		PREDNISOLONE SODIUM PHOSPHATE			
AA		MORTON GROVE	**EQ 5MG BASE/5ML**	**N75099 001**	JUN 28, 2002
AA		PHARM ASSOC	**EQ 5MG BASE/5ML**	**N76123 001**	DEC 23, 2002
AA		WE PHARMS	**EQ 5MG BASE/5ML**	**N75181 001**	DEC 23, 2002
AA			**EQ 15MG BASE/5ML**	**N75250 001**	JUL 12, 2002

SOLUTION/DROPS; OPHTHALMIC

		INFLAMASE FORTE			
AT	+	NOVARTIS	**EQ 0.9% PHOSPHATE**	**N80751 002**	
		INFLAMASE MILD			
AT	+	NOVARTIS	**EQ 0.11% PHOSPHATE**	**N80751 001**	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

		PREDNISOLONE SODIUM PHOSPHATE			
AT		BAUSCH AND LOMB	**EQ 0.11% PHOSPHATE**	**N40065 001**	JUL 29, 1994
AT			**EQ 0.9% PHOSPHATE**	**N40070 001**	JUL 29, 1994

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

		SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE			
AT		ALCON UNIVERSAL	**EQ 0.23% PHOSPHATE;10%**	**N73630 001**	MAY 27, 1993
AT		BAUSCH AND LOMB	**EQ 0.23% PHOSPHATE;10%**	**N74449 001**	DEC 29, 1995
		VASOCIDIN			
AT	+	NOVARTIS	**EQ 0.23% PHOSPHATE;10%**	**N18988 001**	AUG 26, 1988

PREDNISONE

SOLUTION; ORAL

	PREDNISONE			
+	ROXANE	5MG/5ML	N88703 001	NOV 08, 1984
	PREDNISONE INTENSOL			
+	ROXANE	5MG/ML	N88810 001	FEB 20, 1985

TABLET; ORAL

		DELTASONE			
AB	+	PHARMACIA AND UPJOHN	**2.5MG**	**N09986 005**	
AB	+		**5MG**	**N09986 002**	
AB	+		**10MG**	**N09986 006**	
AB	+		**20MG**	**N09986 007**	
AB	+		**50MG**	**N09986 008**	
		PREDNISONE			
AB		GENEVA PHARMS	**10MG**	**N89983 001**	JAN 12, 1989
AB			**20MG**	**N85813 001**	
AB			**50MG**	**N89984 001**	JAN 12, 1989
BX		MARSHALL PHARMA	5MG	N80301 001	
AB		MUTUAL PHARM	**5MG**	**N89245 001**	DEC 04, 1985

FDA data supplied by DrugPatentWatch.com

PREDNISONE

TABLET; ORAL

	PREDNISONE			
AB	MUTUAL PHARM	10MG	N89246 001	
			DEC 04, 1985	
AB		20MG	N89247 001	
			DEC 04, 1985	
AB	PVT FORM	5MG	N80209 001	
AB +	ROXANE	1MG	N87800 001	
			APR 22, 1982	
AB		2.5MG	N87801 001	
			APR 22, 1982	
AB		5MG	N80352 001	
AB		10MG	N84122 001	
AB		20MG	N87342 001	
AB		50MG	N84283 001	
AB	TRIGEN	5MG	N40362 002	
			AUG 29, 2001	
AB		10MG	N40362 001	
			AUG 29, 2001	
AB	VINTAGE PHARMS	5MG	N40256 001	
			JUL 12, 2002	
AB		10MG	N40256 002	
			JUL 12, 2002	
AB	WATSON LABS	5MG	N80356 001	
AB		10MG	N85162 001	
AB		10MG	N87773 001	
			JUL 13, 1982	
AB		20MG	N85161 001	
AB		20MG	N86813 001	
AB		50MG	N87772 001	
			JUL 13, 1982	
AB	WEST WARD	5MG	N80292 001	
AB		10MG	N88832 001	
			DEC 04, 1985	
AB		20MG	N83677 001	
AB		50MG	N88465 001	
			JUN 01, 1984	

PRILOCAINE; *MULTIPLE*
SEE LIDOCAINE; PRILOCAINE

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CITANEST PLAIN		
+	DENTSPLY PHARM	4%	N21382 001

PRILOCAINE HYDROCHLORIDE; *MULTIPLE*
SEE EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

PRIMAQUINE PHOSPHATE

TABLET; ORAL

	PRIMAQUINE		
+	SANOFI SYNTHELABO	EQ 15MG BASE	N08316 001

PRIMIDONE

TABLET; ORAL

	MYSOLINE		
AB	XCEL PHARMS	50MG	N09170 003
AB +		250MG	N09170 002
	PRIMIDONE		
AB	LANNETT	50MG	N84903 002
			MAY 24, 2001
AB		250MG	N84903 001
AB	WATSON LABS	250MG	N83551 001

PROBENECID

TABLET; ORAL

	PROBALAN		
AB	LANNETT	500MG	N80966 001
	PROBENECID		
AB	IVAX PHARMS	500MG	N83740 001
			MAY 09, 1984
AB +	MYLAN	500MG	N84211 002
AB	WATSON LABS	500MG	N84442 004
			MAR 29, 1983

PROBENECID; *MULTIPLE*
SEE COLCHICINE; PROBENECID

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	PROCAINAMIDE HCL		
AB	GENEVA PHARMS	250MG	N89219 001
			JUL 01, 1986
AB		375MG	N89220 001
			JUL 01, 1986

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	PROCAINAMIDE HCL			
AB	GENEVA PHARMS	500MG	N89221 001	
			JUL 01, 1986	
AB	IVAX PHARMS	250MG	N84604 001	
AB		375MG	N84595 001	
AB		500MG	N84606 001	
AB	LANNETT	250MG	N83693 001	
AB	WATSON LABS	250MG	N83287 001	
AB		375MG	N84403 001	
AB		500MG	N84280 001	
	PRONESTYL			
AB	APOTHECON	250MG	N07335 001	
AB		375MG	N07335 004	
AB +		500MG	N07335 003	

INJECTABLE; INJECTION

	PROCAINAMIDE HCL			
AP	ABBOTT	100MG/ML	N89069 001	
			FEB 12, 1986	
AP		500MG/ML	N89070 001	
			FEB 12, 1986	
AP		500MG/ML	N89537 001	
			AUG 25, 1987	
AP	ELKINS SINN	100MG/ML	N89029 001	
			APR 17, 1986	
AP		500MG/ML	N89030 001	
			APR 17, 1986	
AP	INTL MEDICATION	100MG/ML	N88636 001	
			JUL 31, 1984	
AP		500MG/ML	N88637 001	
			JUL 31, 1984	
	PRONESTYL			
AP +	APOTHECON	100MG/ML	N07335 002	
AP +		500MG/ML	N07335 005	

TABLET; ORAL

	PRONESTYL		
	APOTHECON	250MG	N17371 001
		375MG	N17371 002
+		500MG	N17371 003

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL			
AB	COPLEY PHARM	1GM	N40111 001	
			DEC 13, 1996	

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL			
AB	COPLEY PHARM	500MG	N88974 001	
			JUL 22, 1985	
AB		750MG	N89438 001	
			MAR 23, 1987	
AB	GENEVA PHARMS	250MG	N89369 001	
			AUG 14, 1987	
AB		500MG	N89370 001	
			JAN 09, 1987	
AB		750MG	N89371 001	
			AUG 14, 1987	
AB	SIDMAK LABS NJ	500MG	N88959 001	
			DEC 02, 1985	
AB	WATSON LABS	250MG	N89026 001	
			OCT 22, 1985	
AB		500MG	N89027 001	
			OCT 22, 1985	
AB		750MG	N89042 001	
			OCT 22, 1985	
	PROCANBID			
+	KING PHARMS	500MG	N20545 001	
			JAN 31, 1996	
+		1GM	N20545 002	
			JAN 31, 1996	
	PRONESTYL-SR			
BC	APOTHECON	500MG	N87361 001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVOCAIN			
AP +	ABBOTT	1%	N85362 003	
AP +		2%	N85362 004	
+		10%	N86797 001	
	PROCAINE HCL			
AP	ABBOTT	1%	N80416 001	
AP		2%	N80416 002	
AP	AM PHARM PARTNERS	1%	N80421 001	
AP		2%	N80421 002	
AP	ELKINS SINN	1%	N83315 001	
AP		2%	N83315 002	
AP	STERIS	1%	N80658 001	
AP		2%	N80658 002	

FDA data supplied by DrugPatentWatch.com

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

	MATULANE			
	+ SIGMA TAU	EQ 50MG BASE	N16785 001	

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

	COMPAZINE			
AB	GLAXOSMITHKLINE	**2.5MG**	**N11127 003**	
AB		**5MG**	**N11127 001**	
AB	+	**25MG**	**N11127 002**	
	COMPRO			
AB	PADDOCK	**25MG**	**N40246 001**	JUN 28, 2000
	PROCHLORPERAZINE			
AB	ABLE	**2.5MG**	**N40407 001**	JUL 11, 2001
AB		**5MG**	**N40407 002**	JUL 11, 2001
AB		**25MG**	**N40407 003**	JUL 11, 2001
AB	G AND W LABS	**25MG**	**N40058 001**	NOV 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	COMPAZINE			
AP	+ GLAXOSMITHKLINE	**EQ 5MG BASE/ML**	**N10742 002**	
	PROCHLORPERAZINE			
AP	ELKINS SINN	**EQ 5MG BASE/ML**	**N87759 001**	OCT 01, 1982
	PROCHLORPERAZINE EDISYLATE			
AP	ABBOTT	**EQ 5MG BASE/ML**	**N89703 001**	APR 07, 1988
AP	ELKINS SINN	**EQ 5MG BASE/ML**	**N89903 001**	AUG 29, 1989
AP	STERIS	**EQ 5MG BASE/ML**	**N89530 001**	JUL 08, 1987

SYRUP; ORAL

COMPAZINE			
GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N11188 001	

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE				
+ GLAXOSMITHKLINE	EQ 10MG BASE	N21019 001	OCT 06, 1999
+	EQ 15MG BASE	N21019 002	OCT 06, 1999

TABLET; ORAL

	COMPAZINE			
AB	GLAXOSMITHKLINE	**EQ 5MG BASE**	**N10571 001**	
AB		**EQ 10MG BASE**	**N10571 002**	
AB	+	**EQ 25MG BASE**	**N10571 003**	
	PROCHLORPERAZINE MALEATE			
AB	COPLEY PHARM	**EQ 5MG BASE**	**N40120 001**	JUL 11, 1996
AB		**EQ 10MG BASE**	**N40120 002**	JUL 11, 1996
AB	DURAMED PHARM BARR	**EQ 5MG BASE**	**N40207 001**	MAY 01, 1997
AB		**EQ 10MG BASE**	**N40207 002**	MAY 01, 1997
AB	GENEVA PHARMS TECH	**EQ 5MG BASE**	**N40101 001**	JUL 19, 1996
AB		**EQ 10MG BASE**	**N40101 002**	JUL 19, 1996
AB		**EQ 25MG BASE**	**N40101 003**	JUL 19, 1996
AB	IVAX PHARMS	**EQ 5MG BASE**	**N40162 001**	JAN 20, 1998
AB		**EQ 10MG BASE**	**N40162 002**	JAN 20, 1998
AB	MYLAN	**EQ 5MG BASE**	**N40185 002**	OCT 28, 1996
AB		**EQ 10MG BASE**	**N40185 001**	OCT 28, 1996
AB	TRIGEN	**EQ 5MG BASE**	**N40268 001**	FEB 27, 1998
AB		**EQ 10MG BASE**	**N40268 002**	FEB 27, 1998

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN			
+ MONARCH PHARMS	5MG	N09818 003	

FDA data supplied by DrugPatentWatch.com

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM
UNIMED PHARMS 100MG N19781 001 MAY 14, 1998
\+ 200MG N19781 002 OCT 15, 1999

GEL; VAGINAL
CRINONE
COLUMBIA RES LABS 4% N20701 001 JUL 31, 1997
\+ 8% N20701 002 JUL 31, 1997

8% N20756 001 MAY 13, 1997

INJECTABLE; INJECTION
PROGESTERONE
AO AM PHARM PARTNERS **50MG/ML** **N75906 001** APR 25, 2001
AO \+ SCHEIN **50MG/ML** **N17362 002**

PROGUANIL HYDROCHLORIDE; *MULTIPLE*
SEE ATOVAQUONE; PROGUANIL HYDROCHLORIDE

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PHENERGAN
AP \+ WYETH AYERST **25MG/ML** **N08857 002**
AP \+ **50MG/ML** **N08857 003**
PROMETHAZINE HCL
AP ABBOTT **25MG/ML** **N40372 001** JUN 08, 2000
AP **50MG/ML** **N40372 002** JUN 08, 2000
AP **50MG/ML** **N83838 002**
AP ELKINS SINN **25MG/ML** **N83312 001**
AP **50MG/ML** **N83312 002**
AP GENSIA SICOR PHARMS **25MG/ML** **N40454 001** AUG 22, 2002
AP **50MG/ML** **N40454 002** AUG 22, 2002
AP PHARMAFORCE **25MG/ML** **N40471 001** NOV 21, 2002

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL
AP STERIS **25MG/ML** **N84591 001**
AP **50MG/ML** **N80629 002**

SUPPOSITORY; RECTAL
PHENERGAN
AB \+ WYETH AYERST **25MG** **N10926 001**
BR \+ 50MG N11689 001
12.5MG N10926 002
PROMETHACON
BR POLYMEDICA 25MG N84901 001
PROMETHAZINE HCL
AB G AND W LABS **25MG** **N40428 001** FEB 05, 2002
PROMETHEGAN
BR G AND W LABS 50MG N87165 001 AUG 14, 1987

SYRUP; ORAL
PHENERGAN PLAIN
AA \+ WYETH AYERST **6.25MG/5ML** **N08381 004** APR 18, 1984
PROMETH PLAIN
AA ALPHARMA **6.25MG/5ML** **N85953 001**
PROMETHAZINE HCL
AA HI TECH PHARMA **6.25MG** **N40026 001** SEP 25, 1998
AA WHITEWORTH TOWN PLSN **6.25MG/5ML** **N86395 001**
PROMETHAZINE PLAIN
AA MORTON GROVE **6.25MG/5ML** **N87953 001** NOV 15, 1982

TABLET; ORAL
PHENERGAN
BP WYETH AYERST 25MG N07935 003
BP \+ 50MG N07935 004
12.5MG N07935 002
PROMETHAZINE HCL
BP GENEVA PHARMS 25MG N84234 001
BP 50MG N84176 001
BP WATSON LABS 25MG N83426 001
BP 50MG N83711 001

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*
SEE DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
SEE PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

	PROPAFENONE HCL			
AB	KV PHARM	150MG	N76193 001	FEB 07, 2002
AB		225MG	N76193 002	FEB 07, 2002
AB		300MG	N76193 003	FEB 07, 2002
AB	MUTUAL PHARM	150MG	N75998 001	NOV 29, 2001
AB		225MG	N75998 002	NOV 29, 2001
AB		300MG	N75998 003	NOV 29, 2001
AB	VINTAGE PHARMS	150MG	N75938 001	OCT 17, 2002
AB		225MG	N75938 002	OCT 17, 2002
AB		300MG	N75938 003	OCT 17, 2002
AB	WATSON LABS	150MG	N75203 001	OCT 24, 2000
AB		225MG	N75203 002	OCT 24, 2000
	RYTHMOL			
AB	ABBOTT	150MG	N19151 001	NOV 27, 1989
AB		225MG	N19151 003	NOV 20, 1992
AB +		300MG	N19151 002	NOV 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE			
BP +	SHIRE LABS	7.5MG	N08732 003	
BP +		15MG	N08732 002	
	PROPANTHELINE BROMIDE			
BP	ROXANE	7.5MG	N80927 001	
BP		15MG	N80927 002	

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

	PROPARACAINE HCL			
AT	TAYLOR PHARMA	0.5%	N40277 001	MAR 16, 2000

SOLUTION/DROPS; OPHTHALMIC

	ALCAINE			
AT	ALCON	0.5%	N80027 001	
	OPHTHAINE			
AT +	APOTHECON	0.5%	N08883 001	
	OPHTHETIC			
AT +	ALLERGAN	0.5%	N12583 001	
	PARACAINE			
AT	OPTOPICS	0.5%	N87681 001	AUG 05, 1982
	PROPARACAINE HCL			
AT	BAUSCH AND LOMB	0.5%	N40074 001	SEP 29, 1995

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN			
AB +	ASTRAZENECA	10MG/ML	N19627 002	JUN 11, 1996
	PROPOFOL			
AB	GENSIA SICOR PHARMS	10MG/ML	N75102 001	JAN 04, 1999
AB		10MG/ML	N75392 001	SEP 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON			
AA +	AAI PHARMA	32MG	N10997 001	
AA +		65MG	N10997 003	
	DOLENE			
AA	LEDERLE	65MG	N80530 001	
	KESSO-GESIC			
AA	MK LABS	65MG	N83544 001	
	PROPOXYPHENE HCL			
AA	ICN	65MG	N80783 001	
AA	IVAX PHARMS	65MG	N80269 001	
AA	MYLAN	32MG	N83528 001	

FDA data supplied by DrugPatentWatch.com

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	TEVA	65MG	N88615 001	OCT 22, 1984
AA	WEST WARD	65MG	N83501 001	
AA	WHITEWORTH TOWN PLSN	65MG	N84551 001	

PROPOXYPHENE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL
DARVON-N

+	NEOSAN PHARMS	50MG/5ML	N16861 001	

TABLET; ORAL
DARVON-N

+	AAIPHARMA LLC	100MG	N16862 002	

PROPOXYPHENE NAPSYLATE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

	WYETH AYERST	60MG	N18553 004	MAR 18, 1987
		80MG	N18553 002	APR 19, 1983
		120MG	N18553 003	APR 19, 1983
+		160MG	N18553 001	APR 19, 1983

CONCENTRATE; ORAL
PROPRANOLOL HCL INTENSOL

+	ROXANE	80MG/ML	N71388 001	MAY 15, 1987

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
INDERAL

AP	+ WYETH AYERST	1MG/ML	N16419 001	

PROPRANOLOL HCL

AP	BEDFORD	1MG/ML	N75792 001	AUG 29, 2000

SOLUTION; ORAL
PROPRANOLOL HCL

+	ROXANE	20MG/5ML	N70979 001	MAY 15, 1987
+		40MG/5ML	N70690 001	MAY 15, 1987

TABLET; ORAL
INDERAL

AB	+ WYETH AYERST	10MG	N16418 001	
AB		20MG	N16418 003	
AB		40MG	N16418 002	
AB		60MG	N16418 009	OCT 18, 1982
AB	+	80MG	N16418 004	

PROPRANOLOL HCL

AB	GENEVA PHARMS	10MG	N70663 001	JUN 13, 1986
AB		20MG	N70664 001	JUN 13, 1986
AB		40MG	N70665 001	JUN 13, 1986
AB		60MG	N70666 001	OCT 10, 1986
AB		80MG	N70667 001	JUN 13, 1986
AB	MYLAN	10MG	N70211 001	NOV 19, 1985
AB		20MG	N70212 001	NOV 19, 1985
AB		40MG	N70213 001	NOV 19, 1985
AB		80MG	N70214 001	NOV 19, 1985
AB	PAR PHARM	10MG	N70217 001	AUG 01, 1986
AB		20MG	N70218 001	AUG 01, 1986
AB		40MG	N70219 001	AUG 01, 1986

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	PAR PHARM	**60MG**	**N70220 001**	SEP 24, 1986
AB		**80MG**	**N70221 001**	APR 14, 1986
AB		**90MG**	**N71288 001**	OCT 22, 1986
AB	SIDMAK LABS NJ	**10MG**	**N71972 001**	APR 06, 1988
AB		**20MG**	**N71973 001**	APR 06, 1988
AB		**40MG**	**N71974 001**	APR 06, 1988
AB		**60MG**	**N71975 001**	APR 06, 1988
AB		**80MG**	**N71976 001**	APR 06, 1988
AB		**90MG**	**N71977 001**	APR 06, 1988
AB	TEVA	**40MG**	**N70234 001**	JUN 23, 1986
AB	WATSON LABS	**10MG**	**N70175 001**	MAY 13, 1986
AB		**10MG**	**N70548 001**	JUL 10, 1986
AB		**20MG**	**N70176 001**	MAY 13, 1986
AB		**40MG**	**N70177 001**	MAY 13, 1986
AB		**40MG**	**N70550 001**	APR 11, 1986
AB		**60MG**	**N71791 001**	JUL 15, 1987
AB		**80MG**	**N70178 001**	MAY 13, 1986
AB		**80MG**	**N70551 001**	JUL 10, 1986
AB		**90MG**	**N71792 001**	JUL 15, 1987

PROPRANOLOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	IMPAX LABS	50MG	N80159 001	
BD +	LEDERLE	50MG	N06188 001	
BD	PUREPAC PHARM	50MG	N80172 001	
BD	WEST WARD	50MG	N80154 001	

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

AP	AM PHARM PARTNERS	**10MG/ML**	**N89454 001**	APR 07, 1987
AP	ELKINS SINN	**10MG/ML**	**N89474 001**	NOV 05, 1986
AP		**10MG/ML**	**N89475 001**	NOV 05, 1986
AP +	LILLY	**10MG/ML**	**N06460 002**	

PROTIRELIN

INJECTABLE; INJECTION
THYREL TRH

+	FERRING	0.5MG/ML	N18087 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
VIVACTIL

AB	ODYSSEY PHARMS	**5MG**	**N73644 001**	AUG 24, 1995
AB +		**10MG**	**N73645 001**	AUG 24, 1995

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	CORPHED			
AA	GENEVA PHARMS	60MG;2.5MG	N88602 001	APR 11, 1985
	PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL			
AA +	EON	60MG;2.5MG	N88193 001	MAY 17, 1983
	TRILITRON			
AA	NEWTRON PHARMS	60MG;2.5MG	N88515 001	JAN 09, 1985
	TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL			
AA	SUPERPHARM	60MG;2.5MG	N88578 001	FEB 21, 1985

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*

SEE AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

SEE LORATADINE; PSEUDOEPHEDRINE SULFATE

PYRAZINAMIDE

TABLET; ORAL

	PYRAZINAMIDE			
AB +	CLONMEL	500MG	N80157 001	
AB	MIKART	500MG	N81319 001	JUN 30, 1992

PYRAZINAMIDE; *MULTIPLE*

SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

	MESTINON			
AP +	ICN	5MG/ML	N09830 001	
	REGONOL			
AP +	ORGANON	5MG/ML	N17398 001	

SYRUP; ORAL

	MESTINON		
+	ICN	60MG/5ML	N15193 001

TABLET; ORAL

	MESTINON		
AB +	ICN	60MG	N09829 002

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

	PYRIDOSTIGMINE BROMIDE			
AB	COREPHARMA	60MG	N40457 001	DEC 26, 2002

TABLET, EXTENDED RELEASE; ORAL

	MESTINON		
+	ICN	180MG	N11665 001

PYRIDOXINE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PYRIDOXINE HCL			
AP	AM PHARM PARTNERS	100MG/ML	N80618 001	
AP +	STERIS	100MG/ML	N80572 001	

PYRIDOXINE HYDROCHLORIDE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FDA data supplied by DrugPatentWatch.com

PYRILAMINE MALEATE

TABLET; ORAL
PYRILAMINE MALEATE
+ IMPAX LABS 25MG N80808 001

PYRIMETHAMINE

TABLET; ORAL
DARAPRIM
+ GLAXOSMITHKLINE 25MG N08578 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL
FANSIDAR
+ ROCHE 25MG;500MG N18557 001

QUAZEPAM

TABLET; ORAL
DORAL
WALLACE LABS 7.5MG N18708 003 FEB 26, 1987
+ 15MG N18708 001 DEC 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL
SEROQUEL
ASTRAZENECA EQ 25MG BASE N20639 001 SEP 26, 1997
EQ 100MG BASE N20639 002 SEP 26, 1997
EQ 150MG BASE N20639 004 DEC 20, 1998
EQ 200MG BASE N20639 003 SEP 26, 1997
+ EQ 300MG BASE N20639 005 JUL 26, 2000

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
ACCUPRIL
PFIZER PHARMS EQ 5MG BASE N19885 001 NOV 19, 1991
EQ 10MG BASE N19885 002 NOV 19, 1991
EQ 20MG BASE N19885 003 NOV 19, 1991
+ EQ 40MG BASE N19885 004 NOV 19, 1991

QUINAPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

QUINIDINE GLUCONATE

INJECTABLE; INJECTION
QUINIDINE GLUCONATE
+ LILLY 80MG/ML N07529 002 FEB 10, 1989

TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE
BX + BERLEX LABS 324MG N16647 001
QUINIDINE GLUCONATE
BX MUTUAL PHARM 324MG N89338 001 FEB 11, 1987
BX WATSON LABS 324MG N87810 001 SEP 29, 1982

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
AB EON **200MG** **N84631 001**
AB **300MG** **N88072 001** SEP 26, 1983
AB GENEVA PHARMS **200MG** **N84914 001**
AB **300MG** **N89839 001** SEP 29, 1988
AB LANNETT **200MG** **N83743 001**
AB LEDERLE **200MG** **N87011 001**
AB MUTUAL PHARM **100MG** **N81029 001** APR 14, 1989

FDA data supplied by DrugPatentWatch.com

QUINIDINE SULFATE

TABLET; ORAL

		QUINIDINE SULFATE			
AB		MUTUAL PHARM	**200MG**	**N81030 001**	APR 14, 1989
AB		PVT FORM	**200MG**	**N83808 001**	
AB	+	ROXANE	**200MG**	**N83640 001**	
AB	+		**300MG**	**N85632 001**	
AB		SUPERPHARM	**200MG**	**N88973 001**	APR 10, 1985
AB		WATSON LABS	**200MG**	**N83288 001**	
AB			**200MG**	**N85140 002**	
AB			**300MG**	**N85583 001**	

TABLET, EXTENDED RELEASE; ORAL

		QUINIDEX			
AB	+	ROBINS AH	**300MG**	**N12796 002**	
		QUINIDINE SULFATE			
AB		COPLEY PHARM	**300MG**	**N40045 001**	JUN 30, 1994

QUINUPRISTIN; *MULTIPLE*

SEE DALFOPRISTIN; QUINUPRISTIN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

	ACIPHEX			
+	EISAI MEDCL RES	20MG	N20973 002	AUG 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

	EVISTA			
+	LILLY	60MG	N20815 001	DEC 09, 1997

RAMIPRIL

CAPSULE; ORAL

	ALTACE			
	KING PHARMS	1.25MG	N19901 001	JAN 28, 1991

RAMIPRIL

CAPSULE; ORAL

	ALTACE			
	KING PHARMS	2.5MG	N19901 002	JAN 28, 1991
		5MG	N19901 003	JAN 28, 1991
+		10MG	N19901 004	JAN 28, 1991

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

		RANITIDINE HCL			
AB		DR REDDYS LABS LTD	**EQ 150MG BASE**	**N75742 001**	NOV 29, 2000
AB			**EQ 300MG BASE**	**N75742 002**	NOV 29, 2000
AB		GENEVA PHARMS	**EQ 150MG BASE**	**N74655 001**	OCT 22, 1997
AB	+		**EQ 300MG BASE**	**N74655 002**	OCT 22, 1997
AB		GENPHARM	**EQ 150MG BASE**	**N75564 001**	OCT 27, 2000
AB			**EQ 300MG BASE**	**N75564 002**	OCT 27, 2000

GRANULE, EFFERVESCENT; ORAL

	ZANTAC 150			
+	GLAXOSMITHKLINE	EQ 150MG BASE/PACKET	N20251 002	MAR 31, 1994

INJECTABLE; INJECTION

	ZANTAC			
+	GLAXOSMITHKLINE	EQ 25MG BASE/ML	N19090 001	OCT 19, 1984
	ZANTAC IN PLASTIC CONTAINER			
+	GLAXOSMITHKLINE	EQ 1MG BASE/ML	N19593 002	SEP 27, 1991

SYRUP; ORAL

	ZANTAC			
+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N19675 001	DEC 30, 1988

TABLET; ORAL

		RANITIDINE			
AB		RANBAXY	**EQ 150MG BASE**	**N75439 001**	APR 19, 2000

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

AB	RANBAXY	EQ 300MG BASE	N75439 002 APR 19, 2000

RANITIDINE HCL

AB	GENEVA PHARMS	EQ 150MG BASE	N74467 001 AUG 29, 1997
AB		EQ 300MG BASE	N74467 002 AUG 29, 1997
AB	GENPHARM	EQ 150MG BASE	N74023 001 AUG 22, 1997
AB		EQ 300MG BASE	N74023 002 AUG 22, 1997
AB	IVAX PHARMS	EQ 150MG BASE	N75165 001 SEP 30, 1998
AB		EQ 300MG BASE	N75165 002 SEP 30, 1998
AB	MYLAN	EQ 150MG BASE	N74552 001 JUL 30, 1998
AB		EQ 300MG BASE	N74552 002 JUL 30, 1998
AB	PAR PHARM	EQ 150MG BASE	N75180 001 JAN 28, 1999
AB		EQ 300MG BASE	N75180 002 JAN 28, 1999
AB	RANBAXY	EQ 150MG BASE	N75000 001 JAN 30, 1998
AB		EQ 300MG BASE	N75000 002 JAN 30, 1998
AB	TEVA	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB		EQ 300MG BASE	N74488 002 JUL 31, 1997
AB	TORPHARM	EQ 150MG BASE	N74680 001 SEP 12, 1997
AB		EQ 300MG BASE	N74680 002 SEP 12, 1997
AB	WATSON LABS	EQ 150MG BASE	N74864 001 OCT 20, 1997
AB		EQ 300MG BASE	N74864 002 OCT 20, 1997
AB	WOCKHARDT	EQ 150MG BASE	N75208 001 DEC 17, 1998
AB		EQ 300MG BASE	N75208 002 DEC 17, 1998

ZANTAC 150

AB	GLAXOSMITHKLINE	EQ 150MG BASE	N18703 001 JUN 09, 1983

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

ZANTAC 300

AB	+ GLAXOSMITHKLINE	EQ 300MG BASE	N18703 002 DEC 09, 1985

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

	+ GLAXOSMITHKLINE	EQ 150MG BASE	N20251 001 MAR 31, 1994

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

ABBOTT	EQ 1MG BASE/VIAL	N20630 001 JUL 12, 1996
	EQ 2MG BASE/VIAL	N20630 002 JUL 12, 1996
+	EQ 5MG BASE/VIAL	N20630 003 JUL 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

NOVO NORDISK	0.5MG	N20741 001 DEC 22, 1997
	1MG	N20741 002 DEC 22, 1997
+	2MG	N20741 003 DEC 22, 1997

RESCINNAMINE

TABLET; ORAL

MODERIL

PFIZER	0.25MG	N10686 003
+	0.5MG	N10686 006

RESERPINE

TABLET; ORAL

RESERPINE

BP	EON	0.1MG	N09838 001

FDA data supplied by DrugPatentWatch.com

RESERPINE

TABLET; ORAL
RESERPINE
BP + EON 0.25MG N09838 002
SERPALAN
BP LANNETT 0.1MG N10124 001
BP 0.25MG N10124 002

RESERPINE; *MULTIPLE*
SEE CHLOROTHIAZIDE; RESERPINE
SEE HYDROFLUMETHIAZIDE; RESERPINE
SEE POLYTHIAZIDE; RESERPINE

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
METATENSIN #2
AVENTIS PHARMS 0.1MG;2MG N12972 001
METATENSIN #4
+ AVENTIS PHARMS 0.1MG;4MG N12972 002

RIBAVIRIN

CAPSULE; ORAL
REBETOL
+ SCHERING PLOUGH RES 200MG* N20903 001
JUN 03, 1998
+ 200MG N20903 002
JUL 25, 2001

FOR SOLUTION; INHALATION
VIRAZOLE
+ ICN 6GM/VIAL N18859 001
DEC 31, 1985

TABLET; ORAL
COPEGUS
+ ROCHE 200MG N21511 001
DEC 03, 2002

RIBOFLAVIN; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

RIBOFLAVIN; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

RIBOFLAVIN PHOSPHATE SODIUM; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

RIFABUTIN

CAPSULE; ORAL
MYCOBUTIN
+ PHARMACIA AND UPJOHN 150MG N50689 001
DEC 23, 1992

RIFAMPIN

CAPSULE; ORAL
RIFADIN
AB AVENTIS PHARMS **150MG** **N62303 001**
AB + **300MG** **N50420 001**
RIFAMPIN
AB EON **150MG** **N64150 002**
JAN 02, 1998
AB **300MG** **N64150 001**
MAY 28, 1997
AB VERSAPHARM **150MG** **N65028 001**
MAR 14, 2001
AB **300MG** **N65028 002**
MAR 14, 2001
RIMACTANE
AB GENEVA PHARMS **300MG** **N50429 001**

* SEE SECTION 1.8 DESCRIPTION OF SPECIAL SITUATIONS

FDA data supplied by DrugPatentWatch.com

RIFAMPIN

INJECTABLE; INJECTION

	RIFADIN			
AP	+ AVENTIS PHARMS	**600MG/VIAL**	**N50627 001**	MAY 25, 1989
	RIFAMPIN			
AP	BEDFORD	**600MG/VIAL**	**N64217 001**	OCT 29, 1999

RIFAMPIN; *MULTIPLE*

SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN

SEE ISONIAZID; RIFAMPIN

RIFAPENTINE

TABLET; ORAL

	PRIFTIN			
	+ AVENTIS PHARMS	150MG	N21024 001	JUN 22, 1998

RILUZOLE

TABLET; ORAL

	RILUTEK			
	+ AVENTIS	50MG	N20599 001	DEC 12, 1995

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

	FLUMADINE			
	+ FOREST LABS	50MG/5ML	N19650 001	SEP 17, 1993

TABLET; ORAL

	FLUMADINE			
AB	+ FOREST LABS	**100MG**	**N19649 001**	SEP 17, 1993
	RIMANTADINE HCL			
AB	COREPHARMA	**100MG**	**N75916 001**	NOV 02, 2001
AB	IMPAX LABS	**100MG**	**N76132 001**	AUG 30, 2002

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

	VEXOL			
	+ ALCON	1%	N20474 001	DEC 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

	ACTONEL			
	PROCTER AND GAMBLE	5MG	N20835 002	APR 14, 2000
		30MG	N20835 001	MAR 27, 1998
	+	35MG	N20835 003	MAY 25, 2002

RISPERIDONE

SOLUTION; ORAL

	RISPERDAL			
	+ JANSSEN PHARMA	1MG/ML	N20588 001	JUN 10, 1996

TABLET; ORAL

	RISPERDAL			
	JANSSEN PHARMA	0.25MG	N20272 008	MAY 10, 1999
		0.5MG	N20272 007	JAN 27, 1999
	+	1MG	N20272 001	DEC 29, 1993
		2MG	N20272 002	DEC 29, 1993
		3MG	N20272 003	DEC 29, 1993
		4MG	N20272 004	DEC 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

	RITODRINE HCL			
	+ ABBOTT	10MG/ML	N71618 001	FEB 28, 1991

FDA data supplied by DrugPatentWatch.com

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

+	ABBOTT	15MG/ML	N71619 001 FEB 28, 1991

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

+	ABBOTT	30MG/100ML	N71438 001 JAN 22, 1991

RITONAVIR

CAPSULE; ORAL
NORVIR

+	ABBOTT	100MG	N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR

+	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996

RITONAVIR; *MULTIPLE*
SEE LOPINAVIR; RITONAVIR

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

	NOVARTIS	EQ 1.5MG BASE	N20823 003 APR 21, 2000
		EQ 3MG BASE	N20823 004 APR 21, 2000
		EQ 4.5MG BASE	N20823 005 APR 21, 2000
+		EQ 6MG BASE	N20823 006 APR 21, 2000

SOLUTION; ORAL
EXELON

+	NOVARTIS	EQ 2MG BASE/ML	N21025 001 APR 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT

	MERCK	EQ 5MG BASE	N20864 001 JUN 29, 1998
+		EQ 10MG BASE	N20864 002 JUN 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT-MLT

	MERCK	EQ 5MG BASE	N20865 001 JUN 29, 1998
+		EQ 10MG BASE	N20865 002 JUN 29, 1998

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON (P/F)

+	ORGANON	10MG/ML	N20214 001 MAR 17, 1994

ROFECOXIB

SUSPENSION; ORAL
VIOXX

	MERCK	12.5MG/5ML	N21052 001 MAY 20, 1999
+		25MG/5ML	N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX

	MERCK	12.5MG	N21042 001 MAY 20, 1999
		25MG	N21042 002 MAY 20, 1999
+		50MG	N21042 003 FEB 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP

+	GLAXOSMITHKLINE	EQ 0.25MG BASE	N20658 001 SEP 19, 1997

FDA data supplied by DrugPatentWatch.com

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL			
REQUIP			
GLAXOSMITHKLINE	EQ 0.5MG BASE	N20658 002	SEP 19, 1997
	EQ 1MG BASE	N20658 003	SEP 19, 1997
	EQ 2MG BASE	N20658 004	SEP 19, 1997
	EQ 3MG BASE	N20658 006	JAN 27, 1999
	EQ 4MG BASE	N20658 007	JAN 27, 1999
+	EQ 5MG BASE	N20658 005	SEP 19, 1997

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION			
NAROPIN			
ASTRAZENECA	2MG/ML	N20533 001	SEP 24, 1996
	5MG/ML	N20533 003	SEP 24, 1996
	7.5MG/ML	N20533 004	SEP 24, 1996
+	10MG/ML	N20533 005	SEP 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL			
AVANDIA			
GLAXOSMITHKLINE	EQ 2MG BASE	N21071 002	MAY 25, 1999
	EQ 4MG BASE	N21071 003	MAY 25, 1999
+	EQ 8MG BASE	N21071 004	MAY 25, 1999

ROSIGLITAZONE MALEATE; *MULTIPLE*
SEE METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION			
CARDIOGEN-82			
BRACCO	N/A	N19414 001	DEC 29, 1989

SACROSIDASE

SOLUTION; ORAL			
SUCRAID			
+ ORPHAN MEDCL	8,500 IU/ML	N20772 001	APR 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION			
LIPOSYN II 10%			
+ ABBOTT	5%;5% (5GM/100ML); 5%;5% (5GM/100ML)	N18997 001	AUG 27, 1984
LIPOSYN II 20%			
+ ABBOTT	10% (10GM/100ML); 10%;10% (10GM/100ML)	N18991 001	AUG 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION			
SEREVENT			
+ GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N20236 001	FEB 04, 1994
POWDER; INHALATION			
SEREVENT			
+ GLAXOSMITHKLINE	EQ 0.046MG BASE/INH	N20692 001	SEP 19, 1997

SALMETEROL XINAFOATE; *MULTIPLE*
SEE FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

FDA data supplied by DrugPatentWatch.com

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET
+ CYTOGEN 50mCi/ML N20570 001 MAR 28, 1997

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR 200MG N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR EQ 200MG BASE N20628 001 DEC 06, 1995

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP
+ NOVARTIS 1MG/72HR N17874 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA EVERYLIFE **100MG** **N85895 001**
SECONAL SODIUM
AA + RANBAXY **100MG** **N86101 002** OCT 03, 1983
+ 50MG N86101 001 OCT 03, 1983
SODIUM SECOBARBITAL
AA WEST WARD **100MG** **N84926 001**

INJECTABLE; INJECTION
SECOBARBITAL SODIUM
+ ELKINS SINN 100MG/VIAL N83281 001
SODIUM SECOBARBITAL
+ WYETH AYERST 50MG/ML N83262 001

SECRETIN

FOR SOLUTION; INTRAVENOUS
SECREFLO
+ CHIRHOCLIN 16 UGM/VIAL N21209 001 APR 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
AB + SOMERSET **5MG** **N20647 001** MAY 15, 1996
SELEGILINE HCL
AB CLONMEL HLTHCARE **5MG** **N75352 001** NOV 30, 1998
AB TORPHARM **5MG** **N75321 001** DEC 04, 1998

TABLET; ORAL
SELEGILINE HCL
AB ALPHAPHARM **5MG** **N74866 001** NOV 26, 1997
AB APOTEX **5MG** **N74871 001** JUN 06, 1997
AB CLONMEL HLTHCARE **5MG** **N74641 001** AUG 02, 1996
AB ENDO PHARMS **5MG** **N74565 001** AUG 02, 1996
AB IVAX PHARMS **5MG** **N74756 001** NOV 25, 1998
AB SIEGFRIED **5MG** **N74672 001** APR 01, 1997
AB + SOMERSET **5MG** **N19334 001** JUN 05, 1989
AB STASON **5MG** **N74912 001** APR 30, 1998
AB TEVA **5MG** **N74537 001** AUG 02, 1996
AB **5MG** **N74744 001** JAN 27, 1997

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
EXSEL
AT ALLERGAN HERBERT **2.5%** **N83892 001**

FDA data supplied by DrugPatentWatch.com

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

	SELENIUM SULFIDE				
AT	ALPHARMA	**2.5%**	**N84394 001**		
AT	CLAY PARK	**2.5%**	**N89996 001** JAN 10, 1991		
AT	MORTON GROVE	**2.5%**	**N88228 001** SEP 01, 1983		
	SELSUN				
AT	+ CHATTEM	**2.5%**	**N07936 001**		

SERMORELIN ACETATE

INJECTABLE; INJECTION

	GEREF				
	+ SERONO	EQ 0.05MG BASE/AMP	N19863 001 DEC 28, 1990		
	+	EQ 0.5MG BASE/VIAL	N20443 001 SEP 26, 1997		
	+	EQ 1MG BASE/VIAL	N20443 002 SEP 26, 1997		

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

	ZOLOFT				
	+ PFIZER	EQ 20MG BASE/ML	N20990 001 DEC 07, 1999		

TABLET; ORAL

	ZOLOFT				
	PFIZER	EQ 25MG BASE	N19839 005 MAR 06, 1996		
		EQ 50MG BASE	N19839 001 DEC 30, 1991		
	+	EQ 100MG BASE	N19839 002 DEC 30, 1991		

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

	RENAGEL				
	+ GELTEX	403MG	N20926 001 OCT 30, 1998		

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

	RENAGEL				
	GELTEX	400MG	N21179 001 JUL 12, 2000		
	+	800MG	N21179 002 JUL 12, 2000		

SEVOFLURANE

LIQUID; INHALATION

	SEVOFLURANE				
AN	BAXTER HLTHCARE	**100%**	**N75895 001** JUL 02, 2002		
	ULTANE				
AN	+ ABBOTT	**100%**	**N20478 001** JUN 07, 1995		

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	MERIDIA				
	ABBOTT	5MG	N20632 001 NOV 22, 1997		
		10MG	N20632 002 NOV 22, 1997		
	+	15MG	N20632 003 NOV 22, 1997		

SILDENAFIL CITRATE

TABLET; ORAL

	VIAGRA				
	PFIZER	25MG	N20895 001 MAR 27, 1998		
		50MG	N20895 002 MAR 27, 1998		
	+	100MG	N20895 003 MAR 27, 1998		

SILVER SULFADIAZINE

CREAM; TOPICAL

	SILVADENE				
AB	+ KING PHARMS	**1%**	**N17381 001**		

FDA data supplied by DrugPatentWatch.com

SILVER SULFADIAZINE

CREAM; TOPICAL

	SSD			
AB	BASF	**1%**	**N18578 001**	
			FEB 25, 1982	
	SSD AF			
BX	BASF	1%	N18578 003	
			JUL 11, 1990	
	THERMAZENE			
AB	KENDALL LP	**1%**	**N18810 001**	
			DEC 23, 1985	

SIMVASTATIN

TABLET; ORAL

	ZOCOR			
	MERCK	5MG	N19766 001	
			DEC 23, 1991	
		10MG	N19766 002	
			DEC 23, 1991	
		20MG	N19766 003	
			DEC 23, 1991	
		40MG	N19766 004	
			DEC 23, 1991	
	+	80MG	N19766 005	
			JUL 10, 1998	

SINCALIDE

INJECTABLE; INJECTION

	KINEVAC			
	+ BRACCO	0.005MG/VIAL	N17697 001	

SIROLIMUS

SOLUTION; ORAL

	RAPAMUNE			
	+ WYETH AYERST	1MG/ML	N21083 001	
			SEP 15, 1999	

TABLET; ORAL

	RAPAMUNE			
	+ WYETH AYERST	1MG	N21110 001	
			AUG 25, 2000	

SODIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

FDA data supplied by DrugPatentWatch.com

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION
SODIUM ACETATE IN PLASTIC CONTAINER

+	ABBOTT	2MEQ/ML	N18893 001	MAY 04, 1983

SODIUM BICARBONATE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

	LAFAYETTE PHARMS	460MG/GM;420MG/GM	N18509 001	AUG 07, 1985

SODIUM CARBONATE; *MULTIPLE*

SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	ABBOTT	**9MG/ML**	**N18800 001**	OCT 29, 1982
AP		AM PHARM PARTNERS	**9MG/ML**	**N88911 001**	FEB 07, 1985

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		ABBOTT	**450MG/100ML**	**N18090 001**	
AP			**450MG/100ML**	**N19759 001**	JUN 08, 1988
AP		B BRAUN	**450MG/100ML**	**N19635 001**	MAR 09, 1988

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**450MG/100ML**	**N18016 001**	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ABBOTT	**900MG/100ML**	**N16366 001**	
AP			**9MG/ML**	**N18803 001**	OCT 29, 1982
AP			**9MG/ML**	**N19217 001**	JUL 13, 1984
AP			**900MG/100ML**	**N19465 001**	JUL 15, 1985
AP			**9MG/ML**	**N19465 002**	JUL 15, 1985
AP			**900MG/100ML**	**N19480 001**	SEP 17, 1985
AP		AM PHARM PARTNERS	**9MG/ML**	**N88912 001**	JAN 10, 1985
AP		B BRAUN	**900MG/100ML**	**N17464 001**	
AP			**900MG/100ML**	**N19635 002**	MAR 09, 1988
AP		BAXTER HLTHCARE	**900MG/100ML**	**N16677 001**	
AP	+		**9MG/ML**	**N16677 004**	OCT 30, 1985
AP			**900MG/100ML**	**N20178 001**	DEC 07, 1992
AP			**9MG/ML**	**N20178 002**	DEC 07, 1992

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N19022 001	NOV 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML	N19022 002	NOV 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

ABBOTT	2.5MEQ/ML	N18897 001	JUL 20, 1984

SOLUTION FOR SLUSH; IRRIGATION
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE	900MG/100ML	N19319 002	MAY 17, 1985

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	ABBOTT	**450MG/100ML**	**N17670 001**	
AT	BAXTER HLTHCARE	**450MG/100ML**	**N17864 001**	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	ABBOTT	**900MG/100ML**	**N17514 001**	

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	ABBOTT	**900MG/100ML**	**N18314 001**
AT	B BRAUN	**900MG/100ML**	**N16733 001**
AT	BAXTER HLTHCARE	**900MG/100ML**	**N17427 001**
AT		**900MG/100ML**	**N17867 001**

SODIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SODIUM CHLORIDE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE DEXTROSE; SODIUM CHLORIDE

SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE; *MULTIPLE*

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

	BRACCO	200 uCi/ML	N13993 001

SODIUM CHROMATE CR 51

	MALLINCKRODT	100 uCi/ML	N16708 001

SODIUM CITRATE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

SODIUM GLUCONATE; *MULTIPLE*

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	AMERSHAM HLTH	**100 uCi**	**N17630 001**	
AA	MALLINCKRODT	**100 uCi**	**N71909 001**	FEB 28, 1989

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	MALLINCKRODT	**200 uCi**	**N71910 001**	FEB 28, 1989
AA	SYNCOR PHARMS	**100 uCi**	**N18671 001**	MAY 27, 1982
AA		**200 uCi**	**N18671 002**	MAY 27, 1982

SOLUTION; ORAL

SODIUM IODIDE I 123

	AMERSHAM HLTH	2mCi/ML	N17630 002

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE

+	BRACCO	1-130mCi	N10929 001

SODIUM IODIDE I 131

+	MALLINCKRODT	15-100 uCi	N16517 002
+		0.8-100mCi	N16517 001

SOLUTION; ORAL

SODIUM IODIDE I 131

+	CIS	50mCi/ML	N17315 001
+	MALLINCKRODT	3.5-150mCi/VIAL	N16515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP	ABBOTT	**1.87GM/100ML**	**N18249 001**	
AP	BAXTER HLTHCARE	**1.87GM/100ML**	**N16692 001**	

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	B BRAUN	**1.87GM/100ML**	**N20004 001**	APR 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

	ABBOTT	5MEQ/ML	N18947 001 SEP 05, 1984

SODIUM LACTATE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

FDA data supplied by DrugPatentWatch.com

SODIUM LACTATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

	NITROPRESS			
AP	+ ABBOTT	**25MG/ML**	**N71961 001** AUG 01, 1988	
AP		**50MG/VIAL**	**N70566 001** JUN 09, 1986	
	SODIUM NITROPRUSSIDE			
AP	+ ELKINS SINN	**50MG/VIAL**	**N18581 001** JUL 28, 1982	
AP	GENSIA SICOR PHARMS	**25MG/ML**	**N73465 001** MAR 30, 1992	

SODIUM OXYBATE

SOLUTION; ORAL

	XYREM		
+	ORPHAN MEDCL	500MG/ML	N21196 001 JUL 17, 2002

SODIUM PHENYLBUTYRATE

POWDER; ORAL

	BUPHENYL		
+	MEDICIS	3GM/TEASPOONFUL	N20573 001 APR 30, 1996

SODIUM PHENYLBUTYRATE

TABLET; ORAL

	BUPHENYL		
+	MEDICIS	500MG	N20572 001 MAY 13, 1996

SODIUM PHOSPHATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

	VISICOL		
+	INKINE	0.398GM;1.102GM	N21097 001 SEP 21, 2000

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

	SODIUM PHOSPHATES IN PLASTIC CONTAINER		
	ABBOTT	142MG/ML;276MG/ML	N18892 001 MAY 10, 1983

SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

FDA data supplied by DrugPatentWatch.com

SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; *MULTIPLE*
SEE SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
SODIUM PHOSPHATE P 32

	MALLINCKRODT	0.67mCi/ML	N11777 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

AA	+	SANOFI SYNTHELABO	**453.6GM/BOT**	**N11287 001**

KIONEX

AA		PADDOCK	**454GM/BOT**	**N40029 001** FEB 06, 1998

SODIUM POLYSTYRENE SULFONATE

AA		CAROLINA MEDCL	**454GM/BOT**	**N89910 001** JAN 19, 1989

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		ROXANE	**15GM/60ML**	**N89049 001** NOV 17, 1986

SPS

AA	+	CAROLINA MEDCL	**15GM/60ML**	**N87859 001** DEC 08, 1982

SODIUM SULFATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SODIUM SULFATE, ANHYDROUS; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM THIOSULFATE

INJECTABLE; INJECTION
SODIUM THIOSULFATE

+	US ARMY	250MG/ML	N20166 001 FEB 14, 1992

SOMATREM

INJECTABLE; INJECTION
PROTROPIN

+	GENENTECH	5MG/VIAL	N19107 001 OCT 17, 1985
+		10MG/VIAL	N19107 002 OCT 24, 1989

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
BIO-TROPIN

+	BIO TECH GEN	4.8MG/VIAL	N19774 001 MAY 25, 1995

GENOTROPIN

+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006 AUG 24, 1995
+		13.8MG/VIAL	N20280 007 OCT 23, 1996

GENOTROPIN PRESERVATIVE FREE

	PHARMACIA AND UPJOHN	0.2MG/VIAL	N20280 001 JAN 27, 1998
		0.4MG/VIAL	N20280 002 JAN 27, 1998
		0.6MG/VIAL	N20280 003 JAN 27, 1998
		0.8MG/VIAL	N20280 005 JAN 27, 1998
		1MG/VIAL	N20280 008 JAN 27, 1998
		1.2MG/VIAL	N20280 009 JAN 27, 1998
		1.4MG/VIAL	N20280 010 JAN 27, 1998
		1.5MG/VIAL	N20280 004 AUG 24, 1995
		1.6MG/VIAL	N20280 011 JAN 27, 1998

FDA data supplied by DrugPatentWatch.com

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
GENOTROPIN PRESERVATIVE FREE
PHARMACIA AND UPJOHN 1.8MG/VIAL N20280 012 JAN 27, 1998
\+ 2MG/VIAL N20280 013 JAN 27, 1998

HUMATROPE
BX + LILLY 5MG/VIAL N19640 004 MAR 08, 1987
BX 6MG/VIAL N19640 005 FEB 04, 1999
\+ 12MG/VIAL N19640 006 FEB 04, 1999
\+ 24MG/VIAL N19640 007 FEB 04, 1999

NORDITROPIN
NOVO NORDISK 5MG/1.5ML N21148 001 JUN 20, 2000
10MG/1.5ML N21148 002 JUN 20, 2000
\+ 15MG/1.5ML N21148 003 JUN 20, 2000

NUTROPIN
BX GENENTECH 5MG/VIAL N20168 001 NOV 17, 1993
\+ 10MG/VIAL N20168 002 NOV 17, 1993

NUTROPIN AQ
\+ GENENTECH 5MG/ML N20522 001 DEC 29, 1995

NUTROPIN AQ PEN
BX + GENENTECH 5MG/ML N20522 002 APR 22, 2002

NUTROPIN DEPOT
\+ GENENTECH 13.5MG/VIAL N21075 001 DEC 22, 1999
\+ 18MG/VIAL N21075 002 DEC 22, 1999
\+ 22.5MG/VIAL N21075 003 DEC 22, 1999

SAIZEN
BX SERONO 5MG/VIAL N19764 002 OCT 08, 1996
BX 6MG/VIAL N19764 001 OCT 08, 1996
\+ 8.8MG/VIAL N19764 003 AUG 29, 2000

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
SEROSTIM
BX + SERONO 4MG/VIAL N20604 003 JUL 25, 1997
BX 5MG/VIAL N20604 002 AUG 23, 1996
BX 6MG/VIAL N20604 001 AUG 23, 1996
\+ 8.8MG/VIAL N20604 004 SEP 06, 2001

TEV-TROVIN
BX + BIO TECH GEN 5MG/ML N19774 002 JAN 04, 2002

SORBITOL

SOLUTION; IRRIGATION
SORBITOL 3% IN PLASTIC CONTAINER
BAXTER HLTHCARE 3GM/100ML N17863 001
SORBITOL 3.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML N16741 001

SORBITOL; *MULTIPLE*
SEE MANNITOL; SORBITOL

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
AB BERLEX LABS **80MG** **N19865 001** OCT 30, 1992
AB **120MG** **N19865 005** APR 20, 1994
AB + **160MG** **N19865 002** OCT 30, 1992
AB **240MG** **N19865 003** OCT 30, 1992

BETAPACE AF
BERLEX LABS 80MG N21151 001 FEB 22, 2000
120MG N21151 002 FEB 22, 2000
\+ 160MG N21151 003 FEB 22, 2000

FDA data supplied by DrugPatentWatch.com

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	SORINE			
AB	UPSHER SMITH	80MG	N75500 001	APR 27, 2001
AB		120MG	N75500 004	APR 27, 2001
AB		160MG	N75500 002	APR 27, 2001
AB		240MG	N75500 003	APR 27, 2001
	SOTALOL HCL			
AB	APOTEX	80MG	N76140 001	SEP 26, 2002
AB		120MG	N76140 002	SEP 26, 2002
AB		160MG	N76140 003	SEP 26, 2002
AB		240MG	N76140 004	SEP 26, 2002
AB	EON	80MG	N75366 001	MAY 01, 2000
AB		120MG	N75366 002	MAY 01, 2000
AB		160MG	N75366 003	MAY 01, 2000
AB		240MG	N75366 004	MAY 01, 2000
AB	GENPHARM	80MG	N75237 001	MAY 01, 2000
AB		120MG	N75237 002	MAY 01, 2000
AB		160MG	N75237 003	MAY 01, 2000
AB		240MG	N75237 004	MAY 01, 2000
AB	IMPAX PHARM	80MG	N75663 001	NOV 07, 2000
AB		120MG	N75663 002	NOV 07, 2000
AB		160MG	N75663 003	NOV 07, 2000
AB		240MG	N75663 004	NOV 07, 2000
AB	MUTUAL PHARM	80MG	N75515 001	OCT 15, 2001
AB		120MG	N75515 004	OCT 15, 2001

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	SOTALOL HCL			
AB	MUTUAL PHARM	160MG	N75515 002	OCT 15, 2001
AB		240MG	N75515 003	OCT 15, 2001
AB	MYLAN	80MG	N75725 001	DEC 19, 2000
AB		120MG	N75725 002	DEC 19, 2000
AB		160MG	N75725 003	DEC 19, 2000
AB		240MG	N75725 004	DEC 19, 2000
AB	TEVA	80MG	N75429 001	MAY 01, 2000
AB		120MG	N75429 002	MAY 01, 2000
AB		160MG	N75429 003	MAY 01, 2000
AB		240MG	N75429 004	MAY 01, 2000
AB	WATSON LABS	80MG	N75238 001	JUL 13, 2000
AB		120MG	N75238 002	JUL 13, 2000
AB		160MG	N75238 003	JUL 13, 2000
AB		240MG	N75238 004	JUL 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

	INTRALIPID 10%			
AP	+ FRESENIUS KABI	10%	N17643 001	
	INTRALIPID 20%			
AP	+ FRESENIUS KABI	20%	N18449 001	
AP	+	20%	N20248 001	AUG 07, 1996
	INTRALIPID 30%			
AP	+ FRESENIUS KABI	30%	N19942 001	DEC 30, 1993
	LIPOSYN III 10%			
AP	+ ABBOTT	10%	N18969 001	SEP 24, 1984

FDA data supplied by DrugPatentWatch.com

SOYBEAN OIL

INJECTABLE; INJECTION

	LIPOSYN III 20%			
AP	+ ABBOTT	20%	**N18970 001**	SEP 25, 1984
	LIPOSYN III 30%			
AP	+ ABBOTT	30%	**N20181 001**	JAN 13, 1998
	NUTRILIPID 10%			
AP	+ B BRAUN	10%	**N19531 001**	MAY 28, 1993
	NUTRILIPID 20%			
AP	+ B BRAUN	20%	**N19531 002**	MAY 28, 1993
	SOYACAL 10%			
AP	+ ALPHA THERA	10%	**N18465 001**	JUN 29, 1983
	SOYACAL 20%			
AP	+ ALPHA THERA	20%	**N18786 001**	JUN 29, 1983

SOYBEAN OIL; *MULTIPLE*
SEE SAFFLOWER OIL; SOYBEAN OIL

SPARFLOXACIN

TABLET; ORAL

	ZAGAM		
	+ MYLAN	200MG	N20677 001 DEC 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	TROBICIN		
	+ PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N50347 001

SPIRONOLACTONE

TABLET; ORAL

	ALDACTONE		
AB	GD SEARLE LLC	25MG	**N12151 009** DEC 30, 1983

SPIRONOLACTONE

TABLET; ORAL

	ALDACTONE		
AB	GD SEARLE LLC	50MG	**N12151 008** DEC 30, 1982
AB	+	100MG	**N12151 010** DEC 30, 1983
	SPIRONOLACTONE		
AB	GENEVA PHARMS	25MG	**N86809 001**
AB	HALSEY	25MG	**N87265 001**
AB	MUTUAL PHARM	25MG	**N89424 001** JUL 23, 1986
AB		50MG	**N89424 002** AUG 11, 1999
AB		100MG	**N89424 003** AUG 11, 1999
AB	MYLAN	25MG	**N40424 001** AUG 20, 2001
AB		25MG	**N87086 001**
AB		50MG	**N40424 002** AUG 20, 2001
AB		100MG	**N40424 003** AUG 20, 2001
AB	PUREPAC PHARM	50MG	**N40353 001** JUL 29, 1999
AB		100MG	**N40353 002** JUL 29, 1999
AB	SUPERPHARM	25MG	**N89364 001** NOV 07, 1986

SPIRONOLACTONE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

STANOZOLOL

TABLET; ORAL

	WINSTROL		
	+ SANOFI SYNTHELABO	2MG	N12885 001 MAY 14, 1984

STAVUDINE

CAPSULE; ORAL

	ZERIT		
	BRISTOL MYERS SQUIBB	15MG	N20412 002 JUN 24, 1994

FDA data supplied by DrugPatentWatch.com

STAVUDINE

CAPSULE; ORAL					
ZERIT					
BRISTOL MYERS SQUIBB	20MG	N20412 003 JUN 24, 1994			
	30MG	N20412 004 JUN 24, 1994			
+	40MG	N20412 005 JUN 24, 1994			
CAPSULE, EXTENDED RELEASE; ORAL					
ZERIT XR					
BRISTOL MYERS SQUIBB	37.5MG	N21453 001 DEC 31, 2002			
	50MG	N21453 002 DEC 31, 2002			
	75MG	N21453 003 DEC 31, 2002			
+	100MG	N21453 004 DEC 31, 2002			
FOR SOLUTION; ORAL					
ZERIT					
+ BRISTOL MYERS SQUIBB	1MG/ML	N20413 001 SEP 06, 1996			

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION					
STREPTOMYCIN SULFATE					
+ PFIZER	EQ 1GM BASE/2.5ML	N60111 001			
+ PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001 JUN 30, 1998			

STREPTOZOCIN

INJECTABLE; INJECTION					
ZANOSAR					
+ PHARMACIA AND UPJOHN	1GM/VIAL	N50577 001 MAY 07, 1982			

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION					
METASTRON					
+ AMERSHAM HLTH	1mCi/ML	N20134 001 JUN 18, 1993			

SUCCIMER

CAPSULE; ORAL					
CHEMET					
+ SANOFI SYNTHELABO	100MG	N19998 002 JAN 30, 1991			

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION					
ANECTINE					
AP + GLAXOSMITHKLINE	**20MG/ML**	**N08453 002**			
+	500MG/VIAL	N08453 001			
+	1GM/VIAL	N08453 004			
QUELICIN					
AP + ABBOTT	**20MG/ML**	**N08845 006**			
QUELICIN PRESERVATIVE FREE					
AP + ABBOTT	**20MG/ML**	**N08845 001**			
+	100MG/ML	N08845 004			
SUCCINYLCHOLINE CHLORIDE					
AP ORGANON	**20MG/ML**	**N80997 001**			

SUCRALFATE

SUSPENSION; ORAL					
CARAFATE					
+ AVENTIS PHARMS	1GM/10ML	N19183 001 DEC 16, 1993			
TABLET; ORAL					
CARAFATE					
AB + BLUE RIDGE	**1GM**	**N18333 001**			
SUCRALFATE					
AB RATIOPHARM	**1GM**	**N74415 001** JUN 08, 1998			
AB TEVA	**1GM**	**N70848 001** MAR 29, 1996			

FDA data supplied by DrugPatentWatch.com

SUFENTANIL CITRATE

INJECTABLE; INJECTION

	SUFENTA			
AP	+ AKORN	**EQ 0.05MG BASE/ML**	**N19050 001**	MAY 04, 1984
	SUFENTANIL CITRATE			
AP	ELKINS SINN	**EQ 0.05MG BASE/ML**	**N74413 001**	DEC 15, 1995
	SULFENTANIL CITRATE			
AP	ABBOTT	**EQ 0.05MG BASE/ML**	**N74534 001**	DEC 11, 1996

SULBACTAM SODIUM; *MULTIPLE*
SEE AMPICILLIN SODIUM; SULBACTAM SODIUM

SULCONAZOLE NITRATE

CREAM; TOPICAL

	EXELDERM			
	+ WESTWOOD SQUIBB	1%	N18737 001	FEB 28, 1989

SULFACETAMIDE SODIUM

LOTION; TOPICAL

	KLARON			
	+ DERMIK LABS	10%	N19931 001	DEC 23, 1996

OINTMENT; OPHTHALMIC

	CETAMIDE		
AT	+ ALCON	**10%**	**N80021 001**
	SULFACETAMIDE SODIUM		
AT	ALTANA	**10%**	**N80029 001**

SOLUTION/DROPS; OPHTHALMIC

	BLEPH-10		
AT	+ ALLERGAN	**10%**	**N80028 001**
	BLEPH-30		
AT	+ ALLERGAN	**30%**	**N80028 002**
	ISOPTO CETAMIDE		
AT	+ ALCON	**15%**	**N80020 002**
	OCUSULF-10		
AT	MIZA PHARMS USA	**10%**	**N80660 001**
	SULF-10		
AT	NOVARTIS	**10%**	**N80025 001**

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULF-15			
AT	NOVARTIS	**15%**	**N89047 001**	OCT 31, 1995
	SULFACEL-15			
AT	OPTOPICS	**15%**	**N80024 001**	
	SULFACETAMIDE SODIUM			
AT	AKORN	**10%**	**N40215 001**	MAY 25, 1999
AT		**30%**	**N40216 001**	MAY 25, 1999
AT	ALCON UNIVERSAL	**10%**	**N89560 001**	OCT 18, 1988
AT	BAUSCH AND LOMB	**10%**	**N40066 001**	DEC 28, 1994
AT	STERIS	**30%**	**N89068 001**	MAY 05, 1987

SULFACETAMIDE SODIUM; *MULTIPLE*
SEE FLUOROMETHOLONE; SULFACETAMIDE SODIUM
SEE PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
SEE PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SULFACYTINE

TABLET; ORAL

	RENOQUID		
	+ GLENWOOD	250MG	N17569 001

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE		
	+ EON	500MG	N40091 001 JUL 29, 1994

SULFADOXINE; *MULTIPLE*
SEE PYRIMETHAMINE; SULFADOXINE

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	BACTRIM			
AP	+ WOMEN FIRST HLTHCARE	80MG/ML;16MG/ML	N18374 001	
	SEPTRA			
AP	+ MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	ABBOTT	80MG/ML;16MG/ML	N73199 001	SEP 11, 1992
AP	ELKINS SINN	80MG/ML;16MG/ML	N70627 001	DEC 29, 1987
AP		80MG/ML;16MG/ML	N70628 001	DEC 29, 1987
AP	GENSIA SICOR PHARMS	80MG/ML;16MG/ML	N73303 001	OCT 31, 1991

SUSPENSION; ORAL

	SEPTRA			
AB	+ MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001	
	SEPTRA GRAPE			
AB	MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 002	FEB 12, 1986
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	HI TECH PHARMA	200MG/5ML;40MG/5ML	N74650 001	DEC 29, 1997
AB	TEVA	200MG/5ML;40MG/5ML	N18812 001	JAN 28, 1983
AB		200MG/5ML;40MG/5ML	N18812 002	JUN 10, 1983
AB		200MG/5ML;40MG/5ML	N70028 001	JUN 02, 1987
	SULFATRIM			
AB	ALPHARMA	200MG/5ML;40MG/5ML	N18615 002	JAN 07, 1983
	SULFATRIM PEDIATRIC			
AB	ALPHARMA	200MG/5ML;40MG/5ML	N18615 001	JAN 07, 1983

TABLET; ORAL

	BACTRIM			
AB	WOMEN FIRST HLTHCARE	400MG;80MG	N17377 001	
	BACTRIM DS			
AB	+ WOMEN FIRST HLTHCARE	800MG;160MG	N17377 002	
	COTRIM			
AB	TEVA	400MG;80MG	N70034 001	MAY 16, 1985
	COTRIM D.S.			
AB	TEVA	800MG;160MG	N70048 001	MAR 18, 1985

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	SEPTRA			
AB	MONARCH PHARMS	400MG;80MG	N17376 001	
	SEPTRA DS			
AB	MONARCH PHARMS	800MG;160MG	N17376 002	
	SULFAMETHOPRIM			
AB	PAR PHARM	400MG;80MG	N70022 001	FEB 15, 1985
	SULFAMETHOPRIM-DS			
AB	PAR PHARM	800MG;160MG	N70032 001	FEB 15, 1985
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	GENEVA PHARMS	400MG;80MG	N70889 001	NOV 13, 1986
AB		800MG;160MG	N70890 001	NOV 13, 1986
AB	MUTUAL PHARM	400MG;80MG	N71016 001	AUG 25, 1986
AB		800MG;160MG	N71017 001	AUG 25, 1986
AB	SIDMAK LABS NJ	400MG;80MG	N70215 001	SEP 10, 1985
AB		800MG;160MG	N70216 001	SEP 10, 1985
AB	WATSON LABS	400MG;80MG	N18852 001	MAY 09, 1983
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH			
AB	EON	800MG;160MG	N18598 004	MAY 19, 1982
AB	TEVA	800MG;160MG	N70037 001	JUN 02, 1987
AB	WATSON LABS	800MG;160MG	N18854 001	MAY 09, 1983
	SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH			
AB	PLANTEX	400MG;80MG	N70030 001	JUN 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

	AVC			
AT	+ NOVAVAX	15%	N06530 003	JAN 27, 1987
	SULFANILAMIDE			
AT	TEVA	15%	N88718 001	SEP 19, 1985

FDA data supplied by DrugPatentWatch.com

SULFANILAMIDE

SUPPOSITORY; VAGINAL

	AVC			
+	NOVAVAX	1.05GM	N06530 004	JAN 27, 1987

SULFASALAZINE

SUSPENSION; ORAL

	AZULFIDINE			
+	PHARMACIA AND UPJOHN	250MG/5ML	N86983 001	

TABLET; ORAL

	AZULFIDINE			
AB	+ PHARMACIA AND UPJOHN	**500MG**	**N07073 001**	
	SULFASALAZINE			
AB	MUTUAL PHARM	**500MG**	**N89590 001**	OCT 19, 1987
AB	VINTAGE PHARMS	**500MG**	**N40349 001**	JAN 11, 2002
AB	WATSON LABS	**500MG**	**N85828 001**	
AB		**500MG**	**N87197 001**	

TABLET, DELAYED RELEASE; ORAL

	AZULFIDINE EN-TABS			
AB	+ PHARMACIA AND UPJOHN	**500MG**	**N07073 002**	APR 06, 1983
	SULFASALAZINE			
AB	VINTAGE PHARMS	**500MG**	**N75339 001**	JAN 11, 2002

SULFINPYRAZONE

CAPSULE; ORAL

	ANTURANE			
AB	+ NOVARTIS	**200MG**	**N11556 004**	
	SULFINPYRAZONE			
AB	BARR	**200MG**	**N87666 001**	SEP 17, 1982
AB	IVAX PHARMS	**200MG**	**N87770 001**	NOV 19, 1982
AB	PAR PHARM	**200MG**	**N88934 001**	SEP 06, 1985

TABLET; ORAL

	ANTURANE			
AB	+ NOVARTIS	**100MG**	**N11556 003**	

SULFINPYRAZONE

TABLET; ORAL

	SULFINPYRAZONE			
AB	BARR	**100MG**	**N87665 001**	SEP 17, 1982
AB	PAR PHARM	**100MG**	**N88933 001**	SEP 06, 1985

SULFISOXAZOLE

TABLET; ORAL

	SOSOL			
AB	MK LABS	**500MG**	**N80036 001**	
	SULFISOXAZOLE			
AB	ICN	**500MG**	**N80268 002**	
AB	+ IVAX PHARMS	**500MG**	**N80142 001**	
AB	ROXANE	**500MG**	**N80082 001**	

SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

	GANTRISIN PEDIATRIC		
+	ROCHE	EQ 500MG BASE/5ML	N09182 004

SULFISOXAZOLE ACETYL; *MULTIPLE*
SEE ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

SULINDAC

TABLET; ORAL

	CLINORIL			
AB	MERCK	**150MG**	**N17911 001**	
AB	+	**200MG**	**N17911 002**	
	SULINDAC			
AB	GENEVA PHARMS	**150MG**	**N72712 001**	AUG 30, 1991
AB		**200MG**	**N72713 001**	AUG 30, 1991
AB	LEDERLE	**150MG**	**N73261 001**	SEP 06, 1991
AB		**200MG**	**N73262 001**	SEP 06, 1991
AB	MUTUAL PHARM	**150MG**	**N72050 001**	APR 17, 1991

FDA data supplied by DrugPatentWatch.com

SULINDAC

TABLET; ORAL
SULINDAC

AB	MUTUAL PHARM	200MG	N72051 001 APR 17, 1991
AB	MYLAN	150MG	N73038 001 JUN 22, 1993
AB		200MG	N73039 001 JUN 22, 1993
AB	TEVA	150MG	N72972 001 FEB 28, 1992
AB		200MG	N72973 001 FEB 28, 1992
AB	WARNER CHILCOTT	150MG	N72710 001 MAR 25, 1991
AB		200MG	N72711 001 MAR 25, 1991
AB	WATSON LABS	150MG	N71891 001 APR 03, 1990
AB		200MG	N71795 001 APR 03, 1990

SUMATRIPTAN

SPRAY; NASAL
IMITREX

+	GLAXOSMITHKLINE	5MG/SPRAY	N20626 001 AUG 26, 1997
+		10MG/SPRAY	N20626 002 AUG 26, 1997
+		20MG/SPRAY	N20626 003 AUG 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; INJECTION
IMITREX

+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML	N20080 001 DEC 28, 1992

TABLET; ORAL
IMITREX

	GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002 JUN 01, 1995
		EQ 50MG BASE	N20132 003 JUN 01, 1995

SUMATRIPTAN SUCCINATE

TABLET; ORAL
IMITREX

+	GLAXOSMITHKLINE	EQ 100MG BASE	N20132 001 JUN 01, 1995

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	FIRST HORIZON	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
+		EQ 40MG BASE	N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF

	FUJISAWA HLTHCARE	EQ 0.5MG BASE	N50708 003 AUG 24, 1998
		EQ 1MG BASE	N50708 001 APR 08, 1994
+		EQ 5MG BASE	N50708 002 APR 08, 1994

INJECTABLE; INJECTION
PROGRAF

+	FUJISAWA HLTHCARE	EQ 5MG BASE/ML	N50709 001 APR 08, 1994

OINTMENT; TOPICAL
PROTOPIC

	FUJISAWA HLTHCARE	0.03%	N50777 001 DEC 08, 2000
+		0.1%	N50777 002 DEC 08, 2000

FDA data supplied by DrugPatentWatch.com

TALC

AEROSOL, METERED; INTRAPLEURAL
SCLEROSOL
+ BRYAN 400MG/SPRAY N20587 001 DEC 24, 1997

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
ASTRAZENECA EQ 10MG BASE N17970 001
+ EQ 20MG BASE N17970 002 MAR 21, 1994

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
+ BOEHRINGER INGELHEIM 0.4MG N20579 001 APR 15, 1997

TARTARIC ACID; *MULTIPLE*
SEE SODIUM BICARBONATE; TARTARIC ACID

TAZAROTENE

CREAM; TOPICAL
AVAGE
+ ALLERGAN 0.1% N21184 003 SEP 30, 2002

TAZORAC
+ ALLERGAN 0.05% N21184 001 SEP 29, 2000
+ 0.1% N21184 002 SEP 29, 2000

GEL; TOPICAL
TAZORAC
+ ALLERGAN 0.05% N20600 001 JUN 13, 1997
+ 0.1% N20600 002 JUN 13, 1997

TAZOBACTAM SODIUM; *MULTIPLE*
SEE PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
BS BRACCO N/A N17833 001
PULMOLITE
BS CIS N/A N17776 001
TECHNESCAN MAA
BS MALLINCKRODT N/A N17842 001
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
BS DRAXIMAGE N/A N17881 001 DEC 30, 1987

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT
DIATIDE RES LABS N/A N20887 001 SEP 14, 1998

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION
NEUROLITE
BRISTOL MYERS SQUIBB N/A N20256 001 NOV 23, 1994

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT
+ DIATIDE RES LABS N/A N21012 001 AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
CIS N/A N18467 001 MAR 16, 1982

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION
CERETEC
AMERSHAM HLTH N/A N19829 001
DEC 30, 1988

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N18272 001
JAN 27, 1982

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION
CHOLETEC
BRACCO N/A N18963 001
JAN 21, 1987

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP
AP CIS **N/A** **N18124 001**

MDP-BRACCO
AP BRACCO **N/A** **N18107 001**

OSTEOLITE
AP CIS **N/A** **N17972 001**

TECHNESCAN MDP KIT
AP DRAXIMAGE **N/A** **N18035 001**

TECHNETIUM TC 99M MPI MDP
AP AMERSHAM HLTH **N/A** **N18141 001**

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION
TECHNESCAN MAG3
MALLINCKRODT N/A N19882 001
JUN 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN HDP
MALLINCKRODT N/A N18321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA
AP CIS **N/A** **N17714 001**

DTPA
AP DRAXIMAGE **N/A** **N18511 001**
DEC 29, 1989

TECHNETIUM TC-99M PENTETATE KIT
AP AMERSHAM HLTH **N/A** **N17264 002**

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE
CIS N/A N17684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO
AP CIS **N/A** **N19039 001**
JUN 30, 1987

PHOSPHOTEC
AP BRACCO **N/A** **N17680 001**

TECHNESCAN PYP KIT
AP MALLINCKRODT **N/A** **N17538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
ULTRATAG
MALLINCKRODT N/A N19981 001
JUN 10, 1991

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
BRISTOL MYERS SQUIBB N/A N19785 001 DEC 21, 1990

MIRALUMA
BRISTOL MYERS SQUIBB N/A N19785 003 MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE
BRISTOL MYERS SQUIBB 0.0083-2.7 CI/GENERATOR N17771 001
ULTRA-TECHNEKOW FM
MALLINCKRODT 0.25-3 CI/GENERATOR N17243 002

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT
AMERSHAM HLTH N/A N17944 001 MAY 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AN-SULFUR COLLOID
AP CIS **N/A** **N17858 001**
TECHNECOLL
AP MALLINCKRODT **N/A** **N17059 001**

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION
CARDIOTEC
BRACCO N/A N19928 001 DEC 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVIEW
AMERSHAM HLTH N/A N20372 001 FEB 09, 1996

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM
NOVARTIS EQ 2MG BASE N21200 001 JUL 24, 2002
\+ EQ 6MG BASE N21200 002 JUL 24, 2002

TELMISARTAN

TABLET; ORAL
MICARDIS
\+ BOEHRINGER INGELHEIM 20MG N20850 003 APR 04, 2000
40MG N20850 001 NOV 10, 1998
\+ 80MG N20850 002 NOV 10, 1998

TELMISARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TELMISARTAN

TEMAZEPAM

CAPSULE; ORAL
RESTORIL
AB TYCO HLTHCARE **15MG** **N18163 001**
AB \+ **30MG** **N18163 002**
7.5MG N18163 003 OCT 25, 1991

TEMAZEPAM
AB GENEVA PHARMS **15MG** **N71427 001** JAN 12, 1988
AB **30MG** **N71428 001** JAN 12, 1988
AB MYLAN **15MG** **N70919 001** JUL 07, 1986

FDA data supplied by DrugPatentWatch.com

TEMAZEPAM

CAPSULE; ORAL

	TEMAZEPAM			
AB	MYLAN	**30MG**	**N70920 001**	JUL 10, 1986
AB	PAR PHARM	**15MG**	**N71456 001**	APR 21, 1987
AB		**30MG**	**N71457 001**	APR 21, 1987
AB	PUREPAC PHARM	**15MG**	**N71638 001**	AUG 07, 1987
AB		**30MG**	**N71620 001**	AUG 07, 1987
AB	WATSON LABS	**15MG**	**N71446 001**	MAY 21, 1993
AB		**30MG**	**N71447 001**	MAY 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL

	TEMODAR			
	SCHERING	5MG	N21029 001	AUG 11, 1999
		20MG	N21029 002	AUG 11, 1999
		100MG	N21029 003	AUG 11, 1999
+		250MG	N21029 004	AUG 11, 1999

TENIPOSIDE

INJECTABLE; INJECTION

	VUMON			
+	BRISTOL MYERS SQUIBB	10MG/ML	N20119 001	JUL 14, 1992

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

	VIREAD			
+	GILEAD	300MG	N21356 001	OCT 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	HYTRIN			
AB	ABBOTT	**EQ 1MG BASE**	**N20347 001**	DEC 14, 1994
AB +		**EQ 2MG BASE**	**N20347 002**	DEC 14, 1994
AB		**EQ 5MG BASE**	**N20347 003**	DEC 14, 1994
AB		**EQ 10MG BASE**	**N20347 004**	DEC 14, 1994
	TERAZOSIN HCL			
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N74823 001**	MAR 30, 1998
AB		**EQ 2MG BASE**	**N74823 002**	MAR 30, 1998
AB		**EQ 5MG BASE**	**N74823 003**	MAR 30, 1998
AB		**EQ 10MG BASE**	**N74823 004**	MAR 30, 1998
AB	INVAMED	**EQ 1MG BASE**	**N75667 001**	JUL 28, 2000
AB		**EQ 2MG BASE**	**N75667 002**	JUL 28, 2000
AB		**EQ 5MG BASE**	**N75667 003**	JUL 28, 2000
AB		**EQ 10MG BASE**	**N75667 004**	JUL 28, 2000
AB	IVAX PHARMS	**EQ 1MG BASE**	**N75614 002**	JAN 30, 2001
AB		**EQ 2MG BASE**	**N75614 001**	JAN 30, 2001
AB		**EQ 5MG BASE**	**N75614 003**	JAN 30, 2001
AB		**EQ 10MG BASE**	**N75614 004**	JAN 30, 2001
AB	MYLAN	**EQ 1MG BASE**	**N75140 002**	FEB 11, 2000
AB		**EQ 2MG BASE**	**N75140 003**	FEB 11, 2000
AB		**EQ 5MG BASE**	**N75140 001**	FEB 11, 2000
AB		**EQ 10MG BASE**	**N75140 004**	FEB 11, 2000
AB	MYLAN TECHNOLOGIES	**EQ 1MG BASE**	**N75384 001**	DEC 01, 2000
AB		**EQ 2MG BASE**	**N75384 002**	DEC 01, 2000

FDA data supplied by DrugPatentWatch.com

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL

AB	MYLAN TECHNOLOGIES	EQ 5MG BASE	**N75384 003**	DEC 01, 2000
AB		EQ 10MG BASE	**N75384 004**	DEC 01, 2000
AB	RANBAXY	EQ 1MG BASE	**N76021 001**	AUG 22, 2002
AB		EQ 2MG BASE	**N76021 002**	AUG 22, 2002
AB		EQ 5MG BASE	**N76021 003**	AUG 22, 2002
AB		EQ 10MG BASE	**N76021 004**	AUG 22, 2002
AB	TORPHARM	EQ 1MG BASE	**N75498 001**	APR 12, 2001
AB		EQ 2MG BASE	**N75498 002**	APR 12, 2001
AB		EQ 5MG BASE	**N75498 003**	APR 12, 2001
AB		EQ 10MG BASE	**N75498 004**	APR 12, 2001

TABLET; ORAL

HYTRIN

AB	ABBOTT	EQ 1MG BASE	**N19057 001**	AUG 07, 1987
AB	+	EQ 2MG BASE	**N19057 002**	AUG 07, 1987
AB		EQ 5MG BASE	**N19057 003**	AUG 07, 1987
AB		EQ 10MG BASE	**N19057 004**	AUG 07, 1987

TERAZOSIN HCL

AB	GENEVA PHARMS	EQ 1MG BASE	**N74315 001**	DEC 31, 1998
AB		EQ 2MG BASE	**N74315 002**	DEC 31, 1998
AB		EQ 5MG BASE	**N74315 003**	DEC 31, 1998
AB		EQ 10MG BASE	**N74315 004**	DEC 31, 1998
AB	INVAMED	EQ 1MG BASE	**N74657 001**	APR 28, 2000
AB		EQ 2MG BASE	**N74657 002**	APR 28, 2000

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

TERAZOSIN HCL

AB	INVAMED	EQ 5MG BASE	**N74657 003**	APR 28, 2000
AB		EQ 10MG BASE	**N74657 004**	APR 28, 2000
AB	IVAX PHARMS	EQ 1MG BASE	**N74530 001**	APR 21, 2000
AB		EQ 2MG BASE	**N74530 002**	APR 21, 2000
AB		EQ 5MG BASE	**N74530 003**	APR 21, 2000
AB		EQ 10MG BASE	**N74530 004**	APR 21, 2000
AB	TEVA	EQ 1MG BASE	**N74446 001**	MAY 18, 2000
AB		EQ 2MG BASE	**N74446 002**	MAY 18, 2000
AB		EQ 5MG BASE	**N74446 003**	MAY 18, 2000
AB		EQ 10MG BASE	**N74446 004**	MAY 18, 2000

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+	NOVARTIS	1%	N20192 001 DEC 30, 1992

SOLUTION; TOPICAL

LAMISIL

+	NOVARTIS	1%	N20749 001 OCT 17, 1997

TABLET; ORAL

LAMISIL

+	NOVARTIS	EQ 250MG BASE	N20539 001 MAY 10, 1996

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

+	AAIPHARMA	1MG/ML	N18571 001

FDA data supplied by DrugPatentWatch.com

TERBUTALINE SULFATE

TABLET; ORAL

	BRETHINE			
AB	AAIPHARMA	2.5MG	N17849 001	
AB	+	5MG	N17849 002	
	TERBUTALINE SULFATE			
AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001
AB		5MG	N75877 002	JUN 26, 2001

TERCONAZOLE

CREAM; VAGINAL

	TERAZOL 3			
+	ORTHO MCNEIL PHARM	0.8%	N19964 001	FEB 21, 1991
	TERAZOL 7			
+	ORTHO MCNEIL PHARM	0.4%	N19579 001	DEC 31, 1987

SUPPOSITORY; VAGINAL

	TERAZOL 3			
+	ORTHO MCNEIL PHARM	80MG	N19641 001	MAY 24, 1988

TERIPARATIDE ACETATE

INJECTABLE; SUBCUTANEOUS

	FORTEO			
+	LILLY	EQ 0.75MG 3ML(0.25MG/ML)	N21318 001	NOV 26, 2002

TESTOLACTONE

TABLET; ORAL

	TESLAC			
+	BRISTOL MYERS SQUIBB	50MG	N16118 001	

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

	ANDRODERM			
BX	+ WATSON LABS	5MG/24HR	N20489 002	MAY 02, 1997

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

	ANDRODERM			
+	WATSON LABS	2.5MG/24HR	N20489 001	SEP 29, 1995
	TESTODERM			
+	ALZA	4MG/24HR	N19762 001	OCT 12, 1993
+		6MG/24HR	N19762 002	OCT 12, 1993
	TESTODERM TTS			
BX +	ALZA	5MG/24HR	N20791 001	DEC 18, 1997

GEL; TOPICAL

	ANDROGEL			
+	UNIMED PHARMS	1%	N21015 001	FEB 28, 2000
	TESTIM			
+	AUXILIUM A2	1%	N21454 001	OCT 31, 2002

INJECTABLE; INJECTION

	TESTOSTERONE			
+	STERIS	100MG/ML	N86417 001	JUL 07, 1983

PELLET; IMPLANTATION

	TESTOSTERONE			
	BARTOR	75MG	N80911 001	

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

	DEPO-TESTOSTERONE			
AO +	PHARMACIA AND UPJOHN	100MG/ML	N85635 002	
AO +		200MG/ML	N85635 003	
	TESTOSTERONE CYPIONATE			
AO	STERIS	100MG/ML	N86029 001	
AO		200MG/ML	N86030 001	

TESTOSTERONE CYPIONATE; *MULTIPLE*
SEE ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	DELATESTRYL			
AO	+ BTG	**200MG/ML**	**N09165**	**003**
	TESTOSTERONE ENANTHATE			
AO	STERIS	**200MG/ML**	**N85598**	**001**

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

	TESTOSTERONE PROPIONATE			
	+ STERIS	25MG/ML	N80188	001
		50MG/ML	N80188	002
	+	100MG/ML	N80188	003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	ACHROMYCIN V			
AB	LEDERLE	**250MG**	**N50278**	**003**
AB	+	**500MG**	**N50278**	**001**
	BRISTACYCLINE			
AB	BRISTOL	**250MG**	**N61658**	**001**
AB		**250MG**	**N61888**	**001**
AB		**500MG**	**N61658**	**002**
AB		**500MG**	**N61888**	**002**
	SUMYCIN			
AB	APOTHECON	**250MG**	**N60429**	**001**
AB		**500MG**	**N60429**	**003**
	TETRACYCLINE HCL			
AB	BARR	**250MG**	**N61837**	**001**
AB		**500MG**	**N61837**	**002**
AB	HALSEY	**250MG**	**N60736**	**001**
AB		**500MG**	**N60736**	**002**
AB	IMPAX LABS	**250MG**	**N60469**	**001**
AB		**500MG**	**N60469**	**003**
		100MG	N60469	002
AB	IVAX PHARMS	**250MG**	**N60704**	**001**
AB		**500MG**	**N60704**	**002**
AB	LABS ATRAL	**250MG**	**N62752**	**001**
			AUG 12, 1988	
AB		**500MG**	**N62752**	**002**
			AUG 12, 1988	
AB	MAST MM	**250MG**	**N62085**	**001**
AB	MYLAN	**250MG**	**N60783**	**001**
AB		**500MG**	**N60783**	**002**

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL			
AB	ROXANE	**500MG**	**N61214**	**002**

FIBER, EXTENDED RELEASE; PERIODONTAL

	ACTISITE			
	+ ALZA	12.7MG/FIBER	N50653	001
			MAR 25, 1994	

SUSPENSION; ORAL

	SUMYCIN			
	+ APOTHECON	125MG/5ML	N60400	001

TABLET; ORAL

	SUMYCIN			
	PAR PHARM	250MG	N61147	001
	+	500MG	N61147	004

TETRACYCLINE HYDROCHLORIDE; *MULTIPLE*

SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

	TETREX			
	BRISTOL	EQ 100MG HCL	N61653	001
		EQ 250MG HCL	N61653	002
		EQ 250MG HCL	N61889	002
	+	EQ 500MG HCL	N61653	003
		EQ 500MG HCL	N61889	001

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

	TYZINE			
	+ KENWOOD LABS	0.05%	N86576	002
		0.1%	N86576	001

SPRAY; NASAL

	TYZINE			
	+ KENWOOD LABS	0.1%	N86576	003

FDA data supplied by DrugPatentWatch.com

THALIDOMIDE

CAPSULE; ORAL

		THALOMID			
	+	CELGENE	50MG	N20785 001	JUL 16, 1998

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

		THALLOUS CHLORIDE TL 201			
AP	+	AMERSHAM HLTH	**1mCi/ML**	**N18110 002**	FEB 27, 1996
AP	+	BRISTOL MYERS SQUIBB	**1mCi/ML**	**N17806 001**	
AP	+	MALLINCKRODT	**1mCi/ML**	**N18150 001**	
AP		MOUNT SINAI MEDCTR	**1mCi/ML**	**N75569 001**	NOV 21, 2001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		AEROLATE III			
	+	FLEMING PHARMS	65MG	N85075 003	NOV 24, 1986
		AEROLATE JR			
BC		FLEMING PHARMS	130MG	N85075 002	NOV 24, 1986
		AEROLATE SR			
BC		FLEMING PHARMS	260MG	N85075 001	NOV 24, 1986
		SLO-BID			
AB		AVENTIS	**100MG**	**N87892 001**	JAN 31, 1985
AB			**125MG**	**N89540 001**	MAY 10, 1989
AB			**200MG**	**N87893 001**	JAN 31, 1985
AB	+		**300MG**	**N87894 001**	JAN 31, 1985
BC	+		50MG	N88269 001	JAN 31, 1985
BC			75MG	N89539 001	MAY 10, 1989
		THEO-24			
BC		UCB	100MG	N87942 001	AUG 22, 1983

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		THEO-24			
BC		UCB	200MG	N87943 001	AUG 22, 1983
BC			300MG	N87944 001	AUG 22, 1983
			400MG	N81034 001	FEB 28, 1992
		THEOPHYLLINE			
AB		INWOOD LABS	**100MG**	**N40052 001**	FEB 14, 1994
AB			**125MG**	**N40052 002**	FEB 14, 1994
AB			**200MG**	**N40052 003**	FEB 14, 1994
AB			**300MG**	**N40052 004**	FEB 14, 1994

ELIXIR; ORAL

		ELIXOPHYLLIN			
AA		FORREST LABS	**80MG/15ML**	**N85186 001**	
		THEOPHYLLINE			
AA		ALPHARMA	**80MG/15ML**	**N85863 001**	
AA		MORTON GROVE	**80MG/15ML**	**N86748 001**	
AA		PHARM ASSOC	**80MG/15ML**	**N86720 001**	
AA		TARO	**80MG/15ML**	**N89626 001**	OCT 28, 1988

INJECTABLE; INJECTION

		THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**40MG/100ML**	**N19826 001**	AUG 14, 1992
		THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**80MG/100ML**	**N19826 002**	AUG 14, 1992
		THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**160MG/100ML**	**N19826 003**	AUG 14, 1992
		THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**320MG/100ML**	**N19826 006**	AUG 14, 1992
		THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	BAXTER HLTHCARE	**40MG/100ML**	**N18649 001**	JUL 26, 1982
AP	+		**80MG/100ML**	**N18649 002**	JUL 26, 1982

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	**160MG/100ML**	**N18649 003**	JUL 26, 1982
AP	+	**200MG/100ML**	**N18649 004**	JUL 26, 1982
AP	+	**320MG/100ML**	**N18649 006**	NOV 13, 1985
AP	+	**400MG/100ML**	**N18649 005**	JUL 26, 1982
AP	+	**4MG/ML**	**N18649 007**	JUL 26, 1982

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ ABBOTT	**40MG/100ML**	**N19211 001**	DEC 14, 1984
AP	+	**80MG/100ML**	**N19211 002**	DEC 14, 1984
AP	+	**160MG/100ML**	**N19211 003**	DEC 14, 1984
AP	+	**200MG/100ML**	**N19211 004**	DEC 14, 1984
AP	+	**320MG/100ML**	**N19211 006**	JAN 20, 1988
AP	+	**400MG/100ML**	**N19211 005**	DEC 14, 1984
AP	+	**4MG/ML**	**N19211 007**	DEC 14, 1984

SOLUTION; ORAL

	AEROLATE			
	+ FLEMING PHARMS	150MG/15ML	N89141 001	DEC 03, 1986
	THEOLAIR			
AA	+ 3M	**80MG/15ML**	**N86107 001**	
	THEOPHYLLINE			
AA	ROXANE	**80MG/15ML**	**N87449 001**	SEP 15, 1983

SYRUP; ORAL

	SLO-PHYLLIN			
AA	+ AVENTIS	**80MG/15ML**	**N85187 001**	

TABLET; ORAL

	QUIBRON-T			
	+ MONARCH PHARMS	300MG	N88656 001	AUG 22, 1985
	SLO-PHYLLIN			
	+ AVENTIS	100MG	N85202 001	

THEOPHYLLINE

TABLET; ORAL

	SLO-PHYLLIN			
	+ AVENTIS	200MG	N85204 001	
	THEOLAIR			
	+ 3M	125MG	N86399 001	
	+	250MG	N86399 002	

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR			
BC	MONARCH PHARMS	300MG	N87563 001	JUN 21, 1983
	T-PHYL			
BC	PURDUE FREDERICK	200MG	N88253 001	AUG 17, 1983
	THEO-DUR			
AB	SCHERING	**100MG**	**N85328 001**	
AB		**200MG**	**N86998 001**	
AB		**300MG**	**N85328 002**	
AB		**450MG**	**N89131 001**	JUN 25, 1986
	THEOCHRON			
AB	INWOOD LABS	**100MG**	**N88320 001**	FEB 21, 1985
AB		**200MG**	**N88321 001**	FEB 21, 1985
AB		**300MG**	**N87400 002**	JAN 11, 1983
	THEOLAIR-SR			
BC	3M	200MG	N88369 001	JUL 16, 1987
BC		300MG	N88364 001	JUL 16, 1987
		250MG	N86363 002	JUL 16, 1987
	+	500MG	N89132 001	JUL 16, 1987
	THEOPHYLLINE			
AB	INWOOD LABS	**450MG**	**N40034 001**	APR 28, 1995
AB	+ SIDMAK LABS NJ	**100MG**	**N89807 001**	APR 30, 1990
AB	+	**200MG**	**N89808 001**	APR 30, 1990
AB	+	**300MG**	**N89763 001**	APR 30, 1990
AB	+	**450MG**	**N81236 001**	NOV 09, 1992

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

		UNI-DUR			
BC		SCHERING	400MG	N89822 001	JAN 04, 1995
BC			600MG	N89823 001	JAN 04, 1995
		UNIPHYL			
BC	+	PURDUE FREDERICK	400MG	N87571 001	SEP 01, 1982
BC	+		600MG	N40086 001	APR 15, 1996

THIABENDAZOLE

SUSPENSION; ORAL

		MINTEZOL			
	+	MERCK	500MG/5ML	N16097 001	

TABLET, CHEWABLE; ORAL

		MINTEZOL			
	+	MERCK	500MG	N16096 001	

THIAMINE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		THIAMINE HCL			
AP		ABBOTT	**100MG/ML**	**N40079 001**	MAY 03, 1996
AP	+	AM PHARM PARTNERS	**100MG/ML**	**N80556 001**	
AP		ELKINS SINN	**100MG/ML**	**N80575 001**	
AP		STERIS	**100MG/ML**	**N80571 001**	
	+		200MG/ML	N80571 002	
AP		WYETH AYERST	**100MG/ML**	**N80553 001**	

THIAMINE HYDROCHLORIDE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

		TORECAN			
	+	NOVARTIS	10MG		N13247 001

TABLET; ORAL

		TORECAN			
	+	NOVARTIS	10MG		N12753 001

THIOGUANINE

TABLET; ORAL

		THIOGUANINE			
	+	GLAXOSMITHKLINE	40MG		N12429 001

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		THIORIDAZINE HCL			
AA		ALPHARMA	**100MG/ML**	**N88229 001**	AUG 23, 1983
AA	+	COPLEY PHARM	**30MG/ML**	**N89602 001**	NOV 09, 1987
AA	+		**100MG/ML**	**N89603 001**	NOV 09, 1987
AA		HI TECH PHARMA	**30MG/ML**	**N40125 001**	AUG 16, 1996
AA			**100MG/ML**	**N40126 001**	AUG 16, 1996

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIORIDAZINE HCL				
AA	PHARM ASSOC	30MG/ML	**N40187 001**	AUG 28, 1997	
AA		100MG/ML	**N40213 001**	MAY 29, 1998	
	THIORIDAZINE HCL INTENSOL				
AA	ROXANE	30MG/ML	**N88941 001**	DEC 16, 1985	
AA		100MG/ML	**N88942 001**	DEC 16, 1985	

TABLET; ORAL

	THIORIDAZINE HCL				
AB	GENEVA PHARMS	10MG	**N88131 001**	AUG 30, 1983	
AB		15MG	**N88132 001**	AUG 30, 1983	
AB	+	25MG	**N88133 001**	AUG 30, 1983	
AB		50MG	**N88134 001**	AUG 30, 1983	
AB	+	100MG	**N88135 001**	NOV 20, 1984	
AB		150MG	**N88136 001**	SEP 17, 1986	
AB	+	200MG	**N88137 001**	SEP 17, 1986	
AB	HALSEY	50MG	**N88370 001**	NOV 18, 1983	
AB	IVAX PHARMS	10MG	**N88270 001**	APR 14, 1983	
AB		15MG	**N88271 001**	APR 14, 1983	
AB		25MG	**N88272 001**	APR 14, 1983	
AB	MUTUAL PHARM	10MG	**N89431 001**	AUG 01, 1986	
AB		25MG	**N89432 001**	AUG 01, 1986	
AB		50MG	**N89433 001**	AUG 01, 1986	
AB		100MG	**N89953 001**	OCT 07, 1988	
AB	MYLAN	10MG	**N88001 001**	MAR 15, 1983	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL				
AB	MYLAN	25MG	**N88002 001**	MAR 15, 1983	
AB		50MG	**N88003 001**	MAR 15, 1983	
AB		100MG	**N88004 001**	NOV 18, 1983	
AB	TEVA	100MG	**N88456 001**	MAY 17, 1985	
AB	WATSON LABS	10MG	**N88476 001**	NOV 08, 1983	
AB		15MG	**N88477 001**	NOV 08, 1983	
AB		25MG	**N88478 001**	NOV 08, 1983	
AB		25MG	**N88567 001**	MAY 11, 1984	
AB		50MG	**N88479 001**	NOV 08, 1983	
AB		50MG	**N88563 001**	MAY 11, 1984	
AB		100MG	**N88564 001**	MAY 11, 1984	
AB		100MG	**N88736 001**	JUL 24, 1984	
AB		150MG	**N88869 001**	JUN 28, 1985	
AB		200MG	**N88872 001**	APR 26, 1985	

THIOTEPA

INJECTABLE; INJECTION

	THIOPLEX				
AP	+ IMMUNEX	15MG/VIAL	**N20058 001**	DEC 22, 1994	
	THIOTEPA				
AP	AM PHARM PARTNERS	15MG/VIAL	**N75698 001**	SEP 20, 2001	
AP	BEDFORD	15MG/VIAL	**N75547 001**	APR 02, 2001	
AP	GENSIA SICOR PHARMS	15MG/VIAL	**N75730 001**	APR 20, 2001	
	+	30MG/VIAL	N75730 002	APR 20, 2001	

FDA data supplied by DrugPatentWatch.com

THIOTHIXENE

CAPSULE; ORAL

	NAVANE			
AB	ROERIG	1MG	N16584 001	
AB		2MG	N16584 002	
AB	+	5MG	N16584 003	
AB		10MG	N16584 004	
		20MG	N16584 005	
	THIOTHIXENE			
AB	GENEVA PHARMS	1MG	N71610 001	JUN 24, 1987
AB		2MG	N71570 001	JUN 24, 1987
AB		5MG	N71529 001	JUN 24, 1987
AB		10MG	N71530 001	JUN 24, 1987
AB	MYLAN	1MG	N71090 001	JUN 23, 1987
AB		2MG	N71091 001	JUN 23, 1987
AB		5MG	N71092 001	JUN 23, 1987
AB		10MG	N71093 001	JUN 23, 1987
AB	WATSON LABS	1MG	N70600 001	JUN 05, 1987
AB		2MG	N70601 001	JUN 05, 1987
AB		5MG	N70602 001	JUN 05, 1987
AB		10MG	N70603 001	JUN 05, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

	NAVANE			
AA	+ ROERIG	EQ 5MG BASE/ML	N16758 001	
	THIOTHIXENE HCL			
AA	COPLEY PHARM	EQ 5MG BASE/ML	N71554 001	OCT 16, 1987

INJECTABLE; INJECTION

NAVANE			
+	ROERIG	EQ 10MG BASE/VIAL	N16904 002

THONZONIUM BROMIDE; *MULTIPLE*

SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN				
+	GENZYME	1.1MG/VIAL	N20898 001	NOV 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL				
+	CEPHALON	2MG	N20646 005	APR 16, 1999
		4MG	N20646 001	SEP 30, 1997
		12MG	N20646 002	SEP 30, 1997
+		16MG	N20646 003	SEP 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR				
+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50497 001	
+		EQ 3GM BASE/VIAL	N50497 002	
+		EQ 20GM BASE/VIAL	N50497 004	
+		EQ 30GM BASE/VIAL	N50497 005	APR 04, 1984

TICARCILLIN DISODIUM; *MULTIPLE*

SEE CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID			
AB	+ SYNTEX (USA) INC LLC	250MG	N19979 002	OCT 31, 1991

FDA data supplied by DrugPatentWatch.com

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLOPIDINE HCL			
AB	CARACO	250MG	N75526 001	SEP 26, 2002
AB	EON	250MG	N75326 001	AUG 20, 1999
AB	GENEVA PHARMS TECH	250MG	N75318 001	AUG 20, 1999
AB	GENPHARM	250MG	N75161 001	SEP 13, 1999
AB	MYLAN	250MG	N75316 001	NOV 02, 1999
AB	PUREPAC PHARM	250MG	N75253 001	AUG 20, 1999
AB	TEVA	250MG	N75149 001	AUG 20, 1999
AB	TORPHARM	250MG	N75089 001	JUL 01, 1999
AB	WATSON LABS	250MG	N75309 001	APR 26, 2000

TILUDRONATE DISODIUM

TABLET; ORAL

	SKELID			
+	SANOFI SYNTHELABO	EQ 200MG BASE	N20707 001	MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL			
+	SANTEN OY	EQ 0.25% BASE	N20439 001	MAR 31, 1995
+		EQ 0.5% BASE	N20439 002	MAR 31, 1995

TIMOLOL MALEATE

SOLUTION; OPHTHALMIC

	TIMOLOL MALEATE			
AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001	SEP 10, 2002

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AB	FALCON PHARMS	EQ 0.25% BASE	N20963 001	OCT 21, 1998
AB		EQ 0.5% BASE	N20963 002	OCT 21, 1998
	TIMOPTIC-XE			
AB	+ MERCK	EQ 0.25% BASE	N20330 001	NOV 04, 1993
AB	+	EQ 0.5% BASE	N20330 002	NOV 04, 1993

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	AKORN	EQ 0.25% BASE	N74465 001	MAR 25, 1997
AT		EQ 0.25% BASE	N74515 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74466 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74516 001	MAR 25, 1997
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74776 001	MAR 25, 1997
AT	FOUGERA	EQ 0.25% BASE	N74667 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74668 001	MAR 25, 1997
AT	NOVEX	EQ 0.25% BASE	N75411 001	SEP 08, 2000
AT		EQ 0.5% BASE	N75412 001	SEP 08, 2000
AT	PACIFIC PHARMA	EQ 0.25% BASE	N74746 001	MAR 25, 1997
AT		EQ 0.5% BASE	N74747 001	MAR 25, 1997
	TIMOPTIC			
AT	+ MERCK	EQ 0.25% BASE	N18086 001	
AT	+	EQ 0.5% BASE	N18086 002	
	TIMOPTIC IN OCUDOSE			
	+ MERCK	EQ 0.25% BASE	N19463 001	NOV 05, 1986
	+	EQ 0.5% BASE	N19463 002	NOV 05, 1986

FDA data supplied by DrugPatentWatch.com

TIMOLOL MALEATE

TABLET; ORAL

	BLOCADREN			
AB	MERCK	5MG	**N18017 001**	
AB		10MG	**N18017 002**	
AB	+	20MG	**N18017 004**	
	TIMOLOL MALEATE			
AB	GENEVA PHARMS	5MG	**N72550 001**	APR 13, 1989
AB		10MG	**N72551 001**	APR 13, 1989
AB		20MG	**N72552 001**	APR 13, 1989
AB	MYLAN	5MG	**N72666 001**	JUN 08, 1990
AB		10MG	**N72667 001**	JUN 08, 1990
AB		20MG	**N72668 001**	JUN 08, 1990
AB	WATSON LABS	5MG	**N72917 001**	JUL 31, 1991
AB		10MG	**N72918 001**	JUL 31, 1991
AB		20MG	**N72919 001**	JUL 31, 1991

TIMOLOL MALEATE; *MULTIPLE*

SEE DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SEE HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TINZAPARIN SODIUM

INJECTABLE; INJECTION

	INNOHEP			
+	PHARMION	20,000 IU/ML	N20484 001	JUL 14, 2000

TIOPRONIN

TABLET; ORAL

	TIOPRONIN			
+	MISSION PHARMA	100MG	N19569 001	AUG 11, 1988

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

	AGGRASTAT			
+	MERCK	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998
+		EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

	ZANAFLEX			
	ELAN PHARMS	EQ 2MG BASE	N21447 001	AUG 29, 2002
		EQ 4MG BASE	N21447 002	AUG 29, 2002
+		EQ 6MG BASE	N21447 003	AUG 29, 2002

TABLET; ORAL

	TIZANIDINE HCL			
AB	COREPHARMA	**EQ 2MG BASE**	**N76347 001**	OCT 11, 2002
AB		**EQ 4MG BASE**	**N76347 002**	OCT 11, 2002
AB	DR REDDYS LABS INC	**EQ 2MG BASE**	**N76286 001**	JUL 03, 2002
AB		**EQ 4MG BASE**	**N76286 002**	JUL 03, 2002
AB	EON	**EQ 2MG BASE**	**N76399 001**	NOV 26, 2002
AB		**EQ 4MG BASE**	**N76280 002**	JUN 27, 2002
AB	PUREPAC PHARM	**EQ 2MG BASE**	**N76283 001**	JUL 12, 2002
AB		**EQ 4MG BASE**	**N76283 002**	JUL 12, 2002
AB	TEVA	**EQ 2MG BASE**	**N76284 001**	JUL 03, 2002
AB		**EQ 4MG BASE**	**N76284 002**	JUL 03, 2002
	ZANAFLEX			
AB	ELAN PHARMS	**EQ 2MG BASE**	**N20397 002**	FEB 04, 2000
AB	+	**EQ 4MG BASE**	**N20397 001**	NOV 27, 1996

FDA data supplied by DrugPatentWatch.com

TOBRAMYCIN

OINTMENT; OPHTHALMIC

	TOBREX			
	+ ALCON	0.3%	N50555 001	

SOLUTION; INHALATION

	TOBI			
	+ CHIRON	300MG/5ML	N50753 001	DEC 22, 1997

SOLUTION/DROPS; OPHTHALMIC

	AKTOB			
AT	AKORN	**0.3%**	**N64096 001**	JAN 31, 1996
	TOBRAMYCIN			
AT	ALTANA	**0.3%**	**N65026 001**	SEP 11, 2001
AT	BAUSCH AND LOMB	**0.3%**	**N64052 001**	NOV 29, 1993
AT	NOVEX	**0.3%**	**N65087 001**	FEB 25, 2002
	TOBREX			
AT	ALCON	**0.3%**	**N62535 001**	DEC 13, 1984
AT	+ FALCON PHARMS	**0.3%**	**N50541 001**	

TOBRAMYCIN; *MULTIPLE*

SEE DEXAMETHASONE; TOBRAMYCIN

SEE FLUOROMETHOLONE ACETATE; TOBRAMYCIN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	NEBCIN			
AP	+ LILLY	**EQ 1.2GM BASE/VIAL**	**N50519 001**	
AP	+	**EQ 10MG BASE/ML**	**N50477 005**	
AP		**EQ 10MG BASE/ML**	**N62008 004**	
AP		**EQ 10MG BASE/ML**	**N62707 001**	APR 29, 1987
AP	+	**EQ 40MG BASE/ML**	**N62008 001**	
	TOBRAMYCIN			
AP	AM PHARM PARTNERS	**EQ 10MG BASE/ML**	**N65122 001**	NOV 29, 2002
AP		**EQ 40MG BASE/ML**	**N65122 002**	NOV 29, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	TOBRAMYCIN			
AP	PHARMA TEK	**EQ 1.2GM BASE/VIAL**	**N65013 001**	AUG 17, 2001
	TOBRAMYCIN (PHARMACY BULK)			
AP	AM PHARM PARTNERS	**EQ 40MG BASE/ML**	**N65120 001**	NOV 29, 2002
	TOBRAMYCIN SULFATE			
AP	ABBOTT	**EQ 10MG BASE/ML**	**N63080 001**	APR 30, 1991
AP		**EQ 10MG BASE/ML**	**N63112 001**	APR 30, 1991
AP		**EQ 40MG BASE/ML**	**N63111 001**	APR 30, 1991
AP	+	**EQ 40MG BASE/ML**	**N63116 001**	MAY 18, 1992
AP		**EQ 40MG BASE/ML**	**N63161 001**	MAY 29, 1991
AP	APOTHECON	**EQ 10MG BASE/ML**	**N64021 001**	MAY 31, 1994
AP		**EQ 40MG BASE/ML**	**N64021 002**	MAY 31, 1994
AP	GENSIA SICOR PHARMS	**EQ 40MG BASE/ML**	**N63100 001**	JAN 30, 1992
AP	LEDERLE	**EQ 40MG BASE/ML**	**N63117 001**	APR 26, 1991
AP		**EQ 40MG BASE/ML**	**N63118 001**	JUL 29, 1991
AP	MARSAM PHARMS LLC	**EQ 10MG BASE/ML**	**N62945 001**	AUG 09, 1989
AP		**EQ 40MG BASE/ML**	**N62945 002**	AUG 09, 1989

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ ABBOTT	EQ 80MG BASE/100ML	N63081 001	JUL 31, 1990
+	EQ 1.2MG BASE/ML	N63081 003	JUL 31, 1990
+	EQ 1.6MG BASE/ML	N63081 006	JUN 02, 1993

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD			
ASTRAZENECA	400MG	N18257 001	NOV 09, 1984

FDA data supplied by DrugPatentWatch.com

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL
TONOCARD

+	ASTRAZENECA	600MG	N18257 002	NOV 09, 1984

TOCOPHEROL ACETATE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

AB	GENEVA PHARMS	**100MG**	**N71633 001**	DEC 09, 1987
AB		**250MG**	**N70289 001**	MAR 13, 1986
AB		**500MG**	**N70290 001**	MAR 13, 1986
AB	IVAX PHARMS	**100MG**	**N18894 001**	NOV 02, 1984
AB		**250MG**	**N18894 002**	NOV 02, 1984
AB		**500MG**	**N18894 003**	NOV 02, 1984
AB	MUTUAL PHARM	**100MG**	**N71357 001**	JUL 16, 1987
AB		**250MG**	**N71358 001**	JUL 16, 1987
AB		**500MG**	**N71359 001**	JUL 16, 1987
AB	MYLAN	**250MG**	**N70259 001**	JAN 02, 1986
AB		**500MG**	**N70913 001**	MAR 17, 1986
AB	PAR PHARM	**100MG**	**N70159 001**	JAN 06, 1986
AB		**250MG**	**N70160 001**	JAN 06, 1986
AB		**500MG**	**N70161 001**	JAN 06, 1986
AB	WATSON LABS	**100MG**	**N70513 001**	JAN 09, 1986

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

AB	WATSON LABS	**250MG**	**N70514 001**	JAN 09, 1986
AB		**500MG**	**N70515 001**	JAN 09, 1986

TOLINASE

AB	PHARMACIA AND UPJOHN	**100MG**	**N15500 002**	
AB		**250MG**	**N15500 004**	
AB	+	**500MG**	**N15500 005**	

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	GENEVA PHARMS	**500MG**	**N86574 001**	
AB	IVAX PHARMS	**500MG**	**N87093 001**	
AB	LEDERLE	**500MG**	**N86926 001**	
AB	MYLAN	**500MG**	**N86445 001**	
AB	+ WATSON LABS	**500MG**	**N86109 001**	
AB		**500MG**	**N87318 001**	

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION
ORINASE DIAGNOSTIC

+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N12095 001	

TOLCAPONE

TABLET; ORAL
TASMAR

	ROCHE	100MG	N20697 001	JAN 29, 1998
+		200MG	N20697 002	JAN 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL
TOLECTIN DS

AB	+ ORTHO MCNEIL PHARM	**EQ 400MG BASE**	**N18084 001**	

FDA data supplied by DrugPatentWatch.com

TOLMETIN SODIUM

CAPSULE; ORAL

	TOLMETIN SODIUM			
AB	IVAX PHARMS	EQ 400MG BASE	N73392 001	JAN 24, 1992
AB	MUTUAL PHARM	EQ 400MG BASE	N73311 001	NOV 27, 1991
AB	MYLAN	EQ 400MG BASE	N73393 001	MAY 27, 1993
AB	PUREPAC PHARM	EQ 400MG BASE	N73308 001	JAN 24, 1992
AB	TEVA	EQ 400MG BASE	N73290 001	NOV 27, 1991
AB		EQ 400MG BASE	N73519 001	MAY 29, 1992

TABLET; ORAL

	TOLECTIN			
AB	ORTHO MCNEIL PHARM	EQ 200MG BASE	N17628 001	
	TOLECTIN 600			
AB	+ ORTHO MCNEIL PHARM	EQ 600MG BASE	N17628 002	MAR 08, 1989
	TOLMETIN SODIUM			
AB	GENEVA PHARMS	EQ 200MG BASE	N73588 001	JUL 31, 1992
AB		EQ 600MG BASE	N74002 001	SEP 27, 1993
AB	IVAX PHARMS	EQ 600MG BASE	N74399 001	MAR 28, 1996
AB	MUTUAL PHARM	EQ 200MG BASE	N73310 001	NOV 27, 1991
AB	MYLAN	EQ 600MG BASE	N74473 001	AUG 30, 1994
AB	PUREPAC PHARM	EQ 600MG BASE	N73527 001	JUN 30, 1992

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	DETROL LA			
+	PHARMACIA AND UPJOHN	2MG	N21228 001	DEC 22, 2000
+		4MG	N21228 002	DEC 22, 2000

TABLET; ORAL

	DETROL			
	PHARMACIA AND UPJOHN	1MG	N20771 001	MAR 25, 1998

TOLTERODINE TARTRATE

TABLET; ORAL

	DETROL			
+	PHARMACIA AND UPJOHN	2MG	N20771 002	MAR 25, 1998

TOPIRAMATE

CAPSULE; ORAL

	TOPAMAX SPRINKLE			
	ORTHO MCNEIL	15MG	N20844 001	OCT 26, 1998
+		25MG	N20844 002	OCT 26, 1998

TABLET; ORAL

	TOPAMAX			
+	ORTHO MCNEIL PHARM	25MG	N20505 004	DEC 24, 1996
		100MG	N20505 001	DEC 24, 1996
		200MG	N20505 002	DEC 24, 1996

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

	HYCAMTIN			
+	GLAXOSMITHKLINE	EQ 4MG BASE/VIAL	N20671 001	MAY 28, 1996

TOREMIFENE CITRATE

TABLET; ORAL

	FARESTON			
+	ORION	EQ 60MG BASE	N20497 001	MAY 29, 1997

TORSEMIDE

INJECTABLE; INJECTION

	DEMADEX			
+	ROCHE	10MG/ML	N20137 002	AUG 23, 1993

FDA data supplied by DrugPatentWatch.com

TORSEMIDE

TABLET; ORAL

	DEMADEX			
AB	ROCHE	5MG	**N20136 001**	AUG 23, 1993
AB		10MG	**N20136 002**	AUG 23, 1993
AB	+	20MG	**N20136 003**	AUG 23, 1993
AB		100MG	**N20136 004**	AUG 23, 1993
	TORSEMIDE			
AB	TEVA	5MG	**N76110 001**	MAY 14, 2002
AB		10MG	**N76110 002**	MAY 14, 2002
AB		20MG	**N76110 003**	MAY 14, 2002
AB		100MG	**N76110 004**	MAY 14, 2002

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

	TRAMADOL HCL			
AB	ABLE	50MG*	**N75963 001**	JUL 03, 2002
AB	ALPHAPHARM	50MG*	**N75980 001**	NOV 21, 2002
AB	ASTA	50MG*	**N75974 001**	JUL 12, 2002
AB	CARACO	50MG*	**N75964 001**	JUN 19, 2002
AB	COREPHARMA	50MG*	**N76003 001**	JUN 20, 2002
AB	EON	50MG*	**N75968 001**	JUN 25, 2002
AB	MALLINCKRODT	50MG*	**N75983 001**	JUN 25, 2002
AB	MUTUAL PHARM	50MG*	**N76100 001**	JUN 20, 2002
AB	MYLAN	50MG*	**N75986 001**	JUN 21, 2002
AB	PUREPAC PHARM	50MG*	**N75960 001**	JUN 19, 2002
AB	SIDMAK LABS	50MG*	**N75982 001**	JUL 01, 2002
AB	TEVA	50MG*	**N75977 001**	JUN 19, 2002
AB	TORPHARM	50MG*	**N75981 001**	JUL 10, 2002
AB	WATSON LABS	50MG*	**N75962 001**	JUN 24, 2002
	ULTRAM			
AB	+ ORTHO MCNEIL PHARM	50MG	**N20281 002**	MAR 03, 1995

TRAMADOL HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TRANDOLAPRIL

TABLET; ORAL

	MAVIK		
	ABBOTT	1MG	N20528 001 APR 26, 1996
		2MG	N20528 002 APR 26, 1996
	+	4MG	N20528 003 APR 26, 1996

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	TARKA		
+	ABBOTT	1MG;240MG	N20591 003 OCT 22, 1996
+		2MG;180MG	N20591 001 OCT 22, 1996
+		2MG;240MG	N20591 004 OCT 22, 1996
+		4MG;240MG	N20591 002 OCT 22, 1996

* SEE SECTION 1.8 DESCRIPTION OF SPECIAL SITUATIONS

FDA data supplied by DrugPatentWatch.com

TRANEXAMIC ACID

INJECTABLE; INJECTION
CYKLOKAPRON
+ PHARMACIA AND UPJOHN 100MG/ML N19281 001 DEC 30, 1986

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE
+ GLAXOSMITHKLINE EQ 10MG BASE N12342 003 AUG 16, 1985

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVATAN
+ ALCON UNIVERSAL 0.004% N21257 001 MAR 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL

AB	APOTHECON	50MG	**N18207 001**
AB		100MG	**N18207 002**
AB		150MG	**N18207 003** MAR 25, 1985
AB +		300MG	**N18207 004** NOV 07, 1988

TRAZODONE HCL

AB	BARR	50MG	**N71258 001** MAR 25, 1987
AB		100MG	**N71196 001** MAR 25, 1987
AB		150MG	**N71196 002** APR 26, 1999
AB		300MG	**N71196 003** APR 26, 1999
AB	GENEVA PHARMS	50MG	**N72484 001** APR 30, 1990
AB		100MG	**N72483 001** APR 30, 1990
AB	MUTUAL PHARM	50MG	**N73136 001** MAR 24, 1993

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL

AB	MUTUAL PHARM	100MG	**N73137 001** MAR 24, 1993
AB		150MG	**N73138 001** DEC 22, 1995
AB	MYLAN	50MG	**N71405 001** FEB 27, 1991
AB		100MG	**N71406 001** FEB 27, 1991
AB	PUREPAC PHARM	50MG	**N71636 001** APR 18, 1988
AB		100MG	**N71514 001** APR 18, 1988
AB	SIDMAK LABS NJ	50MG	**N71523 001** DEC 11, 1987
AB		100MG	**N71524 001** DEC 11, 1987
AB		150MG	**N71525 001** MAR 09, 1988
AB	TEVA	50MG	**N72192 001** FEB 02, 1989
AB		100MG	**N72193 001** FEB 02, 1989
AB		150MG	**N74357 001** APR 30, 1997
AB	WATSON LABS	50MG	**N70857 001** OCT 10, 1986
AB		100MG	**N70858 001** OCT 10, 1986

TREPROSTINIL SODIUM

INJECTABLE; SUBCUTANEOUS
REMODULIN

	UNITED THERAP	1MG/ML	N21272 001 MAY 21, 2002
		2.5MG/ML	N21272 002 MAY 21, 2002
		5MG/ML	N21272 003 MAY 21, 2002
+		10MG/ML	N21272 004 MAY 21, 2002

FDA data supplied by DrugPatentWatch.com

TRETINOIN

CAPSULE; ORAL

	VESANOID			
	+ ROCHE	10MG	N20438 001	
			NOV 22, 1995	

CREAM; TOPICAL

	AVITA			
AB	BERTEK PHARMS	**0.025%**	**N20404 003**	
			JAN 14, 1997	
	RENOVA			
	+ JOHNSON AND JOHNSON	0.02%	N21108 001	
			AUG 31, 2000	
	RETIN-A			
AB	+ JOHNSON AND JOHNSON	**0.025%**	**N19049 001**	
			SEP 16, 1988	
AB	+	**0.05%**	**N17522 001**	
AB	+	**0.1%**	**N17340 001**	
	TRETINOIN			
AB	SPEAR PHARMS	**0.025%**	**N75264 001**	
			DEC 24, 1998	
AB		**0.05%**	**N75265 001**	
			DEC 24, 1998	
AB		**0.1%**	**N75213 001**	
			DEC 24, 1998	

CREAM, AUGMENTED; TOPICAL

	RENOVA			
	+ JOHNSON AND JOHNSON	0.05%	N19963 001	
			DEC 29, 1995	

GEL; TOPICAL

	AVITA			
BT	BERTEK PHARMS	0.025%	N20400 001	
			JAN 29, 1998	
	RETIN-A			
AB	+ JOHNSON AND JOHNSON	**0.01%**	**N17955 001**	
AB	+	**0.025%**	**N17579 002**	
	RETIN-A MICRO			
	+ JOHNSON AND JOHNSON	0.04%	N20475 002	
			MAY 10, 2002	
	+	0.1%	N20475 001	
			FEB 07, 1997	
	TRETINOIN			
AB	SPEAR PHARMS	**0.01%**	**N75589 001**	
			JUN 11, 2002	
AB		**0.025%**	**N75529 001**	
			FEB 22, 2000	

TRETINOIN

SOLUTION; TOPICAL

	RETIN-A			
AT	+ JOHNSON AND JOHNSON	**0.05%**	**N16921 001**	
	TRETINOIN			
AT	COPLEY PHARM	**0.05%**	**N74873 001**	
			JUN 19, 1998	
AT	MORTON GROVE	**0.05%**	**N75260 001**	
			JAN 25, 1999	

TRETINOIN; *MULTIPLE*

SEE FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

SEE MEQUINOL; TRETINOIN

TRIAMCINOLONE

TABLET; ORAL

	ARISTOCORT		
BP	FUJISAWA HLTHCARE	4MG	N11161 007
	KENACORT		
BP	BRISTOL MYERS SQUIBB	4MG	N11283 006
+		8MG	N11283 010
	TRIAMCINOLONE		
BP	WATSON LABS	4MG	N84270 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

	AZMACORT		
	+ AVENTIS	0.1MG/INH	N18117 001
			APR 23, 1982

AEROSOL, METERED; NASAL

	NASACORT		
	+ AVENTIS	0.055MG/INH	N19798 001
			JUL 11, 1991

CREAM; TOPICAL

	ARISTOCORT		
AT	FUJISAWA HLTHCARE	**0.025%**	**N83017 003**
AT		**0.1%**	**N83016 004**
AT		**0.5%**	**N83015 002**
	ARISTOCORT A		
AT	FUJISAWA HLTHCARE	**0.025%**	**N83017 004**

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	ARISTOCORT A				
AT	FUJISAWA HLTHCARE	0.025%	N88818 001		
			OCT 16, 1984		
AT		0.1%	N83016 005		
AT		0.1%	N88819 001		
			OCT 16, 1984		
AT		0.5%	N83015 003		
AT		0.5%	N88820 001		
			OCT 16, 1984		
	KENALOG				
AT	+ APOTHECON	0.025%	N11601 003		
AT	+	0.1%	N11601 006		
AT	+	0.5%	N83943 001		
	TRIACET				
AT	TEVA	0.025%	N84908 001		
AT		0.1%	N84908 002		
AT		0.5%	N84908 003		
	TRIAMCINOLONE ACETONIDE				
AT	ALPHARMA US PHARM	0.1%	N87798 001		
			JUN 04, 1982		
AT	ALTANA	0.025%	N85692 001		
AT		0.1%	N85692 003		
AT		0.5%	N85692 002		
AT	AMBIX	0.025%	N87932 001		
			MAY 09, 1983		
AT	CLAY PARK	0.025%	N86415 001		
AT		0.1%	N86414 001		
AT		0.5%	N86413 001		
AT	G AND W LABS	0.025%	N89797 001		
			MAY 31, 1991		
AT		0.1%	N89798 001		
			MAY 31, 1991		
AT	TARO	0.025%	N86277 001		
AT		0.1%	N40039 001		
			NOV 26, 1997		
AT		0.1%	N86276 001		
AT		0.5%	N86275 001		
	TRIDERM				
AT	DEL RAY LABS	0.1%	N88042 001		
			MAR 19, 1984		
	TRYMEX				
AT	SAVAGE LABS	0.025%	N88196 001		
			MAR 25, 1983		
AT		0.1%	N88197 001		
			MAR 25, 1983		

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

	KENALOG-10		
	APOTHECON	10MG/ML	N12041 001
	KENALOG-40		
+	APOTHECON	40MG/ML	N14901 001

LOTION; TOPICAL

	KENALOG		
AT	APOTHECON	0.025%	N84343 001
AT	+	0.1%	N84343 002
	TRIAMCINOLONE ACETONIDE		
AT	MORTON GROVE	0.025%	N88450 001
			APR 01, 1985
AT		0.1%	N88451 001
			APR 03, 1985
AT	TARO	0.1%	N89129 001
			AUG 14, 1986

OINTMENT; TOPICAL

	ARISTOCORT		
AT	FUJISAWA HLTHCARE	0.1%	N80750 004
	ARISTOCORT A		
AT	FUJISAWA HLTHCARE	0.1%	N80750 003
AT		0.1%	N88780 001
			OCT 01, 1984
	KENALOG		
AT	APOTHECON	0.025%	N11600 003
AT		0.1%	N11600 001
	TRIAMCINOLONE ACETONIDE		
AT	ALPHARMA US PHARM	0.1%	N87799 001
			JUN 07, 1982
AT	ALTANA	0.025%	N85691 001
AT		0.1%	N85691 003
AT		0.5%	N85691 002
AT	+ CLAY PARK	0.025%	N87356 001
AT	+	0.1%	N87357 001
AT	+	0.5%	N87385 001
AT	TARO	0.025%	N40040 001
			SEP 30, 1994
AT		0.025%	N40374 001
			JUN 05, 2001
AT		0.1%	N40037 001
			SEP 30, 1994
AT		0.1%	N87902 001
			DEC 27, 1982
AT		0.5%	N40386 001
			JUN 05, 2001

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05% N89595 001 MAR 23, 1995

TRYMEX
AT SAVAGE LABS **0.025%** **N88693 001** AUG 02, 1984
AT **0.1%** **N88691 001** AUG 02, 1984

PASTE; DENTAL
KENALOG IN ORABASE
AT + APOTHECON **0.1%** **N12097 001**
ORACORT
AT TARO **0.1%** **N70730 001** OCT 01, 1986
ORALONE
AT TARO **0.1%** **N71383 001** JUL 06, 1987

SPRAY; TOPICAL
KENALOG
+ APOTHECON 0.147MG/GM N12104 001

SPRAY, METERED; NASAL
NASACORT AQ
+ AVENTIS 0.055MG/SPRAY N20468 001 MAY 20, 1996

TRIAMCINOLONE ACETONIDE; *MULTIPLE*
SEE NYSTATIN; TRIAMCINOLONE ACETONIDE

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT
+ FUJISAWA HLTHCARE 25MG/ML N11685 003
+ 40MG/ML N12802 001

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION
ARISTOSPAN
+ FUJISAWA HLTHCARE 5MG/ML N16466 001

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION
ARISTOSPAN
+ FUJISAWA HLTHCARE 20MG/ML N16466 002

TRIAMTERENE

CAPSULE; ORAL
DYRENIUM
WELLSPRING PHARM 50MG N13174 001
+ 100MG N13174 002

TRIAMTERENE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TRIAMTERENE

TRIAZOLAM

TABLET; ORAL
HALCION
AB PHARMACIA AND UPJOHN **0.125MG** **N17892 003** APR 26, 1985
AB + **0.25MG** **N17892 001** NOV 15, 1982

TRIAZOLAM
AB ALPHAPHARM **0.125MG** **N74031 001** MAR 25, 1994
AB **0.25MG** **N74031 002** MAR 25, 1994
AB ROXANE **0.125MG** **N74224 001** JUN 01, 1994
AB **0.25MG** **N74224 002** JUN 01, 1994
AB WATSON LABS **0.125MG** **N74445 001** OCT 20, 1995
AB **0.25MG** **N74445 002** OCT 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL
METAHYDRIN
BP AVENTIS PHARMS 2MG N12594 001 JUN 16, 1988

FDA data supplied by DrugPatentWatch.com

TRICHLORMETHIAZIDE

TABLET; ORAL

	METAHYDRIN			
BP	AVENTIS PHARMS	4MG	N12594 002	JUN 16, 1988
	NAQUA			
BP	+ SCHERING	4MG	N12265 002	
	TRICHLORMETHIAZIDE			
BP	ABC HOLDING	4MG	N85568 001	
BP	PAR PHARM	2MG	N87007 001	
BP		4MG	N87005 001	

TRICHLORMETHIAZIDE; *MULTIPLE*
SEE RESERPINE; TRICHLORMETHIAZIDE

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

	SYPRINE			
	+ MERCK	250MG	N19194 001	NOV 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	STELAZINE			
AA	+ GLAXOSMITHKLINE	**EQ 10MG BASE/ML**	**N11552 006**	

INJECTABLE; INJECTION

	STELAZINE			
	+ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552 005	

TABLET; ORAL

	STELAZINE			
AB	GLAXOSMITHKLINE	**EQ 1MG BASE**	**N11552 001**	
AB		**EQ 2MG BASE**	**N11552 002**	
AB		**EQ 5MG BASE**	**N11552 003**	
AB	+	**EQ 10MG BASE**	**N11552 004**	
	TRIFLUOPERAZINE HCL			
AB	GENEVA PHARMS	**EQ 1MG BASE**	**N85785 001**	
AB		**EQ 2MG BASE**	**N85786 001**	
AB		**EQ 5MG BASE**	**N85789 001**	
AB		**EQ 10MG BASE**	**N85788 001**	
AB	GENEVA PHARMS TECH	**EQ 1MG BASE**	**N40153 001**	OCT 25, 1996

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

	TRIFLUOPERAZINE HCL			
AB	GENEVA PHARMS TECH	**EQ 2MG BASE**	**N40153 002**	OCT 25, 1996
AB		**EQ 5MG BASE**	**N40153 003**	OCT 25, 1996
AB		**EQ 10MG BASE**	**N40153 004**	OCT 25, 1996
AB	MYLAN	**EQ 1MG BASE**	**N40209 001**	JUL 07, 1997
AB		**EQ 2MG BASE**	**N40209 002**	JUL 07, 1997
AB		**EQ 5MG BASE**	**N40209 003**	JUL 07, 1997
AB		**EQ 10MG BASE**	**N40209 004**	JUL 07, 1997

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

	TRIFLURIDINE			
AT	ALCON	**1%**	**N74311 001**	OCT 06, 1995
	VIROPTIC			
AT	+ MONARCH PHARMS	**1%**	**N18299 001**	

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

	ARTANE			
AA	+ LEDERLE	**2MG/5ML**	**N06773 009**	
	TRIHEXYPHENIDYL HCL			
AA	MIKART	**2MG/5ML**	**N40251 001**	SEP 27, 1999
AA	PHARM ASSOC	**2MG/5ML**	**N40177 001**	APR 17, 1997
AA	PHARM VENTURES	**2MG/5ML**	**N89514 001**	APR 07, 1989

TABLET; ORAL

	ARTANE			
AA	+ LEDERLE	**2MG**	**N06773 005**	
AA	+	**5MG**	**N06773 003**	
	TRIHEXYPHENIDYL HCL			
AA	NYLOS	**5MG**	**N85622 001**	

FDA data supplied by DrugPatentWatch.com

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

	TRIHEXYPHENIDYL HCL			
AA	VINTAGE PHARMS	2MG	N40254 001	DEC 24, 1998
AA		5MG	N40254 002	DEC 24, 1998
AA	WATSON LAB	2MG	N40184 001	FEB 06, 1998
AA		5MG	N40184 002	FEB 06, 1998
AA	WATSON LABS	2MG	N84363 001	
AA		5MG	N84364 001	
AA	WEST WARD	2MG	N40337 002	FEB 16, 2000
AA		5MG	N40337 001	FEB 16, 2000

TRIMETHADIONE

TABLET; ORAL

	TRIDIONE		
+	ABBOTT	150MG	N05856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	TIGAN			
+	KING PHARMS	300MG	N17531 006	DEC 13, 2001

INJECTABLE; INJECTION

	TIGAN			
AP	+ KING PHARMS	100MG/ML	N17530 001	
	TRIMETHOBENZAMIDE HCL			
AP	ABBOTT	100MG/ML	N88804 001	APR 03, 1987

TRIMETHOPRIM

TABLET; ORAL

	PROLOPRIM			
AB	MONARCH PHARMS	100MG	N17943 001	
AB	+	200MG	N17943 003	JUL 14, 1982

TRIMETHOPRIM

TABLET; ORAL

	TRIMETHOPRIM			
AB	TEVA	100MG	N18679 001	JUL 30, 1982
AB		200MG	N71259 001	JUN 18, 1987
AB	WATSON LABS	100MG	N70049 001	JUN 06, 1985

TRIMETHOPRIM; *MULTIPLE*

SEE POLYMYXIN B SULFATE; TRIMETHOPRIM

SEE SULFAMETHOXAZOLE; TRIMETHOPRIM

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

	PRIMSOL			
+	ASCENT PEDS	EQ 50MG BASE/5ML	N74973 001	JAN 24, 2000

TRIMETHOPRIM SULFATE; *MULTIPLE*

SEE POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

	NEUTREXIN			
+	MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N20326 001	DEC 17, 1993
+		EQ 200MG BASE/VIAL	N20326 002	JUL 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

	SURMONTIL			
	SIDMAK LABS	EQ 25MG BASE	N16792 001	
		EQ 50MG BASE	N16792 002	
+		EQ 100MG BASE	N16792 003	SEP 15, 1982

FDA data supplied by DrugPatentWatch.com

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

	PBZ			
AA	+ NOVARTIS	**50MG**		**N05914 002**
	+	25MG		N83149 001
	TRIPELENNAMINE HCL			
AA	LANNETT	**50MG**		**N83557 001**
AA	NYLOS	**50MG**		**N85412 001**
AA	WATSON LABS	**50MG**		**N80713 001**

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

	GYNE-SULF			
AT	G AND W LABS	**3.7%;2.86%;3.42%**		**N88607 001**
				JUN 09, 1986
	SULTRIN			
AT	+ ORTHO MCNEIL PHARM	**3.7%;2.86%;3.42%**		**N05794 001**
	TRIPLE SULFA			
AT	ALPHARMA	**3.7%;2.86%;3.42%**		**N87864 001**
				SEP 01, 1982
AT	CLAY PARK	**3.7%;2.86%;3.42%**		**N87285 001**
				NOV 15, 1982
	TRYSUL			
AT	SAVAGE LABS	**3.7%;2.86%;3.42%**		**N87887 001**
				JUL 23, 1982

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

	TRELSTAR		
	+ PHARMACIA AND UPJOHN	11.25MG/VIAL	N21288 001
			JUN 29, 2001
	TRELSTAR DEPOT		
	+ PHARMACIA AND UPJOHN	EQ 3.75MG BASE/VIAL	N20715 001
			JUN 15, 2000

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

	TRIPLE SULFOID		
	+ PAL PAK	167MG;167MG;167MG	N80094 001

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

	CERUMENEX		
	+ PURDUE FREDERICK	10%	N11340 002

TROLEANDOMYCIN

CAPSULE; ORAL

	TAO		
	+ PFIZER	EQ 250MG BASE	N50336 002

TROMETHAMINE

INJECTABLE; INJECTION

	THAM		
	+ ABBOTT	3.6GM/100ML	N13025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	MYDRIACYL			
AT	+ ALCON	**0.5%**		**N84305 001**
AT	+	**1%**		**N84306 001**
	TROPICACYL			
AT	AKORN	**0.5%**		**N40314 001**
				SEP 29, 2000
AT		**1%**		**N40315 001**
				SEP 29, 2000
	TROPICAMIDE			
AT	ALCON UNIVERSAL	**1%**		**N89172 001**
				DEC 28, 1990
AT	BAUSCH AND LOMB	**0.5%**		**N40067 001**
				JUL 27, 1994
AT		**1%**		**N40064 001**
				JUL 27, 1994
AT	MIZA PHARMS USA	**0.5%**		**N87636 001**
				JUL 30, 1982

FDA data supplied by DrugPatentWatch.com

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AT	MIZA PHARMS USA	**1%**	**N87637 001**	AUG 09, 1982

TROPICAMIDE; *MULTIPLE*
SEE HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN

	PFIZER	EQ 100MG BASE	N20759 001	DEC 18, 1997
+		EQ 200MG BASE	N20759 002	DEC 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

AP	+ ABBOTT	**3MG/ML**	**N06095 001**	
AP	+ BRISTOL MYERS SQUIBB	**3MG/ML**	**N05657 001**	

TYLOXAPOL; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA

+	NOVARTIS	0.15%	N21214 001	AUG 03, 2000

UREA

INJECTABLE; INJECTION
UREAPHIL

+	ABBOTT	40GM/VIAL	N12154 001	

UREA; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; UREA

UREA, C-13

FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI

+	MERETEK	EQ 75MG /POUCHE	N20586 002	MAY 10, 2001

HELICOSOL

+	METABOLIC SOLUTIONS	125MG/VIAL	N21092 001	DEC 17, 1999

UREA, C-13; *MULTIPLE*
SEE CITRIC ACID; UREA, C-13

UREA, C-14

CAPSULE; ORAL
PYTEST

+	BALLARD MEDCL	1 uCi	N20617 001	MAY 09, 1997

PYTEST KIT

+	BALLARD MEDCL	1 uCi	N20617 002	MAY 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE

BX	+ FERRING	75 IU/VIAL	N21289 001	MAY 06, 2002

INJECTABLE; SUBCUTANEOUS
FERTINEX

BX	+ SERONO	75 IU/AMP	N19415 005	AUG 23, 1996

URSODIOL

CAPSULE; ORAL
ACTIGALL

AB	+ WATSON PHARMS	**300MG**	**N19594 002**	DEC 31, 1987

URSODIOL

AB	AMIDE PHARM	**300MG**	**N75517 001**	MAR 14, 2000

FDA data supplied by DrugPatentWatch.com

URSODIOL

CAPSULE; ORAL

	URSODIOL			
AB	COPLEY PHARM	**300MG**	**N75592 001**	MAY 25, 2000

TABLET; ORAL

	URSO			
+	AXCAN SCANDIPHARM	250MG	N20675 001	DEC 10, 1997

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

	VALTREX			
	GLAXOSMITHKLINE	EQ 500MG BASE	N20550 001	DEC 15, 1995
+		EQ 1GM BASE	N20550 002	DEC 15, 1995

VALDECOXIB

TABLET; ORAL

	BEXTRA			
	GD SEARLE LLC	10MG	N21341 002	NOV 16, 2001
+		20MG	N21341 003	NOV 16, 2001

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

	VALCYTE			
+	SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001

VALPROATE SODIUM

INJECTABLE; INJECTION

	DEPACON			
AP	+ ABBOTT	**EQ 100MG BASE/ML**	**N20593 001**	DEC 30, 1996
	VALPROATE SODIUM			
AP	BEDFORD	**EQ 100MG BASE/ML**	**N76295 001**	NOV 14, 2002

VALPROIC ACID

CAPSULE; ORAL

	DEPAKENE			
AB	+ ABBOTT	**250MG**	**N18081 001**	
	VALPROIC ACID			
AB	BANNER PHARMACAPS	**250MG**	**N73484 001**	JUN 29, 1993
AB	SCHERER RP	**250MG**	**N73229 001**	OCT 29, 1991
AB	USL PHARMA	**250MG**	**N70631 001**	JUN 11, 1987

SYRUP; ORAL

	DEPAKENE			
AA	+ ABBOTT	**250MG/5ML**	**N18082 001**	
	MYPROIC ACID			
AA	MORTON GROVE	**250MG/5ML**	**N70868 001**	JUL 01, 1986
	VALPROIC ACID			
AA	COPLEY PHARM	**250MG/5ML**	**N73178 001**	AUG 25, 1992
AA	HIGH TECH PHARMA	**250MG/5ML**	**N74060 001**	JAN 13, 1995
AA	PHARM ASSOC	**250MG/5ML**	**N75379 001**	DEC 15, 2000
AA	UDL	**250MG/5ML**	**N75782 001**	DEC 22, 2000

VALRUBICIN

SOLUTION; INTRAVESICAL

	VALSTAR PRESERVATIVE FREE			
+	ANTHRA	40MG/ML	N20892 001	SEP 25, 1998

VALSARTAN

TABLET; ORAL

	DIOVAN			
	NOVARTIS	80MG	N21283 001	JUL 18, 2001
		160MG	N21283 002	JUL 18, 2001
+		320MG	N21283 003	JUL 18, 2001

FDA data supplied by DrugPatentWatch.com

VALSARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; VALSARTAN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL
VANCOCIN HCL

	LILLY	EQ 125MG BASE	N50606 001	APR 15, 1986
+		EQ 250MG BASE	N50606 002	APR 15, 1986

FOR SOLUTION; ORAL
VANCOCIN HCL

AA	LILLY	**EQ 250MG BASE/5ML**	**N61667 002**	JUL 13, 1983
+		EQ 500MG BASE/6ML	N61667 001	

VANCOLED

AA	LEDERLE	**EQ 250MG BASE/5ML**	**N63321 002**	OCT 15, 1993

INJECTABLE; INJECTION
VANCOCIN HCL

AP	+ LILLY	**EQ 500MG BASE/VIAL**	**N60180 001**	
AP		**EQ 500MG BASE/VIAL**	**N62476 001**	MAR 15, 1984
AP		**EQ 500MG BASE/VIAL**	**N62716 001**	MAR 13, 1987
AP		**EQ 500MG BASE/VIAL**	**N62812 001**	NOV 17, 1987
AP	+	**EQ 1GM BASE/VIAL**	**N60180 002**	MAR 21, 1986
AP		**EQ 1GM BASE/VIAL**	**N62476 002**	MAR 21, 1986
AP		**EQ 1GM BASE/VIAL**	**N62716 002**	MAR 13, 1987
AP		**EQ 1GM BASE/VIAL**	**N62812 002**	NOV 17, 1987
AP	+	**EQ 10GM BASE/VIAL**	**N62812 003**	NOV 17, 1987

VANCOCIN HCL IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001	APR 29, 1993

VANCOLED

AP	+ LEDERLE	**EQ 500MG BASE/VIAL**	**N62682 001**	JUL 22, 1986
AP	+	**EQ 1GM BASE/VIAL**	**N62682 002**	MAR 30, 1988

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOLED

AP	+ LEDERLE	**EQ 5GM BASE/VIAL**	**N62682 004**	MAY 11, 1988
AP	+	**EQ 10GM BASE/VIAL**	**N62682 005**	MAY 11, 1988
+		EQ 2GM BASE/VIAL	N62682 003	MAY 11, 1988

VANCOMYCIN HCL

AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N62912 001**	AUG 04, 1988
AP		**EQ 1GM BASE/VIAL**	**N62933 001**	OCT 29, 1992
AP		**EQ 5GM BASE/VIAL**	**N63076 001**	DEC 21, 1990
AP		**EQ 500MG BASE/VIAL**	**N62911 001**	AUG 04, 1988
AP		**EQ 500MG BASE/VIAL**	**N62931 001**	OCT 29, 1992
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N62663 001**	MAR 17, 1987
AP		**EQ 1GM BASE/VIAL**	**N62663 002**	JUL 31, 1987
AP		**EQ 5GM BASE/VIAL**	**N62663 003**	JUN 03, 1988
AP		**EQ 10GM BASE/VIAL**	**N62663 004**	NOV 28, 1997

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON

AP	+ ORGANON	**10MG/VIAL**	**N18776 002**	APR 30, 1984

VECURONIUM BROMIDE

AP	ABBOTT	**10MG/VIAL**	**N75164 001**	OCT 21, 1999
AP		**20MG/VIAL**	**N75164 002**	OCT 21, 1999
+		4MG/VIAL	N75558 001	SEP 11, 2001
AP	BEDFORD	**10MG/VIAL**	**N75549 001**	JUN 13, 2000
AP		**20MG/VIAL**	**N75549 002**	JUN 13, 2000

FDA data supplied by DrugPatentWatch.com

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE			
AP	ESI LEDERLE	**10MG/VIAL**	**N75218 001**	AUG 23, 1999
AP		**20MG/VIAL**	**N75218 002**	AUG 23, 1999
AP	GENSIA	**10MG/VIAL**	**N74688 001**	AUG 25, 1999
AP		**20MG/VIAL**	**N74688 002**	AUG 25, 1999
AP	STERIS	**10MG/VIAL**	**N74334 001**	AUG 31, 1995
AP		**20MG/VIAL**	**N74334 002**	AUG 31, 1995

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	EFFEXOR XR			
	WYETH AYERST	EQ 37.5MG BASE	N20699 001	OCT 20, 1997
+		EQ 75MG BASE	N20699 002	OCT 20, 1997
		EQ 150MG BASE	N20699 004	OCT 20, 1997

TABLET; ORAL

	EFFEXOR			
+	WYETH AYERST	EQ 25MG BASE	N20151 002	DEC 28, 1993
		EQ 37.5MG BASE	N20151 006	DEC 28, 1993
		EQ 50MG BASE	N20151 003	DEC 28, 1993
		EQ 75MG BASE	N20151 004	DEC 28, 1993
+		EQ 100MG BASE	N20151 005	DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	MYLAN	**120MG**	**N75138 001**	APR 20, 1999

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	MYLAN	**180MG**	**N75138 002**	APR 20, 1999
AB		**240MG**	**N75138 003**	APR 20, 1999
	VERELAN			
AB	+ ELAN DRUG	**120MG**	**N19614 001**	MAY 29, 1990
AB	+	**180MG**	**N19614 003**	JAN 09, 1992
AB	+	**240MG**	**N19614 002**	MAY 29, 1990
	+	360MG	N19614 004	MAY 10, 1996
	VERELAN PM			
	+ ELAN PHARM	100MG	N20943 001	NOV 25, 1998
	+	200MG	N20943 002	NOV 25, 1998
	+	300MG	N20943 003	NOV 25, 1998

INJECTABLE; INJECTION

	ISOPTIN			
AP	+ ABBOTT	**2.5MG/ML**	**N18485 001**	
	VERAPAMIL HCL			
AP	ABBOTT	**2.5MG/ML**	**N70577 001**	FEB 02, 1987
AP		**2.5MG/ML**	**N70737 001**	MAY 06, 1987
AP		**2.5MG/ML**	**N70738 001**	MAY 06, 1987
AP		**2.5MG/ML**	**N70739 001**	MAY 06, 1987
AP		**2.5MG/ML**	**N70740 001**	MAY 06, 1987
AP		**2.5MG/ML**	**N75136 001**	OCT 20, 1998
AP	BEDFORD	**2.5MG/ML**	**N72888 001**	JUL 28, 1995
AP	INTL MEDICATION	**2.5MG/ML**	**N70451 001**	DEC 16, 1985
AP	LUITPOLD	**2.5MG/ML**	**N70225 001**	NOV 12, 1985
AP		**2.5MG/ML**	**N70617 001**	NOV 12, 1985

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

CALAN

AB	GD SEARLE LLC	40MG	N18817 003	FEB 23, 1988
AB		80MG	N18817 001	SEP 10, 1984
AB		120MG	N18817 002	SEP 10, 1984

ISOPTIN

AB	ABBOTT	40MG	N18593 003	NOV 23, 1987
AB		80MG	N18593 001	MAR 08, 1982
AB +		120MG	N18593 002	MAR 08, 1982

VERAPAMIL HCL

AB	GENEVA PHARMS	40MG	N73168 001	JUL 31, 1992
AB		80MG	N71423 001	MAY 24, 1988
AB		120MG	N71424 001	MAY 25, 1988
AB	LEDERLE	80MG	N71880 001	APR 05, 1988
AB		120MG	N71881 001	APR 05, 1988
AB	MUTUAL PHARM	80MG	N71488 001	JAN 13, 1988
AB		120MG	N71489 001	JAN 13, 1988
AB	MYLAN	80MG	N71482 001	FEB 15, 1989
AB		120MG	N71483 001	FEB 15, 1989
AB	PUREPAC PHARM	80MG	N71019 001	SEP 24, 1986
AB		120MG	N70468 001	SEP 24, 1986
AB	SIDMAK LABS NJ	40MG	N72751 001	FEB 23, 1996
AB		80MG	N72124 001	JAN 26, 1989
AB		120MG	N72125 001	JAN 26, 1989
AB	WATSON LABS	40MG	N72923 001	JUN 29, 1993

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

AB	WATSON LABS	40MG	N72924 001	JUN 29, 1993
AB		80MG	N70855 001	SEP 24, 1986
AB		80MG	N70995 001	OCT 01, 1986
AB		80MG	N71366 001	OCT 01, 1986
AB		120MG	N70856 001	SEP 24, 1986
AB		120MG	N70994 001	OCT 01, 1986
AB		120MG	N71367 001	OCT 01, 1986

TABLET, EXTENDED RELEASE; ORAL

COVERA-HS

BC +	GD SEARLE LLC	180MG	N20552 001	FEB 26, 1996
BC +		240MG	N20552 002	FEB 26, 1996

ISOPTIN SR

AB +	ABBOTT	120MG	N19152 003	MAR 06, 1991
AB +		180MG	N19152 002	DEC 15, 1989
AB +		240MG	N19152 001	DEC 16, 1986

VERAPAMIL HCL

AB	IVAX PHARMS	120MG	N73568 002	OCT 10, 1997
AB		180MG	N74330 001	JAN 31, 1994
AB		240MG	N73568 001	JUL 31, 1992
AB	MYLAN	120MG	N74587 002	FEB 21, 1997
AB		180MG	N74587 003	SEP 09, 1997
AB		240MG	N74587 001	MAR 23, 1996
AB	SIDMAK LABS NJ	240MG	N72922 001	MAR 01, 1996

VERAPAMIL HYDROCHLORIDE; *MULTIPLE*
SEE TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

VERTEPORFIN

INJECTABLE; INJECTION
VISUDYNE
+ QLT — 15MG/VIAL — N21119 001 — APR 12, 2000

VIDARABINE

OINTMENT; OPHTHALMIC
VIRA-A
+ PARKEDALE — 3% — N50486 001

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE
+ AM PHARM PARTNERS — 1MG/ML — N89515 001 — APR 29, 1987
AP + BEDFORD — **10MG/VIAL** — **N89395 001** — APR 09, 1987
AP FAULDING — **10MG/VIAL** — **N89565 001** — AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION
ONCOVIN
AP + LILLY — **1MG/ML** — **N14103 003** — MAR 07, 1984

VINCASAR PFS
AP PHARMACIA AND UPJOHN — **1MG/ML** — **N71426 001** — JUL 17, 1987

VINCRISTINE SULFATE
+ AM PHARM PARTNERS — 1MG/ML — N76296 001 — DEC 20, 2002

VINCRISTINE SULFATE PFS
AP FAULDING — **1MG/ML** — **N71484 001** — APR 19, 1988
AP GENSIA SICOR PHARMS — **1MG/ML** — **N75493 001** — SEP 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION
NAVELBINE
+ GLAXOSMITHKLINE — EQ 10MG BASE/ML — N20388 001 — DEC 23, 1994

VITAMIN A

CAPSULE; ORAL
VITAMIN A
+ WEST WARD — 50,000 USP UNITS — N80985 001

VITAMIN A; *MULTIPLE*
SEE ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A
AA MK LABS — **EQ 50,000 UNITS BASE** — **N83457 001**
EQ 25,000 UNITS BASE — N83457 002

VITAMIN A PALMITATE
AA ARCUM — **EQ 50,000 UNITS BASE** — **N83311 001**
AA **EQ 50,000 UNITS BASE** — **N83321 001**

INJECTABLE; INJECTION
AQUASOL A
+ AAIPHARMA — EQ 50,000 UNITS BASE/ML — N06823 001

FDA data supplied by DrugPatentWatch.com

VITAMIN A PALMITATE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

VITAMIN E; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN K; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

VORICONAZOLE

INJECTABLE; IV (INFUSION)
VFEND
+ PFIZER 200MG/VIAL N21267 001 MAY 24, 2002

TABLET; ORAL
VFEND
PFIZER 50MG N21266 001 MAY 24, 2002
+ 200MG N21266 002 MAY 24, 2002

WARFARIN SODIUM

INJECTABLE; INJECTION
COUMADIN
+ BRISTOL MYERS SQUIBB 5MG/VIAL N09218 024 FEB 07, 1995

WARFARIN SODIUM

TABLET; ORAL
COUMADIN

AB	BRISTOL MYERS SQUIBB	1MG		**N09218 022** MAR 01, 1990
AB		2MG		**N09218 013**
AB		2.5MG		**N09218 018**
AB		3MG		**N09218 025** NOV 18, 1996
AB		4MG		**N09218 023** AUG 24, 1993
AB		5MG		**N09218 007**
AB		6MG		**N09218 026** NOV 18, 1996
AB		7.5MG		**N09218 016**
AB	+	10MG		**N09218 005**

WARFARIN SODIUM

AB	BARR	1MG		**N40145 001** MAR 26, 1997
AB		2MG		**N40145 002** MAR 26, 1997
AB		2.5MG		**N40145 003** MAR 26, 1997
AB		3MG		**N40145 008** NOV 05, 1998
AB		4MG		**N40145 004** MAR 26, 1997
AB		5MG		**N40145 005** MAR 26, 1997
AB		6MG		**N40145 009** NOV 05, 1998
AB		7.5MG		**N40145 006** MAR 26, 1997
AB		10MG		**N40145 007** MAR 26, 1997
AB	GENEVA PHARMS TECH	1MG		**N40196 001** SEP 30, 1997
AB		2MG		**N40196 002** SEP 30, 1997
AB		2.5MG		**N40196 003** SEP 30, 1997
AB		3MG		**N40196 008** JUL 26, 2000
AB		4MG		**N40196 004** SEP 30, 1997
AB		5MG		**N40196 005** SEP 30, 1997

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	GENEVA PHARMS TECH	6MG	N40196 009	JUL 26, 2000
AB		7.5MG	N40196 006	SEP 30, 1997
AB		10MG	N40196 007	SEP 30, 1997
AB	TARO	1MG	N40301 002	JUL 15, 1999
AB		2MG	N40301 003	JUL 15, 1999
AB		2.5MG	N40301 004	JUL 15, 1999
AB		3MG	N40301 005	JUL 15, 1999
AB		4MG	N40301 006	JUL 15, 1999
AB		5MG	N40301 007	JUL 15, 1999
AB		6MG	N40301 008	JUL 15, 1999
AB		7.5MG	N40301 009	JUL 15, 1999
AB		10MG	N40301 001	JUL 15, 1999

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18802 001	OCT 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18233 001	
AP		100%	N18801 001	OCT 27, 1982
AP		100%	N19869 001	DEC 26, 1989
AP	AM PHARM PARTNERS	100%	N88400 001	JAN 16, 1984
AP	B BRAUN	100%	N19077 001	MAR 02, 1984
AP		100%	N19633 001	FEB 29, 1988

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	100%	N18632 001	JUN 30, 1982
AP		100%	N18632 002	APR 19, 1988

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER

AT	BAXTER HLTHCARE	100%	N17428 001

STERILE WATER IN PLASTIC CONTAINER

AT	ABBOTT	100%	N17513 001
AT		100%	N18313 001
AT	B BRAUN	100%	N16734 001
AT	BAXTER HLTHCARE	100%	N17866 001

XENON, XE-133

GAS; INHALATION

XENON XE 133

AA	BRISTOL MYERS SQUIBB	10mCi/VIAL	N17284 001	
AA		20mCi/VIAL	N17284 002	
	GEN ELECTRIC	1-2.5 CI/AMP	N17550 003	
		5 CI/CYLINDER	N17550 001	
AA	MALLINCKRODT	10mCi/VIAL	N18327 001	MAR 09, 1982
AA		20mCi/VIAL	N18327 002	MAR 09, 1982

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

	ASTRAZENECA	10MG	N20547 003	SEP 17, 1999
+		20MG	N20547 001	SEP 26, 1996

FDA data supplied by DrugPatentWatch.com

ZALCITABINE

TABLET; ORAL
HIVID
ROCHE 0.375MG N20199 001 JUN 19, 1992
\+ 0.75MG N20199 002 JUN 19, 1992

ZALEPLON

CAPSULE; ORAL
SONATA
WYETH AYERST 5MG N20859 001 AUG 13, 1999
\+ 10MG N20859 002 AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION
RELENZA
\+ GLAXOSMITHKLINE 5MG N21036 001 JUL 26, 1999

ZIDOVUDINE

CAPSULE; ORAL
RETROVIR
\+ GLAXOSMITHKLINE 100MG N19655 001 MAR 19, 1987

INJECTABLE; INJECTION
RETROVIR
\+ GLAXOSMITHKLINE 10MG/ML N19951 001 FEB 02, 1990

SYRUP; ORAL
RETROVIR
GLAXOSMITHKLINE 50MG/5ML N19910 001 SEP 28, 1989

TABLET; ORAL
RETROVIR
\+ GLAXOSMITHKLINE 300MG N20518 002 OCT 04, 1996

ZIDOVUDINE; *MULTIPLE*
SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
SEE LAMIVUDINE; ZIDOVUDINE

ZILEUTON

TABLET; ORAL
ZYFLO
\+ ABBOTT 600MG N20471 003 DEC 09, 1996

ZINC ACETATE

CAPSULE; ORAL
GALZIN
TEVA EQ 25MG ZINC N20458 001 JAN 28, 1997
\+ EQ 50MG ZINC N20458 002 JAN 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION
ZINC CHLORIDE IN PLASTIC CONTAINER
\+ ABBOTT EQ 1MG ZINC/ML N18959 001 JUN 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
GEODON
PFIZER 20MG N20825 001 FEB 05, 2001
40MG N20825 002 FEB 05, 2001
60MG N20825 003 FEB 05, 2001
\+ 80MG N20825 004 FEB 05, 2001

FDA data supplied by DrugPatentWatch.com

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON			
+ PFIZER	EQ 20MG BASE/ML	N20919 001	JUN 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA			
+ NOVARTIS	EQ 4MG BASE/VIAL	N21223 001	AUG 20, 2001

ZOLMITRIPTAN

TABLET; ORAL

ZOMIG			
IPR	2.5MG	N20768 001	NOV 25, 1997
+	5MG	N20768 002	NOV 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT			
ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001
+	5MG	N21231 002	SEP 17, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN			
LOREX	5MG	N19908 001	DEC 16, 1992
+	10MG	N19908 002	DEC 16, 1992

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN			
+ DAINIPPON	100MG	N20789 001	MAR 27, 2000

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN			
G AND W LABS	120MG	N18060 001	
	120MG	N72218 001	MAR 27, 1992
	325MG	N18060 003	DEC 18, 1986
	325MG	N72344 001	MAR 27, 1992
	650MG	N18060 002	
	650MG	N72237 001	MAR 27, 1992
ACETAMINOPHEN			
ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983
	325MG	N18337 002	
+	650MG	N18337 001	
SUPPOSITORIA	120MG	N70607 001	APR 06, 1987
	650MG	N70608 001	DEC 01, 1986
INFANTS' FEVERALL			
ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992
NEOPAP			
POLYMEDICA	120MG	N16401 001	

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN			
COREPHARMA	650MG	N76200 001	MAR 19, 2002
PERRIGO	650MG	N75077 001	FEB 25, 2000
TYLENOL			
+ MCNEIL CONS SPECLT	650MG	N19872 001	JUN 08, 1994

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE			
PERRIGO	250MG;250MG;65MG	N75794 001	NOV 26, 2001
EXCEDRIN (MIGRAINE)			
+ BRISTOL MYERS	250MG;250MG;65MG	N20802 001	JAN 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE			
+ NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS			
+ SCHERING PLOUGH	500MG;3MG;60MG	N19453 001	MAY 22, 1987

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD			
+ 3M	61%;1%	N21074 001	JUN 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT			
GUARDIAN DRUG	80MG;20MG	N71793 001	SEP 04, 1987
FOAMICON			
GENEVA PHARMS TECH	80MG;20MG	N72687 001	JUN 28, 1989
GAVISCON			
AVENTIS PHARMS	80MG;20MG	N18685 001	DEC 09, 1983
+	160MG;40MG	N18685 002	DEC 09, 1983

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A			
+ NOVARTIS	0.5%;0.05%	N18746 002	JUL 11, 1994

FDA data supplied by DrugPatentWatch.com

ASPIRIN

TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
+ BAYER 500MG N21317 001
OCT 18, 2001

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

LOTION; TOPICAL
SHADE UVAGUARD
+ SCHERING PLOUGH 3%;7.5%;3% N20045 001
DEC 07, 1992

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
+ NASKA 500 UNITS/GM N62857 001
NOV 13, 1987

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
+ NASKA 400 UNITS/GM;EQ 3.5MG BASE/GM;
5,000 UNITS/GM N62833 001
NOV 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
BACITRACIN ZINC-POLYMYXIN B SULFATE
+ NASKA 500 UNITS/GM;
10,000 UNITS/GM N62849 001
NOV 13, 1987

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK
+ ENVIRODERM 5% N20532 001
AUG 26, 1996

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIMETAPP
+ WYETH CONS 2MG/5ML;12.5MG/5ML N13087 003
MAR 29, 1984

TABLET, EXTENDED RELEASE; ORAL
DIMETAPP
+ WYETH CONS 12MG;75MG N12436 003
MAY 14, 1985

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE
+ ALZA 16MG;240MG N19672 001
MAR 29, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
LOTRIMIN ULTRA
+ SCHERING PLOUGH 1% N21307 001
DEC 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT 3
+ SYNTEX (USA) INC LLC 2% N20421 001
DEC 21, 1995

CAFFEINE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

FDA data supplied by DrugPatentWatch.com

CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE			
+ MERCK	800MG;10MG;165MG	N20958 001	OCT 16, 2000

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED; TOPICAL

EXIDINE			
+ XTTRIUM	4%	N19127 001	DEC 24, 1984

SOLUTION; TOPICAL

BRIAN CARE			
SOAPCO	4%	N71419 001	DEC 17, 1987
CHG SCRUB			
ECOLAB	4%	N19258 002	JUL 22, 1986
CHLORAPREP ONE-STEP SEPP			
+ BECKLOFF	2%	N21555 001	OCT 07, 2002
CIDA-STAT			
ECOLAB	2%	N19258 001	JUL 22, 1986
DYNA-HEX			
XTTRIUM	0.75%	N20111 001	SEP 11, 1997
EXIDINE			
+ XTTRIUM	2%	N19422 001	DEC 17, 1985
	4%	N19125 001	DEC 24, 1984
HIBICLENS			
+ SSL INTL	4%	N17768 001	
HIBISTAT			
+ SSL INTL	0.5%	N18300 001	
MICRODERM			
J AND J	4%	N72255 001	APR 15, 1991
PREVACARE R			
J AND J	0.5%	N72292 001	JAN 28, 1992
STERI-STAT			
MATRIX MEDCL	4%	N70104 001	JUL 24, 1986

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

BIOSCRUB			
GRIFFEN	4%	N19822 001	MAR 31, 1989
CHLORHEXIDINE GLUCONATE			
DESERET	4%	N72525 001	OCT 24, 1989
KENDALL IL	4%	N19490 001	MAR 27, 1987
HIBICLENS			
+ SSL INTL	4%	N18423 001	
MICRODERM			
J AND J	4%	N72295 001	FEB 28, 1991
PHARMASEAL SCRUB CARE			
PHARMASEAL	4%	N19793 001	DEC 02, 1988

CHLORHEXIDINE GLUCONATE; *MULTIPLE*

SEE ALCOHOL; CHLORHEXIDINE GLUCONATE

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP			
+ MEDI FLEX HOSP	2%;70%	N20832 001	JUL 14, 2000

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE			
+ GENEVA PHARMS	12MG	N70797 001	AUG 12, 1988

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON			
+ SCHERING PLOUGH	8MG	N07638 001	
+	12MG	N07638 002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE			
ALZA	16MG	N19746 002	NOV 18, 1994

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY SINUS			
+ WYETH CONS	2MG;200MG;30MG	N21441 001	DEC 19, 2002

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONTAC			
+ NOVARTIS	12MG;75MG	N19613 001	JUN 13, 1986
DEMAZIN			
+ SCHERING PLOUGH	4MG;25MG	N18556 001	MAY 14, 1984

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
+ CENT PHARMS	8MG;120MG	N19428 001	AUG 02, 1988

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON			
+ SCHERING PLOUGH	8MG;120MG	N18397 001	

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
IVAX PHARMS	200MG	N75345 001	JUN 16, 1999
LEINER	200MG	N74961 001	JUN 19, 1998
LEK PHARM	100MG	N75122 001	JUN 19, 1998
	200MG	N75122 002	JUN 19, 1998
PERRIGO	200MG	N75285 001	OCT 29, 1998

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
PHARM FORM	200MG	N74963 001	JUN 19, 1998
TORPHARM	100MG	N74948 001	JUN 19, 1998
	200MG	N74948 002	JUL 26, 2002
WATSON LABS	200MG	N75425 001	JUL 29, 1999
TAGAMET HB			
+ GLAXOSMITHKLINE	200MG	N20238 002	AUG 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE			
GENEVA PHARMS	1.34MG	N73458 001	OCT 31, 1993
PERRIGO	1.34MG	N74512 001	NOV 22, 1995
TEVA	1.34MG	N73282 002	DEC 03, 1992
TAVIST-1			
+ NOVARTIS	1.34MG	N20925 001	AUG 21, 1992

CLEMASTINE FUMARATE; *MULTIPLE*

SEE ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE			
ALPHARMA US PHARM	1%	N74165 001	JUL 16, 1993
TARO	1%	N72641 001	DEC 04, 1995
GYNE-LOTRIMIN			
+ SCHERING PLOUGH	1%	N18052 002	NOV 30, 1990

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE

CREAM; VAGINAL

GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	2%	N20574 001	NOV 24, 1998
MYCELEX-7			
BAYER	1%	N18230 002	DEC 26, 1991
TRIVAGIZOLE 3			
TARO	2%	N21143 001	APR 12, 2000

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK			
+ SCHERING PLOUGH	1%,200MG	N20526 002	JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK			
+ SCHERING PLOUGH	1%,100MG	N20289 002	APR 26, 1993
MYCELEX-7 COMBINATION PACK			
BAYER	1%,100MG	N20389 002	JUN 23, 1994

TABLET; VAGINAL

GYNE-LOTRIMIN			
+ SCHERING PLOUGH	100MG	N17717 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	200MG	N20525 001	JUL 29, 1996
GYNIX			
COPLEY PHARM	100MG	N73249 001	FEB 13, 1998
MYCELEX-7			
BAYER	100MG	N18182 002	DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM			
ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001
BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001
PERRIGO	5.2MG/SPRAY	N75427 001	DEC 12, 2001

CROMOLYN SODIUM

SPRAY, METERED; NASAL

NASALCROM			
+ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463 001	JAN 03, 1997

DEXBROMPHENIRAMINE MALEATE; *MULTIPLE*

SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

BROMPHERIL			
COPLEY PHARM	6MG;120MG	N89116 001	JAN 22, 1987
DISOPHROL			
SCHERING PLOUGH	6MG;120MG	N13483 004	SEP 13, 1982
DRIXORAL			
+ SCHERING PLOUGH	6MG;120MG	N13483 003	SEP 13, 1982

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM			
+ CELLTECH PHARMS	EQ 30MG HBR/5ML	N18658 001	OCT 08, 1982

DOCOSANOL

CREAM; TOPICAL

ABREVA			
+ GLAXOSMITHKLINE	10%	N20941 001	JUL 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE			
COPLEY PHARM	25MG	N88900 002	FEB 12, 1988

FDA data supplied by DrugPatentWatch.com

DOXYLAMINE SUCCINATE

TABLET; ORAL
DOXYLAMINE SUCCINATE
PERRIGO 25MG N40167 001 SEP 18, 1996

UNISOM
+ PFIZER 25MG N18066 001

EPINEPHRINE

AEROSOL, METERED; INHALATION
BRONKAID MIST
+ STERLING 0.25MG/INH N16803 001
EPINEPHRINE
ALPHARMA 0.2MG/INH N87907 001 MAY 23, 1984

PRIMATENE MIST
+ WHITEHALL ROBINS 0.2MG/INH N16126 001

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION
BRONITIN MIST
WHITEHALL ROBINS 0.3MG/INH N16126 002

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE
DR REDDYS LABS LTD 10MG N75758 001 AUG 17, 2001
EON 10MG N76101 001 OCT 21, 2002
GENPHARM 10MG N75674 001 DEC 21, 2001
IVAX PHARMS 10MG N75512 001 JUL 26, 2001
TEVA 10MG N75312 001 MAY 31, 2001
TORPHARM 10MG N75610 001 MAR 12, 2002
WATSON LABS 10MG N75404 001 NOV 28, 2001

PEPCID AC
+ MERCK 10MG N20325 001 APR 28, 1995

FAMOTIDINE

TABLET; ORAL
PEPCID AC
MERCK 10MG N20902 001 AUG 05, 1999

TABLET, CHEWABLE; ORAL
PEPCID AC
+ MERCK 10MG N20801 001 SEP 24, 1998

FAMOTIDINE; *MULTIPLE*
SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL
MUCINEX
+ ADAMS LABS 600MG N21282 001 JUL 12, 2002

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN
BANNER PHARMACAPS 200MG N21472 001 OCT 18, 2002
+ PHARM FORM 200MG N74782 001 JUL 06, 1998

SUSPENSION; ORAL
CHILDREN'S ADVIL
WYETH CONS 100MG/5ML N20589 001 JUN 27, 1996

CHILDREN'S ADVIL-FLAVORED
WYETH CONS 100MG/5ML N20589 002 NOV 07, 1997

CHILDREN'S IBUPROFEN
PERRIGO 100MG/5ML N74937 001 DEC 22, 1998

CHILDREN'S MOTRIN
+ MCNEIL 100MG/5ML N20516 001 JUN 16, 1995

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

ALPHARMA	100MG/5ML	N74916 001 APR 30, 1999

SUSPENSION/DROPS; ORAL
CHILDREN'S MOTRIN

+ MCNEIL	40MG/ML	N20603 001 JUN 10, 1996

IBUPROFEN

PERRIGO	40MG/ML	N75217 001 DEC 16, 1998

PEDIATRIC ADVIL

+ WYETH CONS	100MG/2.5ML	N20812 001 JAN 30, 1998

TABLET; ORAL
ADVIL

WYETH CONS	200MG	N18989 001 MAY 18, 1984

CAP-PROFEN

PERRIGO	200MG	N72097 001 DEC 08, 1987

IBU-TAB 200

ALRA	200MG	N71057 001 AUG 11, 1988

IBUPROFEN

BASF	200MG	N75661 001 DEC 12, 2001
DR REDDYS LABS INC	100MG	N76117 001 NOV 20, 2001
GENEVA PHARMS	200MG	N70733 001 SEP 19, 1986
INTERPHARM	200MG	N71333 001 FEB 17, 1987
	200MG	N72199 001 MAY 23, 1988
INVAMED	200MG	N71807 001 FEB 25, 1988
	200MG	N74525 001 DEC 15, 1995
	200MG	N74533 001 DEC 15, 1995
IVAX PHARMS	200MG	N71144 001 JAN 20, 1987
	200MG	N72901 001 DEC 19, 1991

IBUPROFEN

TABLET; ORAL
IBUPROFEN

IVAX PHARMS	200MG	N72903 001 DEC 19, 1991
LEINER	200MG	N74931 001 JUL 20, 1998
LNK	200MG	N75010 001 MAR 01, 1999
	200MG	N75139 001 MAR 01, 1999
MCNEIL	200MG	N73019 001 MAR 30, 1994
MUTUAL PHARM	200MG	N71229 001 APR 01, 1987
	200MG	N72249 001 JAN 10, 1989
MYLAN	200MG	N71870 001 MAY 05, 1988
OHM	200MG	N71163 001 JUL 15, 1986
PAR PHARM	200MG	N70481 001 SEP 24, 1986
	200MG	N70985 001 OCT 02, 1987
	200MG	N71575 001 MAY 08, 1987
PERRIGO	200MG	N72096 001 DEC 08, 1987
	200MG	N72098 001 DEC 08, 1987
	200MG	N75995 001 MAR 14, 2002
PVT FORM	200MG	N71732 001 SEP 10, 1987
	200MG	N71735 001 SEP 10, 1987
	200MG	N72299 001 JUL 01, 1988
	200MG	N73691 001 FEB 25, 1994
VINTAGE PHARMS	200MG	N71639 001 FEB 02, 1988
WATSON LABS	200MG	N70435 001 MAR 05, 1986

IBUPROHM

OHM LABS	200MG	N71214 001 DEC 01, 1986

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

JUNIOR STRENGTH ADVIL			
WYETH CONS	100MG	N20267 002	DEC 13, 1996
JUNIOR STRENGTH IBUPROFEN			
PERRIGO	100MG	N75367 001	APR 22, 1999
JUNIOR STRENGTH MOTRIN			
+ MCNEIL	100MG	N20602 001	JUN 10, 1996
MEDIPREN			
MCNEIL	200MG	N70475 001	FEB 06, 1986
	200MG	N71215 001	JUN 26, 1986
MOTRIN IB			
+ MCNEIL	200MG	N19012 003	DEC 17, 1990
MOTRIN MIGRAINE PAIN			
+ MCNEIL	200MG	N19012 004	FEB 25, 2000
PROFEN			
PVT FORM	200MG	N71265 001	OCT 15, 1986
TAB-PROFEN			
PERRIGO	200MG	N72095 001	DEC 08, 1987

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL			
WYETH CONS	50MG	N20944 001	DEC 18, 1998
CHILDREN'S MOTRIN			
MCNEIL	50MG	N20601 001	NOV 15, 1996
JUNIOR STRENGTH ADVIL			
WYETH CONS	100MG	N20944 002	DEC 18, 1998
JUNIOR STRENGTH MOTRIN			
+ MCNEIL	100MG	N20601 003	NOV 15, 1996

IBUPROFEN; *MULTIPLE*

SEE CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS			
WYETH CONS	200MG;30MG	N21374 001	MAY 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD			
WYETH CONS	100MG/5ML;15MG/5ML	N21373 001	APR 18, 2002
CHILDREN'S MOTRIN COLD			
+ MCNEIL CONS SPECLT	100MG/5ML;15MG/5ML	N21128 001	AUG 01, 2000

TABLET; ORAL

ADVIL COLD AND SINUS			
+ WYETH CONS	200MG;30MG	N19771 001	SEP 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HCL			
PHARM FORM	200MG;30MG	N75588 001	APR 08, 2002
IBUPROHM COLD AND SINUS			
OHM LABS	200MG;30MG	N74567 001	APR 17, 2001
SINE-AID IB			
MCNEIL CONS SPECLT	200MG;30MG	N19899 001	DEC 31, 1992

IBUPROFEN POTASSIUM

CAPSULE; ORAL

ADVIL LIQUI-GELS			
+ WYETH CONS	200MG	N20402 001	APR 20, 1995
ADVIL MIGRAINE LIQUI-GELS			
+ WYETH CONS	200MG	N20402 002	MAR 16, 2000

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR ILETIN II (PORK)		
+ LILLY	100 UNITS/ML	N18344 001

FDA data supplied by DrugPatentWatch.com

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R			
+ LILLY	100 UNITS/ML	N18780 001	OCT 28, 1982
HUMULIN R PEN			
+ LILLY	100 UNITS/ML	N18780 005	AUG 06, 1998
NOVOLIN R			
+ NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991
VELOSULIN BR			
+ NOVO NORDISK	100 UNITS/ML	N21028 001	JUL 19, 1999

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50			
+ LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992
HUMULIN 70/30			
+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 001	APR 25, 1989
HUMULIN 70/30 PEN			
+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 002	AUG 06, 1998
NOVOLIN 70/30			
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)		
+ LILLY	100 UNITS/ML	N17936 002

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

NPH ILETIN II (PORK)		
+ LILLY	100 UNITS/ML	N18345 001

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N			
+ LILLY	100 UNITS/ML	N18781 001	OCT 28, 1982
NOVOLIN N			
NOVO NORDISK	100 UNITS/ML	N19959 001	JUL 01, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN; *MULTIPLE*
SEE INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U			
+ LILLY	100 UNITS/ML	N19571 002	JUN 10, 1987

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE ILETIN II (PORK)		
+ LILLY	100 UNITS/ML	N18347 001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L			
+ LILLY	100 UNITS/ML	N19377 002	SEP 30, 1985
NOVOLIN L			
NOVO NORDISK	100 UNITS/ML	N19965 001	JUN 25, 1991

ISOPROPYL ALCOHOL; *MULTIPLE*
SEE CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

FDA data supplied by DrugPatentWatch.com

KETOCONAZOLE

SHAMPOO; TOPICAL
NIZORAL A-D
+ MCNEIL CONS SPECLT 1% N20310 001 OCT 10, 1997

KETOPROFEN

TABLET; ORAL
ACTRON
BAYER 12.5MG N20499 001 OCT 06, 1995

KETOPROFEN
PERRIGO 12.5MG N75364 001 FEB 07, 2002

ORUDIS KT
+ WYETH CONS 12.5MG N20429 001 OCT 06, 1995

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
IMODIUM A-D
+ MCNEIL 1MG/5ML N19487 001 MAR 01, 1988

LOPERAMIDE HCL
DURAMED PHARM BARR 1MG/5ML N74991 001 DEC 29, 1997
HI TECH PHARMA 1MG/5ML N74352 001 NOV 17, 1995
MORTON GROVE 1MG/5ML N74730 001 AUG 28, 1997
PERRIGO 1MG/5ML N73243 001 JAN 21, 1992
ROXANE 1MG/5ML N73079 001 APR 30, 1992
TEVA 1MG/5ML N73478 001 JUN 23, 1995

TABLET; ORAL
IMODIUM A-D
+ MCNEIL 2MG N19860 001 NOV 22, 1989

LOPERAMIDE HCL
LEINER 2MG N73254 001 JUL 30, 1993

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL
LOPERAMIDE HCL
OHM LABS 2MG N74091 001 DEC 10, 1992
PERRIGO 2MG N74194 001 OCT 30, 1992
2MG N75232 001 JAN 06, 2000

TABLET, CHEWABLE; ORAL
IMODIUM A-D
+ MCNEIL 2MG N20448 001 JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL
IMODIUM ADVANCED
MCNEIL CONS SPECLT 2MG;125MG N21140 001 NOV 30, 2000

TABLET, CHEWABLE; ORAL
IMODIUM ADVANCED
+ MCNEIL 2MG;125MG N20606 001 JUN 26, 1996

LOPERAMIDE HCL AND SIMETHICONE
PERRIGO 2MG;125MG N76029 001 AUG 30, 2002

LORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL
ALAVERT
+ WYETH CONS 10MG N21375 001 DEC 19, 2002

MAGNESIUM HYDROXIDE; *MULTIPLE*
SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

MAGNESIUM TRISILICATE; *MULTIPLE*
SEE ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

FDA data supplied by DrugPatentWatch.com

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK			
+ PERSONAL PRODS	2%,4%	N21261 001	FEB 02, 2001
CREAM; VAGINAL			
MICONAZOLE 7			
ALPHARMA US PHARM	2%	N74164 001	MAR 29, 1996
MICONAZOLE NITRATE			
COPLEY PHARM	2%	N74030 001	OCT 30, 1992
G AND W LABS	2%	N74366 001	FEB 22, 1996
PERRIGO	2%	N74760 001	MAY 15, 1997
TARO	2%	N74444 001	JAN 13, 1997
TEVA	2%	N74136 001	JAN 04, 1995
MONISTAT 3			
+ ADVANCED CARE PRODS	4%	N20827 001	MAR 30, 1998
MONISTAT 7			
+ ADV CARE	2%	N17450 002	FEB 15, 1991
CREAM, SUPPOSITORY; TOPICAL, VAGINAL			
M-ZOLE 3 COMBINATION PACK			
ALPHARMA US PHARM	2%,200MG	N74926 001	APR 16, 1999
M-ZOLE 7 DUAL PACK			
ALPHARMA	2%,100MG	N74586 001	JUL 17, 1997
MICONAZOLE NITRATE COMBINATION PACK			
PERRIGO	2%,200MG	N75329 001	APR 20, 1999
MONISTAT 7 COMBINATION PACK			
+ ADV CARE	2%,100MG	N20288 002	APR 26, 1993
MONISTAT-3 COMBINATION PACK			
+ ADV CARE	2%,200MG	N20670 002	APR 16, 1996
SUPPOSITORY; VAGINAL			
MICONAZOLE NITRATE			
ALPHARMA US PHARM	100MG	N73507 001	NOV 19, 1993

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE			
G AND W LABS	100MG	N74414 001	APR 30, 1997
+ PERRIGO	100MG	N74395 001	MAR 20, 1997
MONISTAT 7			
+ ADVANCED CARE PRODS	100MG	N18520 002	FEB 15, 1991

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)			
ALPHARMA	2%	N74588 001	APR 05, 1996
BAUSCH AND LOMB	2%	N74643 001	APR 09, 1996
COPLEY PHARM	2%	N74500 001	MAY 23, 1996
HI TECH PHARMA	2%	N74731 001	DEC 24, 1996
MORTON GROVE	2%	N74767 001	FEB 28, 1997
NOVEX	2%	N74924 001	APR 29, 1998
PERRIGO	2%	N75357 001	JUL 30, 1999
SIGHT PHARMS	2%	N74743 002	OCT 18, 1996
TEVA	2%	N74589 001	APR 05, 1996
MINOXIDIL (FOR WOMEN)			
NOVEX	2%	N74924 002	APR 29, 1998
PERRIGO	2%	N75357 002	JUL 30, 1999
SIGHT PHARMS	2%	N74743 001	OCT 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)			
ALPHARMA	5%	N75518 001	NOV 17, 2000
CLAY PARK	5%	N75737 001	MAR 15, 2002
NOVEX	5%	N75839 001	OCT 01, 2001

FDA data supplied by DrugPatentWatch.com

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)		
PERRIGO	5%	N75598 001 JUN 13, 2001
TEVA	5%	N75619 001 NOV 17, 2000
ROGAINE (FOR MEN)		
+ PHARMACIA AND UPJOHN	2%	N19501 002 FEB 09, 1996
ROGAINE (FOR WOMEN)		
+ PHARMACIA AND UPJOHN	2%	N19501 003 FEB 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)		
+ PHARMACIA AND UPJOHN	5%	N20834 001 NOV 14, 1997

NAPHAZOLINE HYDROCHLORIDE; *MULTIPLE*

SEE ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHCON-A		
+ ALCON	0.025%;0.3%	N20226 001 JUN 08, 1994
OPCON-A		
+ BAUSCH AND LOMB	0.02675%;0.315%	N20065 001 JUN 08, 1994
VISINE-A		
PFIZER	0.025%;0.3%	N20485 001 JAN 31, 1996

NAPROXEN SODIUM

TABLET; ORAL

ALEVE		
+ BAYER	EQ 200MG BASE	N20204 002 JAN 11, 1994
NAPROXEN SODIUM		
DR REDDYS LABS INC	EQ 200MG BASE	N75168 001 JUL 28, 1998
INVAMED	EQ 200MG BASE	N74646 001 JAN 13, 1997

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM		
LEINER	EQ 200MG BASE	N74635 001 JAN 13, 1997
PERRIGO	EQ 200MG BASE	N74661 001 JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001 FEB 27, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE COLD AND SINUS		
+ BAYER	EQ 200MG BASE;120MG	N21076 001 NOV 29, 1999

NEOMYCIN SULFATE; *MULTIPLE*

SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL		
+ NOVARTIS	7MG/24HR	N20076 004 NOV 12, 1999
+	14MG/24HR	N20076 005 NOV 12, 1999
+	21MG/24HR	N20076 006 NOV 12, 1999
NICODERM CQ		
+ AVENTIS PHARMS	7MG/24HR	N20165 006 AUG 02, 1996
+	14MG/24HR	N20165 005 AUG 02, 1996
+	21MG/24HR	N20165 004 AUG 02, 1996
NICOTROL		
+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001 JUL 03, 1996
PROSTEP		
+ ELAN PHARM	11MG/24HR	N19983 003 DEC 23, 1998
+	22MG/24HR	N19983 004 DEC 23, 1998

FDA data supplied by DrugPatentWatch.com

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE			
+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612 002	FEB 09, 1996
+	EQ 4MG BASE	N20066 002	FEB 09, 1996
NICORETTE (0RANGE)			
+ GLAXOSMITHKLINE	EQ 4MG BASE	N20066 004	SEP 25, 2000
NICORETTE (MINT)			
+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612 003	DEC 23, 1998
+	EQ 4MG BASE	N20066 003	DEC 23, 1998
NICORETTE (ORANGE)			
+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612 004	SEP 25, 2000
NICOTINE POLACRILEX			
WATSON LAB	EQ 2MG BASE	N74507 001	MAR 15, 1999
	EQ 4MG BASE	N74707 001	MAR 19, 1999

TROCHE/LOZENGE; ORAL

COMMIT			
GLAXOSMITHKLINE CONS	2MG	N21330 001	OCT 31, 2002
+	4MG	N21330 002	OCT 31, 2002

NIZATIDINE

TABLET; ORAL

AXID AR			
+ WYETH CONS	75MG	N20555 001	MAY 09, 1996

OCTYL METHOXYCINNAMATE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYBENZONE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OCUCLEAR			
SCHERING PLOUGH	0.025%	N18471 001	MAY 30, 1986
VISINE L.R.			
+ PFIZER	0.025%	N19407 001	MAR 31, 1989

PERMETHRIN

LOTION; TOPICAL

NIX			
+ WARNER LAMBERT	1%	N19918 001	MAY 02, 1990
PERMETHRIN			
ALPHARMA	1%	N75014 001	MAR 28, 2000
CLAY PARK	1%	N76090 001	DEC 20, 2001

PHENIRAMINE MALEATE; *MULTIPLE*
SEE NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

PHENYLPROPANOLAMINE HYDROCHLORIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE			
+ PFIZER	4%;EQ 0.33% BASE	N21043 001	MAR 07, 2000

POLYMYXIN B SULFATE; *MULTIPLE*
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; POLYMYXIN B SULFATE

FDA data supplied by DrugPatentWatch.com

POTASSIUM IODIDE

TABLET; ORAL

IOSAT		
ANBEX	130MG	N18664 001 OCT 14, 1982
THYRO-BLOCK		
+ WALLACE LABS	130MG	N18307 001
THYROSAFE		
+ R R REGISTRATIONS	65MG	N76350 001 SEP 10, 2002

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP		
+ BECTON DICKINSON	10%	N19382 001 JUL 25, 1989
POVIDONE IODINE		
+ ALLEGIANCE HLTHCARE	1%	N19522 001 MAR 31, 1989

SPONGE; TOPICAL

E-Z PREP		
+ BECTON DICKINSON	5%	N19382 002 JUL 25, 1989
E-Z PREP 220		
+ BECTON DICKINSON	5%	N19382 003 JUL 25, 1989
E-Z SCRUB 201		
+ BECTON DICKINSON	20%	N19240 001 NOV 29, 1985
E-Z SCRUB 241		
+ BECTON DICKINSON	10%	N19476 001 JAN 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HCL		
+ ALZA	240MG	N20021 002 DEC 15, 1992
PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001 FEB 26, 1999
SUDAFED 12 HOUR		
+ WARNER LAMBERT	120MG	N73585 001 OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES		
+ KV PHARM	120MG;5MG	N72758 001 NOV 25, 1991

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL		
+ SCHERING PLOUGH	120MG	N18191 001

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*

SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE
SEE DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

PYRETHRINS; *MULTIPLE*

SEE PIPERONYL BUTOXIDE; PYRETHRINS

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE		
DR REDDYS LABS LTD	EQ 75MG BASE	N75294 001 MAR 28, 2000
GENEVA PHARMS	EQ 75MG BASE	N75519 001 SEP 26, 2002
GENPHARM	EQ 75MG BASE	N75497 001 JAN 14, 2000
IVAX PHARMS	EQ 75MG BASE	N75296 001 JAN 14, 2000

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

LEINER	EQ 75MG BASE	N75094 001 JUN 21, 1999
PERRIGO	EQ 75MG BASE	N76195 001 AUG 30, 2002
RANBAXY	EQ 75MG BASE	N75132 001 JAN 14, 2000
	EQ 75MG BASE	N75254 001 JAN 14, 2000
TORPHARM	EQ 75MG BASE	N75167 001 MAY 04, 2000
WATSON LABS	EQ 75MG BASE	N75212 001 JAN 14, 2000

ZANTAC 75

+ WARNER LAMBERT	EQ 75MG BASE	N20520 001 DEC 19, 1995

SIMETHICONE; *MULTIPLE*
SEE LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION
BRONCHO SALINE

+ BLAIREX	0.9%	N19912 001 SEP 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL

+ COLGATE PALMOLIVE	0.24%;0.3%	N20231 001 JUL 11, 1997

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL
EXTRA-STRENGTH AIM

+ CHESEBROUGH PONDS	1.2%	N19518 002 AUG 06, 1986

SODIUM MONOFLUOROPHOSPHATE

PASTE; DENTAL
EXTRA-STRENGTH AIM

+ CHESEBROUGH PONDS	1.2%	N19518 001 JUN 03, 1987

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL
LAMISIL

+ NOVARTIS	1%	N20980 001 MAR 09, 1999

SOLUTION; TOPICAL
LAMISIL AT

+ NOVARTIS	1%	N21124 001 MAR 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL
TIOCONAZOLE

PERRIGO	6.5%	N75915 001 NOV 21, 2001

VAGISTAT-1

+ BRISTOL MYERS SQUIBB	6.5%	N20676 001 FEB 11, 1997

TRICLOSAN; *MULTIPLE*
SEE SODIUM FLUORIDE; TRICLOSAN

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ACD-A SOLUTION — ANDA
GAMBRO BCT, INC — N010228
FEB 25, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ADSOL WITH ACD-A
BAXTER HEALTHCARE FENWAL DIVISION
N000922
AUG 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A — ANDA
HAEMONETICS CORP — N980728
FEB 6, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N710497
(ANDA)

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC. — N100102
DEC 14, 1961

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N110912
SEP 02, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N100855
JUN 03, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N160918
MAR 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION
AS3 NUTRICEL ADDITIVE SYSTEM ADDITIVE SOLUTION FORMULA 3
GAMBRO BCT, INC
N012142
MAY 29, 2002

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION
CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3
HAEMONETICS CORP — N000127
JAN 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N780519
APR 23, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N820528
NOV 03, 1982

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N940404
JUL 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800077
NOV 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC — N160527
JUN 22, 1970

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800222
AUG 23, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N160907
MAY 16, 1973

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N781211
JUN 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N170401
DEC 06, 1977

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N811012
JUN 28, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION
BAXTER HLTHCARE FENWAL DIV — 2.2GM/100ML;0.9GM/100ML; 0.75GM/100ML;0.027GM/100ML — N811104
MAY 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION
TERUMO MEDICAL CORP — 0.9GM/100ML;0.877GM/100ML; 0.525GM/100ML;0.03GM/100ML — N880217
OCT 07, 1988

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-2 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP — 0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML — N820915 SEP 22, 1983

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-3 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP — 0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML — N820915 OCT 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
CDP BLOOD BAG UNIT IN PLASTIC CONTAINER — N900224
BAXTER HLTHCARE - FENWAL DIVISION — DEC 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
ADSOL IN PLASTIC CONTAINER
BAXTER HLTH CARE - FENWAL DIVISION — N900223 DEC 27, 1991

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N770822 MAY 17, 1978

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N760305 JUN 30, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION
NONE
HAEMONETICS CORPORATION — N980123 MAR 3, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
ALPHA THERPTC — N810416 APR 06, 1983

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N160702 DEC 28, 1970

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N781214 FEB 08, 1980

DEXTRAN 40, 10% IN DEXTROSE 5%

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION N770923
JAN 20, 1978

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION
PROMIT
PHARMALINK BASLAKEMEDEL AB N830715
OCT 30, 1984

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 0.8% NACL 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB N830527
MAR 27, 1985

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 5% DEXTROSE 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB N830627
MAR 27, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE IV SYSTEMS 10GM/100ML;5GM/100ML N840619
FEB 22, 1985

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS 10GM/100ML;5GM/100ML ANDA N720563
OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 10GM/100ML;5GM/100ML N160375
JUL 25, 1967

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
MCGAW, INC 10GM/100ML;5GM/100ML N160767
APR 6, 1970

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
MILES, INC 10GM/100ML;5GM/100ML N160653
SEP 23, 1969

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
PHARMACHEM 10GM/100ML;5GM/100ML N160836
NOV 14, 1972

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK 10GM/100ML;5GM/100ML N140716
BASLAKEMEDEL AB JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE 10GM/100ML;0.9GM/100ML N840620
IV SYSTEMS FEB 22, 1985

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER ANDA
ABBOTT LABS 10GM/100ML;0.9GM/100ML N720562
OCT 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK 10GM/100ML;0.9GM/100ML N140716
BASLAKEMEDEL AB JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 10GM/100ML;0.9GM/100ML N160375
JUL 25, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC 10GM/100ML;0.9GM/100ML N160653
SEP 23, 1969

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 10GM/100ML;0.9GM/100ML N160836
NOV 14, 1972

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC 10GM/100ML;0.9GM/100ML N160767
APR 6, 1970

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 0.9% NACL IN 500 ML PVC BAGS

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB N830613
MAR 27, 1985

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 5% DEXTROSE

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB N830629
MAR 27, 1985

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
MACRODEX
PHARMALINK 6GM/100ML;5GM/100ML N060826
BASLAKEMEDEL AB JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX
PHARMALINK 6GM/100ML;5GM/100ML N060826
BASLAKEMEDEL AB JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC 6GM/100ML;0.9 GM/100ML N090024
AUG 18, 1969

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC 6GM/100ML;0.9 GM/100ML N080716
MAR 13, 1953

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAIN 70
BAXTER HLTHCARE 6GM/100ML;0.9 GM/100ML N160607
IV SYSTEMS JAN 26, 1970

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 6GM/100ML;5GM/100ML N080819
MAR 31, 1953

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 6GM/100ML;0.9GM/100ML N080564
SEP 19, 1952

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 6GM/100ML;0.9GM/100ML N160759
AUG 19, 1970

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION
NONE ANDA
ABBOTT LABORATORIES - HOSPITAL PRODUCTS DIV N720746
FEB 07, 1996

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN
MCGAW, INC 6GM/100ML;0.9GM/100ML N160889
JUL 17, 1972

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN IN PLASTIC CONTAINER

MCGAW, INC	6GM/100ML;0.9GM/100ML		N890105
			APR 04, 1991

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	6GM/100ML;0.9GM/100ML	ANDA	
		N740193	
		JAN 30, 1995	

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE

GENSIA LABS, INC	6GM/100ML;0.9GM/100ML	ANDA	
		N740592	
		NOV 12, 1998	

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE

MCGAW, INC	6GM/100ML;0.9GM/100ML	ANDA	
		N740283	
		OCT 21, 1998	

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION
HEXTEND

BIOTIME, INC	6GM/100ML		N200952
			MAR 31, 1999

INDIUM IN^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR

MEDI-PHYSICS	N/A		N19862
			DEC 29, 1992

INDIUM IN^{111} CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION ULTRAPURE
ULTRAPURE

MALLINCKRODT	N/A		N19841
			SEP 27, 1994

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN

MCGAW, INC	10GM/100ML;0.9GM/100ML		N841207
			MAY 19, 1987

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN IN PLASTIC CONTAINER

MCGAW, INC	10GM/100ML;0.9GM/100ML		N890104
			APR 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION
FLUOSOL

ALPHA THERPTC	17.5GM/100ML;7.5GM/100ML		N860909
			DEC 26, 1989

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

RED BLOOD CELL PROCESSING SOLUTION

INJECATABLE; INJECTION
REJUVESOL
CYTOSOL LABS, INCN/A — N950522
FEB 26, 1997

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE OPEN-CATHETER
ABBOTT LABS — 5,000 IU/VIAL — N761021
DEC 15, 1983

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE
ABBOTT LABS — 9,000 IU/VIAL — N761021

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE
ABBOTT LABS — 250,000 IU/VIAL — N761021

ACETAMINOPHEN		
INJECTABLE		
INJECTAPAP	100MG/ML	N17785
SUPPOSITORY		
ACETAMINOPHEN	120MG	N73106
ACETAMINOPHEN	325MG	N73107
ACETAMINOPHEN	650MG	N73108
ACETAMINOPHEN	120MG	N71010
ACETAMINOPHEN	650MG	N71011
TYLENOL	120MG	N17756
TYLENOL	650MG	N17756
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE		
CAPSULE		
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE	150MG;180MG;15MG	N81095
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE	150MG;180MG;60MG	N81097
CODEINE, ASPIRIN, APAP FORMULA NO. 2	150MG;180MG;15MG	N85640
CODEINE, ASPIRIN, APAP FORMULA NO. 3	150MG;180MG;30MG	N85639
CODEINE, ASPIRIN, APAP FORMULA NO. 4	150MG;180MG;60MG	N85638
ACETAMINOPHEN; BUTALBITAL		
CAPSULE		
BANCAP	325MG;50MG	N88889
TRIAPRIN	325MG;50MG	N89268
TABLET		
BUTALBITAL AND ACETAMINOPHEN	325MG;50MG	N89568
BUTALBITAL AND ACETAMINOPHEN	325MG;50MG	N87550
ACETAMINOPHEN; BUTALBITAL; CAFFEINE		
CAPSULE		
ANOQUAN	325MG;50MG;40MG	N87628
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N88743
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N88765
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N89067
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N88758
FEMCET	325MG;50MG;40MG	N89102
MEDIGESIC PLUS	325MG;50MG;40MG	N89115
TRIAD	325MG;50MG;40MG	N89023
TABLET		
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE	325MG;50MG;40MG	N87629
ESGIC	325MG;50MG;40MG	N89660
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE		
CAPSULE		
DHC PLUS	356.4MG;30MG;16MG	N88584
SYNALGOS-DC-A	356.4MG;30MG;16MG	N89166

ACETAMINOPHEN; CODEINE PHOSPHATE		
CAPSULE		
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N88324
ACETAMINOPHEN W/ CODEINE #2	300MG;15MG	N88537
ACETAMINOPHEN W/ CODEINE #4	300MG;60MG	N88599
PHENAPHEN W/ CODEINE NO. 2	325MG;15MG	N84444
PROVAL #3	325MG;30MG	N85685
TYLENOL W/ CODEINE NO. 3	300MG;30MG	N87422
TYLENOL W/ CODEINE NO. 4	300MG;60MG	N87421
SOLUTION		
TYLENOL W/ CODEINE	120MG/5ML;12MG/5ML	N85057
TABLET		
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N88353
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N88354
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N88355
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N87433
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85917
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N87423
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85291
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N85964
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N85795
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85794
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N86549
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85288
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N85365
ACETAMINOPHEN AND CODEINE PHOSPHATE	325MG;15MG	N85364
ACETAMINOPHEN AND CODEINE PHOSPHATE	325MG;45MG	* N85363
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N89244
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N86683
ACETAMINOPHEN AND CODEINE PHOSPHATE	500MG;15MG	* N89511
ACETAMINOPHEN AND CODEINE PHOSPHATE	500MG;30MG	* N89512
ACETAMINOPHEN AND CODEINE PHOSPHATE	500MG;60MG	* N89513
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N85992
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85218
ACETAMINOPHEN AND CODEINE PHOSPHATE #3	300MG;30MG	N89080
ACETAMINOPHEN AND CODEINE PHOSPHATE #3	300MG;30MG	N89184
ACETAMINOPHEN AND CODEINE PHOSPHATE #3	300MG;30MG	N89253
ACETAMINOPHEN AND CODEINE PHOSPHATE #4	300MG;60MG	N89185
ACETAMINOPHEN AND CODEINE PHOSPHATE #4	300MG;60MG	N89254
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2	300MG;15MG	N89478
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2	300MG;15MG	N89481
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3	300MG;30MG	N89479
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3	300MG;30MG	N89482
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4	300MG;60MG	N89480
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4	300MG;60MG	N89483
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4	300MG;60MG	N84667
ACETAMINOPHEN W/ CODEINE	300MG;60MG	N87653

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET

ACETAMINOPHEN W/ CODEINE	300MG;30MG	N87141
ACETAMINOPHEN W/ CODEINE NO. 2	300MG;15MG	N84659
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;15MG	N83871
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N83872
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N87919
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N87920
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N85676
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N87306
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;15MG	N87277
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N87276
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N87275
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N84360
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N85607
APAP W/ CODEINE PHOSPHATE	325MG;30MG	N85217
CAPITAL WITH CODEINE	325MG;30MG	N83643
CODEINE PHOSPHATE AND ACETAMINOPHEN	300MG;30MG	N85896
EMPRACET W/ CODEINE PHOSPHATE #3	300MG;30MG	N83951
EMPRACET W/ CODEINE PHOSPHATE #4	300MG;60MG	N83951
PAPA-DEINE #3	300MG;30MG	N88037
PAPA-DEINE #4	300MG;60MG	N88715
PHENAPHEN-650 W/ CODEINE	650MG;30MG	N85856
TYLENOL W/ CODEINE	325MG;15MG	N85056
TYLENOL W/ CODEINE	325MG;30MG	N85056
TYLENOL W/ CODEINE	325MG;60MG	N85056
TYLENOL W/ CODEINE	325MG;7.5MG	N85056

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE

BANCAP HC	500MG;5MG	N87961
CO-GESIC	500MG;5MG	N89360

TABLET

DURADYNE DHC	500MG;5MG	N87809
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N88577
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N89554
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N89290
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N89291
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	325MG;7.5MG	N40248
NORCET	500MG;5MG	N88871
TYCOLET	500MG;5MG	N89385
VICODIN	500MG;5MG	N85667

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE

OXYCODONE AND ACETAMINOPHEN	500MG;5MG	N89994
TYLOX-325	325MG;5MG	N88246

TABLET

OXYCODONE 2.5/APAP 500	500MG;2.5MG	N85910
OXYCODONE 5/APAP 500	500MG;5MG	N85911

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE

TYLOX	500MG;4.5MG;0.38MG	N85375

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET

DARVOCET	325MG;32.5MG	N16844
DOLENE AP-65	650MG;65MG	N85100
PROPOXYPHENE HCL AND ACETAMINOPHEN	325MG;32MG	N83689

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET

PROPACET 100	650MG;100MG	N70107
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	325MG;50MG	N70115
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	325MG;50MG	N72105
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N70116
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N72106
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N71319
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N70732
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	325MG;50MG	N70398
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N70399

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE

DIAMOX	500MG	N12945

TABLET

ACETAZOLAMIDE	250MG	N83320
ACETAZOLAMIDE	250MG	N87686
ACETAZOLAMIDE	250MG	N87654
ACETAZOLAMIDE	250MG	N84498

ACETAZOLAMIDE SODIUM

INJECTABLE

ACETAZOLAMIDE SODIUM	EQ 500MG BASE/VIAL	N89619

ACETIC ACID, GLACIAL		
SOLUTION/DROPS		
ACETIC ACID	2%	N85493
ORLEX	2%	N86845
ACETIC ACID, GLACIAL; ALUMINUM ACETATE		
SOLUTION/DROPS		
BOROFAIR	2%;0.79%	N88606
ACETIC ACID, GLACIAL; DESONIDE		
SOLUTION/DROPS		
TRIDESILON	2%;0.05%	N17914
ACETIC ACID, GLACIAL; HYDROCORTISONE		
SOLUTION/DROPS		
ACETIC ACID W/ HYDROCORTISONE	2%;1%	N85492
HYDROCORTISONE AND ACETIC ACID	2%;1%	N40097
ORLEX HC	2%;1%	N86844
ACETOHEXAMIDE		
TABLET		
ACETOHEXAMIDE	250MG	N70753
ACETOHEXAMIDE	500MG	N70754
DYMELOR	250MG	N13378
DYMELOR	500MG	N13378
ACETOPHENAZINE MALEATE		
TABLET		
TINDAL	20MG	N12254
ACETRIZOATE SODIUM		
SOLUTION		
SALPIX	53%	N09008
ACETYLCYSTEINE		
SOLUTION		
ACETYLCYSTEINE	10%	N71740
ACETYLCYSTEINE	20%	N71741
ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE		
SOLUTION		
MUCOMYST W/ ISOPROTERENOL	10%;0.05%	N17366
ACETYLDIGITOXIN		
TABLET		
ACYLANID	0.1MG	N09436
ACRISORCIN		
CREAM		
AKRINOL	2MG/GM	N12470
ACYCLOVIR		
CAPSULE		
ACYCLOVIR	200MG	N74750

ACYCLOVIR		
CAPSULE		
ACYCLOVIR	200MG	N74570
TABLET		
ACYCLOVIR	400MG	N74658
ACYCLOVIR	800MG	N74658
ACYCLOVIR	200MG	* N74556
ACYCLOVIR SODIUM		
INJECTABLE		
ACYCLOVIR SODIUM	EQ 1GM BASE/VIAL	N74897
ACYCLOVIR SODIUM	EQ 500MG BASE/VIAL	N74897
ZOVIRAX	EQ 250MG BASE/VIAL	N18603
ALBUMIN CHROMATED CR-51 SERUM		
INJECTABLE		
CHROMALBIN	100uCi/VIAL	N17835
CHROMALBIN	250uCi/VIAL	N17835
CHROMALBIN	500uCi/VIAL	N17835
ALBUMIN IODINATED I-125 SERUM		
INJECTABLE		
ALBUMOTOPE 125 I	5-50uCi/AMP	N17836
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)	2.5uCi/AMP	N17846
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125	100uCi/ML	N17844
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125	6.67uCi/ML	N17844
ALBUMIN IODINATED I-131 SERUM		
INJECTABLE		
MEGATOPE	20uCi/AMP	N17837
MEGATOPE	2mCi/VIAL	N17837
MEGATOPE	5uCi/AMP	N17837
ALBUTEROL SULFATE		
CAPSULE		
VENTOLIN ROTACAPS	EQ 0.2MG BASE	N19489
SOLUTION		
ALBUTEROL SULFATE	EQ 0.083% BASE	N73495
ALBUTEROL SULFATE	EQ 0.5% BASE	N73307
VENTOLIN	EQ 0.083% BASE	N19773
VENTOLIN	EQ 0.5% BASE	N19269
SYRUP		
ALBUTEROL SULFATE	EQ 2MG BASE/5ML	N74302
ALBUTEROL SULFATE	EQ 2MG BASE/5ML	N73165
VENTOLIN	EQ 2MG BASE/5ML	N19621
TABLET		
ALBUTEROL SULFATE	EQ 2MG BASE	N72449
ALBUTEROL SULFATE	EQ 4MG BASE	N72450

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE		
TABLET		
ALBUTEROL SULFATE	EQ 2MG BASE	N73120
ALBUTEROL SULFATE	EQ 4MG BASE	N73121
ALBUTEROL SULFATE	EQ 2MG BASE	N72966
ALBUTEROL SULFATE	EQ 4MG BASE	N72967
ALBUTEROL SULFATE	EQ 2MG BASE	N72817
ALBUTEROL SULFATE	EQ 4MG BASE	N72818
VENTOLIN	EQ 2MG BASE	N19112
VENTOLIN	EQ 4MG BASE	N19112
ALCOHOL		
INJECTABLE		
ALCOHOL 5% IN DEXTROSE 5%	5ML/100ML	N83483
ALCOHOL; DEXTROSE		
INJECTABLE		
ALCOHOL 5% IN DEXTROSE 5% IN WATER	5ML/100ML;5GM/100ML	N83256
ALGLUCERASE		
INJECTABLE		
CEREDASE	10 UNITS/ML	N20057
ALKAVERVIR		
TABLET		
VERILOID	2MG	N07336
VERILOID	3MG	N07336
ALLOPURINOL		
TABLET		
ALLOPURINOL	100MG	N70466
ALLOPURINOL	300MG	N70467
ALLOPURINOL	100MG	N70579
ALLOPURINOL	300MG	N70580
ALLOPURINOL	100MG	N70950
ALLOPURINOL	100MG	N18241
ALLOPURINOL	300MG	N18241
ALLOPURINOL	100MG	N18785
ALLOPURINOL	300MG	N18785
LOPURIN	100MG	N18297
LOPURIN	300MG	N18297
ALPRAZOLAM		
SOLUTION		
ALPRAZOLAM	0.5MG/5ML	N74314
TABLET		
ALPRAZOLAM	0.25MG	N74199
ALPRAZOLAM	0.5MG	N74199
ALPRAZOLAM	1MG	N74199

ALPROSTADIL		
INJECTABLE		
CAVERJECT	0.005MG/ML	N20755
EDEX	0.005MG/VIAL	N20649
ALSEROXYLON		
TABLET		
RAUTENSIN	2MG	N09215
RAUWILOID	2MG	N08867
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE		
TABLET, CHEWABLE		
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE	80MG;20MG	N89449
AMANTADINE HYDROCHLORIDE		
CAPSULE		
AMANTADINE HCL	100MG	N71382
SYMADINE	100MG	N71000
SYMMETREL	100MG	N16020
AMCINONIDE		
CREAM		
CYCLOCORT	0.025%	N18116
AMDINOCILLIN		
INJECTABLE		
COACTIN	1GM/VIAL	N50565
COACTIN	250MG/VIAL	N50565
COACTIN	500MG/VIAL	N50565
AMIFOSTINE		
INJECTABLE		
ETHYOL	375MG/VIAL	N20221
AMIKACIN SULFATE		
INJECTABLE		
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63265
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63266
AMIKACIN SULFATE	EQ 250MG BASE/ML	N64099
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63169
AMIKACIN SULFATE	EQ 50MG BASE/ML	N63167
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63275
AMIKACIN SULFATE	EQ 50MG BASE/ML	N63274
AMIKIN	EQ 250MG BASE/ML	N50495
AMIKIN	EQ 250MG BASE/ML	N62562
AMIKIN	EQ 50MG BASE/ML	N50495
AMIKIN	EQ 50MG BASE/ML	N62562
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50618
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 5MG BASE/ML	N50618

AMINO ACIDS

INJECTABLE

AMINOSYN 3.5% IN PLASTIC CONTAINER	3.5% (3.5GM/100ML)	N18804
AMINOSYN 3.5% IN PLASTIC CONTAINER	3.5% (3.5GM/100ML)	N18875
AMINOSYN 7%	7% (7GM/100ML)	N17673
AMINOSYN 8.5%	8.5% (8.5GM/100ML)	N17673
AMINOSYN II 3.5%	3.5% (3.5GM/100ML)	N19438
AMINOSYN II 3.5% IN PLASTIC CONTAINER	3.5% (3.5GM/100ML)	N19491
AMINOSYN II 5%	5% (5GM/100ML)	N19438
AMINOSYN-HBC 7% IN PLASTIC CONTAINER	7% (7GM/100ML)	N19400
BRANCHAMIN 4%	4% (4GM/100ML)	N18678
FREAMINE 8.5%	8.5% (8.5GM/100ML)	N16822
FREAMINE II 8.5%	8.5% (8.5GM/100ML)	N16822
NEOPHAM 6.4%	6.4% (6.4GM/100ML)	N18792
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER	15% (15GM/100ML)	N20107
NOVAMINE 8.5%	8.5% (8.5GM/100ML)	N17957

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683

AMINO ACIDS; DEXTROSE

INJECTABLE

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML	N19118
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML	N19120
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	N19119
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML	N19505

AMINO ACIDS; DEXTROSE

INJECTABLE

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML	N19713
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML	N19506
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML	N19713
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML	N19713
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER	4.25%;20GM/100ML	N19713
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	N19504
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	N19713
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	N19565
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	N19713

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N19682
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N19712

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19564
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19564

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N19564
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N19712

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N19564

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

AMINOSYN 3.5% M IN PLASTIC CONTAINER	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N18804
AMINOSYN 3.5% M IN PLASTIC CONTAINER	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N18875

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

AMINOSYN 3.5% M	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N17789

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 3.5% M IN PLASTIC CONTAINER	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N19493

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE

VEINAMINE 8%	8%;61MG/100ML;211MG/100ML;56MG/100ML;388MG/100ML	N17957

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 7% W/ ELECTROLYTES	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N19437

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 3.5% M	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N19437

AMINOCAPROIC ACID

INJECTABLE

AMINOCAPROIC ACID	250MG/ML	N70522
AMINOCAPROIC ACID	250MG/ML	N70694

AMINOHIPPURATE SODIUM

INJECTABLE

AMINOHIPPURATE SODIUM	20%	N89821

AMINOPHYLLINE

ENEMA

SOMOPHYLLIN	300MG/5ML	N18232

INJECTABLE

AMINOPHYLLIN	25MG/ML	N87243
AMINOPHYLLIN	25MG/ML	N87621
AMINOPHYLLINE	25MG/ML	N84568
AMINOPHYLLINE	25MG/ML	N87200
AMINOPHYLLINE	25MG/ML	N87250
AMINOPHYLLINE	25MG/ML	N87431
AMINOPHYLLINE	25MG/ML	N87886
AMINOPHYLLINE	25MG/ML	N88407
AMINOPHYLLINE	25MG/ML	N87867
AMINOPHYLLINE	25MG/ML	N87868
AMINOPHYLLINE	25MG/ML	N86606
AMINOPHYLLINE	25MG/ML	N87387
AMINOPHYLLINE	25MG/ML	N88429
AMINOPHYLLINE	25MG/ML	N88749
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	100MG/100ML	N18924
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	200MG/100ML	N18924
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	400MG/100ML	N18924
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	500MG/100ML	N18924

SOLUTION

AMINOPHYLLINE	105MG/5ML	N88156
SOMOPHYLLIN	105MG/5ML	N86466
SOMOPHYLLIN-DF	105MG/5ML	N87045

TABLET

AMINOPHYLLIN	100MG	N02386
AMINOPHYLLIN	200MG	N02386
AMINOPHYLLINE	100MG	N87522
AMINOPHYLLINE	200MG	N87523
AMINOPHYLLINE	100MG	N88297
AMINOPHYLLINE	200MG	N88298
AMINOPHYLLINE	100MG	N88182
AMINOPHYLLINE	200MG	N88183
AMINOPHYLLINE	100MG	N85261
AMINOPHYLLINE	100MG	N84674
AMINOPHYLLINE	200MG	N84563
AMINOPHYLLINE	100MG	N84574
AMINOPHYLLINE	200MG	N84576

AMINOPHYLLINE		
TABLET		
AMINOPHYLLINE	100MG	N85284
AMINOPHYLLINE	200MG	N85289
AMINOPHYLLINE	100MG	N84588
AMINOPHYLLINE	200MG	N84588
AMINOPHYLLINE	100MG	N84533
AMINOPHYLLINE	100MG	N84552
AMINOPHYLLINE	200MG	N84552
AMINOPHYLLINE	100MG	N84699
AMINOPHYLLINE	200MG	N85333
AMINOPHYLLINE	100MG	N88314
AMINOPHYLLINE	200MG	N88319
AMINOPHYLLINE	100MG	N85409
AMINOPHYLLINE	200MG	N85410
AMINOPHYLLINE	100MG	N85567
AMINOPHYLLINE	200MG	N85564
TABLET, DELAYED RELEASE		
AMINOPHYLLINE	100MG	N84577
AMINOPHYLLINE	200MG	N84575
AMINOPHYLLINE	100MG	N84632
AMINOPHYLLINE	100MG	N84531
AMINOPHYLLINE	200MG	N84530
TABLET, EXTENDED RELEASE		
PHYLLOCONTIN	225MG	N86760
AMINOSALICYLATE SODIUM		
POWDER		
P.A.S. SODIUM	4GM/PACKET	N80947
SODIUM AMINOSALICYLATE	100%	N80097
TABLET		
PARASAL SODIUM	1GM	N06811
PARASAL SODIUM	500MG	N06811
TEEBACIN	500MG	N07320
AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID		
TABLET		
NEOPASALATE	846MG;112MG	N80059
AMINOSALICYLIC ACID		
TABLET		
PARASAL	1GM	N06811
PARASAL	500MG	N06811
AMINOSALICYLIC ACID RESIN COMPLEX		
POWDER		
REZIPAS	EQ 500MG BASE/GM	N09052

AMITRIPTYLINE HYDROCHLORIDE		
INJECTABLE		
AMITRIPTYLINE HCL	10MG/ML	N85594
TABLET		
AMITID	100MG	N86454
AMITID	10MG	N86454
AMITID	25MG	N86454
AMITID	50MG	N86454
AMITID	75MG	N86454
AMITRIL	100MG	N85093
AMITRIL	10MG	N83939
AMITRIL	150MG	N86295
AMITRIL	25MG	N83937
AMITRIL	50MG	N83938
AMITRIL	75MG	N84957
AMITRIPTYLINE HCL	100MG	N88675
AMITRIPTYLINE HCL	25MG	N88672
AMITRIPTYLINE HCL	50MG	N88673
AMITRIPTYLINE HCL	75MG	N88674
AMITRIPTYLINE HCL	100MG	N86336
AMITRIPTYLINE HCL	10MG	N85864
AMITRIPTYLINE HCL	150MG	N86335
AMITRIPTYLINE HCL	25MG	N85935
AMITRIPTYLINE HCL	50MG	N85936
AMITRIPTYLINE HCL	75MG	N86337
AMITRIPTYLINE HCL	100MG	N88425
AMITRIPTYLINE HCL	10MG	N88421
AMITRIPTYLINE HCL	150MG	N88426
AMITRIPTYLINE HCL	25MG	N88422
AMITRIPTYLINE HCL	50MG	N88423
AMITRIPTYLINE HCL	75MG	N88424
AMITRIPTYLINE HCL	100MG	N85742
AMITRIPTYLINE HCL	100MG	N85927
AMITRIPTYLINE HCL	10MG	N85744
AMITRIPTYLINE HCL	10MG	N85923
AMITRIPTYLINE HCL	150MG	N89423
AMITRIPTYLINE HCL	25MG	N85627
AMITRIPTYLINE HCL	25MG	N85922
AMITRIPTYLINE HCL	50MG	N85745
AMITRIPTYLINE HCL	50MG	N85925
AMITRIPTYLINE HCL	50MG	N87557
AMITRIPTYLINE HCL	75MG	N85743
AMITRIPTYLINE HCL	75MG	N85926
AMITRIPTYLINE HCL	100MG	N86747
AMITRIPTYLINE HCL	100MG	N87368
AMITRIPTYLINE HCL	10MG	N86744
AMITRIPTYLINE HCL	10MG	N87366

AMITRIPTYLINE HYDROCHLORIDE

TABLET

AMITRIPTYLINE HCL	150MG	N87370
AMITRIPTYLINE HCL	25MG	N86746
AMITRIPTYLINE HCL	25MG	N87367
AMITRIPTYLINE HCL	50MG	N86743
AMITRIPTYLINE HCL	50MG	N87181
AMITRIPTYLINE HCL	75MG	N86745
AMITRIPTYLINE HCL	75MG	N87369
AMITRIPTYLINE HCL	100MG	N88701
AMITRIPTYLINE HCL	10MG	N88697
AMITRIPTYLINE HCL	150MG	N88702
AMITRIPTYLINE HCL	25MG	N88698
AMITRIPTYLINE HCL	50MG	N88699
AMITRIPTYLINE HCL	75MG	N88700
AMITRIPTYLINE HCL	100MG	N88079
AMITRIPTYLINE HCL	100MG	N88107
AMITRIPTYLINE HCL	10MG	N88075
AMITRIPTYLINE HCL	10MG	N88084
AMITRIPTYLINE HCL	25MG	N88076
AMITRIPTYLINE HCL	25MG	N88085
AMITRIPTYLINE HCL	50MG	N88077
AMITRIPTYLINE HCL	50MG	N88105
AMITRIPTYLINE HCL	75MG	N88078
AMITRIPTYLINE HCL	75MG	N88106
AMITRIPTYLINE HCL	100MG	N86003
AMITRIPTYLINE HCL	100MG	N86146
AMITRIPTYLINE HCL	10MG	N86002
AMITRIPTYLINE HCL	10MG	N86144
AMITRIPTYLINE HCL	150MG	N86090
AMITRIPTYLINE HCL	150MG	N86148
AMITRIPTYLINE HCL	25MG	N85944
AMITRIPTYLINE HCL	25MG	N86145
AMITRIPTYLINE HCL	50MG	N85945
AMITRIPTYLINE HCL	50MG	N86143
AMITRIPTYLINE HCL	75MG	N86004
AMITRIPTYLINE HCL	75MG	N86147
AMITRIPTYLINE HCL	100MG	N86854
AMITRIPTYLINE HCL	10MG	N86610
AMITRIPTYLINE HCL	150MG	N86853
AMITRIPTYLINE HCL	25MG	N86859
AMITRIPTYLINE HCL	50MG	N86857
AMITRIPTYLINE HCL	75MG	N85030
AMITRIPTYLINE HCL	75MG	N86860
AMITRIPTYLINE HCL	25MG	N87775
AMITRIPTYLINE HCL	100MG	N87639
AMITRIPTYLINE HCL	10MG	N87632

AMITRIPTYLINE HYDROCHLORIDE

TABLET

AMITRIPTYLINE HCL	50MG	N87616
AMITRIPTYLINE HCL	75MG	N87617
AMITRIPTYLINE HCL	100MG	N85820
AMITRIPTYLINE HCL	100MG	N88634
AMITRIPTYLINE HCL	10MG	N85816
AMITRIPTYLINE HCL	10MG	N88620
AMITRIPTYLINE HCL	150MG	N85821
AMITRIPTYLINE HCL	150MG	N88635
AMITRIPTYLINE HCL	25MG	N85817
AMITRIPTYLINE HCL	25MG	N88621
AMITRIPTYLINE HCL	50MG	N85815
AMITRIPTYLINE HCL	50MG	N88622
AMITRIPTYLINE HCL	75MG	N85819
AMITRIPTYLINE HCL	75MG	N88633
AMITRIPTYLINE HCL	10MG	N87647
AMITRIPTYLINE HCL	25MG	N87278
ENDEP	100MG	N83639
ENDEP	10MG	N83639
ENDEP	150MG	N85303
ENDEP	25MG	N83639
ENDEP	50MG	N83639
ENDEP	75MG	N83639

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 12.5MG BASE;5MG	N70765
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 25MG BASE;10MG	N70766
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 12.5MG BASE;5MG	N70477
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 25MG BASE;10MG	N70478

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET

ETRAFON-A	10MG;4MG	N14713
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N71077
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N71078
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70297
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N71079
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N70935
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N70937
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70936
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N70938
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N70939
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N70565
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N70620
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70621
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N70595

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET

PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N70574
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N70373
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N70375
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70374
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N70376
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N70377
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N72539
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N72540
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N72541
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N72134
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N71558
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N72135
TRIAVIL 2-10	10MG;2MG	N14715
TRIAVIL 2-25	25MG;2MG	N14715
TRIAVIL 4-10	10MG;4MG	N14715
TRIAVIL 4-25	25MG;4MG	N14715
TRIAVIL 4-50	50MG;4MG	N14715

AMMONIUM CHLORIDE

INJECTABLE

AMMONIUM CHLORIDE	5MEQ/ML	N83130
AMMONIUM CHLORIDE	3MEQ/ML	N86205
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE	900MG/100ML	N06580
AMMONIUM CHLORIDE 2.14%	40MEQ/100ML	N85734

AMODIAQUINE HYDROCHLORIDE

TABLET

CAMOQUIN HCL	EQ 200MG BASE	N06441

AMOXAPINE

TABLET

ASENDIN	100MG	N18021
ASENDIN	150MG	N18021
ASENDIN	25MG	N18021
ASENDIN	50MG	N18021

AMOXICILLIN

CAPSULE

AMOXICILLIN	250MG	N62528
AMOXICILLIN	500MG	N62528
AMOXICILLIN	250MG	N62067
AMOXICILLIN	500MG	N62067
AMOXICILLIN	250MG	N63030
AMOXICILLIN	500MG	N63031
AMOXIL	250MG	N50459
AMOXIL	250MG	N62216
AMOXIL	500MG	N50459
TRIMOX	250MG	N62098

AMOXICILLIN

CAPSULE

TRIMOX	250MG	N62152
TRIMOX	250MG	N63099
TRIMOX	500MG	N62098
TRIMOX	500MG	N62152
TRIMOX	500MG	N63099
UTIMOX	250MG	N62107
UTIMOX	500MG	N62107
WYMOX	250MG	N62120
WYMOX	500MG	N62120

FOR SUSPENSION

AMOXICILLIN	125MG/5ML	N62090
AMOXICILLIN	250MG/5ML	N62090
AMOXIL	125MG/5ML	N50460
AMOXIL	250MG/5ML	N50460
AMOXIL	50MG/ML	N50460
LAROTID	50MG/ML	N50460
POLYMOX	125MG/5ML	N61851
POLYMOX	125MG/5ML	N62323
POLYMOX	250MG/5ML	N61851
POLYMOX	250MG/5ML	N62323
TRIMOX	125MG/5ML	N61886
TRIMOX	125MG/5ML	N62099
TRIMOX	125MG/5ML	N62154
TRIMOX	250MG/5ML	N61886
TRIMOX	250MG/5ML	N62099
TRIMOX	250MG/5ML	N62154
TRIMOX	50MG/ML	N61886
UTIMOX	125MG/5ML	N62127
UTIMOX	250MG/5ML	N62127

TABLET, CHEWABLE

AMOXICILLIN	125MG	N64131
AMOXICILLIN	250MG	N64131

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE

DELCOBESE	1.25MG;1.25MG;1.25MG;1.25MG	N83564
DELCOBESE	2.5MG;2.5MG;2.5MG;2.5MG	N83564
DELCOBESE	3.75MG;3.75MG;3.75MG;3.75MG	N83564
DELCOBESE	5MG;5MG;5MG;5MG	N83564

TABLET

DELCOBESE	1.25MG;1.25MG;1.25MG;1.25MG	N83563
DELCOBESE	2.5MG;2.5MG;2.5MG;2.5MG	N83563

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

TABLET

DELCOBESE	3.75MG;3.75MG;3.75MG;3.75MG	N83563
DELCOBESE	5MG;5MG;5MG;5MG	N83563

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE

BIPHETAMINE 12.5	EQ 6.25MG BASE;EQ 6.25MG BASE	N10093
BIPHETAMINE 20	EQ 10MG BASE;EQ 10MG BASE	N10093
BIPHETAMINE 7.5	EQ 3.75MG BASE;EQ 3.75MG BASE	N10093

AMPHETAMINE SULFATE

TABLET

AMPHETAMINE SULFATE	10MG	N83901
AMPHETAMINE SULFATE	5MG	N83901

AMPHOTERICIN B

INJECTABLE

AMPHOTERICIN B	50MG/VIAL	N64141
AMPHOTERICIN B	50MG/VIAL	N62728

OINTMENT

FUNGIZONE	3%	N50313

SUSPENSION

FUNGIZONE	100MG/ML	N50341

AMPICILLIN SODIUM

INJECTABLE

AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 10GM BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 10GM BASE/VIAL	N63142
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N63143
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62772
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N63139
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N63145
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N63140
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N63141

AMPICILLIN SODIUM

INJECTABLE

AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N63146
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N63147
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N62797
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62797
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62634
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62634
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62565
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62565
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N62565
AMPICILLIN SODIUM	EQ 10GM BASE/VIAL	N62994
OMNIPEN-N	EQ 125MG BASE/VIAL	N62718
OMNIPEN-N	EQ 1GM BASE/VIAL	N62718
OMNIPEN-N	EQ 250MG BASE/VIAL	N62718
OMNIPEN-N	EQ 2GM BASE/VIAL	N62718
OMNIPEN-N	EQ 500MG BASE/VIAL	N62718
PENBRITIN-S	EQ 125MG BASE/VIAL	N50072
PENBRITIN-S	EQ 1GM BASE/VIAL	N50072
PENBRITIN-S	EQ 250MG BASE/VIAL	N50072
PENBRITIN-S	EQ 2GM BASE/VIAL	N50072
PENBRITIN-S	EQ 4GM BASE/VIAL	N50072
PENBRITIN-S	EQ 500MG BASE/VIAL	N50072
POLYCILLIN-N	EQ 125MG BASE/VIAL	N50309
POLYCILLIN-N	EQ 1GM BASE/VIAL	N50309
POLYCILLIN-N	EQ 250MG BASE/VIAL	N50309
POLYCILLIN-N	EQ 2GM BASE/VIAL	N50309
POLYCILLIN-N	EQ 500MG BASE/VIAL	N50309
TOTACILLIN-N	EQ 1GM BASE/VIAL	N62727
TOTACILLIN-N	EQ 2GM BASE/VIAL	N62727

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE

UNASYN	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N50608

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE

AMCILL	EQ 250MG BASE	N62041
AMCILL	EQ 500MG BASE	N62041
AMPICILLIN	EQ 250MG BASE	N62208
AMPICILLIN	EQ 500MG BASE	N62208
AMPICILLIN	EQ 250MG BASE	N61387
AMPICILLIN	EQ 500MG BASE	N61387
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N64082
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N64082
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N60765
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N60765

AMPICILLIN/AMPICILLIN TRIHYDRATE		
CAPSULE		
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N61755
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N61755
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N61853
PENBRITIN	EQ 250MG BASE	N60908
PENBRITIN	EQ 500MG BASE	N60908
PFIZERPEN-A	EQ 250MG BASE	N62050
PFIZERPEN-A	EQ 500MG BASE	N62050
POLYCILLIN	EQ 250MG BASE	N50310
POLYCILLIN	EQ 500MG BASE	N50310
PRINCIPEN '250'	EQ 250MG BASE	N50056
PRINCIPEN '250'	EQ 250MG BASE	N62157
PRINCIPEN '500'	EQ 500MG BASE	N50056
PRINCIPEN '500'	EQ 500MG BASE	N62157
TOTACILLIN	EQ 250MG BASE	N60060
TOTACILLIN	EQ 500MG BASE	N60060
FOR SUSPENSION		
AMCILL	EQ 125MG BASE/5ML	N62030
AMCILL	EQ 250MG BASE/5ML	N62030
AMPICILLIN TRIHYDRATE	EQ 125MG BASE/5ML	N61829
AMPICILLIN TRIHYDRATE	EQ 250MG BASE/5ML	N61829
AMPICILLIN TRIHYDRATE	EQ 125MG BASE/5ML	N61980
OMNIPEN (AMPICILLIN)	500MG/5ML	N60625
PENBRITIN	EQ 100MG BASE/ML	N50019
PENBRITIN	EQ 125MG BASE/5ML	N50019
PENBRITIN	EQ 250MG BASE/5ML	N50019
PFIZERPEN-A	EQ 125MG BASE/5ML	N62049
PFIZERPEN-A	EQ 250MG BASE/5ML	N62049
POLYCILLIN	EQ 125MG BASE/5ML	N62297
POLYCILLIN	EQ 250MG BASE/5ML	N62297
POLYCILLIN	EQ 100MG BASE/ML	N50308
POLYCILLIN	EQ 125MG BASE/5ML	N50308
POLYCILLIN	EQ 250MG BASE/5ML	N50308
POLYCILLIN	EQ 500MG BASE/5ML	N50308
PRINCIPEN '125'	EQ 125MG BASE/5ML	N60127
PRINCIPEN '125'	EQ 125MG BASE/5ML	N62151
PRINCIPEN '250'	EQ 250MG BASE/5ML	N60127
PRINCIPEN '250'	EQ 250MG BASE/5ML	N62151
TOTACILLIN	EQ 125MG BASE/5ML	N60666
TOTACILLIN	EQ 125MG BASE/5ML	N62223
TOTACILLIN	EQ 250MG BASE/5ML	N60666
TOTACILLIN	EQ 250MG BASE/5ML	N62223
TABLET, CHEWABLE		
POLYCILLIN	EQ 125MG BASE	N50093

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID		
CAPSULE		
PRINCIPEN W/ PROBENECID	EQ 389MG BASE;111MG	N50488
PRINCIPEN W/ PROBENECID	EQ 389MG BASE;111MG	N62150
FOR SUSPENSION		
POLYCILLIN-PRB	EQ 3.5GM BASE/BOT;1GM/BOT	N61898
POLYCILLIN-PRB	EQ 3.5GM BASE/BOT;1GM/BOT	N50457
PROBAMPACIN	EQ 3.5GM BASE/BOT;1GM/BOT	N61741
AMPRENAVIR		
CAPSULE		
AGENERASE	150MG	N21007
AGENERASE	50MG	N21007
SOLUTION		
AGENERASE	15MG/ML	N21039
ANILERIDINE HYDROCHLORIDE		
TABLET		
LERITINE	EQ 25MG BASE	N10585
ANILERIDINE PHOSPHATE		
INJECTABLE		
LERITINE	25MG/ML	N10520
ANISOTROPINE METHYLBROMIDE		
TABLET		
ANISOTROPINE METHYLBROMIDE	50MG	N86046
VALPIN 50	50MG	N13428
ARBUTAMINE HYDROCHLORIDE		
INJECTABLE		
GENESA	0.05MG/ML	N20420
ARDEPARIN SODIUM		
INJECTABLE		
NORMIFLO	10,000 UNITS/0.5ML	*N20227
NORMIFLO	5,000 UNITS/0.5ML	*N20227
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E		
INJECTABLE		
BEROCCA PN	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;1.5MG/ML;1,650 IU/ML;5 IU/ML	N06071

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE

M.V.C. 9+3	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N18440
MVC PLUS	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N18439

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE

M.V.I.-12 LYOPHILIZED	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N18933

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE

VITAPED	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;400 IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG/VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML;7 IU/10ML	N20176

ASPIRIN

TABLET, EXTENDED RELEASE

8-HOUR BAYER	650MG	N16030
MEASURIN	650MG	N16030

ASPIRIN; BUTALBITAL

TABLET

AXOTAL	650MG;50MG	N88305

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE

BUTALBITAL, ASPIRIN AND CAFFEINE	325MG;50MG;40MG	N86231

TABLET

BUTALBITAL ASPIRIN AND CAFFEINE	325MG;50MG;40MG	N88972
BUTALBITAL COMPOUND	325MG;50MG;40MG	N85441
BUTALBITAL, ASPIRIN & CAFFEINE	325MG;50MG;40MG	N89448

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET

BUTALBITAL, ASPIRIN AND CAFFEINE	325MG;50MG;40MG	N86237
LANORINAL	325MG;50MG;40MG	N86986

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE

COMPOUND 65	389MG;32.4MG;65MG	N84553
PROPOXYPHENE COMPOUND 65	389MG;32.4MG;65MG	N80044
PROPOXYPHENE COMPOUND 65	389MG;32.4MG;65MG	N83077
PROPOXYPHENE COMPOUND-65	389MG;32.4MG;65MG	N83101
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE	389MG;32.4MG;65MG	N85732

ASPIRIN; CARISOPRODOL

TABLET

CARISOPRODOL COMPOUND	325MG;200MG	N88809

ASPIRIN; HYDROCODONE BITARTRATE

TABLET

VICOPRIN	500MG;5MG	N86333

ASPIRIN; MEPROBAMATE

TABLET

MEPRO-ASPIRIN	325MG;200MG	N89127
MEPROBAMATE AND ASPIRIN	325MG;200MG	N89126
Q-GESIC	325MG;200MG	N88740

ASPIRIN; METHOCARBAMOL

TABLET

METHOCARBAMOL AND ASPIRIN	325MG;400MG	N89193

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET

CODOXY	325MG;4.5MG;0.38MG	N87464
OXYCODONE AND ASPIRIN (HALF-STRENGTH)	325MG;2.25MG;0.19MG	N87742
ROXIPRIN	325MG;4.5MG;0.38MG	N87743

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET

TALWIN COMPOUND	325MG;EQ 12.5MG BASE	N16891

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE

DARVON-N W/ ASA	325MG;100MG	N16829

TABLET

DARVON-N W/ ASA	325MG;100MG	N16863

ATENOLOL

TABLET

ATENOLOL	100MG	N73318
ATENOLOL	50MG	N73317
ATENOLOL	100MG	N74126
ATENOLOL	25MG	N74126

ATENOLOL		
TABLET		
ATENOLOL	50MG	N74126
ATROPINE		
INJECTABLE		
ATROPINE	EQ 2MG SULFATE/0.7ML	N71295
ATROPINE SULFATE		
AEROSOL, METERED		
ATROPINE SULFATE	EQ 0.36MG BASE/INH	N20056
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE		
TABLET		
MOTOFEN HALF-STRENGTH	0.025MG;0.5MG	N17744
ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE		
SOLUTION		
COLONAID	0.025MG/5ML;2.5MG/5ML	N85735
LOMANATE	0.025MG/5ML;2.5MG/5ML	N85746
TABLET		
COLONAID	0.025MG;2.5MG	N85737
DI-ATRO	0.025MG;2.5MG	N85266
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N87934
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85506
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N86798
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85509
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N86950
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N87131
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85035
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N86057
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85876
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N87765
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N87195
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N85659
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N85766
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N87842
LO-TROL	0.025MG;2.5MG	N88009
LOGEN	0.025MG;2.5MG	N88962
LOW-QUEL	0.025MG;2.5MG	N85211
ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE		
INJECTABLE		
MEPERIDINE AND ATROPINE SULFATE	0.4MG/ML;100MG/ML	N85121
MEPERIDINE AND ATROPINE SULFATE	0.4MG/ML;50MG/ML	N85121
MEPERIDINE AND ATROPINE SULFATE	0.4MG/ML;75MG/ML	N85121
ATROPINE; PRALIDOXIME CHLORIDE		
INJECTABLE		
ATNAA	2.1MG/0.7ML;600MG/2ML	N21175
AZATHIOPRINE		
TABLET		
IMURAN	25MG	* N16324
AZATHIOPRINE SODIUM		
INJECTABLE		
AZATHIOPRINE	EQ 100MG BASE/VIAL	N71056
AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE		
FOR SUSPENSION, TABLET		
TROVAN/ZITHROMAX COMPLIANCE PAK	EQ 1GM BASE;EQ 100MG BASE	N50762
AZLOCILLIN SODIUM		
INJECTABLE		
AZLIN	EQ 2GM BASE/VIAL	N50562
AZLIN	EQ 2GM BASE/VIAL	N62388
AZLIN	EQ 2GM BASE/VIAL	N62417
AZLIN	EQ 3GM BASE/VIAL	N50562
AZLIN	EQ 3GM BASE/VIAL	N62388
AZLIN	EQ 3GM BASE/VIAL	N62417
AZLIN	EQ 4GM BASE/VIAL	N50562
AZLIN	EQ 4GM BASE/VIAL	N62388
AZLIN	EQ 4GM BASE/VIAL	N62417
AZTREONAM		
INJECTABLE		
AZACTAM	1GM/VIAL	N50580
AZACTAM	2GM/VIAL	N50580
AZACTAM	500MG/VIAL	N50580
AZACTAM IN PLASTIC CONTAINER	10MG/ML	N50632
BACAMPICILLIN HYDROCHLORIDE		
TABLET		
SPECTROBID	800MG	N50520
BACITRACIN		
INJECTABLE		
BACITRACIN	50,000 UNITS/VIAL	N60282
BACITRACIN	10,000 UNITS/VIAL	N62696
BACITRACIN	50,000 UNITS/VIAL	N62696
OINTMENT		
BACIGUENT	500 UNITS/GM	N60734
BACITRACIN	500 UNITS/GM	N62799
BACITRACIN	500 UNITS/GM	N60687
BACITRACIN	500 UNITS/GM	N62158
BACITRACIN	500 UNITS/GM	N62453
POWDER		
BACITRACIN	5,000,000 UNITS/BOT	N62456

BACITRACIN ZINC

POWDER

ZIBA-RX	500,000 UNITS/BOT	N61737

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N62381
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62389

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

LANABIOTIC	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	N62499

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62386
BACITRACIN-NEOMYCIN-POLYMYXIN	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N62167
NEO-POLYCIN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL

POLYSPORIN	10,000 UNITS/GM;2,000,000 UNITS/GM	N50167

OINTMENT

OCUMYCIN	500 UNITS/GM;10,000 UNITS/GM	N62430

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60731

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

MYCITRACIN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N61048

BACITRACIN; POLYMYXIN B SULFATE

DISC

LANABIOTIC	500 UNITS/GM;5,000 UNITS/GM	N50598

BACLOFEN

TABLET

BACLOFEN	10MG	N73043
BACLOFEN	20MG	N73044
BACLOFEN	10MG	N71260
BACLOFEN	20MG	N71261
LIORESAL	10MG	N17851
LIORESAL	20MG	N17851

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED

VANCENASE AQ	EQ 0.084MG DIPROP/SPRAY	N20469

BENDROFLUMETHIAZIDE

TABLET

NATURETIN-10	10MG	N12164
NATURETIN-2.5	2.5MG	N12164

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS

BENOXINATE HCL	0.4%	N84149

BENTIROMIDE

SOLUTION

CHYMEX	500MG/7.5ML	N18366

BENZPHETAMINE HYDROCHLORIDE

TABLET

DIDREX	25MG	N12427

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY

EMETE-CON	EQ 100MG BASE	N16818

BENZTHIAZIDE

TABLET

AQUATAG	25MG	N16001
AQUATAG	50MG	N16001
BENZTHIAZIDE	50MG	N83206
EXNA	50MG	N12489
FOVANE	50MG	N12128
URESE	25MG	N12128

BENZTROPINE MESYLATE

TABLET

BENZTROPINE MESYLATE	0.5MG	N88514
BENZTROPINE MESYLATE	1MG	N88510

BENZTROPINE MESYLATE		
TABLET		
BENZTROPINE MESYLATE	2MG	N88511
BENZTROPINE MESYLATE	0.5MG	N89211
BENZTROPINE MESYLATE	1MG	N89212
BENZTROPINE MESYLATE	2MG	N89213
COGENTIN	0.5MG	N09193
COGENTIN	1MG	N09193
COGENTIN	2MG	N09193
BENZYL BENZOATE		
EMULSION		
BENZYL BENZOATE	50%	N84535
BEPRIDIL HYDROCHLORIDE		
TABLET		
BEPADIN	200MG	N19001
BEPADIN	300MG	N19001
BEPADIN	400MG	N19001
VASCOR	400MG	N19002
BETA-CAROTENE		
CAPSULE		
SOLATENE	30MG	N17589
BETAMETHASONE		
CREAM		
CELESTONE	0.2%	N14762
BETAMETHASONE BENZOATE		
CREAM		
UTICORT	0.025%	N16998
GEL		
UTICORT	0.025%	N17244
LOTION		
UTICORT	0.025%	N17528
OINTMENT		
UTICORT	0.025%	N18089
BETAMETHASONE DIPROPIONATE		
CREAM		
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N72536
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N74579
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N19136
CREAM, AUGMENTED		
DIPROLENE	EQ 0.05% BASE	N19408
DISC		
DIPROSONE	EQ 0.1% BASE	N17829
LOTION		
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N71085
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N70274

BETAMETHASONE DIPROPIONATE		
OINTMENT		
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N72526
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N19140
DIPROSONE	EQ 0.05% BASE	N17691
BETAMETHASONE VALERATE		
CREAM		
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70053
BETAMETHASONE VALERATE	EQ 0.1% BASE	N18860
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70485
VALISONE	EQ 0.01% BASE	N16322
VALISONE	EQ 0.1% BASE	N16322
LOTION		
BETAMETHASONE VALERATE	EQ 0.1% BASE	N18870
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70484
VALISONE	EQ 0.1% BASE	N16932
OINTMENT		
BETAMETHASONE VALERATE	EQ 0.1% BASE	N71478
BETAMETHASONE VALERATE	EQ 0.1% BASE	N18864
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70486
VALISONE	EQ 0.1% BASE	N16740
BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE		
TABLET		
KERLEDEX	10MG;12.5MG	N19807
KERLEDEX	5MG;12.5MG	N19807
BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE		
SUSPENSION/DROPS		
BETOPTIC PILO	EQ 0.25% BASE;1.75%	N20619
BETAZOLE HYDROCHLORIDE		
INJECTABLE		
HISTALOG	50MG/ML	N09344
BETHANECHOL CHLORIDE		
INJECTABLE		
BETHANECHOL CHLORIDE	5MG/ML	N89815
URECHOLINE	5MG/ML	*N06536
TABLET		
BETHANECHOL CHLORIDE	10MG	N88288
BETHANECHOL CHLORIDE	25MG	N88289
BETHANECHOL CHLORIDE	10MG	N84378
BETHANECHOL CHLORIDE	10MG	N84379
BETHANECHOL CHLORIDE	25MG	N84383
BETHANECHOL CHLORIDE	25MG	N84384
BETHANECHOL CHLORIDE	5MG	N84353
BETHANECHOL CHLORIDE	25MG	N84689
BETHANECHOL CHLORIDE	10MG	N84712

BETHANECHOL CHLORIDE

TABLET

BETHANECHOL CHLORIDE	25MG	N84074
BETHANECHOL CHLORIDE	5MG	N84702
BETHANECHOL CHLORIDE	10MG	N85228
BETHANECHOL CHLORIDE	25MG	N85229
BETHANECHOL CHLORIDE	50MG	N87397
BETHANECHOL CHLORIDE	5MG	N85230
BETHANECHOL CHLORIDE	10MG	N84408
BETHANECHOL CHLORIDE	10MG	N85842
BETHANECHOL CHLORIDE	25MG	N84441
BETHANECHOL CHLORIDE	25MG	N85839
BETHANECHOL CHLORIDE	50MG	N87444
BETHANECHOL CHLORIDE	5MG	N84402
BETHANECHOL CHLORIDE	5MG	N85841
DUVOID	10MG	N86262
DUVOID	25MG	N86263
DUVOID	50MG	N85882
MYOTONACHOL	10MG	N84188
MYOTONACHOL	25MG	N84188
MYOTONACHOL	5MG	N84188
URECHOLINE	10MG	* N06536
URECHOLINE	25MG	* N06536
URECHOLINE	50MG	* N06536
URECHOLINE	5MG	* N06536

BETHANIDINE SULFATE

TABLET

TENATHAN	10MG	N17675
TENATHAN	25MG	N17675

BIPERIDEN LACTATE

INJECTABLE

AKINETON	5MG/ML	N12418

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	10MG;6.25MG	N75642
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	2.5MG;6.25MG	N75642
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	5MG;6.25MG	N75642

BITOLTEROL MESYLATE

AEROSOL, METERED

TORNALATE	0.37MG/INH	N18770

SOLUTION

TORNALATE	0.2%	N19548

BRETYLIUM TOSYLATE

INJECTABLE

BRETYLIUM TOSYLATE	100MG/ML	N71298
BRETYLIUM TOSYLATE	50MG/ML	N70134
BRETYLIUM TOSYLATE	50MG/ML	N71151
BRETYLIUM TOSYLATE	50MG/ML	N71152
BRETYLIUM TOSYLATE	50MG/ML	N71153
BRETYLIUM TOSYLATE	50MG/ML	N71181
BRETYLIUM TOSYLATE IN DEXTROSE 5%	200MG/100ML	N19005
BRETYLIUM TOSYLATE IN DEXTROSE 5%	400MG/100ML	N19005
BRETYLIUM TOSYLATE IN DEXTROSE 5%	800MG/100ML	N19005
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	800MG/100ML	N19008
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N19837
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N19837
BRETYLOL	50MG/ML	N17954

BRIMONIDINE TARTRATE

SOLUTION/DROPS

ALPHAGAN	0.2%	N20613
ALPHAGAN	0.5%	N20490

BROMOCRIPTINE MESYLATE

CAPSULE

BROMOCRIPTINE MESYLATE	EQ 5MG BASE	N75100

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE

AMBODRYL	25MG	N07984

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP

BROMANYL	12.5MG/5ML;10MG/5ML	N88343

BROMPHENIRAMINE MALEATE

ELIXIR

BROMPHENIRAMINE MALEATE	2MG/5ML	N86936
BROMPHENIRAMINE MALEATE	2MG/5ML	N87517
BROMPHENIRAMINE MALEATE	2MG/5ML	N87964

INJECTABLE

BROMPHENIRAMINE MALEATE	100MG/ML	N83820
DIMETANE-TEN	10MG/ML	N11418

TABLET

BROMPHENIRAMINE MALEATE	4MG	N86187
BROMPHENIRAMINE MALEATE	4MG	N84468
BROMPHENIRAMINE MALEATE	4MG	N83215
BROMPHENIRAMINE MALEATE	4MG	N84351
BROMPHENIRAMINE MALEATE	4MG	N86987
BROMPHENIRAMINE MALEATE	4MG	N87009

BROMPHENIRAMINE MALEATE

TABLET		
BROMPHENIRAMINE MALEATE	4MG	N88604
BROMPHENIRAMINE MALEATE	4MG	N85850
BROMPHENIRAMINE MALEATE	4MG	N83123
BROMPHENIRAMINE MALEATE	4MG	N85769
DIMETANE	4MG	N10799
TABLET, EXTENDED RELEASE		
DIMETANE	12MG	N10799
DIMETANE	8MG	N10799

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP		
DIMETANE-DC	2MG/5ML;10MG/5ML;12.5MG/5ML	N11694

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP		
BROMANATE DM	2MG/5ML;10MG/5ML;30MG/5ML	N88722

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR		
BIPHETAP	4MG/5ML;25MG/5ML	N88687
BROMANATE	4MG/5ML;25MG/5ML	N88688
TABLET, EXTENDED RELEASE		
BROMATAPP	12MG;75MG	N71099

BUCLIZINE HYDROCHLORIDE

TABLET		
BUCLADIN-S	50MG	N10911

BUDESONIDE

POWDER, METERED		
PULMICORT	0.32MG/INH	N20441
SUSPENSION		
PULMICORT RESPULES	1MG/2ML	N20929

BUPIVACAINE HYDROCHLORIDE

INJECTABLE		
BUPIVACAINE HCL KIT	0.075%	N19978
BUPIVACAINE HCL KIT	0.114%	N19978
BUPIVACAINE HCL KIT	0.23%	N19978

BUPROPION HYDROCHLORIDE

TABLET		
WELLBUTRIN	50MG	N18644

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE		
ZYBAN	100MG	N20711

BUSPIRONE HYDROCHLORIDE

CAPSULE		
BUSPAR	10MG	N21190
BUSPAR	15MG	N21190
BUSPAR	5MG	N21190
BUSPAR	7.5MG	N21190

BUTABARBITAL SODIUM

CAPSULE		
BUTICAPS	100MG	N85381
BUTICAPS	15MG	N85381
BUTICAPS	30MG	N85381
BUTICAPS	50MG	N85381
ELIXIR		
BUTABARB	30MG/5ML	N85873
BUTABARBITAL SODIUM	30MG/5ML	N85383
BUTALAN	33.3MG/5ML	N85880
SARISOL	30MG/5ML	N84723
TABLET		
BUTABARBITAL SODIUM	15MG	N85938
BUTABARBITAL SODIUM	30MG	N85934
BUTABARBITAL SODIUM	15MG	N84292
BUTABARBITAL SODIUM	30MG	N84272
BUTABARBITAL SODIUM	16.2MG	N83606
BUTABARBITAL SODIUM	32.4MG	N83898
BUTABARBITAL SODIUM	48.6MG	N83897
BUTABARBITAL SODIUM	97.2MG	N83896
BUTABARBITAL SODIUM	15MG	N88632
BUTABARBITAL SODIUM	30MG	N88631
BUTABARBITAL SODIUM	15MG	N85764
BUTABARBITAL SODIUM	30MG	N85772
BUTABARBITAL SODIUM	15MG	N83325
BUTABARBITAL SODIUM	30MG	N83337
BUTISOL SODIUM	100MG	N00793
BUTISOL SODIUM	15MG	N00793
SARISOL NO. 1	15MG	N84719
SARISOL NO. 2	30MG	N84719
SODIUM BUTABARBITAL	15MG	N83484
SODIUM BUTABARBITAL	30MG	N84040
SODIUM BUTABARBITAL	100MG	N85881
SODIUM BUTABARBITAL	15MG	N85849
SODIUM BUTABARBITAL	30MG	N85866
SODIUM BUTABARBITAL	15MG	N85418

BUTABARBITAL SODIUM
TABLET

SODIUM BUTABARBITAL	30MG	N85432

BUTOCONAZOLE NITRATE
CREAM

FEMSTAT	2%	N19215

SUPPOSITORY

FEMSTAT	100MG	N19359

CAFFEINE; ERGOTAMINE TARTRATE
SUPPOSITORY

MIGERGOT	100MG;2MG	N86557

TABLET

CAFERGOT	100MG;1MG	N06620
WIGRAINE	100MG;1MG	N86562

CALCIFEDIOL
CAPSULE

CALDEROL	0.02MG	N18312
CALDEROL	0.05MG	N18312

CALCITONIN HUMAN
INJECTABLE

CIBACALCIN	0.5MG/VIAL	N18470

CALCITONIN, SALMON
INJECTABLE

CALCIMAR	400 IU/VIAL	N17497
CALCITONIN-SALMON	200 IU/ML	N73690
MIACALCIN	100 IU/ML	N17808

CALCIUM ACETATE
CAPSULE

PHOSLO	EQ 169MG CALCIUM	N21160
PHOSLO	EQ 84.5MG CALCIUM	N21160

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
INJECTABLE

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N18271

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
INJECTABLE

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N18269

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SOLUTION

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N18460
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N18460
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N18460

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SOLUTION

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N18460
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER	26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N18460
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER	26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N18460

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
INJECTABLE

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N19634
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N17510
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N18499
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N19395
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N19395
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N19395

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

TPN ELECTROLYTES IN PLASTIC CONTAINER	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N19399

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE

ISOLYTE E IN PLASTIC CONTAINER	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N18899

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

ACETATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N18725

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION

RINGER'S IN PLASTIC CONTAINER	33MG/100ML;30MG/100ML;860MG/100ML	N18462

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE

LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N19485
LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N18023
LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N18417

CALCIUM GLUCEPTATE

INJECTABLE

CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N80001
CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N83159

CALCIUM GLUCEPTATE

INJECTABLE

CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N89373
CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N06470

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE

ISOPAQUE 440	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N16847

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE

ISOPAQUE 280	0.35MG/ML;140.1MG/ML;461.8MG/ML	N17506

CANDICIDIN

OINTMENT

VANOBID	0.6MG/GM	N61596

TABLET

VANOBID	3MG	N61613

CAPTOPRIL

TABLET

CAPOTEN	150MG	N18343
CAPOTEN	37.5MG	N18343
CAPOTEN	75MG	N18343
CAPTOPRIL	100MG	N74640
CAPTOPRIL	12.5MG	N74640
CAPTOPRIL	25MG	N74640
CAPTOPRIL	50MG	N74640

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET

CAPTOPRIL AND HYDROCHLOROTHIAZIDE	50MG;25MG	N74832

CARBACHOL

SOLUTION

CARBACHOL	0.01%	N70292

CARBAMAZEPINE

TABLET

CARBAMAZEPINE	200MG	N70300
CARBAMAZEPINE	200MG	N70429

CARBENICILLIN DISODIUM

INJECTABLE

GEOPEN	EQ 10GM BASE/VIAL	N50306
GEOPEN	EQ 1GM BASE/VIAL	N50306
GEOPEN	EQ 2GM BASE/VIAL	N50306
GEOPEN	EQ 30GM BASE/VIAL	N50306
GEOPEN	EQ 5GM BASE/VIAL	N50306
PYOPEN	EQ 10GM BASE/VIAL	N50298

CARBENICILLIN DISODIUM		
INJECTABLE		
PYOPEN	EQ 1GM BASE/VIAL	N50298
PYOPEN	EQ 20GM BASE/VIAL	N50298
PYOPEN	EQ 2GM BASE/VIAL	N50298
PYOPEN	EQ 5GM BASE/VIAL	N50298
CARBIDOPA; LEVODOPA		
TABLET		
CARBIDOPA AND LEVODOPA	10MG;100MG	N74080
CARBIDOPA AND LEVODOPA	25MG;100MG	N74080
CARBIDOPA AND LEVODOPA	25MG;250MG	N74080
CARBIDOPA AND LEVODOPA	10MG;100MG	N73381
CARBIDOPA AND LEVODOPA	25MG;100MG	N73382
CARBIDOPA AND LEVODOPA	25MG;250MG	N73383
CARBINOXAMINE MALEATE		
ELIXIR		
CLISTIN	4MG/5ML	N08955
TABLET		
CLISTIN	4MG	* N08915
CARISOPRODOL		
CAPSULE		
SOMA	250MG	N11792
TABLET		
CARISOPRODOL	350MG	N89566
CARISOPRODOL	350MG	N89390
CARISOPRODOL	350MG	N85433
RELA	350MG	N12155
CARPHENAZINE MALEATE		
CONCENTRATE		
PROKETAZINE	50MG/ML	N14173
TABLET		
PROKETAZINE	12.5MG	N12768
PROKETAZINE	25MG	N12768
PROKETAZINE	50MG	N12768
CARPROFEN		
TABLET		
RIMADYL	100MG	N18550
RIMADYL	150MG	N18550
CARTEOLOL HYDROCHLORIDE		
TABLET		
CARTROL	10MG	N19204
CEFACLOR		
CAPSULE		
CEFACLOR	EQ 250MG BASE	N64107
CEFACLOR		
CAPSULE		
CEFACLOR	EQ 500MG BASE	N64107
CEFACLOR	EQ 250MG BASE	N64081
CEFACLOR	EQ 500MG BASE	N64081
FOR SUSPENSION		
CEFACLOR	EQ 125MG BASE/5ML	N64087
CEFACLOR	EQ 187MG BASE/5ML	N64086
CEFACLOR	EQ 250MG BASE/5ML	N64085
CEFACLOR	EQ 125MG BASE/5ML	N64114
CEFACLOR	EQ 187MG BASE/5ML	N64115
CEFACLOR	EQ 250MG BASE/5ML	N64116
CEFACLOR	EQ 375MG BASE/5ML	N64110
TABLET, EXTENDED RELEASE		
CECLOR CD	EQ 375MG BASE	N50673
CEFADROXIL/CEFADROXIL HEMIHYDRATE		
CAPSULE		
CEFADROXIL	EQ 500MG BASE	N63017
CEFADROXIL	EQ 500MG BASE	N62695
DURICEF	EQ 250MG BASE	N50512
ULTRACEF	EQ 500MG BASE	N62378
FOR SUSPENSION		
CEFADROXIL	EQ 125MG BASE/5ML	N62334
CEFADROXIL	EQ 250MG BASE/5ML	N62334
CEFADROXIL	EQ 500MG BASE/5ML	N62334
CEFADROXIL	EQ 125MG BASE/5ML	N62698
CEFADROXIL	EQ 250MG BASE/5ML	N62698
CEFADROXIL	EQ 500MG BASE/5ML	N62698
ULTRACEF	EQ 125MG BASE/5ML	N62376
ULTRACEF	EQ 250MG BASE/5ML	N62376
ULTRACEF	EQ 500MG BASE/5ML	N62376
TABLET		
CEFADROXIL	EQ 1GM BASE	N62774
ULTRACEF	EQ 1GM BASE	N62390
ULTRACEF	EQ 1GM BASE	N62408
CEFAMANDOLE NAFATE		
INJECTABLE		
MANDOL	EQ 10GM BASE/VIAL	N50504
MANDOL	EQ 1GM BASE/VIAL	N62560
MANDOL	EQ 2GM BASE/VIAL	N62560
MANDOL	EQ 500MG BASE/VIAL	N50504
CEFAZOLIN SODIUM		
INJECTABLE		
ANCEF	EQ 250MG BASE/VIAL	N50461
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50566

CEFAZOLIN SODIUM

INJECTABLE

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50566
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50566
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50566
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 20GM BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 250MG BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 5GM BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 20GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 250MG BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 5GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N63016
CEFAZOLIN SODIUM	EQ 250MG BASE/VIAL	N63016
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N63016
KEFZOL	EQ 1GM BASE/VIAL	N62557
KEFZOL	EQ 500MG BASE/VIAL	N62557

CEFMENOXIME HYDROCHLORIDE

INJECTABLE

CEFMAX	EQ 1GM BASE/VIAL	N50571
CEFMAX	EQ 2GM BASE/VIAL	N50571
CEFMAX	EQ 500MG BASE/VIAL	N50571

CEFMETAZOLE SODIUM

INJECTABLE

ZEFAZONE	EQ 1GM BASE/VIAL	N50637
ZEFAZONE	EQ 2GM BASE/VIAL	N50637
ZEFAZONE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50683
ZEFAZONE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50683

CEFONICID SODIUM

INJECTABLE

MONOCID	EQ 10GM BASE/VIAL	N50579
MONOCID	EQ 1GM BASE/VIAL	N50579
MONOCID	EQ 1GM BASE/VIAL	N63295
MONOCID	EQ 2GM BASE/VIAL	N50579
MONOCID	EQ 500MG BASE/VIAL	N50579

CEFOPERAZONE SODIUM

INJECTABLE

CEFOBID	EQ 1GM BASE/VIAL	N63333
CEFOBID	EQ 2GM BASE/VIAL	N63333

CEFORANIDE

INJECTABLE

PRECEF	10GM/VIAL	N62579
PRECEF	1GM/VIAL	N62579
PRECEF	20GM/VIAL	N62579
PRECEF	2GM/VIAL	N62579
PRECEF	500MG/VIAL	N62579
PRECEF	10GM/VIAL	N50554
PRECEF	1GM/VIAL	N50554
PRECEF	20GM/VIAL	N50554
PRECEF	2GM/VIAL	N50554
PRECEF	500MG/VIAL	N50554

CEFOTIAM HYDROCHLORIDE

INJECTABLE

CERADON	EQ 1GM BASE/VIAL	N50601

CEFOXITIN SODIUM

INJECTABLE

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50581
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50581
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50581
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50581

CEFPIRAMIDE SODIUM

INJECTABLE

CEFPIRAMIDE SODIUM	EQ 10GM BASE/VIAL	N50633
CEFPIRAMIDE SODIUM	EQ 1GM BASE/VIAL	N50633
CEFPIRAMIDE SODIUM	EQ 2GM BASE/VIAL	N50633

CEFPODOXIME PROXETIL

FOR SUSPENSION

BANAN	EQ 100MG BASE/5ML	N50688
BANAN	EQ 50MG BASE/5ML	N50688

TABLET

BANAN	EQ 100MG BASE	N50687
BANAN	EQ 200MG BASE	N50687

CEFTAZIDIME

INJECTABLE

TAZIDIME IN PLASTIC CONTAINER	1GM/VIAL	N62739
TAZIDIME IN PLASTIC CONTAINER	2GM/VIAL	N62739

CEFTAZIDIME (ARGININE FORMULATION)		
INJECTABLE		
CEPTAZ	500MG/VIAL	N50646
PENTACEF	10GM/VIAL	N64008
PENTACEF	1GM/VIAL	N63322
PENTACEF	1GM/VIAL	N64006
PENTACEF	2GM/VIAL	N63322
PENTACEF	2GM/VIAL	N64006
PENTACEF	6GM/VIAL	N64008
CEFTAZIDIME SODIUM		
INJECTABLE		
FORTAZ IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50634
CEFTIZOXIME SODIUM		
INJECTABLE		
CEFIZOX	EQ 500MG BASE/VIAL	N50560
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50589
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50589
CEFTRIAXONE SODIUM		
INJECTABLE		
ROCEPHIN	EQ 500MG BASE/VIAL	N62654
ROCEPHIN	EQ 1GM BASE/VIAL	N62510
ROCEPHIN	EQ 250MG BASE/VIAL	N62510
ROCEPHIN	EQ 500MG BASE/VIAL	N62510
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50624
CEFTRIAXONE SODIUM; LIDOCAINE		
INJECTABLE		
ROCEPHIN KIT	EQ 1GM BASE/VIAL;1%	N50585
ROCEPHIN KIT	EQ 500MG BASE/VIAL;1%	N50585
CEFUROXIME SODIUM		
INJECTABLE		
KEFUROX IN PLASTIC CONTAINER	EQ 1.5GM BASE/VIAL	N62590
KEFUROX IN PLASTIC CONTAINER	EQ 750MG BASE/VIAL	N62590
CELLULOSE SODIUM PHOSPHATE		
POWDER		
CALCIBIND	2.5GM/PACKET	N18757
CEPHALEXIN		
CAPSULE		
CEPHALEXIN	EQ 250MG BASE	N62973
CEPHALEXIN	EQ 500MG BASE	N62974
CEPHALEXIN	EQ 250MG BASE	N62809
CEPHALEXIN	EQ 500MG BASE	N62809
CEPHALEXIN	EQ 500MG BASE	N62869
CEPHALEXIN	EQ 500MG BASE	N62823
CEPHALEXIN	EQ 250MG BASE	N62872
CEPHALEXIN	EQ 500MG BASE	N62871

CEPHALEXIN		
FOR SUSPENSION		
CEPHALEXIN	EQ 125MG BASE/5ML	N62778
CEPHALEXIN	EQ 125MG BASE/5ML	N62873
CEPHALEXIN	EQ 250MG BASE/5ML	N62867
CEPHALEXIN	EQ 125MG BASE/5ML	N62779
CEPHALEXIN	EQ 250MG BASE/5ML	N62781
KEFLEX	EQ 100MG BASE/ML	N50406
KEFLEX	EQ 125MG BASE/5ML	N50406
KEFLEX	EQ 250MG BASE/5ML	N50406
TABLET		
CEPHALEXIN	EQ 250MG BASE	N62826
CEPHALEXIN	EQ 500MG BASE	N62827
CEPHALEXIN	EQ 1GM BASE	N62863
CEPHALEXIN	EQ 250MG BASE	N62863
CEPHALEXIN	EQ 500MG BASE	N62863
KEFLET	EQ 1GM BASE	N50440
KEFLET	EQ 250MG BASE	N62745
KEFLET	EQ 500MG BASE	N50440
KEFLET	EQ 500MG BASE	N62745
CEPHALEXIN HYDROCHLORIDE		
TABLET		
KEFTAB	EQ 250MG BASE	N50614
KEFTAB	EQ 333MG BASE	N50614
CEPHALOGLYCIN		
CAPSULE		
KAFOCIN	250MG	N50219
CEPHALOTHIN SODIUM		
INJECTABLE		
CEPHALOTHIN	EQ 1GM BASE/VIAL	N62426
CEPHALOTHIN	EQ 2GM BASE/VIAL	N62426
CEPHALOTHIN	EQ 4GM BASE/VIAL	N62426
CEPHALOTHIN	EQ 500MG BASE/VIAL	N62426
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62547
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62548
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62547
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62548
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62666
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62666
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62730
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62422

CEPHALOTHIN SODIUM		
INJECTABLE		
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62730
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62422
KEFLIN	EQ 20GM BASE/VIAL	N50482
KEFLIN IN PLASTIC CONTAINER	EQ 1GM BASE/VIAL	N62549
KEFLIN IN PLASTIC CONTAINER	EQ 2GM BASE/VIAL	N62549
SEFFIN	EQ 10GM BASE/VIAL	N62435
SEFFIN	EQ 1GM BASE/VIAL	N62435
SEFFIN	EQ 2GM BASE/VIAL	N62435
CEPHAPIRIN SODIUM		
INJECTABLE		
CEFADYL	EQ 1GM BASE/VIAL	N50446
CEFADYL	EQ 1GM BASE/VIAL	N62724
CEFADYL	EQ 1GM BASE/VIAL	N62961
CEFADYL	EQ 20GM BASE/VIAL	N50446
CEFADYL	EQ 2GM BASE/VIAL	N50446
CEFADYL	EQ 2GM BASE/VIAL	N62724
CEFADYL	EQ 2GM BASE/VIAL	N62961
CEFADYL	EQ 4GM BASE/VIAL	N50446
CEFADYL	EQ 4GM BASE/VIAL	N62961
CEFADYL	EQ 500MG BASE/VIAL	N50446
CEPHAPIRIN SODIUM	EQ 1GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 20GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 2GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 4GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 500MG BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 1GM BASE/VIAL	N62720
CEPHAPIRIN SODIUM	EQ 20GM BASE/VIAL	N62720
CEPHAPIRIN SODIUM	EQ 2GM BASE/VIAL	N62720
CEPHAPIRIN SODIUM	EQ 500MG BASE/VIAL	N62720
CEPHRADINE		
CAPSULE		
CEPHRADINE	250MG	N62850
CEPHRADINE	500MG	N62851
CEPHRADINE	250MG	N62762
CEPHRADINE	500MG	N62762
CEPHRADINE	250MG	N62813
CEPHRADINE	500MG	N62813
VELOSEF '250'	250MG	N50548
VELOSEF '500'	500MG	N50548

CEPHRADINE		
FOR SUSPENSION		
CEPHRADINE	125MG/5ML	N62858
CEPHRADINE	250MG/5ML	N62859
INJECTABLE		
VELOSEF	1GM/VIAL	N61976
VELOSEF	250MG/VIAL	N61976
VELOSEF	2GM/VIAL	N61976
VELOSEF	4GM/VIAL	N61976
VELOSEF	500MG/VIAL	N61976
TABLET		
VELOSEF	1GM	N50530
CERIVASTATIN SODIUM		
TABLET		
BAYCOL	0.05MG	N20740
BAYCOL	0.1MG	N20740
BAYCOL	0.2MG	N20740
BAYCOL	0.3MG	N20740
BAYCOL	0.4MG	N20740
BAYCOL	0.8MG	N20740
CERULETIDE DIETHYLAMINE		
INJECTABLE		
TYMTRAN	0.02MG/ML	N18296
CHENODIOL		
TABLET		
CHENIX	250MG	N18513
CHLOPHEDIANOL HYDROCHLORIDE		
SYRUP		
ULO	25MG/5ML	N12126
CHLORAMPHENICOL		
CAPSULE		
AMPHICOL	100MG	N60058
AMPHICOL	250MG	N60058
CHLORAMPHENICOL	250MG	N62247
CHLOROMYCETIN	100MG	N60591
CHLOROMYCETIN	250MG	N60591
CHLOROMYCETIN	50MG	N60591
CREAM		
CHLOROMYCETIN	1%	N50183
FOR SOLUTION		
CHLOROMYCETIN	25MG/VIAL	N50143
INJECTABLE		
CHLOROMYCETIN	250MG/ML	N50153
OINTMENT		
CHLOROFAIR	1%	N62439

CHLORAMPHENICOL		
OINTMENT		
ECONOCHLOR	1%	N61648
SOLUTION/DROPS		
CHLORAMPHENICOL	0.5%	N62042
CHLORAMPHENICOL	0.5%	N62628
CHLOROFAIR	0.5%	N62437
ECONOCHLOR	0.5%	N61645
OPHTHOCHLOR	0.5%	N61220
OPTOMYCIN	0.5%	N62171
CHLORAMPHENICOL PALMITATE		
SUSPENSION		
CHLOROMYCETIN PALMITATE	EQ 150MG BASE/5ML	N50152
CHLOROMYCETIN PALMITATE	EQ 150MG BASE/5ML	N62301
CHLORAMPHENICOL SODIUM SUCCINATE		
INJECTABLE		
CHLORAMPHENICOL	EQ 1GM BASE/VIAL	N62406
MYCHEL-S	EQ 1GM BASE/VIAL	N60132
CHLORAMPHENICOL; HYDROCORTISONE ACETATE		
FOR SUSPENSION		
CHLOROMYCETIN HYDROCORTISONE	12.5MG/VIAL;25MG/VIAL	N50202
CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE		
OINTMENT		
OPHTHOCORT	10MG/GM;5MG/GM;10,000 UNITS/GM	N50201
CHLORAMPHENICOL; POLYMYXIN B SULFATE		
OINTMENT		
CHLOROMYXIN	1%;10,000 UNITS/GM	N50203
CHLORAMPHENICOL; PREDNISOLONE		
OINTMENT		
CHLOROPTIC-P S.O.P.	1%;0.5%	N61188
CHLORDIAZEPOXIDE		
CAPSULE, EXTENDED RELEASE		
LIBRELEASE	30MG	N17813
TABLET		
LIBRITABS	10MG	N85481
LIBRITABS	25MG	N85488
LIBRITABS	5MG	N85482
CHLORDIAZEPOXIDE HYDROCHLORIDE		
CAPSULE		
A-POXIDE	10MG	N85447
A-POXIDE	10MG	N85518
A-POXIDE	25MG	N85447
A-POXIDE	25MG	N85513

CHLORDIAZEPOXIDE HYDROCHLORIDE		
CAPSULE		
A-POXIDE	5MG	N85447
A-POXIDE	5MG	N85517
CHLORDIAZACHEL	10MG	N84639
CHLORDIAZACHEL	25MG	N85087
CHLORDIAZACHEL	5MG	N85086
CHLORDIAZEPOXIDE HCL	10MG	N87524
CHLORDIAZEPOXIDE HCL	25MG	N87512
CHLORDIAZEPOXIDE HCL	5MG	N87525
CHLORDIAZEPOXIDE HCL	10MG	N84920
CHLORDIAZEPOXIDE HCL	25MG	N84823
CHLORDIAZEPOXIDE HCL	5MG	N84919
CHLORDIAZEPOXIDE HCL	10MG	N85119
CHLORDIAZEPOXIDE HCL	25MG	N85120
CHLORDIAZEPOXIDE HCL	5MG	N85118
CHLORDIAZEPOXIDE HCL	10MG	N84041
CHLORDIAZEPOXIDE HCL	25MG	N84679
CHLORDIAZEPOXIDE HCL	5MG	N84678
CHLORDIAZEPOXIDE HCL	10MG	N85339
CHLORDIAZEPOXIDE HCL	25MG	N84685
CHLORDIAZEPOXIDE HCL	5MG	N85340
CHLORDIAZEPOXIDE HCL	25MG	N86212
CHLORDIAZEPOXIDE HCL	5MG	N86213
CHLORDIAZEPOXIDE HCL	10MG	N83742
CHLORDIAZEPOXIDE HCL	25MG	N83570
CHLORDIAZEPOXIDE HCL	5MG	N83741
CHLORDIAZEPOXIDE HCL	10MG	N86876
CHLORDIAZEPOXIDE HCL	10MG	N87037
CHLORDIAZEPOXIDE HCL	25MG	N86893
CHLORDIAZEPOXIDE HCL	25MG	N87231
CHLORDIAZEPOXIDE HCL	5MG	N86892
CHLORDIAZEPOXIDE HCL	5MG	N87234
CHLORDIAZEPOXIDE HCL	10MG	N86217
CHLORDIAZEPOXIDE HCL	10MG	N84601
CHLORDIAZEPOXIDE HCL	25MG	N84887
CHLORDIAZEPOXIDE HCL	5MG	N84886
CHLORDIAZEPOXIDE HCL	10MG	N84598
CHLORDIAZEPOXIDE HCL	25MG	N85164
CHLORDIAZEPOXIDE HCL	5MG	N85163
CHLORDIAZEPOXIDE HCL	10MG	N89533
CHLORDIAZEPOXIDE HCL	25MG	N89558
CHLORDIAZEPOXIDE HCL	10MG	N84939
CHLORDIAZEPOXIDE HCL	25MG	N85144
CHLORDIAZEPOXIDE HCL	5MG	N85155
CHLORDIAZEPOXIDE HCL	10MG	N84700
CHLORDIAZEPOXIDE HCL	25MG	N84705

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE

CHLORDIAZEPOXIDE HCL	5MG	N84706
CHLORDIAZEPOXIDE HCL	10MG	N88986
CHLORDIAZEPOXIDE HCL	25MG	N88988
CHLORDIAZEPOXIDE HCL	5MG	N88987
CHLORDIAZEPOXIDE HCL	10MG	N88706
CHLORDIAZEPOXIDE HCL	25MG	N86494
CHLORDIAZEPOXIDE HCL	25MG	N88707
CHLORDIAZEPOXIDE HCL	5MG	N88705
CHLORDIAZEPOXIDE HCL	25MG	N84645
CHLORDIAZEPOXIDE HCL	5MG	N84644
CHLORDIAZEPOXIDE HCL	10MG	N88010
CHLORDIAZEPOXIDE HCL	25MG	N88130
CHLORDIAZEPOXIDE HCL	5MG	N88129
CHLORDIAZEPOXIDE HCL	10MG	N85000
CHLORDIAZEPOXIDE HCL	25MG	N85294
CHLORDIAZEPOXIDE HCL	5MG	N85014
LIBRIUM	10MG	N12249
LIBRIUM	25MG	N12249
LIBRIUM	5MG	N12249
LYGEN	10MG	N85009
LYGEN	25MG	N85108
LYGEN	5MG	N85107

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET

MENRIUM 10-4	10MG;0.4MG	N14740
MENRIUM 5-2	5MG;0.2MG	N14740
MENRIUM 5-4	5MG;0.4MG	N14740

CHLORHEXIDINE GLUCONATE

SOLUTION

EXIDINE	2.5%	N19421

SPONGE

E-Z SCRUB	4%	N73416

CHLORMERODRIN, HG-197

INJECTABLE

CHLORMERODRIN HG 197	0.6-1.4mCi/ML	N17269

CHLORMEZANONE

TABLET

TRANCOPAL	100MG	N11467
TRANCOPAL	200MG	N11467

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE

NESACAINE-MPF	2%	N09435
NESACAINE-MPF	3%	N09435

CHLOROQUINE PHOSPHATE

TABLET

CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N87228
CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N80886
CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N87504

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE	EQ 300MG BASE;EQ 45MG BASE	N14860

CHLOROTHIAZIDE

TABLET

CHLOROTHIAZIDE	250MG	N85569
CHLOROTHIAZIDE	250MG	N85485
CHLOROTHIAZIDE	250MG	N86940
CHLOROTHIAZIDE	500MG	N86938
CHLOROTHIAZIDE	250MG	N85165
CHLOROTHIAZIDE	500MG	N84026
CHLOROTHIAZIDE	250MG	N85173
CHLOROTHIAZIDE	250MG	N86795
CHLOROTHIAZIDE	500MG	N86796

CHLOROTHIAZIDE; METHYLDOPA

TABLET

METHYLDOPA AND CHLOROTHIAZIDE	150MG;250MG	N70783
METHYLDOPA AND CHLOROTHIAZIDE	250MG;250MG	N70654

CHLOROTHIAZIDE; RESERPINE

TABLET

CHLOROTHIAZIDE AND RESERPINE	250MG;0.125MG	N88557
CHLOROTHIAZIDE AND RESERPINE	500MG;0.125MG	N88365
CHLOROTHIAZIDE W/ RESERPINE	250MG;0.125MG	N84853
CHLOROTHIAZIDE W/ RESERPINE	500MG;0.125MG	N88151
CHLOROTHIAZIDE-RESERPINE	250MG;0.125MG	N87744
CHLOROTHIAZIDE-RESERPINE	500MG;0.125MG	N87745

CHLOROTRIANISENE

CAPSULE

CHLOROTRIANISENE	12MG	N84652
TACE	12MG	N08102
TACE	25MG	N11444
TACE	72MG	N16235

CHLORPHENESIN CARBAMATE

TABLET

MAOLATE	400MG	N14217

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE

TELDRIN	12MG	N17369

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE		
TELDRIN	8MG	N17369
INJECTABLE		
CHLOR-TRIMETON	100MG/ML	N08794
CHLOR-TRIMETON	10MG/ML	N08826
CHLORPHENIRAMINE MALEATE	10MG/ML	N80821
CHLORPHENIRAMINE MALEATE	10MG/ML	N80797
CHLORPHENIRAMINE MALEATE	100MG/ML	N86095
CHLORPHENIRAMINE MALEATE	10MG/ML	N83593
CHLORPHENIRAMINE MALEATE	10MG/ML	N86096
PYRIDAMAL 100	100MG/ML	N83733
SYRUP		
CHLOR-TRIMETON	2MG/5ML	N06921
CHLORPHENIRAMINE MALEATE	2MG/5ML	N87520
TABLET		
ANTAGONATE	4MG	N83381
CHLOR-TRIMETON	4MG	N06921
CHLORPHENIRAMINE MALEATE	4MG	N83078
CHLORPHENIRAMINE MALEATE	4MG	N83062
CHLORPHENIRAMINE MALEATE	4MG	N80938
CHLORPHENIRAMINE MALEATE	4MG	N80961
CHLORPHENIRAMINE MALEATE	4MG	N80700
CHLORPHENIRAMINE MALEATE	4MG	N80809
CHLORPHENIRAMINE MALEATE	4MG	N80779
CHLORPHENIRAMINE MALEATE	4MG	N87164
CHLORPHENIRAMINE MALEATE	4MG	N86941
CHLORPHENIRAMINE MALEATE	4MG	N86519
CHLORPHENIRAMINE MALEATE	4MG	N83243
CHLORPHENIRAMINE MALEATE	4MG	N85104
CHLORPHENIRAMINE MALEATE	4MG	N83753
CHLORPHENIRAMINE MALEATE	4MG	N88556
CHLORPHENIRAMINE MALEATE	4MG	N86306
CHLORPHENIRAMINE MALEATE	4MG	N80786
CHLORPHENIRAMINE MALEATE	4MG	N80626
CHLORPHENIRAMINE MALEATE	4MG	N85837
CHLORPHENIRAMINE MALEATE	4MG	N80791
CHLORPHENIRAMINE MALEATE	4MG	N80696
CHLORPHENIRAMINE MALEATE	4MG	N85139
CHLORPHENIRAMINE MALEATE	4MG	N83787
KLOROMIN	4MG	N83629
PHENETRON	4MG	N80846

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE		
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL	12MG;75MG	N88681
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL	12MG;75MG	N88940
COLD CAPSULE IV	12MG;75MG	N18793
COLD CAPSULE V	8MG;75MG	N18794
CONTAC 12 HOUR	8MG;75MG	N18099
DRIZE	12MG;75MG	N88359
ORNADE	12MG;75MG	N12152
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE	8MG;75MG	N18809
TABLET, EXTENDED RELEASE		
TRIAMINIC-12	12MG;75MG	N18115

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE		
CODIMAL-L.A. 12	12MG;120MG	N18935
ISOCLOR	8MG;120MG	N18747
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE	12MG;120MG	N71455
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE	12MG;120MG	N18843
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE	8MG;120MG	N18844

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE		
PENNTUSS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N18928

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE		
CORSYM	EQ 4MG MALEATE/5ML;EQ 37.5MG HCL/5ML	N18050

CHLORPHENTERMINE HYDROCHLORIDE

TABLET		
PRE-SATE	EQ 65MG BASE	N14696

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE		
THORAZINE	150MG	N11120
THORAZINE	30MG	N11120

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE		
THORAZINE	75MG	N11120
CONCENTRATE		
CHLORPROMAZINE HCL	100MG/ML	N87053
CHLORPROMAZINE HCL	30MG/ML	N87032
INJECTABLE		
CHLORPROMAZINE HCL	25MG/ML	N84911
CHLORPROMAZINE HCL	25MG/ML	N89563
CHLORPROMAZINE HCL	25MG/ML	N80365
CHLORPROMAZINE HCL	25MG/ML	N85591
CHLORPROMAZINE HCL	25MG/ML	N80370
SYRUP		
CHLORPROMAZINE HCL	10MG/5ML	N86712
TABLET		
CHLORPROMAZINE HCL	100MG	N84412
CHLORPROMAZINE HCL	10MG	N84414
CHLORPROMAZINE HCL	200MG	N84413
CHLORPROMAZINE HCL	25MG	N84415
CHLORPROMAZINE HCL	50MG	N84411
CHLORPROMAZINE HCL	100MG	N83574
CHLORPROMAZINE HCL	10MG	N83549
CHLORPROMAZINE HCL	200MG	N83575
CHLORPROMAZINE HCL	25MG	N83549
CHLORPROMAZINE HCL	50MG	N83549
CHLORPROMAZINE HCL	100MG	N85752
CHLORPROMAZINE HCL	10MG	N85750
CHLORPROMAZINE HCL	200MG	N85748
CHLORPROMAZINE HCL	25MG	N85751
CHLORPROMAZINE HCL	50MG	N85484
CHLORPROMAZINE HCL	100MG	N84789
CHLORPROMAZINE HCL	200MG	N84802
CHLORPROMAZINE HCL	25MG	N84801
CHLORPROMAZINE HCL	50MG	N84800
CHLORPROMAZINE HCL	100MG	N80403
CHLORPROMAZINE HCL	10MG	N80403
CHLORPROMAZINE HCL	200MG	N80403
CHLORPROMAZINE HCL	25MG	N80403
CHLORPROMAZINE HCL	50MG	N80403
CHLORPROMAZINE HCL	200MG	N80340
CHLORPROMAZINE HCL	25MG	N80340
CHLORPROMAZINE HCL	50MG	N80340
CHLORPROMAZINE HCL	100MG	N85331
CHLORPROMAZINE HCL	10MG	N85331
CHLORPROMAZINE HCL	200MG	N85331
CHLORPROMAZINE HCL	25MG	N85331

CHLORPROMAZINE HYDROCHLORIDE

TABLET		
CHLORPROMAZINE HCL	50MG	N85331
CHLORPROMAZINE HCL	10MG	N88038
CHLORPROMAZINE HCL	25MG	N87645
CHLORPROMAZINE HCL	50MG	N87646
CHLORPROMAZINE HCL	100MG	N85957
CHLORPROMAZINE HCL	10MG	N85959
CHLORPROMAZINE HCL	200MG	N85958
CHLORPROMAZINE HCL	25MG	N85956
CHLORPROMAZINE HCL	50MG	N85960
CHLORPROMAZINE HCL	100MG	N87884
CHLORPROMAZINE HCL	10MG	N87783
CHLORPROMAZINE HCL	200MG	N87880
CHLORPROMAZINE HCL	25MG	N87865
CHLORPROMAZINE HCL	50MG	N87878
PROMAPAR	100MG	N86888
PROMAPAR	10MG	N86886
PROMAPAR	200MG	N86885
PROMAPAR	25MG	N84423
PROMAPAR	50MG	N86887

CHLORPROPAMIDE

TABLET		
CHLORPROPAMIDE	100MG	N88812
CHLORPROPAMIDE	100MG	N89446
CHLORPROPAMIDE	250MG	N88813
CHLORPROPAMIDE	250MG	N89447
CHLORPROPAMIDE	100MG	N88918
CHLORPROPAMIDE	250MG	N88919
CHLORPROPAMIDE	250MG	N84669
CHLORPROPAMIDE	100MG	N89321
CHLORPROPAMIDE	250MG	N88662
CHLORPROPAMIDE	100MG	N88840
CHLORPROPAMIDE	250MG	N87353
CHLORPROPAMIDE	100MG	N89561
CHLORPROPAMIDE	250MG	N89562
CHLORPROPAMIDE	250MG	N88695
CHLORPROPAMIDE	100MG	N88768
CHLORPROPAMIDE	100MG	N88708
CHLORPROPAMIDE	250MG	N88709
CHLORPROPAMIDE	100MG	N88608
CHLORPROPAMIDE	250MG	N88568
CHLORPROPAMIDE	100MG	N86865
CHLORPROPAMIDE	250MG	N86866
GLUCAMIDE	250MG	N88641

CHLORPROTHIXENE		
CONCENTRATE		
TARACTAN	100MG/5ML	N16149
INJECTABLE		
TARACTAN	12.5MG/ML	N12487
TABLET		
TARACTAN	100MG	N12486
TARACTAN	10MG	N12486
TARACTAN	25MG	N12486
TARACTAN	50MG	N12486
CHLORTETRACYCLINE HYDROCHLORIDE		
OINTMENT		
AUREOMYCIN	1%	N50404
CHLORTHALIDONE		
TABLET		
CHLORTHALIDONE	25MG	N87364
CHLORTHALIDONE	50MG	N87384
CHLORTHALIDONE	25MG	N87698
CHLORTHALIDONE	50MG	N87699
CHLORTHALIDONE	50MG	N87118
CHLORTHALIDONE	25MG	N87380
CHLORTHALIDONE	25MG	N87292
CHLORTHALIDONE	50MG	N87293
CHLORTHALIDONE	25MG	N87555
CHLORTHALIDONE	50MG	N87947
CHLORTHALIDONE	25MG	N87311
CHLORTHALIDONE	50MG	N87312
CHLORTHALIDONE	25MG	N87451
CHLORTHALIDONE	50MG	N87450
CHLORTHALIDONE	25MG	N89738
CHLORTHALIDONE	50MG	N89739
CHLORTHALIDONE	50MG	N89591
CHLORTHALIDONE	25MG	N88139
CHLORTHALIDONE	50MG	N88140
CHLORTHALIDONE	25MG	N87473
CHLORTHALIDONE	50MG	N87247
CHLORTHALIDONE	50MG	N88651
CHLORTHALIDONE	50MG	N89052
CHLORTHALIDONE	25MG	N88012
CHLORTHALIDONE	50MG	N88073
CHLORTHALIDONE	25MG	N87515
CHLORTHALIDONE	50MG	N87516
CHLORTHALIDONE	25MG	N87050
CHLORTHALIDONE	50MG	N87029
CHLORTHALIDONE	25MG	N87296
CHLORTHALIDONE	25MG	N87706

CHLORTHALIDONE		
TABLET		
CHLORTHALIDONE	50MG	N87082
CHLORTHALIDONE	50MG	N87521
CHLORTHALIDONE	50MG	N87689
THALITONE	25MG	N88051
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE		
TABLET		
CLONIDINE HCL AND CHLORTHALIDONE	15MG;0.1MG	N71179
CLONIDINE HCL AND CHLORTHALIDONE	15MG;0.2MG	N71178
CLONIDINE HCL AND CHLORTHALIDONE	15MG;0.3MG	N71142
COMBIPRES	15MG;0.1MG	N17503
COMBIPRES	15MG;0.2MG	N17503
COMBIPRES	15MG;0.3MG	N17503
CHLORTHALIDONE; METOPROLOL TARTRATE		
CAPSULE		
LOPRESSIDONE	25MG;100MG	N19451
LOPRESSIDONE	25MG;200MG	N19451
CHLORTHALIDONE; RESERPINE		
TABLET		
DEMI-REGROTON	25MG;0.125MG	N15103
REGROTON	50MG;0.25MG	N15103
CHLORZOXAZONE		
TABLET		
CHLORZOXAZONE	250MG	N89592
CHLORZOXAZONE	500MG	N89948
CHLORZOXAZONE	250MG	N86901
CHLORZOXAZONE	250MG	N86948
CHLORZOXAZONE	500MG	N81019
PARAFLEX	250MG	N11300
CHOLESTYRAMINE		
BAR, CHEWABLE		
CHOLYBAR	EQ 4GM RESIN/BAR	N71621
CHOLYBAR	EQ 4GM RESIN/BAR	N71739
TABLET		
QUESTRAN	EQ 1GM RESIN	N73403
QUESTRAN	EQ 800MG RESIN	N73403
CHROMIC CHLORIDE		
INJECTABLE		
CHROMIC CHLORIDE	EQ 0.004MG CHROMIUM/ML	N19271
CHYMOPAPAIN		
INJECTABLE		
CHYMODIACTIN	10,000 UNITS/VIAL	N18663
CHYMODIACTIN	4,000 UNITS/VIAL	N18663

CHYMOPAPAIN		
INJECTABLE		
DISCASE	12,500 UNITS/VIAL	N18625
CHYMOTRYPSIN		
FOR SOLUTION		
ALPHA CHYMAR	750 UNITS/VIAL	N11837
CATARASE	300 UNITS/VIAL	N16938
CATARASE	150 UNITS/VIAL	N18121
ZOLYSE	750 UNITS/VIAL	N11903
CIMETIDINE		
SUSPENSION		
TAGAMET HB 200	200MG/20ML	N20951
TABLET		
CIMETIDINE	200MG	N74250
CIMETIDINE	100MG	N74972
CIMETIDINE	300MG	N74361
CIMETIDINE	400MG	N74361
CIMETIDINE	800MG	N74371
TAGAMET HB	100MG	*N20238
CINOXACIN		
CAPSULE		
CINOBAC	250MG	N18067
CINOBAC	500MG	N18067
CINOXACIN	250MG	N73005
CINOXACIN	500MG	N73006
CIPROFLOXACIN		
INJECTABLE		
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	200MG/100ML	N19858
CISAPRIDE MONOHYDRATE		
SUSPENSION		
PROPULSID	EQ 1MG BASE/ML	N20398
TABLET		
PROPULSID	EQ 10MG BASE	N20210
PROPULSID	EQ 20MG BASE	N20210
TABLET, ORALLY DISINTEGRATING		
PROPULSID QUICKSOLV	EQ 20MG BASE	N20767
CISPLATIN		
INJECTABLE		
PLATINOL-AQ	0.5MG/ML	N18057
CITALOPRAM HYDROBROMIDE		
TABLET		
CELEXA	EQ 60MG BASE	N20822
CLARITHROMYCIN		
FOR SUSPENSION		
BIAXIN	187MG/5ML	N50698
CLEMASTINE FUMARATE		
TABLET		
CLEMASTINE FUMARATE	1.34MG	N73282
TAVIST-1	1.34MG	N17661
TAVIST-1	1.34MG	N17661
CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
TAVIST D	EQ 1MG BASE;75MG	N18298
TAVIST-D	1.34MG;75MG	N18298
TAVIST-D	1.34MG;75MG	N20640
CLIDINIUM BROMIDE		
CAPSULE		
QUARZAN	2.5MG	N10355
QUARZAN	5MG	N10355
CLINDAMYCIN HYDROCHLORIDE		
CAPSULE		
CLEOCIN	EQ 150MG BASE	N61809
CLEOCIN	EQ 75MG BASE	N61809
CLINDAMYCIN HCL	EQ 75MG BASE	N63082
CLINDAMYCIN PALMITATE HYDROCHLORIDE		
FOR SOLUTION		
CLEOCIN	EQ 75MG BASE/5ML	N61827
CLINDAMYCIN PHOSPHATE		
CREAM		
CLEOCIN	EQ 2% BASE	N50680
INJECTABLE		
CLEOCIN PHOSPHATE	EQ 150MG BASE/ML	N61839
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62943
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62747
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62928
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63163
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62908
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62806
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62953
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63041
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63282
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63068
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62913
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62795
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62877
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62819

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE		
INJECTABLE		
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62852
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62900
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63079
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	EQ 12MG BASE/ML	N50636
SOLUTION		
CLEOCIN T	EQ 1% BASE	N62363
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	N62944
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	N62930
CLIOQUINOL; NYSTATIN		
OINTMENT		
NYSTAFORM	10MG/GM;100,000 UNITS/GM	N50235
CLOFAZIMINE		
CAPSULE		
LAMPRENE	100MG	N19500
CLOFIBRATE		
CAPSULE		
CLOFIBRATE	500MG	N72191
CLOFIBRATE	500MG	N71603
CLONAZEPAM		
TABLET		
KLONOPIN	0.125MG	N17533
KLONOPIN	0.25MG	N17533
TABLET, ORALLY DISINTEGRATING		
KLONOPIN RAPIDLY DISINTEGRATING	0.125MG	N20813
KLONOPIN RAPIDLY DISINTEGRATING	0.25MG	N20813
KLONOPIN RAPIDLY DISINTEGRATING	0.5MG	N20813
KLONOPIN RAPIDLY DISINTEGRATING	1MG	N20813
KLONOPIN RAPIDLY DISINTEGRATING	2MG	N20813
CLONIDINE HYDROCHLORIDE		
TABLET		
CLONIDINE HCL	0.1MG	N70881
CLONIDINE HCL	0.2MG	N70882
CLONIDINE HCL	0.3MG	N70883
CLONIDINE HCL	0.1MG	N71103
CLONIDINE HCL	0.2MG	N71102
CLONIDINE HCL	0.3MG	N71101
CLONIDINE HCL	0.2MG	N70924
CLONIDINE HCL	0.3MG	N70923
CLONIDINE HCL	0.1MG	N71252
CLONIDINE HCL	0.2MG	N71253
CLONIDINE HCL	0.3MG	N71254

CLONIDINE HYDROCHLORIDE		
TABLET		
CLONIDINE HCL	0.1MG	N70461
CLONIDINE HCL	0.2MG	N70460
CLONIDINE HCL	0.3MG	N70459
CLONIDINE HCL	0.1MG	N70747
CLONIDINE HCL	0.2MG	N70702
CLONIDINE HCL	0.3MG	N70659
CLONIDINE HCL	0.1MG	N72138
CLONIDINE HCL	0.2MG	N72139
CLONIDINE HCL	0.3MG	N72140
CLONIDINE HCL	0.1MG	N70395
CLONIDINE HCL	0.2MG	N70396
CLONIDINE HCL	0.3MG	N70397
CLORAZEPATE DIPOTASSIUM		
CAPSULE		
CLORAZEPATE DIPOTASSIUM	15MG	N71779
CLORAZEPATE DIPOTASSIUM	3.75MG	N71777
CLORAZEPATE DIPOTASSIUM	7.5MG	N71778
CLORAZEPATE DIPOTASSIUM	15MG	N71431
CLORAZEPATE DIPOTASSIUM	3.75MG	N71429
CLORAZEPATE DIPOTASSIUM	7.5MG	N71430
CLORAZEPATE DIPOTASSIUM	15MG	N71729
CLORAZEPATE DIPOTASSIUM	3.75MG	N71727
CLORAZEPATE DIPOTASSIUM	7.5MG	N71728
CLORAZEPATE DIPOTASSIUM	15MG	N71926
CLORAZEPATE DIPOTASSIUM	3.75MG	N71924
CLORAZEPATE DIPOTASSIUM	7.5MG	N71925
CLORAZEPATE DIPOTASSIUM	15MG	N71522
CLORAZEPATE DIPOTASSIUM	3.75MG	N71549
CLORAZEPATE DIPOTASSIUM	7.5MG	N71550
CLORAZEPATE DIPOTASSIUM	15MG	N71244
CLORAZEPATE DIPOTASSIUM	3.75MG	N71242
CLORAZEPATE DIPOTASSIUM	7.5MG	N71243
CLORAZEPATE DIPOTASSIUM	15MG	N71776
CLORAZEPATE DIPOTASSIUM	3.75MG	N71774
CLORAZEPATE DIPOTASSIUM	7.5MG	N71775
CLORAZEPATE DIPOTASSIUM	15MG	N71860
CLORAZEPATE DIPOTASSIUM	3.75MG	N71878
CLORAZEPATE DIPOTASSIUM	7.5MG	N71879
TRANXENE	15MG	N17105
TRANXENE	3.75MG	N17105
TRANXENE	7.5MG	N17105
TABLET		
CLORAZEPATE DIPOTASSIUM	15MG	N71749
CLORAZEPATE DIPOTASSIUM	3.75MG	N71747

CLORAZEPATE DIPOTASSIUM

TABLET

CLORAZEPATE DIPOTASSIUM	7.5MG	N71748
CLORAZEPATE DIPOTASSIUM	3.75MG	N72512
CLORAZEPATE DIPOTASSIUM	15MG	N72015
CLORAZEPATE DIPOTASSIUM	3.75MG	N72013
CLORAZEPATE DIPOTASSIUM	7.5MG	N72014
CLORAZEPATE DIPOTASSIUM	15MG	N72332
CLORAZEPATE DIPOTASSIUM	3.75MG	N72330
CLORAZEPATE DIPOTASSIUM	7.5MG	N72331
CLORAZEPATE DIPOTASSIUM	15MG	N71702
CLORAZEPATE DIPOTASSIUM	3.75MG	N71730
CLORAZEPATE DIPOTASSIUM	7.5MG	N71731
CLORAZEPATE DIPOTASSIUM	15MG	N71830
CLORAZEPATE DIPOTASSIUM	3.75MG	N71828
CLORAZEPATE DIPOTASSIUM	7.5MG	N71829

CLOTRIMAZOLE

TABLET

MYCELEX-G	500MG	N19069

CLOXACILLIN SODIUM

CAPSULE

CLOXACILLIN SODIUM	EQ 250MG BASE	N61452
CLOXACILLIN SODIUM	EQ 500MG BASE	N61452
CLOXAPEN	EQ 250MG BASE	N62233
CLOXAPEN	EQ 500MG BASE	N62233

FOR SOLUTION

CLOXACILLIN SODIUM	EQ 125MG BASE/5ML	N62978
TEGOPEN	EQ 125MG BASE/5ML	N50192
TEGOPEN	EQ 125MG BASE/5ML	N61453

CLOZAPINE

TABLET

CLOZAPINE	100MG	N74546
CLOZAPINE	25MG	N74546

COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR

N/A

RUBRATOPE-60 KIT	N/A	N16090

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP

PHERAZINE VC W/ CODEINE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88870
PROMETHAZINE VC W/ CODEINE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88816

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP

PHERAZINE W/ CODEINE	10MG/5ML;6.25MG/5ML	N88739
PROMETHAZINE W/ CODEINE	10MG/5ML;6.25MG/5ML	N88814

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP

ACTIFED W/ CODEINE	10MG/5ML;30MG/5ML;1.25 MG/5ML	N12575
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE	10MG/5ML;30MG/5ML;1.25 MG/5ML	N89018

COLCHICINE; PROBENECID

TABLET

COLBENEMID	0.5MG;500MG	N12383
PROBEN-C	0.5MG;500MG	N85552
PROBENECID AND COLCHICINE	0.5MG;500MG	N84321
PROBENECID AND COLCHICINE	0.5MG;500MG	N86130
PROBENECID AND COLCHICINE	0.5MG;500MG	N83720
PROBENECID W/ COLCHICINE	0.5MG;500MG	N86954
PROBENECID W/ COLCHICINE	0.5MG;500MG	N83221

COLESEVELAM HYDROCHLORIDE

CAPSULE

WELCHOL	375MG	N21141

COLISTIN SULFATE

SUSPENSION

COLY-MYCIN S	EQ 25MG BASE/5ML	N50355

COPPER

INTRAUTERINE DEVICE

CU-7	89MG	N17408
TATUM-T	120MG	N18205

CORTICOTROPIN

INJECTABLE

ACTH	25 UNITS/VIAL	N08317
ACTH	40 UNITS/VIAL	N08317
ACTHAR	25 UNITS/VIAL	N07504
ACTHAR	40 UNITS/VIAL	N07504
CORTICOTROPIN	40 UNITS/VIAL	N88772
H.P. ACTHAR GEL	40 UNITS/ML	N08372
PURIFIED CORTROPHIN GEL	40 UNITS/ML	N08975
PURIFIED CORTROPHIN GEL	80 UNITS/ML	N08975

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE

CORTROPHIN-ZINC	40 UNITS/ML	N09854

FDA data supplied by DrugPatentWatch.com

CORTISONE ACETATE

INJECTABLE

CORTISONE ACETATE	25MG/ML	N08126
CORTISONE ACETATE	25MG/ML	N83147
CORTISONE ACETATE	25MG/ML	N85677
CORTISONE ACETATE	50MG/ML	N83147
CORTISONE ACETATE	50MG/ML	N85677
CORTONE	25MG/ML	N07110
CORTONE	50MG/ML	N07110

TABLET

CORTISONE ACETATE	25MG	N83471
CORTISONE ACETATE	25MG	N80836
CORTISONE ACETATE	25MG	N84246
CORTISONE ACETATE	25MG	N85736
CORTISONE ACETATE	25MG	N09458
CORTISONE ACETATE	25MG	N80731
CORTISONE ACETATE	25MG	N80630
CORTISONE ACETATE	25MG	N83536
CORTISONE ACETATE	25MG	N80694
CORTISONE ACETATE	25MG	N08284
CORTISONE ACETATE	5MG	N08284
CORTISONE ACETATE	25MG	N80493
CORTISONE ACETATE	25MG	N80333
CORTISONE ACETATE	25MG	N85884
CORTISONE ACETATE	25MG	N80341

CROMOLYN SODIUM

CAPSULE

GASTROCROM	100MG	N19188
INTAL	20MG	N16990

CRYPTENAMINE ACETATES

INJECTABLE

UNITENSEN	260CSR UNIT/ML	N08814

CRYPTENAMINE TANNATES

TABLET

UNITENSEN	260CSR UNIT	N09217

CUPRIC SULFATE

INJECTABLE

CUPRIC SULFATE	EQ 0.4MG COPPER/ML	N19350

CYANOCOBALAMIN

INJECTABLE

BERUBIGEN	1MG/ML	N06798
BETALIN 12	0.1MG/ML	N80855
BETALIN 12	1MG/ML	N80855
COBAVITE	0.1MG/ML	N83013
COBAVITE	1MG/ML	N83064

CYANOCOBALAMIN

INJECTABLE

CYANOCOBALAMIN	1MG/ML	N87969
CYANOCOBALAMIN	0.03MG/ML	N80510
CYANOCOBALAMIN	0.1MG/ML	N80510
CYANOCOBALAMIN	1MG/ML	N80510
CYANOCOBALAMIN	1MG/ML	N83075
CYANOCOBALAMIN	1MG/ML	N80564
CYANOCOBALAMIN	0.03MG/ML	N80689
CYANOCOBALAMIN	0.1MG/ML	N80689
CYANOCOBALAMIN	1MG/ML	N80689
CYANOCOBALAMIN	0.03MG/ML	N80668
CYANOCOBALAMIN	1MG/ML	N87551
CYANOCOBALAMIN	0.1MG/ML	N83120
CYANOCOBALAMIN	1MG/ML	N07085
REDISOL	1MG/ML	N06668
RUBIVITE	0.03MG/ML	N10791
RUBIVITE	0.05MG/ML	N10791
RUBIVITE	0.12MG/ML	N10791
RUBIVITE	0.1MG/ML	N10791
RUBIVITE	1MG/ML	N10791
RUBRAMIN PC	0.1MG/ML	N06799
RUBRAMIN PC	1MG/ML	N06799
RUVITE	1MG/ML	N80570
VI-TWEL	1MG/ML	N07012

CYANOCOBALAMIN, CO-60

CAPSULE

RUBRATOPE-60	0.5-1uCi	N16090

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A

DICOPAC KIT	N/A;N/A;N/A	N17406

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT	0.1MG;0.5uCi;60MG	N16635

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE

DEPINAR	0.5MG/ML;2.3MG/ML;1MG/ML	N11208

CYCLACILLIN

FOR SUSPENSION

CYCLAPEN-W	125MG/5ML	N50508
CYCLAPEN-W	250MG/5ML	N50508
CYCLAPEN-W	500MG/5ML	N50508

TABLET

CYCLACILLIN	250MG	N62895

CYCLACILLIN		
TABLET		
CYCLACILLIN	500MG	N62895
CYCLAPEN-W	250MG	N50509
CYCLAPEN-W	500MG	N50509
CYCLIZINE LACTATE		
INJECTABLE		
MAREZINE	50MG/ML	N09495
CYCLOBENZAPRINE HYDROCHLORIDE		
TABLET		
FLEXERIL	5MG	N17821
CYCLOPENTOLATE HYDROCHLORIDE		
SOLUTION/DROPS		
AK-PENTOLATE	1%	N85555
CYCLOPENTOLATE HCL	1%	N84150
CYCLOPENTOLATE HCL	1%	N84863
PENTOLAIR	0.5%	N88643
PENTOLAIR	1%	N88150
CYCLOPHOSPHAMIDE		
INJECTABLE		
CYTOXAN	100MG/VIAL	N12142
CYTOXAN	1GM/VIAL	N12142
CYTOXAN	200MG/VIAL	N12142
CYTOXAN	2GM/VIAL	N12142
CYTOXAN	500MG/VIAL	N12142
CYCLOSPORINE		
CAPSULE		
NEORAL	50MG	*N50715
CYCLOTHIAZIDE		
TABLET		
ANHYDRON	2MG	N13157
FLUIDIL	2MG	N18173
CYCRIMINE HYDROCHLORIDE		
TABLET		
PAGITANE	1.25MG	N08951
PAGITANE	2.5MG	N08951
CYPROHEPTADINE HYDROCHLORIDE		
SYRUP		
CYPROHEPTADINE HCL	2MG/5ML	N89199
CYPROHEPTADINE HCL	2MG/5ML	N87001
CYPROHEPTADINE HCL	2MG/5ML	N89021
TABLET		
CYPROHEPTADINE HCL	4MG	N88798
CYPROHEPTADINE HCL	4MG	N87685

CYPROHEPTADINE HYDROCHLORIDE		
TABLET		
CYPROHEPTADINE HCL	4MG	N88232
CYPROHEPTADINE HCL	4MG	N86808
CYPROHEPTADINE HCL	4MG	N89057
CYPROHEPTADINE HCL	4MG	N86737
CYPROHEPTADINE HCL	4MG	N87566
CYPROHEPTADINE HCL	4MG	N86678
CYPROHEPTADINE HCL	4MG	N87839
CYPROHEPTADINE HCL	4MG	N87405
CYPROHEPTADINE HCL	4MG	N87284
CYPROHEPTADINE HCL	4MG	N85245
CYPROHEPTADINE HCL	4MG	N86165
CYPROHEPTADINE HCL	4MG	N86580
PERIACTIN	4MG	N12649
CYSTEINE HYDROCHLORIDE		
INJECTABLE		
CYSTEINE HCL	7.25%	N19523
CYTARABINE		
INJECTABLE		
CYTARABINE	100MG/VIAL	N71248
CYTARABINE	500MG/VIAL	N71249
DACARBAZINE		
INJECTABLE		
DACARBAZINE	100MG/VIAL	N70962
DACARBAZINE	200MG/VIAL	N70990
DACARBAZINE	100MG/VIAL	N70821
DACARBAZINE	200MG/VIAL	N70822
DACARBAZINE	500MG/VIAL	N71563
DALFOPRISTIN; QUINUPRISTIN		
INJECTABLE		
SYNERCID	420MG/VIAL;180MG/VIAL	N50748
DANAPAROID SODIUM		
INJECTABLE		
ORGARAN	750 UNITS/0.6ML	N20430
DANAZOL		
CAPSULE		
DANAZOL	200MG	N71569
DAUNORUBICIN HYDROCHLORIDE		
INJECTABLE		
CERUBIDINE	EQ 20MG BASE/VIAL	N61876
CERUBIDINE	EQ 20MG BASE/VIAL	N50484

DECAMETHONIUM BROMIDE		
INJECTABLE		
SYNCURINE	1MG/ML	N06931
DEMECARIUM BROMIDE		
SOLUTION/DROPS		
HUMORSOL	0.125%	N11860
HUMORSOL	0.25%	N11860
DEMECLOCYCLINE HYDROCHLORIDE		
CAPSULE		
DECLOMYCIN	150MG	N50262
SYRUP		
DECLOMYCIN	75MG/5ML	N50257
TABLET		
DECLOMYCIN	75MG	N50261
DESERPIDINE		
TABLET		
HARMONYL	0.1MG	N10796
HARMONYL	0.25MG	N10796
DESERPIDINE; HYDROCHLOROTHIAZIDE		
TABLET		
ORETICYL 25	0.125MG;25MG	N12148
ORETICYL 50	0.125MG;50MG	N12148
ORETICYL FORTE	0.25MG;25MG	N12148
DESERPIDINE; METHYCLOTHIAZIDE		
TABLET		
METHYCLOTHIAZIDE AND DESERPIDINE	0.25MG;5MG	N88486
METHYCLOTHIAZIDE AND DESERPIDINE	0.5MG;5MG	N88452
DESIPRAMINE HYDROCHLORIDE		
CAPSULE		
PERTOFRANE	25MG	N13621
PERTOFRANE	50MG	N13621
TABLET		
DESIPRAMINE HCL	100MG	N71867
DESIPRAMINE HCL	25MG	N71864
DESIPRAMINE HCL	50MG	N71865
DESIPRAMINE HCL	75MG	N71866
DESLANOSIDE		
INJECTABLE		
CEDILANID-D	0.2MG/ML	N09282
DESMOPRESSIN ACETATE		
SOLUTION		
CONCENTRAID	0.01%	N19776
SPRAY, METERED		
DDAVP	0.01MG/SPRAY	N17922
DESOGESTREL; ETHINYL ESTRADIOL		
TABLET		
DESOGEN	0.15MG;0.03MG	N20071
DESOXIMETASONE		
OINTMENT		
DESOXIMETASONE	0.25%	N73440
TOPICORT	0.05%	N18594
DESOXYCORTICOSTERONE ACETATE		
INJECTABLE		
DOCA	5MG/ML	N01104
PELLET		
PERCORTEN	125MG	N05151
DESOXYCORTICOSTERONE PIVALATE		
INJECTABLE		
PERCORTEN	25MG/ML	N08822
DEXAMETHASONE		
AEROSOL		
AEROSEB-DEX	0.01%	N83296
DECASPRAY	0.04%	N12731
ELIXIR		
DEXAMETHASONE	0.5MG/5ML	N88997
GEL		
DECADERM	0.1%	N13538
SUSPENSION/DROPS		
DEXAMETHASONE	0.1%	N89170
TABLET		
DEXAMETHASONE	0.75MG	N80399
DEXAMETHASONE	0.25MG	N84013
DEXAMETHASONE	0.25MG	N84764
DEXAMETHASONE	0.5MG	N84084
DEXAMETHASONE	0.5MG	N84766
DEXAMETHASONE	0.75MG	N84081
DEXAMETHASONE	0.75MG	N84765
DEXAMETHASONE	1.5MG	N84086
DEXAMETHASONE	1.5MG	N84763
DEXAMETHASONE	0.75MG	N85376
DEXAMETHASONE	0.75MG	N83806
DEXAMETHASONE	0.75MG	N83420
DEXAMETHASONE	0.25MG	N84614
DEXAMETHASONE	0.75MG	N87534
DEXAMETHASONE	1.5MG	N87533
DEXAMETHASONE	0.75MG	N84457
DEXAMETHASONE	0.25MG	N85455
DEXAMETHASONE	0.5MG	N85458
DEXAMETHASONE	0.75MG	N80968

DEXAMETHASONE

TABLET

DEXAMETHASONE	0.75MG	N85818
DEXAMETHASONE	1.5MG	N85456
DEXAMETHASONE	1.5MG	N85840
DEXAMETHASONE	0.75MG	N84327
DEXONE 0.5	0.5MG	N84991
DEXONE 0.75	0.75MG	N84993
DEXONE 1.5	1.5MG	N84990
DEXONE 4	4MG	N84992
HEXADROL	0.5MG	N12675
HEXADROL	0.75MG	N12675
HEXADROL	1.5MG	N12675

DEXAMETHASONE ACETATE

INJECTABLE

DECADRON-LA	EQ 8MG BASE/ML	N16675
DEXAMETHASONE ACETATE	EQ 16MG BASE/ML	N87711
DEXAMETHASONE ACETATE	EQ 8MG BASE/ML	N84315

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL

DEXACORT	EQ 0.1MG PHOSPHATE/INH	N14242

AEROSOL, METERED

DEXACORT	EQ 0.1MG PHOSPHATE/INH	N13413

CREAM

DECADRON	EQ 0.1% PHOSPHATE	N11983

INJECTABLE

DECADRON	EQ 24MG PHOSPHATE/ML	N12071
DECADRON	EQ 4MG PHOSPHATE/ML	N12071
DEXACEN-4	EQ 4MG PHOSPHATE/ML	N84342
DEXAMETHASONE	EQ 10MG PHOSPHATE/ML	N88469
DEXAMETHASONE	EQ 4MG PHOSPHATE/ML	N88448
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N84493
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N87065
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N84752
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N83161
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N81125
DEXAMETHASONE SODIUM PHOSPHATE	EQ 20MG PHOSPHATE/ML	N88522
DEXAMETHASONE SODIUM PHOSPHATE	EQ 10MG PHOSPHATE/ML	N89281
DEXAMETHASONE SODIUM PHOSPHATE	EQ 20MG PHOSPHATE/ML	N89282
DEXAMETHASONE SODIUM PHOSPHATE	EQ 24MG PHOSPHATE/ML	N89372
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N89280
DEXAMETHASONE SODIUM PHOSPHATE	EQ 10MG PHOSPHATE/ML	N87668
DEXAMETHASONE SODIUM PHOSPHATE	EQ 24MG PHOSPHATE/ML	N85606
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N83702

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE

DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N84355
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N89169
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N85641
HEXADROL	EQ 10MG PHOSPHATE/ML	N14694
HEXADROL	EQ 20MG PHOSPHATE/ML	N14694
HEXADROL	EQ 4MG PHOSPHATE/ML	N14694

OINTMENT

DECADRON	EQ 0.05% PHOSPHATE	N11977
DEXAIR	EQ 0.05% PHOSPHATE	N88071
MAXIDEX	EQ 0.05% PHOSPHATE	N83342

SOLUTION/DROPS

DEXAIR	EQ 0.1% PHOSPHATE	N88433
DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE	N84855
DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE	N84170
DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE	N84173

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE

DECADRON W/ XYLOCAINE	EQ 4MG PHOSPHATE/ML;10MG/ML	N13334

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT

NEODECADRON	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N50324

SOLUTION/DROPS

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N64055
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62539

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

DEXACIDIN	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566
DEXASPORIN	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62411

SUSPENSION/DROPS

DEXASPORIN	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62428

DEXBROMPHENIRAMINE MALEATE

SYRUP

DISOMER	2MG/5ML	N11814

TABLET

DEXBROMPHENIRAMINE MALEATE

TABLET

DISOMER	2MG	N11814

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET

DISOPHROL	2MG;60MG	N12394

TABLET, EXTENDED RELEASE

DISOBROM	6MG;120MG	N70770
RESPORAL	6MG;120MG	N89139

DEXTROAMPHETAMINE SULFATE

CAPSULE

DEXAMPEX	15MG	N85355

ELIXIR

DEXEDRINE	5MG/5ML	N83902

TABLET

DEXAMPEX	10MG	N83735
DEXAMPEX	5MG	N83735
DEXTROAMPHETAMINE SULFATE	10MG	N85371
DEXTROAMPHETAMINE SULFATE	5MG	N85370
DEXTROAMPHETAMINE SULFATE	10MG	N83930
DEXTROAMPHETAMINE SULFATE	10MG	N83903
DEXTROAMPHETAMINE SULFATE	15MG	* N85652
DEXTROAMPHETAMINE SULFATE	5MG	N83903
DEXTROAMPHETAMINE SULFATE	5MG	N86521
DEXTROAMPHETAMINE SULFATE	5MG	N84125
DEXTROAMPHETAMINE SULFATE	10MG	N85892
DEXTROAMPHETAMINE SULFATE	5MG	N84986
FERNDEX	5MG	N84001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP

PHERAZINE DM	15MG/5ML;6.25MG/5ML	N88913

DEXTROSE

INJECTABLE

DEXTROSE 10% IN PLASTIC CONTAINER	10GM/100ML	N18504
DEXTROSE 2.5% IN PLASTIC CONTAINER	2.5GM/100ML	N19626
DEXTROSE 38.5% IN PLASTIC CONTAINER	38.5GM/100ML	N18923
DEXTROSE 50% IN PLASTIC CONTAINER	500MG/ML	N19445
DEXTROSE 60%	60GM/100ML	N17995
DEXTROSE 60% IN PLASTIC CONTAINER	60GM/100ML	N17995
DEXTROSE 60% IN PLASTIC CONTAINER	60GM/100ML	N20047
DEXTROSE 7.7% IN PLASTIC CONTAINER	7.7GM/100ML	N19626

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;37MG/100ML	N19699
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;75MG/100ML	N19699
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;110MG/100ML	N19699
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML	N19699

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%	5GM/100ML;75MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	5GM/100ML;150MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	5GM/100ML;75MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	5GM/100ML;150MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%	5GM/100ML;75MG/100ML;450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	5GM/100ML;150MG/100ML;450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML;450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML;450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER	5GM/100ML;224MG/100ML;450MG/100ML	N18008
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML;450MG/100ML	N18008

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER	5GM/100ML;75MG/100ML;450MG/100ML	N18008

DEXTROSE; SODIUM CHLORIDE

INJECTABLE

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	10GM/100ML;200MG/100ML	N18386
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	10GM/100ML;450MG/100ML	N18229
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	10GM/100ML;900MG/100ML	N18047
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	2.5GM/100ML;450MG/100ML	N18030
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	2.5GM/100ML;900MG/100ML	N18376
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	3.3GM/100ML;300MG/100ML	N18055
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	5GM/100ML;110MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	5GM/100ML;200MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	5GM/100ML;200MG/100ML	N18399
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER	5GM/100ML;225MG/100ML	N19482
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML	N19486
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML	N18501
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	5GM/100ML;330MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5GM/100ML;450MG/100ML	N19484
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5GM/100ML;450MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5GM/100ML;450MG/100ML	N18400
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5GM/100ML;900MG/100ML	N19483
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5GM/100ML;900MG/100ML	N18026
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5GM/100ML;900MG/100ML	N18500

DEXTROTHYROXINE SODIUM

TABLET

CHOLOXIN	1MG	N12302
CHOLOXIN	2MG	N12302
CHOLOXIN	4MG	N12302
CHOLOXIN	6MG	N12302

DEZOCINE

INJECTABLE

DALGAN	10MG/ML	N19082
DALGAN	15MG/ML	N19082
DALGAN	5MG/ML	N19082

DIATRIZOATE MEGLUMINE

INJECTABLE

ANGIOVIST 282	60%	N87726
CARDIOGRAFIN	85%	N11620
DIATRIZOATE MEGLUMINE	76%	N10040
UROVIST MEGLUMINE DIU/CT	30%	N87739

SOLUTION

UROVIST CYSTO	30%	N87729
UROVIST CYSTO PEDIATRIC	30%	N87731

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE

ANGIOVIST 292	52%;8%	N87724
ANGIOVIST 370	66%;10%	N87723
DIATRIZOATE-60	52%;8%	N88166
HYPAQUE-M,75%	50%;25%	N10220
HYPAQUE-M,90%	60%;30%	N10220
MD-60	52%;8%	N87074
MD-76	66%;10%	N87073
RENOVIST	34.3%;35%	N10040
RENOVIST II	28.5%;29.1%	N10040

SOLUTION

GASTROVIST	66%;10%	N87728

DIATRIZOATE SODIUM

INJECTABLE

HYPAQUE	25%	N09561
MD-50	50%	N87075
UROVIST SODIUM 300	50%	N87725

SOLUTION

HYPAQUE	40%	N11386
HYPAQUE SODIUM 20%	20%	N09561

DIAZEPAM

CAPSULE, EXTENDED RELEASE

VALRELEASE	15MG	N18179

INJECTABLE

DIAZEPAM	5MG/ML	N70662
DIAZEPAM	5MG/ML	N71308
DIAZEPAM	5MG/ML	N72371
DIAZEPAM	5MG/ML	N70911
DIAZEPAM	5MG/ML	N70912

DIAZEPAM		
INJECTABLE		
DIAZEPAM	5MG/ML	N70930
DIAZEPAM	5MG/ML	*N20124
DIAZEPAM	5MG/ML	N71613
DIAZEPAM	5MG/ML	N71614
DIZAC	5MG/ML	N19287
VALIUM	5MG/ML	N16087
TABLET		
DIAZEPAM	10MG	N70896
DIAZEPAM	2MG	N70894
DIAZEPAM	5MG	N70895
DIAZEPAM	10MG	N70905
DIAZEPAM	2MG	N70903
DIAZEPAM	5MG	N70904
DIAZEPAM	10MG	N70956
DIAZEPAM	2MG	N70987
DIAZEPAM	5MG	N70996
DIAZEPAM	10MG	N70362
DIAZEPAM	2MG	N70360
DIAZEPAM	5MG	N70361
DIAZEPAM	10MG	N72402
DIAZEPAM	10MG	N70776
DIAZEPAM	2MG	N70787
DIAZEPAM	5MG	N70788
DIAZEPAM	10MG	N70358
DIAZEPAM	2MG	N70356
DIAZEPAM	5MG	N70357
DIAZEPAM	10MG	N70222
DIAZEPAM	2MG	N70209
DIAZEPAM	5MG	N70210
DIAZEPAM	10MG	N70458
DIAZEPAM	2MG	N70456
DIAZEPAM	5MG	N70457
Q-PAM	10MG	N70425
Q-PAM	10MG	N72433
Q-PAM	2MG	N70423
Q-PAM	2MG	N72431
Q-PAM	5MG	N70424
Q-PAM	5MG	N72432
DIAZOXIDE		
CAPSULE		
PROGLYCEM	100MG	N17425
PROGLYCEM	50MG	N17425
INJECTABLE		
DIAZOXIDE	15MG/ML	N71519

DIAZOXIDE		
INJECTABLE		
DIAZOXIDE	15MG/ML	N71908
DIBUCAINE HYDROCHLORIDE		
INJECTABLE		
HEAVY SOLUTION NUPERCAINE	2.5MG/ML	N06203
DICLOFENAC POTASSIUM		
TABLET		
CATAFLAM	25MG	N20142
DICLOFENAC SODIUM		
SOLUTION/DROPS		
DICLOFENAC SODIUM	0.1%	N20809
DICLOXACILLIN SODIUM		
CAPSULE		
DYCILL	EQ 250MG BASE	N60254
DYCILL	EQ 250MG BASE	N62238
DYCILL	EQ 500MG BASE	N60254
DYCILL	EQ 500MG BASE	N62238
FOR SUSPENSION		
DYNAPEN	EQ 62.5MG BASE/5ML	N50337
DICUMAROL		
CAPSULE		
DICUMAROL	25MG	N05509
DICUMAROL	50MG	N05509
TABLET		
DICUMAROL	100MG	N05545
DICUMAROL	25MG	N05545
DICUMAROL	50MG	N05545
DICYCLOMINE HYDROCHLORIDE		
CAPSULE		
DICYCLOMINE HCL	10MG	N84505
DICYCLOMINE HCL	10MG	N89361
DICYCLOMINE HCL	10MG	N83179
INJECTABLE		
DICYCLOMINE HCL	10MG/ML	N80614
SYRUP		
DICYCLOMINE HCL	10MG/5ML	N84479
TABLET		
DICYCLOMINE HCL	20MG	N84600
DICYCLOMINE HCL	20MG	N88585
DICYCLOMINE HCL	20MG	N84361
DIDANOSINE		
FOR SOLUTION		
VIDEX	375MG/PACKET	N20155

DIENESTROL

CREAM		
DV	0.01%	N83518
ESTRAGUARD	0.01%	N84436
SUPPOSITORY		
DV	0.7MG	N83517

DIETHYLCARBAMAZINE CITRATE

TABLET		
HETRAZAN	50MG	N06459

DIETHYLPROPION HYDROCHLORIDE

TABLET		
DIETHYLPROPION HCL	25MG	N85544
DIETHYLPROPION HCL	25MG	N85916
DIETHYLPROPION HCL	25MG	N88642
DIETHYLPROPION HCL	25MG	N85741
TENUATE	25MG	N17668
TEPANIL	25MG	N11673
TABLET, EXTENDED RELEASE		
TENUATE	75MG	N17669
TEPANIL TEN-TAB	75MG	N17956

DIETHYLSTILBESTROL

INJECTABLE		
STILBESTROL	0.2MG/ML	N04056
STILBESTROL	0.5MG/ML	N04056
STILBESTROL	1MG/ML	N04056
STILBESTROL	5MG/ML	N04056
SUPPOSITORY		
DIETHYLSTILBESTROL	0.1MG	N04040
DIETHYLSTILBESTROL	0.5MG	N04040
STILBESTROL	0.1MG	N04056
STILBESTROL	0.5MG	N04056
TABLET		
DIETHYLSTILBESTROL	0.1MG	N04041
DIETHYLSTILBESTROL	0.5MG	N04041
DIETHYLSTILBESTROL	1MG	N04041
DIETHYLSTILBESTROL	5MG	N04041
STILBESTROL	0.5MG	N83004
STILBESTROL	1MG	N83002
STILBESTROL	5MG	N83006
STILBETIN	0.1MG	N04056
STILBETIN	0.25MG	N04056
STILBETIN	0.5MG	N04056
STILBETIN	1MG	N04056
STILBETIN	5MG	N04056

DIETHYLSTILBESTROL

TABLET, DELAYED RELEASE		
DIETHYLSTILBESTROL	0.1MG	N04039
DIETHYLSTILBESTROL	0.25MG	N04039
DIETHYLSTILBESTROL	0.5MG	N04039
DIETHYLSTILBESTROL	1MG	N04039
DIETHYLSTILBESTROL	5MG	N04039
STILBESTROL	0.5MG	N83003
STILBESTROL	1MG	N83005
STILBESTROL	5MG	N83007
STILBETIN	0.1MG	N04056
STILBETIN	0.5MG	N04056
STILBETIN	1MG	N04056
STILBETIN	5MG	N04056

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE		
STILPHOSTROL	250MG/5ML	N10010
TABLET		
STILPHOSTROL	50MG	N10010

DIFLUNISAL

TABLET		
DIFLUNISAL	250MG	N74285
DIFLUNISAL	500MG	N74285

DIGITOXIN

INJECTABLE		
CRYSTODIGIN	0.2MG/ML	N84100

DIGOXIN

CAPSULE		
LANOXICAPS	0.15MG	N18118
INJECTABLE		
DIGOXIN	0.25MG/ML	N83217
TABLET		
LANOXIN	0.0625MG	N20405
LANOXIN	0.1875MG	N20405
LANOXIN	0.375MG	N20405
LANOXIN	0.5MG	N20405

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE		
EMBOLEX	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N18885
EMBOLEX	0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N18885

DILTIAZEM HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
CARDIZEM SR	180MG	N19471
TABLET		
DILTIAZEM HCL	30MG	N74084
DILTIAZEM HCL	60MG	N74084
DIMENHYDRINATE		
INJECTABLE		
DIMENHYDRINATE	50MG/ML	N84767
DIMENHYDRINATE	50MG/ML	N83531
LIQUID		
DIMENHYDRINATE	12.5MG/4ML	N80715
TABLET		
DIMENHYDRINATE	50MG	N85985
DIMENHYDRINATE	50MG	N80841
DIMENHYDRINATE	50MG	N85166
DINOPROST TROMETHAMINE		
INJECTABLE		
PROSTIN F2 ALPHA	EQ 5MG BASE/ML	N17434
DIPHEMANIL METHYLSULFATE		
TABLET		
PRANTAL	100MG	N08114
DIPHENHYDRAMINE HYDROCHLORIDE		
CAPSULE		
BENADRYL	25MG	N05845
BENADRYL	50MG	N05845
DIPHENHYDRAMINE HCL	25MG	N80519
DIPHENHYDRAMINE HCL	50MG	N80519
DIPHENHYDRAMINE HCL	25MG	N83634
DIPHENHYDRAMINE HCL	50MG	N83275
DIPHENHYDRAMINE HCL	25MG	N85701
DIPHENHYDRAMINE HCL	50MG	N85701
DIPHENHYDRAMINE HCL	25MG	N80845
DIPHENHYDRAMINE HCL	50MG	N80845
DIPHENHYDRAMINE HCL	50MG	N87914
DIPHENHYDRAMINE HCL	25MG	N84524
DIPHENHYDRAMINE HCL	50MG	N83953
DIPHENHYDRAMINE HCL	25MG	N80807
DIPHENHYDRAMINE HCL	50MG	N80807
DIPHENHYDRAMINE HCL	25MG	N80762
DIPHENHYDRAMINE HCL	50MG	N80762
DIPHENHYDRAMINE HCL	25MG	N80868
DIPHENHYDRAMINE HCL	50MG	N80868
DIPHENHYDRAMINE HCL	25MG	N86874
DIPHENHYDRAMINE HCL	50MG	N86875

DIPHENHYDRAMINE HYDROCHLORIDE		
CAPSULE		
DIPHENHYDRAMINE HCL	25MG	N86543
DIPHENHYDRAMINE HCL	50MG	N86544
DIPHENHYDRAMINE HCL	25MG	N83061
DIPHENHYDRAMINE HCL	50MG	N83061
DIPHENHYDRAMINE HCL	25MG	N89101
DIPHENHYDRAMINE HCL	50MG	N88880
DIPHENHYDRAMINE HCL	25MG	N85156
DIPHENHYDRAMINE HCL	50MG	N85150
DIPHENHYDRAMINE HCL	50MG	N80635
DIPHENHYDRAMINE HCL	50MG	N89041
DIPHENHYDRAMINE HCL	25MG	N85874
DIPHENHYDRAMINE HCL	50MG	N85874
DIPHENHYDRAMINE HCL	25MG	N88034
DIPHENHYDRAMINE HCL	50MG	N87630
DIPHENHYDRAMINE HCL	25MG	N83797
DIPHENHYDRAMINE HCL	50MG	N83797
DIPHENHYDRAMINE HCL	25MG	N85138
DIPHENHYDRAMINE HCL	50MG	N85083
DIPHENHYDRAMINE HCL	50MG	N83567
DIPHENHYDRAMINE HCL	25MG	N83441
DIPHENHYDRAMINE HCL	50MG	N80800
ELIXIR		
BELIX	12.5MG/5ML	N86586
BENADRYL	12.5MG/5ML	N05845
DIBENIL	12.5MG/5ML	N88304
DIPHEN	12.5MG/5ML	N84640
DIPHENHYDRAMINE HCL	12.5MG/5ML	N83674
DIPHENHYDRAMINE HCL	12.5MG/5ML	N87941
DIPHENHYDRAMINE HCL	12.5MG/5ML	N85621
DIPHENHYDRAMINE HCL	12.5MG/5ML	N86937
DIPHENHYDRAMINE HCL	12.5MG/5ML	N88680
DIPHENHYDRAMINE HCL	12.5MG/5ML	N83063
DIPHENHYDRAMINE HCL	12.5MG/5ML	N83237
DIPHENHYDRAMINE HCL	12.5MG/5ML	N85287
HYDRAMINE	12.5MG/5ML	N80763
INJECTABLE		
BENADRYL	10MG/ML	N06146
DIPHENHYDRAMINE HCL	10MG/ML	N87066
DIPHENHYDRAMINE HCL	10MG/ML	N80822
DIPHENHYDRAMINE HCL	50MG/ML	N83183
DIPHENHYDRAMINE HCL	10MG/ML	N83533
DIPHENHYDRAMINE HCL PRESERVATIVE FREE	50MG/ML	N80586
SYRUP		
ANTITUSSIVE	12.5MG/5ML	N71292
BELDIN	12.5MG/5ML	N89179

DIPHENHYDRAMINE HYDROCHLORIDE
SYRUP

BENYLIN	12.5MG/5ML	N06514
DIPHEN	12.5MG/5ML	N70118
DIPHENHYDRAMINE HCL	12.5MG/5ML	N70497
DIPHENHYDRAMINE HCL	12.5MG/5ML	N73611
DIPHENHYDRAMINE HCL	12.5MG/5ML	N72416
HYDRAMINE	12.5MG/5ML	N70205
SILPHEN	12.5MG/5ML	N72646
VICKS FORMULA 44	12.5MG/5ML	N70524

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SOLUTION

BENYLIN	12.5MG/5ML;30MG/5ML	N19014

DIPHENIDOL HYDROCHLORIDE
TABLET

VONTROL	EQ 25MG BASE	N16033

DIPHENYLPYRALINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE

HISPRIL	5MG	N11945

DIPYRIDAMOLE
TABLET

DIPYRIDAMOLE	50MG	N89426
DIPYRIDAMOLE	75MG	N89427

DISOPYRAMIDE PHOSPHATE
CAPSULE

DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70351
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70352
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N71190
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N71191
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70138
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70139
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70941
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70240
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70241

DISULFIRAM
TABLET

ANTABUSE	500MG	N88483
ANTABUSE	250MG	* N07883
ANTABUSE	500MG	* N07883
DISULFIRAM	250MG	N88792
DISULFIRAM	500MG	N88793
DISULFIRAM	250MG	N86889
DISULFIRAM	250MG	N87973

DISULFIRAM
TABLET

DISULFIRAM	500MG	N86890
DISULFIRAM	500MG	N87974

DIVALPROEX SODIUM
TABLET, DELAYED RELEASE

DEPAKOTE CP	EQ 250MG BASE	N19794
DEPAKOTE CP	EQ 500MG BASE	N19794

DOPAMINE HYDROCHLORIDE
INJECTABLE

DOPAMINE HCL	40MG/ML	N70656
DOPAMINE HCL	80MG/ML	N70657
DOPAMINE HCL	160MG/ML	N70364
DOPAMINE HCL	40MG/ML	N18549
DOPAMINE HCL	40MG/ML	N70012
DOPAMINE HCL	40MG/ML	N70058
DOPAMINE HCL	80MG/ML	N70059
DOPAMINE HCL	160MG/ML	N70093
DOPAMINE HCL	160MG/ML	N70094
DOPAMINE HCL	40MG/ML	N70087
DOPAMINE HCL	80MG/ML	N70089
DOPAMINE HCL	80MG/ML	N70090
DOPAMINE HCL	40MG/ML	N70011
DOPAMINE HCL	40MG/ML	N70046
DOPAMINE HCL	80MG/ML	N70047
DOPAMINE HCL	40MG/ML	N18138
DOPAMINE HCL	40MG/ML	N70558
DOPAMINE HCL	80MG/ML	N70559

DOXEPIN HYDROCHLORIDE
CAPSULE

DOXEPIN HCL	EQ 100MG BASE	N71521
DOXEPIN HCL	EQ 25MG BASE	N71502
DOXEPIN HCL	EQ 50MG BASE	N71653
DOXEPIN HCL	EQ 75MG BASE	N71654
DOXEPIN HCL	EQ 100MG BASE	N71675
DOXEPIN HCL	EQ 10MG BASE	N71685
DOXEPIN HCL	EQ 150MG BASE	N71676
DOXEPIN HCL	EQ 25MG BASE	N71686
DOXEPIN HCL	EQ 50MG BASE	N71673
DOXEPIN HCL	EQ 75MG BASE	N71674
DOXEPIN HCL	EQ 100MG BASE	N16987
DOXEPIN HCL	EQ 10MG BASE	N16987
DOXEPIN HCL	EQ 150MG BASE	N16987
DOXEPIN HCL	EQ 25MG BASE	N16987
DOXEPIN HCL	EQ 50MG BASE	N16987

DOXEPIN HYDROCHLORIDE		
CAPSULE		
DOXEPIN HCL	EQ 75MG BASE	N16987
DOXEPIN HCL	EQ 100MG BASE	N72110
DOXEPIN HCL	EQ 10MG BASE	N73054
DOXEPIN HCL	EQ 150MG BASE	N72387
DOXEPIN HCL	EQ 25MG BASE	N72109
DOXEPIN HCL	EQ 50MG BASE	N73055
DOXEPIN HCL	EQ 75MG BASE	N72386
DOXEPIN HCL	EQ 100MG BASE	N72375
DOXEPIN HCL	EQ 10MG BASE	N70972
DOXEPIN HCL	EQ 150MG BASE	N72376
DOXEPIN HCL	EQ 25MG BASE	N70973
DOXEPIN HCL	EQ 50MG BASE	N70931
DOXEPIN HCL	EQ 75MG BASE	N70932
DOXEPIN HCL	EQ 100MG BASE	N70955
DOXEPIN HCL	EQ 10MG BASE	N70952
DOXEPIN HCL	EQ 150MG BASE	N71764
DOXEPIN HCL	EQ 25MG BASE	N70953
DOXEPIN HCL	EQ 50MG BASE	N70954
DOXEPIN HCL	EQ 75MG BASE	N71763
DOXYCYCLINE		
FOR SUSPENSION		
DOXYCHEL	EQ 25MG BASE/5ML	N61720
DOXYCYCLINE HYCLATE		
CAPSULE		
DOXY-LEMMON	EQ 100MG BASE	N62497
DOXY-LEMMON	EQ 50MG BASE	N62497
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62119
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62418
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62119
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62418
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62463
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62463
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62763
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62763
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62442
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62434
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62631
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62631
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62479
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62479
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62469
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62469
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62594
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62594

DOXYCYCLINE HYCLATE		
CAPSULE		
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62142
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62142
PERIOSTAT	EQ 20MG BASE	N50744
CAPSULE, COATED PELLETS		
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N63187
INJECTABLE		
DOXYCHEL HYCLATE	EQ 100MG BASE/VIAL	N61953
DOXYCYCLINE	EQ 100MG BASE/VIAL	N62569
DOXYCYCLINE	EQ 200MG BASE/VIAL	N62569
DOXYCYCLINE	EQ 100MG BASE/VIAL	N62450
DOXYCYCLINE	EQ 200MG BASE/VIAL	N62450
DOXYCYCLINE HYCLATE	EQ 100MG BASE/VIAL	N62992
DOXYCYCLINE HYCLATE	EQ 200MG BASE/VIAL	N62992
DOXYCYCLINE HYCLATE	EQ 100MG BASE/VIAL	N62643
DOXYCYCLINE HYCLATE	EQ 200MG BASE/VIAL	N62643
TABLET		
DOXY-LEMMON	EQ 100MG BASE	N62581
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62391
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62462
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62764
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62494
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62593
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62392
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62392
DOXYCYCLINE HYLATE	EQ 50MG BASE	N62269
DOXYLAMINE SUCCINATE		
CAPSULE		
UNISOM	25MG	N19440
TABLET		
DECAPRYN	12.5MG	N06412
DECAPRYN	25MG	N06412
DOXY-SLEEP-AID	25MG	N70156
DOXYLAMINE SUCCINATE	25MG	N88603
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
BENDECTIN	10MG;10MG	* N10598
DROMOSTANOLONE PROPIONATE		
INJECTABLE		
DROLBAN	50MG/ML	N12936
DROPERIDOL		
INJECTABLE		
DROPERIDOL	2.5MG/ML	N70992

DROPERIDOL		
INJECTABLE		
DROPERIDOL	2.5MG/ML	N70993
DROPERIDOL	2.5MG/ML	N72018
DROPERIDOL	2.5MG/ML	N72019
DROPERIDOL	2.5MG/ML	N72020
DROPERIDOL	2.5MG/ML	N72021
DROPERIDOL	2.5MG/ML	N71941
DROPERIDOL	2.5MG/ML	N71942
DROPERIDOL	2.5MG/ML	N71750
DROPERIDOL	2.5MG/ML	N71754
DROPERIDOL	2.5MG/ML	N71755
DROPERIDOL	2.5MG/ML	N73520
DROPERIDOL	2.5MG/ML	N73521
DROPERIDOL	2.5MG/ML	N73523
DROPERIDOL; FENTANYL CITRATE		
INJECTABLE		
FENTANYL CITRATE AND DROPERIDOL	2.5MG/ML;EQ 0.05MG BASE/ML	N72026
FENTANYL CITRATE AND DROPERIDOL	2.5MG/ML;EQ 0.05MG BASE/ML	N72027
FENTANYL CITRATE AND DROPERIDOL	2.5MG/ML;EQ 0.05MG BASE/ML	N72028
INNOVAR	2.5MG/ML;EQ 0.05MG BASE/ML	N16049
DYCLONINE HYDROCHLORIDE		
SOLUTION		
DYCLONE	0.5%	N09925
DYCLONE	1%	N09925
DYDROGESTERONE		
TABLET		
GYNOREST	10MG	N17388
GYNOREST	5MG	N17388
DYPHYLLINE		
ELIXIR		
NEOTHYLLINE	160MG/15ML	N07794
INJECTABLE		
NEOTHYLLINE	250MG/ML	N09088
TABLET		
NEOTHYLLINE	200MG	N07794
NEOTHYLLINE	400MG	N07794
ECHOTHIOPHATE IODIDE		
FOR SOLUTION		
PHOSPHOLINE IODIDE	0.03%	N11963
PHOSPHOLINE IODIDE	0.06%	N11963
PHOSPHOLINE IODIDE	0.25%	N11963
EDETATE CALCIUM DISODIUM		
TABLET		
CALCIUM DISODIUM VERSENATE	500MG	N08922
EDETATE DISODIUM		
INJECTABLE		
DISODIUM EDETATE	150MG/ML	N84356
SODIUM VERSENATE	200MG/ML	N10573
EDROPHONIUM CHLORIDE		
INJECTABLE		
EDROPHONIUM CHLORIDE	10MG/ML	N40044
EDROPHONIUM CHLORIDE PRESERVATIVE FREE	10MG/ML	N40043
EFLORNITHINE HYDROCHLORIDE		
INJECTABLE		
ORNIDYL	200MG/ML	N19879
ENOXACIN		
TABLET		
PENETREX	200MG	N19616
PENETREX	400MG	N19616
ENOXAPARIN SODIUM		
INJECTABLE		
LOVENOX	90MG/0.6ML	N20164
EPINEPHRINE		
INJECTABLE		
EPI E Z PEN JR	0.15MG/DELIVERY	N19430
EPIPEN E Z PEN	0.3MG/DELIVERY	N19430
SUS-PHRINE SULFITE-FREE	1.5MG/AMP	N07942
SUS-PHRINE SULFITE-FREE	5MG/ML	N07942
EPINEPHRINE BITARTRATE		
AEROSOL, METERED		
MEDIHALER-EPI	0.3MG/INH	N10374
EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE		
INJECTABLE		
DURANEST	0.005MG/ML;1.5%	N17751
EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE		
INJECTABLE		
CITANEST FORTE	0.005MG/ML;4%	N14763
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE		
INJECTABLE		
DURANEST	0.005MG/ML;0.5%	N17751
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
ALPHACAINE HCL W/ EPINEPHRINE	0.01MG/ML;2%	N84720
ALPHACAINE HCL W/ EPINEPHRINE	0.02MG/ML;2%	N84732

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE		
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N83154
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N80820
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;2%	N80757
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N86402
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N80377
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N85463
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;2%	N80377
LIDOCATON	0.02MG/ML;2%	N84728
XYLOCAINE W/ EPINEPHRINE	0.005MG/ML;1%	N10418
XYLOCAINE W/ EPINEPHRINE	0.005MG/ML;1.5%	N10418
XYLOCAINE W/ EPINEPHRINE	0.005MG/ML;2%	N10418
XYLOCAINE W/ EPINEPHRINE	0.01MG/ML;2%	N06488
XYLOCAINE W/ EPINEPHRINE	0.02MG/ML;2%	N06488

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE		
PROCAINE HCL W/ EPINEPHRINE	0.02MG/ML;1%	N80758
PROCAINE HCL W/ EPINEPHRINE	0.02MG/ML;2%	N80759

ERGOCALCIFEROL

CAPSULE		
DELTALIN	50,000 IU	N80884
VITAMIN D	50,000 IU	N80747
VITAMIN D	50,000 IU	N80956
VITAMIN D	50,000 IU	N80951
VITAMIN D	50,000 IU	N80825
VITAMIN D	50,000 IU	N84053
VITAMIN D	50,000 IU	N83102

ERGOLOID MESYLATES

CAPSULE		
HYDERGINE LC	1MG	N18706
SOLUTION		
HYDERGINE	1MG/ML	N18418
TABLET		
ALKERGOT	0.5MG	N85153
ALKERGOT	1MG	N87417
CIRCANOL	0.5MG	N84868
CIRCANOL	1MG	N85809
DEAPRIL-ST	1MG	N85020
ERGOLOID MESYLATES	0.5MG	N87407
ERGOLOID MESYLATES	1MG	N87552
ERGOLOID MESYLATES	1MG	N88891
ERGOLOID MESYLATES	0.5MG	N85899
ERGOLOID MESYLATES	0.5MG	N86265
ERGOLOID MESYLATES	1MG	N85900
ERGOLOID MESYLATES	1MG	N86264

ERGOLOID MESYLATES

TABLET		
ERGOLOID MESYLATES	0.5MG	N86984
ERGOLOID MESYLATES	1MG	N86985
ERGOLOID MESYLATES	0.5MG	N89233
ERGOLOID MESYLATES	1MG	N89234
ERGOLOID MESYLATES	0.5MG	N88013
ERGOLOID MESYLATES	1MG	N88014
ERGOLOID MESYLATES	0.5MG	N84930
ERGOLOID MESYLATES	1MG	N85177
ERGOLOID MESYLATES	1MG	N86433
ERGOLOID MESYLATES	1MG	N87183
ERGOLOID MESYLATES	1MG	N87244
GERIMAL	1MG	N88207
HYDERGINE	0.5MG	N17993
HYDROGENATED ERGOT ALKALOIDS	0.5MG	N87186

ERGOTAMINE TARTRATE

AEROSOL, METERED		
MEDIHALER ERGOTAMINE	0.36MG/INH	N12102
TABLET		
ERGOSTAT	2MG	N88337
WIGRETTES	2MG	N86750

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS		
ERYC	250MG	N62546
ERYC	250MG	N62618
ERYC	250MG	N62338
ERYC 125	125MG	N62648
ERYC SPRINKLES	125MG	N50593
OINTMENT		
ERYTHROMYCIN	5MG/GM	N62446
ERYTHROMYCIN	5MG/GM	N62481
POWDER		
ERYTHROMYCIN	100%	N50610
SOLUTION		
ERYTHROMYCIN	1.5%	N62328
ERYTHROMYCIN	2%	N62327
ERYTHROMYCIN	2%	N62342
ERYTHROMYCIN	2%	N62957
ERYTHROMYCIN	2%	N50532
ERYTHROMYCIN	1.5%	N62485
ERYTHROMYCIN	2%	N62616
TABLET, DELAYED RELEASE		
E-BASE	333MG	N63028

ERYTHROMYCIN

TABLET, DELAYED RELEASE

ILOTYCIN	250MG	N61910
R-P MYCIN	250MG	N61659
ROBIMYCIN	250MG	N61633

ERYTHROMYCIN ESTOLATE

CAPSULE

ERYTHROMYCIN ESTOLATE	EQ 125MG BASE	N62162
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE	N62237
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE	N62087
ILOSONE	EQ 125MG BASE	N61897
ILOSONE	EQ 250MG BASE	N61897

FOR SUSPENSION

ILOSONE	EQ 125MG BASE/5ML	N61893

SUSPENSION

ERYTHROMYCIN ESTOLATE	EQ 125MG BASE/5ML	N62169
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE/5ML	N62169
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE/5ML	N62362
ILOSONE	EQ 125MG BASE/5ML	N61894
ILOSONE	EQ 250MG BASE/5ML	N61894

SUSPENSION/DROPS

ILOSONE	EQ 100MG BASE/ML	N61894

TABLET

ILOSONE	EQ 500MG BASE	N61896

TABLET, CHEWABLE

ILOSONE	EQ 125MG BASE	N61895
ILOSONE	EQ 250MG BASE	N61895

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION

ILOSONE SULFA	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N50599

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE

PEDIAMYCIN	EQ 200MG BASE/5ML	N62305

SUSPENSION

E-MYCIN E	EQ 200MG BASE/5ML	N62198
E-MYCIN E	EQ 400MG BASE/5ML	N62198
ERYTHROMYCIN ETHYLSUCCINATE	EQ 200MG BASE/5ML	N62177
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62177
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62674
ERYTHROMYCIN ETHYLSUCCINATE	EQ 200MG BASE/5ML	N62231
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62231
ERYTHROMYCIN ETHYLSUCCINATE	EQ 200MG BASE/5ML	N62559
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62558
WYAMYCIN E	EQ 200MG BASE/5ML	N62123

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION

WYAMYCIN E	EQ 400MG BASE/5ML	N62123

SUSPENSION/DROPS

PEDIAMYCIN	EQ 100MG BASE/2.5ML	N62305

TABLET

E.E.S. 400	EQ 400MG BASE	N61905
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE	N62256

TABLET, CHEWABLE

PEDIAMYCIN	EQ 200MG BASE	N62306

ERYTHROMYCIN GLUCEPTATE

INJECTABLE

ILOTYCIN GLUCEPTATE	EQ 1GM BASE/VIAL	N50370
ILOTYCIN GLUCEPTATE	EQ 250MG BASE/VIAL	N50370
ILOTYCIN GLUCEPTATE	EQ 500MG BASE/VIAL	N50370

ERYTHROMYCIN LACTOBIONATE

INJECTABLE

ERYTHROCIN	EQ 1GM BASE/VIAL	N62586
ERYTHROCIN	EQ 500MG BASE/VIAL	N62586
ERYTHROMYCIN LACTOBIONATE	EQ 1GM BASE/VIAL	N62604
ERYTHROMYCIN LACTOBIONATE	EQ 500MG BASE/VIAL	N62604
ERYTHROMYCIN LACTOBIONATE	EQ 1GM BASE/VIAL	N62660
ERYTHROMYCIN LACTOBIONATE	EQ 500MG BASE/VIAL	N62660

ERYTHROMYCIN STEARATE

TABLET

BRISTAMYCIN	EQ 250MG BASE	N61304
BRISTAMYCIN	EQ 250MG BASE	N61887
ERYPAR	EQ 250MG BASE	N62032
ERYPAR	EQ 500MG BASE	N62032
ERYPAR	EQ 250MG BASE	N62322
ERYTHROCIN STEARATE	EQ 125MG BASE	N60359
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N63179
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N61461
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N61461
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N62089
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N62089
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N61743
ETHRIL 250	EQ 250MG BASE	N61605
ETHRIL 500	EQ 500MG BASE	N61605
PFIZER-E	EQ 250MG BASE	N61791
PFIZER-E	EQ 500MG BASE	N61791
WYAMYCIN S	EQ 250MG BASE	N61675
WYAMYCIN S	EQ 500MG BASE	N61675

ESMOLOL HYDROCHLORIDE		
INJECTABLE		
BREVIBLOC	100MG/ML	N19386
ESTRADIOL		
FILM, EXTENDED RELEASE		
ESTRADIOL	0.0375MG/24HR	N20538
ESTRADIOL	0.05MG/24HR	N20538
ESTRADIOL	0.075MG/24HR	N20538
ESTRADIOL	0.1MG/24HR	N20538
ESTRADIOL	0.05MG/24HR	N21048
ESTRADIOL	0.075MG/24HR	N21048
ESTRADIOL	0.1MG/24HR	N21048
FEMPATCH	0.025MG/24HR	N20417
ESTRADIOL CYPIONATE		
INJECTABLE		
DEPO-ESTRADIOL	1MG/ML	N85470
DEPO-ESTRADIOL	3MG/ML	N85470
ESTRADIOL CYPIONATE	5MG/ML	N89310
ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE		
INJECTABLE		
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE	2MG/ML;50MG/ML	N85603
ESTRADIOL VALERATE		
INJECTABLE		
ESTRADIOL VALERATE	10MG/ML	N83546
ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE		
INJECTABLE		
DITATE-DS	8MG/ML;180MG/ML	N86423
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE	4MG/ML;90MG/ML	N85865
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE	8MG/ML;180MG/ML	N85860
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE		
TABLET		
PREMPHASE (PREMARIN;CYCRIN 14/14)	0.625MG;0.625MG;5MG	N20303
PREMPRO (PREMARIN;CYCRIN)	0.625MG;0.625MG;2.5MG;2.5MG	N20303
ESTROGENS, CONJUGATED; MEPROBAMATE		
TABLET		
MILPREM-200	0.45MG;200MG	N11045
MILPREM-400	0.45MG;400MG	N11045
PMB 200	0.45MG;200MG	N10971
PMB 400	0.45MG;400MG	N10971

ESTROGENS, ESTERIFIED		
TABLET		
AMNESTROGEN	0.3MG	N83266
AMNESTROGEN	0.625MG	N83266
AMNESTROGEN	1.25MG	N83266
AMNESTROGEN	2.5MG	N83266
ESTERIFIED ESTROGENS	1.25MG	N85302
ESTERIFIED ESTROGENS	0.625MG	N83414
ESTERIFIED ESTROGENS	1.25MG	N83765
ESTERIFIED ESTROGENS	2.5MG	N85907
ESTRATAB	0.3MG	N86715
ESTRATAB	0.625MG	N83209
ESTRATAB	1.25MG	N83856
ESTRATAB	2.5MG	N83857
EVEX	0.625MG	N84215
EVEX	1.25MG	N83376
FEMOGEN	0.625MG	N85076
FEMOGEN	1.25MG	N85008
FEMOGEN	2.5MG	N85007
ESTRONE		
INJECTABLE		
ESTROGENIC SUBSTANCE	2MG/ML	N83488
ESTRONE	2MG/ML	N83397
NATURAL ESTROGENIC SUBSTANCE-ESTRONE	2MG/ML	N85237
THEELIN	1MG/ML	N03977
THEELIN	2MG/ML	N03977
THEELIN	5MG/ML	N03977
ETHAMBUTOL HYDROCHLORIDE		
TABLET		
MYAMBUTOL	200MG	N16320
MYAMBUTOL	500MG	N16320
ETHCHLORVYNOL		
CAPSULE		
ETHCHLORVYNOL	100MG	N84463
ETHCHLORVYNOL	200MG	N84463
ETHCHLORVYNOL	500MG	N84463
ETHCHLORVYNOL	750MG	N84463
PLACIDYL	100MG	N10021
PLACIDYL	200MG	N10021
PLACIDYL	500MG	N10021
PLACIDYL	750MG	N10021
ETHINAMATE		
CAPSULE		
VALMID	500MG	N09750

ETHINYL ESTRADIOL
TABLET

FEMINONE	0.05MG	N16649
LYNORAL	0.01MG	N05490
LYNORAL	0.05MG	N05490

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
TABLET

NORQUEST FE	0.035MG;75MG;1MG	N18926

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE
TABLET

NORLESTRIN FE 1/50	0.05MG;75MG;1MG	N16766
NORLESTRIN FE 2.5/50	0.05MG;75MG;2.5MG	N16854

ETHINYL ESTRADIOL; NORETHINDRONE
TABLET

N.E.E. 1/35 21	0.035MG;1MG	N71541
N.E.E. 1/35 28	0.035MG;1MG	N71542
ORTHO-NOVUM 7/14-21	0.035MG;0.035MG;0.5MG;1 MG	N19004
OVCON-50	0.05MG;1MG	N18128

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
TABLET

ESTROSTEP 21	0.02MG;0.03MG;0.035MG;1 MG;1MG;1MG	N20130
NORLESTRIN 21 1/50	0.05MG;1MG	N16749
NORLESTRIN 21 2.5/50	0.05MG;2.5MG	N16852
NORLESTRIN 28 1/50	0.05MG;1MG	N16723

ETHINYL ESTRADIOL; NORGESTIMATE
TABLET

ORTHO CYCLEN-21	0.035MG;0.25MG	N19653
ORTHO TRI-CYCLEN	0.035MG;0.035MG;0.035MG ;0.18MG;0.215MG;0.25MG	N19697

ETHOPROPAZINE HYDROCHLORIDE
TABLET

PARSIDOL	100MG	N09078
PARSIDOL	10MG	N09078
PARSIDOL	50MG	N09078

ETHOTOIN
TABLET

PEGANONE	500MG	N10841

ETHOXZOLAMIDE
TABLET

CARDRASE	125MG	N11047
CARDRASE	62.5MG	N11047
ETHAMIDE	125MG	N16144

ETHYLESTRENOL
ELIXIR

MAXIBOLIN	2MG/5ML	N14006

TABLET

MAXIBOLIN	2MG	N14005

ETHYNODIOL DIACETATE; MESTRANOL
TABLET

OVULEN	1MG;0.1MG	N16029
OVULEN-21	1MG;0.1MG	N16029
OVULEN-28	1MG;0.1MG	N16705

ETIDOCAINE HYDROCHLORIDE
INJECTABLE

DURANEST	0.5%	N17751
DURANEST	1%	N17751

ETOPOSIDE
CAPSULE

VEPESID	100MG	N19557

INJECTABLE

ETOPOSIDE	20MG/ML	N74510
ETOPOSIDE	20MG/ML	N74813
ETOPOSIDE	20MG/ML	N74228

ETOPOSIDE PHOSPHATE
INJECTABLE

ETOPOPHOS PRESERVATIVE FREE	EQ 1GM BASE/VIAL	N20906
ETOPOPHOS PRESERVATIVE FREE	EQ 500MG BASE/VIAL	N20906

ETRETINATE
CAPSULE

TEGISON	10MG	N19369
TEGISON	25MG	N19369

EVANS BLUE
INJECTABLE

EVANS BLUE	0.5%	* N08041

FAMOTIDINE
INJECTABLE

FAMOTIDINE	10MG/ML	N75707
FAMOTIDINE PRESERVATIVE FREE	10MG/ML	N75708

TABLET, ORALLY DISINTEGRATING

PEPCID RPD	20MG	N20752
PEPCID RPD	40MG	N20752

FENOFIBRATE
CAPSULE

LIPIDIL	100MG	N19304

FENOPROFEN CALCIUM		
CAPSULE		
FENOPROFEN CALCIUM	EQ 200MG BASE	N72307
FENOPROFEN CALCIUM	EQ 300MG BASE	N72308
FENOPROFEN CALCIUM	EQ 200MG BASE	N72355
FENOPROFEN CALCIUM	EQ 300MG BASE	N72356
FENOPROFEN CALCIUM	EQ 200MG BASE	N72214
FENOPROFEN CALCIUM	EQ 300MG BASE	N71738
FENOPROFEN CALCIUM	EQ 200MG BASE	N72946
FENOPROFEN CALCIUM	EQ 300MG BASE	N72472
FENOPROFEN CALCIUM	EQ 200MG BASE	N72294
FENOPROFEN CALCIUM	EQ 200MG BASE	N72981
FENOPROFEN CALCIUM	EQ 300MG BASE	N72293
FENOPROFEN CALCIUM	EQ 300MG BASE	N72982
TABLET		
FENOPROFEN CALCIUM	EQ 600MG BASE	N72309
FENOPROFEN CALCIUM	EQ 600MG BASE	N72357
FENOPROFEN CALCIUM	EQ 600MG BASE	N72194
FENOPROFEN CALCIUM	EQ 600MG BASE	N72362
FENOPROFEN CALCIUM	EQ 600MG BASE	N72165
NALFON	EQ 600MG BASE	N17710
FENTANYL CITRATE		
INJECTABLE		
FENTANYL CITRATE	EQ 0.05MG BASE/ML	N70636
FENTANYL CITRATE	EQ 0.05MG BASE/ML	N70637
FENTANYL CITRATE	EQ 0.05MG BASE/ML	N73488
FENTANYL CITRATE PRESERVATIVE FREE	EQ 0.05MG BASE/ML	N74917
TROCHE/LOZENGE		
FENTANYL	EQ 0.1MG BASE	N20195
FENTANYL	EQ 0.2MG BASE	N20195
FENTANYL	EQ 0.3MG BASE	N20195
FENTANYL	EQ 0.4MG BASE	N20195
FERRIC AMMONIUM CITRATE		
FOR SOLUTION		
FERRISELTZ	600MG/PACKET	N20292
FERROUS CITRATE, FE-59		
INJECTABLE		
FERROUS CITRATE FE 59	25uCi/ML	N16729
FERROUS SULFATE; FOLIC ACID		
CAPSULE		
FOLVRON	182MG;0.33MG	N06012
FIBRINOGEN, I-125		
INJECTABLE		
IBRIN	154uCi/VIAL	N17879
FIBRINOGEN, I-125		
INJECTABLE		
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR	140uCi/ML	N17787
FLECAINIDE ACETATE		
TABLET		
TAMBOCOR	200MG	N18830
FLOXURIDINE		
INJECTABLE		
FLOXURIDINE	500MG/VIAL	N71055
FLUCONAZOLE		
INJECTABLE		
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER	2MG/ML	N19950
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	2MG/ML	N19950
FLUDEOXYGLUCOSE, F-18		
INJECTABLE		
FLUDEOXYGLUCOSE F 18	4-40mCi/ML	N20306
FLUMETHASONE PIVALATE		
CREAM		
LOCORTEN	0.03%	N16379
FLUOCINOLONE ACETONIDE		
CREAM		
FLUOCET	0.025%	N88360
FLUOCINOLONE ACETONIDE	0.01%	N88361
FLUOCINOLONE ACETONIDE	0.01%	N86810
FLUOCINOLONE ACETONIDE	0.025%	N86811
FLUOCINOLONE ACETONIDE	0.01%	N88047
FLUOCINOLONE ACETONIDE	0.025%	N88045
FLUOCINOLONE ACETONIDE	0.01%	N88499
FLUOCINOLONE ACETONIDE	0.025%	N88506
FLUOCINOLONE ACETONIDE	0.01%	N88757
FLUOCINOLONE ACETONIDE	0.025%	N88756
FLUONID	0.025%	N87156
FLUOTREX	0.01%	N88174
FLUOTREX	0.025%	N88173
SYNALAR-HP	0.2%	N16161
GEL		
FLUONID	0.025%	N87300
OINTMENT		
FLUOCINOLONE ACETONIDE	0.025%	N88046
FLUOCINOLONE ACETONIDE	0.025%	N88507
FLUOCINOLONE ACETONIDE	0.025%	N88742
FLUONID	0.025%	N87157

FLUOCINOLONE ACETONIDE		
OINTMENT		
FLUOTREX	0.025%	N88172
SOLUTION		
FLUOCINOLONE ACETONIDE	0.01%	N40059
FLUOCINOLONE ACETONIDE	0.01%	N88312
FLUOCINOLONE ACETONIDE	0.01%	N88048
FLUOCINOLONE ACETONIDE	0.01%	N88449
FLUONID	0.01%	N87158
FLUOTREX	0.01%	N88171
FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE		
CREAM		
NEO-SYNALAR	0.025%;EQ 3.5MG BASE/GM	N60700
FLUOCINONIDE		
CREAM		
FLUOCINONIDE	0.05%	N71790
FLUOROMETHOLONE		
CREAM		
OXYLONE	0.025%	N11748
FLUOROURACIL		
INJECTABLE		
ADRUCIL	50MG/ML	N17959
ADRUCIL	50MG/ML	N81222
FLUOROURACIL	50MG/ML	N88929
FLUOROURACIL	50MG/ML	N89152
FLUOROURACIL	50MG/ML	N89428
FLUOROURACIL	50MG/ML	N89519
FLUOROURACIL	50MG/ML	N87791
FLUOROURACIL	50MG/ML	N89368
FLUOROURACIL	50MG/ML	N89455
FLUOROURACIL	50MG/ML	N88766
FLUOROURACIL	50MG/ML	N88767
FLUOROURACIL	50MG/ML	N89434
FLUOXETINE HYDROCHLORIDE		
CAPSULE		
PROZAC	EQ 60MG BASE	N18936
TABLET		
PROZAC	EQ 20MG BASE	N20974
FLUOXYMESTERONE		
TABLET		
ANDROID-F	10MG	N87196
FLUOXYMESTERONE	10MG	N88221
FLUOXYMESTERONE	10MG	N88309
FLUOXYMESTERONE	2MG	N88260
FLUOXYMESTERONE		
TABLET		
FLUOXYMESTERONE	5MG	N88265
ORA-TESTRYL	2MG	N11359
ORA-TESTRYL	5MG	N11359
FLUPHENAZINE DECANOATE		
INJECTABLE		
FLUPHENAZINE	25MG/ML	N70762
FLUPHENAZINE ENANTHATE		
INJECTABLE		
PROLIXIN ENANTHATE	25MG/ML	N16110
FLUPHENAZINE HYDROCHLORIDE		
INJECTABLE		
FLUPHENAZINE HCL	2.5MG/ML	N89800
TABLET		
FLUPHENAZINE HCL	10MG	N88550
FLUPHENAZINE HCL	1MG	N88555
FLUPHENAZINE HCL	2.5MG	N88544
FLUPHENAZINE HCL	5MG	N88527
PERMITIL	0.25MG	N12034
PERMITIL	10MG	N12034
PERMITIL	2.5MG	N12034
PERMITIL	5MG	N12034
TABLET, EXTENDED RELEASE		
PERMITIL	1MG	N12419
FLUPREDNISOLONE		
TABLET		
ALPHADROL	1.5MG	N12259
FLURANDRENOLIDE		
LOTION		
FLURANDRENOLIDE	0.05%	N87203
FLURANDRENOLIDE; NEOMYCIN SULFATE		
CREAM		
CORDRAN-N	0.05%;EQ 3.5MG BASE/GM	N50346
OINTMENT		
CORDRAN-N	0.05%;EQ 3.5MG BASE/GM	N50345
FLURAZEPAM HYDROCHLORIDE		
CAPSULE		
FLURAZEPAM HCL	15MG	N70454
FLURAZEPAM HCL	15MG	N71808
FLURAZEPAM HCL	30MG	N70455
FLURAZEPAM HCL	30MG	N71809
FLURAZEPAM HCL	15MG	N71927
FLURAZEPAM HCL	30MG	N71551

FLURAZEPAM HYDROCHLORIDE		
CAPSULE		
FLURAZEPAM HCL	15MG	N71659
FLURAZEPAM HCL	30MG	N71660
FLURAZEPAM HCL	15MG	N70562
FLURAZEPAM HCL	30MG	N70563
FLURAZEPAM HCL	15MG	N71767
FLURAZEPAM HCL	30MG	N71768
FLURAZEPAM HCL	15MG	N72368
FLUVOXAMINE MALEATE		
TABLET		
LUVOX	100MG	N20243
LUVOX	150MG	N20243
LUVOX	25MG	N20243
LUVOX	50MG	N20243
FOLIC ACID		
TABLET		
FOLIC ACID	1MG	N84915
FOLIC ACID	1MG	N89177
FOLIC ACID	1MG	N84472
FOLIC ACID	1MG	N80755
FOLIC ACID	1MG	N83598
FOLIC ACID	1MG	N80686
FOLIC ACID	1MG	N80816
FOLIC ACID	1MG	N06135
FOLIC ACID	1MG	N84158
FOLIC ACID	1MG	N88949
FOLIC ACID	1MG	N80784
FOLIC ACID	1MG	N88199
FOLIC ACID	1MG	N87828
FOLIC ACID	1MG	N88730
FOLIC ACID	1MG	N86296
FOLIC ACID	1MG	N83141
FOLIC ACID	1MG	N85141
FOLIC ACID	1MG	N80691
FOLVITE	1MG	N05897
FOLLITROPIN ALFA/BETA		
INJECTABLE		
GONAL-F	37.5 IU/VIAL	N20378
FURAZOLIDONE		
SUSPENSION		
FUROXONE	50MG/15ML	N11323
TABLET		
FUROXONE	100MG	N11270
FUROSEMIDE		
INJECTABLE		
FUROSEMIDE	10MG/ML	N18507
FUROSEMIDE	10MG/ML	N19036
FUROSEMIDE	10MG/ML	N70014
FUROSEMIDE	10MG/ML	N70095
FUROSEMIDE	10MG/ML	N70096
FUROSEMIDE	10MG/ML	N70017
FUROSEMIDE	10MG/ML	N70023
FUROSEMIDE	10MG/ML	N70078
FUROSEMIDE	10MG/ML	N70019
FUROSEMIDE	10MG/ML	N70604
FUROSEMIDE	10MG/ML	N18420
FUROSEMIDE	10MG/ML	N18670
TABLET		
FUROSEMIDE	40MG	N18750
FUROSEMIDE	20MG	N70043
FUROSEMIDE	40MG	N18790
FUROSEMIDE	80MG	N70100
FUROSEMIDE	20MG	N18370
FUROSEMIDE	40MG	N18370
FUROSEMIDE	20MG	N18419
FUROSEMIDE	40MG	N18419
FUROSEMIDE	80MG	N18419
FUROSEMIDE	20MG	N18369
FUROSEMIDE	40MG	N18369
GALLAMINE TRIETHIODIDE		
INJECTABLE		
FLAXEDIL	100MG/ML	N07842
FLAXEDIL	20MG/ML	N07842
GALLIUM CITRATE, GA-67		
INJECTABLE		
GALLIUM CITRATE GA 67	1mCi/ML	N17700
NEOSCAN	2mCi/ML	N17655
GEMFIBROZIL		
CAPSULE		
GEMFIBROZIL	300MG	N73466
GEMFIBROZIL	300MG	N72929
LOPID	200MG	N18422
LOPID	300MG	N18422
TABLET		
GEMFIBROZIL	600MG	N74360
GEMFIBROZIL	600MG	N74156

GENTAMICIN SULFATE		
CREAM		
GENTAFAIR	EQ 0.1% BASE	N62458
GENTAMICIN SULFATE	EQ 0.1% BASE	N62471
GENTAMICIN SULFATE	EQ 0.1% BASE	N64056
GENTAMICIN SULFATE	EQ 1MG BASE/GM	N62530
INJECTABLE		
APOGEN	EQ 10MG BASE/ML	N62289
APOGEN	EQ 40MG BASE/ML	N62289
BRISTAGEN	EQ 40MG BASE/ML	N62288
GARAMYCIN	EQ 10MG BASE/ML	N61739
GARAMYCIN	EQ 2MG BASE/ML	N50505
GENTAFAIR	EQ 40MG BASE/ML	N62493
GENTAMICIN	EQ 100MG BASE/100ML	N62325
GENTAMICIN	EQ 1MG BASE/ML	N62325
GENTAMICIN	EQ 40MG BASE/ML	N62325
GENTAMICIN SULFATE	EQ 1.2MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 1.4MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 1.6MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 1.8MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 100MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 2MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 60MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 70MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 80MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 90MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N63149
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N63106
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62507
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62507
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62318
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62318
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62264
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62264
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.2MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.4MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.6MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.8MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 100MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 2MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 60MG BASE/100ML	N62588

GENTAMICIN SULFATE		
INJECTABLE		
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 70MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 80MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 90MG BASE/100ML	N62588
U-GENCIN	EQ 10MG BASE/ML	N62248
U-GENCIN	EQ 40MG BASE/ML	N62248
OINTMENT		
GARAMYCIN	EQ 0.1% BASE	N60463
GENTACIDIN	EQ 0.3% BASE	N62501
GENTAFAIR	EQ 0.1% BASE	N62444
GENTAFAIR	EQ 3MG BASE/GM	N62443
GENTAMICIN SULFATE	EQ 0.1% BASE	N62496
GENTAMICIN SULFATE	EQ 0.1% BASE	N64054
GENTAMICIN SULFATE	EQ 0.1% BASE	N62534
SOLUTION/DROPS		
GENTAFAIR	EQ 0.3% BASE	N62440
GENTAMICIN SULFATE	EQ 0.3% BASE	N62523
GENTAMICIN SULFATE	EQ 3MG BASE/ML	N62932
GENTIAN VIOLET		
TAMPON		
GENAPAX	5MG	N85017
GLIPIZIDE		
TABLET		
GLUCOTROL	2.5MG	N17783
GLUCAGON HYDROCHLORIDE		
INJECTABLE		
GLUCAGON	EQ 10MG BASE/VIAL	N12122
GLUCAGON	EQ 1MG BASE/VIAL	N12122
GLUCAGON	EQ 10MG BASE/VIAL	N71023
GLUCAGON	EQ 1MG BASE/VIAL	N71022
GLUTETHIMIDE		
CAPSULE		
DORIDEN	500MG	N09519
TABLET		
DORIDEN	250MG	N09519
DORIDEN	500MG	N09519
GLUTETHIMIDE	500MG	N85171
GLUTETHIMIDE	500MG	N83234
GLUTETHIMIDE	250MG	N89458
GLUTETHIMIDE	500MG	N89459
GLUTETHIMIDE	250MG	N83475
GLUTETHIMIDE	500MG	N85571

GLUTETHIMIDE		
TABLET		
GLUTETHIMIDE	500MG	N87297
GLUTETHIMIDE	500MG	N84362
GLUTETHIMIDE	500MG	N85763
GLYBURIDE		
TABLET		
GLYNASE	4.5MG	* N20051
GLYCINE		
SOLUTION		
GLYCINE 1.5% IN PLASTIC CONTAINER	1.5GM/100ML	N18522
GLYCOPYRROLATE		
INJECTABLE		
GLYCOPYRROLATE	0.2MG/ML	N89393
GLYCOPYRROLATE	0.2MG/ML	N88475
GLYCOPYRROLATE	0.2MG/ML	N81169
GLYCOPYRROLATE	0.2MG/ML	N89397
GLYCOPYRROLATE	0.2MG/ML	N86947
ROBINUL	0.2MG/ML	N14764
TABLET		
GLYCOPYRROLATE	1MG	N85562
GLYCOPYRROLATE	2MG	N85563
GLYCOPYRROLATE	1MG	N86902
GLYCOPYRROLATE	2MG	N86178
GLYCOPYRROLATE	2MG	N86900
GONADORELIN ACETATE		
INJECTABLE		
LUTREPULSE KIT	0.8MG/VIAL	N19687
LUTREPULSE KIT	3.2MG/VIAL	N19687
GONADORELIN HYDROCHLORIDE		
INJECTABLE		
FACTREL	EQ 0.2MG BASE/VIAL	N18123
FACTREL	EQ 0.5MG BASE/VIAL	N18123
GONADOTROPIN, CHORIONIC		
INJECTABLE		
A.P.L.	20,000 UNITS/VIAL	N17055
CHORIONIC GONADOTROPIN	15,000 UNITS/VIAL	N17067
CHORIONIC GONADOTROPIN	20,000 UNITS/VIAL	N17067
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N17067
CHORIONIC GONADOTROPIN	10,000 UNITS/VIAL	N17054
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N17054
CHORIONIC GONADOTROPIN	10,000 UNITS/VIAL	N89314
CHORIONIC GONADOTROPIN	10,000 UNITS/VIAL	N89315
CHORIONIC GONADOTROPIN	20,000 UNITS/VIAL	N89316
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N89312

GONADOTROPIN, CHORIONIC		
INJECTABLE		
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N89313
CHORIONIC GONADOTROPIN	15,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	2,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	2,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	20,000 UNITS/VIAL	N17016
FOLLUTEIN	10,000 UNITS/VIAL	N17056
GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE		
SOLUTION/DROPS		
NEO-POLYCIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N60427
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N62818
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N62788
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N62383
GRANISETRON HYDROCHLORIDE		
INJECTABLE		
KYTRIL	EQ 3MG BASE/ML	N20239
SOLUTION		
KYTRIL	EQ 2MG BASE/10ML	N21238
TABLET		
KYTRIL	EQ 2MG BASE	N20305
GRISEOFULVIN, MICROCRYSTALLINE		
CAPSULE		
GRISACTIN	125MG	N50051
GRISACTIN	250MG	N50051
SUSPENSION		
GRIFULVIN V	125MG/5ML	N50448
TABLET		
GRIFULVIN V	125MG	N60618
GRIFULVIN V	250MG	N60618
GRIFULVIN V	500MG	N60618
GRISACTIN	500MG	N60212
GRISEOFULVIN, ULTRAMICROCRYSTALLINE		
TABLET		
GRISACTIN ULTRA	125MG	N62178
GRISACTIN ULTRA	165MG	N62438
GRISACTIN ULTRA	250MG	N62178
GRISACTIN ULTRA	330MG	N62438
ULTRAGRIS-165	165MG	N62645
ULTRAGRIS-330	330MG	N62646

GUANABENZ ACETATE		
TABLET		
WYTENSIN	EQ 16MG BASE	N18587
GUANADREL SULFATE		
TABLET		
HYLOREL	10MG	N18104
HYLOREL	25MG	N18104
GUANETHIDINE MONOSULFATE		
TABLET		
GUANETHIDINE MONOSULFATE	EQ 10MG SULFATE	N86113
GUANETHIDINE MONOSULFATE	EQ 25MG SULFATE	N86114
ISMELIN	EQ 10MG SULFATE	N12329
ISMELIN	EQ 25MG SULFATE	N12329
GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE		
TABLET		
ESIMIL	10MG;25MG	N13553
GUANFACINE HYDROCHLORIDE		
TABLET		
TENEX	EQ 3MG BASE	N19032
HALCINONIDE		
CREAM		
HALOG	0.025%	N17818
OINTMENT		
HALOG	0.025%	N18125
HALOFANTRINE HYDROCHLORIDE		
TABLET		
HALFAN	250MG	N20250
HALOPERIDOL		
TABLET		
HALDOL	0.5MG	N15921
HALDOL	10MG	N15921
HALDOL	1MG	N15921
HALDOL	20MG	N15921
HALDOL	2MG	N15921
HALDOL	5MG	N15921
HALDOL SOLUTAB	1MG	N17079
HALOPERIDOL	0.5MG	N71216
HALOPERIDOL	10MG	N71220
HALOPERIDOL	1MG	N71217
HALOPERIDOL	20MG	N71221
HALOPERIDOL	2MG	N71218
HALOPERIDOL	5MG	N71219
HALOPERIDOL	0.5MG	N71156
HALOPERIDOL	10MG	N71173
HALOPERIDOL	1MG	N71157

HALOPERIDOL		
TABLET		
HALOPERIDOL	20MG	N71177
HALOPERIDOL	2MG	N71172
HALOPERIDOL	5MG	N71212
HALOPERIDOL	0.5MG	N72727
HALOPERIDOL	10MG	N72731
HALOPERIDOL	1MG	N72728
HALOPERIDOL	20MG	N72732
HALOPERIDOL	2MG	N72729
HALOPERIDOL	5MG	N72730
HALOPERIDOL	20MG	N71328
HALOPERIDOL	0.5MG	N71071
HALOPERIDOL	10MG	N71075
HALOPERIDOL	1MG	N71072
HALOPERIDOL	20MG	N71076
HALOPERIDOL	2MG	N71073
HALOPERIDOL	5MG	N71074
HALOPERIDOL	0.5MG	N71255
HALOPERIDOL	1MG	N71269
HALOPERIDOL	2MG	N71256
HALOPERIDOL	5MG	N71257
HALOPERIDOL	0.5MG	N71128
HALOPERIDOL	10MG	N71132
HALOPERIDOL	1MG	N71129
HALOPERIDOL	20MG	N71133
HALOPERIDOL	2MG	N71130
HALOPERIDOL	5MG	N71131
HALOPERIDOL	0.5MG	N71722
HALOPERIDOL	10MG	N72121
HALOPERIDOL	1MG	N71723
HALOPERIDOL	20MG	N72122
HALOPERIDOL	2MG	N71724
HALOPERIDOL	5MG	N71725
HALOPERIDOL	0.5MG	N70720
HALOPERIDOL	10MG	N70724
HALOPERIDOL	1MG	N70721
HALOPERIDOL	20MG	N70725
HALOPERIDOL	2MG	N70722
HALOPERIDOL	5MG	N70723
HALOPERIDOL	0.5MG	N71571
HALOPERIDOL	10MG	N71375
HALOPERIDOL	1MG	N71572
HALOPERIDOL	20MG	N71376
HALOPERIDOL	2MG	N71573
HALOPERIDOL	5MG	N71374
HALOPERIDOL	10MG	N72113

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL

TABLET

HALOPERIDOL	1MG	N70982
HALOPERIDOL	20MG	N72353

HALOPERIDOL LACTATE

CONCENTRATE

HALDOL	EQ 2MG BASE/ML	N15922
HALOPERIDOL	EQ 2MG BASE/ML	N70318
HALOPERIDOL	EQ 2MG BASE/ML	N70710
HALOPERIDOL	EQ 2MG BASE/ML	N70726
HALOPERIDOL INTENSOL	EQ 2MG BASE/ML	N72045

INJECTABLE

HALOPERIDOL	EQ 5MG BASE/ML	N71187
HALOPERIDOL	EQ 5MG BASE/ML	N72516
HALOPERIDOL	EQ 5MG BASE/ML	N72517
HALOPERIDOL	EQ 5MG BASE/ML	N71082
HALOPERIDOL	EQ 5MG BASE/ML	N70802
HALOPERIDOL	EQ 5MG BASE/ML	N70800
HALOPERIDOL	EQ 5MG BASE/ML	N70801
HALOPERIDOL	EQ 5MG BASE/ML	N70864
HALOPERIDOL	EQ 5MG BASE/ML	N70713
HALOPERIDOL	EQ 5MG BASE/ML	N70744

HALOPROGIN

CREAM

HALOTEX	1%	N16942

SOLUTION

HALOTEX	1%	N16943

HALOTHANE

LIQUID

FLUOTHANE	99.99%	N11338
HALOTHANE	99.99%	N84977

HEPARIN CALCIUM

INJECTABLE

CALCIPARINE	25,000 UNITS/ML	N18237

HEPARIN SODIUM

INJECTABLE

HEP FLUSH KIT IN PLASTIC CONTAINER	10 UNITS/ML	N17029
HEP FLUSH KIT IN PLASTIC CONTAINER	100 UNITS/ML	N17029
HEPARIN LOCK FLUSH	100 UNITS/ML	N05264
HEPARIN LOCK FLUSH	100 UNITS/ML	N17651
HEPARIN LOCK FLUSH	10 UNITS/ML	N86357
HEPARIN LOCK FLUSH	500 UNITS/ML	N86357
HEPARIN LOCK FLUSH	10 UNITS/ML	N89063
HEPARIN LOCK FLUSH	100 UNITS/ML	N89064
HEPARIN LOCK FLUSH	10 UNITS/ML	N17346

HEPARIN SODIUM

INJECTABLE

HEPARIN LOCK FLUSH	10 UNITS/ML	N87904
HEPARIN LOCK FLUSH	10 UNITS/ML	N87958
HEPARIN LOCK FLUSH	10 UNITS/ML	N88458
HEPARIN LOCK FLUSH	10 UNITS/ML	N88580
HEPARIN LOCK FLUSH	100 UNITS/ML	N87906
HEPARIN LOCK FLUSH	100 UNITS/ML	N87959
HEPARIN LOCK FLUSH	100 UNITS/ML	N88460
HEPARIN LOCK FLUSH	100 UNITS/ML	N88581
HEPARIN LOCK FLUSH	10 UNITS/ML	N87903
HEPARIN LOCK FLUSH	10 UNITS/ML	N88457
HEPARIN LOCK FLUSH	100 UNITS/ML	N87905
HEPARIN LOCK FLUSH	100 UNITS/ML	N88459
HEPARIN LOCK FLUSH	100 UNITS/ML	N17064
HEPARIN LOCK FLUSH	10 UNITS/ML	N17007
HEPARIN LOCK FLUSH	100 UNITS/ML	N17007
HEPARIN LOCK FLUSH PRESERVATIVE FREE	10 UNITS/ML	N17029
HEPARIN LOCK FLUSH PRESERVATIVE FREE	100 UNITS/ML	N17029
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER	10 UNITS/ML	N17029
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER	100 UNITS/ML	N17029
HEPARIN SODIUM	10,000 UNITS/ML	N40095
HEPARIN SODIUM	1,000 UNITS/ML	N17486
HEPARIN SODIUM	10,000 UNITS/ML	N17486
HEPARIN SODIUM	20,000 UNITS/ML	N17486
HEPARIN SODIUM	40,000 UNITS/ML	N17486
HEPARIN SODIUM	5,000 UNITS/ML	N17486
HEPARIN SODIUM	1,000 UNITS/ML	N17033
HEPARIN SODIUM	1,000 UNITS/ML	N17651
HEPARIN SODIUM	10,000 UNITS/ML	N17651
HEPARIN SODIUM	20,000 UNITS/ML	N17651
HEPARIN SODIUM	5,000 UNITS/ML	N17029
HEPARIN SODIUM	5,000 UNITS/ML	N17979
HEPARIN SODIUM	1,000 UNITS/ML	N17130
HEPARIN SODIUM	10,000 UNITS/ML	N17130
HEPARIN SODIUM	20,000 UNITS/ML	N17130
HEPARIN SODIUM	5,000 UNITS/ML	N17130
HEPARIN SODIUM	1,000 UNITS/ML	N17540
HEPARIN SODIUM	10,000 UNITS/ML	N17540
HEPARIN SODIUM	20,000 UNITS/ML	N17540
HEPARIN SODIUM	40,000 UNITS/ML	N17540
HEPARIN SODIUM	5,000 UNITS/ML	N17540
HEPARIN SODIUM	1,000 UNITS/ML	N05521
HEPARIN SODIUM	20,000 UNITS/ML	N05521
HEPARIN SODIUM	1,000 UNITS/ML	N87452

HEPARIN SODIUM

INJECTABLE

HEPARIN SODIUM	1,000 UNITS/ML	N00552
HEPARIN SODIUM	10,000 UNITS/ML	N00552
HEPARIN SODIUM	5,000 UNITS/ML	N00552
HEPARIN SODIUM	1,000 UNITS/ML	N17346
HEPARIN SODIUM	10,000 UNITS/ML	N17346
HEPARIN SODIUM	20,000 UNITS/ML	N17346
HEPARIN SODIUM	5,000 UNITS/ML	N17346
HEPARIN SODIUM	7,500 UNITS/ML	N17346
HEPARIN SODIUM	1,000 UNITS/ML	N17780
HEPARIN SODIUM	10,000 UNITS/ML	N17780
HEPARIN SODIUM	20,000 UNITS/ML	N17780
HEPARIN SODIUM	40,000 UNITS/ML	N17780
HEPARIN SODIUM	5,000 UNITS/ML	N17780
HEPARIN SODIUM	1,000 UNITS/ML	N88239
HEPARIN SODIUM	1,000 UNITS/ML	N87043
HEPARIN SODIUM	10,000 UNITS/0.5ML	N87363
HEPARIN SODIUM	10,000 UNITS/ML	N87107
HEPARIN SODIUM	5,000 UNITS/0.5ML	N87395
HEPARIN SODIUM	5,000 UNITS/ML	N87077
HEPARIN SODIUM	1,000 UNITS/ML	N17064
HEPARIN SODIUM	10,000 UNITS/ML	N17064
HEPARIN SODIUM	2,500 UNITS/ML	N17064
HEPARIN SODIUM	20,000 UNITS/ML	N17064
HEPARIN SODIUM	3,000 UNITS/ML	N17064
HEPARIN SODIUM	4,000 UNITS/ML	N17064
HEPARIN SODIUM	40,000 UNITS/ML	N17064
HEPARIN SODIUM	5,000 UNITS/ML	N17064
HEPARIN SODIUM	6,000 UNITS/ML	N17064
HEPARIN SODIUM	7,500 UNITS/ML	N17064
HEPARIN SODIUM	1,000 UNITS/ML	N17007
HEPARIN SODIUM	10,000 UNITS/ML	N17007
HEPARIN SODIUM	15,000 UNITS/ML	N17007
HEPARIN SODIUM	2,500 UNITS/ML	N17007
HEPARIN SODIUM	20,000 UNITS/ML	N17007
HEPARIN SODIUM	5,000 UNITS/0.5ML	N17007
HEPARIN SODIUM	5,000 UNITS/ML	N17007
HEPARIN SODIUM	7,500 UNITS/ML	N17007
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	200 UNITS/100ML	N19130
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	200 UNITS/100ML	N19042
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%	10,000 UNITS/100ML	N18911
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	2,000 UNITS/100ML	N18814
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%	10,000 UNITS/100ML	N18911

HEPARIN SODIUM

INJECTABLE

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%	10,000 UNITS/100ML	N18916
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%	10,000 UNITS/100ML	N18911
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%	10,000 UNITS/100ML	N18916
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19802
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%	5,000 UNITS/100ML	N18916
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	200 UNITS/100ML	N19130
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	200 UNITS/100ML	N19042
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%	10,000 UNITS/100ML	N18911
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19134
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	10,000 UNITS/100ML	N19802
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19802
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N18916
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19135
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19802
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	500 UNITS/100ML	N18609
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	1,000 UNITS/100ML	N19130
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%	100 UNITS/ML	N18911
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%	100 UNITS/ML	N18916
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%	1,000 UNITS/100ML	N18916
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	1,000 UNITS/100ML	N19042
HEPARIN SODIUM PRESERVATIVE FREE	1,000 UNITS/ML	N86129
LIPO-HEPIN	1,000 UNITS/0.5ML	N17027
LIPO-HEPIN	1,000 UNITS/ML	N17027
LIPO-HEPIN	10,000 UNITS/0.5ML	N17027
LIPO-HEPIN	10,000 UNITS/ML	N17027

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM
INJECTABLE

LIPO-HEPIN	15,000 UNITS/0.5ML	N17027
LIPO-HEPIN	20,000 UNITS/0.5ML	N17027
LIPO-HEPIN	20,000 UNITS/ML	N17027
LIPO-HEPIN	40,000 UNITS/ML	N17027
LIPO-HEPIN	5,000 UNITS/0.5ML	N17027
LIPO-HEPIN	5,000 UNITS/ML	N17027
LIPO-HEPIN	7,500 UNITS/0.5ML	N17027
LIQUAEMIN LOCK FLUSH	100 UNITS/ML	N00552
LIQUAEMIN SODIUM	1,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	10,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	20,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	40,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	5,000 UNITS/ML	N00552
LIQUAEMIN SODIUM PRESERVATIVE FREE	1,000 UNITS/ML	N00552
LIQUAEMIN SODIUM PRESERVATIVE FREE	10,000 UNITS/ML	N00552
LIQUAEMIN SODIUM PRESERVATIVE FREE	5,000 UNITS/ML	N00552
PANHEPRIN	1,000 UNITS/ML	N05264
PANHEPRIN	10,000 UNITS/ML	N05264
PANHEPRIN	20,000 UNITS/ML	N05264
PANHEPRIN	40,000 UNITS/ML	N05264
PANHEPRIN	5,000 UNITS/ML	N05264
SODIUM HEPARIN	10,000 UNITS/ML	N17033
SODIUM HEPARIN	20,000 UNITS/ML	N17033
SODIUM HEPARIN	5,000 UNITS/ML	N17033

HETACILLIN
FOR SUSPENSION

VERSAPEN	EQ 112.5MG AMPICIL/5ML	N50060
VERSAPEN	EQ 112.5MG AMPICIL/ML	N50060
VERSAPEN	EQ 112.5MG AMPICIL/ML	N61398
VERSAPEN	EQ 225MG AMPICIL/5ML	N61398

HETACILLIN POTASSIUM
CAPSULE

VERSAPEN-K	EQ 225MG AMPICIL	N61396
VERSAPEN-K	EQ 450MG AMPICIL	N61396

HEXACHLOROPHENE
AEROSOL

SEPTISOL	0.23%	N17424
TURGEX	3%	N18375

EMULSION

HEXA-GERM	3%	N17411
PHISOHEX	3%	N08402
SOY-DOME	3%	N17405
TURGEX	3%	N19055

SOAP

HEXACHLOROPHENE
SOAP

GAMOPHEN	2%	N06270

SOLUTION

DIAL	0.25%	N17421
GERMA-MEDICA	1%	N17412
GERMA-MEDICA "MG"	0.25%	N17412
SEPTI-SOFT	0.25%	N17460
SEPTISOL	0.25%	N17423

SPONGE

E-Z SCRUB	450MG	N17452
HEXASCRUB	3%	N18363
PHISO-SCRUB	3%	N17446
SCRUBTEAM SURGICAL SPONGEBRUSH	330MG	N17413

HEXAFLUORENIUM BROMIDE
INJECTABLE

MYLAXEN	20MG/ML	N09789

HEXOCYCLIUM METHYLSULFATE
TABLET

TRAL	25MG	N10599

HEXYLCAINE HYDROCHLORIDE
SOLUTION

CYCLAINE	5%	N08472

HISTAMINE PHOSPHATE
INJECTABLE

HISTAMINE PHOSPHATE	EQ 0.1MG BASE/ML	N00734
HISTAMINE PHOSPHATE	EQ 0.2MG BASE/ML	N00734
HISTAMINE PHOSPHATE	EQ 1MG BASE/ML	N00734

HISTRELIN ACETATE
INJECTABLE

SUPPRELIN	EQ 0.2MG BASE/ML	N19836
SUPPRELIN	EQ 0.5MG BASE/ML	N19836
SUPPRELIN	EQ 1MG BASE/ML	N19836

HOMATROPINE METHYLBROMIDE
TABLET

HOMAPIN-10	10MG	N86308
HOMAPIN-5	5MG	N86309

TABLET, CHEWABLE

EQUIPIN	3MG	N86310

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
SYRUP

HYDROPANE	1.5MG/5ML;5MG/5ML	N88066

HYALURONIDASE

INJECTABLE

WYDASE	1,500 UNITS/VIAL	N06343
WYDASE	150 UNITS/ML	N06343
WYDASE	150 UNITS/VIAL	N06343

HYDRALAZINE HYDROCHLORIDE

INJECTABLE

APRESOLINE	20MG/ML	N08303
HYDRALAZINE HCL	20MG/ML	N89532
HYDRALAZINE HCL	20MG/ML	N88518
HYDRALAZINE HCL	20MG/ML	N88517

TABLET

DRALZINE	25MG	N84301
HYDRALAZINE HCL	25MG	N88560
HYDRALAZINE HCL	50MG	N88649
HYDRALAZINE HCL	25MG	N88310
HYDRALAZINE HCL	50MG	N88311
HYDRALAZINE HCL	50MG	N85088
HYDRALAZINE HCL	100MG	N88729
HYDRALAZINE HCL	100MG	N89178
HYDRALAZINE HCL	10MG	N88728
HYDRALAZINE HCL	10MG	N89218
HYDRALAZINE HCL	25MG	N84106
HYDRALAZINE HCL	25MG	N89130
HYDRALAZINE HCL	50MG	N84107
HYDRALAZINE HCL	50MG	N89222
HYDRALAZINE HCL	25MG	N84922
HYDRALAZINE HCL	100MG	N84581
HYDRALAZINE HCL	10MG	N84443
HYDRALAZINE HCL	25MG	N84437
HYDRALAZINE HCL	50MG	N84469
HYDRALAZINE HCL	25MG	N88177
HYDRALAZINE HCL	50MG	N88178
HYDRALAZINE HCL	100MG	N88686
HYDRALAZINE HCL	10MG	N88671
HYDRALAZINE HCL	25MG	N88657
HYDRALAZINE HCL	50MG	N88652
HYDRALAZINE HCL	10MG	N88787
HYDRALAZINE HCL	25MG	N88788
HYDRALAZINE HCL	50MG	N88789
HYDRALAZINE HCL	25MG	N87780
HYDRALAZINE HCL	50MG	N87751
HYDRALAZINE HCL	25MG	N87712
HYDRALAZINE HCL	50MG	N87908
HYDRALAZINE HCL	25MG	N86088
HYDRALAZINE HCL	25MG	N85532

HYDRALAZINE HYDROCHLORIDE

TABLET

HYDRALAZINE HCL	50MG	N85533
HYDRALAZINE HCL	25MG	N88240
HYDRALAZINE HCL	50MG	N88241

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE

APRESAZIDE	100MG;50MG	N84811
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	100MG;50MG	N87609
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;25MG	N87608
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	50MG;50MG	N87213
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;25MG	N89200
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	100MG;50MG	N85440
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;25MG	N85457
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	50MG;50MG	N85446
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50	100MG;50MG	N88358
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25	25MG;25MG	N88356
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50	50MG;50MG	N88357

TABLET

APRESOLINE-ESIDRIX	25MG;15MG	N12026
HYDRALAZINE AND HYDROCHLORTHIAZIDE	25MG;15MG	N85827
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE	25MG;15MG	N85373

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET

CAM-AP-ES	25MG;15MG;0.1MG	N84897
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE	25MG;15MG;0.1MG	N84291
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE	25MG;15MG;0.1MG	N87085
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;15MG;0.1MG	N85771
HYDRAP-ES	25MG;15MG;0.1MG	N84876
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE	25MG;15MG;0.1MG	N83770
HYDROSERPINE PLUS (R-H-H)	25MG;15MG;0.1MG	N83877
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N88570
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N88376
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N85549
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N87556
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL	25MG;15MG;0.1MG	N87709
SER-A-GEN	25MG;15MG;0.1MG	N87210

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET

SER-AP-ES	25MG;15MG;0.1MG	N12193
UNIPRES	25MG;15MG;0.1MG	N85893
UNIPRES	25MG;15MG;0.1MG	N86298

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET

DRALSERP	25MG;0.1MG	N84617
SERPASIL-APRESOLINE	25MG;0.1MG	N09296
SERPASIL-APRESOLINE	50MG;0.2MG	N09296

HYDROCHLOROTHIAZIDE

SOLUTION

HYDROCHLOROTHIAZIDE	50MG/5ML	N89661
HYDROCHLOROTHIAZIDE INTENSOL	100MG/ML	N88588

TABLET

ESIDRIX	100MG	N11793
HYDRO-D	25MG	N86504
HYDRO-D	50MG	N83891
HYDROCHLOROTHIAZIDE	25MG	N86369
HYDROCHLOROTHIAZIDE	50MG	N83554
HYDROCHLOROTHIAZIDE	25MG	N87539
HYDROCHLOROTHIAZIDE	50MG	N87540
HYDROCHLOROTHIAZIDE	50MG	N84771
HYDROCHLOROTHIAZIDE	50MG	N85152
HYDROCHLOROTHIAZIDE	25MG	N83899
HYDROCHLOROTHIAZIDE	100MG	N83972
HYDROCHLOROTHIAZIDE	25MG	N83972
HYDROCHLOROTHIAZIDE	50MG	N83972
HYDROCHLOROTHIAZIDE	50MG	N84135
HYDROCHLOROTHIAZIDE	100MG	N85098
HYDROCHLOROTHIAZIDE	25MG	N84029
HYDROCHLOROTHIAZIDE	50MG	N83607
HYDROCHLOROTHIAZIDE	25MG	N84776
HYDROCHLOROTHIAZIDE	25MG	N85067
HYDROCHLOROTHIAZIDE	50MG	N84776
HYDROCHLOROTHIAZIDE	50MG	N84658
HYDROCHLOROTHIAZIDE	100MG	N87060
HYDROCHLOROTHIAZIDE	25MG	N86192
HYDROCHLOROTHIAZIDE	50MG	N86192
HYDROCHLOROTHIAZIDE	25MG	N84880
HYDROCHLOROTHIAZIDE	50MG	N85112
HYDROCHLOROTHIAZIDE	25MG	N84325
HYDROCHLOROTHIAZIDE	50MG	N84324
HYDROCHLOROTHIAZIDE	50MG	N86597
HYDROCHLOROTHIAZIDE	25MG	N85004
HYDROCHLOROTHIAZIDE	50MG	N85005

HYDROCHLOROTHIAZIDE

TABLET

HYDROCHLOROTHIAZIDE	25MG	N85323
HYDROCHLOROTHIAZIDE	100MG	N88829
HYDROCHLOROTHIAZIDE	25MG	N88827
HYDROCHLOROTHIAZIDE	50MG	N88828
HYDROCHLOROTHIAZIDE	25MG	N88924
HYDROCHLOROTHIAZIDE	50MG	N88923
HYDROCHLOROTHIAZIDE	25MG	N87827
HYDROCHLOROTHIAZIDE	50MG	N87752
HYDROCHLOROTHIAZIDE	25MG	N87638
HYDROCHLOROTHIAZIDE	50MG	N87610
HYDROCHLOROTHIAZIDE	25MG	N87586
HYDROCHLOROTHIAZIDE	50MG	N87587
HYDROCHLOROTHIAZIDE	100MG	N85099
HYDROCHLOROTHIAZIDE	25MG	N83458
HYDROCHLOROTHIAZIDE	50MG	N83456
HYDROCHLOROTHIAZIDE	100MG	N81190
HYDROCHLOROTHIAZIDE	100MG	N87002
HYDROCHLOROTHIAZIDE	25MG	N85232
HYDROCHLOROTHIAZIDE	50MG	N83232
HYDROCHLOROTHIAZIDE	50MG	N85233
HYDROCHLOROTHIAZIDE	50MG	N86087
HYDROCHLOROTHIAZIDE	50MG	N86594
HYDROCHLOROTHIAZIDE	25MG	N84899
HYDROCHLOROTHIAZIDE	50MG	N84878
HYDROCHLOROTHIAZIDE	100MG	N85347
HYDROCHLOROTHIAZIDE	25MG	N83809
HYDROCHLOROTHIAZIDE	50MG	N83809
HYDRODIURIL	100MG	N11835
HYDRODIURIL	25MG	N11835
HYDRODIURIL	50MG	N11835
ORETIC	25MG	N11971
ZIDE	50MG	N83925

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET

AVALIDE	12.5MG;75MG	N20758

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET

NORMOZIDE	25MG;100MG	N19046
NORMOZIDE	25MG;200MG	N19046
NORMOZIDE	25MG;300MG	N19046
NORMOZIDE	25MG;400MG	N19046
TRANDATE HCT	25MG;100MG	N19174
TRANDATE HCT	25MG;200MG	N19174
TRANDATE HCT	25MG;300MG	N19174

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET

TRANDATE HCT	25MG;400MG	N19174

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET

METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N70829
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N70830
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71458
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71459
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71460
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71461
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71897
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71898
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71899
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71900
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N70853
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N70688
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N70854
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N70689
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71819
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71820
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71821
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71822
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N70365
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N70366
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N70367
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N70368
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71920
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71921
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71922
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71923

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET

VISKAZIDE	25MG;10MG	N18872
VISKAZIDE	25MG;5MG	N18872

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE

INDERIDE LA 120/50	50MG;120MG	N19059
INDERIDE LA 160/50	50MG;160MG	N19059
INDERIDE LA 80/50	50MG;80MG	N19059

TABLET

PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE	25MG;40MG	N71126
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE	25MG;80MG	N71127
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;40MG	N71552
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;80MG	N71553

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;40MG	N71771
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;80MG	N71772
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;40MG	N71498
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;80MG	N71501

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET

H.R.-50	50MG;0.125MG	N85338
HYDRO-RESERP	50MG;0.125MG	N84714
HYDRO-SERP "25"	25MG;0.125MG	N84827
HYDRO-SERP "50"	50MG;0.125MG	N85213
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N83571
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.1MG	N83572
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N83573
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.1MG	N83568
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N85421
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N85420
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N84603
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N85317
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N83666
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N84466
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N86330
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N84467
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N86331
HYDROPRES 25	25MG;0.125MG	N11958
HYDROPRES 50	50MG;0.125MG	N11958
RESERPINE AND HYDROCHLOROTHIAZIDE	25MG;0.125MG	N84580
RESERPINE AND HYDROCHLOROTHIAZIDE	50MG;0.125MG	N84579
RESERPINE AND HYDROCHLOROTHIAZIDE	50MG;0.125MG	N88200
RESERPINE AND HYDROCHLOROTHIAZIDE-50	50MG;0.125MG	N88189
SERPASIL-ESIDRIX #1	25MG;0.1MG	N11878
SERPASIL-ESIDRIX #2	50MG;0.1MG	N11878

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET

SPIRONOLACTONE + HYDROCHLOROTHIAZIDE	25MG;25MG	N88025
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE	25MG;25MG	N87999
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE	25MG;25MG	N89137
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87004
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87511
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N88054
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87553
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87651
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87655
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N85974
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N86026

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE		
DYAZIDE	25MG;50MG	N16042
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	25MG;37.5MG	N74857
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	25MG;50MG	N71737
TABLET		
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	50MG;75MG	N72022
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	50MG;75MG	N71980

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP		
CODAMINE	5MG/5ML;25MG/5ML	N75103
HYCOMINE	5MG/5ML;25MG/5ML	N19410
HYCOMINE PEDIATRIC	2.5MG/5ML;12.5MG/5ML	N19411

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT		
MAGNACORT	0.5%	N10554

HYDROCORTISONE

AEROSOL		
AEROSEB-HC	0.5%	N85805
CREAM		
CORT-DOME	0.5%	N09585
CORT-DOME	1%	N09585
DERMACORT	1%	N83011
ELDECORT	1%	N80459
ELDECORT	2.5%	N84055
FLEXICORT	0.5%	N87136
FLEXICORT	1%	N87136
FLEXICORT	2.5%	N87136
H-CORT	0.5%	N86823
HC #1	0.5%	N80438
HC #4	1%	N80438
HC (HYDROCORTISONE)	0.5%	N80482
HC (HYDROCORTISONE)	1%	N80482
HYDROCORTISONE	2.5%	N89754
HYDROCORTISONE	1%	N86080
HYDROCORTISONE	2.5%	N86271
HYDROCORTISONE	0.5%	N84970
HYDROCORTISONE	1%	N85026
HYDROCORTISONE	0.5%	N80452
HYDROCORTISONE	1%	N84059
HYDROCORTISONE	1%	N85733
HYDROCORTISONE	1%	N89706
HYDROCORTISONE	1%	N88845
HYDROCORTISONE	1%	N87838
HYDROCORTISONE	1%	N86170
HYDROCORTISONE	0.5%	N86154

HYDROCORTISONE

CREAM		
HYDROCORTISONE	0.5%	N80400
HYDROCORTISONE	1%	N80400
HYDROCORTISONE	1%	N85191
HYDROCORTISONE	2.5%	N80400
HYDROCORTISONE	1%	N89273
HYDROCORTISONE	1%	N88027
HYDROCORTISONE	2.5%	N88029
HYDROCORTISONE	1%	N80496
NOGENIC HC	1%	N87427
NUTRACORT	0.5%	N80442
NUTRACORT	1%	N80442
PROCTOCORT	1%	N83011
SYNACORT	0.5%	N87459
GEL		
NUTRACORT	1%	N84698
PENECORT	1%	N88215
INJECTABLE		
CORTEF	50MG/ML	N09864
LOTION		
ACTICORT	1%	N86535
BALNEOL-HC	1%	N88041
BETA-HC	1%	N89495
CORT-DOME	0.5%	N09895
CORT-DOME	1%	N09895
DERMACORT	0.5%	N84573
DERMACORT	1%	N86462
GLYCORT	1%	N87489
H-CORT	0.5%	N86824
HYDROCORTISONE	0.5%	N87317
HYDROCORTISONE	1%	N87315
HYDROCORTISONE	0.5%	N85662
HYDROCORTISONE	1%	N85663
HYDROCORTISONE	0.5%	N85282
HYDROCORTISONE	1%	N85282
HYDROCORTISONE	1%	N89705
HYDROCORTISONE	1%	N89024
NUTRACORT	0.5%	N80443
OINTMENT		
HC (HYDROCORTISONE)	0.5%	N80481
HC (HYDROCORTISONE)	1%	N80481
HYDROCORTISONE	0.5%	N80489
HYDROCORTISONE	1%	N86079
HYDROCORTISONE	2.5%	N86272
HYDROCORTISONE	0.5%	N84969
HYDROCORTISONE	1%	N85028

HYDROCORTISONE		
OINTMENT		
HYDROCORTISONE	1%	N89704
HYDROCORTISONE	1%	N88842
HYDROCORTISONE	0.5%	N86256
HYDROCORTISONE	1%	N88061
HYDROCORTISONE	2.5%	N88039
HYTONE	1%	N80474
HYTONE	2.5%	N80474
PENECORT	2.5%	N88217
POWDER		
H-CORT	100%	N87834
TABLET		
CORTRIL	10MG	N09796
CORTRIL	10MG	N09127
CORTRIL	20MG	N09127
HYDROCORTISONE	20MG	N83140
HYDROCORTISONE	20MG	N83999
HYDROCORTISONE	20MG	N80624
HYDROCORTISONE	20MG	N80642
HYDROCORTISONE	10MG	N80568
HYDROCORTISONE	20MG	N80568
HYDROCORTISONE	20MG	N80781
HYDROCORTISONE	20MG	N80732
HYDROCORTISONE	20MG	N85070
HYDROCORTISONE	10MG	N09659
HYDROCORTISONE	20MG	N09659
HYDROCORTISONE	20MG	N84243
HYDROCORTISONE	10MG	N84247
HYDROCORTISONE	20MG	N80395
HYDROCORTISONE	20MG	N84247
HYDROCORTISONE	10MG	N88539
HYDROCORTISONE	20MG	N80355
HYDROCORTISONE	10MG	N80344
HYDROCORTISONE	20MG	N80344
HYDROCORTISONE ACETATE		
CREAM		
HEMSOL-HC	1%	N81274
HYDROCORTISONE ACETATE	1%	N80419
HYDROCORTISONE ACETATE	1%	N89914
HYDROCORTISONE ACETATE	0.5%	N86050
HYDROCORTISONE ACETATE	1%	N86052
INJECTABLE		
CORTEF ACETATE	50MG/ML	N09378
CORTRIL	25MG/ML	N09164
HYDROCORTISONE ACETATE	25MG/ML	N09637

HYDROCORTISONE ACETATE		
INJECTABLE		
HYDROCORTISONE ACETATE	50MG/ML	N09637
HYDROCORTISONE ACETATE	25MG/ML	N83739
HYDROCORTISONE ACETATE	50MG/ML	N83739
HYDROCORTISONE ACETATE	25MG/ML	N83128
HYDROCORTISONE ACETATE	25MG/ML	N83759
HYDROCORTISONE ACETATE	50MG/ML	N83759
HYDROCORTISONE ACETATE	50MG/ML	N85214
HYDROCORTONE	25MG/ML	N08228
HYDROCORTONE	50MG/ML	N08228
OINTMENT		
CORTEF ACETATE	1%	N08917
CORTEF ACETATE	2.5%	N08917
HYDROCORTONE	1.5%	N09018
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE		
CREAM		
NEO-CORTEF	1%;EQ 3.5MG BASE/GM	N61049
NEO-CORTEF	2.5%;EQ 3.5MG BASE/GM	N61049
OINTMENT		
NEO-CORTEF	0.5%;EQ 3.5MG BASE/GM	N60610
NEO-CORTEF	0.5%;EQ 3.5MG BASE/GM	N60751
NEO-CORTEF	1%;EQ 3.5MG BASE/GM	N60751
NEO-CORTEF	1.5%;EQ 3.5MG BASE/GM	N60610
NEO-CORTEF	2.5%;EQ 3.5MG BASE/GM	N60751
SUSPENSION/DROPS		
COR-OTICIN	1.5%;EQ 3.5MG BASE/ML	N60188
NEO-CORTEF	0.5%;EQ 3.5MG BASE/ML	N60612
NEO-CORTEF	1.5%;EQ 3.5MG BASE/ML	N60612
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE		
LOTION		
PRAMOSONE	0.5%;1%	N83213
HYDROCORTISONE BUTYRATE		
CREAM		
LOCOID	0.1%	N18795
OINTMENT		
LOCOID	0.1%	N19106
SOLUTION		
LOCOID	0.1%	N19819
HYDROCORTISONE SODIUM PHOSPHATE		
INJECTABLE		
HYDROCORTISONE SODIUM PHOSPHATE	EQ 50MG BASE/ML	N89581
HYDROCORTISONE SODIUM SUCCINATE		
INJECTABLE		
A-HYDROCORT	EQ 100MG BASE/VIAL	N85928

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE

A-HYDROCORT	EQ 100MG BASE/VIAL	N89577
A-HYDROCORT	EQ 1GM BASE/VIAL	N89580
A-HYDROCORT	EQ 250MG BASE/VIAL	N89578
A-HYDROCORT	EQ 500MG BASE/VIAL	N89579
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N88667
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N88712
HYDROCORTISONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N88670
HYDROCORTISONE SODIUM SUCCINATE	EQ 250MG BASE/VIAL	N88668
HYDROCORTISONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N88669
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N86619
HYDROCORTISONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N87569
HYDROCORTISONE SODIUM SUCCINATE	EQ 250MG BASE/VIAL	N87567
HYDROCORTISONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N87568
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N84737
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N84738
HYDROCORTISONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N84748
HYDROCORTISONE SODIUM SUCCINATE	EQ 250MG BASE/VIAL	N84737
HYDROCORTISONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N84747

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS

NEO-OTOSOL-HC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62394
OTOCORT	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N60730

SUSPENSION/DROPS

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62617
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62623
OTICAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62399
OTOBIONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N61816
OTOCORT	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62521

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS

PYOCIDIN	5MG/ML;EQ 10,000 UNITS BASE/ML	N61606

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT

ACHROMYCIN	1.5%;1%	N50272

HYDROCORTISONE; UREA

CREAM

ALPHADERM	1%;10%	N86008
CALMURID HC	1%;10%	N83947

HYDROFLUMETHIAZIDE

TABLET

HYDROFLUMETHIAZIDE	50MG	N88031
HYDROFLUMETHIAZIDE	50MG	N88528

HYDROFLUMETHIAZIDE; RESERPINE

TABLET

HYDROFLUMETHIAZIDE AND RESERPINE	50MG;0.125MG	N88195
HYDROFLUMETHIAZIDE AND RESERPINE	25MG;0.125MG	N88127
HYDROFLUMETHIAZIDE AND RESERPINE	50MG;0.125MG	N88110
RESERPINE AND HYDROFLUMETHIAZIDE	50MG;0.125MG	N88932
RESERPINE AND HYDROFLUMETHIAZIDE	50MG;0.125MG	N88907
SALUTENSIN-DEMI	25MG;0.125MG	N12359

HYDROXOCOBALAMIN

INJECTABLE

ALPHAREDISOL	1MG/ML	N80778
HYDROXOCOBALAMIN	1MG/ML	N84921
HYDROXOCOBALAMIN	1MG/ML	N85528
HYDROXOMIN	1MG/ML	N84629

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS

PAREDRINE	1%	N00004

HYDROXYPROGESTERONE CAPROATE

INJECTABLE

DELALUTIN	125MG/ML	N10347
DELALUTIN	125MG/ML	N16911
DELALUTIN	250MG/ML	N10347
DELALUTIN	250MG/ML	N16911
HYDROXYPROGESTERONE CAPROATE	125MG/ML	N18004
HYDROXYPROGESTERONE CAPROATE	125MG/ML	N89330
HYDROXYPROGESTERONE CAPROATE	250MG/ML	N89331
HYDROXYPROGESTERONE CAPROATE	125MG/ML	N17439
HYDROXYPROGESTERONE CAPROATE	250MG/ML	N17439

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE

HYDROXYSTILBAMIDINE ISETHIONATE	225MG/AMP	N09166

HYDROXYZINE HYDROCHLORIDE

INJECTABLE

HYDROXYZINE HCL	50MG/ML	N86821
HYDROXYZINE HCL	25MG/ML	N87273
HYDROXYZINE HCL	50MG/ML	N87273
HYDROXYZINE HCL	25MG/ML	N88184
HYDROXYZINE HCL	50MG/ML	N88185
HYDROXYZINE HCL	25MG/ML	N88862
HYDROXYZINE HCL	25MG/ML	N89106
HYDROXYZINE HCL	50MG/ML	N88881
HYDROXYZINE HCL	50MG/ML	N89107
HYDROXYZINE HCL	25MG/ML	N87592
HYDROXYZINE HCL	25MG/ML	N86822
HYDROXYZINE HCL	25MG/ML	N87591
HYDROXYZINE HCL	50MG/ML	N87310
HYDROXYZINE HCL	50MG/ML	N87593
HYDROXYZINE HCL	50MG/ML	N87595
HYDROXYZINE HCL	50MG/ML	N87596
HYDROXYZINE HCL	25MG/ML	N85778
HYDROXYZINE HCL	25MG/ML	N87274
HYDROXYZINE HCL	50MG/ML	N87274
HYDROXYZINE HCL	25MG/ML	N86258
HYDROXYZINE HCL	50MG/ML	N86258
ORGATRAX	25MG/ML	N87014
ORGATRAX	50MG/ML	N87014

SYRUP

HYDROXYZINE HCL	10MG/5ML	N88785
HYDROXYZINE HCL	10MG/5ML	N87730

TABLET

HYDROXYZINE HCL	10MG	N89071
HYDROXYZINE HCL	25MG	N89072
HYDROXYZINE HCL	50MG	N89073
HYDROXYZINE HCL	10MG	N87246
HYDROXYZINE HCL	25MG	N85247
HYDROXYZINE HCL	50MG	N87245
HYDROXYZINE HCL	100MG	N87862
HYDROXYZINE HCL	10MG	N88409
HYDROXYZINE HCL	10MG	N89366
HYDROXYZINE HCL	25MG	N87857
HYDROXYZINE HCL	25MG	N89117
HYDROXYZINE HCL	50MG	N87860
HYDROXYZINE HCL	50MG	N89396
HYDROXYZINE HCL	10MG	N87216
HYDROXYZINE HCL	25MG	N87410
HYDROXYZINE HCL	50MG	N87411
HYDROXYZINE HCL	100MG	N87822
HYDROXYZINE HCL	10MG	N87819

HYDROXYZINE HYDROCHLORIDE

TABLET

HYDROXYZINE HCL	25MG	N87820
HYDROXYZINE HCL	50MG	N87821
HYDROXYZINE HCL	10MG	N87602
HYDROXYZINE HCL	25MG	N87603
HYDROXYZINE HCL	50MG	N87604
HYDROXYZINE HCL	10MG	N88120
HYDROXYZINE HCL	25MG	N88121
HYDROXYZINE HCL	50MG	N88122
HYDROXYZINE HCL	10MG	N88540
HYDROXYZINE HCL	25MG	N88551
HYDROXYZINE HCL	50MG	N88529
HYDROXYZINE HCL	10MG	N88794
HYDROXYZINE HCL	25MG	N88795
HYDROXYZINE HCL	50MG	N88796
HYDROXYZINE HCL	10MG	N89121
HYDROXYZINE HCL	25MG	N89122
HYDROXYZINE HCL	50MG	N89123
HYDROXYZINE HCL	10MG	N86827
HYDROXYZINE HCL	25MG	N86829
HYDROXYZINE HCL	50MG	N86836

HYDROXYZINE PAMOATE

CAPSULE

HY-PAM "25"	EQ 25MG HCL	N88713
HYDROXYZINE PAMOATE	EQ 100MG HCL	N88595
HYDROXYZINE PAMOATE	EQ 25MG HCL	N88593
HYDROXYZINE PAMOATE	EQ 50MG HCL	N88594
HYDROXYZINE PAMOATE	EQ 100MG HCL	N81129
HYDROXYZINE PAMOATE	EQ 50MG HCL	N81128
HYDROXYZINE PAMOATE	EQ 100MG HCL	N87658
HYDROXYZINE PAMOATE	EQ 25MG HCL	N87656
HYDROXYZINE PAMOATE	EQ 25MG HCL	N89145
HYDROXYZINE PAMOATE	EQ 50MG HCL	N87657
HYDROXYZINE PAMOATE	EQ 50MG HCL	N89146
HYDROXYZINE PAMOATE	EQ 100MG HCL	N89033
HYDROXYZINE PAMOATE	EQ 25MG HCL	N89031
HYDROXYZINE PAMOATE	EQ 50MG HCL	N89032
HYDROXYZINE PAMOATE	EQ 25MG HCL	N88392
HYDROXYZINE PAMOATE	EQ 50MG HCL	N88393
HYDROXYZINE PAMOATE	EQ 100MG HCL	N86697
HYDROXYZINE PAMOATE	EQ 25MG HCL	N86698
HYDROXYZINE PAMOATE	EQ 50MG HCL	N86695
HYDROXYZINE PAMOATE	EQ 100MG HCL	N86728
HYDROXYZINE PAMOATE	EQ 100MG HCL	N87790
HYDROXYZINE PAMOATE	EQ 25MG HCL	N86840

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE PAMOATE		
CAPSULE		
HYDROXYZINE PAMOATE	EQ 50MG HCL	N86705
HYDROXYZINE PAMOATE	EQ 50MG HCL	N87767
IBUPROFEN		
CAPSULE		
MIDOL	200MG	* N70626
MIDOL	200MG	* N71002
SUSPENSION		
IBU	100MG/5ML	N19784
SUSPENSION/DROPS		
MOTRIN	40MG/ML	N20476
TABLET		
ACHES-N-PAIN	200MG	N71065
IBU-TAB	800MG	N71965
IBUPRIN	200MG	N71773
IBUPROFEN	600MG	N70556
IBUPROFEN	800MG	N71264
IBUPROFEN	200MG	N70493
IBUPROFEN	200MG	N70908
IBUPROFEN	200MG	N71462
IBUPROFEN	400MG	N70079
IBUPROFEN	600MG	N70080
IBUPROFEN	800MG	N71448
IBUPROFEN	200MG	N71027
IBUPROFEN	300MG	N71028
IBUPROFEN	400MG	N71029
IBUPROFEN	600MG	N71030
IBUPROFEN	800MG	N72137
IBUPROFEN	400MG	N72064
IBUPROFEN	600MG	N72065
IBUPROFEN	800MG	N71938
IBUPROFEN	200MG	N71154
IBUPROFEN	200MG	N72040
IBUPROFEN	400MG	N70629
IBUPROFEN	600MG	N70630
IBUPROFEN	400MG	N70081
IBUPROFEN	600MG	N70476
IBUPROFEN	300MG	N70328
IBUPROFEN	200MG	N71122
IBUPROFEN	200MG	N71664
IBUPROFEN	300MG	N71123
IBUPROFEN	400MG	N71124
IBUPROFEN	600MG	N71125
IBUPROFEN	800MG	N71964
IBUPROFEN	600MG	N70709
IBUPROFEN		
TABLET		
IBUPROFEN	200MG	N73141
IBUPROFEN	400MG	N73343
IBUPROFEN	600MG	N73344
IBUPROFEN	800MG	N73345
IBUPROFEN	200MG	N71765
IBUPROFEN	200MG	N71905
IBUPROFEN	300MG	N71338
IBUPROFEN	400MG	N70038
IBUPROFEN	600MG	N70041
IBUPROFEN	800MG	N71911
MIDOL	200MG	N70591
MIDOL	200MG	N71001
MOTRIN	100MG	N20418
NUPRIN	200MG	N72035
NUPRIN	200MG	N72036
NUPRIN	200MG	N19012
NUPRIN	200MG	N19012
RUFEN	600MG	N18197
TABLET, CHEWABLE		
MOTRIN	100MG	N20135
MOTRIN	50MG	N20135
IDARUBICIN HYDROCHLORIDE		
INJECTABLE		
IDAMYCIN	10MG/VIAL	N50661
IDAMYCIN	20MG/VIAL	N50661
IDAMYCIN	5MG/VIAL	N50661
IDOXURIDINE		
OINTMENT		
STOXIL	0.5%	N15868
SOLUTION/DROPS		
STOXIL	0.1%	N13934
IFOSFAMIDE		
INJECTABLE		
IFEX	1GM/VIAL	* N19763
IFEX	3GM/VIAL	* N19763
IMIPRAMINE HYDROCHLORIDE		
INJECTABLE		
TOFRANIL	12.5MG/ML	N11838
TABLET		
IMIPRAMINE HCL	10MG	N85200
IMIPRAMINE HCL	25MG	N84869
IMIPRAMINE HCL	50MG	N85133
IMIPRAMINE HCL	10MG	N86269

IMIPRAMINE HYDROCHLORIDE		
TABLET		
IMIPRAMINE HCL	25MG	N86267
IMIPRAMINE HCL	50MG	N86268
IMIPRAMINE HCL	25MG	N83799
IMIPRAMINE HCL	50MG	N83799
IMIPRAMINE HCL	25MG	N87776
IMIPRAMINE HCL	10MG	N88036
IMIPRAMINE HCL	25MG	N87619
IMIPRAMINE HCL	50MG	N87631
IMIPRAMINE HCL	10MG	N85220
IMIPRAMINE HCL	25MG	N84252
IMIPRAMINE HCL	50MG	N85221
IMIPRAMINE HCL	10MG	N85875
IMIPRAMINE HCL	25MG	N85878
IMIPRAMINE HCL	50MG	N85877
IMIPRAMINE HCL	25MG	N88222
IMIPRAMINE HCL	50MG	N88223
JANIMINE	10MG	N17895
JANIMINE	25MG	N17895
JANIMINE	50MG	N17895
PRAMINE	10MG	N83827
PRAMINE	25MG	N83827
PRAMINE	50MG	N83827
PRESAMINE	10MG	N11836
PRESAMINE	25MG	N11836
PRESAMINE	50MG	N11836
INAMRINONE LACTATE		
INJECTABLE		
INOCOR	EQ 5MG BASE/ML	N18700
INDAPAMIDE		
TABLET		
INDAPAMIDE	1.25MG	N74665
INDAPAMIDE	2.5MG	N74665
INDECAINIDE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
DECABID	EQ 100MG BASE	N19693
DECABID	EQ 50MG BASE	N19693
DECABID	EQ 75MG BASE	N19693
INDOCYANINE GREEN		
INJECTABLE		
CARDIO-GREEN	10MG/VIAL	N11525
CARDIO-GREEN	40MG/VIAL	N11525
CARDIO-GREEN	50MG/VIAL	N11525
INDOMETHACIN		
CAPSULE		
INDOMETHACIN	25MG	N70326
INDOMETHACIN	50MG	N70327
INDOMETHACIN	25MG	N70067
INDOMETHACIN	25MG	N70782
INDOMETHACIN	50MG	N70068
INDOMETHACIN	50MG	N70635
INDOMETHACIN	25MG	N18730
INDOMETHACIN	50MG	N18730
INDOMETHACIN	25MG	N18806
INDOMETHACIN	50MG	N18806
INDOMETHACIN	25MG	N70813
INDOMETHACIN	50MG	N70592
INDOMETHACIN	25MG	N70353
INDOMETHACIN	50MG	N70354
INDOMETHACIN	25MG	N70487
INDOMETHACIN	50MG	N70488
INDOMETHACIN	25MG	N70784
INDOMETHACIN	50MG	N70785
INDOMETHACIN	25MG	N18690
INDOMETHACIN	25MG	N70529
INDOMETHACIN	25MG	N72996
INDOMETHACIN	50MG	N18690
INDOMETHACIN	50MG	N70530
INDOMETHACIN	50MG	N71635
INDOMETHACIN	50MG	N72997
CAPSULE, EXTENDED RELEASE		
INDOCIN SR	75MG	N18185
SUPPOSITORY		
INDOCIN	50MG	N17814
INSULIN PORK		
INJECTABLE		
ILETIN I	500 UNITS/ML	N17931
INSULIN	40 UNITS/ML	N17926
REGULAR INSULIN	100 UNITS/ML	N17926
INSULIN PURIFIED BEEF		
INJECTABLE		
REGULAR ILETIN II	100 UNITS/ML	N18478
INSULIN PURIFIED PORK		
INJECTABLE		
REGULAR PURIFIED PORK INSULIN	100 UNITS/ML	N18381
VELOSULIN	100 UNITS/ML	N18193

FDA data supplied by DrugPatentWatch.com

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE

INSULIN NORDISK MIXTARD (PORK)	30 UNITS/ML;70 UNITS/ML	N18195

INSULIN RECOMBINANT HUMAN

INJECTABLE

HUMULIN BR	100 UNITS/ML	N19529

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE

NOVOLIN R	100 UNITS/ML	N18778
VELOSULIN BR HUMAN	100 UNITS/ML	N19450

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE

MIXTARD HUMAN 70/30	30 UNITS/ML;70 UNITS/ML	N19585
NOVOLIN 70/30	30 UNITS/ML;70 UNITS/ML	N19441

INSULIN SUSP ISOPHANE BEEF

INJECTABLE

NPH INSULIN	40 UNITS/ML	N17929

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE

NPH ILETIN I (BEEF-PORK)	40 UNITS/ML	N17936

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE

NPH ILETIN II	100 UNITS/ML	N18479

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE

INSULIN INSULATARD NPH NORDISK	100 UNITS/ML	N18194
NPH PURIFIED PORK ISOPHANE INSULIN	100 UNITS/ML	N18623

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE

INSULATARD NPH HUMAN	100 UNITS/ML	N19449
NOVOLIN N	100 UNITS/ML	N19065

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE

PROTAMINE, ZINC & ILETIN I (BEEF-PORK)	100 UNITS/ML	N17932
PROTAMINE, ZINC & ILETIN I (BEEF-PORK)	40 UNITS/ML	N17932

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE

PROTAMINE ZINC AND ILETIN II	100 UNITS/ML	N18476
PROTAMINE ZINC INSULIN	100 UNITS/ML	N17928
PROTAMINE ZINC INSULIN	40 UNITS/ML	N17928

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE

PROTAMINE ZINC AND ILETIN II (PORK)	100 UNITS/ML	N18346

INSULIN ZINC SUSP BEEF

INJECTABLE

LENTE INSULIN	100 UNITS/ML	N17998
LENTE INSULIN	40 UNITS/ML	N17998

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE

ULTRALENTE INSULIN	100 UNITS/ML	N17997

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE

ULTRALENTE	100 UNITS/ML	N18385

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE

HUMULIN U	40 UNITS/ML	N19571

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE

SEMILENTE INSULIN	100 UNITS/ML	N17996

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE

SEMILENTE	100 UNITS/ML	N18382

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE

LENTE ILETIN II	100 UNITS/ML	N18477

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE

LENTARD	100 UNITS/ML	N18384

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE

LENTE	100 UNITS/ML	N18383

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE

NOVOLIN L	100 UNITS/ML	N18777

INVERT SUGAR

INJECTABLE

TRAVERT 10% IN PLASTIC CONTAINER	10GM/100ML	N16717

IOCETAMIC ACID

TABLET

CHOLEBRINE	750MG	N17129

IODAMIDE MEGLUMINE

INJECTABLE

RENOVUE-65	65%	N17902

IODAMIDE MEGLUMINE		
INJECTABLE		
RENOVUE-DIP	24%	N17903
IODIPAMIDE MEGLUMINE		
INJECTABLE		
CHOLOGRAFIN MEGLUMINE	10.3%	N09321
IODIPAMIDE SODIUM		
INJECTABLE		
CHOLOGRAFIN SODIUM	20%	N09321
IODIXANOL		
INJECTABLE		
VISIPAQUE 270	55%	N20808
VISIPAQUE 320	65.2%	N20808
IODOHIPPURATE SODIUM, I-123		
INJECTABLE		
NEPHROFLOW	1mCi/ML	N18289
IODOHIPPURATE SODIUM, I-131		
INJECTABLE		
HIPPURAN I 131	0.25mCi/ML	N16666
HIPPUTOPE	1-2mCi/VIAL	N15419
IODOHIPPURATE SODIUM I 131	0.2mCi/ML	N17313
IODOXAMATE MEGLUMINE		
INJECTABLE		
CHOLOVUE	40.3%	N18076
CHOLOVUE	9.9%	N18077
IOFETAMINE HYDROCHLORIDE I-123		
INJECTABLE		
SPECTAMINE	1mCi/ML	N19432
IOHEXOL		
INJECTABLE		
OMNIPAQUE 210	45.3%	N18956
SOLUTION		
OMNIPAQUE 70	15.1%	N18956
IOPAMIDOL		
INJECTABLE		
IOPAMIDOL	61%	N74734
IOPAMIDOL	76%	N74734
IOPAMIDOL-300	61%	N74638
ISOVUE-128	26%	N18735
ISOVUE-200	41%	N20327
IOPHENDYLATE		
INJECTABLE		
PANTOPAQUE	100%	N05319
IOTHALAMATE SODIUM		
INJECTABLE		
ANGIO-CONRAY	80%	N13319
CONRAY 325	54.3%	N17685
IOTROLAN		
INJECTABLE		
OSMOVIST 190	40.6%	N19580
OSMOVIST 240	51.3%	N19580
IPODATE CALCIUM		
GRANULE		
ORAGRAFIN CALCIUM	3GM/PACKET	N12968
IPODATE SODIUM		
CAPSULE		
BILIVIST	500MG	N87768
ORAGRAFIN SODIUM	500MG	N12967
IRON DEXTRAN		
INJECTABLE		
IRON DEXTRAN	EQ 50MG IRON/ML	N10787
ISOETHARINE HYDROCHLORIDE		
SOLUTION		
BRONKOSOL	0.25%	N12339
BRONKOSOL	1%	N12339
ISOETHARINE HCL	1%	N87101
ISOETHARINE HCL	0.062%	N87937
ISOETHARINE HCL	0.062%	N89614
ISOETHARINE HCL	0.125%	N87938
ISOETHARINE HCL	0.125%	N89615
ISOETHARINE HCL	0.167%	N88470
ISOETHARINE HCL	0.167%	N89616
ISOETHARINE HCL	0.2%	N88471
ISOETHARINE HCL	0.2%	N89617
ISOETHARINE HCL	0.25%	N88472
ISOETHARINE HCL	0.25%	N89618
ISOETHARINE HCL	0.08%	N88144
ISOETHARINE HCL	0.14%	N88145
ISOETHARINE HCL	0.25%	N88146
ISOETHARINE HCL	0.08%	N88187
ISOETHARINE HCL	0.17%	N87390
ISOETHARINE HCL	0.25%	N88188
ISOETHARINE HCL	1%	N86763
ISOETHARINE HCL	0.077%	N86651
ISOETHARINE HCL	0.1%	N86651
ISOETHARINE HCL	0.167%	N86651
ISOETHARINE HCL	0.2%	N86651
ISOETHARINE HCL	0.25%	N86651

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HYDROCHLORIDE		
SOLUTION		
ISOETHARINE HCL	1%	N86651
ISOETHARINE HCL	0.5%	N85997
ISOETHARINE HCL	1%	N85889
ISOETHARINE HCL	0.1%	N87396
ISOETHARINE HCL	0.125%	N87025
ISOETHARINE HCL	0.25%	N88275
ISOETHARINE HCL S/F	0.08%	N89817
ISOETHARINE HCL S/F	0.1%	N89818
ISOETHARINE HCL S/F	0.17%	N89819
ISOETHARINE HCL S/F	0.25%	N89820
ISOETHARINE HCL S/F	1%	N89252
ISOETHARINE MESYLATE		
AEROSOL, METERED		
BRONKOMETER	0.34MG/INH	N12339
ISOETHARINE MESYLATE	0.34MG/INH	N87858
ISOFLUROPHATE		
OINTMENT		
FLOROPRYL	0.025%	N10656
ISONIAZID		
INJECTABLE		
ISONIAZID	100MG/ML	N89816
RIMIFON	100MG/ML	N08420
RIMIFON	25MG/ML	N08420
SYRUP		
ISONIAZID	50MG/5ML	N81118
LANIAZID	50MG/5ML	N89243
RIMIFON	50MG/5ML	N08420
TABLET		
DOW-ISONIAZID	300MG	N80330
HYZYD	100MG	N80134
HYZYD	300MG	N80134
INH	300MG	N80935
ISONIAZID	100MG	N84050
ISONIAZID	100MG	N88231
ISONIAZID	100MG	N80136
ISONIAZID	50MG	N83632
ISONIAZID	100MG	N80153
ISONIAZID	100MG	N80270
ISONIAZID	300MG	N83610
ISONIAZID	100MG	N08499
ISONIAZID	300MG	N08499
ISONIAZID	100MG	N80941
ISONIAZID	100MG	N08428
ISONIAZID	300MG	N08428

ISONIAZID		
TABLET		
ISONIAZID	50MG	N08428
ISONIAZID	100MG	N83060
ISONIAZID	100MG	N85091
ISONIAZID	100MG	N80368
ISONIAZID	50MG	N80368
ISONIAZID	100MG	N80132
ISONIAZID	50MG	N80132
ISONIAZID	100MG	N80401
ISONIAZID	300MG	N83178
ISONIAZID	100MG	N80523
ISONIAZID	100MG	N85790
ISONIAZID	300MG	N85784
ISONIAZID	50MG	N80522
ISONIAZID	100MG	N80120
NYDRAZID	100MG	N08392
STANOZIDE	100MG	N80126
STANOZIDE	300MG	N80126
ISOPROPAMIDE IODIDE		
TABLET		
DARBID	EQ 5MG BASE	N10744
ISOPROTERENOL HYDROCHLORIDE		
AEROSOL, METERED		
ISOPROTERENOL HCL	0.12MG/INH	N10375
ISOPROTERENOL HCL	0.12MG/INH	N85904
ISUPREL	0.103MG/INH	N11178
DISC		
NORISODRINE AEROTROL	0.25%	N16814
INJECTABLE		
ISOPROTERENOL HCL	0.2MG/ML	N83431
SOLUTION		
AEROLONE	0.25%	N07245
ISOPROTERENOL HCL	0.031%	N87935
ISOPROTERENOL HCL	0.062%	N87936
ISOPROTERENOL HCL	0.5%	N86764
ISOPROTERENOL HCL	0.25%	N85994
ISOPROTERENOL HCL	0.5%	N85540
ISUPREL	0.5%	N06327
ISUPREL	1%	N06327
VAPO-ISO	0.5%	N16813
TABLET		
ISUPREL	10MG	N06328
ISUPREL	15MG	N06328

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE		
AEROSOL, METERED		
DUO-MEDIHALER	0.16MG/INH;0.24MG/INH	N13296
ISOPROTERENOL SULFATE		
AEROSOL, METERED		
MEDIHALER-ISO	0.08MG/INH	N10375
POWDER		
NORISODRINE	10%	N06905
NORISODRINE	25%	N06905
ISOSORBIDE		
SOLUTION		
ISMOTIC	100GM/220ML	N17063
ISOSORBIDE DINITRATE		
TABLET		
ISOSORBIDE DINITRATE	10MG	N86169
ISOSORBIDE DINITRATE	10MG	N87545
ISOSORBIDE DINITRATE	2.5MG	N84204
ISOSORBIDE DINITRATE	20MG	N86167
ISOSORBIDE DINITRATE	30MG	N87564
ISOSORBIDE DINITRATE	5MG	N86166
ISOSORBIDE DINITRATE	5MG	N86168
ISOSORBIDE DINITRATE	10MG	N89191
ISOSORBIDE DINITRATE	20MG	N89192
ISOSORBIDE DINITRATE	5MG	N89190
SORBITRATE	10MG	N16192
SORBITRATE	2.5MG	N16191
SORBITRATE	30MG	N88124
SORBITRATE	5MG	N16191
SORBITRATE	5MG	N16192
TABLET, CHEWABLE		
SORBITRATE	5MG	N16776
TABLET, EXTENDED RELEASE		
ISORDIL	40MG	N12882
KANAMYCIN SULFATE		
CAPSULE		
KANTREX	EQ 500MG BASE	N60516
KANTREX	EQ 500MG BASE	N61911
INJECTABLE		
KANAMYCIN	EQ 1GM BASE/3ML	N62324
KANAMYCIN	EQ 500MG BASE/2ML	N62324
KANAMYCIN	EQ 75MG BASE/2ML	N62324
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62504
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62504
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62504

KANAMYCIN SULFATE		
INJECTABLE		
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62466
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62466
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N63025
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N63022
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N63021
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62669
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62672
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62668
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62642
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62642
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62642
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62605
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62605
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62605
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62520
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N63092
KANTREX	EQ 1GM BASE/3ML	N61655
KANTREX	EQ 1GM BASE/3ML	N62564
KANTREX	EQ 500MG BASE/2ML	N61655
KANTREX	EQ 500MG BASE/2ML	N62564
KANTREX	EQ 75MG BASE/2ML	N61655
KANTREX	EQ 75MG BASE/2ML	N62564
KLEBCIL	EQ 1GM BASE/3ML	N62170
KLEBCIL	EQ 500MG BASE/2ML	N62170
KLEBCIL	EQ 75MG BASE/2ML	N62170
KETAMINE HYDROCHLORIDE		
INJECTABLE		
KETAMINE HCL	EQ 100MG BASE/ML	N71951
KETAMINE HCL	EQ 10MG BASE/ML	N71949
KETAMINE HCL	EQ 50MG BASE/ML	N71950
KETOCONAZOLE		
SUSPENSION		
NIZORAL	100MG/5ML	N70767
KETOROLAC TROMETHAMINE		
INJECTABLE		
KETOROLAC TROMETHAMINE	15MG/ML	N75348
KETOROLAC TROMETHAMINE	30MG/ML	N75348
KETOROLAC TROMETHAMINE	15MG/ML	N75230
KETOROLAC TROMETHAMINE	30MG/ML	N75230
TABLET		
KETOROLAC TROMETHAMINE	10MG	N74790

KRYPTON, KR-81M		
GAS		
MPI KRYPTON 81M GAS GENERATOR	N/A	N18088
LABETALOL HYDROCHLORIDE		
INJECTABLE		
LABETALOL HCL	5MG/ML	N75355
TABLET		
NORMODYNE	400MG	N18687
TRANDATE	400MG	N18716
LACTULOSE		
SOLUTION		
CEPHULAC	10GM/15ML	N17657
DUPHALAC	10GM/15ML	N72372
GENERLAC	10GM/15ML	N71842
LACTULOSE	10GM/15ML	N71841
LACTULOSE	10GM/15ML	N72029
LACTULOSE	10GM/15ML	N73160
LACTULOSE	10GM/15ML	N73590
LACTULOSE	10GM/15ML	N17906
PORTALAC	10GM/15ML	N72374
LAMOTRIGINE		
TABLET		
LAMICTAL	250MG	N20241
LAMICTAL	50MG	N20241
TABLET, CHEWABLE		
LAMICTAL CD	100MG	N20764
LEUCOVORIN CALCIUM		
FOR SOLUTION		
LEUCOVORIN CALCIUM	EQ 60MG BASE/VIAL	N08107
INJECTABLE		
LEUCOVORIN CALCIUM	EQ 3MG BASE/ML	N89352
LEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL	N89353
LEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL	N88939
LEUCOVORIN CALCIUM	EQ 100MG BASE/VIAL	N89636
LEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL	N89496
LEUCOVORIN CALCIUM	EQ 5MG BASE/ML	N89503
LEUCOVORIN CALCIUM	EQ 5MG BASE/ML	N89504
LEUCOVORIN CALCIUM	EQ 3MG BASE/ML	N08107
WELLCOVORIN	EQ 100MG BASE/VIAL	N89834
WELLCOVORIN	EQ 25MG BASE/VIAL	N89833
WELLCOVORIN	EQ 50MG BASE/VIAL	N89465
TABLET		
LEUCOVORIN CALCIUM	EQ 25MG BASE	N71598
LEUCOVORIN CALCIUM	EQ 5MG BASE	N71600
WELLCOVORIN	EQ 25MG BASE	N18342

LEUCOVORIN CALCIUM		
TABLET		
WELLCOVORIN	EQ 5MG BASE	N18342
LEUPROLIDE ACETATE		
INJECTABLE		
LUPRON DEPOT-PED	3.75MG/VIAL;7.5MG/VIAL	N20263
LUPRON DEPOT-PED	7.5MG/VIAL;7.5MG/VIAL	N20263
LEVALLORPHAN TARTRATE		
INJECTABLE		
LORFAN	1MG/ML	N10423
LEVOCARNITINE		
SOLUTION		
CARNITOR	1GM/10ML	N18948
LEVODOPA		
CAPSULE		
BENDOPA	100MG	N16948
BENDOPA	250MG	N16948
BENDOPA	500MG	N16948
DOPAR	100MG	N16913
DOPAR	250MG	N16913
DOPAR	500MG	N16913
LARODOPA	100MG	N16912
LARODOPA	250MG	N16912
LARODOPA	500MG	N16912
TABLET		
DOPAR	250MG	N16913
DOPAR	500MG	N16913
LARODOPA	100MG	N16912
LARODOPA	250MG	N16912
LARODOPA	500MG	N16912
LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE		
INJECTABLE		
ARESTOCAINE HCL W/ LEVONORDEFRIN	0.05MG/ML;2%	N85010
LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE		
INJECTABLE		
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN	0.05MG/ML;2%;0.4%	N08592
LEVONORGESTREL		
IMPLANT		
NORPLANT	36MG/IMPLANT	N19897
LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS		
CAPSULE		
NOVRAD	EQ 100MG BASE	N12928
NOVRAD	EQ 50MG BASE	N12928

LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS		
SUSPENSION		
NOVRAD	EQ 50MG BASE/5ML	N12928
LIDOCAINE		
AEROSOL		
XYLOCAINE	10%	N14394
FILM, EXTENDED RELEASE		
LIDOCAINE	23MG/PATCH	N20575
OINTMENT		
ALPHACAINE	5%	N84944
ALPHACAINE	5%	N84946
XYLOCAINE	5%	N08048
SUPPOSITORY		
XYLOCAINE	100MG	N13077
LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
ALPHACAINE HCL	2%	N84721
LIDOCAINE HCL	1.5%	N88330
LIDOCAINE HCL	10%	N87980
LIDOCAINE HCL	20%	N89362
LIDOCAINE HCL	1%	N85037
LIDOCAINE HCL	2%	N85037
LIDOCAINE HCL	1%	N80390
LIDOCAINE HCL	1%	N80420
LIDOCAINE HCL	1%	N86761
LIDOCAINE HCL	1.5%	N80420
LIDOCAINE HCL	2%	N17508
LIDOCAINE HCL	2%	N80390
LIDOCAINE HCL	2%	N80420
LIDOCAINE HCL	2%	N80420
LIDOCAINE HCL	2%	N86761
LIDOCAINE HCL	20%	N17508
LIDOCAINE HCL	4%	N17508
LIDOCAINE HCL	1%	N80710
LIDOCAINE HCL	2%	N80760
LIDOCAINE HCL	1%	N83387
LIDOCAINE HCL	2%	N83388
LIDOCAINE HCL	0.5%	N85131
LIDOCAINE HCL	4%	N84626
LIDOCAINE HCL	1%	N83135
LIDOCAINE HCL	2%	N83135
LIDOCAINE HCL	1%	N17701
LIDOCAINE HCL	1GM/VIAL	N18543
LIDOCAINE HCL	2%	N17701
LIDOCAINE HCL	2GM/VIAL	N18543

LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
LIDOCAINE HCL	1%	N80414
LIDOCAINE HCL	2%	N80414
LIDOCAINE HCL	1%	N80377
LIDOCAINE HCL	1%	N83627
LIDOCAINE HCL	2%	N80377
LIDOCAINE HCL	2%	N83627
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER	100MG/100ML	N18461
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N18954
LIDOCAINE HCL PRESERVATIVE FREE	4%	N17702
LIDOCATON	2%	N84727
XYLOCAINE	1%	N10418
XYLOCAINE	1.5%	N10418
XYLOCAINE	2%	N06488
XYLOCAINE	2%	N10418
XYLOCAINE 5% W/ GLUCOSE 7.5%	5%	N10496
SOLUTION		
LARYNGOTRACHEAL ANESTHESIA KIT	4%	N87931
LIDOCAINE HCL	4%	N89688
LIDOCAINE HCL VISCOUS	2%	N86389
PEDIATRIC LTA KIT	2%	N88572
LINCOMYCIN HYDROCHLORIDE		
CAPSULE		
LINCOCIN	EQ 250MG BASE	N50316
LINCOCIN	EQ 500MG BASE	N50316
INJECTABLE		
LINCOMYCIN HCL	EQ 300MG BASE/ML	N62784
LINCOMYCIN HCL	EQ 300MG BASE/ML	N63180
LINDANE		
CREAM		
KWELL	1%	N06309
KWELL	1%	N84218
LOTION		
GAMENE	1%	N84989
KWELL	1%	N06309
KWELL	1%	N84218
SCABENE	1%	N86769
SHAMPOO		
GAMENE	1%	N84988
KWELL	1%	N10718
KWELL	1%	N84219
SCABENE	1%	N87940

LINEZOLID		
TABLET		
ZYVOX	400MG	N21130
LIOTHYRONINE SODIUM		
TABLET		
LIOTHYRONINE SODIUM	EQ 0.025MG BASE	N85755
LIOTHYRONINE SODIUM	EQ 0.05MG BASE	N85753
LIOTRIX (T4;T3)		
TABLET		
EUTHROID-0.5	0.03MG;0.0075MG	N16680
EUTHROID-1	0.06MG;0.015MG	N16680
EUTHROID-2	0.12MG;0.03MG	N16680
EUTHROID-3	0.18MG;0.045MG	N16680
THYROLAR-5	0.25MG;0.0625MG	N16807
LITHIUM CARBONATE		
CAPSULE		
LITHIUM CARBONATE	300MG	N72542
LITHIUM CARBONATE	300MG	N70407
LITHONATE	300MG	N16782
TABLET		
ESKALITH	300MG	N17971
LITHANE	300MG	N18833
LITHOTABS	300MG	N16980
LITHIUM CITRATE		
SYRUP		
LITHONATE	EQ 300MG CARBONATE/5ML	N17672
LOPERAMIDE HYDROCHLORIDE		
CAPSULE		
IMODIUM	2MG	N17690
LOPERAMIDE HCL	2MG	N73080
SOLUTION		
IMODIUM	1MG/5ML	N19037
LOPERAMIDE HCL	1MG/5ML	N73187
LOPERAMIDE HCL	1MG/5ML	N73062
TABLET		
LOPERAMIDE HCL	2MG	N73528
LORAZEPAM		
TABLET		
LORAZ	0.5MG	N70200
LORAZ	1MG	N70201
LORAZ	2MG	N70202
LORAZEPAM	0.5MG	N70727
LORAZEPAM	1MG	N70728
LORAZEPAM	2MG	N70729

LORAZEPAM		
TABLET		
LORAZEPAM	0.5MG	N70472
LORAZEPAM	0.5MG	N71434
LORAZEPAM	1MG	N70473
LORAZEPAM	1MG	N71435
LORAZEPAM	2MG	N70474
LORAZEPAM	2MG	N71436
LORAZEPAM	0.5MG	N70675
LORAZEPAM	1MG	N70676
LORAZEPAM	2MG	N70677
LORAZEPAM	0.5MG	N71245
LORAZEPAM	1MG	N71246
LORAZEPAM	2MG	N71247
LORAZEPAM	1MG	N70539
LORAZEPAM	2MG	N70540
LORAZEPAM	1MG	N71038
LORAZEPAM	2MG	N71039
LORAZEPAM	0.5MG	N71086
LOTEPREDNOL ETABONATE		
SUSPENSION/DROPS		
LOTEMAX	0.5%	N20841
LOXAPINE HYDROCHLORIDE		
CONCENTRATE		
LOXITANE C	EQ 25MG BASE/ML	N17658
INJECTABLE		
LOXITANE IM	EQ 50MG BASE/ML	N18039
LOXAPINE SUCCINATE		
TABLET		
LOXITANE	EQ 10MG BASE	N17525
LOXITANE	EQ 25MG BASE	N17525
LOXITANE	EQ 50MG BASE	N17525
LYPRESSIN		
SOLUTION		
DIAPID	0.185MG/ML	N16755
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE		
INJECTABLE		
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER	30MG/100ML;37MG/100ML; 0.82MG/100ML;370MG/100 ML;530MG/100ML;500MG/1 00ML;12MG/100ML	N19006

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION

PHYSIOSOL IN PLASTIC CONTAINER	14MG/100ML;37MG/100ML; 222MG/100ML;526MG/100ML;502MG/100ML	N18406
SYNOVALYTE IN PLASTIC CONTAINER	30MG/100ML;37MG/100ML; 368MG/100ML;526MG/100ML;502MG/100ML	N19326

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION

LUMENHANCE	3.49MG/GM	N20686

MANGANESE SULFATE

INJECTABLE

MANGANESE SULFATE	EQ 0.1MG MANGANESE/ML	N19228

MANNITOL

INJECTABLE

MANNITOL 10%	10GM/100ML	N16269
MANNITOL 10%	10GM/100ML	N16472
MANNITOL 15%	15GM/100ML	N16269
MANNITOL 15%	15GM/100ML	N16472
MANNITOL 20%	20GM/100ML	N16269
MANNITOL 20%	20GM/100ML	N16472
MANNITOL 25%	12.5GM/50ML	N16269
MANNITOL 25%	12.5GM/50ML	N86754
MANNITOL 25%	12.5GM/50ML	N89239
MANNITOL 25%	12.5GM/50ML	N89240
MANNITOL 25%	12.5GM/50ML	N05620
MANNITOL 25%	12.5GM/50ML	N87460
MANNITOL 5%	5GM/100ML	N16269

SOLUTION

RESECTISOL	5GM/100ML	N16704

MANNITOL; SORBITOL

SOLUTION

SORBITOL-MANNITOL	540MG/100ML;2.7GM/100ML	N80224

MAPROTILINE HYDROCHLORIDE

TABLET

MAPROTILINE HCL	25MG	N72129
MAPROTILINE HCL	50MG	N72130
MAPROTILINE HCL	75MG	N72131
MAPROTILINE HCL	25MG	N71943
MAPROTILINE HCL	50MG	N71944
MAPROTILINE HCL	75MG	N71945

MASOPROCOL

CREAM

ACTINEX	10%	N19940

MAZINDOL

TABLET

MAZANOR	1MG	N17980
MAZANOR	2MG	N17980
SANOREX	1MG	N17247
SANOREX	2MG	N17247

MEBUTAMATE

TABLET

DORMATE	600MG	N17374

MECLIZINE HYDROCHLORIDE

TABLET

MECLIZINE HCL	25MG	N85891
MECLIZINE HCL	12.5MG	N83784
MECLIZINE HCL	12.5MG	N85524
MECLIZINE HCL	25MG	N85523
MECLIZINE HCL	12.5MG	N89113
MECLIZINE HCL	25MG	N89114
MECLIZINE HCL	12.5MG	N88256
MECLIZINE HCL	25MG	N88257
MECLIZINE HCL	12.5MG	N87877
MECLIZINE HCL	25MG	N87620
MECLIZINE HCL	12.5MG	N85195
MECLIZINE HCL	12.5MG	N85269

TABLET, CHEWABLE

MECLIZINE HCL	25MG	N86392
MECLIZINE HCL	25MG	N84976

MECLOCYCLINE SULFOSALICYLATE

CREAM

MECLAN	1%	N50518

MECLOFENAMATE SODIUM

CAPSULE

MECLODIUM	EQ 100MG BASE	N71381
MECLODIUM	EQ 50MG BASE	N71380
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71363
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71362
MECLOFENAMATE SODIUM	EQ 100MG BASE	N72809
MECLOFENAMATE SODIUM	EQ 50MG BASE	N72848
MECLOFENAMATE SODIUM	EQ 100MG BASE	N72078
MECLOFENAMATE SODIUM	EQ 50MG BASE	N72077
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71008
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71007
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71684

MECLOFENAMATE SODIUM
CAPSULE

MECLOFENAMATE SODIUM	EQ 50MG BASE	N71710
MECLOFENAMATE SODIUM	EQ 100MG BASE	N70401
MECLOFENAMATE SODIUM	EQ 50MG BASE	N70400
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71641
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71640

MEDROXYPROGESTERONE ACETATE
INJECTABLE

DEPO-PROVERA	100MG/ML	* N12541

TABLET

AMEN	10MG	N83242
CURRETAB	10MG	N85686
CYCRIN	10MG	N89386
CYCRIN	2.5MG	N81239
CYCRIN	5MG	N81240

MEFLOQUINE HYDROCHLORIDE
TABLET

MEFLOQUINE HCL	250MG	N19578

MEGESTROL ACETATE
TABLET

MEGESTROL ACETATE	20MG	N70646
MEGESTROL ACETATE	40MG	N70647

MENADIOL SODIUM DIPHOSPHATE
INJECTABLE

KAPPADIONE	10MG/ML	N05725
SYNKAYVITE	10MG/ML	N03718
SYNKAYVITE	37.5MG/ML	N03718
SYNKAYVITE	5MG/ML	N03718

TABLET

SYNKAYVITE	5MG	N03718

MENADIONE
TABLET

MENADIONE	5MG	N02139

MENOTROPINS (FSH;LH)
INJECTABLE

HUMEGON	150 IU/VIAL;150 IU/VIAL	N20328
HUMEGON	75 IU/VIAL;75 IU/VIAL	N20328
MENOTROPINS	150 IU/VIAL;150 IU/VIAL	N73599
MENOTROPINS	75 IU/VIAL;75 IU/VIAL	N73598
PERGONAL	150 IU/AMP;150 IU/AMP	N17646

MEPENZOLATE BROMIDE
SOLUTION

CANTIL	25MG/5ML	N10679

MEPERIDINE HYDROCHLORIDE
INJECTABLE

DEMEROL	100MG/ML	N05010
DEMEROL	25MG/ML	N05010
DEMEROL	50MG/ML	N05010
DEMEROL	75MG/ML	N05010
MEPERIDINE HCL	100MG/ML	N80386
MEPERIDINE HCL	25MG/ML	N80388
MEPERIDINE HCL	50MG/ML	N80385
MEPERIDINE HCL	50MG/ML	N80387
MEPERIDINE HCL	75MG/ML	N80389
MEPERIDINE HCL	100MG/ML	N89786
MEPERIDINE HCL	100MG/ML	N89787
MEPERIDINE HCL	100MG/ML	N89788
MEPERIDINE HCL	25MG/ML	N89781
MEPERIDINE HCL	50MG/ML	N89782
MEPERIDINE HCL	50MG/ML	N89783
MEPERIDINE HCL	50MG/ML	N89784
MEPERIDINE HCL	75MG/ML	N89785
MEPERIDINE HCL	100MG/ML	N88282
MEPERIDINE HCL	25MG/ML	N88279
MEPERIDINE HCL	50MG/ML	N88280
MEPERIDINE HCL	75MG/ML	N88281
MEPERIDINE HCL	10MG/ML	N86332
MEPERIDINE HCL	100MG/ML	N80364
MEPERIDINE HCL	50MG/ML	N80364
MEPERIDINE HCL	75MG/ML	N80364

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
INJECTABLE

MEPERGAN	25MG/ML;25MG/ML	N11730

MEPHENTERMINE SULFATE
INJECTABLE

WYAMINE SULFATE	EQ 15MG BASE/ML	N08248
WYAMINE SULFATE	EQ 30MG BASE/ML	N08248

MEPHENYTOIN
TABLET

MESANTOIN	100MG	N06008

MEPIVACAINE HYDROCHLORIDE
INJECTABLE

ARESTOCAINE HCL	3%	N84777
MEPIVACAINE HCL	1%	N87509

MEPREDNISONE
TABLET

BETAPAR	4MG	N16053

MEPROBAMATE		
CAPSULE		
EQUANIL	400MG	N12455
CAPSULE, EXTENDED RELEASE		
MEPROSPAN	200MG	N11284
MEPROSPAN	400MG	N11284
TABLET		
AMOSENE	400MG	N84030
BAMATE	200MG	N80380
BAMATE	400MG	N80380
MEPRIAM	400MG	N16069
MEPROBAMATE	200MG	N84220
MEPROBAMATE	400MG	N84589
MEPROBAMATE	600MG	N84230
MEPROBAMATE	200MG	N15426
MEPROBAMATE	400MG	N15426
MEPROBAMATE	200MG	N80699
MEPROBAMATE	400MG	N80699
MEPROBAMATE	400MG	N16928
MEPROBAMATE	600MG	N84329
MEPROBAMATE	200MG	N15139
MEPROBAMATE	400MG	N15139
MEPROBAMATE	200MG	N14322
MEPROBAMATE	400MG	N14322
MEPROBAMATE	200MG	N15438
MEPROBAMATE	400MG	N15438
MEPROBAMATE	600MG	N84181
MEPROBAMATE	200MG	N14882
MEPROBAMATE	400MG	N14882
MEPROBAMATE	400MG	N86299
MEPROBAMATE	400MG	N89538
MEPROBAMATE	400MG	N15072
MEPROBAMATE	200MG	N14368
MEPROBAMATE	400MG	N14368
MEPROBAMATE	200MG	N84744
MEPROBAMATE	400MG	N84744
MEPROBAMATE	200MG	N84546
MEPROBAMATE	400MG	N84547
MEPROBAMATE	400MG	N84438
MEPROBAMATE	400MG	N84153
MEPROBAMATE	200MG	N84804
MEPROBAMATE	400MG	N84804
MEPROBAMATE	400MG	N14601
MEPROBAMATE	200MG	N84435
MEPROBAMATE	200MG	N14474
MEPROBAMATE	400MG	N14474

MEPROBAMATE		
TABLET		
MEPROBAMATE	200MG	N87825
MEPROBAMATE	400MG	N87826
MEPROBAMATE	400MG	N88011
MEPROBAMATE	600MG	N84274
MEPROBAMATE	600MG	N85719
MEPROBAMATE	200MG	N83830
MEPROBAMATE	400MG	N83442
NEURAMATE	200MG	N14359
NEURAMATE	400MG	N14359
TRANMEP	400MG	N84369
MERSALYL SODIUM; THEOPHYLLINE		
INJECTABLE		
MERSALYL-THEOPHYLLINE	100MG/ML;50MG/ML	N84875
MESALAMINE		
SUPPOSITORY		
ROWASA	500MG	* N19919
MESORIDAZINE BESYLATE		
INJECTABLE		
SERENTIL	EQ 25MG BASE/ML	N16775
MESTRANOL; NORETHINDRONE		
TABLET		
NORINYL	0.1MG;2MG	N13625
NORINYL 1+80 21-DAY	0.08MG;1MG	N16724
NORINYL 1+80 28-DAY	0.08MG;1MG	N16725
ORTHO-N0VUM 1/80 28	0.08MG;1MG	N16715
ORTHO-NOVUM 1/80 21	0.08MG;1MG	N16715
ORTHO-NOVUM 10-21	0.06MG;10MG	N12728
ORTHO-NOVUM 2-21	0.1MG;2MG	N12728
MESTRANOL; NORETHYNODREL		
TABLET		
ENOVID	0.075MG;5MG	N10976
ENOVID	0.075MG;5MG	N10976
ENOVID	0.15MG;9.85MG	N10976
ENOVID-E	0.1MG;2.5MG	N10976
ENOVID-E 21	0.1MG;2.5MG	N10976
METAPROTERENOL SULFATE		
SOLUTION		
ALUPENT	5%	N17659
METAPROTERENOL SULFATE	0.4%	N71275
METAPROTERENOL SULFATE	0.6%	N71018
METAPROTERENOL SULFATE	0.33%	N71806
METAPROTERENOL SULFATE	0.5%	N71805
METAPROTERENOL SULFATE	5%	N70805

METAPROTERENOL SULFATE		
SOLUTION		
METAPROTERENOL SULFATE	5%	N72190
PROMETA	5%	N73340
SYRUP		
ALUPENT	10MG/5ML	N17571
METAPROTERENOL SULFATE	10MG/5ML	N73034
METAPROTERENOL SULFATE	10MG/5ML	N71656
METAPROTERENOL SULFATE	10MG/5ML	N72761
PROMETA	10MG/5ML	N72023
TABLET		
ALUPENT	10MG	N15874
ALUPENT	20MG	N15874
METAPROTERENOL SULFATE	10MG	N72054
METAPROTERENOL SULFATE	20MG	N72055
METAPROTERENOL SULFATE	10MG	N71013
METAPROTERENOL SULFATE	20MG	N71014
METARAMINOL BITARTRATE		
INJECTABLE		
METARAMINOL BITARTRATE	EQ 10MG BASE/ML	N80431
METARAMINOL BITARTRATE	EQ 10MG BASE/ML	N83363
METARAMINOL BITARTRATE	EQ 10MG BASE/ML	N86418
METARAMINOL BITARTRATE	EQ 20MG BASE/ML	N86418
METFORMIN HYDROCHLORIDE		
TABLET		
GLUCOPHAGE	625MG	* N20357
GLUCOPHAGE	750MG	* N20357
METHACYCLINE HYDROCHLORIDE		
CAPSULE		
RONDOMYCIN	EQ 140MG BASE	N60641
RONDOMYCIN	EQ 280MG BASE	N60641
SYRUP		
RONDOMYCIN	EQ 70MG BASE/5ML	N60641
METHADONE HYDROCHLORIDE		
SYRUP		
DOLOPHINE HCL	10MG/30ML	N06134
TABLET, DISPERSIBLE		
WESTADONE	2.5MG	N17108
TABLET, EFFERVESCENT		
WESTADONE	10MG	N17108
WESTADONE	40MG	N17108
WESTADONE	5MG	N17108

METHAMPHETAMINE HYDROCHLORIDE		
TABLET		
METHAMPEX	10MG	N83889
METHAMPHETAMINE HCL	10MG	N84931
METHAMPHETAMINE HCL	5MG	N84931
METHAMPHETAMINE HCL	5MG	N86359
TABLET, EXTENDED RELEASE		
DESOXYN	10MG	N05378
DESOXYN	15MG	N05378
DESOXYN	5MG	N05378
METHANTHELINE BROMIDE		
TABLET		
BANTHINE	50MG	N07390
METHARBITAL		
TABLET		
GEMONIL	100MG	N08322
METHAZOLAMIDE		
TABLET		
METHAZOLAMIDE	25MG	N40011
METHAZOLAMIDE	50MG	N40011
METHDILAZINE		
TABLET, CHEWABLE		
TACARYL	3.6MG	N11950
METHDILAZINE HYDROCHLORIDE		
SYRUP		
METHDILAZINE HCL	4MG/5ML	N87122
TACARYL	4MG/5ML	N11950
TABLET		
TACARYL	8MG	N11950
METHICILLIN SODIUM		
INJECTABLE		
STAPHCILLIN	EQ 3.6GM BASE/VIAL	N50117
STAPHCILLIN	EQ 3.6GM BASE/VIAL	N61449
STAPHCILLIN	EQ 5.4GM BASE/VIAL	N50117
STAPHCILLIN	EQ 5.4GM BASE/VIAL	N61449
STAPHCILLIN	EQ 900MG BASE/VIAL	N50117
STAPHCILLIN	EQ 900MG BASE/VIAL	N61449
METHIXENE HYDROCHLORIDE		
TABLET		
TREST	1MG	N13420
METHOCARBAMOL		
INJECTABLE		
METHOCARBAMOL	100MG/ML	N89849

METHOCARBAMOL

TABLET

DELAXIN	500MG	N85454
FORBAXIN	750MG	N85136
METHOCARBAMOL	500MG	N89417
METHOCARBAMOL	750MG	N89418
METHOCARBAMOL	500MG	N87660
METHOCARBAMOL	750MG	N87661
METHOCARBAMOL	500MG	N84488
METHOCARBAMOL	750MG	N84486
METHOCARBAMOL	500MG	N84675
METHOCARBAMOL	750MG	N84924
METHOCARBAMOL	500MG	N85137
METHOCARBAMOL	500MG	N84648
METHOCARBAMOL	750MG	N84649
METHOCARBAMOL	500MG	N85660
METHOCARBAMOL	750MG	N85658
METHOCARBAMOL	500MG	N84259
METHOCARBAMOL	750MG	N84323
METHOCARBAMOL	500MG	N84231
METHOCARBAMOL	750MG	N84471
METHOCARBAMOL	500MG	N88731
METHOCARBAMOL	750MG	N89082
METHOCARBAMOL	500MG	N85718
METHOCARBAMOL	750MG	N85718
METHOCARBAMOL	500MG	N88646
METHOCARBAMOL	750MG	N88647
METHOCARBAMOL	500MG	N84448
METHOCARBAMOL	750MG	N84449
METHOCARBAMOL	500MG	N87453
METHOCARBAMOL	750MG	N87454
METHOCARBAMOL	500MG	N83605
METHOCARBAMOL	750MG	N83605

METHOTREXATE SODIUM

INJECTABLE

ABITREXATE	EQ 100MG BASE/VIAL	N89355
ABITREXATE	EQ 250MG BASE/VIAL	N89356
ABITREXATE	EQ 25MG BASE/ML	N89161
ABITREXATE	EQ 50MG BASE/VIAL	N89354
FOLEX PFS	EQ 25MG BASE/ML	N81242
FOLEX PFS	EQ 25MG BASE/ML	N89180
METHOTREXATE SODIUM	EQ 100MG BASE/VIAL	N88937
METHOTREXATE SODIUM	EQ 2.5MG BASE/ML	N89323
METHOTREXATE SODIUM	EQ 20MG BASE/VIAL	N88935
METHOTREXATE SODIUM	EQ 25MG BASE/ML	N89263
METHOTREXATE SODIUM	EQ 25MG BASE/ML	N89322

METHOTREXATE SODIUM

INJECTABLE

METHOTREXATE SODIUM	EQ 50MG BASE/VIAL	N88936
METHOTREXATE SODIUM	EQ 100MG BASE/VIAL	N11719
METHOTREXATE SODIUM	EQ 2.5MG BASE/ML	N11719
METHOTREXATE SODIUM	EQ 50MG BASE/VIAL	N11719
METHOTREXATE SODIUM	EQ 100MG BASE/VIAL	N89295
METHOTREXATE SODIUM	EQ 20MG BASE/VIAL	N89293
METHOTREXATE SODIUM	EQ 250MG BASE/VIAL	N89296
METHOTREXATE SODIUM	EQ 25MG BASE/ML	N89308
METHOTREXATE SODIUM	EQ 25MG BASE/ML	N89309
METHOTREXATE SODIUM	EQ 50MG BASE/VIAL	N89294
MEXATE	EQ 100MG BASE/VIAL	N86358
MEXATE	EQ 20MG BASE/VIAL	N86358
MEXATE	EQ 250MG BASE/VIAL	N86358
MEXATE	EQ 50MG BASE/VIAL	N86358
MEXATE-AQ PRESERVED	EQ 25MG BASE/ML	N89887

METHOTRIMEPRAZINE

INJECTABLE

LEVOPROME	20MG/ML	N15865

METHOXAMINE HYDROCHLORIDE

INJECTABLE

VASOXYL	10MG/ML	N06772
VASOXYL	20MG/ML	N06772

METHOXSALEN

CAPSULE

METHOXSALEN	10MG	N87781

METHOXYFLURANE

LIQUID

PENTHRANE	99.9%	N13056

METHSCOPOLAMINE BROMIDE

TABLET

METHSCOPOLAMINE BROMIDE	2.5MG	N80970

METHYCLOTHIAZIDE

TABLET

METHYCLOTHIAZIDE	5MG	N87786
METHYCLOTHIAZIDE	2.5MG	N87671
METHYCLOTHIAZIDE	2.5MG	N89135
METHYCLOTHIAZIDE	5MG	N89136
METHYCLOTHIAZIDE	5MG	N88745
METHYCLOTHIAZIDE	2.5MG	N85487
METHYCLOTHIAZIDE	5MG	N85476
METHYCLOTHIAZIDE	2.5MG	N88750

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET		
EUTRON	5MG;25MG	N16047

METHYCLOTHIAZIDE; RESERPINE

TABLET		
DIUTENSEN-R	2.5MG;0.1MG	N12708

METHYLDOPA

SUSPENSION		
ALDOMET	250MG/5ML	N18389
TABLET		
METHYLDOPA	250MG	N71006
METHYLDOPA	500MG	N71009
METHYLDOPA	125MG	N70073
METHYLDOPA	125MG	N71751
METHYLDOPA	250MG	N70060
METHYLDOPA	250MG	N71752
METHYLDOPA	500MG	N70074
METHYLDOPA	500MG	N71753
METHYLDOPA	125MG	N70070
METHYLDOPA	125MG	N70331
METHYLDOPA	250MG	N70332
METHYLDOPA	500MG	N70333
METHYLDOPA	125MG	N70749
METHYLDOPA	250MG	N70750
METHYLDOPA	500MG	N70452
METHYLDOPA	125MG	N70192
METHYLDOPA	250MG	N70193
METHYLDOPA	500MG	N70194
METHYLDOPA	125MG	N71105
METHYLDOPA	250MG	N71106
METHYLDOPA	500MG	N71067
METHYLDOPA	125MG	N70245
METHYLDOPA	250MG	N70246
METHYLDOPA	500MG	N70247
METHYLDOPA	125MG	N70260
METHYLDOPA	250MG	N70261
METHYLDOPA	500MG	N70262

METHYLDOPATE HYDROCHLORIDE

INJECTABLE		
METHYLDOPATE HCL	50MG/ML	N70652
METHYLDOPATE HCL	50MG/ML	N70691
METHYLDOPATE HCL	50MG/ML	N70849
METHYLDOPATE HCL	50MG/ML	N71812
METHYLDOPATE HCL	50MG/ML	N71024
METHYLDOPATE HCL	50MG/ML	N70841

METHYLPREDNISOLONE

TABLET		
METHYLPREDNISOLONE	4MG	N87341
METHYLPREDNISOLONE	4MG	N85650
METHYLPREDNISOLONE	16MG	N86159
METHYLPREDNISOLONE	4MG	N86161

METHYLPREDNISOLONE ACETATE

ENEMA		
MEDROL	40MG/BOT	N18102
INJECTABLE		
M-PREDROL	40MG/ML	N86666
M-PREDROL	80MG/ML	N87135
METHYLPREDNISOLONE ACETATE	40MG/ML	N86903
METHYLPREDNISOLONE ACETATE	80MG/ML	N86903
METHYLPREDNISOLONE ACETATE	20MG/ML	N85597
METHYLPREDNISOLONE ACETATE	20MG/ML	N87248
METHYLPREDNISOLONE ACETATE	40MG/ML	N85374
METHYLPREDNISOLONE ACETATE	40MG/ML	N85600
METHYLPREDNISOLONE ACETATE	80MG/ML	N85595
METHYLPREDNISOLONE ACETATE	80MG/ML	N86507
OINTMENT		
MEDROL ACETATE	1%	N12421

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM		
NEO-MEDROL ACETATE	0.25%;EQ 3.5MG BASE/GM	N60611
NEO-MEDROL ACETATE	1%;EQ 3.5MG BASE/GM	N60611

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE		
A-METHAPRED	EQ 125MG BASE/VIAL	N89574
A-METHAPRED	EQ 1GM BASE/VIAL	N89576
A-METHAPRED	EQ 40MG BASE/VIAL	N89573
A-METHAPRED	EQ 500MG BASE/VIAL	N89575
METHYLPREDNISOLONE	EQ 125MG BASE/VIAL	N86906
METHYLPREDNISOLONE	EQ 1GM BASE/VIAL	N86906
METHYLPREDNISOLONE	EQ 500MG BASE/VIAL	N86906
METHYLPREDNISOLONE	EQ 1GM BASE/VIAL	N87535
METHYLPREDNISOLONE	EQ 500MG BASE/VIAL	N87535
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N88677
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N89144
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N88679
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N89188
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N89189
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N88676
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N89143
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N88678
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N89186

METHYLPREDNISOLONE SODIUM SUCCINATE		
INJECTABLE		
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N89187
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N86906
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N81268
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N81267
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N87813
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N87852
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N87812
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N87851
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N89265
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N89267
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N89264
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N89266
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N87030
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N88524
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N86953
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N88523
METHYLPREDNISOLONE; NEOMYCIN SULFATE		
OINTMENT		
NEO-MEDROL	0.1%;EQ 3.5MG BASE/GM	N60645
METHYLTESTOSTERONE		
CAPSULE		
METHYLTESTOSTERONE	10MG	N84967
TABLET		
ANDROID 5	5MG	N87222
METANDREN	10MG	N03240
METANDREN	10MG	N03240
METANDREN	25MG	N03240
METANDREN	5MG	N03240
METHYLTESTOSTERONE	10MG	N84287
METHYLTESTOSTERONE	10MG	N80839
METHYLTESTOSTERONE	25MG	N80973
METHYLTESTOSTERONE	10MG	N84312
METHYLTESTOSTERONE	10MG	N87092
METHYLTESTOSTERONE	25MG	N87111
METHYLTESTOSTERONE	10MG	N80256
METHYLTESTOSTERONE	25MG	N80256
METHYLTESTOSTERONE	10MG	N84244
METHYLTESTOSTERONE	25MG	N84241
METHYLTESTOSTERONE	10MG	N80308
METHYLTESTOSTERONE	10MG	N80309
METHYLTESTOSTERONE	10MG	N80475
METHYLTESTOSTERONE	10MG	N80475
METHYLTESTOSTERONE	25MG	N80310
METHYLTESTOSTERONE	25MG	N80475

METHYLTESTOSTERONE		
TABLET		
METHYLTESTOSTERONE	10MG	N80214
METHYLTESTOSTERONE	25MG	N80214
METHYLTESTOSTERONE	5MG	N80214
METHYLTESTOSTERONE	5MG	N83836
METHYLTESTOSTERONE	10MG	N80313
METHYLTESTOSTERONE	10MG	N85125
METHYLTESTOSTERONE	25MG	N85270
METHYLTESTOSTERONE	10MG	N80271
METHYLTESTOSTERONE	10MG	N80933
METHYLTESTOSTERONE	25MG	N80931
METHYLTESTOSTERONE	10MG	N84331
METHYLTESTOSTERONE	25MG	N84331
METHYLTESTOSTERONE	25MG	N84642
ORETON	10MG	N80281
ORETON METHYL	10MG	N03158
ORETON METHYL	25MG	N03158
METHYPRYLON		
CAPSULE		
NOLUDAR	300MG	N09660
ELIXIR		
NOLUDAR	50MG/5ML	N09660
TABLET		
NOLUDAR	200MG	N09660
NOLUDAR	50MG	N09660
METOCLOPRAMIDE HYDROCHLORIDE		
INJECTABLE		
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N70506
METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70293
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N72155
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N72244
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N72247
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N71990
METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70892
METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70671
METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70622
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N70623
REGLAN	EQ 10MG BASE/ML	N17862
SOLUTION		
METOCLOPRAMIDE HCL	EQ 5MG BASE/5ML	N70949
METOCLOPRAMIDE HCL	EQ 5MG BASE/5ML	N71665
REGLAN	EQ 5MG BASE/5ML	N18821
TABLET		
CLOPRA	EQ 10MG BASE	N70294
CLOPRA	EQ 5MG BASE	N72384

METOCLOPRAMIDE HYDROCHLORIDE		
TABLET		
CLOPRA-"YELLOW"	EQ 10MG BASE	N70632
MAXOLON	EQ 10MG BASE	N70106
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70660
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70906
METOCLOPRAMIDE HCL	EQ 10MG BASE	N71213
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70850
METOCLOPRAMIDE HCL	EQ 5MG BASE	N72436
METOCLOPRAMIDE HCL	EQ 10MG BASE	N71536
METOCLOPRAMIDE HCL	EQ 5MG BASE	N71536
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70342
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70598
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70926
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70339
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70363
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70453
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70645
METOCURINE IODIDE		
INJECTABLE		
METOCURINE IODIDE	2MG/ML	N89443
METUBINE IODIDE	2MG/ML	N06632
METOLAZONE		
TABLET		
DIULO	10MG	N18535
DIULO	2.5MG	N18535
DIULO	5MG	N18535
METOPROLOL FUMARATE		
TABLET, EXTENDED RELEASE		
LOPRESSOR	EQ 100MG TARTRATE	N19786
LOPRESSOR	EQ 200MG TARTRATE	N19786
LOPRESSOR	EQ 300MG TARTRATE	N19786
LOPRESSOR	EQ 400MG TARTRATE	N19786
METOPROLOL TARTRATE		
TABLET		
METOPROLOL TARTRATE	100MG	N74380
METOPROLOL TARTRATE	50MG	N74380
METRIZAMIDE		
INJECTABLE		
AMIPAQUE	13.5GM/VIAL	N17982
AMIPAQUE	2.5GM/VIAL	N17982
AMIPAQUE	3.75GM/VIAL	N17982
AMIPAQUE	6.75GM/VIAL	N17982
METRONIDAZOLE		
INJECTABLE		
METRO I.V.	500MG/100ML	N18674
METRONIDAZOLE	500MG/100ML	N18889
METRONIDAZOLE	500MG/100ML	N70071
METRONIDAZOLE	500MG/100ML	N18907
METRONIDAZOLE	500MG/100ML	N70004
METRONIDAZOLE	500MG/100ML	N70042
METRONIDAZOLE	500MG/100ML	N70170
TABLET		
METRONIDAZOLE	250MG	N18818
METRONIDAZOLE	250MG	N70021
METRONIDAZOLE	500MG	N18818
METRONIDAZOLE	500MG	N70593
METRONIDAZOLE	250MG	N70008
METRONIDAZOLE	500MG	N70009
METRONIDAZOLE	250MG	N18599
METRONIDAZOLE	500MG	N18599
PROTOSTAT	250MG	N18871
PROTOSTAT	500MG	N18871
SATRIC	250MG	N70029
SATRIC	500MG	N70731
METRONIDAZOLE HYDROCHLORIDE		
INJECTABLE		
METRONIDAZOLE HCL	EQ 500MG BASE/VIAL	N70295
METYRAPONE		
TABLET		
METOPIRONE	250MG	N12911
MEZLOCILLIN SODIUM MONOHYDRATE		
INJECTABLE		
MEZLIN	EQ 1GM BASE/VIAL	N62333
MEZLIN	EQ 1GM BASE/VIAL	N62372
MEZLIN	EQ 20GM BASE/VIAL	N62372
MEZLIN	EQ 2GM BASE/VIAL	N62333
MEZLIN	EQ 2GM BASE/VIAL	N62372
MEZLIN	EQ 3GM BASE/VIAL	N62333
MEZLIN	EQ 3GM BASE/VIAL	N62372
MEZLIN	EQ 3GM BASE/VIAL	N62697
MEZLIN	EQ 4GM BASE/VIAL	N62333
MEZLIN	EQ 4GM BASE/VIAL	N62372
MEZLIN	EQ 4GM BASE/VIAL	N62697
MICONAZOLE		
INJECTABLE		
MONISTAT	10MG/ML	N18040

MICONAZOLE NITRATE		
CREAM, INSERT		
MONISTAT DUAL- PAK	1.2GM;2%	N20968
LOTION		
MONISTAT-DERM	2%	N17739
TAMPON		
MONISTAT 5	100MG	N18592
MIDAZOLAM HYDROCHLORIDE		
INJECTABLE		
MIDAZOLAM HCL	EQ 1MG BASE/ML	N75620
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75620
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75641
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75263
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75249
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75455
VERSED	EQ 1MG BASE/ML	N18654
VERSED	EQ 5MG BASE/ML	N18654
SYRUP		
VERSED	EQ 2MG BASE/ML	N20942
MILRINONE LACTATE		
INJECTABLE		
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 10MG BASE/100ML	N20343
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 15MG BASE/100ML	N20343
MINOCYCLINE HYDROCHLORIDE		
CAPSULE		
MINOCIN	EQ 100MG BASE	N50315
MINOCIN	EQ 50MG BASE	N50315
VECTRIN	EQ 100MG BASE	N63067
VECTRIN	EQ 75MG BASE	N63067
INJECTABLE		
MINOCIN	EQ 100MG BASE/VIAL	N62139
SUSPENSION		
MINOCIN	EQ 50MG BASE/5ML	N50445
TABLET		
MINOCYCLINE HCL	EQ 100MG BASE	* N50451
MINOCYCLINE HCL	EQ 50MG BASE	* N50451
MINOXIDIL		
TABLET		
MINODYL	10MG	N71534
MINODYL	2.5MG	N72153
MINOXIDIL	10MG	N71796
MINOXIDIL	2.5MG	N71799
MINOXIDIL	2.5MG	N71537

MITOMYCIN		
INJECTABLE		
MUTAMYCIN	20MG/VIAL	N50450
MUTAMYCIN	5MG/VIAL	N50450
MIVACURIUM CHLORIDE		
INJECTABLE		
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 0.5MG BASE/ML	N20098
MOLINDONE HYDROCHLORIDE		
CAPSULE		
MOBAN	10MG	N17111
MOBAN	25MG	N17111
MOBAN	5MG	N17111
MONOCTANOIN		
LIQUID		
MOCTANIN	100%	N19368
MOXALACTAM DISODIUM		
INJECTABLE		
MOXAM	EQ 10GM BASE/VIAL	N50550
MOXAM	EQ 1GM BASE/VIAL	N50550
MOXAM	EQ 250MG BASE/VIAL	N50550
MOXAM	EQ 2GM BASE/VIAL	N50550
MOXAM	EQ 500MG BASE/VIAL	N50550
NABILONE		
CAPSULE		
CESAMET	1MG	N18677
NAFCILLIN SODIUM		
CAPSULE		
UNIPEN	EQ 250MG BASE	N50111
FOR SOLUTION		
UNIPEN	EQ 250MG BASE/5ML	N50199
INJECTABLE		
NAFCILLIN SODIUM	EQ 1GM BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 2GM BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 4GM BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 500MG BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 1.5GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 10GM BASE/VIAL	N63008
NAFCILLIN SODIUM	EQ 1GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 2GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 4GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 500MG BASE/VIAL	N62844
NALLPEN	EQ 10GM BASE/VIAL	N61999
NALLPEN	EQ 1GM BASE/VIAL	N61999
NALLPEN	EQ 1GM BASE/VIAL	N62755

NAFCILLIN SODIUM

INJECTABLE

NALLPEN	EQ 2GM BASE/VIAL	N61999
NALLPEN	EQ 2GM BASE/VIAL	N62755
NALLPEN	EQ 500MG BASE/VIAL	N61999
UNIPEN	EQ 10GM BASE/VIAL	N50320
UNIPEN	EQ 1GM BASE/VIAL	N62717
UNIPEN	EQ 20GM BASE/VIAL	N50320
UNIPEN	EQ 2GM BASE/VIAL	N50320
UNIPEN	EQ 2GM BASE/VIAL	N62717
UNIPEN	EQ 4GM BASE/VIAL	N50320
UNIPEN	EQ 500MG BASE/VIAL	N50320
UNIPEN	EQ 500MG BASE/VIAL	N62717
UNIPEN IN PLASTIC CONTAINER	EQ 1GM BASE/VIAL	N50320

TABLET

UNIPEN	EQ 500MG BASE	N50462

NALBUPHINE HYDROCHLORIDE

INJECTABLE

NALBUPHINE	10MG/ML	N70751
NALBUPHINE	20MG/ML	N70752
NALBUPHINE	10MG/ML	N70692
NALBUPHINE	20MG/ML	N70693
NALBUPHINE HCL	1.5MG/ML	N20200
NALBUPHINE HCL	10MG/ML	N72070
NALBUPHINE HCL	10MG/ML	N72071
NALBUPHINE HCL	10MG/ML	N72072
NALBUPHINE HCL	20MG/ML	N72073
NALBUPHINE HCL	20MG/ML	N72074
NALBUPHINE HCL	20MG/ML	N72075

NALIDIXIC ACID

SUSPENSION

NEGGRAM	250MG/5ML	N17430

TABLET

NALIDIXIC ACID	1GM	N70272
NALIDIXIC ACID	250MG	N70270
NALIDIXIC ACID	500MG	N70271

NALOXONE HYDROCHLORIDE

INJECTABLE

NALOXONE	0.4MG/ML	N70496
NALOXONE	0.02MG/ML	N70188
NALOXONE	0.02MG/ML	N70189
NALOXONE	0.4MG/ML	N70190
NALOXONE	0.4MG/ML	N70191
NALOXONE HCL	0.4MG/ML	N70172
NALOXONE HCL	0.02MG/ML	N70648
NALOXONE HCL	0.02MG/ML	N70661

NALOXONE HYDROCHLORIDE

INJECTABLE

NALOXONE HCL	0.4MG/ML	N70649
NALOXONE HCL	1MG/ML	N71604
NALOXONE HCL	0.02MG/ML	N72081
NALOXONE HCL	0.02MG/ML	N72082
NALOXONE HCL	0.02MG/ML	N72083
NALOXONE HCL	0.02MG/ML	N72084
NALOXONE HCL	0.02MG/ML	N72085
NALOXONE HCL	0.4MG/ML	N72086
NALOXONE HCL	0.4MG/ML	N72087
NALOXONE HCL	0.4MG/ML	N72088
NALOXONE HCL	0.4MG/ML	N72089
NALOXONE HCL	0.4MG/ML	N72090
NALOXONE HCL	1MG/ML	N72091
NALOXONE HCL	1MG/ML	N72092
NALOXONE HCL	1MG/ML	N72093
NALOXONE HCL	0.4MG/ML	N70417
NALOXONE HCL	1MG/ML	N72115
NALOXONE HCL	0.4MG/ML	N71811
NALOXONE HCL	0.02MG/ML	N70678
NALOXONE HCL	0.4MG/ML	N70679
NALOXONE HCL	1MG/ML	N70680
NALOXONE HCL	0.02MG/ML	N71671
NALOXONE HCL	0.4MG/ML	N71681
NALOXONE HCL	0.4MG/ML	N71682
NALOXONE HCL	0.02MG/ML	N71672
NALOXONE HCL	0.4MG/ML	N71683
NALOXONE HCL	0.4MG/ML	N71339
NARCAN	0.4MG/ML	N71083
NARCAN	1MG/ML	N71084
NARCAN	1MG/ML	N71311

NANDROLONE DECANOATE

INJECTABLE

NANDROLONE DECANOATE	100MG/ML	N87519
NANDROLONE DECANOATE	100MG/ML	N88290
NANDROLONE DECANOATE	200MG/ML	N88317
NANDROLONE DECANOATE	100MG/ML	N89249
NANDROLONE DECANOATE	200MG/ML	N89250
NANDROLONE DECANOATE	50MG/ML	N89248
NANDROLONE DECANOATE	100MG/ML	N87599
NANDROLONE DECANOATE	50MG/ML	N87598
NANDROLONE DECANOATE	50MG/ML	N88554

NANDROLONE PHENPROPIONATE

INJECTABLE

DURABOLIN	25MG/ML	N11891

NANDROLONE PHENPROPIONATE		
INJECTABLE		
DURABOLIN	50MG/ML	N11891
NANDROLONE PHENPROPIONATE	25MG/ML	N89297
NANDROLONE PHENPROPIONATE	50MG/ML	N89298
NANDROLONE PHENPROPIONATE	25MG/ML	N86386
NANDROLONE PHENPROPIONATE	50MG/ML	N87488
NAPHAZOLINE HYDROCHLORIDE		
SOLUTION/DROPS		
NAFAZAIR	0.1%	N88101
NAPHCON FORTE	0.1%	N80229
OPCON	0.1%	N87506
NAPROXEN		
TABLET		
NAPROXEN	250MG	N74110
NAPROXEN	375MG	N74110
NAPROXEN	500MG	N74110
NAPROXEN SODIUM		
TABLET		
NAPROXEN SODIUM	EQ 250MG BASE	N74106
NAPROXEN SODIUM	EQ 500MG BASE	N74106
NAPROXEN SODIUM	EQ 250MG BASE	N74319
NAPROXEN SODIUM	EQ 500MG BASE	N74319
TABLET, EXTENDED RELEASE		
NAPRELAN	EQ 750MG BASE	N20353
NEDOCROMIL SODIUM		
SOLUTION		
TILADE	0.5%	N20750
NEFAZODONE HYDROCHLORIDE		
TABLET		
SERZONE	300MG	N20152
NEOMYCIN SULFATE		
SOLUTION		
MYCIFRADIN	EQ 87.5MG BASE/5ML	N50285
TABLET		
MYCIFRADIN	EQ 350MG BASE	N60520
NEOBIOTIC	EQ 350MG BASE	N60475
NEOMYCIN SULFATE	EQ 350MG BASE	N60365
NEOMYCIN SULFATE	EQ 350MG BASE	N61586
NEOMYCIN SULFATE	EQ 350MG BASE	N60607
NEOMYCIN SULFATE	EQ 350MG BASE	N60385
NEOMYCIN SULFATE	EQ 350MG BASE	N62173

NEOMYCIN SULFATE; POLYMYXIN B SULFATE		
CREAM		
NEOSPORIN	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50176
OINTMENT		
STATROL	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50344
SOLUTION		
NEOMYCIN AND POLYMYXIN B SULFATES	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664
SOLUTION/DROPS		
STATROL	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N50456
STATROL	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339
NEOMYCIN SULFATE; PREDNISOLONE ACETATE		
OINTMENT		
NEO-DELTA-CORTEF	EQ 3.5MG BASE/GM;0.25%	N61039
NEO-DELTA-CORTEF	EQ 3.5MG BASE/GM;0.5%	N61039
SUSPENSION/DROPS		
NEO-DELTA-CORTEF	EQ 3.5MG BASE/ML;0.25%	N61037
NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE		
OINTMENT		
NEO-HYDELTRASOL	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N50378
NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE		
CREAM		
MYTREX A	EQ 3.5MG BASE/GM;0.1%	N62598
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62600
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62595
OINTMENT		
MYTREX A	EQ 3.5MG BASE/GM;0.1%	N62609
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62608
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62607
NETILMICIN SULFATE		
INJECTABLE		
NETROMYCIN	EQ 100MG BASE/ML	N50544
NETROMYCIN	EQ 10MG BASE/ML	N50544
NETROMYCIN	EQ 25MG BASE/ML	N50544
NIACIN		
CAPSULE		
WAMPOCAP	500MG	N11073
TABLET		
NIACIN	500MG	N83203

NIACIN		
TABLET		
NIACIN	500MG	N83306
NIACIN	500MG	N83453
NIACIN	500MG	N83115
NIACIN	500MG	N83180
NIACIN	500MG	N83271
NIACIN	500MG	N83136
NIACIN	500MG	N83305
NIACIN	500MG	N85172
NIACIN	500MG	N83718
TABLET, EXTENDED RELEASE		
NIASPAN	375MG	N20381
NIASPAN TITRATION STARTER PACK	375MG;500MG;750MG	N20381
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE		
SUSPENSION		
TPN SUSPENSION	15MG/5ML;3.75MG/5ML;600 MG/5ML	N08378
NICLOSAMIDE		
TABLET, CHEWABLE		
NICLOCIDE	500MG	N18669
NICOTINE		
FILM, EXTENDED RELEASE		
HABITROL	14MG/24HR	N20076
HABITROL	21MG/24HR	N20076
HABITROL	7MG/24HR	N20076
PROSTEP	11MG/24HR	N19983
PROSTEP	22MG/24HR	N19983
INHALANT		
NICOTROL	4MG/CARTRIDGE	N20714
NIFEDIPINE		
CAPSULE		
NIFEDIPINE	10MG	N72409
NIFEDIPINE	20MG	N73421
TABLET, EXTENDED RELEASE		
NIFEDIPINE	30MG	N75108
NILUTAMIDE		
TABLET		
NILANDRON	50MG	N20169
NITROFURANTOIN		
CAPSULE		
NITROFURANTOIN	100MG	N84326
NITROFURANTOIN		
CAPSULE		
NITROFURANTOIN	50MG	N84326
TABLET		
FURALAN	100MG	N80017
FURALAN	50MG	N80017
NITROFURANTOIN	100MG	N80003
NITROFURANTOIN	50MG	N80003
NITROFURANTOIN	100MG	N80043
NITROFURANTOIN	50MG	N80043
NITROFURANTOIN	100MG	N80078
NITROFURANTOIN	50MG	N80078
NITROFURANTOIN	100MG	N80447
NITROFURANTOIN	100MG	N85796
NITROFURANTOIN	50MG	N85797
NITROFURANTOIN SODIUM		
INJECTABLE		
IVADANTIN	EQ 180MG BASE/VIAL	N12402
NITROFURANTOIN, MACROCRYSTALLINE		
CAPSULE		
NITROFURANTOIN MACROCRYSTALLINE	100MG	N70249
NITROFURANTOIN MACROCRYSTALLINE	50MG	N70248
NITROFURAZONE		
CREAM		
FURACIN	0.2%	N83789
DRESSING		
ACTIN-N	0.2%	N17343
OINTMENT		
NITROFURAZONE	0.2%	N86077
NITROFURAZONE	0.2%	N84968
NITROFURAZONE	0.2%	N84393
POWDER		
FURACIN	0.2%	N83791
SOLUTION		
NITROFURAZONE	0.2%	N85130
NITROGLYCERIN		
AEROSOL		
NITROLINGUAL	0.4MG/SPRAY	N18705
INJECTABLE		
NITRO IV	5MG/ML	N18672
NITRO-BID	10MG/ML	N71159
NITROGLYCERIN	5MG/ML	N70077
NITROGLYCERIN	5MG/ML	N71203
NITROGLYCERIN	5MG/ML	N70026
NITROGLYCERIN	5MG/ML	N71492

NITROGLYCERIN		
INJECTABLE		
NITROGLYCERIN	10MG/ML	N71095
NITROGLYCERIN	5MG/ML	N71094
NITROGLYCERIN	5MG/ML	N70633
NITROGLYCERIN	5MG/ML	N70634
NITROL	0.8MG/ML	N18774
NITRONAL	1MG/ML	N18672
NITROSTAT	0.8MG/ML	N18588
NITROSTAT	10MG/ML	N70871
NITROSTAT	10MG/ML	N70872
NITROSTAT	5MG/ML	N18588
NITROSTAT	5MG/ML	N70863
NONOXYNOL-9		
AEROSOL		
DELFEN	12.5%	N14349
SPONGE		
TODAY	1GM	N18683
NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE		
INJECTABLE		
RAVOCAINE AND NOVOCAIN W/ LEVOPHED	EQ 0.033MG BASE/ML;2%;0.4%	N08592
NORETHINDRONE		
TABLET		
NORLUTIN	5MG	N10895
NORETHINDRONE ACETATE		
TABLET		
NORLUTATE	5MG	N12184
NOVOBIOCIN SODIUM		
CAPSULE		
ALBAMYCIN	EQ 250MG BASE	N50339
NYSTATIN		
CREAM		
CANDEX	100,000 UNITS/GM	N61810
MYKINAC	100,000 UNITS/GM	N62387
NILSTAT	100,000 UNITS/GM	N61445
NYSTATIN	100,000 UNITS/GM	N61966
LOTION		
CANDEX	100,000 UNITS/ML	N50233
OINTMENT		
MYCOSTATIN	100,000 UNITS/GM	N60571
MYKINAC	100,000 UNITS/GM	N62731
NILSTAT	100,000 UNITS/GM	N61444
POWDER		
NYSTATIN		
POWDER		
BARSTATIN 100	100%	N62489
SUPPOSITORY		
NYSERT	100,000 UNITS	N50478
SUSPENSION		
NYSTATIN	100,000 UNITS/ML	N62571
NYSTATIN	100,000 UNITS/ML	N62835
NYSTATIN	100,000 UNITS/ML	N62518
NYSTATIN	100,000 UNITS/ML	N62541
NYSTATIN	100,000 UNITS/ML	N62832
NYSTATIN	100,000 UNITS/ML	N62876
NYSTATIN	100,000 UNITS/ML	N62670
NYSTATIN	100,000 UNITS/ML	N62776
TABLET		
KOROSTATIN	100,000 UNITS	N61718
MYCOSTATIN	100,000 UNITS	N60577
NILSTAT	100,000 UNITS	N61325
NILSTAT	500,000 UNITS	N61151
NYSTATIN	100,000 UNITS	N61965
NYSTATIN	500,000 UNITS	N62065
NYSTATIN	100,000 UNITS	N62509
NYSTATIN	500,000 UNITS	N62525
NYSTATIN	100,000 UNITS	N62502
NYSTATIN	500,000 UNITS	N62524
NYSTATIN	100,000 UNITS	N62176
NYSTATIN	500,000 UNITS	N62402
NYSTATIN; TRIAMCINOLONE ACETONIDE		
CREAM		
MYCOLOG-II	100,000 UNITS/GM;0.1%	N60576
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N63010
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62186
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62657
NYSTATIN-TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62596
OINTMENT		
MYCO-TRIACET II	100,000 UNITS/GM;0.1%	N62045
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62280
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62656
NYSTATIN-TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62603
OFLOXACIN		
INJECTABLE		
FLOXIN	20MG/ML	N20087
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	4MG/ML	N20087

ORPHENADRINE CITRATE		
TABLET, EXTENDED RELEASE		
ORPHENADRINE CITRATE	100MG	N88067
ORPHENADRINE CITRATE	100MG	N85046
ORPHENADRINE CITRATE	100MG	N84303
ORPHENADRINE HYDROCHLORIDE		
TABLET		
DISIPAL	50MG	N10653
OXACILLIN SODIUM		
CAPSULE		
OXACILLIN SODIUM	EQ 250MG BASE	N61450
OXACILLIN SODIUM	EQ 500MG BASE	N61450
PROSTAPHLIN	EQ 500MG BASE	N50118
FOR SOLUTION		
PROSTAPHLIN	EQ 250MG BASE/5ML	N50194
INJECTABLE		
BACTOCILL	EQ 10GM BASE/VIAL	N61334
BACTOCILL	EQ 1GM BASE/VIAL	N61334
BACTOCILL	EQ 1GM BASE/VIAL	N62736
BACTOCILL	EQ 2GM BASE/VIAL	N61334
BACTOCILL	EQ 2GM BASE/VIAL	N62736
BACTOCILL	EQ 4GM BASE/VIAL	N61334
BACTOCILL	EQ 500MG BASE/VIAL	N61334
OXACILLIN SODIUM	EQ 1GM BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 250MG BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 2GM BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 4GM BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 500MG BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 10GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 1GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 250MG BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 2GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 4GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 500MG BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 125MG BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 1GM BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 250MG BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 2GM BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 500MG BASE/VIAL	N62798
OXAZEPAM		
CAPSULE		
OXAZEPAM	10MG	N71955
OXAZEPAM	15MG	N71956
OXAZEPAM	30MG	N71957
OXAZEPAM	10MG	N70957

OXAZEPAM		
CAPSULE		
OXAZEPAM	15MG	N71025
OXAZEPAM	30MG	N71026
OXAZEPAM	10MG	N71713
OXAZEPAM	15MG	N71714
OXAZEPAM	30MG	N71715
ZAXOPAM	10MG	N70650
ZAXOPAM	15MG	N70640
ZAXOPAM	30MG	N70641
TABLET		
OXAZEPAM	15MG	N70683
OXAZEPAM	15MG	N71508
OXAZEPAM	15MG	N71494
OXPRENOLOL HYDROCHLORIDE		
CAPSULE		
TRASICOR	160MG	N18166
TRASICOR	20MG	N18166
TRASICOR	40MG	N18166
TRASICOR	80MG	N18166
OXTRIPHYLLINE		
SOLUTION		
CHOLEDYL	100MG/5ML	N09268
OXTRIPHYLLINE	100MG/5ML	N88243
SYRUP		
CHOLEDYL	50MG/5ML	N09268
OXTRIPHYLLINE PEDIATRIC	50MG/5ML	N88242
TABLET, DELAYED RELEASE		
CHOLEDYL	100MG	N09268
CHOLEDYL	200MG	N09268
OXTRIPHYLLINE	100MG	N87866
OXTRIPHYLLINE	200MG	N87835
OXYBUTYNIN CHLORIDE		
TABLET		
OXYBUTYNIN CHLORIDE	5MG	N72296
OXYBUTYNIN CHLORIDE	5MG	N70746
OXYBUTYNIN CHLORIDE	5MG	N72485
OXYCODONE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
OXYCONTIN	160MG	N20553
ROXICODONE	10MG	N20932
ROXICODONE	30MG	N20932

OXYPHENBUTAZONE		
TABLET		
OXYPHENBUTAZONE	100MG	N88399
TANDEARIL	100MG	N12542
OXYPHENCYCLIMINE HYDROCHLORIDE		
TABLET		
DARICON	10MG	N11612
OXYPHENONIUM BROMIDE		
TABLET		
ANTRENYL	5MG	N08492
OXYTETRACYCLINE		
TABLET		
TERRAMYCIN	250MG	N50287
OXYTETRACYCLINE CALCIUM		
SYRUP		
TERRAMYCIN	EQ 125MG BASE/5ML	N60595
OXYTETRACYCLINE HYDROCHLORIDE		
CAPSULE		
OXY-KESSO-TETRA	EQ 250MG BASE	N60179
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60760
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60869
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60634
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60770
TERRAMYCIN	EQ 125MG BASE	N50286
INJECTABLE		
TERRAMYCIN	EQ 250MG BASE/VIAL	N60586
TERRAMYCIN	EQ 500MG BASE/VIAL	N60586
OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE		
OINTMENT		
TERRAMYCIN W/ POLYMYXIN	EQ 5MG BASE/GM;10,000 UNITS/GM	N61841
TABLET		
TERRAMYCIN-POLYMYXIN	EQ 100MG BASE;100,000 UNITS	N61009
OXYTOCIN		
INJECTABLE		
OXYTOCIN	10USP UNITS/ML	N18243
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%	1USP UNITS/100ML	N19185
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%	2USP UNITS/100ML	N19185
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%	2USP UNITS/100ML	N19185
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%	1USP UNITS/100ML	N19185
SOLUTION		
SYNTOCINON	40USP UNITS/ML	N12285

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)		
CAPSULE		
COTAZYM	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N20580
PANCURONIUM BROMIDE		
INJECTABLE		
PANCURONIUM BROMIDE	1MG/ML	N72210
PANCURONIUM BROMIDE	2MG/ML	N72211
PANCURONIUM BROMIDE	2MG/ML	N72212
PANCURONIUM BROMIDE	2MG/ML	N72213
PANCURONIUM BROMIDE	1MG/ML	N72209
PANCURONIUM BROMIDE	2MG/ML	N72208
PARAMETHADIONE		
CAPSULE		
PARADIONE	150MG	N06800
PARADIONE	300MG	N06800
SOLUTION		
PARADIONE	300MG/ML	N06800
PARAMETHASONE ACETATE		
TABLET		
HALDRONE	1MG	N12772
HALDRONE	2MG	N12772
PARGYLINE HYDROCHLORIDE		
TABLET		
EUTONYL	10MG	N13448
EUTONYL	25MG	N13448
EUTONYL	50MG	N13448
PAROMOMYCIN SULFATE		
CAPSULE		
HUMATIN	EQ 250MG BASE	N60521
SYRUP		
HUMATIN	EQ 125MG BASE/5ML	N60522
PAROXETINE HYDROCHLORIDE		
CAPSULE		
PAXIL	EQ 10MG BASE	N20885
PAXIL	EQ 20MG BASE	N20885
PAXIL	EQ 30MG BASE	N20885
PAXIL	EQ 40MG BASE	N20885
TABLET		
PAXIL	EQ 50MG BASE	N20031
PENBUTOLOL SULFATE		
TABLET		
LEVATOL	10MG	N18976

FDA data supplied by DrugPatentWatch.com

PENICILLIN G BENZATHINE		
INJECTABLE		
BICILLIN L-A	300,000 UNITS/ML	N50131
SUSPENSION		
BICILLIN	300,000 UNITS/5ML	N50126
TABLET		
BICILLIN	200,000 UNITS	N50128
PENICILLIN G POTASSIUM		
FOR SOLUTION		
PENICILLIN	200,000 UNITS/5ML	N60307
PENICILLIN	400,000 UNITS/5ML	N60307
PENICILLIN G POTASSIUM	200,000 UNITS/5ML	N60752
PENICILLIN G POTASSIUM	250,000 UNITS/5ML	N60752
PENICILLIN G POTASSIUM	400,000 UNITS/5ML	N60752
PENICILLIN G POTASSIUM	250,000 UNITS/5ML	N61740
PENICILLIN G POTASSIUM	400,000 UNITS/5ML	N61740
PENICILLIN-2	250,000 UNITS/5ML	N60307
PENTIDS '200'	200,000 UNITS/5ML	N62149
PENTIDS '400'	400,000 UNITS/5ML	N62149
PFIZERPEN G	400,000 UNITS/5ML	N60587
INJECTABLE		
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	10,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	10,000,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	500,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N60601
PENICILLIN G POTASSIUM	200,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	500,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N62003
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N62003
TABLET		
PENICILLIN G POTASSIUM	250,000 UNITS	N60392
PENICILLIN G POTASSIUM	400,000 UNITS	N60073
PENICILLIN G POTASSIUM	250,000 UNITS	N60403
PENICILLIN G POTASSIUM	200,000 UNITS	N60781
PENICILLIN G POTASSIUM	250,000 UNITS	N60781
PENICILLIN G POTASSIUM	400,000 UNITS	N60781
PENICILLIN G POTASSIUM	500,000 UNITS	N60781
PENICILLIN G POTASSIUM	800,000 UNITS	N60781

PENICILLIN G POTASSIUM		
TABLET		
PENICILLIN G POTASSIUM	200,000 UNITS	N61588
PENICILLIN G POTASSIUM	250,000 UNITS	N61588
PENICILLIN G POTASSIUM	400,000 UNITS	N61588
PENICILLIN G POTASSIUM	200,000 UNITS	N60306
PENICILLIN G POTASSIUM	250,000 UNITS	N60306
PENICILLIN G POTASSIUM	400,000 UNITS	N60306
PENICILLIN G POTASSIUM	500,000 UNITS	N60306
PENTIDS '200'	200,000 UNITS	N62155
PENTIDS '250'	250,000 UNITS	N62155
PENTIDS '400'	400,000 UNITS	N60392
PENTIDS '400'	400,000 UNITS	N62155
PENTIDS '800'	800,000 UNITS	N60392
PENTIDS '800'	800,000 UNITS	N62155
PFIZERPEN G	100,000 UNITS	N60075
PFIZERPEN G	200,000 UNITS	N60075
PFIZERPEN G	250,000 UNITS	N60075
PFIZERPEN G	400,000 UNITS	N60075
PFIZERPEN G	50,000 UNITS	N60075
PFIZERPEN G	800,000 UNITS	N60075
PENICILLIN G PROCAINE		
INJECTABLE		
DURACILLIN A.S.	300,000 UNITS/ML	N60093
PENICILLIN G PROCAINE	300,000 UNITS/ML	N60800
PENICILLIN G PROCAINE	600,000 UNITS/1.2ML	N60800
PENICILLIN G PROCAINE	300,000 UNITS/ML	N62029
PENICILLIN G PROCAINE	1,500,000 UNITS/VIAL	N60099
PENICILLIN G PROCAINE	300,000 UNITS/VIAL	N60099
PFIZERPEN-AS	300,000 UNITS/ML	N60286
PFIZERPEN-AS	600,000 UNITS/ML	N60286
PENICILLIN G SODIUM		
INJECTABLE		
PENICILLIN G SODIUM	5,000,000 UNITS/VIAL	N61935
PENICILLIN G SODIUM	5,000,000 UNITS/VIAL	N61051
PENICILLIN G SODIUM	5,000,000 UNITS/VIAL	N63014
PENICILLIN G SODIUM	1,000,000 UNITS/VIAL	N61046
PENICILLIN V		
FOR SUSPENSION		
V-CILLIN	125MG/0.6ML	N60002
PENICILLIN V POTASSIUM		
FOR SOLUTION		
BETAPEN-VK	EQ 125MG BASE/5ML	N61149
BETAPEN-VK	EQ 250MG BASE/5ML	N61149
PEN-VEE K	EQ 125MG BASE/5ML	N60007
PEN-VEE K	EQ 250MG BASE/5ML	N60007

PENICILLIN V POTASSIUM		
FOR SOLUTION		
PENAPAR-VK	EQ 125MG BASE/5ML	N62002
PENAPAR-VK	EQ 250MG BASE/5ML	N62002
PENICILLIN V POTASSIUM	EQ 125MG BASE/5ML	N61624
PENICILLIN V POTASSIUM	EQ 250MG BASE/5ML	N61624
PENICILLIN V POTASSIUM	EQ 125MG BASE/5ML	N61758
PENICILLIN V POTASSIUM	EQ 250MG BASE/5ML	N61758
PFIZERPEN VK	EQ 125MG BASE/5ML	N61815
PFIZERPEN VK	EQ 250MG BASE/5ML	N61815
V-CILLIN K	EQ 125MG BASE/5ML	N60004
V-CILLIN K	EQ 250MG BASE/5ML	N60004
VEETIDS '125'	EQ 125MG BASE/5ML	N61206
VEETIDS '125'	EQ 125MG BASE/5ML	N62153
VEETIDS '250'	EQ 250MG BASE/5ML	N61206
VEETIDS '250'	EQ 250MG BASE/5ML	N62153
TABLET		
PEN-VEE K	EQ 125MG BASE	N60006
PENAPAR-VK	EQ 250MG BASE	N62001
PENAPAR-VK	EQ 500MG BASE	N62001
PENICILLIN V POTASSIUM	EQ 125MG BASE	N60518
PENICILLIN V POTASSIUM	EQ 250MG BASE	N60518
PENICILLIN V POTASSIUM	EQ 500MG BASE	N60518
PENICILLIN V POTASSIUM	EQ 250MG BASE	N61530
PENICILLIN V POTASSIUM	EQ 500MG BASE	N61530
PENICILLIN V POTASSIUM	EQ 125MG BASE	N61571
PENICILLIN V POTASSIUM	EQ 250MG BASE	N61571
PENICILLIN V POTASSIUM	EQ 500MG BASE	N61571
PFIZERPEN VK	EQ 250MG BASE	N61836
PFIZERPEN VK	EQ 500MG BASE	N61836
UTICILLIN VK	EQ 500MG BASE	N61651
V-CILLIN K	EQ 125MG BASE	N60003
V-CILLIN K	EQ 250MG BASE	N60003
V-CILLIN K	EQ 500MG BASE	N60003
VEETIDS '250'	EQ 250MG BASE	N61164
VEETIDS '250'	EQ 250MG BASE	N62156
VEETIDS '500'	EQ 500MG BASE	N61164
VEETIDS '500'	EQ 500MG BASE	N62156
PENTAGASTRIN		
INJECTABLE		
PEPTAVLON	0.25MG/ML	N17048
PENTAMIDINE ISETHIONATE		
INJECTABLE		
PENTACARINAT	300MG/VIAL	N73447
PENTAZOCINE HYDROCHLORIDE		
TABLET		
TALWIN 50	EQ 50MG BASE	N16732
PENTETATE CALCIUM TRISODIUM YB-169		
INJECTABLE		
YTTERBIUM YB 169 DTPA	2mCi/ML	N17518
PENTOBARBITAL		
ELIXIR		
NEMBUTAL	18.2MG/5ML	N83244
PENTOBARBITAL SODIUM		
CAPSULE		
NEMBUTAL SODIUM	50MG	N84093
PENTOBARBITAL SODIUM	100MG	N85915
PENTOBARBITAL SODIUM	50MG	N85937
PENTOBARBITAL SODIUM	100MG	N83284
PENTOBARBITAL SODIUM	100MG	N83338
SODIUM PENTOBARBITAL	100MG	N84590
SODIUM PENTOBARBITAL	100MG	N83368
SODIUM PENTOBARBITAL	100MG	N83259
SODIUM PENTOBARBITAL	100MG	N84677
SODIUM PENTOBARBITAL	100MG	N83461
SODIUM PENTOBARBITAL	50MG	N83461
SODIUM PENTOBARBITAL	100MG	N84156
SODIUM PENTOBARBITAL	100MG	N84560
SODIUM PENTOBARBITAL	100MG	N83301
SODIUM PENTOBARBITAL	100MG	N85791
SODIUM PENTOBARBITAL	100MG	N83239
INJECTABLE		
PENTOBARBITAL SODIUM	50MG/ML	N83270
SUPPOSITORY		
NEMBUTAL	120MG	N83247
NEMBUTAL	200MG	N83247
NEMBUTAL	30MG	N83247
NEMBUTAL	60MG	N83247
TABLET		
PENTOBARBITAL SODIUM	100MG	N83285
SODIUM PENTOBARBITAL	100MG	N84238
PENTOLINIUM TARTRATE		
INJECTABLE		
ANSOLYSEN	10MG/ML	N09372
PERFLUBRON		
LIQUID		
IMAGENT	100%	N20091

FDA data supplied by DrugPatentWatch.com

PERMETHRIN
LOTION
NIX 1% N19435

PERPHENAZINE
CONCENTRATE
TRILAFON 16MG/5ML N11557
SYRUP
TRILAFON 2MG/5ML N11294
TABLET, EXTENDED RELEASE
TRILAFON 8MG N11361

PHENACEMIDE
TABLET
PHENURONE 500MG N07707

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE
TABLET
AZO GANTANOL 100MG;500MG N13294

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
TABLET
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL 200MG;800MG;160MG N21105

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE
TABLET
AZO GANTRISIN 50MG;500MG N19358

PHENDIMETRAZINE TARTRATE
CAPSULE
PHENAZINE 35MG N86523
PHENAZINE 35MG N86524
PHENAZINE 35MG N86525
PHENDIMETRAZINE TARTRATE 35MG N85633
PHENDIMETRAZINE TARTRATE 35MG N85694
PHENDIMETRAZINE TARTRATE 35MG N85702
PHENDIMETRAZINE TARTRATE 35MG N85634
PHENDIMETRAZINE TARTRATE 35MG N85645
PHENDIMETRAZINE TARTRATE 35MG N85670
PHENDIMETRAZINE TARTRATE 35MG N86403
PHENDIMETRAZINE TARTRATE 35MG N86408
PHENDIMETRAZINE TARTRATE 35MG N86410
PHENDIMETRAZINE TARTRATE 35MG N87424
SPRX-3 35MG N85897
STATOBEX 35MG N85507
CAPSULE, EXTENDED RELEASE
MELFIAT-105 105MG N87487
PHENDIMETRAZINE TARTRATE 105MG N87378

PHENDIMETRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE
PHENDIMETRAZINE TARTRATE 105MG N87214
PHENDIMETRAZINE TARTRATE 105MG N88020
PHENDIMETRAZINE TARTRATE 105MG N88028
PHENDIMETRAZINE TARTRATE 105MG N88062
PHENDIMETRAZINE TARTRATE 105MG N88063
PHENDIMETRAZINE TARTRATE 105MG N88111
SPRX-105 105MG N88024
TABLET
ADPHEN 35MG N83655
ALPHAZINE 35MG N85034
DI-METREX 35MG N85698
MELFIAT 35MG N83790
METRA 35MG N83754
PHENAZINE 35MG N87305
PHENAZINE-35 35MG N85512
PHENDIMETRAZINE TARTRATE 35MG N86020
PHENDIMETRAZINE TARTRATE 35MG N83644
PHENDIMETRAZINE TARTRATE 35MG N83684
PHENDIMETRAZINE TARTRATE 35MG N83686
PHENDIMETRAZINE TARTRATE 35MG N83687
PHENDIMETRAZINE TARTRATE 35MG N84831
PHENDIMETRAZINE TARTRATE 35MG N84834
PHENDIMETRAZINE TARTRATE 35MG N84835
PHENDIMETRAZINE TARTRATE 35MG N85402
PHENDIMETRAZINE TARTRATE 35MG N85497
PHENDIMETRAZINE TARTRATE 35MG N86834
PHENDIMETRAZINE TARTRATE 35MG N86365
PHENDIMETRAZINE TARTRATE 35MG N86370
PHENDIMETRAZINE TARTRATE 35MG N84740
PHENDIMETRAZINE TARTRATE 35MG N84741
PHENDIMETRAZINE TARTRATE 35MG N84742
PHENDIMETRAZINE TARTRATE 35MG N84743
PHENDIMETRAZINE TARTRATE 35MG N83682
PHENDIMETRAZINE TARTRATE 35MG N85611
PHENDIMETRAZINE TARTRATE 35MG N85612
PHENDIMETRAZINE TARTRATE 35MG N84138
PHENDIMETRAZINE TARTRATE 35MG N84141
PHENDIMETRAZINE TARTRATE 35MG N85525
PHENDIMETRAZINE TARTRATE 35MG N85914
PHENDIMETRAZINE TARTRATE 35MG N83790
PHENDIMETRAZINE TARTRATE 35MG N85199
PHENDIMETRAZINE TARTRATE 35MG N85697
PHENDIMETRAZINE TARTRATE 35MG N83993
PHENDIMETRAZINE TARTRATE 35MG N83805

PHENDIMETRAZINE TARTRATE

TABLET

PHENDIMETRAZINE TARTRATE	35MG	N84398
PHENDIMETRAZINE TARTRATE	35MG	N84399
PHENDIMETRAZINE TARTRATE	35MG	N85519
PHENDIMETRAZINE TARTRATE	35MG	N86005
PHENDIMETRAZINE TARTRATE	35MG	N86106
PHENDIMETRAZINE TARTRATE	35MG	N85767
PHENDIMETRAZINE TARTRATE	35MG	N85768
PHENDIMETRAZINE TARTRATE	35MG	N85770
PHENDIMETRAZINE TARTRATE	35MG	N85773
PLEGINE	35MG	N12248
STATOBEX	35MG	N86013
STATOBEX-G	35MG	N85095
X-TROZINE	35MG	N86550
X-TROZINE	35MG	N86551
X-TROZINE	35MG	N86552

PHENINDIONE

TABLET

HEDULIN	50MG	N08767

PHENMETRAZINE HYDROCHLORIDE

TABLET

PRELUDIN	25MG	N10460

TABLET, EXTENDED RELEASE

PRELUDIN	50MG	N11752
PRELUDIN	75MG	N11752

PHENPROCOUMON

TABLET

LIQUAMAR	3MG	N11228

PHENSUXIMIDE

CAPSULE

MILONTIN	500MG	N08855

PHENTERMINE HYDROCHLORIDE

CAPSULE

FASTIN	30MG	N17352
OBESTIN-30	30MG	N87144
OBY-TRIM	30MG	N87764
PHENTERMINE HCL	30MG	N85411
PHENTERMINE HCL	30MG	N88948
PHENTERMINE HCL	37.5MG	N88414
PHENTERMINE HCL	30MG	N86329
PHENTERMINE HCL	30MG	N87022
PHENTERMINE HCL	30MG	N86911
PHENTERMINE HCL	30MG	N87126

PHENTERMINE HYDROCHLORIDE

CAPSULE

PHENTERMINE HCL	30MG	N87777
PHENTERMINE HCL	30MG	N88612
PHENTERMINE HCL	30MG	N88613
PHENTERMINE HCL	30MG	N88614
PHENTERMINE HCL	30MG	N84487
PHENTERMINE HCL	30MG	N88430
PHENTERMINE HCL	30MG	N87202
PHENTERMINE HCL	30MG	N87235
PHENTERMINE HCL	30MG	N86740

TABLET

PHENTERMINE HCL	8MG	N85671
PHENTERMINE HCL	8MG	N85689
PHENTERMINE HCL	8MG	N85553
PHENTERMINE HCL	8MG	N86453
PHENTERMINE HCL	8MG	N86456
PHENTERMINE HCL	8MG	N85739
TORA	8MG	N84035

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE

PHENTERMINE RESIN 30	EQ 30MG BASE	N89120

PHENYL AMINOSALICYLATE

POWDER

PHENY-PAS-TEBAMIN	50%	N11695

TABLET

PHENY-PAS-TEBAMIN	500MG	N11695

PHENYLBUTAZONE

CAPSULE

AZOLID	100MG	N87260
BUTAZOLIDIN	100MG	N08319
PHENYLBUTAZONE	100MG	N87774
PHENYLBUTAZONE	100MG	N88994
PHENYLBUTAZONE	100MG	N88218
PHENYLBUTAZONE	100MG	N87756

TABLET

AZOLID	100MG	N87091
BUTAZOLIDIN	100MG	N08319
PHENYLBUTAZONE	100MG	N84339
PHENYLBUTAZONE	100MG	N88863
PHENYLBUTAZONE	100MG	N86151
PHENYLBUTAZONE	100MG	N87674

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP

PHERAZINE VC	5MG/5ML;6.25MG/5ML	N88868

FDA data supplied by DrugPatentWatch.com

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE		
SYRUP		
PROMETHAZINE VC PLAIN	5MG/5ML;6.25MG/5ML	N88815
PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE		
SOLUTION/DROPS		
PREFRIN-A	0.12%;0.1%	N07953
PHENYTOIN		
SUSPENSION		
DILANTIN-30	30MG/5ML	N08762
PHENYTOIN SODIUM		
INJECTABLE		
PHENYTOIN SODIUM	50MG/ML	N89003
PHENYTOIN SODIUM	50MG/ML	N89501
PHENYTOIN SODIUM	50MG/ML	N89779
PHENYTOIN SODIUM	50MG/ML	N88519
PHENYTOIN SODIUM	50MG/ML	N88521
PHENYTOIN SODIUM	50MG/ML	N88520
PHENYTOIN SODIUM	50MG/ML	N85434
PHENYTOIN SODIUM	50MG/ML	N89900
PHENYTOIN SODIUM, EXTENDED		
CAPSULE		
EXTENDED PHENYTOIN SODIUM	100MG	N89441
PHENYTEX	100MG	N88711
PHENYTOIN SODIUM, PROMPT		
CAPSULE		
DIPHENYLAN SODIUM	100MG	N80857
DIPHENYLAN SODIUM	30MG	N80857
PHENYTOIN SODIUM	100MG	N85435
PHENYTOIN SODIUM	100MG	N85894
PROMPT PHENYTOIN SODIUM	100MG	N80905
PHYTONADIONE		
INJECTABLE		
KONAKION	10MG/ML	N11745
KONAKION	1MG/0.5ML	N11745
PHYTONADIONE	10MG/ML	N84060
PHYTONADIONE	1MG/0.5ML	N84060
VITAMIN K1	10MG/ML	N87956
PILOCARPINE		
DRUG DELIVERY SYSTEM		
OCUSERT PILO-40	11MG	N17548
INSERT, EXTENDED RELEASE		
OCUSERT PILO-20	5MG	N17431
PINACIDIL		
CAPSULE, EXTENDED RELEASE		
PINDAC	12.5MG	N19456
PINDAC	25MG	N19456
PINDOLOL		
TABLET		
PINDOLOL	10MG	N74125
PINDOLOL	5MG	N74125
PIPECURONIUM BROMIDE		
INJECTABLE		
ARDUAN	10MG/VIAL	N19638
PIPERACETAZINE		
TABLET		
QUIDE	10MG	N13615
QUIDE	25MG	N13615
PIPERACILLIN SODIUM		
INJECTABLE		
PIPRACIL	EQ 40GM BASE/VIAL	*N50545
PIPERAZINE CITRATE		
SYRUP		
ANTEPAR	EQ 500MG BASE/5ML	N09102
BRYREL	EQ 500MG BASE/5ML	N17796
PIPERAZINE CITRATE	EQ 500MG BASE/5ML	N80774
PIPERAZINE CITRATE	EQ 500MG BASE/5ML	N80963
VERMIDOL	EQ 500MG BASE/5ML	N80992
TABLET		
ANTEPAR	EQ 500MG BASE	N09102
PIPERAZINE CITRATE	EQ 250MG BASE	N80874
PIPOBROMAN		
TABLET		
VERCYTE	10MG	N16245
VERCYTE	25MG	N16245
PIROXICAM		
CAPSULE		
PIROXICAM	10MG	N73651
PIROXICAM	20MG	N73651
POLYESTRADIOL PHOSPHATE		
INJECTABLE		
ESTRADURIN	40MG/AMP	N10753

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION

COLYTE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N18983
COLYTE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N18983
COLYTE	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N18983

FOR SUSPENSION

PEG-LYTE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N73098

POLYMYXIN B SULFATE

INJECTABLE

AEROSPORIN	EQ 500,000 U BASE/VIAL	N62036

POWDER

POLYMYXIN B SULFATE	100,000,000 UNITS/BOT	N62455

POTASSIUM AMINOSALICYLATE

POWDER

POTASSIUM AMINOSALICYLATE	100%	N80098

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE

K-LEASE	10MEQ	N72427
K-LEASE	8MEQ	N73398

FOR SUSPENSION, EXTENDED RELEASE

MICRO-K LS	20MEQ/PACKET	N19561

INJECTABLE

POTASSIUM CHLORIDE	1MEQ/ML	N80205
POTASSIUM CHLORIDE	1MEQ/ML	N83345
POTASSIUM CHLORIDE	2.4MEQ/ML	N80205
POTASSIUM CHLORIDE	3.2MEQ/ML	N80205
POTASSIUM CHLORIDE	2MEQ/ML	N88286
POTASSIUM CHLORIDE	2MEQ/ML	N80204
POTASSIUM CHLORIDE	2MEQ/ML	N84290
POTASSIUM CHLORIDE	2MEQ/ML	N86713
POTASSIUM CHLORIDE	2MEQ/ML	N86714
POTASSIUM CHLORIDE	2MEQ/ML	N87787
POTASSIUM CHLORIDE	2MEQ/ML	N87885
POTASSIUM CHLORIDE	2MEQ/ML	N80203
POTASSIUM CHLORIDE	1MEQ/ML	N86219

POTASSIUM CHLORIDE

INJECTABLE

POTASSIUM CHLORIDE	2MEQ/ML	N86219
POTASSIUM CHLORIDE	2MEQ/ML	N86220
POTASSIUM CHLORIDE	3MEQ/ML	N86219
POTASSIUM CHLORIDE	3MEQ/ML	N86220
POTASSIUM CHLORIDE	4MEQ/ML	N86219
POTASSIUM CHLORIDE	2MEQ/ML	N07865
POTASSIUM CHLORIDE	2MEQ/ML	N80221
POTASSIUM CHLORIDE	2MEQ/ML	N80736
POTASSIUM CHLORIDE	1MEQ/ML	N80195
POTASSIUM CHLORIDE	2MEQ/ML	N80195
POTASSIUM CHLORIDE	3MEQ/ML	N80195
POTASSIUM CHLORIDE	4MEQ/ML	N80195
POTASSIUM CHLORIDE	2MEQ/ML	N86208
POTASSIUM CHLORIDE	2MEQ/ML	N89163
POTASSIUM CHLORIDE	2MEQ/ML	N89421
POTASSIUM CHLORIDE	3MEQ/ML	N86210
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER	14.9MG/ML	N20161
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER	745MG/100ML	N20161
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER	1.49GM/100ML	N20161

TABLET, EXTENDED RELEASE

KAON CL	6.7MEQ	N17046
KAON CL-10	10MEQ	N17046
TEN-K	10MEQ	N19381

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	37MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	75MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	110MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	220MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	300MG/100ML;900MG/100ML	N19708
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	75MG/100ML;900MG/100ML	N18722
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	75MG/100ML;900MG/100ML	N17648
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	150MG/100ML;900MG/100ML	N18722
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	220MG/100ML;900MG/100ML	N18722

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	300MG/100ML;900MG/100ML	N18722

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE

THAM-E	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025

POTASSIUM CITRATE

FOR SOLUTION

POTASSIUM CITRATE	10MEQ/PACKET	N19647
POTASSIUM CITRATE	20MEQ/PACKET	N19647

POTASSIUM IODIDE

SOLUTION

POTASSIUM IODIDE	1GM/ML	N18551

PRALIDOXIME CHLORIDE

INJECTABLE

PRALIDOXIME CHLORIDE	1GM/VIAL	N72224
PRALIDOXIME CHLORIDE	300MG/ML	N18799

TABLET

PROTOPAM CHLORIDE	500MG	N14122

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET

MIRAPEX	1.25MG	N20667

PRAZEPAM

CAPSULE

CENTRAX	10MG	N18144
CENTRAX	20MG	N18144
CENTRAX	5MG	N18144
PRAZEPAM	10MG	N70428
PRAZEPAM	5MG	N70427

TABLET

CENTRAX	10MG	N17415

PRAZOSIN HYDROCHLORIDE

CAPSULE

PRAZOSIN HCL	EQ 1MG BASE	N72782
PRAZOSIN HCL	EQ 2MG BASE	N72783
PRAZOSIN HCL	EQ 5MG BASE	N72784
PRAZOSIN HCL	EQ 1MG BASE	N72991
PRAZOSIN HCL	EQ 2MG BASE	N72921
PRAZOSIN HCL	EQ 5MG BASE	N72992

PREDNISOLONE

CREAM

METI-DERM	0.5%	N10209

TABLET

CORTALONE	1MG	N80304
CORTALONE	2.5MG	N80304
CORTALONE	5MG	N80304
DELTA-CORTEF	5MG	N09987
FERNISOLONE-P	5MG	N83941
PREDNISOLONE	5MG	N84426
PREDNISOLONE	5MG	N83675
PREDNISOLONE	5MG	N80625
PREDNISOLONE	5MG	N84773
PREDNISOLONE	1MG	N84439
PREDNISOLONE	2.5MG	N80562
PREDNISOLONE	5MG	N80562
PREDNISOLONE	5MG	N80339
PREDNISOLONE	5MG	N80326
PREDNISOLONE	5MG	N80236
PREDNISOLONE	5MG	N80780
PREDNISOLONE	5MG	N80748
PREDNISOLONE	5MG	N80378
PREDNISOLONE	1MG	N80351
PREDNISOLONE	5MG	N80351
PREDNISOLONE	5MG	N84542
PREDNISOLONE	5MG	N80322
PREDNISOLONE	5MG	N80325
PREDNISOLONE	5MG	N80211
PREDNISOLONE	5MG	N80327
PREDNISOLONE	5MG	N88892
PREDNISOLONE	5MG	N85170
PREDNISOLONE	5MG	N80398
PREDNISOLONE	5MG	N87987
PREDNISOLONE	5MG	N80534
PREDNISOLONE	5MG	N85085
PREDNISOLONE	5MG	N85415
PREDNISOLONE	5MG	N85416
PREDNISOLONE	5MG	N80324
PREDNISOLONE	5MG	N80342
STERANE	5MG	N09996

PREDNISOLONE ACETATE

INJECTABLE

METICORTELONE	25MG/ML	N10255
PREDNISOLONE ACETATE	25MG/ML	N83032
PREDNISOLONE ACETATE	50MG/ML	N84492
PREDNISOLONE ACETATE	25MG/ML	N83738
PREDNISOLONE ACETATE	50MG/ML	N83738
PREDNISOLONE ACETATE	25MG/ML	N84717

PREDNISOLONE ACETATE		
INJECTABLE		
PREDNISOLONE ACETATE	50MG/ML	N84717
PREDNISOLONE ACETATE	25MG/ML	N83654
PREDNISOLONE ACETATE	40MG/ML	N83767
STERANE	25MG/ML	N11446
PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM		
OINTMENT		
METIMYD	0.5%;10%	N10210
PREDSULFAIR	0.5%;10%	N88032
SUSPENSION		
ISOPTO CETAPRED	0.25%;10%	N87547
SUSPENSION/DROPS		
METIMYD	0.5%;10%	N10210
PREDAMIDE	0.5%;10%	N88059
PREDSULFAIR	0.5%;10%	N88007
PREDSULFAIR II	0.2%;10%	N88837
SULPHRIN	0.5%;10%	N88089
PREDNISOLONE SODIUM PHOSPHATE		
INJECTABLE		
HYDELTRASOL	EQ 20MG PHOSPHATE/ML	N11583
PREDNISOLONE SODIUM PHOSPHATE	EQ 20MG PHOSPHATE/ML	N80517
OINTMENT		
HYDELTRASOL	EQ 0.25% PHOSPHATE	N11028
SOLUTION/DROPS		
METRETON	EQ 0.5% PHOSPHATE	N83834
PREDAIR	EQ 0.11% PHOSPHATE	N88415
PREDAIR FORTE	EQ 0.9% PHOSPHATE	N88165
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.11% PHOSPHATE	N83358
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N83358
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.11% PHOSPHATE	N81043
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N81044
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.11% PHOSPHATE	N84171
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N84168
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N84169
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N84172
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM		
SOLUTION/DROPS		
SULSTER	EQ 0.23% PHOSPHATE;10%	N74511
PREDNISOLONE TEBUTATE		
INJECTABLE		
HYDELTRA-TBA	20MG/ML	N10562
PREDNISOLONE TEBUTATE	20MG/ML	N83362

PREDNISONE		
SOLUTION		
PREDNISONE	5MG/5ML	N89726
SYRUP		
LIQUID PRED	5MG/5ML	N87611
TABLET		
CORTAN	20MG	N87480
DELTA-DOME	5MG	N80293
FERNISONE	5MG	N83364
METICORTEN	1MG	N09766
METICORTEN	5MG	N09766
ORASONE	10MG	N83009
ORASONE	1MG	N83009
ORASONE	20MG	N83009
ORASONE	50MG	N85999
ORASONE	5MG	N83009
PARACORT	5MG	N10962
PREDNICEN-M	5MG	N84655
PREDNISONE	10MG	N89388
PREDNISONE	20MG	N89389
PREDNISONE	5MG	N89387
PREDNISONE	5MG	N83676
PREDNISONE	10MG	N88395
PREDNISONE	20MG	N88396
PREDNISONE	5MG	N88394
PREDNISONE	20MG	N85811
PREDNISONE	5MG	N80491
PREDNISONE	5MG	N84774
PREDNISONE	1MG	N84440
PREDNISONE	2.5MG	N84440
PREDNISONE	5MG	N84440
PREDNISONE	2.5MG	N80563
PREDNISONE	5MG	N80563
PREDNISONE	5MG	N80336
PREDNISONE	10MG	N86595
PREDNISONE	20MG	N84634
PREDNISONE	50MG	N86596
PREDNISONE	5MG	N80300
PREDNISONE	5MG	N80701
PREDNISONE	10MG	N84341
PREDNISONE	20MG	N84417
PREDNISONE	20MG	N85543
PREDNISONE	50MG	N86946
PREDNISONE	5MG	N80320
PREDNISONE	5MG	N80237
PREDNISONE	5MG	N80782
PREDNISONE	10MG	N89598

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

TABLET

PREDNISONE	20MG	N89599
PREDNISONE	5MG	N89597
PREDNISONE	1MG	N80328
PREDNISONE	2.5MG	N80306
PREDNISONE	5MG	N80279
PREDNISONE	10MG	N84133
PREDNISONE	20MG	N84134
PREDNISONE	5MG	N80283
PREDNISONE	5MG	N84236
PREDNISONE	20MG	N84275
PREDNISONE	5MG	N80514
PREDNISONE	5MG	N86968
PREDNISONE	5MG	N85115
PREDNISONE	1MG	N80350
PREDNISONE	2.5MG	N80350
PREDNISONE	5MG	N80350
PREDNISONE	5MG	N83059
PREDNISONE	5MG	N84662
PREDNISONE	20MG	N83807
PREDNISONE	5MG	N80321
PREDNISONE	10MG	N86062
PREDNISONE	20MG	N86061
PREDNISONE	5MG	N80353
PREDNISONE	20MG	N85151
PREDNISONE	5MG	N80232
PREDNISONE	20MG	N17109
PREDNISONE	25MG	N87833
PREDNISONE	5MG	N80371
PREDNISONE	1MG	N80359
PREDNISONE	2.5MG	N80359
PREDNISONE	5MG	N80359
PREDNISONE	10MG	N88866
PREDNISONE	20MG	N88867
PREDNISONE	5MG	N88865
PREDNISONE	5MG	N80397
PREDNISONE	10MG	N87985
PREDNISONE	20MG	N87986
PREDNISONE	5MG	N87984
PREDNISONE	20MG	N87470
PREDNISONE	5MG	N87471
PREDNISONE	20MG	N87701
PREDNISONE	5MG	N87682
PREDNISONE	5MG	N80334
PREDNISONE	5MG	N80506
PREDNISONE	50MG	N86867

PREDNISONE

TABLET

PREDNISONE	5MG	N85084
PREDNISONE	10MG	N89028
PREDNISONE	2.5MG	N84913
PREDNISONE	20MG	N84913
PREDNISONE	5MG	N80343
SERVISONE	5MG	N80223

PRILOCAINE HYDROCHLORIDE

INJECTABLE

CITANEST	1%	N14763
CITANEST	2%	N14763
CITANEST	3%	N14763
CITANEST PLAIN	4%	N14763

PRIMIDONE

SUSPENSION

MYSOLINE	250MG/5ML	N10401

TABLET

PRIMIDONE	250MG	N85052

PROBENECID

TABLET

BENEMID	500MG	N07898
PROBENECID	500MG	N86917
PROBENECID	500MG	N86150

PROBUCOL

TABLET

LORELCO	250MG	N17535
LORELCO	500MG	N17535

PROCAINAMIDE HYDROCHLORIDE

CAPSULE

PROCAINAMIDE HCL	250MG	N87542
PROCAINAMIDE HCL	375MG	N87697
PROCAINAMIDE HCL	500MG	N87543
PROCAINAMIDE HCL	500MG	N84696
PROCAINAMIDE HCL	250MG	N86942
PROCAINAMIDE HCL	375MG	N86952
PROCAINAMIDE HCL	500MG	N86943
PROCAINAMIDE HCL	250MG	N88989
PROCAINAMIDE HCL	500MG	N88990
PROCAINAMIDE HCL	250MG	N87643
PROCAINAMIDE HCL	500MG	N87875
PROCAINAMIDE HCL	250MG	N83795
PROCAINAMIDE HCL	500MG	N84357
PROCAINAMIDE HCL	250MG	N85167
PROCAINAMIDE HCL	375MG	N87020

PROCAINAMIDE HYDROCHLORIDE		
CAPSULE		
PROCAINAMIDE HCL	500MG	N87021
PROCAN	250MG	N85804
PROCAN	375MG	N87502
PROCAN	500MG	N85079
PROCAPAN	250MG	N83553
INJECTABLE		
PROCAINAMIDE HCL	100MG/ML	N89415
PROCAINAMIDE HCL	500MG/ML	N89416
PROCAINAMIDE HCL	100MG/ML	N88824
PROCAINAMIDE HCL	500MG/ML	N88830
PROCAINAMIDE HCL	100MG/ML	N89256
PROCAINAMIDE HCL	500MG/ML	N89257
PROCAINAMIDE HCL	100MG/ML	N88530
PROCAINAMIDE HCL	500MG/ML	N88531
PROCAINAMIDE HCL	500MG/ML	N88532
PROCAINAMIDE HCL	100MG/ML	N87079
PROCAINAMIDE HCL	500MG/ML	N87080
PROCAINAMIDE HCL	100MG/ML	N89528
PROCAINAMIDE HCL	500MG/ML	N89529
TABLET, EXTENDED RELEASE		
PROCAINAMIDE HCL	500MG	N89284
PROCAINAMIDE HCL	500MG	N89840
PROCAINAMIDE HCL	250MG	N88958
PROCAINAMIDE HCL	1GM	N89520
PROCAINAMIDE HCL	250MG	N88533
PROCAINAMIDE HCL	500MG	N88534
PROCAINAMIDE HCL	750MG	N88535
PROCAN SR	250MG	N86468
PROCAN SR	1GM	N88489
PROCAN SR	500MG	N86065
PROCAN SR	750MG	N87510
PROCAINE HYDROCHLORIDE		
INJECTABLE		
PROCAINE HCL	1%	N80384
PROCAINE HCL	2%	N80384
PROCAINE HCL	1%	N80711
PROCAINE HCL	2%	N80756
PROCAINE HCL	1%	N86202
PROCAINE HCL	2%	N86202
PROCAINE HCL	1%	N80415
PROCAINE HCL	2%	N80415
PROCAINE HCL	1%	N83535
PROCAINE HCL	2%	N83535

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE		
INJECTABLE		
ACHROMYCIN	40MG/VIAL;100MG/VIAL	N50276
ACHROMYCIN	40MG/VIAL;250MG/VIAL	N50276
TETRACYN	40MG/VIAL;100MG/VIAL	N60285
TETRACYN	40MG/VIAL;250MG/VIAL	N60285
PROCAINE MERETHOXYLLINE; THEOPHYLLINE		
INJECTABLE		
DICURIN PROCAINE	100MG/ML;50MG/ML	N08869
PROCHLORPERAZINE EDISYLATE		
CONCENTRATE		
COMPAZINE	EQ 10MG BASE/ML	N11276
PROCHLORPERAZINE	EQ 10MG BASE/ML	N87153
PROCHLORPERAZINE EDISYLATE	EQ 10MG BASE/ML	N88598
INJECTABLE		
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89523
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89675
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89637
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89638
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89251
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89605
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89606
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N86348
SYRUP		
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/5ML	N87154
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/5ML	N88597
PROCHLORPERAZINE MALEATE		
CAPSULE, EXTENDED RELEASE		
COMPAZINE	EQ 10MG BASE	N11000
COMPAZINE	EQ 15MG BASE	N11000
COMPAZINE	EQ 30MG BASE	N11000
COMPAZINE	EQ 75MG BASE	N11000
TABLET		
PROCHLORPERAZINE	EQ 10MG BASE	N85178
PROCHLORPERAZINE	EQ 25MG BASE	N85579
PROCHLORPERAZINE	EQ 5MG BASE	N85580
PROCHLORPERAZINE MALEATE	EQ 10MG BASE	N89485
PROCHLORPERAZINE MALEATE	EQ 25MG BASE	N89486
PROCHLORPERAZINE MALEATE	EQ 5MG BASE	N89484
PROCYCLIDINE HYDROCHLORIDE		
TABLET		
KEMADRIN	2MG	N09818

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

PROGESTERONE		
CAPSULE		
PROMETRIUM	300MG	N19781
INJECTABLE		
PROGESTERONE	25MG/ML	N09238
PROGESTERONE	50MG/ML	N09238
INSERT, EXTENDED RELEASE		
PROGESTASERT	38MG	N17553
PROMAZINE HYDROCHLORIDE		
CONCENTRATE		
SPARINE	100MG/ML	N10942
SPARINE	30MG/ML	N10942
INJECTABLE		
PROMAZINE HCL	25MG/ML	N84510
PROMAZINE HCL	50MG/ML	N84517
SPARINE	25MG/ML	N10349
SPARINE	50MG/ML	N10349
SYRUP		
SPARINE	10MG/5ML	N10942
TABLET		
SPARINE	100MG	N10348
SPARINE	10MG	N10348
SPARINE	200MG	N10348
SPARINE	25MG	N10348
SPARINE	50MG	N10348
PROMETHAZINE HYDROCHLORIDE		
INJECTABLE		
PROMETHAZINE HCL	25MG/ML	N84223
PROMETHAZINE HCL	50MG/ML	N84222
PROMETHAZINE HCL	25MG/ML	N83955
PROMETHAZINE HCL	50MG/ML	N83955
PROMETHAZINE HCL	25MG/ML	N89463
PROMETHAZINE HCL	50MG/ML	N89477
PROMETHAZINE HCL	25MG/ML	N83532
PROMETHAZINE HCL	50MG/ML	N83532
ZIPAN-25	25MG/ML	N83997
ZIPAN-50	50MG/ML	N83997
SUPPOSITORY		
PROMETHACON	50MG	N84902
SYRUP		
MYMETHAZINE FORTIS	25MG/5ML	N87996
PHENERGAN FORTIS	25MG/5ML	N08381
PROMETH FORTIS	25MG/5ML	N84772
PROMETHAZINE	6.25MG/5ML	N89013
PROMETHAZINE HCL	25MG/5ML	N85385

PROMETHAZINE HYDROCHLORIDE		
SYRUP		
PROMETHAZINE HCL	6.25MG/5ML	N85388
PROMETHAZINE HCL	6.25MG/5ML	N87518
TABLET		
PROMETHAZINE HCL	12.5MG	N84160
PROMETHAZINE HCL	25MG	N84166
PROMETHAZINE HCL	50MG	N84539
PROMETHAZINE HCL	25MG	N85146
PROMETHAZINE HCL	50MG	N85146
PROMETHAZINE HCL	12.5MG	N84233
PROMETHAZINE HCL	12.5MG	N84555
PROMETHAZINE HCL	25MG	N84554
PROMETHAZINE HCL	50MG	N84557
PROMETHAZINE HCL	25MG	N84214
PROMETHAZINE HCL	12.5MG	N83604
PROMETHAZINE HCL	25MG	N83603
PROMETHAZINE HCL	50MG	N83613
PROMETHAZINE HCL	12.5MG	N80949
PROMETHAZINE HCL	25MG	N80949
PROMETHAZINE HCL	50MG	N80949
PROMETHAZINE HCL	12.5MG	N83214
PROMETHAZINE HCL	25MG	N83658
PROMETHAZINE HCL	12.5MG	N84080
PROMETHAZINE HCL	25MG	N84027
PROMETHAZINE HCL	25MG	N89109
PROMETHAZINE HCL	12.5MG	N83401
PROMETHAZINE HCL	25MG	N83204
PROMETHAZINE HCL	50MG	N83403
PROMETHAZINE HCL	12.5MG	N83712
PROMETHAZINE HCL	12.5MG	N85986
PROMETHAZINE HCL	25MG	N85684
PROMETHAZINE HCL	50MG	N85664
REMSED	25MG	N83176
REMSED	50MG	N83176
PROPANTHELINE BROMIDE		
INJECTABLE		
PRO-BANTHINE	30MG/VIAL	N08843
TABLET		
PROPANTHELINE BROMIDE	15MG	N87663
PROPANTHELINE BROMIDE	15MG	N80928
PROPANTHELINE BROMIDE	15MG	N85780
PROPANTHELINE BROMIDE	15MG	N84541
PROPANTHELINE BROMIDE	15MG	N83706
PROPANTHELINE BROMIDE	15MG	N88377
PROPANTHELINE BROMIDE	15MG	N80977

PROPANTHELINE BROMIDE		
TABLET		
PROPANTHELINE BROMIDE	15MG	N84428
PROPANTHELINE BROMIDE	15MG	N83151
PROPANTHELINE BROMIDE	15MG	N83029
PROPARACAINE HYDROCHLORIDE		
SOLUTION/DROPS		
KAINAIR	0.5%	N88087
PROPARACAINE HCL	0.5%	N84144
PROPARACAINE HCL	0.5%	N84151
PROPIOLACTONE		
SOLUTION		
BETAPRONE	N/A	N11657
PROPIOMAZINE HYDROCHLORIDE		
INJECTABLE		
LARGON	20MG/ML	N12382
PROPOFOL		
INJECTABLE		
DIPRIVAN	10MG/ML	N19627
PROPOXYPHENE HYDROCHLORIDE		
CAPSULE		
PROPHENE 65	65MG	N83538
PROPOXYPHENE HCL	65MG	N83184
PROPOXYPHENE HCL	65MG	N83185
PROPOXYPHENE HCL	32MG	N84014
PROPOXYPHENE HCL	65MG	N83688
PROPOXYPHENE HCL	65MG	N83870
PROPOXYPHENE HCL	65MG	N86495
PROPOXYPHENE HCL	65MG	N83125
PROPOXYPHENE HCL	65MG	N83186
PROPOXYPHENE HCL	65MG	N83317
PROPOXYPHENE HCL	32MG	N83597
PROPOXYPHENE HCL	65MG	N83299
PROPOXYPHENE HCL	65MG	N83278
PROPOXYPHENE HCL	32MG	N83464
PROPOXYPHENE HCL	65MG	N83113
PROPOXYPHENE HCL	32MG	N83089
PROPOXYPHENE HCL	65MG	N83089
PROPOXYPHENE HCL	65MG	N80908
PROPOXYPHENE HCL	65MG	N85190
PROPOXYPHENE HCL 65	65MG	N83786
PROPRANOLOL HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
PROPRANOLOL HCL	120MG	N72501

PROPRANOLOL HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
PROPRANOLOL HCL	160MG	N72502
PROPRANOLOL HCL	60MG	N72499
PROPRANOLOL HCL	80MG	N72500
INJECTABLE		
PROPRANOLOL HCL	1MG/ML	N70135
PROPRANOLOL HCL	1MG/ML	N70137
PROPRANOLOL HCL	1MG/ML	N70136
SOLUTION		
PROPRANOLOL HCL	20MG/5ML	N71984
PROPRANOLOL HCL	40MG/5ML	N71985
SUSPENSION		
INDERAL	10MG/ML	N19536
TABLET		
INDERAL	90MG	N16418
PROPRANOLOL HCL	10MG	N70306
PROPRANOLOL HCL	20MG	N70307
PROPRANOLOL HCL	40MG	N70308
PROPRANOLOL HCL	60MG	N70309
PROPRANOLOL HCL	80MG	N70310
PROPRANOLOL HCL	90MG	N71327
PROPRANOLOL HCL	10MG	N70319
PROPRANOLOL HCL	20MG	N70320
PROPRANOLOL HCL	40MG	N70103
PROPRANOLOL HCL	60MG	N70321
PROPRANOLOL HCL	80MG	N70322
PROPRANOLOL HCL	10MG	N71368
PROPRANOLOL HCL	20MG	N71369
PROPRANOLOL HCL	40MG	N71370
PROPRANOLOL HCL	80MG	N71371
PROPRANOLOL HCL	10MG	N71658
PROPRANOLOL HCL	20MG	N71687
PROPRANOLOL HCL	40MG	N71688
PROPRANOLOL HCL	60MG	N72197
PROPRANOLOL HCL	80MG	N71689
PROPRANOLOL HCL	90MG	N72198
PROPRANOLOL HCL	10MG	N72063
PROPRANOLOL HCL	20MG	N72066
PROPRANOLOL HCL	40MG	N72067
PROPRANOLOL HCL	60MG	N72068
PROPRANOLOL HCL	80MG	N72069
PROPRANOLOL HCL	10MG	N70125
PROPRANOLOL HCL	10MG	N72117
PROPRANOLOL HCL	20MG	N70126
PROPRANOLOL HCL	20MG	N72118

PROPRANOLOL HYDROCHLORIDE
TABLET

PROPRANOLOL HCL	40MG	N70127
PROPRANOLOL HCL	40MG	N72119
PROPRANOLOL HCL	60MG	N71495
PROPRANOLOL HCL	80MG	N70128
PROPRANOLOL HCL	80MG	N72120
PROPRANOLOL HCL	90MG	N71496
PROPRANOLOL HCL	60MG	N72275
PROPRANOLOL HCL	10MG	N70814
PROPRANOLOL HCL	20MG	N70815
PROPRANOLOL HCL	40MG	N70816
PROPRANOLOL HCL	60MG	N70817
PROPRANOLOL HCL	80MG	N70757
PROPRANOLOL HCL	10MG	N70516
PROPRANOLOL HCL	20MG	N70517
PROPRANOLOL HCL	40MG	N70518
PROPRANOLOL HCL	60MG	N70519
PROPRANOLOL HCL	80MG	N70520
PROPRANOLOL HCL	90MG	N70521
PROPRANOLOL HCL	10MG	N70120
PROPRANOLOL HCL	20MG	N70121
PROPRANOLOL HCL	40MG	N70122
PROPRANOLOL HCL	60MG	N70123
PROPRANOLOL HCL	80MG	N70124
PROPRANOLOL HCL	10MG	N71515
PROPRANOLOL HCL	20MG	N71516
PROPRANOLOL HCL	40MG	N71517
PROPRANOLOL HCL	80MG	N71518
PROPRANOLOL HCL	10MG	N70232
PROPRANOLOL HCL	20MG	N70233
PROPRANOLOL HCL	10MG	N70438
PROPRANOLOL HCL	20MG	N70439
PROPRANOLOL HCL	40MG	N70440
PROPRANOLOL HCL	60MG	N70441
PROPRANOLOL HCL	80MG	N70442
PROPRANOLOL HCL	10MG	N70378
PROPRANOLOL HCL	20MG	N70379
PROPRANOLOL HCL	40MG	N70380
PROPRANOLOL HCL	60MG	N70381
PROPRANOLOL HCL	80MG	N70382
PROPRANOLOL HCL	10MG	N70140
PROPRANOLOL HCL	20MG	N70141
PROPRANOLOL HCL	20MG	N70549
PROPRANOLOL HCL	40MG	N70142
PROPRANOLOL HCL	60MG	N70143
PROPRANOLOL HCL	60MG	N71098

PROPRANOLOL HYDROCHLORIDE
TABLET

PROPRANOLOL HCL	80MG	N70144
PROPRANOLOL HCL	90MG	N71183

PROPYLIODONE
SUSPENSION

DIONOSIL AQUEOUS	50%	N09309
DIONOSIL OILY	60%	N09309

PROPYLTHIOURACIL
TABLET

PROPYLTHIOURACIL	50MG	N84075
PROPYLTHIOURACIL	50MG	N80285
PROPYLTHIOURACIL	50MG	N80015
PROPYLTHIOURACIL	50MG	N83982
PROPYLTHIOURACIL	50MG	N80215
PROPYLTHIOURACIL	50MG	N80016
PROPYLTHIOURACIL	50MG	N06213
PROPYLTHIOURACIL	50MG	N84543
PROPYLTHIOURACIL	50MG	N80840
PROPYLTHIOURACIL	50MG	N80932
PROPYLTHIOURACIL	50MG	N85201

PROTAMINE SULFATE
INJECTABLE

PROTAMINE SULFATE	250MG/VIAL	N07413
PROTAMINE SULFATE	50MG/VIAL	N07413
PROTAMINE SULFATE	10MG/ML	N89306
PROTAMINE SULFATE	50MG/VIAL	N89307

PROTEIN HYDROLYSATE
INJECTABLE

AMINOSOL 5%	5%	N05932
HYPROTIGEN 5%	5%	N06170

PROTIRELIN
INJECTABLE

THYPINONE	0.5MG/ML	N17638

PROTOKYLOL HYDROCHLORIDE
TABLET

VENTAIRE	2MG	N83459

PROTRIPTYLINE HYDROCHLORIDE
TABLET

VIVACTIL	10MG	N16012
VIVACTIL	5MG	N16012

PSEUDOEPHEDRINE HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
NOVAFED	120MG	N17603
SUDAFED 12 HOUR	120MG	* N17941
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
ACTIFED	120MG;5MG	N18996
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES	120MG;5MG	N71798
SYRUP		
ACTAHIST	30MG/5ML;1.25MG/5ML	N88344
HISTAFED	30MG/5ML;1.25MG/5ML	N88283
MYFED	30MG/5ML;1.25MG/5ML	N88116
TRILITRON	30MG/5ML;1.25MG/5ML	N88474
TABLET		
ALLERFED	60MG;2.5MG	N88860
TRIPHED	60MG;2.5MG	N88630
TRIPROLIDINE AND PSEUDOEPHEDRINE	60MG;2.5MG	N88318
TRIPROLIDINE AND PSEUDOEPHEDRINE	60MG;2.5MG	N88117
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL	60MG;2.5MG	N85273
PSEUDOEPHEDRINE POLISTIREX		
SUSPENSION, EXTENDED RELEASE		
PSEUDO-12	EQ 60MG HCL/5ML	N19401
PYRIDOSTIGMINE BROMIDE		
TABLET		
PYRIDOSTIGMINE BROMIDE	30MG	N89572
PYRIDOXINE HYDROCHLORIDE		
INJECTABLE		
HEXA-BETALIN	100MG/ML	N80854
PYRIDOXINE HCL	100MG/ML	N87967
PYRIDOXINE HCL	100MG/ML	N80761
PYRIDOXINE HCL	100MG/ML	N83772
PYRIDOXINE HCL	50MG/ML	N83771
PYRIDOXINE HCL	100MG/ML	N80581
PYRIDOXINE HCL	100MG/ML	N80669
PYRIDOXINE HCL	100MG/ML	N83760
PYRILAMINE MALEATE		
TABLET		
PYRILAMINE MALEATE	25MG	N85231
PYRITHIONE ZINC		
LOTION		
HEAD & SHOULDERS CONDITIONER	0.3%	N19412
PYRVINIUM PAMOATE		
SUSPENSION		
POVAN	EQ 50MG BASE/5ML	N11964
TABLET		
POVAN	EQ 50MG BASE	N12485
QUINESTROL		
TABLET		
ESTROVIS	0.1MG	N16768
ESTROVIS	0.2MG	N16768
QUINETHAZONE		
TABLET		
HYDROMOX	50MG	N13264
QUINETHAZONE; RESERPINE		
TABLET		
HYDROMOX R	50MG;0.125MG	N13927
QUINIDINE GLUCONATE		
TABLET		
QUINACT	266MG	N85978
QUINACT	400MG	N86099
TABLET, EXTENDED RELEASE		
DURAQUIN	330MG	N17917
QUINALAN	324MG	N88081
QUINATIME	324MG	N87448
QUINIDINE GLUCONATE	324MG	N88582
QUINIDINE GLUCONATE	324MG	N89894
QUINIDINE GLUCONATE	324MG	N89476
QUINIDINE GLUCONATE	324MG	N88431
QUINIDINE GLUCONATE	324MG	N89164
QUINIDINE GLUCONATE	324MG	N87785
QUINIDINE POLYGALACTURONATE		
TABLET		
CARDIOQUIN	275MG	N11642
QUINIDINE SULFATE		
CAPSULE		
CIN-QUIN	200MG	N85296
CIN-QUIN	300MG	N85297
QUINIDINE SULFATE	200MG	N85103
TABLET		
CIN-QUIN	100MG	N85299
CIN-QUIN	200MG	N84932
CIN-QUIN	300MG	N85298
QUINIDINE SULFATE	200MG	N84177
QUINIDINE SULFATE	200MG	N83622
QUINIDINE SULFATE	200MG	N83439

FDA data supplied by DrugPatentWatch.com

QUINIDINE SULFATE		
TABLET		
QUINIDINE SULFATE	200MG	N83583
QUINIDINE SULFATE	200MG	N83393
QUINIDINE SULFATE	200MG	N83347
QUINIDINE SULFATE	200MG	N84549
QUINIDINE SULFATE	200MG	N85175
QUINIDINE SULFATE	200MG	N85276
QUINIDINE SULFATE	200MG	N86176
QUINIDINE SULFATE	200MG	N85038
QUINIDINE SULFATE	300MG	N81031
QUINIDINE SULFATE	200MG	N85322
QUINIDINE SULFATE	200MG	N84627
QUINIDINE SULFATE	200MG	N84003
QUINIDINE SULFATE	200MG	N85068
QUINIDINE SULFATE	200MG	N87837
QUINIDINE SULFATE	200MG	N87909
QUINIDINE SULFATE	200MG	N83963
QUINIDINE SULFATE	200MG	N83879
QUINIDINE SULFATE	100MG	N85584
QUINIDINE SULFATE	200MG	N83862
QUINIDINE SULFATE	200MG	N85444
QUINORA	200MG	N83576
QUINORA	300MG	N85222
RABEPRAZOLE SODIUM		
TABLET, DELAYED RELEASE		
ACIPHEX	10MG	N20973
RANITIDINE BISMUTH CITRATE		
TABLET		
TRITEC	400MG	N20559
RANITIDINE HYDROCHLORIDE		
CAPSULE		
ZANTAC 150	EQ 150MG BASE	N20095
ZANTAC 300	EQ 300MG BASE	N20095
INJECTABLE		
ZANTAC IN PLASTIC CONTAINER	EQ 50MG BASE/100ML	N19593
TABLET		
RANITIDINE HCL	EQ 150MG BASE	N74662
RANITIDINE HCL	EQ 300MG BASE	N74662
TABLET, EFFERVESCENT		
ZANTAC 75	EQ 75MG BASE	N20745
RAPACURONIUM BROMIDE		
INJECTABLE		
RAPLON	100MG/VIAL	N20984
RAPACURONIUM BROMIDE		
INJECTABLE		
RAPLON	200MG/VIAL	N20984
RAUWOLFIA SERPENTINA		
TABLET		
HIWOLFIA	100MG	N09276
HIWOLFIA	50MG	N09276
HIWOLFIA	50MG	N09276
HYSERPIN	50MG	N10581
KOGLUCOID	100MG	N09278
KOGLUCOID	50MG	N09278
RAUDIXIN	100MG	N08842
RAUDIXIN	50MG	N08842
RAUSERPIN	100MG	N09926
RAUSERPIN	50MG	N09926
RAUVAL	100MG	N09108
RAUVAL	50MG	N09108
RAUWOLFIA SERPENTINA	100MG	N09477
RAUWOLFIA SERPENTINA	50MG	N09477
RAUWOLFIA SERPENTINA	100MG	N80498
RAUWOLFIA SERPENTINA	50MG	N80498
RAUWOLFIA SERPENTINA	100MG	N09668
RAUWOLFIA SERPENTINA	50MG	N09668
RAUWOLFIA SERPENTINA	100MG	N09273
RAUWOLFIA SERPENTINA	50MG	N09273
RAUWOLFIA SERPENTINA	100MG	N11521
RAUWOLFIA SERPENTINA	50MG	N11521
RAUWOLFIA SERPENTINA	100MG	N80842
RAUWOLFIA SERPENTINA	50MG	N80842
RAUWOLFIA SERPENTINA	100MG	N80583
RAUWOLFIA SERPENTINA	50MG	N80583
RAUWOLFIA SERPENTINA	100MG	N80500
RAUWOLFIA SERPENTINA	50MG	N80500
RAUWOLFIA SERPENTINA	100MG	N83444
RAUWOLFIA SERPENTINA	50MG	N83867
RAUWOLFIA SERPENTINA	100MG	N80914
RAUWOLFIA SERPENTINA	50MG	N80907
WOLFINA	100MG	N09255
WOLFINA	50MG	N09255
RESCINNAMINE		
CAPSULE		
CINNASIL	0.5MG	N84736
RESERPINE		
ELIXIR		
SERPASIL	0.2MG/4ML	N09115
INJECTABLE		

RESERPINE		
INJECTABLE		
SANDRIL	2.5MG/ML	N10012
SERPASIL	2.5MG/ML	N09434
TABLET		
HISERPIA	0.1MG	N09631
HISERPIA	0.25MG	N09631
RAU-SED	0.1MG	N09357
RAU-SED	0.25MG	N09357
RAU-SED	0.5MG	N09357
RAU-SED	1MG	N09357
RESERPINE	0.25MG	N80721
RESERPINE	0.1MG	N83058
RESERPINE	0.25MG	N83058
RESERPINE	0.1MG	N09663
RESERPINE	0.25MG	N09663
RESERPINE	0.1MG	N83145
RESERPINE	0.25MG	N83145
RESERPINE	0.1MG	N10441
RESERPINE	0.25MG	N10441
RESERPINE	0.5MG	N10441
RESERPINE	1MG	N10441
RESERPINE	0.1MG	N80457
RESERPINE	0.25MG	N80457
RESERPINE	1MG	N80457
RESERPINE	0.1MG	N09667
RESERPINE	0.25MG	N09667
RESERPINE	0.1MG	N09627
RESERPINE	0.25MG	N09627
RESERPINE	0.1MG	N11185
RESERPINE	0.25MG	N11185
RESERPINE	0.1MG	N80492
RESERPINE	0.25MG	N80492
RESERPINE	0.1MG	N80525
RESERPINE	0.25MG	N80525
RESERPINE	1MG	N84974
RESERPINE	0.25MG	N84663
RESERPINE	0.1MG	N80753
RESERPINE	0.25MG	N80753
RESERPINE	0.1MG	N86117
RESERPINE	0.25MG	N80582
RESERPINE	0.25MG	N85775
RESERPINE	1MG	N80582
RESERPINE	0.25MG	N80637
RESERPINE	0.1MG	N09859
RESERPINE	0.25MG	N09859
RESERPINE	0.25MG	N80446

RESERPINE		
TABLET		
RESERPINE	0.25MG	N85207
RESERPINE	0.1MG	N89020
RESERPINE	0.25MG	N89019
RESERPINE	0.1MG	N80679
RESERPINE	0.25MG	N80393
RESERPINE	0.25MG	N85401
RESERPINE	1MG	N80749
RESERPINE	0.1MG	N80975
RESERPINE	0.25MG	N80975
RESERPINE	1MG	N80975
RESERPINE	0.1MG	N80723
RESERPINE	0.25MG	N80723
RESERPINE	1MG	N80723
SANDRIL	0.1MG	N09376
SANDRIL	0.25MG	N09376
SERPANRAY	0.1MG	N09391
SERPANRAY	0.25MG	N09391
SERPANRAY	1MG	N09391
SERPASIL	0.1MG	N09115
SERPASIL	0.25MG	N09115
SERPASIL	1MG	N09115
SERPATE	0.1MG	N09453
SERPATE	0.25MG	N09453
SERPIVITE	0.25MG	N09645
RESERPINE; TRICHLORMETHIAZIDE		
TABLET		
NAQUIVAL	0.1MG;4MG	N12265
TRICHLORMETHIAZIDE W/ RESERPINE	0.1MG;4MG	N85248
RISPERIDONE		
TABLET		
RISPERDAL	5MG	N20272
RITODRINE HYDROCHLORIDE		
INJECTABLE		
RITODRINE HCL	10MG/ML	N71188
RITODRINE HCL	15MG/ML	N71189
RITODRINE HCL	10MG/ML	N70700
RITODRINE HCL	15MG/ML	N70701
YUTOPAR	10MG/ML	N18580
YUTOPAR	15MG/ML	N18580
TABLET		
YUTOPAR	10MG	N18555

FDA data supplied by DrugPatentWatch.com

RITONAVIR		
CAPSULE		
NORVIR	100MG	N20680
ROCURONIUM BROMIDE		
INJECTABLE		
ZEMURON	10MG/ML	N20214
ROSE BENGAL SODIUM, I-131		
INJECTABLE		
ROBENGATOPE	0.5mCi/VIAL	N16224
ROBENGATOPE	1mCi/VIAL	N16224
ROBENGATOPE	2mCi/VIAL	N16224
SODIUM ROSE BENGAL I 131	0.5mCi/ML	N17318
SAFFLOWER OIL		
INJECTABLE		
LIPOSYN 10%	10% (10GM/100ML)	N18203
LIPOSYN 20%	20% (20GM/100ML)	N18614
SARALASIN ACETATE		
INJECTABLE		
SARENIN	EQ 0.6MG BASE/ML	N18009
SECOBARBITAL SODIUM		
CAPSULE		
SECOBARBITAL SODIUM	100MG	N85477
SECOBARBITAL SODIUM	100MG	N85869
SECOBARBITAL SODIUM	100MG	N85903
SECOBARBITAL SODIUM	50MG	N85909
SECOBARBITAL SODIUM	100MG	N84762
SECOBARBITAL SODIUM	100MG	N85867
SECOBARBITAL SODIUM	100MG	N85898
SECOBARBITAL SODIUM	100MG	N86273
SECOBARBITAL SODIUM	100MG	N85798
SECOBARBITAL SODIUM	100MG	N86390
SODIUM SECOBARBITAL	100MG	N84422
SODIUM SECOBARBITAL	100MG	N84225
SODIUM SECOBARBITAL	100MG	N84676
SODIUM SECOBARBITAL	100MG	N85285
SODIUM SECOBARBITAL	100MG	N84561
SODIUM SECOBARBITAL	100MG	N85792
INJECTABLE		
SECONAL SODIUM	50MG/ML	N07392
SUPPOSITORY		
SECONAL SODIUM	120MG	N86530
SECONAL SODIUM	200MG	N86530
SECONAL SODIUM	30MG	N86530
SECONAL SODIUM	60MG	N86530

SECRETIN		
INJECTABLE		
SECRETIN-FERRING	75CU/VIAL	N18290
SELENIUM SULFIDE		
LOTION/SHAMPOO		
SELENIUM SULFIDE	2.5%	N85777
SELENIUM SULFIDE	2.5%	N86209
SELENOMETHIONINE, SE-75		
INJECTABLE		
SELENOMETHIONINE SE 75	250uCi/ML	N17257
SELENOMETHIONINE SE 75	500uCi/ML	N17322
SELENOMETHIONINE SE 75	100uCi/ML	N17098
SETHOTOPE	85-550uCi/ML	N17047
SERACTIDE ACETATE		
INJECTABLE		
ACTHAR GEL-SYNTHETIC	40 UNITS/ML	N17861
ACTHAR GEL-SYNTHETIC	80 UNITS/ML	N17861
SERTRALINE HYDROCHLORIDE		
TABLET		
ZOLOFT	EQ 150MG BASE	N19839
ZOLOFT	EQ 200MG BASE	N19839
SILVER SULFADIAZINE		
DRESSING		
SILDAFLO	1%	N19608
SIMETHICONE-CELLULOSE		
SUSPENSION		
SONORX	7.5MG/ML	N20773
SODIUM BENZOATE; SODIUM PHENYLACETATE		
SOLUTION		
UCEPHAN	100MG/ML;100MG/ML	N19530
SODIUM BICARBONATE		
INJECTABLE		
SODIUM BICARBONATE IN PLASTIC CONTAINER	0.9MEQ/ML	N19443
SODIUM BICARBONATE IN PLASTIC CONTAINER	1MEQ/ML	N19443
SODIUM CHLORIDE		
INJECTABLE		
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	9MG/ML	N88909
SODIUM CHLORIDE	20GM/100ML	N17013
SODIUM CHLORIDE	20GM/100ML	N17038
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18184
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18503
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	9MG/ML	N19218
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	900MG/100ML	N18502

SODIUM CHLORIDE		
INJECTABLE		
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER	234MG/ML	N19329
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER	3GM/100ML	N19635
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER	5GM/100ML	N19635
SOLUTION		
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18380
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18497
SODIUM CHLORIDE IN PLASTIC CONTAINER	900MG/100ML	N18247
SODIUM CHROMATE, CR-51		
INJECTABLE		
CHROMITOPE SODIUM	2mCi/VIAL	N13993
SODIUM FLUORIDE, F-18		
INJECTABLE		
FLUORINE F-18	2mCi/ML	N17042
SODIUM IODIDE, I-123		
CAPSULE		
SODIUM IODIDE I 123	400uCi	N18671
SODIUM IODIDE, I-131		
CAPSULE		
IODOTOPE	1-150mCi	N10929
SODIUM IODIDE I 131	100uCi	N17316
SODIUM IODIDE I 131	50uCi	N17316
SODIUM IODIDE I 131	0.8-100mCi	N16515
SOLUTION		
IODOTOPE	7-106mCi/BOT	N10929
SODIUM LACTATE		
INJECTABLE		
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER	1.87GM/100ML	N18186
SODIUM NITROPRUSSIDE		
INJECTABLE		
NIPRIDE	50MG/VIAL	N17546
NITROPRESS	50MG/VIAL	N18450
NITROPRESS	50MG/VIAL	N71555
SODIUM NITROPRUSSIDE	50MG/VIAL	N70031
SODIUM PHOSPHATE, P-32		
SOLUTION		
PHOSPHOTOPE	1-8mCi/VIAL	N10927
SODIUM PHOSPHATE P 32	1.5mCi/VIAL	N11777
SODIUM POLYSTYRENE SULFONATE		
POWDER		
SODIUM POLYSTYRENE SULFONATE	453.6GM/BOT	N88786
SUSPENSION		
SODIUM POLYSTYRENE SULFONATE		
SUSPENSION		
SODIUM POLYSTYRENE SULFONATE	15GM/60ML	N88717
SODIUM POLYSTYRENE SULFONATE	15GM/60ML	N88453
SODIUM SUCCINATE		
INJECTABLE		
SODIUM SUCCINATE	30%	N80516
SODIUM TETRADECYL SULFATE		
INJECTABLE		
SOTRADECOL	1%	* N05970
SOTRADECOL	3%	* N05970
SOMATROPIN		
INJECTABLE		
ASELLACRIN 10	10 IU/VIAL	N17726
ASELLACRIN 2	2 IU/VIAL	N17726
CRESCORMON	4 IU/VIAL	N17992
SOMATROPIN RECOMBINANT		
INJECTABLE		
HUMATROPE	2MG/VIAL	N19640
NORDITROPIN	4MG/VIAL	N19721
NORDITROPIN	8MG/VIAL	N19721
SORBITOL		
SOLUTION		
SORBITOL 3% IN PLASTIC CONTAINER	3GM/100ML	N18512
SOTALOL HYDROCHLORIDE		
TABLET		
BETAPACE	320MG	N19865
SOYBEAN OIL		
INJECTABLE		
TRAVAMULSION 10%	10%	N18660
TRAVAMULSION 20%	20%	N18758
SPECTINOMYCIN HYDROCHLORIDE		
INJECTABLE		
TROBICIN	EQ 4GM BASE/VIAL	N50347
SPIRAPRIL HYDROCHLORIDE		
TABLET		
RENORMAX	12MG	N20240
RENORMAX	24MG	N20240
RENORMAX	3MG	N20240
RENORMAX	6MG	N20240
SPIRONOLACTONE		
TABLET		
SPIRONOLACTONE	25MG	N87687
SPIRONOLACTONE	25MG	N87108

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE		
TABLET		
SPIRONOLACTONE	25MG	N87634
SPIRONOLACTONE	25MG	N87998
SPIRONOLACTONE	25MG	N88053
SPIRONOLACTONE	25MG	N87554
SPIRONOLACTONE	25MG	N87648
SPIRONOLACTONE	25MG	N87952
SPIRONOLACTONE	25MG	N86898
SPIRONOLACTONE	25MG	N87078
STAVUDINE		
CAPSULE		
ZERIT	5MG	N20412
STREPTOMYCIN SULFATE		
INJECTABLE		
STREPTOMYCIN SULFATE	EQ 500MG BASE/ML	N60684
STREPTOMYCIN SULFATE	EQ 1GM BASE/2ML	N60404
STREPTOMYCIN SULFATE	EQ 1GM BASE/VIAL	N60107
STREPTOMYCIN SULFATE	EQ 5GM BASE/VIAL	N60107
STREPTOMYCIN SULFATE	EQ 1GM BASE/VIAL	N60076
STREPTOMYCIN SULFATE	EQ 5GM BASE/VIAL	N60076
SUCCINYLCHOLINE CHLORIDE		
INJECTABLE		
ANECTINE	50MG/ML	N08453
QUELICIN PRESERVATIVE FREE	50MG/ML	N08845
SUCCINYLCHOLINE CHLORIDE	100MG/VIAL	N85400
SUCOSTRIN	100MG/ML	N08847
SUCOSTRIN	20MG/ML	N08847
SUFENTANIL CITRATE		
INJECTABLE		
SUFENTANIL CITRATE	EQ 0.05MG BASE/ML	N74406
SULCONAZOLE NITRATE		
SOLUTION		
EXELDERM	1%	N18738
SULFACETAMIDE SODIUM		
OINTMENT		
BLEPH-10	10%	N84015
SODIUM SULAMYD	10%	N05963
SULFAIR 10	10%	N88000
SOLUTION/DROPS		
OCUSULF-30	30%	N80660
SODIUM SULAMYD	10%	N05963
SODIUM SULAMYD	30%	N05963
SODIUM SULFACETAMIDE	10%	N83021
SODIUM SULFACETAMIDE	15%	N83021

SULFACETAMIDE SODIUM		
SOLUTION/DROPS		
SODIUM SULFACETAMIDE	30%	N83021
SODIUM SULFACETAMIDE	10%	N84143
SODIUM SULFACETAMIDE	10%	N84145
SODIUM SULFACETAMIDE	30%	N84146
SODIUM SULFACETAMIDE	30%	N84147
SULFACETAMIDE SODIUM	10%	N88947
SULFAIR 10	10%	N87949
SULFAIR FORTE	30%	N88385
SULFAIR-15	15%	N88186
SULTEN-10	10%	N87818
SULFADIAZINE		
TABLET		
SULFADIAZINE	300MG	N04125
SULFADIAZINE	500MG	N80088
SULFADIAZINE	500MG	N80081
SULFADIAZINE	500MG	N80084
SULFADIAZINE	500MG	N04054
SULFADIAZINE	500MG	N04122
SULFADIAZINE SODIUM		
INJECTABLE		
SULFADIAZINE SODIUM	250MG/ML	N04054
SULFADIAZINE; SULFAMERAZINE		
SUSPENSION		
SULFONAMIDES DUPLEX	250MG/5ML;250MG/5ML	N06317
SULFAMETER		
TABLET		
SULLA	500MG	N16000
SULFAMETHIZOLE		
TABLET		
MICROSUL	1GM	N86012
PROKLAR	500MG	N80273
THIOSULFIL	250MG	N08565
THIOSULFIL	500MG	N08565
SULFAMETHOXAZOLE		
SUSPENSION		
GANTANOL	500MG/5ML	N13664
TABLET		
GANTANOL	500MG	N12715
GANTANOL-DS	1GM	N12715
SULFAMETHOXAZOLE	500MG	N87662
SULFAMETHOXAZOLE	500MG	N87189
SULFAMETHOXAZOLE	500MG	N85844
SULFAMETHOXAZOLE	500MG	N86163

SULFAMETHOXAZOLE		
TABLET		
SULFAMETHOXAZOLE	1GM	N86000
SULFAMETHOXAZOLE	500MG	N85053
UROBAK	500MG	N87307
SULFAMETHOXAZOLE; TRIMETHOPRIM		
INJECTABLE		
SULFAMETHOPRIM	80MG/ML;16MG/ML	N71341
SULFAMETHOXAZOLE AND TRIMETHOPRIM	80MG/ML;16MG/ML	N70223
SULFAMETHOXAZOLE AND TRIMETHOPRIM	80MG/ML;16MG/ML	N72383
SULFAMETHOXAZOLE AND TRIMETHOPRIM	80MG/ML;16MG/ML	N71556
SUSPENSION		
BACTRIM	200MG/5ML;40MG/5ML	N17560
BACTRIM PEDIATRIC	200MG/5ML;40MG/5ML	N17560
SULMEPRIM	200MG/5ML;40MG/5ML	N70063
SULMEPRIM PEDIATRIC	200MG/5ML;40MG/5ML	N70064
TRIMETH/SULFA	200MG/5ML;40MG/5ML	N72289
TRIMETH/SULFA	200MG/5ML;40MG/5ML	N72398
TRIMETH/SULFA	200MG/5ML;40MG/5ML	N72399
TABLET		
SULFAMETHOXAZOLE & TRIMETHOPRIM	400MG;80MG	N18946
SULFAMETHOXAZOLE & TRIMETHOPRIM	800MG;160MG	N18946
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N18598
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N70006
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N71299
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N71300
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N72408
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N72768
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N18242
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N18242
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N70203
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N70204
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N70002
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N70000
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH	800MG;160MG	N70007
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH	800MG;160MG	N72417
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH	800MG;160MG	N72769
SULFATRIM-DS	800MG;160MG	N70066
SULFATRIM-SS	400MG;80MG	N70065
UROPLUS DS	800MG;160MG	N71816
UROPLUS SS	400MG;80MG	N71815
SULFAPHENAZOLE		
SUSPENSION		
SULFABID	500MG/5ML	N13093
SULFAPHENAZOLE		
TABLET		
SULFABID	500MG	N13092
SULFAPYRIDINE		
TABLET		
SULFAPYRIDINE	500MG	N00159
SULFASALAZINE		
SUSPENSION		
AZULFIDINE	250MG/5ML	N18605
TABLET		
S.A.S.-500	500MG	N83450
SULFASALAZINE	500MG	N86184
SULFASALAZINE	500MG	N80197
SULFASALAZINE	500MG	N89339
SULFASALAZINE	500MG	N84964
TABLET, DELAYED RELEASE		
SULFASALAZINE	500MG	N88052
SULFINPYRAZONE		
CAPSULE		
SULFINPYRAZONE	200MG	N88666
TABLET		
SULFINPYRAZONE	100MG	N87769
SULFINPYRAZONE	100MG	N87667
SULFISOXAZOLE		
TABLET		
GANTRISIN	500MG	N06525
SOXAZOLE	500MG	N80366
SULFALAR	500MG	N84955
SULFISOXAZOLE	500MG	N84031
SULFISOXAZOLE	500MG	N85628
SULFISOXAZOLE	500MG	N80189
SULFISOXAZOLE	500MG	N80109
SULFISOXAZOLE	500MG	N80085
SULFISOXAZOLE	500MG	N87649
SULFISOXAZOLE	500MG	N84385
SULFISOXAZOLE	500MG	N80087
SULFISOXAZOLE	500MG	N87332
SULFISOXAZOLE	500MG	N85534
SULFISOXAZOLE	500MG	N80379
SULSOXIN	500MG	N80040
SULFISOXAZOLE ACETYL		
EMULSION		
LIPO GANTRISIN	EQ 1GM BASE/5ML	N09182
SYRUP		

SULFISOXAZOLE ACETYL		
SYRUP		
GANTRISIN	EQ 500MG BASE/5ML	N09182
SULFISOXAZOLE DIOLAMINE		
INJECTABLE		
GANTRISIN	EQ 400MG BASE/ML	N06917
OINTMENT		
GANTRISIN	EQ 4% BASE	N08414
SOLUTION/DROPS		
GANTRISIN	EQ 4% BASE	N07757
SULFISOXAZOLE DIOLAMINE	EQ 4% BASE	N84148
SULFOXONE SODIUM		
TABLET, DELAYED RELEASE		
DIASONE SODIUM	165MG	N06044
SULFUR		
POWDER		
BENSULFOID	33.32%	N02918
SUPROFEN		
SOLUTION/DROPS		
PROFENAL	1%	N19387
SUTILAINS		
OINTMENT		
TRAVASE	82,000 UNITS/GM	*N12828
TALBUTAL		
TABLET		
LOTUSATE	120MG	N09410
TECHNETIUM TC-99M ALBUMIN AGGREGATED		
INJECTABLE		
TC 99M-LUNGAGGREGATE	5mCi/ML	N17848
TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT		
INJECTABLE		
A-N STANNOUS AGGREGATED ALBUMIN	N/A	N17916
AN-MAA	N/A	N17792
LUNGAGGREGATE REAGENT	N/A	N17838
TECHNETIUM TC 99M MAA	N/A	N17773
TECHNETIUM TC-99M ALBUMIN COLLOID KIT		
INJECTABLE		
MICROLITE	N/A	N18263
TECHNETIUM TC-99M ALBUMIN KIT		
INJECTABLE		
TECHNETIUM TC 99M HSA	N/A	N17775
TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT		
INJECTABLE		
INSTANT MICROSPHERES	N/A	N17832
TECHNETIUM TC-99M ETIDRONATE KIT		
INJECTABLE		
CINTICHEM TECHNETIUM 99M HEDSPA	N/A	N17653
MPI STANNOUS DIPHOSPHONATE	N/A	N17667
OSTEOSCAN	N/A	N17454
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT	N/A	N17562
TECHNETIUM TC-99M FERPENTETATE KIT		
INJECTABLE		
RENOTEC	N/A	N17045
TECHNETIUM TC-99M GLUCEPTATE KIT		
INJECTABLE		
GLUCOSCAN	N/A	N17907
TECHNETIUM TC-99M LIDOFENIN KIT		
INJECTABLE		
TECHNESCAN HIDA	N/A	N18489
TECHNETIUM TC-99M MEDRONATE KIT		
INJECTABLE		
AMERSCAN MDP KIT	N/A	N18335
TECHNETIUM TC-99M PENTETATE KIT		
INJECTABLE		
MPI DTPA KIT - CHELATE	N/A	N17255
TECHNETIUM TC-99M POLYPHOSPHATE KIT		
INJECTABLE		
SODIUM POLYPHOSPHATE-TIN KIT	N/A	N17664
TECHNETIUM TC-99M RED BLOOD CELL KIT		
INJECTABLE		
RBC-SCAN	N/A	N20063
TECHNETIUM TC-99M SODIUM PERTECHNETATE		
SOLUTION		
SODIUM PERTECHNETATE TC 99M	2-100mCi/ML	N17471
SODIUM PERTECHNETATE TC 99M	12mCi/ML	N17321
SODIUM PERTECHNETATE TC 99M	24mCi/ML	N17321
SODIUM PERTECHNETATE TC 99M	48mCi/ML	N17321
SODIUM PERTECHNETATE TC 99M	10-60mCi/ML	N17725
TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR		
SOLUTION		
MINITEC	0.22-2.22 CI/GENERATOR	N17339
TECHNETIUM TC 99M GENERATOR	830-16600mCi/GENERATOR	N17693

TECHNETIUM TC-99M SULFUR COLLOID		
SOLUTION		
TECHNETIUM TC 99M SULFUR COLLOID	4mCi/ML	N17456
TECHNETIUM TC 99M SULFUR COLLOID	3mCi/ML	N17724
TECHNETIUM TC-99M SULFUR COLLOID KIT		
SOLUTION		
TECHNETIUM TC 99M TSC	N/A	N17784
TESULOID	N/A	N16923
TEMAZEPAM		
CAPSULE		
TEMAZ	15MG	N70564
TEMAZ	30MG	N70547
TEMAZEPAM	15MG	N71708
TEMAZEPAM	30MG	N71709
TEMAZEPAM	15MG	N71174
TEMAZEPAM	30MG	N71175
TEMAZEPAM	15MG	N70489
TEMAZEPAM	30MG	N70490
TEMAZEPAM	15MG	N70383
TEMAZEPAM	30MG	N70384
TERBINAFINE		
GEL		
LAMISIL	1%	N20846
TERBUTALINE SULFATE		
AEROSOL, METERED		
BRETHAIRE	0.2MG/INH	N18762
BRICANYL	0.2MG/INH	N18000
INJECTABLE		
BRICANYL	1MG/ML	N17466
TABLET		
BRICANYL	2.5MG	N17618
BRICANYL	5MG	N17618
TERIPARATIDE ACETATE		
INJECTABLE		
PARATHAR	200 UNITS/VIAL	N19498
TESTOLACTONE		
INJECTABLE		
TESLAC	100MG/ML	N16119
TABLET		
TESLAC	250MG	N16118
TESTOSTERONE		
INJECTABLE		
TESTOSTERONE	25MG/ML	N86420
TESTOSTERONE	50MG/ML	N86419

TESTOSTERONE CYPIONATE		
INJECTABLE		
DEPO-TESTOSTERONE	50MG/ML	N85635
TESTOSTERONE CYPIONATE	100MG/ML	N89326
TESTOSTERONE CYPIONATE	200MG/ML	N89327
TESTOSTERONE CYPIONATE	100MG/ML	N84401
TESTOSTERONE CYPIONATE	200MG/ML	N84401
TESTOSTERONE ENANTHATE		
INJECTABLE		
DELATESTRYL	200MG/ML	N09165
TESTOSTERONE ENANTHATE	100MG/ML	N89324
TESTOSTERONE ENANTHATE	200MG/ML	N89325
TESTOSTERONE ENANTHATE	100MG/ML	N83667
TESTOSTERONE ENANTHATE	100MG/ML	N85599
TESTOSTERONE ENANTHATE	200MG/ML	N83667
TESTOSTERONE PROPIONATE		
INJECTABLE		
TESTOSTERONE PROPIONATE	100MG/ML	N80743
TESTOSTERONE PROPIONATE	25MG/ML	N80741
TESTOSTERONE PROPIONATE	50MG/ML	N80742
TESTOSTERONE PROPIONATE	25MG/ML	N80276
TESTOSTERONE PROPIONATE	50MG/ML	N80254
TESTOSTERONE PROPIONATE	100MG/ML	N89283
TESTOSTERONE PROPIONATE	100MG/ML	N83595
TESTOSTERONE PROPIONATE	25MG/ML	N85490
TESTOSTERONE PROPIONATE	50MG/ML	N85490
TETRACYCLINE HYDROCHLORIDE		
CAPSULE		
CYCLOPAR	250MG	N61725
CYCLOPAR	250MG	N62175
CYCLOPAR	250MG	N62332
CYCLOPAR	500MG	N61725
CYCLOPAR	500MG	N62332
PANMYCIN	250MG	N60347
RETET	250MG	N61443
RETET	500MG	N61443
ROBITET	250MG	N61734
ROBITET	500MG	N61734
SUMYCIN	100MG	N60429
SUMYCIN	125MG	N60429
TETRACHEL	250MG	N60343
TETRACHEL	500MG	N60343
TETRACYCLINE HCL	250MG	N61802
TETRACYCLINE HCL	500MG	N61802
TETRACYCLINE HCL	250MG	N60059
TETRACYCLINE HCL	250MG	N61471

TETRACYCLINE HYDROCHLORIDE		
CAPSULE		
TETRACYCLINE HCL	125MG	N60173
TETRACYCLINE HCL	250MG	N60173
TETRACYCLINE HCL	250MG	N61148
TETRACYCLINE HCL	500MG	N61148
TETRACYCLINE HCL	250MG	N60471
TETRACYCLINE HCL	500MG	N60471
TETRACYCLINE HCL	250MG	N60290
TETRACYCLINE HCL	500MG	N60290
TETRACYCLINE HCL	250MG	N62686
TETRACYCLINE HCL	500MG	N62686
TETRACYCLINE HCL	250MG	N62540
TETRACYCLINE HCL	500MG	N62540
TETRACYCLINE HCL	250MG	N62300
TETRACYCLINE HCL	500MG	N62300
TETRACYCLINE HCL	250MG	N62103
TETRACYCLINE HCL	250MG	N62343
TETRACYCLINE HCL	500MG	N62103
TETRACYCLINE HCL	500MG	N62343
TETRACYCLINE HCL	250MG	N60768
TETRACYCLINE HCL	500MG	N60768
TETRACYCLINE HCL	250MG	N61685
TETRACYCLINE HCL	500MG	N61685
TETRACYN	250MG	N60082
TETRACYN	500MG	N60082
FOR SOLUTION		
TOPICYCLINE	2.2MG/ML	N50493
INJECTABLE		
ACHROMYCIN	250MG/VIAL	N50273
ACHROMYCIN	500MG/VIAL	N50273
TETRACYN	250MG/VIAL	N60096
TETRACYN	500MG/VIAL	N60096
OINTMENT		
ACHROMYCIN	10MG/GM	N50266
SUSPENSION		
ACHROMYCIN V	125MG/5ML	N50263
TETRACYCLINE HCL	125MG/5ML	N60633
TETRACYCLINE HCL	125MG/5ML	N60174
TETRACYCLINE HCL	125MG/5ML	N60446
TETRACYCLINE HCL	125MG/5ML	N60291
TETRACYN	125MG/5ML	N60095
TETRAMED	125MG/5ML	N61468
SUSPENSION/DROPS		
ACHROMYCIN	1%	N50268
TABLET		
PANMYCIN	250MG	N61705

TETRACYCLINE HYDROCHLORIDE		
TABLET		
PANMYCIN	500MG	N61705
SUMYCIN	100MG	N61147
SUMYCIN	50MG	N61147
TETRACYCLINE PHOSPHATE COMPLEX		
CAPSULE		
TETREX	EQ 250MG HCL	N50212
TETREX	EQ 500MG HCL	N50212
THALLOUS CHLORIDE, TL-201		
INJECTABLE		
THALLOUS CHLORIDE TL 201	1mCi/ML	N18548
THEOPHYLLINE		
CAPSULE		
BRONKODYL	100MG	N85264
BRONKODYL	200MG	N85264
ELIXOPHYLLIN	100MG	N85545
ELIXOPHYLLIN	200MG	N83921
SOMOPHYLLIN-T	100MG	N87155
SOMOPHYLLIN-T	200MG	N87155
SOMOPHYLLIN-T	250MG	N87155
THEOPHYLLINE	100MG	N85263
THEOPHYLLINE	200MG	N85263
THEOPHYLLINE	100MG	N84731
THEOPHYLLINE	200MG	N84731
THEOPHYLLINE	250MG	N84731
CAPSULE, EXTENDED RELEASE		
ELIXOPHYLLIN SR	125MG	N86826
ELIXOPHYLLIN SR	250MG	N86826
SLO-PHYLLIN	125MG	N85203
SLO-PHYLLIN	250MG	N85205
SLO-PHYLLIN	60MG	N85206
SOMOPHYLLIN-CRT	100MG	N87194
SOMOPHYLLIN-CRT	200MG	N88382
SOMOPHYLLIN-CRT	250MG	N87193
SOMOPHYLLIN-CRT	300MG	N88383
SOMOPHYLLIN-CRT	50MG	N87763
THEO-DUR	125MG	N88016
THEO-DUR	200MG	N87995
THEO-DUR	50MG	N88022
THEO-DUR	75MG	N88015
THEOBID	260MG	N85983
THEOBID JR.	130MG	N87854
THEOCLEAR L.A.-130	130MG	N86569
THEOCLEAR L.A.-260	260MG	N86569

THEOPHYLLINE		
CAPSULE, EXTENDED RELEASE		
THEOPHYL-SR	125MG	N86480
THEOPHYL-SR	250MG	N86471
THEOPHYLLINE	125MG	N88654
THEOPHYLLINE	250MG	N88689
THEOPHYLLINE	260MG	N87462
THEOPHYLLINE	100MG	N89976
THEOPHYLLINE	200MG	N89977
THEOPHYLLINE	300MG	N89932
THEOPHYLLINE-SR	300MG	N88255
THEOVENT	125MG	N87010
THEOVENT	250MG	N87910
ELIXIR		
ELIXOMIN	80MG/15ML	N88303
LANOPHYLLIN	80MG/15ML	N84578
THEOLIXIR	80MG/15ML	N84559
THEOPHYL-225	112.5MG/15ML	N86485
THEOPHYLLINE	80MG/15ML	N89223
THEOPHYLLINE	80MG/15ML	N87679
THEOPHYLLINE	80MG/15ML	N85169
THEOPHYLLINE	80MG/15ML	N85952
THEOPHYLLINE	80MG/15ML	N84739
INJECTABLE		
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER	40MG/100ML	N19083
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER	80MG/100ML	N19083
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER	160MG/100ML	N19083
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N19212
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N19826
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N19212
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N19826
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	4MG/ML	N19212
SUSPENSION		
ELIXICON	100MG/5ML	N85502
SYRUP		
ACCURBRON	150MG/15ML	N88746
AQUAPHYLLIN	80MG/15ML	N87917
THEOCLEAR-80	80MG/15ML	N87095
THEOPHYLLINE	150MG/15ML	N86545
THEOPHYLLINE	80MG/15ML	N86001
THEOPHYLLINE		
TABLET		
THEOCLEAR-100	100MG	N85353
THEOCLEAR-200	200MG	N85353
THEOPHYL-225	225MG	N84726
TABLET, CHEWABLE		
THEOPHYL	100MG	N86506
TABLET, EXTENDED RELEASE		
DURAPHYL	100MG	N88503
DURAPHYL	200MG	N88504
DURAPHYL	300MG	N88505
LABID	250MG	N87225
SUSTAIRE	100MG	N85665
SUSTAIRE	300MG	N85665
THEOPHYLLINE SODIUM GLYCINATE		
ELIXIR		
SYNOPHYLATE	EQ 165MG BASE/15ML	N06333
TABLET		
ASBRON	EQ 150MG BASE	N85148
THIAMINE HYDROCHLORIDE		
INJECTABLE		
BETALIN S	100MG/ML	N80853
THIAMINE HCL	100MG/ML	N87968
THIAMINE HCL	100MG/ML	N80509
THIAMINE HCL	100MG/ML	N80718
THIAMINE HCL	200MG/ML	N80712
THIAMINE HCL	100MG/ML	N83775
THIAMINE HCL	100MG/ML	N80667
THIAMINE HCL	100MG/ML	N80770
THIAMINE HCL	100MG/ML	N83534
THIAMINE HCL	200MG/ML	N83534
THIAMYLAL SODIUM		
INJECTABLE		
SURITAL	10GM/VIAL	N07600
SURITAL	1GM/VIAL	N07600
SURITAL	5GM/VIAL	N07600
THIETHYLPERAZINE MALATE		
INJECTABLE		
TORECAN	5MG/ML	N12754
THIOPENTAL SODIUM		
SUSPENSION		
PENTOTHAL	400MG/GM	N11679

THIORIDAZINE		
SUSPENSION		
MELLARIL-S	EQ 100MG HCL/5ML	N17923
MELLARIL-S	EQ 25MG HCL/5ML	N17923
THIORIDAZINE HYDROCHLORIDE		
CONCENTRATE		
MELLARIL	100MG/ML	N11808
MELLARIL	30MG/ML	N11808
THIORIDAZINE HCL	30MG/ML	N87766
THIORIDAZINE HCL	100MG/ML	N88308
THIORIDAZINE HCL	30MG/ML	N88307
THIORIDAZINE HCL	100MG/ML	N88227
THIORIDAZINE HCL	30MG/ML	N88258
TABLET		
MELLARIL	100MG	N11808
MELLARIL	10MG	N11808
MELLARIL	150MG	N11808
MELLARIL	15MG	N11808
MELLARIL	200MG	N11808
MELLARIL	25MG	N11808
MELLARIL	50MG	N11808
THIORIDAZINE HCL	100MG	N88379
THIORIDAZINE HCL	10MG	N88375
THIORIDAZINE HCL	150MG	N88737
THIORIDAZINE HCL	15MG	N88461
THIORIDAZINE HCL	200MG	N88738
THIORIDAZINE HCL	25MG	N87264
THIORIDAZINE HCL	100MG	N88273
THIORIDAZINE HCL	50MG	N88194
THIORIDAZINE HCL	100MG	N88335
THIORIDAZINE HCL	10MG	N88332
THIORIDAZINE HCL	25MG	N88333
THIORIDAZINE HCL	50MG	N88334
THIORIDAZINE HCL	100MG	N88480
THIORIDAZINE HCL	10MG	N88351
THIORIDAZINE HCL	150MG	N89764
THIORIDAZINE HCL	15MG	N88352
THIORIDAZINE HCL	200MG	N89765
THIORIDAZINE HCL	25MG	N88336
THIORIDAZINE HCL	50MG	N88322
THIORIDAZINE HCL	100MG	N89048
THIORIDAZINE HCL	10MG	N88663
THIORIDAZINE HCL	25MG	N88664
THIORIDAZINE HCL	50MG	N88665
THIORIDAZINE HCL	10MG	N89103
THIORIDAZINE HCL	25MG	N89104

THIORIDAZINE HYDROCHLORIDE		
TABLET		
THIORIDAZINE HCL	50MG	N89105
THIORIDAZINE HCL	10MG	N88493
THIORIDAZINE HCL	100MG	N88284
THIORIDAZINE HCL	10MG	N88412
THIORIDAZINE HCL	150MG	N88410
THIORIDAZINE HCL	15MG	N88345
THIORIDAZINE HCL	200MG	N88381
THIORIDAZINE HCL	25MG	N88296
THIORIDAZINE HCL	50MG	N88323
THIORIDAZINE HCL	10MG	N88561
THIORIDAZINE HCL	15MG	N88562
THIORIDAZINE HCL	25MG	N88755
THIORIDAZINE HCL	10MG	N88658
THIORIDAZINE HCL	15MG	N88659
THIORIDAZINE HCL	25MG	N88660
THIORIDAZINE HCL	50MG	N88661
THIOTEPA		
INJECTABLE		
THIOTEPA	15MG/VIAL	N11683
THIOTHIXENE		
CAPSULE		
THIOTHIXENE	10MG	N71887
THIOTHIXENE	1MG	N71884
THIOTHIXENE	20MG	N72200
THIOTHIXENE	2MG	N71885
THIOTHIXENE	5MG	N71886
THIOTHIXENE	10MG	N71628
THIOTHIXENE	2MG	N71626
THIOTHIXENE	5MG	N71627
THIOTHIXENE HYDROCHLORIDE		
CONCENTRATE		
THIOTHIXENE HCL	EQ 5MG BASE/ML	N70969
THIOTHIXENE HCL	EQ 1MG BASE/ML	N71917
THIOTHIXENE HCL	EQ 5MG BASE/ML	N71939
THIOTHIXENE HCL	EQ 5MG BASE/ML	N71184
THIOTHIXENE HCL INTENSOL	EQ 5MG BASE/ML	N73494
INJECTABLE		
NAVANE	EQ 2MG BASE/ML	N16904
THYROGLOBULIN		
TABLET		
PROLOID	100MG	N02245
PROLOID	130MG	N02245
PROLOID	16MG	N02245

THYROGLOBULIN		
TABLET		
PROLOID	200MG	N02245
PROLOID	325MG	N02245
PROLOID	32MG	N02245
PROLOID	65MG	N02245
THYROGLOBULIN	64.8MG	N80151
THYROTROPIN		
INJECTABLE		
THYTROPAR	10 IU/VIAL	N08682
TIAGABINE HYDROCHLORIDE		
TABLET		
GABITRIL	20MG	N20646
TICARCILLIN DISODIUM		
INJECTABLE		
TICAR	EQ 3GM BASE/VIAL	N62690
TICAR	EQ 6GM BASE/VIAL	N50497
TICLOPIDINE HYDROCHLORIDE		
TABLET		
TICLID	125MG	N19979
TIMOLOL MALEATE		
SOLUTION/DROPS		
TIMOLOL MALEATE	EQ 0.25% BASE	N74261
TIMOLOL MALEATE	EQ 0.5% BASE	N74262
TABLET		
TIMOLOL MALEATE	10MG	N72467
TIMOLOL MALEATE	20MG	N72468
TIMOLOL MALEATE	5MG	N72466
TIMOLOL MALEATE	10MG	N72649
TIMOLOL MALEATE	20MG	N72650
TIMOLOL MALEATE	5MG	N72648
TIMOLOL MALEATE	10MG	N72002
TIMOLOL MALEATE	20MG	N72003
TIMOLOL MALEATE	5MG	N72001
TIMOLOL MALEATE	10MG	N72270
TIMOLOL MALEATE	20MG	N72271
TIMOLOL MALEATE	5MG	N72269
TIOCONAZOLE		
CREAM		
TZ-3	1%	N18682
TOBRAMYCIN		
SOLUTION/DROPS		
TOBRAMYCIN	0.3%	N63176

TOBRAMYCIN SULFATE		
INJECTABLE		
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N64026
TOBRAMYCIN SULFATE	EQ 10MG BASE/ML	N63119
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63120
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63121
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63122
TOBRAMYCIN SULFATE	EQ 10MG BASE/ML	N63128
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63127
TOBRAMYCIN SULFATE	EQ 10MG BASE/ML	N63113
TOLAZAMIDE		
TABLET		
TOLAZAMIDE	100MG	N70162
TOLAZAMIDE	250MG	N70163
TOLAZAMIDE	500MG	N70164
TOLAZAMIDE	100MG	N70165
TOLAZAMIDE	250MG	N70166
TOLAZAMIDE	500MG	N70167
TOLAZAMIDE	250MG	N71270
TOLAZAMIDE	500MG	N71271
TOLAZAMIDE	250MG	N70763
TOLAZAMIDE	500MG	N70764
TOLAZAMIDE	100MG	N71355
TOLAZAMIDE	250MG	N70168
TOLAZAMIDE	500MG	N70169
TOLAZAMIDE	100MG	N70242
TOLAZAMIDE	250MG	N70243
TOLAZAMIDE	500MG	N70244
TOLAZOLINE HYDROCHLORIDE		
INJECTABLE		
PRISCOLINE	25MG/ML	N06403
TOLBUTAMIDE		
TABLET		
ORINASE	250MG	N10670
ORINASE	500MG	N10670
TOLBUTAMIDE	500MG	N86141
TOLBUTAMIDE	500MG	N87541
TOLBUTAMIDE	500MG	N87121
TOLBUTAMIDE	500MG	N12678
TOLBUTAMIDE	500MG	N86047
TOLBUTAMIDE	500MG	N88950
TOLBUTAMIDE	500MG	N88893
TOLBUTAMIDE	500MG	N87876
TOLBUTAMIDE	250MG	N89110
TOLBUTAMIDE	500MG	N89111

TOLMETIN SODIUM		
CAPSULE		
TOLMETIN SODIUM	EQ 400MG BASE	N73462
TABLET		
TOLMETIN SODIUM	EQ 600MG BASE	N74729
TOPIRAMATE		
CAPSULE		
TOPAMAX SPRINKLE	50MG	N20844
TABLET		
TOPAMAX	300MG	N20505
TOPAMAX	400MG	N20505
TOPAMAX	50MG	N20505
TRAMADOL HYDROCHLORIDE		
TABLET		
ULTRAM	100MG	N20281
TRANEXAMIC ACID		
TABLET		
CYKLOKAPRON	500MG	N19280
TRAZODONE HYDROCHLORIDE		
TABLET		
TRAZODONE HCL	100MG	N71140
TRAZODONE HCL	50MG	N71139
TRAZODONE HCL	100MG	N70921
TRAZODONE HCL	100MG	N70492
TRAZODONE HCL	50MG	N70491
TRAZODONE HCL	100MG	N71113
TRAZODONE HCL	50MG	N71112
TRIALODINE	50MG	N70942
TRETINOIN		
SWAB		
RETIN-A	0.05%	N16921
TRIAMCINOLONE		
TABLET		
ARISTOCORT	16MG	N11161
ARISTOCORT	1MG	N11161
ARISTOCORT	2MG	N11161
ARISTOCORT	8MG	N11161
KENACORT	1MG	N11283
KENACORT	2MG	N11283
TRIAMCINOLONE	2MG	N84286
TRIAMCINOLONE	2MG	N84318
TRIAMCINOLONE	4MG	N84267
TRIAMCINOLONE	4MG	N84319
TRIAMCINOLONE	8MG	N84268
TRIAMCINOLONE	8MG	N84320
TRIAMCINOLONE		
TABLET		
TRIAMCINOLONE	4MG	N85601
TRIAMCINOLONE	4MG	N84340
TRIAMCINOLONE	4MG	N83750
TRIAMCINOLONE	2MG	N84406
TRIAMCINOLONE	2MG	N84020
TRIAMCINOLONE	4MG	N84020
TRIAMCINOLONE	2MG	N84708
TRIAMCINOLONE	4MG	N84709
TRIAMCINOLONE	8MG	N84707
TRIAMCINOLONE	4MG	N84775
TRIAMCINOLONE	4MG	N85834
TRIAMCINOLONE ACETONIDE		
CREAM		
FLUTEX	0.025%	N85539
FLUTEX	0.1%	N85539
FLUTEX	0.5%	N85539
KENALOG-H	0.1%	N86240
TRIACORT	0.1%	N87113
TRIAMCINOLONE ACETONIDE	0.025%	N87797
TRIAMCINOLONE ACETONIDE	0.025%	N88094
TRIAMCINOLONE ACETONIDE	0.1%	N88095
TRIAMCINOLONE ACETONIDE	0.5%	N88096
TRIAMCINOLONE ACETONIDE	0.025%	N87990
TRIAMCINOLONE ACETONIDE	0.1%	N87991
TRIAMCINOLONE ACETONIDE	0.5%	N87992
TRIAMCINOLONE ACETONIDE	0.025%	N87921
TRIAMCINOLONE ACETONIDE	0.1%	N87912
TRIAMCINOLONE ACETONIDE	0.5%	N87922
TRIAMCINOLONE ACETONIDE	0.025%	N40038
TRIAMCINOLONE ACETONIDE	0.025%	N89274
TRIAMCINOLONE ACETONIDE	0.1%	N89275
TRIAMCINOLONE ACETONIDE	0.5%	N89276
TRIATEX	0.025%	N87430
TRIATEX	0.1%	N87429
TRIATEX	0.5%	N87428
TRYMEX	0.5%	N88198
GEL		
ARISTOGEL	0.1%	N83380
INJECTABLE		
TRIAMCINOLONE ACETONIDE	3MG/ML	N19503
TRIAMCINOLONE ACETONIDE	40MG/ML	N85825
LOTION		
KENALOG	0.025%	N11602
KENALOG	0.1%	N11602

TRIAMCINOLONE ACETONIDE		
LOTION		
TRIAMCINOLONE ACETONIDE	0.025%	N87191
TRIAMCINOLONE ACETONIDE	0.1%	N87192
OINTMENT		
ARISTOCORT	0.5%	N80745
ARISTOCORT A	0.5%	N80745
ARISTOCORT A	0.5%	N88781
FLUTEX	0.025%	N87375
FLUTEX	0.1%	N87377
FLUTEX	0.5%	N87376
KENALOG	0.5%	N83944
TRIAMCINOLONE ACETONIDE	0.5%	N89913
TRIAMCINOLONE ACETONIDE	0.025%	N89795
TRIAMCINOLONE ACETONIDE	0.1%	N89796
TRIAMCINOLONE ACETONIDE	0.025%	N88090
TRIAMCINOLONE ACETONIDE	0.1%	N88091
TRIAMCINOLONE ACETONIDE	0.5%	N88092
TRIAMCINOLONE ACETONIDE	0.025%	N88692
TRIAMCINOLONE ACETONIDE	0.1%	N88690
SPRAY, METERED		
TRI-NASAL	0.05MG/SPRAY	N20120
TRIAMCINOLONE DIACETATE		
INJECTABLE		
TRIAMCINOLONE DIACETATE	25MG/ML	N85122
TRIAMCINOLONE DIACETATE	40MG/ML	N86394
TRIAMCINOLONE DIACETATE	40MG/ML	N84072
TRIAMCINOLONE DIACETATE	40MG/ML	N85529
SYRUP		
ARISTOCORT	2MG/5ML	N11960
KENACORT	EQ 4MG BASE/5ML	N12515
TRIAZOLAM		
TABLET		
HALCION	0.5MG	N17892
TRICHLORMETHIAZIDE		
TABLET		
NAQUA	2MG	N12265
TRICHLOREX	4MG	N83436
TRICHLOREX	4MG	N85630
TRICHLORMAS	4MG	N86259
TRICHLORMETHIAZIDE	4MG	N86171
TRICHLORMETHIAZIDE	4MG	N83967
TRICHLORMETHIAZIDE	4MG	N83462
TRICHLORMETHIAZIDE	2MG	N83847
TRICHLORMETHIAZIDE	2MG	N86458
TRICHLORMETHIAZIDE	4MG	N83855

TRICHLORMETHIAZIDE		
TABLET		
TRICHLORMETHIAZIDE	4MG	N85962
TRICLOFOS SODIUM		
SOLUTION		
TRICLOS	1.5GM/15ML	N16830
TABLET		
TRICLOS	750MG	N16809
TRIDIHEXETHYL CHLORIDE		
INJECTABLE		
PATHILON	10MG/ML	N09729
TABLET		
PATHILON	25MG	N09489
TRIFLUOPERAZINE HYDROCHLORIDE		
CONCENTRATE		
TRIFLUOPERAZINE HCL	EQ 10MG BASE/ML	N85787
TRIFLUOPERAZINE HCL	EQ 10MG BASE/ML	N88143
INJECTABLE		
TRIFLUOPERAZINE HCL	EQ 2MG BASE/ML	N89893
TABLET		
TRIFLUOPERAZINE HCL	EQ 10MG BASE	N88970
TRIFLUOPERAZINE HCL	EQ 1MG BASE	N88967
TRIFLUOPERAZINE HCL	EQ 2MG BASE	N88968
TRIFLUOPERAZINE HCL	EQ 5MG BASE	N88969
TRIFLUOPERAZINE HCL	EQ 10MG BASE	N87614
TRIFLUOPERAZINE HCL	EQ 1MG BASE	N87612
TRIFLUOPERAZINE HCL	EQ 2MG BASE	N87613
TRIFLUOPERAZINE HCL	EQ 5MG BASE	N87328
TRIFLUOPERAZINE HCL	EQ 10MG BASE	N88710
TRIFLUOPERAZINE HCL	EQ 1MG BASE	N85975
TRIFLUOPERAZINE HCL	EQ 2MG BASE	N85976
TRIFLUOPERAZINE HCL	EQ 5MG BASE	N85973
TRIFLUPROMAZINE		
SUSPENSION		
VESPRIN	EQ 50MG HCL/5ML	N11491
TRIFLUPROMAZINE HYDROCHLORIDE		
INJECTABLE		
VESPRIN	10MG/ML	N11325
VESPRIN	20MG/ML	N11325
VESPRIN	3MG/ML	N11325
TABLET		
VESPRIN	10MG	N11123
VESPRIN	25MG	N11123
VESPRIN	50MG	N11123

TRIHEXYPHENIDYL HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
ARTANE	5MG	N06773
ARTANE	5MG	N12947
TABLET		
TREMIN	2MG	N80381
TREMIN	5MG	N80381
TRIHEXYPHENIDYL HCL	2MG	N88035
TRIHEXYPHENIDYL HCL	2MG	N85117
TRIHEXYPHENIDYL HCL	5MG	N85105
TRILOSTANE		
CAPSULE		
MODRASTANE	30MG	N18719
MODRASTANE	60MG	N18719
TRIMEPRAZINE TARTRATE		
CAPSULE, EXTENDED RELEASE		
TEMARIL	EQ 5MG BASE	N11316
SYRUP		
TEMARIL	EQ 2.5MG BASE/5ML	N11316
TRIMEPRAZINE TARTRATE	EQ 2.5MG BASE/5ML	N85015
TRIMEPRAZINE TARTRATE	EQ 2.5MG BASE/5ML	N88285
TABLET		
TEMARIL	EQ 2.5MG BASE	N11316
TRIMETHADIONE		
CAPSULE		
TRIDIONE	300MG	N05856
SOLUTION		
TRIDIONE	200MG/5ML	N05856
TRIMETHAPHAN CAMSYLATE		
INJECTABLE		
ARFONAD	50MG/ML	N08983
TRIMETHOBENZAMIDE HYDROCHLORIDE		
INJECTABLE		
TRIMETHOBENZAMIDE HCL	100MG/ML	N88960
TRIMETHOBENZAMIDE HCL	100MG/ML	N89043
TRIMETHOBENZAMIDE HCL	100MG/ML	N89094
TRIMETHOBENZAMIDE HCL	100MG/ML	N86577
TRIMETHOBENZAMIDE HCL	100MG/ML	N87939
TRIMETHOPRIM		
TABLET		
TRIMETHOPRIM	100MG	N70494
TRIMETHOPRIM	200MG	N70495
TRIMPEX	100MG	N17952
TRIMETHOPRIM		
TABLET		
TRIMPEX 200	200MG	N17952
TRIMETHOPRIM HYDROCHLORIDE		
SOLUTION		
PRIMSOL	EQ 25MG BASE/5ML	N74374
TRIMIPRAMINE MALEATE		
CAPSULE		
TRIMIPRAMINE MALEATE	EQ 100MG BASE	N71285
TRIMIPRAMINE MALEATE	EQ 25MG BASE	N71283
TRIMIPRAMINE MALEATE	EQ 50MG BASE	N71284
TRIOXSALEN		
TABLET		
TRISORALEN	5MG	N12697
TRIPELENNAMINE CITRATE		
ELIXIR		
PBZ	EQ 25MG HCL/5ML	N05914
TRIPELENNAMINE HYDROCHLORIDE		
TABLET		
TRIPELENNAMINE HCL	50MG	N83037
TRIPELENNAMINE HCL	50MG	N80744
TRIPELENNAMINE HCL	50MG	N83989
TRIPELENNAMINE HCL	50MG	N80785
TRIPELENNAMINE HCL	25MG	N83625
TRIPELENNAMINE HCL	50MG	N83626
TRIPELENNAMINE HCL	50MG	N80790
TRIPELENNAMINE HCL	50MG	N85188
TABLET, EXTENDED RELEASE		
PBZ-SR	100MG	N10533
PBZ-SR	50MG	N10533
TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)		
CREAM		
TRIPLE SULFA	3.7%;2.86%;3.42%	N86424
VAGILIA	3.7%;2.86%;3.42%	N88821
TABLET		
SULTRIN	184MG;143.75MG;172.5MG	N05794
TRIPLE SULFA	184MG;143.75MG;172.5MG	N88463
TRIPLE SULFA	184MG;143.75MG;172.5MG	N88462
TRIPROLIDINE HYDROCHLORIDE		
SYRUP		
ACTIDIL	1.25MG/5ML	N11496
MYIDYL	1.25MG/5ML	N87963
TRIPROLIDINE HCL	1.25MG/5ML	N85940
TRIPROLIDINE HCL	1.25MG/5ML	N88735

TRIPROLIDINE HYDROCHLORIDE		
SYRUP		
TRIPROLIDINE HCL	1.25MG/5ML	N87514
TABLET		
ACTIDIL	2.5MG	N11110
TRIPROLIDINE HCL	2.5MG	N85610
TRIPROLIDINE HCL	2.5MG	N85094
TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)		
SUSPENSION		
LANTRISUL	167MG/5ML;167MG/5ML;167MG/5ML	N80123
NEOTRIZINE	167MG/5ML;167MG/5ML;167MG/5ML	N06317
SULFALOID	167MG/5ML;167MG/5ML;167MG/5ML	N80100
SULFOSE	167MG/5ML;167MG/5ML;167MG/5ML	N80013
TERFONYL	167MG/5ML;167MG/5ML;167MG/5ML	N06904
TRIPLE SULFA	167MG/5ML;167MG/5ML;167MG/5ML	N80280
TRIPLE SULFAS	167MG/5ML;167MG/5ML;167MG/5ML	N06920
TABLET		
NEOTRIZINE	167MG;167MG;167MG	N06317
SULFA-TRIPLE #2	167MG;167MG;167MG	N80079
SULFALOID	167MG;167MG;167MG	N80099
SULFOSE	167MG;167MG;167MG	N80013
TERFONYL	167MG;167MG;167MG	N06904
TRIPLE SULFA	167MG;167MG;167MG	N80086
TRIPLE SULFAS	167MG;167MG;167MG	N06920
TROGLITAZONE		
TABLET		
PRELAY	200MG	N20719
PRELAY	300MG	N20719
PRELAY	400MG	N20719
REZULIN	200MG	N20720
REZULIN	300MG	N20720
REZULIN	400MG	N20720
TROLEANDOMYCIN		
SUSPENSION		
TAO	EQ 125MG BASE/5ML	N50332
TROPICAMIDE		
SOLUTION/DROPS		
MYDRIACYL	0.5%	N12111
MYDRIACYL	1%	N12111
MYDRIAFAIR	0.5%	N88274
TROPICAMIDE		
SOLUTION/DROPS		
MYDRIAFAIR	1%	N88230
TROPICAMIDE	1%	N88447
TROPICAMIDE	0.5%	N89171
TUBOCURARINE CHLORIDE		
INJECTABLE		
TUBOCURARINE CHLORIDE	3MG/ML	N06325
TUBOCURARINE CHLORIDE	3MG/ML	N89442
TYROPANOATE SODIUM		
CAPSULE		
BILOPAQUE	750MG	N13731
UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX		
SOLUTION		
VIRAC REX	0.5%;1.8%	N11914
URACIL MUSTARD		
CAPSULE		
URACIL MUSTARD	1MG	N12892
UREA		
INJECTABLE		
STERILE UREA	40GM/VIAL	N17698
UREA, C-13		
FOR SOLUTION		
MERETEK UBT KIT (W/ PRANACTIN)	125MG/VIAL	N20586
PYLORI-CHEK BREATH TEST	100MG/VIAL	N20900
UROFOLLITROPIN		
INJECTABLE		
FERTINEX	150 IU/AMP	N19415
METRODIN	150 IU/AMP	N19415
METRODIN	75 IU/AMP	N19415
URSODIOL		
CAPSULE		
ACTIGALL	150MG	N19594
VALACYCLOVIR HYDROCHLORIDE		
TABLET		
VALTREX	EQ 1GM BASE	N20487
VALTREX	EQ 500MG BASE	N20487
VALPROIC ACID		
CAPSULE		
VALPROIC ACID	250MG	N70431
VALPROIC ACID	250MG	N70195

VALSARTAN		
CAPSULE		
DIOVAN	160MG	N20665
DIOVAN	80MG	N20665
VANCOMYCIN HYDROCHLORIDE		
FOR SOLUTION		
VANCOLED	EQ 500MG BASE/6ML	N63321
INJECTABLE		
VANCOMYCIN HCL	EQ 1GM BASE/VIAL	N62879
VANCOMYCIN HCL	EQ 500MG BASE/VIAL	N62879
VANCOMYCIN HCL	EQ 1GM BASE/VIAL	N62845
VANCOMYCIN HCL	EQ 500MG BASE/VIAL	N62845
VANCOR	EQ 1GM BASE/VIAL	N62956
VANCOR	EQ 500MG BASE/VIAL	N62956
VASOPRESSIN TANNATE		
INJECTABLE		
PITRESSIN TANNATE	5PRESSOR UNITS/ML	N03402
VECURONIUM BROMIDE		
INJECTABLE		
NORCURON	20MG/VIAL	N18776
VENLAFAXINE HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
EFFEXOR XR	EQ 100MG BASE	N20699
TABLET		
EFFEXOR	EQ 12.5MG BASE	N20151
VERAPAMIL HYDROCHLORIDE		
INJECTABLE		
CALAN	2.5MG/ML	N18925
CALAN	2.5MG/ML	N19038
VERAPAMIL HCL	2.5MG/ML	N70348
VERAPAMIL HCL	2.5MG/ML	N72233
VERAPAMIL HCL	2.5MG/ML	N73485
VERAPAMIL HCL	2.5MG/ML	N70672
VERAPAMIL HCL	2.5MG/ML	N70696
VERAPAMIL HCL	2.5MG/ML	N70697
VERAPAMIL HCL	2.5MG/ML	N70695
TABLET		
CALAN	160MG	N18817
VERAPAMIL HCL	120MG	N70483
VERAPAMIL HCL	80MG	N70482
VERAPAMIL HCL	120MG	N70341
VERAPAMIL HCL	80MG	N70340
VERAPAMIL HCL	40MG	N72799
VERAPAMIL HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
VERAPAMIL HCL	120MG	N75072
VERAPAMIL HCL	240MG	N75072
VERATRUM VIRIDE		
TABLET		
VERTAVIS	130CSR UNIT	N05691
VIDARABINE		
INJECTABLE		
VIRA-A	EQ 187.4MG BASE/ML	N50523
VINBLASTINE SULFATE		
INJECTABLE		
VELBAN	10MG/VIAL	N12665
VINBLASTINE SULFATE	10MG/VIAL	N89011
VINBLASTINE SULFATE	10MG/VIAL	N89365
VINBLASTINE SULFATE	1MG/ML	N89311
VINCRISTINE SULFATE		
INJECTABLE		
ONCOVIN	1MG/VIAL	N14103
ONCOVIN	5MG/VIAL	N14103
VINCREX	5MG/VIAL	N70867
VINCRISTINE SULFATE	1MG/ML	N70873
VINCRISTINE SULFATE	1MG/ML	N70411
VINCRISTINE SULFATE	1MG/VIAL	N71559
VINCRISTINE SULFATE	2MG/VIAL	N71560
VINCRISTINE SULFATE	5MG/VIAL	N71561
VINCRISTINE SULFATE	1MG/ML	N70777
VINCRISTINE SULFATE	1MG/ML	N70778
VINCRISTINE SULFATE	1MG/VIAL	N71222
VINCRISTINE SULFATE	2MG/VIAL	N71223
VINCRISTINE SULFATE	5MG/VIAL	N71937
VIOMYCIN SULFATE		
INJECTABLE		
VIOCIN SULFATE	EQ 1GM BASE/VIAL	N61086
VIOCIN SULFATE	EQ 5GM BASE/VIAL	N61086
VITAMIN A		
CAPSULE		
AQUASOL A	25,000USP UNITS	N83080
AQUASOL A	50,000USP UNITS	N83080
VITAMIN A	50,000USP UNITS	N83973
VITAMIN A	50,000 IU	N83351
VITAMIN A	50,000 IU	N83134
VITAMIN A	50,000USP UNITS	N80952

VITAMIN A PALMITATE		
CAPSULE		
AFAXIN	EQ 50,000 UNITS BASE	N83187
ALPHALIN	EQ 50,000 UNITS BASE	N80883
DEL-VI-A	EQ 50,000 UNITS BASE	N80830
VI-DOM-A	EQ 50,000 UNITS BASE	N80972
VITAMIN A	EQ 50,000 UNITS BASE	N80702
VITAMIN A	EQ 50,000 UNITS BASE	N80860
VITAMIN A	EQ 50,000 UNITS BASE	N80746
VITAMIN A	EQ 50,000 UNITS BASE	N83207
VITAMIN A	EQ 50,000 UNITS BASE	N85479
VITAMIN A	EQ 50,000 UNITS BASE	N80943
VITAMIN A	EQ 50,000 UNITS BASE	N83114
VITAMIN A	EQ 50,000 UNITS BASE	N80953
VITAMIN A	EQ 50,000 UNITS BASE	N80955
VITAMIN A	EQ 50,000 UNITS BASE	N83035
VITAMIN A	EQ 50,000 UNITS BASE	N83190
VITAMIN A	EQ 50,000 UNITS BASE	N80967
VITAMIN A	EQ 50,000 UNITS BASE	N83665
VITAMIN A PALMITATE	EQ 50,000 UNITS BASE	N83948
VITAMIN A PALMITATE	EQ 50,000 UNITS BASE	N83981
VITAMIN A SOLUBILIZED	EQ 50,000 UNITS BASE	N80921
INJECTABLE		
VITAMIN A PALMITATE	EQ 50,000 UNITS BASE/ML	N80819
WARFARIN POTASSIUM		
TABLET		
ATHROMBIN-K	10MG	N11771
ATHROMBIN-K	25MG	N11771
ATHROMBIN-K	2MG	N11771
ATHROMBIN-K	5MG	N11771
WARFARIN SODIUM		
INJECTABLE		
COUMADIN	50MG/VIAL	N09218
COUMADIN	75MG/VIAL	N09218
TABLET		
ATHROMBIN	10MG	N11771
ATHROMBIN	25MG	N11771
ATHROMBIN	5MG	N11771
PANWARFIN	10MG	N17020
PANWARFIN	2.5MG	N17020
PANWARFIN	2MG	N17020
PANWARFIN	5MG	N17020
PANWARFIN	7.5MG	N17020
WARFARIN SODIUM	2.5MG	N88720
WARFARIN SODIUM	2MG	N88719
WARFARIN SODIUM	5MG	N88721

WARFARIN SODIUM		
TABLET		
WARFARIN SODIUM	10MG	N86122
WARFARIN SODIUM	2.5MG	N86120
WARFARIN SODIUM	2MG	N86123
WARFARIN SODIUM	5MG	N86119
WARFARIN SODIUM	7.5MG	N86118
WATER FOR INJECTION, STERILE		
LIQUID		
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	100%	N89099
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	100%	N89100
WATER FOR IRRIGATION, STERILE		
LIQUID		
STERILE WATER IN PLASTIC CONTAINER	100%	N18246
XENON, XE-127		
GAS		
XENON XE 127	10mCi/VIAL	N18536
XENON XE 127	5mCi/VIAL	N18536
XENON, XE-133		
GAS		
XENON XE 133	1 CI/AMP	N17256
XENON XE 133	10mCi/VIAL	N17687
XENON XE 133	20mCi/VIAL	N17687
XENON XE 133-V.S.S.	10mCi/VIAL	N17687
INJECTABLE		
XENON XE 133	1.3-1.7 CI/AMP	N17256
XENON XE 133	6.3mCi/ML	N17283
SOLUTION		
XENEISOL	18-25mCi/AMP	N17262
XYLOSE		
POWDER		
XYLO-PFAN	25GM/BOT	N17605
XYLOSE	25GM/BOT	N18856
ZIDOVUDINE		
TABLET		
RETROVIR	200MG	N20518
ZILEUTON		
TABLET		
ZYFLO	300MG	N20471
ZINC SULFATE		
INJECTABLE		
ZINC SULFATE	EQ 1MG ZINC/ML	N19229

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and is not edited prior to publication.

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved= MA*	*Indication Designation*	*Sponsor and Address*
(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3, 4,12,14-tetrahydro-1-H-pyrano[3',4': 6,7]-indolizino-[1,2-b]-quinoline-11 -carbaldehyde O-(tert-butyl)-(E)-oxime	DD: 11/29/2002	Treatment malignant glioma	Sigma-Tau Research, Inc. 800 South Frederick Avenue
Gimatecan	MA: MA: 2002-1616		Suite 103 Gaithersburg MD 20877-4150
(R)-N-[2-(6-chloro-5-methoxy-1H-in dol-3-yl)propyl]acetamide	DD: 10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc. 3130 Highland Avenue, Third Floor
	MA: 2001-1475		Cincinnati OH 45219-2374
1,5-(Butylimino)-1,5 dideoxy,D-glucitol	DD: 5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant
	MA: 1998-1121		Abington Science Park, Abington Oxfordshire OX14 3YS UK
1,5-(Butylimino)-1,5 dideoxy,D-glucitol	DD: 5/29/1998	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant
	MA: 1998-1125		Abington Science Park, Abington Oxfordshire OX14 3YS UK
1-(11-dodecylamino-10-hydroxyund ecyl)-3,7-dimethylxanthine hydrogen methanesulfonate	DD: 1/18/2000	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West
	MA: 1999-1258		Suite 400 Seattle WA 98119
111Indium pentetreotide	DD: 6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
SomatoTher	MA: 1998-1211		1600 Canal St. 10th Floor New Orleans LA 70112
166Ho-DOTMP	DD: 2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Street
	MA: 1998-1199		Seattle WA 98119-4007
2'-3'-dideoxyadenosine	DD: 7/21/1987	Treatment of aquired immunodeficiency syndrome.	National Cancer Institute, Dct NIH, Exec. Plaza N., Room 7-18
	MA: 1987-0205		Bethesda MD 20892
2'-deoxycytidine	DD: 9/9/1996	As a host-protective agent in the treatment of acute myelogenous	Grant, Steven M.D. Massey Cancer Center, VCU
	MA: MA: 1996-0999	leukemia.	P.O. Box 980230 Richmond VA 23298-0230
2-0-desulfated heparin *Aeropin*	DD: 9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University of Utah Health Sciences Center
	MA: 1993-0755		50 North Medical Drive, Room 4R240 Salt Lake City UT 84132
2-chloroethyl-3-sarcosinamide-1-ni trosourea *Sarmustine*	DD: 11/15/2001 MA:	Treatment for malignant glioma	Pangene Corporation 5500 Stewart Avenue

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 2001-1506		Fremont CA 94538
2-chloroethyl-3-sarcosinamide-1-nitrosourea	DD: 8/3/2001 MA: 2001-1461	Treatment for malignant gliomas	Lawrence Panasci, MD Professor of Medicine, McGill University 3755 Cote Ste Catherine Montreal, Quebec H3T 1E2
2-methoxyestradiol *Panzem*	DD: 7/10/2001 MA: 2001-1438	Treatment of multiple myeloma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
24,25 dihydroxycholecalciferol	DD: 2/27/1987 MA: 1986-0157	Treatment of uremic osteodystrophy.	Lemmon Company 1510 Delp Drive Kulpsville PA 19443
3'-azido-2',3'dideoxyuridine *AZDU*	DD: 11/20/1989 MA: 1989-0398	Treatment of acquired immunodeficiency syndrome.	Berlex Laboratories, Inc. 1401 Harbor Bay Parkway 1401 Harbor Bay Parkway Alameda CA 94501
3,4-diaminopyridine	DD: 12/18/1990 MA: 1990-0515	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company 37 Cleveland Avenue P.O. Box 5290 Princeton NJ 08540
3,5,3'-triiodothyroacetate	DD: 9/20/2000 MA: MA: 2000-1372	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D. University of Vermont 84 Beartown Road Underhill VT 05489
3-(3,5-Dimethyl-1H-2ylmethylene)-1, 3-dihydro-indol-2-one	DD: 3/23/2000 MA: 1999-1276	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080
3-(3,5-dimethyl-1H-2ylmethylene)-1, 3-dihydro-indol-2-one	DD: 9/11/1998 MA: 1998-1163	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080-4811
3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione *Revimid (proposed)*	DD: 9/20/2001 MA: MA: 2001-1477	Treatment for multiple myeloma	Celegene Corporation 7 Powder Horn Drive Warren NJ 07059
4-aminosalicylic acid *Pamisyl (P-D), Rezipas (Squibb)*	DD: 12/13/1989 MA: MA: 1989-0379	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D. University Of Vermont University Of Vermont Given C-317 Burlington VT 05405
40SD02	DD: 12/21/1998 MA: MA: 1998-1176	Treatment of chronic iron overload resulting from conventional transfusional sickle cell anemia. treatment of beta-thalassemia major and	Biomedical Frontiers, Inc. 1095 10th Ave., S.E. Minneapolis MN 55414
5,6-dihydro-5-azacytidine	DD: 5/11/1992 MA: 1992-0672	Treatment of malignant mesothelioma.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
5-aza-2'-deoxycytidine	DD: 8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1987-0206		4140 Dublin Blvd. Suite 200 Dublin CA 94568
506U78	DD: 9/2/1999 MA: 1999-1259	Treatment of chronic lymphocytic leukemia.	GlaxoSmithKline Five Moore Dr. P.O. Box 13398 Research Triangle Park NC 27709-3398
5a8, monoclonal antibody to CD4	DD: 12/20/1993 MA: MA: 1992-0706	For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
6-hydroxymethylacylfulvene	DD: 7/6/1999 MA: 1999-1243	Treatment of ovarian cancer.	MGI Pharma, Inc. 5775 West Old Shakoppe Rd. Suite 100 Bloomington MN 55437-3107
6-hydroxymethylacylfulvene	DD: 4/6/1999 MA: MA: 1998-1221	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
6-hydroxymethylacylfulvene	DD: 7/27/1999 MA: 1999-1253	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
8 Cyclopentyl 1,3-dipropylxanthine	DD: 3/24/1997 MA: 1997-1039	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard San Mateo CA 94404-1593
8-methoxsalen *Uvadex*	DD: 6/22/1993 MA: MA: 1993-0742	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc. Oaklands Corporate Center Oaklands Corporate Center 437 Creamery Way Exton PA 19341
8-methoxsalen *Uvadex*	DD: 5/12/1994 MA: 1994-0805	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc. Oaklands Corporate Center Oaklands Corporate Center 437 Creamery Way Exton PA 19341
9-cis retinoic acid *Panretin*	DD: 4/10/1992 MA: 1992-0665	Treatment of acute promyelocytic leukemia.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. 10275 Science Center Dr. San Diego CA 92121-1117
9-cis-retinoic acid	DD: 1/2/1997 MA: 1996-1012	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
9-nitro-20-(S)-camptothecin	DD: 9/16/1996 MA: 1996-1001	Treatment of pancreatic cancer.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
9-nitro-20-(S)-camptothecin *Camvirex*	DD: 5/15/2001 MA: 2001-1422	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900
Abetimus	DD: 7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 2000-1336		6455 Nancy Ridge Dr. San Diego CA 92121
acetylcysteine *Acetadote*	DD: 10/19/2001 MA: MA: 2001-1484	For the intravenous treatment of moderate to severe acetaminophen overdose	Ligand 209 10th Street South 209 10th Street South Suite 332 Nashville TN 37203
Acetylcysteine *Mucomyst/Mucomyst 10 IV*	DD: 8/13/1987 MA: MA: 1987-0207	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company P.O. Box 4500 P.O. Box 4500 Princeton NJ 08543-4500
Aconiazide	DD: 6/20/1988 MA: 1988-0282	Treatment of tuberculosis.	Lincoln Diagnostics P.O. Box 1128 Decatur IL 62525
Adeno-associated viral vector containing the gene for human coagulation factor IX *Coagulin-B*	DD: 6/13/2001 MA: MA: 2001-1453	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502
Adeno-associated viral vector containing the gene for human coagulation factor IX *Coagulin-B*	DD: 6/13/2001 MA: MA: 2001-1444	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502
Adeno-associated viral-based vector cystic fibrosis gene therapy	DD: 2/15/1995 MA: 1994-0849	Treatment of cystic fibrosis.	Targeted Genetics Corporation 1100 Olive Way, Suite 100 Seattle WA 98101
Adenosine	DD: 8/1/1989 MA: 1988-0323	For use in conjunction with BCNU in the treatment of brain tumors.	Medco Research, Inc. 8455 Beverly Boulevard Suite 308 Los Angeles CA 90048
Adenovirus-based vector Factor VIII complementary DNA to somatic *MiniAdFVIII*	DD: 12/15/1999 MA: MA: 1999-1274	Treatment of hemophilia A.	GenStar Therapeutics Corporation 10835 Altman Row Suite 150 San Diego CA 92121
adenovirus-mediated herpes simplex virus-thymidine kinase	DD: 7/31/2001 MA: 2001-1458	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd 6 Warren Mews London W1T6AR UK
Aerosolized pooled immune	DD: 1/3/1989 MA: 1988-0336	Treatment of respiratory syncytial virus lower respiratory tract disease.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
AI-RSA	DD: 10/8/1992 MA: 1991-0600	Treatment of autoimmune uveitis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02173
Albendazole *Albenza*	DD: 1/17/1996 MA: 6/11/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to	SmithKline Beecham Pharmaceuticals One Franklin Plaza One Franklin Plaza

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 6/11/1996 1995-0941	E. multilocularis larvae).	P.O. Box 7929 Philadelphia PA 19101
Albendazole *Albenza*	DD: 1/18/1996 MA: 6/11/1996 MA: 6/11/1996 1995-0942	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals One Franklin Plaza One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
albuterol	DD: 3/12/2002 MA: 2001-1525	Prevention of paralysis due to spinal cord injury	MotoGen, Inc. 3 Pine View Road Mount Kisco NY 10549
Aldesleukin *Proleukin*	DD: 7/31/1998 MA: 1998-1130	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. 4560 Horton St. Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: 11/24/1998 MA: 1998-1165	For the treatment non-Hodgkin's lymphoma.	Chiron Corporation 4560 Horton St. 4560 Horton St. Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: 9/10/1996 MA: 1/9/1998 1996-1006	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: 9/14/1988 MA: 5/5/1992 1988-0290	Treatment of metastatic renal cell carcinoma.	Chiron Corporation 4560 Horton Street 4560 Horton Street Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: 3/22/1989 MA: 1988-0289	Treatment of primary immunodeficiency disease associated with T-cell defects.	Chiron Corporation 4560 Horton Street 4560 Horton Street Emeryville CA 94608-2916
alemtuzumab *Campath*	DD: 10/20/1997 MA: 5/7/2001 1997-1071	Treatment of chronic lymphocytic leukemia.	Millennium and ILEX Partners, LP 75 Sidney Street 75 Sidney Street Cambridge MA 02138
Alendronate disodium *Fosamax*	DD: 2/13/2001 MA: 2000-1400	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Division of Human Genetics Children's Hospital Research Foundation Cincinnati OH 45229-3039
Alglucerase injection *Ceredase*	DD: 7/21/1995 MA: 1995-0910	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562
Alglucerase injection *Ceredase*	DD: 3/11/1985 MA: 4/5/1991	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1985-0055		
Alitretinoin	DD: 3/24/1998	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive
Panretin	MA: 2/2/1999 MA: 2/2/1999 1998-1109		10275 Science Center Drive San Diego CA 92121-1117
allantoin	DD: 11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Alwyn Company, Inc. 2301 Highway 60 East
Alwextin	MA: MA: 2001-1510		2301 Highway 60 East Lake Crystal MN 56055
Allogeneic human retinal pigment epithelial cells on gelatin microcarriers	DD: 7/18/1997	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Titan Pharmaceuticals, Inc. Post Office Plaza
Spheramine	MA: MA: 1997-1057		50 Division Street, Suite 503 Somerville NJ 08876
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	DD: 6/13/1997	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard
CYTOIMPLANT	MA: MA: 1997-1049		Santa Fe Springs CA 90670
Allopurinol riboside	DD: 12/4/1985	Treatment of Chagas' disease.	Burroughs Wellcome Company 3030 Cornwallis Road
	MA: 1985-0106		P.O. Box 12700 Research Triangle Park NC 27709
Allopurinol riboside	DD: 12/4/1985	Treatment of cutaneous and visceral leishmaniasis.	Burroughs Wellcome Company 3030 Cornwallis Road
	MA: 1985-0106A		P.O. Box 12700 Research Triangle Park NC 27709
Allopurinol sodium	DD: 10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc PO Box 1887
Aloprim for Injection	MA: 5/17/1996 MA: 5/17/1996 1992-0683		PO Box 1887 Greenville NC 27835-1887
Allopurinol sodium	DD: 11/9/1987	Ex-vivo preservation of cadaveric kidneys for transplantation	Burroughs Wellcome Company 3030 Cornwallis Road
	MA: 1987-0227		Research Triangle Pk NC 27709
Alpha-1-antitrypsin (recombinant DNA Origin)	DD: 1/1/1984	As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.	Chiron Corporation 4560 Horton Street
	MA: 1983-0002		Emeryville CA 94608-2916
Alpha-galactosidase A	DD: 6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St.
Replagal	MA: 1998-1129		195 Albany St. Cambridge MA 02139
Alpha-galactosidase A *Fabrase*	DD: 7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D. The Mount Sinai School Of Medicine
	MA: 1990-0471		Fifth Avenue at 100th Street, Box New York NY 10029
Alpha-galactosidase A	DD: 6/17/1991	Treatment of alpha-galactosidase A	Orphan Medical, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		deficiency (Fabry's disease).	13911 Ridgedale Drive
CC-galactosidase			13911 Ridgedale Drive
	MA:		Suite 475
	1991-0586		Minnetonka MN 55305
Alpha-melanocyte stimulating hormone	DD: 8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases
	MA:		National Institutes of Health, 31 Center Drive MSC 2560
	1997-1064		Building 31, Room 9N-222 Bethesda MD 20892-2560
Alpha1-proteinase inhibitor	DD: 12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital	Bayer Corporation
Prolastin	MA: 12/2/1987	deficiency state.	Pharmaceutical Division, Biological
	MA: 12/2/1987		Pharmaceutical Division, Biological Products
	1984-0030		400 Morgan Lane New Haven CT 06516
Alpha1-proteinase inhibitor	DD: 11/24/1999	For slowing the progression of emphysema in alpha1-antitrypsin deficient	Aventis Behring L.L.C.
	MA:		1020 First Ave.
	MA:	patients.	PO Box 61501
	1999-1242		King of Prussia PA 19406-0901
Alprostadil	DD: 10/20/1993	Treatment of severe peripheral arterial occlusive disease (critical limb ischemia)	Schwarz Pharma, Inc.
	MA:	or angioplasty, are not indicated.	P.O. Box 2038
	MA:	in patients where other procedures, grafts	Milwaukee WI 53201
	1992-0700		
Alronidase	DD: 9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
Aldurazyme			371 Bel Marin Keys Boulevard, Suite
	MA:		371 Bel Marin Keys Boulevard, Suite 210
	1997-1060		Novato CA 94949-5608
Altretamine	DD: 2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
Hexalen			One Tower Bridge
	MA: 12/26/1990		One Tower Bridge
	1983-0009		100 Front Street, Suite 400 Conshohocken PA 19428
Amifostine	DD: 5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced	Medimmune Oncology, Inc.
Ethyol	MA: 12/8/1995	ovarian carcinoma.	One Tower Bridge
	MA: 12/8/1995		One Tower Bridge
	1989-0427		100 Front Street, Suite 400 West Conshohocken PA 19428
Amifostine	DD: 5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of	Medimmune Oncology, Inc.
Ethyol	MA:	advanced ovarian carcinoma.	35 West Watkins Mill Rd.
	MA:		35 West Watkins Mill Rd.
	1989-0428		Gaithersburg MD 20878
Amifostine	DD: 5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing	Medimmune Oncology, Inc.
Ethyol	MA: 6/24/1999	post-operative radiation treatment for	One Tower Bridge
	MA: 6/24/1999	head and neck cancer.	One Tower Bridge
	1998-1116		100 Front Street, Suite 400 Conshohocken PA 19428
Amifostine	DD: 5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic	Medimmune Oncology, Inc.
Ethyol	MA:	melanoma.	35 West Watkins Mills Rd.
	MA:		35 West Watkins Mills Rd.
	1989-0429		Gaithersburg MD 20878
Amifostine	DD: 11/24/1998	For the reduction of the incidence and	Medimmune Oncology, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Ethyol	MA: MA: 1998-1162	severity of toxicities associated with cisplatin administration.	35 West Watkins Mill Rd. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Amifostine *Ethyol*	DD: 10/4/1999 MA: 1999-1283	Treatment of myelodysplastic syndromes.	Medimmune Oncology, Inc. 35 West Watkins Mill Rd. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Amiloride HCl solution for	DD: 7/18/1990 MA: 1990-0481	Treatment of cystic fibrosis.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Aminocaproic acid *Caprogel*	DD: 1/6/1995 MA: 1994-0832	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School Department of Ophthalomology Department of Ophthalomology 880 Kempsville Road, Suite 2500 Norfolk VA 23502-3990
Aminosalicylate sodium	DD: 4/6/1993 MA: 1992-0685	Treatment of Crohn's disease.	Syncom Pharmaceuticals, Inc. 66 Hanover Road Florham Park NJ 07932
Aminosalicylic acid *Paser Granules*	DD: 2/19/1992 MA: 6/30/1994 1992-0657	Treatment of tuberculosis infections.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Aminosidine *Gabbromicina*	DD: 11/15/1993 MA: 1993-0771	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D. University of Illinois at Chicago University of Illinois at Chicago College of Pharmacy 833 South Wood Street (m/c886) Rm. 176 Chicago IL 60612
Aminosidine *Paromomycin*	DD: 9/9/1994 MA: 1994-0831	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D. University of Illinois at Chicago University of Illinois at Chicago College of Pharmacy 833 South Wood Street (m/c886) Rm. 176 Chicago IL 60612
Aminosidine *Gabbromicina*	DD: 5/14/1993 MA: 1993-0746	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D. University Of Illinois At Chicago College of Pharmacy 833 South Wood Street (m/c886) Rm. 176 Chicago IL 60612
Amiodarone *Amio-Aqueous*	DD: 8/17/1993 MA: 1992-0702	Treatment of incessant ventricular tachycardia.	Wyeth-Ayerst Research PO Box 8299 PO Box 8299 Philadelphia PA 19101-8299
Amiodarone HCl *Cordarone*	DD: 3/16/1994 MA: 8/3/1995 MA: 8/3/1995 1993-0772	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories P.O. Box 8299 P.O. Box 8299 Philadelphia PA 19101
Ammonium tetrathiomolybdate	DD: 1/31/1994	Treatment of Wilson's disease.	Brewer, George J. M.D. University Of Michigan Medical

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1993-0799		4708 Medical Science Building II 0618 Ann Arbor MI 48109
Amphotericin B lipid complex *Abelcet*	DD: 6/27/1996 MA: 1996-0969	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 12/3/1996 MA: 10/18/1996 1991-0578	Treatment of invasive fungal infections.	Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 5/6/1996 MA: 1996-0970	Treatment of invasive zygomycosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 9/23/1996 MA: 1996-0976	Treatment of invasive sporotrichosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 5/6/1996 MA: 1996-0973	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 8/21/1996 MA: 1996-0977	Treatment of invasive protothecosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amsacrine *Amsidyl*	DD: 12/7/1984 MA: 1984-0045	Treatment of acute adult leukemia.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48106
Anagrelide *Agrylin*	DD: 7/14/1986 MA: 1986-0145	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp. Meridian Center II Meridian Center II 4 Industrial Way West Eatontown NJ 07724-2274
Anagrelide *Agrylin*	DD: 6/11/1985 MA: 1985-0069	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp. Meridian Center II 4 Industrial Way West Eatontown NJ 07724-2274
Anagrelide *Agrylin*	DD: 1/27/1988 MA: 3/14/1997 1987-0208	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown NJ 07724
Ananain, comosain *Vianain*	DD: 1/21/1992 MA: 1991-0630	For the enzymatic debridement of severe burns.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139
Anaritide acetate *Auriculin*	DD: 4/10/1992 MA: 1991-0622	Improvement of early renal allograft function following renal transplantation.	Scios, Inc. 2450 Bayshore Parkway 2450 Bayshore Parkway Mountain View CA 94043
Anaritide acetate	DD: 8/27/1992	Treatment of patients with acute renal failure.	Scios, Inc. 2450 Bayshore Parkway

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Auriculin	MA: 1991-0623		2450 Bayshore Parkway Mountain View CA 94043
Ancestim	DD: 7/5/1995	For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative	Amgen, Inc. One Amgen Center Drive
Stemgen	MA: MA: 1994-0865		One Amgen Center Drive Thousand Oaks CA 91320-1799
Ancrod	DD: 10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company 3000 Continental Dr., North
Viprinex	MA: MA: 1989-0371		3000 Continental Dr., North Mt. Olive NJ 07828
Angiotensin 1-7 *MARstem*	DD: 8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation 4041 MacArthur Boulevard, Suite 375 Newport Beach CA 92660
	MA: 2001-1446		
Angiotensin 1-7	DD: 2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660
	MA: 1999-1299		
Anti pan T lymphocyte monoclonal antibody	DD: 1/29/1986	For in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.	Xoma Corporation 2910 Seventh Street
Anti-t Lymphocyte Immunotoxin	MA: MA: 1985-0109B		Berkeley CA 94710
Anti pan T lymphocyte monoclonal antibody	DD: 1/29/1986	For ex-vivo treatment to eliminate mature T cells from potential bone marrow grafts.	Xoma Corporation 2910 Seventh Street
Anti-t Lymphocyte Immunotoxin	MA: MA: 1985-0109A		Berkeley CA 94710
Anti-CD45 monoclonal antibodies	DD: 9/10/1990	Prevention of acute graft rejection of human organ transplants.	Baxter Healthcare Corporation 1620 Waukegan Road Mcgaw Park IL 60085
	MA: 1990-0483		
Anti-cytomegalovirus monoclonal antibodies	DD: 5/2/1990	Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients.	Biomedical Research Institute 345 North Smith Avenue
	MA: 1989-0404B		St. Paul MN 55102
Anti-cytomegalovirus monoclonal antibodies	DD: 5/2/1990	Treatment of human cytomegalovirus infection in bone marrow and organ transplant patients.	Biomedical Research Institute 345 North Smith Avenue
	MA: 1989-0404A		St. Paul MN 55102
Anti-cytomegalovirus monoclonal antibodies	DD: 5/3/1990	Treatment of human cytomegalovirus infection in patients diagnosed with AIDS.	Biomedical Research Institute 345 North Smith Avenue
	MA: 1989-0414A		St. Paul MN 55102
Anti-cytomegalovirus monoclonal antibodies	DD: 5/3/1990	Prevention of human cytomegalovirus infection in patients diagnosed with AIDS.	Biomedical Research Institute 345 North Smith Avenue
	MA: 1989-0414B		St. Paul MN 55102
Anti-tap-72 immunotoxin	DD: 3/6/1987	Treatment of metastatic colorectal adenocarcinoma.	Xoma Corporation 2910 Seventh Street
Xomazyme-791			2910 Seventh Street

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1986-0172		Berkeley CA 94710
Anti-thymocyte Globulin (Rabbitt) *Thymoglobulin*	DD: 9/6/2000 MA: 2000-1368	Treatment of myelodysplastic syndrome (MDS)	SangStat Medical Corporation 6300 Dumbarton Circle 6300 Dumbarton Circle Freemont CA 94555
Anti-thymocyte serum *Nashville Rabbit Anti-thymocyte Serum*	DD: 6/2/1993 MA: MA: 1991-0644	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research 1600 Hayes Street 1600 Hayes Street Nashville TN 37203
antiangiogenic components extracted from marine cartilage *Neovastat (AE-941)*	DD: 10/16/2002 MA:	Treatment of renal cell carcinoma	AEterna Laboratories, Inc. Dr. Claude Hariton, Chief Medical Officer, VP, Clinical & Regulatory Affairs 1405 boul. Du Parc –
Technologique	2002-1592		Quebec G1P 4P5 CANADA
Antiepilepsirine	DD: 3/23/1989 MA: MA: 1988-0345	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital 700 Children's Drive Columbus OH 43205
Antihemophilic factor (human) *Alphanate*	DD: 1/5/1996 MA: 1995-0938	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032-3520
Antihemophilic factor *ReFacto*	DD: 2/8/1996 MA: MA: 1995-0944	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Genetics Institute, Inc. 87 CambridgePark Drive 87 CambridgePark Drive Cambridge MA 02140
Antihemophilic factor *Kogenate*	DD: 9/25/1989 MA: 2/25/1993 MA: 2/25/1993 1989-0392	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation 1884 Miles Avenue 1884 Miles Avenue Elkhart IN 46515
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized *Humate-P*	DD: 10/16/1992 MA: 4/1/1999 1992-0679 1992-0679	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King Of Prussia PA 19406-0901
Antimelanoma Antibody XMMME-001-DTPA 111 Indium *Antimelanoma Antibody*	DD: 11/14/1984 MA: MA: 1984-0034	Diagnostic use in imaging systemic and nodal melanoma metastasis.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710
Antimelanoma Antibody XMMME-001-RTA *Antimelanoma Antibody*	DD: 11/14/1984 MA: MA: 1984-0035	Treatment of stage III melanoma not amenable to surgical resection.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Antipyrine Test	DD: 2/21/1985 MA: 1984-0052	For use as an index of hepatic drug-metabolizing capacity.	Upsher-Smith Laboratories, Inc 4905 23rd Avenue North Minneapolis MN 55447
Antithrombin III (human) *Thrombate III*	DD: 11/26/1984 MA: 12/30/1991 MA: 12/30/1991 1984-0040	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation Pharmaceutical Division, Biological Pharmaceutical Division, Biological Products 400 Morgan Lane New Haven CT 06516
Antithrombin III (human) *ATnativ*	DD: 2/8/1985 MA: 12/13/1989 MA: 12/13/1989 1984-0050	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB Lindhagensgatan 133 Lindhagensgatan 133 SE-112 87 Stockholm Sweden SE
Antithrombin III (human) concentrate IV *Kybernin P*	DD: 7/2/1985 MA: MA: 1985-0071	For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
Antithrombin III human *Antithrombin III human*	DD: 1/2/1986 MA: MA: 1985-0114	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross 9312 Old Georgetown Road 9312 Old Georgetown Road Bethesda MD 20814
Antivenin, crotalidae polyvalent immune Fab (ovine) *CroFab*	DD: 1/12/1994 MA: 10/2/2000 MA: 10/2/2000 1993-0789	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc. 1207 17th Ave. S., Suite 103 Nashville TN 37212
Antivenom (crotalidae) purified (avian)	DD: 2/12/1991 MA: 1990-0546	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc. 5445 East Cheryl Parkway Madison WI 53711
AP1903	DD: 11/24/1999 MA: MA: 1999-1262	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Ariad Gene Therapeutics, Inc. 26 Landsdowne St. Cambridge MA 02139-4234
APL 400-020 V-Beta DNA vaccine	DD: 3/8/1995 MA: 1995-0882	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics 211 Bailey Rd. West Henrietta NY 14586-9728
Apomorphine	DD: 10/20/1997 MA: MA: 1997-1079	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon SN5 8RU Wiltshire UK
Apomorphine	DD: 7/17/1995 MA: MA: 1995-0892	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc. 1110 Lake Cook Rd. Suite 257 Buffalo Grove IL 60089

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Apomorphine HCl	DD: 4/22/1993 MA: MA: 1991-0575	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Mylan Pharmaceuticals, Inc. 781 Chestnut Ridge Rd. PO Box 4310 Morgantown WV 26505-4310
Aprotinin *Trasylol*	DD: 11/17/1993 MA: 12/29/1993 MA: 12/29/1993 1992-0669	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation Pharmaceutical Division Pharmaceutical Division 400 Morgan Lane West Haven CT 06516
Arcitumomab *99m Tc-labeled CEA-Scan*	DD: 5/10/1996 MA: MA: 1996-0965	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road 300 American Road Morris Plains NJ 07950
Arginine butyrate	DD: 4/7/1992 MA:	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D. Boston University Cancer Research Center
Arginine butyrate	DD: 5/25/1994 MA: 1994-0820	Treatment of sickle cell disease and beta thalassemia.	Vertex Pharmaceuticals Inc. 130 Waverly Street Cambridge MA 02139-4242
arsenic *Trisenox*	DD: 11/2/2001 MA: 2001-1460	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Cell Therapeutics, Inc. 201 Elliott Avenue West 201 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide *Trisenox*	DD: 7/17/2000 MA: 2000-1352	Treatment of myelodysplastic syndrome.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide *Trisenox*	DD: 10/18/2001 MA: 2001-1457	Treatment of chronic myeloid leukemia	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119
Arsenic trioxide *Trisenox*	DD: 4/28/2000 MA: 2000-1347	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite 400 Seattle WA 98119
Arsenic trioxide *Trisenox*	DD: 3/3/1998 MA: 9/25/2000 1997-1096	Treatment of acute promyelocytic leukemia.	Cell Therapeutics, Inc. 201 Elliott Ave. West 201 Elliott Ave. West Suite 400 Seattle WA 98119
Artesunate	DD: 7/19/1999 MA: 1999-1255	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia , Geneva 27 Switzerland CH
As-101	DD: 11/9/1987 MA:	Treatment of acquired immunodeficiency syndrome.	NPDC-AS101, Inc. 783 Jersey Avenue New Brunswick NJ 08901

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1987-0223		
Atovaquone	DD: 9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc. 5 Moore Drive
Mepron	MA: 11/25/1992 1990-0488		5 Moore Drive Research Triangle Park NC 27709
Atovaquone	DD: 3/16/1993	Treatment and suppression of Toxoplasma gondii encephalitis.	Glaxo Wellcome Inc. 5 Moore Drive
Mepron	MA: 1992-0666		5 Moore Drive PO Box 13398 Research Triangle Park NC 27709-3398
Atovaquone	DD: 3/16/1993	Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.	Glaxo Wellcome Inc. 5 Moore Drive
Mepron	MA: MA: 1992-0667		5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Atovaquone	DD: 8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to	Glaxo Wellcome Research and Development 5 Moore Drive
Mepron	MA: 1/5/1999 MA: 1/5/1999 1990-0489		5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
augmerosen	DD: 8/28/2001	Treatment of acute myelocytic leukemia	Genta Incorporated Two Oak Way
Genasense	MA: 2001-1449		Berkeley Heights NJ 07922
augmerosen	DD: 8/28/2001	Treatment of chronic lymphocytic leukemia	Genta Incorporated Two Oak Way
Genasense	MA: 2001-1455		Two Oak Way Berkeley Heights NJ 07922
augmerosen	DD: 8/28/2001	Treatment of multiple myeloma	Genta Incorporated Two Oak Way
Genasense	MA: 2001-1456		Berkeley Heights NJ 07922
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype	DD: 4/18/2002	Treatment of multiple myeloma	Dendreon Corporation 3005 First Avenue
Mylovenge	MA: MA: 2001-1537		Seattle WA 98121
Autologous dendritic cells pulsed with autologous glioblastoma multiforme acid-eluted tumor antigens	DD: 11/29/2002	Treatment of glioblastoma multiforme	Northwest Biotherapeutics, Inc. 21720 23rd Drive, SE
DCVax-Brain	MA: MA: 2002-1629		Suite 100 Bothell WA 98021
Autologous DNP-conjugated tumor vaccine	DD: 2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 9200 Indian Creek Parkway
M-Vax	MA: 1998-1194		Building 9, Suite 200 Overland Park KS 66210
autologous tumor-derived gp96 heat shock protein-peptide	DD: 7/11/2002	Treatment of metastatic melanoma	Antigenics, Inc. 34 Commerce Way
Oncophage	MA: MA:		Woburn MA 01702

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	2002-1542		
autologous tumor-derived gp96 heat shock protein-peptide *Oncophage*	DD: 5/10/2002 MA: MA: 2001-1502	Treatment of renal cell carcinoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
Autolymphocyte therapy	DD: 7/12/1994 MA: 1993-0795	Treatment of renal cell carcinoma.	Cytogen Corporation 600 College Road East CN 5308 Princeton NJ 08540-5308
azacitidine	DD: 12/3/2001 MA: 2001-1501	Treatament of myelodysplastic syndromes	Pharmion Corporation 4865 Riverbend Road Boulder CO 80301
Azathioprine *Imuran*	DD: 9/14/1999 MA: 1999-1280	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor 787 Seventh Ave., 48th Floor New York NY 10019
aztreonam	DD: 3/12/2002 MA: MA: 2002-1550	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Corus Pharma 2025 First Ave., Suite 800 Seattle WA 98121
B Lymphocyte Stimulator *BLyS*	DD: 2/21/2001 MA: 2000-1406	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue 9410 Key West Avenue Rockville MD 20850
Bacitracin *Altracin*	DD: 3/13/1984 MA: MA: 1984-0012	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc. One Executive Drive One Executive Drive P.O. Box 1399 Fort Lee NJ 07024
Baclofen *Lioresal Intrathecal*	DD: 9/26/1994 MA: 1994-0804	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc. 800 53rd Avenue N.E. 800 53rd Avenue N.E. P.O. 1250 Minneapolis MN 55440-9087
Baclofen *Lioresal Intrathecal*	DD: 11/10/1987 MA: 6/25/1992 MA: 6/25/1992 1987-0239	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc. 800 53rd Avenue N.E. 800 53rd Avenue N.E. Minneapolis MN 55432
Baclofen	DD: 12/16/1991 MA: 1991-0640	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc. 1400 Providence Highway Norwood MA 02062
Basiliximab *Simulect*	DD: 12/12/1997 MA: 5/12/1998 1997-1091	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080
beclomethasone	DD: 8/28/2001 MA: 2001-1465	Prevention of gastrointestinal graft-versus-host disease	Enteron Pharmaceuticals, Inc. 1680 Michigan Ave. Suite 700 Miami FL 33139

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Beclomethasone dipropionate	DD: 3/27/1998 MA: 1998-1111	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle WA 98109
Benzoate and phenylacetate *Ucephan*	DD: 1/21/1986 MA: 12/23/1987 MA: 12/23/1987 1985-0113A	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	Immunex Immunex 2525 McGaw Avenue 2525 McGaw Avenue P.O. Box 19791 Irvine CA 92623
benzoate/phenylacetate *Ammonul*	DD: 11/22/1993 MA: MA: 1993-0779	For the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road 8125 N. Hayden Road Scottsdale AZ 85258
Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide *Total Block VL SPF 75*	DD: 8/13/2001 MA: MA: 2001-1424	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd. 677 W. Dekalb Pike King of Prussia PA 19406
Benzydamine hydrochloride *Tantum*	DD: 5/18/1998 MA: MA: 1998-1118	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue 70 Grand Avenue River Edge NJ 07661
Benzylpenicillin, benzylpenicilloic, benzylpenilloic *Pre-Pen/MDM*	DD: 9/29/1987 MA: 1987-0187 1987-0187	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	Hollister-Stier Laboratories LLC PO Box 3145 Spokane WA 99220-3145
Beractant *Survanta intratracheal suspension*	DD: 2/5/1986 MA: 7/1/1991 1985-0108A	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories 625 Cleveland Avenue 625 Cleveland Avenue Columbus OH 43215
Beractant *Survanta Intratracheal Suspension*	DD: 12/20/1993 MA: MA: 1993-0767	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories 625 Cleveland Avenue 625 Cleveland Avenue Columbus OH 43215
Beractant *Survanta intratracheal suspension*	DD: 2/5/1986 MA: 7/1/1991 1985-0108B	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories 625 Cleveland Avenue 625 Cleveland Avenue Columbus OH 43215
Beraprost	DD: 4/29/1999 MA: 1999-1230	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park NC 27709
Beta alethine	DD: 3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Betathine	MA: 1997-1032		Bldg. 337, Paint Branch Drive College Park MD 20742
Beta alethine *Betathine*	DD: 3/24/1997 MA: 1997-1033	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park MD 20742
Betaine *Cystadane*	DD: 5/16/1994 MA: 10/25/1996 1994-0817	Treatment of homocystinuria.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305
Bethanidine sulfate	DD: 11/24/1989 MA: 1988-0325	Prevention of recurrence of primary ventricular fibrillation.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048
Bethanidine sulfate	DD: 9/20/1988 MA: 1987-0260	Treatment of primary ventricular fibrillation.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048
Bexarotene *Targretin*	DD: 6/18/1999 MA: 12/29/1999 MA: 12/29/1999 1999-1246	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. 10275 Science Center Dr. San Diego CA 92121
Bindarit	DD: 2/3/1998 MA: 1997-1100	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge NJ 07661
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	DD: 2/11/2002 MA: 2000-1366	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc. Suite 235 7200 Hudson Blvd. Oakdale MN 55128
Bis(4-fluorophenyl)phenylacetamid	DD: 3/2/2000 MA: 1999-1319	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709
Bispecific antibody 520c9x22	DD: 10/5/1993 MA: 1992-0724	For in vivo serotherapy of patients with ovarian cancer.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801-0953
Bleomycin *Blenoxane*	DD: 2/9/1999 MA: 1998-1184	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego CA 92121-1334
Bleomycin sulfate *Blenoxane*	DD: 9/17/1993 MA: 2/20/1996 1993-0761	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543
BMY-45622	DD: 10/15/1990 MA: 1990-0501	Treatment of ovarian cancer.	Bristol-Myers Squibb 5 Research Parkway Wallingford CT 06492
Bosentan *Tracleer*	DD: 10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd. 1840 Gateway Dr. 1840 Gateway Dr.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 11/20/2001 2000-1342		2nd Floor San Mateo CA 94404
Botulinum toxin type A *Botox*	DD: 3/22/1984 MA: 12/29/1989 MA: 12/29/1989 1983-0004B	Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above).	Allergan, Inc. 2525 Dupont Drive 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713
Botulinum toxin type A	DD: 9/15/1992 MA: 1991-0645	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc. 1261 Furnace Brook Parkway Quincy MA 02169
Botulinum toxin type A *Botox*	DD: 8/20/1986 MA: 12/21/2000 1985-0098	Treatment of cervical dystonia.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Botulinum toxin type A *Botox*	DD: 3/22/1984 MA: 12/29/1989 MA: 12/29/1989 1983-0004A	Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above).	Allergan, Inc. 2525 Dupont Drive 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713
Botulinum toxin type A *Dysport*	DD: 8/12/1998 MA: 1998-1141	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH GB
Botulinum toxin type A *Botox*	DD: 12/6/1991 MA: 1991-0565	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc. 2525 Dupont Drive 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Botulinum toxin type A *Dysport*	DD: 10/20/1999 MA: MA: 1999-1282	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead 1 Bath Rd., Maidenhead Berkshire SL6 4UH England GB
Botulinum toxin type A *Dysport*	DD: 3/23/1989 MA: 1989-0357	Treatment of essential blepharospasm.	Porton International, Inc. 1155 15th Street, N.W., #315 Washington DC 20005
Botulinum toxin type B *NeuroBloc*	DD: 1/16/1992 MA: 12/8/2000 1991-0647	Treatment of cervical dystonia.	Elan Pharmaceuticals, Inc. 800 Gateway Blvd. South San Francisco CA 94080
Botulinum toxin type F	DD: 12/5/1991 MA: 1991-0608	Treatment of essential blepharospasm.	Ipsen Limited (name changed from Porton International Inc) Milford MA
Botulinum toxin type F	DD: 10/24/1991 MA: 1991-0610	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited (name changed from Porton International Inc.) Milford MA
Botulism immune globulin	DD: 1/31/1989 MA: 1988-0344	Treatment of infant botulism.	California Department of Health Services 2151 Berkeley Way Berkeley CA 94704-1011

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Bovine colostrum	DD: 11/19/1990 MA: 1990-0551	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM 1030 North Parkview Drive Bismarck ND 58501
Bovine immunoglobulin concentrate, Cryptosporidium parvum *Sporidin-G*	DD: 3/1/1994 MA: MA: 1993-0782	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc. 4001 Lexington Avenue North Arden Hills MN 55126
Bovine whey protein concentrate *Immuno-C*	DD: 9/30/1993 MA: MA: 1993-0765	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or	Biomune Systems, Inc. 540 Arapeen Drive, Suite 202 540 Arapeen Drive, Suite 202 Salt Lake City UT 84108
Branched chain amino acids	DD: 12/23/1988 MA: 1988-0335	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center One Gustave L. Levy Place New York NY 10029
Brimonidine *Alphagan*	DD: 2/7/2000 MA: 1999-1256	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr. 2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534
Bromhexine *Bisolvon*	DD: 5/15/1989 MA: 1989-0347	Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Box 368 900 Ridgebury Road, Box 368 Ridgefield CT 06877-0368
Broxuridine *Broxine/Neomark*	DD: 9/18/1995 MA: 1995-0912	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc. 225 East Deerpath, Suite 250 225 East Deerpath, Suite 250 Lake Forest IL 60045
bryostatin-1	DD: 12/3/2001 MA: 2001-1482	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc. 610 Lincoln Street Waltham MA 02451
Buffered intrathecal electrolyte/dextrose injection *Elliotts B Solution*	DD: 8/24/1994 MA: 9/27/1996 1994-0839 1994-0839	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305
Buprenorphine hydrochloride *Subutex*	DD: 6/15/1994 MA: 10/8/2002 1993-0752	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc. 1901 Huguenot Road Richmond VA 23235
Buprenorphine in combination with naloxone *Suboxone*	DD: 10/27/1994 MA: 10/8/2002 1993-0790	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc. 1901 Huguenot Road Richmond VA 23235
Busulfan	DD: 3/5/2001	Intrathecal therapy for neoplastic meningitis	SuperGen, Inc. 4140 Dublin Boulevard

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Spartajet-Busulfan	MA: 2000-1407		4140 Dublin Boulevard Dublin CA 94568
Busulfan *Spartaject*	DD: 7/7/1997 MA: 1997-1058	Treatment of primary brain malignancies.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583
Busulfan *Busulfex*	DD: 7/28/1994 MA: 2/4/1999 MA: 2/4/1999 1994-0830	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
busulfan *Partaject*	DD: 11/25/2002 MA: 2002-1604	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc. 4140 Dublin Blvd 4140 Dublin Blvd Suite 200 Dublin CA 94568
Busulfan *Spartaject*	DD: 4/21/1994 MA: MA: 1994-0816	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc. 111 Rock Road 111 Rock Road Horsham PA 19044-2310
Butyrylcholinesterase	DD: 9/30/1992 MA: 1992-0691	Treatment of post-surgical apnea.	Shire Laboratories Inc. 1550 East Gude Drive Rockville MD 20850
Butyrylcholinesterase	DD: 3/25/1992 MA: MA: 1991-0635	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc. 1550 East Gude Drive Rockville MD 20850
BW 12C	DD: 10/23/1987 MA: 1987-0220	Treatment of sickle cell disease.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Pk NC 27709
C1 esterase inhibitor (human)	DD: 8/21/1996 MA: MA: 1996-0952	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032
C1-esterase-inhibitor, human, pasteurized *Berinert P*	DD: 10/16/1992 MA: MA: 1992-0675	Prevention and/or treatment of acute attacks of hereditary angioedema.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
C1-inhibitor *C1-inhibitor (human) vapor heated,*	DD: 8/30/1990 MA: 1990-0464	Treatment of acute attacks of angioedema.	Baxter Healthcare Corp. Hyland Division (Baxter Hyland) Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203
C1-inhibitor *C1-inhibitor (human) vapor heated,*	DD: 8/30/1990 MA: MA: 1990-0465	Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.	Baxter Healthcare Corp. Hyland Division (Baxter Hyland) Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203
Caffeine *Cafcit*	DD: 9/20/1988 MA: 9/21/1999	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence KS 66047

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1988-0312		
Calcitonin salmon nasal spray *Miacalcin Nasal Spray*	DD: 10/29/1990 MA: 1990-0482	Treatment of symptomatic Paget's disease (osteitis deformans).	Sandoz Pharmaceuticals Corp. 59 Route 10 59 Route 10 East Hanover NJ 07936
Calcitonin-human for injection *Cibacalcin*	DD: 1/20/1987 MA: 10/31/1986 1986-0131	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation 59 Route 10 59 Route 10 East Hanover NJ 07936
Calcium acetate	DD: 6/27/1989 MA: 1989-0364	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company 28101 Ballard Road, Suite F Lake Forest IL 60045
Calcium acetate *Phos-Lo*	DD: 12/22/1988 MA: 12/10/1990 1988-0315	Treatment of hyperphosphatemia in end stage renal failure.	Braintree Laboratories 60 Columbian Street 60 Columbian Street P.O. Box 361 Braintree MA 02184
Calcium carbonate *R & D calcium carbonate/600*	DD: 6/6/1990 MA: 1989-0421	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc. 4204 Glencoe Avenue 4204 Glencoe Avenue Marina Del Rey CA 90292
Calcium gluconate *Calgonate*	DD: 11/20/1997 MA: 1997-1089	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp. 190 Commerce Drive 190 Commerce Drive Warwick RI 02886
Calcium gluconate gel *H-F Gel*	DD: 5/21/1991 MA: MA: 1985-0064	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	LTR Pharmaceuticals, Inc. 145 Sakonnet Blvd. 145 Sakonnet Blvd. Narragansett RI 02882
Calcium gluconate gel 2.5%	DD: 9/10/1990 MA: 1990-0462	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc. 3940 Quebec Avenue North Minneapolis MN 55427
Calfactant *Infasurf*	DD: 9/5/2000 MA: 2000-1364	Acute respiratory distress syndrome (ARDS)	ONY, Inc. Baird Research Park Baird Research Park 1576 Sweet Home Road Amherst NY 14228
capsaicin	DD: 10/23/2002 MA: 2002-1582	Treatment of erythromelalgia	NeurogesX, Inc. 981F Industrial Road San Carlos CA 94070
carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,eth	DD: 1/15/2002 MA: 2001-1486	Management of cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road P.O. Box 368 Ridgefield CT 06877
Carbamylglutamic acid	DD: 1/20/1998 MA: 1997-1099	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60, avenue du General de Gaulle - Cedex 70

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
			92046 Paris La Defense FR
Carbovir	DD: 12/13/1989 MA: MA: 1989-0411	Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Carmustine	DD: 7/3/2000 MA: 2000-1345	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 1001 Bayhill Dr., Suite 100 San Bruno CA 94066
Cascara sagrada fluid extract	DD: 3/21/1989 MA: 1988-0342	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation 102 Tremont Way Augusta GA 30907
CD4 human truncated 369 AA polypeptide *Soluble T4*	DD: 11/21/1989 MA: 1989-0388	Treatment of acquired immunodeficiency syndrome.	SmithKline Beecham Route 23 & Woodmont Ave., P.O. Box 1510 King Of Prussia PA 19406
CD5-T lymphocyte immunotoxin *Xomazyme-H65*	DD: 8/27/1987 MA: MA: 1987-0195	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	Xoma Corporation 2910 Seventh Street 2910 Seventh Street Berkeley CA 94710
CDP571	DD: 12/11/1997 MA: 1997-1084	Treatment of Crohn's disease.	Celltech Chiroscience Limited 216 Bath Road Slough SL1 4EN Berkshire UK
cells produced using the AastromReplicelle System and SC-I Therapy Kit	DD: 7/10/2002 MA: 2001-1534 2001-1534	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated P.O. Box 376 Ann Arbor MI 48106
Centruroides immune F(ab)2 *Alacramyn*	DD: 6/12/2000 MA: 2000-1359	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de C.V. Amores #1034 Col Del Valle Amores #1034 Col Del Valle C.P. 03100 Mexico D.F.
Ceramide trihexosidase/alpha-galactosidase *Fabrazyme*	DD: 1/19/1988 MA: MA: 1986-0152	Treatment of Fabry's disease.	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562
Cetiedil citrate injection	DD: 12/22/1988 MA: 1988-0314	Treatment of sickle cell disease crisis.	Baker Cummins Pharmaceuticals,
Cetuximab	DD: 7/3/2000 MA: MA: 2000-1327	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876
Chenodiol *Chenix*	DD: 9/21/1984 MA: 7/28/1983 MA: 7/28/1983 1984-0033	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.	Solvay 901 Sawyer Road 901 Sawyer Road Marietta GA 30062

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Chimeric (human-murine) G250 IgG monoclonal antibody	DD: 7/24/2000 MA: 2000-1333	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE
Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4	DD: 6/5/1991 MA: 1990-0544	Treatment of multiple sclerosis.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Chimeric, humanized monoclonal antibody to staphylococcus	DD: 8/3/2000 MA: 1999-1320	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc. 9610 Medical Center Drive Suite 100 Rockville MD 20850
Chlorhexidine gluconate *Peridex*	DD: 8/18/1986 MA: MA: 1986-0130	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company Sharon Wood Technical Center Sharon Wood Technical Center 11370 Reed Hartman Highway Cincinnati OH 45241
Choline chloride *Intrachol*	DD: 2/10/1994 MA: MA: 1993-0769	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Chondrocyte-alginate gel suspension	DD: 12/1/1997 MA: 1997-1076	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc. 61 Moulton Street Cambridge MA 02138
Chondroitinase	DD: 2/9/1995 MA: 1994-0877	Treatment of patients undergoing vitrectomy.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Pkwy. Tampa FL 33637
Ciliary neurotrophic factor	DD: 1/30/1992 MA: 1991-0636	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc 777 Old Saw Mill River Road Tarrytown NY 10591
Ciliary neurotrophic factor, recombinant human	DD: 5/8/1992 MA: 1992-0664 1992-0664	Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis).	Syntex-Synergen Neuroscience 3200 Walnut Street Boulder CO 80301
Ciliary neurotrophic factor, recombinant human	DD: 4/2/1992 MA: 1992-0663	Treatment of spinal muscular atrophies.	Syntex-Synergen Neuroscience 3200 Walnut Street Boulder CO 80301
Cisplatin/epinephrine *IntraDose*	DD: 4/3/2000 MA: 2000-1332	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc. 34700 Campus Drive 34700 Campus Drive Fremont CA 94555-3612
Cisplatin/epinephrine *IntraDose*	DD: 9/7/2000 MA: 2000-1348	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc. 34700 Campus Drive 34700 Campus Drive Fremont CA 94555-3612
Citric acid, glucono-delta-lactone and magnesium carbonate	DD: 8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc. P.O. Box 2500

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Renacidin Irrigation	MA: 10/2/1990 MA: 10/2/1990 1989-0401		Smithtown NY 11787
civamide *Zucapsaicin*	DD: 12/9/2002 MA: 2002-1591	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc. 100 Fairway Drive, Suite 134 100 Fairway Drive, Suite 134 Vernon Hills IL 60061
Cladribine *Leustatin Injection*	DD: 12/31/1990 MA: 1990-0541	Treatment of chronic lymphocytic leukemia.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602
Cladribine *Leustatin Injection*	DD: 4/19/1993 MA: 1992-0680	Treatment of non-Hodgkin's lymphoma.	R. W. Johnson Pharmaceutical Research Institute Route 202 South, P.O. Box 300 Raritan NJ 08869-0602
ladribine *Leustatin Injection*	DD: 11/15/1990 MA: 2/26/1993 1990-0516	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869
Cladribine *Leustatin*	DD: 7/20/1990 MA: 1990-0479	Treatment of acute myeloid leukemia.	R. W. Johnson Pharmaceutical Research Institute Route 202 P.O. Box 300 Raritan NJ 08869
Cladribine *Mylinax*	DD: 4/19/1994 MA: 1993-0777	Treatment of the chronic progressive form of multiple sclerosis.	R. W. Johnson Pharmaceutical Research Institute Route 202 PO Box 300 Raritan NJ 08869-0602
Clindamycin *Cleocin*	DD: 10/28/1988 MA: 1988-0270	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Clindamycin *Cleocin*	DD: 10/28/1988 MA: 1988-0269	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
clofarabine *Clofarex*	DD: 3/14/2002 MA: 2002-1548	Treatment of acute myelogenous leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
clofarabine *Clofarex*	DD: 2/7/2002 MA: 2001-1532	Treatment of acute lymphoblastic leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Clofazimine *Lamprene*	DD: 6/11/1984 MA: 12/15/1986 MA: 12/15/1986 1984-0026	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation 59 Route 10 59 Route 10 East Hanover NJ 07936

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Clonazepam	DD: 8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc. 340 Kingsland Street
Klonopin	MA: 1994-0827		340 Kingsland Street Nutley NJ 07110
Clonidine	DD: 1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates	Roxane Laboratories, Inc. PO Box 16532
Duraclon	MA: 10/2/1996 MA: 10/2/1996	for the treatment of pain in cancer patients tolerant to, or unresponsive to,	PO Box 16532 Columbus OH 43216-6532
	1988-0343	intraspinal opiates.	
ostridial collagenase	DD: 5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. Ph.D. State University of New York at
	MA: 1995-0925		Stony Brook School of Medicine, Health Sciences Center T18-020 Stony Brook NY 11794-8181
Clotrimazole	DD: 4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D. The Children's Hospital
	MA: 1994-0880		300 Longwood Avenue, Bader 760 Boston MA 02115
Coagulation factor IX	DD: 6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of	Armour Pharmaceutical Company 500 Arcola Road, P.O. Box 1200
Mononine	MA: 8/20/1992 MA: 8/20/1992 1989-0361	hemophilia B.	500 Arcola Road, P.O. Box 1200 Collegeville PA 19426
Coagulation Factor IX (human)	DD: 7/5/1990	For use as replacement therapy in patients with hemophilia B for the	Alpha Therapeutic Corporation 5555 Valley Boulevard
AlphaNine	MA: 12/31/1990 MA: 12/31/1990	prevention and control of bleeding episodes, and during surgery to correct	5555 Valley Boulevard Los Angeles CA 90032
	1990-0458	defective hemostasis.	
Coagulation Factor IX *BeneFix*	DD: 10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive
	MA: 2/11/1997 1994-0822		Cambridge MA 02140
Coagulation factor VIIa (recombinant)	DD: 6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center
NovoSeven	MA: 3/25/1999 MA: 3/25/1999 1988-0265		Suite 200 Princeton NJ 08540-7810
Coenzyme Q10	DD: 3/5/2001	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way
	MA: 2000-1387		Ashland OR 97520
Colchicine	DD: 12/9/1985	For arresting the progression of neurologic disability caused by chronic progressive	Pharmacontrol Corporation 661 Palisade Ave., P.O. Box 931
	MA: MA: 1985-0110	multiple sclerosis.	Englewood Cliffs NJ 07632
Colfosceril palmitate, cetyl alcohol, tyloxapol *Exosurf*	DD: 1/11/1993 MA: MA: 1992-0684	Treatment of adult respiratory distress syndrome.	GlaxoSmithKline 5 Moore Drive P.O. Box 13398 Research Triangle Park NC 27709
Colfosceril palmitate, cetyl alcohol, tyloxapol *Exosurf Neonatal for Intratracheal*	DD: 10/20/1989 MA: 8/2/1990	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc. 5 Moore Drive

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 8/2/1990 1986-0148B		Research Triangle Park NC 27709
Colfosceril palmitate, cetyl alcohol, tyloxapol *Exosurf Neonatal for Intratracheal*	DD: 10/20/1989 MA: 8/2/1990 1986-0148A	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Collagenase (lyophilized) for injection *Plaquase*	DD: 3/12/1996 MA: MA: 1996-0954	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook NY 11563-2358
conjugate of human transferrin and a mutant diphtheria toxin *TransMID*	DD: 12/3/2001 MA: MA: 2001-1509	Treatment of malignant tumors of the central nervous system	INTELLIgene Expressions Inc. 1938-94 St. Edmonton, AB T6N 1J3
Corticorelin ovine triflutate *Acthrel*	DD: 11/24/1989 MA: 5/23/1996 MA: 5/23/1996 1989-0350	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Corticotropin-releasing factor, human *Xerecept*	DD: 4/6/1998 MA: MA: 1997-1080	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond CA 94804
Coumarin *Onkolox*	DD: 12/22/1994 MA: 1994-0842	Treatment of renal cell carcinoma.	Drossapharm LTD 4002 Basel Switzerland CH
creatine *Creapure*	DD: 2/12/2002 MA: 2001-1527	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104
Cromolyn sodium *Gastrocrom*	DD: 3/8/1984 MA: 12/22/1989 1983-0011	Treatment of mastocytosis.	Fisons Corporation 755 Jefferson Rd P.O. Box 1710 Rochester NY 14603
Cromolyn sodium 4% ophthalmic solution *Opticrom 4% ophthalmic solution*	DD: 7/24/1985 MA: 10/3/1984 MA: 10/3/1984 1985-0082	Treatment of vernal keratoconjunctivitis.	Fisons Corporation 755 Jefferson Rd. P.O. Box 1710 Rochester NY 14603
Cryptosporidium hyperimmune bovine colostrum IgG concentrate	DD: 12/30/1991 MA: 1991-0625	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation 56 Evergreen Drive Portland ME 04103
CT-2584 mesylate	DD: 4/16/1999 MA: 1999-1248	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle WA 98119
CT-2584 mesylate	DD: 4/16/1999 MA: 1998-1217	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle WA 98119
CY-1503	DD: 12/22/1993	Treatment of post-ischemic pulmonary	Cytel Corporation

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Cylexin	MA: 1993-0776	reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	3525 John Hopkins Court
CY-1503 *Cylexin*	DD: 7/18/1997 MA: 1997-1062	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court
CY-1899	DD: 3/16/1994 MA: 1993-0748	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation 3525 John Hopkins Court San Diego CA 92121
Cyclosporine 2% ophthalmic ointment	DD: 8/1/1991 MA: 1991-0589	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Cyclosporine 2% ophthalmic ointment	DD: 8/1/1991 MA: 1990-0517	Treatment of patients at high risk of graft rejection following penetrating keratoplasty.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Cyclosporine in combination with omega-3 polyunsaturated fatty	DD: 12/6/2000 MA: 2000-1385	Prevention of solid organ graft rejection.	RTP Pharma Corporation 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280
Cyclosporine ophthalmic *Optimmune*	DD: 11/9/1988 MA: 1988-0299	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia College Of Veterinary Medicine College Of Veterinary Medicine Department of Small Animal Medicine Athens GA 30602
Cyproterone acetate *Androcur*	DD: 10/26/1984 MA: 1984-0038	Treatment of severe hirsutism.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470
Cysteamine	DD: 5/1/1986 MA: 1986-0139	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D. University of Michigan Medical 300 NIB, 1192 SE Ann Arbor MI 48109-0408
Cysteamine *Cystagon*	DD: 1/25/1991 MA: 8/15/1994 1990-0556	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown WV 26504
Cysteamine hydrochloride	DD: 8/19/1997 MA: 1997-1059	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877
Cystic fibrosis gene therapy	DD: 6/30/1992 MA: 1992-0661	Treatment of cystic fibrosis.	Genzyme Corporation One Mountain Rd. P.O. Box 9322 Framingham MA 01701-9322
Cystic fibrosis Tr gene therapy (recombinant adenovirus) *AdGVCFTR.10*	DD: 3/9/1995 MA: MA: 1994-0876	Treatment of cystic fibrosis.	GenVec, Inc. 12111 Parklawn Drive Rockville MD 20852

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Cystic fibrosis transmembrane conductance regulator	DD: 1/14/1992 MA: 1991-0638	For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Cystic fibrosis transmembrane conductance regulator gene	DD: 1/8/1993 MA: 1992-0704	Treatment of cystic fibrosis.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878
Cytarabine liposomal *DepoCyt*	DD: 6/2/1993 MA: 4/1/1999 1993-0733	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego CA 92121
Cytomegalovirus immune globulin (human) *CytoGam*	DD: 8/3/1987 MA: 12/4/1998 MA: 12/4/1998 1986-0153	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Massachussetts Public Health Biologic Laboratories 305 South Street 305 South Street Boston MA 02130-3597
Cytomegalovirus immune globulin intravenous (human)	DD: 1/28/1991 MA: 1990-0521	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation Pharmaceutical Division, Biological Products 400 Morgan Lane New Haven CT 06516
D-peptide of the sequence AKRHHGYKRKFH - NH2 *PulmaDex*	DD: 10/23/2002 MA: MA: 2002-1565	Treatment of cystic fibrosis	Demegen, Inc. 1051 Brinton Road Pittsburgh PA 15221
Daclizumab *Zenapax*	DD: 3/5/1993 MA: 12/10/1997 1992-0676	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Dantrolene sodium *Dantrium*	DD: 12/14/1987 MA: 1987-0232	Treatment of the neuroleptic malignant syndrome.	Norwich Eaton Pharmaceuticals P.O. Box 191 P.O. Box 191 Norwich NY 13815
Dapsone	DD: 11/7/1994 MA: 1994-0856	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc. 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Dapsone USP *Dapsone*	DD: 12/24/1991 MA: 1991-0611	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company 37 Cleveland Lane 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Dapsone USP *Dapsone*	DD: 1/8/1992 MA: MA: 1991-0612	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company 37 Cleveland Lane 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Daunorubicin citrate liposome injection *DaunoXome*	DD: 5/14/1993 MA: 4/8/1996 MA: 4/8/1996 1993-0736	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas CA 91773

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Decitabine	DD: 3/8/1999 MA: 1998-1222	Treatment of myelodysplastic syndromes.	SuperGen, Inc. 4140 Dublin Blvd. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Decitabine	DD: 3/8/1999 MA: 1999-1233	Treatment of chronic myelogenous leukemia.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
decitabine	DD: 9/9/2002 MA: 2002-1597	Treatment of sickle cell anemia	SuperGen, Inc. 4140 Dublin Blvd., Suite 200 Dublin CA 94568
Deferasirox	DD: 11/21/2002 MA: MA: 2002-1610	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080
deferiprone *Ferriprox*	DD: 12/12/2001 MA: MA: 2001-1507	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Apotex Research Inc. 150 Signet Drive 150 Signet Drive Toronto, Canada M9L 1T9
Defibrotide	DD: 7/5/1985 MA: 1985-0072	Treatment of thrombotic thrombocytopenic purpura.	Crinos International Via Belvedere 1 Villa Guardia, Italy 22079
Dehydroepiandrosterone	DD: 7/13/1994 MA: MA: 1994-0837	Treatment of systemic lupus erythematosus (SLE) and the reduction in SLE patients. the use of steroids in steroid-dependent	Genelabs Technologies, Inc. 505 Penobscot Drive Redwood City CA 94063
Dehydroepiandrosterone sulfate sodium	DD: 1/29/1997 MA: 1996-1021	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City UT 84109-1405
Dehydroepiandrosterone sulfate sodium	DD: 1/28/1997 MA: 1996-1019	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City UT 84109-1405
Denileukin diftitox *Ontak*	DD: 8/21/1996 MA: 2/5/1999 MA: 2/5/1999 1996-0993	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive 10275 Science Center Drive San Diego CA 92121
Deoxyribose, phosphorothioate	DD: 7/31/2000 MA: 2000-1346	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966
Deslorelin *Somagard*	DD: 11/5/1987 MA: 1986-0160		Roberts Pharmaceutical Corp. Meridian Center II Four Industrial Way West Eatontown NJ 07724-2274
Desmopressin acetate	DD: 1/22/1991 MA: 3/7/1994 1990-0514	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King of Prussia PA 19406-0901

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Dexamethasone	DD: 9/11/1998 MA: MA: 1998-1152	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals, Inc. 639 N. Pastoria Avenue Sunnyvale CA 94086-2917
Dexrazoxane *Zinecard*	DD: 12/17/1991 MA: 5/26/1995 1991-0632	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Kalamazoo MI 49001-0199
Dextran 70 *Dehydrex*	DD: 3/5/1990 MA: 1989-0426	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc. 30 Forest Notch 30 Forest Notch Cohasset MA 02025
Dextran and deferoxamine *Bio-Rescue*	DD: 3/8/1991 MA: 1990-0522	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc. 1095 10th Avenue S.E. Minneapolis MN 55414
Dextran sulfate (inhaled, aerosolized) *Uendex*	DD: 10/5/1990 MA: MA: 1990-0506	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University Of Utah Medical Center 50 North Medical Drive, Room 4R240 Salt Lake City UT 84132
Dextran sulfate sodium	DD: 11/19/1987 MA: 1987-0231	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd. 2-31 Koraibashi, Higashi-ku Osaka 541, Japan
DHA-paclitaxel *Taxoprexin*	DD: 9/25/2001 MA: 2001-1478	Treatment of pancreatic cancer	Protarga, Inc. 2200 Renaissance Blvd. Suite 450 King of Prussia PA 19406
DHA-paclitaxel *Taxoprexin*	DD: 10/10/2002 MA: 2001-1530	Treatment of metastatic malignant melanoma	Protarga, Inc. 2200 Renaissance Boulevard 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406
Dianeal peritoneal dialysis solution with 1.1% amino acids *Nutrineal (Peritoneal Dialysis Solution*	DD: 6/11/1992 MA: 1991-0641	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation 1620 Waukegan Road McGaw Park IL 60085
Diazepam viscous solution for rectal administration	DD: 2/25/1992 MA: 7/29/1997 1991-0615 1991-0615	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco CA 94080
Diaziquone	DD: 11/10/1983 MA: 1983-0003	Treatment of primary brain malignancies (grade III and IV astrocytomas).	Warner-Lambert Company 2800 Plymouth Rd., P.O. Box 1047 Ann Arbor MI 48106
Dideoxyinosine	DD: 6/22/1988 MA: 1988-0294	Treatment of acquired immunodeficiency syndrome.	Bristol-Myers Squibb
Diethyldithiocarbamate *Imuthiol*	DD: 4/3/1986 MA:	Treatment of AIDS.	Connaught Laboratories Route 611, P.O. Box 187 Swiftwater PA 18370

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1986-0132		
digitoxin	DD: 10/18/2001 MA: 2001-1497	Treatment of soft tissue sarcomas	PrimeCyte, Inc. 130 Fifth Ave., N. Seattle WA 98109-4933
digitoxin	DD: 11/2/2001 MA: 2001-1496	Treatment of ovarian cancer	PrimeCyte, Inc. 130 Fifth Ave., N. Seattle WA 98109-4933
Digoxin immune FAB (Ovine) *Digibind*	DD: 11/1/1984 MA: 4/22/1986 MA: 4/22/1986 1984-0025	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Digoxin immune fab(ovine) *Digidote*	DD: 3/11/1985 MA: MA: 1985-0056	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp. 1301 Piccard Drive 1301 Piccard Drive Rockville MD 20850
Dihydrotestosterone *Androgel -DHT*	DD: 2/5/1996 MA: 1995-0939	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. Four Parkway North Four Parkway North Deerfield IL 60015-2544
Dimethyl sulfoxide	DD: 11/22/1994 MA: MA: 1994-0813	Treatment of increased intracranial pressure in patients with severe, traumatic brain coma, for whom no other closed-head injury, also known as effective treatment is available.	Pharma 21 c/o Univ. of Calif., San Diego 9500 Gilman Dr. La Jolla CA 92093-0624
Dimethyl sulfoxide	DD: 6/6/1986 MA: 1986-0149	Treatment of cutaneous manifestations of scleroderma.	Research Industries Corp.
Dimethylsulfoxide	DD: 4/6/1998 MA: 1997-1086	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson AZ 85710
Dimethylsulfoxide	DD: 4/15/1997 MA: MA: 1997-1040	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson AZ 85710
Dipalmitoylphosphatidylcholine /phosphatidylglycerol *ALEC*	DD: 7/28/1988 MA: MA: 1988-0296	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc. 33 Flying Point Road Southampton NY 11968
Disaccharide tripeptide glycerol dipalmitoyl *Immther*	DD: 3/1/1990 MA: MA: 1989-0397	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc. 3505 Riverview Circle Moorhead MN 56560
Disodium clodronate	DD: 6/16/1993 MA:	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc. 29949 S.R. 54 West Wesley Chapel FL 33543

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1992-0722		
Disodium clodronate tetrahydrate *Bonefos*	DD: 3/5/1990 MA: 1989-0406	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 103 Carnegie Center, Suite 102 Princeton NJ 08540
Disodium silibinin *Legalon*	DD: 7/10/1986 MA: 1986-0150	Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).	Pharmaquest Corporation 4470 Redwood Highway 4470 Redwood Highway San Rafael CA 94903
DMP 777	DD: 6/4/1996 MA: 1996-0964	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company Chestnut Run, Maple Run Centre Rd. Wilmington DE 19805
DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2 *Leuvectin*	DD: 4/28/2000 MA: MA: 2000-1344	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088
DNP-Modified autologous tumor vaccine *O-Vax*	DD: 9/21/2000 MA: MA: 2000-1380	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210
docosahexanoic acid-paclitaxel *Taxoprexin*	DD: 3/5/2001 MA: 2001-1417	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377
Dornase alfa *Pulmozyme*	DD: 1/16/1991 MA: 12/30/1993 MA: 12/30/1993 1990-0480	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Doxorubicin liposome *Doxil*	DD: 11/4/1998 MA: 6/28/1999 1998-1173	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View CA 94039-7210
Dronabinol *Marinol*	DD: 1/15/1991 MA: 12/22/1992 MA: 12/22/1992 1990-0548	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 2150 East Lake Cook Road, Suite Buffalo Grove IL 60089-1862
Duramycin	DD: 12/11/1997 MA: 1997-1078	Treatment of cystic fibrosis.	MoliChem Medicines Inc. 207 South Elliott Road PMB#231 Chapel Hill NC 27514
Dynamine	DD: 10/16/1991 MA: MA: 1990-0560	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation 200 First Street Southwest Rochester MN 55905
Dynamine	DD: 2/5/1990 MA:	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation 200 First Street Southwest Rochester MN 55905

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1989-0431		
eculizumab	DD: 3/5/2001 MA: 2000-1388	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410
Eflornithine HCl *Ornidyl*	DD: 4/18/1986 MA: 1986-0136	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Marion Merrell Dow, Inc. P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Eflornithine HCl *Ornidyl*	DD: 4/23/1986 MA: 11/28/1990 1986-0135	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Elcatonin	DD: 9/25/1995 MA: 1994-0815	Intrathecal treatment of intractable pain.	Innapharma, Inc. 10 Mountainview Road Upper Saddle River NJ 07458
Enadoline hydrochloride	DD: 1/28/1997 MA: 1996-1024	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48105
Encapsulated porcine islet preparation *BetaRx*	DD: 7/5/1995 MA: MA: 1995-0901	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx 2825 Santa Monica Blvd. 2nd Floor Santa Monica CA 90404-2429
Enisoprost	DD: 10/20/1989 MA: MA: 1989-0372B	For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.	G.D. Searle & Company 4901 Searle Parkway Skokie IL 60077
Enisoprost	DD: 10/20/1989 MA: MA: 1989-0372A	For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection.	G.D. Searle & Company 4901 Searle Parkway Skokie IL 60077
Epidermal growth factor (human)	DD: 3/6/1985 MA: 1985-0054	For promotion of cutaneous wound healing in extreme burn treatment protocols.	Ethicon, Inc. P.O. Box 151 Somerville NJ 08876
Epidermal growth factor (human)	DD: 10/5/1987 MA: MA: 1986-0143	For acceleration of corneal epithelial regeneration and the healing of stromal corneal defects. tissue in the condition of non-healing	Chiron Vision 500 Iolab Drive Claremont CA 91711
Epirubicin *Ellence*	DD: 9/14/1999 MA: 9/15/1999 1998-1214	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo MI 49001-0199
Epoetin alfa *Epogen*	DD: 7/1/1991 MA: 12/31/1990 1990-0564	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Epoetin alfa	DD: 12/20/1993	Treatment of myelodysplastic syndrome.	R. W. Johnson Pharmaceutical

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
			Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602
	MA: 1993-0787		
Epoetin alfa *Epogen*	DD: 4/10/1986 MA: 6/1/1989 1986-0124	Treatment of anemia associated with end stage renal disease.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Epoetin alpha *Procrit*	DD: 7/21/1988 MA: 1987-0219	Treatment of anemia of prematurity in preterm infants.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602
Epoetin alpha *Procrit*	DD: 3/7/1989 MA: 1988-0326	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869
Epoetin alpha *Procrit*	DD: 8/27/1987 MA: 1986-0171	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute Route 202 South P.O. Box 300 Raritan NJ 08869
Epoetin beta *Marogen*	DD: 10/22/1987 MA: 1987-0229	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc. 3780 Hawthorn Court 3780 Hawthorn Court Waukegan IL 60087
Epoprostenol *Flolan*	DD: 3/29/1984 MA: MA: 1983-0007A	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Epoprostenol *Cycloprostin*	DD: 10/29/1984 MA: MA: 1984-0028A	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Upjohn Company 301 Henrietta Street 301 Henrietta Street Kalamazoo MI 49001
Epoprostenol *Flolan*	DD: 3/22/1999 MA: 4/14/2000 MA: 4/14/2000 1998-1216	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline Five Moore Dr. Five Moore Dr. PO Box 13398 Research Triangle Park NC 27709-3398
Epoprostenol *Flolan*	DD: 9/25/1985 MA: 9/20/1995 1985-0087	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
eprafuzumab *LymphoCIDE*	DD: 7/13/1998 MA: 1998-1132	Treatment of non-Hodgkin's lymphoma.	Amgen One Amgen Center Drive Thousand Oaks CA 20857
Erwinia L-asparaginase *Erwinase*	DD: 7/30/1986 MA: 1986-0151	Treatment of acute lymphocytic leukemia.	Porton International, Inc. 7114 Springbrook Terrace, #200 Spotsylvania VA 22553

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Erwinia L-asparaginase	DD: 1/25/1985 MA: 1984-0046 1984-0046	For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the E. coli	Lyphomed, Inc.
Erythropoietin (human,	DD: 11/19/1987 MA: 1987-0189	Treatment of anemia associated with end stage renal disease.	Organon Teknika Corporation
Erythropoietin (recombinant	DD: 8/19/1987 MA: 1986-0178	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp P.O. Box 516, 107/2 MS10 St. Louis MO 63166
Etanercept *Enbrel*	DD: 4/6/1999 MA: 1999-1229	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle WA 98101-2936
Etanercept *Enbrel*	DD: 10/27/1998 MA: 5/27/1999 MA: 5/27/1999 1998-1161	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. 51 University St. Seattle WA 98101-2936
Ethanolamine oleate *Ethamolin*	DD: 3/22/1984 MA: 12/22/1988 MA: 12/22/1988 1984-0014	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	Block Drug Company, Inc. 257 Cornelison Avenue 257 Cornelison Avenue Jersey City NJ 07302
Ethinyl Estradiol, USP	DD: 6/22/1988 MA: 1988-0287	Treatment of Turner's syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Ethiofos	DD: 8/1/1989 MA: 1987-0241	Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.	U.S. Bioscience
Ethyl eicosapentaenoate	DD: 4/6/2000 MA: 2000-1343	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Business Park Polmaise Road, Stirling FK7 9JQ United Kingdom UK
Etidronate disodium *Didronel*	DD: 3/21/1986 MA: 4/21/1987 MA: 4/21/1987 1985-0121	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
Etidronate disodium *Didronel IV infusion*	DD: 5/2/1991 MA: MA: 1990-0498	Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
Etidronate disodium *Didronel IV Infusion*	DD: 5/2/1991 MA: MA: 1990-0497	Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Etiocholanedione	DD: 5/7/1996 MA: 1996-0958	Treatment of Prader-Willi syndrome.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583
Etiocholanedione	DD: 11/3/1995 MA: 1995-0926	Treatment of aplastic anemia.	SuperGen, Inc. Two Annabel Lane, Suite 220 Suite 10 San Ramon CA 94583
Exemestane *Aromasin*	DD: 9/19/1991 MA: 10/21/1999 MA: 10/21/1999 1991-0601	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo MI 49001-0199
Exisulind	DD: 2/14/1994 MA: MA: 1993-0792	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	Cell Pathways, Inc. 702 Electronic Drive Horsham PA 19044
factor XIII concentrate (human), pasteurized *Fibrogammin P*	DD: 1/16/1985 MA: MA: 1984-0044	Treatment of congenital factor XIII deficiency.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
Factor XIII, recombinant	DD: 4/22/1993 MA: 1993-0739	Treatment of congenital factor XIII deficiency.	Zymogenetics, Inc. 4225 Roosevelt Way Seattle WA 98105
Fampridine *Neurelan*	DD: 6/2/1987 MA: 1986-0181	Relief of symptoms of multiple sclerosis.	Acorda Therapeutics 15 Skyline Dr. Hawthorne NY 10532
Fampridine *Neurelan*	DD: 6/2/1997 MA: 1997-1044	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 15 Skyline Dr. 15 Skyline Dr. Hawthorne NY 10532
Felbamate *Felbatol*	DD: 1/24/1989 MA: 7/29/1993 1988-0334	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories 301B College Road East Princeton NJ 08540
FIAU	DD: 7/24/1992 MA: 1992-0678	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc. 100 Pelican Way San Rafael CA 94901
Fibrinogen (human)	DD: 8/23/1995 MA: MA: 1995-0885	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032
Fibronectin (human plasma	DD: 9/5/1988 MA: MA: 1987-0249	Treatment of non-healing corneal ulcers or epithelial defects which have been the underlying cause has been unresponsive to conventional therapy and eliminated.	Melville Biologics, Inc. 310 East 67th Street New York NY 10021
Fibronectin (plasma derived)	DD: 12/5/1988 MA: MA:	Treatment of non-healing corneal ulcers or epithelial defects which are unresponsive infectious cause of the defect has been to conventional therapy and for which any	Chiron Vision 9342 Jeronimo Road Irvine CA 92718

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1987-0242	eliminated.	
Filgrastim *Neupogen*	DD: 10/1/1990 MA: 6/15/1994 1990-0500	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 8/30/1990 MA: 1990-0490	Treatment of myelodysplastic syndrome.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 9/3/1991 MA: MA: 1990-0499	Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir.	Amgen, Inc. One Amgen Center Dr. One Amgen Center Dr. Thousand Oaks CA 91320-1799
Filgrastim *Neupogen*	DD: 11/7/1990 MA: 12/19/1994 MA: 12/19/1994 1990-0493	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 7/17/1995 MA: 12/28/1995 MA: 12/28/1995 1995-0893	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 11/7/1996 MA: 4/2/1998 MA: 4/2/1998 1996-1010	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. One Amgen Center Dr. One Amgen Center Dr. Thousand Oaks CA 91320-1799
Flucinolone	DD: 7/31/2000 MA: 2000-1328	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Parkway Tampa FL 33637
Fludarabine phosphate *Fludara*	DD: 4/18/1989 MA: 1989-0358	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc. 15049 San Pablo Avenue 15049 San Pablo Avenue P.O. Box 4099 Richmond CA 94804-0099
Fludarabine phosphate *Fludara*	DD: 4/18/1989 MA: 4/18/1991 1988-0276	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc. 15049 San Pablo Avenue, P.O. Box 15049 San Pablo Avenue, P.O. Box 4099 Richmond CA 94804
Flumecinol *Zixoryn*	DD: 1/15/1985 MA: MA: 1984-0029	Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.	Farmacon, Inc. Post House, Suite 213 Post House, Suite 213 1720 Post Road East Westport CT 06880-5643
Flunarizine *Sibelium*	DD: 1/6/1986 MA: MA: 1985-0094	Treatment of alternating hemiplegia.	Janssen Research Foundation P.O. Box 200 Titusville NJ 08560
Fluorouracil	DD: 4/18/1990 MA:	For use in combination with interferon alpha-2a, recombinant, for the treatment	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1989-0422	of advanced colorectal carcinoma.	
Fluorouracil	DD: 2/6/1989	For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.	Lederle Laboratories Division of American Cyanamid
Adrucil	MA:		Division of American Cyanamid Company
	MA: 1988-0320		401 N. Middletown Road Pearl River NY 10965
Fluorouracil	DD: 10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199
	MA:		
	MA: 1989-0405	of esophageal carcinoma.	
Fluorouracil	DD: 6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - Batiment 92213 Saint-Cloud Cedex France FR
	MA: 1999-1317		
Fluoxetine *Prozac*	DD: 4/30/1999	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry
	MA:		Box 1230, One Gustave L. Levy New York NY 10029-6574
	1999-1231		
Follitropin alfa, recombinant	DD: 12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with	Serono Laboratories, Inc. 100 Longwater Circle
Gonal-F	MA: 5/24/2000	reproductive failure due to hypothalamic	100 Longwater Circle
	MA: 5/24/2000	or pituitary dysfunction, hypogonadotropic	Norwell MA 02061
	1998-1193	hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	
Fomepizole	DD: 12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive
Antizole			13911 Ridgedale Drive Suite 250
	MA: 12/8/2000 1988-0333b		Minnetonka MN 55305
Fomepizole	DD: 12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive
Antizole			13911 Ridgedale Drive Suite 250
	MA: 12/4/1997 1988-0333		Minnetonka MN 55305
Fosphenytoin	DD: 6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company 2800 Plymouth Road
Cerebyx			2800 Plymouth Road
	MA: 8/5/1996 1990-0557		Ann Arbor MI 48106
Fructose-1,6-diphosphate	DD: 5/29/1998	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Questcor Pharmaceuticals, Inc. 3260 Whipple Road
Cordox	MA:		3260 Whipple Road
	MA: 1998-1123		Union City CA 94587-1217
G17DT Immunogen	DD: 7/10/2002	Treatment of adenocarcinoma of the pancreas	Aphton Corporation 26 Harter Avenue
	MA: 2002-1569		Suite 14 Woodland CA 95776
G17DT Immunogen	DD: 7/18/2002	Treatment of gastric cancer	Aphton Corporation

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 2002-1570		26 Harter Avenue Suite 14 Woodland CA 95776
Gabapentin *Neurontin*	DD: 7/5/1995 MA: 1995-0886	Treatment of amyotrophic lateral sclerosis.	Warner-Lambert Company Parke-Davis Pharmaceutical Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48105
Gallium nitrate injection *Ganite*	DD: 12/5/1988 MA: 1/17/1991 1987-0244	Treatment of hypercalcemia of malignancy.	Solopak Pharmaceutical Co. 1845 Tonne Road 1845 Tonne Road Elk Grove Village IL 60007
Gamma hydroxybutyrate	DD: 12/3/1987 MA: MA: 1987-0263	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, behavior. hypnagogic hallucinations and automatic	Biocraft Laboratories, Inc. 18-01 River Road Fair Lawn NJ 07410
Gamma-hydroxybutyric acid	DD: 1/22/1985 MA: 1984-0053 1984-0053	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.	Sigma Chemical Company
Gammalinolenic acid	DD: 7/27/1994 MA: 1994-0829	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D. University of Massachusetts Medical Center 55 Lake Avenue Worcester MA 01655
Ganaxolone	DD: 5/25/1994 MA: 1994-0818	Treatment of infantile spasms.	Purdue Pharma L.P. Purdue Pharma L.P. One Stamford Forum Stamford CT 06901-3431
Ganciclovir intravitreal implant *Vitrasert Implant*	DD: 6/7/1995 MA: 3/4/1996 1994-0864	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products 9342 Jeronimo Road Irvine CA 92718-1903
Ganciclovir sodium *Cytovene*	DD: 10/31/1985 MA: 6/23/1989 1985-0079	Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.	Syntex (USA), Inc. 3401 Hillview Avenue 3401 Hillview Avenue Palo Alto CA 94304
Gancyclovir	DD: 6/7/1985 MA: MA: 1985-0058	Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.	Burroughs Wellcome Company 3030 Cornwallis Road
Gangliosides as sodium salts *Cronassial*	DD: 11/17/1988 MA: 1988-0313	Treatment of retinitis pigmentosa.	Fidia Pharmaceutical Corp. 1401 Eye Street, N.W. Suite 900 Washington DC 20005
Gavilimomab	DD: 11/20/2000 MA: 2000-1369	Acute graft-versus-host disease (aGVHD)	Abgenix, Inc. 7601 Dumbarton Circle Fremont CA 94555

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Gemtuzumab zogamicin	DD: 11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories PO Box 8299 PO Box 8299
Mylotarg	MA: 5/17/2000 1999-1278		Philadelphia PA 19101-8299
Gene plasmid hVEGF165 driven by human cytomegalovirus, and [2,3-bis(oleoyl)propyl]trimethyl ammonium and dioleoyl phosphatidyl ethanolamine	DD: 10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Ark Therapeutics Ltd. 1 Fitzroy Mews
Trinam	MA: MA: 1999-1232		London W1T6DE UK
genetically engineered herpes simplex virus (G207)	DD: 4/29/2002	Tretament of malignant glioma	MediGene, Inc. 9880 Campus Point Drive, Suite A
	MA: 2002-1552		San Diego CA 92121
Gentamicin impregnated PMMA beads on surgical wire	DD: 1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc. 9 West 57th Street
Septopal	MA: MA: 1990-0520		Suite 3825 New York NY 10019-2701
Gentamicin liposome injection	DD: 7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc. One Research Way
Maitec	MA: MA: 1990-0473		One Research Way Princeton NJ 08540
Glatiramer acetate *Copaxone*	DD: 11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA 1510 Delp Drive
	MA: 12/20/1996 1987-0240		Kulpsville PA 19443
Glatiramer acetate for injection	DD: 6/5/2001	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road
Copaxone	MA: 2000-1405		1090 Horsham Road North Wales PA 19454
Glutamine	DD: 3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Nutritional Restart Pharmaceutical, L.P. 4364 South Alston Avenue
	MA: MA: 1994-0857		Durham NC 27713
Glyceol	DD: 2/22/1990	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Chugai Pharmaceutical Co., Ltd.
	MA: 1988-0281		
Glyceryl trioleate and glyceryl trierucate	DD: 2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D. Johns Hopkins University
	MA: 1994-0875		Kennedy Krieger Institute, 707 North Broadway Baltimore MD 21205
Gonadorelin acetate	DD: 4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201
Lutrepulse	MA: 10/10/1989 MA: 10/10/1989 1986-0170		400 Rella Boulevard, Suite 201 Suffern NY 10901

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Gossypol	DD: 10/22/1990 MA: 1990-0463	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D. The New York Hospital - Cornell Medical Center 525 East 68th Street, Box 70 New York NY 10021
Gp100 adenoviral gene therapy	DD: 3/25/1997 MA: 1997-1043	Treatment of metastatic melanoma.	Genzyme Corporation One Mountain Rd. P.O. Box 9322 Framingham MA 01701-9322
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 8/7/1989 MA: MA: 1989-0378	Treatment of myelodysplastic syndrome.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 5/3/1990 MA: MA: 1989-0412	Treatment of neutropenia due to hairy cell leukemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 12/12/1989 MA: MA: 1989-0413	Treatment of neutropenia associated with bone marrow transplants.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 5/4/1990 MA: MA: 1989-0432	Treatment of chronic lymphocytic leukemia to increase granulocyte count.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 6/6/1989 MA: MA: 1988-0275	Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Group B streptococcus immune globulin	DD: 5/8/1990 MA: 1990-0441	Treatment of neonates for disseminated group B streptococcal infection.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852
Growth hormone releasing factor	DD: 8/7/1989 MA: MA: 1989-0373	For the long-term treatment of children who have growth failure due to a lack of secretion. adequate endogenous growth hormone	ICN Pharmaceuticals, Inc. ICN Plaza 3300 Hyland Avenue Costa Mesa CA 92626
Guanethidine monosulfate *Ismelin*	DD: 1/6/1986 MA: 1985-0063	Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080
Guanfacine *Tenex*	DD: 8/5/1999 MA: 1999-1241	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona CA 91718-1900
Gusperimus *Spanidin*	DD: 6/27/1996 MA: 1996-0968	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford CT 06492-7660

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
h5G1.1-mAb	DD: 9/21/2000 MA: 2000-1361	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc. 352 Knotter Drive 25 Science Park Cheshire CT 06410
Halofantrine *Halfan*	DD: 11/4/1991 MA: 7/24/1992 MA: 7/24/1992 1991-0617	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals One Franklin Plaza One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
Halofuginone *Stenorol*	DD: 2/7/2000 MA: 1999-1316	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd. Textile House, 2 Koifman St. Tel-Aviv 68012 Israel IL
heat killed mycobacterium with immunomodulator *CADI Mw*	DD: 11/21/2002 MA: MA: 2002-1612	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc. 16020 Swingley Ridge Road Suite 145 Chesterfield MO 63017
Heme arginate *Normosang*	DD: 3/10/1988 MA: 1985-0091	Treatment of symptomatic stage of acute porphyria.	Berlex Laboratories, Inc. 15049 San Pablo Avenue 15049 San Pablo Avenue Richmond CA 94804-0099
Heme arginate *Normosang*	DD: 3/1/1994 MA: 1993-0798	Treatment of myelodysplastic syndromes.	Berlex Laboratories, Inc. 15049 San Pablo Avenue 15049 San Pablo Avenue Richmond CA 94804-0099
Hemin *Panhematin*	DD: 3/16/1984 MA: 7/20/1983 MA: 7/20/1983 1983-0006	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories Diagnostics Division Diagnostics Division Abbott Park IL 60064
Hemin and zinc mesoporphyrin *Hemex*	DD: 12/20/1993 MA: 1993-0773	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D. University Of Massachusetts Medical Center 55 Lake Avenue North Worcester MA 01655
Hepatitis B immune globulin intravenous (human) *Nabi-HB*	DD: 3/8/1995 MA: MA: 1993-0760	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	NABI 12280 Wilkins Avenue Rockville MD 20852
Hepatitis C virus immune globulin (human)	DD: 11/14/2002 MA: 1993-0731	Prophylaxis of hepatitis C infection in liver transplant recipients.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
Herpes simplex virus gene	DD: 10/16/1992 MA: 1992-0668	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878
Histamine	DD: 2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Maxamine	MA: 1999-1271		8899 University Center Lane Suite 400 San Diego CA 92122
Histamine *Maxamine*	DD: 12/15/1999 MA: 1999-1273	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane 8899 University Center Lane Suite 400 San Diego CA 92122
Histrelin	DD: 5/3/1991 MA: 1988-0284	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D. University of Texas Medical Branch at Galveston Route J-09, 700 The Strand Galveston TX 77550
Histrelin acetate *Supprelin Injection*	DD: 8/10/1988 MA: 12/24/1991 1986-0169	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown NJ 07724
HIV neutralizing antibodies *Immupath*	DD: 3/24/1992 MA: 1991-0619	Treatment of acquired immunodeficiency syndrome.	Hemacare Corporation 4954 Van Nuys Boulevard 4954 Van Nuys Boulevard Sherman Oaks CA 91403
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex *Allovectin-7*	DD: 9/30/1999 MA: MA: 1999-1281	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego CA 92121
homoharringtonine	DD: 2/8/2002 MA: 2001-1529	Treatment for chronic myelogenous leukemia	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403
HPA-23	DD: 7/17/1985 MA: 1985-0077	Treatment of acquired immunodeficiency syndrome.	Rhone-Poulenc Rorer Pharm. 500 Arcola Road Collegeville PA 19426
Hsp E7	DD: 3/19/2001 MA: 2000-1412	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655
Hu1D10, humanized monoclonal antibody *Remitogen*	DD: 11/28/2001 MA: MA: 2001-1447	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
Human acid precursor alpha-glucosidase, recombinant	DD: 9/10/1996 MA: 1996-1004	Treatment of glycogen storage disease type II.	Pharming/Genzyme LLC c/o Genzyme Corporation 1 Mountain Rd. Framingham MA 01701-9322
human anti-transforming growth factor beta 1 monoclonal antibody	DD: 1/11/2002 MA: 2001-1511	Treatment of systemic sclerosis	Genzyme Corporation One Kendall Square Cambridge MA 02139
human gammaglobulin	DD: 5/25/2001 MA: 2001-1429	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
human gammaglobulin	DD: 9/16/2002 MA: MA: 2001-1521	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and regression-onset autism in pediatric abdominal pain) associated with patients.	Protein Therapeutics, Inc. 9040 S. Rita Road Suite 1100 Tucson AZ 85747
Human IgM monoclonal antibody (C-58) To CMV *Centovir*	DD: 8/7/1989 MA: MA: 1988-0329	Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Human IgM monoclonal antibody (C-58) To CMV *Centovir*	DD: 8/7/1989 MA: MA: 1988-0330	Prophylaxis of cytomegalovirus infections in bone marrow transplant patients.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Human immunodeficiency virus immune globulin *Hivig*	DD: 1/4/1995 MA: MA: 1994-0859	Treatment of HIV-infected pediatric patients.	NABI 5800 Park of Commerce Blvd., NW Boca Raton FL 33487
Human immunodeficiency virus immune globulin	DD: 11/21/1989 MA: 1989-0374	Treatment of AIDS.	NABI 5800 Park of Commerce Blvd., NW Boca Raton FL 33487
Human immunodeficiency virus immune globulin	DD: 3/25/1992 MA: 1991-0637	Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
Human T-lymphotropic virus type III Gp160 antigens *Vaxsyn HIV-1*	DD: 11/20/1989 MA: MA: 1989-0409	Treatment of AIDS.	MicroGeneSys, Inc. 1000 Research Parkway Meriden CT 06450
Humanized anti-CD2 monoclonal antibody	DD: 11/13/1998 MA: 1998-1164	Treatment of graft-versus-host disease.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Humanized anti-human CD2 MAb *MEDI-507*	DD: 9/17/1998 MA: MA: 1997-1077	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.	Biotransplant, Inc. Building 75, 3rd. Ave. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown MA 02129
Humanized anti-tac *Zenapax*	DD: 3/5/1993 MA: 1992-0677	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110-1199
Humanized MAb (IDEC-131) to CD40L	DD: 2/9/1999 MA: 1998-1192	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego CA 92121
humanized monoclonal antibody against Shiga-like toxin II	DD: 9/12/2001	To prevent the development of or to decrease the incidence and severity of	Teijin America, Inc. 600 Alexander Park

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 2001-1481 2001-1481	hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Suite 304 Princeton NJ 08540
hyaluronic acid	DD: 3/19/2002 MA: 2001-1535	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002
Hydroxocobalamin *CYANOKIT*	DD: 9/22/2000 MA: 2000-1376	Treatment of acute cyanide poisoning	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Hydroxycobalamin/sodium thiosulfate	DD: 10/4/1985 MA: 1985-0095	Treatment of severe acute cyanide poisoning.	Hall, Alan H., M.D. Mile 5.0 Pass Creek Road PO Box 24 Elk Mountain WY 82324
Hydroxyurea *Droxia*	DD: 10/1/1990 MA: 2/25/1998 1990-0495	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 P.O. Box 4000 Princeton NJ 08543
Hypericin	DD: 2/7/2000 MA: 1999-1310	Treatment of cutaneous T-cell lymphoma.	Nexell Therapeutics, Inc. 2751 Centerville Rd., Suite 210 Wilmington DE 19808
Hypericin	DD: 8/3/2000 MA: 1999-1311	Treatment of glioblastoma multiforme.	Nexell Therapeutics 2751 Centerville Rd., Suite 210 Wilmington DE 19808
I(131)-TM-601 (chlorotoxin)	DD: 2/14/2002 MA: 2001-1522	treatment of malignant glioma	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243
ibritumomab tiuxetan *Zevalin*	DD: 9/6/1994 MA: 2/19/2002 1994-0848	Treatment of B-cell non-Hodgkin's lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road 3030 Callan Road San Diego CA 92121
Ibuprofen i.v. solution	DD: 10/29/1996 MA: 1996-1014	Treatment of patent ductus arteriosus.	Farmacon-IL-LLC 1720 Post Road East Suite 213 Westport CT 06880-5643
Ibuprofen i.v. solution *Salprofen*	DD: 10/29/1996 MA: 1996-1008	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC 1720 Post Road East Suite 213 Westport CT 06880-5643
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution *Extraneal (with 7.5% Icodextrin)*	DD: 7/18/1997 MA: MA: 1997-1056	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road McGaw Park IL 60085
Idarubicin *Idamycin*	DD: 12/1/1992 MA: 1992-0708	Treatment of myelodysplastic syndromes.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Idarubicin *Idamycin*	DD: 12/2/1992 MA: 1992-0709	Treatment of chronic myelogenous leukemia.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Idarubicin HCl for injection *Idamycin*	DD: 2/12/1991 MA: 1990-0558	Treatment of acute lymphoblastic leukemia in pediatric patients.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Idarubicin HCl for injection *Idamycin*	DD: 7/25/1988 MA: 9/27/1990 MA: 9/27/1990 1988-0293	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Idoxuridine	DD: 4/8/1996 MA: 1996-0956	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest IL 60045
iduronate-2-sulfatase	DD: 11/28/2001 MA: MA: 2001-1473	Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome)	Transkaryotic Therapies Inc. 195 Albany Street Cambridge MA 02139
Ifosfamide *Ifex*	DD: 1/20/1987 MA: 12/30/1988 1986-0177	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway, P.O. Box 5100 Wallingford CT 06492
Ifosfamide *Ifex*	DD: 8/7/1985 MA: 1985-0085	Treatment of bone sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543-4000
Ifosfamide *Ifex*	DD: 8/7/1985 MA: 1985-0085A	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	DD: 4/6/2000 MA: 1999-1321	Treatment of astrocytic glioma.	Neurocrine Biosciences, Inc. 10555 Science Center Dr. San Diego CA 92121
IL13-PE38QQR	DD: 11/2/2001 MA: 2001-1498	Treatment of malignant glioma	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
Iloprost solution for infusion	DD: 5/14/1990 MA: 1989-0400	Treatment of heparin-associated thrombocytopenia.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470
Iloprost solution for infusion	DD: 9/21/1989 MA: 1989-0387	Treatment of Raynaud's phenomenon secondary to systemic sclerosis.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470
Imatinib	DD: 1/31/2001	Treatment of chronic myelogenous	Novartis Pharmaceuticals

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		leukemia	59 Route 10
Gleevec			59 Route 10
	MA: 5/10/2001		East Hanover NJ 07936-1080
	2000-1401		
imatinib mesylate	DD: 11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
			One Health Plaza
Gleevec			One Health Plaza
	MA: 2/1/2002		East Hanover NJ 07936-1080
	2001-1492		
Imciromab pentetate	DD: 1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
			244 Great Valley Parkway
Myoscint	MA:		244 Great Valley Parkway
	MA:		Malvern PA 19355
	1988-0328		
Imexon	DD: 8/3/2001	Treatment of metastatic malignant melanoma	AmpliMed Corporation
			2321 Camino La Zorrela
n/a			2321 Camino La Zorrela
	MA:		Tucson AZ 85718
	2001-1425		
Imexon	DD: 11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
			2321 Camino La Zorrela
	MA:		Tucson AZ 85718
	1996-1009		
Imiglucerase	DD: 11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
			One Kendall Square
Cerezyme			One Kendall Square
	MA: 5/23/1994		Cambridge MA 02139-1562
	1991-0624		
Immune globulin intravenous (human)	DD: 12/16/1992	Treatment of juvenile rheumatoid arthritis.	Immuno Clinical Research Corp.
			750 Lexington Avenue, 19th Floor
Iveegam, Immuno	MA:		
	MA:		New York NY 10022
	1992-0688		
Immune globulin intravenous (human)	DD: 11/22/1993	Treatment of patients with acute myocarditis.	Immuno Clinical Research Corp.
			750 Lexington Avenue
Immune Globulin Intravenous (human)	MA:		
	MA:		New York NY 10022
	1993-0758		
Immune globulin intravenous (human)	DD: 10/13/1992	Treatment of polymyositis/dermatomyositis.	Immuno Clinical Research Corp.
			155 East 56th Street
Iveegam, Immuno	MA:		
	MA:		New York NY 10022
	1992-0689		
Immune globulin intravenous, human	DD: 2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
			Pharmaceutical Division, Biological Products
Gamimune N			Products
	MA: 12/27/1993		400 Morgan Lane
	1992-0705		New Haven CT 06516
Imported fire ant venom, allergenic extract	DD: 5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
			Research Center
	MA:		27 Village Lane
	1991-0626		
	1991-0626		Wallingford CT 06492
Indium In 111 murine monoclonal antibody FAB to myosin	DD: 8/7/1989	To aid in the diagnosis of myocarditis.	Centocor, Inc.
			244 Great Valley Parkway
Myoscint	MA:		
	MA:		Malvern PA 19355
	1988-0337		

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Indium In-111 altumomab pentetate *Hybri-ceaker*	DD: 2/6/1990 MA: MA: 1985-0100	Detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.	Hybritech, Inc. 11095 Torreyanna Road 11095 Torreyanna Road San Diego CA 92196
Infliximab *Remicade*	DD: 11/14/1995 MA: 8/24/1998 MA: 8/24/1998 1995-0924	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway 200 Great Valley Parkway Malvern PA 19355-1307
infliximab *Remicade*	DD: 10/23/2002 MA: MA: 2002-1602	Treatment of juvenile rheumatoid arthritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
INH-A00021 *Veronate*	DD: 6/13/2001 MA: MA: 2001-1445	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway 8995 Westside Parkway Suite 150 Alpharetta GA 30004
inolimomab *Leukotac*	DD: 10/23/2002 MA: 2002-1586	Treatment of graft versus host disease	Opi 6, Chemin de l'industrie 69570 DARDILLY - France
Inosine pranobex *Isoprinosine*	DD: 9/20/1988 MA: 1988-0268	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals 897 West Sixteenth Street 897 West Sixteenth Street Newport Beach CA 92663
Interferon alfa-2a *Roferon A*	DD: 6/6/1989 MA: 10/19/1995 1989-0369	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 10/27/1989 MA: 1989-0408	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110-1199
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 12/14/1987 MA: 11/21/1988 1987-0259	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 4/18/1988 MA: 1988-0274	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 5/11/1990 MA: 1990-0446	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 5/2/1990 MA: MA:	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07119

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1990-0445		
Interferon alfa-2a (recombinant)	DD: 5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110-1199
Roferon-A	MA: MA: 1989-0423		
Interferon alfa-2b (recombinant)	DD: 8/10/1988	Treatment of carcinoma in situ of the urinary bladder.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0204		
Interferon alfa-2b (recombinant)	DD: 5/13/1988	Treatment of primary malignant brain tumors.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0210		
Interferon alfa-2b (recombinant)	DD: 4/18/1988	Treatment of invasive carcinoma of the cervix.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0203		
Interferon alfa-2b (recombinant)	DD: 6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 11/21/1988 1987-0191		
Interferon alfa-2b (recombinant)	DD: 6/22/1987	Treatment of chronic myelogenous leukemia.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0200		
Interferon alfa-2b (recombinant)	DD: 8/3/1987	Treatment of ovarian carcinoma.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0201		
Interferon alfa-2b (recombinant)	DD: 11/17/1988	Treatment of acute hepatitis B.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0264		
Interferon alfa-2b (recombinant)	DD: 6/22/1987	Treatment of metastatic renal cell carcinoma.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0197		
Interferon alfa-2b (recombinant)	DD: 5/4/1990	Treatment of chronic delta hepatitis.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1989-0402		
Interferon alfa-2b (recombinant)	DD: 8/17/1988	Treatment of laryngeal (respiratory) papillomatosis.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Intron A	MA: 1987-0214		
Interferon alfa-nl	DD: 10/16/1987	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Wellferon	MA: MA: 1986-0129		

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Interferon alfa-nl *Wellferon*	DD: 8/25/1986 MA: 1986-0128	Treatment of AIDS related Kaposi's sarcoma.	Burroughs Wellcome Company 3030 Cornwallis Road 3030 Cornwallis Road Research Triangle Pk NC 27709
Interferon beta (recombinant *Avonex*	DD: 1/13/1993 MA: 1992-0693	Treatment of primary brain tumors.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta (recombinant) *R-IFN-beta*	DD: 2/12/1991 MA: 1990-0538	For the systemic treatment of metastatic renal cell carcinoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Interferon beta (recombinant) *r-HuIFN-beta*	DD: 5/9/1991 MA: MA: 1990-0535	For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Interferon beta (recombinant) *r-HuIFN-beta*	DD: 4/18/1991 MA: 1990-0533	For the systemic treatment of cutaneous T-cell lymphoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Interferon beta, recombinant *Betaseron*	DD: 11/15/1988 MA: 1988-0317	Treatment of acquired immunodeficiency syndrome.	Berlex Laboratories, Inc. 15049 San Pablo Avenue, P.O. Box 15049 San Pablo Avenue, P.O. Box 4099 Richmond CA 94804
Interferon beta-1a *Avonex*	DD: 12/16/1991 MA: 5/17/1996 1991-0627	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a *Rebif*	DD: 3/11/1996 MA: 1995-0951	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Interferon Beta-1a *Avonex*	DD: 10/14/1998 MA: 1998-1154	Treatment of juvenile rheumatoid arthritis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a (recombinant human) *Avonex*	DD: 1/7/1999 MA: MA: 1998-1115	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a (recombinant human)	DD: 7/24/1992 MA: 1991-0628	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a (recombinant) *Rebif*	DD: 12/2/1992 MA: MA: 1991-0633	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Interferon beta-1a (recombinant)	DD: 4/3/1991	For the systemic treatment of cutaneous	Biogen, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		malignant melanoma.	14 Cambridge Center
r-HulFN-beta	MA: 1990-0532		14 Cambridge Center Cambridge MA 02142
Interferon beta-1b *Betaseron*	DD: 11/17/1988 MA: 7/23/1993 1988-0318	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories 4560 Horton Street Emeryville CA 94608
Interferon gamma 1-b *Actimmune*	DD: 9/30/1988 MA: 12/20/1990 1988-0297	Treatment of chronic granulomatous disease.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
interferon gamma-1b *Actimmune*	DD: 9/12/2002 MA: 2001-1523	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc. 3280 Bayshore Boulevard Brisbane CA 94005
Interferon gamma-1b *Actimmune*	DD: 12/4/1995 MA: 1995-0935	Treatment of renal cell carcinoma.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
Interferon gamma-1b *Actimmune*	DD: 9/30/1996 MA: 2/10/2000 MA: 2/10/2000 1996-0987	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	InterMune , Inc. 3280 Bayshore Boulevard 3280 Bayshore Boulevard Brisbane CA 94005
Interferon-alfa-1b	DD: 4/17/2001 MA: 2001-1426	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery and Development 9500 Euclid Avenue Clevland OH 44195
Interleukin-1 alpha, human recombinant	DD: 6/17/1991 MA: 1991-0571	For the promotion of early engraftment in bone marrow transplantation.	Immunex Corporation 51 University Street Seattle WA 98101
Interleukin-1 alpha, human recombinant	DD: 6/17/1991 MA: 1991-0572	For hematopoietic potentiation in aplastic anemia.	Immunex Corporation 51 University Street Seattle WA 98101
Interleukin-1 receptor antagonist, human recombinant *Antril*	DD: 9/23/1991 MA: MA: 1991-0599	Treatment of juvenile rheumatoid arthritis.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Interleukin-1 receptor antagonist, human recombinant *Antril*	DD: 10/16/1992 MA: MA: 1992-0658	Prevention and treatment of graft versus host disease in transplant recipients.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Interleukin-2 *Teceleukin*	DD: 5/11/1990 MA: MA: 1990-0447	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interleukin-2 *Teceleukin*	DD: 5/3/1990 MA: MA:	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1990-0444		
Interleukin-2	DD: 2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Teceleukin	MA: 1989-0362		
Interleukin-2	DD: 2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Teleleukin	MA: 1989-0363		
Interleukin-3 human (recombinant)	DD: 5/20/1991 MA: MA: 1990-0534	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	Immunex Corporation 51 University Street Seattle WA 98101
Interleukin-3, human, recombinant	DD: 9/30/1993 MA: MA: 1993-0740	For sequential administration with sargramostim to accelerate neutrophil and autologous bone marrow transplantation platelet recovery in patients undergoing for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma.	Sandoz Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936
Intraoral fluoride releasing system	DD: 7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc. 1120 Win Drive 1120 Win Drive Bethlehem PA 18017
IFRS	MA: MA: 2001-1439		
Iobenguane Sulfate I 131	DD: 11/14/1984 MA: 3/21/1990 1984-0022	For use as a diagnostic adjunct in patients with pheochromocytoma.	University of Michigan UH B1 H410/0028 1500 E. Medical Center Drive Ann Arbor MI 48109-0028
Iodine 131 6B-iodomethyl-19-norcholesterol	DD: 8/1/1984 MA: 1984-0021	For use in adrenal cortical imaging.	David E. Kuhl, M.D. University of Michigan Medical Center/1500 E. Med. Ctr. Drive B1G412 /0028 University Hospital Ann Arbor MI 48109-0028
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA: 1987-0254B	Detection of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA: 1987-0254A	Detection of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 123 murine monoclonal antibody to hCG	DD: 11/7/1988 MA: 1987-0250	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	DD: 2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C. 300 American Rd.
Pentacea	MA: MA: 2000-1324		Morris Plains NJ 07950
Iodine I 131 Lym-1 Monoclonal	DD: 11/2/1987	Treatment of B-cell lymphoma.	Lederle Laboratories Division

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Antibody	MA: 1987-0218		American Cyanamide Company Pearl River NY 10965
Iodine I 131 murine monoclonal antibody IgG2a to B cell *Immurait, LI-2-I-131*	DD: 9/18/1989 MA: MA: 1989-0382	Treatment of B-cell leukemia and B-cell lymphoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA: 1987-0256A	Treatment of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA: 1987-0256B	Treatment of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 murine monoclonal antibody to hCG	DD: 11/7/1988 MA: 1987-0255	Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) *131IchTNT-1*	DD: 2/12/1999 MA: MA: 1998-1190	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc. 14282 Franklin Ave. Tustin CA 92780-7017
Isobutyramide *Isobutyramide oral solution*	DD: 12/18/1992 MA: 1992-0717	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D. Boston University Boston University Cancer Research Center Boston MA 02118
Isobutyramide	DD: 5/25/1994 MA: 1994-0824	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032
Japanese encephalitis vaccine (live, attenuated)	DD: 5/19/1999 MA: 1998-1209	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul South Korea KR
Ketoconazole *Nizoral*	DD: 3/27/1991 MA: MA: 1990-0519	For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.	Pharmedic Company 28101 Ballard Road 28101 Ballard Road Lake Forest IL 60045
L-2-oxothiazolidine-4-carboxylic *Procysteine*	DD: 6/14/1994 MA: 1994-0819	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West 640 Memorial Drive, 3rd Floor West Cambridge MA 02139
L-2-oxothiazolidine-4-carboxylic *Procysteine*	DD: 7/30/1996 MA: 1996-0992	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West 640 Memorial Drive, 3rd Floor West Cambridge MA 02139
L-5-hydroxytryptophan	DD: 1/20/1999 MA:	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1998-1182		Corona CA 91718-1900
L-baclofen	DD: 1/6/1998 MA: 1997-1093	Treatment of trigeminal neuralgia.	Pharmascience Inc. 6111 Royalmount, #100 Montreal, Quebec Canada H4P 2T4 CA
L-baclofen	DD: 7/13/1990 MA: 1990-0456	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D. University Of Pittsburgh School of Medicine Pittsburgh PA 15261
L-baclofen *Neuralgon*	DD: 1/30/1992 MA: 1992-0655	Treatment of intractable spasticity in children with cerebral palsy.	Pharmascience Inc. 6111 Royalmount, Suite 100 6111 Royalmount, Suite 100 Montreal, Quebec H4P 2T4 Canada CA
L-baclofen *Neuralgon*	DD: 12/17/1991 MA: MA: 1991-0573	Treatment of intractable spasticity associated with spinal cord injury or multiple sclerosis.	Pharmascience Inc. 6111 Royalmount, Suite 100 6111 Royalmount, Suite 100 Montreal, Quebec H4P 2T4 Canada CA
L-cycloserine	DD: 8/1/1989 MA: 1989-0384	Treatment of Gaucher's disease.	Lev, Meir M.D. The City College, City University Of NY Medical School Convent Avenue at 138 Street New York NY 10031
L-cysteine	DD: 5/16/1994 MA: 1993-0796	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Orphan Pharmaceuticals, U.S.A., Inc. 1101 Kermit Dr. 1101 Kermit Dr. Suite 608 Nashville TN 37217
L-glutamine	DD: 8/1/2001 MA: 2001-1459	Treatment of sickle cell disease	Orphan Drugs International, LLC (d.b.a. Hope Therapeutics) PO Box 0401 Montrose CA 91021-0401
L-glutamyl-L-tryptophan	DD: 10/20/1999 MA: 1999-1267	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland WA 98033-7869
L-leucovorin *Isovorin*	DD: 12/18/1990 MA: MA: 1990-0485	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
L-leucovorin *Isovorin*	DD: 8/1/1991 MA: MA: 1990-0484	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
L-threonine	DD: 7/24/1992 MA: 1991-0621	Treatment of spasticity associated with familial spastic paraparesis.	Interneuron Pharmaceuticals, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966
L-threonine	DD: 2/6/1989	Treatment of amyotrophic lateral sclerosis.	Tyson And Associates 12832 Chadron Avenue

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Threostat	MA: 1988-0338		12832 Chadron Avenue Hawthorne CA 90250
Lactic acid *Aphthaid*	DD: 6/29/1999 MA: MA: 1998-1220	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale SUNY Farmingdale Conklin Hall Farmingdale NY 11735
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	DD: 1/15/2002 MA: 2001-1452	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	DD: 1/15/2002 MA: 2002-1541	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave. Gaithersburg MD 20877
Lactobin *Lactobin*	DD: 9/12/1990 MA: MA: 1990-0469	Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.	Roxane Laboratories, Inc. P.O. Box 16532 P.O. Box 16532 Columbus OH 43216-6532
Lamotrigine *Lamictal*	DD: 8/23/1995 MA: 8/24/1998 1995-0916	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park NC 27709
Lanreotide, Somatostatin *Ipstyl*	DD: 9/11/2000 MA: 2000-1363	Treatment for acromegly	IPSEN, Inc. 27 Maple Street Milford MA 01757
Latrodectus immune F(ab)2 *Aracmyn*	DD: 6/18/2001 MA: 2001-1440	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 1101 Kermit Drive, Suite 608 Nashville TN 37217
Leflunomide	DD: 10/18/1996 MA: 1996-1002	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W. Rush-Presbyterian-St. Luke's Medical Ctr., Dept. of General Surgery 1653 West Congress Parkway Chicago IL 60612-3833
Lepirudin *Refluden*	DD: 2/13/1997 MA: 3/6/1998 1996-1027	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Frankfurt am Main Germany DE
Leucovorin *Leucovorin calcium*	DD: 12/8/1986 MA: 12/12/1991 MA: 12/12/1991 1986-0167	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Leucovorin *Leucovorin calcium*	DD: 8/17/1988 MA: 8/31/1988 MA: 8/31/1988 1988-0305	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Leucovorin calcium	DD: 6/23/1988	For use in combination with 5-fluorouracil	Glaxo Wellcome Research and

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		for the treatment of metastatic colorectal cancer.	Development 5 Moore Drive
Wellcovorin	MA: 1988-0292		5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Leupeptin	DD: 9/18/1990 MA: 1990-0496	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc. S.U.N.Y. at Stony Brook H.S.C. T18-020 Stony Brook NY 11794-8181
Leuprolide acetate *Lupron Injection*	DD: 7/25/1988 MA: 4/16/1993 1988-0286	Treatment of central precocious puberty.	Tap Pharmaceuticals, Inc. 2355 Waukegan Road Deerfield IL 60015
Levocabastine HCl ophthalmic suspension 0.05%	DD: 2/29/1988 MA: 1987-0247	Treatment of vernal keratoconjunctivitis.	Iolab Pharmaceuticals 500 Iolab Drive Claremont CA 94608
Levocarnitine *Carnitor*	DD: 11/15/1989 MA: 1988-0324A	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 2/28/1984 MA: 4/10/1986 1984-0013	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 11/24/1986 MA: MA: 1986-0173	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 11/15/1989 MA: 1988-0324B	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 7/26/1984 MA: 12/16/1992 1984-0015	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 9/6/1988 MA: 12/15/1999 MA: 12/15/1999 1988-0278	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue, Suite 800 South Frederick Avenue, Suite 300 Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 4/7/1997 MA: 1997-1038	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 800 S. Frederick Avenue, Suite 300 Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 11/22/1993 MA: 1993-0763	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877
Levodopa and carbidopa	DD: 1/18/2000	Treatment of late stage Parkinson's disease.	Nouvel Pharma, Inc. 11384 Strang Line Road

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Duodopa	MA: 1999-1294		11384 Strang Line Road Lenexa KS 66215
Levomethadyl acetate *Orlaam*	DD: 1/24/1985 MA: 7/9/1993 1984-0047	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation 8180 Greensboro Drive, Suite 1000 8180 Greensboro Drive, Suite 1000 McLean VA 22102
Lidocaine patch 5% *Lidoderm Patch*	DD: 10/24/1995 MA: 3/19/1999 MA: 3/19/1999 1995-0923	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Teikoku Pharma USA, Inc. 745-D Camden Ave. 745-D Camden Ave. Campbell CA 95008-4146
lintuzumab *Zamyl*	DD: 9/9/2002 MA: 2002-1585	Treatment of acute myelogenous leukemia	Protein Design Labs, Inc. 34801 Campus Drive 34801 Campus Drive Fremont CA 94555
Liothyronine sodium injection *Triostat*	DD: 7/30/1990 MA: 12/31/1991 1990-0460	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
Lipid/DNA human cystic fibrosis gene	DD: 4/8/1996 MA: 1995-0900	Treatment of cystic fibrosis.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Liposomal amphotericin B *AmBisome*	DD: 12/6/1996 MA: 8/11/1997 1996-0995	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
Liposomal amphotericin B *AmBisome*	DD: 12/10/1996 MA: 1996-0996	Treatment of histoplasmosis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
Liposomal amphotericin B *AmBisome*	DD: 12/10/1996 MA: 8/11/1997 1996-0994	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
Liposomal cyclosporin A *Cyclospire*	DD: 4/30/1998 MA: MA: 1998-1127	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston TX 77030
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala *ImmTher*	DD: 6/10/1998 MA: MA: 1998-1140	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff IL 60044
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala *ImmTher*	DD: 6/10/1998 MA: MA: 1998-1148	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff IL 60044
Liposomal nystatin	DD: 6/13/2000	Treatment of invasive fungal infections.	Antigenics, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Nyotran	MA: 2000-1338		34 Commerce Way Woburn MA 01801
Liposomal prostaglandin E1 injection	DD: 4/25/1996 MA: 1996-0955	Treatment of acute respiratory distress syndrome.	Liposome Company, Inc. One Research Way Princeton NJ 08540
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)	DD: 9/1/1999 MA: 1999-1265	Treatment of malignant mesothelioma.	Antigenics Incorporated 34 Commerce Way Woburn MA 01801
Liposome encapsulated recombinant interleukin-2	DD: 6/20/1994 MA: 1993-0784	Treatment of cancers of the kidney and renal pelvis.	Biomira USA, Inc. 1002 Eastpark Boulevard Cranbury NJ 08512
Liposome encapsulated recombinant interleukin-2	DD: 11/25/1991 MA: 1991-0629	Treatment of brain and CNS tumors.	Biomira USA, Inc. 1002 Eastpark Boulevard Cranbury NJ 08512
Lisofylline	DD: 6/10/1999 MA: 1999-1240	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Avenue West 201 Elliott Avenue West 201 Elliott Avenue West Suite 400 Seattle WA 98119
Lodoxamide tromethamine *Alomide Ophthalmic Solution*	DD: 10/16/1991 MA: 9/23/1993 1991-0597	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134
Loxoribine	DD: 2/24/1992 MA: 1990-0543	Treatment of common variable immunodeficiency.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869
Lucinactant *Surfaxin*	DD: 7/17/1995 MA: 1995-0899	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc. 350 South Main Street 350 South Main Street Suite 307 Doylestown PA 18901
Lucinactant *Surfaxin*	DD: 7/30/1996 MA: 1996-0997	Treatment of meconium aspiration syndrome in newborn infants.	Discovery Laboratories, Inc. 350 South Main Street 350 South Main Street Suite 307 Doylestown PA 18901
Lucinactant *Surfaxin*	DD: 10/18/1995 MA: 1995-0913	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc. 350 South Main Street 350 South Main Street Suite 307 Doylestown PA 18901
Lysine acetylsalicylate injectable	DD: 8/1/1989 MA: 1988-0339	Treatment of pain and fever secondary to sickle cell disease crisis.	G.D. Searle & Company
Mafenide acetate solution *Sulfamylon solution*	DD: 7/18/1990 MA: 6/5/1998	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings	Mylan Laboratories, Inc. 781 Chestnut Ridge Road 781 Chestnut Ridge Road

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 6/5/1998 1990-0478	over meshed autografts on excised burn wounds.	P.O. Box 4310 Morgantown WV 26504-4310
Marijuana	DD: 5/25/1999 MA: 1997-1053	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont MA 02478
MART-1 adenoviral gene therapy for malignant melanoma	DD: 3/28/1997 MA: 1996-1030	Treatment of metastatic melanoma.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Matrix metalloproteinase inhibitor *Galardin*	DD: 12/5/1991 MA: 1991-0639	Treatment of corneal ulcers.	Glycomed, Inc 860 Atlantic Avenue Alameda CA 94501
Mazindol *Sanorex*	DD: 12/8/1986 MA: 1986-0161	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D. 176 Memorial Drive 176 Memorial Drive Jesup GA 31545
Mecamylamine *Inversine*	DD: 10/14/1998 MA: 1998-1175	Treatment of Tourette's syndrome.	Layton Bioscience, Inc. 709 E. Evelyn Avenue Sunnyvale CA 94086
Mecasermin *Myotrophin*	DD: 8/5/1991 MA: 1991-0591	Treatment of amyotrophic lateral sclerosis.	Cephalon, Inc. 145 Brandywine Parkway 145 Brandywine Parkway West Chester PA 19380-4245
Mecasermin	DD: 12/12/1995 MA: 1995-0936	Treatment of growth hormone insufficency syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080
Medroxyprogesterone acetate *Hematrol*	DD: 2/22/2001 MA: 2001-1419	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422
Mefloquine HCl *Lariam*	DD: 4/13/1988 MA: 5/2/1989 MA: 5/2/1989 1987-0262B	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Mefloquine HCl *Lariam*	DD: 4/13/1988 MA: 5/2/1989 MA: 5/2/1989 1987-0262A	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Mefloquine HCl *Mephaquin*	DD: 7/22/1987 MA: 1987-0186A	Treatment of chloroquine-resistant Falciparummalaria.	Mepha AG 4143 Dornach 4143 Dornach POSTFASH 137 Aesch Basel, Switzerland CH
Mefloquine HCl *Mephaquin*	DD: 7/22/1987 MA:	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG 4143 Dornach 4143 Dornach POSTFASH 137

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1987-0186B		Aesch Basel, Switzerland CH
Megestrol acetate	DD: 4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and	Bristol-Myers Squibb Pharmaceutical Research Institute 2400 West Lloyd Expressway
Megace	MA: 9/10/1993 MA: 9/10/1993 1987-0261	confirmed diagnosis of AIDS.	2400 West Lloyd Expressway Evansville IN 47721
Melanoma cell vaccine	DD: 10/13/1994	Treatment of invasive melanoma.	Morton, Donald L. M.D. John Wayne Cancer Institute 2200 Santa Monica Boulevard
	MA: 1994-0841		Santa Monica CA 90404
Melanoma vaccine *Melacine*	DD: 12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc. 533 Old Corvallis Road
	MA: 1989-0415		Hamilton MT 59840
Melatonin	DD: 11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light	Sack, Robert, M.D. Oregon Health Sciences University 3181 S.W. Sam Jackson Park Road
	MA: MA: 1993-0775	perception.	Portland OR 97201
meloxicam	DD: 11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road
Mobic	MA: 2002-1606		P. O. Box 368 Ridgefield CT 06877-0368
Melphalan	DD: 2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is	Glaxo Wellcome Inc. 5 Moore Drive
Alkeran For Injection	MA: 11/18/1992 MA: 11/18/1992 1991-0609	inappropriate.	5 Moore Drive Research Triangle Park NC 27709
Melphalan	DD: 3/3/1992	For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.	Glaxo Wellcome Research and Development 5 Moore Drive
Alkeran for Injection	MA: 1991-0642		5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Meropenem	DD: 4/27/2000	Management of acute pulmonary exacerbations, in cystic fibrosis patients,	Zeneca Pharmaceuticals 1800 Concord Pike
Merrem IV	MA: MA: 1999-1307	due to respiratory tract infection with susceptible organisms.	1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437
Mesna	DD: 11/14/1985	For use as a prophylactic agent in reducing the incidence of	Degussa Corporation 65 Challenger Road
Mesnex	MA: 12/30/1988 MA: 12/30/1988 1985-0086	ifosfamide-induced hemorrhagic cystitis.	65 Challenger Road Ridgefield Park NJ 07660
Mesna	DD: 12/16/1987	Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as	Asta Medica , Inc. 890 East St.
	MA: MA: 1987-0248	cyclophosphamide.	Tewksbury MA 01876-1496
Methionine/L-methionine	DD: 8/21/1996	Treatment of AIDS myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Care Ctr.
	MA: 1995-0917		Philips Building, Suite 2R; 10 Union Square East New York NY 10003
Methotrexate	DD: 8/23/1993	Treatment of juvenile rheumatoid arthritis.	Wyeth-Ayerst Laboratories

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Rheumatrex	MA: 1993-0766		P.O. Box 8299 Philadelphia PA 19101-8299
Methotrexate sodium *Methotrexate*	DD: 10/21/1985 MA: 4/7/1988 1985-0099	Treatment of osteogenic sarcoma.	Lederle Laboratories Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
Methotrexate with laurocapram *Methotrexate/azone*	DD: 10/15/1990 MA: 1989-0433	Topical treatment of mycosis fungoides.	Durham Pharmaceuticals LLC 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280
Methoxsalen *Uvadex*	DD: 10/14/1998 MA: MA: 1998-1172	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc. 437 Creamery Way 437 Creamery Way Exton PA 19431
methylbicyclone	DD: 11/14/2002 MA: 2002-1583	Treatment of cystic fibrosis	Sucampo Pharmaceuticals, Inc. 4733 Bethesda Ave. Suite 450 Bethesda MD 20814
Methylnaltrexone	DD: 6/17/1996 MA: MA: 1995-0921	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	University of Chicago 5841 South Maryland Avenue MC 4028 Chicago IL 60637
metreleptin	DD: 8/22/2001 MA: MA: 2001-1443	Treatment of leptin deficiency secondary to generalized lipodystrophy lipodystrophy and partial familial	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
metreleptin	DD: 8/22/2001 MA: 2001-1467	Treatment of metabolic disorders secondary to lipodystrophy	Amgen, Inc., One Amgen Center Drive Thousand Oaks CA 91320-1799
Metronidazole *Metrogel*	DD: 10/24/1991 MA: 1991-0618	Treatment of perioral dermatitis.	Galderma Laboratories, Inc. P.O. Box 331329 Fort Worth TX 76163
Metronidazole (topical) *Metrogel*	DD: 10/22/1987 MA: 11/22/1988 1987-0216	Treatment of acne rosacea.	Galderma Laboratories, Inc. P.O. Box 331329 Fort Worth TX 76163
Metronidazole (topical) *Flagyl*	DD: 11/24/1987 MA: 1986-0174	Treatment of grade III and IV, anaerobically infected, decubitus ulcers.	Searle 4901 Searle Parkway 4901 Searle Parkway Skokie IL 60077
Microbubble contrast agent *Filmix Neurosonographic Contrast*	DD: 11/16/1990 MA: 1990-0487	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc. 55 Knollwood Road 55 Knollwood Road Farmington CT 06032
Midodrine HCl *Amatine*	DD: 12/5/1996 MA: 9/6/1996 1985-0075	Treatment of patients with symptomatic orthostatic hypotension.	Schier Ridgewood F.K.A. (Roberts Pharmaceutical Corp.) Meridian Center III 6 Industrial Way West Eatontown NJ 07724

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Minocycline HCl	DD: 6/19/1992	Treatment of chronic malignant pleural effusion.	Lederle Laboratories Division
Minocin Intravenous	MA: MA: 1992-0670		Pearl River NY 10965
Mitoguazone	DD: 3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
apep	MA: MA: 1994-0800		
Mitolactol	DD: 7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Biopharmaceutics, Inc. 990 Station Road Bellport NY 11713
	MA: 1995-0902		
Mitolactol	DD: 1/23/1989	Treatment of recurrent invasive or metastatic squamous carcinoma of the	Biopharmaceutics, Inc. 990 Station Road Bellport NY 11713
	MA: MA: 1988-0331	cervix.	
Mitomycin-C	DD: 8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc. 3100 Airway Avenue, Suite 106 Costa Mesa CA 92626
	MA: 1993-0734		
Mitoxantrone	DD: 8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. 51 University St. Seattle WA 98101
Novantrone	MA: 10/13/2000 1999-1284		
Mitoxantrone	DD: 8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. 51 University St. Seattle WA 98101
Novantrone	MA: 10/13/2000 1999-1251		
Mitoxantrone	DD: 8/21/1996	Treatment of hormone refractory prostate cancer.	Serono One Technology Place One Technology Place Rockland MA 02370
Novantrone	MA: 11/13/1996 1996-0966		
Mitoxantrone HCl	DD: 7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
Novantrone	MA: 12/23/1987 MA: 12/23/1987 1987-0192		
MN14 monoclonal antibody to carcinoembryonic antigen	DD: 11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc. 300 American Road
Cea-Cide	MA: MA: 1998-1179		Morris Plains NJ 07950
MN14 monoclonal antibody to carcinoembryonic antigen	DD: 9/18/1998	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd.
Cea-Cide	MA: MA: 1998-1134		Morris Plains NJ 07950
Modafinil	DD: 3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc. 145 Brandywine Parkway 145 Brandywine Parkway
Provigil			

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 12/24/1998 1993-0737		West Chester PA 19380
Molgramostim *Leucomax*	DD: 1/24/1989 MA: MA: 1988-0341	Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Molgramostim *Leucomax*	DD: 9/25/1989 MA: 1989-0399	Treatment of aplastic anemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Monoclonal Ab(murine) anti-idiotype melanoma-associated antigen *Melimmune*	DD: 9/19/1994 MA: MA: 1994-0840	Treatment of invasive cutaneous melanoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
Monoclonal antibodies (murine or human) to B-cell lymphoma	DD: 5/6/1986 MA: 1985-0070	Treatment of B-cell lymphoma.	IDEC Pharmaceuticals Corporation 11011 Torreyana Road San Diego CA 92121
Monoclonal antibodies PM-81 and AML-2-23	DD: 3/12/1990 MA: 1989-0396	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801-0953
Monoclonal antibody 17-1a *Panorex*	DD: 4/4/1988 MA: 1988-0273	Treatment of pancreatic cancer.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Monoclonal antibody for immunization against lupus nephritis	DD: 1/7/1993 MA: 1992-0719	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc. 2825 Santa Monica Blvd., Suite 200 Santa Monica CA 90404
Monoclonal antibody PM-81	DD: 6/27/1991 MA: 1991-0587	Adjunctive treatment of acute myelogenous leukemia.	Medarex, Inc. 519 Route 173 West Bloomsbury NJ 08804
Monoclonal antibody to cytomegalovirus (human)	DD: 9/13/1991 MA: 1991-0594	Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.	Protein Design Labs, Inc. 2375 Garcia Avenue Mountain View CA 94043
Monoclonal antibody to cytomegalovirus (human)	DD: 11/15/1991 MA: 1991-0595	Treatment of cytomegalovirus retinitis in patients with AIDS.	Protein Design Labs, Inc. 2375 Garcia Avenue Mountain View CA 94043
Monoclonal antibody to hepatitis B virus (human)	DD: 6/17/1991 MA: 1991-0583	Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.	Protein Design Labs, Inc. 34801 Campus Dr. Fremont CA 94555
Monoclonal antibody-B43.13 *Ovarex MAb-B43.13*	DD: 11/25/1996 MA: 1996-1013	Treatment of epithelial ovarian cancer.	AltaRex US Corp. 610 Lincoln Street Waltham MA 02451

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Monoclonal antiendotoxin antibody XMMEn-0e5	DD: 11/4/1985 MA: 1985-0068	Treatment of patients with gram-negative sepsis which has progressed to shock.	Pfizer, Inc. 235 East 42nd Street New York NY 10017
Monolaurin *Glylorin*	DD: 4/29/1993 MA: 1992-0718	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Monooctanoin *Moctanin*	DD: 5/30/1984 MA: 10/31/1985 1984-0024	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc. 7855 Gross Point Road, Unit L 7855 Gross Point Road, Unit L Skokie IL 60077
Morphine sulfate concentrate (preservative free) *Infumorph*	DD: 7/12/1990 MA: 7/19/1991 MA: 7/19/1991 1987-0185	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc. 2 Esterbrook Lane Cherry Hill NJ 08003
MTC-DOX for Injection	DD: 1/3/2001 MA: 2000-1398	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin *MEP IGIV*	DD: 11/7/1990 MA: MA: 1990-0504	Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin *MEP IGIV*	DD: 1/9/1991 MA: MA: 1990-0505	Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852
Multi-vitamin infusion (neonatal formula)	DD: 12/12/1989 MA: 1989-0417	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P. 725 Chesterbrook Blvd. Wayne PA 19087-5677
muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar	DD: 6/5/2001 MA: 2001-1434	Treatment of children and adolescent osteosarcoma	Jenner Biotherapies, Inc. 541 Kenosa Street Walworth WI 53184
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma *Oncolym*	DD: 11/27/1998 MA: MA: 1998-1181	Treatment of B-cell non-Hodgkin's lymphoma.	Berlex Laboratories 15049 San Pablo Ave. PO Box 4099 Richmond CA 94804-0099
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 *Theragyn*	DD: 3/22/1999 MA: MA: 1998-1180	Adjuvant treatment of ovarian cancer.	Antisoma plc West Africa House Hanger Lane Ealing London W5 3QR UK

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Mycobacterium avium sensitin RS-10	DD: 10/11/1995 MA: 1995-0904	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut 5 Artillerivej DK-2300 Copenhagen S Denmark
Myelin	DD: 6/27/1991 MA: 1991-0577	Treatment of multiple sclerosis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02173
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	DD: 5/13/2002 MA: 2001-1539	Treatment of sickle cell disease	NeuroSearch A/S 93 Pederstrupvej DK-2750 Ballerup Denmark
N-acetyl-procainamide	DD: 12/10/1996 MA: MA: 1996-0991	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas 3560 Pennsylvania Avenue, Suite 7 Dubuque IA 52002
N-acetylcysteinate Lysine *Nacystelyn Dry Powder Inhaler*	DD: 12/27/2000 MA: 2000-1392	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc. Road 198, No. 100 km. 14.7 Juncos Industrial Park Juncos PR 00777-3873
N-acetylcysteine	DD: 9/9/2002 MA: 2002-1581	Treatment of acute liver failure	William M. Lee, MD, FACP University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Dallas TX 75390-9151
N-acetylgalactosamine-4-sulfatase, recombinant human	DD: 2/17/1999 MA: 1998-1198	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato CA 94949-5608
N-acetylprocainamide *Napa*	DD: 3/23/1990 MA: MA: 1989-0359	To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.	Medco Research, Inc. 8455 Beverly Blvd. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048
Nafarelin acetate *Synarel Nasal Solution*	DD: 7/20/1988 MA: 2/26/1992 1988-0298	Treatment of central precocious puberty.	Syntex (USA), Inc. 3401 Hillview Avenue Palo Alto CA 94303
Naltrexone HCl *Trexan*	DD: 3/11/1985 MA: 11/30/1984 MA: 11/30/1984 1985-0060	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals E.I. Du Pont De Nemours & Co. E.I. Du Pont De Nemours & Co. Wilmington DE 19880
Natural human lymphoblastoid interferon-alpha	DD: 1/18/2000 MA: 1999-1312	Treatment of Behcet's disease.	Amarillo Biosciences, Inc. 800 West Ninth Avenue Amarillo TX 79101-3206
Natural human lymphoblastoid interferon-alpha	DD: 11/18/2002 MA: 2002-1596	Treatment of polycythemia vera	Amarillo Biosciences, Inc. 800 West 9th Avenue Amarillo TX 79101

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Natural human lymphoblastoid interferon-alpha	DD: 8/10/2000 MA: 2000-1360	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Atrix Laboratories, Inc. 2579 Midpoint Drive Fort Collins CO 80525-4417
NDROGE	DD: 11/1/1984 MA: 1984-0039	Treatment of postanoxic intention myoclonus.	WATSON Laboratories, Inc. 33 Ralph Avenue P.O. Box 30 Copiaque NY 11726-0030
Nebacumab *Centoxin*	DD: 10/1/1986 MA: MA: 1986-0141	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc. 200 Great Valley Parkway 200 Great Valley Parkway Malvern PA 19355
Neurotrophin-1	DD: 9/13/1994 MA: 1994-0845	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D. 6560 Fannin, Scurlock Tower, Suite 720 Houston TX 77303
NG-29 *Somatrel*	DD: 8/8/1989 MA: 1989-0366	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Nifedipine	DD: 6/13/1991 MA: 1991-0579	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D. MetroHealth Medical Center 3395 Scranton Road Cleveland OH 44109
nitazoxanide *Alinia*	DD: 2/14/2002 MA: 11/22/2002 2001-1504	Treatment of intestinal giardiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
nitazoxanide *Cryptaz*	DD: 10/23/2001 MA: 2001-1505	Treatment for intestinal amebiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
Nitazoxanide *Alinia*	DD: 12/12/1996 MA: 11/22/2002 1995-0918	Treatment of cryptosporidiosis.	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
Nitisinone *Orfadin*	DD: 5/16/1995 MA: 1/18/2002 1995-0890	Treatment of tyrosinemia type 1.	Swedish Orphan AB Drottninggatan 98 SE-111 60 Stockholm Sweden SE
Nitisinone *Orfadin*	DD: 10/19/2001 MA: 2001-1487	Treatment of alkaptonuria	Swedish Orphan AB Kungsgatan 37, 7th Floor SE-111 56 Stockholm, Sweden
Nitric oxide	DD: 7/10/1995 MA: 1995-0905	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc. 54 Old Highway 22 Clinton NJ 08809
Nitric oxide *INOmax*	DD: 6/22/1993 MA: 12/23/1999 1993-0744	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc. 54 Old Highway 22 54 Old Highway 22 Clinton NJ 08809

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Nitroprusside	DD: 2/21/2001 MA: 1998-1124	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and Wills Neurosensory Institute 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102
nolatrexed *THYMITAQ*	DD: 10/18/2001 MA: 2001-1488	Treatment of hepatocellular carcinoma	Zarix, Inc. 1055 Westlakes Drive Suite 200 Berwyn PA 19312
Novel Acting Thrombolytic (NAT)	DD: 1/26/2001 MA: 2000-1377	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
NZ-1002	DD: 4/11/2001 MA: MA: 2001-1418	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104
octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A *Aerugen*	DD: 5/16/2002 MA: MA: 2002-1557	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Orphan Europe Immeuble "Le Wilson" 70 avenue du General de Gaulle, 92046 Paris La Defense France
Octreotide *Sandostatin LAR*	DD: 8/24/1998 MA: 11/25/1998 MA: 11/25/1998 1998-1146	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080
Octreotide *Sandostatin LAR*	DD: 8/24/1998 MA: 11/25/1998 1998-1145	Treatment of acromegaly.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080
Octreotide *Sandostatin LAR*	DD: 8/24/1998 MA: 11/25/1998 MA: 11/25/1998 1998-1168	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080
Ofloxacin *Ocuflox Ophthalmic Solution*	DD: 4/18/1991 MA: 5/22/1996 1991-0567	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713
oglufanide disodium	DD: 9/24/2001 MA: 2001-1479	Treatment of ovarian cancer	Cytran, Inc. 10230 NE Points Dr., NE Suite 530 Kirkland WA 98033-7869
OM 401 *Drepanol*	DD: 10/24/1991 MA: 1988-0322	Prophylactic treatment of sickle cell disease.	Omex International, Inc. 6001 Savoy, Suite 110 6001 Savoy, Suite 110 Houston TX 77036
Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	DD: 11/22/1995 MA: 1995-0931	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals 4364 South Alston Avenue Durham NC 27713

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Omega-3 (n-3) polyunsaturated fatty acids *Omacor*	DD: 5/4/2000 MA: MA: 1999-1287	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker Norway
Oncorad Ov103	DD: 4/24/1990 MA: 1989-0416	Treatment of ovarian cancer.	Cytogen Corporation 600 College Road East Princeton NJ 08540
Oprelvekin *Neumega*	DD: 12/17/1996 MA: 11/25/1997 MA: 11/25/1997 1996-0967	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc. 87 Cambridge Park Drive 87 Cambridge Park Drive Cambridge MA 02140
Orgotein for injection	DD: 12/22/1994 MA: MA:	Treatment of familial amyotrophic lateral sclerosis associated with a mutation of copper, zinc superoxide dismutase. the gene (on chromosome 21q) for	Oxis International, Inc. 6040 N. Cutter Circle, Suite 317 Portland OR 97217-3935
Oxaliplatin	DD: 10/6/1992 MA: 1992-0694	Treatment of ovarian cancer.	Debio Pharm S.A. Rue des Terreaux 17 CH-1000 Lausanne 9 Switzerland CH
Oxandrolone	DD: 10/5/1990 MA: 1990-0457	Treatment of constitutional delay of growth and puberty.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Oxandrolone *Oxandrin*	DD: 9/6/1991 MA: 1991-0590	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp. One Tower Center Boulevard, 12 th One Tower Center Boulevard, 12 th floor East Brunswick NJ 08816
Oxandrolone *Hepandrin*	DD: 3/18/1994 MA: MA: 1993-0757	Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.	Bio-Technology General Corp. 70 Wood Avenue South 70 Wood Avenue South Iselin NJ 08830
Oxandrolone *Oxandrin*	DD: 7/5/1990 MA: 1990-0455	Treatment of short stature associated with Turner's syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South 70 Wood Avenue, South Iselin NJ 08830
Oxandrolone *Oxandrin*	DD: 4/22/1997 MA: MA: 1997-1037	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. One Tower Center Boulevard, 12th One Tower Center Boulevard, 12th floor East Brunswick NJ 08816
Oxybate *Xyrem*	DD: 11/7/1994 MA: 7/17/2002 1994-0858	Treatment of narcolepsy.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Oxymorphone *Numorphan H.P.*	DD: 3/19/1985 MA: 1985-0061	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company P.O. Box 80027 Wilmington DE 19880
Oxypurinol	DD: 11/9/1998	Treatment of hyperuricemia in patients	Cardiome Pharma Corp.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		intolerant to allopurinol.	3650 Westbrook Mall
	MA: 1998-1157		Vancouver, B.C. Canada V65 2L2
P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium	DD: 10/27/1998	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd., Suite 470
	MA: 1998-1169		Durham NC 27703
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium	DD: 3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd.
	MA: 2000-1394		Suite 470 Durham NC 27703
Paclitaxel	DD: 3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
Taxol	MA: 8/4/1997		5 Research Parkway P.O. Box 5100
	1997-1034		Wallingford CT 06492-7660
Paclitaxel	DD: 4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard
Paxene	MA: 1997-1047		4400 Biscayne Boulevard Miami FL 33137
Papain, trypsin, and chymotrypsin *Wobe-Mugos*	DD: 12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc. 14851 N. Scottsdale Rd.
	MA: 1998-1174		Scottsdale AZ 85254
Papaverine topical gel	DD: 2/6/1992	Treatment of sexual dysfunction in spinal cord injury patients.	Pharmedic Company 417 Harvester Court
	MA: 1991-0649		Wheeling IL 60090
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) *MEDI-491*	DD: 5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd.
	MA: MA: 1999-1236		Gaithersburg MD 20878
Patul-end	DD: 2/18/1997	Treatment of patulous eustachian tube.	Ear Foundation 2420 Castillo Street, Suite 100
	MA: MA: 1996-0988		Santa Barbara CA 93105
PEG-glucocerebrosidase	DD: 12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, 49 Convent Dr. MSC4405
Lysodase	MA: MA: 1992-0714		49 Convent Dr. MSC4405 Bldg. 49, Room B1EE16 Bethesda MD 20892-4405
PEG-interleukin-2	DD: 2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation 4560 Horton Street
	MA: 1989-0425		Emeryville CA 94608
Pegademase bovine	DD: 5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Enzon, Inc. 20 Kingsbridge Road
Adagen	MA: 3/21/1990 MA: 3/21/1990 1984-0020		20 Kingsbridge Road Piscataway NJ 08854
Pegaspargase *Oncaspar*	DD: 10/20/1989	Treatment of acute lymphocytic leukemia.	Enzon, Inc. 20 Kingsbridge Road
	MA: 2/1/1994		Piscataway NJ 08854

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1989-0395		
Peginterferon alfa-2a *PEGASYS*	DD: 7/13/1998 MA: 1998-1138	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley NJ 07110-1199
Peginterferon alfa-2a *PEGASYS*	DD: 9/30/1999 MA: 1999-1252	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. 340 Kingsland St. Nutley NJ 07110-1199
Pegvisomant *Somavert*	DD: 6/24/1997 MA: 1997-1050	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin TX 78701
Pegylated arginine deiminase *Melanocid*	DD: 4/12/1999 MA: 1998-1208	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. 115 John Robert Thomas Dr. Exton PA 19341
Pegylated arginine deiminase *Hepacid*	DD: 3/26/1999 MA: 1998-1183	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341
Pegylated recombinant human megakaryocyte growth and development factor *MEGAGEN*	DD: 10/20/1997 MA: MA: 1997-1070	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1789
Peldesine	DD: 10/5/1993 MA: 1993-0762	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244
pemetrexed disodium *Alimta*	DD: 8/28/2001 MA: 2001-1451	Treatment of malignant pleural mesothelioma	Eli Lilly and Company Lilly Corporate Center Lilly Corporate Center Indianapolis IN 46285
Pentamidine isethionate *Nebupent*	DD: 1/12/1988 MA: 6/15/1989 MA: 6/15/1989 1987-0258	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc. 3 Parkway North Center 3 Parkway North Center Deerfield IL 60015
Pentamidine isethionate *Pentam 300*	DD: 2/28/1984 MA: 10/16/1984 1983-0010	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc. 3 Parkway North Center 3 Parkway North Center Deerfield IL 60015
Pentamidine isethionate	DD: 10/29/1984 MA: 1984-0037	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King of Prussia PA 19406-0901
Pentamidine isethionate *Pneumopent*	DD: 10/5/1987 MA: MA: 1987-0211A	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation 755 Jefferson Rd., P.O. Box 1710 755 Jefferson Rd., P.O. Box 1710 Rochester NY 14603
Pentastarch	DD: 8/28/1985	As an adjunct in leukapheresis to improve	Du Pont Pharmaceuticals

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		the harvesting and increase the yield of	E.I. Du Pont De Nemours & Co.
Pentaspan	MA: 5/19/1987 MA: 5/19/1987 1985-0080	leukocytes by centrifugal means.	E.I. Du Pont De Nemours & Co. Wilmington DE 19898
Pentosan polysulfate sodium *Elmiron*	DD: 8/7/1985 MA: 9/26/1996 1984-0017	Treatment of interstitial cystitis.	Alza Corporation 950 Page Mill Rd. PO Box 10950 Palo Alto CA 94303-0802
Pentostatin *Nipent*	DD: 11/24/1999 MA: 1999-1238	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc. 4140 Dublin Blvd. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Pentostatin *Nipent*	DD: 3/27/1998 MA: 1998-1119	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Pentostatin *Nipent*	DD: 1/29/1991 MA: 1990-0503	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc. 4140 Dublin Blvd. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Pentostatin for injection *Nipent*	DD: 9/10/1987 MA: 10/11/1991 1987-0212	Treatment of hairy cell leukemia.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Perflubron *LiquiVent*	DD: 4/26/2001 MA: 2000-1411	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road 3040 Science Park Road San Diego CA 92191
Perfosfamide *Pergamid*	DD: 12/4/1989 MA: MA: 1989-0377	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Scios Nova, Inc. 2450 Bayshore Parkway 2450 Bayshore Parkway Mountain View CA 94043
Pergolide *Permax*	DD: 11/20/1997 MA: 1997-1081	Treatment of Tourette's syndrome.	Sallee, Floyd R. M.D., Ph.D. Cincinnati Children's Hospital Medical Center 3333 Burnet Ave. Cincinnati OH 45229-3039
Phenylacetate	DD: 3/6/1998 MA: MA: 1998-1106	For use as an adjunct to surgery, radiation therapy and chemotherapy for the recurrent malignant glioma. treatment of patients with primary or	Elan Drug Delivery, Inc. 1300 Gould Dr. Gainesville GA 30504
Phenylalanine ammonia-lyase *Phenylase*	DD: 3/8/1995 MA: 1995-0881	Treatment of hyperphenylalaninemia.	Ibex Technologies, Inc. 5485 Pare Montreal, Quebec Canada H4P 1P7 CA
Phenylbutyrate	DD: 1/19/2000 MA: 1999-1261	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc. 1300 Gould Dr. Gainesville GA 30504
phenylephrine	DD: 2/14/2002 MA:	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	2001-1472		United Kingdom WD25 7SA
Phosphocysteamine	DD: 9/12/1988 MA: 1988-0295	Treatment of cystinosis.	Medea Research Laboratories Port Jefferson Business Center 200 Wilson Street, Building D-6 Port Jefferson NY 11776
physostigmine salicylate	DD: 1/16/1985 MA: 1983-0001	Treatment of Friedreich's and other inherited ataxias.	Forest Pharmaceuticals .3- .3- .30 6 150 East 58th Street New York NY 10155
Pilocarpine *Salagen*	DD: 9/24/1990 MA: 3/22/1994 MA: 3/22/1994 1990-0459	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc. 6300 West Old Shakopee Rd. 6300 West Old Shakopee Rd. Suite 110 Bloomington MN 55438-2318
Pilocarpine HCl *Salagen*	DD: 2/28/1992 MA: 2/11/1998 MA: 2/11/1998 1991-0620	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 6300 West Old Shakopee Rd. 6300 West Old Shakopee Rd. Suite 110 Bloomington MN 55438-2318
Piracetam *Nootropil*	DD: 10/2/1987 MA: 1987-0209	Treatment of myoclonus.	UCB Pharma, Inc. 1950 Lake Park Drive Smyrna GA 30080
Piritrexim isethionate	DD: 6/13/1988 MA: MA: 1988-0291	Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709
Polifeprosan 20 with carmustine *Gliadel*	DD: 12/13/1989 MA: 9/23/1996 1989-0370	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc. 6611 Tributary Street Baltimore MD 21224
Poloxamer 188 *Flocor*	DD: 6/27/1989 MA: 1989-0381	Treatment of sickle cell crisis.	CytRx Corporation 154 Technology Parkway Norcross GA 30092
Poloxamer 188	DD: 8/5/1997 MA: MA: 1996-1026	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross GA 30092
Poloxamer 188 *Florcor*	DD: 2/22/1990 MA: 1989-0403	Treatment of severe burns requiring hospitalization.	CytRx Corporation 154 Technology Parkway 154 Technology Parkway Norcross GA 30092
Poloxamer 331 *Protox*	DD: 3/21/1991 MA: 1990-0559	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation 154 Technology Parkway 154 Technology Parkway Norcross GA 30092
Poly I: poly C12U *Ampligen*	DD: 12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc. One Penn Center

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1993-0759		1617 JFK Boulevard Philadelphia PA 19103
Poly I: poly C12U *Ampligen*	DD: 7/19/1988 MA: 1985-0116	Treatment of AIDS.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly I: poly C12U *Ampligen*	DD: 5/20/1991 MA: 1991-0570	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly I: poly C12U *Ampligen*	DD: 12/9/1993 MA: 1993-0768	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc. One Penn Center One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly-ICLC	DD: 3/17/1997 MA: 1997-1031	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington DC 20008
Polyethylene glycol (PEG)-uricase	DD: 2/21/2001 MA: 2000-1356	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation One Tower Center Boulevard, 12th floor East Brunswick NJ 08816
Polyethylene glycol-modified *Zurase*	DD: 9/14/1999 MA: MA: 1998-1185	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. 115 John Robert Thomas Dr. Exton PA 19341
Polyethylene glycol-modified *Zurase*	DD: 12/21/1998 MA: MA: 1998-1177	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. 115 John Robert Thomas Dr. Exton PA 19341
polyinosinic-polycytidilic acid *Poly-ICLC*	DD: 11/19/2002 MA: 2002-1577	Treatment for orthopox virus infections	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
polyinosinic-polycytidilic acid *Poly-ICLC*	DD: 8/2/2002 MA: 2002-1578	As an adjuvant to smallpox vaccination	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
Polymeric oxygen	DD: 3/25/1992 MA: 1988-0311	Treatment of sickle cell anemia.	Capmed USA P.O. Box 14 Bryn Mawr PA 19010
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral *NeuroCell-PD*	DD: 12/17/1996 MA: MA: 1996-1025	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC One Kendall Square Cambridge MA 02139-1562
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral	DD: 12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC One Kendall Square

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
implantation.			
NeuroCell-PD	MA: MA: 1995-0933		Cambridge MA 02139-1562
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral	DD: 12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC One Kendall Square
NeuroCell-HD	MA: MA: 1996-1028		Cambridge MA 02129-1562
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	DD: 12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC One Kendall Square
NeuroCell-HD	MA: MA: 1995-0932		Cambridge MA 02139-1562
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural	DD: 6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc. Post Office Plaza
N-Graft	MA: MA: 1997-1046		50 Division Street, Suite 503 Somerville NJ 08876
porfimer	DD: 10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc. 22 Inverness Parkway
Photofrin	MA: MA: 2001-1466		22 Inverness Parkway Suite 310 Birmingham AL 35242
Porfimer sodium	DD: 6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc. Lederle Laboratories
Photofrin	MA: 12/27/1995 MA: 12/27/1995 1989-0355		Lederle Laboratories 401 North Middletown Road Pearl River NY 10965
Porfimer sodium	DD: 11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc. Lederle Laboratories
Photofrin	MA: MA: 1989-0394		Lederle Laboratories 401 North Middletown Road Pearl River NY 10965
Porfiromycin	DD: 9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
Promycin	MA: 1995-0914		900 Ridgebury Road PO Box 368 Ridgefield CT 06877
Porfiromycin	DD: 3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
Promycin	MA: 1997-1035		900 Ridgebury Road PO Box 368 Ridgefield CT 06877
Potassium citrate	DD: 11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
Urocit-K	MA: 8/30/1985 1984-0027		5323 Harry Hines Boulevard Dallas TX 75235
Potassium citrate	DD: 9/16/1985	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Urocit-K	MA: 8/30/1985 1985-0096A		5323 Harry Hines Blvd Dallas TX 75235
Potassium citrate	DD: 9/12/1985	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas 5323 Harry Hines Blvd
Urocit-K	MA: 8/30/1985 1985-0096B		5323 Harry Hines Blvd Dallas TX 75235
Potassium citrate and citric acid	DD: 2/14/1986 MA: 1985-0097	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Willen Drug Company
Pr-122 (redox-phenytoin)	DD: 7/5/1990 MA: 1990-0434	For the emergency rescue treatment of status epilepticus, grand mal type.	Pharmos 2 Innovation Drive Alachua FL 32615
PR-225 (redox-acyclovir)	DD: 5/29/1990 MA: 1989-0375	Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.	Pharmos 2 Innovation Drive Alachua FL 32615
PR-239 (redox penicillin G)	DD: 5/23/1990 MA: 1989-0376	Treatment of AIDS associated neurosyphilis.	Pharmos 2 Innovation Drive Alachua FL 32615
Pr-320 (molecusol-carbamazepine)	DD: 7/20/1990 MA: 1990-0435	For the emergency rescue treatment of status epilepticus, grand mal type.	Pharmos 2 Innovation Drive Alachua FL 32615
Pramiracetam Sulfate	DD: 11/4/1991 MA: MA: 1991-0616	For the management of cognitive dysfunction and enhancement of electroconvulsive therapy. antidepressant activity associated with	Cambridge Neuroscience, Inc. 1 Kendall Square, Bldg. 700 Cambridge MA 02139
Praziquantel	DD: 4/18/1988 MA: 1987-0194	Treatment of neurocysticercosis.	EM Pharmaceuticals, Inc.
Prednimustine	DD: 6/17/1985	Treatment of malignant non-Hodgkin's lymphomas.	Pharmacia Inc. P.O. Box 16529
Sterecyt	MA: 1985-0066		P.O. Box 16529 Columbus OH 43216-6529
Primaquine phosphate	DD: 7/23/1993 MA: MA: 1993-0747	For use in combination with clindamycin hydrochloride in the treatment of associated with AIDS. Pneumocystis carinii pneumonia	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016
Progesterone	DD: 12/22/1994 MA: MA: 1994-0826	Establishment and maintenance of pregnancy in women undergoing in vitro procedures. fertilization or embryo transfer	Watson Laboratories, Inc. 311 Bonnie Circle Corona CA 91720
Propamidine isethionate 0.1% ophthalmic solution *Brolene*	DD: 3/10/1988 MA: MA: 1988-0272	Treatment of acanthamoeba keratitis.	Bausch & Lomb Pharmaceuticals Division 8500 Hidden River Parkway Tampa FL 33637
Prostaglandin E1 enol ester	DD: 6/12/1998	Treatment of Fontaine Stage IV chronic	Welfide International Corporation

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
(AS-013)		critical limb ischemia.	5555 Valley Boulevard
	MA: 1998-1128		Los Angeles CA 90032
Prostaglandin E1 in lipid emulsion	DD: 9/10/1996	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard
Lipo-PGE1	MA:		5555 Valley Boulevard
	MA: 1995-0887		Los Angeles CA 90032
Protein C concentrate	DD: 6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation Hyland Division (Baxter Hyland)
Protein C Concentrate (human) Vapor	MA:		Hyland Division (Baxter Hyland) 550 North Brand Blvd.
	MA: 1992-0653		Glendale CA 91203
Protein C concentrate	DD: 4/22/1993	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor
Protein C Concentrate (human) Vapor			750 Lexington Avenue, 19th Floor
	MA: 1992-0652		New York NY 10022
Protein C concentrate	DD: 6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor
Protein C Concentrate (human) Vapor	MA:		750 Lexington Avenue, 19th Floor
	MA: 1992-0651		New York NY 10022
Protirelin	DD: 8/24/1993	Prevention of infant respiratory distress syndrome associated with prematurity.	UCB Pharma, Inc. 1950 Lake Park Drive
	MA: 1993-0750		Smyrna GA 30080
Protirelin injection	DD: 1/10/1985	Treatment of amyothrophic lateral sclerosis.	Abbott Laboratories
	MA: 1984-0051		
Pulmonary surfactant replacement	DD: 12/5/1988	Prevention and treatment of infant respiratory distress syndrome.	Scios Nova, Inc. 2450 Bayshore Parkway
	MA: 1988-0309		Mountain View CA 94043
Pulmonary surfactant replacement, porcine	DD: 8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Dey Laboratories 2751 Napa Valley Corporate Drive
Curosurf	MA:		
	MA: 1992-0711		Napa CA 94558
Purified extract of Pseudomonas aeruginosa	DD: 9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street
ImmuDyn	MA:		
	MA: 1997-1066		Cambridge MA 02139
Purified type II collagen *Colloral*	DD: 2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc. 128 Spring Street
	MA: 1994-0874		Lexington MA 02421
pVGI.1(VEGF2)	DD: 11/9/1999	Treatment of thromboangiitis obliterans.	Vascular Genetics, Inc. 200 Westpark Corporate Center
	MA: 1999-1245		4364 South Alston Ave. Durham NC 27713-2280
Pyruvate	DD: 2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue
	MA:		P.O. Box 968

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	2000-1409		Flemington NJ 08822
Quinacrine hydrochloride	DD: 10/17/1984 MA: 1984-0041	For prevention of recurrence of pneumothorax in patients at high risk of recurrence.	Lyphomed, Inc.
R-etodolac	DD: 12/9/2002 MA: 2002-1627	The treatment of chronic lymphocytic leukemia	Salmedix, Inc. 4330 La Jolla Village Drive Suite 250 San Diego CA 92122
rasburicase *Elitek*	DD: 10/11/2000 MA: 7/12/2002 1999-1314	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway 9 Great Valley Parkway Malvern PA 19355
Recombinant bactericidal/permeability-increasing protein *Neuprex*	DD: 6/22/1998 MA: MA: 1998-1122	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710
Recombinant glycine2-human glucagon-like peptide-2	DD: 6/29/2000 MA: 1999-1269	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario L4V 1V7 Canada CA
Recombinant human acid alpha-glucosidase	DD: 8/19/1997 MA: 1997-1065	Treatment of glycogen storage disease type II.	Genzyme Corporation One Kendall Square Cambridge MA 02139
recombinant human alpha 1-antitrypsin (rAAT)	DD: 11/20/2001 MA: 2001-1493	Treatment of cystic fibrosis	Arriva Pharmaceuticals, Inc. 2020 Challenger Drive Alameda CA 94501
recombinant human alpha-1 antitrypsin	DD: 3/6/1998 MA: 1998-1110	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland GB
recombinant human alpha-1 antitrypsin (rAAT)	DD: 8/28/2001 MA: 2001-1476	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Baxter Healthcare Corporation 550 N. Brand Blvd. Glendale CA 91203
Recombinant Human Alpha-Fetoprotein (rhAFP)	DD: 2/22/2001 MA: 2000-1403	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc. 101 Binney Street Cambridge MA 02142
Recombinant human antithrombin	DD: 4/6/2000 MA: MA: 1998-1187	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, P.O. Box 9322 Framingham MA 01701
Recombinant human C1-esterase inhibitor	DD: 2/23/1999 MA: 1998-1224	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium BE
Recombinant human C1-esterase	DD: 2/23/1999	Treatment of (acute attacks of)	Pharming N.V.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
inhibitor		angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Cipalstreet 3
	MA: 1999-1235		B-2440 Geel Belgium BE
Recombinant human CD4 immunoglobulin G	DD: 8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc. 460 Point San Bruno Boulevard
	MA: 1990-0440		South San Francisco CA 94080
Recombinant human Clara Cell 10kDa protein	DD: 7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive
	MA: 1998-1139		College Park MD 20742
recombinant human endostatin protein	DD: 2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc. 9640 Medical Center Drive
	MA: 2001-1531		Rockville MD 20850
recombinant human endostatin protein	DD: 8/13/2001	Treatment of neuroendocrine tumors.	EntreMed, Inc. 9640 Medical Center Drive
	MA: 2001-1463		Rockville MD 20850
Recombinant human gelsolin	DD: 3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	Biogen, Inc. 14 Cambridge Center
	MA: 1994-0853		Cambridge MA 02142
Recombinant human gelsolin	DD: 1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	Biogen, Inc. 14 Cambridge Center
	MA: 1993-0783		Cambridge MA 02124
Recombinant human highly phosphorylated acid alpha-glucosidase	DD: 9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc. 800 Research Parkway
TBD	MA: MA: 2000-1378		Suite 200 Oklahoma City OK 73104
Recombinant human insulin-like growth factor 1	DD: 6/7/1995	Treatment of growth hormone receptor deficiency.	Pharmacia & Upjohn 7000 Portage Road
IGF-1	MA: MA: 1995-0897		Kalamazoo MI 49001-0199
Recombinant human insulin-like growth factor 1	DD: 6/7/1995	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	Pharmacia & Upjohn 7000 Portage Road
IGF-1	MA: MA: 1995-0908		Kalamazoo MI 49001-0199
Recombinant human insulin-like growth factor-I	DD: 10/13/1995	Treatment of post-poliomyelitis syndrome.	Cephalon, Inc. 145 Brandywine Parkway
	MA: 1995-0919		West Chester PA 19380-4245
Recombinant human insulin-like growth factor-I	DD: 2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr.
PV802	MA: 1999-1289		Adelaide SA 5000 Australia AU
recombinant human insulin-like growth factor-I/insulin-like growth	DD: 5/17/2002	Treatment of growth hormone insensitivity syndrome	Celtrix Pharmaceuticals, Inc. a subsidiary of Insmed, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
factor binding protein-3 *SomatoKine*	MA: MA: 2002-1563		4851 Lake Brook Drive Glen Allen VA 23060
Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	DD: 6/15/1999 MA: 1998-1142	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. P.O. Box 2400 Glen Allen VA 23058-2400
Recombinant human interleukin-12	DD: 10/20/1997 MA: 1997-1075	Treatment of renal cell carcinoma.	Genetics Institute, Inc. 87 CambridgePark Drive Cambridge MA 02140
Recombinant human keratinocyte growth factor	DD: 12/20/1999 MA: 1999-1306	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799
Recombinant human luteinizing hormone *LHadi*	DD: 10/7/1994 MA: 1992-0802 1992-0802	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061
recombinant human monoclonal antibody to hsp90 *Mycograb*	DD: 9/16/2002 MA: MA: 2002-1584	Treatment of invasive candidiasis	NeuTec Pharma plc 2dn floor, Clinical Sciences Bldg. Central Manchester Healthcare Trust, Oxford Rd., Manchester M139WL, UK
Recombinant human nerve growth factor	DD: 4/16/1999 MA: 1998-1108	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080
recombinant human porphobilinogen deaminase	DD: 9/9/2002 MA: 2002-1572	Treatment of acute intermittent porphyria attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod Denmark
Recombinant human relaxin	DD: 11/3/1995 MA: 1995-0929	Treatment of progressive systemic sclerosis.	Connetics Corporation 3400 West Bayshore Road Palo Alto CA 94303
Recombinant human superoxide dismutase *Oxsodrol*	DD: 4/18/1991 MA: 1990-0549	Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.	Bio-Technology General Corp. One Tower Center Boulevard, 12th floor floor East Brunswick NJ 08816
Recombinant human	DD: 9/29/1997 MA: MA: 1997-1068	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
Recombinant humanized MAb 5c8	DD: 3/22/1999 MA: 1999-1234	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Recombinant humanized MAb 5c8	DD: 10/14/1998	Prevention and treatment of Factor	Biogen, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		VIII/Factor IX inhibitors in patients with	14 Cambridge Center Cambridge MA 02142
	MA: MA: 1998-1137	hemophilia A or B.	
Recombinant humanized MAb 5c8	DD: 3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
	MA: 1998-1200		
Recombinant humanized monclonal antibody 5c8	DD: 2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
	MA: 1997-1098		
Recombinant humanized monoclonal antibody 5c8	DD: 2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
	MA: 1998-1112		
Recombinant methionyl brain-derived neurotrophic factor	DD: 11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799
	MA: 1994-0863		
Recombinant methionyl human stem cell factor	DD: 11/22/1995	Treatment of primary bone marrow failure.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
	MA: 1995-0883		
Recombinant retroviral vector - glucocerebrosidase	DD: 11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878
	MA: 1993-0743		
Recombinant secretory leucocyte protease inhibitor	DD: 3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc. 3200 Walnut Street Boulder CO 80301
	MA: 1990-0555		
Recombinant secretory leucocyte protease inhibitor	DD: 3/29/1991	Treatment of congenital alpha-1 antitrypsin deficiency.	Amgen Inc. 3200 Walnut Street Boulder CO 80301
	MA: 1990-0554		
Recombinant soluble human CD4 *Receptin*	DD: 11/20/1989	Treatment of acquired immunodeficiency syndrome.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
	MA: 1989-0389		
Recombinant soluble human CD4 (rCD4)	DD: 3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080
	MA: 1989-0348		
Recombinant urate oxidase	DD: 10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
	MA: 1999-1315		
Recombinant vaccinia (human papillomavirus) *TA-HPV*	DD: 8/24/1994	Treatment of cervical cancer.	Xenova Research Limited 310 Cambridge Science Park
	MA: MA: 1994-0843		Cambridge CB4 OWG Great Britain GB
Reduced L-glutathione	DD: 2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Cachexon	MA: 1993-0774		146 Flanders Drive Hillsborough NJ 08876
Remacemide *Ecovia*	DD: 3/6/2000 MA: 1999-1305	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677
repertaxin	DD: 1/27/2003 MA: 2002-1628	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila Italy
Respiratory Syncytial Virus Immune Globulin (human) *Hypermune RSV*	DD: 9/27/1990 MA: MA: 1990-0512	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg MD 20878
Respiratory syncytial virus immune globulin (Human) *Respigam*	DD: 9/27/1990 MA: 1/18/1996 MA: 1/18/1996 1990-0511	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachussetts Public Health Biologics Labs. 35 West Watkins Mill Road 35 West Watkins Mill Road Gaithersburg MD 20878
retroviral gamma-c cDNA containing vector	DD: 4/29/2002 MA: 2001-1516	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210
Retroviral vector, R-GC and GC gene 1750	DD: 5/6/1997 MA: 1996-1023	Treatment of Gaucher disease.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Reviparin sodium *Clivarine*	DD: 6/18/2001 MA: 2001-1435	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Knoll AG Ludwigshafen, Germany
Reviparin sodium *Clivarine*	DD: 6/18/2001 MA: 2001-1436	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG Ludwigshafen, Germany
RGG0853, E1A lipid complex	DD: 9/15/1995 MA: 1995-0909	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive Way, Suite 100 Seattle WA 98101
Rho (D) immune globulin intravenous (human) *WinRho SD*	DD: 11/9/1993 MA: 3/24/1995 MA: 3/24/1995 1993-0749	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc. 104 Chancellor Matheson Road Winnipeg, Manitoba Canada R3T 2N2 CA
Ribavirin *Virazole*	DD: 4/12/1991 MA: 1991-0574	Treatment of hemorrhagic fever with renal syndrome.	ICN Pharmaceuticals, Inc. ICN Plaza ICN Plaza 3300 Hyland Avenue Costa Mesa CA 92626
Ricin (blocked) conjugated murine MCA (anti-B4)	DD: 11/17/1988 MA: 1988-0302	Treatment of B-cell leukemia and B-cell lymphoma.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Ricin (blocked) conjugated murine mca (anti-b4)	DD: 1/24/1991 MA: 1990-0491	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine MCA (anti-my9)	DD: 8/3/1989 MA: 1989-0383	Treatment of myeloid leukemia, including AML, and blast crisis of CML.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine MCA (anti-my9)	DD: 2/1/1990 MA: 1989-0424	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine MCA (n901)	DD: 1/25/1991 MA: 1990-0524	Treatment of small cell lung cancer.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine monoclonal antibody (CD6)	DD: 9/6/1994 MA: 1993-0770	Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Rifabutin	DD: 12/18/1989 MA: 1989-0418	Treatment of disseminated Mycobacterium avium complex disease.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Rifabutin *Mycobutin*	DD: 12/18/1989 MA: 12/23/1992 MA: 12/23/1992 1989-0419	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Rifalazil	DD: 4/13/1999 MA: 1999-1226	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle WA 98119
Rifampin *Rifadin I.V.*	DD: 12/9/1985 MA: 5/25/1989 MA: 5/25/1989 1985-0076	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Rifampin, isoniazid, pyrazinamide *Rifater*	DD: 9/12/1985 MA: 5/31/1994 1985-0065	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Rifapentine *Priftin*	DD: 6/9/1995 MA: 6/22/1998 1995-0894	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627
Rifapentine *Priftin*	DD: 6/9/1995 MA: 1995-0895	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc. P.O. Box 9627 P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627
Rifapentine *Priftin*	DD: 3/12/1996 MA:	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to	Hoechst Marion Roussel, Inc. P.O. Box 9627 P.O. Box 9627

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1995-0896	75/mm3.	Mail Station: H3-M2516 Kansas City MO 64134-0627
Rifaximin *Normix*	DD: 2/10/1998 MA: 1997-1094	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road, Suite 205 Palo Alto CA 94303
RII retinamide	DD: 5/6/1993 MA: 1993-0741	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham PA 19044-2310
Riluzole *Rilutek*	DD: 10/15/1996 MA: 1996-1007	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road PO Box 5096 Collegeville PA 19426-0800
Riluzole *Rilutek*	DD: 3/16/1993 MA: 12/12/1995 1992-0727	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road, P.O. Box 1200 Collegeville PA 19426
Rituximab *Rituxan*	DD: 6/13/1994 MA: 11/26/1997 1993-0797	Treatment of non-Hodgkin's B-cell lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road 3030 Callan Road San Diego CA 92121
rituximab *Rituxan*	DD: 3/12/2002 MA: 2002-1551	Treatment of immune thrombocytopenic purpura	Genentech, Inc. 1 DNA Way 1 DNA Way South San Francisco CA 94080-4990
Roquinimex *Linomide*	DD: 7/1/1993 MA: MA: 1993-0728	To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Kalamazoo MI 49001-0199
rSP-C lung surfactant *Venticute*	DD: 4/3/2000 MA: 1998-1191	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals Byk-Gulden StraBe 2 Byk-Gulden StraBe 2 78467 Konstanz Germany DE
rubitecan	DD: 7/17/2002 MA: MA: 2002-1566	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
S(-)-3-[3-amino-phthalimido]-glutar amide	DD: 3/14/2002 MA: 2001-1517	Treatment of multiple myeloma	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850
S-adenosylmethionine	DD: 4/30/1998 MA: 1998-1114	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Care Center Philips Building, Suite 2Q; 10 Union Square East New York NY 10003
Sacrosidase *Sucraid*	DD: 12/10/1993	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 4/9/1998 1993-0786		Suite 475 Minnetonka MN 55305
Sargramostim *Leukine*	DD: 3/6/1995 MA: 9/15/1995 MA: 9/15/1995 1994-0814	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Sargramostim *Leukine*	DD: 5/3/1990 MA: 3/5/1991 MA: 3/5/1991 1990-0442	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Satumomab pendetide *Oncoscint CR/OV*	DD: 9/25/1989 MA: 12/29/1992 1989-0367	Detection of ovarian carcinoma.	Cytogen Corporation 600 College Road East Princeton NJ 08540
SB-408075	DD: 12/7/2000 MA: 2000-1384	For pancreatic cancer	SmithKline Beecham Pharmaceuticals 1250 S. Collegeville Road Collegeville PA 19426-0989
SCH 58500	DD: 4/12/1999 MA: 1998-1223	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth NJ 07033
Secalciferol *Osteo-D*	DD: 7/26/1993 MA: 1993-0751	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA 650 Cathill Rd. 650 Cathill Rd. Sellersville PA 18960
Secretory leukocyte protease inhibitor	DD: 6/30/1992 MA: 1992-0682	Treatment of bronchopulmonary dysplasia.	Synergen, Inc. 1885 33rd Street Boulder CO 80301
Selegiline HCl *Eldepryl*	DD: 11/7/1984 MA: 6/5/1989 MA: 6/5/1989 1983-0005	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc. 777 South Harbor Island Boulevard 777 South Harbor Island Boulevard Tampa FL 33602
Sermorelin acetate *Geref*	DD: 9/14/1988 MA: 9/26/1997 MA: 9/26/1997 1987-0246	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Sermorelin acetate *Geref*	DD: 12/5/1991 MA: 1991-0614	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. One Technology Place One Technology Place Rockland MA 02370
Sermorelin acetate *Geref*	DD: 2/13/1990 MA: MA: 1988-0319	Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy	Serono Laboratories, Inc. One Technology Place One Technology Place Rockland MA 02370
Serratia marcescens extract (polyribosomes)	DD: 9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc. 1668 Valtec Lane

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Imuvert	MA: MA: 1988-0301		Boulder CO 80306
Short chain fatty acid enema *Colomed*	DD: 8/19/1997 MA: 1997-1063	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D. 1000 Central Street, Suite 615 Evanston IL 60201
Short chain fatty acid solution *Colomed*	DD: 5/29/1990 MA: MA: 1990-0448	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer 1000 Central Street, Suite 615 1000 Central Street, Suite 615 Evanston IL 60201
Silver sulfadiazine and cerium nitrate *Flammacerium*	DD: 11/17/1999 MA: MA: 1998-1107	Prevention of mortality in severely burned patients.	Synthes (USA) 1690 Russell Road PO Box 1766 Paoli PA 19301
SK&F 110679	DD: 5/23/1990 MA: MA: 1990-0461	For the long term treatment of children who have growth failure due to a lack of secretion. adequate endogenous growth hormone	SmithKline Beecham Pharmaceuticals One Franklin Plaza Philadelphia PA 19101
Sodium 1,3-propanedisulfonate	DD: 4/6/1999 MA: 1998-1189	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1 CA
Sodium dichloroacetate	DD: 12/31/1997 MA: 1997-1087	Treatment of congenital lactic acidosis.	Questcor Pharmaceuticals, Inc. 3260 Whipple Rd. Union City CA 94587-1217
Sodium dichloroacetate	DD: 6/11/1990 MA: 1990-0452	Treatment of congenital lactic acidosis.	Stacpoole, Peter W. M.D., Ph.D. University of Florida P.O. Box 100277 Gainesville FL 32610
Sodium dichloroacetate *Ceresine*	DD: 6/14/1999 MA: 1998-1147	Treatment of severe head injury.	Questcor Pharmaceuticals, Inc. 26118 Research Road Hayward CA 94545
Sodium dichloroacetate	DD: 11/10/1994 MA: 1994-0836	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D. University Of Florida P.O. Box 100277 Gainesville FL 32610
Sodium dichloroacetate	DD: 6/11/1990 MA: 1990-0453	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D. University of Florida P.O. Box 100277 Gainesville FL 32610
Sodium monomercaptoundecahydro-closo-dodecaborate	DD: 12/18/1984 MA: 1984-0042	For use in conjunction with a thermal or epithermal neutron beam in boron nuclear capture therapy of glioblastoma multiforme.	Theragenics Corporation
Sodium Monomercaptoundecahydro-closo-dodecaborate *Borocell*	DD: 4/15/1992 MA: MA: 1992-0656	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner 877 Main Street, Suite 402 Boise ID 83702

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Sodium phenylbutyrate	DD: 4/24/1998 MA: MA: 1998-1105	For use as an adjuct to surgery, radiation therapy and chemotherapy for the recurrent malignant glioma. treatment of patients with primary or	Elan Drug Delivery, Inc. 1300 Gould Dr. Gainesville GA 30504
sodium phenylbutyrate *Buphenyl*	DD: 11/22/1993 MA: 4/30/1996 MA: 4/30/1996 1993-0778	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road 8125 N. Hayden Road Scottsdale AZ 85258
sodium phenylbutyrate	DD: 7/2/1992 MA: MA: 1992-0681	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy. hemoglobinopathy, and S-thalassemia	Medicis Pharmaceutical Corp. 8125 N. Hayden Road Scottsdale AZ 85258
Sodium tetradecyl sulfate *Sotradecol*	DD: 6/10/1986 MA: 1986-0127	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc. 2 Esterbrook Lane Cherry Hill NJ 08003
Soluble complement receptor type	DD: 3/6/2000 MA: MA: 1999-1318	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc. 119 Fourth Ave. Needham MA 02494-2725
Soluble recombinant human complement receptor type 1	DD: 11/21/1994 MA: 1994-0828	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc. 119 Fourth Avenue Needham Heights MA 02194
Somatostatin	DD: 12/22/1994 MA: 1994-0860	Treatment of bleeding esophageal varices.	UCB Pharmaceuticals, Inc. 1950 Lake Park Drive Smyrna GA 30080
Somatostatin *Zecnil*	DD: 6/20/1988 MA: MA: 1987-0215	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Somatrem for injection *Protropin*	DD: 12/9/1985 MA: 10/17/1985 MA: 10/17/1985 1985-0107A	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatrem for injection *Protropin*	DD: 12/9/1985 MA: 1985-0107B	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin *Nutropin*	DD: 3/6/1987 MA: 10/17/1985 MA: 10/17/1985 1986-0125	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin *Humatrope*	DD: 5/8/1990 MA: 12/30/1996	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company Lilly Corporate Center Lilly Corporate Center Indianapolis IN 46285

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	1990-0450		
Somatropin	DD: 9/1/1987	Adjunct for the induction of ovulation in women with infertility due to	Novo Nordisk Pharmaceuticals 100 Overlook Center
Norditropin	MA: MA:	hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained	100 Overlook Center Suite 200
	1987-0217	infertility, who are undergoing in vivo or in vitro fertilization procedures.	Princeton NJ 08540
Somatropin	DD: 2/12/1993	Treatment of cachexia associated with AIDS.	Bio-Technology General Corp. 70 Wood Avenue, South
Biotropin	MA: 1992-0715		70 Wood Avenue, South Iselin NJ 08830
Somatropin	DD: 11/5/1987	Treatment of short stature associated with Turner's syndrome.	Novo Nordisk Pharmaceuticals 100 Overlook Center
Norditropin	MA: 1986-0133B		100 Overlook Center Suite 200 Princeton NJ 08540
Somatropin	DD: 9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn 7000 Portage Road
Genotropin	MA: 10/31/1997 1994-0835		7000 Portage Road Kalamazoo MI 49001-0199
Somatropin (rDNA)	DD: 5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from	Serono Laboratories, Inc. One Technology Place
Saizen	MA: MA: 1987-0245	severe burns.	One Technology Place Rockland MA 02370
Somatropin (r-DNA)	DD: 3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel	Serono Laboratories, Inc. One Technology Place
Serostim	MA: MA: 1994-0803	syndrome.	One Technology Place Roackland MA 02370
Somatropin (r-DNA) for injection	DD: 3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including	Serono Laboratories, Inc. One Technology Place
Serostim	MA: MA: 1995-0946	AIDS-associated wasting.	One Technology Place Rockland MA 02370
Somatropin (rDNA origin)	DD: 3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth	Serono Laboratories, Inc. 100 Longwater Circle
Saizen	MA: MA: 1986-0154	failure.	100 Longwater Circle Norwell MA 02061
Somatropin (rDNA origin)	DD: 10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate	Genentech, Inc. 1 DNA Way
Nutropin Depot	MA: MA: 1998-1150	endogenous growth hormone secretion.	1 DNA Way South San Francisco CA 94080-4990
Somatropin (rDNA origin) injection	DD: 7/10/1987	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals 100 Overlook Center
Norditropin	MA: 1986-0133A		100 Overlook Center Suite 200 Princeton NJ 08540
Somatropin [rDNA]	DD: 7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd.
Genotropin	MA: 6/20/2000 1999-1247		7000 Portage Rd. 0633-298-113 Kalamazoo MI 49001-0199
somatropin [rDNA]	DD: 12/27/2000	Treatment of growth failure in children who	Pharmacia and Upjohn Company

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		were born small for gestational age.	7000 Portage Road
Genotropin	MA: 7/25/2001 2000-1354		7000 Portage Road Kalamazoo MI 49001
Somatropin for injection	DD: 3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard
Nutropin	MA: 12/30/1996 1986-0126		460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin for injection	DD: 11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. 100 Longwater Circle
Serostim	MA: 8/23/1996 1991-0604		100 Longwater Circle Norwell MA 02061
Somatropin for injection	DD: 6/12/1986	For the long-term treatment of children who have growth failure due to inadequate	Eli Lilly and Company Lilly Corporate Center
Humatrope	MA: 3/8/1987 MA: 3/8/1987 1985-0112	secretion of normal endogenous growth hormone.	Lilly Corporate Center Indianapolis IN 46285
Somatropin for injection	DD: 11/18/1996	As replacement therapy for growth hormone deficiency in adults after	Genentech, Inc. 460 Point San Bruno Boulevard
Nutropin	MA: 12/15/1997 MA: 12/15/1997 1996-1003	epiphyseal closure.	460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin for injection	DD: 8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc. 460 Point San Bruno Boulevard
Nutropin	MA: 11/17/1993 1989-0349		460 Point San Bruno Boulevard South San Francisco CA 94080
Sorivudine	DD: 11/9/1995	Treatment of herpes zoster (shingles) in immunocompromised patients.	Bristol-Myers Squibb 5 Research Parkway
BRAVAVIR	MA: 1995-0922		5 Research Parkway P.O. Box 5100 Wallingford CT 06492
Sotalol HCl	DD: 9/23/1988	Prevention of life threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc. 300 Fairfield Road
Betapace	MA: 1988-0300B		300 Fairfield Road Wayne NJ 07470
Sotalol HCl	DD: 9/23/1988	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc. 300 Fairfield Road
Betapace	MA: 10/30/1992 1988-0300A		300 Fairfield Road Wayne NJ 07470
Spiramycin	DD: 10/17/1984	For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients	Rhone-Poulenc Rorer 500 Arcola Road
Rovamycine	MA: MA: 1984-0036	with immunodeficiency.	500 Arcola Road Collegeville PA 19426
squalamine lactate	DD: 5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive
	MA: 2001-1431		Plymouth Meeting PA 19462
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of malignant mesothelioma	NeoPharm Incorporated 150 Field Drive
	MA: 2001-1518		Suite 195 Lake Forest IL 60045
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of epithelial ovarian cancer	NeoPharm, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 2001-1508		150 Field Drive Suite 195 Lake Forest IL 60045
ST1-RTA immunotoxin (SR 44163)	DD: 8/12/1987 MA: 1986-0168B	Treatment of patients with B-chronic lymphocytic leukemia.	Sanofi Winthrop, Inc. 9 Great Valley Parkway Malvern PA 19355
ST1-RTA immunotoxin (SR 44163)	DD: 8/12/1987 MA: MA: 1986-0168A	Prevention of acute graft versus host disease in allogenic bone marrow transplantation.	Sanofi Winthrop, Inc. 9 Great Valley Parkway Malvern PA 19355
Sterile talc *Steritalc*	DD: 12/8/1997 MA: 1997-1092	Treatment of pneumothorax.	Novatech SA Avenue du Vent des Dames - Z.I. les Paluds 13685 Aubagne France
Sterile talc *Steritalc*	DD: 12/8/1997 MA: 1997-1067	Treatment of malignant pleural effusion.	Novatech SA Avenue du Vent des Dames - Z.I. les Paluds 13685 Aubagne France
Sterile talc powder *Sclerosol Intrapleural Aerosol*	DD: 9/18/1995 MA: 12/24/1997 1995-0915	Treatment of malignant pleural effusion.	Bryan Corporation 4 Plympton Street Woburn MA 01801
SU101	DD: 3/12/1996 MA: 1995-0950	Treatment of ovarian cancer.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080-4811
SU101	DD: 5/25/1995 MA: 1995-0898	Treatment of malignant glioma.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080-4811
Succimer *Chemet*	DD: 3/22/1991 MA: 1990-0508	Treatment of mercury intoxication.	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016-1389
Succimer *Chemet*	DD: 11/5/1990 MA: MA: 1990-0507	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc. 90 Park Avenue 90 Park Avenue New York NY 10016-1389
Succimer *Chemet capsules*	DD: 5/9/1984 MA: 12/22/1988 1984-0019	Treatment of lead poisoning in children.	Bock Pharmacal Company P.O. Box 419056 Saint Louis MO 63141-9056
Sucralfate	DD: 7/15/1993 MA: MA: 1993-0738	Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.	Fuisz Technologies, Ltd. 14555 Avion at Lakeside Chantilly VA 20151
Sucralfate suspension	DD: 3/4/1991 MA: MA: 1990-0470	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc. 100 Banks Avenue Rockville Centre NY 11570

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Sucralfate suspension	DD: 3/12/1990 MA: MA: 1989-0410	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc. 100 Banks Avenue Rockville Centre NY 11570
Sulfadiazine	DD: 3/14/1994 MA: 7/29/1994 MA: 7/29/1994 1993-0780	For use in combination with pyrimethamine for the treatment of encephalitis in patients with and without Toxoplasma gondii AIDS.	Eon Labs Manufacturing, Inc. 227-15 North Conduit Avenue Laurelton NY 11413
Sulfapyridine	DD: 9/10/1990 MA: 1990-0510	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Superoxide dismutase (human)	DD: 3/6/1985 MA: MA: 1985-0059	For protection of donor organ tissue from damage or injury mediated by generated during the necessary periods of oxygen-derived free radicals that are ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership 4560 Horton Street Emeryville CA 94608
Superoxide dismutase (recombinant human) *Oxsodrol*	DD: 5/17/1988 MA: MA: 1988-0271	Prevention of reperfusion injury to donor organ tissue.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Suramin *Metaret*	DD: 5/6/1997 MA: 1997-1048	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48105-2430
Surface active extract of saline lavage of bovine lungs *Infasurf*	DD: 6/7/1985 MA: MA: 1985-0062	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc. 1576 Sweet Home Road Amherst NY 14228
Surfactant (human) (amniotic fluid derived) *Human Surf*	DD: 3/25/1987 MA: MA: 1986-0165	Prevention and treatment of neonatal respiratory distress syndrome.	Merritt, T. Allen M.D. 2516 Stockton Boulevard Sacramento CA 95817
Synsorb Pk	DD: 7/17/1995 MA: 1995-0903	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc. 201, 1204 Kensington Road, N.W. Calgary, Alberta Canada T2N 3P5 CA
Synthetic Human Parathyroid Hormone 1-34	DD: 1/26/2001 MA: 2000-1381	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217
Synthetic human secretin	DD: 6/16/1999 MA: MA: 1998-1207	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic human secretin	DD: 6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic	ChiRhoClin, Inc. 15500 Gallaudet Ave.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA:		Silver Spring MD 20905-4176
	MA: 1998-1206	examination in pancreatic carcinoma.	
Synthetic human secretin	DD: 3/7/2000	For use in conjunction with diagnostic procedures for pancreatic disorders to	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
	MA:		
	MA: 1999-1301	increase pancreatic fluid secretion.	
Synthetic human secretin	DD: 6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring MD 20905-4176
	MA: 1998-1205		
Synthetic porcine secretin	DD: 3/7/2000	For use in conjunction with diagnostic procedures for pancreatic disorders to	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
	MA: 4/4/2002		
	MA: 4/4/2002 1999-1302	increase pancreatic fluid secretion.	
Synthetic porcine secretin	DD: 6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
	MA: 4/4/2002		
	MA: 4/4/2002 1998-1204	syndrome.	
Synthetic porcine secretin	DD: 6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
	MA:		
	MA: 1998-1203	examination in pancreatic carcinoma.	
Synthetic porcine secretin	DD: 6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
	MA: 11/1/2002 1998-1202		
T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	DD: 11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc. 9 Parker
	MA: 2001-1490		Irvine CA 92618-1605
T4 endonuclease V, liposome encapsulated	DD: 6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics 205 Buffalo Avenue
	MA: 1989-0385		Freeport NY 11520
Tacrolimus *Prograf*	DD: 4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
	MA: 1998-1113		
TAK-603	DD: 5/13/1998	Treatment of Crohn's disease.	Tap Holdings Inc. 2355 Waukegan Road Deerfield IL 60015
	MA: 1998-1126		
Technetium Tc 99m pterotetramide	DD: 2/16/2000	For the identification of ovarian carcinomas.	Endocyte, Inc. 1205 Kent Ave. Lafayette IN 47906
	MA: 1999-1313		
Technetium Tc99m anti-melanoma murine monoclonal antibody *Oncotrac Melanoma Imaging Kit*	DD: 6/2/1987	For use in detecting, by imaging, metastases of malignant melanoma.	NeoRx Corporation 410 West Harrison
	MA:		
	MA: 1987-0183		Seattle WA 98119-4007

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	DD: 4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute	Immunomedics, Inc. 300 American Road
LymphoScan	MA: 1992-0654 1992-0654	B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Morris Plains NJ 07950
Technetium Tc99m murine monoclonal antibody to hCG	DD: 8/7/1989	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road
Immuraid, hCG-Tc-99m	MA: MA: 1989-0356		Morris Plains NJ 07950
Technetium Tc99m murine monoclonal antibody to human	DD: 8/1/1989	Detection of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road
AFP-Scan	MA: MA: 1989-0354		Morris Plains NJ 07950
Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein	DD: 8/1/1989	Detection of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road
Immuraid, AFP-Scan	MA: MA: 1989-0353		Morris Plains NJ 07950
Technetium Tc99m rh-Annexin V	DD: 11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or	Theseus Imaging Corporation 124 Mount Auburn Street
Apomate	MA: MA: 2000-1355	bilateral lung transplants.	124 Mount Auburn Street Suite 200 North Cambridge MA 02138
Temoporfin	DD: 10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Park
Foscan	MA: MA: 1999-1288	cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia House, Castle Business Park Stirling Scotland FK9 4TZ GB
Temozolomide	DD: 10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd.
Temodar	MA: 8/11/1999 1998-1167		Kenilworth NJ 07033
Temozolomide	DD: 10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute 2000 Galloping Hill Rd.
Temodal	MA: 1998-1171		2000 Galloping Hill Rd. Kenilworth NJ 07033
Teniposide	DD: 11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
Vumon for injection	MA: 7/14/1992 1983-0008		5 Research Parkway P.O. Box 5100 Wallingford CT 06492
Teriparatide	DD: 1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road
Parathar	MA: 12/23/1987 MA: 12/23/1987 1986-0144	hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	500 Arcola Road Collegeville PA 19426
Teriparatide	DD: 10/28/1999	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, Inc. 27 Maple St.
Parathar	MA: 1999-1270		Milford MA 01757

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Terlipressin *Glypressin*	DD: 3/6/1986 MA: 1985-0117	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901
Testosterone *TheraDerm Testosterone Transdermal*	DD: 9/22/1997 MA: MA: 1997-1041	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories Research Park Research Park 417 Wakara Way Salt Lake City UT 84108
Testosterone *Androgel*	DD: 2/5/1996 MA: 1995-0945	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. Four Parkway North Four Parkway North Deerfield IL 60015-2544
Testosterone propionate ointment 2%	DD: 7/31/1991 MA: 1991-0576	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc. 1990 N.W. 44th Street Pompano Beach FL 33064
Testosterone sublingual	DD: 1/16/1991 MA: 1990-0525	Treatment of constitutional delay of growth and puberty in boys.	Bio-Technology General Corp. 70 Wood Avenue South Iselin NJ 08830
Tetrabenazine	DD: 5/12/1998 MA: 1997-1097	Treatment of moderate/severe tardive dyskinesia.	Lifehealth Limited 23 Winkfield Road Windsor, Berkshire SL4 4BA UK
Tetrabenazine	DD: 12/11/1997 MA: 1997-1088	Treatment of Huntington's disease.	Lifehealth Limited 23 Winkfield Road Doltic House Kingfisher WA Windor, Berkshire SL4 4BA UK
Tetraiodothyroacetic acid	DD: 5/1/2000 MA: MA: 2000-1331	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489
TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide *Oncomun*	DD: 6/5/2002 MA: MA: 2002-1556	Treatment of malignant glioma	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensberg Germany
Thalidomide	DD: 5/1/1995 MA: MA: 1994-0801	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation P.O. Box 4914 7 Powder Horn Srive Warren NJ 07059
Thalidomide	DD: 9/19/1988 MA: MA: 1988-0307B	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
Thalidomide *Thalomid*	DD: 10/14/1998 MA: 1998-1155	Treatment of multiple myeloma.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide	DD: 2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation 7 Powder Horn Dr.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1997-1101		Warren NJ 07059
Thalidomide	DD: 5/15/1995 MA: MA: 1994-0825	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite 113 Beltsville MD 20705
Thalidomide	DD: 3/5/1990 MA: 1990-0438	Prevention of graft versus host disease.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite 113 Beltsville MD 20705
Thalidomide	DD: 11/15/1988 MA: 1988-0321	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
Thalidomide *Thalomid*	DD: 7/26/1995 MA: 7/16/1998 1995-0907	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059
Thalidomide *Thalomid*	DD: 4/6/1999 MA: 1998-1218	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide	DD: 3/5/1990 MA: 1990-0437	Treatment of graft versus host disease.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite 113 Beltsville MD 20705
Thalidomide	DD: 1/12/1993 MA: MA: 1992-0720	Treatment of the clinical manifestations of mycobacterial infection caused by non-tuberculous mycobacteria. Mycobacterium tuberculosis and	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059
Thalidomide	DD: 9/19/1988 MA: MA: 1988-0307A	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
Thalidomide	DD: 7/29/1998 MA: 1998-1149	Treatment of Kaposi's sarcoma.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide *Synovir*	DD: 3/11/1996 MA: 1995-0949	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059
Thymalfasin *Zadaxin*	DD: 3/6/2000 MA: 2000-1326	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc. 901 Mariner's Blvd., Suite 205 San Mateo CA 94404
Thymalfasin *Zadaxin*	DD: 5/3/1991 MA: 1990-0529	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo CA 94404-1593
Thymalfasin *Zadaxin*	DD: 1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. 901 Mariner's Island Blvd.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 1997-1095		San Mateo CA 94404-1593
Thymoxamine HCl	DD: 11/16/1987 MA: MA: 1987-0198	Reversal of phenylephrine-induced mydriasis in patients who have narrow developing an acute attack of anterior angles and are at risk of angle-closure glaucoma following	Iolab Pharmaceuticals 500 Iolab Drive Claremont CA 91711
Thyrotropin alfa *Thyrogen*	DD: 8/3/2001 MA: MA: 2001-1423	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562
Thyrotropin alpha *Thyrogen*	DD: 2/24/1992 MA: 11/30/1998 1991-0631	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139
Tiapride	DD: 4/21/1998 MA: 1998-1117	Treatment of Tourette's syndrome.	Sanofi-Synthelabo, Inc. 9 Great Valley Parkway PO Box 3026 Malvern PA 19355
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolec	DD: 12/27/2000 MA: 2000-1395	Chronic myelogenous leukemia (CML)	Ribapharm 3300 Hyland Avenue Costa Mesa CA 92626
tinidazole	DD: 4/18/2002 MA: 2002-1554	Treatment of giardiasis	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004
Tiopronin *Thiola*	DD: 1/17/1986 MA: 8/11/1988 1986-0123	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D. The University of Texas Health The University of Texas Health Scienc Center at Dallas 5323 Harry Hines Boulevard Dallas TX 75235
tirapazamine	DD: 10/23/2002 MA: 2002-1555	For the treatment of head and neck cancer	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
Tiratricol *Triacana*	DD: 8/13/1991 MA: MA: 1990-0468	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires 48 Bis, Rue des Belles-Feuilles 48 Bis, Rue des Belles-Feuilles 75116 Paris France FR
Tizanidine HCl *Zanaflex*	DD: 1/31/1994 MA: 1993-0791	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc. 800 Gateway Boulevard 800 Gateway Boulevard South San Francisco CA 94080
Tobramycin *Tobi*	DD: 6/18/1999 MA: 1998-1210	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Chiron Corporation 201 Elliott Avenue West 201 Elliott Avenue West Suite 150 Seattle WA 98119
Tobramycin for inhalation *TOBI*	DD: 10/13/1994 MA: 12/22/1997	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Pathogenesis Corporation 201 Elliott Avenue West, Suite 150 201 Elliott Avenue West, Suite 150

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
	MA: 12/22/1997 1994-0844		Seattle WA 98119
Tocophersolan oral solution (vitamin E-tpgs)	DD: 4/15/1988 MA: 1987-0226	Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.	Sterling Winthrop 9 Great Valley Parkway Malvern PA 19355
Topiramate *Topamax*	DD: 11/25/1992 MA: 8/28/2001 1992-0707	Treatment of Lennox-Gastaut syndrome.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602
toralizumab	DD: 3/14/2002 MA: 2002-1543	Treatment of immune thrombocytopenic purpura	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
Toremifene *Fareston*	DD: 9/19/1991 MA: 5/29/1997 1991-0602	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 P.O. Box 65 02101 ESPOO Finland
Toremifene	DD: 8/17/1993 MA: 1993-0753	Treatment of desmoid tumors.	Orion Corporation P.O. Box 65 02101 Espoo Finland
Tositumomab and iodine I 131 tositumomab *Bexxar*	DD: 5/16/1994 MA: MA: 1993-0794	Treatment of non-Hodgkin's B-cell lymphoma.	Coulter Pharmaceutical, Inc. 550 California Avenue Suite 200 Palo Alto CA 94306
Tranexamic acid *Cyklokapron*	DD: 9/9/1985 MA: 1985-0088A	Treatment of hereditary angioneurotic edema.	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Tranexamic acid *Cyklokapron*	DD: 7/23/1987 MA: MA: 1985-0088B	Treatment of patients undergoing prostatectomy where there is hemorrhage or risk of hemorrhage as a result of increased fibrinolysis or fibrinogenolysis.	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Tranexamic acid *Cyklokapron*	DD: 10/29/1985 MA: 12/30/1986 MA: 12/30/1986 1985-0088C	Treatment of patients with congenital coagulopathies who are undergoing surgical procedures (e.g. dental extractions).	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Transforming growth factor-beta 2	DD: 12/18/1992 MA: 1992-0710	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Drive Santa Clara CA 95054
Transgenic human alpha 1 antitrypsin	DD: 5/19/1999 MA: 1999-1228	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland GB
Trastuzumab *Herceptin*	DD: 12/14/1999 MA: 1999-1293	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc. 1 DNA Way 1 DNA Way South San Francisco CA 94080-4990

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Treosulfan *Ovastat*	DD: 5/16/1994 MA: 1994-0812	Treatment of ovarian cancer.	Medac GmbH Fehlandtstrasse 3 D-20354 Hamburg Germany DE
treprostinil *Remodulin*	DD: 6/4/1997 MA: 5/21/2002 1997-1051	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp. 68 T.W. Alexander Dr. 68 T.W. Alexander Dr. P.O. Box 14186 Research Triangle Park NC 27709
Tretinoin	DD: 4/15/1985 MA: MA: 1985-0057	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc 34 Sherrill Rd. Marshfield MA 02050
Tretinoin *ATRA-IV*	DD: 1/14/1993 MA: 1992-0716	Treatment of acute and chronic leukemia.	Antigenics, Inc. 34 Commerce Way Woburn MA 01801
Tretinoin *Vesanoid*	DD: 10/24/1990 MA: 11/22/1995 1990-0509	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate	DD: 11/23/2001 MA: 2001-1503	Treatment for hepatocellular carcinoma	Cell Works Inc. 6200 Seaforth Street Baltimore MD 21224-6506
Trientine HCl *Syprine*	DD: 12/24/1984 MA: 11/8/1985 MA: 11/8/1985 1984-0048	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research Division Of Merck And Company Division Of Merck And Company West Point PA 19486
Trimetrexate *Neutrexin*	DD: 8/10/2000 MA: 1999-1322	Treatment of metastatic osteogenic sarcoma.	Medimmune Oncology, Inc. One Tower Bridge One Tower Bridge 100 Front St., Suite 400 West Conshohocken PA 19428
Trimetrexate glucuronate *Neutrexin*	DD: 5/15/1986 MA: 12/17/1993 1986-0142	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc. One Tower Bridge One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428
Trimetrexate glucuronate	DD: 1/13/1988 MA: 1986-0146	Treatment of patients with advanced non-small cell carcinoma of the lung.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428
Trimetrexate glucuronate	DD: 7/25/1985 MA: 1985-0083C	Treatment of pancreatic adenocarcinoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428
Trimetrexate glucuronate	DD: 7/25/1985 MA: 1985-0083B	Treatment of metastatic colorectal adenocarcinoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Trimetrexate glucuronate	DD: 7/25/1985 MA: MA: 1985-0083A	Treatment of metastatic carcinoma of the head and neck (i.e. buccal cavity, pharynx, and larynx).	Medimmune Oncology, Inc. 35 West Watkins Mills Road Gaithersburg MD 20878
Triptorelin pamoate *Decapeptyl Injection*	DD: 8/10/1990 MA: MA: 1988-0346	For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.	Debio R.A. Inc. 7929 Westpark Drive, Suite 400 7929 Westpark Drive, Suite 400 Mclean VA 22102
Trisaccharides A and B *Biosynject*	DD: 4/15/1988 MA: MA: 1988-0279	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd. P.O. Box 8050, Station F P.O. Box 8050, Station F Edmonton, Alberta Canada T6H 4NP CA
Trisaccharides A and B *Biosynject*	DD: 4/20/1987 MA: MA: 1987-0188	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd. P.O. Box 8050, Station F P.O. Box 8050, Station F Edmonton, Alberta Canada T6H 4NP CA
Trisaccharides A and B *Biosynject*	DD: 4/12/1987 MA: MA: 1986-0180	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd. P.O. Box 8050, Station F P.O. Box 8050, Station F Edmonton, Alberta Canada T6H 4NP CA
Trisaccharides A and B	DD: 8/3/1987 MA: MA: 1987-0202	Treatment of moderate to very severe clinical forms of transfusion reactions transfusions of blood, blood products, and arising from ABO incompatible blood derivatives.	Chembiomed, Ltd. P.O. Box 8050, Edmonton, Alberta CA
Trisodium citrate concentration *Hemocitrate*	DD: 6/15/1995 MA: 1994-0870	For use in leukapheresis procedures.	Hemotec Medical Products, Inc. Box 19255 Johnston RI 02919
Troleandomycin	DD: 9/21/1989 MA: 1989-0390	Treatment of severe steroid-requiring asthma.	Szefler, Stanley M. M.D. National Jewish Center for Immunology and Respiratory 1400 Jackson Street Denver CO 80206
Tumor necrosis factor-binding protein 1	DD: 1/6/1993 MA: 1991-0634	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061
Tumor necrosis factor-binding protein II	DD: 1/6/1993 MA: 1991-0646	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061
Tyloxapol *Supervent*	DD: 3/8/1995 MA: 1994-0879	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University of Utah Health Sciences Center 50 North Medical Drive, Room 4R240 Salt Lake City UT 84132-0001
Ubiquinone *Ubiqgel*	DD: 12/14/1999 MA: 1999-1250	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp. 30 New York Ave. PO Box 331 Westbury NY 11590

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	DD: 3/22/2001 MA: 2000-1390	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE
Uridine 5'-triphosphate	DD: 6/26/1996 MA: MA: 1996-0990	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham NC 27703
Uridine 5'-triphosphate	DD: 12/4/1995 MA: 1995-0934	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham NC 27703
Urofollitropin *Fertinex*	DD: 12/5/1997 MA: MA: 1997-1073	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Urofollitropin *Metrodin*	DD: 11/25/1987 MA: 9/18/1986 MA: 9/18/1986 1986-0140	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Urogastrone	DD: 11/1/1984 MA: MA: 1984-0016	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision 500 Iolab Drive Claremont CA 91711
Ursodiol *URSO*	DD: 6/20/1991 MA: 12/10/1997 1987-0221	Treatment of patients with primary biliary cirrhosis.	Axcan Pharma Inc. 597 Laurier Blvd 597 Laurier Blvd Mount St. Hilaire Quebec H7L 4S3 Canada CA
Ursodiol *Actigall*	DD: 2/19/1991 MA: MA: 1990-0553	Management of the clinical signs and symptoms associated with primary biliary cirrhosis.	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080
Valine, isoleucine and leucine *VIL*	DD: 1/5/1996 MA: 1995-0930	Treatment of hyperphenylalaninemia.	Leas Research Products 78 Fallon Drive North Haven CT 06473
Valrubicin *Valstar*	DD: 5/23/1994 MA: 9/25/1998 1994-0821	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 103 Carnegie Center, Suite 102 Princeton NJ 08540
Vapreotide *Octastatin*	DD: 1/10/2000 MA: MA: 1999-1298	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH
Vapreotide	DD: 1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Octastatin	MA: 1999-1295		17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH
Vapreotide	DD: 3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17 rue des Terreaux
Octastatin	MA: MA: 1999-1296		17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH
Vasoactive intestinal peptide	DD: 3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Stony Brook Health Sciences Center T17, 040
	MA: 2001-1420		Health Sciences Center T17, 040 Stony Brook NY 11794-8172
Vasoactive intestinal polypeptide	DD: 6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals 200 Westpark Corporate Center 4364 South Alston Avenue
	MA: 1992-0721		Durham NC 27713-2280
vigabatrin *Sabril*	DD: 6/12/2000	Treatment of infantile spasms.	Aventis Pharmaceuticals Inc. P.O. Box 9627
	MA: 2000-1351		Kansas City MO 64137
Viloxazine HCl *Catatrol*	DD: 6/11/1984	Treatment of narcolepsy.	Stuart Pharmaceuticals Division of ICI Americas
	MA: 1984-0023B		Wilmington DE 19897
Viloxazine HCl *Catatrol*	DD: 6/11/1984	Treatment of cataplexy.	Stuart Pharmaceuticals Division of ICI Americas
	MA: 1984-0023A		Wilmington DE 19897
Virulizin *Virulizin*	DD: 2/1/2001	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215
	MA: 2000-1396		Markham, ON L3R 5J2 Canada
Xenogeneic hepatocytes *HepatAssist Liver Assist System*	DD: 11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc. 99 Hayden Ave.
	MA: 1998-1170		Lexington MA 02421-7995
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen	DD: 8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd.
Cea-Cide	MA: MA: 1999-1244		Morris Plains NJ 07950
Zalcitabine *Hivid*	DD: 6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc. 340 Kingsland Street
	MA: 6/19/1992 1988-0283		Nutley NJ 07110
Zalcitabine	DD: 12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT NIH, Executive Plaza North, Room 7-18
	MA: 1986-0175		Bethesda MD 20892
Zidovudine *Retrovir*	DD: 7/17/1985	Treatment of AIDS.	Glaxo Wellcome Inc. 5 Moore Drive
	MA: 3/19/1987 1985-0081A		Research Triangle Park NC 27709

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2002

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Zidovudine *Retrovir*	DD: 5/12/1987 MA: 3/19/1987 1985-0081	Treatment of AIDS related complex.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Zinc acetate *Galzin*	DD: 11/6/1985 MA: 1/28/1997 1985-0111	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville PA 19443
Zoledronate *Zometa, Zabel*	DD: 8/18/2000 MA: 8/20/2001 1999-1308	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp. 59 Route 10 59 Route 10 East Hanover NJ 07936-1080

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG; 40MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG; 40MG

ACETAMINOPHEN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG
500MG; 50MG; 40MG

AMINOPHYLLINE
TABLET; ORAL
100MG
200MG

ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG

ASPIRIN; CAFFEINE; CARISOPRODOL
TABLET; ORAL
160MG; 32MG; 200MG

ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
160MG; 32MG; 200MG; 16MG

ASPIRIN; CARISOPRODOL
TABLET; ORAL
325MG; 200MG

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
325MG; 200MG; 16MG

ASPIRIN; MEPROBAMATE
TABLET; ORAL
325MG; 200MG

ASPIRIN; METHOCARBAMOL
TABLET; ORAL
325MG; 400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG; 25MG; 50MG; 100MG

PREDNISONE
TABLET; ORAL
1MG; 2.5MG; 5MG; 10MG; 20MG; 25MG; 50MG

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

** 8 **

8-HOUR BAYER, ASPIRIN (OTC)
8-MOP, METHOXSALEN

** A **

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
A.P.L., GONADOTROPIN, CHORIONIC
A/T/S, ERYTHROMYCIN
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABITREXATE, METHOTREXATE SODIUM
ABREVA, DOCOSANOL (OTC)
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURBRON, THEOPHYLLINE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACCUTANE, ISOTRETINOIN
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
ACETAMINOPHEN AND PENTAZOCINE HCL, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ACILAC, LACTULOSE
ACIPHEX, RABEPRAZOLE SODIUM
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
ACTH, CORTICOTROPIN
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
ACTHAR, CORTICOTROPIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICORT, HYDROCORTISONE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ACTIGALL, URSODIOL
ACTIN-N, NITROFURAZONE
ACTINEX, MASOPROCOL
ACTIQ, FENTANYL CITRATE
ACTISITE, TETRACYCLINE HYDROCHLORIDE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACTRON, KETOPROFEN (OTC)
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUTECT, TECHNETIUM TC-99M APCITIDE
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR, ACYCLOVIR SODIUM
ACYLANID, ACETYLDIGITOXIN
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE

FDA data supplied by DrugPatentWatch.com

ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE
ADDERALL 7.5, AMPHETAMINE ASPARTATE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADPHEN, PHENDIMETRAZINE TARTRATE
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL, IBUPROFEN (OTC)
AEROBID, FLUNISOLIDE
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
AEROSPORIN, POLYMYXIN B SULFATE
AFAXIN, VITAMIN A PALMITATE
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGENERASE, AMPRENAVIR
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKRINOL, ACRISORCIN
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALAVERT, LORATADINE (OTC)
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBAMYCIN, NOVOBIOCIN SODIUM
ALBENZA, ALBENDAZOLE
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% IN D5-W, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALESSE, ETHINYL ESTRADIOL
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALKERGOT, ERGOLOID MESYLATES
ALLAY, ACETAMINOPHEN
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALPHA CHYMAR, CHYMOTRYPSIN
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE
ALPHADERM, HYDROCORTISONE
ALPHADROL, FLUPREDNISOLONE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPHAGAN, BRIMONIDINE TARTRATE
ALPHALIN, VITAMIN A PALMITATE
ALPHAREDISOL, HYDROXOCOBALAMIN
ALPHATREX, BETAMETHASONE DIPROPIONATE

FDA data supplied by DrugPatentWatch.com

ALPHAZINE, PHENDIMETRAZINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTACE, RAMIPRIL
ALTOCOR, LOVASTATIN
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)
ALUPENT, METAPROTERENOL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMCINONIDE, AMCINONIDE
AMEN, MEDROXYPROGESTERONE ACETATE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLIN, AMINOPHYLLINE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMIPAQUE, METRIZAMIDE
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMNESTEEM, ISOTRETINOIN
AMNESTROGEN, ESTROGENS, ESTERIFIED
AMOSENE, MEPROBAMATE
AMOXAPINE, AMOXAPINE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTSSSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHICOL, CHLORAMPHENICOL
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRINONE, INAMRINONE LACTATE
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANESTACON, LIDOCAINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
ANGIO-CONRAY, IOTHALAMATE SODIUM
ANGIOMAX, BIVALIRUDIN
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
ANHYDRON, CYCLOTHIAZIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
ANOQUAN, ACETAMINOPHEN
ANSAID, FLURBIPROFEN
ANSOLYSEN, PENTOLINIUM TARTRATE
ANSPOR, CEPHRADINE
ANTABUSE, DISULFIRAM
ANTAGON, GANIRELIX ACETATE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
ANTEPAR, PIPERAZINE CITRATE
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
APHTHASOL, AMLEXANOX
APOGEN, GENTAMICIN SULFATE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AQUAMEPHYTON, PHYTONADIONE
AQUAPHYLLIN, THEOPHYLLINE
AQUASOL A, VITAMIN A
AQUASOL A, VITAMIN A PALMITATE
AQUATAG, BENZTHIAZIDE
AQUATENSEN, METHYCLOTHIAZIDE
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
ARAMINE, METARAMINOL BITARTRATE
ARAVA, LEFLUNOMIDE
ARDUAN, PIPECURONIUM BROMIDE
AREDIA, PAMIDRONATE DISODIUM
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

ARFONAD, TRIMETHAPHAN CAMSYLATE
ARGATROBAN, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
AROMASIN, EXEMESTANE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL, MESALAMINE
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
ASENDIN, AMOXAPINE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
ATARAX, HYDROXYZINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
ATIVAN, LORAZEPAM
ATNAA, ATROPINE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRIDOX, DOXYCYCLINE HYCLATE
ATROMID-S, CLOFIBRATE
ATROPEN, ATROPINE
ATROPINE AND DEMEROL, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE, ATROPINE
ATROVENT, IPRATROPIUM BROMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
AVIANE-21, ETHINYL ESTRADIOL
AVIANE-28, ETHINYL ESTRADIOL
AVINZA, MORPHINE SULFATE
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXID, NIZATIDINE
AXOTAL, ASPIRIN
AYGESTIN, NORETHINDRONE ACETATE
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZACTAM, AZTREONAM
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE, AZATHIOPRINE SODIUM
AZDONE, ASPIRIN
AZELEX, AZELAIC ACID
AZLIN, AZLOCILLIN SODIUM
AZMACORT, TRIAMCINOLONE ACETONIDE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
AZOLID, PHENYLBUTAZONE
AZOPT, BRINZOLAMIDE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE

** B **

BACI-RX, BACITRACIN
BACIGUENT, BACITRACIN
BACIIM, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN
BACITRACIN, BACITRACIN (OTC)
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTOCILL, OXACILLIN SODIUM
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALNEOL-HC, HYDROCORTISONE
BAMATE, MEPROBAMATE
BANAN, CEFPODOXIME PROXETIL
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
BANTHINE, METHANTHELINE BROMIDE
BAROS, SODIUM BICARBONATE
BARSTATIN 100, NYSTATIN
BAYCOL, CERIVASTATIN SODIUM
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, ASPIRIN (OTC)
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENDOPA, LEVODOPA
BENEMID, PROBENECID
BENICAR, OLMESARTAN MEDOXOMIL
BENOQUIN, MONOBENZONE
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
BENSULFOID, SULFUR
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZTHIAZIDE, BENZTHIAZIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BENZYL BENZOATE, BENZYL BENZOATE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID
BERUBIGEN, CYANOCOBALAMIN
BETA-2, ISOETHARINE HYDROCHLORIDE
BETA-HC, HYDROCORTISONE
BETA-VAL, BETAMETHASONE VALERATE
BETADERM, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPAR, MEPREDNISONE
BETAPEN-VK, PENICILLIN V POTASSIUM
BETAPRONE, PROPIOLACTONE
BETATREX, BETAMETHASONE VALERATE
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETIMOL, TIMOLOL
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BEXTRA, VALDECOXIB
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BILIVIST, IPODATE SODIUM
BILOPAQUE, TYROPANOATE SODIUM
BILTRICIDE, PRAZIQUANTEL
BIO-TROPIN, SOMATROPIN RECOMBINANT
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
BIPHETAP, BROMPHENIRAMINE MALEATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BLENOXANE, BLEOMYCIN SULFATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
BLOCADREN, TIMOLOL MALEATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
BOROFAIR, ACETIC ACID, GLACIAL

FDA data supplied by DrugPatentWatch.com

BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS
BRAVELLE, UROFOLLITROPIN
BREATHTEK UBT FOR H-PYLORI, UREA, C-13
BRETHAIRE, TERBUTALINE SULFATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BRETYLOL, BRETYLIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRICANYL, TERBUTALINE SULFATE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
BRONKAID MIST, EPINEPHRINE (OTC)
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
BUCET, ACETAMINOPHEN
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPAR, BUSPIRONE HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTABARB, BUTABARBITAL SODIUM
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTABARBITAL, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
BUTALAN, BUTABARBITAL SODIUM
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL COMPOUND, ASPIRIN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
BUTAZOLIDIN, PHENYLBUTAZONE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

** C **

C-SOLVE-2, ERYTHROMYCIN
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CALAN, VERAPAMIL HYDROCHLORIDE
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
CALCIJEX, CALCITRIOL
CALCIMAR, CALCITONIN, SALMON
CALCIPARINE, HEPARIN CALCIUM
CALCITONIN-SALMON, CALCITONIN, SALMON
CALCITRIOL, CALCITRIOL
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CALDEROL, CALCIFEDIOL
CALMURID HC, HYDROCORTISONE
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CAMILA, NORETHINDRONE
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDEX, NYSTATIN

FDA data supplied by DrugPatentWatch.com

CANTIL, MEPENZOLATE BROMIDE
CAP-PROFEN, IBUPROFEN (OTC)
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL WITH CODEINE, ACETAMINOPHEN
CAPITROL, CHLOROXINE
CAPOTEN, CAPTOPRIL
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBACHOL, CARBACHOL
CARBAMAZEPINE, CARBAMAZEPINE
CARBASTAT, CARBACHOL
CARBATROL, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CARDURA, DOXAZOSIN MESYLATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARMOL HC, HYDROCORTISONE ACETATE
CARNITOR, LEVOCARNITINE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CATARASE, CHYMOTRYPSIN
CAVERJECT, ALPROSTADIL
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CEDAX, CEFTIBUTEN DIHYDRATE
CEDILANID-D, DESLANOSIDE
CEENU, LOMUSTINE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFMAX, CEFMENOXIME HYDROCHLORIDE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEFTIN, CEFUROXIME AXETIL
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEFZIL, CEFPROZIL
CELEBREX, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTRAX, PRAZEPAM
CEPHALEXIN, CEPHALEXIN
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CEPHRADINE, CEPHRADINE
CEPHULAC, LACTULOSE
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CERADON, CEFOTIAM HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CEREBYX, FOSPHENYTOIN SODIUM
CEREDASE, ALGLUCERASE
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERNEVIT-12, ALPHA-TOCOPHEROL
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETACORT, HYDROCORTISONE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CETROTIDE, CETRORELIX
CHEMET, SUCCIMER
CHENIX, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHIBROXIN, NORFLOXACIN
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHLOROFAIR, CHLORAMPHENICOL
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROMYXIN, CHLORAMPHENICOL
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLOROTRIANISENE, CHLOROTRIANISENE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEBRINE, IOCETAMIC ACID
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHOLYBAR, CHOLESTYRAMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CHRONULAC, LACTULOSE
CHYMEX, BENTIROMIDE
CHYMODIACTIN, CHYMOPAPAIN
CIBACALCIN, CALCITONIN HUMAN
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIN-QUIN, QUINIDINE SULFATE
CINNASIL, RESCINNAMINE
CINOBAC, CINOXACIN
CINOXACIN, CINOXACIN
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN

FDA data supplied by DrugPatentWatch.com

CIPRO XR, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIRCANOL, ERGOLOID MESYLATES
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISPLATIN, CISPLATIN
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLADRIBINE, CLADRIBINE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLARINEX, DESLORATADINE
CLARITIN REDITABS, LORATADINE
CLARITIN, LORATADINE
CLARITIN-D 24 HOUR, LORATADINE
CLARITIN-D, LORATADINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLIMARA, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINORIL, SULINDAC
CLISTIN, CARBINOXAMINE MALEATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFIBRATE, CLOFIBRATE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE

FDA data supplied by DrugPatentWatch.com

DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CLOXAPEN, CLOXACILLIN SODIUM
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
CO-GESIC, ACETAMINOPHEN
CO-LAV, POLYETHYLENE GLYCOL 3350
COACTIN, AMDINOCILLIN
COBAVITE, CYANOCOBALAMIN
CODAMINE, HYDROCODONE BITARTRATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
CODOXY, ASPIRIN
COGENTIN, BENZTROPINE MESYLATE
COGNEX, TACRINE HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLBENEMID, COLCHICINE
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
COLESTID, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLONAID, ATROPINE SULFATE
COLOVAGE, POLYETHYLENE GLYCOL 3350
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
COMBIPATCH, ESTRADIOL
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
COMPOUND 65, ASPIRIN
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCENTRAID, DESMOPRESSIN ACETATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONTAC 12 HOUR, CHLORPHENIRAMINE MALEATE (OTC)
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
COPPER T MODEL TCU 380A, COPPER
COR-OTICIN, HYDROCORTISONE ACETATE
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN-N, FLURANDRENOLIDE
COREG, CARVEDILOL
CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
CORT-DOME, HYDROCORTISONE
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTENEMA, HYDROCORTISONE
CORTICOTROPIN, CORTICOTROPIN
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTONE, CORTISONE ACETATE
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COTAZYM, LIPASE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRESCORMON, SOMATROPIN
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM

FDA data supplied by DrugPatentWatch.com

CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOPTIC, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CRYSTODIGIN, DIGITOXIN
CU-7, COPPER
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CURRETAB, MEDROXYPROGESTERONE ACETATE
CUTIVATE, FLUTICASONE PROPIONATE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLACILLIN, CYCLACILLIN
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
CYCLAPEN-W, CYCLACILLIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOCORT, AMCINONIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYCRIN, MEDROXYPROGESTERONE ACETATE
CYKLOKAPRON, TRANEXAMIC ACID
CYLERT, PEMOLINE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE, ANHYDROUS
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYTADREN, AMINOGLUTETHIMIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTRIX (T4;T3)
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
CYTOXAN, CYCLOPHOSPHAMIDE

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DALGAN, DEZOCINE
DALMANE, FLURAZEPAM HYDROCHLORIDE
DANAZOL, DANAZOL
DANOCRINE, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARANIDE, DICHLORPHENAMIDE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO ALTA, OXAPROZIN POTASSIUM
DAYPRO, OXAPROZIN
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEAPRIL-ST, ERGOLOID MESYLATES
DECA-DURABOLIN, NANDROLONE DECANOATE
DECABID, INDECAINIDE HYDROCHLORIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON-LA, DEXAMETHASONE ACETATE
DECAPRYN, DOXYLAMINE SUCCINATE
DECASPRAY, DEXAMETHASONE
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DEFINITY, PERFLUTREN
DEL-VI-A, VITAMIN A PALMITATE
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DELATESTRYL, TESTOSTERONE ENANTHATE
DELAXIN, METHOCARBAMOL
DELCOBESE, AMPHETAMINE ADIPATE
DELESTROGEN, ESTRADIOL VALERATE
DELFEN, NONOXYNOL-9 (OTC)
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELTA-CORTEF, PREDNISOLONE
DELTA-DOME, PREDNISONE
DELTALIN, ERGOCALCIFEROL
DELTASONE, PREDNISONE
DEMADEX, TORSEMIDE
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMI-REGROTON, CHLORTHALIDONE
DEMSER, METYROSINE
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DENAVIR, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPINAR, CYANOCOBALAMIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMACORT, HYDROCORTISONE
DERMATOP, PREDNICARBATE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESYREL, TRAZODONE HYDROCHLORIDE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
DEXACIDIN, DEXAMETHASONE
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
DHC PLUS, ACETAMINOPHEN
DI-ATRO, ATROPINE SULFATE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAL, HEXACHLOROPHENE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAPID, LYPRESSIN
DIASONE SODIUM, SULFOXONE SODIUM
DIASTAT, DIAZEPAM
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICOPAC KIT, CYANOCOBALAMIN
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIENESTROL, DIENESTROL
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DIFFERIN, ADAPALENE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DIPENTUM, OLSALAZINE SODIUM
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISCASE, CHYMOPAPAIN
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISODIUM EDETATE, EDETATE DISODIUM
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITATE-DS, ESTRADIOL VALERATE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
DIULO, METOLAZONE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIUTENSEN-R, METHYCLOTHIAZIDE
DIZAC, DIAZEPAM
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DOCA, DESOXYCORTICOSTERONE ACETATE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOLOBID, DIFLUNISAL
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
DOMEBORO, ACETIC ACID, GLACIAL
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOPAR, LEVODOPA
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIDEN, GLUTETHIMIDE
DORMATE, MEBUTAMATE
DORYX, DOXYCYCLINE HYCLATE
DOSTINEX, CABERGOLINE
DOVONEX, CALCIPOTRIENE
DOW-ISONIAZID, ISONIAZID
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRALSERP, HYDRALAZINE HYDROCHLORIDE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
DRICORT, HYDROCORTISONE ACETATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIZE, CHLORPHENIRAMINE MALEATE
DROLBAN, DROMOSTANOLONE PROPIONATE
DROPERIDOL, DROPERIDOL
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE

FDA data supplied by DrugPatentWatch.com

DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
DUONEB, ALBUTEROL SULFATE
DUPHALAC, LACTULOSE
DURABOLIN, NANDROLONE PHENPROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
DURACLON, CLONIDINE HYDROCHLORIDE
DURADYNE DHC, ACETAMINOPHEN
DURAGESIC, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DURAPHYL, THEOPHYLLINE
DURAQUIN, QUINIDINE GLUCONATE
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DUVOID, BETHANECHOL CHLORIDE
DV, DIENESTROL
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
DYCLONE, DYCLONINE HYDROCHLORIDE
DYMELOR, ACETOHEXAMIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNABAC, DIRITHROMYCIN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
DYNAPEN, DICLOXACILLIN SODIUM
DYRENIUM, TRIAMTERENE

** E **

E-BASE, ERYTHROMYCIN
E-GLADES, ERYTHROMYCIN
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
E-MYCIN, ERYTHROMYCIN
E-SOLVE 2, ERYTHROMYCIN
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED PLUS, PREDNISOLONE ACETATE
ECONOPRED, PREDNISOLONE ACETATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDETATE DISODIUM, EDETATE DISODIUM
EDEX, ALPROSTADIL
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
EFUDEX, FLUOROURACIL
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
ELDECORT, HYDROCORTISONE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELIDEL, PIMECROLIMUS
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELIXICON, THEOPHYLLINE
ELIXOMIN, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
EMGEL, ERYTHROMYCIN
EMLA, LIDOCAINE
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ENFLURANE, ENFLURANE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOVID, MESTRANOL

FDA data supplied by DrugPatentWatch.com

ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
ENPRESSE-21, ETHINYL ESTRADIOL
ENPRESSE-28, ETHINYL ESTRADIOL
ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EPI E Z PEN JR, EPINEPHRINE
EPICORT, HYDROCORTISONE
EPIFOAM, HYDROCORTISONE ACETATE
EPINEPHRINE, EPINEPHRINE (OTC)
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EQUAGESIC, ASPIRIN
EQUANIL, MEPROBAMATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
ERCATAB, CAFFEINE
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERRIN, NORETHINDRONE
ERY-TAB, ERYTHROMYCIN
ERYC 125, ERYTHROMYCIN
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYCETTE, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
ESCLIM, ESTRADIOL
ESGIC, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
ESTAZOLAM, ESTAZOLAM
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ESTINYL, ETHINYL ESTRADIOL
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
ESTRING, ESTRADIOL
ESTROGENIC SUBSTANCE, ESTRONE
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
ESTROVIS, QUINESTROL
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
ETHAMIDE, ETHOXZOLAMIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHCHLORVYNOL, ETHCHLORVYNOL
ETHIODOL, ETHIODIZED OIL
ETHMOZINE, MORICIZINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
EURAX, CROTAMITON
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
EVALOSE, LACTULOSE
EVANS BLUE, EVANS BLUE
EVEX, ESTROGENS, ESTERIFIED
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)

FDA data supplied by DrugPatentWatch.com

EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE TARTRATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXNA, BENZTHIAZIDE
EXOSURF NEONATAL, CETYL ALCOHOL
EXSEL, SELENIUM SULFIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
EXTRA-STRENGTH AIM, DISODIUM MONOFLUOROPHOSPHATE (OTC)
EXTRANEAL, CALCIUM CHLORIDE

** F **

FACTREL, GONADORELIN HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FAMVIR, FAMCICLOVIR
FANSIDAR, PYRIMETHAMINE
FARESTON, TOREMIFENE CITRATE
FASLODEX, FULVESTRANT
FASTIN, PHENTERMINE HYDROCHLORIDE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FEMARA, LETROZOLE
FEMCET, ACETAMINOPHEN
FEMHRT, ETHINYL ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FEMOGEN, ESTROGENS, ESTERIFIED
FEMPATCH, ESTRADIOL
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE
FERIDEX I.V., FERUMOXIDES
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
FERRISELTZ, FERRIC AMMONIUM CITRATE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
FERTINEX, UROFOLLITROPIN
FINACEA, AZELAIC ACID
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAXEDIL, GALLAMINE TRIETHIODIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLEXICORT, HYDROCORTISONE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLORINEF, FLUDROCORTISONE ACETATE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLOROPRYL, ISOFLUROPHATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUDARA, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUIDIL, CYCLOTHIAZIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUNISOLIDE, FLUNISOLIDE
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOR-OP, FLUOROMETHOLONE
FLUORINE F-18, SODIUM FLUORIDE, F-18
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOTHANE, HALOTHANE
FLUOTREX, FLUOCINOLONE ACETONIDE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLUPHENAZINE, FLUPHENAZINE DECANOATE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE

FDA data supplied by DrugPatentWatch.com

FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOAMICON, ALUMINUM HYDROXIDE (OTC)
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FOLIC ACID, FOLIC ACID
FOLICET, FOLIC ACID
FOLLISTIM, FOLLITROPIN ALFA/BETA
FOLLUTEIN, GONADOTROPIN, CHORIONIC
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORBAXIN, METHOCARBAMOL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE ACETATE
FORTOVASE, SAQUINAVIR
FOSAMAX, ALENDRONATE SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOVANE, BENZTHIAZIDE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FS SHAMPOO, FLUOCINOLONE ACETONIDE
FUDR, FLOXURIDINE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
FUNGIZONE, AMPHOTERICIN B
FURACIN, NITROFURAZONE
FURADANTIN, NITROFURANTOIN
FURALAN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUROXONE, FURAZOLIDONE

** G **

GABITRIL, TIAGABINE HYDROCHLORIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
GALZIN, ZINC ACETATE
GAMENE, LINDANE
GAMOPHEN, HEXACHLOROPHENE
GANITE, GALLIUM NITRATE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
GARAMYCIN, GENTAMICIN SULFATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GASTROMARK, FERUMOXSIL
GASTROVIST, DIATRIZOATE MEGLUMINE
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GEMFIBROZIL, GEMFIBROZIL
GEMONIL, METHARBITAL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENAPAX, GENTIAN VIOLET
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
GENERLAC, LACTULOSE
GENESA, ARBUTAMINE HYDROCHLORIDE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GENTACIDIN, GENTAMICIN SULFATE
GENTAFAIR, GENTAMICIN SULFATE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN, GENTAMICIN SULFATE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GEOPEN, CARBENICILLIN DISODIUM
GEREF, SERMORELIN ACETATE
GERIMAL, ERGOLOID MESYLATES
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
GLEEVEC, IMATINIB MESYLATE
GLIADEL, CARMUSTINE
GLIPIZIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCAMIDE, CHLORPROPAMIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPREP, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYCORT, HYDROCORTISONE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GO-EVAC, POLYETHYLENE GLYCOL 3350
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA
GONAL-F, FOLLITROPIN ALFA/BETA
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
GVS, GENTIAN VIOLET
GYNAZOLE-1, BUTOCONAZOLE NITRATE
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
GYNIX, CLOTRIMAZOLE (OTC)
GYNODIOL, ESTRADIOL
GYNOREST, DYDROGESTERONE

** H **

H-CORT, HYDROCORTISONE
H.P. ACTHAR GEL, CORTICOTROPIN
H.R.-50, HYDROCHLOROTHIAZIDE
HABITROL, NICOTINE
HABITROL, NICOTINE (OTC)
HALCION, TRIAZOLAM
HALDOL SOLUTAB, HALOPERIDOL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALDRONE, PARAMETHASONE ACETATE
HALFAN, HALOFANTRINE HYDROCHLORIDE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOTESTIN, FLUOXYMESTERONE
HALOTEX, HALOPROGIN
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HECTOROL, DOXERCALCIFEROL
HEDULIN, PHENINDIONE
HELICOSOL, UREA, C-13
HELIDAC, BISMUTH SUBSALICYLATE
HEMABATE, CARBOPROST TROMETHAMINE
HEMSOL-HC, HYDROCORTISONE ACETATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATASOL 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPFLUSH-10, HEPARIN SODIUM
HEPSERA, ADEFOVIR DIPIVOXIL
HEPTALAC, LACTULOSE
HERPLEX, IDOXURIDINE
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HEXA-GERM, HEXACHLOROPHENE
HEXABRIX, IOXAGLATE MEGLUMINE
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HEXALEN, ALTRETAMINE
HEXASCRUB, HEXACHLOROPHENE
HI-COR, HYDROCORTISONE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
HIPREX, METHENAMINE HIPPURATE
HISERPIA, RESERPINE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HIVID, ZALCITABINE
HIWOLFIA, RAUWOLFIA SERPENTINA
HMS, MEDRYSONE
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATIN, PAROMOMYCIN SULFATE
HUMATROPE, SOMATROPIN RECOMBINANT
HUMEGON, MENOTROPINS (FSH;LH)
HUMORSOL, DEMECARIUM BROMIDE
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
HY-PAM "25", HYDROXYZINE PAMOATE
HY-PHEN, ACETAMINOPHEN
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCET, ACETAMINOPHEN
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE SODIUM PHOSPHATE, HYDROCORTISONE SODIUM PHOSPHATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXOMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
HYGROTON, CHLORTHALIDONE
HYLOREL, GUANADREL SULFATE
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
HYPERSTAT, DIAZOXIDE
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
HYSERPIN, RAUWOLFIA SERPENTINA
HYTONE, HYDROCORTISONE
HYTRIN, TERAZOSIN HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
HYZYD, ISONIAZID

** I **

IBRIN, FIBRINOGEN, I-125
IBU, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HCL, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HCL PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HCL, IDARUBICIN HYDROCHLORIDE
IDKIT:HP, UREA, C-13
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
IFSOFAMIDE, IFOSFAMIDE
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN

FDA data supplied by DrugPatentWatch.com

IMAGENT, DIMYRISTOYL LECITHIN
IMAGENT, PERFLUBRON
IMDUR, ISOSORBIDE MONONITRATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
INAPSINE, DROPERIDOL
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDO-LEMMON, INDOMETHACIN
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
INDOMETHEGAN, INDOMETHACIN
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INH, ISONIAZID
INJECTAPAP, ACETAMINOPHEN
INNOFEM, ESTRADIOL
INNOHEP, TINZAPARIN SODIUM
INNOVAR, DROPERIDOL
INOCOR, INAMRINONE LACTATE
INOMAX, NITRIC OXIDE
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INSPRA, EPLERENONE
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
INTAL, CROMOLYN SODIUM
INTEGRILIN, EPTIFIBATIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROPIN, DOPAMINE HYDROCHLORIDE
INULIN AND SODIUM CHLORIDE, INULIN
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
INVANZ, ERTAPENEM SODIUM
INVERSINE, MECAMYLAMINE HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
IONAMIN, PHENTERMINE RESIN COMPLEX
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONTOCAINE, EPINEPHRINE
IOPAMIDOL, IOPAMIDOL
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRON DEXTRAN, IRON DEXTRAN
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISMELIN, GUANETHIDINE MONOSULFATE
ISMO, ISOSORBIDE MONONITRATE
ISMOTIC, ISOSORBIDE
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISONIAZID, ISONIAZID
ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
IVADANTIN, NITROFURANTOIN SODIUM
IVY BLOCK, BENTOQUATAM (OTC)

** J **

JANIMINE, IMIPRAMINE HYDROCHLORIDE
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

** K **

K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
K-LEASE, POTASSIUM CHLORIDE
K-TAB, POTASSIUM CHLORIDE
KADIAN, MORPHINE SULFATE
KAFOCIN, CEPHALOGLYCIN
KAINAIR, PROPARACAINE HYDROCHLORIDE
KALETRA, LOPINAVIR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KANAMYCIN, KANAMYCIN SULFATE
KANTREX, KANAMYCIN SULFATE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KEPPRA, LEVETIRACETAM
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOPROFEN, KETOPROFEN (OTC)
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOZOLE, KETOCONAZOLE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM

FDA data supplied by DrugPatentWatch.com

KLEBCIL, KANAMYCIN SULFATE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
KLOROMIN, CHLORPHENIRAMINE MALEATE
KLOTRIX, POTASSIUM CHLORIDE
KOGLUCOID, RAUWOLFIA SERPENTINA
KONAKION, PHYTONADIONE
KOROSTATIN, NYSTATIN
KWELL, LINDANE
KYTRIL, GRANISETRON HYDROCHLORIDE

** L **

LABETALOL HCL, LABETALOL HYDROCHLORIDE
LABID, THEOPHYLLINE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMPRENE, CLOFAZIMINE
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANOXICAPS, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
LANTUS, INSULIN GLARGINE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LAXILOSE, LACTULOSE
LEDERCILLIN VK, PENICILLIN V POTASSIUM
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LESSINA-21, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVLITE, ETHINYL ESTRADIOL
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LEVO-T, LIOTRIX (T4;T3)
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVONORGESTREL, LEVONORGESTREL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVOPROME, METHOTRIMEPRAZINE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LIOTRIX (T4;T3)
LEVOXYL, LIOTRIX (T4;T3)
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXXEL, ENALAPRIL MALEATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LIPIDIL, FENOFIBRATE
LIPITOR, ATORVASTATIN CALCIUM
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LIPO-HEPIN, HEPARIN SODIUM
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LIQUID PRED, PREDNISONE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHANE, LITHIUM CARBONATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LITHOTABS, LITHIUM CARBONATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
LOCORTEN, FLUMETHASONE PIVALATE
LODINE XL, ETODOLAC
LODINE, ETODOLAC
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGEN, ATROPINE SULFATE
LOMANATE, ATROPINE SULFATE
LOMOTIL, ATROPINE SULFATE
LONITEN, MINOXIDIL
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORABID, LORACARBEF
LORAZ, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
LORCET-HD, ACETAMINOPHEN
LORELCO, PROBUCOL
LORFAN, LEVALLORPHAN TARTRATE
LORTAB, ACETAMINOPHEN
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRIMIN, CLOTRIMAZOLE
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOTUSATE, TALBUTAL
LOVASTATIN, LOVASTATIN
LOVENOX, ENOXAPARIN SODIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOW-QUEL, ATROPINE SULFATE

FDA data supplied by DrugPatentWatch.com

LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
LOZOL, INDAPAMIDE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
LUMIGAN, BIMATOPROST
LUNELLE, ESTRADIOL CYPIONATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
LYMPHAZURIN, ISOSULFAN BLUE
LYNORAL, ETHINYL ESTRADIOL
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
LYSODREN, MITOTANE

** M **

M-PREDROL, METHYLPREDNISOLONE ACETATE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
M.V.C. 9+3, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MANDOL, CEFAMANDOLE NAFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
MAOLATE, CHLORPHENESIN CARBAMATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MAREZINE, CYCLIZINE LACTATE
MARINOL, DRONABINOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE
MAXIBOLIN, ETHYLESTRENOL
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MAXITROL, DEXAMETHASONE
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAZANOR, MAZINDOL
MD-50, DIATRIZOATE SODIUM
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEASURIN, ASPIRIN (OTC)
MEBENDAZOLE, MEBENDAZOLE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLODIUM, MECLOFENAMATE SODIUM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MECLOMEN, MECLOFENAMATE SODIUM
MEDIGESIC PLUS, ACETAMINOPHEN
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)

FDA data supplied by DrugPatentWatch.com

MEDIHALER-ISO, ISOPROTERENOL SULFATE
MEDIPREN, IBUPROFEN (OTC)
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MENADIONE, MENADIONE
MENEST, ESTROGENS, ESTERIFIED
MENOTROPINS, MENOTROPINS (FSH;LH)
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
MENTAX, BUTENAFINE HYDROCHLORIDE
MENTAX-TC, BUTENAFINE HYDROCHLORIDE
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MEPRIAM, MEPROBAMATE
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE AND ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MEPROSPAN, MEPROBAMATE
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
MERREM I.V., MEROPENEM
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
MESANTOIN, MEPHENYTOIN
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAGLIP, GLIPIZIDE
METAHYDRIN, TRICHLORMETHIAZIDE
METANDREN, METHYLTESTOSTERONE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE, SR-89
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCURINE IODIDE, METOCURINE IODIDE
METOPIRONE, METYRAPONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRA, PHENDIMETRAZINE TARTRATE
METRETON, PREDNISOLONE SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METRODIN, UROFOLLITROPIN
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METROMIDOL, METRONIDAZOLE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METUBINE IODIDE, METOCURINE IODIDE
MEVACOR, LOVASTATIN
MEXATE, METHOTREXATE SODIUM
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MEXATE-AQ, METHOTREXATE SODIUM
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MEXITIL, MEXILETINE HYDROCHLORIDE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MIACALCIN, CALCITONIN, SALMON
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRAININ, ASPIRIN
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
MICRONASE, GLYBURIDE
MICRONOR, NORETHINDRONE
MICROSUL, SULFAMETHIZOLE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MIDOL, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILONTIN, PHENSUXIMIDE
MILOPHENE, CLOMIPHENE CITRATE
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTOSE IN 5% DEXTROSE, MILRINONE LACTATE
MILTOWN, MEPROBAMATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
MINITRAN, NITROGLYCERIN
MINIZIDE, POLYTHIAZIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINODYL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINTEZOL, THIABENDAZOLE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRADON, ANISINDIONE
MIRALAX, POLYETHYLENE GLYCOL 3350
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MISOPROSTOL, MISOPROSTOL
MITHRACIN, PLICAMYCIN
MITOMYCIN, MITOMYCIN
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MIXTARD HUMAN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
MOBAN, MOLINDONE HYDROCHLORIDE
MOBIC, MELOXICAM
MOCTANIN, MONOCTANOIN
MODERIL, RESCINNAMINE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MODRASTANE, TRILOSTANE
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT DUAL- PAK, MICONAZOLE NITRATE
MONISTAT, MICONAZOLE
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT-DERM, MICONAZOLE NITRATE
MONOCID, CEFONICID SODIUM
MONODOX, DOXYCYCLINE

FDA data supplied by DrugPatentWatch.com

MONOKET, ISOSORBIDE MONONITRATE
MONOPRIL, FOSINOPRIL SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
MOXAM, MOXALACTAM DISODIUM
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE
MUCOMYST, ACETYLCYSTEINE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE
MULTIFUGE, PIPERAZINE CITRATE
MUPIROCIN, MUPIROCIN
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MUTAMYCIN, MITOMYCIN
MVC PLUS, ASCORBIC ACID
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCELEX, CLOTRIMAZOLE
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
MYCHEL, CHLORAMPHENICOL
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCO-TRIACET II, NYSTATIN
MYCOBUTIN, RIFABUTIN
MYCODONE, HOMATROPINE METHYLBROMIDE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
MYDRIACYL, TROPICAMIDE
MYDRIAFAIR, TROPICAMIDE
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYKACET, NYSTATIN
MYKINAC, NYSTATIN
MYKROX, METOLAZONE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
MYLERAN, BUSULFAN
MYLOTARG, GEMTUZUMAB OZOGAMICIN
MYMETHASONE, DEXAMETHASONE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
MYOTONACHOL, BETHANECHOL CHLORIDE
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
MYSOLINE, PRIMIDONE
MYTELASE, AMBENONIUM CHLORIDE
MYTOZYTREX, MITOMYCIN
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN

** N **

N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
NALIDIXIC ACID, NALIDIXIC ACID
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALLPEN, NAFCILLIN SODIUM
NALOXONE HCL AND PENTAZOCAINE, NALOXONE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NASALCROM, CROMOLYN SODIUM (OTC)
NASALIDE, FLUNISOLIDE

FDA data supplied by DrugPatentWatch.com

NASAREL, FLUNISOLIDE
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE MONOHYDRATE
NATACYN, NATAMYCIN
NATRECOR, NESIRITIDE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
NAVELBINE, VINORELBINE TARTRATE
NEBCIN, TOBRAMYCIN SULFATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEGGRAM, NALIDIXIC ACID
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-FRADIN, NEOMYCIN SULFATE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NEO-OTOSOL-HC, HYDROCORTISONE
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
NEO-RX, NEOMYCIN SULFATE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOBIOTIC, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPASALATE, AMINOSALICYLATE SODIUM
NEOPHAM 6.4%, AMINO ACIDS
NEORAL, CYCLOSPORINE
NEOSAR, CYCLOPHOSPHAMIDE
NEOSCAN, GALLIUM CITRATE, GA-67
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NEOTHYLLINE, DYPHYLLINE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NEPHRAMINE 5.4%, AMINO ACIDS
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
NEPTAZANE, METHAZOLAMIDE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NETROMYCIN, NETILMICIN SULFATE
NEURAMATE, MEPROBAMATE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEUTREXIN, TRIMETREXATE GLUCURONATE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NICLOCIDE, NICLOSAMIDE
NICODERM CQ, NICOTINE (OTC)
NICOLAR, NIACIN
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NILSTAT, NYSTATIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NIMOTOP, NIMODIPINE
NIPENT, PENTOSTATIN
NIPRIDE, SODIUM NITROPRUSSIDE

FDA data supplied by DrugPatentWatch.com

NITRO IV, NITROGLYCERIN
NITRO-BID, NITROGLYCERIN
NITRO-DUR, NITROGLYCERIN
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURAZONE, NITROFURAZONE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROL, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
NOGENIC HC, HYDROCORTISONE
NOLUDAR, METHYPRYLON
NOLVADEX, TAMOXIFEN CITRATE
NOR-QD, NORETHINDRONE
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL
NORCET, ACETAMINOPHEN
NORCO, ACETAMINOPHEN
NORCURON, VECURONIUM BROMIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN, SOMATROPIN RECOMBINANT
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORINYL, MESTRANOL
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORITATE, METRONIDAZOLE
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
NORMIFLO, ARDEPARIN SODIUM
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
NOROXIN, NORFLOXACIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPLANT II, LEVONORGESTREL
NORPLANT SYSTEM IN PLASTIC CONTAINER, LEVONORGESTREL
NORPLANT, LEVONORGESTREL
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORQUEST FE, ETHINYL ESTRADIOL
NORTREL 0.5/35-21, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
NOVOCAIN, PROCAINE HYDROCHLORIDE
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART
NOVOLOG, INSULIN ASPART

FDA data supplied by DrugPatentWatch.com

NOVOTHYROX, LIOTRIX (T4;T3)
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NUBAIN, NALBUPHINE HYDROCHLORIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
NUPRIN, IBUPROFEN (OTC)
NUROMAX, DOXACURIUM CHLORIDE
NUTRACORT, HYDROCORTISONE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NYDRAZID, ISONIAZID
NYSERT, NYSTATIN
NYSTAFORM, CLIOQUINOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTEX, NYSTATIN
NYSTOP, NYSTATIN

** O **

OBESTIN-30, PHENTERMINE HYDROCHLORIDE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
OCL, POLYETHYLENE GLYCOL 3350
OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUMYCIN, BACITRACIN ZINC
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
OFLOXACIN, OFLOXACIN
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLUX FOAM, CLOBETASOL PROPIONATE
OMEPRAZOLE, OMEPRAZOLE
OMNICEF, CEFDINIR
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
OMNISCAN, GADODIAMIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
ONCOVIN, VINCRISTINE SULFATE
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
OPTICROM, CROMOLYN SODIUM
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIMINE, AZATADINE MALEATE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
OPTOMYCIN, CHLORAMPHENICOL
ORA-TESTRYL, FLUOXYMESTERONE
ORABASE HCA, HYDROCORTISONE ACETATE
ORACORT, TRIAMCINOLONE ACETONIDE
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
ORALONE, TRIAMCINOLONE ACETONIDE
ORAMORPH SR, MORPHINE SULFATE
ORAP, PIMOZIDE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORASONE, PREDNISONE
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE

FDA data supplied by DrugPatentWatch.com

ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
ORFADIN, NITISINONE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
ORNADE, CHLORPHENIRAMINE MALEATE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-N0VUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORTHO-PREFEST, ESTRADIOL
ORUDIS KT, KETOPROFEN (OTC)
ORUDIS, KETOPROFEN
ORUVAIL, KETOPROFEN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OTICAIR, HYDROCORTISONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
OTOCORT, HYDROCORTISONE
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXANDRIN, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYLONE, FLUOROMETHOLONE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN, OXYTOCIN

** P **

P.A.S. SODIUM, AMINOSALICYLATE SODIUM
PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAGITANE, CYCRIMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PAMINE, METHSCOPOLAMINE BROMIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANCURONIUM, PANCURONIUM BROMIDE

FDA data supplied by DrugPatentWatch.com

PANDEL, HYDROCORTISONE PROBUTATE
PANHEPRIN, HEPARIN SODIUM
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PANRETIN, ALITRETINOIN
PANTOPAQUE, IOPHENDYLATE
PANWARFIN, WARFARIN SODIUM
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PARACAINE, PROPARACAINE HYDROCHLORIDE
PARACORT, PREDNISONE
PARADIONE, PARAMETHADIONE
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PARAPLATIN, CARBOPLATIN
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PARATHAR, TERIPARATIDE ACETATE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PASKALIUM, POTASSIUM AMINOSALICYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PATHILON, TRIDIHEXETHYL CHLORIDE
PATHOCIL, DICLOXACILLIN SODIUM
PAVULON, PANCURONIUM BROMIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIPAM, HALAZEPAM
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
PEDIOTIC, HYDROCORTISONE
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PEMOLINE, PEMOLINE
PEN-VEE K, PENICILLIN V POTASSIUM
PENAPAR-VK, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENECORT, HYDROCORTISONE
PENETREX, ENOXACIN
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
PENTACARINAT, PENTAMIDINE ISETHIONATE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PENTHRANE, METHOXYFLURANE
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOTHAL, THIOPENTAL SODIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PEPTAVLON, PENTAGASTRIN
PERCHLORACAP, POTASSIUM PERCHLORATE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PERGOLIDE MESYLATE, PERGOLIDE MESYLATE
PERGONAL, MENOTROPINS (FSH;LH)
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMAX, PERGOLIDE MESYLATE
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PERMITIL, FLUPHENAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PERSANTINE, DIPYRIDAMOLE
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
PHENAZINE, PHENDIMETRAZINE TARTRATE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENTYTOIN, PHENYTOIN
PHENURONE, PHENACEMIDE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PHENYTEK, PHENYTOIN SODIUM, EXTENDED
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PHENYTOIN, PHENYTOIN
PHENYTOIN, PHENYTOIN SODIUM
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLO, CALCIUM ACETATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PHOTOFRIN, PORFIMER SODIUM
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN
PHYLLOCONTIN, AMINOPHYLLINE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PINDAC, PINACIDIL
PINDOLOL, PINDOLOL
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PIPRACIL, PIPERACILLIN SODIUM
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PITRESSIN TANNATE, VASOPRESSIN TANNATE
PLACIDYL, ETHCHLORVYNOL
PLAN B, LEVONORGESTREL
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
PLAVIX, CLOPIDOGREL BISULFATE
PLEGINE, PHENDIMETRAZINE TARTRATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENDIL, FELODIPINE
PLETAL, CILOSTAZOL
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
PODOFILOX, PODOFILOX
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN

FDA data supplied by DrugPatentWatch.com

POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYSPORIN, BACITRACIN ZINC
POLYSPORIN, BACITRACIN ZINC (OTC)
POLYTRIM, POLYMYXIN B SULFATE
PONSTEL, MEFENAMIC ACID
PORTALAC, LACTULOSE
PORTIA-21, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POVAN, PYRVINIUM PAMOATE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIN, REPAGLINIDE
PRANTAL, DIPHEMANIL METHYLSULFATE
PRAVACHOL, PRAVASTATIN SODIUM
PRAZEPAM, PRAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PRECEF, CEFORANIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNICEN-M, PREDNISONE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELAY, TROGLITAZONE
PRELONE, PREDNISOLONE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN), ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)
PREVACID, LANSOPRAZOLE
PREVALITE, CHOLESTYRAMINE
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PRIFTIN, RIFAPENTINE
PRILOSEC, OMEPRAZOLE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROAMATINE, MIDODRINE HYDROCHLORIDE
PROBALAN, PROBENECID
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROBEN-C, COLCHICINE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
PROCARDIA XL, NIFEDIPINE
PROCARDIA, NIFEDIPINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROCTOCORT, HYDROCORTISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROFEN, IBUPROFEN (OTC)
PROFENAL, SUPROFEN

FDA data supplied by DrugPatentWatch.com

PROFERDEX, IRON DEXTRAN
PROGESTASERT, PROGESTERONE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROKETAZINE, CARPHENAZINE MALEATE
PROKLAR, SULFAMETHIZOLE
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROLOPRIM, TRIMETHOPRIM
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETA, METAPROTERENOL SULFATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHACON, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSOM, ESTAZOLAM
PROSTAPHLIN, OXACILLIN SODIUM
PROSTEP, NICOTINE
PROSTEP, NICOTINE (OTC)
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTOSTAT, METRONIDAZOLE
PROTROPIN, SOMATREM
PROVAL #3, ACETAMINOPHEN
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSORCON, DIFLORASONE DIACETATE
PULMICORT RESPULES, BUDESONIDE

FDA data supplied by DrugPatentWatch.com

PULMICORT, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PYLORI-CHEK BREATH TEST, UREA, C-13
PYOCIDIN, HYDROCORTISONE
PYOPEN, CARBENICILLIN DISODIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
PYRILAMINE MALEATE, PYRILAMINE MALEATE
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

** Q **

Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM
QUARZAN, CLIDINIUM BROMIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
QUIDE, PIPERACETAZINE
QUINACT, QUINIDINE GLUCONATE
QUINAGLUTE, QUINIDINE GLUCONATE
QUINALAN, QUINIDINE GLUCONATE
QUINATIME, QUINIDINE GLUCONATE
QUINIDEX, QUINIDINE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUINORA, QUINIDINE SULFATE
QUIXIN, LEVOFLOXACIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
R-P MYCIN, ERYTHROMYCIN
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAMUNE, SIROLIMUS
RAPLON, RAPACURONIUM BROMIDE
RAU-SED, RESERPINE
RAUDIXIN, RAUWOLFIA SERPENTINA
RAUSERPIN, RAUWOLFIA SERPENTINA
RAUTENSIN, ALSEROXYLON
RAUVAL, RAUWOLFIA SERPENTINA
RAUWILOID, ALSEROXYLON
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN
RAXAR, GREPAFLOXACIN HYDROCHLORIDE
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT
REBETOL, RIBAVIRIN
REDISOL, CYANOCOBALAMIN
REFLUDAN, LEPIRUDIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
REGROTON, CHLORTHALIDONE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
RELA, CARISOPRODOL
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
REMINYL, GALANTAMINE HYDROBROMIDE
REMODULIN, TREPROSTINIL SODIUM
REMSED, PROMETHAZINE HYDROCHLORIDE
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENESE, POLYTHIAZIDE
RENESE-R, POLYTHIAZIDE
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOQUID, SULFACYTINE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVA, TRETINOIN
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE

FDA data supplied by DrugPatentWatch.com

RENOVUE-DIP, IODAMIDE MEGLUMINE
REPRONEX, MENOTROPINS (FSH;LH)
REQUIP, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
RESTASIS, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETET, TETRACYCLINE HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETROVIR, ZIDOVUDINE
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE
REVERSOL, EDROPHONIUM CHLORIDE
REVEX, NALMEFENE HYDROCHLORIDE
REVIA, NALTREXONE HYDROCHLORIDE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
REZULIN, TROGLITAZONE
RHINOCORT, BUDESONIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
RIDAURA, AURANOFIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RIMACTANE, RIFAMPIN
RIMADYL, CARPROFEN
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
RIMIFON, ISONIAZID
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RISPERDAL, RISPERIDONE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
ROBIMYCIN, ERYTHROMYCIN
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
ROBITET, TETRACYCLINE HYDROCHLORIDE
ROCALTROL, CALCITRIOL
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMAZICON, FLUMAZENIL
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
RUBRAMIN PC, CYANOCOBALAMIN
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
RUFEN, IBUPROFEN
RUVITE, CYANOCOBALAMIN
RYTHMOL, PROPAFENONE HYDROCHLORIDE

** S **

S.A.S.-500, SULFASALAZINE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALPIX, ACETRIZOATE SODIUM
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDRIL, RESERPINE
SANOREX, MAZINDOL
SANSAC, ERYTHROMYCIN
SANSERT, METHYSERGIDE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SARENIN, SARALASIN ACETATE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SATRIC, METRONIDAZOLE

FDA data supplied by DrugPatentWatch.com

SCABENE, LINDANE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCLEROSOL, TALC
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SECONAL SODIUM, SECOBARBITAL SODIUM
SECREFLO, SECRETIN
SECRETIN-FERRING, SECRETIN
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SEDAPAP, ACETAMINOPHEN
SEFFIN, CEPHALOTHIN SODIUM
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SELSUN, SELENIUM SULFIDE
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
SEMPREX-D, ACRIVASTINE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTI-SOFT, HEXACHLOROPHENE
SEPTISOL, HEXACHLOROPHENE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERAX, OXAZEPAM
SERENTIL, MESORIDAZINE BESYLATE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERPALAN, RESERPINE
SERPANRAY, RESERPINE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SERPATE, RESERPINE
SERPIVITE, RESERPINE
SERVISONE, PREDNISONE
SERZONE, NEFAZODONE HYDROCHLORIDE
SETHOTOPE, SELENOMETHIONINE, SE-75
SEVOFLURANE, SEVOFLURANE
SHADE UVAGUARD, AVOBENZONE (OTC)
SILDAFLO, SILVER SULFADIAZINE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
SILVADENE, SILVER SULFADIAZINE
SINE-AID IB, IBUPROFEN (OTC)
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SINEQUAN, DOXEPIN HYDROCHLORIDE
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SKELAXIN, METAXALONE
SKELID, TILUDRONATE DISODIUM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SLOW-K, POTASSIUM CHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M

FDA data supplied by DrugPatentWatch.com

POLYPHOSPHATE KIT
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SODIUM SULAMYD, SULFACETAMIDE SODIUM
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SODIUM VERSENATE, EDETATE DISODIUM
SOLAGE, MEQUINOL
SOLARAZE, DICLOFENAC SODIUM
SOLATENE, BETA-CAROTENE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-CRT, THEOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
SONATA, ZALEPLON
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SONORX, SIMETHICONE-CELLULOSE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
SORBITRATE, ISOSORBIDE DINITRATE
SORIATANE, ACITRETIN
SORINE, SOTALOL HYDROCHLORIDE
SOSOL, SULFISOXAZOLE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOXAZOLE, SULFISOXAZOLE
SOY-DOME, HEXACHLOROPHENE
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL
SPARINE, PROMAZINE HYDROCHLORIDE
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123
SPECTAZOLE, ECONAZOLE NITRATE
SPECTRACEF, CEFDITOREN PIVOXIL
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRX-105, PHENDIMETRAZINE TARTRATE
SPRX-3, PHENDIMETRAZINE TARTRATE
SPS, SODIUM POLYSTYRENE SULFONATE
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STANOZIDE, ISONIAZID
STAPHCILLIN, METHICILLIN SODIUM
STARLIX, NATEGLINIDE
STATICIN, ERYTHROMYCIN
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
STATROL, NEOMYCIN SULFATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
STIE-CORT, HYDROCORTISONE
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
STIMATE, DESMOPRESSIN ACETATE
STOXIL, IDOXURIDINE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIFON FORTE DSC, CHLORZOXAZONE
STROMECTOL, IVERMECTIN
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBUTEX, BUPRENORPHINE HYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFABID, SULFAPHENAZOLE
SULFACEL-15, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;

FDA data supplied by DrugPatentWatch.com

SULFAMERAZINE;SULFAMETHAZINE)
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
SULFALAR, SULFISOXAZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL, PHENAZOPYRIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFANILAMIDE, SULFANILAMIDE
SULFAPYRIDINE, SULFAPYRIDINE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE
SULFISOXAZOLE, SULFISOXAZOLE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULINDAC, SULINDAC
SULLA, SULFAMETER
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
SULPHRIN, PREDNISOLONE ACETATE
SULSOXIN, SULFISOXAZOLE
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
SULTEN-10, SULFACETAMIDE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
SUPPRELIN, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SURITAL, THIAMYLAL SODIUM
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
SUSTAIRE, THEOPHYLLINE
SUSTIVA, EFAVIRENZ
SYMADINE, AMANTADINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
SYNAREL, NAFARELIN ACETATE
SYNCURINE, DECAMETHONIUM BROMIDE
SYNERCID, DALFOPRISTIN
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
SYNTHROID, LIOTRIX (T4;T3)
SYNTOCINON, OXYTOCIN
SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

T-PHYL, THEOPHYLLINE
T-STAT, ERYTHROMYCIN
TAB-PROFEN, IBUPROFEN (OTC)
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
TACE, CHLOROTRIANISENE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TANDEARIL, OXYPHENBUTAZONE
TAO, TROLEANDOMYCIN
TAPAZOLE, METHIMAZOLE
TARACTAN, CHLORPROTHIXENE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASMAR, TOLCAPONE
TATUM-T, COPPER
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)

FDA data supplied by DrugPatentWatch.com

TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TAZORAC, TAZAROTENE
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TECZEM, DILTIAZEM MALATE
TEEBACIN, AMINOSALICYLATE SODIUM
TEGISON, ETRETINATE
TEGOPEN, CLOXACILLIN SODIUM
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TELEPAQUE, IOPANOIC ACID
TEMARIL, TRIMEPRAZINE TARTRATE
TEMAZ, TEMAZEPAM
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TEN-K, POTASSIUM CHLORIDE
TENATHAN, BETHANIDINE SULFATE
TENCON, ACETAMINOPHEN
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
TEQUIN, GATIFLOXACIN
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TESLAC, TESTOLACTONE
TESLASCAN, MANGAFODIPIR TRISODIUM
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTODERM TTS, TESTOSTERONE
TESTODERM, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
TESTRED, METHYLTESTOSTERONE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
TETRACHEL, TETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
TEV-TROVIN, SOMATROPIN RECOMBINANT
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
THEELIN, ESTRONE

FDA data supplied by DrugPatentWatch.com

THEO-24, THEOPHYLLINE
THEO-DUR, THEOPHYLLINE
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
THEOLIXIR, THEOPHYLLINE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE-SR, THEOPHYLLINE
THEOVENT, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOPLEX, THIOTEPA
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
THIOTEPA, THIOTEPA
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
THYPINONE, PROTIRELIN
THYREL TRH, PROTIRELIN
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
THYRO-TABS, LIOTRIX (T4;T3)
THYROGEN, THYROTROPIN ALFA
THYROGLOBULIN, THYROGLOBULIN
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)
THYROSAFE, POTASSIUM IODIDE (OTC)
THYTROPAR, THYROTROPIN
TIAMATE, DILTIAZEM MALATE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TICLID, TICLOPIDINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TILADE, NEDOCROMIL SODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAL, ACETOPHENAZINE MALEATE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIOPRONIN, TIOPRONIN
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRAMYCIN (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN, TOBRAMYCIN SULFATE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TOLINASE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TONOCARD, TOCAINIDE HYDROCHLORIDE
TOPAMAX SPRINKLE, TOPIRAMATE

FDA data supplied by DrugPatentWatch.com

TOPAMAX, TOPIRAMATE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE
TOPOSAR, ETOPOSIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORA, PHENTERMINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TORNALATE, BITOLTEROL MESYLATE
TORSEMIDE, TORSEMIDE
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPN SUSPENSION, NIACINAMIDE
TRACLEER, BOSENTAN
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRANCOPAL, CHLORMEZANONE
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRANSDERM SCOP, SCOPOLAMINE
TRANSDERM-NITRO, NITROGLYCERIN
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TRASYLOL, APROTININ BOVINE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASE, SUTILAINS
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVATAN, TRAVOPROST
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRECATOR-SC, ETHIONAMIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TREST, METHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-NASAL, TRIAMCINOLONE ACETONIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACET, TRIAMCINOLONE ACETONIDE

FDA data supplied by DrugPatentWatch.com

TRIACIN-C, CODEINE PHOSPHATE
TRIACORT, TRIAMCINOLONE ACETONIDE
TRIAD, ACETAMINOPHEN
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAPRIN, ACETAMINOPHEN
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
TRICHLOREX, TRICHLORMETHIAZIDE
TRICHLORMAS, TRICHLORMETHIAZIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRICLOS, TRICLOFOS SODIUM
TRICOR (MICRONIZED), FENOFIBRATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDESILON, ACETIC ACID, GLACIAL
TRIDESILON, DESONIDE
TRIDIL, NITROGLYCERIN
TRIDIONE, TRIMETHADIONE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRILEPTAL, OXCARBAZEPINE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRIMOX, AMOXICILLIN
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
TRINALIN, AZATADINE MALEATE
TRIOSTAT, LIOTRIX (T4;T3)
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE
TRISORALEN, TRIOXSALEN
TRITEC, RANITIDINE BISMUTH CITRATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
TROVAN, TROVAFLOXACIN MESYLATE
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
TRUPHYLLINE, AMINOPHYLLINE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
TURGEX, HEXACHLOROPHENE
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLENOL, ACETAMINOPHEN (OTC)
TYLOX, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

TYLOX-325, ACETAMINOPHEN
TYMTRAN, CERULETIDE DIETHYLAMINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)

** U **

U-CORT, HYDROCORTISONE ACETATE
U-GENCIN, GENTAMICIN SULFATE
UCEPHAN, SODIUM BENZOATE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ULTRACET, ACETAMINOPHEN
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNI-DUR, THEOPHYLLINE
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
UNIPHYL, THEOPHYLLINE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
UNITHROID, LIOTRIX (T4;T3)
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD
UREAPHIL, UREA
URECHOLINE, BETHANECHOL CHLORIDE
URESE, BENZTHIAZIDE
UREX, METHENAMINE HIPPURATE
URISPAS, FLAVOXATE HYDROCHLORIDE
UROBAK, SULFAMETHOXAZOLE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
URSO, URSODIOL
URSODIOL, URSODIOL
UTICILLIN VK, PENICILLIN V POTASSIUM
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
UVADEX, METHOXSALEN

** V **

V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VAGIFEM, ESTRADIOL
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VAGISTAT-1, TIOCONAZOLE (OTC)
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALISONE, BETAMETHASONE VALERATE
VALIUM, DIAZEPAM
VALMID, ETHINAMATE
VALNAC, BETAMETHASONE VALERATE
VALPIN 50, ANISOTROPINE METHYLBROMIDE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALRELEASE, DIAZEPAM
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOBID, CANDICIDIN
VANSIL, OXAMNIQUINE
VANTIN, CEFPODOXIME PROXETIL
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE
VASCOR, BEPRIDIL HYDROCHLORIDE
VASCORAY, IOTHALAMATE MEGLUMINE
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
VASOXYL, METHOXAMINE HYDROCHLORIDE
VECTRIN, MINOCYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VEETIDS, PENICILLIN V POTASSIUM
VEINAMINE 8%, AMINO ACIDS
VELBAN, VINBLASTINE SULFATE
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE
VELOSEF, CEPHRADINE
VELOSULIN BR HUMAN, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
VELOSULIN, INSULIN PURIFIED PORK (OTC)
VELTANE, BROMPHENIRAMINE MALEATE
VENOFER, IRON SUCROSE
VENTAIRE, PROTOKYLOL HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE
VEPESID, ETOPOSIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VERILOID, ALKAVERVIR
VERMIDOL, PIPERAZINE CITRATE
VERMOX, MEBENDAZOLE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM
VERSED, MIDAZOLAM HYDROCHLORIDE
VERTAVIS, VERATRUM VIRIDE
VESANOID, TRETINOIN
VESPRIN, TRIFLUPROMAZINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VEXOL, RIMEXOLONE
VFEND, VORICONAZOLE
VI-DOM-A, VITAMIN A PALMITATE
VI-TWEL, CYANOCOBALAMIN
VIADUR, LEUPROLIDE ACETATE
VIAGRA, SILDENAFIL CITRATE
VIBISONE, CYANOCOBALAMIN
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE
VIDEX EC, DIDANOSINE
VIDEX, DIDANOSINE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCASAR PFS, VINCRISTINE SULFATE
VINCREX, VINCRISTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VIOXX, ROFECOXIB
VIRA-A, VIDARABINE
VIRAC REX, UNDECOYLIUM CHLORIDE
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIRILON, METHYLTESTOSTERONE
VIROPTIC, TRIFLURIDINE
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITAPED, ASCORBIC ACID
VITRASERT, GANCICLOVIR
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLMAX, ALBUTEROL SULFATE
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VONTROL, DIPHENIDOL HYDROCHLORIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
VUMON, TENIPOSIDE

** W **

WAMPOCAP, NIACIN
WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
WESTADONE, METHADONE HYDROCHLORIDE
WESTCORT, HYDROCORTISONE VALERATE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
WINSTROL, STANOZOLOL
WOLFINA, RAUWOLFIA SERPENTINA
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYCILLIN, PENICILLIN G PROCAINE
WYDASE, HYALURONIDASE
WYGESIC, ACETAMINOPHEN
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE

** X **

X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
XELODA, CAPECITABINE
XENEISOL, XENON, XE-133
XENICAL, ORLISTAT
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XYLO-PFAN, XYLOSE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOSE, XYLOSE
XYREM, SODIUM OXYBATE

** Y **

YASMIN, DROSPIRENONE
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
YUTOPAR, RITODRINE HYDROCHLORIDE

** Z **

ZADITOR, KETOTIFEN FUMARATE
ZAGAM, SPARFLOXACIN
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAXOPAM, OXAZEPAM
ZEBETA, BISOPROLOL FUMARATE
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZELNORM, TEGASEROD MALEATE
ZEMPLAR, PARICALCITOL
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE
ZERIT XR, STAVUDINE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIBA-RX, BACITRACIN ZINC
ZIDE, HYDROCHLOROTHIAZIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE &
HYDROCORTISONE, BACITRACIN ZINC
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
ZOCOR, SIMVASTATIN
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLYSE, CHYMOTRYPSIN
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE
ZYFLO, ZILEUTON
ZYLOPRIM, ALLOPURINOL
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE
ZYVOX, LINEZOLID

FDA data supplied by DrugPatentWatch.com

** 3 **

3M
* 3M CO
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
* 3M MEDICAL PRODUCTS DIV
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
* 3M PHARMACEUTICALS INC
ALDARA, IMIQUIMOD
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CIRCANOL, ERGOLOID MESYLATES
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIPO-HEPIN, HEPARIN SODIUM
MAXAIR, PIRBUTEROL ACETATE
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
PROVENTIL-HFA, ALBUTEROL SULFATE
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
RAUWILOID, ALSEROXYLON
SODIUM VERSENATE, EDETATE DISODIUM
TAMBOCOR, FLECAINIDE ACETATE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE
VERILOID, ALKAVERVIR

** A **

AAI PHARMA
* AAI PHARMA LLC
DARVON, PROPOXYPHENE HYDROCHLORIDE

AAIPHARMA
* AAIPHARMA INC
AQUASOL A, VITAMIN A PALMITATE
BRETHINE, TERBUTALINE SULFATE
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID

AAIPHARMA LLC
* AAIPHARMA LLC
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE

AB GENERICS
* AB GENERICS LP
MORPHINE SULFATE, MORPHINE SULFATE

ABANA
* ABANA PHARMACEUTICALS INC
NORCET, ACETAMINOPHEN

ABBOTT
* ABBOTT LABORATORIES
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
ALCOHOL 5% IN D5-W, ALCOHOL
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATROPINE AND DEMEROL, ATROPINE SULFATE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOFLURANE, ISOFLURANE

FDA data supplied by DrugPatentWatch.com

ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KALETRA, LOPINAVIR
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NORVIR, RITONAVIR
NOVOCAIN, PROCAINE HYDROCHLORIDE
NUROMAX, DOXACURIUM CHLORIDE
OMNICEF, CEFDINIR
PACLITAXEL, PACLITAXEL
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
SYNTHROID, LIOTRIX (T4;T3)
TALWIN, PENTAZOCINE LACTATE
TAZICEF, CEFTAZIDIME
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRICOR, FENOFIBRATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEMPLAR, PARICALCITOL
ZYFLO, ZILEUTON

* ABBOTT LABORATORIES HOSP PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMRINONE, INAMRINONE LACTATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
CALCIJEX, CALCITRIOL
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
ENFLURANE, ENFLURANE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE, FENTANYL CITRATE
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN III 30%, SOYBEAN OIL
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANHEPRIN, HEPARIN SODIUM
PENTHRANE, METHOXYFLURANE
PENTOTHAL, THIOPENTAL SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
UREAPHIL, UREA
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHYMODIACTIN, CHYMOPAPAIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYLERT, PEMOLINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIASONE SODIUM, SULFOXONE SODIUM
DICUMAROL, DICUMAROL
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DISCASE, CHYMOPAPAIN
DROPERIDOL, DROPERIDOL
E-MYCIN, ERYTHROMYCIN
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE

FDA data supplied by DrugPatentWatch.com

ERY-TAB, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN, ERYTHROMYCIN
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
FENTANYL CITRATE, FENTANYL CITRATE
GEMONIL, METHARBITAL
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYTRIN, TERAZOSIN HYDROCHLORIDE
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
JANIMINE, IMIPRAMINE HYDROCHLORIDE
K-TAB, POTASSIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPIDIL, FENOFIBRATE
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LOPURIN, ALLOPURINOL
LTA II KIT, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5%, MANNITOL
MAVIK, TRANDOLAPRIL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NITROPRESS, SODIUM NITROPRUSSIDE
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORVIR, RITONAVIR
OCL, POLYETHYLENE GLYCOL 3350
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN

FDA data supplied by DrugPatentWatch.com

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
PANWARFIN, WARFARIN SODIUM
PARADIONE, PARAMETHADIONE
PCE, ERYTHROMYCIN
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEGANONE, ETHOTOIN
PHENURONE, PHENACEMIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLACIDYL, ETHCHLORVYNOL
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSOM, ESTAZOLAM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TARKA, TRANDOLAPRIL
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THYPINONE, PROTIRELIN
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRAVASE, SUTILAINS
TRICOR (MICRONIZED), FENOFIBRATE
TRIDIONE, TRIMETHADIONE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE
VITAMIN K1, PHYTONADIONE

ABC HOLDING

FDA data supplied by DrugPatentWatch.com

* ABC HOLDING CORP
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE

ABIC
* ABIC LTD
ABITREXATE, METHOTREXATE SODIUM
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
VINCRISTINE SULFATE, VINCRISTINE SULFATE

ABLE
* ABLE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HEMSOL-HC, HYDROCORTISONE ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL, PHENAZOPYRIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

ACTELION
* ACTELION LTD
TRACLEER, BOSENTAN

ADAMS LABS
* ADAMS LABORATORIES INC
MUCINEX, GUAIFENESIN (OTC)

ADV CARE
* ADVANCED CARE PRODUCTS DIV ORTHO PHARMACEUTICAL CORP
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

ADV MAGNETICS
* ADVANCED MAGNETICS INC
FERIDEX I.V., FERUMOXIDES
GASTROMARK, FERUMOXSIL

ADVANCED CARE PRODS
* ADVANCED CARE PRODUCTS
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)

AESGEN
* AESGEN INC
ACYCLOVIR, ACYCLOVIR
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

AGOURON
* AGOURON PHARMACEUTICALS INC
RESCRIPTOR, DELAVIRDINE MESYLATE
VIRACEPT, NELFINAVIR MESYLATE

AH ROBINS INC
* AH ROBINS INC
EXNA, BENZTHIAZIDE

AKORN
* AKORN INC
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTOB, TOBRAMYCIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CHLORAMPHENICOL, CHLORAMPHENICOL
COR-OTICIN, HYDROCORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
INAPSINE, DROPERIDOL

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SUFENTA, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE

AKORN MFG
* AKORN MANUFACTURING INC
INNOVAR, DROPERIDOL
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE

AL HIKMA
* AL HIKMA PHARMACEUTICALS
NAPROXEN SODIUM, NAPROXEN SODIUM

ALCON
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
AZOPT, BRINZOLAMIDE
BETADINE, POVIDONE-IODINE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED, PREDNISOLONE ACETATE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISMOTIC, ISOSORBIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
NEO-OTOSOL-HC, HYDROCORTISONE
PANTOPAQUE, IOPHENDYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PROFENAL, SUPROFEN
STATROL, NEOMYCIN SULFATE
TOBRADEX, DEXAMETHASONE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TRIFLURIDINE, TRIFLURIDINE
VEXOL, RIMEXOLONE
ZOLYSE, CHYMOTRYPSIN

ALCON UNIVERSAL
* ALCON UNIVERSAL LTD
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRAVATAN, TRAVOPROST
TROPICAMIDE, TROPICAMIDE

ALIMENTERICS
* ALIMENTERICS INC

FDA data supplied by DrugPatentWatch.com

PYLORI-CHEK BREATH TEST, UREA, C-13

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLENDALE PHARMS
* ALLENDALE PHARMACEUTICALS
TODAY, NONOXYNOL-9 (OTC)

ALLERGAN
* ALLERGAN
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
* ALLERGAN INC
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPHAGAN, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
ELIMITE, PERMETHRIN
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OPTICROM, CROMOLYN SODIUM
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
ETHAMIDE, ETHOXZOLAMIDE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
HMS, MEDRYSONE
OCUFEN, FLURBIPROFEN SODIUM
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERGAN HERBERT
* ALLERGAN HERBERT DIV ALLERGAN INC
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
EXSEL, SELENIUM SULFIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOROPLEX, FLUOROURACIL
PENECORT, HYDROCORTISONE
* ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC
FLUOROPLEX, FLUOROURACIL
NAFTIN, NAFTIFINE HYDROCHLORIDE
PENECORT, HYDROCORTISONE
TEMARIL, TRIMEPRAZINE TARTRATE

ALLIANCE PHARM
* ALLIANCE PHARMACEUTICAL CORP
IMAGENT, DIMYRISTOYL LECITHIN
IMAGENT, PERFLUBRON

ALPHA THERA
* ALPHA THERAPEUTIC CORP
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL

ALPHAPHARM
* ALPHAPHARM PARTY LTD
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM

ALPHARMA
* ALPHARMA INC
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
* ALPHARMA USPD INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARB, BUTABARBITAL SODIUM
CAPITAL AND CODEINE, ACETAMINOPHEN
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CODAMINE, HYDROCODONE BITARTRATE
CONSTULOSE, LACTULOSE
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ENULOSE, LACTULOSE
EPINEPHRINE, EPINEPHRINE (OTC)
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LOMANATE, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYKINAC, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PHENYTOIN, PHENYTOIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARM

* ALPHARMA US PHARMACEUTICAL DIV
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE, HYDROCORTISONE
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

FDA data supplied by DrugPatentWatch.com

VALNAC, BETAMETHASONE VALERATE

ALRA
* ALRA LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
BAMATE, MEPROBAMATE
CHOLAC, LACTULOSE
COMPOUND 65, ASPIRIN
CONSTILAC, LACTULOSE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
SOXAZOLE, SULFISOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ALTANA
* ALTANA INC
AMCINONIDE, AMCINONIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE

ALZA
* ALZA CORP
ACTISITE, TETRACYCLINE HYDROCHLORIDE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DURAGESIC, FENTANYL
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
PROGESTASERT, PROGESTERONE
TESTODERM TTS, TESTOSTERONE
TESTODERM, TESTOSTERONE
VIADUR, LEUPROLIDE ACETATE

AM PHARM PARTNERS
* AMERICAN PHARMACEUTICAL PARTNERS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
BACITRACIN, BACITRACIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITRIOL, CALCITRIOL
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

FDA data supplied by DrugPatentWatch.com

PRODUCT NAME INDEX LISTED BY APPLICANT

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CUPRIC SULFATE, CUPRIC SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIGOXIN, DIGOXIN
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPFLUSH-10, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IFSOFAMIDE, IFOSFAMIDE
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KANAMYCIN, KANAMYCIN SULFATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M.V.C. 9+3, ASCORBIC ACID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NITROGLYCERIN, NITROGLYCERIN
OXYTOCIN, OXYTOCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
TOBRAMYCIN (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN SULFATE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE

FDA data supplied by DrugPatentWatch.com

VINCRISTINE SULFATE, VINCRISTINE SULFATE
ZINC SULFATE, ZINC SULFATE

AM THERAP
* AMERICAN THERAPEUTICS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
LORAZEPAM, LORAZEPAM
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
OXAZEPAM, OXAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
THIOTHIXENE, THIOTHIXENE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

AMARIN PHARMS
* AMARIN PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMEN, MEDROXYPROGESTERONE ACETATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN

AMBIX
* AMBIX LABORATORIES DIV ORGANICS CORP AMERICA
HYDROCORTISONE, HYDROCORTISONE
NITROFURAZONE, NITROFURAZONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

AMERSHAM HLTH
* AMERSHAM HEALTH
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMIPAQUE, METRIZAMIDE
BILOPAQUE, TYROPANOATE SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
DICOPAC KIT, CYANOCOBALAMIN
FERRISELTZ, FERRIC AMMONIUM CITRATE
FLUORINE F-18, SODIUM FLUORIDE, F-18
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
IBRIN, FIBRINOGEN, I-125
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
METASTRON, STRONTIUM CHLORIDE, SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
NEOSCAN, GALLIUM CITRATE, GA-67
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNISCAN, GADODIAMIDE
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT

FDA data supplied by DrugPatentWatch.com

TELEPAQUE, IOPANOIC ACID
TESLASCAN, MANGAFODIPIR TRISODIUM
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133

AMIDE PHARM
* AMIDE PHARMACEUTICAL INC
ACETAMINOPHEN AND PENTAZOCINE HCL, ACETAMINOPHEN
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
DIGOXIN, DIGOXIN
GLYBURIDE, GLYBURIDE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
NALOXONE HCL AND PENTAZOCAINE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
URSODIOL, URSODIOL

ANABOLIC
* ANABOLIC INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

ANBEX
* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANDRX
* ANDRX CORP
ALTOCOR, LOVASTATIN
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE

ANDRX PHARM
* ANDRX PHARMACEUTICALS LLC
ETODOLAC, ETODOLAC

ANDRX PHARMS
* ANDRX PHARMACEUTICALS INC
CARTIA XT, DILTIAZEM HYDROCHLORIDE
KETOPROFEN, KETOPROFEN
METFORMIN HCL, METFORMIN HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

ANESTA
* ANESTA CORP
ACTIQ, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE

ANGELINI
* ANGELINI PHARMACEUTICALS INC
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE

ANGUS
* ANGUS CHEMICAL CO
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
TETRACHEL, TETRACYCLINE HYDROCHLORIDE

ANTHRA
* ANTHRA PHARMACEUTICALS INC
VALSTAR PRESERVATIVE FREE, VALRUBICIN

APOTEX
* APOTEX CORP
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBAMAZEPINE, CARBAMAZEPINE
CEFUROXIME AXETIL, CEFUROXIME AXETIL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
EDETATE DISODIUM, EDETATE DISODIUM
ETODOLAC, ETODOLAC
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

FDA data supplied by DrugPatentWatch.com

LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BETAPEN-VK, PENICILLIN V POTASSIUM
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHALEXIN, CEPHALEXIN
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CORGARD, NADOLOL
DESYREL, TRAZODONE HYDROCHLORIDE
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DYNAPEN, DICLOXACILLIN SODIUM
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUNGIZONE, AMPHOTERICIN B
KANTREX, KANAMYCIN SULFATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOTRIX, POTASSIUM CHLORIDE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MUCOMYST, ACETYLCYSTEINE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NYDRAZID, ISONIAZID
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
PRECEF, CEFORANIDE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROSTAPHLIN, OXACILLIN SODIUM
QUESTRAN, CHOLESTYRAMINE
RAUDIXIN, RAUWOLFIA SERPENTINA
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STAPHCILLIN, METHICILLIN SODIUM
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TEGOPEN, CLOXACILLIN SODIUM
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRIMOX, AMOXICILLIN
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEETIDS, PENICILLIN V POTASSIUM
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF, CEPHRADINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE

* APOTHECON SUB BRISTOL MYERS SQUIBB CO
ATENOLOL, ATENOLOL
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
TRIMOX, AMOXICILLIN
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VESPRIN, TRIFLUPROMAZINE

APOTHEKERNES

* APOTHEKERNES LABORATORIUM A/S
BACITRACIN, BACITRACIN

FDA data supplied by DrugPatentWatch.com

APPLIED ANAL
* APPLIED ANALYTICAL INDUSTRIES
METHAZOLAMIDE, METHAZOLAMIDE
* APPLIED ANALYTICAL INDUSTRIES INC
AZATHIOPRINE, AZATHIOPRINE
ESTRADIOL, ESTRADIOL

ARBROOK
* ARBROOK INC
GAMOPHEN, HEXACHLOROPHENE

ARCUM
* ARCUM PHARMACEUTICAL CORP
VITAMIN A PALMITATE, VITAMIN A PALMITATE

ARMENPHARM
* ARMENPHARM LTD
MYCHEL, CHLORAMPHENICOL

ARMOUR PHARM
* ARMOUR PHARMACEUTICAL CO
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
DEPINAR, CYANOCOBALAMIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
PENTACARINAT, PENTAMIDINE ISETHIONATE

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
ALBUTEROL, ALBUTEROL

ASCENT PEDS
* ASCENT PEDIATRICS INC
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

ASCHER
* BF ASCHER AND CO INC
DRIZE, CHLORPHENIRAMINE MALEATE
HY-PHEN, ACETAMINOPHEN

ASCOT
* ASCOT HOSP PHARMACEUTICALS INC DIV TRAVENOL LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOCARBAMOL, METHOCARBAMOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ASLUNG PHARM
* ASLUNG PHARMACEUTICAL LP
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

ASTA
* ASTA MEDICA INC
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

ASTRAZENECA
* ASTRAZENECA LP
AMIKACIN SULFATE, AMIKACIN SULFATE
AQUASOL A, VITAMIN A
ASTRAMORPH PF, MORPHINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITONIN-SALMON, CALCITONIN, SALMON
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DALGAN, DEZOCINE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DYCLONE, DYCLONINE HYDROCHLORIDE
EMLA, LIDOCAINE
ENTOCORT EC, BUDESONIDE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FOSCAVIR, FOSCARNET SODIUM
FUROSEMIDE, FUROSEMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NEXIUM, ESOMEPRAZOLE MAGNESIUM

FDA data supplied by DrugPatentWatch.com

PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
PRILOSEC, OMEPRAZOLE
PULMICORT RESPULES, BUDESONIDE
RHINOCORT, BUDESONIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEROQUEL, QUETIAPINE FUMARATE
TENORMIN, ATENOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPROL-XL, METOPROLOL SUCCINATE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
YUTOPAR, RITODRINE HYDROCHLORIDE

* ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
FASLODEX, FULVESTRANT
LEXXEL, ENALAPRIL MALEATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NOLVADEX, TAMOXIFEN CITRATE
PLENDIL, FELODIPINE
PULMICORT, BUDESONIDE
SORBITRATE, ISOSORBIDE DINITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TONOCARD, TOCAINIDE HYDROCHLORIDE
ZOMIG-ZMT, ZOLMITRIPTAN

* ASTRAZENECA UK LTD
ACCOLATE, ZAFIRLUKAST
ARIMIDEX, ANASTROZOLE
CASODEX, BICALUTAMIDE
DIPRIVAN, PROPOFOL
MERREM I.V., MEROPENEM
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZOLADEX, GOSERELIN ACETATE

ATRIX

* ATRIX LABORATORIES INC
ATRIDOX, DOXYCYCLINE HYCLATE
ELIGARD, LEUPROLIDE ACETATE

AUXILIUM A2

* AUXILIUM A2 INC
TESTIM, TESTOSTERONE

AVENTIS

* AVENTIS PHARMACEUTICAL PRODUCTS INC
ACTHAR, CORTICOTROPIN
AZMACORT, TRIAMCINOLONE ACETONIDE
AZOLID, PHENYLBUTAZONE
CALCIMAR, CALCITONIN, SALMON
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DORIDEN, GLUTETHIMIDE
INTAL, CROMOLYN SODIUM
LOVENOX, ENOXAPARIN SODIUM
LOZOL, INDAPAMIDE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NICOLAR, NIACIN
PARATHAR, TERIPARATIDE ACETATE
PENETREX, ENOXACIN
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
RILUTEK, RILUZOLE
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SYNERCID, DALFOPRISTIN
THYTROPAR, THYROTROPIN
TILADE, NEDOCROMIL SODIUM

AVENTIS BEHRING

* AVENTIS BEHRING LLC
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
STIMATE, DESMOPRESSIN ACETATE

AVENTIS PHARMS

* AVENTIS PHARMACEUTICALS INC
A/T/S, ERYTHROMYCIN
ACCURBRON, THEOPHYLLINE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
ARAVA, LEFLUNOMIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BRICANYL, TERBUTALINE SULFATE
CANTIL, MEPENZOLATE BROMIDE
CARAFATE, SUCRALFATE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CEPHULAC, LACTULOSE
CHRONULAC, LACTULOSE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DECAPRYN, DOXYLAMINE SUCCINATE
DEMI-REGROTON, CHLORTHALIDONE
DIABETA, GLYBURIDE
DV, DIENESTROL
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GLYBURIDE (MICRONIZED), GLYBURIDE
HEDULIN, PHENINDIONE
HIPREX, METHENAMINE HIPPURATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
HYGROTON, CHLORTHALIDONE
INTAL, CROMOLYN SODIUM
LANTUS, INSULIN GLARGINE
LASIX, FUROSEMIDE
LORELCO, PROBUCOL
METAHYDRIN, TRICHLORMETHIAZIDE
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
NICODERM CQ, NICOTINE (OTC)
NILANDRON, NILUTAMIDE
NITRO-BID, NITROGLYCERIN
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
PRIFTIN, RIFAPENTINE
REGROTON, CHLORTHALIDONE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TACE, CHLOROTRIANISENE
TAXOTERE, DOCETAXEL
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TRICLOS, TRICLOFOS SODIUM
VANOBID, CANDICIDIN
VENTAIRE, PROTOKYLOL HYDROCHLORIDE

AXCAN SCANDIPHARM
* AXCAN SCANDIPHARM INC
CANASA, MESALAMINE
CHENIX, CHENODIOL
PHOTOFRIN, PORFIMER SODIUM
URSO, URSODIOL

AYERST
* AYERST LABORATORIES INC
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED

** B **

B BRAUN
* B BRAUN MEDICAL INC
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
UCEPHAN, SODIUM BENZOATE

BAKER NORTON
* BAKER NORTON
PROGLYCEM, DIAZOXIDE
* BAKER NORTON PHARMACEUTICALS INC
ACTICORT, HYDROCORTISONE
PACLITAXEL, PACLITAXEL
PROGLYCEM, DIAZOXIDE

BALLARD MEDCL
* BALLARD MEDICAL PRODUCTS INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

BANNER PHARMACAPS
* BANNER PHARMACAPS INC
BENZONATATE, BENZONATATE

FDA data supplied by DrugPatentWatch.com

CHLOROTRIANISENE, CHLOROTRIANISENE
CLOFIBRATE, CLOFIBRATE
ETHCHLORVYNOL, ETHCHLORVYNOL
ETHOSUXIMIDE, ETHOSUXIMIDE
IBUPROFEN, IBUPROFEN (OTC)
VALPROIC ACID, VALPROIC ACID
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

BARLAN
* BARLAN PHARMACAL CO INC
BARSTATIN 100, NYSTATIN

BARR
* BARR LABORATORIES INC
ACETOHEXAMIDE, ACETOHEXAMIDE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CAMILA, NORETHINDRONE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CORTISONE ACETATE, CORTISONE ACETATE
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
E-BASE, ERYTHROMYCIN
ERRIN, NORETHINDRONE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
KARIVA, DESOGESTREL
LESSINA-21, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORTREL 0.5/35-21, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PORTIA-21, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL
PREDNISOLONE, PREDNISOLONE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPRINTEC, ETHINYL ESTRADIOL
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TREXALL, METHOTREXATE SODIUM
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR PHARMS
* BARR PHARMACEUTICALS INC
REVIA, NALTREXONE HYDROCHLORIDE

BARTOR
* BARTOR PHARMACAL CO
TESTOSTERONE, TESTOSTERONE

BASF
* BASF CORP
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
RUFEN, IBUPROFEN
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

BAUSCH AND LOMB
* BAUSCH AND LOMB INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPREDNOL ETABONATE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
LOTEMAX, LOTEPREDNOL ETABONATE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
SULPHRIN, PREDNISOLONE ACETATE
SULTEN-10, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
* BAUSCH AND LOMB PHARMACEUTICALS INC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NYSTATIN, NYSTATIN
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE
* BAUSCH AND LOMB SURGICAL INC
VITRASERT, GANCICLOVIR

BAXTER HLTHCARE
* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CERNEVIT-12, ALPHA-TOCOPHEROL

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, CALCIUM CHLORIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATASOL 8%, AMINO ACIDS
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15%

FDA data supplied by DrugPatentWatch.com

IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
AMRINONE LACTATE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ETHRANE, ENFLURANE
FORANE, ISOFLURANE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
REVEX, NALMEFENE HYDROCHLORIDE
SUPRANE, DESFLURANE

BAYER

* BAYER CORP
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
AZLIN, AZLOCILLIN SODIUM
BILTRICIDE, PRAZIQUANTEL
CANDEX, NYSTATIN
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CORT-DOME, HYDROCORTISONE
DELTA-DOME, PREDNISONE
DOMEBORO, ACETIC ACID, GLACIAL
DTIC-DOME, DACARBAZINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
LITHANE, LITHIUM CARBONATE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MYCELEX, CLOTRIMAZOLE
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NICLOCIDE, NICLOSAMIDE
NIMOTOP, NIMODIPINE
NYSTAFORM, CLIOQUINOL
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
SOY-DOME, HEXACHLOROPHENE
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
TRASYLOL, APROTININ BOVINE
TRIDESILON, ACETIC ACID, GLACIAL
VI-DOM-A, VITAMIN A PALMITATE

* BAYER CORP CONSUMER CARE DIV
8-HOUR BAYER, ASPIRIN (OTC)
ACTRON, KETOPROFEN (OTC)
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, ASPIRIN (OTC)
MEASURIN, ASPIRIN (OTC)
MIDOL, IBUPROFEN (OTC)
MYCELEX, CLOTRIMAZOLE

* BAYER CORP PHARMACEUTICAL DIV
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BAYCOL, CERIVASTATIN SODIUM
CIPRO, CIPROFLOXACIN

BAYER PHARMS

* BAYER PHARMACEUTICALS CORP
CIPRO XR, CIPROFLOXACIN
PRECOSE, ACARBOSE

BECKLOFF

* BECKLOFF ASSOC INC
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)

BECTON DICKINSON

* BECTON DICKINSON AND CO
E-Z PREP 220, POVIDONE-IODINE (OTC)

FDA data supplied by DrugPatentWatch.com

E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
* BECTON DICKINSON SURGICAL SYSTEM
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD
* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMRINONE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ENALAPRILAT, ENALAPRILAT
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
OFLOXACIN, OFLOXACIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIOTEPA, THIOTEPA
VALPROATE SODIUM, VALPROATE SODIUM
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE

BEDFORD LABS
* BEDFORD LABORATORIES
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
* BEDFORD LABORATORIES INC
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE

BEECHAM
* BEECHAM LABORATORIES DIV BEECHAM INC
PROBENECID AND COLCHICINE, COLCHICINE

BEL MAR
* BEL MAR LABORATORIES INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXOMIN, HYDROXOCOBALAMIN
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M-PREDROL, METHYLPREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VITAMIN A PALMITATE, VITAMIN A PALMITATE

FDA data supplied by DrugPatentWatch.com

BELL PHARMA
* BELL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
RESERPINE, RESERPINE

BEN VENUE
* BEN VENUE LABORATORIES INC
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE

BERLEX
* BERLEX
FINACEA, AZELAIC ACID
* BERLEX LABORATORIES INC SUB SCHERING AG
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
BILIVIST, IPODATE SODIUM
FLUDARA, FLUDARABINE PHOSPHATE
GASTROVIST, DIATRIZOATE MEGLUMINE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
QUINACT, QUINIDINE GLUCONATE
SULLA, SULFAMETER
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
VI-TWEL, CYANOCOBALAMIN

BERLEX LABS
* BERLEX LABORATORIES INC
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
CLIMARA, ESTRADIOL
LEVLITE, ETHINYL ESTRADIOL
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MIRENA, LEVONORGESTREL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
QUINAGLUTE, QUINIDINE GLUCONATE
REFLUDAN, LEPIRUDIN
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
YASMIN, DROSPIRENONE

BERTEK
* BERTEK PHARMACEUTICALS INC
MENTAX-TC, BUTENAFINE HYDROCHLORIDE

BERTEK PHARMS
AVITA, TRETINOIN
MENTAX, BUTENAFINE HYDROCHLORIDE
SULFAMYLON, MAFENIDE ACETATE

BETA DERMAC
* BETA DERMACEUTICALS INC
BETA-HC, HYDROCORTISONE

BH
* BH CHEMICALS INC
HALOTHANE, HALOTHANE

BIGMAR
* BIGMAR INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM

BIO TECH GEN
* BIO TECHNOLOGY GENERAL CORP
BIO-TROPIN, SOMATROPIN RECOMBINANT
OXANDRIN, OXANDROLONE
TEV-TROVIN, SOMATROPIN RECOMBINANT

BIOCHEMIE
* BIOCHEMIE GMBH
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

BIOENVISION
* BIOENVISION INC
MODRASTANE, TRILOSTANE

BIOGLAN
* BIOGLAN LABORATORIES LTD
ALPHADERM, HYDROCORTISONE

BIOGLAN PHARMA
* BIOGLAN PHARMA INC
C-SOLVE-2, ERYTHROMYCIN
SOLARAZE, DICLOFENAC SODIUM

BIOGLAN PHARMS
* BIOGLAN PHARMACEUTICALS CO
ZONALON, DOXEPIN HYDROCHLORIDE

BIONICHE (CANADA)

FDA data supplied by DrugPatentWatch.com

* BIONICHE PHARMA (CANADA) LTD
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
EDETATE DISODIUM, EDETATE DISODIUM
KETAMINE HCL, KETAMINE HYDROCHLORIDE

BIOVAIL
* BIOVAIL CORP INTERNATIONAL
TIAZAC, DILTIAZEM HYDROCHLORIDE
* BIOVAIL LABORATORIES INC
CARDIZEM, DILTIAZEM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE
TECZEM, DILTIAZEM MALATE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
* BIOVAIL TECHNOLOGIES
CEDAX, CEFTIBUTEN DIHYDRATE

BIOVAIL PHARMS
* BIOVAIL PHARMACEUTICALS INC
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE

BLAIREX
* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE RIDGE
* BLUE RIDGE LABORATORIES INC
CARAFATE, SUCRALFATE

BLULINE
* BLULINE LABORATORIES INC
EPICORT, HYDROCORTISONE
MULTIFUGE, PIPERAZINE CITRATE

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
ALUPENT, METAPROTERENOL SULFATE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
MEXITIL, MEXILETINE HYDROCHLORIDE
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
* BOEHRINGER INGELHEIM CORP
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
ALUPENT, METAPROTERENOL SULFATE
ATROVENT, IPRATROPIUM BROMIDE
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
MOBIC, MELOXICAM
PERSANTINE, DIPYRIDAMOLE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
VIRAMUNE, NEVIRAPINE

BONE CARE
* BONE CARE INTERNATIONAL INC
HECTOROL, DOXERCALCIFEROL

BOWMAN PHARMS
* BOWMAN PHARMACEUTICALS INC
HISERPIA, RESERPINE
HIWOLFIA, RAUWOLFIA SERPENTINA

BRACCO
* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT

FDA data supplied by DrugPatentWatch.com

PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PROHANCE, GADOTERIDOL
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
SETHOTOPE, SELENOMETHIONINE, SE-75
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SONORX, SIMETHICONE-CELLULOSE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

BRADLEY PHARMS
* BRADLEY PHARMACEUTICALS INC
PAMINE, METHSCOPOLAMINE BROMIDE

BRAINTREE
* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
MIRALAX, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLO, CALCIUM ACETATE

BRIGHTSTONE
* BRIGHTSTONE PHARMA INC
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

BRISTOL
* BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO
BETAPEN-VK, PENICILLIN V POTASSIUM
BICNU, CARMUSTINE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
LYSODREN, MITOTANE
MEXATE, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRECEF, CEFORANIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEPESID, ETOPOSIDE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM

BRISTOL MYERS
* BRISTOL MYERS CO
MEXATE-AQ, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
* BRISTOL MYERS PRODUCTS INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
NUPRIN, IBUPROFEN (OTC)

BRISTOL MYERS SQUIBB
* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
FOLLUTEIN, GONADOTROPIN, CHORIONIC
GLUCOVANCE, GLYBURIDE
HALOG, HALCINONIDE
MEGACE, MEGESTROL ACETATE
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
MYCOSTATIN, NYSTATIN
ORA-TESTRYL, FLUOXYMESTERONE
PRAVACHOL, PRAVASTATIN SODIUM
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
TESLAC, TESTOLACTONE
VINCREX, VINCRISTINE SULFATE
* BRISTOL MYERS SQUIBB CO
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMNESTROGEN, ESTROGENS, ESTERIFIED
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
CEENU, LOMUSTINE
DROXIA, HYDROXYUREA
ESTRACE, ESTRADIOL

FDA data supplied by DrugPatentWatch.com

ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
FUNGIZONE, AMPHOTERICIN B
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
METAGLIP, GLIPIZIDE
MYCOSTATIN, NYSTATIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYDRAZID, ISONIAZID
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
RAU-SED, RESERPINE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBRAMIN PC, CYANOCOBALAMIN
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TESLAC, TESTOLACTONE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
VAGISTAT-1, TIOCONAZOLE (OTC)
VELOSEF, CEPHRADINE
VEPESID, ETOPOSIDE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VIDEX EC, DIDANOSINE
VITAMIN A, VITAMIN A PALMITATE
ZERIT XR, STAVUDINE

* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
BLENOXANE, BLEOMYCIN SULFATE
BUSPAR, BUSPIRONE HYDROCHLORIDE
CEFZIL, CEFPROZIL
CYTOXAN, CYCLOPHOSPHAMIDE
DEAPRIL-ST, ERGOLOID MESYLATES
DOVONEX, CALCIPOTRIENE
ESTRACE, ESTRADIOL
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MONOPRIL, FOSINOPRIL SODIUM
PARAPLATIN, CARBOPLATIN
SERZONE, NEFAZODONE HYDROCHLORIDE
STADOL, BUTORPHANOL TARTRATE
TAXOL, PACLITAXEL
TEQUIN, GATIFLOXACIN
VIDEX, DIDANOSINE
VUMON, TENIPOSIDE
ZERIT, STAVUDINE

* BRISTOL MYERS SQUIBB MEDICAL IMAGING
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
XENON XE 133, XENON, XE-133

* BRISTOL MYERS SQUIBB PHARMA CO
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COUMADIN, WARFARIN SODIUM
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
LODOSYN, CARBIDOPA
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
NARCAN, NALOXONE HYDROCHLORIDE
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
REMSED, PROMETHAZINE HYDROCHLORIDE
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SUSTIVA, EFAVIRENZ

* BRISTOL MYERS SQUIBB SPA
PENICILLIN G SODIUM, PENICILLIN G SODIUM

BRYAN

* BRYAN CORP
SCLEROSOL, TALC

BTG

* BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP
DELATESTRYL, TESTOSTERONE ENANTHATE

BUNDY

* CM BUNDY CO
BUTABARBITAL, BUTABARBITAL SODIUM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE

** C **

C AND M PHARMA

* C AND M PHARMACAL INC
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HI-COR, HYDROCORTISONE

CADEMA

* CADEMA MEDICAL PRODUCTS INC

FDA data supplied by DrugPatentWatch.com

RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT

CALGON
* CALGON CORP DIV MERCK AND CO INC
SEPTI-SOFT, HEXACHLOROPHENE

CAMALL
* CAMALL CO INC
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE

CARACO
* CARACO PHARMACEUTICAL LABORATORIES LTD
CARBAMAZEPINE, CARBAMAZEPINE
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
FLURBIPROFEN, FLURBIPROFEN
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
OXAPROZIN, OXAPROZIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

CARLISLE
* CARLISLE LABORATORIES INC
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE

CARLSBAD
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN

CARNRICK
* CARNRICK LABORATORIES INC DIV GW CARNRICK CO
CAPITAL WITH CODEINE, ACETAMINOPHEN

CAROLINA MEDCL
* CAROLINA MEDICAL PRODUCTS CO
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CELGENE
* CELGENE CORP
THALOMID, THALIDOMIDE

CELL THERAP
* CELL THERAPEUTICS INC
TRISENOX, ARSENIC TRIOXIDE

CELLTECH MFG
* CELLTECH MANUFACTURING INC
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE

CELLTECH PHARMS
* CELLTECH PHARMACEUTICALS INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
GASTROCROM, CROMOLYN SODIUM
GLUTETHIMIDE, GLUTETHIMIDE
IONAMIN, PHENTERMINE RESIN COMPLEX
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
MYKROX, METOLAZONE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
SEMPREX-D, ACRIVASTINE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
ZAROXOLYN, METOLAZONE

CENCI
* CENCI POWDER PRODUCTS INC
THEOPHYLLINE, THEOPHYLLINE
* HR CENCI LABORATORIES INC
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ELIXOMIN, THEOPHYLLINE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE

CENT PHARMS

FDA data supplied by DrugPatentWatch.com

* CENTRAL PHARMACEUTICALS INC
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
AZDONE, ASPIRIN
CO-GESIC, ACETAMINOPHEN
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

CENTURY PHARMS
* CENTURY PHARMACEUTICALS INC
P.A.S. SODIUM, AMINOSALICYLATE SODIUM

CEPH INTL
* CEPH INTERNATIONAL CORP
CECLOR, CEFACLOR
KEFLEX, CEPHALEXIN

CEPHALON
* CEPHALON INC
GABITRIL, TIAGABINE HYDROCHLORIDE
PROVIGIL, MODAFINIL

CHAMBERLIN PARENTERL
* CHAMBERLIN PARENTERAL CORP
HEPARIN SODIUM, HEPARIN SODIUM

CHASE CHEM
* CHASE CHEMICAL CO LP
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

CHASE LABS NJ
* CHASE LABORATORIES INC
NIFEDIPINE, NIFEDIPINE

CHATTEM
* CHATTEM INC
SELSUN, SELENIUM SULFIDE

CHESEBROUGH PONDS
* CHESEBROUGH PONDS INC
EXTRA-STRENGTH AIM, DISODIUM MONOFLUOROPHOSPHATE (OTC)
VIRAC REX, UNDECOYLIUM CHLORIDE

CHIRHOCLIN
* CHIRHOCLIN INC
SECREFLO, SECRETIN

CHIRON
* CHIRON CORP
TOBI, TOBRAMYCIN

CIBA
* CIBA VISION CORP DIV NOVARTIS CO
CATARASE, CHYMOTRYPSIN

CIS
* CIS BIOINDUSTRIES COMPAGNIE
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
* CIS US INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE

CLAY PARK
* CLAY PARK LABORATORIES INC
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN (OTC)
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIDESILON, DESONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;

FDA data supplied by DrugPatentWatch.com

SULFATHIAZOLE)

CLAY PARK LABS
* CLAY PARK LABS
MUPIROCIN, MUPIROCIN

CLINTEC NUTR
* CLINTEC NUTRITION CO SUB CLINIQUE
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

CLONMEL
* CLONMEL HEALTHCARE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE

CLONMEL HLTHCARE
* CLONMEL HEALTHCARE LTD
CAPTOPRIL, CAPTOPRIL
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
GLYBURIDE (MICRONIZED), GLYBURIDE
LORAZEPAM, LORAZEPAM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NAPROXEN, NAPROXEN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

COLGATE
* COLGATE ORAL PHARMACEUTICALS INC
ORABASE HCA, HYDROCORTISONE ACETATE
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE
* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLLAGENEX
* COLLAGENEX INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLLAGENEX PHARMS
* COLLAGENEX PHARMACEUTICALS INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLUMBIA RES LABS
* COLUMBIA RESEARCH LABORATORIES INC
CRINONE, PROGESTERONE

COMBE
* COMBE INC
BACITRACIN, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)

CONNETICS
* CONNETICS CORP
LUXIQ, BETAMETHASONE VALERATE
OLUX FOAM, CLOBETASOL PROPIONATE

CONSOLIDATED MIDLAND
* CONSOLIDATED MIDLAND CORP
TEEBACIN, AMINOSALICYLATE SODIUM

CONSOLIDATED PHARM
* CONSOLIDATED PHARMACEUTICAL GROUP INC
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

CONTROLLED THERAP
* CONTROLLED THERAPEUTICS (SCOTLAND) LTD
CERVIDIL, DINOPROSTONE

COOK IMAGING
* COOK IMAGING CORP
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL

COPANOS
* JOHN D COPANOS AND CO INC
PENICILLIN G SODIUM, PENICILLIN G SODIUM
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE

COPLEY PHARM
* COPLEY PHARMACEUTICAL INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
CAPTOPRIL, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE

FDA data supplied by DrugPatentWatch.com

CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CO-LAV, POLYETHYLENE GLYCOL 3350
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
ETHOSUXIMIDE, ETHOSUXIMIDE
EVALOSE, LACTULOSE
FLUOCINONIDE, FLUOCINONIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
GO-EVAC, POLYETHYLENE GLYCOL 3350
GUANABENZ ACETATE, GUANABENZ ACETATE
GYNIX, CLOTRIMAZOLE (OTC)
HALOPERIDOL, HALOPERIDOL LACTATE
HEPTALAC, LACTULOSE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEBENDAZOLE, MEBENDAZOLE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHAZOLAMIDE, METHAZOLAMIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
PEMOLINE, PEMOLINE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID

COREPHARMA
* COREPHARMA LLC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARISOPRODOL, CARISOPRODOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
GLYBURIDE, GLYBURIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

CUMBERLAND SWAN
* CUMBERLAND SWAN INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

CYTOGEN
* CYTOGEN CORP
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

** D **

DAIICHI
* DAIICHI PHARMACEUTICAL CO LTD
FLOXIN, OFLOXACIN
* DAIICHI PHARMACEUTICAL CORP
EVOXAC, CEVIMELINE HYDROCHLORIDE

DAINIPPON
* DAINIPPON PHARMACEUTICAL USA CORP
ZONEGRAN, ZONISAMIDE

DANCO LABS LLC
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
FLAXEDIL, GALLAMINE TRIETHIODIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DEL RAY LABS
* DEL RAY LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
DEL-VI-A, VITAMIN A PALMITATE
TRIDERM, TRIAMCINOLONE ACETONIDE

DELL LABS
* DELL LABORATORIES INC
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
DURANEST, EPINEPHRINE BITARTRATE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIK LABS
* DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
HYTONE, HYDROCORTISONE
KLARON, SULFACETAMIDE SODIUM
NORITATE, METRONIDAZOLE
PSORCON, DIFLORASONE DIACETATE
* DERMIK LABORATORIES INC
DERMATOP, PREDNICARBATE
PENLAC, CICLOPIROX
* DERMIK LABORATORIES INC SUB RORER
HYTONE, HYDROCORTISONE

DESERET
* DESERET MEDICAL INC DIV BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

DEXCEL LTD
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA
* DEXCEL PHARMA TECHNOLOGIES LTD
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DEY
* DEY LP
ACCUNEB, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CUROSURF, PORACTANT ALFA
DUONEB, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE

DHL
* DHL LABORATORIES INC
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DIAL
* DIAL CORP DIV GREYHOUND CO
DIAL, HEXACHLOROPHENE

DIATIDE RES LABS
* DIATIDE RESEARCH LABORATORIES DIV BERLEX LABS INC
ACUTECT, TECHNETIUM TC-99M APCITIDE
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE

DISTA
* DISTA PRODUCTS CO DIV ELI LILLY AND CO
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
NALFON, FENOPROFEN CALCIUM
VALMID, ETHINAMATE

DOW PHARM
* DOW PHARMACEUTICAL CORP SUB DOW CHEMICAL CO
DOW-ISONIAZID, ISONIAZID
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
QUIDE, PIPERACETAZINE

DOWNSTATE CLINCL
* DOWNSTATE CLINICAL PET CENTER
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18

DPT
* DPT LABORATORIES INC
EMBELINE, CLOBETASOL PROPIONATE

DR REDDYS LABS INC
* DR REDDYS LABORATORIES INC
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

FLUOXETINE, FLUOXETINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE

DR REDDYS LABS LTD
* DR REDDYS LABORATORIES LTD
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
OXAPROZIN, OXAPROZIN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

DRAXIMAGE
* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DRAXIS HLTH
* DRAXIS HEALTH INC
FLUOCINONIDE, FLUOCINONIDE

DSM PHARMS
* DSM PHARMACEUTICALS INC
ALOPRIM, ALLOPURINOL SODIUM

DUNHALL
* DUNHALL PHARMACEUTICALS INC
TRIAPRIN, ACETAMINOPHEN

DURAMED
* DURAMED PHARMACEUTICALS INC
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A

DURAMED PHARM BARR
* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
AVIANE-21, ETHINYL ESTRADIOL
AVIANE-28, ETHINYL ESTRADIOL
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE HCL, CIMETIDINE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CRYSELLE, ETHINYL ESTRADIOL
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAZEPAM, DIAZEPAM
ENPRESSE-21, ETHINYL ESTRADIOL
ENPRESSE-28, ETHINYL ESTRADIOL
ESTROPIPATE, ESTROPIPATE
GLIPIZIDE, GLIPIZIDE
GYNODIOL, ESTRADIOL
HALOPERIDOL, HALOPERIDOL
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TOLAZAMIDE, TOLAZAMIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE

DUSA
* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DYNAPHARM
* DYNAPHARM INC
COLOVAGE, POLYETHYLENE GLYCOL 3350

** E **

E Z EM
* E Z EM CO INC
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350

EASTMAN KODAK
* EASTMAN KODAK CO
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN

ECOLAB
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)

FDA data supplied by DrugPatentWatch.com

CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EGIS
* EGIS PHARMACEUTICALS
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
PIROXICAM, PIROXICAM

EGIS PHARMS
* EGIS PHARMACEUTICALS LTD
CAPTOPRIL, CAPTOPRIL

EISAI MEDCL RES
* EISAI MEDICAL RESEARCH INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT, DONEPEZIL HYDROCHLORIDE

ELAN DRUG
* ELAN DRUG DELIVERY INC
VERELAN, VERAPAMIL HYDROCHLORIDE

ELAN PHARM
* ELAN PHARMACEUTICAL RESEARCH CORP
AVINZA, MORPHINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOPROFEN, KETOPROFEN
NAPRELAN, NAPROXEN SODIUM
NIFEDIPINE, NIFEDIPINE
PROSTEP, NICOTINE
PROSTEP, NICOTINE (OTC)
VERELAN PM, VERAPAMIL HYDROCHLORIDE

ELAN PHARMS
* ELAN PHARMACEUTICALS
FROVA, FROVATRIPTAN SUCCINATE
ORAMORPH SR, MORPHINE SULFATE
SKELAXIN, METAXALONE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
* ELAN PHARMACEUTICALS INC
DURACLON, CLONIDINE HYDROCHLORIDE
ROXICODONE, OXYCODONE HYDROCHLORIDE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ELKINS SINN
* ELKINS SINN DIV AH ROBINS CO INC
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN, KANAMYCIN SULFATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXACILLIN SODIUM, OXACILLIN SODIUM
PANCURONIUM, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYTOIN, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

ELKINS SINN PHARM
* ELKINS SINN PHARMACEUTICAL CO
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
NALOXONE, NALOXONE HYDROCHLORIDE

ENDO LABS
* ENDO LABORATORIES INC DIV DUPONT MERCK PHARMACEUTICAL CO
CAPTOPRIL, CAPTOPRIL
* ENDO LABORATORIES LLC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL

ENDO PHARMS
* ENDO PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ETODOLAC, ETODOLAC
GLIPIZIDE, GLIPIZIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MOBAN, MOLINDONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARCAN, NALOXONE HYDROCHLORIDE
NUBAIN, NALBUPHINE HYDROCHLORIDE
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
VALPIN 50, ANISOTROPINE METHYLBROMIDE

ENVIRODERM
* ENVIRODERM PHARMACEUTICALS INC
IVY BLOCK, BENTOQUATAM (OTC)

ENZON
* ENZON INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE

EON
* EON LABORATORIES MANUFACTURING INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALKERGOT, ERGOLOID MESYLATES
ALPHAZINE, PHENDIMETRAZINE TARTRATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DRALSERP, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOCIN SR, INDOMETHACIN
ISONIAZID, ISONIAZID
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOVASTATIN, LOVASTATIN
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
NABUMETONE, NABUMETONE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NYSTATIN, NYSTATIN
OMEPRAZOLE, OMEPRAZOLE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAPROZIN, OXAPROZIN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
RIFAMPIN, RIFAMPIN
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
WESTADONE, METHADONE HYDROCHLORIDE

ERSANA
* ERSANA INC SUB ER SQUIBB AND SONS
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE

ESI
* ESI PHARMACAL
CYCRIN, MEDROXYPROGESTERONE ACETATE

ESI LEDERLE
* ESI LEDERLE GENERICS
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
* ESI LEDERLE INC
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFOXITIN, CEFOXITIN SODIUM
ESTRADIOL, ESTRADIOL
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTOSE IN 5% DEXTROSE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE, MORPHINE SULFATE
PENTOXIFYLLINE, PENTOXIFYLLINE

ESP PHARMA
* ESP PHARMA INC
ISMO, ISOSORBIDE MONONITRATE
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

ETHITEK
* ETHITEK PHARMACEUTICALS CO
MOCTANIN, MONOCTANOIN

EVERYLIFE
* EVERYLIFE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
CORTISONE ACETATE, CORTISONE ACETATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
STANOZIDE, ISONIAZID
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

** F **

FALCON PHARMS
* FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE
* FALCON PHARMACEUTICALS LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ECONOPRED PLUS, PREDNISOLONE ACETATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FAULDING
* FAULDING PHARMACEUTICAL CO
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN, BLEOMYCIN SULFATE
BRETYLOL, BRETYLIUM TOSYLATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUDR, FLOXURIDINE
INTROPIN, DOPAMINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
LABETALOL HCL, LABETALOL HYDROCHLORIDE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
TRIDIL, NITROGLYCERIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
* FH FAULDING AND CO LTD
DORYX, DOXYCYCLINE HYCLATE
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
THEOPHYLLINE, THEOPHYLLINE

FAULDING PHARMS
* FAULDING PHARMACEUTICALS INC
KADIAN, MORPHINE SULFATE
SERAX, OXAZEPAM

FERNDALE LABS
* FERNDALE LABORATORIES INC
ADPHEN, PHENDIMETRAZINE TARTRATE
AMOSENE, MEPROBAMATE
AQUAPHYLLIN, THEOPHYLLINE
DELAXIN, METHOCARBAMOL
DIAZEPAM, DIAZEPAM
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE

FDA data supplied by DrugPatentWatch.com

LOCOID, HYDROCORTISONE BUTYRATE
MICORT-HC, HYDROCORTISONE ACETATE
OBESTIN-30, PHENTERMINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PRAMOSONE, HYDROCORTISONE ACETATE
RAUSERPIN, RAUWOLFIA SERPENTINA
STRIFON FORTE DSC, CHLORZOXAZONE

FERRANTE
* JOHN J FERRANTE
AMPHICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

FERRING
* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
BRAVELLE, UROFOLLITROPIN
CONCENTRAID, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
MENOTROPINS, MENOTROPINS (FSH;LH)
REPRONEX, MENOTROPINS (FSH;LH)
SECRETIN-FERRING, SECRETIN
THYREL TRH, PROTIRELIN

FIRST HORIZON
* FIRST HORIZON PHARMACEUTICAL CORP
COGNEX, TACRINE HYDROCHLORIDE
FURADANTIN, NITROFURANTOIN
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
SULAR, NISOLDIPINE

FISONS
* FISONS CORP
IRON DEXTRAN, IRON DEXTRAN
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE

FLEMING PHARMS
* FLEMING AND CO PHARMACEUTICALS INC
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE

FLEMINGTON PHARM
* FLEMINGTON PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE

FONDA BV
* FONDA BV
ARIXTRA, FONDAPARINUX SODIUM

FOREST LABS
* FOREST LABORATORIES INC
CELEXA, CITALOPRAM HYDROBROMIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
TESSALON, BENZONATATE

FOREST PHARMS
* FOREST PHARMACEUTICALS INC
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
DURADYNE DHC, ACETAMINOPHEN
ESGIC, ACETAMINOPHEN
METRA, PHENDIMETRAZINE TARTRATE
MICROSUL, SULFAMETHIZOLE
PROKLAR, SULFAMETHIZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
WOLFINA, RAUWOLFIA SERPENTINA

FORREST LABS
* FORREST LABORATORIES INC
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BETAPRONE, PROPIOLACTONE
DURAPHYL, THEOPHYLLINE
ELIXICON, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
FORBAXIN, METHOCARBAMOL
PYOCIDIN, HYDROCORTISONE
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)

FOUGERA
* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

FRANKLIN PHARMS

* FRANKLIN PHARMACEUTICALS INC
SILDAFLO, SILVER SULFADIAZINE

FRESENIUS

* FRESENIUS USA INC
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FRESENIUS KABI

* FRESENIUS KABI CLAYTON L P
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
NEOPHAM 6.4%, AMINO ACIDS
VITAPED, ASCORBIC ACID
* FRESENIUS KABI CLAYTON R&D INC
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
VEINAMINE 8%, AMINO ACIDS

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FUJISAWA HLTHCARE

* FUJISAWA HEALTHCARE INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CYCLOCORT, AMCINONIDE
PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS

** G **

G AND W LABS

FDA data supplied by DrugPatentWatch.com

* G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
HYDROCORTISONE, HYDROCORTISONE
INDOMETHEGAN, INDOMETHACIN
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRUPHYLLINE, AMINOPHYLLINE

GALDERMA LABS
* GALDERMA LABORATORIES INC
SOLAGE, MEQUINOL

GALDERMA LABS LP
* GALDERMA LABORATORIES LP
CLINDAGEL, CLINDAMYCIN PHOSPHATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
FS SHAMPOO, FLUOCINOLONE ACETONIDE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE

GD SEARLE LLC
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMINOPHYLLIN, AMINOPHYLLINE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
BEXTRA, VALDECOXIB
CALAN, VERAPAMIL HYDROCHLORIDE
CELEBREX, CELECOXIB
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CU-7, COPPER
CYTOTEC, MISOPROSTOL
DAYPRO, OXAPROZIN
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DIULO, METOLAZONE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORQUEST FE, ETHINYL ESTRADIOL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SYNAREL, NAFARELIN ACETATE
TATUM-T, COPPER

GELTEX
* GELTEX PHARMACEUTICALS INC
RENAGEL, SEVELAMER HYDROCHLORIDE

GEN ELECTRIC
* GENERAL ELECTRIC CO
XENON XE 133, XENON, XE-133

GENENTECH
* GENENTECH INC
CRESCORMON, SOMATROPIN
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
PROTROPIN, SOMATREM

GENEVA PHARMS
* GENEVA PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATENOLOL, ATENOLOL
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERCATAB, CAFFEINE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KETOPROFEN, KETOPROFEN
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHOCARBAMOL, METHOCARBAMOL
METHOXSALEN, METHOXSALEN
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIMACTANE, RIFAMPIN
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

GENEVA PHARMS TECH

* GENEVA PHARMACEUTICALS TECHNOLOGY CORP
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CIMETIDINE, CIMETIDINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETODOLAC, ETODOLAC
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOAMICON, ALUMINUM HYDROXIDE (OTC)
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDAPAMIDE, INDAPAMIDE
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PEMOLINE, PEMOLINE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

GENPHARM

* GENPHARM INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL, ALBUTEROL
AMNESTEEM, ISOTRETINOIN
AZATHIOPRINE, AZATHIOPRINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
NOVOTHYROX, LIOTRIX (T4;T3)
OXAPROZIN, OXAPROZIN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SOTALOL HCL, SOTALOL HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
* GENPHARM PHARMACEUTICALS INC
ATENOLOL, ATENOLOL
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM

GENSIA

* GENSIA LABORATORIES LTD
VECURONIUM BROMIDE, VECURONIUM BROMIDE

GENSIA AUTOMEDICS

* GENSIA AUTOMEDICS INC

FDA data supplied by DrugPatentWatch.com

GENESA, ARBUTAMINE HYDROCHLORIDE

GENSIA SICOR PHARMS
* GENSIA SICOR PHARMACEUTICALS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
IDARUBICIN HCL PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HCL, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOCARNITINE, LEVOCARNITINE
MESNA, MESNA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOFOL, PROPOFOL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIOTEPA, THIOTEPA
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

GENTA
* GENTA INC
GANITE, GALLIUM NITRATE

GENZYME
* GENZYME CORP
CEREDASE, ALGLUCERASE
CEREZYME, IMIGLUCERASE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
THYROGEN, THYROTROPIN ALFA

GILBERT LABS
* GILBERT LABORATORIES
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN

GILEAD
* GILEAD SCIENCES INC
DAUNOXOME, DAUNORUBICIN CITRATE
HEPSERA, ADEFOVIR DIPIVOXIL
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VISTIDE, CIDOFOVIR

GLADES PHARMS
* GLADES PHARMACEUTICALS INC
E-GLADES, ERYTHROMYCIN

GLAXO WELLCOME
* GLAXO WELLCOME INC
LANOXICAPS, DIGOXIN
LANOXIN, DIGOXIN

GLAXOSMITHKLINE
* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
AEROSPORIN, POLYMYXIN B SULFATE
AGENERASE, AMPRENAVIR
ALBENZA, ALBENDAZOLE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

AMOXIL, AMOXICILLIN
ANCEF, CEFAZOLIN SODIUM
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANSPOR, CEPHRADINE
ANTEPAR, PIPERAZINE CITRATE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVODART, DUTASTERIDE
BACTOCILL, OXACILLIN SODIUM
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFTIN, CEFUROXIME AXETIL
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CLOXAPEN, CLOXACILLIN SODIUM
COMBIVIR, LAMIVUDINE
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
CONTAC 12 HOUR, CHLORPHENIRAMINE MALEATE (OTC)
COREG, CARVEDILOL
CUTIVATE, FLUTICASONE PROPIONATE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
EMGEL, ERYTHROMYCIN
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
EXOSURF NEONATAL, CETYL ALCOHOL
FASTIN, PHENTERMINE HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
FLONASE, FLUTICASONE PROPIONATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
HALFAN, HALOFANTRINE HYDROCHLORIDE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LAROTID, AMOXICILLIN
LEUKERAN, CHLORAMBUCIL
LOTRONEX, ALOSETRON HYDROCHLORIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MAREZINE, CYCLIZINE LACTATE
MEPRON, ATOVAQUONE
MONOCID, CEFONICID SODIUM
MYLERAN, BUSULFAN
NALLPEN, NAFCILLIN SODIUM
NAVELBINE, VINORELBINE TARTRATE
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NIX, PERMETHRIN
ORNADE, CHLORPHENIRAMINE MALEATE
OXISTAT, OXICONAZOLE NITRATE
PARNATE, TRANYLCYPROMINE SULFATE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PHYTONADIONE, PHYTONADIONE
POLYSPORIN, BACITRACIN ZINC (OTC)
PURINETHOL, MERCAPTOPURINE
PYOPEN, CARBENICILLIN DISODIUM
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
REQUIP, ROPINIROLE HYDROCHLORIDE
RETROVIR, ZIDOVUDINE
SEFFIN, CEPHALOTHIN SODIUM
SEREVENT, SALMETEROL XINAFOATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STOXIL, IDOXURIDINE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SYNCURINE, DECAMETHONIUM BROMIDE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)

FDA data supplied by DrugPatentWatch.com

TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
THIOGUANINE, THIOGUANINE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRITEC, RANITIDINE BISMUTH CITRATE
TRIZIVIR, ABACAVIR SULFATE
URISPAS, FLAVOXATE HYDROCHLORIDE
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VASOXYL, METHOXAMINE HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE
VONTROL, DIPHENIDOL HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZIAGEN, ABACAVIR SULFATE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE

GLAXOSMITHKLINE CONS
* GLAXOSMITHKLINE CONSUMER HEALTHCARE
APHTHASOL, AMLEXANOX
COMMIT, NICOTINE POLACRILEX (OTC)

GLENWOOD
* GLENWOOD INC
MYOTONACHOL, BETHANECHOL CHLORIDE
PASKALIUM, POTASSIUM AMINOSALICYLATE
RENOQUID, SULFACYTINE

GOLDLINE
* GOLDLINE LABORATORIES INC
GLYCOPREP, POLYETHYLENE GLYCOL 3350
METFORMIN HCL, METFORMIN HYDROCHLORIDE

GRAHAM CHEM
* GRAHAM CHEMICAL CO
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE

GRAHAM DM
* DM GRAHAM LABORATORIES INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SOMOPHYLLIN-CRT, THEOPHYLLINE

GRIFFEN
* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

GRUPPO LEPETIT
* GRUPPO LEPETIT SPA SUB MERRELL DOW PHARMACEUTICALS INC
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE

GUARDIAN DRUG
* GUARDIAN DRUG CO INC
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET
* GUERBET LLC
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

GUILFORD PHARMS
* GUILFORD PHARMACEUTICALS INC
GLIADEL, CARMUSTINE

GYNETICS
* GYNETICS INC
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL

GYNOPHARMA
* GYNOPHARMA INC

FDA data supplied by DrugPatentWatch.com

NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL

** H **

HALLMARK PHARMS
* HALLMARK PHARMACEUTICALS
CAPTOPRIL, CAPTOPRIL

HALOCARBON
* HALOCARBON LABORATORIES DIV HALOCARBON PRODUCTS CORP
HALOTHANE, HALOTHANE

HALOCARBON PRODS
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE

HALSEY
* HALSEY DRUG CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CODOXY, ASPIRIN
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KLOROMIN, CHLORPHENIRAMINE MALEATE
LORAZEPAM, LORAZEPAM
LOW-QUEL, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NALIDIXIC ACID, NALIDIXIC ACID
NEURAMATE, MEPROBAMATE
NIACIN, NIACIN
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA

FDA data supplied by DrugPatentWatch.com

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

HAMILTON PHARMS
* HAMILTON PHARMACEUTICALS LTD
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN

HANFORD GC
* GC HANFORD MANUFACTURING CO
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

HEALTHPOINT
* HEALTHPOINT LTD
AKNE-MYCIN, ERYTHROMYCIN
CETACORT, HYDROCORTISONE
CLODERM, CLOCORTOLONE PIVALATE
CORMAX, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
NUTRACORT, HYDROCORTISONE
SANSAC, ERYTHROMYCIN

HEATHER
* HEATHER DRUG CO INC
CORTISONE ACETATE, CORTISONE ACETATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

HERAN
* HERAN PHARMACEUTICAL INC
GLYCORT, HYDROCORTISONE

HERCON LABS
* HERCON LABORATORIES CORP
NITROGLYCERIN, NITROGLYCERIN

HEXCEL
* HEXCEL CHEMICAL PRODUCTS
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM

HI TECH PHARMA
* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ERYTHRO-STATIN, ERYTHROMYCIN
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

HIGH TECH PHARMA
* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKMA
* HIKMA FARMACEUTICA LDA

FDA data supplied by DrugPatentWatch.com

CEFOTAXIME, CEFOTAXIME SODIUM

HILL DERMAC
* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
TRI-LUMA, FLUOCINOLONE ACETONIDE

HLR
* HLR TECHNOLOGY
ACCUTANE, ISOTRETINOIN
FORTOVASE, SAQUINAVIR
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROMAZICON, FLUMAZENIL
SORIATANE, ACITRETIN
VERSED, MIDAZOLAM HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT

HOLLAND RANTOS
* HOLLAND RANTOS CO INC
KOROSTATIN, NYSTATIN

HUNTINGTON LABS
* HUNTINGTON LABORATORIES INC
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
HEXA-GERM, HEXACHLOROPHENE

** I **

IBI
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM

ICN
* ICN PHARMACEUTICALS INC
8-MOP, METHOXSALEN
AMINOPHYLLINE, AMINOPHYLLINE
ANCOBON, FLUCYTOSINE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
BENDOPA, LEVODOPA
BENOQUIN, MONOBENZONE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
DALMANE, FLURAZEPAM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
EFUDEX, FLUOROURACIL
ELDECORT, HYDROCORTISONE
FLUOXYMESTERONE, FLUOXYMESTERONE
FOLIC ACID, FOLIC ACID
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRISORALEN, TRIOXSALEN
VIRAZOLE, RIBAVIRIN

ICN PUERTO RICO
* ICN PUERTO RICO INC
FLUOROURACIL, FLUOROURACIL

IMMUNEX
* IMMUNEX CORP
LEVOPROME, METHOTRIMEPRAZINE
THIOPLEX, THIOTEPA
THIOTEPA, THIOTEPA

IMP
* IMP INC
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123

IMPAX LABS
* IMPAX LABORATORIES INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
NIACIN, NIACIN
OMEPRAZOLE, OMEPRAZOLE
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THYROGLOBULIN, THYROGLOBULIN
TRIAMCINOLONE, TRIAMCINOLONE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

IMPAX PHARM
* IMPAX PHARMACEUTICALS
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE

INALCO
* INALCO SPA
LACTULOSE, LACTULOSE

INGRAM PHARM
* INGRAM PHARMACEUTICAL CO
DRICORT, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE

INKINE
* INKINE PHARMACEUTICAL CO INC
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

INO
* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INTERMUNE PHARMS
* INTERMUNE PHARMACEUTICALS INC
AMPHOTEC, AMPHOTERICIN B

INTERPHARM
* INTERPHARM INC
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NAPROXEN, NAPROXEN
PREDNISONE, PREDNISONE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TOLAZAMIDE, TOLAZAMIDE

INTL MEDICATED
* INTERNATIONAL MEDICATED SYSTEMS LTD
BUPIVACINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN, GENTAMICIN SULFATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INTL MINERALS
* INTERNATIONAL MINERALS CHEMICAL CORP
TPN SUSPENSION, NIACINAMIDE

INVAMED
* INVAMED INC
FAMOTIDINE, FAMOTIDINE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METHAZOLAMIDE, METHAZOLAMIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OXAPROZIN, OXAPROZIN
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

INWOOD LABS
* INWOOD LABORATORIES INC SUB FOREST LABORATORIES INC
CARBAMAZEPINE, CARBAMAZEPINE
CORTISONE ACETATE, CORTISONE ACETATE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

IOMED
* IOMED INC
IONTOCAINE, EPINEPHRINE

IPHARM
* IPHARM DIV LYPHOMED INC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN

IPR
* IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ZOMIG, ZOLMITRIPTAN

ISO TEX
* ISO TEX DIAGNOSTICS INC
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

IVAX PHARMS
* IVAX PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALLAY, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUMETANIDE, BUMETANIDE
BUTALBITAL COMPOUND, ASPIRIN
C-SOLVE-2, ERYTHROMYCIN

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLOZAPINE, CLOZAPINE
CORTISONE ACETATE, CORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METRONIDAZOLE, METRONIDAZOLE
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NOGENIC HC, HYDROCORTISONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PACLITAXEL, PACLITAXEL
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

IVAX RES
* IVAX RESEARCH INC
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE

** J **

J AND J
* JOHNSON AND JOHNSON CONSUMER PRODUCTS INC
ERYCETTE, ERYTHROMYCIN
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
* JOHNSON AND JOHNSON MEDICAL INC
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)

JACOBUS
* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JANSSEN
* JANSSEN PHARMACEUTICA INC
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MONISTAT, MICONAZOLE
NIZORAL, KETOCONAZOLE

JANSSEN PHARMA
* JANSSEN PHARMACEUTICA PRODUCTS LP
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
NIZORAL, KETOCONAZOLE
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
REMINYL, GALANTAMINE HYDROBROMIDE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE

JOHNSON AND JOHNSON
* JOHNSON AND JOHNSON CONSUMER COMPANIES INC
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MONISTAT-DERM, MICONAZOLE NITRATE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
SPECTAZOLE, ECONAZOLE NITRATE
* JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL

JONES PHARMA
* JONES PHARMA INC SUB KING PHARMACEUTICALS INC
CYTOMEL, LIOTRIX (T4;T3)
LEVOXYL, LIOTRIX (T4;T3)
METHIMAZOLE, METHIMAZOLE
TRIOSTAT, LIOTRIX (T4;T3)
TUSSIGON, HOMATROPINE METHYLBROMIDE

JVL
* JVL CORP
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE

** K **

KALAPHARM
* KALAPHARM INC
FUROSEMIDE, FUROSEMIDE

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE, GENTAMICIN SULFATE

KENDALL IL
* KENDALL CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE

KENDALL LP
* KENDALL CO LP
THERMAZENE, SILVER SULFADIAZINE

KENWOOD LABS
* KENWOOD LABORATORIES DIV BRADLEY PHARMACEUTICALS
CARMOL HC, HYDROCORTISONE ACETATE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

KEY PHARMS
* KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP
GENAPAX, GENTIAN VIOLET
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
NITRO-DUR, NITROGLYCERIN
QUINORA, QUINIDINE SULFATE

KIEL
* KIEL LABORATORIES INC
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

KING PHARMS
* KING PHARMACEUTICALS INC
ALTACE, RAMIPRIL
AMINOPHYLLINE, AMINOPHYLLINE
APOGEN, GENTAMICIN SULFATE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BREVITAL SODIUM, METHOHEXITAL SODIUM
CORZIDE, BENDROFLUMETHIAZIDE
CROMOPTIC, CROMOLYN SODIUM
DELESTROGEN, ESTRADIOL VALERATE
FLORINEF, FLUDROCORTISONE ACETATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KLEBCIL, KANAMYCIN SULFATE
LORABID, LORACARBEF
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
ORTHO-PREFEST, ESTRADIOL
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SILVADENE, SILVER SULFADIAZINE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
WYCILLIN, PENICILLIN G PROCAINE

KOS
* KOS PHARMACEUTICALS INC
ADVICOR, LOVASTATIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN

KREMERS URBAN
* KREMERS URBAN CO
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

KREMERS URBAN DEV
* KREMERS URBAN DEVELOPMENT CO
OMEPRAZOLE, OMEPRAZOLE

KRKA DD NOVO MESTO
* KRKA DD NOVO MESTO
ENALAPRIL MALEATE, ENALAPRIL MALEATE

KV PHARM
* KV PHARMACEUTICAL CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
AMINOPHYLLINE, AMINOPHYLLINE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
QUINIDINE SULFATE, QUINIDINE SULFATE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
THEOPHYLLINE, THEOPHYLLINE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

** L **

LABS AF
* LABORATORIOS APLICACIONES FARMACEUTICAS SA DE CV
METROMIDOL, METRONIDAZOLE

LABS ATRAL
* LABORATORIOS ATRAL SARL
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

LACHMAN CONSULT
* LACHMAN CONSULTANT SERVICES INC
LACTULOSE, LACTULOSE

LAFAYETTE PHARMS
* LAFAYETTE PHARMACEUTICALS INC
BAROS, SODIUM BICARBONATE

LANNETT
* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BENZYL BENZOATE, BENZYL BENZOATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUTALAN, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
FOLIC ACID, FOLIC ACID
FURALAN, NITROFURANTOIN
GLUTETHIMIDE, GLUTETHIMIDE
HYDROCORTISONE, HYDROCORTISONE
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURAZONE, NITROFURAZONE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINALAN, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPALAN, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TRICHLOREX, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VELTANE, BROMPHENIRAMINE MALEATE
VITAMIN D, ERGOCALCIFEROL

LAYTON
* LAYTON BIOSCIENCE INC
INVERSINE, MECAMYLAMINE HYDROCHLORIDE

LEDERLE
* LEDERLE LABORATORIES DIV AMERICAN CYANAMID CO
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ASENDIN, AMOXAPINE
ATENOLOL, ATENOLOL
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
CEFACLOR, CEFACLOR
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
IBUPROFEN, IBUPROFEN
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEDERCILLIN VK, PENICILLIN V POTASSIUM
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
NAPROXEN, NAPROXEN
NEPTAZANE, METHAZOLAMIDE
NILSTAT, NYSTATIN
PATHILON, TRIDIHEXETHYL CHLORIDE
PIPRACIL, PIPERACILLIN SODIUM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
SERVISONE, PREDNISONE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFASALAZINE, SULFASALAZINE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
SUPRAX, CEFIXIME
TOLBUTAMIDE, TOLBUTAMIDE
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEBETA, BISOPROLOL FUMARATE
ZIAC, BISOPROLOL FUMARATE

* LEDERLE PARENTERALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAMOX, ACETAZOLAMIDE SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
FUROSEMIDE, FUROSEMIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOLED, VANCOMYCIN HYDROCHLORIDE

* LEDERLE PIPERACILLIN INC DIV AMERICAN CYANAMID CO
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM

LEE KM

* KM LEE LABORATORIES INC
MEPROBAMATE, MEPROBAMATE

LEINER

* LEINER HEALTH PRODUCTS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

LEK LJUBLJANA

* LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO
CIMETIDINE, CIMETIDINE

LEK PHARM

* LEK PHARMACEUTICAL AND CHEMICAL CO DD
ACYCLOVIR, ACYCLOVIR

FDA data supplied by DrugPatentWatch.com

BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CIMETIDINE, CIMETIDINE (OTC)
ENALAPRIL MALEATE, ENALAPRIL MALEATE
LISINOPRIL, LISINOPRIL

LEK SVCS
* LEK SERVICES INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTSSSIUM, AMOXICILLIN
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

LEO PHARM
* LEO PHARMACEUTICAL PRODUCTS LTD
PINDAC, PINACIDIL

LIFE LABS
* LIFE LABORATORIES INC
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE

LIGAND
* LIGAND PHARMACEUTICALS INC
PANRETIN, ALITRETINOIN
TARGRETIN, BEXAROTENE

LILLY
* ELI LILLY AND CO
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
ALPHALIN, VITAMIN A PALMITATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ANHYDRON, CYCLOTHIAZIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
BACITRACIN, BACITRACIN
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CESAMET, NABILONE
CINOBAC, CINOXACIN
CORDRAN-N, FLURANDRENOLIDE
CRYSTODIGIN, DIGITOXIN
DECABID, INDECAINIDE HYDROCHLORIDE
DELTALIN, ERGOCALCIFEROL
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DROLBAN, DROMOSTANOLONE PROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
ERYTHROMYCIN, ERYTHROMYCIN
EVISTA, RALOXIFENE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FORTEO, TERIPARATIDE ACETATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HALDRONE, PARAMETHASONE ACETATE
HEPARIN SODIUM, HEPARIN SODIUM
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ISONIAZID, ISONIAZID
KAFOCIN, CEPHALOGLYCIN
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
MANDOL, CEFAMANDOLE NAFATE
MENADIONE, MENADIONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METUBINE IODIDE, METOCURINE IODIDE
MOXAM, MOXALACTAM DISODIUM
NEBCIN, TOBRAMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK

FDA data supplied by DrugPatentWatch.com

(OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
ONCOVIN, VINCRISTINE SULFATE
PAGITANE, CYCRIMINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PERMAX, PERGOLIDE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
SANDRIL, RESERPINE
SECONAL SODIUM, SECOBARBITAL SODIUM
SEROMYCIN, CYCLOSERINE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAPYRIDINE, SULFAPYRIDINE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TAPAZOLE, METHIMAZOLE
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VELBAN, VINBLASTINE SULFATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

* ELI LILLY INDUSTRIES INC
DYMELOR, ACETOHEXAMIDE
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS

* LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO
CECLOR, CEFACLOR
ILOSONE, ERYTHROMYCIN ESTOLATE
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

LILLY RES LABS

* LILLY RESEARCH LABORATORIES
DYNABAC, DIRITHROMYCIN

LLOYD

* LLOYD INC
THYRO-TABS, LIOTRIX (T4;T3)

LNK

* LNK INTERNATIONAL INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METRONIDAZOLE, METRONIDAZOLE

LOCH

* LOCH PHARMACEUTICALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FOLIC ACID, FOLIC ACID
KANAMYCIN SULFATE, KANAMYCIN SULFATE

LOREX

* LOREX PHARMACEUTICALS
AMBIEN, ZOLPIDEM TARTRATE
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE

LPI

* LPI HOLDINGS INC
N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM

FDA data supplied by DrugPatentWatch.com

LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

LYNE
* LYNE LABORATORIES INC
XYLOSE, XYLOSE

** M **

MALLARD
* MALLARD INC
MEPROBAMATE, MEPROBAMATE

MALLINCKRODT
* MALLINCKRODT CHEMICAL INC
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
BONTRIL, PHENDIMETRAZINE TARTRATE
BUCET, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
FEMCET, ACETAMINOPHEN
HYDROCET, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORCET-HD, ACETAMINOPHEN
LORTAB, ACETAMINOPHEN
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TENCON, ACETAMINOPHEN
TRIAD, ACETAMINOPHEN
* MALLINCKRODT INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MD-50, DIATRIZOATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTISON, ALBUMIN HUMAN
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OXYCET, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
XENEISOL, XENON, XE-133
* MALLINCKRODT MEDICAL INC
ANGIO-CONRAY, IOTHALAMATE SODIUM
CHOLEBRINE, IOCETAMIC ACID
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY, IOTHALAMATE MEGLUMINE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HEXABRIX, IOXAGLATE MEGLUMINE
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
PERCHLORACAP, POTASSIUM PERCHLORATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID

FDA data supplied by DrugPatentWatch.com

THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
VASCORAY, IOTHALAMATE MEGLUMINE
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133

MALLINCKRODT BAKER
* MALLINCKRODT BAKER INC
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE

MARCHAR
* MARCHAR LABORATORIES INC LTD
FLUOROURACIL, FLUOROURACIL

MARSAM PHARMS LLC
* MARSAM PHARMACEUTICALS LLC
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFACLOR, CEFACLOR
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
ISOFLURANE, ISOFLURANE
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALOXONE HCL, NALOXONE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MARSHALL PHARMA
* MARSHALL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM

MARTEC
* MARTEC PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
DIAZEPAM, DIAZEPAM
PINDOLOL, PINDOLOL
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
* MARTEC SCIENTIFIC INC
DICLOFENAC SODIUM, DICLOFENAC SODIUM

MAST MM
* MM MAST AND CO
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
PHENAZINE, PHENDIMETRAZINE TARTRATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRICHLORMAS, TRICHLORMETHIAZIDE

MATRIX MEDCL
* MATRIX MEDICAL CORP
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)

MAYRAND
* MAYRAND INC
SEDAPAP, ACETAMINOPHEN

MCGAW
* MCGAW INC
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

FDA data supplied by DrugPatentWatch.com

MEDIPREN, IBUPROFEN (OTC)
METHOCARBAMOL AND ASPIRIN, ASPIRIN
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
NUPRIN, IBUPROFEN (OTC)
* MCNEIL PHARMACEUTICAL CO DIV MCNEILAB INC
CLISTIN, CARBINOXAMINE MALEATE

MCNEIL CONS SPECLT
* MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIV MCNEIL PCC
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MOTRIN, IBUPROFEN
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
SINE-AID IB, IBUPROFEN (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
VERMOX, MEBENDAZOLE

MD PHARM
* MD PHARMACEUTICAL INC
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DI-ATRO, ATROPINE SULFATE

MEAD JOHNSON
* MEAD JOHNSON AND CO SUB BRISTOL MYERS CO
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE

MEDI FLEX HOSP
* MEDI FLEX HOSP PRODUCTS INC
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)

MEDICIS
* MEDICIS PHARMACEUTICAL CORP
BUPHENYL, SODIUM PHENYLBUTYRATE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
OVIDE, MALATHION
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
VECTRIN, MINOCYCLINE HYDROCHLORIDE

MEDIMMUNE ONCOLOGY
* MEDIMMUNE ONCOLOGY INC
ETHYOL, AMIFOSTINE
NEUTREXIN, TRIMETREXATE GLUCURONATE

MEDS (TMC)
* MEDICINES CO (TMC)
ANGIOMAX, BIVALIRUDIN

MEDTRONIC
* MEDTRONIC INC
LIORESAL, BACLOFEN

MEPHA
* MEPHA AG
PIROXICAM, PIROXICAM

MERCK
* MERCK AND CO INC
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALPHAREDISOL, HYDROXOCOBALAMIN
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AQUAMEPHYTON, PHYTONADIONE
ARAMINE, METARAMINOL BITARTRATE
BENEMID, PROBENECID
COGENTIN, BENZTROPINE MESYLATE
COLBENEMID, COLCHICINE
CORTONE, CORTISONE ACETATE
CUPRIMINE, PENICILLAMINE
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
DARANIDE, DICHLORPHENAMIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECASPRAY, DEXAMETHASONE
DEMSER, METYROSINE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DOLOBID, DIFLUNISAL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
FLOROPRYL, ISOFLUROPHATE
FOSAMAX, ALENDRONATE SODIUM
HUMORSOL, DEMECARIUM BROMIDE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE

FDA data supplied by DrugPatentWatch.com

HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
MANNITOL 25%, MANNITOL
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEPHYTON, PHYTONADIONE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MINTEZOL, THIABENDAZOLE
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
REDISOL, CYANOCOBALAMIN
SINGULAIR, MONTELUKAST SODIUM
SYPRINE, TRIENTINE HYDROCHLORIDE
TIAMATE, DILTIAZEM MALATE
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
ALDOMET, METHYLDOPA
BLOCADREN, TIMOLOL MALEATE
CHIBROXIN, NORFLOXACIN
CLINORIL, SULINDAC
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRIXIVAN, INDINAVIR SULFATE
DECADRON-LA, DEXAMETHASONE ACETATE
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
LACRISERT, HYDROXYPROPYL CELLULOSE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEVACOR, LOVASTATIN
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
NOROXIN, NORFLOXACIN
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
STROMECTOL, IVERMECTIN
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
VIOXX, ROFECOXIB
ZOCOR, SIMVASTATIN

MERCK RES
* MERCK RESEARCH LABORATORIES
CANCIDAS, CASPOFUNGIN ACETATE

MERETEK
* MERETEK DIAGNOSTICS INC
BREATHTEK UBT FOR H-PYLORI, UREA, C-13
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13

MERICON
* MERICON INDUSTRIES INC
HYDROCORTISONE, HYDROCORTISONE

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ATROPEN, ATROPINE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
EPI E Z PEN JR, EPINEPHRINE
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

METABOLIC SOLUTIONS
* METABOLIC SOLUTIONS INC
HELICOSOL, UREA, C-13

METHAPHARM
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

MFG CHEMISTS

FDA data supplied by DrugPatentWatch.com

* MANUFACTURING CHEMISTS INC
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

MGI PHARMA INC
* MGI PHARMA INC
DIDRONEL, ETIDRONATE DISODIUM
HEXALEN, ALTRETAMINE
SALAGEN, PILOCARPINE HYDROCHLORIDE

MIKART
* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
METHAZOLAMIDE, METHAZOLAMIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PYRAZINAMIDE, PYRAZINAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

MILES
* MILES LABORATORIES INC
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 10%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20%, MANNITOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE

MILEX
* MILEX PRODUCTS INC
MILOPHENE, CLOMIPHENE CITRATE

MILLENNIUM PHARMS
* MILLENNIUM PHARMACEUTICALS INC
INTEGRILIN, EPTIFIBATIDE

MINRAD
* MINRAD INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE

MISSION PHARMA
* MISSION PHARMACAL CO
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
FOLICET, FOLIC ACID
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
LITHOSTAT, ACETOHYDROXAMIC ACID
POTASSIUM CITRATE, POTASSIUM CITRATE
TIOPRONIN, TIOPRONIN

MIZA PHARMS USA
* MIZA PHARMACEUTICALS USA INC
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
TROPICAMIDE, TROPICAMIDE

MJ PHARMS
* MJ PHARMACEUTICALS LTD
CEPHALEXIN, CEPHALEXIN

MK LABS
* MK LABORATORIES INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
ISONIAZID, ISONIAZID
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NIACIN, NIACIN
RESERPINE, RESERPINE
SOSOL, SULFISOXAZOLE
VITAMIN A, VITAMIN A PALMITATE

MONARCH PHARMS
* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC

FDA data supplied by DrugPatentWatch.com

CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
DERMACORT, HYDROCORTISONE
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE
POLYSPORIN, BACITRACIN ZINC
PROCTOCORT, HYDROCORTISONE
PROLOPRIM, TRIMETHOPRIM
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
THALITONE, CHLORTHALIDONE
VIROPTIC, TRIFLURIDINE

MORTON GROVE
* MORTON GROVE ACQUISITION CORP
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* MORTON GROVE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
BIPHETAP, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CARBAMAZEPINE, CARBAMAZEPINE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCODONE, HOMATROPINE METHYLBROMIDE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYMETHASONE, DEXAMETHASONE
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
NYSTATIN, NYSTATIN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
PHENTYTOIN, PHENYTOIN
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE

MOUNT SINAI MEDCTR
* MOUNT SINAI MEDCTR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

MOVA
* MOVA PHARMACEUTICALS CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
LEVO-T, LIOTRIX (T4;T3)

MSP SINGAPORE
* MSP SINGAPORE CO LLC
ZETIA, EZETIMIBE

MURO
* MURO PHARMACEUTICAL INC
LIQUID PRED, PREDNISONE

FDA data supplied by DrugPatentWatch.com

OPTIVAR, AZELASTINE HYDROCHLORIDE
PRELONE, PREDNISOLONE
PROMETA, METAPROTERENOL SULFATE
TRI-NASAL, TRIAMCINOLONE ACETONIDE
VOLMAX, ALBUTEROL SULFATE

MUTUAL PHARM
* MUTUAL PHARMACEUTICAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MUTUAL PHARMA
* MUTUAL PHARMACAL CO
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
METFORMIN HCL, METFORMIN HYDROCHLORIDE

MYLAN
* MYLAN LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
ETODOLAC, ETODOLAC
IBUPROFEN, IBUPROFEN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
* MYLAN PHARMACEUTICALS INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE

FDA data supplied by DrugPatentWatch.com

CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOTHYROXINE SODIUM, LIOTRIX (T4;T3)
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
NIZATIDINE, NIZATIDINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PACLITAXEL, PACLITAXEL
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM, EXTENDED
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMYLON, MAFENIDE ACETATE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE

FDA data supplied by DrugPatentWatch.com

TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZAGAM, SPARFLOXACIN

MYLAN TECHNOLOGIES
* MYLAN TECHNOLOGIES INC
ESTRADIOL, ESTRADIOL
NITROGLYCERIN, NITROGLYCERIN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

** N **

NAPRO
* NAPRO BIOTHERAPEUTICS INC
PACLITAXEL, PACLITAXEL

NASKA
* NASKA PHARMACAL CO INC DIV RUGBY DARBY GROUP COSMETICS
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
HYDROCORTISONE, HYDROCORTISONE
TRIMETH/SULFA, SULFAMETHOXAZOLE

NASTECH PHARM
* NASTECH PHARMACEUTICAL CO INC
NASCOBAL, CYANOCOBALAMIN

NEOSAN PHARMS
* NEOSAN PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
DARVON-N, PROPOXYPHENE NAPSYLATE
ETODOLAC, ETODOLAC
KETOCONAZOLE, KETOCONAZOLE

NEPHRON
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-2, ISOETHARINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

NEW RIVER
* NEW RIVER PHARMACEUTICALS INC
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERGOMAR, ERGOTAMINE TARTRATE
PROFERDEX, IRON DEXTRAN
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE

NEWTRON PHARMS
* NEWTRON PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE

NORBROOK
* NORBROOK LABORATORIES LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE

NOVARTIS
* NOVARTIS CONSUMER HEALTH INC
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
DENAVIR, PENCICLOVIR SODIUM
HABITROL, NICOTINE
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
RAUTENSIN, ALSEROXYLON
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TRANSDERM SCOP, SCOPOLAMINE
* NOVARTIS OPHTHALMICS INC
CARBASTAT, CARBACHOL
CATARASE, CHYMOTRYPSIN
DEXACIDIN, DEXAMETHASONE
FLUOR-OP, FLUOROMETHOLONE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
GENTACIDIN, GENTAMICIN SULFATE
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OCUPRESS, CARTEOLOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

RESCULA, UNOPROSTONE ISOPROPYL
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VOLTAREN, DICLOFENAC SODIUM
ZADITOR, KETOTIFEN FUMARATE

* NOVARTIS PHARMACEUTICALS CORP
ACYLANID, ACETYLDIGITOXIN
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AREDIA, PAMIDRONATE DISODIUM
BRETHAIRE, TERBUTALINE SULFATE
BUTAZOLIDIN, PHENYLBUTAZONE
CAFERGOT, CAFFEINE
CATAFLAM, DICLOFENAC POTASSIUM
CEDILANID-D, DESLANOSIDE
CIBACALCIN, CALCITONIN HUMAN
CLOZARIL, CLOZAPINE
COMBIPATCH, ESTRADIOL
CYTADREN, AMINOGLUTETHIMIDE
DESFERAL, DEFEROXAMINE MESYLATE
DIAPID, LYPRESSIN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
ELIDEL, PIMECROLIMUS
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESTRADERM, ESTRADIOL
ESTRADIOL, ESTRADIOL
EXELON, RIVASTIGMINE TARTRATE
FAMVIR, FAMCICLOVIR
FEMARA, LETROZOLE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FORADIL, FORMOTEROL FUMARATE
GLEEVEC, IMATINIB MESYLATE
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INH, ISONIAZID
ISMELIN, GUANETHIDINE MONOSULFATE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LIORESAL, BACLOFEN
LOCORTEN, FLUMETHASONE PIVALATE
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MESANTOIN, MEPHENYTOIN
METANDREN, METHYLTESTOSTERONE
METHERGINE, METHYLERGONOVINE MALEATE
METOPIRONE, METYRAPONE
MIACALCIN, CALCITONIN, SALMON
NEORAL, CYCLOSPORINE
PARLODEL, BROMOCRIPTINE MESYLATE
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
REGITINE, PHENTOLAMINE MESYLATE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANOREX, MAZINDOL
SANSERT, METHYSERGIDE MALEATE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERENTIL, MESORIDAZINE BESYLATE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SLOW-K, POTASSIUM CHLORIDE
STARLIX, NATEGLINIDE
SYNTOCINON, OXYTOCIN
TANDEARIL, OXYPHENBUTAZONE
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE

FDA data supplied by DrugPatentWatch.com

TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEN-K, POTASSIUM CHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TRANSDERM-NITRO, NITROGLYCERIN
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TREST, METHIXENE HYDROCHLORIDE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRILEPTAL, OXCARBAZEPINE
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
ZELNORM, TEGASEROD MALEATE
ZOMETA, ZOLEDRONIC ACID

NOVAVAX
* NOVAVAX INC
AVC, SULFANILAMIDE

NOVEN
* NOVEN PHARMACEUTICALS INC
LIDOCAINE, LIDOCAINE

NOVEX
* NOVEX PHARMA
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CROMOLYN SODIUM, CROMOLYN SODIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LACTULOSE, LACTULOSE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
ACTIVELLA, ESTRADIOL
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
INNOFEM, ESTRADIOL
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
MIXTARD HUMAN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NORDITROPIN, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART
NOVOLOG, INSULIN ASPART
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
PRANDIN, REPAGLINIDE
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
VAGIFEM, ESTRADIOL
VELOSULIN BR HUMAN, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
VELOSULIN, INSULIN PURIFIED PORK (OTC)

NOVOCOL
* NOVOCOL PHARMACEUTICAL INC
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE

NUMARK
* NUMARK LABORATORIES INC
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

FDA data supplied by DrugPatentWatch.com

SPRX-105, PHENDIMETRAZINE TARTRATE

NYLOS
* NYLOS TRADING CO INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
METHOCARBAMOL, METHOCARBAMOL
PREDNISONE, PREDNISONE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

** O **

OCLASSEN
* OCLASSEN PHARMACEUTICALS INC
CONDYLOX, PODOFILOX
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE

ODYSSEY PHARMS
* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM
* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS
* OHM LABORATORIES INC
CHLORZOXAZONE, CHLORZOXAZONE
IBUPROFEN, IBUPROFEN
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)

ONY
* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

OPR DEVELOP LP
* OPR DEVELOPMENT LP
CAFCIT, CAFFEINE CITRATE

OPTOPICS
* OPTOPICS LABORATORIES CORP
OPTOMYCIN, CHLORAMPHENICOL
PARACAINE, PROPARACAINE HYDROCHLORIDE
SULFACEL-15, SULFACETAMIDE SODIUM

ORAPHARMA
* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORGANICS LAGRANGE
* ORGANICS LAGRANGE INC
CORTICOTROPIN, CORTICOTROPIN

ORGANON
* ORGANON INC SUB AKZO NOBEL INC
MIRCETTE, DESOGESTREL
RAPLON, RAPACURONIUM BROMIDE
* ORGANON INC SUB AKZONA INC
ARDUAN, PIPECURONIUM BROMIDE
CALDEROL, CALCIFEDIOL
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
COTAZYM, LIPASE
DECA-DURABOLIN, NANDROLONE DECANOATE
DESOGEN, DESOGESTREL
DOCA, DESOXYCORTICOSTERONE ACETATE
DURABOLIN, NANDROLONE PHENPROPIONATE
FOLLISTIM, FOLLITROPIN ALFA/BETA
FUROSEMIDE, FUROSEMIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HUMEGON, MENOTROPINS (FSH;LH)
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LYNORAL, ETHINYL ESTRADIOL
MAXIBOLIN, ETHYLESTRENOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
NORCURON, VECURONIUM BROMIDE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
PAVULON, PANCURONIUM BROMIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
REGONOL, PYRIDOSTIGMINE BROMIDE
REMERON, MIRTAZAPINE
REVERSOL, EDROPHONIUM CHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE

ORGANON INC
* ORGANON INC
ANTAGON, GANIRELIX ACETATE
CYCLESSA, DESOGESTREL

FDA data supplied by DrugPatentWatch.com

NUVARING, ETHINYL ESTRADIOL
REMERON SOLTAB, MIRTAZAPINE

ORIDION
* ORIDION BREATHID INC
IDKIT:HP, UREA, C-13

ORION
* ORION CORP
COMTAN, ENTACAPONE
FARESTON, TOREMIFENE CITRATE

ORPHAN MEDCL
* ORPHAN MEDICAL INC
ANTIZOL, FOMEPIZOLE
BUSULFEX, BUSULFAN
CYSTADANE, BETAINE, ANHYDROUS
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
SUCRAID, SACROSIDASE
XYREM, SODIUM OXYBATE

ORTHO BIOTECH
* ORTHO BIOTECH PRODUCTS LP
LEUSTATIN, CLADRIBINE

ORTHO MCNEIL
* ORTHO MCNEIL PHARMACEUTICAL
DIENESTROL, DIENESTROL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
TOPAMAX SPRINKLE, TOPIRAMATE

ORTHO MCNEIL PHARM
* ORTHO MCNEIL PHARMACEUTICAL INC
CLISTIN, CARBINOXAMINE MALEATE
ESTRADIOL, ESTRADIOL
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
HALDOL SOLUTAB, HALOPERIDOL
INJECTAPAP, ACETAMINOPHEN
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MONISTAT 3, MICONAZOLE NITRATE
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-N0VUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PROTOSTAT, METRONIDAZOLE
SALPIX, ACETRIZOATE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TOPAMAX, TOPIRAMATE
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
VASCOR, BEPRIDIL HYDROCHLORIDE

OTSUKA
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE
PLETAL, CILOSTAZOL
RAXAR, GREPAFLOXACIN HYDROCHLORIDE

OVATION PHARMS
* OVATION PHARMACEUTICALS INC
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM

OXFORD PHARM

FDA data supplied by DrugPatentWatch.com

* OXFORD PHARMACEUTICAL SERVICES INC
  MARPLAN, ISOCARBOXAZID

** P **

PACIFIC PHARMA
* PACIFIC PHARMA
  TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
  TIMOLOL MALEATE, TIMOLOL MALEATE

PACO
* PACO PHARMACEUTICAL SERVICES INC
  LACTULOSE, LACTULOSE
* PACO RESEARCH CORP
  GENTAMICIN SULFATE, GENTAMICIN SULFATE
  LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
  METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
  THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE

PADDOCK
* PADDOCK LABORATORIES INC
  AMMONIUM LACTATE, AMMONIUM LACTATE
  BACITRACIN, BACITRACIN
  CLINDA-DERM, CLINDAMYCIN PHOSPHATE
  COLOCORT, HYDROCORTISONE
  COMPRO, PROCHLORPERAZINE
  CONDYLOX, PODOFILOX
  ERYTHRA-DERM, ERYTHROMYCIN
  ERYTHROMYCIN, ERYTHROMYCIN
  HYDROCORTISONE, HYDROCORTISONE
  KIONEX, SODIUM POLYSTYRENE SULFONATE
  NYSTATIN, NYSTATIN
  NYSTOP, NYSTATIN
  PODOFILOX, PODOFILOX
  POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

PAL PAK
* PAL PAK INC
  AMINOPHYLLINE, AMINOPHYLLINE
  RAUVAL, RAUWOLFIA SERPENTINA
  TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)

PANRAY
* PANRAY CORP SUB ORMONT DRUG AND CHEMICAL CO INC
  AMINOPHYLLINE, AMINOPHYLLINE
  CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
  CINNASIL, RESCINNAMINE
  CORTISONE ACETATE, CORTISONE ACETATE
  HYDROCORTISONE, HYDROCORTISONE
  ISONIAZID, ISONIAZID
  KOGLUCOID, RAUWOLFIA SERPENTINA
  PARASAL SODIUM, AMINOSALICYLATE SODIUM
  PARASAL, AMINOSALICYLIC ACID
  PREDNISOLONE, PREDNISOLONE
  PREDNISONE, PREDNISONE
  PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
  SERPANRAY, RESERPINE
  THEOLIXIR, THEOPHYLLINE

PAR PHARM
* PAR PHARMACEUTICAL INC
  ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
  ALLOPURINOL, ALLOPURINOL
  AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
  AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
  BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
  CAPOTEN, CAPTOPRIL
  CAPTOPRIL, CAPTOPRIL
  CARISOPRODOL AND ASPIRIN, ASPIRIN
  CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
  CHLORPROPAMIDE, CHLORPROPAMIDE
  CHLORZOXAZONE, CHLORZOXAZONE
  CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
  CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
  CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
  CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
  DEXAMETHASONE, DEXAMETHASONE
  DIAZEPAM, DIAZEPAM
  DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
  DISULFIRAM, DISULFIRAM
  DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
  DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  DOXYCYCLINE, DOXYCYCLINE
  FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
  FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
  FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
  HALOPERIDOL, HALOPERIDOL
  HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
  HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
  HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
  HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
  HYDROXYUREA, HYDROXYUREA
  HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
  HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)
  IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
  INDOMETHACIN, INDOMETHACIN
  ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
  LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

FDA data supplied by DrugPatentWatch.com

LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE AND ASPIRIN, ASPIRIN
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
VALPROIC ACID, VALPROIC ACID

PARKE DAVIS

* PARKE DAVIS
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL

* PARKE DAVIS DIV WARNER LAMBERT CO
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTRAX, PRAZEPAM
CEREBYX, FOSPHENYTOIN SODIUM
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLYBAR, CHOLESTYRAMINE
COLY-MYCIN S, COLISTIN SULFATE
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERYC 125, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESTROVIS, QUINESTROL
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EVANS BLUE, EVANS BLUE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HUMATIN, PAROMOMYCIN SULFATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MECLOMEN, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MILONTIN, PHENSUXIMIDE
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
OXAZEPAM, OXAZEPAM
PARACORT, PREDNISONE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PENAPAR-VK, PENICILLIN V POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PITRESSIN TANNATE, VASOPRESSIN TANNATE
POVAN, PYRVINIUM PAMOATE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFALAR, SULFISOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
ZARONTIN, ETHOSUXIMIDE

* PARKE DAVIS LABORATORIES DIV WARNER LAMBERT CO
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL

* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYXIN, CHLORAMPHENICOL
DILANTIN, PHENYTOIN SODIUM
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMPATCH, ESTRADIOL
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
UTICORT, BETAMETHASONE BENZOATE
ZARONTIN, ETHOSUXIMIDE

PARKEDALE

* PARKEDALE PHARMACEUTICALS INC
ACTH, CORTICOTROPIN
ANUSOL HC, HYDROCORTISONE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
HUMATIN, PAROMOMYCIN SULFATE
KETALAR, KETAMINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
PITOCIN, OXYTOCIN
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
SURITAL, THIAMYLAL SODIUM
THEELIN, ESTRONE
VIRA-A, VIDARABINE

PARNELL

* PARNELL PHARMACEUTICALS INC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PEDINOL

* PEDINOL PHARMACAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE

PENNEX

* PENNEX PRODUCTS CO INC
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAP-PROFEN, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CIMETIDINE, CIMETIDINE (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
KETOPROFEN, KETOPROFEN (OTC)
LOPERAMIDE HCL AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEPROBAMATE, MEPROBAMATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TAB-PROFEN, IBUPROFEN (OTC)
THEOPHYLLINE, THEOPHYLLINE
TIOCONAZOLE, TIOCONAZOLE (OTC)

* PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

PERSONAL PRODS

* PERSONAL PRODUCTS CO
DELFEN, NONOXYNOL-9 (OTC)

FDA data supplied by DrugPatentWatch.com

MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT DUAL- PAK, MICONAZOLE NITRATE

PFIPHARMECS
* PFIPHARMECS DIV PFIZER INC
CORTRIL, HYDROCORTISONE
TETRACYN, TETRACYCLINE HYDROCHLORIDE

PFIZER
* PFIZER AGRICULTURAL DIV
ANTIVERT, MECLIZINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
VIAGRA, SILDENAFIL CITRATE
* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
TROVAN, TROVAFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN DIHYDRATE
* PFIZER INC
CEFOBID, CEFOPERAZONE SODIUM
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
LIPITOR, ATORVASTATIN CALCIUM
LITHIUM CARBONATE, LITHIUM CARBONATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIZIDE, POLYTHIAZIDE
PROCARDIA, NIFEDIPINE
RELPAX, ELETRIPTAN HYDROBROMIDE
RENESE, POLYTHIAZIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
UNASYN, AMPICILLIN SODIUM
VFEND, VORICONAZOLE
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
ZITHROMAX, AZITHROMYCIN DIHYDRATE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE
* PFIZER LABORATORIES DIV PFIZER INC
BACITRACIN, BACITRACIN
CARDURA, DOXAZOSIN MESYLATE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM
FOVANE, BENZTHIAZIDE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MITHRACIN, PLICAMYCIN
MODERIL, RESCINNAMINE
NEOBIOTIC, NEOMYCIN SULFATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PERMAPEN, PENICILLIN G BENZATHINE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PROCARDIA XL, NIFEDIPINE
RENESE-R, POLYTHIAZIDE
SINEQUAN, DOXEPIN HYDROCHLORIDE
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TAO, TROLEANDOMYCIN
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
URESE, BENZTHIAZIDE
VANSIL, OXAMNIQUINE
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS INC

FDA data supplied by DrugPatentWatch.com

TAO, TROLEANDOMYCIN
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER PHARMS
* PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
DILANTIN, PHENYTOIN
FEMHRT, ETHINYL ESTRADIOL
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
REZULIN, TROGLITAZONE

PHARM ASSOC
* PHARMACEUTICAL ASSOC INC
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
H-CORT, HYDROCORTISONE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARM FORM
* PHARMACEUTICAL FORMULATIONS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HCL, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)

PHARM SPEC
* PHARMACEUTICAL SPECIALIST ASSOC
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM

PHARM VENTURES
* PHARMACEUTICAL VENTURES LTD
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

PHARMA SERVE NY
* PHARMA SERVE INC SUB TORIGIAN LABORATORIES
AMINOPHYLLINE, AMINOPHYLLINE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMA TEK
* PHARMA TEK INC
AMPHOTERICIN B, AMPHOTERICIN B
BACI-RX, BACITRACIN
BACIIM, BACITRACIN
COLISTIMETHATE, COLISTIMETHATE SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
NEO-RX, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN SULFATE
ZIBA-RX, BACITRACIN ZINC

PHARMACHEMIE
* PHARMACHEMIE BV
CISPLATIN, CISPLATIN
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

PHARMACHEMIE USA
* PHARMACHEMIE USA INC
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM

PHARMACIA
* PHARMACIA CORP
DAYPRO ALTA, OXAPROZIN POTASSIUM
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE

PHARMACIA AND UPJOHN
* PHARMACIA AND UPJOHN CO
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ALBAMYCIN, NOVOBIOCIN SODIUM

FDA data supplied by DrugPatentWatch.com

PRODUCT NAME INDEX LISTED BY APPLICANT

ALPHADROL, FLUPREDNISOLONE
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AXERT, ALMOTRIPTAN MALATE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACIGUENT, BACITRACIN
BACITRACIN, BACITRACIN
BERUBIGEN, CYANOCOBALAMIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CALMURID HC, HYDROCORTISONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CAVERJECT, ALPROSTADIL
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTISONE ACETATE, CORTISONE ACETATE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
CYTOSAR-U, CYTARABINE
DELTA-CORTEF, PREDNISOLONE
DELTASONE, PREDNISONE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIPENTUM, OLSALAZINE SODIUM
DIZAC, DIAZEPAM
DOSTINEX, CABERGOLINE
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLUIDIL, CYCLOTHIAZIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FRAGMIN, DALTEPARIN SODIUM
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HALOTESTIN, FLUOXYMESTERONE
HEMABATE, CARBOPROST TROMETHAMINE
HEPARIN SODIUM, HEPARIN SODIUM
HYLOREL, GUANADREL SULFATE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LONITEN, MINOXIDIL
LUNELLE, ESTRADIOL CYPIONATE
MAOLATE, CHLORPHENESIN CARBAMATE
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MICRONASE, GLYBURIDE
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCOBUTIN, RIFABUTIN
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NEOSAR, CYCLOPHOSPHAMIDE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NORMIFLO, ARDEPARIN SODIUM
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
OXYLONE, FLUOROMETHOLONE
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PSORCON, DIFLORASONE DIACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

FDA data supplied by DrugPatentWatch.com

SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
TOLINASE, TOLAZAMIDE
TOPOSAR, ETOPOSIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TYMTRAN, CERULETIDE DIETHYLAMINE
U-GENCIN, GENTAMICIN SULFATE
UTICILLIN VK, PENICILLIN V POTASSIUM
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANTIN, CEFPODOXIME PROXETIL
VINCASAR PFS, VINCRISTINE SULFATE
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZANOSAR, STREPTOZOCIN
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN CO NUTRITION DIV
ELLENCE, EPIRUBICIN HYDROCHLORIDE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CONSUMER HEALTHCARE
NASALCROM, CROMOLYN SODIUM (OTC)

PHARMADERM

* PHARMADERM DIV ALTANA INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

PHARMAFAIR

* PHARMAFAIR INC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BOROFAIR, ACETIC ACID, GLACIAL
CARBACHOL, CARBACHOL
CHLOROFAIR, CHLORAMPHENICOL
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAFAIR, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KAINAIR, PROPARACAINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
MYDRIAFAIR, TROPICAMIDE
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OCUMYCIN, BACITRACIN ZINC
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC

PHARMAFORCE

* PHARMAFORCE INC
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE

PHARMASEAL

* PHARMASEAL DIV BAXTER HEALTHCARE CORP
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

PHARMATEK

* PHARMATEK INC
NEO-FRADIN, NEOMYCIN SULFATE

FDA data supplied by DrugPatentWatch.com

PHARMATON
* PHARMATON LTD
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE

PHARMAVITE
* PHARMAVITE PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE

PHARMERAL
* PHARMERAL INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
SULFISOXAZOLE, SULFISOXAZOLE

PHARMEX PRODS
* PHARMEX PRODUCTS INC
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE

PHARMION
* PHARMION CORP
INNOHEP, TINZAPARIN SODIUM

PHARMOS
* PHARMOS CORP
LOTEMAX, LOTEPREDNOL ETABONATE

PHOENIX LABS NY
* PHOENIX LABORATORIES INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DEXAMETHASONE, DEXAMETHASONE
ISONIAZID, ISONIAZID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

PHYS PRODS VA
* PHYSICIANS PRODUCTS CO INC DIV INTERNATIONAL LATEX CORP
HYSERPIN, RAUWOLFIA SERPENTINA

PIERRE FABRE
* PIERRE FABRE MEDICAMENT
ETOPOSIDE, ETOPOSIDE

PIONEER PHARMS
* PIONEER PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
INDOMETHACIN, INDOMETHACIN
METHOCARBAMOL, METHOCARBAMOL
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)

PLANTEX
* PLANTEX USA INC DIV IKAPHARM INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE

POHL BOSKAMP
* G POHL BOSKAMP GMBH AND CO
NITRO IV, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN

POINT HOLDINGS
* POINT HOLDINGS INC
ETODOLAC, ETODOLAC

POLYMEDICA
* POLYMEDICA INDUSTRIES INC
ANESTACON, LIDOCAINE HYDROCHLORIDE
NEOPAP, ACETAMINOPHEN (OTC)
PROMETHACON, PROMETHAZINE HYDROCHLORIDE

POPULATION COUNCIL
* POPULATION COUNCIL
COPPER T MODEL TCU 380A, COPPER
NORPLANT, LEVONORGESTREL
* POPULATION COUNCIL CENTER FOR BIOMEDICAL RESEARCH
NORPLANT II, LEVONORGESTREL

POYTHRESS
* WILLIAM P POYTHRESS AND CO INC
BENSULFOID, SULFUR

PROCTER AND GAMBLE

FDA data supplied by DrugPatentWatch.com

* PROCTER AND GAMBLE CO
DANTRIUM, DANTROLENE SODIUM
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBL
ACTONEL, RISEDRONATE SODIUM
ASACOL, MESALAMINE
DANTRIUM, DANTROLENE SODIUM
DIDRONEL, ETIDRONATE DISODIUM
FURADANTIN, NITROFURANTOIN
IVADANTIN, NITROFURANTOIN SODIUM
LABID, THEOPHYLLINE
MACROBID, NITROFURANTOIN
NYSERT, NYSTATIN
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
SARENIN, SARALASIN ACETATE

PROF DSPLS
* PROFESSIONAL DISPOSABLES INC
HEXASCRUB, HEXACHLOROPHENE

PROMETHEUS LABS
* PROMETHEUS LABORATORIES INC
HELIDAC, BISMUTH SUBSALICYLATE
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
RIDAURA, AURANOFIN
TRANDATE, LABETALOL HYDROCHLORIDE
ZYLOPRIM, ALLOPURINOL

PROTER
* PROTER LABORATORY SPA
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

PURDUE FREDERICK
* PURDUE FREDERICK CO
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
DHC PLUS, ACETAMINOPHEN
MS CONTIN, MORPHINE SULFATE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHYLLOCONTIN, AMINOPHYLLINE
SULFABID, SULFAPHENAZOLE
T-PHYL, THEOPHYLLINE
UNIPHYL, THEOPHYLLINE

PURDUE PHARMA LP
* PURDUE PHARMA LP
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM
* PUREPAC PHARMACEUTICAL CO DIV PUREPAC INC
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPTOPRIL, CAPTOPRIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NIFEDIPINE, NIFEDIPINE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFISOXAZOLE, SULFISOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

PVT FORM
* PRIVATE FORMULATIONS INC
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
BENZTHIAZIDE, BENZTHIAZIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
FEMOGEN, ESTROGENS, ESTERIFIED
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
MEPROBAMATE, MEPROBAMATE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

** Q **

QLT
* QLT INC
VISUDYNE, VERTEPORFIN

QUAD PHARMS
* QUAD PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM

FDA data supplied by DrugPatentWatch.com

AZATHIOPRINE, AZATHIOPRINE SODIUM
BACITRACIN, BACITRACIN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZOXIDE, DIAZOXIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLUPHENAZINE, FLUPHENAZINE DECANOATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE SODIUM PHOSPHATE, HYDROCORTISONE SODIUM PHOSPHATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
ISONIAZID, ISONIAZID
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCURINE IODIDE, METOCURINE IODIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NITROGLYCERIN, NITROGLYCERIN
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROTAMINE SULFATE, PROTAMINE SULFATE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE

QUANTUM PHARMICS
* QUANTUM PHARMICS LTD
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LORAZ, LORAZEPAM
MECLODIUM, MECLOFENAMATE SODIUM
MINODYL, MINOXIDIL
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
TEMAZ, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZAXOPAM, OXAZEPAM

QUESTCOR PHARMS
* QUESTCOR PHARMACEUTICALS INC
ETHAMOLIN, ETHANOLAMINE OLEATE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
H.P. ACTHAR GEL, CORTICOTROPIN
INULIN AND SODIUM CHLORIDE, INULIN

** R **

R AND D LABS
* R AND D LABORATORIES INC
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX

R AND S PHARMA
* R AND S PHARMA INC
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE

R R REGISTRATIONS
* R AND R REGISTRATIONS
THYROSAFE, POTASSIUM IODIDE (OTC)

FDA data supplied by DrugPatentWatch.com

RACHELLE
* RACHELLE LABORATORIES INC
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE

RANBAXY
* RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
* RANBAXY PHARMACEUTICALS INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ISOTRETINOIN, ISOTRETINOIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SECONAL SODIUM, SECOBARBITAL SODIUM

RATIOPHARM
* RATIOPHARM GMBH AND CO ARZNEIMITTEL
SUCRALFATE, SUCRALFATE

RECKITT BENCKISER
* RECKITT BENCKISER PHARMACEUTICALS INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBUTEX, BUPRENORPHINE HYDROCHLORIDE

REED AND CARNRICK
* REED AND CARNRICK PHARMACEUTICALS DIV BLOCK DRUG CO INC
KWELL, LINDANE

RELIANT PHARMS
* RELIANT PHARMACEUTICALS LLC
AXID, NIZATIDINE

RES INDS
* RESEARCH INDUSTRIES CORP
RIMSO-50, DIMETHYL SULFOXIDE

REXALL
* REXALL DRUG CO
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE

REXAR
* REXAR PHARMACAL
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE

RHODIA
* RHODIA LTD
ISOFLURANE, ISOFLURANE

ROACO
* TJ ROACO LTD
BETADERM, BETAMETHASONE VALERATE

ROBINS AH
* AH ROBINS CO
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DOPRAM, DOXAPRAM HYDROCHLORIDE
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
QUINIDEX, QUINIDINE SULFATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBIMYCIN, ERYTHROMYCIN
ROBINUL, GLYCOPYRROLATE
TENATHAN, BETHANIDINE SULFATE

ROCHE
* HOFFMANN LA ROCHE INC
ARFONAD, TRIMETHAPHAN CAMSYLATE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID

FDA data supplied by DrugPatentWatch.com

BUMEX, BUMETANIDE
COACTIN, AMDINOCILLIN
COPEGUS, RIBAVIRIN
DEMADEX, TORSEMIDE
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
FANSIDAR, PYRIMETHAMINE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
HIVID, ZALCITABINE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KONAKION, PHYTONADIONE
KYTRIL, GRANISETRON HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LORFAN, LEVALLORPHAN TARTRATE
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
NIPRIDE, SODIUM NITROPRUSSIDE
NOLUDAR, METHYPRYLON
QUARZAN, CLIDINIUM BROMIDE
RIMADYL, CARPROFEN
RIMIFON, ISONIAZID
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
SOLATENE, BETA-CAROTENE
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TARACTAN, CHLORPROTHIXENE
TASMAR, TOLCAPONE
TEGISON, ETRETINATE
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
VALIUM, DIAZEPAM
VALRELEASE, DIAZEPAM
VERSED, MIDAZOLAM HYDROCHLORIDE
VESANOID, TRETINOIN

ROCHE GLOBAL DEV
* ROCHE GLOBAL DEVELOPMENT DIV SYNTEX (USA) LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROERIG
* ROERIG DIV PFIZER INC
ATARAX, HYDROXYZINE HYDROCHLORIDE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GEOPEN, CARBENICILLIN DISODIUM
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
SUSTAIRE, THEOPHYLLINE

ROMARK
* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

RORER
* RORER PHARMACEUTICAL CORP SUB RORER GROUP
NITROL, NITROGLYCERIN

ROSS LABS
* ROSS LABORATORIES DIV ABBOTT LABORATORIES
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
* ROSS LABORATORIES DIV ABBOTT LABORATORIES INC
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
SURVANTA, BERACTANT

ROXANE
* ROXANE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AZATHIOPRINE, AZATHIOPRINE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IPATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTULOSE, LACTULOSE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
PIROXICAM, PIROXICAM
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAZOLAM, TRIAZOLAM

ROYCE LABS
* ROYCE LABORATORIES INC
HALOPERIDOL, HALOPERIDOL
MINOXIDIL, MINOXIDIL

** S **

SABEX 2002
* SABEX 2002 INC
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID

SALIX PHARMS
* SALIX PHARMACEUTICALS INC
COLAZAL, BALSALAZIDE DISODIUM

SANKYO
* SANKYO PHARMA INC
BENICAR, OLMESARTAN MEDOXOMIL
WELCHOL, COLESEVELAM HYDROCHLORIDE
* SANKYO USA CORP
BANAN, CEFPODOXIME PROXETIL
PRELAY, TROGLITAZONE

SANO
* SANO CORP
NICOTINE, NICOTINE

SANOFI
* SANOFI RESEARCH DIV SANOFI INC
ELOXATIN, OXALIPLATIN

FDA data supplied by DrugPatentWatch.com

SANOFI SYNTHELABO
* SANOFI SYNTHELABO INC
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
CALCIPARINE, HEPARIN CALCIUM
CHEMET, SUCCIMER
DANOCRINE, DANAZOL
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
INOCOR, INAMRINONE LACTATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
LOTUSATE, TALBUTAL
MYTELASE, AMBENONIUM CHLORIDE
NEGGRAM, NALIDIXIC ACID
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
SKELID, TILUDRONATE DISODIUM
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TORNALATE, BITOLTEROL MESYLATE
TRANCOPAL, CHLORMEZANONE
WINSTROL, STANOZOLOL

SANTEN
* SANTEN INC
ALAMAST, PEMIROLAST POTASSIUM
QUIXIN, LEVOFLOXACIN

SANTEN OY
* SANTEN OY
BETIMOL, TIMOLOL

SAVAGE LABS
* SAVAGE LABORATORIES INC DIV ALTANA INC
ALPHATREX, BETAMETHASONE DIPROPIONATE
AXOTAL, ASPIRIN
BETATREX, BETAMETHASONE VALERATE
CHYMEX, BENTIROMIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DITATE-DS, ESTRADIOL VALERATE
ETHIODOL, ETHIODIZED OIL
FLUOTREX, FLUOCINOLONE ACETONIDE
GVS, GENTIAN VIOLET
K-LEASE, POTASSIUM CHLORIDE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN
NYSTEX, NYSTATIN
PANDEL, HYDROCORTISONE PROBUTATE
RUVITE, CYANOCOBALAMIN
SATRIC, METRONIDAZOLE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
XYLO-PFAN, XYLOSE

SCHEIN
* SCHEIN PHARMACEUTICAL INC
INFED, IRON DEXTRAN
PROGESTERONE, PROGESTERONE

SCHERER LABS
* SCHERER LABORATORIES INC
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE

SCHERER RP
* RP SCHERER CORP
NIFEDIPINE, NIFEDIPINE
* RP SCHERER NORTH AMERICA
NIFEDIPINE, NIFEDIPINE
THEOPHYLLINE, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID
* RP SCHERER NORTH AMERICA DIV RP SCHERER CORP
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
THEOPHYLLINE-SR, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID

SCHERING
* SCHERING CORP
CLARINEX, DESLORATADINE
CLARITIN REDITABS, LORATADINE

FDA data supplied by DrugPatentWatch.com

CLARITIN, LORATADINE
CLARITIN-D 24 HOUR, LORATADINE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
IMDUR, ISOSORBIDE MONONITRATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
QUINORA, QUINIDINE SULFATE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
TEMODAR, TEMOZOLOMIDE
THEO-DUR, THEOPHYLLINE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE

* SCHERING CORP SUB SCHERING PLOUGH CORP
AKRINOL, ACRISORCIN
BETAPAR, MEPREDNISONE
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CLARITIN, LORATADINE
CLARITIN-D, LORATADINE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
ELOCON, MOMETASONE FUROATE
ESTINYL, ETHINYL ESTRADIOL
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
GARAMYCIN, GENTAMICIN SULFATE
HYPERSTAT, DIAZOXIDE
LOTRIMIN, CLOTRIMAZOLE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
MIRADON, ANISINDIONE
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NETROMYCIN, NETILMICIN SULFATE
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
OPTIMINE, AZATADINE MALEATE
ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
PAXIPAM, HALAZEPAM
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
PRANTAL, DIPHEMANIL METHYLSULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
RELA, CARISOPRODOL
SODIUM SULAMYD, SULFACETAMIDE SODIUM
THEOVENT, THEOPHYLLINE
TINDAL, ACETOPHENAZINE MALEATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRINALIN, AZATADINE MALEATE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE

SCHERING PLOUGH

* SCHERING PLOUGH CORP
CLARINEX, DESLORATADINE
NASONEX, MOMETASONE FUROATE MONOHYDRATE

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRIMIN, CLOTRIMAZOLE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)

SCHERING PLOUGH RES

* SCHERING PLOUGH RESEARCH INSTITUTE
LOTRISONE, BETAMETHASONE DIPROPIONATE
REBETOL, RIBAVIRIN

SCHWARZ

* SCHWARZ GMBH

FDA data supplied by DrugPatentWatch.com

MONOKET, ISOSORBIDE MONONITRATE

SCHWARZ PHARMA
* SCHWARZ PHARMA AG
EDEX, ALPROSTADIL
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE
* SCHWARZ PHARMA INC
CO-GESIC, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DILATRATE-SR, ISOSORBIDE DINITRATE
EPIFOAM, HYDROCORTISONE ACETATE
LEVATOL, PENBUTOLOL SULFATE
PREDNICEN-M, PREDNISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNIVASC, MOEXIPRIL HYDROCHLORIDE

SCIOS
* SCIOS INC
NATRECOR, NESIRITIDE

SCS
* SCS PHARMACEUTICALS
ATENOLOL, ATENOLOL
CARBIDOPA AND LEVODOPA, CARBIDOPA
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM

SEPRACOR
* SEPRACOR INC
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SEPTODONT
* SEPTODONT INC
OCTOCAINE, EPINEPHRINE

SERONO
* SERONO LABORATORIES INC
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
FERTINEX, UROFOLLITROPIN
GEREF, SERMORELIN ACETATE
GONAL-F, FOLLITROPIN ALFA
GONAL-F, FOLLITROPIN ALFA/BETA
METRODIN, UROFOLLITROPIN
PERGONAL, MENOTROPINS (FSH;LH)
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT

SERONO INC
* SERONO INC
CETROTIDE, CETRORELIX
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
OVIDREL, CHORIOGONADOTROPIN ALFA

SHERWOOD MEDCL
* SHERWOOD MEDICAL CO
ACTIN-N, NITROFURAZONE

SHIONOGI
* SHIONOGI USA INC
UROBAK, SULFAMETHOXAZOLE
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE

SHIRE LABS
* SHIRE LABORATORIES INC
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE
ADDERALL 7.5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
BANTHINE, METHANTHELINE BROMIDE
DOPAR, LEVODOPA
ETHMOZINE, MORICIZINE HYDROCHLORIDE
FURACIN, NITROFURAZONE
FUROXONE, FURAZOLIDONE
PENTASA, MESALAMINE
PRO-BANTHINE, PROPANTHELINE BROMIDE
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SUPPRELIN, HISTRELIN ACETATE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE

SHIRE PHARM
* SHIRE PHARMACEUTICAL DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE

FDA data supplied by DrugPatentWatch.com

ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ANOQUAN, ACETAMINOPHEN
CARBATROL, CARBAMAZEPINE
FURACIN, NITROFURAZONE
PROAMATINE, MIDODRINE HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD

SHIRE RICHWOOD
* SHIRE RICHWOOD INC
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE

SIDMAK LABS
* SIDMAK LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ANTABUSE, DISULFIRAM
CYCLOSPORINE, CYCLOSPORINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NAPROXEN, NAPROXEN
SURMONTIL, TRIMIPRAMINE MALEATE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

SIDMAK LABS NJ
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FLURBIPROFEN, FLURBIPROFEN
GLIPIZIDE, GLIPIZIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SIEGFRIED
* SIEGFRIED LTD
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

SIGHT PHARMS
* SIGHT PHARMACEUTICALS INC
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)

SIGMA TAU
* SIGMA TAU PHARMACEUTICALS INC
CARNITOR, LEVOCARNITINE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SILARX
* SILARX PHARMACEUTICALS INC
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

SIRIUS LABS
* SIRIUS LABORATORIES INC
TEXACORT, HYDROCORTISONE

SKYEPHARMA
* SKYEPHARMA INC

FDA data supplied by DrugPatentWatch.com

DEPOCYT, CYTARABINE

SMITH AND NEPHEW
* SMITH AND NEPHEW SOLOPAK DIV SMITH AND NEPHEW
AMINOPHYLLINE, AMINOPHYLLINE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SOAPCO
* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOLA BARNES HIND
* SOLA BARNES HIND
ALPHA CHYMAR, CHYMOTRYPSIN
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GAMENE, LINDANE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE

SOLOPAK
* SOLOPAK LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DROPERIDOL, DROPERIDOL
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
* SOLOPAK MEDICAL PRODUCTS INC
CYANOCOBALAMIN, CYANOCOBALAMIN
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SOLVAY
* SOLVAY PHARMACEUTICALS
AQUATAG, BENZTHIAZIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ATROPINE, ATROPINE
BALNEOL-HC, HYDROCORTISONE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CIN-QUIN, QUINIDINE SULFATE
CORTENEMA, HYDROCORTISONE
CURRETAB, MEDROXYPROGESTERONE ACETATE
DERMACORT, HYDROCORTISONE
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DUPHALAC, LACTULOSE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
GYNOREST, DYDROGESTERONE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LACTULOSE, LACTULOSE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOTABS, LITHIUM CARBONATE
LUVOX, FLUVOXAMINE MALEATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
ORASONE, PREDNISONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PORTALAC, LACTULOSE
PROVAL #3, ACETAMINOPHEN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
R-P MYCIN, ERYTHROMYCIN
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RETET, TETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

ROWASA, MESALAMINE
S.A.S.-500, SULFASALAZINE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SPRX-3, PHENDIMETRAZINE TARTRATE
SULSOXIN, SULFISOXAZOLE
SYMADINE, AMANTADINE HYDROCHLORIDE
TORA, PHENTERMINE HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRIACORT, TRIAMCINOLONE ACETONIDE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
VERMIDOL, PIPERAZINE CITRATE
ZIDE, HYDROCHLOROTHIAZIDE

SOLVAY PHARMA
* SOLVAY PHARMA INC
ACEON, PERINDOPRIL ERBUMINE

SOMERSET
* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

SORIN
* SORIN BIOMEDICA SPA
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131

SPEAR PHARMS
* SPEAR PHARMACEUTICALS INC
TRETINOIN, TRETINOIN

SPERTI
* SPERTI DRUG PRODUCTS INC
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

SSL INTL
* SSL INTERNATIONAL
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

STANLABS PHARM
* STANLABS PHARMACEUTICAL CO SUB SIMPAK CORP
MEPROBAMATE, MEPROBAMATE

STAR PHARMS FL
* STAR PHARMACEUTICALS INC
VIRILON, METHYLTESTOSTERONE

STASON
* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

STERIS
* STERIS LABORATORIES INC
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COBAVITE, CYANOCOBALAMIN
CORTICOTROPIN, CORTICOTROPIN
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISODIUM EDETATE, EDETATE DISODIUM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDETATE DISODIUM, EDETATE DISODIUM
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRONE, ESTRONE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE, FENTANYL CITRATE
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
MVC PLUS, ASCORBIC ACID
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OTOCORT, HYDROCORTISONE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TROPICAMIDE, TROPICAMIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

STERLING
* STERLING HEALTH DIV STERLING WINTHROP INC
BRONKAID MIST, EPINEPHRINE (OTC)

STERLING WINTHROP
* STERLING WINTHROP INC
AFAXIN, VITAMIN A PALMITATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

STEVENS J
* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LIOTRIX (T4;T3)

STIEFEL
* STIEFEL LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DUAC, BENZOYL PEROXIDE
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
SCABENE, LINDANE
STIE-CORT, HYDROCORTISONE

STORZ
* STORZ OPHTHALMICS INC SUB AMERICAN CYANAMID CO
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE

STUART PHARMS
* STUART PHARMACEUTICALS DIV ICI AMERICAS
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE

SUMMERS
* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUPERGEN
* SUPERGEN INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
MITOMYCIN, MITOMYCIN
MYTOZYTREX, MITOMYCIN
NIPENT, PENTOSTATIN

SUPERPHARM
* SUPERPHARM CORP

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LOGEN, ATROPINE SULFATE
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFASALAZINE, SULFASALAZINE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE

SUPPOSITORIA
* SUPPOSITORIA LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)

SWEDISH ORPHAN
* SWEDISH ORPHAN AB
ORFADIN, NITISINONE

SYNCOR PHARMS
* SYNCOR PHARMACEUTICALS INC
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
SODIUM IODIDE I 123, SODIUM IODIDE, I-123

SYNTEX (USA) INC LLC
* SYNTEX (USA) INC LLC
AEROBID, FLUNISOLIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
EC-NAPROSYN, NAPROXEN
EVEX, ESTROGENS, ESTERIFIED
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
NAPROSYN, NAPROXEN
TICLID, TICLOPIDINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

SYNTHON PHARMS
* SYNTHON PHARMACEUTICALS LTD
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE

SYOSSET
* SYOSSET LABORATORIES INC
E-SOLVE 2, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE

** T **

TABLICAPS
* TABLICAPS INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL

FDA data supplied by DrugPatentWatch.com

RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
STILBESTROL, DIETHYLSTILBESTROL

TAKEDA
* TAKEDA CHEMICAL INDUSTRIES LTD
ACTOS, PIOGLITAZONE HYDROCHLORIDE
CERADON, CEFOTIAM HYDROCHLORIDE

TAKEDA PHARMS NA
* TAKEDA PHARMACEUTICALS NORTH AMERICA INC
ACTOS, PIOGLITAZONE HYDROCHLORIDE

TAP PHARM
* TAP PHARMACEUTICAL PRODUCTS INC
CEFMAX, CEFMENOXIME HYDROCHLORIDE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
SPECTRACEF, CEFDITOREN PIVOXIL

TARO
* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
KETOCONAZOLE, KETOCONAZOLE
* TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
WARFARIN SODIUM, WARFARIN SODIUM
* TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORACORT, TRIAMCINOLONE ACETONIDE
ORALONE, TRIAMCINOLONE ACETONIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
THEOPHYLLINE, THEOPHYLLINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS
* TARO PHARMACEUTICAL INDUSTRIES LTD
CARBAMAZEPINE, CARBAMAZEPINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC

TAYLOR
* TAYLOR PHARMACEUTICALS
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE

TAYLOR PHARMA
* TAYLOR PHARMACAL CO
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

TECHNILAB
* TECHNILAB INC
ACILAC, LACTULOSE
LAXILOSE, LACTULOSE

TEIKOKU PHARMA USA

FDA data supplied by DrugPatentWatch.com

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TEVA

* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CALCITRIOL, CALCITRIOL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CINOXACIN, CINOXACIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
COPAXONE, GLATIRAMER ACETATE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
CYCLACILLIN, CYCLACILLIN
DELCOBESE, AMPHETAMINE ADIPATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLUCAMIDE, CHLORPROPAMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HY-PAM "25", HYDROXYZINE PAMOATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE

FDA data supplied by DrugPatentWatch.com

INDO-LEMMON, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LOVASTATIN, LOVASTATIN
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPRIAM, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYCO-TRIACET II, NYSTATIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTHYLLINE, DYPHYLLINE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NIZATIDINE, NIZATIDINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORAP, PIMOZIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXAPROZIN, OXAPROZIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PERGOLIDE MESYLATE, PERGOLIDE MESYLATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFANILAMIDE, SULFANILAMIDE
SULINDAC, SULINDAC
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TORSEMIDE, TORSEMIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIACET, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE

THERAKOS
* THERAKOS INC
UVADEX, METHOXSALEN

TOPIDERM
* TOPIDERM INC
HYDROCORTISONE, HYDROCORTISONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TORCH
* TORCH LABORATORIES INC
H-CORT, HYDROCORTISONE

TORPHARM
* TORPHARM INC

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
KETOCONAZOLE, KETOCONAZOLE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

TRIGEN
* TRIGEN LABORATORIES INC
INDAPAMIDE, INDAPAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

TX BIOTECH
* TEXAS BIOTECHNOLOGY CORP
ARGATROBAN, ARGATROBAN

TYCO HLTHCARE
* TYCO HEALTHCARE GROUP LP
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE

** U **

UCB
* UCB PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KEPPRA, LEVETIRACETAM
LORTAB, ACETAMINOPHEN
THEO-24, THEOPHYLLINE

UDL
* UDL LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FOLIC ACID, FOLIC ACID
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
VALPROIC ACID, VALPROIC ACID

UNIMED
* UNIMED INC
MARINOL, DRONABINOL

UNIMED PHARMS
* UNIMED PHARMACEUTICALS INC
ANADROL-50, OXYMETHOLONE
ANDROGEL, TESTOSTERONE
PROMETRIUM, PROGESTERONE

UNITED GUARDIAN
* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP
* UNITED THERAPEUTICS CORP
REMODULIN, TREPROSTINIL SODIUM

UNIV AZ CANCER CTR
* UNIV ARIZONA CANCER CENTER
ACTINEX, MASOPROCOL

UPSHER SMITH
* UPSHER SMITH LABORATORIES INC
DEXAMETHASONE, DEXAMETHASONE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NIACOR, NIACIN
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREDNISONE, PREDNISONE
PREVALITE, CHOLESTYRAMINE
SORINE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE

US ARMY
* UNITED STATES ARMY OFFICE SURGEON GENERAL

FDA data supplied by DrugPatentWatch.com

ATROPINE SULFATE, ATROPINE SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
* US ARMY MEDICAL RESEARCH MATERIEL COMMAND
ATNAA, ATROPINE
DIAZEPAM, DIAZEPAM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER

US ARMY WALTER REED
* UNITED STATES ARMY WALTER REED ARMY INSTITUTE RESEARCH
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE

US CHEM
* US CHEMICAL MARKETING GROUP INC
MEDIGESIC PLUS, ACETAMINOPHEN

US SURGCL
* UNITED STATES SURGICAL DIV TYCO HEALTHCARE GROUP LP
LYMPHAZURIN, ISOSULFAN BLUE

USL PHARMA
* USL PHARMA INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETOHEXAMIDE, ACETOHEXAMIDE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOFIBRATE, CLOFIBRATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
ESTRADIOL, ESTRADIOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM, LORAZEPAM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PRAZEPAM, PRAZEPAM
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VALPROIC ACID, VALPROIC ACID
WARFARIN SODIUM, WARFARIN SODIUM

** V **

VALE
* VALE CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
SERPATE, RESERPINE

VANGARD
* VANGARD LABORATORIES INC DIV MIDWAY MEDICAL CO
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
TOLBUTAMIDE, TOLBUTAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VERSAPHARM
* VERSAPHARM INC
RIFAMPIN, RIFAMPIN

VERUM PHARMS
* VERUM PHARMACEUTICALS INC
BROMFED-DM, BROMPHENIRAMINE MALEATE

VESTAL LABS
* VESTAL LABORATORIES DIV CHEMED CORP
SEPTISOL, HEXACHLOROPHENE

VINTAGE PHARMS
* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LACTULOSE, LACTULOSE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
QUINIDINE SULFATE, QUINIDINE SULFATE
SULFASALAZINE, SULFASALAZINE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VITARINE
* VITARINE PHARMACEUTICALS INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GLUTETHIMIDE, GLUTETHIMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPIVITE, RESERPINE
SULFISOXAZOLE, SULFISOXAZOLE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VITAMIN D, ERGOCALCIFEROL

VIVUS
* VIVUS INC
MUSE, ALPROSTADIL

** W **

WALLACE LABS
* WALLACE LABORATORIES DIV CARTER WALLACE INC
AQUATENSEN, METHYCLOTHIAZIDE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
COLONAID, ATROPINE SULFATE
DEPEN, PENICILLAMINE
DIUTENSEN-R, METHYCLOTHIAZIDE
DORAL, QUAZEPAM
FELBATOL, FELBAMATE
HYZYD, ISONIAZID
LUFYLLIN, DYPHYLLINE
MILTOWN, MEPROBAMATE
MYLAXEN, HEXAFLUORENIUM BROMIDE

FDA data supplied by DrugPatentWatch.com

NEOPASALATE, AMINOSALICYLATE SODIUM
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
SOMA, CARISOPRODOL
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
VERTAVIS, VERATRUM VIRIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
WAMPOCAP, NIACIN

WALLACE PHARMS
* WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC
DORMATE, MEBUTAMATE
MEPROSPAN, MEPROBAMATE
MICRAININ, ASPIRIN
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILTOWN, MEPROBAMATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
* WALLACE PHARMACEUTICALS DIV MEDPOINTE HEALTHCARE INC
ASTELIN, AZELASTINE HYDROCHLORIDE

WARNER CHILCOTT
* WARNER CHILCOTT BERMUDA LTD
CHOLEDYL SA, OXTRIPHYLLINE
DORYX, DOXYCYCLINE HYCLATE
* WARNER CHILCOTT DIV WARNER LAMBERT CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DURAQUIN, QUINIDINE GLUCONATE
ERYPAR, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LORAZEPAM, LORAZEPAM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE, SPIRONOLACTONE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* WARNER CHILCOTT INC
CARBAMAZEPINE, CARBAMAZEPINE
CYANOCOBALAMIN, CYANOCOBALAMIN
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ERYC, ERYTHROMYCIN
ESTRACE, ESTRADIOL
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULINDAC, SULINDAC
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

WARNER LAMBERT
* WARNER LAMBERT CO
NIX, PERMETHRIN (OTC)
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

WARRICK PHARMS
* WARRICK PHARMACEUTICALS
CROMOLYN SODIUM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

WATSON LAB
* WATSON LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

FOLIC ACID, FOLIC ACID
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LITHIUM CARBONATE, LITHIUM CARBONATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NIACIN, NIACIN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PRIMIDONE, PRIMIDONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINATIME, QUINIDINE GLUCONATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
WARFARIN SODIUM, WARFARIN SODIUM

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
METFORMIN HCL, METFORMIN HYDROCHLORIDE
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORCO, ACETAMINOPHEN
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

* WATSON LABORATORIES INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETOHEXAMIDE, ACETOHEXAMIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALORA, ESTRADIOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ANDRODERM, TESTOSTERONE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREVICON 21-DAY, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

BREVICON 28-DAY, ETHINYL ESTRADIOL
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COL-PROBENECID, COLCHICINE
CORTISONE ACETATE, CORTISONE ACETATE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GERIMAL, ERGOLOID MESYLATES
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM, LORAZEPAM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICROZIDE, HYDROCHLOROTHIAZIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MORPHINE SULFATE, MORPHINE SULFATE
NALIDIXIC ACID, NALIDIXIC ACID
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NIZATIDINE, NIZATIDINE
NORCO, ACETAMINOPHEN
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL, MESTRANOL
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PEMOLINE, PEMOLINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBEN-C, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL

* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS (UTAH)

* WATSON LABORATORIES INC
NOR-QD, NORETHINDRONE

WATSON PHARMS

* WATSON PHARMACEUTICALS INC
ACTIGALL, URSODIOL

WE PHARMS

* WE PHARMACEUTICALS INC
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE

WELLSPRING PHARM

* WELLSPRING PHARMACEUTICAL CORP
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
DYRENIUM, TRIAMTERENE

WENDT

* WENDT LABORATORIES INC
NITROFURAZONE, NITROFURAZONE

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE, ACETAMINOPHEN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

WESTWARD
* WESTWARD PHARMACEUTICAL CORP
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM

WESTWOOD SQUIBB
* WESTWOOD SQUIBB PHARMACEUTICALS INC
CAPITROL, CHLOROXINE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FLEXICORT, HYDROCORTISONE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOTEX, HALOPROGIN
LAC-HYDRIN, AMMONIUM LACTATE
MYCOSTATIN, NYSTATIN
STATICIN, ERYTHROMYCIN
T-STAT, ERYTHROMYCIN
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
WESTCORT, HYDROCORTISONE VALERATE

WHARTON LABS
* WHARTON LABORATORIES INC DIV US ETHICALS
VITAMIN A, VITAMIN A PALMITATE

WHITBY
* WHITBY PHARMACEUTICALS INC
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE

WHITEHALL ROBINS
* WHITEHALL ROBINS HEALTHCARE DIV AMERICAN HOME PRODUCTS CORP
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
PRIMATENE MIST, EPINEPHRINE (OTC)

WHITEWORTH TOWN PLSN
* WHITEWORTH TOWNE PAULSEN INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
H.R.-50, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
NITROFURANTOIN, NITROFURANTOIN
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM

WOCKHARDT
* WOCKHARDT AMERICAS INC
CAPTOPRIL, CAPTOPRIL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* WOCKHARDT LTD
NIACIN, NIACIN

WOMEN FIRST HLTHCARE
* WOMEN FIRST HEALTHCARE INC
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
EQUAGESIC, ASPIRIN
ESCLIM, ESTRADIOL
ORTHO-EST, ESTROPIPATE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
VANIQA, EFLORNITHINE HYDROCHLORIDE
WYGESIC, ACETAMINOPHEN

WOMENS CAPITAL
* WOMENS CAPITAL CORP
PLAN B, LEVONORGESTREL

WYETH AYERST
* WYETH AYERST LABORATORIES
A.P.L., GONADOTROPIN, CHORIONIC
ALESSE, ETHINYL ESTRADIOL
ANSOLYSEN, PENTOLINIUM TARTRATE
ATIVAN, LORAZEPAM
ATROMID-S, CLOFIBRATE
AYGESTIN, NORETHINDRONE ACETATE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CORDARONE, AMIODARONE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLAPEN-W, CYCLACILLIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EQUANIL, MEPROBAMATE
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTROGENIC SUBSTANCE, ESTRONE
FACTREL, GONADORELIN HYDROCHLORIDE
FLUOTHANE, HALOTHANE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
ISORDIL, ISOSORBIDE DINITRATE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LODINE XL, ETODOLAC
LODINE, ETODOLAC
MAZANOR, MAZINDOL
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MYLOTARG, GEMTUZUMAB OZOGAMICIN
NALOXONE, NALOXONE HYDROCHLORIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORPLANT SYSTEM IN PLASTIC CONTAINER, LEVONORGESTREL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
ORUDIS, KETOPROFEN
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OXYTOCIN, OXYTOCIN
PATHOCIL, DICLOXACILLIN SODIUM
PEN-VEE K, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PEPTAVLON, PENTAGASTRIN
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PLEGINE, PHENDIMETRAZINE TARTRATE
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN), ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROKETAZINE, CARPHENAZINE MALEATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
RAPAMUNE, SIROLIMUS
ROBITET, TETRACYCLINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SONATA, ZALEPLON
SPARINE, PROMAZINE HYDROCHLORIDE
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
TRECATOR-SC, ETHIONAMIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYDASE, HYALURONIDASE
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE
ZOSYN, PIPERACILLIN SODIUM

* WYETH AYERST RESEARCH
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
ORUVAIL, KETOPROFEN
RAPAMUNE, SIROLIMUS

WYETH CONS

FDA data supplied by DrugPatentWatch.com

* WYETH CONSUMER HEALTHCARE
  ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
  ADVIL COLD AND SINUS, IBUPROFEN (OTC)
  ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
  ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
  ADVIL, IBUPROFEN (OTC)
  ALAVERT, LORATADINE (OTC)
  AXID AR, NIZATIDINE (OTC)
  CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
  CHILDREN'S ADVIL, IBUPROFEN
  CHILDREN'S ADVIL, IBUPROFEN (OTC)
  CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
  DIMETANE, BROMPHENIRAMINE MALEATE
  DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
  DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
  JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
  ORUDIS KT, KETOPROFEN (OTC)
  PEDIATRIC ADVIL, IBUPROFEN (OTC)

** X **

XANODYNE PHARM
* XANODYNE PHARMACAL INC
  AMICAR, AMINOCAPROIC ACID
  LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

XCEL PHARM
* XCEL PHARMACEUTICALS INC
  MIGRANAL, DIHYDROERGOTAMINE MESYLATE

XCEL PHARMS
* XCEL PHARMACEUTICALS
  D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
  DIASTAT, DIAZEPAM
  MYSOLINE, PRIMIDONE

XTTRIUM
* XTTRIUM LABORATORIES INC
  DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
  EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
  TURGEX, HEXACHLOROPHENE

** Y **

YAMANOUCHI
* YAMANOUCHI EUROPE BV
  LOCOID, HYDROCORTISONE BUTYRATE

YOSHITOMI
* YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD
  CEPHALEXIN, CEPHALEXIN

** Z **

ZAMBON
* ZAMBON CORP
  MONUROL, FOSFOMYCIN TROMETHAMINE

ZENITH GOLDLINE
* ZENITH GOLDLINE LABORATORIES INC
  METFORMIN HCL, METFORMIN HYDROCHLORIDE
* ZENITH GOLDLINE PHARMACEUTICALS
  BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
  FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
* ZENITH GOLDLINE PHARMACEUTICALS INC
  NIZATIDINE, NIZATIDINE

ZILA
* ZILA PHARMACEUTICALS INC
  PERIDEX, CHLORHEXIDINE GLUCONATE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL
AEROSOL, METERED
CAPSULE
CAPSULE, COATED PELLETS
CAPSULE, DELAYED REL PELLETS
CAPSULE, EXTENDED RELEASE
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, SUPPOSITORY
DISC
ELIXIR
EMULSION
ENEMA
FIBER, EXTENDED RELEASE
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULE, EFFERVESCENT
I GUM, CHEWING
MPLANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LIQUID, EXTENDED RELEASE
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
N/A
OIL
OINTMENT
OINTMENT, AUGMENTED
PASTE
PASTILLE
PELLET
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION/DROPS
SOLUTION, CONCENTRATE
SOLUTION, GEL FORMING/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION/DROPS
SUSPENSION, EXTENDED RELEASE
SWAB
SYRUP
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, FOR SOLUTION
TABLET, ORALLY DISINTEGRATING
TAPE
TROCHE/LOZENGE

NOTE: TERMS COMPRISE CURRENTLY MARKETED PRODUCTS

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
DENTAL
ENDOCERVICAL
FOR RX COMPOUNDING
IM-IV
IM-IV-SC
IM-SC
IMPLANTATION
INHALATION
INJECTION
INTRACRANIAL
INTRALYMPHATIC
INTRAMUSCULAR
INTRAOCULAR
I INTRAPERITONEAL
INTRAPLEURAL
NTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TOPICAL, VAGINAL
TRANSDERMAL
URETERAL
URETHRAL
VAGINAL

NOTE: TERMS COMPRISE CURRENTLY MARKETED PRODUCTS

ABBREVIATIONS

AMP	AMPULE	GM	GRAM	ML	MILLILITER
AMPICIL	AMPICILLIN	HBR	HYDROBROMIDE	N/A	NOT APPLICABLE
APPROX	APPROXIMATELY	HCL	HYDROCHLORIDE	PPM	PARTS PER MILLION
BOT	BOTTLE	HR	HOUR	REL	RELEASE
CI	CURIE	INH	INHALATION	SQ CM	SQUARE CENTIMETER
CSR	CAROTID SINUS REFLEX	IU	INTERNATIONAL UNITS	U	UNITS
CU	CLINICAL UNITS	KIU	KALLIKREIN INHIBITOR UNITS	UCI	MICROCURIE
DIPROP	DIPROPIONATE			UGM	MICROGRAM
EQ	EQUIVALENT TO	MCI	MILLICURIE	UMOLAR	MICROMOLAR
ELECT	ELECTROLYTE	MEQ	MILLIEQUIVALENT	USP	UNITED STATES PHARMACOPEIA
ER	EXTENDED RELEASE	MG	MILLIGRAM		

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* page. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second full NDA. Applications qualifying for periods of exclusivity are:

(1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) (2) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.

(2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications use or indication, this does not preclude the approval of an ANDA not covered by the exclusivity.

(3) A supplement to a new drug application for a drug containing a previously approved active ingredient including any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent application for a change approved in the supplement may not be *made effective* for *three years* from the date of approval of the original supplement.

FDA data supplied by DrugPatentWatch.com

The Act requires that patent information must now be filed with all newly submitted Section 505 drug applications, and that no NDA may be approved after September 24, 1984, without the submission of pertinent patent information to the Agency. The patent numbers and the expiration dates of appropriate patents claiming drug products that are the subject of approved applications will be published in this *Addendum* or in the monthly Cumulative Supplement to this publication. Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient or ingredients; drug product patents, which include formulation/composition patents; and use patents for a particular approved indication or method of using the product. NDA holders or applicants amending or supplementing applications with formulation/composition patent information are asked to declare that the patent(s) is appropriate for publication and refers to an approved product or one for which approval is being sought. The Agency asks all applicants or application holders with use patents to provide information as to the approved indications or uses covered by such patents. This information will be included in the Cumulative Supplement to the List as it becomes available.

Since all parts of this publication are subject to changes, additions, or deletions, the *Addendum* must be used in conjunction with the most current Cumulative Supplement.

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394	JUN 26, 2009		NCE	DEC 17, 2003
		5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5047407	NOV 17, 2009			
		5905082	MAY 18, 2016			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4828838	SEP 17, 2005			
		5034394*PED	DEC 26, 2009			
		5047407*PED	MAY 17, 2010			
		5089500*PED	DEC 26, 2009	U-248		
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U-248		
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6180639*PED	JUL 30, 2018	U-248		
		6417191	MAR 28, 2016	U-248		
		6417191*PED	SEP 28, 2016	U-248		
020977 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	JUN 26, 2009			
		5034394*PED	DEC 26, 2009			
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
020978 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	JUN 26, 2009			
		5034394*PED	DEC 26, 2009			
		6294540*PED	NOV 14, 2018	U-65		
		6294540	MAY 14, 2018	U-65		
020482 001	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 002	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)	5972916	JUL 14, 2017	U-296		
		4943565	JUL 24, 2007			
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS/HEADACHE				NC	MAR 01, 2004
019872 001	ACETAMINOPHEN;TYLENOL	5004613	JUL 27, 2007			
		4820522	JUL 27, 2007			
		4968509	NOV 06, 2007			
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
019806 001	ACRIVASTINE;SEMPREX-D	4501893	FEB 01, 2003			
		4650807	MAR 26, 2008	U-93		
021478 001	ACYCLOVIR;ZOVIRAX				NDF	DEC 30, 2005
020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAR 31, 2010	U-275		
020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U-275		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NDF	MAY 26, 2003
		RE34440	MAY 31, 2010	U-275		
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	U-470	NCE	SEP 20, 2007
		4808716	APR 25, 2006			
		5663159	SEP 02, 2014	U-470		
		4724233	APR 21, 2006	U-470		
019937 002	ADENOSINE;ADENOCARD	4673563	JUN 16, 2004	U-38		
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
		5731296	MAR 24, 2015	U-221		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020666 001	ALBENDAZOLE;ALBENZA				ODE	JUN 11, 2003
020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020291 001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015			
020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
018062 001	ALBUTEROL SULFATE;PROVENTIL	4499108	JUN 08, 2003			
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5439670	JUL 06, 2010			
		5605674	FEB 25, 2014			
		5225183	JUL 06, 2010			
		5766573	JUN 16, 2015			
		6352684	NOV 28, 2009			
		5695743	JUL 06, 2010	U-491		
019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012			
019604 001	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
019604 002	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114	I-309	SEP 29, 2003
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		M-3	NOV 24, 2002
		4621077	AUG 06, 2007	U-114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U-303		
		6090410	DEC 02, 2012			
020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		5994329	JUL 17, 2018			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6225294	JUL 17, 2018			
020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
					NCE	FEB 02, 2004
020298 001	ALLOPURINOL SODIUM;ALOPRIM				ODE	MAY 17, 2003
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		NCE	MAY 07, 2006
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010		NCE	FEB 09, 2005
		6284770	OCT 05, 2018	U-405		
018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 004	ALPRAZOLAM;XANAX	5061494	OCT 29, 2008			
		4508726	SEP 16, 2002	U-46		
020379 001	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 002	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 003	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 004	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
021212 001	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
021212 002	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
020700 001	ALPROSTADIL;MUSE	5242391	SEP 07, 2010	U-155		
		4801587	JAN 31, 2007	U-155		
		5474535	DEC 12, 2012	U-155		
020700 002	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5242391	SEP 07, 2010	U-155		
		5474535	DEC 12, 2012	U-155		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020700 003	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5474535	DEC 12, 2012	U-155		
		5242391	SEP 07, 2010	U-155		
020700 004	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U-155		
		5242391	SEP 07, 2010	U-155		
		5474535	DEC 12, 2012	U-155		
020221 001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		ODE	JUN 24, 2006
		5591731	JUL 31, 2012		ODE	DEC 08, 2002
		5994409	DEC 08, 2017	U-305		
020221 002	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		ODE	JUN 24, 2006
		5591731	JUL 31, 2012		ODE	DEC 08, 2002
		5994409	DEC 08, 2017	U-305		
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5079262	JUL 28, 2009	U-289	NCE	DEC 03, 2004
		5211938	MAY 18, 2010	U-289		
		5422093	JUL 28, 2009	U-289		
020377 001	AMIODARONE HYDROCHLORIDE;CORDARONE				ODE	AUG 03, 2002
020511 001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
020364 002	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
020364 003	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
020364 004	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U-367		
020364 005	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003		NS	JUN 20, 2005
		4572909	JUL 31, 2006			
		4879303	MAR 25, 2007			
		6162802	DEC 19, 2017	U-367		
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
020508 001	AMMONIUM LACTATE;LAC-HYDRIN				M-4	AUG 25, 2003
					PED	FEB 25, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	NOV 27, 2018		NDF	OCT 11, 2004
011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020	JUL 06, 2020			
011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020			
011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020			
011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020			
011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020			
011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020			
011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020			
050724 001	AMPHOTERICIN B;ABELCET				ODE	OCT 18, 2003
050740 001	AMPHOTERICIN B;AMBISOME				ODE	AUG 11, 2004
021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
		5723490	MAR 03, 2015	U-257		
		5646180	JUL 08, 2014	U-257		
020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
					I-363	SEP 05, 2005
019779 001	APRACLONIDINE HYDROCHLORIDE;IOPIDINE	5212196	MAY 18, 2010	U-120		
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220	NCE	SEP 12, 2002
		5234404	AUG 10, 2010	U-220		
		5395970	MAR 07, 2012			
020883 001	ARGATROBAN;ARGATROBAN	5214052	MAR 13, 2012		NCE	JUN 30, 2005
		5925760	AUG 04, 2017		I-352	APR 03, 2005
021436 001	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
021436 002	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
021436 003	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
021436 004	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
021436 005	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
021436 006	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
021248 001	ARSENIC TRIOXIDE;TRISENOX				ODE	SEP 25, 2007
					NCE	SEP 25, 2005
020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
020884 001	ASPIRIN;AGGRENOX	6015577	JAN 18, 2017	U-302	NC	NOV 22, 2002
021317 001	ASPIRIN;BAYER EXTRA STRENGTH ASPIRIN FOR				NP	OCT 18, 2004
012365 005	ASPIRIN;SOMA COMPOUND	4534973	AUG 13, 2002			
012366 002	ASPIRIN;SOMA COMPOUND W/ CODEINE	4534974	AUG 13, 2002			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213	D-77	APR 22, 2005
		5969156	JUL 08, 2016		I-350	OCT 18, 2005
		6126971	JAN 19, 2013		PED	APR 18, 2006
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213	D-77	APR 22, 2005
		5969156	JUL 08, 2016		I-350	OCT 18, 2005
		6126971	JAN 19, 2013		PED	APR 18, 2006
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 18, 2017			
		6126971*PED	JUL 19, 2013			
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213	D-77	APR 22, 2005
		5969156	JUL 08, 2016		I-350	OCT 18, 2005
		6126971	JAN 19, 2013		PED	APR 18, 2006
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
		5686104	NOV 11, 2014	U-213	D-77	APR 22, 2005
		5969156	JUL 08, 2016		I-350	OCT 18, 2005
		6126971	JAN 19, 2013		PED	APR 18, 2006
		4681893*PED	MAR 24, 2010	U-161		
		5273995*PED	JUN 28, 2011	U-162		
		5686104*PED	MAY 11, 2015	U-213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
		5053432	OCT 01, 2008			
		6291488	NOV 25, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046	NOV 25, 2013		NC	JUL 14, 2003
		5053432	OCT 01, 2008			
		6291488	NOV 25, 2013	U-406		
020259 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U-69		
		5053432	OCT 01, 2008			
020500 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U-69	ODE	JAN 05, 2006
		5053432	OCT 01, 2008			
019677 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U-54		
019678 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U-54		
021470 001	AZELAIC ACID;FINACEA	4713394	JAN 17, 2006	U-492	NDF	DEC 24, 2005
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207		
021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NDF	MAY 22, 2003
		5164194*PED	MAY 01, 2011		PED	NOV 22, 2003
					NCE	JUL 18, 2005
020610 001	BALSALAZIDE DISODIUM;COLAZAL					
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	5776432	JUL 07, 2015		NP	SEP 15, 2003
		5605674	FEB 25, 2014		NPP	MAY 10, 2005
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
		6352684	NOV 28, 2009			
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	5776432	JUL 07, 2015		NP	SEP 15, 2003
		5605674	FEB 25, 2014		NPP	MAY 10, 2005
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
		6352684	NOV 28, 2009			
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020033 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
020032 001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020576 001	BETAINE, ANHYDROUS;CYSTADANE				ODE	OCT 25, 2003
019408 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
019716 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4775529	MAY 21, 2007			
019555 001	BETAMETHASONE DIPROPIONATE;DIPROLENE AF	4489071	DEC 09, 2003			
020010 001	BETAMETHASONE DIPROPIONATE;LOTRISONE				NP	DEC 08, 2003
020934 001	BETAMETHASONE VALERATE;LUXIQ	6126920	MAR 01, 2016	U-484		
020619 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191		
019845 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC S	4911920	MAR 27, 2007			
021055 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		NCE	DEC 29, 2004
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
		5962731	OCT 05, 2016	U-475		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		NCE	DEC 29, 2004
		5962731	OCT 05, 2016		NDF	JUN 28, 2003
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
020498 001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
		6403649	SEP 21, 2012	U-446		
020873 001	BIVALIRUDIN;ANGIOMAX	5196404	MAR 23, 2010		NCE	DEC 15, 2005
050443 001	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
021290 001	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
					PED	JUN 20, 2005
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394	NPP	DEC 20, 2004
		6248741	JUN 28, 2015	U-394	PED	JUN 20, 2005
		6194415*PED	DEC 28, 2015	U-394		
		6248741*PED	DEC 28, 2015	U-394		
		6465464	JUN 28, 2015	U-394		
		6465464*PED	DEC 28, 2015	U-394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U-399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U-399	NPP	DEC 20, 2004
		6248741	JUN 28, 2015	U-395	PED	JUN 20, 2005
		6194415	JUN 28, 2015	U-395		
		6248741*PED	DEC 28, 2015	U-395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
		6465464	JUN 28, 2015	U-395		
		6465464*PED	DEC 28, 2015	U-395		
020816 001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
		5378703	APR 01, 2012	U-224		
		5461081	OCT 24, 2012	U-225		
020535 002	BROMFENAC SODIUM;DURACT				NCE	JUL 15, 2002
019672 001	BROMPHENIRAMINE MALEATE;EFIDAC 24 PSEUDOEPHEDRINE HCL/BRO	4673405	MAR 18, 2003			
		4810502	MAR 14, 2006			
		4662880	MAR 14, 2006			
		4801461	MAR 14, 2006			
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
		5643602*PED	JAN 01, 2015		PED	APR 02, 2005
020441 002	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020929 003	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
					PED	APR 26, 2005
					PED	APR 01, 2003
020746 002	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
					PED	APR 26, 2005
					PED	APR 01, 2003
020733 001	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020733 002	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 002	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5427798	AUG 12, 2013		M-10	JUN 11, 2004
		5358970	AUG 12, 2013			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020358 004	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		D-54	SEP 10, 2002
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		D-54	SEP 10, 2002
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008		M-12	JUL 19, 2004
		5015646*PED	NOV 14, 2008		PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008		M-12	JUL 19, 2004
		5015646*PED	NOV 14, 2008		PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008		M-12	JUL 19, 2004
		5015646*PED	NOV 14, 2008		PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008		M-12	JUL 19, 2004
		5015646*PED	NOV 14, 2008		PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
021190 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED	NOV 14, 2008			
		5015646	MAY 14, 2008			
021190 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	PED	AUG 04, 2002
		5430057*PED	MAR 30, 2014	U-263	PED	AUG 04, 2006
		5559148*PED	NOV 24, 2015	U-264		
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177	I-333	JUN 06, 2004
021408 001	BUTENAFINE HYDROCHLORIDE;MENTAX-TC				NP	OCT 17, 2005
019881 001	BUTOCONAZOLE NITRATE;GYNAZOLE-1	5266329	NOV 30, 2010	U-457		
		4551148	NOV 05, 2002			
020664 001	CABERGOLINE;DOSTINEX	4526892	DEC 29, 2005			
020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
					NE	SEP 21, 2002
020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020554 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020313 002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
		5759565	MAR 31, 2015			
018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U-349	NC	OCT 15, 2003
		5817340	DEC 01, 2012		PED	APR 15, 2004
		5989588	SEP 30, 2015	U-349		
		5989588*PED	MAR 30, 2018	U-349		
		5229137*PED	NOV 16, 2012			
		5817340*PED	JUN 01, 2013			
018469 001	CALCIUM CHLORIDE;BSS PLUS	4550022	OCT 29, 2002			
020577 001	CALCIUM CHLORIDE;ELLIOTTS B SOLUTION				ODE	SEP 27, 2003
020521 001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013		M-21	SEP 13, 2005
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013		M-21	SEP 13, 2005
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013		M-21	SEP 13, 2005
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	NCE	JUN 04, 2003
		5534534	JUL 09, 2013		M-21	SEP 13, 2005
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	JUN 04, 2012	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	JUN 04, 2012	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271	NCE	APR 30, 2003
		4966891	JAN 13, 2011	U-272	I-323	APR 30, 2004
					I-341	SEP 07, 2004
020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271	NCE	APR 30, 2003
		4966891	JAN 13, 2011	U-272	I-323	APR 30, 2004
					I-341	SEP 07, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018343 001	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 002	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 003	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 004	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 005	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 006	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
018343 007	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U-92		
020712 001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
		5912013	JUN 15, 2016	U-277		
020712 002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
		5912013	JUN 15, 2016	U-277		
020234 001	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 002	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 003	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
019856 001	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019856 002	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
020637 001	CARMUSTINE;GLIADEL	4789724	AUG 01, 2006		ODE	SEP 23, 2003
		4757128	AUG 01, 2006			
020297 001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U-233		
		5902821	FEB 07, 2016	U-313		
021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021222 001	CEFDITOREN PIVOXIL;SPECTRACEF	4839350	JUN 13, 2006		NCE	AUG 29, 2006
		4918068	JUN 13, 2006		I-364	AUG 21, 2005
		5958915	OCT 14, 2016			
020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
		5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013		I-338	OCT 17, 2004
		5972986	OCT 14, 2017	U-299		
		5760068	JUN 02, 2015	U-299		
020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
		5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013		I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U-299		
		5972986	OCT 14, 2017	U-299		
020998 003	CELECOXIB;CELEBREX	5466823	NOV 30, 2013		I-284	DEC 23, 2002
		5563165	NOV 30, 2013		NCE	DEC 31, 2003
		5760068	JUN 02, 2015	U-19	I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U-299		
		5972986	OCT 14, 2017	U-299		
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	JAN 26, 2011		I-303	JUL 21, 2003
					NS	JUL 21, 2003
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
		6319192	APR 23, 2018	U-426		
021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
		6319192	APR 23, 2018	U-426		
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	4312860	AUG 20, 2003			
		4826821	MAY 02, 2006			
		5110806	MAY 02, 2006			
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
		5340821	AUG 23, 2011	U-309		
		5580880	JUN 06, 2015	U-310		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
021555 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP ONE-STEP SEPP				NP	OCT 07, 2005
021441 001	CHLORPHENIRAMINE MALEATE;ADVIL ALLERGY SINUS				NP	DEC 19, 2005
019746 002	CHLORPHENIRAMINE MALEATE;EFIDAC 24 CHLORPHENIRAMINE MALEAT	4576604	MAR 18, 2003			
		4673405	MAR 18, 2003			
		4857330	AUG 15, 2006			
019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
019574 001	CHLORTHALIDONE;THALITONE	4933360	JUN 12, 2007			
021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379	NDF	DEC 17, 2002
020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
020863 001	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
020863 002	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
019992 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003			
		4670444*PED	JUN 09, 2004			
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U-223		
		4670444*PED	JUN 09, 2004	U-223		
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
		4670444	DEC 09, 2003	U-36		
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
		5286754	FEB 15, 2011			
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003			
		4844902	FEB 11, 2008			
		4670444*PED	JUN 09, 2004			
		4844902*PED	AUG 11, 2008			
019847 001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4808583	FEB 28, 2006			
020780 001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U-362		
020780 002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U-362		
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
020210 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020210 002	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020398 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U-79		
020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U-79		
		5648093	JUL 15, 2014			
020551 001	CISATRACURIUM BESYLATE;NIMBEX	5453510	SEP 26, 2012	U-127		
020551 002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
020551 003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
018057 001	CISPLATIN;PLATINOL	5562925	MAY 08, 2012			
018057 002	CISPLATIN;PLATINOL	5562925	MAY 08, 2012			
018057 003	CISPLATIN;PLATINOL-AQ	5562925	MAY 08, 2012			
018057 004	CISPLATIN;PLATINOL-AQ	5562925	MAY 08, 2012			
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021142 001	CLOBETASOL PROPIONATE;OLUX FOAM	6126920	MAR 01, 2016	U-484	NDF	MAY 26, 2003
					I-374	DEC 20, 2005
020615 001	CLONIDINE HYDROCHLORIDE;DURACLON				ODE	OCT 02, 2003
018891 001	CLONIDINE;CATAPRES-TTS-1	4559222	MAY 04, 2003			
018891 002	CLONIDINE;CATAPRES-TTS-2	4559222	MAY 04, 2003			
018891 003	CLONIDINE;CATAPRES-TTS-3	4559222	MAY 04, 2003			
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003		NCE	NOV 17, 2002
		4847265	NOV 17, 2011		I-349	FEB 27, 2005
		5576328	JAN 31, 2014	U-432		
		6429210	JUN 10, 2019			
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
		5679717	APR 29, 2014	U-323		
		5693675	DEC 02, 2014			
		5607669	JUN 10, 2014	U-323		
		5917007	APR 29, 2014	U-323		
		5919832	JUN 10, 2014			
		6433026	JUN 10, 2014			
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
		5917007	APR 29, 2014	U-323		
		5607669	JUN 10, 2014	U-323		
		5693675	DEC 02, 2014			
		5679717	APR 29, 2014	U-323		
		5624963	APR 29, 2014	U-323		
		6433026	JUN 10, 2014			
019722 001	CYANOCOBALAMIN;NASCOBAL	4724231	APR 16, 2005	U-157		
012142 006	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 007	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
012142 008	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 009	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
012142 010	CYCLOPHOSPHAMIDE;LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
020287 001	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		D-60	AUG 03, 2003
020287 003	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		D-60	AUG 03, 2003
020287 004	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		D-60	AUG 03, 2003
020430 001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
019849 001	DAPIPRAZOLE HYDROCHLORIDE;REV-EYES	4252721	FEB 07, 2003			
050704 002	DAUNORUBICIN CITRATE;DAUNOXOME				ODE	APR 08, 2003
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013			
		6177101	JUN 11, 2018			
020118 001	DESFLURANE;SUPRANE	4762856	FEB 02, 2007	U-67		
021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
		4863931	SEP 15, 2008			
		4804666	FEB 14, 2006	U-428		
		5595997	DEC 30, 2014	U-429		
		6100274	JUL 07, 2019			
021312 001	DESLORATADINE;CLARINEX				NCE	DEC 21, 2006
017922 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
018938 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5763407	JUN 29, 2013			
021090 001	DESOGESTREL;CYCLESSA	4616006	OCT 07, 2003		NP	DEC 20, 2003
		4544554	SEP 26, 2003			
		4628051	SEP 26, 2003			
020713 001	DESOGESTREL;MIRCETTE	4921843	OCT 20, 2008			
		RE35724	OCT 20, 2008			
021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U-421	NCE	DEC 17, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
019082 001	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 002	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 003	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
020648 001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
		5698225	FEB 03, 2017	U-392		
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
		5698225	FEB 03, 2017	U-392		
020809 001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
		5653972	NOV 16, 2014	U-239		
021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
		5792753	AUG 11, 2015			
		5852002	JUN 17, 2014	U-402		
		5914322	AUG 11, 2015			
		5929048	JUL 27, 2016	U-402		
		5985850	NOV 16, 2016			
020037 001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
		4829088	APR 14, 2007			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	5169849	DEC 08, 2009	U-227		
020062 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5470584	MAY 20, 2011			
		5364620	NOV 14, 2011	U-3		
		5439689	AUG 08, 2012	U-107		
		5002776	MAR 26, 2008			
020062 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5364620	NOV 14, 2011	U-3		
		5470584	MAY 20, 2011			
		5002776	MAR 26, 2008			
		4894240	JAN 16, 2007			
		5439689	AUG 08, 2012	U-107		
020062 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U-3		
		5470584	MAY 20, 2011			
020062 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U-3		
		5439689	AUG 08, 2012	U-107		
		5470584	MAY 20, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019471 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
020092 001	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 002	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 003	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020507 001	DILTIAZEM MALATE;TECZEM	4968507	JUL 25, 2006			
		4880631	SEP 24, 2007			
		4983598	JAN 08, 2008			
020506 001	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 002	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 003	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
021191 001	DIMYRISTOYL LECITHIN;IMAGENT	6280704	JUL 30, 2013		NCE	MAY 31, 2007
		6280705	JUL 30, 2013			
		6287539	JUL 30, 2013			
		5605673	FEB 25, 2014			
		5626833	MAY 16, 2014	U-458		
		5639443	JUN 17, 2014			
		5695741	DEC 09, 2014	U-458		
		5720938	FEB 24, 2015			
		5798091	AUG 25, 2015	U-458		
020411 001	DINOPROSTONE;CERVIDIL	4931288	JAN 16, 2007			
		5269321	DEC 14, 2010	U-110		
019617 001	DINOPROSTONE;PREPIDIL	4680312	JUL 14, 2004			
018723 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 002	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018723 003	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019680 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019794 001	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
019794 002	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
		4913906	APR 03, 2007			
		6419953	DEC 18, 2018			
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	4913906	APR 03, 2007		NP	AUG 04, 2003
		4988731	JAN 29, 2008			
020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010		I-282	DEC 23, 2002
		5438072	NOV 22, 2013		I-379	NOV 27, 2005
		5698582	JUL 03, 2012			
		5714512	JUL 03, 2012			
020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011		NCE	SEP 11, 2002
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011		NCE	SEP 11, 2002
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011		NCE	SEP 11, 2002
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
		6372760	MAR 31, 2019			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
		6372760	MAR 31, 2019			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103		
		4619939	OCT 28, 2003	U-104		
		6248735	APR 17, 2011			
020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U-103		
		4619939	OCT 28, 2003	U-104		
019946 001	DOXACURIUM CHLORIDE;NUROMAX	4701460	MAR 06, 2005			
020862 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U-278	NCE	JUN 09, 2004
		5707980	AUG 17, 2010	U-278		
		5861386	AUG 02, 2008	U-278		
		5869473	AUG 02, 2008	U-278		
021027 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U-321	NDF	APR 06, 2003
		5707980	AUG 17, 2010	U-321	NCE	JUN 09, 2004
050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021098 001	DROSPIRENONE;YASMIN	5569652	OCT 29, 2013	U-1	NC	MAY 11, 2004
021319 001	DUTASTERIDE;AVODART	5565467	OCT 15, 2013		NCE	NOV 20, 2006
		5846976	DEC 08, 2015	U-476		
		5998427	OCT 15, 2013	U-477		
020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-257		
		6238695	APR 06, 2019			
020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-257		
		6238695	APR 06, 2019			
020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014	U-257		
		5811423	AUG 07, 2012	U-256		
		6238695	APR 06, 2019			
021360 001	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014			
		5811423	AUG 07, 2012	U-256		
021360 002	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014	U-248		
		5811423	AUG 07, 2012	U-256		
021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4720489	JAN 19, 2005	U-334	NP	JUL 27, 2003
		5648394	JUL 15, 2014	U-334		
021016 001	ELETRIPTAN HYDROBROMIDE;RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
021016 002	ELETRIPTAN HYDROBROMIDE;RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403	NCE	DEC 29, 2002
		5441958	DEC 08, 2013	U-404		
020668 001	ENALAPRIL MALEATE;LEXXEL	4803081	APR 03, 2007			
		4703038	OCT 07, 2005	U-3		
		4803081*PED	OCT 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4703038	OCT 07, 2005	U-3		
		4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
020164 001	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 002	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 003	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020164 004	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012			
020164 006	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 008	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020796 001	ENTACAPONE;COMTAN	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		5112861	MAY 12, 2009			
050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
021437 001	EPLERENONE;INSPRA	6410054	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
		6495165	DEC 08, 2019	U-3		
021437 002	EPLERENONE;INSPRA	6410054	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
		6495165	DEC 08, 2019	U-3		
021437 003	EPLERENONE;INSPRA	6410054	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
		6495165	DEC 08, 2019	U-3		
020444 001	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002		ODE	APR 14, 2007
		4883812	MAY 12, 2006	U-185	I-296	APR 14, 2003
					ODE	SEP 20, 2002
020444 002	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002		ODE	APR 14, 2007
		4883812	MAY 12, 2006	U-185	I-296	APR 14, 2003
					ODE	SEP 20, 2002
020738 004	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
		5185351	FEB 09, 2010	U-3		
020738 005	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
		5185351	FEB 09, 2010	U-3		
020738 006	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	NCE	DEC 22, 2002
		5656650	AUG 12, 2014	U-3		
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
		5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
		5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
020718 001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014		D-66	JUN 08, 2004
		5807825	SEP 15, 2015	U-244		
		5968902	JUN 02, 2015	U-453		
		5747447	MAY 05, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020718 002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
		5686570	NOV 11, 2014		D-66	JUN 08, 2004
		5807825	SEP 15, 2015	U-244		
		5968902	JUN 02, 2015	U-453		
		5747447	MAY 05, 2015			
021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
		5652233	FEB 02, 2013			
		5952323	MAY 15, 2017			
021323 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
021323 002	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
021323 003	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
021365 001	ESCITALOPRAM OXALATE;LEXAPRO				NP	AUG 14, 2005
					I-366	AUG 29, 2005
					PED	FEB 14, 2006
					PED	MAR 01, 2006
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
		5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
		5017609	MAY 21, 2008			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		4593119	JUN 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
		5900424	MAY 04, 2016	U-373	PED	AUG 20, 2004
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		6369085	MAY 25, 2018			
		6428810	NOV 03, 2019	U-469		
		4738974*PED	OCT 19, 2005	U-373		
		4786505*PED	OCT 20, 2007	U-373		
		4853230*PED	OCT 20, 2007	U-373		
		5690960*PED	MAY 25, 2015	U-373		
		5714504*PED	AUG 03, 2015	U-373		
		5877192*PED	NOV 27, 2014	U-373		
		5900424*PED	NOV 04, 2016	U-373		
		6147103	OCT 09, 2018			
		6147103*PED	APR 09, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		6369085*PED	NOV 25, 2018			
		6428810*PED	MAY 03, 2020	U-469		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
		5900424	MAY 04, 2016	U-373	PED	AUG 20, 2004
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		6369085	MAY 25, 2018			
		6428810	NOV 03, 2019	U-469		
		4738974*PED	OCT 19, 2005	U-373		
		4786505*PED	OCT 20, 2007	U-373		
		4853230*PED	OCT 20, 2007	U-373		
		5690960*PED	MAY 25, 2015	U-373		
		5714504*PED	AUG 03, 2015	U-373		
		5877192*PED	NOV 27, 2014	U-373		
		5900424*PED	NOV 04, 2016	U-373		
		6147103*PED	APR 09, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		6369085*PED	NOV 25, 2018			
		6428810*PED	MAY 03, 2020	U-469		
020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLA	RE36247	MAY 02, 2006		I-295	APR 11, 2003
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 004	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020375 001	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 002	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020847 001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020472 001	ESTRADIOL;ESTRING	4871543	JUN 12, 2007	U-306		
		5188835	JUN 12, 2007	U-306		
020417 001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007			
		5006342	APR 09, 2008			
021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
		5382573	JAN 17, 2012			
020323 001	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 002	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 003	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 004	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
		5300291	APR 05, 2011		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020992 001	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		I-359	JUN 21, 2005
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
		5210081	FEB 26, 2012			
020527 001	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006	U-284		
		5210081	FEB 26, 2012			
020527 003	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015			
		RE36247	MAY 02, 2006	U-284		
		5210081	FEB 26, 2012			
020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN)	5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006	U-284		
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	4962098	OCT 09, 2007	U-112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	4962098	OCT 09, 2007	U-112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
021187 001	ETHINYL ESTRADIOL;NUVARING	5989581	APR 08, 2018		NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA				NP	NOV 20, 2004
019697 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003	U-66		
		4628051	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
019697 002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66		
		4616006	SEP 26, 2003	U-66		
		4628051	SEP 26, 2003	U-66		
		4530839	SEP 26, 2003	U-112		
021241 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN LO	4616006	SEP 26, 2003	U-112	NP	AUG 22, 2005
		6214815	JUN 09, 2019	U-112		
		4530839	SEP 26, 2003	U-112		
		4544554	SEP 26, 2003	U-112		
		4628051	SEP 26, 2003	U-112		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018985 001	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-21	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
018985 002	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-28	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CONTRACEPTIVE KI	6156742	DEC 05, 2020	U-374		
020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
		4904650	JUL 07, 2006		ODE	OCT 21, 2006
021445 001	EZETIMIBE;ZETIA	5846966	SEP 21, 2013	U-474	NCE	OCT 25, 2007
		RE37721	JUN 16, 2015	U-473		
020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
020363 002	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
020325 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015	U-205		
		5854267	DEC 29, 2015	U-267		
		5667794*PED	NOV 02, 2015	U-205		
		5854267*PED	JUN 29, 2016	U-267		
020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
		5854267	DEC 29, 2015	U-267		
		5075114	DEC 24, 2008			
		5075114*PED	JUN 24, 2009			
		5667794*PED	NOV 02, 2015			
		5854267*PED	JUN 29, 2016			
020902 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-368		
		5854267*PED	JUN 29, 2016	U-368		
		5667794	MAY 02, 2015	U-368		
		5667794*PED	NOV 02, 2015	U-368		
		4820524	FEB 20, 2007			
		4820524*PED	AUG 20, 2007			
020189 001	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
020189 002	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020189 003	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U-83		
		5082861	SEP 26, 2009	U-83		
019834 001	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 002	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 004	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
075753 002	FENOFIBRATE;FENOFIBRATE (MICRONIZED)				PC	SEP 15, 2002
075753 003	FENOFIBRATE;FENOFIBRATE (MICRONIZED)				PC	SEP 15, 2002
021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009		I-298	APR 24, 2003
019922 001	FENOLDOPAM MESYLATE;CORLOPAM				NCE	SEP 23, 2002
020747 001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020747 006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U-253		
020195 001	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 002	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 003	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
020195 007	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U-87		
019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
020416 001	FERUMOXIDES;FERIDEX I.V.	4951675	AUG 28, 2007	U-143		
		5102652	FEB 06, 2009			
		5248492	SEP 28, 2010			
		4770183	SEP 13, 2005	U-145		
		4827945	MAY 09, 2006	U-144		
		5055288	OCT 08, 2008			
		5219554	JUN 15, 2010			
020410 001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171		
		5219554	JUN 15, 2010			
		4827945	MAY 09, 2006	U-170		
		4951675	SEP 13, 2005	U-169		
		5055288	OCT 08, 2008			
		4695392	SEP 22, 2004			
		4695393	SEP 22, 2004			
		4770183	SEP 13, 2005	U-169		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192		
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	5578610	NOV 26, 2013			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
020788 001	FINASTERIDE;PROPECIA	4760071	JUN 19, 2006			
		5571817	NOV 05, 2013	U-259		
		5547957	OCT 15, 2013	U-236		
		5886184	NOV 19, 2012			
020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
		5886184	NOV 19, 2012			
		5942519	OCT 23, 2018	U-280		
075442 001	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
075442 002	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
075442 003	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
018830 001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018830 002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 004	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004			
019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
020038 001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
020073 001	FLUMAZENIL;ROMAZICON	4316839	OCT 10, 2004			
018340 001	FLUNISOLIDE;AEROBID	4933168	JUN 12, 2007			
018148 001	FLUNISOLIDE;NASALIDE	4933168	JUN 12, 2007			
020409 001	FLUNISOLIDE;NASAREL	4782047	MAY 22, 2006			
		4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
					I-340	OCT 10, 2004
021112 001	FLUOCINOLONE ACETONIDE;TRI-LUMA				NC	JAN 18, 2005
020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005		NP	OCT 27, 2003
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154		
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154		
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U-154		
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		4971998*PED	MAY 20, 2008	U-338	PED	JAN 06, 2004
					D-75	JUN 12, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		4971998*PED	MAY 20, 2008	U-338	PED	JAN 06, 2004
					D-75	JUN 12, 2005
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003		D-76	MAY 23, 2005
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
		5356896	DEC 12, 2011			
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
		5356896	DEC 12, 2011			
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413	NDF	OCT 06, 2003
		5356896	DEC 12, 2011			
		6242003	APR 13, 2020			
020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U-206		
		5767251	JUN 16, 2015			
020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U-206		
		5767251	JUN 16, 2015			
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015		I-306	MAY 24, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015		I-306	MAY 24, 2003
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	I-306	MAY 24, 2003
		5767251	JUN 16, 2015		ODE	MAY 24, 2007
020696 001	FOMEPIZOLE;ANTIZOL				NCE	DEC 04, 2002
					ODE	DEC 04, 2004
					ODE	DEC 08, 2007
					I-319	DEC 08, 2003
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
021345 001	FONDAPARINUX SODIUM;ARIXTRA	4818816	AUG 19, 2003		NCE	DEC 07, 2006
020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
					NCE	FEB 16, 2006
019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
020450 001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003		ODE	AUG 05, 2003
		4925860	AUG 05, 2007			
021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U-436	NCE	NOV 08, 2006
		5616603	APR 01, 2014	U-436		
		5637611	JUN 10, 2014	U-436		
		5827871	OCT 27, 2015	U-436		
		5962501	DEC 16, 2013	U-436		
021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
020235 001	GABAPENTIN;NEURONTIN	4894476*PED	NOV 02, 2008		I-311	OCT 12, 2003
		4894476	MAY 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020235 003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020882 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020882 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
021129 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020123 001	GADODIAMIDE;OMNISCAN	4687659	MAY 04, 2007	U-76		
019596 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	4647447	MAR 03, 2004			
		4963344	MAR 03, 2004			
		4957939	MAR 03, 2004			
		5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
		4963344	MAR 03, 2004			
020131 001	GADOTERIDOL;PROHANCE	4885363	DEC 05, 2006			
		5474756	DEC 12, 2012	U-480		
		5846519	DEC 08, 2015			
		6143274	DEC 12, 2012	U-480		
020937 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020975 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020976 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
019961 002	GALLIUM NITRATE;GANITE	4529593	JAN 17, 2005	U-49		
019661 001	GANCICLOVIR SODIUM;CYTOVENE IV	4355032	JUN 23, 2003	U-64		
020460 001	GANCICLOVIR;CYTOVENE	4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
020460 002	GANCICLOVIR;CYTOVENE	4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
020569 001	GANCICLOVIR;VITRASERT	5378475	JAN 03, 2012		ODE	MAR 04, 2003
021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
		5767082	JUN 16, 2015			
021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
021062 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
021062 003	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
021062 004	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
		5464826	NOV 07, 2012	U-146		
020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012	U-146		
		4808614	MAY 15, 2010			
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
		5693762	DEC 02, 2014		NCE	MAY 17, 2005
		5739116	APR 14, 2015			
		5767285	JUN 16, 2015			
		5773001	JUN 30, 2015	U-320		
		4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
		5585089	DEC 17, 2013			
020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014		ODE	DEC 20, 2003
		6054430	MAY 24, 2014			
		6342476	MAY 24, 2014	U-441		
		6362161	MAY 24, 2014	U-441		
020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
020329 001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
		5024843	SEP 05, 2009			
		5091190	JUN 18, 2008	U-111		
		4612008	SEP 16, 2003			
		5082668	SEP 16, 2003			
		5545413	JUL 02, 2008	U-150		
020329 002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
		5082668	SEP 16, 2003			
		5091190	JUN 18, 2008	U-111		
		5545413	JUL 02, 2008	U-150		
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
021460 001	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021460 002	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021460 003	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
					I-368	SEP 30, 2005
021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
					I-368	SEP 30, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412	NC	JUL 31, 2003
					I-368	SEP 30, 2005
020051 001	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
020051 002	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 003	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 004	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
019726 001	GOSERELIN ACETATE;ZOLADEX	5366734	NOV 22, 2011			
		4767628	AUG 30, 2005			
020578 001	GOSERELIN ACETATE;ZOLADEX	4767628	AUG 30, 2005			
		5366734	NOV 22, 2011			
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89	I-369	AUG 16, 2005
		6294548	MAY 04, 2019			
020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89	I-369	AUG 16, 2005
		6294548	MAY 04, 2019			
020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 20, 2007	U-105	I-264	JUL 27, 2002
021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
020695 001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013		NCE	NOV 06, 2002
021282 001	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U-489		
019967 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 17, 2004			
019968 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 17, 2004			
020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007		PED	JUN 28, 2003
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007		NC	DEC 28, 2002
		4344949	OCT 03, 2002	U-3		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007			
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011		NCE	SEP 30, 2002
		5994348	JUN 07, 2015			
020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3		
		6294197	JUN 18, 2017	U-3		
020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3		
		6294197	JUN 18, 2017	U-3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
019129 001	HYDROCHLOROTHIAZIDE;MAXZIDE	4444769	JUL 27, 2002			
019129 003	HYDROCHLOROTHIAZIDE;MAXZIDE-25	4444769	JUL 27, 2002			
021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
020729 001	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 002	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 003	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
		6348216	JUN 10, 2017			
020769 001	HYDROCORTISONE BUTYRATE;LOCOID LIPOCREAM	5635497	JUN 03, 2014			
016295 002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI-GELS				NP	MAR 16, 2003
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
		4552899*PED	OCT 09, 2004			
021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
		5071643*PED	JUN 10, 2009			
		5360615	DEC 10, 2008			
		5360615*PED	JUN 10, 2009			
019833 002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
		4788220*PED	MAY 29, 2006			
020589 001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007			
		4788220*PED	JAN 08, 2008			
021373 001	IBUPROFEN;CHILDREN'S ADVIL COLD				NP	AUG 01, 2003
					PED	FEB 01, 2004
020516 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020601 001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
020603 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
021128 001	IBUPROFEN;CHILDREN'S MOTRIN COLD	6211246	JUN 10, 2019		NP	AUG 01, 2003
020601 003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019842 001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020135 001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020135 002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
019012 004	IBUPROFEN;MOTRIN MIGRAINE PAIN				NP	FEB 26, 2003
020491 001	IBUTILIDE FUMARATE;CORVERT	5155268	DEC 28, 2009			
019763 001	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 002	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
		5696172	OCT 06, 2013			
019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
		5696172	OCT 06, 2013			
075874 001	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
075874 002	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
					I-376	DEC 20, 2005
021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
					I-376	DEC 20, 2005
020367 001	IMIGLUCERASE;CEREZYME	5236838	AUG 17, 2010			
		5549892	AUG 27, 2013	U-252		
020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U-172		
		5238944	AUG 24, 2010			
019693 001	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
019693 002	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
019693 003	INDECAINIDE HYDROCHLORIDE;DECABID	4452745	JUN 05, 2003			
020685 001	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020685 003	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020685 005	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020685 006	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
020986 001	INSULIN ASPART;NOVOLOG	5618913	APR 08, 2014		NCE	JUN 07, 2005
		5866538	JUN 20, 2017		NR	DEC 21, 2004
021172 001	INSULIN ASPART;NOVOLOG MIX 70/30	5547930	SEP 28, 2013		NC	NOV 01, 2004
		5834422	SEP 28, 2013	U-471		
		5948751	JUN 19, 2017			
		5840680	SEP 28, 2013	U-471		
		5618913	APR 08, 2014			
021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014		PED	OCT 20, 2005
		5656722*PED	MAR 12, 2015		NCE	APR 20, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020563 001	INSULIN LISPRO;HUMALOG	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111		
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50	5461031	JUN 26, 2014		NC	DEC 22, 2002
		5474978	JUN 16, 2014			
		5514646	MAY 07, 2013			
		5747642	JUN 16, 2014			
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014		NC	DEC 22, 2002
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111		
021028 001	INSULIN RECOMBINANT HUMAN;VELOSULIN BR				NP	JUL 19, 2002
020084 001	IOBENGUANE SULFATE I 131;IOBENGUANE SULFATE I 131	4584187	APR 22, 2003			
020351 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020808 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020351 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
020808 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
021425 001	IOPROMIDE;ULTRAVIST (PHARMACY BULK)	4364921	MAR 06, 2005			
021425 002	IOPROMIDE;ULTRAVIST (PHARMACY BULK)	4364921	MAR 06, 2005			
020220 004	IOPROMIDE;ULTRAVIST 150	4364921	MAR 06, 2005	U-113		
020220 003	IOPROMIDE;ULTRAVIST 240	4364921	MAR 06, 2005	U-113		
020220 002	IOPROMIDE;ULTRAVIST 300	4364921	MAR 06, 2005	U-113		
020220 001	IOPROMIDE;ULTRAVIST 370	4364921	MAR 06, 2005	U-113		
019710 003	IOVERSOL;OPTIRAY 160	4396598	DEC 30, 2002	U-31		
019710 002	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-29		
020923 001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
019710 004	IOVERSOL;OPTIRAY 300	4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-464		
019710 001	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002	U-28		
		4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-463		
020923 002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
019710 005	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002	U-62		
		4396598	DEC 30, 2002	U-464		
		4396598	DEC 30, 2002	U-465		
020923 003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
020316 001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009			
020316 002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009			
020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		NCE	SEP 30, 2002
		6342247	JUN 07, 2015		I-373	SEP 17, 2005
020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		NCE	SEP 30, 2002
		6342247	JUN 07, 2015		I-373	SEP 17, 2005
020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		NCE	SEP 30, 2002
		6342247	JUN 07, 2015		I-373	SEP 17, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007		I-299	APR 20, 2003
		6403569	APR 28, 2020	U-449		
040024 001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
018662 002	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 003	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 004	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
019546 001	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U-3		
019546 002	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U-3		
020336 001	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U-3		
		4466972	AUG 21, 2003	U-3		
		4783337	SEP 16, 2003	U-3		
		4946687	AUG 07, 2007			
		5030456	JUL 09, 2008			
		4950486	AUG 21, 2007			
020336 002	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U-3		
		4783337	SEP 16, 2003	U-3		
		4946687	AUG 07, 2007			
		4466972	AUG 21, 2003	U-3		
		4950486	AUG 21, 2007			
		5030456	JUL 09, 2008			
020083 001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
020657 001	ITRACONAZOLE;SPORANOX	5707975	JAN 13, 2015		I-332	MAY 09, 2004
		4727064	FEB 23, 2005			
		6407079	JUN 18, 2019			
020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
		4727064	FEB 23, 2005			
		6407079	JUN 18, 2019			
019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
019927 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
020310 001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
		5456851	APR 07, 2014			
019700 001	KETOROLAC TROMETHAMINE;ACULAR	5110493	MAY 05, 2009	U-75	M-16	FEB 08, 2005
		4454151*PED	SEP 22, 2002	U-75		
		5110493*PED	NOV 05, 2009	U-75		
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE FREE	4454151*PED	SEP 22, 2002		M-16	FEB 08, 2005
021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
020857 001	LAMIVUDINE;COMBIVIR	4828838*PED	MAR 17, 2006			
		4833130*PED	MAR 17, 2006			
		4837208	SEP 17, 2005			
		5047407*PED	AUG 08, 2009			
		4724232*PED	MAR 17, 2006			
		4818538*PED	MAR 17, 2006			
		5859021*PED	NOV 15, 2012	U-248		
		5905082*PED	NOV 18, 2016	U-248		
		6113920	OCT 23, 2017	U-257		
		6113920*PED	APR 23, 2018	U-257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	FEB 08, 2009			
		5859021	MAY 15, 2012	U-248		
		5905082	MAY 18, 2016	U-248		
		4837208*PED	MAR 17, 2006			
		6180639	JAN 30, 2018	U-248		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		6180639*PED	JUL 30, 2018	U-248		
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020564 003	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NS	JUN 24, 2005
		5047407*PED	MAY 17, 2010		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		D-2	JUN 24, 2005
		6004968	MAR 20, 2018			
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-339	AUG 16, 2004
		5532246	JUL 02, 2013	U-250	PED	FEB 16, 2005
		5905082	MAY 18, 2016			
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		5905082*PED	NOV 18, 2016			
021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		PED	FEB 16, 2005
		5532246	JUL 02, 2013	U-250	I-339	AUG 16, 2004
		6004968	MAR 20, 2018			
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		6004968*PED	SEP 20, 2018			
020241 001	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 002	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 003	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 004	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 005	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020241 006	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U-106	ODE	AUG 24, 2005
020764 001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U-106		
020764 002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U-106		
020764 003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U-106		
020406 001	LANSOPRAZOLE;PREVACID	5093132	SEP 03, 2008		M-1	JUL 06, 2002
		5045321	SEP 03, 2008		I-316	NOV 30, 2003
		4689333	JUL 29, 2005	U-126	M-12	JUL 31, 2005
		5026560	JUN 25, 2008			
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
		5013743	FEB 12, 2010	U-452		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020406 002	LANSOPRAZOLE;PREVACID	4689333	JUL 29, 2005	U-126	M-1	JUL 06, 2002
		5026560	JUN 25, 2008		I-316	NOV 30, 2003
		5045321	SEP 03, 2008		M-12	JUL 31, 2005
		5093132	SEP 03, 2008			
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
		5013743	FEB 12, 2010	U-452		
021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
021428 001	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U-126		
		5013743	FEB 12, 2010	U-452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
021428 002	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U-126		
		5013743	FEB 12, 2010	U-452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260	I-375	DEC 20, 2005
		5422368	MAR 22, 2011	U-260		
		4599353	JUL 28, 2006	U-260		
		6429226	SEP 06, 2009	U-260		
020905 001	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
020905 002	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
020905 003	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
020807 001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
					NCE	MAR 06, 2003
020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203	NCE	JUL 25, 2002
					I-318	JAN 10, 2004
021343 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014		NP	JAN 23, 2005
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021379 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014		NP	JUL 24, 2005
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
		5631021	MAY 20, 2014			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	NOV 19, 2013			
		5480656	JAN 02, 2013			
		4849228	JUL 18, 2006			
		5330767	NOV 01, 2004			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		5330767	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5476663	NOV 01, 2004			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5643607	JAN 02, 2013			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5330767	NOV 01, 2004			
		5643607	JAN 02, 2013			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
021088 001	LEUPROLIDE ACETATE;VIADUR	5728396	JAN 30, 2017	U-316	NP	MAR 03, 2003
		5932547	JUN 13, 2017			
		5985305	JAN 30, 2017			
		6113938	JUL 24, 2018			
		6124261	JUN 13, 2017			
		6132420	JAN 30, 2017			
		6156331	JAN 30, 2017			
		6235712	JUN 13, 2017			
		6375978	DEC 17, 2018			
		6395292	JAN 30, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362555	NOV 08, 2011		I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
		6083993	JAN 05, 2010	U-332		
		6451289	MAR 21, 2021			
020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
		6083993	JAN 05, 2010	U-332		
		6451289	MAR 21, 2021			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020837 003	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
		6083993	JAN 05, 2010	U-332		
		6451289	MAR 21, 2021			
020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U-42		
021035 001	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 002	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 003	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON	4911920	MAR 27, 2007	U-369	NP	FEB 23, 2003
		5540918	JUL 30, 2013			
020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	4369184	DEC 02, 2004			
020182 001	LEVOCARNITINE;CARNITOR	6335369	JAN 18, 2021	U-433	I-280	DEC 15, 2002
		6429230	JAN 18, 2021	U-433	ODE	DEC 15, 2006
020634 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
020634 002	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
020634 003	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
020635 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-305	FEB 02, 2003
					I-357	APR 08, 2003
					I-372	OCT 30, 2005
021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
		5503407	OCT 01, 2008			
		4551456	NOV 14, 2003			
		5053407	OCT 01, 2008			
021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
021342 001	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 002	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021342 003	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 004	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 005	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 006	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 007	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 008	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 009	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 010	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 011	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
019941 001	LIDOCAINE;EMLA	4529601	JUL 16, 2002		I-314	JAN 28, 2003
		4562060	DEC 31, 2002			
020575 001	LIDOCAINE;LIDOCAINE	5446070	FEB 27, 2011			
		5234957	FEB 27, 2011			
		5332576	JUL 26, 2011			
020575 002	LIDOCAINE;LIDOCAINE	5332576	JUL 26, 2011			
		5234957	FEB 27, 2011			
		5446070	FEB 27, 2011			
020612 001	LIDOCAINE;LIDODERM	5589180	MAR 05, 2016	U-485	ODE	MAR 19, 2006
		5441738	MAY 01, 2012	U-485		
		5827529	JUN 10, 2011	U-486		
		5709869	DEC 23, 2016	U-487		
		5601838	MAY 18, 2010	U-488		
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
019777 001	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 002	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 003	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 004	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 005	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
					PED	AUG 07, 2003
019777 006	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
					PED	AUG 07, 2003
020191 001	LODOXAMIDE TROMETHAMINE;ALOMIDE	5457126	OCT 10, 2012	U-117		
020013 001	LOMEFLOXACIN HYDROCHLORIDE;MAXAQUIN	4528287	FEB 21, 2006	U-36		
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
		5716641	MAY 21, 2012	U-226		
021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5612054	SEP 28, 2010			
		5248505	SEP 28, 2010	U-434		
		6103260	JUL 17, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U-351	NC	SEP 15, 2003
		5635523	JUN 30, 2014	U-352		
		5541206	JUL 30, 2013	U-348		
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
		6232333	NOV 07, 2017			
		6284767	FEB 14, 2016	U-401		
		6458818	NOV 07, 2017			
021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U-348	NC	SEP 15, 2003
		5914332	DEC 13, 2005	U-351		
		5635523	JUN 03, 2014	U-352		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
		6284767	FEB 14, 2016	U-401		
019658 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
		4282233*PED	DEC 19, 2002	U-77		
		6132758	JUN 01, 2018			
020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4863931*PED	MAR 15, 2009			
019670 001	LORATADINE;CLARITIN-D	4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
		5314697*PED	APR 23, 2013			
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4863931*PED	MAR 15, 2009			
		5314697	OCT 23, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	MAR 09, 2012		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	MAR 09, 2012		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
020841 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
		5540930	OCT 25, 2013			
021249 001	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U-448		
		6406715	OCT 31, 2017	U-450		
021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U-448		
		6406715	OCT 31, 2017	U-450		
021249 003	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U-448		
		6406715	OCT 31, 2017	U-450		
021316 001	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456		
021316 002	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456		
021316 003	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456		
021316 004	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U-456		
019643 002	LOVASTATIN;MEVACOR				PED	SEP 11, 2002
					PED	AUG 14, 2005
					I-350	FEB 14, 2005
019643 003	LOVASTATIN;MEVACOR				PED	SEP 11, 2002
					PED	AUG 14, 2005
					I-350	FEB 14, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019643 004	LOVASTATIN;MEVACOR				PED	SEP 11, 2002
					PED	AUG 14, 2005
					I-350	FEB 14, 2005
021047 001	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
021047 002	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
019832 003	MAFENIDE ACETATE;SULFAMYLON				ODE	JUN 05, 2005
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	NOV 27, 2011		NCE	NOV 26, 2002
		4992554	FEB 12, 2008			
		5091169	FEB 25, 2009			
		5223243	JUN 29, 2010	U-237		
		4647447	MAR 03, 2004	U-238		
019940 001	MASOPROCOL;ACTINEX	4695590	APR 17, 2008			
		5008294	APR 15, 2008	U-68		
019591 001	MEFLOQUINE HYDROCHLORIDE;LARIAM	4579855	OCT 01, 2004			
076175 001	MEFLOQUINE HYDROCHLORIDE;MEFLOQUINE HCL				PC	NOV 03, 2002
020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011			
020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
020938 002	MELOXICAM;MOBIC				NCE	APR 13, 2005
020207 001	MELPHALAN HYDROCHLORIDE;ALKERAN	4997651	NOV 18, 2008			
020922 001	MEQUINOL;SOLAGE	5194247	MAR 16, 2010	U-294	NC	DEC 10, 2004
		5470567	MAR 19, 2010	U-294		
		6353029	AUG 24, 2020			
019651 001	MESALAMINE;ASACOL	5541170	JUL 30, 2013	U-141		
		5541171	JUL 30, 2013	U-141		
019618 001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
		RE33239	MAY 12, 2004			
019884 001	MESNA;MESNEX	5696172	OCT 06, 2013			
020855 001	MESNA;MESNEX	5252341	JUL 16, 2011		NDF	MAR 21, 2005
		5262169	JUL 16, 2011			
013217 001	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
013217 003	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
		5741803	APR 21, 2015	U-493		
		6288095	FEB 11, 2017	U-493		
		5965584	JUN 19, 2016	U-493		
		6166042	JUN 19, 2016	U-493		
021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
		5741803	APR 21, 2015	U-493		
		6288095	FEB 11, 2017	U-493		
		5965584	JUN 19, 2016	U-493		
		6166042	JUN 19, 2016	U-493		
021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
		5741803	APR 21, 2015	U-493		
		6288095	FEB 11, 2017	U-493		
		5965584	JUN 19, 2016	U-493		
		6166042	JUN 19, 2016	U-493		
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018		NDF	OCT 13, 2003
020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009			
		5036102	JUL 30, 2008	U-273		
		4999375	MAR 12, 2008			
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U-372		
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U-372		
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U-372		
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4519801	JUL 12, 2002		NP	AUG 01, 2003
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003	U-372		
		5082668	SEP 16, 2003			
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019	U-472		
021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019	U-472		
021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	NOV 01, 2019	U-472		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
017862 001	METOCLOPRAMIDE HYDROCHLORIDE;REGLAN	4536386	AUG 20, 2002	U-9		
017862 004	METOCLOPRAMIDE HYDROCHLORIDE;REGLAN	4536386	AUG 20, 2002	U-9		
019532 001	METOLAZONE;MYKROX	4517179	APR 29, 2003			
019786 003	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019786 004	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007	U-107		
		5081154	JAN 14, 2009			
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007	U-107		
		5081154	JAN 14, 2009			
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	I-194	FEB 05, 2004
		5001161	MAR 19, 2008			
		5081154	JAN 14, 2009			
		4927640	MAY 27, 2007			
		5246714	SEP 21, 2010			
019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
		5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
		5081154	JAN 14, 2009	U-107		
		4927640	MAY 22, 2007			
		5246714	SEP 21, 2010			
019737 001	METRONIDAZOLE;METROGEL	4837378	JUN 06, 2006			
020208 001	METRONIDAZOLE;METROGEL-VAGINAL	5536743	JUL 16, 2013	U-137		
		4837378	JUN 06, 2006			
		5840744	JAN 15, 2008	U-370		
020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014			
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATION PACK	6153635	NOV 28, 2020			
		5514698	MAR 21, 2014			
019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 003	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
020687 001	MIFEPRISTONE;MIFEPREX	4626531	OCT 12, 2004		NCE	SEP 28, 2005
020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
020415 001	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017		M-18	APR 09, 2005
020415 002	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017		M-18	APR 09, 2005
020415 003	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017		M-18	APR 09, 2005
021208 001	MIRTAZAPINE;REMERON SOLTAB	5977099	JUN 26, 2017		M-18	APR 09, 2005
		5178878	JAN 12, 2010			
021208 002	MIRTAZAPINE;REMERON SOLTAB	5977099	JUN 16, 2017		M-18	APR 09, 2005
		5178878	JAN 12, 2010			
021208 003	MIRTAZAPINE;REMERON SOLTAB	5977099	JUN 16, 2017		M-18	APR 09, 2005
		5178878	JAN 12, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4820738	APR 11, 2006	U-98	ODE	NOV 13, 2003
		4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
					ODE	OCT 13, 2007
020098 001	MIVACURIUM CHLORIDE;MIVACRON	4761418	JAN 22, 2006			
020098 002	MIVACURIUM CHLORIDE;MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006			
020717 001	MODAFINIL;PROVIGIL	4927855	MAY 22, 2007	U-255	ODE	DEC 24, 2005
		RE37516	OCT 06, 2014	U-255	NCE	DEC 24, 2003
020717 002	MODAFINIL;PROVIGIL	4927855	MAY 22, 2007	U-255	ODE	DEC 24, 2005
		RE37516	OCT 06, 2014	U-255	NCE	DEC 24, 2003
020312 001	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020312 002	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699	JAN 27, 2014	U-249	I-285	DEC 02, 2002
		6127353	OCT 03, 2017		PED	JUN 02, 2003
		5837699*PED	JUL 27, 2014	U-249	I-360	JUL 17, 2005
		6127353*PED	APR 03, 2018		PED	JAN 17, 2006
019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
		4808610*PED	APR 02, 2007			
019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
		4775529*PED	NOV 21, 2007			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
					I-378	DEC 31, 2005
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
					I-378	DEC 31, 2005
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	I-300	MAR 03, 2003
		5565473*PED	AUG 03, 2012	U-228	NS	MAR 03, 2003
					NCE	FEB 20, 2003
					PED	SEP 03, 2003
					PED	AUG 20, 2003
					PED	SEP 03, 2003
					I-378	DEC 31, 2005
021409 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012		NDF	JUL 26, 2005
		5565473*PED	AUG 03, 2012		PED	JAN 26, 2006
					NCE	FEB 20, 2003
					PED	AUG 20, 2003
					I-378	DEC 31, 2005
021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
020616 001	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
020616 002	MORPHINE SULFATE;KADIAN	5378474	MAR 23, 2010			
		5202128	APR 13, 2010			
020616 003	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	4990517	JUN 30, 2009	U-298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U-298	I-329	APR 27, 2004
		5849752	DEC 05, 2016	U-298		
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHLORIDE 0.8%				NCE	DEC 10, 2004
					NDF	NOV 30, 2004
					I-329	APR 27, 2004
019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
		4420639*PED	JUN 13, 2003			
019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
		4420639*PED	JUN 13, 2003			
021076 001	NAPROXEN SODIUM;ALEVE COLD AND SINUS				NC	NOV 29, 2002
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U-232	NCE	FEB 10, 2003
020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U-232	NCE	FEB 10, 2003
021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012			
		5488150	JAN 30, 2013			
021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012			
		5488150	JAN 30, 2013			
021009 001	NEDOCROMIL SODIUM;ALOCRIL	4474787	OCT 02, 2006	U-304	NP	DEC 08, 2002
		4760072	JUL 26, 2005			
019660 001	NEDOCROMIL SODIUM;TILADE	4474787	OCT 02, 2006			
		4760072	JUL 26, 2005			
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
		4338317*PED	SEP 16, 2003			
		5256664*PED	OCT 28, 2012			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
		4338317*PED	SEP 16, 2003			
		5256664*PED	OCT 28, 2012			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
		4338317*PED	SEP 16, 2003			
		5256664*PED	OCT 28, 2012			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
		4338317*PED	SEP 16, 2003			
		5256664*PED	OCT 28, 2012			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
		4338317*PED	SEP 16, 2003			
		5256664*PED	OCT 28, 2012			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	APR 28, 2012			
		4338317*PED	SEP 16, 2003			
		5256664*PED	OCT 28, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		D-52	NOV 24, 2002
		5952343	OCT 07, 2013	U-257		
		6162812	OCT 07, 2013	U-248		
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		D-52	NOV 24, 2002
		5952343	OCT 07, 2013	U-257		
		6162812	OCT 07, 2013	U-248		
020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
		5674710	OCT 07, 2014			
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167		
020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011			
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
		6406715	OCT 31, 2017	U-450		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
		6406715	OCT 31, 2017	U-450		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
		6406715	OCT 31, 2017	U-450		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
		6406715	OCT 31, 2017	U-450		
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK	6080428	MAY 27, 2017	U-331		
		6406715	OCT 31, 2017	U-450		
		6129930	SEP 20, 2013	U-354		
019734 001	NICARDIPINE HYDROCHLORIDE;CARDENE	4880823	NOV 14, 2006			
		5164405	NOV 17, 2009			
020005 001	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 002	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 003	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
021330 001	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
021330 002	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
020076 001	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 002	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 003	NICOTINE;HABITROL	4597961	JAN 23, 2005	U-56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U-355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355	D-71	NOV 12, 2002
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355	D-71	NOV 12, 2002
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355	D-71	NOV 12, 2002
020165 004	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		6165497	JUN 14, 2008	U-388		
		5633008	JUN 14, 2008	U-389		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020165 005	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U-389		
		6165497	JUN 14, 2008	U-388		
020165 006	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U-389		
		6165497	JUN 14, 2008	U-388		
020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	5400808	JUN 08, 2010			
		4917120	APR 17, 2007			
		4800903	JAN 31, 2006			
		4793366	DEC 27, 2005			
		5167242	JUN 08, 2010			
		5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
019983 001	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U-56		
019983 002	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U-56		
020198 001	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 002	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 003	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
019684 001	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 002	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 003	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
018869 001	NIMODIPINE;NIMOTOP	4406906	SEP 27, 2002	U-22		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020356 001	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U-3		
020356 002	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U-3		
020356 003	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U-3		
020356 004	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U-3		
021498 001	NITAZOXANIDE;ALINIA				NCE	NOV 22, 2007
					ODE	NOV 22, 2009
021232 001	NITISINONE;ORFADIN				NCE	JAN 18, 2007
					ODE	JAN 18, 2009
021232 002	NITISINONE;ORFADIN				NCE	JAN 18, 2007
					ODE	JAN 18, 2009
021232 003	NITISINONE;ORFADIN				NCE	JAN 18, 2007
					ODE	JAN 18, 2009
020845 002	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
					NCE	DEC 23, 2004
020845 003	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
					NCE	DEC 23, 2004
020064 001	NITROFURANTOIN;MACROBID	4772473	JUN 16, 2006			
		4798725	JUN 16, 2006			
020145 001	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 002	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 003	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 004	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 005	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 006	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5186925	FEB 16, 2010			
021134 001	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018		NDF	MAY 01, 2003
021134 002	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018		NDF	MAY 01, 2003
021134 003	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018		NDF	MAY 01, 2003
019757 001	NORFLOXACIN;CHIBROXIN	4551456	NOV 14, 2003	U-57		
019384 002	NORFLOXACIN;NOROXIN	4639458	JAN 22, 2005			
019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
		5753618	MAY 19, 2015			
019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	4395403	OCT 21, 2002			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
		4395403	NOV 21, 2002	U-269		
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
		6395292	JAN 30, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
		4395403	NOV 21, 2002	U-269		
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
		4395403	NOV 21, 2002	U-269		
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
019735 001	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 002	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 003	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		ODE	MAY 22, 2003
		4551456	NOV 14, 2003	U-80		
020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
					I-313	NOV 09, 2003
020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
					I-313	NOV 09, 2003
020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
					I-313	NOV 09, 2003
020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
					I-313	NOV 09, 2003
020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
					I-313	NOV 09, 2003
020592 006	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	I-297	MAR 17, 2003
					I-313	NOV 09, 2003
021086 001	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U-324		
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U-324		
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U-324		
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U-324		
021286 001	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
021286 003	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
021286 004	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184	I-301	MAR 20, 2003
		4871865	OCT 03, 2006			
		4923892	MAY 08, 2007	U-174		
		5116863	DEC 18, 2010			
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
019810 001	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U-108	M-19	JUL 12, 2005
		4853230	APR 20, 2007	U-108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		4508905*PED	OCT 02, 2002			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019810 002	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U-108	M-19	JUL 12, 2005
		4853230	APR 20, 2007	U-108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		4508905*PED	OCT 02, 2002			
019810 003	OMEPRAZOLE;PRILOSEC	4853230	APR 20, 2007	U-108	M-19	JUL 12, 2005
		4786505	APR 20, 2007	U-108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		4508905*PED	OCT 02, 2002			
020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U-44		
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44	I-269	AUG 27, 2002
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U-44		
		5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44	I-269	AUG 27, 2002
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U-44		
		5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
		5578628	FEB 16, 2005	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U-44		
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005	U-183		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE FREE	5578628	FEB 16, 2005	U-44		
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009		NCE	APR 23, 2004
		6004996	JAN 06, 2018			
021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
		5866601	FEB 02, 2016		I-317	NOV 17, 2003
		5952375	FEB 02, 2016			
021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
		5866601	FEB 02, 2016		NDF	DEC 14, 2003
		5952375	FEB 02, 2016		NCE	OCT 27, 2004
021492 001	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
		5290961	JAN 12, 2013			
021492 002	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
		5290961	JAN 12, 2013			
020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA				NE	OCT 17, 2005
015539 002	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 004	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 006	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		5840754	MAY 22, 2015			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
		4783337*PED	MAR 16, 2004			
		4519801*PED	JAN 12, 2003			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U-378		
		6262115*PED	NOV 22, 2015	U-393		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
		4783337*PED	MAR 16, 2004			
		4519801*PED	JAN 12, 2003			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U-378		
		6262115*PED	NOV 22, 2015	U-393		
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
		4783337*PED	MAR 16, 2004			
		4519801*PED	JAN 12, 2003			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U-378		
		6262115*PED	NOV 22, 2015	U-393		
020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		4861598	AUG 29, 2006			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		4861598	AUG 29, 2006			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
		4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
020262 001	PACLITAXEL;TAXOL	5670537	AUG 03, 2012	U-198	D-57	JUN 20, 2003
		5496804	MAR 09, 2013	U-204	I-270	OCT 25, 2002
		6150398	MAY 08, 2011	U-380	ODE	AUG 04, 2004
020036 001	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 003	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 004	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
		5997903	DEC 07, 2016		I-330	JUN 12, 2004
					I-356	APR 19, 2005
020987 002	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		I-356	APR 19, 2005
		5997903	DEC 07, 2016		I-330	JUN 12, 2004
					NCE	FEB 02, 2005
020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
					NCE	FEB 02, 2005
					I-337	OCT 19, 2004
020819 001	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U-314	NCE	APR 17, 2003
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	NOV 17, 2002
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	NOV 17, 2002
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	NOV 17, 2002
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	NOV 17, 2002
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
		6121291	MAR 17, 2017	U-286		
		6121291	MAR 17, 2017	U-431		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	NOV 17, 2002
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		PED	NOV 17, 2002
		5811436	SEP 22, 2015		I-345	DEC 14, 2004
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		PED	JUN 14, 2005
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007			
		5789449*PED	JUL 06, 2009	U-285		
		5811436*PED	MAR 22, 2016			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		PED	NOV 17, 2002
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	I-326	APR 13, 2004
		4721723	DEC 29, 2006	U-12	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		PED	NOV 17, 2002
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	I-326	APR 13, 2004
		4721723	DEC 29, 2006	U-12	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		PED	NOV 17, 2002
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	I-326	APR 13, 2004
		4721723	DEC 29, 2006	U-12	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6172233*PED	JUL 15, 2018			
		5872132	MAY 19, 2015		PED	NOV 17, 2002
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	I-326	APR 13, 2004
		4721723	DEC 29, 2006	U-12	PED	JUN 14, 2005
		6062927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U-286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6133289*PED	NOV 19, 2015	U-286		
		6172233*PED	JUL 15, 2018			
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U-286		
		5872132*PED	NOV 19, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6133289*PED	NOV 19, 2015	U-286		
		6172233*PED	JUL 15, 2018			
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		5789449	JAN 06, 2009	U-286		
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U-286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6133289*PED	NOV 19, 2015	U-286		
		6172233*PED	JUL 15, 2018			
021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
		5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	SEP 24, 2010			
020193 001	PENTOSAN POLYSULFATE SODIUM;ELMIRON	5180715	JAN 19, 2010	U-159	ODE	SEP 26, 2003
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCTION	5607979	MAY 30, 2015		NCE	FEB 17, 2005
021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
		5547656	APR 05, 2011			
		5769080	JUL 20, 2010			
019385 001	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 002	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 003	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
020184 001	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 002	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 003	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020237 001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
021302 001	PIMECROLIMUS;ELIDEL	5912238	JUN 15, 2016		NCE	DEC 13, 2006
		5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
		6352998	OCT 26, 2015			
		6352998*PED	APR 26, 2016			
		6423722	JUN 26, 2018			
		6423722*PED	DEC 26, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2006		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U-410		
		6271243	JUN 19, 2016	U-411		
		6303640	AUG 09, 2016	U-425		
		6166042	JUN 19, 2016	U-414		
		6166043	JUN 19, 2016	U-415		
		6172090	JUN 19, 2016	U-416		
		5965584	JUN 19, 2016	U-417		
		6150383	JUN 19, 2016	U-418		
		6150384	JUN 19, 2016	U-419		
		6329404	JUN 19, 2016	U-430		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2006		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U-410		
		6271243	JUN 19, 2016	U-411		
		6303640	AUG 09, 2016	U-425		
		6166042	JUN 19, 2016	U-414		
		6166043	JUN 19, 2016	U-415		
		6172090	JUN 19, 2016	U-416		
		5965584	JUN 19, 2016	U-417		
		6150383	JUN 19, 2016	U-418		
		6150384	JUN 19, 2016	U-419		
		6329404	JUN 19, 2016	U-430		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2006		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U-410		
		6271243	JUN 19, 2016	U-411		
		6303640	AUG 09, 2016	U-425		
		6166042	JUN 19, 2016	U-414		
		6166043	JUN 19, 2016	U-415		
		6172090	JUN 19, 2016	U-416		
		5965584	JUN 19, 2016	U-417		
		6150383	JUN 19, 2016	U-418		
		6150384	JUN 19, 2016			
		6329404	JUN 19, 2016	U-430		
020014 001	PIRBUTEROL ACETATE;MAXAIR	4664107	MAY 12, 2004			
020529 001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004			
		5057616	OCT 15, 2008			
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265		
		6048901	APR 20, 2019	U-343		
020744 001	PORACTANT ALFA;CUROSURF				NCE	NOV 18, 2004
020451 001	PORFIMER SODIUM;PHOTOFRIN	4866168	MAR 10, 2004		ODE	DEC 27, 2002
		5028621	MAR 10, 2004			
		5438071	AUG 01, 2012			
		4649151	MAR 10, 2004			
		4932934	JUN 12, 2007	U-128		
		5145863	DEC 15, 2009	U-129		
019439 002	POTASSIUM CHLORIDE;K-DUR 10	4863743	SEP 05, 2006	U-99		
019439 001	POTASSIUM CHLORIDE;K-DUR 20	4863743	SEP 05, 2006	U-99		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	NOV 23, 2007	U-231		
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	NOV 23, 2007	U-231		
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	NOV 23, 2007	U-231		
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	NOV 23, 2007	U-231		
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011		NCE	JUL 01, 2002
		4843086	NOV 23, 2007	U-231		
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U-231		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5180589	JUL 09, 2008		I-304	JAN 18, 2003
		5030447	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
		5030447	JUL 09, 2008		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	JUN 18, 2005
		5622985	APR 22, 2014	U-335	PED	JUN 18, 2005
		4346227*PED	APR 20, 2006		I-281	JUN 09, 2003
		5180589*PED	JAN 09, 2009		PED	DEC 09, 2003
		5622985*PED	OCT 22, 2014	U-335	D-51	JAN 18, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					I-286	JAN 18, 2003
					PED	JUL 18, 2003
					I-287	FEB 10, 2003
					PED	AUG 10, 2003
					I-304	JAN 18, 2003
					PED	JUL 18, 2003
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019775 001	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
019775 002	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
020545 001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208		
		5543150	SEP 15, 2013	U-209		
020701 002	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208		
		5543150	SEP 15, 2013	U-209		
019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015		I-322	FEB 20, 2004
		5714520*PED	SEP 22, 2015		PED	AUG 20, 2004
		5731355	MAR 22, 2015	U-217		
		5731355*PED	SEP 22, 2015	U-217		
		5731356	MAR 22, 2015	U-218		
		5731356*PED	SEP 22, 2015	U-218		
		5908869	MAR 22, 2015	U-270		
		5908869*PED	SEP 22, 2015	U-270		
019536 001	PROPRANOLOL HYDROCHLORIDE;INDERAL	4600708	JUL 19, 2005			
020021 002	PSEUDOEPHEDRINE HYDROCHLORIDE;EFIDAC 24 PSEUDOEPHEDRINE HCL	4801461	MAR 14, 2006			
		4576604	MAR 18, 2003			
020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385	NCE	AUG 19, 2004
		5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385	NCE	AUG 19, 2004
		5035899	APR 04, 2009	U-385	I-346	FEB 12, 2005
					I-371	NOV 08, 2005
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003		I-271	SEP 30, 2002
		5393763	JUL 28, 2012	U-114	NCE	DEC 09, 2002
		5457117	JUL 28, 2012	U-114		
		5478847	MAR 02, 2014	U-114		
		5811120	MAR 02, 2014			
		5972383	MAR 02, 2014	U-287		
		6458811	MAR 10, 2017			
019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 002	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008		I-310	OCT 04, 2003
		4587258	JAN 27, 2005			
020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U-186		
		5008256	JUL 17, 2009			
		5256684	OCT 26, 2010	U-199		
		5403830	APR 04, 2012	U-200		
		5407688	APR 04, 2012	U-201		
		5601848	FEB 11, 2014	U-202		
		5456925	OCT 10, 2012			
019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		4585790*PED	NOV 11, 2004			
019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		4585790*PED	NOV 11, 2004			
019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004		D-53	OCT 29, 2002
		5068249	NOV 26, 2008		PED	APR 29, 2003
		5068249*PED	MAY 26, 2009			
		4521431*PED	DEC 04, 2002			
		4585790*PED	NOV 11, 2004			
018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4880636	MAY 13, 2008		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		4880636*PED	NOV 13, 2008			
020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		5028432*PED	AUG 22, 2010			
020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		5102665*PED	DEC 23, 2009			
020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		5102665*PED	DEC 23, 2009			
018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4880636	MAY 13, 2008		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		4880636*PED	NOV 13, 2008			
020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5028432	FEB 22, 2010		D-53	OCT 29, 2002
		4521431*PED	DEC 04, 2002		PED	APR 29, 2003
		5028432*PED	AUG 22, 2010			
020520 001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4880636	MAY 13, 2008			
		4880636*PED	NOV 13, 2008			
		4521431*PED	DEC 04, 2002			
020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583	FEB 15, 2009			
		5466700*PED	MAR 01, 2014	U-156		
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009			
		5466700*PED	MAR 01, 2014			
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009			
		5466700*PED	MAR 01, 2014	U-156		
020741 001	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006		NCE	DEC 22, 2002
		4873080	OCT 10, 2006		I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
020741 002	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U-214	NCE	DEC 22, 2002
		4873080	OCT 10, 2006		I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
020741 003	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U-214	NCE	DEC 22, 2002
		4873080	OCT 10, 2006		I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
021511 001	RIBAVIRIN;COPEGUS				NP	DEC 03, 2005
020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235		
		5914128	DEC 22, 2017			
		6051252	DEC 22, 2017			
		6063772	JAN 23, 2016	U-375		
		6172046	SEP 21, 2017	U-377		
		5767097*PED	JUL 23, 2016	U-235		
		5914128*PED	JUN 22, 2018			
		6051252*PED	JUN 22, 2018			
		6063772*PED	JUL 23, 2016	U-375		
		6172046*PED	MAR 21, 2018	U-377		
		6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018			
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			
		6177074	NOV 01, 2016	U-454		
		6177074*PED	MAY 01, 2017	U-454		
		6461605	NOV 01, 2016	U-478		
		6461605*PED	MAY 01, 2017	U-478		
		6472373	SEP 21, 2017	U-479		
		6472373*PED	MAR 21, 2018	U-479		
020903 002	RIBAVIRIN;REBETOL	6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018			
		5767097	JAN 23, 2016	U-235		
		5767097*PED	JUL 23, 2016	U-235		
		5914128	DEC 22, 2017			
		5914128*PED	JUN 22, 2018			
		6051252	DEC 22, 2017			
		6051252*PED	JUN 22, 2018			
		6063772	JAN 23, 2016	U-375		
		6063772*PED	JUL 23, 2016	U-375		
		6172046	SEP 21, 2017	U-377		
		6172046*PED	MAR 21, 2018	U-377		
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
021024 001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
					ODE	JUN 22, 2005
020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013		ODE	DEC 12, 2002
020474 001	RIMEXOLONE;VEXOL	4686214	JUL 22, 2008	U-100		
020835 001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
		6096342	MAR 12, 2017		I-291	APR 14, 2003
		6165513	JUN 10, 2018		I-290	APR 14, 2003
					I-293	APR 14, 2003
					NCE	MAR 27, 2003
020835 002	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
		6096342	MAR 12, 2017		NCE	MAR 27, 2003
		6165513	JUN 10, 2018		I-291	APR 14, 2003
					I-293	APR 14, 2003
					I-290	APR 14, 2003
020835 003	RISEDRONATE SODIUM;ACTONEL	5994329	JUL 17, 2018	U-353	NCE	MAR 27, 2003
		6015801	JUL 17, 2018	U-353	I-292	APR 14, 2003
					I-291	APR 14, 2003
					D-73	MAY 17, 2005
					D-74	MAY 17, 2005
020272 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020272 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020272 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020272 004	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020272 005	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020272 007	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
020588 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	M-15	MAR 03, 2005
		5453425	JUL 11, 2014			
		5616587	JUL 11, 2014			
020659 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
		5484801	JAN 28, 2014			
		5541206	JUL 30, 2013	U-140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-190		
		6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			
020680 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
		5541206	JUL 30, 2013	U-140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-190		
		5948436	SEP 13, 2013			
020945 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U-347		
		5541206	JUL 30, 2013	U-348		
		5635523	JUN 03, 2014	U-347		
		6232333	NOV 07, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014			
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014			
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014	U-240		
		5457895	OCT 01, 2013			
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240	NCE	JUN 29, 2003
		5602162	FEB 11, 2014	U-240		
		5457895	OCT 01, 2013			
020214 002	ROCURONIUM BROMIDE;ZEMURON	4894369	APR 13, 2008			
020214 001	ROCURONIUM BROMIDE;ZEMURON (P/F)	4894369	APR 13, 2008			
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
		6239173	JUN 24, 2013			
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
		6239173	JUN 24, 2013			
021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013		NCE	MAY 20, 2004
		5474995	JUN 24, 2013	U-266	I-353	APR 11, 2005
		5691374	MAY 18, 2015			
		6063811	MAY 06, 2017			
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
		6239173	JUN 24, 2013			
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
		6239173	JUN 24, 2013			
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007		NCE	SEP 19, 2002
		4824860	MAY 19, 2008	U-212		
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010		D-64	NOV 02, 2003
		4695576	SEP 22, 2004			
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	JUL 28, 2010			
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	JUL 28, 2010			
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	JUL 28, 2010			
021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
		6288095	FEB 11, 2017	U-420		
021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
		6288095	FEB 11, 2017	U-420		
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329	NCE	MAY 25, 2004
		6288095	FEB 11, 2017	U-420		
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4400358	AUG 23, 2002			
020772 001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
					NCE	APR 09, 2003
020236 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		M-5	JUN 30, 2003
		5225445	FEB 12, 2008	U-182		
		5126375	FEB 12, 2008			
020692 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		M-5	JUN 30, 2003
		5225445	FEB 12, 2008	U-211	I-348	MAR 22, 2005
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187		
020628 001	SAQUINAVIR MESYLATE;INVIRASE	5196438	NOV 19, 2010			
020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
		6352717	NOV 16, 2019			
		6008228	JUN 06, 2015			
021209 001	SECRETIN;SECREFLO				NP	APR 04, 2005
					ODE	APR 04, 2009
019863 001	SERMORELIN ACETATE;GEREF	4703035	DEC 28, 2004	U-47		
020443 001	SERMORELIN ACETATE;GEREF	4703035	DEC 28, 2004		ODE	SEP 26, 2004
020443 002	SERMORELIN ACETATE;GEREF	4703035	DEC 28, 2004		ODE	SEP 26, 2004
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-279	DEC 07, 2002
		4962128*PED	MAY 02, 2010	U-152	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U-152	PED	JUN 07, 2003
		4536518*PED	JUN 30, 2006	U-12	PED	FEB 06, 2005
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-279	DEC 07, 2002
		4536518*PED	JUN 30, 2006	U-12	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U-152	PED	JUN 07, 2003
		4962128*PED	MAY 02, 2010	U-152	PED	FEB 06, 2005
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-279	DEC 07, 2002
		4536518*PED	JUN 30, 2006	U-12	PED	JUN 07, 2003
		4962128	NOV 02, 2009	U-152	PED	FEB 06, 2005
		4962128*PED	MAY 02, 2010	U-152	M-11	AUG 06, 2004
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-279	DEC 07, 2002
		4536518*PED	JUN 30, 2006	U-12	PED	JUN 07, 2003
		4962128	NOV 02, 2009	U-152	PED	FEB 06, 2005
		4962128*PED	MAY 02, 2010	U-152	M-11	AUG 06, 2004
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-279	DEC 07, 2002
		4536518*PED	JUN 30, 2006	U-12	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U-152	PED	JUN 07, 2003
		4962128*PED	MAY 02, 2010	U-152	PED	FEB 06, 2005
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U-286	PED	FEB 06, 2005
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		M-17	MAR 30, 2004
		6074668	JAN 09, 2018		PED	SEP 30, 2004
		5990176*PED	JUL 27, 2017			
		6074668*PED	JUL 09, 2018			
		6288127	JAN 27, 2017			
		6288127*PED	JUL 27, 2017			
		6444859	JAN 27, 2017			
		6444859*PED	JUL 27, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007		NCE	NOV 22, 2002
		4929629	MAY 29, 2007		D-65	FEB 16, 2004
		5436272	JUL 25, 2012	U-439	M-9	FEB 16, 2004
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007		NCE	NOV 22, 2002
		4929629	MAY 29, 2007		D-65	FEB 16, 2004
		5436272	JUL 25, 2012	U-439	M-9	FEB 16, 2004
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007		NCE	NOV 22, 2002
		4929629	MAY 29, 2007		D-65	FEB 16, 2004
		5436272	JUL 25, 2012	U-439	M-9	FEB 16, 2004
020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012		NCE	MAR 27, 2003
		6469012	OCT 22, 2019	U-155		
020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012		NCE	MAR 27, 2003
		6469012	OCT 22, 2019	U-155		
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012		NCE	MAR 27, 2003
		6469012	OCT 22, 2019	U-155		
019608 001	SILVER SULFADIAZINE;SILDAFLO	4563184	JAN 07, 2003			
019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
					I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
					I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
					I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
					I-350	OCT 18, 2005
					PED	APR 18, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019766 005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
		RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
		RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
		4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
		RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
		RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
					I-350	OCT 18, 2005
					PED	APR 18, 2006
021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U-291		
		5308847	MAY 03, 2011	U-292		
		5403833	APR 04, 2012	U-293		
		5536729	SEP 30, 2013			
021110 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U-291		
		5308847	MAY 03, 2011	U-292		
		5403833	APR 04, 2012	U-293		
		5989591	MAR 11, 2018			
020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT				NCE	FEB 18, 2004
021196 001	SODIUM OXYBATE;XYREM				ODE	JUL 17, 2009
					NCE	JUL 17, 2007
020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136	ODE	APR 30, 2003
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U-359	NP	SEP 21, 2003
019107 001	SOMATREM;PROTROPIN	4658021	APR 14, 2004			
020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
					ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
		5633352	MAR 10, 2015		ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		ODE	OCT 31, 2004
					ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		6152897	JUN 11, 2018		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		5633352	MAR 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5716338	FEB 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
		5633352	MAR 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		5633352	MAR 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
		5633352	MAR 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
					ODE	OCT 29, 2004
019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
					ODE	OCT 29, 2004
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
					M-2	DEC 01, 2002
021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
		5912015	MAR 12, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
		5912015	MAR 12, 2012			
021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U-340		
		5912015	MAR 12, 2012			
020604 001	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020604 002	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020604 004	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020677 001	SPARFLOXACIN;ZAGAM	4795751	FEB 04, 2010	U-160		
020240 001	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 002	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 003	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020240 004	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U-3		
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008			
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
		6368627	MAR 02, 2012	U-444		
		5863559	JAN 26, 2016	U-72		
		6020001	MAR 02, 2012	U-444		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008	U-72		
		6368627	MAR 02, 2012	U-444		
		5863559	JAN 26, 2016	U-72		
		6020001	MAR 02, 2012	U-444		
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U-72		
		4816470	DEC 28, 2006	U-72		
		6368627	MAR 02, 2012	U-444		
		5863559	JAN 26, 2016	U-72		
		6020001	MAR 02, 2012	U-444		
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U-232		
		5705520	DEC 10, 2011	U-232		
019387 001	SUPROFEN;PROFENAL	4559343	DEC 17, 2002			
020070 001	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 002	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 003	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020070 004	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U-97		
		4816456	SEP 09, 2007			
020587 001	TALC;SCLEROSOL				NCE	DEC 24, 2002
					ODE	DEC 24, 2004
017970 001	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002		M-20	AUG 30, 2005
		4536516*PED	FEB 20, 2003		PED	MAR 01, 2006
017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
		4536516*PED	FEB 20, 2003			
020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181		
		4731478	OCT 27, 2004			
		4703063	OCT 27, 2009			
		4772475	FEB 27, 2006			
021184 003	TAZAROTENE;AVAGE	5089509	JUN 13, 2011	U-481	NP	SEP 30, 2005
020600 001	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-193		
		5089509	JUN 13, 2011	U-481		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020600 002	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-193		
		5089509	JUN 13, 2011	U-481		
021184 001	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-481	NDF	SEP 29, 2003
021184 002	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-481	NDF	SEP 29, 2003
					I-344	OCT 11, 2004
020887 001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
		5645815	JUL 08, 2014			
		5443815	AUG 22, 2012			
020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5279811	NOV 23, 2008	U-101		
		5431900	JUL 11, 2012	U-336		
021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
019829 001	TECHNETIUM TC-99M EXAMETAZIME KIT;CERETEC	4615876	OCT 07, 2003			
		4789736	DEC 06, 2005			
019981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT;ULTRATAG	4755375	JUL 05, 2005	U-51		
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT;CARDIOTEC	4705849	NOV 10, 2004			
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008			
021200 001	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U-466	NCE	JUL 24, 2007
021200 002	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U-466	NCE	JUL 24, 2007
020850 001	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
020850 002	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
018163 003	TEMAZEPAM;RESTORIL	5030632	JUL 09, 2008	U-70		
		5326758	JUL 09, 2008	U-70		
		5211954	MAY 18, 2010			
021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U-248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U-248		
		5935946	JUL 25, 2017	U-248		
		4808716	APR 25, 2006	U-248		
		6057305	MAY 02, 2017	U-248		
		5922695	JUL 25, 2017	U-248		
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
		4680291	JUL 14, 2004	U-281		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006			
020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
		5681849	OCT 28, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020846 001	TERBINAFINE;LAMISIL	4755534	DEC 30, 2006	U-445		
		4680291	JUL 14, 2004	U-445		
021318 001	TERIPARATIDE ACETATE;FORTEO				NP	NOV 26, 2005
020489 001	TESTOSTERONE;ANDRODERM	4863970	SEP 05, 2006			
		4983395	JAN 08, 2009			
		5152997	OCT 06, 2009			
		5164190	NOV 17, 2008			
		4849224	JUL 18, 2006			
		4855294	AUG 08, 2006			
021015 001	TESTOSTERONE;ANDROGEL	6503894	AUG 30, 2020	U-490	NDF	FEB 28, 2003
021454 001	TESTOSTERONE;TESTIM	5023252	JUN 11, 2008	U-483		
019762 001	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4725439	FEB 16, 2005			
		4867982	FEB 16, 2005			
		5840327	AUG 15, 2016			
019762 002	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		5840327	AUG 15, 2016			
020791 001	TESTOSTERONE;TESTODERM TTS	6348210	NOV 10, 2019	U-440		
020785 001	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U-371	NCE	JUL 16, 2003
		6315720	OCT 23, 2020	U-442	ODE	JUL 16, 2005
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010		ODE	NOV 30, 2005
		5602006	FEB 11, 2014		NCE	NOV 30, 2003
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019979 001	TICLOPIDINE HYDROCHLORIDE;TICLID	4591592	MAY 27, 2003			
019979 002	TICLOPIDINE HYDROCHLORIDE;TICLID	4591592	MAY 27, 2003			
020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010			
		4980171	APR 06, 2009			
020963 001	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020963 002	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	AUG 29, 2006			
		4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	AUG 29, 2006			
		4861760	SEP 25, 2006			
020439 001	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020439 002	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230	NCE	MAY 14, 2003
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U-254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230	NCE	MAY 14, 2003
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U-254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
021447 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 003	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012		NCE	JAN 29, 2003
		5476875	DEC 19, 2012	U-219		
020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012		NCE	JAN 29, 2003
		5476875	DEC 19, 2012	U-219		
020771 001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
		5559269	NOV 05, 2013	U-318		
020771 002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
		5559269	NOV 05, 2013	U-318		
021228 001	TOLTERODINE TARTRATE;DETROL LA	5382600	JAN 17, 2012		NDF	DEC 22, 2003
		5559269	NOV 05, 2013	U-318	NCE	MAR 25, 2003
021228 002	TOLTERODINE TARTRATE;DETROL LA	5382600	JAN 17, 2012		NDF	DEC 22, 2003
		5559269	NOV 05, 2013	U-318	NCE	MAR 25, 2003
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-266	JUL 23, 2002
					I-274	OCT 01, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2003		I-274	OCT 01, 2002
					I-266	JUL 23, 2002
					ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
		5004758*PED	NOV 28, 2010			
020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2009	U-196	ODE	MAY 29, 2004
020136 001	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 003	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 004	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
		4861786	JUL 08, 2007			
076110 001	TORSEMIDE;TORSEMIDE				PC	FEB 17, 2003
076110 002	TORSEMIDE;TORSEMIDE				PC	DEC 10, 2002
076110 003	TORSEMIDE;TORSEMIDE				PC	DEC 07, 2002
076110 004	TORSEMIDE;TORSEMIDE				PC	DEC 10, 2002
020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435		
		6339105*PED	APR 12, 2020	U-435		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435	D-63	DEC 23, 2002
		6339105*PED	APR 12, 2020	U-435	PED	JUN 23, 2003
020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
		5744496	APR 28, 2015	U-229		
020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
		5744496	APR 28, 2015	U-229		
020528 003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
		4933361	JUN 12, 2007			
020591 001	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 002	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 003	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 004	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
		5631287	DEC 22, 2014	U-382		
		5849792	DEC 22, 2014	U-383		
		5889052	AUG 03, 2013	U-383		
		6235781	JUN 15, 2019	U-382		
021272 001	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 002	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 003	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 004	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
		5045317	SEP 03, 2008	U-179		
019963 001	TRETINOIN;RENOVA	4603146	JUL 29, 2003	U-131		
		RE36068	JUL 29, 2003	U-131		
021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131	NP	AUG 31, 2003
		4603146	JUL 29, 2003	U-131		
020475 001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134		
		5955109	SEP 21, 2016	U-134		
020475 002	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NS	MAY 10, 2005
		5955109	SEP 21, 2016	U-134		
020438 001	TRETINOIN;VESANOID				ODE	NOV 22, 2002
019798 001	TRIAMCINOLONE ACETONIDE;NASACORT	4767612	JAN 23, 2007	U-85		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573	JUL 03, 2016	U-295		
		6143329	JUL 03, 2016			
074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
		5962461	AUG 07, 2016			
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4694007	MAY 20, 2006	U-91		
		4376858	MAY 09, 2004			
		6017922	MAY 18, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
					NCE	JUN 15, 2005
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5225205	JUL 20, 2010		NCE	JUN 15, 2005
		5776885	JUL 07, 2015			
020719 001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
		5602133	SEP 15, 2013	U-173		
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020719 002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
		5602133	SEP 15, 2013	U-173		
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020719 003	TROGLITAZONE;PRELAY	5602133	SEP 15, 2013	U-173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 001	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020720 003	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U-251		
		6011049	NOV 13, 2017	U-301		
		6046202	SEP 15, 2013	U-317		
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6187341	JAN 20, 2019			
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282	NCE	DEC 18, 2002
		5763454	JUN 15, 2015	U-282		
		6187341	JAN 20, 2019			
021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
		5151444	MAR 19, 2008	U-333		
		5166178	NOV 24, 2009	U-333		
		5212200	MAY 18, 2010	U-333		
		5208256	MAY 21, 2011	U-333		
		5221763	JUN 22, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020586 002	UREA, C-13;BREATHTEK UBT FOR H-PYLORI	4830010	OCT 27, 2009	U-147		
		5140993	AUG 24, 2009	U-148		
021092 001	UREA, C-13;HELICOSOL				NP	DEC 17, 2002
020586 001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147		
		5140993	AUG 24, 2009	U-148		
020617 001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U-195		
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195		
021289 001	UROFOLLITROPIN;BRAVELLE				NP	MAY 06, 2005
					I-377	DEC 19, 2005
019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
		4589402	JUL 26, 2004	U-482		
019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
		4589402	JUL 26, 2004	U-482		
020675 001	URSODIOL;URSO	4859660	AUG 22, 2006		ODE	DEC 10, 2004
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
		4957924	JUN 23, 2009			
020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009		D-67	JUN 25, 2004
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009		D-67	JUN 25, 2004
		5879706	JAN 19, 2016			
		6107302	JAN 19, 2016			
021341 002	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U-462	NCE	NOV 16, 2006
021341 003	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U-462	NCE	NOV 16, 2006
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
020593 001	VALPROATE SODIUM;DEPACON				D-72	JAN 24, 2005
020892 001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
					ODE	SEP 25, 2005
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3	I-365	AUG 14, 2005
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3	I-365	AUG 14, 2005
021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U-3		
021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U-3		
021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U-3		
021283 004	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U-3		
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
		6419958*PED	SEP 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
		6419958*PED	SEP 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
		6419958*PED	SEP 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U-398		
		6403120	MAR 20, 2017	U-451		
		6419958	MAR 20, 2017	U-459		
		6444708	JUN 28, 2013			
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U-398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U-451		
		6419958*PED	SEP 20, 2017	U-459		
		6444708*PED	DEC 28, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	DEC 21, 2004			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	DEC 21, 2004			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
019614 001	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 002	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 003	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U-3		
019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
021119 001	VERTEPORFIN;VISUDYNE	5707608	AUG 02, 2015		NCE	APR 12, 2005
		6074666	FEB 05, 2012		I-336	AUG 22, 2004
		4920143	APR 24, 2007			
		5095030	APR 24, 2007			
		5214036	MAY 25, 2010			
		5770619	JAN 06, 2015	U-357		
		5798349	AUG 25, 2015	U-357		
		5756541	MAR 11, 2016	U-357		
		4883790	JAN 20, 2007			
		5283255	JAN 20, 2007	U-357		
014103 003	VINCRISTINE SULFATE;ONCOVIN	4619935	OCT 28, 2003			
020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
		4307100*PED	JAN 08, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021266 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
021266 002	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
021267 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
020547 001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189	I-328	SEP 17, 2002
		5583152	SEP 26, 2010			
		4859692	SEP 26, 2010			
		5319097	DEC 11, 2011			
		5294636	DEC 11, 2011			
		5482963	JAN 09, 2013			
		6143775	DEC 11, 2011			
020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		NS	SEP 17, 2002
		5294636	DEC 11, 2011		I-328	SEP 17, 2002
		5319097	DEC 11, 2011			
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U-189		
		6143775	DEC 11, 2011			
020199 001	ZALCITABINE;HIVID	5028595	JUL 02, 2008	U-65		
		4879277	NOV 07, 2006	U-65		
020199 002	ZALCITABINE;HIVID	4879277	NOV 07, 2006	U-65		
		5028595	JUL 02, 2008	U-65		
020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
					M-8	FEB 22, 2004
020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
					M-8	FEB 22, 2004
021036 001	ZANAMIVIR;RELENZA	5360817	NOV 01, 2011		I-294	APR 26, 2003
		5648379	JUL 15, 2014	U-274	NCE	JUL 26, 2004
		6294572	DEC 15, 2014			
019655 001	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
019910 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
019951 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4837208	SEP 17, 2005			
020518 001	ZIDOVUDINE;RETROVIR	4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
020518 002	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020471 001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
020471 003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
020458 001	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020458 002	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020919 001	ZIPRASIDONE MESYLATE;GEODON	6399777	APR 01, 2017		NCE	FEB 05, 2006
		4831031	MAR 02, 2007		NDF	JUN 21, 2005
		6110918	MAR 26, 2017			
		6232304	APR 01, 2017			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U-53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
					I-361	FEB 22, 2005
020768 001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
		5863935	NOV 14, 2012			
020768 002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
		5863935	NOV 14, 2012			
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012		NDF	FEB 13, 2004
					NCE	NOV 25, 2002
019908 001	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U-74		
019908 002	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U-74		
020789 001	ZONISAMIDE;ZONEGRAN	6342515	DEC 21, 2018	U-438	NCE	MAR 27, 2005

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE ANNUAL EDITION SECTION 1.8 WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY DOSING SCHEDULE

D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY DOSING SCHEDULE

D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES

I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY

I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS

I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...

I-129 TREATMENT OF ALCOHOL DEPENDENCE

I-130 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS

I-131 PERIPHERAL ARTERIOGRAPHY

I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER

I-133 MANAGEMENT OF CHRONIC STABLE ANGINA

I-134 HEART FAILURE POST MYOCARDIAL INFARCTION

I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA

I-136 IDIOPATHIC CHRONIC URTICARIA

I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES

I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES

I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN

I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE

I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL

I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION□

I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS□

I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS

I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN

I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS

I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS

I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR

I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER

I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA

I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS

I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]

I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE

I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT

I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE

I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES

I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER

I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES

I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS

I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY

I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE

I-163 TREATMENT OF PHOTOPHOBIA

I-164 CHRONIC BACTERIAL PROSTATITIS

I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OF PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PYSCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PERSSARY
U-111	DIABETES

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	MEHTOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	METHOD OF USE OF LOTRONEX
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	METHOD OF TREATING
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS

FDA data supplied by DrugPatentWatch.com